PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Bonetta, L				Bonetta, L			Protein purification - Fast forward	NATURE			English	Article																			0	8	8	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 23	2006	439	7079					1017	+		10.1038/4391017a	http://dx.doi.org/10.1038/4391017a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014NE	16496010	Bronze			2022-12-28	WOS:000235486100058
J	Kramer, M; Lyne, AG; O'Brien, JT; Jordan, CA; Lorimer, DR				Kramer, M; Lyne, AG; O'Brien, JT; Jordan, CA; Lorimer, DR			A periodically active pulsar giving insight into magnetospheric physics	SCIENCE			English	Article								PSR 81931+24 (11933+2421) behaves as an ordinary isolated radio pulsar during active phases that are 5 to 10 days long. However, when the radio emission ceases, it switches off in less than 10 seconds and remains undetectable for the next 25 to 35 days, then switches on again. This pattern repeats quasi-periodically. The origin of this behavior is unclear. Even more remarkably, the pulsar rotation slows down 50% faster when it is on than when it is off. This indicates a massive increase in magnetospheric currents when the pulsar switches on, proving that pulsar wind plays a substantial role in pulsar spin-down. This allows us, for the first time, to estimate the magnetospheric currents in a pulsar magnetosphere during the occurrence of radio emission.	Univ Manchester, Jodrell Bank Observ, Macclesfield SK11 9DL, Cheshire, England	University of Manchester; Jodrell Bank Centre for Astrophysics	Kramer, M (corresponding author), Univ Manchester, Jodrell Bank Observ, Macclesfield SK11 9DL, Cheshire, England.		Lorimer, Duncan/ABH-7909-2020	Kramer, Michael/0000-0002-4175-2271				BACKER DC, 1970, NATURE, V228, P42, DOI 10.1038/228042a0; Cordes J. M, 2002, ASTROPH0207156; GOLDREICH P, 1969, ASTROPHYS J, V157, P869, DOI 10.1086/150119; GUNN JE, 1969, NATURE, V221, P454, DOI 10.1038/221454a0; Harding AK, 1999, ASTROPHYS J, V525, pL125, DOI 10.1086/312339; Hobbs G, 2004, MON NOT R ASTRON SOC, V353, P1311, DOI 10.1111/j.1365-2966.2004.08157.x; Hyman SD, 2005, NATURE, V434, P50, DOI 10.1038/nature03400; Lorimer D. R., 2012, HDB PULSAR ASTRONOMY; LYNE AG, 1985, MON NOT R ASTRON SOC, V213, P613, DOI 10.1093/mnras/213.3.613; Michel FC., 1991, THEORY NEUTRON STAR; PACINI F, 1967, NATURE, V216, P567, DOI 10.1038/216567a0; SPITKOVSKY A, 2004, IAU S, V218, P357; Stairs IH, 2000, NATURE, V406, P484, DOI 10.1038/35020010; STOKES GH, 1985, NATURE, V317, P787, DOI 10.1038/317787a0	14	340	346	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 28	2006	312	5773					549	551		10.1126/science.1124060	http://dx.doi.org/10.1126/science.1124060			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	039HN	16497886				2022-12-28	WOS:000237296700036
J	Huizink, AC; Ferdinand, RF; van der Ende, J; Verhulst, FC				Huizink, AC; Ferdinand, RF; van der Ende, J; Verhulst, FC			Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study	BRITISH MEDICAL JOURNAL			English	Article							(ECSTASY)-INDUCED SEROTONIN NEUROTOXICITY; SUBSTANCE USE DISORDERS; GENDER-DIFFERENCES; MENTAL-DISORDERS; ECSTASY USERS; 3,4-METHYLENEDIOXYMETHAMPHETAMINE; HEALTH; MOOD; DRUG	Objective To investigate whether using ecstasy (3,4-methylenedioxymethamphetamine, MDMA) is preceded by symptoms of behavioural and emotional problems in childhood and early adolescence. Design Prospective, longitudinal, population based study. Setting The Dutch province of Zuid-Holland. Participants A sample of 1580 individuals, followed up across a 14 year period, From childhood into adulthood. Main outcome measures The first assessment took place in 1983 before MDMA appeared as a recreational drug in the Netherlands and included the child behaviour checklist to obtain standardised parent's reports of their children's behavioural and emotional problems. Use of the drug was assessed with the composite international diagnostic interview 14 years later. Results Eight syndrome scales of childhood behaviour were examined. Scores in the deviant range for the scales designated as anxious or depressed in in childhood were significantly related to use of MDMA in adolescents and adults, resulting in an increased risk (hazard ratio 2.22, 95% confidence interval 1.20 to 4.11, P=0.01). Conclusions Individuals with childhood Symptoms of anxiety and depression may have all increased tendency to use MDMA in adolescence or young adulthood. Its effects are supposed to include enhanced feelings of bonding with other people, euphoria, or relaxation. Especially individuals With Symptoms of anxiety or depression may be susceptible to these positive effects.	Sophia Childrens Univ Hosp, Erasmus Med Ctr Rotterdam, Dept Child & Adoelscent Psychiat, NL-3000 CB Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital	Huizink, AC (corresponding author), Sophia Childrens Univ Hosp, Erasmus Med Ctr Rotterdam, Dept Child & Adoelscent Psychiat, POB 2060, NL-3000 CB Rotterdam, Netherlands.	a.c.huizink@erasmusmc.nl	Ferdinand, Robert/AAK-5532-2020					*AM PSYCH ASS, 1991, DIAGN STAT MAN MENT; Andrews G, 1998, SOC PSYCH PSYCH EPID, V33, P80, DOI 10.1007/s001270050026; [Anonymous], 1997, COMP INT DIAGN INT C; [Anonymous], 1991, MANUAL CHILD BEHAV C; Brady KT, 1999, PSYCHIAT CLIN N AM, V22, P241, DOI 10.1016/S0193-953X(05)70074-5; *BUR NDM, 2002, NAT DRUGM JAARB; COX DR, 1972, J R STAT SOC B, V34, P187; de Win MML, 2004, PSYCHOPHARMACOLOGY, V173, P376, DOI 10.1007/s00213-003-1723-4; Fergusson DM, 2002, J ABNORM CHILD PSYCH, V30, P419, DOI 10.1023/A:1015774125952; Gowing LR, 2002, DRUG ALCOHOL REV, V21, P53, DOI 10.1080/09595230220119363; Green AR, 2003, PHARMACOL REV, V55, P463, DOI 10.1124/pr.55.3.3; GRIFFITHS P, 1997, NEW TRENDS SYNTHETIC; Hofstra MB, 2002, J AM ACAD CHILD PSY, V41, P182, DOI 10.1097/00004583-200202000-00012; Kasius MC, 1997, J CHILD PSYCHOL PSYC, V38, P625, DOI 10.1111/j.1469-7610.1997.tb01689.x; Latimer WW, 2002, EXP CLIN PSYCHOPHARM, V10, P310, DOI 10.1037//1064-1297.10.3.310; Levy KB, 2005, SUBST USE MISUSE, V40, P1427, DOI 10.1081/JA-200066810; Lieb R, 2002, DRUG ALCOHOL DEPEN, V68, P195, DOI 10.1016/S0376-8716(02)00190-4; Lieb R, 2002, ARCH GEN PSYCHIAT, V59, P365, DOI 10.1001/archpsyc.59.4.365; Maes Michael, 1995, P933; McCann UD, 2000, NEUROPSYCHOBIOLOGY, V42, P11, DOI 10.1159/000026665; McCardle K, 2004, PSYCHOPHARMACOLOGY, V173, P434, DOI 10.1007/s00213-004-1791-0; Meltzer HY., 1987, PSYCHOPHARMACOLOGY 3, VVol. 1, P513; Parrott AC, 2002, HUM PSYCHOPHARM CLIN, V17, P309, DOI 10.1002/hup.415; Parrott AC, 2001, PSYCHOPHARMACOLOGY, V159, P77, DOI 10.1007/s002130100897; Pennings E J, 1998, Ned Tijdschr Geneeskd, V142, P1942; RICAURTE G, 1985, SCIENCE, V229, P986, DOI 10.1126/science.4023719; Ricaurte GA, 2000, NEUROPSYCHOBIOLOGY, V42, P5, DOI 10.1159/000026664; ROYS A, 2001, HLTH ED RES, V16, P457; Schifano F, 1998, DRUG ALCOHOL DEPEN, V52, P85, DOI 10.1016/S0376-8716(98)00051-9; Sprague JE, 1998, NEUROTOXICOLOGY, V19, P427; VANWESTERLAAK JH, 1975, BEROEPERKLAPPER; Verheyden SL, 2003, J PSYCHOPHARMACOL, V17, P371, DOI 10.1177/0269881103174014; Verhulst F C, 1985, Acta Psychiatr Scand Suppl, V324, P1; VERHULST FC, 1985, ACTA PSYCHIAT SCAND, V72, P1; VERHULST FC, 1996, HANDLEIDING CBCI 4; Vollenweider FX, 1998, NEUROPSYCHOPHARMACOL, V19, P241, DOI 10.1016/S0893-133X(98)00013-X	36	55	55	0	13	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 8	2006	332	7545					825	827		10.1136/bmj.38743.539398.3A	http://dx.doi.org/10.1136/bmj.38743.539398.3A			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	032ZQ	16500927	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000236815900020
J	Zackrisson, S; Andersson, I; Janzon, L; Manjer, J; Garne, JP				Zackrisson, S; Andersson, I; Janzon, L; Manjer, J; Garne, JP			Rate of over-diagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: follow-up study	BRITISH MEDICAL JOURNAL			English	Article							SWEDISH RANDOMIZED TRIALS; OVERDIAGNOSIS; MORTALITY; SWEDEN; CARCINOMA; OVERTREATMENT	Objective To evaluate the rate of over-diagnosis of breast cancer 15 years after the end of the Malmo mammographic screening trial. Design Follow-up Study. Setting Malmo, Sweden. Subjects 42 283 women aged 45-69 years at randomisation. Interventions Screening for breast cancer with mammography or not (controls). Screening was offered at end of randomisation design to both groups aged 45-54 at randomisation but not to groups aged 55-69 at randomisation. Main outcome measures Rate of over-diagnosis of breast cancer (in situ and invasive), calculated as incidence in the invited and control groups, during period of randomised design (period 1), during period randomised design ended (period 2), and at end of follow-up. Results In women aged 55-69 years at randomisation the relative rates of over-diagnosis of breast cancer (95% confidence intervals) were 1.32 (1.14 to 1.53) for period 1, 0.92 (0.79 to 1.06) for period 2, and 1.10 (0.99 to 1.22) at the end of follow-up. Conclusion Conclusions on over-diagnosis of breast cancer in the Malmo mammographic screening trial can be drawn mainly in women aged 55-69 years at randomisation whose control groups were never screened. Fifteen years after die trial ended the rate of over-diagnosis of breast cancer was 10% in this age group.	Lund Univ, Malmo Univ Hosp, Dept Clin Sci Malmo, Epidemiol Res Grp, SE-20502 Malmo, Sweden; Aarhus Univ Hosp, Dept Surg, DK-8000 Aarhus C, Denmark	Lund University; Skane University Hospital; Aarhus University	Zackrisson, S (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Clin Sci Malmo, Epidemiol Res Grp, SE-20502 Malmo, Sweden.	sophia.zackrisson@med.lu.se						ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; Baines CJ, 2005, BREAST J, V11, pS7, DOI 10.1111/j.1075-122X.2005.217162.x; Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518; Day NE, 2005, BREAST CANCER RES, V7, P228, DOI 10.1186/bcr1321; Duffy SW, 2005, J MED SCREEN, V12, P128, DOI 10.1258/0969141054855319; Duffy SW, 2005, BREAST CANCER RES, V7, P258, DOI 10.1186/bcr1354; Duffy SW, 2002, CANCER-AM CANCER SOC, V95, P458, DOI 10.1002/cncr.10765; International Agency for Research on Cancer, 2002, IARC HDB CANC PREV; Jonsson H, 2005, INT J CANCER, V117, P842, DOI 10.1002/ijc.21228; Jonsson H, 2001, J MED SCREEN, V8, P152, DOI 10.1136/jms.8.3.152; Matson S, 2001, CANCER DETECT PREV, V25, P132; Moller B, 2005, EUR J CANCER PREV, V14, P117, DOI 10.1097/00008469-200504000-00007; MOSKOWITZ M, 1986, RADIOLOGY, V161, P37, DOI 10.1148/radiology.161.1.3532183; Moss S, 2005, BREAST CANCER RES, V7, P230, DOI 10.1186/bcr1314; Nystrom L, 2002, LANCET, V359, P909, DOI 10.1016/S0140-6736(02)08020-0; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; Olsen AH, 2003, BRIT J CANCER, V88, P362, DOI 10.1038/sj.bjc.6600712; Paci E, 2004, J MED SCREEN, V11, P23, DOI 10.1258/096914104772950718; PEETERS PHM, 1989, INT J EPIDEMIOL, V18, P295, DOI 10.1093/ije/18.2.295; SHAPIRO S, 1974, AM J EPIDEMIOL, V100, P357, DOI 10.1093/oxfordjournals.aje.a112046; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; Yen MF, 2003, EUR J CANCER, V39, P1746, DOI 10.1016/S0959-8049(03)00260-0; Zackrisson S, 2004, INT J CANCER, V108, P754, DOI 10.1002/ijc.11622; Zahl PH, 2004, BMJ-BRIT MED J, V328, P921, DOI 10.1136/bmj.38044.666157.63	24	254	263	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAR 25	2006	332	7543					689	691		10.1136/bmj.38764.572569.7C	http://dx.doi.org/10.1136/bmj.38764.572569.7C			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	027VH	16517548	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000236443300015
J	Graham, DW; Blichert-Toft, J; Russo, CJ; Rubin, KH; Albarede, F				Graham, DW; Blichert-Toft, J; Russo, CJ; Rubin, KH; Albarede, F			Cryptic striations in the upper mantle revealed by hafnium isotopes in southeast Indian ridge basalts	NATURE			English	Article							HF; CONSTRAINTS; SYSTEMS; BENEATH; ATLANTIC; HOTSPOT; LU	The Earth's mantle is isotopically heterogeneous on length scales ranging from centimetres to more than 10(4) kilometres(1,2). This heterogeneity originates from partial melt extraction and plate tectonic recycling, whereas stirring during mantle convection tends to reduce it. Here we show that mid-ocean ridge basalts from 2,000 km along the southeast Indian ridge (SEIR) display a bimodal hafnium isotopic distribution. This bimodality reveals the presence of ancient compositional striations (streaks) in the Indian Ocean upper mantle. The number density of the streaks is described by a Poisson distribution, with an average thickness of similar to 40 km. Such a distribution is anticipated for a well-stirred upper mantle, in which heterogeneity is continually introduced by plate tectonic recycling, and redistributed by viscous stretching and convective refolding.	Oregon State Univ, Coll Ocean & Atmospher Sci, Corvallis, OR 97331 USA; Ecole Normale Super, Lab Sci Terre, F-69364 Lyon, France; Univ Hawaii, SOEST, Honolulu, HI 96822 USA	Oregon State University; Ecole Normale Superieure de Lyon (ENS de LYON); University of Hawaii System	Graham, DW (corresponding author), Oregon State Univ, Coll Ocean & Atmospher Sci, Corvallis, OR 97331 USA.	dgraham@coas.oregonstate.edu	Graham, David/C-3612-2014; Blichert-Toft, Janne/C-8280-2012; Albarede, Francis/A-8871-2011; Rubin, Kenneth H/B-3685-2008	Graham, David/0000-0002-7411-1905; Blichert-Toft, Janne/0000-0002-4932-4079; Albarede, Francis/0000-0003-1994-1428; Rubin, Kenneth H/0000-0002-8554-1337				Albarede F, 2005, GEOPHYS MONOGR SER, V160, P27, DOI 10.1029/160GM04; Albarede F, 2001, EARTH PLANET SC LETT, V189, P59, DOI 10.1016/S0012-821X(01)00350-8; Allegre CJ, 1995, EARTH PLANET SC LETT, V136, P629, DOI 10.1016/0012-821X(95)00184-E; ALLEGRE CJ, 1986, NATURE, V323, P123, DOI 10.1038/323123a0; Andres M, 2004, EARTH PLANET SC LETT, V225, P89, DOI 10.1016/j.epsl.2004.05.041; Bedini RM, 2004, EARTH PLANET SC LETT, V223, P99, DOI 10.1016/j.epsl.2004.04.012; Blichert-Toft J, 2005, GEOCHEM GEOPHY GEOSY, V6, DOI 10.1029/2004GC000788; Blichert-Toft J, 2004, CHEM GEOL, V207, P261, DOI 10.1016/j.chemgeo.2004.03.005; BlichertToft J, 1997, CONTRIB MINERAL PETR, V127, P248, DOI 10.1007/s004100050278; BLICHERTTOFT J, 1994, SCIENCE, V263, P1593, DOI 10.1126/science.263.5153.1593; Burnard P, 2004, EARTH PLANET SC LETT, V227, P457, DOI 10.1016/j.epsl.2004.08.021; Chauvel C, 2001, EARTH PLANET SC LETT, V190, P137, DOI 10.1016/S0012-821X(01)00379-X; Donnelly KE, 2004, EARTH PLANET SC LETT, V226, P347, DOI 10.1016/j.epsl.2004.07.019; Doucet S, 2004, EARTH PLANET SC LETT, V218, P179, DOI 10.1016/S0012-821X(03)00636-8; Graham DW, 2001, NATURE, V409, P701, DOI 10.1038/35055529; Hanan BB, 2004, NATURE, V432, P91, DOI 10.1038/nature03026; HANAN BB, 1986, NATURE, V322, P137, DOI 10.1038/322137a0; HART SR, 1984, NATURE, V309, P753, DOI 10.1038/309753a0; Janney PE, 2005, J PETROL, V46, P2427, DOI 10.1093/petrology/egi060; Kempton PD, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2002GC000320; Mahoney JJ, 2002, J PETROL, V43, P1155, DOI 10.1093/petrology/43.7.1155; Muzzio FJ, 2000, CHEM ENG SCI, V55, P1497, DOI 10.1016/S0009-2509(99)00359-0; NICOLAYSEN KE, 2001, THESIS MIT, P1; OLSON P, 1984, J GEOPHYS RES, V89, P425, DOI 10.1029/JB089iB01p00425; Salters VJM, 1998, CHEM GEOL, V145, P447, DOI 10.1016/S0009-2541(97)00154-X; SALTERS VJM, 1995, EARTH PLANET SC LETT, V129, P13, DOI 10.1016/0012-821X(94)00234-P; Schmitz MD, 2004, GEOLOGY, V32, P405, DOI 10.1130/G20241.1; Schubert G., 2001, MANTLE CONVECTION EA, P1; SEMPERE JC, 1991, GEOLOGY, V19, P429, DOI 10.1130/0091-7613(1991)019<0429:AAD>2.3.CO;2; Woodhead JD, 2001, EARTH PLANET SC LETT, V192, P331, DOI 10.1016/S0012-821X(01)00453-8	30	47	47	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	2006	440	7081					199	202		10.1038/nature04582	http://dx.doi.org/10.1038/nature04582			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019MC	16525470	Bronze			2022-12-28	WOS:000235839500043
J	Gessler, D; Dye, C; Farmer, P; Murray, M; Navin, T; Reves, R; Shinnick, T; Small, PM; Yates, T; Simpson, G				Gessler, D; Dye, C; Farmer, P; Murray, M; Navin, T; Reves, R; Shinnick, T; Small, PM; Yates, T; Simpson, G			A national tuberculosis archive	SCIENCE			English	Editorial Material							NEW-YORK-CITY; RESISTANT MYCOBACTERIUM-TUBERCULOSIS; HANTAVIRUS PULMONARY SYNDROME; MOLECULAR EPIDEMIOLOGY; DISEASE; SPREAD; STRAIN		Natl Ctr Genome Resources, Santa Fe, NM 87505 USA; WHO, Stop TB, Geneva 27, Switzerland; Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA; US Dept HHS, Washington, DC 20201 USA; Denver Hlth & Hosp Author, Denver Publ Hlth, Denver, CO 80204 USA; Inst Syst Biol, Seattle, WA 98103 USA; Bill & Melinda Gates Fdn, Global Hlth Program, Seattle, WA 98102 USA; Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA; Univ New Mexico, Museum SW Biol, Albuquerque, NM 87131 USA; New Mexico Dept Hlth, Santa Fe, NM 87502 USA	National Center for Genome Resources (NCGR); World Health Organization; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Centers for Disease Control & Prevention - USA; Denver Health Medical Center; Institute for Systems Biology (ISB); Bill & Melinda Gates Foundation; University of New Mexico; University of New Mexico; New Mexico Department of Health	Gessler, D (corresponding author), Natl Ctr Genome Resources, Santa Fe, NM 87505 USA.	ddg@ncgr.org	Dye, Christopher/AIC-4659-2022	Dye, Christopher/0000-0002-2957-1793				Agerton TB, 1999, CLIN INFECT DIS, V29, P85, DOI 10.1086/520187; AZIZ MA, 2004, ANTITUBERCULOSIS DRU; Bifani PJ, 1996, JAMA-J AM MED ASSOC, V275, P452, DOI 10.1001/jama.275.6.452; *CDC, 2004, TECHN NOT REP TUB US; CDC, 2005, REP TUB US; CDC, 2005, MMWR-MORBID MORTAL W, V54; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DeRiemer K, 2005, LANCET, V365, P1239, DOI 10.1016/S0140-6736(05)74812-1; DUCHIN JS, 1994, NEW ENGL J MED, V330, P949, DOI 10.1056/NEJM199404073301401; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; Gagneux S, 2006, P NATL ACAD SCI USA, V103, P2869, DOI 10.1073/pnas.0511240103; Han LL, 2005, INT J TUBERC LUNG D, V9, P818; HUGHES JM, 1993, SCIENCE, V262, P850, DOI 10.1126/science.8235607; Kato-Maeda M, 2000, WESTERN J MED, V172, P256, DOI 10.1136/ewjm.172.4.256; Munsiff SS, 2003, J INFECT DIS, V188, P356, DOI 10.1086/376837; Munsiff SS, 2002, EMERG INFECT DIS, V8, P1230; National TB Controllers Association/Center for Disease Control and Prevention Advisory Group on Tubercolosis Genotyping, 2004, GUID APPL GEN TUB PR; PORTER JDH, 1994, ANNU REV PUBL HEALTH, V15, P303; Schwartzman K, 2005, NEW ENGL J MED, V353, P1008, DOI 10.1056/NEJMsa043194; Shin SS, 2005, MICROB DRUG RESIST, V11, P26, DOI 10.1089/mdr.2005.11.26; *US DEP HHS, 2004, REP TUB US 2003; *WHO, 2005, GLOB TUB CONTR SURV; *WHO, S E AS REG FACTS; World Health Organization (WHO), 2005, ADDR POV TB CONTR; Yates TL, 2002, BIOSCIENCE, V52, P989, DOI 10.1641/0006-3568(2002)052[0989:TEAEHO]2.0.CO;2	25	6	6	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	2006	311	5765					1245	1246		10.1126/science.1125762	http://dx.doi.org/10.1126/science.1125762			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019XB	16513968				2022-12-28	WOS:000235870400025
J	Makadon, HJ				Makadon, HJ			Improving health care for the lesbian and gay communities	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Fenway Inst, Boston, MA USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Makadon, HJ (corresponding author), Fenway Inst, Boston, MA USA.							American Thoracic Society, 2003, MMWR Recomm Rep, V52, P1; Ciesielski Carol A., 2003, Curr Infect Dis Rep, V5, P145, DOI 10.1007/s11908-003-0051-5; Garofalo R, 1999, ARCH PEDIAT ADOL MED, V153, P487; Incorporating HIV prevention into the medical care of persons living with HIV, 2004, MMWR RECOMM REP; WHITE J, 2001, TXB PRIMARY CARE MED, P336; 1994, MMWR MORB MORTAL WKL, V42, P988	6	48	47	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 2	2006	354	9					895	897		10.1056/NEJMp058259	http://dx.doi.org/10.1056/NEJMp058259			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	017FN	16510743				2022-12-28	WOS:000235679600002
J	Tobie, G; Lunine, JI; Sotin, C				Tobie, G; Lunine, JI; Sotin, C			Episodic outgassing as the origin of atmospheric methane on Titan	NATURE			English	Article							INTERNAL STRUCTURE; CLATHRATE; MODEL; ABUNDANCES; PRESSURES; HYDRATE; SURFACE; DRIVEN; SYSTEM	Saturn's largest satellite, Titan, has a massive nitrogen atmosphere containing up to 5 per cent methane near its surface. Photochemistry in the stratosphere would remove the present-day atmospheric methane in a few tens of millions of years(1). Before the Cassini-Huygens mission arrived at Saturn, widespread liquid methane or mixed hydrocarbon seas hundreds of metres in thickness were proposed as reservoirs from which methane could be resupplied to the atmosphere over geologic time(2). Titan fly-by observations(3-5) and ground-based observations(6) rule out the presence of extensive bodies of liquid hydrocarbons at present, which means that methane must be derived from another source over Titan's history. Here we show that episodic outgassing of methane stored as clathrate hydrates within an icy shell above an ammonia-enriched water ocean is the most likely explanation for Titan's atmospheric methane. The other possible explanations all fail because they cannot explain the absence of surface liquid reservoirs and/or the low dissipative state of the interior. On the basis of our models, we predict that future fly-bys should reveal the existence of both a subsurface water ocean and a rocky core, and should detect more cryovolcanic edifices.	Univ Nantes, Lab Planetol & Geodynam, CNRS, UMR 6112, F-44322 Nantes 03, France; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; INAF, Ist Fis Spazio Interplanetario, I-00133 Rome, Italy	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); Nantes Universite; University of Arizona; Istituto Nazionale Astrofisica (INAF)	Tobie, G (corresponding author), Univ Nantes, Lab Planetol & Geodynam, CNRS, UMR 6112, F-44322 Nantes 03, France.	gabriel.tobie@univ-nantes.fr		Lunine, Jonathan/0000-0003-2279-4131				CASTILLO J, 2002, LUNAR PLANET SCI, V33, P1989; Durham WB, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB001872; Dyadin YA, 1997, MENDELEEV COMMUN, P34; Dyadin YA, 1997, MENDELEEV COMMUN, P32; Elachi C, 2005, SCIENCE, V308, P970, DOI 10.1126/science.1109919; ENGEL S, 1994, J GEOPHYS RES-PLANET, V99, P3745, DOI 10.1029/93JE03433; Grasset O, 2005, PLANET SPACE SCI, V53, P371, DOI 10.1016/j.pss.2004.09.062; Grasset O, 2000, PLANET SPACE SCI, V48, P617, DOI 10.1016/S0032-0633(00)00039-8; KURAMOTO K, 1994, J GEOPHYS RES-PLANET, V99, P21183, DOI 10.1029/94JE01864; Lorenz RD, 1997, SCIENCE, V275, P642, DOI 10.1126/science.275.5300.642; Loveday JS, 2001, NATURE, V410, P661, DOI 10.1038/35070513; Lowell RP, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014411; LUNINE JI, 1987, ICARUS, V70, P61, DOI 10.1016/0019-1035(87)90075-3; Lunine JI, 1999, PLANET SPACE SCI, V47, P1291, DOI 10.1016/S0032-0633(99)00052-5; LUNINE JI, 1983, SCIENCE, V222, P1229, DOI 10.1126/science.222.4629.1229; Mousis O, 2002, ICARUS, V156, P162, DOI 10.1006/icar.2001.6782; Niemann HB, 2005, NATURE, V438, P779, DOI 10.1038/nature04122; Owen TC, 2000, PLANET SPACE SCI, V48, P747, DOI 10.1016/S0032-0633(00)00040-4; Porco CC, 2005, NATURE, V434, P159, DOI 10.1038/nature03436; Rappaport N, 1997, ICARUS, V126, P313, DOI 10.1006/icar.1996.5661; SLOAN ED, 1998, CLATHRATES HYDRATES; Sohl F, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002044; Sotin C, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013844; Sotin C, 2005, NATURE, V435, P786, DOI 10.1038/nature03596; STEVENSON DJ, 1992, P S TIT TOUL FRANC, P29; Tobie G, 2005, ICARUS, V175, P496, DOI 10.1016/j.icarus.2004.12.007; Tomasko MG, 2005, NATURE, V438, P765, DOI 10.1038/nature04126; Waite JH, 2005, SCIENCE, V308, P982, DOI 10.1126/science.1110652; West RA, 2005, NATURE, V436, P670, DOI 10.1038/nature03824; YUNG YL, 1984, ASTROPHYS J SUPPL S, V55, P465, DOI 10.1086/190963	30	302	305	0	69	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	2006	440	7080					61	64		10.1038/nature04497	http://dx.doi.org/10.1038/nature04497			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017HW	16511489				2022-12-28	WOS:000235685700038
J	Akira, S; Uematsu, S; Takeuchi, O				Akira, S; Uematsu, S; Takeuchi, O			Pathogen recognition and innate immunity	CELL			English	Review							TOLL-LIKE RECEPTOR; NF-KAPPA-B; DOUBLE-STRANDED-RNA; PLASMACYTOID DENDRITIC CELLS; INTERFERON-ALPHA INDUCTION; IFN-BETA PROMOTER; HEPATITIS-C VIRUS; SIGNALING PATHWAY; RIG-I; ANTIVIRAL RESPONSE	Microorganisms that invade a vertebrate host are initially recognized by the innate immune system through germline-encoded pattern-recognition receptors (PRRs). Several classes of PRRs, including Toll-like receptors and cytoplasmic receptors, recognize distinct microbial components and directly activate immune cells. Exposure of immune cells to the ligands of these receptors activates intracellular signaling cascades that rapidly induce the expression of a variety of overlapping and unique genes involved in the inflammatory and immune responses. New insights into innate immunity are changing the way we think about pathogenesis and the treatment of infectious diseases, allergy, and autoimmunity.	Osaka Univ, Res Inst Microbial Dis, Dept Host Defense, Suita, Osaka 5650871, Japan; ERATO, Japan Sci & Technol Agcy, Suita, Osaka 5650871, Japan	Osaka University; Japan Science & Technology Agency (JST)	Akira, S (corresponding author), Osaka Univ, Res Inst Microbial Dis, Dept Host Defense, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	sakira@biken.osaka-u.ac.jp	Yang, Chen/G-1379-2010; Takeuchi, Osamu/D-6007-2011; Connor, Toni R/C-6964-2012; Takeuchi, Osamu/AAG-9359-2019	Takeuchi, Osamu/0000-0002-1260-6232				Adachi K, 2001, J IMMUNOL, V167, P5928, DOI 10.4049/jimmunol.167.10.5928; Agrawal S, 2003, J IMMUNOL, V171, P4984, DOI 10.4049/jimmunol.171.10.4984; Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alexopoulou L, 2002, NAT MED, V8, P878, DOI 10.1038/nm732; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Andersen-Nissen E, 2005, P NATL ACAD SCI USA, V102, P9247, DOI 10.1073/pnas.0502040102; Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101; Balachandran S, 2004, NATURE, V432, P401, DOI 10.1038/nature03124; Barton GM, 2006, NAT IMMUNOL, V7, P49, DOI 10.1038/ni1280; Belkhadir Y, 2004, CURR OPIN PLANT BIOL, V7, P391, DOI 10.1016/j.pbi.2004.05.009; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Bieback K, 2002, J VIROL, V76, P8729, DOI 10.1128/JVI.76.17.8729-8736.2002; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; Bowie A, 2000, P NATL ACAD SCI USA, V97, P10162, DOI 10.1073/pnas.160027697; Bowie A, 2000, J LEUKOCYTE BIOL, V67, P508, DOI 10.1002/jlb.67.4.508; Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470; Burzyn D, 2004, J VIROL, V78, P576, DOI 10.1128/JVI.78.2.576-584.2004; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253; Coban C, 2005, J EXP MED, V201, P19, DOI 10.1084/jem.20041836; Compton T, 2003, J VIROL, V77, P4588, DOI 10.1128/JVI.77.8.4588-4596.2003; Cook DN, 2004, NAT IMMUNOL, V5, P975, DOI 10.1038/ni1116; Couillault C, 2004, NAT IMMUNOL, V5, P488, DOI 10.1038/ni1060; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Diez E, 2003, NAT GENET, V33, P55, DOI 10.1038/ng1065; DiPerna G, 2004, J BIOL CHEM, V279, P36570, DOI 10.1074/jbc.M400567200; Dostert C, 2005, NAT IMMUNOL, V6, P946, DOI 10.1038/ni1237; Echchannaoui H, 2002, J INFECT DIS, V186, P798, DOI 10.1086/342845; Edelmann KH, 2004, VIROLOGY, V322, P231, DOI 10.1016/j.virol.2004.01.033; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Fortune SM, 2004, J IMMUNOL, V172, P6272, DOI 10.4049/jimmunol.172.10.6272; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Gazzinelli RT, 2004, IMMUNOL REV, V201, P9, DOI 10.1111/j.0105-2896.2004.00174.x; Gilleron M, 2003, J BIOL CHEM, V278, P29880, DOI 10.1074/jbc.M303446200; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Gomez-Gomez L, 2000, MOL CELL, V5, P1003, DOI 10.1016/S1097-2765(00)80265-8; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Hacker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hawn TR, 2003, J EXP MED, V198, P1563, DOI 10.1084/jem.20031220; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hochrein H, 2004, P NATL ACAD SCI USA, V101, P11416, DOI 10.1073/pnas.0403555101; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Honda K, 2005, NATURE, V434, P1035, DOI 10.1038/nature03547; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Honda K, 2004, P NATL ACAD SCI USA, V101, P15416, DOI 10.1073/pnas.0406933101; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Ishii KJ, 2006, NAT IMMUNOL, V7, P40, DOI 10.1038/ni1282; Kaisho T, 2001, J IMMUNOL, V166, P5688, DOI 10.4049/jimmunol.166.9.5688; Kang DC, 2002, P NATL ACAD SCI USA, V99, P637, DOI 10.1073/pnas.022637199; KANNEGANTI TD, 2003, NATURE, DOI DOI 10.1038/NATURE.04517; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U; Krug A, 2004, IMMUNITY, V21, P107, DOI 10.1016/j.immuni.2004.06.007; Krug A, 2004, BLOOD, V103, P1433, DOI 10.1182/blood-2003-08-2674; Krutzik SR, 2003, NAT MED, V9, P525, DOI 10.1038/nm864; Kurt-Jones EA, 2004, P NATL ACAD SCI USA, V101, P1315, DOI 10.1073/pnas.0308057100; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Lin RT, 2004, J VIROL, V78, P1675, DOI 10.1128/JVI.78.4.1675-1684.2004; Lopez CB, 2004, J IMMUNOL, V173, P6882, DOI 10.4049/jimmunol.173.11.6882; Lund J, 2003, J EXP MED, V198, P513, DOI 10.1084/jem.20030162; Malhotra D, 2005, HUM GENET, V116, P413, DOI 10.1007/s00439-004-1249-9; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; MARIATHASAN S, 2006, NATURE, DOI DOI 10.1035/NATURE04515; Martinon F, 2005, TRENDS IMMUNOL, V26, P447, DOI 10.1016/j.it.2005.06.004; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Netea MG, 2004, EUR J CLIN MICROBIOL, V23, P672, DOI 10.1007/s10096-004-1192-7; Oganesyan G, 2006, NATURE, V439, P208, DOI 10.1038/nature04374; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Pai RK, 2003, J IMMUNOL, V171, P175, DOI 10.4049/jimmunol.171.1.175; Perry AK, 2004, J EXP MED, V199, P1651, DOI 10.1084/jem.20040528; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Pichyangkul S, 2004, J IMMUNOL, V172, P4926, DOI 10.4049/jimmunol.172.8.4926; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Pujol N, 2001, CURR BIOL, V11, P809, DOI 10.1016/S0960-9822(01)00241-X; Quesniaux V, 2004, MICROBES INFECT, V6, P946, DOI 10.1016/j.micinf.2004.04.016; Roach JC, 2005, P NATL ACAD SCI USA, V102, P9577, DOI 10.1073/pnas.0502272102; Rogers NC, 2005, IMMUNITY, V22, P507, DOI 10.1016/j.immuni.2005.03.004; Rothenfusser S, 2005, J IMMUNOL, V175, P5260, DOI 10.4049/jimmunol.175.8.5260; Rutz M, 2004, EUR J IMMUNOL, V34, P2541, DOI 10.1002/eji.200425218; Sakaguchi S, 2003, BIOCHEM BIOPH RES CO, V306, P860, DOI 10.1016/S0006-291X(03)01049-0; Schulz O, 2005, NATURE, V433, P887, DOI 10.1038/nature03326; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Sing A, 2002, J EXP MED, V196, P1017, DOI 10.1084/jem.20020908; Stack J, 2005, J EXP MED, V201, P1007, DOI 10.1084/jem.20041442; Suzuki N, 2003, J IMMUNOL, V170, P4031, DOI 10.4049/jimmunol.170.8.4031; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Takahara K, 2004, INT IMMUNOL, V16, P819, DOI 10.1093/intimm/dxh084; Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; Uematsu S, 2005, J EXP MED, V201, P915, DOI 10.1084/jem.20042372; Underhill DM, 2005, BLOOD, V106, P2543, DOI 10.1182/blood-2005-03-1239; Verthelyi D, 2001, J IMMUNOL, V166, P2372, DOI 10.4049/jimmunol.166.4.2372; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang T, 2004, NAT MED, V10, P1366, DOI 10.1038/nm1140; Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yamamoto M, 2004, NATURE, V430, P218, DOI 10.1038/nature02738; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Yarovinsky F, 2005, SCIENCE, V308, P1626, DOI 10.1126/science.1109893; Yates RM, 2005, IMMUNITY, V23, P409, DOI 10.1016/j.immuni.2005.09.007; Yonekura K, 2003, NATURE, V424, P643, DOI 10.1038/nature01830; Yoneyama M, 2005, J IMMUNOL, V175, P2851, DOI 10.4049/jimmunol.175.5.2851; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Yu YX, 2005, IMMUNITY, V22, P59, DOI 10.1016/j.immuni.2004.11.011; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	141	8207	8748	90	2286	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 24	2006	124	4					783	801		10.1016/j.cell.2006.02.015	http://dx.doi.org/10.1016/j.cell.2006.02.015			19	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	038RO	16497588	Bronze			2022-12-28	WOS:000237240900021
J	Ji, Q; Luo, ZX; Yuan, CX; Tabrum, AR				Ji, Q; Luo, ZX; Yuan, CX; Tabrum, AR			A swimming mammaliaform from the Middle Jurassic and ecomorphological diversification of early mammals	SCIENCE			English	Article							INNER-MONGOLIA; EVOLUTION; DOCODONT; CHINA; DISCOVERY; ORIGIN; TEETH	A docodontan mammaliaform from the Middle Jurassic of China possesses swimming and burrowing skeletal adaptations and some dental features for aquatic feeding. It is the most primitive taxon in the mammalian lineage known to have fur and has a broad, flattened, partly scaly tail analogous to that of modern beavers. We infer that docodontans were semiaquatic, convergent to the modern platypus and many Cenozoic placentals. This fossil demonstrates that some mammaliaforms, or proximal relatives to modern mammals, developed diverse locomotory and feeding adaptations and were ecomorphologically different from the majority of generalized small terrestrial Mesozoic mammalian insectivores.	Carnegie Museum Nat Hist, Pittsburgh, PA 15213 USA; Chinese Acad Geol Sci, Beijing 100037, Peoples R China; Nanjing Univ, Dept Earth Sci, Nanjing 200017, Peoples R China	Chinese Academy of Geological Sciences; Nanjing University	Luo, ZX (corresponding author), Carnegie Museum Nat Hist, Pittsburgh, PA 15213 USA.	LuoZ@CarnegieMNH.org	Luo, Zhe-XI/AAU-2263-2021					Alibardi L, 2003, J MORPHOL, V258, P49, DOI 10.1002/jmor.10118; ALLIN EF, 1992, EVOLUTIONARY BIOLOGY OF HEARING, P587; Averianov AO, 2005, ACTA PALAEONTOL POL, V50, P789; BRINK A. S., 1955, PALAEONTOL AFRICANA, V3, P3; Butler PM, 2001, PALAEONTOLOGY, V44, P1, DOI 10.1111/1475-4983.00166; Butler PM, 1997, J VERTEBR PALEONTOL, V17, P435, DOI 10.1080/02724634.1997.10010988; [陈文 Chen Wen], 2004, [地质通报, Geological Bulletin of China], V23, P1165; CROMPTON AW, 1993, MAMMAL PHYLOGENY, P30; Fish FE, 2001, J EXP BIOL, V204, P797; Flynn JJ, 1999, NATURE, V401, P57, DOI 10.1038/43420; Gambaryan Petr P., 2002, Russian Journal of Theriology, V1, P1; Gao KQ, 2003, NATURE, V422, P424, DOI 10.1038/nature01491; Gingerich P.D., 1984, SIZE SCALING PRIMATE, P257; Jenkins Jr F. A., 1971, PEABODY MUS NAT HIST, V36, P1; Ji Q, 2002, NATURE, V416, P816, DOI 10.1038/416816a; Ji Q., 2004, MESOZOIC JEHOL BIOTA; KEMP TS, 2005, ORIGIN EVOLUTION MAM; KERMACK KA, 1987, ZOOL J LINN SOC-LOND, V89, P1, DOI 10.1111/j.1096-3642.1987.tb01342.x; KERMACK KA, 1973, ZOOL J LINN SOC-LOND, V53, P87, DOI 10.1111/j.1096-3642.1973.tb00786.x; KIELAN-JAWOROWSKA Z, 2004, MAMMALS AGE DINOSAUR; Lillegraven J.A., 1991, Contributions to Geology University of Wyoming, V28, P39; Liu YQ, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL022466; Luo ZX, 2003, SCIENCE, V302, P1934, DOI 10.1126/science.1090718; Luo ZX, 2002, ACTA PALAEONTOL POL, V47, P1; Luo ZX, 2001, SCIENCE, V292, P1535, DOI 10.1126/science.1058476; Luo ZX, 2001, NATURE, V409, P53, DOI 10.1038/35051023; Martin T, 2005, ZOOL J LINN SOC-LOND, V145, P219, DOI 10.1111/j.1096-3642.2005.00187.x; Martin T, 2005, J VERTEBR PALEONTOL, V25, P414, DOI 10.1671/0272-4634(2005)025[0414:MADOAP]2.0.CO;2; Martin T, 2004, J VERTEBR PALEONTOL, V24, P195, DOI 10.1671/15; Martin Thomas, 2000, P91; O'Leary MA, 1998, ADV VERT PALEOBIOL, P133; Pfretzschner HU, 2005, ACTA PALAEONTOL POL, V50, P799; [任东 Ren Dong], 2002, [地质通报, Geological Bulletin of China], V21, P584; Rybczynski N, 2005, J VERTEBR PALEONTOL, V25, p107A; Shen Yan-bin, 2003, Journal of Stratigraphy, V27, P311; Sigogneau-Russell D, 2003, ACTA PALAEONTOL POL, V48, P357; Sigogneau-Russell D, 1998, CR ACAD SCI II A, V327, P571, DOI 10.1016/S1251-8050(99)80040-8; Thewissen JGM, 1997, PALEOBIOLOGY, V23, P482, DOI 10.1017/S0094837300019850; Wang XL, 2002, CHINESE SCI BULL, V47, P226, DOI 10.1360/02tb9054; Xu X, 2005, NATURWISSENSCHAFTEN, V92, P173, DOI 10.1007/s00114-004-0604-y	40	217	248	0	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	2006	311	5764					1123	1127		10.1126/science.1123026	http://dx.doi.org/10.1126/science.1123026			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017IU	16497926				2022-12-28	WOS:000235688100040
J	Oppenheim, J				Oppenheim, J			Implementing a quantum computation by free failing	SCIENCE			English	Editorial Material								Quantum computers may become more powerful than conventional computers, especially at solving hard problems. Finding efficient ways to tackle such problems turns out to resemble understanding the path taken by a falling object.	Univ Cambridge, Dept Appl Math & Theoret Phys, Cambridge CB3 0WA, England	University of Cambridge	Oppenheim, J (corresponding author), Univ Cambridge, Dept Appl Math & Theoret Phys, Cambridge CB3 0WA, England.	j.oppenheim@damtp.cam.ac.uk	Oppenheim, Jonathan/E-1518-2017	Oppenheim, Jonathan/0000-0002-8993-412X				Grover L. K., 1996, Proceedings of the Twenty-Eighth Annual ACM Symposium on the Theory of Computing, P212, DOI 10.1145/237814.237866; Khaneja N, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.032301; NIELSEN M, IN PRESS QUANTUM INF; Nielsen MA, 2006, SCIENCE, V311, P1133, DOI 10.1126/science.1121541; Shor PW, 1997, SIAM J COMPUT, V26, P1484, DOI [10.1137/S0097539795293172, 10.1137/S0036144598347011]	5	0	0	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	2006	311	5764					1106	1107		10.1126/science.1124295	http://dx.doi.org/10.1126/science.1124295			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017IU	16497920				2022-12-28	WOS:000235688100033
J	Felson, DT				Felson, DT			Osteoarthritis of the knee	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RANDOMIZED CONTROLLED-TRIAL; OLDER-ADULTS; DOUBLE-BLIND; PAIN; ARTHRITIS; METAANALYSIS; ASSOCIATION; GLUCOSAMINE; MANAGEMENT	A 66-year-old woman who is overweight reports bilateral knee pain of gradual onset during the past several months that increasingly has limited her activities. Last week, when walking down the stairs, she nearly fell when her knee gave way. She does not recall having injured her knee, and she has no morning stiffness and no pain in other joints. She has tried taking up to eight extra-strength ( 500 mg each) acetaminophen tablets daily without success and has never had ulcers or stomach bleeding. How should the patient be evaluated and treated?	Boston Univ, Sch Med, Boston, MA 02118 USA	Boston University	Felson, DT (corresponding author), Boston Univ, Sch Med, A203,80 E Concord St, Boston, MA 02118 USA.	jendez@bu.edu		Felson, David/0000-0002-2668-2447	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR047785] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR47785] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905; Baker KR, 2001, J RHEUMATOL, V28, P1655; BELLAMY N, 2005, COCHRANE DB SYST REV, V2; Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006; Bhattacharyya T, 2003, J BONE JOINT SURG AM, V85A, P4, DOI 10.2106/00004623-200301000-00002; Cibere J, 2004, ARTHRIT RHEUM-ARTHR, V51, P738, DOI 10.1002/art.20697; Cibere J, 2004, ARTHRITIS RHEUM, V50, P458, DOI 10.1002/art.20025; Clegg DO, 2006, NEW ENGL J MED, V354, P795, DOI 10.1056/NEJMoa052771; Creamer P, 1997, ANN RHEUM DIS, V56, P634, DOI 10.1136/ard.56.11.634; CUSHNAGHAN J, 1994, BRIT MED J, V308, P753, DOI 10.1136/bmj.308.6931.753; DEAL CL, 1991, CLIN THER, V13, P383; Eccles M, 1998, BRIT MED J, V317, P526; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; FELSON DT, 1989, J RHEUMATOL, V16, P1241; Felson DT, 2001, ANN INTERN MED, V134, P541, DOI 10.7326/0003-4819-134-7-200104030-00007; Felson DT, 2003, ANN INTERN MED, V139, P330, DOI 10.7326/0003-4819-139-5_Part_1-200309020-00008; Felson DT, 2001, ARTHRITIS RHEUM-US, V44, P1477, DOI 10.1002/1529-0131(200107)44:7<1477::AID-ART267>3.0.CO;2-O; FELSON DT, 2003, OSTEOARTHRITIS, P9; FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288; FRIES JF, 1991, ARTHRITIS RHEUM, V34, P1353; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; GUCCIONE AA, 1994, AM J PUBLIC HEALTH, V84, P351, DOI 10.2105/AJPH.84.3.351; Hannan MT, 2000, J RHEUMATOL, V27, P1513; Hill CL, 2005, ARTHRITIS RHEUM, V52, P794, DOI 10.1002/art.20943; Hill CL, 2001, J RHEUMATOL, V28, P1330; Hill CL, 2003, ARTHRITIS RHEUM, V48, P2836, DOI 10.1002/art.11254; Hinman RS, 2003, BRIT MED J, V327, P135, DOI 10.1136/bmj.327.7407.135; HURLEY MV, 1993, BRIT J RHEUMATOL, V32, P127; Kerrigan DC, 2002, ARCH PHYS MED REHAB, V83, P889, DOI 10.1053/apmr.2002.33225; Kirkley A, 1999, J BONE JOINT SURG AM, V81A, P539, DOI 10.2106/00004623-199904000-00012; Lo GH, 2003, JAMA-J AM MED ASSOC, V290, P3115, DOI 10.1001/jama.290.23.3115; Maillefert JF, 2001, OSTEOARTHR CARTILAGE, V9, P738, DOI 10.1053/joca.2001.0470; McAlindon T, 2004, AM J MED, V117, P643, DOI 10.1016/j.amjmed.2004.06.023; MCALINDON TE, 1992, ANN RHEUM DIS, V51, P844, DOI 10.1136/ard.51.7.844; McAlindon TE, 2000, JAMA-J AM MED ASSOC, V283, P1469, DOI 10.1001/jama.283.11.1469; Messier SP, 2004, ARTHRITIS RHEUM-US, V50, P1501, DOI 10.1002/art.20256; Moseley JB, 2002, NEW ENGL J MED, V347, P81, DOI 10.1056/NEJMoa013259; O'Reilly SC, 1998, ANN RHEUM DIS, V57, P588, DOI 10.1136/ard.57.10.588; Peat G, 2001, ANN RHEUM DIS, V60, P91, DOI 10.1136/ard.60.2.91; Pelletier JP, 2001, ARTHRITIS RHEUM-US, V44, P1237, DOI 10.1002/1529-0131(200106)44:6<1237::AID-ART214>3.0.CO;2-F; Pendleton A, 2000, ANN RHEUM DIS, V59, P936, DOI 10.1136/ard.59.12.936; Pincus T, 2001, ARTHRITIS RHEUM-US, V44, P1587, DOI 10.1002/1529-0131(200107)44:7<1587::AID-ART282>3.0.CO;2-X; Sharma L, 2003, ANN INTERN MED, V138, P613, DOI 10.7326/0003-4819-138-8-200304150-00006; Sharma L, 2001, JAMA-J AM MED ASSOC, V286, P792; Solomon DH, 2001, JAMA-J AM MED ASSOC, V286, P1610, DOI 10.1001/jama.286.13.1610; Wolfe MM, 1999, NEW ENGL J MED, V341, P548; Yeomans ND, 1998, NEW ENGL J MED, V338, P719, DOI 10.1056/NEJM199803123381104	49	506	554	2	51	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 23	2006	354	8					841	848		10.1056/NEJMcp051726	http://dx.doi.org/10.1056/NEJMcp051726			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014CL	16495396				2022-12-28	WOS:000235456200008
J	Kainuma, R; Imano, Y; Ito, W; Sutou, Y; Morito, H; Okamoto, S; Kitakami, O; Oikawa, K; Fujita, A; Kanomata, T; Ishida, K				Kainuma, R; Imano, Y; Ito, W; Sutou, Y; Morito, H; Okamoto, S; Kitakami, O; Oikawa, K; Fujita, A; Kanomata, T; Ishida, K			Magnetic-field-induced shape recovery by reverse phase transformation	NATURE			English	Article							INDUCED STRAIN; MARTENSITIC-TRANSFORMATION; NI-GA; MAGNETOSTRICTION	Large magnetic-field-induced strains(1) have been observed in Heusler alloys with a body-centred cubic ordered structure and have been explained by the rearrangement of martensite structural variants due to an external magnetic field(1-3). These materials have attracted considerable attention as potential magnetic actuator materials. Here we report the magnetic-field-induced shape recovery of a compressively deformed NiCoMnIn alloy. Stresses of over 100 MPa are generated in the material on the application of a magnetic field of 70 kOe; such stress levels are approximately 50 times larger than that generated in a previous ferromagnetic shape-memory alloy(4). We observed 3 per cent deformation and almost full recovery of the original shape of the alloy. We attribute this deformation behaviour to a reverse transformation from the antiferromagnetic (or paramagnetic) martensitic to the ferromagnetic parent phase at 298 K in the Ni45Co5Mn36.7In13.3 single crystal.	Tohoku Univ, Grad Sch Engn, Dept Mat Sci, Sendai, Miyagi 9808579, Japan; Tohoku Univ, Biomed Engn Res Org, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Sendai, Miyagi 9808577, Japan; Tohoku Gakuin Univ, Fac Engn, Tagajo, Miyagi 9808537, Japan	Tohoku University; Tohoku University; Tohoku University; Tohoku Gakuin University	Kainuma, R (corresponding author), Tohoku Univ, Grad Sch Engn, Dept Mat Sci, 6-6-02 Aoba Yama, Sendai, Miyagi 9808579, Japan.	kainuma@material.tohoku.ac.jp	Oikawa, Katsunari/C-6660-2009; Fujita, Asaya/M-4030-2018; Kitakami, Osamu/AAC-2942-2019; Sutou, Yuji/GNM-7287-2022; Morito, Haruhiko/A-9372-2016; Kainuma, Ryosuke/I-6482-2013	Oikawa, Katsunari/0000-0002-5269-8426; Fujita, Asaya/0000-0001-9011-9125; Kitakami, Osamu/0000-0003-3547-9253; Sutou, Yuji/0000-0002-3067-2727				Cherechukin AA, 2001, PHYS LETT A, V291, P175, DOI 10.1016/S0375-9601(01)00688-0; Fallot M., 1939, REV SCI, V77, P498; Fujita A, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.104416; James RD, 1998, PHILOS MAG A, V77, P1273, DOI 10.1080/01418619808214252; Kainuma R, 2000, MATER T JIM, V41, P943, DOI 10.2320/matertrans1989.41.943; Kakeshita T, 2000, APPL PHYS LETT, V77, P1502, DOI 10.1063/1.1290694; KOUVEL JS, 1962, J APPL PHYS, V33, P1343, DOI 10.1063/1.1728721; Morito H, 2002, APPL PHYS LETT, V81, P1657, DOI 10.1063/1.1503851; Murray SJ, 2000, APPL PHYS LETT, V77, P886, DOI 10.1063/1.1306635; O'Handley RC, 1998, J APPL PHYS, V83, P3263, DOI 10.1063/1.367094; Oikawa K, 2002, MATER TRANS, V43, P2360, DOI 10.2320/matertrans.43.2360; Oikawa K, 2001, MATER TRANS, V42, P2472, DOI 10.2320/matertrans.42.2472; Oikawa K, 2001, APPL PHYS LETT, V79, P3290, DOI 10.1063/1.1418259; Oikawa K, 2002, APPL PHYS LETT, V81, P5201, DOI 10.1063/1.1532105; Pecharsky VK, 1997, PHYS REV LETT, V78, P4494, DOI 10.1103/PhysRevLett.78.4494; Sakamoto T, 2003, J APPL PHYS, V93, P8647, DOI 10.1063/1.1540132; Sozinov A, 2002, APPL PHYS LETT, V80, P1746, DOI 10.1063/1.1458075; Sutou Y, 2004, APPL PHYS LETT, V85, P4358, DOI 10.1063/1.1808879; Sutou Y, 2003, PROC SPIE, V5053, P159, DOI 10.1117/12.484349; Ullakko K, 1996, APPL PHYS LETT, V69, P1966, DOI 10.1063/1.117637; Wada H, 2001, APPL PHYS LETT, V79, P3302, DOI 10.1063/1.1419048; Wada T, 2003, MAT SCI ENG A-STRUCT, V361, P75, DOI 10.1016/S0921-5093(03)00444-1; WOLLANTS P, 1979, Z METALLKD, V70, P113; Wuttig M, 2001, SCRIPTA MATER, V44, P2393, DOI 10.1016/S1359-6462(01)00939-3	24	1484	1520	18	719	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 23	2006	439	7079					957	960		10.1038/nature04493	http://dx.doi.org/10.1038/nature04493			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014NE	16495995				2022-12-28	WOS:000235486100043
J	Nourbakhsh, I; Sargent, R; Wright, A; Cramer, K; Mcclendon, B; Jones, M				Nourbakhsh, I; Sargent, R; Wright, A; Cramer, K; Mcclendon, B; Jones, M			Mapping disaster zones	NATURE			English	Editorial Material									Carnegie Mellon Univ, Pittsburgh, PA 15213 USA; NASA Ames, Moffett Field, CA USA	Carnegie Mellon University; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Nourbakhsh, I (corresponding author), Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.								0	61	66	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 16	2006	439	7078					787	788		10.1038/439787a	http://dx.doi.org/10.1038/439787a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012JA	16482134				2022-12-28	WOS:000235333600024
J	Wactawski-Wende, J; Kotchen, JM; Anderson, GL; Assaf, AR; Brunner, RL; O'Sullivan, MJ; Margolis, KL; Ockene, JK; Phillips, L; Pottern, L; Prentice, RL; Robbins, J; Rohan, TE; Sarto, GE; Sharma, S; Stefanick, ML; Van Horn, L; Wallace, RB; Whitlock, E; Bassford, T; Beresford, SAA; Black, HR; Bonds, DE; Brzyski, RG; Caan, B; Chlebowski, RT; Cochrane, B; Garland, C; Gass, M; Hays, J; Heiss, G; Hendrix, SL; Howard, BV; Hsia, J; Hubbell, FA; Jackson, RD; Johnson, KC; Judd, H; Kooperberg, CL; Kuller, LH; LaCroix, AZ; Lane, DS; Langer, RD; Lasser, NL; Lewis, CE; Limacher, MC; Manson, JE				Wactawski-Wende, J; Kotchen, JM; Anderson, GL; Assaf, AR; Brunner, RL; O'Sullivan, MJ; Margolis, KL; Ockene, JK; Phillips, L; Pottern, L; Prentice, RL; Robbins, J; Rohan, TE; Sarto, GE; Sharma, S; Stefanick, ML; Van Horn, L; Wallace, RB; Whitlock, E; Bassford, T; Beresford, SAA; Black, HR; Bonds, DE; Brzyski, RG; Caan, B; Chlebowski, RT; Cochrane, B; Garland, C; Gass, M; Hays, J; Heiss, G; Hendrix, SL; Howard, BV; Hsia, J; Hubbell, FA; Jackson, RD; Johnson, KC; Judd, H; Kooperberg, CL; Kuller, LH; LaCroix, AZ; Lane, DS; Langer, RD; Lasser, NL; Lewis, CE; Limacher, MC; Manson, JE		Womens Hlth Initative Investigat	Calcium plus vitamin D supplementation and the risk of colorectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BASE-LINE CHARACTERISTICS; PROSPECTIVE COHORT; DIETARY CALCIUM; DAIRY-PRODUCTS; COLON-CANCER; TRIAL; WOMEN; PREVENTION; PARTICIPANTS; ADENOMA	BACKGROUND: Higher intake of calcium and vitamin D has been associated with a reduced risk of colorectal cancer in epidemiologic studies and polyp recurrence in polyp-prevention trials. However, randomized-trial evidence that calcium with vitamin D supplementation is beneficial in the primary prevention of colorectal cancer is lacking. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 36,282 postmenopausal women from 40 Women's Health Initiative centers: 18,176 women received 500 mg of calcium carbonate with 200 IU of vitamin D-3 twice daily (1000 mg of elemental calcium and 400 IU of vitamin D-3) and 18,106 received a matching placebo for an average of 7.0 years. The incidence of pathologically confirmed colorectal cancer was the designated secondary outcome. Baseline levels of serum 25-hydroxyvitamin D were assessed in a nested case-control study. RESULTS: The incidence of invasive colorectal cancer did not differ significantly between women assigned to calcium plus vitamin D supplementation and those assigned to placebo (168 and 154 cases; hazard ratio, 1.08; 95 percent confidence interval, 0.86 to 1.34; P=0.51), and the tumor characteristics were similar in the two groups. The frequency of colorectal-cancer screening and abdominal symptoms was similar in the two groups. There were no significant treatment interactions with baseline characteristics. CONCLUSIONS: Daily supplementation of calcium with vitamin D for seven years had no effect on the incidence of colorectal cancer among postmenopausal women. The long latency associated with the development of colorectal cancer, along with the seven-year duration of the trial, may have contributed to this null finding. Ongoing follow-up will assess the longer-term effect of this intervention.	SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14214 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Brown Univ, Mem Hosp Rhode Isl, Pawtucket, RI 02860 USA; Pfizer, New London, CT USA; Univ Nevada, Sch Med, Reno, NV 89557 USA; Univ Miami, Miami, FL 33152 USA; Univ Minnesota, Minneapolis, MN USA; Univ Massachusetts, Fallon Clin, Worcester, MA 01605 USA; Emory Univ, Atlanta, GA 30322 USA; NHLBI, Bethesda, MD 20892 USA; Univ Calif Davis, Sacramento, CA 95817 USA; Albert Einstein Coll Med, Bronx, NY 10467 USA; Univ Wisconsin, Madison, WI USA; Univ Hawaii, Honolulu, HI 96822 USA; Stanford Ctr Res Dis Prevent, Stanford, CA USA; Northwestern Univ, Chicago, IL 60611 USA; Univ Iowa, Iowa City, IA USA; Kaiser Permanente Ctr Hlth Res, Portland, OR USA; Univ Arizona, Tucson, AZ USA; Univ Washington, Seattle, WA 98195 USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA; Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; Kaiser Permanente, Div Res, Oakland, CA USA; Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA; Univ Washington, Sch Nursing, Seattle, WA 98195 USA; Univ Calif San Diego, La Jolla, CA 92093 USA; Univ Cincinnati, Cincinnati, OH USA; Baylor Coll Med, Houston, TX 77030 USA; Univ N Carolina, Chapel Hill, NC USA; Wayne State Univ, Sch Med, Detroit, MI USA; Hutzel Hosp, Detroit, MI 48201 USA; Howard Univ, MedStar Res Inst, Washington, DC 20059 USA; George Washington Univ, Med Ctr, Washington, DC 20037 USA; Univ Calif Irvine, Irvine, CA USA; Ohio State Univ, Columbus, OH 43210 USA; Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; Univ Calif Los Angeles, Los Angeles, CA USA; Univ Pittsburgh, Pittsburgh, PA USA; SUNY Stony Brook, Stony Brook, NY 11794 USA; Univ Med & Dent New Jersey, Newark, NJ 07103 USA; Univ Alabama, Birmingham, AL USA; Univ Florida, Gainesville, FL USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Medical College of Wisconsin; Fred Hutchinson Cancer Center; Brown University; Pfizer; Nevada System of Higher Education (NSHE); University of Nevada Reno; University of Miami; University of Minnesota System; University of Minnesota Twin Cities; University of Massachusetts System; University of Massachusetts Worcester; Emory University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of California System; University of California Davis; Yeshiva University; Albert Einstein College of Medicine; University of Wisconsin System; University of Wisconsin Madison; University of Hawaii System; Stanford University; Northwestern University; University of Iowa; Kaiser Permanente; University of Arizona; University of Washington; University of Washington Seattle; Rush University; Wake Forest University; University of Texas System; University of Texas Health San Antonio; Kaiser Permanente; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute; University of Washington; University of Washington Seattle; University of California System; University of California San Diego; University System of Ohio; University of Cincinnati; Baylor College of Medicine; University of North Carolina; University of North Carolina Chapel Hill; Wayne State University; Howard University; George Washington University; University of California System; University of California Irvine; University System of Ohio; Ohio State University; University of Tennessee System; University of Tennessee Health Science Center; University of California System; University of California Los Angeles; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Alabama System; University of Alabama Birmingham; State University System of Florida; University of Florida; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Wactawski-Wende, J (corresponding author), SUNY Buffalo, Dept Social & Prevent Med, 270 Farber Hall, Buffalo, NY 14214 USA.	jww@buffalo.edu	Wactawski-Wende, Jean/AGH-5457-2022	Wactawski-Wende, Jean/0000-0003-3096-9595; Margolis, Karen/0000-0003-1862-7402; Hays-Grudo, Jennifer/0000-0002-8107-1243; Caan, Bette/0000-0002-5803-310X				Anderson GL, 2003, ANN EPIDEMIOL, V13, pS5, DOI 10.1016/S1047-2797(03)00043-7; Baron JA, 1999, NEW ENGL J MED, V340, P101, DOI 10.1056/NEJM199901143400204; BergsmaKadijk JA, 1996, EPIDEMIOLOGY, V7, P590, DOI 10.1097/00001648-199611000-00005; BIALOSTOSKY K, 2002, VITAL HLTH STAT, V11; Bonithon-Kopp C, 2000, LANCET, V356, P1300, DOI 10.1016/S0140-6736(00)02813-0; Cho E, 2004, JNCI-J NATL CANCER I, V96, P1015, DOI 10.1093/jnci/djh185; CHO E, 2004, JNCI-J NATL CANCER I, V96, P1724; COX DR, 1972, J R STAT SOC B, V34, P187; Curb JD, 2003, ANN EPIDEMIOL, V13, pS122, DOI 10.1016/S1047-2797(03)00048-6; Ervin R. B., 2004, ADV DATA VITAL HLTH; Flood A, 2005, CANCER EPIDEM BIOMAR, V14, P126; GARLAND CF, 1980, INT J EPIDEMIOL, V9, P227, DOI 10.1093/ije/9.3.227; Gorham ED, 2005, J STEROID BIOCHEM, V97, P179, DOI 10.1016/j.jsbmb.2005.06.018; Grau MV, 2003, J NATL CANCER I, V95, P1765, DOI 10.1093/jnci/djg110; Hays J, 2003, ANN EPIDEMIOL, V13, pS18, DOI 10.1016/S1047-2797(03)00042-5; Institute of Medicine, 1997, DIETARY REFERENCE IN, P448; Jackson RD, 2006, NEW ENGL J MED, V354, P669, DOI 10.1056/NEJMoa055218; Jackson RD, 2003, ANN EPIDEMIOL, V13, pS98, DOI 10.1016/S1047-2797(03)00046-2; Janne PA, 2000, NEW ENGL J MED, V342, P1960, DOI 10.1056/NEJM200006293422606; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kesse E, 2005, INT J CANCER, V117, P137, DOI 10.1002/ijc.21148; Majumdar SR, 1999, AM J GASTROENTEROL, V94, P3039, DOI 10.1111/j.1572-0241.1999.01454.x; Marcus PM, 1998, INT J EPIDEMIOL, V27, P788, DOI 10.1093/ije/27.5.788; McCullough ML, 2003, CANCER CAUSE CONTROL, V14, P1, DOI 10.1023/A:1022591007673; Mor V, 1990, J Community Health, V15, P253, DOI 10.1007/BF01350291; *NAT CANC I, SEER INC STAT; Peters U, 2004, AM J CLIN NUTR, V80, P1358, DOI 10.1093/ajcn/80.5.1358; Prentice RL, 2005, AM J EPIDEMIOL, V162, P404, DOI 10.1093/aje/kwi223; Ries LAG, 2003, SEER CANC STAT REV 1; Ritenbaugh C, 2003, ANN EPIDEMIOL, V13, pS87, DOI 10.1016/S1047-2797(03)00044-9; Stefanick ML, 2003, ANN EPIDEMIOL, V13, pS78, DOI 10.1016/S1047-2797(03)00045-0; Terry P, 2002, NUTR CANCER, V43, P39, DOI 10.1207/S15327914NC431_4; Wu K, 2002, JNCI-J NATL CANCER I, V94, P437, DOI 10.1093/jnci/94.6.437	33	742	769	1	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 16	2006	354	7					684	696		10.1056/NEJMoa055222	http://dx.doi.org/10.1056/NEJMoa055222			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	012CP	16481636	Green Submitted			2022-12-28	WOS:000235316100005
J	Hoelscher, MA; Garg, S; Bangari, DS; Belser, JA; Lu, XH; Stephenson, I; Bright, RA; Katz, JM; Mittal, SK; Sambhara, S				Hoelscher, MA; Garg, S; Bangari, DS; Belser, JA; Lu, XH; Stephenson, I; Bright, RA; Katz, JM; Mittal, SK; Sambhara, S			Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice	LANCET			English	Article							AVIAN INFLUENZA; MF59-ADJUVANTED INFLUENZA; RECOMBINANT ADENOVIRUS; REVERSE GENETICS; IMMUNOGENICITY; SAFETY; VIRUS; PROTECTION; CELLS; RESPONSES	Introduction Avian H5N1 influenza viruses currently circulating in southeast Asia could potentially cause the next pandemic. However, currently licensed human vaccines are subtype-specific and do not protect against these H5N1 viruses. We aimed to develop art influenza vaccine and assessed its immunogenicity and efficacy to confer protection in BALB/c mice. Methods We developed an egg-independent strategy to combat the avian influenza virus, because the virus is highly lethal to chickens and the maintenance of a constant supply of embryonated eggs would be difficult in a pandemic. We used a replication-incompetent, human adenoviral-vector-based, haemagglutinin subtype 5 influenza vaccine (HAd-H5HA), which induces both humoral and cell-mediated immune responses against avian H5N1 influenza viruses isolated from people. Findings Immunisation of mice with HAd-H5HA provided effective protection from H5N1 disease, death, and primary viral replication (p<0.0001) against antigenically distinct strains of H5N1 influenza viruses. Unlike the recombinant H5HA vaccine, which is based on a traditional subunit vaccine approach, HAd-H5HA vaccine induced a three-fold to eight-fold increase in HA-518-epitope-specific interferon-gamma-secreting CD8 T cells (p=0.01). Interpretation Our findings highlight the potential of an Ad-vector-based delivery system, which is both egg-independent and adjuvant-independent and offers stockpiling options for the development of a pandemic influenza vaccine.	Ctr Dis Control & Prevent, Influenza Branch, Div Viral & Rickettsial Dis, Atlanta, GA 30333 USA; Purdue Univ, Dept Vet Pathobiol, W Lafayette, IN 47907 USA	Centers for Disease Control & Prevention - USA; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Sambhara, S (corresponding author), Ctr Dis Control & Prevent, Influenza Branch, Div Viral & Rickettsial Dis, Atlanta, GA 30333 USA.	ssambhara@cdc.gov	Sambhara, Suryaprakash/AAC-4428-2021		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059374] Funding Source: NIH RePORTER; NIAID NIH HHS [AI059374, R01 AI059374-03, R01 AI059374] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aubin JT, 2005, EMERG INFECT DIS, V11, P1515; Bangari DS, 2006, VACCINE, V24, P849, DOI 10.1016/j.vaccine.2005.08.101; Bangari DS, 2005, BIOCHEM BIOPH RES CO, V327, P960, DOI 10.1016/j.bbrc.2004.12.099; Bender B S, 1992, Semin Respir Infect, V7, P38; BUTLER D, BIRD FLU VACCINE NOT; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P547; Chen WS, 2000, IMMUNITY, V12, P83, DOI 10.1016/S1074-7613(00)80161-2; deJong JC, 1997, NATURE, V389, P554, DOI 10.1038/39218; Epstein SL, 2005, VACCINE, V23, P5404, DOI 10.1016/j.vaccine.2005.04.047; Fries LF, 2001, INFECT IMMUN, V69, P4545, DOI 10.1128/IAI.69.7.4545-4553.2001; Gao P, 1999, J VIROL, V73, P3184, DOI 10.1128/JVI.73.4.3184-3189.1999; Hien TT, 2004, NEW ENGL J MED, V351, P2363, DOI 10.1056/NEJMp048267; HOELSCHER M, 2001, P RES C ORH NOV 2 4, P36; Hoffmann E, 2005, P NATL ACAD SCI USA, V102, P12915, DOI 10.1073/pnas.0506416102; Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859; Lipatov AS, 2005, J INFECT DIS, V191, P1216, DOI 10.1086/428951; Lu XH, 1999, J VIROL, V73, P5903, DOI 10.1128/JVI.73.7.5903-5911.1999; Morelli AE, 2000, J VIROL, V74, P9617, DOI 10.1128/JVI.74.20.9617-9628.2000; Nanda A, 2005, J VIROL, V79, P14161, DOI 10.1128/JVI.79.22.14161-14168.2005; Ng P, 1999, HUM GENE THER, V10, P2667, DOI 10.1089/10430349950016708; Nicholson KG, 2001, LANCET, V357, P1937, DOI 10.1016/S0140-6736(00)05066-2; Noblitt LW, 2004, CANCER GENE THER, V11, P757, DOI 10.1038/sj.cgt.7700761; Peiris JSM, 2004, LANCET, V363, P617, DOI 10.1016/S0140-6736(04)15595-5; Rowe T, 1999, J CLIN MICROBIOL, V37, P937, DOI 10.1128/JCM.37.4.937-943.1999; Sailaja G, 2002, GENE THER, V9, P1722, DOI 10.1038/sj.gt.3301858; Sambhara S, 1998, J INFECT DIS, V177, P1266, DOI 10.1086/515285; Sambhara S, 2001, CELL IMMUNOL, V211, P143, DOI 10.1006/cimm.2001.1835; Stephenson I, 2004, VIRUS RES, V103, P91, DOI 10.1016/j.virusres.2004.02.019; Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393; Tian GB, 2005, VIROLOGY, V341, P153, DOI 10.1016/j.virol.2005.07.011; Treanor JJ, 2001, VACCINE, V19, P1732, DOI 10.1016/S0264-410X(00)00395-9; Ungchusak K, 2005, NEW ENGL J MED, V352, P333, DOI 10.1056/NEJMoa044021; Van Kampen KR, 2005, VACCINE, V23, P1029, DOI 10.1016/j.vaccine.2004.07.043; Webby RJ, 2004, LANCET, V363, P1099, DOI 10.1016/S0140-6736(04)15892-3; *WHO, 2004, WKLY EPIDEMIOL REC, V79, P65; *WHO, AV INFL A H5N1 UPD 2; World Health Organization, CUM NUMB CONF HUM CA; YAP KL, 1978, NATURE, V273, P238, DOI 10.1038/273238a0	38	157	185	1	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 11	2006	367	9509					475	481		10.1016/S0140-6736(06)68076-8	http://dx.doi.org/10.1016/S0140-6736(06)68076-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013FF	16473124	Green Accepted			2022-12-28	WOS:000235394500028
J	Jamison, KR				Jamison, KR			The many stigmas of mental illness	LANCET			English	Editorial Material									Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21287 USA	Johns Hopkins University	Jamison, KR (corresponding author), Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21287 USA.							Jamison K.R, 2015, UNQUIET MIND MEMOIR	1	39	42	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 11	2006	367	9509					533	534		10.1016/S0140-6736(06)68187-7	http://dx.doi.org/10.1016/S0140-6736(06)68187-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	013FF	16473132				2022-12-28	WOS:000235394500036
J	Prymula, R; Peeters, P; Chrobok, V; Kriz, P; Novakova, E; Kaliskova, E; Kohl, I; Lommel, P; Poolman, J; Prieels, JP; Schuerman, L				Prymula, R; Peeters, P; Chrobok, V; Kriz, P; Novakova, E; Kaliskova, E; Kohl, I; Lommel, P; Poolman, J; Prieels, JP; Schuerman, L			Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study	LANCET			English	Article							VACCINE	Background Acute otitis media is one of the most commonly-diagnosed childhood infections. This study assessed the efficacy of a novel vaccine that contained polysaccharides from 11 different Streptococcus pneumoniae serotypes each conjugated to Haemophilus influenzae-derived protein D in prevention of acute otitis media. Methods 4968 infants were randomly assigned to receive either pneumococcal protein D conjugate or hepatitis A vaccine at the ages of 3, 4, 5, and 12-15 months and were followed-up until the end of the second year of life. Middle-ear fluid was obtained for bacteriological culture and serotyping in children who presented with abnormal tympanic membrane or presence of middle-ear effusion, plus two predefined clinical symptoms. The primary endpoint was protective efficacy against the first episode of acute otitis media caused by vaccine pneumococcal serotypes. Analysis was per protocol. Findings From 2 weeks after the third dose to 24-27 months of age, 333 clinical episodes of acute otitis media were recorded in the protein D conjugate group (n=2455) and 499 in the control group (n=2452), giving a significant (33.6% [95% CI 20.8-44.3]) reduction in the overall incidence of acute otitis media. Vaccine efficacy was shown for episodes of acute otitis media caused by pneumococcal vaccine serotypes (52.6% [35.0-65.5] for the first episode and 57.6% [41.4-69.3] for any episode). Efficacy was also shown against episodes of acute otitis media caused by non-typable H influenzae (35.3% [1.8-57.4]). The vaccine reduced frequency of infection from vaccine-related cross-reactive pneumococcal serotypes by 65.5%, but did not significantly change the number of episodes caused by other non-vaccine serotypes. Interpretation These results confirm that using the H influenzae-derived protein D as a carrier protein for pneumococcal polysaccharides not only allowed protection against pneumococcal otitis, but also against acute otitis media due to non-typable H influenzae. Whether this approach would also allow improved protection against lower respiratory tract infections warrants further investigation.	Univ Def, Fac Mil Hlth Sci, Dept Epidemiol, Hradec Kralove, Czech Republic; GlaxoSmithKline Biol, Rixensart, Belgium; Dept Otorhinolaryngol Head & Neck Surg, Pardubice, Czech Republic; Natl Inst Publ Hlth, Collaborating Ctr Streptococci, Prague, Czech Republic; Comenius Univ, Jessenius Med Fac, Inst Microbiol & Immunol, Martin, Slovakia; GlaxoSmithKline, Prague, Czech Republic	University of Defence - Czech Republic; GlaxoSmithKline; National Institute of Public Health (SZU) - Czech Republic; Comenius University Bratislava; GlaxoSmithKline	Prymula, R (corresponding author), Univ Def, Fac Mil Hlth Sci, Dept Epidemiol, Hradec Kralove, Czech Republic.	prymula@pmfhk.cz	Novakova, Elena/X-7553-2018; Krizova, Pavla/M-6120-2015; Prymula, Roman/AEG-7401-2022; Chrobok, Viktor/J-9626-2017	Novakova, Elena/0000-0001-5939-3820; Prymula, Roman/0000-0003-1567-2259; Chrobok, Viktor/0000-0001-7537-139X				ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; AUSTRIAN R, 1976, MT SINAI J MED, V43, P699; BERMAN S, 1995, PEDIATRICS, V96, P126; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; Block SL, 2004, PEDIATR INFECT DIS J, V23, P829, DOI 10.1097/01.inf.0000136868.91756.80; Blumer JL, 1998, PEDIATR INFECT DIS J, V17, P1070, DOI 10.1097/00006454-199811000-00037; Casey JR, 2004, PEDIATR INFECT DIS J, V23, P824, DOI 10.1097/01.inf.0000136871.51792.19; Concepcion NF, 2001, CLIN DIAGN LAB IMMUN, V8, P266, DOI 10.1128/CDLI.8.2.266-272.2001; Cripps AW, 2005, VACCINE, V23, P2304, DOI 10.1016/j.vaccine.2005.01.023; Eskola J, 2001, NEW ENGL J MED, V344, P403, DOI 10.1056/NEJM200102083440602; Faden H, 1998, PEDIATR INFECT DIS J, V17, P1105, DOI 10.1097/00006454-199812000-00002; Foxwell AR, 1998, MICROBIOL MOL BIOL R, V62, P294, DOI 10.1128/MMBR.62.2.294-308.1998; HENCKAERTS I, 2004, 4 INT S PNEUUM PNEUM; Jokinen JT, 2004, J INFECT DIS, V190, P545, DOI 10.1086/422531; Kilpi T, 2003, CLIN INFECT DIS, V37, P1155, DOI 10.1086/378744; Klein JO, 2000, VACCINE, V19, pS2, DOI 10.1016/S0264-410X(00)00271-1; Leibovitz E, 2004, PEDIATR INFECT DIS J, V23, P1142, DOI 10.1097/01.inf.0000148233.57296.90; McEllistrem MC, 2003, J INFECT DIS, V188, P1679, DOI 10.1086/379665; Murray P.R., 1995, MANUAL CLIN MICROBIO; Nurkka A, 2004, PEDIATR INFECT DIS J, V23, P1008, DOI 10.1097/01.inf.0000143640.03214.18; O'Brien KL, 2004, AM J EPIDEMIOL, V159, P634, DOI 10.1093/aje/kwh082; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PALMU AAI, 2001, 19 ANN M EUR SOC PAE; Pelton SI, 2004, PEDIATR INFECT DIS J, V23, P839, DOI 10.1097/01.inf.0000138453.32886.a6; Poolman JT, 2000, VACCINE, V19, pS108, DOI 10.1016/S0264-410X(00)00288-7; PRYMULA R, 2001, 19 ANN M EUR SOC PAE; QUATAERT SA, 1995, CLIN DIAGN LAB IMMUN, V2, P590, DOI 10.1128/CDLI.2.5.590-597.1995; SCHAPPERT SM, 1992, DHHS PUBL; Straetemans M, 2003, PEDIATR INFECT DIS J, V22, P515, DOI 10.1097/00006454-200306000-00007; Whitney CG, 2002, PEDIATR INFECT DIS J, V21, P961, DOI 10.1097/00006454-200210000-00016; *WHO EXP COMM BIO, 2003, PNEUUM CONJ VACC REC	32	472	530	1	44	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 4	2006	367	9512					740	748		10.1016/S0140-6736(06)68304-9	http://dx.doi.org/10.1016/S0140-6736(06)68304-9			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	020JX	16517274				2022-12-28	WOS:000235906000028
J	Sammonds, PR				Sammonds, PR			Creep and flow on the icy moons of the outer planets	SCIENCE			English	Editorial Material							RHEOLOGY		UCL, Dept Earth Sci, London WC1E 6BT, England	University of London; University College London	Sammonds, PR (corresponding author), UCL, Dept Earth Sci, Gower St, London WC1E 6BT, England.	p.sammonds@ucl.ac.uk						DUVAL P, 2002, J GEOPHYS RES, V107, DOI DOI 10.1029/2001JB000946; Goldsby DL, 2001, J GEOPHYS RES-SOL EA, V106, P11017, DOI 10.1029/2000JB900336; Kubo T, 2006, SCIENCE, V311, P1267, DOI 10.1126/science.1121296; Peltier WR, 2000, ANN GLACIOL-SER, V30, P163, DOI 10.3189/172756400781820859; POIRIER JP, 1982, NATURE, V299, P683, DOI 10.1038/299683a0	5	4	4	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	2006	311	5765					1250	1251		10.1126/science.1123985	http://dx.doi.org/10.1126/science.1123985			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019XB	16513972				2022-12-28	WOS:000235870400029
J	Hoge, CW; Auchterlonie, JL; Milliken, CS				Hoge, CW; Auchterlonie, JL; Milliken, CS			Mental health problems, use of mental health services, and attrition from military service after returning from deployment to Iraq or Afghanistan	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTTRAUMATIC-STRESS-DISORDER; PSYCHIATRIC-DISORDERS; GULF-WAR; POPULATION; DEPRESSION; VETERANS; VALIDITY; ILLNESS; RISK	Context The US military has conducted population-level screening for mental health problems among all service members returning from deployment to Afghanistan, Iraq, and other locations. To date, no systematic analysis of this program has been conducted, and studies have not assessed the impact of these deployments on mental health care utilization after deployment. Objectives To determine the relationship between combat deployment and mental health care use during the first year after return and to assess the lessons learned from the postdeployment mental health screening effort, particularly the correlation between the screening results, actual use of mental health services, and attrition from military service. Design, Setting, and Participants Population-based descriptive study of all Army soldiers and Marines who completed the routine postdeployment health assessment between May 1, 2003, and April 30, 2004, on return from deployment to Operation Enduring Freedom in Afghanistan ( n= 16 318), Operation Iraqi Freedom ( n= 222 620), and other locations ( n= 64 967). Health care utilization and occupational outcomes were measured for 1 year after deployment or until leaving the service if this occurred sooner. Main Outcome Measures Screening positive for posttraumatic stress disorder, major depression, or other mental health problems; referral for a mental health reason; use of mental health care services after returning from deployment; and attrition from military service. Results The prevalence of reporting a mental health problem was 19.1% among service members returning from Iraq compared with 11.3% after returning from Afghanistan and 8.5% after returning from other locations ( P <. 001). Mental health problems reported on the postdeployment assessment were significantly associated with combat experiences, mental health care referral and utilization, and attrition from military service. Thirty-five percent of Iraq war veterans accessed mental health services in the year after returning home; 12% per year were diagnosed with a mental health problem. More than 50% of those referred for a mental health reason were documented to receive follow-up care although less than 10% of all service members who received mental health treatment were referred through the screening program. Conclusions Combat duty in Iraq was associated with high utilization of mental health services and attrition from military service after deployment. The deployment mental health screening program provided another indicator of the mental health impact of deployment on a population level but had limited utility in predicting the level of mental health services that were needed after deployment. The high rate of using mental health services among Operation Iraqi Freedom veterans after deployment highlights challenges in ensuring that there are adequate resources to meet the mental health needs of returning veterans.	Walter Reed Army Inst Res, Div Psychiat & Neurosci, Silver Spring, MD 20910 USA; USA, Ctr Hlth Promot & Prevent Med, Washington, DC 20310 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Hoge, CW (corresponding author), Walter Reed Army Inst Res, Div Psychiat & Neurosci, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	charles.hoge@usarmy.mil						[Anonymous], 1988, JAMA, V259, P2701; [Anonymous], [No title captured]; BLIESE PD, 2004, 2004002 USA MED RES; Dlugosz LJ, 1999, J CLIN EPIDEMIOL, V52, P1267, DOI 10.1016/S0895-4356(99)00131-6; GARVEYWILSON AL, 2003, AM PSYCH ASS SYLL P, P23; Grunebaum M, 1996, PSYCHIAT SERV, V47, P848; HELZER JE, 1987, NEW ENGL J MED, V317, P1630, DOI 10.1056/NEJM198712243172604; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hoge CW, 2005, AM J PSYCHIAT, V162, P585, DOI 10.1176/appi.ajp.162.3.585; Hoge CW, 2002, AM J PSYCHIAT, V159, P1576, DOI 10.1176/appi.ajp.159.9.1576; JORDAN BK, 1991, ARCH GEN PSYCHIAT, V48, P207, DOI 10.1001/archpsyc.1991.01810270019002; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Meyer GS, 1998, MIL MED, V163, P461, DOI 10.1093/milmed/163.7.461; *NEW FREED COMM ME, 2003, PUBL EPT HLTH HUM SE; Prigerson HG, 2002, AM J PUBLIC HEALTH, V92, P59, DOI 10.2105/AJPH.92.1.59; Prigerson HG, 2001, J NERV MENT DIS, V189, P99, DOI 10.1097/00005053-200102000-00005; Prins A, 2003, PRIMARY CARE PSYCHIA, V9, P9; Rona RJ, 2005, JAMA-J AM MED ASSOC, V293, P1257, DOI 10.1001/jama.293.10.1257; Rubertone MV, 2002, AM J PUBLIC HEALTH, V92, P1900, DOI 10.2105/AJPH.92.12.1900; Schwartz DA, 1997, JAMA-J AM MED ASSOC, V277, P238, DOI 10.1001/jama.277.3.238; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Whooley MA, 1997, J GEN INTERN MED, V12, P439, DOI 10.1046/j.1525-1497.1997.00076.x; WINKENWERDER W, 2005, COMMUNICATION   0310	25	1349	1365	2	111	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	2006	295	9					1023	1032		10.1001/jama.295.9.1023	http://dx.doi.org/10.1001/jama.295.9.1023			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	016XJ	16507803				2022-12-28	WOS:000235656600022
J	Bjorklund, M; Taipale, M; Varjosalo, M; Saharinen, J; Lahdenpera, J; Taipale, J				Bjorklund, M; Taipale, M; Varjosalo, M; Saharinen, J; Lahdenpera, J; Taipale, J			Identification of pathways regulating cell size and cell-cycle progression by RNAi	NATURE			English	Article							DNA-DAMAGE; DROSOPHILA-MELANOGASTER; CHECKPOINT KINASE; COP9 SIGNALOSOME; GENOME; GROWTH; SCREEN; CDC25; MAP	Many high-throughput loss-of-function analyses of the eukaryotic cell cycle have relied on the unicellular yeast species Saccharomyces cerevisiae and Schizosaccharomyces pombe. In multicellular organisms, however, additional control mechanisms regulate the cell cycle to specify the size of the organism and its constituent organs(1). To identify such genes, here we analysed the effect of the loss of function of 70% of Drosophila genes (including 90% of genes conserved in human) on cell-cycle progression of S2 cells using flow cytometry. To address redundancy, we also targeted genes involved in protein phosphorylation simultaneously with their homologues. We identify genes that control cell size, cytokinesis, cell death and/or apoptosis, and the G1 and G2/M phases of the cell cycle. Classification of the genes into pathways by unsupervised hierarchical clustering on the basis of these phenotypes shows that, in addition to classical regulatory mechanisms such asMyc/Max, Cyclin/Cdk and E2F, cell-cycle progression in S2 cells is controlled by vesicular and nuclear transport proteins, COP9 signalosome activity and four extracellular-signal-regulated pathways (Wnt, p38 beta MAPK, FRAP/TOR and JAK/STAT). In addition, by simultaneously analysing several phenotypes, we identify a translational regulator, eIF-3p66, that specifically affects the Cyclin/Cdk pathway activity.	Univ Helsinki, Biomedicum Helsinki, Mol & Canc Biol Program, FI-00014 Helsinki, Finland; Univ Helsinki, Biomedicum Helsinki, High Throughput Ctr, FI-00014 Helsinki, Finland; Natl Publ Hlth Inst, Dept Mol Med, FI-00251 Helsinki, Finland; Biomedicum, Biomedicum Bioinformat Unit, FI-00251 Helsinki, Finland	University of Helsinki; University of Helsinki; Finland National Institute for Health & Welfare; University of Helsinki	Taipale, M (corresponding author), Univ Helsinki, Biomedicum Helsinki, Mol & Canc Biol Program, POB 63,Haartmaninkatu 8, FI-00014 Helsinki, Finland.	minna.taipale@helsinki.fi	Varjosalo, Markku/K-6424-2015; Bjorklund, Mikael/AAA-2894-2020; Björklund, Mikael/D-3362-2009	Varjosalo, Markku/0000-0002-1340-9732; Björklund, Mikael/0000-0002-2176-681X; Taipale, Minna/0000-0002-1905-2551				Bettencourt-Dias M, 2004, NATURE, V432, P980, DOI 10.1038/nature03160; Boutros M, 2004, SCIENCE, V303, P832, DOI 10.1126/science.1091266; Brumby A, 2004, GENETICS, V168, P227, DOI 10.1534/genetics.104.026617; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Cope GA, 2003, CELL, V114, P663, DOI 10.1016/S0092-8674(03)00722-0; Doronkin S, 2003, DEV CELL, V4, P699, DOI 10.1016/S1534-5807(03)00121-7; Eggert US, 2004, PLOS BIOL, V2, P2135, DOI 10.1371/journal.pbio.0020379; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hu J, 2004, NAT CELL BIOL, V6, P1003, DOI 10.1038/ncb1172; Huang JY, 2002, J CELL SCI, V115, P2847; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kim YO, 2004, P NATL ACAD SCI USA, V101, P159, DOI 10.1073/pnas.0307205101; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Neufeld TP, 1998, CURR OPIN CELL BIOL, V10, P784, DOI 10.1016/S0955-0674(98)80122-1; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Reis T, 2004, CELL, V117, P253, DOI 10.1016/S0092-8674(04)00247-8; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Stapleton M., 2002, GENOME BIOL, V3, DOI [10.1186/gb-2002-3-12-research0080, DOI 10.1186/GB-2002-3-12-RESEARCH0080]; Sveiczer Akos, 2004, Theor Biol Med Model, V1, P12, DOI 10.1186/1742-4682-1-12; Tomoda K, 2004, J BIOL CHEM, V279, P43013, DOI 10.1074/jbc.M406559200; Yandell M, 2005, P NATL ACAD SCI USA, V102, P1566, DOI 10.1073/pnas.0409421102	30	212	217	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 23	2006	439	7079					1009	1013		10.1038/nature04469	http://dx.doi.org/10.1038/nature04469			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014NE	16496002				2022-12-28	WOS:000235486100054
J	Stern, SA; Weaver, HA; Steffl, AJ; Mutchler, MJ; Merline, WJ; Buie, MW; Young, EF; Young, LA; Spencer, JR				Stern, SA; Weaver, HA; Steffl, AJ; Mutchler, MJ; Merline, WJ; Buie, MW; Young, EF; Young, LA; Spencer, JR			A giant impact origin for Pluto's small moons and satellite multiplicity in the Kuiper belt	NATURE			English	Article							CHARON; DISK	The two newly discovered(1) satellites of Pluto (P1 and P2) have masses that are small compared to both Pluto and Charon-that is, between 5x10(-4) and 1x10(-5) of Pluto's mass, and between 5x10(-3) and 1x10(-4) of Charon's mass. This discovery, combined with the constraints on the absence of more distant satellites of Pluto(2), reveal that Pluto and its moons comprise an unusual, highly compact, quadruple system. These facts naturally raise the question of how this puzzling satellite system came to be. Here we show that P1 and P2's proximity to Pluto and Charon, the fact that P1 and P2 are on near-circular orbits in the same plane as Pluto's large satellite Charon(1), along with their apparent locations in or near high-order mean-motion resonances, all probably result from their being constructed from collisional ejecta that originated from the Pluto-Charon formation event. We also argue that dust-ice rings of variable optical depths form sporadically in the Pluto system, and that rich satellite systems may be found-perhaps frequently-around other large Kuiper belt objects.	SW Res Inst, Boulder, CO 80302 USA; Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20723 USA; Space Telescope Sci Inst, Baltimore, MD 21218 USA; Lowell Observ, Flagstaff, AZ 86001 USA	Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; Space Telescope Science Institute	Stern, SA (corresponding author), SW Res Inst, 1050 Walnut St,Suite 400, Boulder, CO 80302 USA.	astern@swri.edu	Weaver, Harold A/D-9188-2016	Weaver, Harold A/0000-0003-0951-7762; Mutchler, Maximilian/0000-0002-0088-3021				Canup RM, 2005, SCIENCE, V307, P546, DOI 10.1126/science.1106818; Dobrovolskis A. R, 1997, PLUTO CHARON, P159; Durda DD, 2000, ICARUS, V145, P220, DOI 10.1006/icar.1999.6333; MCKINNON WB, 1984, NATURE, V311, P355, DOI 10.1038/311355a0; MCKINNON WB, 1989, ASTROPHYS J, V344, pL41, DOI 10.1086/185526; Mukai T, 2004, ADV SPACE RES-SERIES, V34, P172, DOI 10.1016/j.asr.2003.03.052; STEFFL AJ, UNPUB ASTRON J; Stephens DC, 2006, ASTRON J, V131, P1142, DOI 10.1086/498715; Stern S. A., 1997, PLUTO CHARON, P605; STERN SA, 1991, ICARUS, V94, P246, DOI 10.1016/0019-1035(91)90154-L; STERN SA, 1995, ASTRON J, V110, P856, DOI 10.1086/117568; THOLEN DJ, 1997, PLUTO CHARON, P193	12	71	72	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 23	2006	439	7079					946	948		10.1038/nature04548	http://dx.doi.org/10.1038/nature04548			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014NE	16495992				2022-12-28	WOS:000235486100040
J	Gu, DF; He, J; Duan, XF; Reynolds, K; Wu, XG; Chen, J; Huang, GY; Chen, CS; Whelton, PK				Gu, DF; He, J; Duan, XF; Reynolds, K; Wu, XG; Chen, J; Huang, GY; Chen, CS; Whelton, PK			Body weight and mortality among men and women in China	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MASS INDEX; WAIST CIRCUMFERENCE; PROSPECTIVE COHORT; OVERWEIGHT; OBESITY; PREVALENCE; METAANALYSIS; UNDERWEIGHT; ADIPOSITY; DISEASE	Context The effect of underweight and obesity on mortality has not been well characterized in Asian populations. Objective To examine the relationship between body mass index (BMI) and mortality in Chinese adults. Design, Setting, and Participants A prospective cohort study in a nationally representative sample of 169 871 Chinese men and women aged 40 years or older. Data on body weight and covariables were obtained at a baseline examination in 1991 using a standard protocol. Follow-up evaluation was conducted in 1999-2000, with a response rate of 93.4% (n = 158 666). Main Outcome Measures Body mass index and all-cause mortality. Results After excluding those participants with missing body weight or height values, 154 736 adults were included in the analysis. After adjustment for age, sex, cigarette smoking, alcohol consumption, physical activity, education, geographic region (north vs south), and urbanization (urban vs rural), a U-shaped association between BMI and all-cause mortality was observed (P<.001). Using those participants with a BMI of 24.0 to 24.9 as the reference group, the relative risks of all-cause mortality across categories of BMI were 1.65 (95% confidence interval [CI], 1.54-1.77) for BMI less than 18.5, 1.31 (95% CI, 1.22-1.41) for BMI 18.5 to 19.9, 1.20 (95% CI, 1.11-1.29) for BMI 20.0 to 20.9, 1.12 (95% CI, 1.04-1.21) for BMI 21.0 to 21.9, 1.11 (95% CI, 1.03-1.20) for BMI 22.0 to 22.9, 1.09 (95% CI, 1.01-1.19) for BMI 23.0 to 23.9, 1.00 ( 95% CI, 0.92-1.08) for BMI 25.0 to 26.9, 1.15 (95% CI, 1.06-1.24) for BMI 27.0 to 29.9, and 1.29 (95% CI, 1.16-1.42) for BMI 30.0 or more. The U-shaped association existed even after excluding participants who were current or former smokers, heavy alcohol drinkers, or who had prevalent chronic illness at the baseline examination, or who died during the first 3 years of follow-up. A similar association was observed between BMI and mortality from cardiovascular disease, cancer, and other causes. Conclusions Our results indicate that both underweight and obesity were associated with increased mortality in the Chinese adult population. Furthermore, our findings support the use of a single common recommendation for defining overweight and obesity among all racial and ethnic groups.	Chinese Acad Med Sci, Cardiovasc Inst, Div Populat Genet & Prevent, Beijing 100037, Peoples R China; Chinese Acad Med Sci, Fu Wai Hosp, Beijing 100037, Peoples R China; Peking Union Med Coll, Beijing, Peoples R China; Chinese Natl Ctr Cardiovasc Dis Control & Res, Beijing, Peoples R China; Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA USA; Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Tulane University; Tulane University	Gu, DF (corresponding author), Chinese Acad Med Sci, Cardiovasc Inst, Div Populat Genet & Prevent, 167 Beilishi Rd, Beijing 100037, Peoples R China.	gudongfeng@vip.sina.com; jhe@tulane.edu	Reynolds, Kristi/AAN-1434-2021; He, Jiang/AAF-5303-2020	Reynolds, Kristi/0000-0001-7619-1649; He, Jiang/0000-0002-8286-9652	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL072507] Funding Source: NIH RePORTER; NHLBI NIH HHS [U01 HL072507] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abelson P, 2004, SCIENCE, V304, P1413, DOI 10.1126/science.304.5676.1413; Aekplakorn Wichai, 2004, Journal of the Medical Association of Thailand, V87, P685; Allison DB, 1999, JAMA-J AM MED ASSOC, V282, P1530, DOI 10.1001/jama.282.16.1530; Bender R, 1999, JAMA-J AM MED ASSOC, V281, P1498, DOI 10.1001/jama.281.16.1498; Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; Deurenberg P, 1998, INT J OBESITY, V22, P1164, DOI 10.1038/sj/ijo/0800741; Deurenberg-Yap M, 2002, Obes Rev, V3, P209, DOI 10.1046/j.1467-789X.2002.00069.x; Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.293.15.1861; Gu DF, 2005, LANCET, V365, P1398, DOI 10.1016/S0140-6736(05)66375-1; Hart CL, 1999, BMJ-BRIT MED J, V318, P1725, DOI 10.1136/bmj.318.7200.1725; He M, 2001, INT J OBESITY, V25, P748, DOI 10.1038/sj.ijo.0801612; Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847; Hu FB, 2004, NEW ENGL J MED, V351, P2694, DOI 10.1056/NEJMoa042135; INGRAM DD, 1994, VITAL HLTH STAT 2, V121, P1; James PT, 2001, OBES RES, V9, p228S, DOI 10.1038/oby.2001.123; Krauss R M, 1998, Circulation, V98, P1472; Laatikainen T, 2003, J EPIDEMIOL COMMUN H, V57, P379, DOI 10.1136/jech.57.5.379; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; Misra A, 2004, NUTRITION, V20, P482, DOI 10.1016/j.nut.2004.01.020; Miyazaki Motonobu, 2002, J Epidemiol, V12, P40; Must A, 1999, JAMA-J AM MED ASSOC, V282, P1523, DOI 10.1001/jama.282.16.1523; Pan WH, 2004, AM J CLIN NUTR, V79, P31; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Song YM, 2001, EPIDEMIOLOGY, V12, P173, DOI 10.1097/00001648-200103000-00008; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; Tsugane S, 2002, INT J OBESITY, V26, P529, DOI 10.1038/sj.ijo.0801961; *WHO W PAC REG INT, 2000, AS PAC PERSP RED OB; Wildman RP, 2004, AM J CLIN NUTR, V80, P1129, DOI 10.1093/ajcn/80.5.1129; Wu XG, 1995, INT J CARDIOL, V52, P39, DOI 10.1016/0167-5273(95)02443-Z; Yuan JM, 1998, INT J EPIDEMIOL, V27, P824, DOI 10.1093/ije/27.5.824; Zhou BF, 2002, BIOMED ENVIRON SCI, V15, P245	31	285	307	1	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	2006	295	7					776	783		10.1001/jama.295.7.776	http://dx.doi.org/10.1001/jama.295.7.776			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011YZ	16478900				2022-12-28	WOS:000235306700022
J	Pi-Sunyer, F; Aronne, LJ; Heshmati, HM; Devin, J; Rosenstock, J				Pi-Sunyer, F; Aronne, LJ; Heshmati, HM; Devin, J; Rosenstock, J		RIO-N Amer Study Grp	Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients - RIO-North America: A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTAGONIST SR141716; GLUCOSE; METABOLISM; EXPRESSION	Context Rimonabant, a selective cannabinoid-1 receptor blocker, may reduce body weight and improve cardiometabolic risk factors in patients who are overweight or obese. Objective To compare the efficacy and safety of rimonabant with placebo each in conjunction with diet and exercise for sustained changes in weight and cardiometabolic risk factors over 2 years. Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial of 3045 obese (body mass index >= 30) or overweight (body mass index >27 and treated or untreated hypertension or dyslipidemia) adult patients at 64 US and 8 Canadian clinical research centers from August 2001 to April 2004. Intervention After a 4-week single-blind placebo plus diet (600 kcal/d deficit) run-in period, patients were randomized to receive placebo, 5 mg/d of rimonabant, or 20 mg/d of rimonabant for 1 year. Rimonabant-treated patients were rerandomized to receive placebo or continued to receive the same rimonabant dose while the placebo group continued to receive placebo during year 2. Main Outcome Measures Body weight change over year 1 and prevention of weight regain during year 2. Additional efficacy measures included changes in waist circumference, plasma lipid levels, and other cardiometabolic risk factors. Results At year 1, the completion rate was 309 (51%) patients in the placebo group, 620 (51%) patients in the 5 mg of rimonabant group, and 673 (55%) patients in the 20 mg of rimonabant group. Compared with the placebo group, the 20 mg of rimonabant group produced greater mean (SEM) reductions in weight (-6.3 [0.2] kg vs -1.6 [0.2] kg; P<.001), waist circumference (-6.1 [0.2] cm vs -2.5 [0.3] cm; P<.001), and level of triglycerides (percentage change, -5.3 [1.2] vs 7.9 [2.0]; P<.001) and a greater increase in level of high-density lipoprotein cholesterol (percentage change, 12.6 [0.5] vs 5.4 [0.7]; P<.001). Patients who were switched from the 20 mg of rimonabant group to the placebo group during year 2 experienced weight regain while those who continued to receive 20 mg of rimonabant maintained their weight loss and favorable changes in cardiometabolic risk factors. Use of different imputation methods to account for the high rate of dropouts in all 3 groups yielded similar results. Rimonabant was generally well tolerated; the most common drug-related adverse event was nausea (11.2% for the 20 mg of rimonabant group vs 5.8% for the placebo group). Conclusions In this multicenter trial, treatment with 20 mg/d of rimonabant plus diet for 2 years promoted modest but sustained reductions in weight and waist circumference and favorable changes in cardiometabolic risk factors. However, the trial was limited by a high drop-out rate and longer-term effects of the drug require further study.	Columbia Univ, Coll Phys & Surg, St Lukes Roosevelt Hosp Ctr, Obes Res Ctr, New York, NY USA; Cornell Weil Med Coll, Dept Med, New York, NY USA; Dallas Diabet & Endocrine Ctr, Dallas, TX USA	Columbia University; Mount Sinai St. Luke's; Mount Sinai West; Cornell University; Diabetes & Endocrine Center	Pi-Sunyer, F (corresponding author), St Lukes Roosevelt Hosp, Obes Res Ctr, 1111 Amsterdam Ave,WH1020, New York, NY 10025 USA.	fxp1@columbia.edu	Aronne, Louis/ABC-8865-2020					Bensaid M, 2003, MOL PHARMACOL, V63, P908, DOI 10.1124/mol.63.4.908; BERG AH, 2002, DIABETES, V13, P84; Buyse M, 1998, BIOMETRICS, V54, P1014, DOI 10.2307/2533853; Cota D, 2003, J CLIN INVEST, V112, P423, DOI 10.1172/JCI17725; Despres JP, 2005, NEW ENGL J MED, V353, P2121, DOI 10.1056/NEJMoa044537; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Gadbury G L, 2003, Obes Rev, V4, P175, DOI 10.1046/j.1467-789X.2003.00109.x; Harris J. A., 1919, PUBLICATION CARNEGIE, V279; Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; Howlett AC, 2002, PROSTAG OTH LIPID M, V68-9, P619, DOI 10.1016/S0090-6980(02)00060-6; Jacobs D. S., 1996, LAB TEST HDB; Klein S, 2004, CIRCULATION, V110, P2952, DOI 10.1161/01.CIR.0000145546.97738.1E; Liu YL, 2005, INT J OBESITY, V29, P183, DOI 10.1038/sj.ijo.0802847; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; *NCEP EXP PAN DET, 1924, JAMA-J AM MED ASSOC, P285; Osei-Hyiaman D, 2005, J CLIN INVEST, V115, P1298, DOI 10.1172/JCI200523057; Padwal R, 2003, INT J OBESITY, V27, P1437, DOI 10.1038/sj.ijo.0802475; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; RIFAI N, 1994, LAB MEASUREMENT LIPI; Salmenniemi U, 2004, CIRCULATION, V110, P3842, DOI 10.1161/01.CIR.0000150391.38660.9B; Solomon CG, 1997, AM J CLIN NUTR, V66, P1044, DOI 10.1093/ajcn/66.4.1044S; Trillou CR, 2003, AM J PHYSIOL-REG I, V284, pR345, DOI 10.1152/ajpregu.00545.2002; Van Gaal LF, 2005, LANCET, V365, P1389, DOI 10.1016/S0140-6736(05)66374-X; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	27	949	997	0	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	2006	295	7					761	775		10.1001/jama.295.7.761	http://dx.doi.org/10.1001/jama.295.7.761			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011YZ	16478899	Bronze			2022-12-28	WOS:000235306700021
J	Bensing, JM; Verhaak, PFM				Bensing, JM; Verhaak, PFM			Somatisation: a joint responsibility of doctor and patient	LANCET			English	Editorial Material							UNEXPLAINED PHYSICAL SYMPTOMS; GENERAL-PRACTITIONERS; PRIMARY-CARE		Netherlands Inst Hlth Serv Res, NL-3500 BN Utrecht, Netherlands; Univ Utrecht, Dept Hlth Psychol, NL-3508 TC Utrecht, Netherlands	Netherlands Institute for Health Services Research; Utrecht University	Bensing, JM (corresponding author), Netherlands Inst Hlth Serv Res, NL-3500 BN Utrecht, Netherlands.	J.Bensing@nivel.nl						Balint M., 1957, DOCTOR; Biderman A, 2003, SOC SCI MED, V56, P1135, DOI 10.1016/S0277-9536(02)00108-9; Cockburn J, 1997, BRIT MED J, V315, P520, DOI 10.1136/bmj.315.7107.520; GROL R, 1983, HEAL HARM PREVENTION; Hartz AJ, 2000, GEN HOSP PSYCHIAT, V22, P144, DOI 10.1016/S0163-8343(00)00060-8; Kravitz RL, 2003, ARCH INTERN MED, V163, P1673, DOI 10.1001/archinte.163.14.1673; Little P, 2004, BMJ-BRIT MED J, V328, P444, DOI 10.1136/bmj.38013.644086.7C; Malterud K, 2005, LANCET, V366, P785, DOI 10.1016/S0140-6736(05)67031-6; Ring A, 2005, SOC SCI MED, V61, P1505, DOI 10.1016/j.socscimed.2005.03.014; Ring A, 2004, BMJ-BRIT MED J, V328, P1057, DOI 10.1136/bmj.38057.622639.EE; Rosendal M, 2005, SCAND J PRIM HEALTH, V23, P3, DOI 10.1080/02813430510015304; Rosendal M, 2005, BRIT MED J, V330, P4, DOI 10.1136/bmj.330.7481.4; Salmon P, 2004, BRIT J GEN PRACT, V54, P171; Wessely S, 1999, LANCET, V354, P936, DOI 10.1016/S0140-6736(98)08320-2	14	25	25	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 11	2006	367	9509					452	454		10.1016/S0140-6736(06)68155-5	http://dx.doi.org/10.1016/S0140-6736(06)68155-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013FF	16473108	Green Submitted			2022-12-28	WOS:000235394500006
J	Chen, JZ; Raymond, K				Chen, JZ; Raymond, K			Nuclear receptors, bile-acid detoxification, and cholestasis	LANCET			English	Editorial Material							PRIMARY BILIARY-CIRRHOSIS; URSODEOXYCHOLIC-ACID; CONTROLLED-TRIAL; METABOLISM; RIFAMPICIN; EXPRESSION		La Trobe Univ, Fac Sci Technol & Engn, Sch Pharm & Appl Sci, Bendigo, Vic 3550, Australia	La Trobe University	Raymond, K (corresponding author), La Trobe Univ, Fac Sci Technol & Engn, Sch Pharm & Appl Sci, Bendigo, Vic 3550, Australia.	K.Raymond@latrobe.edu.au		Chen, Jiezhong/0000-0003-1977-6143				BACHS L, 1989, LANCET, V1, P574; Chen JH, 1998, HEPATOLOGY, V28, P624, DOI 10.1002/hep.510280304; Chen JZ, 1996, J GASTROEN HEPATOL, V11, P870, DOI 10.1111/j.1440-1746.1996.tb00095.x; Chitturi S, 2001, Semin Gastrointest Dis, V12, P113; Denson LA, 2001, GASTROENTEROLOGY, V121, P140, DOI 10.1053/gast.2001.25503; Dilger K, 2005, HEPATOLOGY, V41, P595, DOI 10.1002/hep.20568; Fiorucci S, 2005, J PHARMACOL EXP THER, V313, P604, DOI 10.1124/jpet.104.079665; Gnerre C, 2004, PHARMACOGENETICS, V14, P635, DOI 10.1097/00008571-200410000-00001; Goulis J, 1999, LANCET, V354, P1053, DOI 10.1016/S0140-6736(98)11293-X; Huang L, 2003, J BIOL CHEM, V278, P51085, DOI 10.1074/jbc.M308321200; Liu YP, 2003, J CLIN INVEST, V112, P1678, DOI 10.1172/JCI200318945; Marschall HU, 2005, GASTROENTEROLOGY, V129, P476, DOI 10.1053/j.gastro.2005.05.009; Papatheodoridis GV, 2002, AM J GASTROENTEROL, V97, P2063; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Payen L, 2002, CELL BIOL TOXICOL, V18, P221, DOI 10.1023/A:1016020626941; Roncaglia N, 2004, BJOG-INT J OBSTET GY, V111, P17, DOI 10.1046/j.1471-0528.2003.00029.x; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Talwalkar JA, 2003, LANCET, V362, P53, DOI 10.1016/S0140-6736(03)13808-1; Trauner M, 2003, CURR OPIN GASTROEN, V19, P216, DOI 10.1097/00001574-200305000-00005; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398	20	28	31	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 11	2006	367	9509					454	456		10.1016/S0140-6736(06)68156-7	http://dx.doi.org/10.1016/S0140-6736(06)68156-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013FF	16473109				2022-12-28	WOS:000235394500007
J	Rubin, GJ; Hahn, G; Everitt, BS; Cleare, AJ; Wessely, S				Rubin, GJ; Hahn, G; Everitt, BS; Cleare, AJ; Wessely, S			Are some people sensitive to mobile phone signals? Within participants double blind randomised provocation study	BRITISH MEDICAL JOURNAL			English	Article							SELF-REPORTED HYPERSENSITIVITY; ELECTROMAGNETIC HYPERSENSITIVITY; SYMPTOMS; FIELDS; NOCEBO	Objective To test whether people who report being sensitive to mobile phone signals have more symptoms when exposed to a pulsing mobile signal than when exposed to a sham signal Of a non-puling signal. Design Double blind, randomised, within participants provocation study. Setting Dedicated suite Of Offices at King's College London, between September 2003 and June 2005. Participants 60 "sensitive" people who reported often getting headache-like symptoms within 20 minutes of using a global system for mobile communication (GSM) mobile phone and 60 "control" participants who did not report any such symptoms. Intervention Participants were exposed to three conditions: a 900 MHz GSM mobile phone signal, a non-pulsing carrier wave signal, and a sham condition with no signal present. Each exposure lasted for 50 minutes. Main outcome measures The principal outcome measure was headache severity assessed with a 0-100 visual analogue scale. Other outcomes included six other subjective symptoms mid participants' ability to judge whether a signal was present. Results Headache severity increased during exposure and decreased immediately afterwards. However, no strong evidence was found of air), difference between the conditions in terms of symptom severity. Nor did evidence of any differential effect of condition between the two groups exist. The proportion of sensitive participants who believed a signal was present (during GSM exposure (60%) was similar to the proportion who believed one was present during sham exposure (63%). Conclusions No evidence Was found to indicate that people with self reported sensitivity to mobile phone signals are able to detect such signals or that they react to them with increased symptom severity. As sham exposure was sufficient to trigger severe symptoms in sonic participants, psychological factors may have an important role in causing this condition.	Univ London Kings Coll, Inst Psychiat, Dept Psychol Med, Sect Gen Hosp Psychiat,Weston Educ Ctr PO62, London SE5 9RJ, England; Univ London Kings Coll, Inst Psychiat, Dept Biostat & Comp, London SE5 8AF, England	University of London; King's College London; University of London; King's College London	Rubin, GJ (corresponding author), Univ London Kings Coll, Inst Psychiat, Dept Psychol Med, Sect Gen Hosp Psychiat,Weston Educ Ctr PO62, London SE5 9RJ, England.	g.rubin@iop.kcl.ac.uk	Cleare, Anthony/AAN-5418-2021; Wessely, Simon C/A-8713-2008; Cleare, Anthony J/B-4506-2008	Everitt, Barry/0000-0003-4431-6536; Wessely, Simon Charles/0000-0002-6743-9929				Andersson B, 1996, J OCCUP ENVIRON MED, V38, P752, DOI 10.1097/00043764-199608000-00009; Barsky AJ, 2002, JAMA-J AM MED ASSOC, V287, P622, DOI 10.1001/jama.287.5.622; Benedetti F, 2003, J NEUROSCI, V23, P4315; EVERIN B, 2003, MODERN MED STAT; Everitt B. S., 2003, MODERN MED STAT; Hillert L, 2002, SCAND J WORK ENV HEA, V28, P33, DOI 10.5271/sjweh.644; Hocking B, 1998, OCCUP MED-OXFORD, V48, P357, DOI 10.1093/occmed/48.6.357; Hyland GJ, 2000, LANCET, V356, P1833, DOI 10.1016/S0140-6736(00)03243-8; Koivisto M, 2001, BIOELECTROMAGNETICS, V22, P212, DOI 10.1002/bem.41; Levallois P, 2002, ENVIRON HEALTH PERSP, V110, P619, DOI 10.1289/ehp.02110s4619; MCDOWELL I, 1996, MEASURING HLTH GUIDE, P341; Mundt JC, 2002, BRIT J PSYCHIAT, V180, P461, DOI 10.1192/bjp.180.5.461; *NAT RAD PROT BOAR, 2004, DOCUMENTS NRPB, V15; Oftedal G, 2000, OCCUP MED-OXFORD, V50, P237, DOI 10.1093/occmed/50.4.237; Oftedal G, 1999, SCAND J WORK ENV HEA, V25, P415, DOI 10.5271/sjweh.454; Petrie KJ, 2004, BRIT J HEALTH PSYCH, V9, P101, DOI 10.1348/135910704322778759; PETRIE KJ, 2004, BR J HLTH PSYCHOL, V9, P11; Rubin GJ, 2005, PSYCHOSOM MED, V67, P224, DOI 10.1097/01.psy.0000155664.13300.64; Rubin GJ, 2006, PSYCHOTHER PSYCHOSOM, V75, P12, DOI 10.1159/000089222; SCHWEIGER A, 1981, PAVLOVIAN J BIOL SCI, V16, P140; MCL MTHR GSM TETRA H	21	67	67	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 15	2006	332	7546					886	889		10.1136/bmj.38765.519850.55	http://dx.doi.org/10.1136/bmj.38765.519850.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	037FK	16520326	Green Published, Bronze			2022-12-28	WOS:000237132100019
J	Latch, DE; McNeill, K				Latch, DE; McNeill, K			Microheterogeneity of singlet oxygen distributions in irradiated humic acid solutions	SCIENCE			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; ORGANIC-COMPOUNDS; INTRAHUMIC DECHLORINATION; SORPTION KINETICS; MOLECULAR-WEIGHT; RATE CONSTANTS; SUBSTANCES; BINDING; SOIL; TRANSPORT	Singlet oxygen (O-1(2)) is a highly reactive species formed through solar irradiation of organic matter in environmental waters. Implicated in a range of reactions, it has proven difficult to quantify its spatial distribution in natural waters. We assessed the microheterogeneous distribution of O-1(2) in irradiated solutions containing chromophoric dissolved organic matter (CDOM) by using molecular probes of varying hydrophobicity. The apparent O-1(2) concentrations ([O-1(2)](app)), measured by recently developed hydrophobic trap-and-trigger chemiluminescent probe molecules, were orders of magnitude higher than those measured by the conventional hydrophilic probe molecule furfuryl alcohol. The differential [O-1(2)](app) values measured by these probes reflect a steep concentration gradient between the CDOM macromolecules and the aqueous phase. A detailed kinetic model based on the data predicts probabilistic O-1(2) distributions under different solvent conditions.	Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	McNeill, K (corresponding author), Univ Minnesota, Dept Chem, 76 Kolthoff Hall, Minneapolis, MN 55455 USA.	mcneill@chem.umn.edu	McNeill, Kristopher/A-9834-2009	McNeill, Kristopher/0000-0002-2981-2227				BACKHUS DA, 1990, ENVIRON SCI TECHNOL, V24, P1214, DOI 10.1021/es00078a009; Battino R., 1981, IUPAC SOLUBILITY DAT; BLOUGH NV, 1988, ENVIRON SCI TECHNOL, V22, P77, DOI 10.1021/es00166a008; Blough NV, 1995, ACTIVE OXYGEN CHEM, P280, DOI DOI 10.1007/978-94-007-0874-7_8; Briviba K, 1997, BIOL CHEM, V378, P1259; Burns SE, 1996, ENVIRON SCI TECHNOL, V30, P2934, DOI 10.1021/es950906i; Burns SE, 1997, ENVIRON SCI TECHNOL, V31, P1365, DOI 10.1021/es960581l; Chin YP, 1997, ENVIRON SCI TECHNOL, V31, P1630, DOI 10.1021/es960404k; CHIN YP, 1994, ENVIRON SCI TECHNOL, V28, P1853, DOI 10.1021/es00060a015; CHIOU CT, 1983, ENVIRON SCI TECHNOL, V17, P227, DOI 10.1021/es00110a009; Cooper W.J., 1989, ADV CHEM SER, P333; FU YX, 1995, PHOTOCHEM PHOTOBIOL, V62, P692, DOI 10.1111/j.1751-1097.1995.tb08718.x; GAUTHIER TD, 1986, ENVIRON SCI TECHNOL, V20, P1162, DOI 10.1021/es00153a012; HAAG WR, 1984, CHEMOSPHERE, V13, P641, DOI 10.1016/0045-6535(84)90200-5; HAAG WR, 1987, PHOTOCHEM PHOTOBIOL, V45, P317, DOI 10.1111/j.1751-1097.1987.tb05381.x; Hecht S, 2001, J AM CHEM SOC, V123, P6959, DOI 10.1021/ja016076s; Hessler DP, 1996, J PHOTOCH PHOTOBIO B, V36, P55, DOI 10.1016/S1011-1344(96)07322-8; KARICKHOFF SW, 1979, WATER RES, V13, P241, DOI 10.1016/0043-1354(79)90201-X; Larson R. A., 1994, REACTION MECH ENV OR; MacCarthy P., 1985, Humic substances in soil, sediment and water: geochemistry, isolation and characterization., P527; MacManus-Spencer LA, 2005, J AM CHEM SOC, V127, P8954, DOI 10.1021/ja052045b; MacManus-Spencer LA, 2005, ANAL CHEM, V77, P1200, DOI 10.1021/ac048293s; MALCOLM RL, 1986, ENVIRON SCI TECHNOL, V20, P904, DOI 10.1021/es00151a009; MEANS JC, 1982, SCIENCE, V215, P968, DOI 10.1126/science.215.4535.968; MERKEL PB, 1972, J AM CHEM SOC, V94, P1030, DOI 10.1021/ja00758a072; NECKERS DC, 1986, J AM CHEM SOC, V108, P291, DOI 10.1021/ja00262a016; OGNER G, 1970, SCIENCE, V170, P317, DOI 10.1126/science.170.3955.317; Siegel DA, 2002, J GEOPHYS RES-OCEANS, V107, DOI 10.1029/2001JC000965; VEITH GD, 1979, WATER RES, V13, P43, DOI 10.1016/0043-1354(79)90252-5; Wershaw RL, 1999, SOIL SCI, V164, P803, DOI 10.1097/00010694-199911000-00004; WILKINSON F, 1995, J PHYS CHEM REF DATA, V24, P663, DOI 10.1063/1.555965; WU SC, 1986, ENVIRON SCI TECHNOL, V20, P717, DOI 10.1021/es00149a011; WU SC, 1988, WATER RESOUR RES, V24, P1373, DOI 10.1029/WR024i008p01373; ZEPP RG, 1977, NATURE, V267, P421, DOI 10.1038/267421a0	34	265	279	11	246	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	2006	311	5768					1743	1747		10.1126/science.1121636	http://dx.doi.org/10.1126/science.1121636			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	024OA	16497888				2022-12-28	WOS:000236204300035
J	Mant, J; McManus, RJ; Hare, R				Mant, J; McManus, RJ; Hare, R			Applicability to primary care of national clinical guidelines on blood pressure lowering for people with stroke: cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HYPERTENSION; SOCIETY; RISK	Objective To compare the characteristics of patients with cerebrovascular disease in primary care with those of the participants in the PROGRESS trial, on which national guidelines for blood pressure lowering are based. Design Population based cross sectional survey of patients with confirmed stroke or transient ischaemic attack. Setting Seven general practices in south Birmingham, England. Participants All patients with a validated history of stroke (n = 413) or transient ischaemic attack (n = 107). Main outcome measures Patient characteristics: age, sex, time since last cerebrovascular event, blood pressure, and whether receiving antihypertensive treatment. Results Patients were 12 years older than the participants in PROGRESS and twice as likely to be women. The median time that had elapsed since their cerebrovascular event was two and a half years, compared with eight months in PROGRESS. The systolic blood pressure of 315 (61%) patients was over 140 mm Hg, and for 399 (77%) it was over 130 mm Hg. One hundred and forty seven (28%) patients were receiving a thiazide diuretic, and 136 (26%) were receiving an angiotensin converting enzyme inhibitor. Conclusions Important differences exist between the PROGRESS trial participants and a typical primary care stroke population, which undermine the applicability of the trial's findings. Research in appropriate populations is urgently needed before the international guidelines are implemented in primary care.	Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Mant, J (corresponding author), Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England.	j.w.mant@bham.ac.uk		Mant, Jonathan/0000-0002-9531-0268				Chalmers J, 2003, J HYPERTENS, V21, P651, DOI 10.1097/01.hjh.0000052490.18130.95; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Gueyffier F, 1999, LANCET, V353, P793, DOI 10.1016/S0140-6736(98)08127-6; *INT STROK WORK PA, 2004, NAT CLIN GUID STROK; Lovett JK, 2003, STROKE, V34, pE138, DOI 10.1161/01.STR.0000080935.01264.91; Mant J, 2003, BRIT J GEN PRACT, V53, P520; *OFF NAT STAT, 2000, KEY HLTH STAT GEN PR; PROGRESS Collaborat Grp, 2001, LANCET, V358, P1556; Rothwell PM, 2004, LANCET, V363, P1925, DOI 10.1016/S0140-6736(04)16405-2; Sproston K., 2006, HLTH SURVEY ENGLAND; *W MIDL PUBL HLTH, 2002, 31 DEP PUBL HLTH EP; Wennberg R, 2004, BMJ-BRIT MED J, V329, P968, DOI 10.1136/bmj.329.7472.968; Williams B, 2004, J HUM HYPERTENS, V18, P139, DOI 10.1038/sj.jhh.1001683	13	36	36	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 18	2006	332	7542					635	637		10.1136/bmj.38758.600116.AE	http://dx.doi.org/10.1136/bmj.38758.600116.AE			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	026CQ	16500926	Green Published, Bronze			2022-12-28	WOS:000236314700015
J	Grebmeier, JM; Overland, JE; Moore, SE; Farley, EV; Carmack, EC; Cooper, LW; Frey, KE; Helle, JH; McLaughlin, FA; McNutt, SL				Grebmeier, JM; Overland, JE; Moore, SE; Farley, EV; Carmack, EC; Cooper, LW; Frey, KE; Helle, JH; McLaughlin, FA; McNutt, SL			A major ecosystem shift in the northern Bering Sea	SCIENCE			English	Article							LATE WINTER; ICE COVER; PACK ICE; SHELF; WATER; POLYNYA; SUMMER		Univ Tennessee, Dept Ecol & Evolutionary Biol, Marine Biogeochem & Ecol Grp, Knoxville, TN 37932 USA; NOAA, Pacific Marine Environm Lab, Seattle, WA 98115 USA; NOAA, Alaska Fisheries Sci Ctr, Seattle, WA 98115 USA; NOAA, Auke Bay Lab, Alaska Fisheries Sci Ctr, Natl Marine Fisheries Serv, Juneau, AK 99801 USA; Fisheries & Oceans Canada, Inst Ocean Sci, Sidney, BC V8L 4B2, Canada; Univ Calif Los Angeles, Dept Geog, Los Angeles, CA 90095 USA; Univ Alaska Fairbanks, Inst Geophys, Fairbanks, AK 99775 USA	University of Tennessee System; University of Tennessee Knoxville; National Oceanic Atmospheric Admin (NOAA) - USA; National Oceanic Atmospheric Admin (NOAA) - USA; National Aeronautics & Space Administration (NASA); National Oceanic Atmospheric Admin (NOAA) - USA; Fisheries & Oceans Canada; University of California System; University of California Los Angeles; University of Alaska System; University of Alaska Fairbanks	Grebmeier, JM (corresponding author), Univ Tennessee, Dept Ecol & Evolutionary Biol, Marine Biogeochem & Ecol Grp, 10515 Res Dr,Bldg A,Suite 100, Knoxville, TN 37932 USA.	jgrebmei@utk.edu	Farley, E/HHM-4227-2022; Moore, Sue E/M-2103-2018; Grebmeier, Jacqueline/L-9805-2013; Cooper, Lee W./E-5251-2012	Grebmeier, Jacqueline/0000-0001-7624-3568; Cooper, Lee W./0000-0001-7734-8388				Chapin FS, 2005, SCIENCE, V310, P657, DOI 10.1126/science.1117368; Clement JL, 2004, J GEOPHYS RES-OCEANS, V109, DOI 10.1029/2003JC002047; Cooper LW, 2002, MAR ECOL PROG SER, V226, P13, DOI 10.3354/meps226013; COOPER LW, IN PRESS AQUAT MAMMA; GREBMEIER JM, 1989, MAR ECOL PROG SER, V51, P253, DOI 10.3354/meps051253; Grebmeier JM, 2005, DEEP-SEA RES PT II, V52, P3109, DOI 10.1016/j.dsr2.2005.10.004; GREBMEIER JM, 1995, J GEOPHYS RES-OCEANS, V100, P4439, DOI 10.1029/94JC02198; GREBMEIER JM, 1995, ARCTIC OCEANOGRAPHY, P231, DOI DOI 10.1029/CE049P0231; GREBMEIER JM, 2004, ARCTIC CLIMATE IMPAC; Grebmeier JM, 2000, IMPACTS CHANGES SEA, P80; GREBMEIER JM, IN PRESS POLYNYAS WI; HIGHSMITH RC, 1990, NATURE, V344, P862, DOI 10.1038/344862a0; Krupnik Igor, 2002, EARTH IS FASTER NOW, P156; LEAN C, COMMUNICATION; Lovvorn JR, 2005, MAR ECOL PROG SER, V291, P135, DOI 10.3354/meps291135; Lovvorn JR, 2003, POLAR BIOL, V26, P259, DOI 10.1007/s00300-003-0477-0; Moore SE, 2006, BIOSCIENCE, V56, P49, DOI 10.1641/0006-3568(2006)056[0049:LFLWIT]2.0.CO;2; Moore SE, 2003, CAN J ZOOL, V81, P734, DOI 10.1139/Z03-043; MOORE SE, IN PRESS ECOL APPL; Osterkamp TE, 1999, PERMAFROST PERIGLAC, V10, P17, DOI 10.1002/(SICI)1099-1530(199901/03)10:1&lt;17::AID-PPP303&gt;3.0.CO;2-4; Overland J.E., 2004, EOS T AGU, V85, P309, DOI DOI 10.1029/2004E0330001; Overland JE, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL024254; Pungowiyi Caleb, 2000, IMPACTS CHANGES SEA, P18; Ray C, 1989, RAPPORTS PROCES VERB, V188, P22; SCHUMACHER JD, 1983, J GEOPHYS RES-OCEANS, V88, P2723, DOI 10.1029/JC088iC05p02723; Stroeve JC, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021810; Sturm M, 2001, NATURE, V411, P546, DOI 10.1038/35079180; Thompson DWJ, 1998, GEOPHYS RES LETT, V25, P1297, DOI 10.1029/98GL00950; Wyllie-Echeverria T, 1998, FISH OCEANOGR, V7, P159, DOI 10.1046/j.1365-2419.1998.00058.x	29	642	674	3	222	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2006	311	5766					1461	1464		10.1126/science.1121365	http://dx.doi.org/10.1126/science.1121365			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527980				2022-12-28	WOS:000236029400049
J	Gagnier, JJ; Boon, H; Rochon, P; Moher, D; Barnes, J; Bombardier, C				Gagnier, JJ; Boon, H; Rochon, P; Moher, D; Barnes, J; Bombardier, C		CONSORT Grp	Reporting randomized, controlled trials of herbal interventions: An elaborated CONSORT statement	ANNALS OF INTERNAL MEDICINE			English	Article							LIQUID-CHROMATOGRAPHIC DETERMINATION; GINKGO-BILOBA; PHARMACEUTICAL QUALITY; PARTHENOLIDE CONTENT; FEVERFEW; MEDICINE	Herbal medicinal products are widely used, vary greatly in content and quality, and are actively tested in randomized, controlled trials (RCTs). The authors' objective was to develop recommendations for reporting RCTs of herbal medicine interventions, based on the need to elaborate on the 22-item CONSORT (Consolidated Standards of Reporting Trials) checklist. Telephone calls were made and a consensus meeting was held with 16 participants in Toronto, Canada, to develop these recommendations. The group agreed on context-specific elaborations of 9 CONSORT checklist items for RCTs of herbal medicines. Item 4, concerning the herbal medicine intervention, required the most extensive elaboration. These recommendations have been developed to improve the reporting of RCTs using herbal medicine interventions.	Univ Toronto, Toronto, ON, Canada; Inst Evaluat Sci, Toronto, ON, Canada; Inst Work & Hlth, Toronto, ON, Canada; Toronto Gen Res Inst, Toronto, ON, Canada; Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada; Univ London, London, England	University of Toronto; Institute for Work & Health; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Ottawa; Children's Hospital of Eastern Ontario; University of London	Gagnier, JJ (corresponding author), 5955 Ontario St,Unit 307, Windsor, ON N81S W6, Canada.	j.gagnier@utoronto.ca	Rochon, Paula A/J-2918-2016	Rochon, Paula A/0000-0002-5973-4151; Moher, David/0000-0003-2434-4206; Barnes, Joanne/0000-0002-1522-8433; Bombardier, Claire/0000-0001-5083-2137				Carlson M, 1998, J AOAC INT, V81, P691; DREW S, 2001, BMJ-BRIT MED J, V321, P1; Dubber MJ, 2004, J PHARM PHARM SCI, V7, P303; GAGNIER JJ, 2006, IN PRESS J CLIN EPID; GROENEWEGEN WA, 1986, LANCET, V1, P44; Gurley BJ, 2000, AM J HEALTH-SYST PH, V57, P963, DOI 10.1093/ajhp/57.10.963; Haller CA, 2004, J ANAL TOXICOL, V28, P145, DOI 10.1093/jat/28.3.145; Harkey M. R., 2002, AM J CLIN NUTR, V75, P600; HEPTINSTALL S, 1992, J PHARM PHARMACOL, V44, P391, DOI 10.1111/j.2042-7158.1992.tb03631.x; Klassen TP, 2005, J CLIN EPIDEMIOL, V58, P763, DOI 10.1016/j.jclinepi.2004.08.020; Kressmann S, 2002, J PHARM PHARMACOL, V54, P1507, DOI 10.1211/002235702199; Kressmann S, 2002, J PHARM PHARMACOL, V54, P661, DOI 10.1211/0022357021778970; Li WK, 2002, J PHARMACEUT BIOMED, V30, P67, DOI 10.1016/S0731-7085(02)00201-7; Linde K, 2001, INT J EPIDEMIOL, V30, P526, DOI 10.1093/ije/30.3.526; Little C., 2000, COCHRANE LIB, P4; Manning Jared, 2003, Journal of Herbal Pharmacotherapy, V3, P19, DOI 10.1080/J157v03n03_03; Moher D, 2001, BMC Med Res Methodol, V1, P2, DOI 10.1186/1471-2288-1-2; Moher David, 2002, BMC Pediatr, V2, P2, DOI 10.1186/1471-2431-2-2; Nelson MH, 2002, AM J HEALTH-SYST PH, V59, P1527, DOI 10.1093/ajhp/59.16.1527; Saper RB, 2004, JAMA-J AM MED ASSOC, V292, P2868, DOI 10.1001/jama.292.23.2868; Schulte-Lobbert S, 2004, J PHARM PHARMACOL, V56, P813, DOI 10.1211/0022357023493; Wolsko PM, 2005, AM J MED, V118, P1087, DOI 10.1016/j.amjmed.2005.01.076	22	369	389	1	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 7	2006	144	5					364	367		10.7326/0003-4819-144-5-200603070-00013	http://dx.doi.org/10.7326/0003-4819-144-5-200603070-00013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	021EA	16520478				2022-12-28	WOS:000235965300008
J	Lim, W; Crowther, MA; Eikelboom, JW				Lim, W; Crowther, MA; Eikelboom, JW			Management of antiphospholipid antibody syndrome - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							INTERNATIONAL CONSENSUS STATEMENT; RANDOMIZED CONTROLLED-TRIAL; LOW-DOSE ASPIRIN; ANTICARDIOLIPIN ANTIBODIES; VENOUS THROMBOEMBOLISM; LUPUS ANTICOAGULANT; RECURRENT MISCARRIAGE; PREGNANT-WOMEN; FETAL LOSS; CLASSIFICATION CRITERIA	Context Antiphospholipid antibodies are autoantibodies directed against proteins that bind to phospholipid. Antiphospholipid antibody syndrome (APS) refers to the association between antiphospholipid antibodies and thrombosis risk or pregnancy morbidity. Patients with APS may be at increased risk of recurrent arterial or venous thrombosis or pregnancy loss. Objective To systematically review the evidence for treatment of thrombosis risk in patients with antiphospholipid antibodies or APS. Evidence Acquisition Search of MEDLINE ( 1966 to November 2005) and Cochrane Library electronic databases ( 2005) and reference lists for randomized trials, metaanalyses of randomized trials, and prospective cohort studies of the treatment of thrombosis risk in patients with antiphospholipid antibodies or APS. Studies were selected on the basis of clinical relevance. Evidence Synthesis Among patients with antiphospholipid antibodies, the absolute risk of developing new thrombosis is low ( < 1% per year) in otherwise healthy patients without prior thrombotic events, may be moderately increased ( up to 10% per year) in women with recurrent fetal loss without prior thrombosis, and is highest ( > 10% in the first year) in patients with a history of venous thrombosis who have discontinued anticoagulant drugs within 6 months. Compared with placebo or untreated control, anticoagulation with moderate-intensity warfarin ( adjusted to a target international normalized ratio [INR] of 2.0- 3.0) reduces the risk of recurrent venous thrombosis by 80% to 90% irrespective of the presence of antiphospholipid antibodies and may be effective for preventing recurrent arterial thrombosis. No evidence exists that high-intensity warfarin ( target INR, > 3.0) is more effective than moderate-intensity warfarin. For patients with a single positive antiphospholipid antibody test result and prior stroke, aspirin and moderate-intensity warfarin appear equally effective for preventing recurrent stroke. Treatment issues that have not been addressed in clinical trials, or for which the evidence is conflicting, include the role of antithrombotic prophylaxis in patients with antiphospholipid antibodies without prior thrombosis, the optimal treatment of noncerebrovascular arterial thrombosis, recurrent thrombosis despite warfarin therapy, and treatment of women with antiphospholipid antibodies and recurrent fetal loss. Conclusions In patients with APS, moderate-intensity warfarin is effective for preventing recurrent venous thrombosis and perhaps also arterial thrombosis. Aspirin appears to be as effective as moderate-intensity warfarin for preventing recurrent stroke in patients with prior stroke and a single positive test result for antiphospholipid antibody. The optimal treatment of other thrombotic aspects of APS needs to be addressed in well-designed prospective studies.	McMaster Univ, Dept Med, Hamilton Gen Hosp McMaster Clin, Hamilton, ON L9K 1H8, Canada	McMaster University	Eikelboom, JW (corresponding author), McMaster Univ, Dept Med, Hamilton Gen Hosp McMaster Clin, 237 Barton St E, Hamilton, ON L9K 1H8, Canada.	eikelbj@mcmaster.ca	Eikelboom, John/AAG-6117-2019	Eikelboom, John/0000-0003-4126-1285				Alarcon-Segovia D, 2003, LUPUS, V12, P499, DOI 10.1191/0961203303lu388oa; ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; Asherson RA, 2003, LUPUS, V12, P530, DOI 10.1191/0961203303lu394oa; Audrain MAP, 2002, RHEUMATOLOGY, V41, P550, DOI 10.1093/rheumatology/41.5.550; Bates SA, 2004, CHEST, V126, p627S, DOI 10.1378/chest.126.3_suppl.627S; BRANCH DW, 1992, OBSTET GYNECOL, V80, P614; BRANDT JT, 1995, THROMB HAEMOSTASIS, V74, P1185; Brandt JT, 1995, THROMB HAEMOSTASIS, V74, P1597; Brey RL, 2003, LUPUS, V12, P508, DOI 10.1191/0961203303lu390oa; Buller HR, 2004, CHEST, V126, p401S, DOI 10.1378/chest.126.3_suppl.401S; CANOSO RT, 1990, BIOL PSYCHIAT, V27, P863, DOI 10.1016/0006-3223(90)90467-G; Cervera R, 2002, ARTHRITIS RHEUM-US, V46, P1019, DOI 10.1002/art.10187; Cowchock S, 1997, AM J OBSTET GYNECOL, V176, P1099, DOI 10.1016/S0002-9378(97)70409-5; Crowther MA, 2003, NEW ENGL J MED, V349, P1133, DOI 10.1056/NEJMoa035241; Crowther MA, 2005, THROMB RES, V115, P3, DOI 10.1016/j.thromres.2004.06.041; De Groot PG, 2005, J THROMB HAEMOST, V3, P1854; de Groot PG, 1998, LUPUS, V7, pS32, DOI 10.1177/096120339800700208; Dentali F, 2005, J THROMB HAEMOST, V3, P2121, DOI 10.1111/j.1538-7836.2005.01516.x; Empson M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002859.pub2; Erkan D, 2001, ARTHRITIS RHEUM, V44, P1466, DOI 10.1002/1529-0131(200106)44:6<1466::AID-ART242>3.0.CO;2-C; Erkan D, 1999, LUPUS, V8, P560, DOI 10.1191/096120399678840846; ERKAN D, 2002, LUPUS, V11, pA573; Farquharson RG, 2002, OBSTET GYNECOL, V100, P408, DOI 10.1016/S0029-7844(02)02165-8; Finazzi G, 2005, J THROMB HAEMOST, V3, P848, DOI 10.1111/j.1538-7836.2005.01340.x; Finazzi G, 1996, AM J MED, V100, P530, DOI 10.1016/S0002-9343(96)00060-5; Finazzi G, 1997, HAEMATOLOGICA, V82, P101; Forastiero R, 2005, J THROMB HAEMOST, V3, P1231, DOI 10.1111/j.1538-7836.2005.01295.x; Galli M, 2003, BLOOD, V101, P1827, DOI 10.1182/blood-2002-02-0441; Galli M, 2003, BLOOD, V102, P2717, DOI 10.1182/blood-2002-11-3334; GHARAVI AE, 1994, J RHEUMATOL, V21, P94; GINSBERG JS, 1995, BLOOD, V86, P3685, DOI 10.1182/blood.V86.10.3685.bloodjournal86103685; Ginsberg JS, 2003, J THROMB HAEMOST, V1, P1435, DOI 10.1046/j.1538-7836.2003.00307.x; Harris EN, 2002, LUPUS, V11, P269, DOI 10.1191/0961203302lu202cr; HARRIS EN, 1983, LANCET, V2, P1211; HARRIS EN, 1990, AM J CLIN PATHOL, V94, P476, DOI 10.1093/ajcp/94.4.476; Janardhan V, 2004, STROKE, V35, P736, DOI 10.1161/01.STR.0000117575.48205.2D; Kearon C, 2003, NEW ENGL J MED, V349, P631, DOI 10.1056/NEJMoa035422; Kearon C, 1999, NEW ENGL J MED, V340, P901, DOI 10.1056/NEJM199903253401201; KHAMASHTA MA, 1995, NEW ENGL J MED, V332, P993, DOI 10.1056/NEJM199504133321504; Khamashta MA, 2000, J AUTOIMMUN, V15, P249, DOI 10.1006/jaut.2000.0421; Kutteh WH, 1996, AM J OBSTET GYNECOL, V174, P1584, DOI 10.1016/S0002-9378(96)70610-5; Laskin CA, 1997, NEW ENGL J MED, V337, P148, DOI 10.1056/NEJM199707173370302; Levine SR, 2004, JAMA-J AM MED ASSOC, V291, P576, DOI 10.1001/jama.291.5.576; LILLICRAP DP, 1990, AM J CLIN PATHOL, V93, P771, DOI 10.1093/ajcp/93.6.771; LOCKWOOD CJ, 1989, AM J OBSTET GYNECOL, V161, P369, DOI 10.1016/0002-9378(89)90522-X; LONG AA, 1991, THROMB HAEMOSTASIS, V66, P520; LYNCH A, 1994, ANN INTERN MED, V120, P470, DOI 10.7326/0003-4819-120-6-199403150-00004; Mateo J, 1997, THROMB HAEMOSTASIS, V77, P444; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; Mohr JP, 2001, NEW ENGL J MED, V345, P1444, DOI 10.1056/NEJMoa011258; Oshiro BT, 1996, OBSTET GYNECOL, V87, P489, DOI 10.1016/0029-7844(95)00498-X; Ost D, 2005, JAMA-J AM MED ASSOC, V294, P706, DOI 10.1001/jama.294.6.706; OUT HJ, 1992, AM J OBSTET GYNECOL, V167, P26, DOI 10.1016/S0002-9378(11)91619-6; Pattison NS, 2000, AM J OBSTET GYNECOL, V183, P1008, DOI 10.1067/mob.2000.106754; PATTISON NS, 1993, BRIT J OBSTET GYNAEC, V100, P909, DOI 10.1111/j.1471-0528.1993.tb15105.x; Petri M, 1996, SCAND J RHEUMATOL, V25, P191, DOI 10.3109/03009749609069986; Rai R, 1997, BRIT MED J, V314, P253, DOI 10.1136/bmj.314.7076.253; Rai RS, 1995, HUM REPROD, V10, P3301, DOI 10.1093/oxfordjournals.humrep.a135907; ROSOVE MH, 1992, ANN INTERN MED, V117, P303, DOI 10.7326/0003-4819-117-4-303; Satoh A, 1999, J RHEUMATOL, V26, P1715; Schulman S, 1998, AM J MED, V104, P332, DOI 10.1016/S0002-9343(98)00060-6; SHI W, 1990, AUST NZ J MED, V20, P231, DOI 10.1111/j.1445-5994.1990.tb01025.x; Tenedios F, 2005, LUPUS, V14, P691, DOI 10.1191/0961203305lu2202oa; Tincani A, 2003, LUPUS, V12, P524, DOI 10.1191/0961203303lu393oa; Tincani A, 2001, THROMB HAEMOSTASIS, V86, P575; Triplett DA, 2002, ARCH PATHOL LAB MED, V126, P1424; Tripodi A, 2002, THROMB HAEMOSTASIS, V88, P583; Tsapanos V, 2000, ARCH GYNECOL OBSTET, V263, P111, DOI 10.1007/s004040050007; Tulppala M, 1997, HUM REPROD, V12, P1567, DOI 10.1093/humrep/12.7.1567; VILA P, 1994, THROMB HAEMOSTASIS, V72, P209; Wahl DG, 1998, LUPUS, V7, P15, DOI 10.1191/096120398678919688; Wassermann A, 1906, DEUT MED WOCHENSCHR, V32, P0745, DOI 10.1055/s-0028-1142018; Wilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F; YASUDA M, 1995, OBSTET GYNECOL, V86, P555, DOI 10.1016/S0029-7844(95)80015-8; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; Zoghlami-Rintelen C, 2005, J THROMB HAEMOST, V3, P1160, DOI 10.1111/j.1538-7836.2005.01394.x	76	298	315	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	2006	295	9					1050	1057		10.1001/jama.295.9.1050	http://dx.doi.org/10.1001/jama.295.9.1050			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	016XJ	16507806				2022-12-28	WOS:000235656600025
J	Duley, L; Meher, S; Abalos, E				Duley, L; Meher, S; Abalos, E			Management of pre-eclampsia	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MAGNESIUM-SULFATE; PREGNANCY; RISK; HYPERTENSION; ECLAMPSIA		John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England; Liverpool Womens Hosp, Liverpool L8 7SS, Merseyside, England; Ctr Rosarino Estudios Perinatales, RA-2000 Rosario, Santa Fe, Argentina	University of Oxford; University of Liverpool	Duley, L (corresponding author), John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England.	lelia.duley@ndm.ox.ac.uk	Duley, Lelia/E-8107-2015	Duley, Lelia/0000-0001-6721-5178				Aaserud M, 2005, BMC HEALTH SERV RES, V5, DOI 10.1186/1472-6963-5-68; ATALLAH AN, 2002, COCHRANE DB SYST REV; Conde-Agudelo A, 2004, OBSTET GYNECOL, V104, P1367, DOI 10.1097/01.AOG.0000147599.47713.5d; DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395; Duckitt K, 2005, BRIT MED J, V330, P565, DOI 10.1136/bmj.38380.674340.E0; DULEY I, 2002, COCHRANE DB SYST REV; DULEY L, 1992, BRIT J OBSTET GYNAEC, V99, P547, DOI 10.1111/j.1471-0528.1992.tb13818.x; Gifford RW, 2000, AM J OBSTET GYNECOL, V183, pS1, DOI 10.1067/mob.2000.107928; Magee LA, 2005, AM J OBSTET GYNECOL, V193, P153, DOI 10.1016/j.ajog.2004.11.059; Magee LA, 2003, BMJ-BRIT MED J, V327, P955, DOI 10.1136/bmj.327.7421.955; Milne F, 2005, BRIT MED J, V330, P576, DOI 10.1136/bmj.330.7491.576; Roberts JM, 2001, LANCET, V357, P53, DOI 10.1016/S0140-6736(00)03577-7; Shennan A, 2003, PREECLAMPSIA, P305; Thompson S, 2004, BRIT MED J, V328, P269, DOI 10.1136/bmj.328.7434.269; Turnbull DA, 2004, LANCET, V363, P1104, DOI 10.1016/S0140-6736(04)15893-5; VILLAR J, IN PRESS AM J OBSTET; von Dadelszen P, 2000, LANCET, V355, P87, DOI 10.1016/S0140-6736(98)08049-0; [No title captured]	18	104	111	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 25	2006	332	7539					463	468		10.1136/bmj.332.7539.463	http://dx.doi.org/10.1136/bmj.332.7539.463			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	018VM	16497761	Green Published			2022-12-28	WOS:000235792900019
J	Campbell, AM; Eckdahl, TT; Fowlks, E; Heyer, LJ; Hoopes, LLM; Ledbetter, ML; Rosenwald, AG				Campbell, AM; Eckdahl, TT; Fowlks, E; Heyer, LJ; Hoopes, LLM; Ledbetter, ML; Rosenwald, AG			Genome Consortium for Active Teaching (GCAT)	SCIENCE			English	Editorial Material								A supportive network of scientists and faculty brings sophisticated microarray experiments to the undergraduate lab and classroom.	Davidson Coll, Dept Biol, Davidson, NC 28035 USA; Davidson Coll, Genome Consortium Act Teaching, Davidson, NC 28035 USA; Davidson Coll, Dept Math, Davidson, NC 28035 USA; Missouri Western State Univ, Dept Biol, St Joseph, MO 64507 USA; Hampton Univ, Dept Biol, Hampton, VA 23668 USA; Pomona Coll, Dept Biol, Claremont, CA 91711 USA; Coll Holy Cross, Dept Biol, Worcester, MA 01610 USA; Georgetown Univ, Dept Biol, Washington, DC 20057 USA	Davidson College; Davidson College; Davidson College; Hampton University; Claremont Colleges; Pomona College; College of the Holy Cross; Georgetown University	Campbell, AM (corresponding author), Davidson Coll, Dept Biol, Davidson, NC 28035 USA.	macampbell@davidson.edu						Brewster JL, 2004, BIOCHEM MOL BIOL EDU, V32, P217, DOI 10.1002/bmb.2004.494032040362; Campbell A Malcolm, 2002, Cell Biol Educ, V1, P70, DOI 10.1187/cbe.02-06-0014; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Heyer LJ, 2005, BIOINFORMATICS, V21, P2114, DOI 10.1093/bioinformatics/bti247; National Research Council, 2005, FAC INT RES; National Research Council, 2003, BIO2010 TRANSF UND E; *PROJ KAL, 2001, INV FAC; STEEN LA, 2005, MATH BIO 2010 LINK U	9	14	15	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	2006	311	5764					1103	1104		10.1126/science.1121955	http://dx.doi.org/10.1126/science.1121955			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017IU	16497918				2022-12-28	WOS:000235688100031
J	Clegg, DO; Reda, DJ; Harris, CL; Klein, MA; O'Dell, JR; Hooper, MM; Bradley, JD; Bingham, CO; Weisman, MH; Jackson, CG; Lane, NE; Cush, JJ; Moreland, LW; Schumacher, HR; Oddis, CV; Wolfe, F; Molitor, JA; Yocum, DE; Schnitzer, TJ; Furst, DE; Sawitzke, AD; Shi, H; Brandt, KD; Moskowitz, RW; Williams, HJ				Clegg, DO; Reda, DJ; Harris, CL; Klein, MA; O'Dell, JR; Hooper, MM; Bradley, JD; Bingham, CO; Weisman, MH; Jackson, CG; Lane, NE; Cush, JJ; Moreland, LW; Schumacher, HR; Oddis, CV; Wolfe, F; Molitor, JA; Yocum, DE; Schnitzer, TJ; Furst, DE; Sawitzke, AD; Shi, H; Brandt, KD; Moskowitz, RW; Williams, HJ			Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLE-BLIND; CLINICAL-TRIAL; RHEUMATOID-ARTHRITIS; RESEARCH-SOCIETY; OSTEO-ARTHRITIS; EFFICACY; PLACEBO; ACETAMINOPHEN; ROFECOXIB; CELECOXIB	BACKGROUND: Glucosamine and chondroitin sulfate are used to treat osteoarthritis. The multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) evaluated their efficacy and safety as a treatment for knee pain from osteoarthritis. METHODS: We randomly assigned 1583 patients with symptomatic knee osteoarthritis to receive 1500 mg of glucosamine daily, 1200 mg of chondroitin sulfate daily, both glucosamine and chondroitin sulfate, 200 mg of celecoxib daily, or placebo for 24 weeks. Up to 4000 mg of acetaminophen daily was allowed as rescue analgesia. Assignment was stratified according to the severity of knee pain (mild [N=1229] vs. moderate to severe [N=354]). The primary outcome measure was a 20 percent decrease in knee pain from baseline to week 24. RESULTS: The mean age of the patients was 59 years, and 64 percent were women. Overall, glucosamine and chondroitin sulfate were not significantly better than placebo in reducing knee pain by 20 percent. As compared with the rate of response to placebo (60.1 percent), the rate of response to glucosamine was 3.9 percentage points higher (P=0.30), the rate of response to chondroitin sulfate was 5.3 percentage points higher (P=0.17), and the rate of response to combined treatment was 6.5 percentage points higher (P=0.09). The rate of response in the celecoxib control group was 10.0 percentage points higher than that in the placebo control group (P=0.008). For patients with moderate-to-severe pain at baseline, the rate of response was significantly higher with combined therapy than with placebo (79.2 percent vs. 54.3 percent, P=0.002). Adverse events were mild, infrequent, and evenly distributed among the groups. CONCLUSIONS: Glucosamine and chondroitin sulfate alone or in combination did not reduce pain effectively in the overall group of patients with osteoarthritis of the knee. Exploratory analyses suggest that the combination of glucosamine and chondroitin sulfate may be effective in the subgroup of patients with moderate-to-severe knee pain.	Univ Utah, Sch Med, Salt Lake City, UT USA; Hines Vet Affairs Cooperat Studies Program Coordi, Hines, IL USA; Clin Res Pharm Coordinating Ctr, Albuquerque, NM USA; NIH, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA; Univ Nebraska, Med Ctr, Omaha, NE USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Indiana Univ, Sch Med, Indianapolis, IN USA; Hosp Joint Dis & Med Ctr, New York, NY USA; Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Presbyterian Med Ctr, Dallas, TX USA; Univ Alabama Birmingham, Birmingham, AL USA; Hosp Univ Penn, Philadelphia, PA 19104 USA; Univ Pittsburgh, Pittsburgh, PA 15260 USA; Arthrit Res Ctr, Wichita, KS USA; Ctr Clin, Wichita, KS USA; Virginia Mason Med Ctr, Seattle, WA 98101 USA; Univ Arizona, Coll Med, Tucson, AZ USA; Northwestern Univ, Chicago, IL 60611 USA; Univ Calif Los Angeles, Los Angeles, CA USA	Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine; University of Nebraska System; University of Nebraska Medical Center; Case Western Reserve University; Indiana University System; Indiana University-Purdue University Indianapolis; NYU Langone Medical Center; Hospital for Joint Disease NYULMC; Cedars Sinai Medical Center; University of California System; University of California San Francisco; University of Alabama System; University of Alabama Birmingham; University of Pennsylvania; Pennsylvania Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Data Bank for Rheumatic Diseases; Virginia Mason Medical Center; University of Arizona; Northwestern University; University of California System; University of California Los Angeles	Clegg, DO (corresponding author), Univ Utah, Sch Med 4B200, Div Rheumatol, 50 N Med Dr, Salt Lake City, UT 84132 USA.	gait.study@hsc.utah.edu	Bannuru, Raveendhara/G-2601-2011	Bannuru, Raveendhara/0000-0002-8069-5783; Moreland, Larry/0000-0003-4483-0359; , Domenic/0000-0003-1831-4270	NIAMS NIH HHS [N01AR92236] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [N01AR092236] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Altman RD, 1999, J RHEUMATOL, V26, P1216; Altman RD, 1998, J RHEUMATOL, V25, P2203; BELLAMY N, 1989, SEMIN ARTHRITIS RHEU, V18, P14, DOI 10.1016/0049-0172(89)90010-3; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Cannon GW, 2000, ARTHRITIS RHEUM-US, V43, P978, DOI 10.1002/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0; Cibere J, 2004, ARTHRIT RHEUM-ARTHR, V51, P738, DOI 10.1002/art.20697; Conrozier T, 1998, PRESSE MED, V27, P1862; Deeks JJ, 2002, BRIT MED J, V325, P619, DOI 10.1136/bmj.325.7365.619; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; HOCHBERG MC, 1992, ARTHRITIS RHEUM, V35, P498, DOI 10.1002/art.1780350502; Hochberg MC, 1997, J RHEUMATOL, V24, P792; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1541, DOI 10.1002/art.1780381104; Houpt JB, 1999, J RHEUMATOL, V26, P2423; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; Lehmann R, 2005, CURR MED RES OPIN, V21, P517, DOI 10.1185/030079905X38196; Liang, 2000, JANA, V3, P37; MAZIERES B, 1992, REV RHUM, V59, P466; McAlindon T, 2004, AM J MED, V117, P643, DOI 10.1016/j.amjmed.2004.06.023; McAlindon TE, 2000, JAMA-J AM MED ASSOC, V283, P1469, DOI 10.1001/jama.283.11.1469; Nussmeier NA, 2005, NEW ENGL J MED, V352, P1081, DOI 10.1056/NEJMoa050330; Pavelka K, 2002, ARCH INTERN MED, V162, P2113, DOI 10.1001/archinte.162.18.2113; Pham T, 2004, OSTEOARTHR CARTILAGE, V12, P389, DOI 10.1016/j.joca.2004.02.001; Ray WA, 2004, NEW ENGL J MED, V351, P2767, DOI 10.1056/NEJMc045711; Reginster JY, 2001, LANCET, V357, P251, DOI 10.1016/S0140-6736(00)03610-2; Russell AS, 2002, J RHEUMATOL, V29, P2407; SAS, 2000, SAS US GUID VERS 8; Schnitzer TJ, 2005, J RHEUMATOL, V32, P1093; Towheed TE, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002946.pub2; *US SEN COMM HLTH, 2004, CTR DIS CONTR ROL CO; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILLIAMS HJ, 1993, ARTHRITIS RHEUM-US, V36, P1196, DOI 10.1002/art.1780360904; 2005, NUTR BUSINESS J, V10, P6; 2002, CONSUM REP, V67, P18	36	792	895	2	162	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 23	2006	354	8					795	808		10.1056/NEJMoa052771	http://dx.doi.org/10.1056/NEJMoa052771			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014CL	16495392	Green Published, Bronze			2022-12-28	WOS:000235456200004
J	Keeley, EC; Boura, JA; Grines, CL				Keeley, EC; Boura, JA; Grines, CL			Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials	LANCET			English	Article							PRIMARY ANGIOPLASTY; EMERGENCY-ROOM; ABCIXIMAB; REPERFUSION; TIROFIBAN; FLOW; THROMBOLYSIS; PRETREATMENT; INHIBITION; STRATEGY	Background Facilitated percutaneons coronary intervention for ST-segment-elevation myocardial infarction (STEMI) is defined as the use of pharmacological substances before a planned immediate intervention, to improve coronary patency. We undertook a meta-analysis of randomised controlled trials (published and unpublished) to compare facilitated and primary percutaneous coronary intervention. Methods We identified 17 trials of patients with STEMI assigned to facilitated (n=2237) or primary (n=2267) percutaneous coronary intervention. We identified short-term outcomes (up to 42 days) of death, stroke, non-fatal reinfarction, urgent target vessel revascularisation, and major bleeding. Grade 3 flow rates for prethrombolysis and post-thrombolysis in myocardial infarction (TIMI) were also analysed. Findings The facilitated approach resulted in a greater than two-fold increase in the number of patients with initial TIMI grade 3 flow, compared with the primary approach (832 patients [37%] vs 342 [15%], odds ratio 3.18, 95% CI 2.22-4.55); however, final rates did not differ (1706 [89%] vs 1803 [88%]; 1.19, 0.86-1.64). Significantly more patients assigned to the facilitated approach than those assigned to the primary approach died (106 [5%] vs 78 [3%]; 1.38, 1.01-1.87), had higher non-fatal reinfarction rates (74 [3%] vs 41 [2%]; 1.71, 1.16-2.51), and had higher urgent target vessel revascularisation rates (66 [4%] vs 21 [1%]; 2.39, 1.23-4.66); the increased rates of adverse events seen with the facilitated approach were mainly seen in thrombolytic-therapy-based regimens. Facilitated intervention was associated with higher rates of major bleeding than primary intervention (159 [7%] vs 108 [5%]; 1.51, 1.10-2.08). Haemorrhagic stroke and total stroke rates were higher in thrombolytic-therapy-containing facilitated regimens than in primary intervention (haemorrhagic stroke 15 [0.7%] vs two [0.1%], p=0.0014; total stroke 24 [1.1%] vs six [0.3%], p=0.0008). Interpretation Facilitated percutaneous coronary intervention offers no benefit over primary percutaneous coronary intervention in STEMI treatment and should not be used outside the context of randomised controlled trials. Furthermore, facilitated interventions with thrombolytic-based regimens should be avoided.	Univ Texas, SW Med Ctr, Dept Internal Med, Div Cardiol, Dallas, TX 75390 USA; William Beaumont Hosp, Royal Oak, MI 48072 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Beaumont Health	Keeley, EC (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Div Cardiol, Dallas, TX 75390 USA.	Ellen.Keeley@UTSouthwestern.edu						Adams RJ, 2004, CIRCULATION, V110, P2512, DOI 10.1161/01.CIR.0000134791.68010.FA; Adgey J, 2005, AM HEART J, V150, P116, DOI 10.1016/j.ahj.2005.04.005; Arntz HR, 2003, EUR HEART J, V24, P268, DOI 10.1016/S0195-668X(03)94640-9; BELLANDI F, 2005, INT J CARDIOL, DOI DOI 10.1016/IJCARD.2005.04.025; Brodie BR, 2000, AM J CARDIOL, V85, P13, DOI 10.1016/S0002-9149(99)00598-6; Cutlip DE, 2003, AM J CARDIOL, V92, P977, DOI 10.1016/S0002-9149(03)00983-4; De Luca G, 2004, J AM COLL CARDIOL, V43, P1363, DOI 10.1016/j.jacc.2003.11.042; Fernandez-Aviles F, 2004, EUR HEART J, V25, P33; Gabriel HM, 2003, EUR HEART J, V24, P543, DOI 10.1016/S0195-668X(03)95631-4; Gersh BJ, 2005, JAMA-J AM MED ASSOC, V293, P979, DOI 10.1001/jama.293.8.979; Gyongyosi M, 2004, EUR HEART J, V25, P2125, DOI 10.1016/j.ehj.2004.09.018; Ishihara M, 2002, AM J CARDIOL, V90, P5, DOI 10.1016/S0002-9149(02)02376-7; Kastrati A, 2004, JAMA-J AM MED ASSOC, V291, P947, DOI 10.1001/jama.291.8.947; Lee DP, 2003, CIRCULATION, V107, P1497, DOI 10.1161/01.CIR.0000056120.00513.7A; Liem A, 2000, J AM COLL CARDIOL, V35, P600, DOI 10.1016/S0735-1097(99)00597-5; Martinez-Rios MA, 2004, AM J CARDIOL, V93, P280, DOI 10.1016/j.amjcard.2003.10.005; Montalescot G, 2001, NEW ENGL J MED, V344, P1895, DOI 10.1056/NEJM200106213442503; ONEILL WW, 1992, CIRCULATION, V86, P1710, DOI 10.1161/01.CIR.86.6.1710; Ross AM, 1999, J AM COLL CARDIOL, V34, P1954, DOI 10.1016/S0735-1097(99)00444-1; Silber S, 2005, EUR HEART J, V26, P804, DOI 10.1093/eurheartj/ehi138; Stone GW, 2001, CIRCULATION, V104, P636, DOI 10.1161/hc3101.093701; Topol EJ, 2001, LANCET, V357, P1905; Van de Werf F, 2006, LANCET, V367, P569, DOI 10.1016/S0140-6736(06)68147-6; van't Hof AWJ, 2004, EUR HEART J, V25, P837, DOI 10.1016/j.ehj.2004.04.003; Vermeer F, 1999, HEART, V82, P426, DOI 10.1136/hrt.82.4.426; Widimsky P, 2000, EUR HEART J, V21, P823, DOI 10.1053/euhj.1999.1993; Zeymer U, 2005, EUR HEART J, V26, P1971, DOI 10.1093/eurheartj/ehi293; Zorman S, 2002, AM J CARDIOL, V90, P533, DOI 10.1016/S0002-9149(02)02530-4	28	373	406	1	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 18	2006	367	9510					579	588		10.1016/S0140-6736(06)68148-8	http://dx.doi.org/10.1016/S0140-6736(06)68148-8			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013GM	16488801				2022-12-28	WOS:000235397800032
J	Olson, VG; Heusner, CL; Bland, RJ; During, MJ; Weinshenker, D; Palmiter, RD				Olson, VG; Heusner, CL; Bland, RJ; During, MJ; Weinshenker, D; Palmiter, RD			Role of noradrenergic signaling by the nucleus tractus solitarius in mediating opiate reward	SCIENCE			English	Article							CONDITIONED PLACE PREFERENCE; MORPHINE-WITHDRAWAL; DOPAMINE RELEASE; MICE; RATS; NOREPINEPHRINE; NORADRENALINE; LOCOMOTOR; LOCUS; PSYCHOSTIMULANTS	Norepinephrine (NE) is widely implicated in opiate withdrawal, but much less is known about its role in opiate-induced locomotion and reward. in mice lacking dopamine beta-hydroxytase (DBH), an enzyme critical for NE synthesis, we found that NE was necessary for morphine-induced conditioned place preference (CPP; a measure of reward) and locomotion. These deficits were rescued by systemic NE restoration. Viral restoration of DBH expression in the nucleus tractus solitarius, but not in the locus coeruleus, restored CPP for morphine. Morphine-induced locomotion was partially restored by DBH expression in either brain region. These data suggest that NE signaling by the nucleus tractus solitarius is necessary for morphine reward.	Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Neurologix, New York, NY 10032 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Palmiter, RD (corresponding author), Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA.	palmiter@u.washington.edu	During, Matthew/AAC-1388-2020; Weinshenker, David/V-3998-2019					Arnsten AFT, 2005, BIOL PSYCHIAT, V57, P1377, DOI 10.1016/j.biopsych.2004.08.019; Auclair A, 2004, EUR J NEUROSCI, V20, P3073, DOI 10.1111/j.1460-9568.2004.03805.x; Christie MJ, 1997, TRENDS PHARMACOL SCI, V18, P134, DOI 10.1016/S0165-6147(97)01045-6; DAVIS WM, 1975, PHARMACOL BIOCHEM BE, V3, P477, DOI 10.1016/0091-3057(75)90059-3; Delfs JM, 1998, BRAIN RES, V806, P127, DOI 10.1016/S0006-8993(98)00672-6; Delfs JM, 2000, NATURE, V403, P430, DOI 10.1038/35000212; Drouin C, 2002, J NEUROSCI, V22, P2873, DOI 10.1523/JNEUROSCI.22-07-02873.2002; Drouin C, 2001, NEUROREPORT, V12, P3483, DOI 10.1097/00001756-200111160-00022; GRENHOFF J, 1993, J NEURAL TRANSM-GEN, V93, P11, DOI 10.1007/BF01244934; Hnasko TS, 2005, NATURE, V438, P854, DOI 10.1038/nature04172; Knauber J, 2000, EUR NEUROPSYCHOPHARM, V10, P423, DOI 10.1016/S0924-977X(00)00100-0; Laorden ML, 2002, BRIT J PHARMACOL, V136, P67, DOI 10.1038/sj.bjp.0704684; Maldonado R, 1997, NEUROSCI BIOBEHAV R, V21, P91, DOI 10.1016/0149-7634(95)00061-5; MILNER PM, 1991, CAN J PSYCHOL, V45, P1, DOI 10.1037/h0084275; MOORE RY, 1979, ANNU REV NEUROSCI, V2, P113, DOI 10.1146/annurev.ne.02.030179.000553; Nader K, 1996, BEHAV NEUROSCI, V110, P389, DOI 10.1037/0735-7044.110.2.389; Sahraei H, 2004, PHARMACOL BIOCHEM BE, V78, P135, DOI 10.1016/j.pbb.2004.03.004; SCHANK JR, 2005, NEUROPSYCHOPHARMACOL; Shaham Y, 2000, EUR J NEUROSCI, V12, P292, DOI 10.1046/j.1460-9568.2000.00899.x; Spreng M, 2001, NEUROBIOL LEARN MEM, V75, P214, DOI 10.1006/nlme.2000.3965; STEIN L, 1978, PSYCHOPHARMACOLOGY G, P569; Thomas SA, 1998, J NEUROCHEM, V70, P2468; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; Tzschentke TM, 1998, PROG NEUROBIOL, V56, P613, DOI 10.1016/S0301-0082(98)00060-4; Ventura R, 2005, CEREB CORTEX, V15, P1877, DOI 10.1093/cercor/bhi066; Wang XY, 2001, EUR J PHARMACOL, V432, P153, DOI 10.1016/S0014-2999(01)01487-X; Watanabe T, 2003, PSYCHOPHARMACOLOGY, V170, P80, DOI 10.1007/s00213-003-1504-0; Zarrindast MR, 2002, PHARMACOL BIOCHEM BE, V73, P941, DOI 10.1016/S0091-3057(02)00951-6	28	102	106	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 17	2006	311	5763					1017	1020		10.1126/science.1119311	http://dx.doi.org/10.1126/science.1119311			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014CS	16484499				2022-12-28	WOS:000235456900050
J	Earle, MJ; Esperanca, JMSS; Gilea, MA; Lopes, JNC; Rebelo, LPN; Magee, JW; Seddon, KR; Widegren, JA				Earle, MJ; Esperanca, JMSS; Gilea, MA; Lopes, JNC; Rebelo, LPN; Magee, JW; Seddon, KR; Widegren, JA			The distillation and volatility of ionic liquids	NATURE			English	Article							VAPOR-PRESSURE; TEMPERATURE	It is widely believed that a defining characteristic of ionic liquids ( or low-temperature molten salts) is that they exert no measurable vapour pressure, and hence cannot be distilled(1,2.) Here we demonstrate that this is unfounded, and that many ionic liquids can be distilled at low pressure without decomposition. Ionic liquids represent matter solely composed of ions, and so are perceived as non-volatile substances. During the last decade, interest in the field of ionic liquids has burgeoned(3), producing a wealth of intellectual and technological challenges and opportunities for the production of new chemical and extractive processes(4-6), fuel cells and batteries(7), and new composite materials(8,9). Much of this potential is underpinned by their presumed involatility. This characteristic, however, can severely restrict the attainability of high purity levels for ionic liquids ( when they contain poorly volatile components) in recycling schemes, as well as excluding their use in gas-phase processes. We anticipate that our demonstration that some selected families of commonly used aprotic ionic liquids can be distilled at 200 - 300 degrees C and low pressure, with concomitant recovery of significant amounts of pure substance, will permit these currently excluded applications to be realized.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780901 Oeiras, Portugal; Queens Univ Belfast, QUILL Ctr, Belfast BT9 5AG, Antrim, North Ireland; Natl Inst Stand & Technol, Phys & Chem Properties Div, Boulder, CO 80305 USA	Universidade Nova de Lisboa; Queens University Belfast; National Institute of Standards & Technology (NIST) - USA	Rebelo, LPN (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Av Republ,Apartado 127, P-2780901 Oeiras, Portugal.	luis.rebelo@itqb.unl.pt	Lopes, José Nuno A Canongia/B-8109-2008; Magee, Joseph W/A-8496-2009; Lopes, Jose Nuno A Canongia/H-7166-2012; Esperança, José M. S. S./B-5116-2008; Lopes, J N Canongia/AAC-3020-2019; Rebelo, Luis Paulo/N-1017-2019; Rebelo, Luis Paulo N/B-5285-2008	Lopes, José Nuno A Canongia/0000-0002-4483-6294; Magee, Joseph W/0000-0002-9312-8593; Esperança, José M. S. S./0000-0001-9615-8678; Lopes, J N Canongia/0000-0002-4483-6294; Rebelo, Luis Paulo/0000-0002-5247-2443; Widegren, Jason/0000-0003-1077-7035; Canon Lop, Jos Nun/0000-0003-1527-105X	Engineering and Physical Sciences Research Council [EP/D029538/1] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		AbdulSada AK, 1997, EUR MASS SPECTROM, V3, P245, DOI 10.1255/ejms.18; Atkins M.P., 2004, IONIC LIQUIDS MAP IN; Baranyai KJ, 2004, AUST J CHEM, V57, P145, DOI 10.1071/CH03221; DYMEK CJ, 1987, JOINT 6 INT S MOLT S, P93; *ISI ESS SCI IND, 2004, SPEC TOP ION LIQ; JEAPEAS AJ, 2001, Patent No. 0115175; Kreher UP, 2004, MOLECULES, V9, P387, DOI 10.3390/90600387; Masse M., 2003, [No title captured], DOI WO03/062171A2, Patent No. 03062171; Ohno H, 2005, ELECTROCHEMICAL ASPECTS OF IONIC LIQUIDS, P1, DOI 10.1002/0471762512; OYE HA, 1991, MATER SCI FORUM, V73, P183, DOI 10.4028/www.scientific.net/MSF.73-75.183; OYE HA, 1984, 4 INT S MOLT SALTS E, P58; Paulechka YU, 2005, THERMOCHIM ACTA, V439, P158, DOI 10.1016/j.tca.2005.08.035; Rebelo LPN, 2005, J PHYS CHEM B, V109, P6040, DOI 10.1021/jp050430h; Rogers R.D., 2005, IONIC LIQUIDS A; Rogers R. D., 2005, IONIC LIQUIDS B; Rogers R.D., 2002, GREEN IND APPL IONIC; Rogers R. D., 2002, IONIC LIQUIDS IND AP; Seddon KR, 1996, KINET CATAL+, V37, P693; SEDDON KR, 1998, MOLTEN SALT FORUM, V5, P53; Wasserscheid P., 2003, IONIC LIQUIDS SYNTHE, DOI 10.1002/3527600701; Yoshizawa M, 2003, J AM CHEM SOC, V125, P15411, DOI 10.1021/ja035783d	21	1693	1739	9	673	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 16	2006	439	7078					831	834		10.1038/nature04451	http://dx.doi.org/10.1038/nature04451			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012JA	16482154				2022-12-28	WOS:000235333600046
J	Gedney, N; Cox, PM; Betts, RA; Boucher, O; Huntingford, C; Stott, PA				Gedney, N; Cox, PM; Betts, RA; Boucher, O; Huntingford, C; Stott, PA			Detection of a direct carbon dioxide effect in continental river runoff records	NATURE			English	Article							LAND-SURFACE SCHEME; CLIMATE; MODEL; TRANSPIRATION; SIMULATION; RADIATION; DATABASE; IMPACT; SCALE; CO2	Continental runoff has increased through the twentieth century(1,2) despite more intensive human water consumption(3). Possible reasons for the increase include: climate change and variability, deforestation, solar dimming(4), and direct atmospheric carbon dioxide (CO2) effects on plant transpiration(5). All of these mechanisms have the potential to affect precipitation and/or evaporation and thereby modify runoff. Here we use a mechanistic land-surface model(6) and optimal fingerprinting statistical techniques(7) to attribute observational runoff changes(1) into contributions due to these factors. The model successfully captures the climate-driven inter-annual runoff variability, but twentieth-century climate alone is insufficient to explain the runoff trends. Instead we find that the trends are consistent with a suppression of plant transpiration due to CO2-induced stomatal closure. This result will affect projections of freshwater availability, and also represents the detection of a direct CO2 effect on the functioning of the terrestrial biosphere.	Hadley Ctr Climate Predict & Res JCHMR, Met Off, Wallingford OX10 8BB, Oxon, England; Winfrith Technol Ctr, Ctr Ecol & Hydrol Dorset, Dorchester DT2 8ZD, Dorchester, England; Hadley Ctr Climate Predict & Res, Met Off, Exeter EX1 3PB, Devon, England; Ctr Ecol & Hydrol Wallingford, Wallingford OX10 8BB, Oxon, England; Univ Reading, Hadley Ctr Climate Predict & Res, Reading Unit, Met Off, Reading RG6 6BB, Berks, England	Met Office - UK; Hadley Centre; UK Centre for Ecology & Hydrology (UKCEH); Met Office - UK; Hadley Centre; UK Centre for Ecology & Hydrology (UKCEH); Met Office - UK; Hadley Centre; University of Reading	Gedney, N (corresponding author), Hadley Ctr Climate Predict & Res JCHMR, Met Off, Maclean Bldg, Wallingford OX10 8BB, Oxon, England.	nicola.gedney@metoffice.gov.uk	Cox, Peter Michae;/B-3299-2012; Boucher, Olivier/K-7483-2012; Huntingford, Christopher/A-4307-2008; Boucher, Olivier/J-5810-2012; Stott, Peter/N-1228-2016; Betts, Richard A/P-8976-2015; Scott, Peter/GYA-5335-2022	Cox, Peter Michae;/0000-0002-0679-2219; Boucher, Olivier/0000-0003-2328-5769; Huntingford, Christopher/0000-0002-5941-7770; Boucher, Olivier/0000-0003-2328-5769; Stott, Peter/0000-0003-4853-7686; Betts, Richard A/0000-0002-4929-0307; 	Natural Environment Research Council [ceh010022] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Betts RA, 1997, NATURE, V387, P796, DOI 10.1038/42924; Boucher O, 2004, CLIM DYNAM, V22, P597, DOI 10.1007/s00382-004-0402-4; Compagnucci R, 2001, CLIMATE CHANGE 2001: IMPACTS, ADAPTATION, AND VULNERABILITY, P191; Cox PM, 1999, CLIM DYNAM, V15, P183, DOI 10.1007/s003820050276; Cox PM, 1998, J HYDROL, V212, P79, DOI 10.1016/S0022-1694(98)00203-0; Dirmeyer P, 2003, COLA TECHNIC REP, V159, P1; Essery RLH, 2003, J HYDROMETEOROL, V4, P530, DOI 10.1175/1525-7541(2003)004<0530:EROSHI>2.0.CO;2; Fekete BM, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/1999GB001254; FIELD CB, 1995, PLANT CELL ENVIRON, V18, P1214, DOI 10.1111/j.1365-3040.1995.tb00630.x; Goldewijk KK, 2001, GLOBAL BIOGEOCHEM CY, V15, P417, DOI 10.1029/1999GB001232; Gordon C, 2000, CLIM DYNAM, V16, P147, DOI 10.1007/s003820050010; Harding RJ, 2000, AGR FOREST METEOROL, V100, P309, DOI 10.1016/S0168-1923(99)00152-5; HENNING D, 1989, ATLAS SURFACE HEAT B, P6; Labat D, 2004, ADV WATER RESOUR, V27, P631, DOI 10.1016/j.advwatres.2004.02.020; Lambert FH, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019545; Liepert BG, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014910; Loveland TR, 2000, INT J REMOTE SENS, V21, P1303, DOI 10.1080/014311600210191; MCNAUGHTON KG, 1991, AGR FOREST METEOROL, V54, P279, DOI 10.1016/0168-1923(91)90010-N; MITCHELL JFB, 2001, CLIMATE CHANGE 2001, P697; New M, 2000, J CLIMATE, V13, P2217, DOI 10.1175/1520-0442(2000)013<2217:RTCSTC>2.0.CO;2; Pope VD, 2000, CLIM DYNAM, V16, P123, DOI 10.1007/s003820050009; PROBST JL, 1987, J HYDROL, V94, P289, DOI 10.1016/0022-1694(87)90057-6; Roderick ML, 2002, SCIENCE, V298, P1410; Sellers PJ, 1996, SCIENCE, V271, P1402, DOI 10.1126/science.271.5254.1402; Shiklomanov IA, 2000, WATER INT, V25, P11, DOI 10.1080/02508060008686794; Stanhill G, 2001, AGR FOREST METEOROL, V107, P255, DOI 10.1016/S0168-1923(00)00241-0; STOTT PA, IN PRESS J CLIM; Tett SFB, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2000JD000028; *UN FAO, 2005, FAOSTAT STAT DAT POP; *UN FAO, 2005, FAOSTAT STAT DAT LAN	30	604	630	10	235	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 16	2006	439	7078					835	838		10.1038/nature04504	http://dx.doi.org/10.1038/nature04504			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012JA	16482155				2022-12-28	WOS:000235333600047
J	Bomback, A				Bomback, A			Errands	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												abomback@unch.unc.edu	Bomback, Andrew/A-8063-2009						0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	2006	295	7					731	733		10.1001/jama.295.7.731	http://dx.doi.org/10.1001/jama.295.7.731			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011YZ	16478890				2022-12-28	WOS:000235306700001
J	Berton, O; McClung, CA; DiLeone, RJ; Krishnan, V; Renthal, W; Russo, SJ; Graham, D; Tsankova, NM; Bolanos, CA; Rios, M; Monteggia, LM; Self, DW; Nestler, EJ				Berton, O; McClung, CA; DiLeone, RJ; Krishnan, V; Renthal, W; Russo, SJ; Graham, D; Tsankova, NM; Bolanos, CA; Rios, M; Monteggia, LM; Self, DW; Nestler, EJ			Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress	SCIENCE			English	Article							NEUROTROPHIC FACTOR; BEHAVIORAL SENSITIZATION; NUCLEUS-ACCUMBENS; DRUG-ADDICTION; BRAIN; NEURONS; COCAINE; REWARD; MECHANISMS; EXPRESSION	Mice experiencing repeated aggression develop a long-tasting aversion to social contact, which can be normalized by chronic, but not acute, administration of antidepressant. Using viral-mediated, mesolimbic dopamine pathway-specific knockdown of brain-derived neurotrophic factor (BDNF), we showed that BDNF is required for the development of this experience-dependent social aversion. Gene profiling in the nucleus accumbens indicates that local knockdown of BDNF obliterates most of the effects of repeated aggression on gene expression within this circuit, with similar effects being produced by chronic treatment with antidepressant. These results establish an essential rote for BDNF in mediating long-term neural and behavioral plasticity in response to aversive social experiences.	Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA; Tufts Univ, Sch Med, Dept Neurosci, Boston, MA 02111 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Tufts University	Nestler, EJ (corresponding author), Univ Texas, SW Med Ctr, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	eric.nestler@utsouthwestern.edu	McClung, Colleen/AAA-5943-2019; Graham, Danielle L/K-8459-2014; Winwood, Peter/A-6363-2008; Russo, Scott/R-7107-2019	Russo, Scott/0000-0002-6470-1805; Krishnan, Vaishnav/0000-0002-2847-0069; DiLeone, Ralph/0000-0002-4770-2590; Renthal, William/0000-0003-0206-2101				Avgustinovich D F, 2005, Neurosci Behav Physiol, V35, P917, DOI 10.1007/s11055-005-0146-6; Baquet ZC, 2005, J NEUROSCI, V25, P6251, DOI 10.1523/JNEUROSCI.4601-04.2005; Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8; Bolanos CA, 2004, NEUROMOL MED, V5, P69, DOI 10.1385/NMM:5:1:069; Buwalda B, 2005, NEUROSCI BIOBEHAV R, V29, P83, DOI 10.1016/j.neubiorev.2004.05.005; Cabib S, 2000, BEHAV BRAIN RES, V112, P13, DOI 10.1016/S0166-4328(00)00157-1; Conner JM, 1997, J NEUROSCI, V17, P2295; Duman RS, 2004, BIOL PSYCHIAT, V56, P140, DOI 10.1016/j.biopsych.2004.02.033; Eisch AJ, 2003, BIOL PSYCHIAT, V54, P994, DOI 10.1016/j.biopsych.2003.08.003; Goggi J, 2003, BRAIN RES, V968, P156, DOI 10.1016/S0006-8993(03)02234-0; Grimm JW, 2003, J NEUROSCI, V23, P742; Guillin O, 2001, NATURE, V411, P86, DOI 10.1038/35075076; Horger BA, 1999, J NEUROSCI, V19, P4110; Huhman KL, 2003, HORM BEHAV, V44, P293, DOI 10.1016/j.yhbeh.2003.05.001; Hung H C, 1996, Brain Res Mol Brain Res, V41, P14; Insel TR, 2004, ANNU REV NEUROSCI, V27, P697, DOI 10.1146/annurev.neuro.27.070203.144148; Isovich E, 2001, EUR J NEUROSCI, V13, P1254, DOI 10.1046/j.0953-816x.2001.01492.x; Izzo E, 2002, NAT NEUROSCI, V5, P1263, DOI 10.1038/nn977; Keedwell PA, 2005, BIOL PSYCHIAT, V58, P843, DOI 10.1016/j.biopsych.2005.05.019; Koob GF, 2004, NEUROSCI BIOBEHAV R, V27, P739, DOI 10.1016/j.neubiorev.2003.11.007; LOUILOT A, 1986, BRAIN RES, V397, P395, DOI 10.1016/0006-8993(86)90646-3; Nikulina EM, 2004, NEUROSCIENCE, V123, P857, DOI 10.1016/j.neuroscience.2003.10.029; Ochsner KN, 2004, CURR OPIN NEUROBIOL, V14, P254, DOI 10.1016/j.conb.2004.03.011; Porritt MJ, 2005, EXP NEUROL, V192, P226, DOI 10.1016/j.expneurol.2004.11.030; Rilling JK, 2002, NEURON, V35, P395, DOI 10.1016/S0896-6273(02)00755-9; Robbins TW, 2002, NEUROBIOL LEARN MEM, V78, P625, DOI 10.1006/nlme.2002.4103; Robinson R, 2004, HIGH EDUC, V47, P1, DOI 10.1023/B:HIGH.0000009803.70418.9c; Scammell TE, 2003, J NEUROSCI, V23, P5762; Schneier FR, 2000, AM J PSYCHIAT, V157, P457, DOI 10.1176/appi.ajp.157.3.457; Schneier FR, 2002, PSYCHIAT CLIN N AM, V25, P757, DOI 10.1016/S0193-953X(02)00018-7; Schultz W, 2006, ANNU REV PSYCHOL, V57, P87, DOI 10.1146/annurev.psych.56.091103.070229; Segal RA, 2003, ANNU REV NEUROSCI, V26, P299, DOI 10.1146/annurev.neuro.26.041002.131421; SEROOGY KB, 1994, J COMP NEUROL, V342, P321, DOI 10.1002/cne.903420302; SIEGFRIED B, 1984, BEHAV NEURAL BIOL, V42, P91, DOI 10.1016/S0163-1047(84)90484-9; Singer T, 2004, NEURON, V41, P653, DOI 10.1016/S0896-6273(04)00014-5; Tidey JW, 1996, BRAIN RES, V721, P140, DOI 10.1016/0006-8993(96)00159-X; Tiihonen J, 1997, AM J PSYCHIAT, V154, P239; Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406; Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327	39	1480	1517	8	222	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	2006	311	5762					864	868		10.1126/science.1120972	http://dx.doi.org/10.1126/science.1120972			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XT	16469931				2022-12-28	WOS:000235374900053
J	Clarke, M				Clarke, M			Commentary: Does amblyopia matter?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Royal Victoria Infirm, Eye Dept, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK	Clarke, M (corresponding author), Royal Victoria Infirm, Eye Dept, Claremont Wing, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	m.p.clarke@ncl.ac.uk						Attebo K, 1998, OPHTHALMOLOGY, V105, P154, DOI 10.1016/S0161-6420(98)91862-0; Chua B, 2004, BRIT J OPHTHALMOL, V88, P1119, DOI 10.1136/bjo.2004.041863; Membreno JH, 2002, OPHTHALMOLOGY, V109, P2265, DOI 10.1016/S0161-6420(02)01286-1; Rahi JS, 2006, BRIT MED J, V332, P820, DOI 10.1136/bmj.38751.597963.AE; Rahi JS, 2003, LANCET, V362, P1359, DOI 10.1016/S0140-6736(03)14631-4	5	1	1	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 8	2006	332	7545					824	824		10.1136/bmj.38772.411146.AE	http://dx.doi.org/10.1136/bmj.38772.411146.AE			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	032ZQ	16520327	Green Published, Bronze			2022-12-28	WOS:000236815900019
J	Annas, GJ				Annas, GJ			Congress, controlled substances, and physician-assisted suicide - Elephants in mouseholes	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SCHIAVO,TERRI; CARE		Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA.			Annas, George/0000-0001-5836-7831				ANNAS GJ, 1994, NEW ENGL J MED, V331, P1240, DOI 10.1056/NEJM199411033311822; Annas GJ, 2005, NEW ENGL J MED, V353, P2291, DOI 10.1056/NEJMlim053151; Annas GJ, 2005, NEW ENGL J MED, V352, P1710, DOI 10.1056/NEJMlim050643; [Anonymous], 2001, FED REG; Berwick DM, 2006, JAMA-J AM MED ASSOC, V295, P324, DOI 10.1001/jama.295.3.324; Blendon RJ, 2005, ARCH INTERN MED, V165, P2580, DOI 10.1001/archinte.165.22.2580; Fins J. J, 2005, PALLIATIVE ETHICS CA; Johnson SH, 2005, J LAW MED ETHICS, V33, P741, DOI 10.1111/j.1748-720X.2005.tb00541.x; Quill TE, 2006, NEW ENGL J MED, V354, P1, DOI 10.1056/NEJMp058289	9	6	6	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 9	2006	354	10					1079	1084		10.1056/NEJMlim060731	http://dx.doi.org/10.1056/NEJMlim060731			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	019FY	16525147	Green Published			2022-12-28	WOS:000235822200015
J	Haislip, JB; Nysewander, MC; Reichart, DE; Levan, A; Tanvir, N; Cenko, SB; Fox, DB; Price, PA; Castro-Tirado, AJ; Gorosabel, J; Evans, CR; Figueredo, E; MacLeod, CL; Kirschbrown, JR; Jelinek, M; Guziy, S; Postigo, AD; Cypriano, ES; LaCluyze, A; Graham, J; Priddey, R; Chapman, R; Rhoads, J; Fruchter, AS; Lamb, DQ; Kouveliotou, C; Wijers, RAMJ; Bayliss, MB; Schmidt, BP; Soderberg, AM; Kulkarni, SR; Harrison, FA; Moon, DS; Gal-Yam, A; Kasliwal, MM; Hudec, R; Vitek, S; Kubanek, P; Crain, JA; Foster, AC; Clemens, JC; Bartelme, JW; Canterna, R; Hartmann, DH; Henden, AA; Klose, S; Park, HS; Williams, GG; Rol, E; O'Brien, P; Bersier, D; Prada, F; Pizarro, S; Maturana, D; Ugarte, P; Alvarez, A; Fernandez, AJM; Jarvis, MJ; Moles, M; Alfaro, E; Ivarsen, KM; Kumar, ND; Mack, CE; Zdarowicz, CM; Gehrels, N; Barthelmy, S; Burrows, DN				Haislip, JB; Nysewander, MC; Reichart, DE; Levan, A; Tanvir, N; Cenko, SB; Fox, DB; Price, PA; Castro-Tirado, AJ; Gorosabel, J; Evans, CR; Figueredo, E; MacLeod, CL; Kirschbrown, JR; Jelinek, M; Guziy, S; Postigo, AD; Cypriano, ES; LaCluyze, A; Graham, J; Priddey, R; Chapman, R; Rhoads, J; Fruchter, AS; Lamb, DQ; Kouveliotou, C; Wijers, RAMJ; Bayliss, MB; Schmidt, BP; Soderberg, AM; Kulkarni, SR; Harrison, FA; Moon, DS; Gal-Yam, A; Kasliwal, MM; Hudec, R; Vitek, S; Kubanek, P; Crain, JA; Foster, AC; Clemens, JC; Bartelme, JW; Canterna, R; Hartmann, DH; Henden, AA; Klose, S; Park, HS; Williams, GG; Rol, E; O'Brien, P; Bersier, D; Prada, F; Pizarro, S; Maturana, D; Ugarte, P; Alvarez, A; Fernandez, AJM; Jarvis, MJ; Moles, M; Alfaro, E; Ivarsen, KM; Kumar, ND; Mack, CE; Zdarowicz, CM; Gehrels, N; Barthelmy, S; Burrows, DN			A photometric redshift of z = 6.39 +/- 0.12 for GRB 050904	NATURE			English	Article							GAMMA-RAY BURST; OPTICAL AFTERGLOW; RADIATION; EMISSION; PROBE	Gamma-ray bursts (GRBs) and their afterglows are the most brilliant transient events in the Universe. Both the bursts themselves and their afterglows have been predicted to be visible out to redshifts of z approximate to 20, and therefore to be powerful probes of the early Universe(1,2). The burst GRB 000131, at z = 4.50, was hitherto the most distant such event identified(3). Here we report the discovery of the bright near-infrared afterglow of GRB 050904 (ref. 4). From our measurements of the near-infrared afterglow, and our failure to detect the optical afterglow, we determine the photometric redshift of the burst to be z = 6.39(-0.12)(+0.11) (refs 5-7). Subsequently, it was measured(8) spectroscopically to be z = 6.29 +/- 0.01, in agreement with our photometric estimate. These results demonstrate that GRBs can be used to trace the star formation, metallicity, and reionization histories of the early Universe.	Univ N Carolina, Dept Phys & Astron, Chapel Hill, NC 27599 USA; Univ Hertfordshire, Ctr Astrophys Res, Hatfield AL10 9AB, Herts, England; CALTECH, Dept Astron, Pasadena, CA 91125 USA; Penn State Univ, Dept Astron & Astrophys, Davey Lab 525, University Pk, PA 16802 USA; Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; Inst Astrofis Andalucia, E-18080 Granada, Spain; Univ Sao Paulo, Inst Astron Geofis & Ciencias Atmosfer, BR-05508900 Sao Paulo, Brazil; So Observ Astrophys, La Serena, Chile; Lab Nacl Astrofis, BR-37500000 Itajuba, MG, Brazil; Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; Space Telescope Sci Inst, Baltimore, MD 21218 USA; Univ Chicago, Dept Astron & Astrophys, Chicago, IL 60637 USA; NASA, George C Marshall Space Flight Ctr, Natl Space Sci Technol Ctr, Huntsville, AL 35805 USA; Univ Amsterdam, Astron Inst Anton Pannekoek, NL-1098 SJ Amsterdam, Netherlands; Ctr High Energy Astrophys, NL-1098 SJ Amsterdam, Netherlands; Australian Natl Univ, Mt Stromlo & Siding Spring Observ, Canberra, ACT 2611, Australia; CALTECH, Space Radiat Lab, Pasadena, CA 91125 USA; Acad Sci Czech Republ, Inst Astron, CS-25165 Ondrejov, Czech Republic; Czech Tech Univ, Fac Electrotech, Prague 12135, Czech Republic; Integral Sci Data Ctr, CH-1290 Versoix, Switzerland; Univ Wyoming, Dept Phys & Astron, Laramie, WY 82072 USA; Clemson Univ, Dept Phys & Astron, Clemson, SC 29634 USA; Amer Assoc Variable Star Observers, Cambridge, MA 02138 USA; Thueringer Landessternwarte Tautenburg, D-07778 Tautenburg, Germany; Lawrence Livermore Natl Lab, Livermore, CA 94550 USA; Univ Arizona, Multiple Mirror Telescope Observ, Tucson, AZ 85721 USA; Univ Leicester, Dept Phys & Astron, Leicester LE1 7RH, Leics, England; Liverpool John Moores Univ, Astrophys Res Inst, Birkenhead CH41 1LD, Merseyside, England; Univ Oxford, Dept Phys, Oxford OX1 3RH, England; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Hertfordshire; California Institute of Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Hawaii System; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Astrofisica de Andalucia (IAA); Universidade de Sao Paulo; University of California System; University of California Berkeley; Space Telescope Science Institute; University of Chicago; National Aeronautics & Space Administration (NASA); NASA Marshall Space Flight Center; University of Amsterdam; Australian National University; California Institute of Technology; Czech Academy of Sciences; Astronomical Institute of the Czech Academy of Sciences; Czech Technical University Prague; University of Geneva; University of Wyoming; Clemson University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of Arizona; University of Leicester; Liverpool John Moores University; University of Oxford; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Reichart, DE (corresponding author), Univ N Carolina, Dept Phys & Astron, Campus Box 3255, Chapel Hill, NC 27599 USA.	reichart@physics.unc.edu	Jelínek, Martin/E-5290-2016; Kubánek, Petr/G-7209-2014; Kirschbrown, Justin/B-3636-2013; Vitek, Stanislav/B-3332-2015; Cypriano, Eduardo Serra/V-8027-2019; Barthelmy, Scott D/D-2943-2012; Gehrels, Neil/D-2971-2012; Evans, Charles/M-2377-2015; Cypriano, Eduardo S/C-7293-2012; Hudec, Rene/G-9018-2014; Levan, Andrew/F-6179-2014	Jelínek, Martin/0000-0003-3922-7416; Kubánek, Petr/0000-0002-1877-1386; Vitek, Stanislav/0000-0002-3185-1495; Cypriano, Eduardo Serra/0000-0001-9196-7038; Evans, Charles/0000-0001-5578-1033; Cypriano, Eduardo S/0000-0001-9196-7038; Levan, Andrew/0000-0001-7821-9369; Wijers, Ralph/0000-0002-3101-1808; Alfaro, E. J./0000-0002-2234-7035; de Ugarte Postigo, Antonio/0000-0001-7717-5085; Schmidt, Brian/0000-0002-8538-9195; Bayliss, Matthew/0000-0003-1074-4807; Castro-Tirado, A. J./0000-0003-2999-3563; Schmidt, Brian/0000-0001-6589-1287; Cypriano, Elysandra/0000-0003-3140-5783; Williams, George/0000-0002-3452-0560				Akerlof C, 1999, NATURE, V398, P400, DOI 10.1038/18837; Andersen MI, 2000, ASTRON ASTROPHYS, V364, pL54; Castro-Tirado AJ, 2005, NUOVO CIMENTO C, V28, P715, DOI 10.1393/ncc/i2005-10137-x; Chevalier RA, 1999, ASTROPHYS J, V520, pL29, DOI 10.1086/312147; Ciardi B, 2000, ASTROPHYS J, V540, P687, DOI 10.1086/309384; CUMMINGS J, 2005, 3910 GCN; DAVANZO P, 2005, 3921 GCN; DAVANZO P, 2005, 3930 GCN; Draine BT, 2000, ASTROPHYS J, V532, P273, DOI 10.1086/308581; FOX DB, 2005, 3912 GCN; Fox DW, 2003, NATURE, V422, P284, DOI 10.1038/nature01504; Frail DA, 2001, ASTROPHYS J, V562, pL55, DOI 10.1086/338119; Haislip J., 2005, 3913 GCN; HAISLIP J, 2005, 3919 GCN; HAISLIP J, 2005, 3914 GCN; JELINEK M, 2005, 3929 GCN; KAWAI N, 2005, 3937 GCN; KLOTZ A, 2005, 3917 GCN; Li WD, 2003, ASTROPHYS J, V586, pL9, DOI 10.1086/374684; Price PA, 2003, NATURE, V423, P844, DOI 10.1038/nature01734; Reichart D, 2005, NUOVO CIMENTO C, V28, P767, DOI 10.1393/ncc/i2005-10149-6; REICHART D, 2005, 3915 GCN; Reichart DE, 2001, ASTROPHYS J, V553, P235, DOI 10.1086/320630; SAKAMOTO T, 2005, 3938 GCN; Sari R, 1998, ASTROPHYS J, V497, pL17, DOI 10.1086/311269; Schlegel DJ, 1998, ASTROPHYS J, V500, P525, DOI 10.1086/305772; Smith JA, 2002, ASTRON J, V123, P2121, DOI 10.1086/339311; Spergel DN, 2003, ASTROPHYS J SUPPL S, V148, P175, DOI 10.1086/377226; WATSON D, UNPUB ASTROPHYS J	30	126	127	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	2006	440	7081					181	183		10.1038/nature04552	http://dx.doi.org/10.1038/nature04552			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019MC	16525465	Green Submitted, Bronze			2022-12-28	WOS:000235839500038
J	Yousry, TA; Major, EO; Ryschkewitsch, C; Fahle, G; Fischer, S; Hou, J; Curfman, B; Miszkiel, K; Mueller-Lenke, N; Sanchez, E; Barkhof, F; Radue, EW; Jager, HR; Clifford, DB				Yousry, TA; Major, EO; Ryschkewitsch, C; Fahle, G; Fischer, S; Hou, J; Curfman, B; Miszkiel, K; Mueller-Lenke, N; Sanchez, E; Barkhof, F; Radue, EW; Jager, HR; Clifford, DB			Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							JC VIRUS-DNA; CEREBROSPINAL-FLUID; MULTIPLE-SCLEROSIS; CROHNS-DISEASE; THERAPY	Background: Progressive multifocal leukoencephalopathy (PML) was reported to have developed in three patients treated with natalizumab. We conducted an evaluation to determine whether PML had developed in any other treated patients. Methods: We invited patients who had participated in clinical trials in which they received recent or long-term treatment with natalizumab for multiple sclerosis, Crohn's disease, or rheumatoid arthritis to participate. The clinical history, physical examination, brain magnetic resonance imaging (MRI), and testing of cerebrospinal fluid for JC virus DNA were used by an expert panel to evaluate patients for PML. We estimated the risk of PML in patients who completed at least a clinical examination for PML or had an MRI. Results: Of 3417 patients who had recently received natalizumab while participating in clinical trials, 3116 (91 percent) who were exposed to a mean of 17.9 monthly doses underwent evaluation for PML. Of these, 44 patients were referred to the expert panel because of clinical findings of possible PML, abnormalities on MRI, or a high plasma viral load of JC virus. No patient had detectable JC virus DNA in the cerebrospinal fluid. PML was ruled out in 43 of the 44 patients, but it could not be ruled out in one patient who had multiple sclerosis and progression of neurologic disease because data on cerebrospinal fluid testing and follow-up MRI were not available. Only the three previously reported cases of PML were confirmed (1.0 per 1000 treated patients; 95 percent confidence interval, 0.2 to 2.8 per 1000). Conclusions: A detailed review of possible cases of PML in patients exposed to natalizumab found no new cases and suggested a risk of PML of roughly 1 in 1000 patients treated with natalizumab for a mean of 17.9 months. The risk associated with longer treatment is not known.	Natl Inst Neurol Disorders & Stroke, Lab Mol Med & Neurosci, NIH, Bethesda, MD 20892 USA; Inst Neurol, London WC1N 3BG, England; NIH, Dept Lab Med, Ctr Clin, Bethesda, MD USA; Univ Basel, Dept Neuroradiol, Basel, Switzerland; Vrije Univ Amsterdam, Med Ctr, Dept Radiol, Amsterdam, Netherlands; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of London; University College London; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); University of Basel; Vrije Universiteit Amsterdam; Washington University (WUSTL); Washington University (WUSTL)	Major, EO (corresponding author), Natl Inst Neurol Disorders & Stroke, Lab Mol Med & Neurosci, NIH, 10 Ctr Dr,Bldg 10,Rm 3B14, Bethesda, MD 20892 USA.	majorg@ninds.nih.gov	Barkhof, Frederik/AAJ-6226-2020; Yousry, Tarek A/B-3417-2009; Jäger, Hans Rolf/K-1868-2013	Barkhof, Frederik/0000-0003-3543-3706; Jäger, Hans Rolf/0000-0002-6403-4184	Intramural NIH HHS Funding Source: Medline; Multiple Sclerosis Society [748] Funding Source: Medline; NINDS NIH HHS [U01 NS032228] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS001983, U01NS032228, Z01NS003049] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Multiple Sclerosis Society(National Multiple Sclerosis Society); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adelman B, 2005, NEW ENGL J MED, V353, P432, DOI 10.1056/NEJMc055235; GEISSLER A, 1995, LANCET, V345, P897; Kleinschmidt-DeMasters BK, 2005, NEW ENGL J MED, V353, P1745; Kleinschmidt-DeMasters BK, 2005, NEW ENGL J MED, V353, P369, DOI 10.1056/NEJMoa051782; Koralnik IJ, 2004, CURR OPIN NEUROL, V17, P365, DOI 10.1097/00019052-200406000-00019; Langer-Gould A, 2005, NEW ENGL J MED, V353, P375, DOI 10.1056/NEJMoa051847; Major EO, 2005, MULT SCLER J, V11, pS181; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; Rice GPA, 2005, NEUROLOGY, V64, P1336, DOI 10.1212/01.WNL.0000158329.30470.D0; Rudick RA, 2006, NEW ENGL J MED, V354, P911, DOI 10.1056/NEJMoa044396; Ryschkewitsch C, 2004, J VIROL METHODS, V121, P217, DOI 10.1016/j.jviromet.2004.06.021; Sandborn WJ, 2005, NEW ENGL J MED, V353, P1912, DOI 10.1056/NEJMoa043335; Thurnher MM, 2001, AM J NEURORADIOL, V22, P977; Van Assche G, 2005, NEW ENGL J MED, V353, P362, DOI 10.1056/NEJMoa051586; WHITEMAN MLH, 1993, RADIOLOGY, V187, P233, DOI 10.1148/radiology.187.1.8451420; Yiannoutsos CT, 1999, ANN NEUROL, V45, P816, DOI 10.1002/1531-8249(199906)45:6<816::AID-ANA21>3.0.CO;2-W	16	559	589	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 2	2006	354	9					924	933		10.1056/NEJMoa054693	http://dx.doi.org/10.1056/NEJMoa054693			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	017FN	16510746	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000235679600005
J	Fauci, AS				Fauci, AS			Emerging and re-emerging infectious diseases: Influenza as a prototype of the host-pathogen balancing act	CELL			English	Editorial Material								To respond to emerging and re-emerging infections, it is necessary to understand the interactions between microbial pathogens and their hosts and the impact of environmental and social factors on these interactions. The importance of understanding host-pathogen interactions is underscored by the emergence of virulent H5N1 avian influenza viruses and their transmission to humans, and the potential pandemic threat they pose.	NIAID, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Fauci, AS (corresponding author), NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	afauci@niaid.nih.gov						[Anonymous], FIELDS VIROLOGY; *FAO, 2006, AN HLTH AV INFL; Morens DM, 2004, NATURE, V430, P242, DOI 10.1038/nature02759; Taubenberger JK, 2005, NATURE, V437, P889, DOI 10.1038/nature04230; Taylor LH, 2001, PHILOS T R SOC B, V356, P983, DOI 10.1098/rstb.2001.0888; *WHO, 2002, AV INFL; Zheng B., 2006, P NATL ACAD SCI US, DOI [10.1073/pnas.0607974103, DOI 10.1073/PNAS.0607974103, DOI 10.1073/PNAS.051120103]	7	60	68	1	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 24	2006	124	4					665	670		10.1016/j.cell.2006.02.010	http://dx.doi.org/10.1016/j.cell.2006.02.010			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	038RO	16497575	Green Published, Bronze			2022-12-28	WOS:000237240900008
J	Tsukamoto, K				Tsukamoto, K			Spawning of eels near a seamount	NATURE			English	Editorial Material									Univ Tokyo, Ocean Res Inst, Nakano Ku, Tokyo 1648639, Japan	University of Tokyo	Tsukamoto, K (corresponding author), Univ Tokyo, Ocean Res Inst, Nakano Ku, Tokyo 1648639, Japan.	ktpc@ori.u-tokyo.ac.jp						[Anonymous], 2003, FISHERIES, V28, P28; Aoyama J, 1999, MAR ECOL PROG SER, V188, P193, DOI 10.3354/meps188193; Kimura S, 2001, FISH OCEANOGR, V10, P51, DOI 10.1046/j.1365-2419.2001.00159.x; McCleave JD, 1987, AM FISH SOC S SERIES, V1, P286; Schmidt J., 1925, Annual Report Smithsonian Institution, V1924, P279; Tsukamoto K, 2003, ENVIRON BIOL FISH, V66, P221, DOI 10.1023/A:1023926705906; TSUKAMOTO K, 1992, NATURE, V356, P789, DOI 10.1038/356789a0; Watanabe S, 2004, MAR BIOTECHNOL, V6, P566, DOI 10.1007/s10126-004-1000-5	8	183	212	5	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 23	2006	439	7079					929	929		10.1038/439929a	http://dx.doi.org/10.1038/439929a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014NE	16495988				2022-12-28	WOS:000235486100036
J	Lembo, AJ; Reynolds				Lembo, AJ; Reynolds			A 54-year-old woman with constipation-predominant irritable bowel syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FUNCTIONAL GASTROINTESTINAL DISORDERS; INTESTINAL BACTERIAL OVERGROWTH; RANDOMIZED CONTROLLED-TRIAL; RECEPTOR PARTIAL AGONIST; DOUBLE-BLIND; PSYCHOSOCIAL FACTORS; COST-EFFECTIVENESS; GENERAL-PRACTICE; UNITED-STATES; RISK-FACTORS		Beth Israel Deaconess Med Ctr, Gastrointestinal Motil Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Lembo, AJ (corresponding author), Beth Israel Deaconess Med Ctr, Gastrointestinal Motil Ctr, 330 Brookline Ave,DA-501 E, Boston, MA 02215 USA.	alembo@bidmc.harvard.edu						AGREUS L, 1995, GASTROENTEROLOGY, V109, P671, DOI 10.1016/0016-5085(95)90373-9; Akehurst RL, 2002, PHARMACOECONOMICS, V20, P455, DOI 10.2165/00019053-200220070-00003; [Anonymous], 2005, Drugs R D, V6, P245; Azpiroz F, 2000, DIGESTION, V62, P66, DOI 10.1159/000007780; BAZZOCCHI G, 1990, GASTROENTEROLOGY, V98, P686, DOI 10.1016/0016-5085(90)90289-D; Bensoussan A, 1998, JAMA-J AM MED ASSOC, V280, P1585, DOI 10.1001/jama.280.18.1585; BLIJKERK CJ, 2004, ALIMENT PHARM THER, V19, P245; Brandt LJ, 2002, AM J GASTROENTEROL, V97, pS7; Brinker AD, 2004, NEW ENGL J MED, V351, P1361; Camilleri M, 2000, PHARMACOECONOMICS, V17, P331, DOI 10.2165/00019053-200017040-00003; Cash BD, 2004, ALIMENT PHARM THER, V19, P1235, DOI 10.1111/j.1365-2036.2004.02001.x; Cash BD, 2002, AM J GASTROENTEROL, V97, P2812; Chan J, 1997, HEPATO-GASTROENTEROL, V44, P1328; Chey William D, 2003, Rev Gastroenterol Disord, V3 Suppl 2, pS35; Clouse RE, 2003, GUT, V52, P598, DOI 10.1136/gut.52.4.598; Coates MD, 2004, GASTROENTEROLOGY, V126, P1657, DOI 10.1053/j.gastro.2004.03.013; Corazziari E, 2000, GUT, V46, P522, DOI 10.1136/gut.46.4.522; Creed F, 2003, GASTROENTEROLOGY, V124, P303, DOI 10.1053/gast.2003.50055; DiPalma JA, 2000, AM J GASTROENTEROL, V95, P446; Drossman DA, 2003, GASTROENTEROLOGY, V125, P19, DOI 10.1016/S0016-5085(03)00669-3; DROSSMAN DA, 1993, DIGEST DIS SCI, V38, P1569, DOI 10.1007/BF01303162; Drossman DA, 2002, GASTROENTEROLOGY, V123, P2108, DOI 10.1053/gast.2002.37095; DROSSMAN DA, 1988, GASTROENTEROLOGY, V95, P701, DOI 10.1016/S0016-5085(88)80017-9; Dunlop SP, 2003, AM J GASTROENTEROL, V98, P1578, DOI 10.1016/S0002-9270(03)000375-7; Evans BW, 2004, COCHRANE DB SYST REV, pCD003960, DOI DOI 10.1002/14651858.CD003960.PUB2; EVERHART JE, 1991, GASTROENTEROLOGY, V100, P998, DOI 10.1016/0016-5085(91)90275-P; Francis CY, 1997, ALIMENT PHARM THERAP, V11, P395, DOI 10.1046/j.1365-2036.1997.142318000.x; Gralnek IM, 2000, GASTROENTEROLOGY, V119, P654, DOI 10.1053/gast.2000.16484; GRUSS HJ, 2004, AM J GASTROENTEROL, V126, pA640; Higgins PDR, 2004, ALIMENT PHARM THER, V19, P729, DOI 10.1111/j.1365-2036.2004.01903.x; Houghton LA, 2003, GUT, V52, P663, DOI 10.1136/gut.52.5.663; Hungin APS, 2005, ALIMENT PHARM THER, V21, P1365, DOI 10.1111/j.1365-2036.2005.02463.x; Jackson JL, 2000, AM J MED, V108, P65, DOI 10.1016/S0002-9343(99)00299-5; Johanson JF, 2004, CLIN GASTROENTEROL H, V2, P796, DOI 10.1016/S1542-3565(04)00356-8; Jones MP, 2002, DIGEST DIS SCI, V47, P2222, DOI 10.1023/A:1020131126397; JONES R, 1992, BRIT J CLIN PRACT, V46, P95; Kamm MA, 2005, AM J GASTROENTEROL, V100, P362, DOI 10.1111/j.1572-0241.2005.40749.x; Kellow J, 2003, GUT, V52, P671, DOI 10.1136/gut.52.5.671; Kim HJ, 2003, ALIMENT PHARM THER, V17, P895, DOI 10.1046/j.1365-2036.2003.01543.x; Kravitz RL, 2005, JAMA-J AM MED ASSOC, V293, P1995, DOI 10.1001/jama.293.16.1995; Lembo A, 2003, NEW ENGL J MED, V349, P1360, DOI 10.1056/NEJMra020995; Lembo A, 2003, DRUGS, V63, P1895, DOI 10.2165/00003495-200363180-00002; Lembo TJ, 2002, J CLIN GASTROENTEROL, V35, pS31, DOI 10.1097/00004836-200207001-00007; Lin HC, 2004, JAMA-J AM MED ASSOC, V292, P852, DOI 10.1001/jama.292.7.852; Locke GR, 2004, AM J GASTROENTEROL, V99, P350, DOI 10.1111/j.1572-0241.2004.04043.x; LONGSTRETH GF, 1993, DIGEST DIS SCI, V38, P1581, DOI 10.1007/BF01303163; Longstreth GF, 2003, AM J GASTROENTEROL, V98, P600, DOI 10.1016/S0002-9270(02)06018-5; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; Mertz H, 2000, GASTROENTEROLOGY, V118, P842, DOI 10.1016/S0016-5085(00)70170-3; MERTZ H, 1995, GASTROENTEROLOGY, V109, P40, DOI 10.1016/0016-5085(95)90267-8; Morganroth J, 2002, AM J GASTROENTEROL, V97, P2321; Muller-Lissner SA, 2001, ALIMENT PHARM THER, V15, P1655, DOI 10.1046/j.1365-2036.2001.01094.x; Muller-Lissner SA, 2005, AM J GASTROENTEROL, V100, P232, DOI 10.1111/j.1572-0241.2005.40885.x; Nobaek S, 2000, AM J GASTROENTEROL, V95, P1231; Novick J, 2002, ALIMENT PHARM THER, V16, P1877, DOI 10.1046/j.1365-2036.2002.01372.x; Nyhlin H, 2004, SCAND J GASTROENTERO, V39, P119, DOI 10.1080/00365520310006748; OWENS DM, 1995, ANN INTERN MED, V122, P107, DOI 10.7326/0003-4819-122-2-199501150-00005; Palsson AS, 2005, GASTROENTEROL CLIN N, V34, P281, DOI 10.1016/j.gtc.2005.02.004; Parry S, 2005, EUR J GASTROEN HEPAT, V17, P5, DOI 10.1097/00042737-200501000-00002; Pata C, 2002, AM J GASTROENTEROL, V97, P1780; Patel S, 2004, EXPERT OPIN PHARMACO, V5, P2369, DOI 10.1517/14656566.5.11.2369; Pimentel M, 2005, AM J GASTROENTEROL, V100, pS324, DOI 10.14309/00000434-200509001-00882; Pimentel M, 2003, AM J GASTROENTEROL, V98, P412, DOI 10.1016/S0002-9270(02)05902-6; Pimentel M, 2003, DIGEST DIS SCI, V48, P86, DOI 10.1023/A:1021738515885; Pimentel M, 2000, AM J GASTROENTEROL, V95, P3503, DOI 10.1111/j.1572-0241.2000.03368.x; Pittler MH, 1998, AM J GASTROENTEROL, V93, P1131, DOI 10.1111/j.1572-0241.1998.00343.x; Pitz M, 2005, CLIN GASTROENTEROL H, V3, P237, DOI 10.1016/S1542-3565(04)00626-3; Quartero AO, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003460.pub2; Rosenthal MB, 2002, NEW ENGL J MED, V346, P498, DOI 10.1056/NEJMsa012075; Sanders DS, 2001, LANCET, V358, P1504, DOI 10.1016/S0140-6736(01)06581-3; SCHNEIDER A, 2005, GUT             0908, DOI DOI 10.1136/GUT.2005.074518; Schoenfeld P, 2004, ALIMENT PHARM THER, V20, P25, DOI 10.1111/j.1365-2036.2004.02182.x; Schoenfeld P, 2004, ALIMENT PHARM THER, V19, P263, DOI 10.1111/j.1365-2036.2004.01864.x; Spiegel BMR, 2004, GASTROENTEROLOGY, V126, P1721, DOI 10.1053/j.gastro.2004.03.012; Spiller RC, 2000, GUT, V47, P804, DOI 10.1136/gut.47.6.804; Stedman C, 2002, SEMIN LIVER DIS, V22, P195, DOI 10.1055/s-2002-30104; Tack J, 2005, GUT, V54, P1707, DOI 10.1136/gut.2005.070789; TACK J, 2006, GUT             0109, DOI DOI 10.1136/GUT.2005.077503; TALLEY NJ, 1995, AM J EPIDEMIOL, V142, P76, DOI 10.1093/oxfordjournals.aje.a117548; TALLEY NJ, 1992, GASTROENTEROLOGY, V102, P1259; Talley NJ, 2003, AM J GASTROENTEROL, V98, P1107, DOI 10.1016/S0002-9270(03)00239-9; TALLEY NJ, 1995, GASTROENTEROLOGY, V109, P1736, DOI 10.1016/0016-5085(95)90738-6; Talley NJ, 1997, GUT, V41, P394, DOI 10.1136/gut.41.3.394; Thompson WG, 1999, GUT, V45, P43; Thompson WG, 2000, GUT, V46, P78, DOI 10.1136/gut.46.1.78; TOLLIVER BA, 1994, AM J GASTROENTEROL, V89, P176; Tougas G, 2002, ALIMENT PHARM THER, V16, P1701, DOI 10.1046/j.1365-2036.2002.01347.x; Vanner SJ, 1999, AM J GASTROENTEROL, V94, P2912; Walters B, 2005, AM J GASTROENTEROL, V100, P1566, DOI 10.1111/j.1572-0241.2005.40795.x; Weeks J, 2001, Health Forum J, V44, P44; Winawer S, 2003, GASTROENTEROLOGY, V124, P544, DOI 10.1053/gast.2003.50044; YADAV S K, 1989, Indian Journal of Medical Research Section B, V90, P496	92	5	6	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	2006	295	8					925	933		10.1001/jama.295.8.925	http://dx.doi.org/10.1001/jama.295.8.925			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014DO	16493106				2022-12-28	WOS:000235459200026
J	Bevan, G; Hood, C				Bevan, G; Hood, C			Health policy - Have targets improved performance in the English NHS?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material								The star rating system for NHS trusts seems to have improved performance, but we still don't know how genuine the improvements are or the costs to other services.	Univ London London Sch Econ & Polit Sci, Dept Operat Res, London WC2A 2AE, England; Univ Oxford All Souls Coll, Oxford OX1 4AL, England	University of London; London School Economics & Political Science; University of Oxford	Bevan, G (corresponding author), Univ London London Sch Econ & Polit Sci, Dept Operat Res, Houghton St, London WC2A 2AE, England.	R.G.Bevan@lse.ac.uk			Economic and Social Research Council [RES-153-34-1003, RES-572-28-5001] Funding Source: researchfish	Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))		*AUD COMM, 2004, INF DAT QUAL NHS; *AUD GEN WAL, 2005, NHS WAIT TIM WAL, V2; Audit Commission, 2003, WAIT LIST ACC; Behn R.D., 2001, RETHINKING DEMOCRATI; Berliner J., 1988, SOVIET IND STALIN GO; Bevan G, 2004, BRIT MED J, V328, P598, DOI 10.1136/bmj.328.7440.598; BEVAN G, IN PRESS PUBLIC ADMI; Bird SM, 2005, J ROY STAT SOC A STA, V168, P1, DOI 10.1111/j.1467-985X.2004.00333.x; *BRIT MED ASS, 2005, BMA SURV A E WAIT TI; CARTER N, 1995, ORG MEASURE SUCCESS; *COMM HLTH IMPR, 2004, WHAT CHI HAS FOUND A; *COMM HLTH IMPR, 2003, NHS PERF RAT PRIM CA; Commission for Health Improvement, 2003, NHS PERF RAT AC TRUS; Commission for Health Improvement, 2003, WHAT CHI HAS FOUND A; *DEP HLTH, 2005, AMB SERV; *DEP HLTH, 1999, 1999091 HSC DEP HLTH; *DEP HLTH, 2005, CHIEF EX REP NHS S; *DOH, 2001, NHS PERF RAT AC TRUS; *DOH, 2002, NHS PERF RAT AC TRUS; *HEALTHC COMM, 2005, PRIM CAR TRUST SURV; *HEALTHC COMM, 2005, ANN HLTH CHECK; *HEALTHC COMM, 2005, NHS PERF RAT 2004 20; *HLTHC COMM, 2004, PERF RAT; Kornai J., 1994, OVERCENTRALISATION E; MAYOR S, 2003, BMJ-BRIT MED J, V326, P1054; *NAT ASS WAL, 2001, HLTH STAT WAL 2001, pCH12; *NAT ASS WAL, 2005, HLTH STAT WAL 2005, pCH13; *NAT AUD OFF, 2001, 452 HC NAT AUD OFF S; *NAT AUD OFF, 2004, 1075 HC NAT AUD OFF, P2; *PUBL ADM SEL COMM, 2003, 5 REP TARG GOV MEAS; TIMMINS N, 2005, FINANC TIMES, P2; 2005, ECONOMIST       0323	32	154	155	1	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 18	2006	332	7538					419	422B		10.1136/bmj.332.7538.419	http://dx.doi.org/10.1136/bmj.332.7538.419			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	017HZ	16484272	Green Published			2022-12-28	WOS:000235686000027
J	Lundin, R; Winningham, D; Barabash, S; Frahm, R; Holmstrom, M; Sauvaud, JA; Fedorov, A; Asamura, K; Coates, AJ; Soobiah, Y; Hsieh, KC; Grande, M; Koskinen, H; Kallio, E; Kozyra, J; Woch, J; Fraenz, M; Brain, D; Luhmann, J; McKenna-Lawler, S; Orsini, RS; Brandt, P; Wurz, P				Lundin, R; Winningham, D; Barabash, S; Frahm, R; Holmstrom, M; Sauvaud, JA; Fedorov, A; Asamura, K; Coates, AJ; Soobiah, Y; Hsieh, KC; Grande, M; Koskinen, H; Kallio, E; Kozyra, J; Woch, J; Fraenz, M; Brain, D; Luhmann, J; McKenna-Lawler, S; Orsini, RS; Brandt, P; Wurz, P			Plasma acceleration above martian magnetic anomalies	SCIENCE			English	Article							CRUSTAL MAGNETIZATION; FIELD; MARS; IONOSPHERE; PARTICLE	Auroras are caused by accelerated charged particles precipitating along magnetic field lines into a planetary atmosphere, the auroral brightness being roughly proportional to the precipitating particle energy flux. The Analyzer of Space plasma and Energetic Atoms experiment on the Mars Express spacecraft has made a detailed study of acceleration processes on the nightside of Mars. We observed accelerated electrons and ions in the deep nightside high-attitude region of Mars that map geographically to interface/cleft regions associated with martian crustal magnetization regions. By integrating electron and ion acceleration energy down to the upper atmosphere, we saw energy fluxes in the range of 1 to 50 milliwatts per square meter per second. These conditions are similar to those producing bright discrete auroras above Earth. Discrete auroras at Mars are therefore expected to be associated with plasma acceleration in diverging magnetic flux tubes above crustal magnetization regions, the auroras being distributed geographically in a complex pattern by the many multipole magnetic field lines extending into space.	Swedish Inst Space Phys, S-98128 Kiruna, Sweden; SW Res Inst, San Antonio, TX 78228 USA; Ctr Etud Spatiale Rayonnements, F-31028 Toulouse, France; Inst Space & Astronaut Sci, Sagamihara, Japan; UCL, Mullard Space Sci Labs, Dorking RH5 6NT, Surrey, England; Univ Arizona, Dept Space Phys, Tucson, AZ 85721 USA; Rutherford Appleton Lab, Didcot OX11 0QX, Oxon, England; Finnish Meteorol Inst, FIN-00101 Helsinki, Finland; Univ Helsinki, Dept Phys Sci, Helsinki, Finland; Univ Michigan, Space Phys Res Lab, Ann Arbor, MI 48109 USA; Max Planck Inst Sonnensyst Forsch, D-37191 Katlenburg Lindau, Germany; Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA; Natl Univ Ireland, Space Technol Ltd, Maynooth, Kildare, Ireland; Inst Fis Spazio Interplanetari, I-00133 Rome, Italy; Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20723 USA; Univ Bern, Inst Phys, CH-3012 Bern, Switzerland	Southwest Research Institute; Japan Aerospace Exploration Agency (JAXA); Institute of Space & Astronautical Science (ISAS); University of London; University College London; University of Arizona; UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory; Finnish Meteorological Institute; University of Helsinki; University of Michigan System; University of Michigan; Max Planck Society; University of California System; University of California Berkeley; Maynooth University; Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; University of Bern	Lundin, R (corresponding author), Swedish Inst Space Phys, Box 812, S-98128 Kiruna, Sweden.		Brandt, Pontus C/N-1218-2016; Grande, Manuel/C-2242-2013; Kallio, Esa/F-9410-2014; Koskinen, Hannu E. J./B-4971-2017; Wurz, Peter/R-2273-2017; Coates, Andrew/C-2396-2008; kallio, esa/M-9541-2019	Brandt, Pontus C/0000-0002-4644-0306; Grande, Manuel/0000-0002-2233-2618; Kallio, Esa/0000-0002-9791-804X; Koskinen, Hannu E. J./0000-0003-3839-6461; Wurz, Peter/0000-0002-2603-1169; Coates, Andrew/0000-0002-6185-3125; kallio, esa/0000-0002-9791-804X; BRAIN, DAVID/0000-0001-8932-368X; asamura, kazushi/0000-0002-6076-3814	UK Space Agency [PP/D000831/1] Funding Source: researchfish	UK Space Agency		Acuna MH, 1999, SCIENCE, V284, P790, DOI 10.1126/science.284.5415.790; ALBERT RD, 1967, PHYS REV LETT, V18, P369, DOI 10.1103/PhysRevLett.18.369; BARABASH S, 2004, ESA SPECIAL PUBLICAT, P121; Bertaux JL, 2005, NATURE, V435, P790, DOI 10.1038/nature03603; CALVERT W, 1981, GEOPHYS RES LETT, V8, P919, DOI 10.1029/GL008i008p00919; CHIU YT, 1978, J GEOPHYS RES-SPACE, V83, P629, DOI 10.1029/JA083iA02p00629; EVANS DS, 1974, J GEOPHYS RES, V79, P2853, DOI 10.1029/JA079i019p02853; FRANK LA, 1971, J GEOPHYS RES, V76, P3612, DOI 10.1029/JA076i016p03612; Hanson W. B., 1977, Journal of Geophysical Research, V82, P4351, DOI 10.1029/JS082i028p04351; Krymskii AM, 2002, J GEOPHYS RES-SPACE, V107, DOI 10.1029/2001JA000239; LUHMANN JG, 1992, GEOPHYS MONOGR SER, V66, P417, DOI DOI 10.1029/GM066P0417; Lundin R, 2004, SCIENCE, V305, P1933, DOI 10.1126/science.1101860; LUNDIN R, 1989, NATURE, V341, P609, DOI 10.1038/341609a0; LUNDIN R, IN PRESS ICARUS; McElroy M. B., 1977, Journal of Geophysical Research, V82, P4379, DOI 10.1029/JS082i028p04379; MCILWAIN CE, 1960, J GEOPHYS RES, V65, P2727, DOI 10.1029/JZ065i009p02727; Mitchell DL, 2001, J GEOPHYS RES-PLANET, V106, P23419, DOI 10.1029/2000JE001435; Moore TE, 1999, SPACE SCI REV, V88, P7, DOI 10.1023/A:1005299616446; PEREZDETEJADA H, 1987, J GEOPHYS RES, V92, P4713, DOI 10.1029/JA092iA05p04713; SHARP RD, 1977, J GEOPHYS RES-SPACE, V82, P3324, DOI 10.1029/JA082i022p03324; SHELLEY EG, 1976, GEOPHYS RES LETT, V3, P654, DOI 10.1029/GL003i011p00654; WINNINGHAM JD, IN PRESS ICARUS	22	93	96	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 17	2006	311	5763					980	983		10.1126/science.1122071	http://dx.doi.org/10.1126/science.1122071			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014CS	16484488				2022-12-28	WOS:000235456900039
J	Clevers, H				Clevers, H			Colon cancer - Understanding how NSAIDs work	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Netherlands Inst Dev Biol, Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Clevers, H (corresponding author), Netherlands Inst Dev Biol, Utrecht, Netherlands.							Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Clevers H, 2004, CELL, V118, P671, DOI 10.1016/j.cell.2004.09.005; Koehne CH, 2004, SEMIN ONCOL, V31, P12, DOI 10.1053/j.seminoncol.2004.03.041; Oshima M, 2002, CURR PHARM DESIGN, V8, P1021, DOI 10.2174/1381612023394953	4	69	75	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 16	2006	354	7					761	763		10.1056/NEJMcibr055457	http://dx.doi.org/10.1056/NEJMcibr055457			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	012CP	16481647				2022-12-28	WOS:000235316100017
J	Ostojic, S; Somfai, E; Nienhuis, B				Ostojic, S; Somfai, E; Nienhuis, B			Scale invariance and universality of force networks in static granular matter	NATURE			English	Article							NUMERICAL-MODEL; FLUCTUATIONS	Force networks form the skeleton of static granular matter(1,2). They are the key factor that determines mechanical properties such as stability(3), elasticity(4,5) and sound transmission(6,7), which are important for civil engineering and industrial processing. Previous studies have focused on investigations of the global structure of external forces(8-11) ( the boundary condition) and on the probability distribution of individual contact forces(4,12). So far, however, precise knowledge of the disordered spatial structure of the force network has remained elusive. Here we report that molecular dynamics simulations of realistic granular packings reveal scale invariance of clusters of particles interacting by means of relatively strong forces. Despite visual variation, force networks for various values of the confining pressure and other parameters have identical scaling exponents and scaling function, thereby determining a universality class. Unexpectedly, the flat ensemble of force configurations(13-15) (a simple generalization of equilibrium statistical mechanics) belongs to this universality class, whereas some widely studied simplified models(16-18) do not. This implies that the elasticity of the grains and their geometrical disorder do not affect the universal mechanical properties.	Univ Amsterdam, Inst Theoret Phys, NL-1018 XE Amsterdam, Netherlands; Leiden Univ, Inst Lorentz, NL-2300 RA Leiden, Netherlands	University of Amsterdam; Leiden University; Leiden University - Excl LUMC	Nienhuis, B (corresponding author), Univ Amsterdam, Inst Theoret Phys, Valckenierstr 65, NL-1018 XE Amsterdam, Netherlands.	nienhuis@science.uva.nl	Somfai, Ellák/A-9277-2009	Somfai, Ellák/0000-0002-2218-8855				Blair DL, 2001, PHYS REV E, V63, DOI 10.1103/PhysRevE.63.041304; Brujic J, 2003, FARADAY DISCUSS, V123, P207, DOI 10.1039/b204414e; Coppersmith SN, 1996, PHYS REV E, V53, P4673, DOI 10.1103/PhysRevE.53.4673; CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47; Da Silva M, 2000, NATURE, V406, P708, DOI 10.1038/35021023; Daerr A, 1999, NATURE, V399, P241, DOI 10.1038/20392; EDWARDS SF, 1989, PHYSICA A, V157, P1080, DOI 10.1016/0378-4371(89)90034-4; Erikson JM, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.040301; FORTUIN CM, 1972, PHYSICA, V57, P536, DOI 10.1016/0031-8914(72)90045-6; GARCIAROJO R, 2005, POWDERS GRAINS; Geng JF, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.035506; Goldenberg C, 2005, NATURE, V435, P188, DOI 10.1038/nature03497; Jaeger HM, 1996, REV MOD PHYS, V68, P1259, DOI 10.1103/RevModPhys.68.1259; Jia X, 1999, PHYS REV LETT, V82, P1863, DOI 10.1103/PhysRevLett.82.1863; Johnson KL, 1985, CONTACT MECH, DOI 10.1201/b17110-2; LIU CH, 1995, SCIENCE, V269, P513, DOI 10.1126/science.269.5223.513; Majmudar TS, 2005, NATURE, V435, P1079, DOI 10.1038/nature03805; Makse HA, 1999, PHYS REV LETT, V83, P5070, DOI 10.1103/PhysRevLett.83.5070; Makse HA, 2000, PHYS REV LETT, V84, P4160, DOI 10.1103/PhysRevLett.84.4160; Makse HA, 2002, NATURE, V415, P614, DOI 10.1038/415614a; Mueth DM, 1998, PHYS REV E, V57, P3164, DOI 10.1103/PhysRevE.57.3164; Ostojic S, 2005, EUROPHYS LETT, V71, P70, DOI 10.1209/epl/i2004-10530-9; Radjai F, 1996, PHYS REV LETT, V77, P274, DOI 10.1103/PhysRevLett.77.274; Reydellet G, 2001, PHYS REV LETT, V86, P3308, DOI 10.1103/PhysRevLett.86.3308; Snoeijer JH, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.054302; Somfai E, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.021301; Stauffer D., 1992, INTRO PERCOLATION TH; Vanel L, 1999, PHYS REV E, V60, pR5040, DOI 10.1103/PhysRevE.60.R5040; Wittmer JP, 1996, NATURE, V382, P336, DOI 10.1038/382336a0	29	113	116	4	48	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 16	2006	439	7078					828	830		10.1038/nature04549	http://dx.doi.org/10.1038/nature04549			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012JA	16482153	Green Submitted			2022-12-28	WOS:000235333600045
J	Paton, JJ; Belova, MA; Morrison, SE; Salzman, CD				Paton, JJ; Belova, MA; Morrison, SE; Salzman, CD			The primate amygdala represents the positive and negative value of visual stimuli during learning	NATURE			English	Article							ORBITOFRONTAL CORTEX; BASOLATERAL AMYGDALA; REWARD PREFERENCE; NEURONAL-ACTIVITY; MACAQUE MONKEY; ALERT MONKEY; ORGANIZATION; CONNECTIONS; CIRCUITRY; RESPONSES	Visual stimuli can acquire positive or negative value through their association with rewards and punishments, a process called reinforcement learning. Although we now know a great deal about how the brain analyses visual information, we know little about how visual representations become linked with values. To study this process, we turned to the amygdala, a brain structure implicated in reinforcement learning(1-5). We recorded the activity of individual amygdala neurons in monkeys while abstract images acquired either positive or negative value through conditioning. After monkeys had learned the initial associations, we reversed image value assignments. We examined neural responses in relation to these reversals in order to estimate the relative contribution to neural activity of the sensory properties of images and their conditioned values. Here we show that changes in the values of images modulate neural activity, and that this modulation occurs rapidly enough to account for, and correlates with, monkeys' learning. Furthermore, distinct populations of neurons encode the positive and negative values of visual stimuli. Behavioural and physiological responses to visual stimuli may therefore be based in part on the plastic representation of value provided by the amygdala.	Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA; Columbia Univ, WM Keck Ctr Brain Plast & Cognit, New York, NY 10032 USA; Columbia Univ, Dept Psychiat, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Salzman, CD (corresponding author), Columbia Univ, Ctr Neurobiol & Behav, 1051 Riverside Dr,Unit 87, New York, NY 10032 USA.	cds2005@columbia.edu		Morrison, Sara/0000-0003-0334-1284; Paton, Joseph/0000-0002-1663-6455	NATIONAL INSTITUTE OF MENTAL HEALTH [K01MH001724] Funding Source: NIH RePORTER; NIMH NIH HHS [K01 MH001724-03, K01 MH001724, K01 MH001724-01A1, K01 MH001724-04, K01 MH001724-05, K01 MH001724-02, K01 MH001724-06] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AMARAL D G, 1992, P1; Baxter MG, 2002, NAT REV NEUROSCI, V3, P563, DOI 10.1038/nrn875; Davis M., 2000, AMYGDALA, P213; Everitt BJ, 2003, ANN NY ACAD SCI, V985, P233; Freese JL, 2005, J COMP NEUROL, V486, P295, DOI 10.1002/cne.20520; Fudge JL, 2000, NEUROSCIENCE, V97, P479, DOI 10.1016/S0306-4522(00)00092-0; Gallistel CR, 2004, P NATL ACAD SCI USA, V101, P13124, DOI 10.1073/pnas.0404965101; Ghashghaei HT, 2002, NEUROSCIENCE, V115, P1261, DOI 10.1016/S0306-4522(02)00446-3; Gottfried JA, 2003, SCIENCE, V301, P1104, DOI 10.1126/science.1087919; Green DM, 1966, SIGNAL DETECTION THE; Holland PC, 1999, TRENDS COGN SCI, V3, P65, DOI 10.1016/S1364-6613(98)01271-6; LaBar KS, 1998, NEURON, V20, P937, DOI 10.1016/S0896-6273(00)80475-4; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Lee HJJ, 2005, J NEUROSCI, V25, P3881, DOI 10.1523/JNEUROSCI.0416-05.2005; Maren S, 2004, NAT REV NEUROSCI, V5, P844, DOI 10.1038/nrn1535; McDonald AJ, 1998, PROG NEUROBIOL, V55, P257, DOI 10.1016/S0301-0082(98)00003-3; NISHIJO H, 1988, J NEUROSCI, V8, P3570; Pavlov I.P., 1927, CONDITIONED REFLEXES; Roesch MR, 2004, SCIENCE, V304, P307, DOI 10.1126/science.1093223; Rolls E. T., 2000, AMYGDALA FUNCTIONAL, P447; Rolls ET, 1996, J NEUROPHYSIOL, V75, P1970, DOI 10.1152/jn.1996.75.5.1970; Saddoris MP, 2005, NEURON, V46, P321, DOI 10.1016/j.neuron.2005.02.018; SANGHERA MK, 1979, EXP NEUROL, V63, P610, DOI 10.1016/0014-4886(79)90175-4; Schoenbaum G, 2003, NEURON, V39, P855, DOI 10.1016/S0896-6273(03)00474-4; Schoenbaum G, 1998, NAT NEUROSCI, V1, P155, DOI 10.1038/407; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Stefanacci L, 1996, J COMP NEUROL, V375, P552; Stefanacci L, 2002, J COMP NEUROL, V451, P301, DOI 10.1002/cne.10339; Tremblay L, 1999, NATURE, V398, P704, DOI 10.1038/19525; Wallis JD, 2003, EUR J NEUROSCI, V18, P2069, DOI 10.1046/j.1460-9568.2003.02922.x	30	629	633	2	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 16	2006	439	7078					865	870		10.1038/nature04490	http://dx.doi.org/10.1038/nature04490			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012JA	16482160	Green Accepted			2022-12-28	WOS:000235333600054
J	Guerrini, R				Guerrini, R			Epilepsy in children	LANCET			English	Review							TEMPORAL-LOBE EPILEPSY; NONCONVULSIVE STATUS EPILEPTICUS; CHILDHOOD ABSENCE EPILEPSY; SEVERE MYOCLONIC EPILEPSY; LANDAU-KLEFFNER-SYNDROME; TECHNOLOGY-ASSESSMENT SUBCOMMITTEE; QUALITY STANDARDS SUBCOMMITTEE; CONVULSIVE STATUS EPILEPTICUS; ANTIEPILEPTIC DRUG-TREATMENT; DOMINANT PARTIAL EPILEPSY	10.5 million children worldwide are estimated to have active epilepsy. Over the past 15 years, syndrome-oriented clinical and EEG diagnosis, and better aetiological diagnosis, especially supported by neuroimaging, has helped to clarify the diversity of epilepsy in children, and has improved management. Perinatal and postinfective encephalopathy, cortical dysplasia, and hippocampal sclerosis account for the most severe symptomatic epilepsies. Ion channel defects can underlie both benign age-related disorders and severe epileptic encephalopathies with a progressive disturbance in cerebral function. However, the reasons for age-related expression in children are not understood. Neither are the mechanisms whereby an epileptic encephalopathy originates. Several new drugs have been recently introduced but have provided limited therapeutic benefits. However, treatment and quality of life have improved because the syndrome-specific efficacy profile of drugs is better known, and there is heightened awareness that compounds with severe cognitive side-effects and heavy polytherapies should be avoided. Epilepsy surgery is an important option for a few well-selected individuals, but should be considered with great caution when there is no apparent underlying brain lesion.	Univ Pisa, Dept Child Neurol & Psychiat, I-56018 Pisa, Italy; IRCCS Fdn Stella Maris, I-56018 Pisa, Italy	University of Pisa; IRCCS Fondazione Stella Maris	Guerrini, R (corresponding author), Univ Pisa, Dept Child Neurol & Psychiat, I-56018 Pisa, Italy.	renzo.querrini@inpe.unipi.it		Guerrini, Renzo/0000-0002-7272-7079				AICARDI J, 1982, DEV MED CHILD NEUROL, V24, P281, DOI 10.1111/j.1469-8749.1982.tb13620.x; Aicardi J, 1998, DIS NERVOUS SYSTEM C; ALLDREDGE BK, 1995, PEDIATR NEUROL, V12, P213, DOI 10.1016/0887-8994(95)00044-G; Alldredge BK, 2001, NEW ENGL J MED, V345, P631, DOI 10.1056/NEJMoa002141; ALLEN JW, 1983, BRIT MED J, V286, P1246, DOI 10.1136/bmj.286.6373.1246; AMBROSETTO G, 1990, EPILEPSIA, V31, P802, DOI 10.1111/j.1528-1157.1990.tb05522.x; ANNEGERS JF, 1987, NEW ENGL J MED, V316, P493, DOI 10.1056/NEJM198702263160901; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; ANNEGERS JF, 1982, NEUROLOGY, V32, P174, DOI 10.1212/WNL.32.2.174; [Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Appleton R, 2000, BRIT MED J, V320, P1404; Appleton R, 2001, DEV MED CHILD NEUROL, V43, P269, DOI 10.1017/S0012162201000500; Appleton RE, 2002, J NEUROL NEUROSUR PS, V72, P669, DOI 10.1136/jnnp.72.5.669; Appleton RE, 1999, EPILEPSIA, V40, P1627, DOI 10.1111/j.1528-1157.1999.tb02049.x; Arcas J, 2001, EPILEPSIA, V42, P1363, DOI 10.1046/j.1528-1157.2001.09201.x; ARZIMANOGLOU A, 2004, EPILEPSY CHILDREN; Arzimanoglou AA, 2000, NEUROLOGY, V55, P1472, DOI 10.1212/WNL.55.10.1472; Asano E, 2001, BRAIN DEV-JPN, V23, P668, DOI 10.1016/S0387-7604(01)00305-9; Augustijn PB, 2001, NEUROLOGY, V57, P1108, DOI 10.1212/WNL.57.6.1108; Bailet LL, 2000, EPILEPSIA, V41, P426, DOI 10.1111/j.1528-1157.2000.tb00184.x; Bancaud J GS, 1973, EEG SEEG TUMEURS CER; Baram TZ, 1996, PEDIATRICS, V97, P375; Barkovich AJ, 2005, NEUROLOGY, V65, P1873, DOI 10.1212/01.wnl.0000183747.05269.2d; Barkovich AJ, 1999, AM J NEURORADIOL, V20, P1814; BARKOVICH AJ, 1995, PEDIAT NEUROIMAGING; Barlow WE, 2001, NEW ENGL J MED, V345, P656, DOI 10.1056/NEJMoa003077; BARUZZI A, 1988, DIAGNOSTIC THERAPEUT, P117; Baulac S, 2001, NAT GENET, V28, P46, DOI 10.1038/88254; BEGHI E, 1987, DEV MED CHILD NEUROL, V29, P363; Berg AT, 2000, EPILEPSIA, V41, P1269, DOI 10.1111/j.1528-1157.2000.tb04604.x; Berg AT, 1999, EPILEPSIA, V40, P445, DOI 10.1111/j.1528-1157.1999.tb00739.x; Berg AT, 2003, NEUROLOGY, V60, P186, DOI 10.1212/01.WNL.0000031792.89992.EC; BERG AT, 1992, NEW ENGL J MED, V327, P1122, DOI 10.1056/NEJM199210153271603; Berkovic SF, 2004, ANN NEUROL, V55, P550, DOI 10.1002/ana.20029; Berkovic SF, 1998, ANN NEUROL, V43, P435, DOI 10.1002/ana.410430405; BERKOVIC SF, 1991, ANN NEUROL, V29, P175, DOI 10.1002/ana.410290210; Berkovic SF, 2001, EPILEPSIA, V42, P16, DOI 10.1046/j.1528-1157.2001.0420s5016.x; BESAG FMC, 1995, J PEDIATR-US, V127, P991, DOI 10.1016/S0022-3476(95)70047-1; BIANCHI A, 1993, EPILEPSIA, V34, P819; Binnie CD, 2003, LANCET NEUROL, V2, P725, DOI 10.1016/S1474-4422(03)00584-2; Biraben A, 1997, MARIANI F P, V6, P125; Biton V, 1999, NEUROLOGY, V52, P1330, DOI 10.1212/WNL.52.7.1330; Bittencourt PR, 1999, HDB CLIN NEUROLOGY, V72, P145; Blume Warren T., 2001, Epilepsia, V42, P1212, DOI 10.1046/j.1528-1157.2001.22001.x; Bonanni P, 2004, EPILEPSIA, V45, P149, DOI 10.1111/j.0013-9580.2004.04303.x; Bouma PAD, 1997, NEUROLOGY, V48, P430, DOI 10.1212/WNL.48.2.430; Bourgeois BF, 2004, EPILEPSY CHILDREN, P387; Bourgeois M, 1999, J NEUROSURG, V90, P833, DOI 10.3171/jns.1999.90.5.0833; BRAATHEN G, 1988, EPILEPSIA, V29, P548, DOI 10.1111/j.1528-1157.1988.tb03759.x; CALLAGHAN N, 1982, DEV MED CHILD NEUROL, V24, P830; Camfield CS, 2002, LANCET, V359, P1891, DOI 10.1016/S0140-6736(02)08779-2; CAMFIELD P, 1994, DEV MED CHILD NEUROL, V36, P887; CAMFIELD PR, 1985, NEUROLOGY, V35, P1657, DOI 10.1212/WNL.35.11.1657; Camfield PR, 2000, EPILEPTIC DISORD, V2, P45; Casse-Perrot Catherine, 2001, VVolume 50, P131; Chan Elayne M, 2005, Adv Neurol, V95, P47; Chin RFM, 2005, ARCH DIS CHILD, V90, P66, DOI 10.1136/adc.2003.038844; Chiron C, 2000, LANCET, V356, P1638, DOI 10.1016/S0140-6736(00)03157-3; Chiron C, 1997, EPILEPSY RES, V26, P389, DOI 10.1016/S0920-1211(96)01006-6; Cossette P, 2002, NAT GENET, V31, P184, DOI 10.1038/ng885; Cossette P, 1999, NEUROLOGY, V52, P1691, DOI 10.1212/WNL.52.8.1691; Covanis A, 2004, EPILEPSIA, V45, P40, DOI 10.1111/j.0013-9580.2004.451006.x; COWAN LD, 1991, J CHILD NEUROL, V6, P355, DOI 10.1177/088307389100600412; Cross JH, 1996, ANN NEUROL, V39, P107, DOI 10.1002/ana.410390116; Crumrine P K, 2000, Semin Pediatr Neurol, V7, P216, DOI 10.1053/spen.2000.9218; Dabora SL, 2001, AM J HUM GENET, V68, P64, DOI 10.1086/316951; Dalla Bernardina B, 2002, CURR PROB E, V17, P181; Dalla Bernardina B, 1983, Prog Clin Biol Res, V124, P165; De Fusco M, 2000, NAT GENET, V26, P275; de Menezes MAS, 2002, EPILEPSIA, V43, P623, DOI 10.1046/j.1528-1157.2002.28401.x; Dedek K, 2001, P NATL ACAD SCI USA, V98, P12272, DOI 10.1073/pnas.211431298; DELANEROLLE NC, 1992, EPILEPSY RES, P235; Delgado MR, 1996, PEDIATRICS, V97, P192; DEONNA T, 2004, EPILEPSY IN CHILDREN, P250; deSilva M, 1996, LANCET, V347, P709, DOI 10.1016/S0140-6736(96)90074-4; DETRE JA, 1995, ANN NEUROL, V38, P618, DOI 10.1002/ana.410380410; Devlin AM, 2003, BRAIN, V126, P556, DOI 10.1093/brain/awg052; DIMARIO FJ, 1987, CLIN PEDIATR, V26, P505, DOI 10.1177/000992288702601002; Donovan SJ, 2000, AM J PSYCHIAT, V157, P818, DOI 10.1176/appi.ajp.157.5.818; DOOSE H, 1987, EUR J PEDIATR, V146, P550, DOI 10.1007/BF02467351; Dravet C, 2002, CURR PROB E, V17, P81; DRAVET C, 1986, NEUROPEDIATRICS, V17, P33, DOI 10.1055/s-2008-1052496; DREIFUSS F, 1986, ARCH NEUROL-CHICAGO, V43, P1107, DOI 10.1001/archneur.1986.00520110007005; Duane DC, 2004, EPILEPSIA, V45, P1001, DOI 10.1111/j.0013-9580.2004.60303.x; Duchowny M, 1999, NEUROLOGY, V53, P1724, DOI 10.1212/WNL.53.8.1724; Duchowny M, 1999, EPILEPTIC DISORD, V1, P143; DULAC O, 1983, ARCH FR PEDIATR, V40, P299; Dulac O, 1997, J CHILD NEUROL, V12, pS23, DOI 10.1177/0883073897012001071; DULAC O, 1997, EPILEPSY COMPREHENSI, P2277; Duncan JS, 2000, EPILEPSIA, V41, P1350; EEGOLOFSSON O, 1971, NEUROPADIATRIE, V2, P375, DOI 10.1055/s-0028-1091791; Elterman RD, 1999, NEUROLOGY, V52, P1338, DOI 10.1212/WNL.52.7.1338; Elterman RD, 2001, NEUROLOGY, V57, P1416, DOI 10.1212/WNL.57.8.1416; Engel J, 2001, EPILEPSIA, V42, P796, DOI 10.1046/j.1528-1157.2001.10401.x; ERBA G, 1990, J EPILEPSY S, V3, P287; Ericksson AS, 1998, EPILEPSIA, V39, P495, DOI 10.1111/j.1528-1157.1998.tb01411.x; Ettinger AB, 1999, EPILEPSIA, V40, P1159, DOI 10.1111/j.1528-1157.1999.tb00835.x; FARRELL K, 2004, EPILEPSY CHILDREN, P62; FARWELL JR, 1990, NEW ENGL J MED, V322, P364, DOI 10.1056/NEJM199002083220604; Fernandez G, 1998, NEUROLOGY, V50, P909, DOI 10.1212/WNL.50.4.909; Ferrie CD, 1997, EPILEPSIA, V38, P285, DOI 10.1111/j.1528-1157.1997.tb01119.x; Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x; FORSYTHE I, 1991, DEV MED CHILD NEUROL, V33, P524; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Frank LM, 1999, EPILEPSIA, V40, P973, DOI 10.1111/j.1528-1157.1999.tb00805.x; Freeman JM, 1998, PEDIATRICS, V102, P1358, DOI 10.1542/peds.102.6.1358; French JA, 2004, NEUROLOGY, V62, P1252, DOI 10.1212/01.WNL.0000123693.82339.FC; French JA, 2004, NEUROLOGY, V62, P1261, DOI 10.1212/01.WNL.0000123695.22623.32; GAILLARD WD, 2001, TREATMENT EPILEPSY P, P1053; Gaily E, 2001, DEV MED CHILD NEUROL, V43, P658, DOI 10.1017/S0012162201001207; Gastaut Henri, 1992, P201; Gilbert DL, 1999, J CHILD NEUROL, V14, P602, DOI 10.1177/088307389901400909; Gilliam FG, 2003, NEUROLOGY, V60, P196, DOI 10.1212/01.WNL.0000048200.12663.BC; Glauser TA, 2000, NEUROLOGY, V54, P2237, DOI 10.1212/WNL.54.12.2237; Glauser TA, 2002, EPILEPSIA, V43, P518, DOI 10.1046/j.1528-1157.2002.13101.x; Gleeson Joseph G., 2000, Current Opinion in Neurology, V13, P121, DOI 10.1097/00019052-200004000-00002; Gobbi G, 1999, EPILEPSY RES, V35, P29, DOI 10.1016/S0920-1211(98)00124-7; GORDON N, 1999, BRAIN DEV, V16, P153; Gospe SM, 1998, J PEDIATR-US, V132, P919, DOI 10.1016/S0022-3476(98)70384-1; Granata T, 2003, NEUROLOGY, V61, P1807, DOI 10.1212/01.WNL.0000099074.04539.E0; Granata T, 1997, NEUROLOGY, V48, P1403, DOI 10.1212/WNL.48.5.1403; Grote CL, 1999, BRAIN, V122, P561, DOI 10.1093/brain/122.3.561; Guerreiro MM, 1997, EPILEPSY RES, V27, P205, DOI 10.1016/S0920-1211(97)00025-9; Guerrini R, 2004, EPILEPSIA, V45, P14, DOI 10.1111/j.0013-9580.2004.451011.x; Guerrini R, 2003, J CLIN NEUROPHYSIOL, V20, P449, DOI 10.1097/00004691-200311000-00007; Guerrini R, 1998, EPILEPSIA, V39, P508, DOI 10.1111/j.1528-1157.1998.tb01413.x; Guerrini R, 1998, EPILEPSIA, V39, pS2, DOI 10.1111/j.1528-1157.1998.tb05118.x; Guerrini R, 2004, NEUROLOGY, V63, P51, DOI 10.1212/01.WNL.0000132818.84827.4D; Guerrini R, 1998, NEUROLOGY, V51, P504, DOI 10.1212/WNL.51.2.504; Guerrini R, 2002, EPILEPTIC DISORD, V4, pS9; Guerrini R, 2003, EPILEPTIC DISORD, V5, pS9; Guerrini R, 2003, TRENDS MOL MED, V9, P300, DOI 10.1016/S1471-4914(03)00116-3; Guerrini R, 2001, SEIZURE-EUR J EPILEP, V10, P532, DOI 10.1053/seiz.2001.0650; Guerrini R, 2001, EPILEPSIA, V42, P36, DOI 10.1046/j.1528-1157.2001.042suppl.3036.x; GUERRINI R, 1995, EPILEPSIA, V36, P883, DOI 10.1111/j.1528-1157.1995.tb01631.x; GUERRINI R, 2000, INTRACTABLE FOCAL EP, P77; GUERRINI R, 1997, EPILEPSY COMPREHENSI, P2533; Guipponi M, 1997, HUM MOL GENET, V6, P473, DOI 10.1093/hmg/6.3.473; Guiwer J, 2003, PROGNOSIS OF EPILEPSIES, P249; Hadjipanayis A, 1997, DEV MED CHILD NEUROL, V39, P659; Hamer HM, 1999, EPILEPSIA, V40, P837, DOI 10.1111/j.1528-1157.1999.tb00789.x; HANCOCK E, 2002, COCHRANE DB SYST REV, V2; HANCOCK E, 2003, COCHRANE DB SYST REV, V3; Harkin LA, 2002, AM J HUM GENET, V70, P530, DOI 10.1086/338710; Hart Y, 2004, EPILEPTIC DISORD, V6, P133; Harvey AS, 1997, NEUROLOGY, V49, P960, DOI 10.1212/WNL.49.4.960; HARVEY AS, 1995, PEDIATR NEUROL, V12, P201, DOI 10.1016/0887-8994(95)00022-8; Haug K, 2003, NAT GENET, V33, P527, DOI 10.1038/ng1121; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; Heiskala H, 1996, BRAIN DEV-JPN, V18, P456, DOI 10.1016/S0387-7604(96)00024-1; Hoffmann-Riem M, 2000, NEUROPEDIATRICS, V31, P169, DOI 10.1055/s-2000-7456; HOLTHAUSEN H, 2000, EPILEPTIC SEIZURES P, P439; Hong SE, 2000, NAT GENET, V26, P93, DOI 10.1038/79246; HUTTENLOCHER PR, 1976, PEDIATR RES, V10, P536, DOI 10.1203/00006450-197605000-00006; *INT LEAG EP COMM, 1996, EPILEPSIA, V37, P1128; Ishiguro Y, 2004, EPILEPSIA, V45, P377, DOI 10.1111/j.0013-9580.2004.18903.x; Jambaque I, 2000, EPILEPSY RES, V38, P151, DOI 10.1016/S0920-1211(99)00082-0; JOHANNESSEN SI, 2002, ANTIEPILEPTIC DRUGS, P103; Jonas R, 2004, NEUROLOGY, V62, P1712, DOI 10.1212/01.WNL.0000127109.14569.C3; JUHASZ C, 2004, EPILEPSY CHILDREN, P352; Kalachikov S, 2002, NAT GENET, V30, P335, DOI 10.1038/ng832; Kaminska A, 2003, BRAIN, V126, P248, DOI 10.1093/brain/awg013; Kaminska A, 1999, EPILEPSY RES, V36, P15, DOI 10.1016/S0920-1211(99)00021-2; Kananura C, 2002, ARCH NEUROL-CHICAGO, V59, P1137, DOI 10.1001/archneur.59.7.1137; Kanemoto K, 2000, ANN NEUROL, V47, P571, DOI 10.1002/1531-8249(200005)47:5<571::AID-ANA3>3.3.CO;2-1; Kang HC, 2004, EPILEPSIA, V45, P1116, DOI 10.1111/j.0013-9580.2004.10004.x; Karenfort M, 2002, NEUROPEDIATRICS, V33, P255, DOI 10.1055/s-2002-36740; KEENE DL, 1990, CAN J NEUROL SCI, V17, P317, DOI 10.1017/S0317167100030651; Kepecs MR, 2004, EPILEPSIA, V45, P1158, DOI 10.1111/j.0013-9580.2004.07004.x; King MA, 1998, LANCET, V352, P1007, DOI 10.1016/S0140-6736(98)03543-0; Kitamura K, 2002, NAT GENET, V32, P359, DOI 10.1038/ng1009; Kivity S, 2004, EPILEPSIA, V45, P255, DOI 10.1111/j.0013-9580.2004.30503.x; Kloss S, 2002, NEUROPEDIATRICS, V33, P21, DOI 10.1055/s-2002-23595; Kossoff EH, 2002, PEDIATRICS, V109, P780, DOI 10.1542/peds.109.5.780; Kotagal P, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.4.e46; Kramer U, 1997, PEDIATR NEUROL, V16, P213, DOI 10.1016/S0887-8994(97)00013-1; KUKS JBM, 1993, LANCET, V342, P1391; KUZNIECKY R, 1993, NEUROLOGY, V43, P681, DOI 10.1212/WNL.43.4.681; KUZNIECKY RI, 2004, EPILEPSY CHILDREN, P331; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Lerman Pinchas, 1992, P189; LEVESQUE MF, 1991, J NEUROSURG, V75, P364, DOI 10.3171/jns.1991.75.3.0364; Lewis H, 2001, DEV MED CHILD NEUROL, V43, P833, DOI 10.1017/S0012162201001517; LIVINGSTON JH, 2004, EPILEPSY CHILDREN, P290; Loring DW, 2004, NEUROLOGY, V62, P872, DOI 10.1212/01.WNL.0000115653.82763.07; Luders Hans O., 1993, P137; MARESCAUX C, 1990, EPILEPSIA, V31, P768, DOI 10.1111/j.1528-1157.1990.tb05518.x; MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499; Marini C, 2003, BRAIN, V126, P230, DOI 10.1093/brain/awg018; Massa R, 2001, NEUROLOGY, V57, P1071, DOI 10.1212/WNL.57.6.1071; Mbodj I, 2000, NEUROPHYSIOL CLIN, V30, P165, DOI 10.1016/S0987-7053(00)00203-3; McCormick DA, 2001, ANNU REV PHYSIOL, V63, P815, DOI 10.1146/annurev.physiol.63.1.815; McNamara JO, 1999, NATURE, V399, pA15, DOI 10.1038/399a015; Medina Marco T, 2005, Adv Neurol, V95, P307; Meisler MH, 2001, ANNU REV GENET, V35, P567, DOI 10.1146/annurev.genet.35.102401.091142; Men S, 2000, AM J NEURORADIOL, V21, P1837; METRICK ME, 1991, EPILEPSIA, V32, P322, DOI 10.1111/j.1528-1157.1991.tb04658.x; Mikaeloff Y, 2003, EPILEPSY RES, V53, P225, DOI 10.1016/S0920-1211(03)00028-7; Mikati MA, 2000, EPILEPSIA, V41, P880, DOI 10.1111/j.1528-1157.2000.tb00257.x; MITCHELL WG, 1987, EPILEPSIA, V28, P56, DOI 10.1111/j.1528-1157.1987.tb03623.x; Mohamed A, 2001, NEUROLOGY, V56, P1643, DOI 10.1212/WNL.56.12.1643; Morrell F, 1995, BRAIN, V118, P1529, DOI 10.1093/brain/118.6.1529; Motte J, 1997, NEW ENGL J MED, V337, P1807, DOI 10.1056/NEJM199712183372504; Munari C, 2000, EPILEPSIA, V41, pS18; Munari C, 1980, ADV EP 9 EP INT S, P111; MURPHY JV, 1987, J PEDIATR-US, V111, P145, DOI 10.1016/S0022-3476(87)80366-9; Muzik O, 2000, NEUROLOGY, V54, P171, DOI 10.1212/WNL.54.1.171; Nabbout R, 2003, NEUROLOGY, V60, P1961, DOI 10.1212/01.WNL.0000069463.41870.2F; Naquet, 1989, REFLEX SEIZURES REFL, P363; Nordli DR, 2001, PEDIATRICS, V108, P129, DOI 10.1542/peds.108.1.129; OGUNI H, 1991, ANN NEUROL, V30, P357, DOI 10.1002/ana.410300307; Oguni H, 2002, NEUROPEDIATRICS, V33, P122, DOI 10.1055/s-2002-33675; Oldani A, 1998, BRAIN, V121, P205, DOI 10.1093/brain/121.2.205; Opeskin K, 2000, NEUROLOGY, V55, P1101, DOI 10.1212/WNL.55.8.1101; Painter MJ, 1999, NEW ENGL J MED, V341, P485, DOI 10.1056/NEJM199908123410704; Pakalnis A, 2000, J CHILD NEUROL, V15, P78, DOI 10.1177/088307380001500202; Pal DK, 2000, J NEUROL NEUROSUR PS, V68, P137, DOI 10.1136/jnnp.68.2.137; PANAYIOTOPOULOS CP, 1994, J NEUROL NEUROSUR PS, V57, P1371, DOI 10.1136/jnnp.57.11.1371; Panteliadis CP, 2004, CEREBRAL PALSY: PRINCIPLES AND MANAGEMENT, P21; Parmeggiani L, 2004, CLIN NEUROPHYSIOL, V115, P50, DOI 10.1016/S1388-2457(03)00327-4; Pasquier B, 1996, ANN PATHOL, V16, P174; Piao XH, 2004, SCIENCE, V303, P2033, DOI 10.1126/science.1092780; PICCIRILLI M, 1988, EPILEPSIA, V29, P19, DOI 10.1111/j.1528-1157.1988.tb05092.x; PINTO ALR, 2004, EPILEPSY CHILDREN, P76; PLAZZI G, 1995, SLEEP, V18, P749, DOI 10.1093/sleep/18.9.749; POMEROY SL, 1990, NEW ENGL J MED, V323, P1651, DOI 10.1056/NEJM199012133232402; Porciatti V, 2000, NAT NEUROSCI, V3, P259, DOI 10.1038/72972; POSNER EB, 2003, COCHRANE DB SYST REV, V3, P3032; PRANZATELLI MR, 1991, COMPREHENSIVE EPILEP, P423; PRAYSON RA, 2001, EPILEPSY SURG, P915; Privitera MD, 2003, ACTA NEUROL SCAND, V107, P165, DOI 10.1034/j.1600-0404.2003.00093.x; Privitera MD, 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002896, DOI 10.1002/14651858.CD002896]; Pulsifer MB, 2004, EPILEPSIA, V45, P243, DOI 10.1111/j.0013-9580.2004.15303.x; RAMSAY RE, 1992, J EPILEPSY, V5, P55, DOI 10.1016/S0896-6974(05)80021-0; Rantala H, 1997, J PEDIATR-US, V131, P922, DOI 10.1016/S0022-3476(97)70045-3; Rating D, 2000, EPILEPSIA, V41, P1284, DOI 10.1111/j.1528-1157.2000.tb04606.x; Ricci S, 1998, NEUROLOGY, V50, P790, DOI 10.1212/WNL.50.3.790; Riikonen R, 1996, EPILEPSIA, V37, P367, DOI 10.1111/j.1528-1157.1996.tb00573.x; Riikonen R, 2001, BRAIN DEV-JPN, V23, P539, DOI 10.1016/S0387-7604(01)00263-7; RITTER FJ, 1993, NEW ENGL J MED, V328, P29; Riva D, 1999, J CHILD NEUROL, V14, P357, DOI 10.1177/088307389901400603; ROBAIN O, 1988, NEUROPATH APPL NEURO, V14, P125, DOI 10.1111/j.1365-2990.1988.tb00875.x; ROGAWSKI MA, 2002, ANTIEPILEPTIC DRUGS, P3; Rossi PG, 1999, BRAIN DEV-JPN, V21, P90; Sachdeo RC, 1999, NEUROLOGY, V52, P1882, DOI 10.1212/WNL.52.9.1882; Saltik S, 2002, EPILEPSIA, V43, P246, DOI 10.1046/j.1528-1157.2002.14001.x; SANDER JWAS, 1993, EPILEPSIA, V34, P1007, DOI 10.1111/j.1528-1157.1993.tb02126.x; SAPIN JI, 1988, PEDIATR NEUROL, V4, P292, DOI 10.1016/0887-8994(88)90068-9; SATO S, 1982, NEUROLOGY, V32, P157, DOI 10.1212/WNL.32.2.157; Schmidt D, 1996, DRUGS, V52, P870, DOI 10.2165/00003495-199652060-00008; Scott RC, 1999, LANCET, V353, P623, DOI 10.1016/S0140-6736(98)06425-3; Scott RC, 2003, BRAIN, V126, P1968, DOI 10.1093/brain/awg199; Scott RC, 2001, NEUROLOGY, V56, P1659, DOI 10.1212/WNL.56.12.1659; Seidel WT, 1999, J CHILD NEUROL, V14, P716, DOI 10.1177/088307389901401106; Seki T, 2004, SEIZURE-EUR J EPILEP, V13, pS26, DOI 10.1016/j.seizure.2004.04.001; Seri S, 1998, EVOKED POTENTIAL, V108, P506, DOI 10.1016/S0168-5597(98)00027-6; Sheen VL, 2004, NAT GENET, V36, P69, DOI 10.1038/ng1276; SHEWMON DA, 1988, ANN NEUROL, V23, P131, DOI 10.1002/ana.410230205; Shimizu T, 1997, BRAIN DEV-JPN, V19, P366, DOI 10.1016/S0387-7604(97)00029-6; SHINNAR S, 1990, PEDIATRICS, V85, P1076; Shinnar S, 1996, PEDIATRICS, V98, P216; Shinnar S, 2001, EPILEPSIA, V42, P47, DOI 10.1046/j.1528-1157.2001.10000.x; SHORVON SS, 2000, TREATMENT EPILEPSY; Sicca F, 2003, NEUROLOGY, V61, P1042, DOI 10.1212/WNL.61.8.1042; Sillanpaa M, 2002, ANN NEUROL, V52, P303, DOI 10.1002/ana.10286; Sillanpaa M, 2000, EPILEPTIC DISORD, V2, P79; Singer R B, 2001, J Insur Med, V33, P42; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; Singh P, 2002, EPILEPSIA, V43, P127, DOI 10.1046/j.1528-1157.2002.19498.x; Singh R, 2001, EPILEPSIA, V42, P837, DOI 10.1046/j.1528-1157.2001.042007837.x; SIRVEN JI, 2001, COCHRANE DB SYST REV, V3; SONNEN AEH, 1991, COMPREHENSIVE EPILEP, P753; STEINLEIN OK, 1995, NAT GENET, V11, P201, DOI 10.1038/ng1095-201; Stephenson J.B.P., 1990, FITS FAINTS; Stromme P, 2002, NAT GENET, V30, P441, DOI 10.1038/ng862; Sulzbacher S, 1999, CLIN PEDIATR, V38, P387, DOI 10.1177/000992289903800702; Takahashi Y, 2001, NEUROLOGY, V57, P1767, DOI 10.1212/WNL.57.10.1767; Tassi L, 2002, BRAIN, V125, P1719, DOI 10.1093/brain/awf175; TASSINARI CA, 2002, EPILEPTIC SYNDROMES, P69; TASSINARI CA, 1998, EPILEPSY, V1, P897; Taylor DC, 1997, EPILEPSIA, V38, P625, DOI 10.1111/j.1528-1157.1997.tb01230.x; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Tinuper P, 1996, NEUROLOGY, V47, P76, DOI 10.1212/WNL.47.1.76; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; Trenite DGAKN, 2001, EPILEPSIA, V42, P692, DOI 10.1046/j.1528-1157.2001.30600.x; Trevathan E, 1999, EPILEPSIA, V40, P748, DOI 10.1111/j.1528-1157.1999.tb00773.x; Trevathan E, 2002, J CHILD NEUROL, V17, p2S9, DOI 10.1177/08830738020170021201; TSUBOI T, 1988, EPILEPSIA, V29, P103, DOI 10.1111/j.1528-1157.1988.tb04404.x; Uldall P, 2000, EPILEPSY RES, V42, P159, DOI 10.1016/S0920-1211(00)00173-X; VanLandingham KE, 1998, ANN NEUROL, V43, P413, DOI 10.1002/ana.410430403; VARGHAKHADEM F, 1992, BRAIN, V115, P315, DOI 10.1093/brain/115.1.315; VERITY CM, 1995, DEV MED CHILD NEUROL, V37, P97; Vigevano F, 1997, EPILEPSIA, V38, P1270; VIGEVANO F, 1993, EPILEPSIA, V34, P110, DOI 10.1111/j.1528-1157.1993.tb02382.x; Vining EPG, 1998, ARCH NEUROL-CHICAGO, V55, P1433, DOI 10.1001/archneur.55.11.1433; Wallace RH, 2001, NAT GENET, V28, P49, DOI 10.1038/ng0501-49; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; WALLACE S, 2004, EPILEPSY CHILDREN, P123; WASTERLAIN CG, 1993, EPILEPSIA, V34, pS37, DOI 10.1111/j.1528-1157.1993.tb05905.x; WEBB DW, 1991, J MED GENET, V28, P395, DOI 10.1136/jmg.28.6.395; WILLIAMSON PD, 1992, ANN NEUROL, V31, P3, DOI 10.1002/ana.410310103; Winawer MR, 2000, NEUROLOGY, V54, P2173, DOI 10.1212/WNL.54.11.2173; Woermann FG, 1999, BRAIN, V122, P2101, DOI 10.1093/brain/122.11.2101; WOLF P, 1986, J NEUROL NEUROSUR PS, V49, P1386, DOI 10.1136/jnnp.49.12.1386; Wolf P, 2002, CURR PROB E, V17, P331; WOLF SM, 1995, EPILEPSIA, V36, P1203, DOI 10.1111/j.1528-1157.1995.tb01063.x; Wong ICK, 2000, DRUG SAFETY, V23, P35, DOI 10.2165/00002018-200023010-00003; Wong M, 2001, PEDIATR NEUROL, V24, P89, DOI 10.1016/S0887-8994(00)00238-1; Wyllie E, 1998, ANN NEUROL, V44, P740, DOI 10.1002/ana.410440507; Yetkin FZ, 1998, AM J NEURORADIOL, V19, P1095; Zamponi N, 1999, ARCH NEUROL-CHICAGO, V56, P605, DOI 10.1001/archneur.56.5.605; [No title captured]	313	262	272	1	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 11	2006	367	9509					499	524		10.1016/S0140-6736(06)68182-8	http://dx.doi.org/10.1016/S0140-6736(06)68182-8			26	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013FF	16473127				2022-12-28	WOS:000235394500031
J	Waite, JH; Combi, MR; Ip, WH; Cravens, TE; McNutt, RL; Kasprzak, W; Yelle, R; Luhmann, J; Niemann, H; Gell, D; Magee, B; Fletcher, G; Lunine, J; Tseng, WL				Waite, JH; Combi, MR; Ip, WH; Cravens, TE; McNutt, RL; Kasprzak, W; Yelle, R; Luhmann, J; Niemann, H; Gell, D; Magee, B; Fletcher, G; Lunine, J; Tseng, WL			Cassini ion and neutral mass spectrometer: Enceladus plume composition and structure	SCIENCE			English	Article							SPECTROSCOPY; DISCOVERY; PARTICLES; ORIGIN; SATURN; ICE		Univ Michigan, Dept Atmospher Ocean & Space Sci, Ann Arbor, MI 48109 USA; Natl Cent Univ, Inst Astron, Chungli 32054, Taiwan; Natl Cent Univ, Inst Space Sci, Chungli 32054, Taiwan; Univ Kansas, Dept Phys & Astron, Lawrence, KS 66045 USA; Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20723 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA; Ist Fis Spazio Interplanetario, I-00133 Rome, Italy	University of Michigan System; University of Michigan; National Central University; National Central University; University of Kansas; Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of Arizona; University of California System; University of California Berkeley; Istituto Nazionale Astrofisica (INAF)	Waite, JH (corresponding author), Univ Michigan, Dept Atmospher Ocean & Space Sci, Ann Arbor, MI 48109 USA.		Combi, Michael/J-1697-2012; McNutt, Ralph L/E-8006-2010	Combi, Michael/0000-0002-9805-0078; McNutt, Ralph L/0000-0002-4722-9166; Lunine, Jonathan/0000-0003-2279-4131				Bockelee-Morvan D, 2004, SPACE SCI S, P391; BOONE S, 1991, LUN PLAN SCI C 21 HO, P603; Brown RH, 2006, SCIENCE, V311, P1425, DOI 10.1126/science.1121031; Combi MR, 2004, SPACE SCI S, P523; Combi MR, 1996, ICARUS, V123, P207, DOI 10.1006/icar.1996.0150; Cruikshank DP, 2005, ICARUS, V175, P268, DOI 10.1016/j.icarus.2004.09.003; Davidsson BJR, 2004, ICARUS, V168, P163, DOI 10.1016/j.icarus.2003.11.002; Emery JP, 2005, ASTRON ASTROPHYS, V435, P353, DOI 10.1051/0004-6361:20042482; Esposito LW, 2005, SCIENCE, V307, P1251, DOI 10.1126/science.1105606; Hansen CJ, 2006, SCIENCE, V311, P1422, DOI 10.1126/science.1121254; Jurac S, 2005, J GEOPHYS RES-SPACE, V110, DOI 10.1029/2004JA010635; Jurac S, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015855; Kasprzak W, 1996, P SOC PHOTO-OPT INS, V2803, P129, DOI 10.1117/12.253413; Porco CC, 2006, SCIENCE, V311, P1393, DOI 10.1126/science.1123013; Press WH, 1986, NUMERICAL RECIPIES; Roddier C, 1998, ICARUS, V136, P50, DOI 10.1006/icar.1998.6014; SHEMANSKY DE, 1993, NATURE, V363, P329, DOI 10.1038/363329a0; Spahn F, 2006, SCIENCE, V311, P1416, DOI 10.1126/science.1121375; Spencer JR, 2006, SCIENCE, V311, P1401, DOI 10.1126/science.1121661; SQUYRES SW, 1983, ICARUS, V53, P319, DOI 10.1016/0019-1035(83)90152-5; Waite JH, 2004, SPACE SCI REV, V114, P113, DOI 10.1007/s11214-004-1408-2; YAMAMOTO T, 1985, ASTRON ASTROPHYS, V152, pL17; Yelle RV, 2004, ICARUS, V167, P30, DOI 10.1016/j.icarus.2003.08.020	23	472	478	3	118	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2006	311	5766					1419	1422		10.1126/science.1121290	http://dx.doi.org/10.1126/science.1121290			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527970				2022-12-28	WOS:000236029400036
J	Young, D; Dye, C				Young, D; Dye, C			The development and impact of tuberculosis vaccines	CELL			English	Editorial Material							MYCOBACTERIUM-TUBERCULOSIS; IMMUNE-RESPONSES; BCG; EFFICACY; STRAINS	Vaccination is expected to make a major contribution to the goal of eliminating tuberculosis worldwide by 2050. But developing a new effective vaccine will require innovation in scientific research, a proactive approach to clinical trials of new vaccine candidates, and application of vaccines as part of an integrated approach to disease control.	Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England; WHO, StopTB Dept, CH-1211 Geneva 12, Switzerland	Imperial College London; World Health Organization	Young, D (corresponding author), Univ London Imperial Coll Sci Technol & Med, S Kensington Campus, London SW7 2AZ, England.	d.young@imperial.ac.uk	Dye, Christopher/AIC-4659-2022	Dye, Christopher/0000-0002-2957-1793	MRC [MC_U117581288] Funding Source: UKRI; Medical Research Council [MC_U117581288] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aronson NE, 2004, JAMA-J AM MED ASSOC, V291, P2086, DOI 10.1001/jama.291.17.2086; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Dye C, 1998, LANCET, V352, P1886, DOI 10.1016/S0140-6736(98)03199-7; Hirsh AE, 2004, P NATL ACAD SCI USA, V101, P4871, DOI 10.1073/pnas.0305627101; Kaufmann SHE, 2005, TRENDS IMMUNOL, V26, P660, DOI 10.1016/j.it.2005.09.012; McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128; Orme IM, 2006, VACCINE, V24, P2, DOI 10.1016/j.vaccine.2005.07.078; Pym AS, 2003, NAT MED, V9, P533, DOI 10.1038/nm859; Reed MB, 2004, NATURE, V431, P84, DOI 10.1038/nature02837; Rook GAW, 2005, NAT REV IMMUNOL, V5, P661, DOI 10.1038/nri1666; Skeiky YAW, 2004, J IMMUNOL, V172, P7618, DOI 10.4049/jimmunol.172.12.7618; Soysal A, 2005, LANCET, V366, P1443, DOI 10.1016/S0140-6736(05)67534-4; Stewart GR, 2003, NAT REV MICROBIOL, V1, P97, DOI 10.1038/nrmicro749; *STOP TB PARTN WHO, 2006, WHOHTMSTB200635 STOP; *WHO, 2006, GLOB TUB CONTR SURV	15	99	113	0	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 24	2006	124	4					683	687		10.1016/j.cell.2006.02.013	http://dx.doi.org/10.1016/j.cell.2006.02.013			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	038RO	16497578	Bronze			2022-12-28	WOS:000237240900011
J	Chien, KR				Chien, KR			Docus on research: Herceptin and the heart - A molecular modifier of cardiac failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Chien, KR (corresponding author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.							Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Crone SA, 2002, NAT MED, V8, P459, DOI 10.1038/nm0502-459	2	135	142	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 23	2006	354	8					789	790		10.1056/NEJMp058315	http://dx.doi.org/10.1056/NEJMp058315			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014CL	16495390				2022-12-28	WOS:000235456200002
J	Belfer, ML; Saxena, S				Belfer, ML; Saxena, S			WHO Child Atlas project	LANCET			English	Editorial Material							ADOLESCENTS; DISORDERS; COSTS		WHO, Dept Mental Hlth & Subst Abuse, CH-1211 Geneva, Switzerland	World Health Organization	Saxena, S (corresponding author), WHO, Dept Mental Hlth & Subst Abuse, CH-1211 Geneva, Switzerland.	saxenas@who.int						Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kotler LA, 2001, J AM ACAD CHILD PSY, V40, P1434, DOI 10.1097/00004583-200112000-00014; Leibson CL, 2001, JAMA-J AM MED ASSOC, V285, P60, DOI 10.1001/jama.285.1.60; Leslie DL, 2001, HEALTH SERV RES, V36, P113; Levav I, 2004, EUR CHILD ADOLES PSY, V13, P395, DOI 10.1007/s00787-004-0427-6; RICHMOND JB, 1983, HDB HLTH PROFESSIONS; Scott S, 2001, BRIT MED J, V323, P191, DOI 10.1136/bmj.323.7306.191; Shatkin Jess P, 2004, Child Adolesc Ment Health, V9, P104, DOI 10.1111/j.1475-3588.2004.00090.x; Verhulst FC, 2004, FACILITATING PATHWAYS: CARE, TREATMENT AND PREVENTION IN CHILD AND ADOLESCENT MENTAL HEALTH, P3; Weissman MM, 1999, JAMA-J AM MED ASSOC, V281, P1707, DOI 10.1001/jama.281.18.1707; WHO, 2001, WORLD HLTH REPORT 20; Woodward LJ, 2001, J AM ACAD CHILD PSY, V40, P1086, DOI 10.1097/00004583-200109000-00018; World Health Organization, 2005, ATL CHILD AD MENT HL	13	44	45	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 18	2006	367	9510					551	552		10.1016/S0140-6736(06)68199-3	http://dx.doi.org/10.1016/S0140-6736(06)68199-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013GM	16488783				2022-12-28	WOS:000235397800008
J	Chaudhuri, A				Chaudhuri, A			Drugs - Lessons for clinical trials from natalizumab in multiple sclerosis	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; MS; THERAPY	The approval of natalizumab and its recall after three months raises questions about the fast tracking of new drugs by the Food and Drug Administration for commercial licensing.	Oldchurch Hosp, Essex Ctr Neurol Sci, Romford RM7 0BE, Essex, England		Chaudhuri, A (corresponding author), Oldchurch Hosp, Essex Ctr Neurol Sci, Romford RM7 0BE, Essex, England.	chaudhuria@gmail.com						Berger JR, 2005, NEW ENGL J MED, V353, P414, DOI 10.1056/NEJMe058122; BJURSTEN M, 2005, EUR J IMMUNOL, V2274, P35; Chaudhuri A, 2005, J ROY SOC MED, V98, P303, DOI 10.1258/jrsm.98.7.303; Chaudhuri A, 2005, QJM-INT J MED, V98, P373, DOI 10.1093/qjmed/hci059; Chaudhuri A, 2005, LANCET NEUROL, V4, P208, DOI 10.1016/S1474-4422(05)70028-4; Chaudhuri A, 2003, NEW ENGL J MED, V348, P1598; Confavreux C, 2003, BRAIN, V126, P770, DOI 10.1093/brain/awg081; Eriksson M, 2003, MULT SCLER J, V9, P260, DOI 10.1191/1352458503ms914oa; KEINSCHIMDTDEMA.BK, 2005, NEW ENGL J MED, V353, P369; Kleinke JD, 1998, BRIT MED J, V317, P899; Langer-Gould A, 2005, NEW ENGL J MED, V353, P375, DOI 10.1056/NEJMoa051847; Miller David H, 2004, NeuroRx, V1, P284, DOI 10.1602/neurorx.1.2.284; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; O'Connor PW, 2004, NEUROLOGY, V62, P2038, DOI 10.1212/01.WNL.0000128136.79044.D6; Rice GPA, 2005, NEUROLOGY, V64, P1336, DOI 10.1212/01.WNL.0000158329.30470.D0; Tubridy N, 1999, NEUROLOGY, V53, P466, DOI 10.1212/WNL.53.3.466; *US FDA, FDA ISS PUBL HLTH AD; *US FDA CTR DRUG E, TYS NAT; Van Assche G, 2005, NEW ENGL J MED, V353, P362, DOI 10.1056/NEJMoa051586	19	21	28	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 18	2006	332	7538					416	419		10.1136/bmj.332.7538.416	http://dx.doi.org/10.1136/bmj.332.7538.416			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	017HZ	16484271	Green Published			2022-12-28	WOS:000235686000026
J	Dijksterhuis, A; Bos, MW; Nordgren, LF; van Baaren, RB				Dijksterhuis, A; Bos, MW; Nordgren, LF; van Baaren, RB			On making the right choice: The deliberation-without-attention effect	SCIENCE			English	Article							INFORMATION; REDUCE; SLEEP	Contrary to conventional Wisdom, it is not always advantageous to engage in thorough conscious deliberation before choosing. On the basis of recent insights into the characteristics of conscious and unconscious thought, we tested the hypothesis that simple choices (such as between different towels or different sets of oven mitts) indeed produce better results after conscious thought, but that choices in complex matters (such as between different houses or different cars) should be left to unconscious thought. Named the "deliberation-without-attention" hypothesis, it was confirmed in four studies on consumer choice, both in the laboratory as well as among actual shoppers, that purchases of complex products were viewed more favorably when decisions had been made in the absence of attentive deliberation.	Univ Amsterdam, Dept Psychol, NL-1018 WB Amsterdam, Netherlands	University of Amsterdam	Dijksterhuis, A (corresponding author), Univ Amsterdam, Dept Psychol, Roetersstr 15, NL-1018 WB Amsterdam, Netherlands.	a.j.dijksterhuis@uva.nl	van Baaren, Rick B/E-8036-2012					Bettman JR, 1998, J CONSUM RES, V25, P187, DOI 10.1086/209535; BOWERS KS, 1990, COGNITIVE PSYCHOL, V22, P72, DOI 10.1016/0010-0285(90)90004-N; CHAIKEN S, 1980, J PERS SOC PSYCHOL, V39, P752, DOI 10.1037/0022-3514.39.5.752; Claxton G., 1997, HARE BRAIN TORTOISE; Descartes R., 1984, PHILOS WRITINGS DESC, VVol. II,; Dijksterhuis A, 2004, J PERS SOC PSYCHOL, V87, P586, DOI 10.1037/0022-3514.87.5.586; DIJKSTERHUIS A, IN PRESS J EXP SOC P; Janis I.L., 1977, DECISION MAKING PSYC; Kahneman D, 2003, AM PSYCHOL, V58, P697, DOI 10.1037/0003-066X.58.9.697; Levine GM, 1996, J PERS SOC PSYCHOL, V70, P230, DOI 10.1037/0022-3514.70.2.230; Locke, 1997, ESSAY HUMAN UNDERSTA; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/h0043158; ORRETRANDERS T, 1998, USER ILLUSION CUTTIN; Petty R.E., 1986, ADV EXPT SOCIAL PSYC, V19, P123, DOI [10.1016/S0065-2601(08)60214-2, DOI 10.1016/S0065-2601(08)60214-2, https://doi.org/10.1016/S0065-2601(08)60214-2]; SCHOPENHAUER A, 1970, ESSAYS APHORISMS, P123; Simon HA, 1955, Q J ECON, V69, P99, DOI 10.2307/1884852; Sloman SA, 1996, PSYCHOL BULL, V119, P3, DOI 10.1037/0033-2909.119.1.3; Smith ER, 1999, DUAL-PROCESS THEORIES IN SOCIAL PSYCHOLOGY, P323; Stickgold R, 2004, TRENDS COGN SCI, V8, P191, DOI 10.1016/j.tics.2004.03.003; Stickgold R, 2001, SCIENCE, V294, P1052, DOI 10.1126/science.1063530; WILSON TD, 1991, J PERS SOC PSYCHOL, V60, P181, DOI 10.1037/0022-3514.60.2.181; WILSON TD, 1993, PERS SOC PSYCHOL B, V19, P331, DOI 10.1177/0146167293193010	22	626	645	33	382	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 17	2006	311	5763					1005	1007		10.1126/science.1121629	http://dx.doi.org/10.1126/science.1121629			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014CS	16484496				2022-12-28	WOS:000235456900047
J	Guido, NJ; Wang, X; Adalsteinsson, D; McMillen, D; Hasty, J; Cantor, CR; Elston, TC; Collins, JJ				Guido, NJ; Wang, X; Adalsteinsson, D; McMillen, D; Hasty, J; Cantor, CR; Elston, TC; Collins, JJ			A bottom-up approach to gene regulation	NATURE			English	Article							NOISE-PROPAGATION; ESCHERICHIA-COLI; TOGGLE SWITCH; NETWORKS; EXPRESSION	The ability to construct synthetic gene networks enables experimental investigations of deliberately simplified systems that can be compared to qualitative and quantitative models(1-23). If simple, well-characterized modules can be coupled together into more complex networks with behaviour that can be predicted from that of the individual components, we may begin to build an understanding of cellular regulatory processes from the 'bottom up'. Here we have engineered a promoter to allow simultaneous repression and activation of gene expression in Escherichia coli. We studied its behaviour in synthetic gene networks under increasingly complex conditions: unregulated, repressed, activated, and simultaneously repressed and activated. We develop a stochastic model that quantitatively captures the means and distributions of the expression from the engineered promoter of this modular system, and show that the model can be extended and used to accurately predict the in vivo behaviour of the network when it is expanded to include positive feedback. The model also reveals the counterintuitive prediction that noise in protein expression levels can increase upon arrest of cell growth and division, which we confirm experimentally. This work shows that the properties of regulatory subsystems can be used to predict the behaviour of larger, more complex regulatory networks, and that this bottom-up approach can provide insights into gene regulation.	Boston Univ, Ctr Biodynam, Bioinformat Program, Dept Biomed Engn, Boston, MA 02215 USA; Univ N Carolina, Dept Stat & Operat Res, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Math, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ Toronto, Inst Opt Sci, Mississauga, ON L5L 1C6, Canada; Univ Toronto, Dept Chem & Phys Sci, Mississauga, ON L5L 1C6, Canada; Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA	Boston University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Toronto; University Toronto Mississauga; University of Toronto; University Toronto Mississauga; University of California System; University of California San Diego	Collins, JJ (corresponding author), Boston Univ, Ctr Biodynam, Bioinformat Program, Dept Biomed Engn, 44 Cummington St, Boston, MA 02215 USA.	jcollins@bu.edu	Wang, Xiao/A-8414-2008	Wang, Xiao/0000-0002-4056-0155; McMillen, David/0000-0003-2676-5450				Adalsteinsson D, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-24; Atkinson MR, 2003, CELL, V113, P597, DOI 10.1016/S0092-8674(03)00346-5; Basu S, 2004, P NATL ACAD SCI USA, V101, P6355, DOI 10.1073/pnas.0307571101; Becskei A, 2000, NATURE, V405, P590, DOI 10.1038/35014651; Becskei A, 2001, EMBO J, V20, P2528, DOI 10.1093/emboj/20.10.2528; Blake WJ, 2003, NATURE, V422, P633, DOI 10.1038/nature01546; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Fung E, 2005, NATURE, V435, P118, DOI 10.1038/nature03508; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; GREENWOOD D, 1973, J INFECT DIS, V128, P211, DOI 10.1093/infdis/128.2.211; Guet CC, 2002, SCIENCE, V296, P1466, DOI 10.1126/science.1067407; Hooshangi S, 2005, P NATL ACAD SCI USA, V102, P3581, DOI 10.1073/pnas.0408507102; Isaacs FJ, 2004, NAT BIOTECHNOL, V22, P841, DOI 10.1038/nbt986; Isaacs FJ, 2003, P NATL ACAD SCI USA, V100, P7714, DOI 10.1073/pnas.1332628100; Isalan M, 2005, PLOS BIOL, V3, P488, DOI 10.1371/journal.pbio.0030064; Kepler TB, 2001, BIOPHYS J, V81, P3116, DOI 10.1016/S0006-3495(01)75949-8; Kobayashi H, 2004, P NATL ACAD SCI USA, V101, P8414, DOI 10.1073/pnas.0402940101; Kramer BP, 2005, P NATL ACAD SCI USA, V102, P9517, DOI 10.1073/pnas.0500345102; Kramer BP, 2004, NAT BIOTECHNOL, V22, P867, DOI 10.1038/nbt980; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; Ozbudak EM, 2002, NAT GENET, V31, P69, DOI 10.1038/ng869; Paulsson J, 2001, Q REV BIOPHYS, V34, P1, DOI 10.1017/S0033583501003663; Pedraza JM, 2005, SCIENCE, V307, P1965, DOI 10.1126/science.1109090; Ptashne M, 1992, GENETIC SWITCH PHAGE; Rosenfeld N, 2005, SCIENCE, V307, P1962, DOI 10.1126/science.1106914; Rosenfeld N, 2002, J MOL BIOL, V323, P785, DOI 10.1016/S0022-2836(02)00994-4; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Weiss R., 2003, Natural Computing, V2, P47, DOI 10.1023/A:1023307812034; You LC, 2004, NATURE, V428, P868, DOI 10.1038/nature02491	30	254	270	0	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 16	2006	439	7078					856	860		10.1038/nature04473	http://dx.doi.org/10.1038/nature04473			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012JA	16482159				2022-12-28	WOS:000235333600052
J	Fisker, N; Carlsen, NLT; Kolmos, HJ; Tonning-Sorensen, L; Host, A; Christensen, PB				Fisker, N; Carlsen, NLT; Kolmos, HJ; Tonning-Sorensen, L; Host, A; Christensen, PB			Identifying a hepatitis B outbreak by molecular surveillance: a case study	BRITISH MEDICAL JOURNAL			English	Article							VIRUS-INFECTION; NOSOCOMIAL TRANSMISSION; DENMARK; DISEASE; VIALS		Odense Univ Hosp, Dept Clin Immunol, DK-5000 Odense C, Denmark; Odense Univ Hosp, Dept Paediat, DK-5000 Odense, Denmark; Odense Univ Hosp, Dept Clin Microbiol, DK-5000 Odense C, Denmark; Odense Univ Hosp, Dept Internal Med, Infect Dis Sect, DK-5000 Odense C, Denmark	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital	Fisker, N (corresponding author), Odense Univ Hosp, Dept Clin Immunol, Sdr Blvd 29, DK-5000 Odense C, Denmark.	niels.fisker@dadlnet.dk	Christensen, Peer B./B-8042-2015	Christensen, Peer Brehm/0000-0003-1394-058X				Abulrahi HA, 1997, LANCET, V349, P23, DOI 10.1016/S0140-6736(96)03508-8; BRUGUERA M, 1990, J CLIN GASTROENTEROL, V12, P298, DOI 10.1097/00004836-199006000-00013; Christensen PB, 2001, J CLIN VIROL, V22, P133, DOI 10.1016/S1386-6532(01)00175-5; Dumpis U, 2003, J MED VIROL, V69, P331, DOI 10.1002/jmv.10293; Fisker N, 2004, J CLIN VIROL, V31, P46, DOI 10.1016/j.jcv.2004.05.004; HADLER SC, 1991, J INFECT DIS, V163, P454, DOI 10.1093/infdis/163.3.454; Katzenstein TL, 1999, AIDS, V13, P1737, DOI 10.1097/00002030-199909100-00018; Kidd-Ljunggren K, 1999, J HOSP INFECT, V43, P57, DOI 10.1053/jhin.1999.0607; Krause G, 2003, INFECT CONT HOSP EP, V24, P122, DOI 10.1086/502176; MCMAHON BJ, 1985, J INFECT DIS, V151, P599, DOI 10.1093/infdis/151.4.599; NORDER H, 1995, 9 C VIR VERS LE CHES, P39; Osterhaus ADME, 1998, J HEART LUNG TRANSPL, V17, P158; TEDDER RS, 1995, LANCET, V346, P137, DOI 10.1016/S0140-6736(95)91207-X; Widell A, 1999, ANN INTERN MED, V130, P130, DOI 10.7326/0003-4819-130-2-199901190-00007	14	12	12	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	FEB 11	2006	332	7537					343	345		10.1136/bmj.332.7537.343	http://dx.doi.org/10.1136/bmj.332.7537.343			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	012YI	16470056	Green Published			2022-12-28	WOS:000235376400020
J	Nisbet, AC				Nisbet, AC			Intramuscular gluteal injections in the increasingly obese population: retrospective study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PLASMA-LEVELS; ABSORPTION	Aims To examine depth of subcutaneous fat at gluteal intramuscular injection sites. Design Retrospective study. Setting General hospital. Participants 100 consecutive adults who had computed tomography of the pelvis. Main outcome measures Minimum distance between the surface of the skin and the nearest edge of muscle at intramuscular injection sites. Results 12 patients had a ventrogluteal site depth of more than 35 mm, the maximum depth of a green needle, and 26 had a ventrogluteal depth of more than 25 mm, the maximum depth of a blue needle. 43 patients had a dorsogluteal site depth of more than 35 mm, and 72 had a dorsogluteal depth of more than 25 mm. The intramuscular site was likely to be deeper in women. Conclusion Standard green and blue needles do not reach the gluteal muscles in a considerable number of patients.	Jersey Gen Hosp, St Helier LE2 3QS, Jersey, England		Nisbet, AC (corresponding author), Les Grupieaux, Le Grupe, St Peter JE3 7ED, Jersey, England.	kaltarn@yahoo.co.uk						COHEN LS, 1972, AM J CARDIOL, V29, P520, DOI 10.1016/0002-9149(72)90442-0; EVANS EF, 1975, CLIN PHARMACOL THER, V17, P44; Grabinski P Y, 1983, PRN Forum, V2, P2; GRABINSKI PY, 1983, J CLIN PHARMACOL, V23, P48, DOI 10.1002/j.1552-4604.1983.tb02704.x; Greenway Kathleen, 2004, Nurs Stand, V18, P39; LINDSAY KL, 1985, HEPATOLOGY, V5, P1088, DOI 10.1002/hep.1840050605; VUKOVICH RA, 1975, CLIN PHARMACOL THER, V18, P215	7	49	51	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 18	2006	332	7542					637	638		10.1136/bmj.38706.742731.47	http://dx.doi.org/10.1136/bmj.38706.742731.47			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	026CQ	16524934	Green Published, Bronze			2022-12-28	WOS:000236314700016
J	McMahon, CN; Smith, CJ; Shabsigh, R				McMahon, CN; Smith, CJ; Shabsigh, R			Practice pointer - Treating erectile dysfunction when PDE5 inhibitors fail	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SILDENAFIL CITRATE; EFFICACY; THERAPY; SAFETY; MEN; TACHYPHYLAXIS; OPTIMIZATION; COMBINATION; REPLACEMENT; ALPROSTADIL		Columbia Univ, Dept Urol, New York, NY 10019 USA; St Vincents Hosp, Darlinghurst, NSW 2010, Australia; Princess Alexandra Hosp, Woolloongabba, Qld 4102, Australia	Columbia University; St Vincents Hospital Sydney	Shabsigh, R (corresponding author), Columbia Univ, Dept Urol, New York, NY 10019 USA.	rs66@columbia.edu						Althof SE, 2002, INT J IMPOT RES, V14, pS99, DOI 10.1038/sj.ijir.3900799; Arver S, 1996, J UROLOGY, V155, P1604, DOI 10.1016/S0022-5347(01)66141-X; Atiemo HO, 2003, J UROLOGY, V170, P2356, DOI 10.1097/01.ju.0000096221.67967.ae; Aversa A, 2003, CLIN ENDOCRINOL, V58, P632, DOI 10.1046/j.1365-2265.2003.01764.x; *BAYER AG, LEV VARD HCL TABL PR; Carson CC, 2003, BJU INT, V91, P176, DOI 10.1046/j.1464-410X.2003.t01-1-03064.x; De Rose AF, 2002, INT J IMPOT RES, V14, P50, DOI 10.1038/sj.ijir.3900815; Droggin D, 2005, J SEX MED, V2, P565, DOI 10.1111/j.1743-6109.2005.00073.x; Dula E, 2000, UROLOGY, V56, P130, DOI 10.1016/S0090-4295(00)00575-6; *E LILL CORP, CIAL TAD HCL TABL PR; El-Galley R, 2001, J UROLOGY, V166, P927, DOI 10.1016/S0022-5347(05)65866-1; Fagelman E, 2001, UROLOGY, V57, P1141, DOI 10.1016/S0090-4295(01)00984-0; Guay AT, 2001, J ANDROL, V22, P793; Kalinchenko S Y, 2003, Aging Male, V6, P94, DOI 10.1080/713604767; Lin GT, 2003, J UROLOGY, V170, pS15, DOI 10.1097/01.ju.0000075500.11519.e8; McCullough AR, 2002, UROLOGY, V60, P28, DOI 10.1016/S0090-4295(02)01688-6; McMahon CG, 1999, J UROLOGY, V162, P1992, DOI 10.1016/S0022-5347(05)68085-8; McMahon CG, 2002, INT J IMPOT RES, V14, P533, DOI 10.1038/sj.ijir.3900936; McMahon CG, 1991, INT J IMPOT RES, V3, P133; McMahon C, 2004, J SEX MED, V1, P292, DOI 10.1111/j.1743-6109.04042.x; Mydlo JH, 2000, EUR UROL, V38, P30, DOI 10.1159/000020248; Nehra A, 2002, INT J IMPOT RES, V14, pS38, DOI 10.1038/sj.ijir.3900795; Perelman MA, 2000, SEXUAL DYSFUNCTION M, V1, P98; *PFIZ CORP, VIAGR SILD HCL TABL; Porst H, 1996, J UROLOGY, V155, P802, DOI 10.1016/S0022-5347(01)66315-8; Shabsigh R, 2003, J UROLOGY, V169, P247; Shabsigh R, 1998, UROLOGY, V52, P723, DOI 10.1016/S0090-4295(98)00233-7; Shabsigh R, 2000, UROLOGY, V55, P477, DOI 10.1016/S0090-4295(99)00612-3; Traish AM, 1999, ENDOCRINOLOGY, V140, P1861, DOI 10.1210/en.140.4.1861; VRIJHOF HJEJ, 1994, BRIT J UROL, V74, P102, DOI 10.1111/j.1464-410X.1994.tb16555.x	30	87	91	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 11	2006	332	7541					589	592		10.1136/bmj.332.7541.589	http://dx.doi.org/10.1136/bmj.332.7541.589			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	026CN	16528082	Green Published			2022-12-28	WOS:000236314400018
J	Sever, MS; Vanholder, R; Lameire, N				Sever, MS; Vanholder, R; Lameire, N			Medical progress - Management of crush-related injuries after disasters	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE-RENAL-FAILURE; HANSHIN-AWAJI EARTHQUAKE; MARMARA EARTHQUAKE; FLUID RESUSCITATION; REPLACEMENT THERAPY; VICTIMS; RELIEF; DIALYSIS; CALIFORNIA; FEATURES		Istanbul Sch Med, Dept Internal Med, Istanbul, Turkey; Istanbul Sch Med, Dept Nephrol, Istanbul, Turkey; Univ Hosp, Dept Internal Med, Ghent, Belgium; Univ Hosp, Dept Nephrol, Ghent, Belgium	Istanbul University; Istanbul University; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital	Sever, MS (corresponding author), Atakoy 4,Kisim TO 216,D 15, TR-34390 Istanbul, Turkey.	severm@hotmail.com	Sever, Mehmet Sukru/AAY-6272-2020					Adams B. J., 2003, BOUMERDES ALGERIA EA; ALEXANDER D, 2003, LOCAL PLANNING BEATS; ATEF MR, 1994, Q J MED, V87, P35; AUTIER P, 1990, LANCET, V335, P1388; Baba S, 1996, LANCET, V347, P307, DOI 10.1016/S0140-6736(96)90473-0; BETTER OS, 1990, NEW ENGL J MED, V322, P825; Better OS, 2003, KIDNEY INT, V63, P1155, DOI 10.1046/j.1523-1755.2003.00822.x; Better OS, 1999, MIL MED, V164, P366, DOI 10.1093/milmed/164.5.366; BETTER OS, 1990, NEPHRON, V55, P97, DOI 10.1159/000185934; Better OS, 1997, KIDNEY INT, V52, P886, DOI 10.1038/ki.1997.409; Bywaters EGL, 1941, BRIT MED J, V1941, P427, DOI 10.1136/bmj.1.4185.427; COLLINS AJ, 1991, CRIT CARE CLIN, V7, P421, DOI 10.1016/S0749-0704(18)30313-0; COLLINS AJ, 1989, NEW ENGL J MED, V320, P1291, DOI 10.1056/NEJM198905113201930; EKNOYAN G, 1992, RENAL FAILURE, V14, P241, DOI 10.3109/08860229209106624; Goldfarb DS, 2002, AM J MED, V113, P260, DOI 10.1016/S0002-9343(02)01188-9; Gunal AI, 2004, J AM SOC NEPHROL, V15, P1862, DOI 10.1097/01.asn.0000129336.09976.73; Hatamizadeh P, 2006, AM J KIDNEY DIS, V47, P428, DOI 10.1053/j.ajkd.2005.11.019; HAYNES BE, 1992, ANN EMERG MED, V21, P368, DOI 10.1016/S0196-0644(05)82652-6; HONDA N, 1983, KIDNEY INT, V23, P888, DOI 10.1038/ki.1983.112; Hwang SJ, 2001, NEPHROL DIAL TRANSPL, V16, P78, DOI 10.1093/ndt/16.suppl_5.78; *INT SOC NEPHR, AS QUAK ISNS AID ACT; Knochel JP, 1998, CURRENT THERAPY NEPH, P262; Kuwagata Y, 1997, J TRAUMA, V43, P427, DOI 10.1097/00005373-199709000-00007; Lameire N, 1997, RENAL FAILURE, V19, P665, DOI 10.3109/08860229709109032; Lameire N, 2003, ADV RENAL REPLACE TH, V10, P93, DOI 10.1053/jarr.2003.50012; MAHONEY LE, 1987, ANN EMERG MED, V16, P1085, DOI 10.1016/S0196-0644(87)80764-3; Nadjafi I, 1997, RENAL FAILURE, V19, P655, DOI 10.3109/08860229709109031; Naito H, 1997, RENAL FAILURE, V19, P701, DOI 10.3109/08860229709109036; NAJAFI I, 2005, 42 EUR REN ASS EUR D; NOJI EK, 1991, CRIT CARE CLIN, V7, P271, DOI 10.1016/S0749-0704(18)30306-3; NOJI EK, 1992, RENAL FAILURE, V14, P245, DOI 10.3109/08860229209106625; Oda J, 1997, J TRAUMA, V42, P470, DOI 10.1097/00005373-199703000-00015; Parsons T, 2000, SCIENCE, V288, P661, DOI 10.1126/science.288.5466.661; Peek-Asa C, 1998, INT J EPIDEMIOL, V27, P459, DOI 10.1093/ije/27.3.459; Peek-Asa C, 2003, INJ PREV, V9, P62, DOI 10.1136/ip.9.1.62; PEPE PE, 1991, CRIT CARE CLIN, V7, P401, DOI 10.1016/S0749-0704(18)30312-9; REDMOND AD, 1991, BRIT MED J, V302, P1521, DOI 10.1136/bmj.302.6791.1521; REIS ND, 1986, J BONE JOINT SURG AM, V68A, P414, DOI 10.2106/00004623-198668030-00015; RICHARDS NT, 1989, BMJ-BRIT MED J, V298, P443, DOI 10.1136/bmj.298.6671.443; RICHARDS NT, 1989, BRIT MED J, V298, P655; RON D, 1984, ARCH INTERN MED, V144, P277, DOI 10.1001/archinte.144.2.277; ROSANSKY SJ, 1989, NEW ENGL J MED, V321, P264; Rose BD., 2001, CLIN PHYSL ACID BASE, V5th ed., P888; Roy Nobhojit, 2002, Prehosp Disaster Med, V17, P186; Salomone JP, 2004, TRAUMA, P105; Schultz CH, 1996, NEW ENGL J MED, V334, P438, DOI 10.1056/NEJM199602153340706; Schultz CH, 2003, NEW ENGL J MED, V348, P1349, DOI 10.1056/NEJMsa021807; SEAMAN J, 1990, INJURY, V21, P5, DOI 10.1016/0020-1383(90)90143-I; Sever MS, 2004, CLIN NEPHROL, V61, P413; Sever MS, 2004, J AM SOC NEPHROL, V15, P1071, DOI 10.1097/01.ASN.0000119145.40232.67; Sever MS, 2003, CLIN NEPHROL, V59, P326; Sever MS, 2002, NEPHROL DIAL TRANSPL, V17, P1025, DOI 10.1093/ndt/17.6.1025; Sever MS, 2002, KIDNEY INT, V62, P2264, DOI 10.1046/j.1523-1755.2002.00669.x; Sever MS, 2002, NEPHROL DIAL TRANSPL, V17, P1942, DOI 10.1093/ndt/17.11.1942; Sever MS, 2002, NEPHRON, V92, P64, DOI 10.1159/000064487; Sever MS, 2001, KIDNEY INT, V60, P1114, DOI 10.1046/j.1523-1755.2001.0600031114.x; Sharma R, 2002, BRIT MED J, V324, P259; SHENG ZY, 1987, J TRAUMA, V27, P1130; Shimazu T, 1997, J TRAUMA, V42, P641, DOI 10.1097/00005373-199704000-00010; Shoaf KI, 1998, DISASTERS, V22, P218, DOI 10.1111/1467-7717.00088; Slater MS, 1998, J AM COLL SURGEONS, V186, P693, DOI 10.1016/S1072-7515(98)00089-1; SOLEZ K, 1993, KIDNEY INT, V44, P479, DOI 10.1038/ki.1993.271; Tanaka H, 1999, AM J EMERG MED, V17, P186, DOI 10.1016/S0735-6757(99)90059-1; Uemoto M, 1996, BRIT MED J, V313, P1144, DOI 10.1136/bmj.313.7065.1144a; Ukai T, 1997, RENAL FAILURE, V19, P633, DOI 10.3109/08860229709109029; *US GEOL SURV, SIGN EARTHQ WORLD YE; *USGS EARTHQ HAZ P, 2003, INV SAF FUT; Vanholder R, 2000, NEPHROL DIAL TRANSPL, V15, P1517, DOI 10.1093/ndt/15.10.1517; Vanholder R, 2000, J AM SOC NEPHROL, V11, P1553, DOI 10.1681/ASN.V1181553; Vanholder R, 2001, KIDNEY INT, V59, P783, DOI 10.1046/j.1523-1755.2001.059002783.x; Viroja D., 2003, NEPHROL DIAL TRANSPL, V18, P659; WAECKERLE JF, 1991, NEW ENGL J MED, V324, P815; WHITTAKER R, 1974, J TRAUMA, V14, P37, DOI 10.1097/00005373-197401000-00005; WOODROW G, 1995, RENAL FAILURE, V17, P467, DOI 10.3109/08860229509037610; 1976, LANCET, V2, P1394	75	197	231	1	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 9	2006	354	10					1052	1063		10.1056/NEJMra054329	http://dx.doi.org/10.1056/NEJMra054329			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	019FY	16525142				2022-12-28	WOS:000235822200009
J	Murray, TJ				Murray, TJ			Diagnosis and treatment of multiple sclerosis	BRITISH MEDICAL JOURNAL			English	Review							TECHNOLOGY-ASSESSMENT SUBCOMMITTEE; ACADEMY-OF-NEUROLOGY; INTERFERON BETA-1A; THERAPEUTICS; MITOXANTRONE; GUIDELINES; ANTIBODIES; CRITERIA; MS		Dalhousie Univ, Halifax, NS B3H 4H7, Canada	Dalhousie University	Murray, TJ (corresponding author), Dalhousie Univ, Sir Charles Tupper Med Bldg,5849 Univ Ave, Halifax, NS B3H 4H7, Canada.	jock.murray@dal.ca						BOWLING AC, 2001, ALTERNATIVE MED MULT; COHEN BA, 2004, NEUROLOGY S6, V63; Fangerau T, 2004, ACTA NEUROL SCAND, V109, P385, DOI 10.1111/j.1600-0404.2004.00246.x; Feinstein A, 2004, CAN J PSYCHIAT, V49, P157, DOI 10.1177/070674370404900302; Frohman EM, 2003, NEUROLOGY, V61, P602, DOI 10.1212/01.WNL.0000082654.99838.EF; Giovannoni G, 2005, NEUROLOGY, V65, P6, DOI 10.1212/01.wnl.0000172080.54415.f1; Goodin DS, 2003, NEUROLOGY, V61, P1332, DOI 10.1212/01.WNL.0000095425.84407.39; Goodin DS, 2002, NEUROLOGY, V58, P169, DOI 10.1212/WNL.58.2.169; Hartung HP, 2002, LANCET, V360, P2018, DOI 10.1016/S0140-6736(02)12023-X; Jacobs LD, 2000, NEW ENGL J MED, V343, P898, DOI 10.1056/NEJM200009283431301; Kappos L, 2005, NEUROLOGY, V65, P40, DOI 10.1212/01.wnl.0000171747.59767.5c; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Morrow SA, 2004, NEUROLOGY, V63, P1079, DOI 10.1212/01.WNL.0000138572.82125.F5; Murray T.J., 2005, MULTIPLE SCLEROSIS H; MURRAY TJ, 2005, INT MS J, V13, P3; Pittock SJ, 2004, ANN NEUROL, V56, P303, DOI 10.1002/ana.20197; *SER, NOV PRESCR INF PACK; SHAPIRO RT, 2003, MANAGING SYMPTOMS MU	18	114	121	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAR 4	2006	332	7540					525	527		10.1136/bmj.332.7540.525	http://dx.doi.org/10.1136/bmj.332.7540.525			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	023WB	16513709	Green Published			2022-12-28	WOS:000236155800017
J	Forde, A				Forde, A			A meeting of minds, expertise, and imagination	SCIENCE			English	Editorial Material																			0	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	2006	311	5765					1306	1307		10.1126/science.311.5765.1306	http://dx.doi.org/10.1126/science.311.5765.1306			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019XB	16513988				2022-12-28	WOS:000235870400048
J	Thurmer, K; Hwang, RQ; Bartelt, NC				Thurmer, K; Hwang, RQ; Bartelt, NC			Surface self-organization caused by dislocation networks	SCIENCE			English	Article							NANOSTRUCTURES; TRANSITIONS; AU(111); DOMAINS	We report a new mechanism of self-organization that can lead to robust surface ordering. We have quantitatively analyzed the thermal motion of holes created by sulfur atoms in a silver monolayer on a ruthenium surface, which we observed in real time with scanning tunneling microscopy. We find that the stability of the array of holes is determined by the arrangement and structure of misfit dislocations in the film.	Sandia Natl Labs, Livermore, CA 94550 USA	United States Department of Energy (DOE); Sandia National Laboratories	Thurmer, K (corresponding author), Sandia Natl Labs, Livermore, CA 94550 USA.	kthurme@sandia.gov	Thürmer, Konrad/ABF-6374-2021; Thürmer, Konrad/L-4699-2013; Bartelt, Norman C/G-2927-2012	Thürmer, Konrad/0000-0002-3078-7372; Thürmer, Konrad/0000-0002-3078-7372; 				ALERHAND OL, 1988, PHYS REV LETT, V61, P1973, DOI 10.1103/PhysRevLett.61.1973; Barth JV, 2005, NATURE, V437, P671, DOI 10.1038/nature04166; BRUCH LW, 1997, PHYS ADSORPTION FORC, P190; Brune H, 1998, NATURE, V394, P451, DOI 10.1038/28804; CHAMBLISS DD, 1991, J VAC SCI TECHNOL B, V9, P933, DOI 10.1116/1.585498; Corso M, 2004, SCIENCE, V303, P217, DOI 10.1126/science.1091979; CROSET B, 2002, PHYS REV LETT, V88; FRANK FC, 1949, PROC R SOC LON SER-A, V198, P205, DOI 10.1098/rspa.1949.0095; HALDANE FDM, 1981, J PHYS-PARIS, V42, P1673, DOI 10.1051/jphys:0198100420120167300; HARTEN U, 1985, PHYS REV LETT, V54, P2619, DOI 10.1103/PhysRevLett.54.2619; KHARE SV, 1995, PHYS REV LETT, V75, P2148, DOI 10.1103/PhysRevLett.75.2148; Leroy F, 2003, SURF SCI, V545, P211, DOI 10.1016/j.susc.2003.08.051; MARCHENKO VI, 1981, JETP LETT+, V33, P381; Pohl K, 1999, NATURE, V397, P238, DOI 10.1038/16667; Prevot G, 2004, SURF SCI, V549, P52, DOI 10.1016/j.susc.2003.11.020; RICKMAN JM, 1993, SURF SCI, V284, P211, DOI 10.1016/0039-6028(93)90538-U; Rosei F, 2004, J PHYS-CONDENS MAT, V16, pS1373, DOI 10.1088/0953-8984/16/17/001; Thayer GE, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.036101; Theobald JA, 2003, NATURE, V424, P1029, DOI 10.1038/nature01915; Thurmer K, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.106101; van Gastel R, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.055503; VANDERBILT D, 1992, SURF SCI, V268, pL300, DOI 10.1016/0039-6028(92)90939-4; Whitesides GM, 2002, SCIENCE, V295, P2418, DOI 10.1126/science.1070821; YAFET Y, 1988, PHYS REV B, V38, P9145, DOI 10.1103/PhysRevB.38.9145; ZEPPENFELD P, 1994, PHYS REV LETT, V72, P2737, DOI 10.1103/PhysRevLett.72.2737	25	21	22	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	2006	311	5765					1272	1274		10.1126/science.1120224	http://dx.doi.org/10.1126/science.1120224			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019XB	16513979	Green Submitted			2022-12-28	WOS:000235870400037
J	Warneken, F; Tomasello, M				Warneken, F; Tomasello, M			Altruistic helping in human infants and young chimpanzees	SCIENCE			English	Article							PRO-SOCIAL BEHAVIOR; PROSOCIAL BEHAVIOR; EMPATHY; MONKEYS; OTHERS; SELF	Human beings routinely help others to achieve their goals, even when the helper receives no immediate benefit and the person helped is a stranger. Such altruistic behaviors (toward non-kin) are extremely rare evolutionarily, with some theorists even proposing that they are uniquely human. Here we show that human children as young as 18 months of age (prelinguistic or just-linguistic) quite readily help others to achieve their goals in a variety of different situations. This requires both an understanding of others' goals and an altruistic motivation to help. In addition, we demonstrate similar though less robust skills and motivations in three young chimpanzees.	Max Planck Inst Evolutionary Anthropol, Dept Dev & Comparat Psychol, D-04103 Leipzig, Germany	Max Planck Society	Warneken, F (corresponding author), Max Planck Inst Evolutionary Anthropol, Dept Dev & Comparat Psychol, Deutsch Pl 6, D-04103 Leipzig, Germany.	warneken@eva.mpg.de						Alexander R., 1987, BIOL MORAL SYSTEMS; BECK B B, 1973, Science (Washington D C), V182, P594, DOI 10.1126/science.182.4112.594; Bischof-Kohler D, 2000, PSYCHOL ERZ UNTERR, V47, P142; Bischof-Kohler D., 1991, INFANT DEV PERSPECTI, P245; BISCHOFKOHLER D, 1994, Z PSYCHOL, V202, P349; De Waal F., 1996, GOOD NATURED; DUNN J, 1986, INT J BEHAV DEV, V9, P265, DOI 10.1177/016502548600900301; Eisenberg N., 2006, HDB CHILD PSYCHOL VO, V(6th ed., pp., P646, DOI 10.1002/9780470147658.chpsy0311; Fehr E, 2003, NATURE, V425, P785, DOI 10.1038/nature02043; Hare B, 2004, ANIM BEHAV, V68, P571, DOI 10.1016/j.anbehav.2003.11.011; Hauser MD, 2003, P ROY SOC B-BIOL SCI, V270, P2363, DOI 10.1098/rspb.2003.2509; Hoffman M. L., 2001, EMPATHY MORAL DEV IM; JENSEN K, 2006, P R SOC LONDON  0117; Joan Grusec., 2002, BLACKWELL HDB CHILDH, P457; JOHNSON DB, 1982, MERRILL PALMER QUART, V28, P379; LISZKOWSKI U, IN PRESS J COGN DEV; OCONNELL SM, 1995, PRIMATES, V36, P397, DOI 10.1007/BF02382862; Preston SD, 2002, BEHAV BRAIN SCI, V25, P1, DOI 10.1017/S0140525X02000018; RHEINGOLD HL, 1982, CHILD DEV, V53, P114, DOI 10.1111/j.1467-8624.1982.tb01298.x; Silk JB, 2005, NATURE, V437, P1357, DOI 10.1038/nature04243; Stevens JR, 2004, TRENDS COGN SCI, V8, P60, DOI 10.1016/j.tics.2003.12.003; TOMASELLO M, 2005, BEHAV BRAIN SCI, V28, P5; Wolfle DL, 1939, PEDAGOG SEMIN J GEN, V55, P137; ZAHNWAXLER C, 1979, CHILD DEV, V50, P319, DOI 10.1111/j.1467-8624.1979.tb04112.x; ZAHNWAXLER C, 1992, DEV PSYCHOL, V28, P126, DOI 10.1037/0012-1649.28.1.126	25	831	846	12	620	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	2006	311	5765					1301	1303		10.1126/science.1121448	http://dx.doi.org/10.1126/science.1121448			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	019XB	16513986				2022-12-28	WOS:000235870400046
J	Parker, NR; Barralet, JH; Bell, AM				Parker, NR; Barralet, JH; Bell, AM			Q fever	LANCET			English	Review							COXIELLA-BURNETII INFECTION; TERM VASCULAR COMPLICATIONS; LINKED-IMMUNOSORBENT-ASSAY; FOLLOW-UP; Q-VAX; COMPARATIVE EFFICACY; VACCINE PROPHYLAXIS; IMMUNOGLOBULIN-G; DAIRY-CATTLE; RESIDUE CMR	Q fever is a zoonosis with many manifestations. The most common clinical presentation is an influenza-like illness with varying degrees of pneumonia and hepatitis. Although acute disease is usually self-limiting, people do occasionally die from this condition. Endocarditis is the most frequent chronic presentation. Although Q fever is widespread, practitioner awareness and clinical manifestations vary from region to region. Geographically limited studies suggest that chronic fatigue syndrome and cardiovascular disease are long-term sequelae. An effective whole-cell vaccine is licensed in Australia. Live and acellular vaccines have also been studied, but are not currently licensed.	Queensland Hlth, Darling Downs Publ Hlth Unit, Toowoomba, Qld 4350, Australia; Queensland Hlth, Communicable Dis Unit, Toowoomba, Qld 4350, Australia	Queensland Health; Queensland Health	Parker, NR (corresponding author), Queensland Hlth, Darling Downs Publ Hlth Unit, POB 1775, Toowoomba, Qld 4350, Australia.	neil_parker@health.qld.gov.au						ACKLAND JR, 1994, MED J AUSTRALIA, V160, P704, DOI 10.5694/j.1326-5377.1994.tb125909.x; Ayres JG, 2002, QJM-INT J MED, V95, P539, DOI 10.1093/qjmed/95.8.539; Ayres JG, 1996, LANCET, V347, P978, DOI 10.1016/S0140-6736(96)91470-1; Barralet JH, 2004, MED J AUSTRALIA, V180, P596, DOI 10.5694/j.1326-5377.2004.tb06106.x; Bartlett JG, 2000, MEDICINE, V79, P124, DOI 10.1097/00005792-200003000-00006; BECK MD, 1949, PUBLIC HEALTH REP, V64, P41, DOI 10.2307/4586820; Bell M, 1997, Commun Dis Intell, V21, P29; Berri M, 2000, VET MICROBIOL, V72, P285, DOI 10.1016/S0378-1135(99)00178-9; Berri M, 2002, VET MICROBIOL, V85, P55, DOI 10.1016/S0378-1135(01)00480-1; Berri M, 2001, VET REC, V148, P502, DOI 10.1136/vr.148.16.502; Boland PJ, 1999, MED J AUSTRALIA, V171, P446, DOI 10.5694/j.1326-5377.1999.tb123737.x; Bolanos M, 2003, EUR J EPIDEMIOL, V18, P259, DOI 10.1023/A:1023342624475; Boschini A, 1999, CLIN INFECT DIS, V28, P866, DOI 10.1086/515192; Bouvery NA, 2003, VET RES, V34, P423, DOI 10.1051/vetres:2003017; BURNET F. M., 1937, Medical Journal of Australia, V2, P299; Camacho MT, 2000, VACCINE, V18, P1773, DOI 10.1016/S0264-410X(99)00484-3; Capuano F, 2001, VET REC, V149, P669, DOI 10.1136/vr.149.22.669; Carrieri MP, 2002, EUR J CLIN MICROBIOL, V21, P17, DOI 10.1007/s10096-001-0645-5; *CDCP, 2003, Q FEV; *CDCP, 2004, MORB MORTAL WKLY REP, V53; Cetinkaya B, 2000, VET REC, V146, P131, DOI 10.1136/vr.146.5.131; Chomel Bruno B., 1993, Southeast Asian Journal of Tropical Medicine and Public Health, V24, P321; Cone L. A., 2000, Antimicrobics and Infectious Diseases Newsletter, V18, P38, DOI 10.1016/S1069-417X(00)89006-8; Crespo M, 1999, INFECTION, V27, P132, DOI 10.1007/BF02560514; Davies TR, 1997, J PUBLIC HEALTH MED, V19, P324, DOI 10.1093/oxfordjournals.pubmed.a024638; Davis G. E., 1938, Public Health Reports Washington, V53, P2259, DOI 10.2307/4582746; de Alarcon A, 2003, J INFECTION, V47, P110, DOI 10.1016/S0163-4453(03)00013-6; DERRICK E. H., 1964, Queensland Health., V1, P1; DERRICK E. H., 1937, Medical Journal of Australia, V2, P281; DERRICK EH, 1961, PATHOL MICROBIOL, V24, P73, DOI 10.1159/000161245; DERRICK EH, 1973, MED J AUSTRALIA, V1, P1051, DOI 10.5694/j.1326-5377.1973.tb110910.x; Dolce Patrick, 2003, Can J Infect Dis, V14, P97; Domingo P, 1999, CLIN INFECT DIS, V29, P874, DOI 10.1086/520452; DUMLER SJ, 2002, CURR TREAT OPTIONS I, V4, P437; DUPONT HT, 1994, CLIN DIAGN LAB IMMUN, V1, P189, DOI 10.1128/CDLI.1.2.189-196.1994; DUPONT HT, 1992, AM J MED, V93, P427, DOI 10.1016/0002-9343(92)90173-9; DUPUIS G, 1987, INT J EPIDEMIOL, V16, P282, DOI 10.1093/ije/16.2.282; ENRIGHT JB, 1971, AM J EPIDEMIOL, V94, P72, DOI 10.1093/oxfordjournals.aje.a121297; Fenollar F, 2001, CLIN INFECT DIS, V33, P312, DOI 10.1086/321889; Field PR, 2000, J CLIN MICROBIOL, V38, P1645, DOI 10.1128/JCM.38.4.1645-1647.2000; Field PR, 2002, J CLIN MICROBIOL, V40, P3526, DOI 10.1128/JCM.40.9.3526-3529.2002; FISHBEIN DB, 1992, AM J TROP MED HYG, V47, P35, DOI 10.4269/ajtmh.1992.47.35; Fournier PE, 2003, J CLIN MICROBIOL, V41, P5094, DOI 10.1128/JCM.41.11.5094-5098.2003; Fournier PE, 1998, J CLIN MICROBIOL, V36, P1823, DOI 10.1128/JCM.36.7.1823-1834.1998; Fournier PE, 2001, CLIN INFECT DIS, V32, P1440, DOI 10.1086/320159; FRIES LF, 1993, INFECT IMMUN, V61, P1251, DOI 10.1128/IAI.61.4.1251-1258.1993; Garner MG, 1997, AUST NZ J PUBL HEAL, V21, P722, DOI 10.1111/j.1467-842X.1997.tb01787.x; Gikas A, 2001, ANTIMICROB AGENTS CH, V45, P3644, DOI 10.1128/AAC.45.12.3644-3646.2001; Greenslade E, 2003, EMERG INFECT DIS, V9, P138, DOI 10.3201/eid0901.010305; Gregory AT, 2004, MED J AUSTRALIA, V181, P9, DOI 10.5694/j.1326-5377.2004.tb06149.x; Hatchette TF, 2003, EPIDEMIOL INFECT, V130, P491, DOI 10.1017/S0950268803008343; Hatchette TF, 2001, EMERG INFECT DIS, V7, P413; Hawker J I, 1998, Commun Dis Public Health, V1, P180; Heinzen RA, 1999, TRENDS MICROBIOL, V7, P149, DOI 10.1016/S0966-842X(99)01475-4; HILBINK F, 1993, INT J EPIDEMIOL, V22, P945, DOI 10.1093/ije/22.5.945; Hirai K, 1998, J VET MED SCI, V60, P781, DOI 10.1292/jvms.60.781; Hoover TA, 2002, INFECT IMMUN, V70, P6726, DOI 10.1128/IAI.70.12.6726-2733.2002; Howe D, 2000, INFECT IMMUN, V68, P3815, DOI 10.1128/IAI.68.7.3815-3821.2000; Jager C, 1998, EPIDEMIOL INFECT, V120, P157, DOI 10.1017/S0950268897008510; JORM LR, 1990, EPIDEMIOL INFECT, V104, P467, DOI 10.1017/S0950268800047476; KANFER E, 1988, BONE MARROW TRANSPL, V3, P165; Kermode M, 2003, AUST NZ J PUBL HEAL, V27, P390, DOI 10.1111/j.1467-842X.2003.tb00415.x; Kovacova E, 2002, ACTA VIROL, V46, P193; Lang G. H., 1990, Q fever. Volume 1. The disease., P23; Langley JM, 2003, AM J OBSTET GYNECOL, V189, P228, DOI 10.1067/mob.2003.448; Lawrence Glenda, 2003, Commun Dis Intell Q Rep, V27, P307; Leone M, 2004, J INFECT DIS, V189, P339, DOI 10.1086/380798; Lepidi H, 2003, J INFECT DIS, V187, P1097, DOI 10.1086/368219; Levy PY, 1999, CLIN INFECT DIS, V29, P393, DOI 10.1086/520221; Lovey PY, 1999, BRIT MED J, V319, P284, DOI 10.1136/bmj.319.7205.284; Madariaga MG, 2003, LANCET INFECT DIS, V3, P709, DOI 10.1016/S1473-3099(03)00804-1; Mak Donna B, 2003, Commun Dis Intell Q Rep, V27, P267; Maltezou HC, 2002, LANCET INFECT DIS, V2, P686, DOI 10.1016/S1473-3099(02)00440-1; MARMION B. P., 1956, JOUR HYG, V54, P118; MARMION BP, 1959, P ROY SOC MED, V52, P613, DOI 10.1177/003591575905200810; Marmion BP, 2005, QJM-INT J MED, V98, P7, DOI 10.1093/qjmed/hci009; Marmion BP, 1997, AUST NZ J PUBL HEAL, V21, P677, DOI 10.1111/j.1467-842X.1997.tb01778.x; MARMION BP, 1990, EPIDEMIOL INFECT, V104, P275, DOI 10.1017/S0950268800059458; Marmion BP, 1996, LANCET, V347, P977, DOI 10.1016/S0140-6736(96)91469-5; Marrie T. J., 1990, Q fever. Volume 1. The disease., P49; MARRIE TJ, 1988, J INFECT DIS, V158, P101, DOI 10.1093/infdis/158.1.101; Marrie TJ, 2003, EUR RESPIR J, V21, P713, DOI 10.1183/09031936.03.00099703; Marrie TJ, 1997, INT J ANTIMICROB AG, V8, P145, DOI 10.1016/S0924-8579(96)00369-X; MARRIE TJ, 1993, AM J TROP MED HYG, V49, P613, DOI 10.4269/ajtmh.1993.49.613; MARRIE TJ, 1995, EUR J EPIDEMIOL, V11, P47, DOI 10.1007/BF01719945; Maurin M, 1999, CLIN MICROBIOL REV, V12, P518, DOI 10.1128/CMR.12.4.518; McDade JE, 1990, Q FEVER DIS, P6; Mcquiston JH, 2002, VECTOR-BORNE ZOONOT, V2, P179, DOI 10.1089/15303660260613747; Milazzo A, 2001, CLIN INFECT DIS, V33, P399, DOI 10.1086/321878; Mossienko EV, 2003, FOLIA MICROBIOL, V48, P103, DOI 10.1007/BF02931284; MURPHY AM, 1970, MED J AUSTRALIA, V1, P1148, DOI 10.5694/j.1326-5377.1970.tb84481.x; *NAT NOT DIS SURV, 2005, NOT DIS STAT TERR YE; Nourse C, 2004, CLIN INFECT DIS, V39, pE61, DOI 10.1086/424014; ORMSBEE RA, 1990, Q FEVER DIS, P226; Osorio S, 2003, J HOSP INFECT, V54, P162, DOI 10.1016/S0195-6701(03)00111-7; Pantanowitz L, 2002, TRANSFUSION MED, V12, P85, DOI 10.1046/j.1365-3148.2002.00358.x; Penttila IA, 1998, QJM-MON J ASSOC PHYS, V91, P549, DOI 10.1093/qjmed/91.8.549; Raoult D, 1999, ARCH INTERN MED, V159, P167, DOI 10.1001/archinte.159.2.167; Raoult D, 1996, J MED MICROBIOL, V44, P77, DOI 10.1099/00222615-44-2-77; RAOULT D, 1995, CLIN INFECT DIS, V20, P489, DOI 10.1093/clinids/20.3.489; Raoult D, 2002, QJM-INT J MED, V95, P491, DOI 10.1093/qjmed/95.8.491; RAOULT D, 1994, NEW ENGL J MED, V330, P371, DOI 10.1056/NEJM199402033300518; Raoult D, 2002, ARCH INTERN MED, V162, P701, DOI 10.1001/archinte.162.6.701; Raoult D, 2000, MEDICINE, V79, P109, DOI 10.1097/00005792-200003000-00005; RICHARDUS JH, 1985, PEDIATR INFECT DIS J, V4, P369, DOI 10.1097/00006454-198507000-00007; RICHARDUS JH, 1987, EPIDEMIOL INFECT, V98, P211, DOI 10.1017/S0950268800061938; Rolain JM, 2005, QJM-INT J MED, V98, P615, DOI 10.1093/qjmed/hci099; Rolain JM, 2003, J INFECT DIS, V188, P1322, DOI 10.1086/379082; Rolain JM, 2001, ANTIMICROB AGENTS CH, V45, P301, DOI 10.1128/AAC.45.1.301-302.2001; SALMON MM, 1982, LANCET, V1, P1002; Samuel JE, 2003, ANN NY ACAD SCI, V990, P653, DOI 10.1111/j.1749-6632.2003.tb07440.x; Santoro D, 2004, EMERG INFECT DIS, V10, P159, DOI 10.3201/eid1001.030467; SAWYER LA, 1987, REV INFECT DIS, V9, P935; Schelling E, 2003, PREV VET MED, V61, P279, DOI 10.1016/j.prevetmed.2003.08.004; Serbezov V, 1999, EMERG INFECT DIS, V5, P388, DOI 10.3201/eid0503.990309; Seshadri R, 2003, P NATL ACAD SCI USA, V100, P5455, DOI 10.1073/pnas.0931379100; SOBRADILLO V, 1992, THORAX, V47, P276, DOI 10.1136/thx.47.4.276; SPELMAN D, 1982, MED J AUSTRALIA, P547; Stein A, 1998, CLIN INFECT DIS, V27, P592, DOI 10.1086/514698; STOKER M G, 1955, Bull World Health Organ, V13, P781; TIGERTT WD, 1961, BACTERIOL REV, V25, P285, DOI 10.1128/MMBR.25.3.285-293.1961; Tissot-Dupont H, 1999, AM J EPIDEMIOL, V150, P67, DOI 10.1093/oxfordjournals.aje.a009920; To H, 1998, J VET MED SCI, V60, P859, DOI 10.1292/jvms.60.859; van Woerden HC, 2004, EMERG INFECT DIS, V10, P1282, DOI 10.3201/eid1007.030536; Varga V, 1997, Cent Eur J Public Health, V5, P180; Vogel JP, 2004, TRENDS MICROBIOL, V12, P103, DOI 10.1016/j.tim.2004.01.008; Waag DM, 1997, VACCINE, V15, P1779, DOI 10.1016/S0264-410X(97)00107-2; Waag DM, 2002, VACCINE, V20, P2623, DOI 10.1016/S0264-410X(02)00176-7; Wildman M, 2000, BRIT MED J, V320, P58; Wildman MJ, 2002, QJM-INT J MED, V95, P527, DOI 10.1093/qjmed/95.8.527; WILLIAMS JC, 1991, Q FEVER BIOL COXIELL, P21; WILSON HG, 1976, CIRCULATION, V53, P680, DOI 10.1161/01.CIR.53.4.680; Woldehiwet Z, 2004, RES VET SCI, V77, P93, DOI 10.1016/j.rvsc.2003.09.001; WORSWICK D, 1985, J MED MICROBIOL, V19, P281, DOI 10.1099/00222615-19-3-281; Yanase T, 1997, MICROBIOL IMMUNOL, V41, P73, DOI 10.1111/j.1348-0421.1997.tb01184.x	135	323	343	0	30	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 25	2006	367	9511					679	688		10.1016/S0140-6736(06)68266-4	http://dx.doi.org/10.1016/S0140-6736(06)68266-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	016HR	16503466				2022-12-28	WOS:000235611800032
J	Ye, Z; Liu, EHC; Higgins, JPT; Keavney, BD; Lowe, GDO; Collins, R; Danesh, J				Ye, Z; Liu, EHC; Higgins, JPT; Keavney, BD; Lowe, GDO; Collins, R; Danesh, J			Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66 155 cases and 91 307 controls	LANCET			English	Article							FACTOR-V-LEIDEN; PLATELET GLYCOPROTEIN RECEPTOR; ACTIVATED PROTEIN-C; MYOCARDIAL-INFARCTION; HEART-DISEASE; RISK-FACTORS; CARDIOVASCULAR-DISEASES; VENOUS THROMBOEMBOLISM; ARTERIAL THROMBOSIS; PROTHROMBIN GENE	Background Variants of certain haemostatic genes (such as that encoding factor V Leiden) are involved in the development of venous thrombosis, but studies of such variants in coronary disease have reported apparently conflicting results. We did meta-analyses on seven such haemostatic genetic variants for which the available evidence on each comprises at least 5000 coronary disease cases and at least 5000 controls. Methods Meta-analyses were done of 191 studies in relation to factor V G1691A (ie, factor V Leiden), factor VII G10976A, prothrombin G20210A, plasminogen activator inhibitor-1 (PAI-1) [-675] 4G/5G, and three platelet glycoprotein (GP) receptor variants (GPla C807T, GPIb alpha T[-5]C, GPIIIa C1565T), involving a total of 66155 coronary disease cases and 91307 controls. We explored potential sources of heterogeneity. Findings In a combined analysis of all studies, the per-allele relative risks (RR) for coronary disease of factor V 1691A and of prothrombin 20210A were 1.17 (95% CI 1.08-1.28) and 1.31 (1.12-1.52), respectively. Combined analyses of studies of the PAI-1 [-675] 4G variant yielded a per-allele relative risk for coronary disease of 1.06 (1.02-1.10), but there was an indication of publication bias in these studies. Combined analyses of the factor VII 10976A, GPIa 807T, GPIba [-5]C, and GPIIIa 156ST variants showed no significant overall associations with coronary disease, yielding per-allele RRs of 0.97 (0.91-1.04), 1.02 (0.97-1.08), 1.05 (0.96-1.13), and 1.03 (0.98-1.07), respectively. Interpretation The 1691A variant of the factor V gene and the 20210A variant of the prothrombin gene, both of which increase circulating thrombin generation, might each be moderately associated with the risk of coronary disease. Further studies are merited to assess these associations in greater detail (including any gene-gene and gene-environment interactions) and to determine any implications with regard to potential therapies designed to reverse patients' prothrombotic phenotype, such as selective plasma factor V or factor Xa inhibition.	Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge CB1 8RN, England; Natl Univ Singapore, Dept Anaesthesia, Natl Univ Hosp, Yong Loo Lin Sch Med,Dept Anaesthesia, Singapore 117548, Singapore; Inst Publ Hlth, Publ Hlth Genet Unit, Cambridge, England; Inst Publ Hlth, MRC, Biostat Unit, Cambridge, England; Univ Newcastle, Sch Clin Med Sci, Newcastle Upon Tyne, Tyne & Wear, England; Univ Glasgow, Div Cardiovasc & Med Sci, Glasgow, Lanark, Scotland; Univ Oxford, Clin Trial Serv Unit, Oxford, England; Univ Oxford, Epidemiol Studies Unit, Oxford, England	University of Cambridge; National University of Singapore; University of Cambridge; MRC Biostatistics Unit; University of Cambridge; Newcastle University - UK; University of Glasgow; University of Oxford; University of Oxford	Danesh, J (corresponding author), Univ Cambridge, Dept Publ Hlth & Primary Care, Strangeways Site,Worts Causeway, Cambridge CB1 8RN, England.	john.danesh@phpc.cam.ac.uk	Higgins, Julian PT/H-4008-2011	Higgins, Julian PT/0000-0002-8323-2514; Keavney, Bernard/0000-0001-9573-0812	Medical Research Council [MC_U105285807] Funding Source: researchfish; MRC [MC_U105285807] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Afshar-Kharghan V, 1999, BLOOD, V94, P186, DOI 10.1182/blood.V94.1.186.413k19_186_191; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Boekholdt SM, 2001, CIRCULATION, V104, P3063, DOI 10.1161/hc5001.100793; Burr D, 2003, STAT MED, V22, P1741, DOI 10.1002/sim.1375; Burzotta F, 2004, HEART, V90, P82, DOI 10.1136/heart.90.1.82; Colhoun HM, 2003, LANCET, V361, P865, DOI 10.1016/S0140-6736(03)12715-8; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Di Castelnuovo A, 2001, THROMB HAEMOSTASIS, V85, P626; Doix S., 2003, Annales de Cardiologie et d'Angeiologie, V52, P143, DOI 10.1016/S0003-3928(02)00192-0; Eitzman DT, 2005, CIRCULATION, V111, P1822, DOI 10.1161/01.CIR.0000160854.75779.E8; El-Hazmi MAF, 2002, MED PRIN PRACT, V11, P56, DOI 10.1159/000066407; ERIKSSON P, 1995, P NATL ACAD SCI USA, V92, P1851, DOI 10.1073/pnas.92.6.1851; GREENLAND S, 1994, AM J EPIDEMIOL, V140, P290, DOI 10.1093/oxfordjournals.aje.a117248; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hunault M, 1997, ARTERIOSCL THROM VAS, V17, P2825, DOI 10.1161/01.ATV.17.11.2825; Ioannidis JPA, 2003, LANCET, V361, P567, DOI 10.1016/S0140-6736(03)12516-0; Juul K, 2004, ANN INTERN MED, V140, P330, DOI 10.7326/0003-4819-140-5-200403020-00008; Juul K, 2002, BLOOD, V100, P3, DOI 10.1182/blood-2002-01-0111; Keavney B, 2000, LANCET, V355, P434; Kim RJ, 2003, AM HEART J, V146, P948, DOI 10.1016/S0002-8703(03)00519-2; Kunicki TJ, 1997, BLOOD, V89, P1939, DOI 10.1182/blood.V89.6.1939; LACOVIELLO L, 1998, THROMB HAEMOSTASIS, V80, P1029; Lane DA, 2005, BLOOD, V106, P2605, DOI 10.1182/blood-2005-04-1710; Lane DA, 2000, BLOOD, V95, P1517, DOI 10.1182/blood.V95.5.1517.005k48_1517_1532; Lentz SR, 2005, CIRCULATION, V111, P1733, DOI 10.1161/01.CIR.0000162489.34887.FA; Lowe GDO, 2004, J INTERN MED, V256, P361, DOI 10.1111/j.1365-2796.2004.01400.x; Manzoli A, 2000, Ital Heart J, V1, P184; Meisel C, 2004, N-S ARCH PHARMACOL, V369, P38, DOI 10.1007/s00210-003-0828-y; Middendorf K, 2004, AM HEART J, V147, P897, DOI 10.1016/j.ahj.2003.10.048; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; RASCHE H, 2004, EUR HEART J SUPPL, V3, pQ3; Simmonds RE, 2001, THROMB HAEMOSTASIS, V86, P374, DOI 10.1055/s-0037-1616235; Smith GD, 2005, ARTERIOSCL THROM VAS, V25, P2228, DOI 10.1161/01.ATV.0000183937.65887.9c; Tsunoda T, 2004, HUM MOL GENET, V13, P1623, DOI 10.1093/hmg/ddh177; Voetsch B, 2004, ARTERIOSCL THROM VAS, V24, P216, DOI 10.1161/01.ATV.0000107402.79771.fc; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703; Wu AHB, 2001, AM J CARDIOL, V87, P1361, DOI 10.1016/S0002-9149(01)01553-3; Zhu MM, 2000, AM J CARDIOL, V86, P1000, DOI 10.1016/S0002-9149(00)01136-X	38	328	345	0	21	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 25	2006	367	9511					651	658		10.1016/S0140-6736(06)68263-9	http://dx.doi.org/10.1016/S0140-6736(06)68263-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	016HR	16503463				2022-12-28	WOS:000235611800029
J	Ley, RE; Peterson, DA; Gordon, JI				Ley, RE; Peterson, DA; Gordon, JI			Ecological and evolutionary forces shaping microbial diversity in the human intestine	CELL			English	Review							GASTROINTESTINAL-TRACT; BACTERIAL DIVERSITY; DEFICIENT MICE; COMMUNITY; COLITIS; MICROFLORA; BACTEROIDES; FLORA; POOL	The human gut is populated with as many as 100 trillion cells, whose collective genome, the microbiome, is a reflection of evolutionary selection pressures acting at the level of the host and at the level of the microbial cell. The ecological rules that govern the shape of microbial diversity in the gut apply to mutualists and pathogens alike.	Washington Univ, Sch Med, Ctr Gen Sci, St Louis, MO 63108 USA	Washington University (WUSTL)	Gordon, JI (corresponding author), Washington Univ, Sch Med, Ctr Gen Sci, St Louis, MO 63108 USA.	jgordon@molecool.wustl.edu	Eckhardt, Erik/G-1567-2010; Ley, Ruth E/M-8542-2014	Ley, Ruth E/0000-0002-9087-1672	NCI NIH HHS [T32-CA09547] Funding Source: Medline; NIDDK NIH HHS [T32-DK07130, DK30292, DK58529] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009547] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007130, R01DK058529, R01DK030292, R37DK030292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acinas SG, 2004, NATURE, V430, P551, DOI 10.1038/nature02649; Asseman C, 2003, J IMMUNOL, V171, P971, DOI 10.4049/jimmunol.171.2.971; Axelrood PE, 2002, CAN J MICROBIOL, V48, P655, DOI [10.1139/w02-059, 10.1139/W02-059]; Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816; Barker J, 2005, J APPL MICROBIOL, V99, P339, DOI 10.1111/j.1365-2672.2005.02610.x; BEIKO RG, 2005, P NATL ACAD SCI USA, V10, P2230; Bjedov I, 2003, SCIENCE, V300, P1404, DOI 10.1126/science.1082240; Breitbart M, 2003, J BACTERIOL, V185, P6220, DOI 10.1128/JB.185.20.6220-6223.2003; Buckling A, 2003, SCIENCE, V302, P2107, DOI 10.1126/science.1088848; Clavero M, 2005, TRENDS ECOL EVOL, V20, P110, DOI 10.1016/j.tree.2005.01.003; Cobb BA, 2004, CELL, V117, P677, DOI 10.1016/j.cell.2004.05.001; Cohan FM, 2002, GENETICA, V116, P359, DOI 10.1023/A:1021232409545; CZUPRYNSKI CJ, 1981, INFECT IMMUN, V32, P323, DOI 10.1128/IAI.32.1.323-331.1981; DeLong EE, 2001, SYST BIOL, V50, P470, DOI 10.1080/106351501750435040; Dianda L, 1997, AM J PATHOL, V150, P91; Duchmann R, 1999, GUT, V44, P812, DOI 10.1136/gut.44.6.812; Dunbar J, 2002, APPL ENVIRON MICROB, V68, P3035, DOI 10.1128/AEM.68.6.3035-3045.2002; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Emerson BC, 2005, NATURE, V434, P1015, DOI 10.1038/nature03450; Falkowski P, 2000, SCIENCE, V290, P291, DOI 10.1126/science.290.5490.291; Fernandez A, 1999, APPL ENVIRON MICROB, V65, P3697; Ferriere R, 2002, P ROY SOC B-BIOL SCI, V269, P773, DOI 10.1098/rspb.2001.1900; Frank DN, 2003, J CLIN MICROBIOL, V41, P295, DOI 10.1128/JCM.41.1.295-303.2003; Garrett A, 1884, J ACAD NATURAL SCI 2, V9, P17; Giraud A, 2001, CURR OPIN MICROBIOL, V4, P582, DOI 10.1016/S1369-5274(00)00254-X; Giraud A, 2001, SCIENCE, V291, P2606, DOI 10.1126/science.1056421; Gogarten JP, 2002, MOL BIOL EVOL, V19, P2226, DOI 10.1093/oxfordjournals.molbev.a004046; GORDON JI, 2005, EXTENDING OUR VIEW M; Griffin AS, 2004, NATURE, V430, P1024, DOI 10.1038/nature02744; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; Koestler A, 1967, GHOST MACHINE; Leclerc M, 2004, ENVIRON MICROBIOL, V6, P809, DOI 10.1111/j.1462-2920.2004.00616.x; Lederberg J, 2000, SCIENCE, V288, P287, DOI 10.1126/science.288.5464.287; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Majewski J, 2000, J BACTERIOL, V182, P1016, DOI 10.1128/JB.182.4.1016-1023.2000; Mandar R, 1996, BIOL NEONATE, V69, P30; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; Mizoguchi A, 2000, GASTROENTEROLOGY, V119, P983, DOI 10.1053/gast.2000.18153; Mooney HA, 2001, P NATL ACAD SCI USA, V98, P5446, DOI 10.1073/pnas.091093398; Murphy WJ, 2001, SCIENCE, V294, P2348, DOI 10.1126/science.1067179; Nataro JP, 1998, CLIN MICROBIOL REV, V11, P403; Palys T, 1997, INT J SYST BACTERIOL, V47, P1145, DOI 10.1099/00207713-47-4-1145; Papineau D, 2005, APPL ENVIRON MICROB, V71, P4822, DOI 10.1128/AEM.71.8.4822-4832.2005; Putman R. J., 1994, COMMUNITY ECOLOGY; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rappe MS, 2003, ANNU REV MICROBIOL, V57, P369, DOI 10.1146/annurev.micro.57.030502.090759; Rawls JF, 2004, P NATL ACAD SCI USA, V101, P4596, DOI 10.1073/pnas.0400706101; Rieu-Lesme F, 2005, CURR MICROBIOL, V51, P317, DOI 10.1007/s00284-005-0036-8; Rondon MR, 1999, TRENDS BIOTECHNOL, V17, P403, DOI 10.1016/S0167-7799(99)01352-9; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Schloss PD, 2005, APPL ENVIRON MICROB, V71, P1501, DOI 10.1128/AEM.71.3.1501-1506.2005; SCHUTER D, 2000, ECOLOGY ADAPTIVE RAD; Scupham AJ, 2006, APPL ENVIRON MICROB, V72, P793, DOI 10.1128/AEM.72.1.793-801.2006; Sellon RK, 1998, INFECT IMMUN, V66, P5224, DOI 10.1128/IAI.66.11.5224-5231.1998; Sonnenburg JL, 2004, NAT IMMUNOL, V5, P569, DOI 10.1038/ni1079; Sonnenburg JL, 2005, SCIENCE, V307, P1955, DOI 10.1126/science.1109051; STROCCHI A, 1994, GUT, V35, P1098, DOI 10.1136/gut.35.8.1098; Suzuki K, 2004, P NATL ACAD SCI USA, V101, P1981, DOI 10.1073/pnas.0307317101; Sydora BC, 2005, DIGEST DIS SCI, V50, P905, DOI 10.1007/s10620-005-2663-0; THAUER RK, 1977, BACTERIOL REV, V41, P100, DOI 10.1128/MMBR.41.1.100-180.1977; Tringe SG, 2005, SCIENCE, V308, P554, DOI 10.1126/science.1107851; Whitman WB, 1998, P NATL ACAD SCI USA, V95, P6578, DOI 10.1073/pnas.95.12.6578; WILSON DS, 1975, P NATL ACAD SCI USA, V72, P143, DOI 10.1073/pnas.72.1.143; Woese CR, 2002, P NATL ACAD SCI USA, V99, P8742, DOI 10.1073/pnas.132266999; Xu J, 2003, SCIENCE, V299, P2074, DOI 10.1126/science.1080029; Yachi S, 1999, P NATL ACAD SCI USA, V96, P1463, DOI 10.1073/pnas.96.4.1463; ZACHAR Z, 1979, INFECT IMMUN, V23, P168, DOI 10.1128/IAI.23.1.168-174.1979; Zhou JZ, 2002, APPL ENVIRON MICROB, V68, P326, DOI 10.1128/AEM.68.1.326-334.2002; Zoetendal EG, 2002, APPL ENVIRON MICROB, V68, P3401, DOI 10.1128/AEM.68.7.3401-3407.2002; ZOETENDAL EG, 2001, ECOL HLTH DIS, V13, P129	72	2069	2262	23	676	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 24	2006	124	4					837	848		10.1016/j.cell.2006.02.017	http://dx.doi.org/10.1016/j.cell.2006.02.017			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	038RO	16497592	Bronze			2022-12-28	WOS:000237240900025
J	Marsh, M; Helenius, A				Marsh, M; Helenius, A			Virus entry: Open sesame	CELL			English	Review							INDIVIDUAL INFLUENZA-VIRUSES; VIRAL ENTRY; ENVELOPE GLYCOPROTEIN; HEPARAN-SULFATE; MEMBRANE-FUSION; LIPID RAFTS; CELL ENTRY; RETROVIRUS RESTRICTION; ENDOPLASMIC-RETICULUM; MEDIATED ENDOCYTOSIS	Detailed information about the replication cycle of viruses and their interactions with host organisms is required to develop strategies to stop them. Cell biology studies, live-cell imaging, and systems biology have started to illuminate the multiple and subtly different pathways that animal viruses use to enter host cells. These insights are revolutionizing our understanding of endocytosis and the movement of vesicles within cells. In addition, such insights reveal new targets for attacking viruses before they can usurp the host-cell machinery for replication.	UCL, Cell Biol Unit, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Cell Biol Unit, MRC, Dept Biochem & Mol Biol, London WC1E 6BT, England; ETH Honggerberg, Inst Biochem, CH-8093 Zurich, Switzerland	University of London; University College London; University of London; University College London; Swiss Federal Institutes of Technology Domain; ETH Zurich	Marsh, M (corresponding author), UCL, Cell Biol Unit, MRC, Mol Cell Biol Lab, Gower St, London WC1E 6BT, England.	m.marsh@ucl.ac.uk; ari.helenius@bc.biol.ethz.ch	Marsh, Mark/B-4105-2009	Marsh, Mark/0000-0002-0213-3259	Medical Research Council [MC_U122665002, U.1226.00.003.00001.01(65002), MC_U122663296] Funding Source: Medline; MRC [MC_U122663296] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abrami L, 2004, J CELL BIOL, V166, P645, DOI 10.1083/jcb.200312072; ALTENBURG BC, 1980, J GEN VIROL, V46, P75, DOI 10.1099/0022-1317-46-1-75; Anderson HA, 1996, MOL BIOL CELL, V7, P1825, DOI 10.1091/mbc.7.11.1825; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Best S, 1996, NATURE, V382, P826, DOI 10.1038/382826a0; BORROW P, 1994, VIROLOGY, V198, P1, DOI 10.1006/viro.1994.1001; Bubeck D, 2005, J VIROL, V79, P7745, DOI 10.1128/JVI.79.12.7745-7755.2005; Byrnes AP, 2000, J VIROL, V74, P644, DOI 10.1128/JVI.74.2.644-651.2000; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; Chandran K, 2005, SCIENCE, V308, P1643, DOI 10.1126/science.1110656; Chen JJ, 2004, CELL, V119, P915, DOI 10.1016/j.cell.2004.11.007; Chen YZ, 1999, EXP CELL RES, V246, P83, DOI 10.1006/excr.1998.4301; COYNE CB, 2006, IN PRESS CELL; Damico RL, 1998, P NATL ACAD SCI USA, V95, P2580, DOI 10.1073/pnas.95.5.2580; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; Damm EM, 2005, J CELL BIOL, V168, P477, DOI 10.1083/jcb.200407113; de Haan CAM, 2005, J VIROL, V79, P14451, DOI 10.1128/JVI.79.22.14451-14456.2005; Dohner K, 2005, CURR TOP MICROBIOL, V285, P67; Earp LJ, 2005, CURR TOP MICROBIOL, V285, P25; Ebert DH, 2002, J BIOL CHEM, V277, P24609, DOI 10.1074/jbc.M201107200; Ehrlich M, 2004, CELL, V118, P591, DOI 10.1016/j.cell.2004.08.017; Garcia E, 2005, TRAFFIC, V6, P488, DOI 10.1111/j.1600-0854.2005.00293.x; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Greber UF, 2006, CELL, V124, P741, DOI 10.1016/j.cell.2006.02.018; Greber UF, 2002, CELL MOL LIFE SCI, V59, P608, DOI 10.1007/s00018-002-8453-3; Harrison SC, 2005, ADV VIRUS RES, V64, P231, DOI 10.1016/S0065-3527(05)64007-9; HELENIUS A, 1980, J CELL BIOL, V84, P404, DOI 10.1083/jcb.84.2.404; Hernandez LD, 1997, J CELL BIOL, V139, P1455, DOI 10.1083/jcb.139.6.1455; Hogle JM, 2002, ANNU REV MICROBIOL, V56, P677, DOI 10.1146/annurev.micro.56.012302.160757; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; Imelli N, 2004, J VIROL, V78, P3089, DOI 10.1128/JVI.78.6.3089-3098.2004; Jackson WT, 2005, PLOS BIOL, V3, P861, DOI 10.1371/journal.pbio.0030156; Johnson DC, 2002, J VIROL, V76, P1, DOI 10.1128/JVI.76.1.1-8.2002; Jolly C, 2004, TRAFFIC, V5, P643, DOI 10.1111/j.1600-0854.2004.00209.X; Jung A, 2002, NATURE, V418, P144, DOI 10.1038/418144a; KARTENBECK J, 1989, J CELL BIOL, V109, P2721, DOI 10.1083/jcb.109.6.2721; Kielian M, 2006, NAT REV MICROBIOL, V4, P67, DOI 10.1038/nrmicro1326; Kim SS, 2001, J VIROL, V75, P2288, DOI 10.1128/JVI.75.5.2288-2300.2001; Kirkham M, 2005, J CELL BIOL, V168, P465, DOI 10.1083/jcb.200407078; Klimstra WB, 1998, J VIROL, V72, P7357, DOI 10.1128/JVI.72.9.7357-7366.1998; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lakadamyali M, 2003, P NATL ACAD SCI USA, V100, P9280, DOI 10.1073/pnas.0832269100; Le Blanc I, 2005, NAT CELL BIOL, V7, P653, DOI 10.1038/ncb1269; Lehmann MJ, 2005, J CELL BIOL, V170, P317, DOI 10.1083/jcb.200503059; Li E, 1998, J VIROL, V72, P8806, DOI 10.1128/JVI.72.11.8806-8812.1998; LONG D, 1994, J VIROL, V68, P5890, DOI 10.1128/JVI.68.9.5890-5898.1994; Magnuson B, 2005, MOL CELL, V20, P289, DOI 10.1016/j.molcel.2005.08.034; Marchant D, 2005, J VIROL, V79, P9410, DOI 10.1128/JVI.79.15.9410-9418.2005; Marsh M, 1997, J CELL SCI, V110, P95; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238; Meier O, 2002, J CELL BIOL, V158, P1119, DOI 10.1083/jcb.200112067; Mothes W, 2000, CELL, V103, P679, DOI 10.1016/S0092-8674(00)00170-7; Nemerow GR, 1999, MICROBIOL MOL BIOL R, V63, P725, DOI 10.1128/MMBR.63.3.725-734.1999; O'Doherty U, 2000, J VIROL, V74, P10074, DOI 10.1128/JVI.74.21.10074-10080.2000; Ono A, 2005, ADV VIRUS RES, V64, P311, DOI 10.1016/S0065-3527(05)64010-9; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; Pelkmans L, 2004, CELL, V118, P767, DOI 10.1016/j.cell.2004.09.003; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Pelkmans L, 2005, NATURE, V436, P78, DOI 10.1038/nature03571; Pietiainen V, 2004, MOL BIOL CELL, V15, P4911, DOI 10.1091/mbc.E04-01-0070; Pietiainen VM, 2005, ANN MED, V37, P394, DOI 10.1080/07853890510011976; Puri A, 1998, P NATL ACAD SCI USA, V95, P14435, DOI 10.1073/pnas.95.24.14435; Robinson MS, 2004, TRENDS CELL BIOL, V14, P167, DOI 10.1016/j.tcb.2004.02.002; Rossmann MG, 2002, TRENDS MICROBIOL, V10, P324, DOI 10.1016/S0966-842X(02)02383-1; Rust MJ, 2004, NAT STRUCT MOL BIOL, V11, P567, DOI 10.1038/nsmb769; Salonen A, 2005, CURR TOP MICROBIOL, V285, P139; Schmitz C, 2004, J VIROL, V78, P2006, DOI 10.1128/JVI.78.4.2006-2016.2004; Sharma DK, 2004, MOL BIOL CELL, V15, P3114, DOI 10.1091/mbc.E04-03-0189; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Shieh JTC, 2002, J VIROL, V76, P9474, DOI 10.1128/JVI.76.18.9474-9480.2002; Sieczkarski SB, 2002, J VIROL, V76, P10455, DOI 10.1128/JVI.76.20.10455-10464.2002; Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Smith AE, 2003, FEBS LETT, V555, P199, DOI 10.1016/S0014-5793(03)01220-1; Smith AE, 2004, SCIENCE, V304, P237, DOI 10.1126/science.1094823; Smith GL, 2003, ANNU REV MICROBIOL, V57, P323, DOI 10.1146/annurev.micro.57.030502.091037; Stang E, 1997, MOL BIOL CELL, V8, P47, DOI 10.1091/mbc.8.1.47; Stehle T, 1996, STRUCTURE, V4, P165, DOI 10.1016/S0969-2126(96)00020-2; Stehle T, 1997, EMBO J, V16, P5139, DOI 10.1093/emboj/16.16.5139; Steven AC, 2005, CURR OPIN STRUC BIOL, V15, P227, DOI 10.1016/j.sbi.2005.03.008; Stewart PL, 2003, ADV PROTEIN CHEM, V64, P455; Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343; Tagawa A, 2005, J CELL BIOL, V170, P769, DOI 10.1083/jcb.200506103; Towers G, 2000, P NATL ACAD SCI USA, V97, P12295, DOI 10.1073/pnas.200286297; Towers GJ, 2005, HUM GENE THER, V16, P1125, DOI 10.1089/hum.2005.16.1125; Towers Greg J., 2003, AIDS Reviews, V5, P156; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Tsai B, 2003, EMBO J, V22, P4346, DOI 10.1093/emboj/cdg439; Turville SG, 2002, NAT IMMUNOL, V3, P975, DOI 10.1038/ni841; Turville SG, 2004, BLOOD, V103, P2170, DOI 10.1182/blood-2003-09-3129; Ugolini S, 1999, TRENDS MICROBIOL, V7, P144, DOI 10.1016/S0966-842X(99)01474-2; Upla P, 2004, MOL BIOL CELL, V15, P625, DOI 10.1091/mbc.E03-08-0588; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; Vlasak M, 2005, J VIROL, V79, P5963, DOI 10.1128/JVI.79.10.5963-5970.2005; Vonderheit A, 2005, PLOS BIOL, V3, P1225, DOI 10.1371/journal.pbio.0030233; Wolffe EJ, 1998, VIROLOGY, V244, P20, DOI 10.1006/viro.1998.9103; Ylinen LMJ, 2005, J VIROL, V79, P11580, DOI 10.1128/JVI.79.18.11580-11587.2005; YOUNG JAT, 2001, FIELDS VIROLOGY, P87; Zhang YM, 2005, J VIROL, V79, P12125, DOI 10.1128/JVI.79.19.12125-12131.2005	102	838	871	3	196	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 24	2006	124	4					729	740		10.1016/j.cell.2006.02.007	http://dx.doi.org/10.1016/j.cell.2006.02.007			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	038RO	16497584	Green Published, Bronze			2022-12-28	WOS:000237240900017
J	Muller, M				Muller, M			Making sure public health policies work	SCIENCE			English	Letter											Muller, M (corresponding author), Univ Witwatersrand, Sch Publ & Dev Management, ZA-2050 Wits, South Africa.								0	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	2006	311	5764					1098	1098						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017IU	16523543				2022-12-28	WOS:000235688100018
J	Sanchez-Elsner, T; Gou, DW; Kremmer, E; Sauer, F				Sanchez-Elsner, T; Gou, DW; Kremmer, E; Sauer, F			Noncoding RNAs of trithorax response elements recruit Drosophila Ash1 to ultrabithorax	SCIENCE			English	Article							SET-DOMAIN; EPIGENETIC REGULATION; DOSAGE COMPENSATION; HISTONE METHYLATION; BITHORAX COMPLEX; GENE-EXPRESSION; CELLULAR MEMORY; POLYCOMB; TRANSCRIPTION; CHROMATIN	Homeotic genes contain cis-regulatory trithorax response elements (TREs) that are targeted by epigenetic activators and transcribed in a tissue-specific manner. We show that the transcripts of three TREs located in the Drosophila homeotic gene Ultrabithorax (Ubx) mediate transcription activation by recruiting the epigenetic regulator Ash1 to the template TREs. TRE transcription coincides with Ubx transcription and recruitment of Ash1 to TREs in Drosophila. The SET domain of Ash1 binds all three TRE transcripts, with each TRE transcript hybridizing with and recruiting Ash1 only to the corresponding TRE in chromatin. Transgenic transcription of TRE transcripts restores recruitment of Ash1 to Ubx TREs and restores Ubx expression in Drosophila cells and tissues that lack endogenous TRE transcripts. Small interfering RNA-induced degradation of TRE transcripts attenuates Ash1 recruitment to TREs and Ubx expression, which suggests that noncoding TRE transcripts play an important role in epigenetic activation of gene expression.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; GSF Forschungszentrum Umwelt & Gesundheit GMBH, Inst Mol Immunol, D-81377 Munich, Germany	University of California System; University of California Riverside; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Sauer, F (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.	frank.sauer@ucr.edu						Akhtar A, 2003, CURR OPIN GENET DEV, V13, P161, DOI 10.1016/S0959-437X(03)00016-9; Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Allain FHT, 1997, EMBO J, V16, P5764, DOI 10.1093/emboj/16.18.5764; Bae E, 2002, P NATL ACAD SCI USA, V99, P16847, DOI 10.1073/pnas.222671299; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Beisel C, 2002, NATURE, V419, P857, DOI 10.1038/nature01126; Breiling A, 2002, NAT STRUCT BIOL, V9, P894, DOI 10.1038/nsb1202-894; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Chan SWL, 2004, SCIENCE, V303, P1336, DOI 10.1126/science.1095989; Chen Y, 2005, FEBS J, V272, P2088, DOI 10.1111/j.1742-4658.2005.04650.x; Christmann M, 2003, TOXICOLOGY, V193, P3, DOI 10.1016/S0300-483X(03)00287-7; Dejardin J, 2005, NATURE, V434, P533, DOI 10.1038/nature03386; Grewal SIS, 2004, CURR OPIN CELL BIOL, V16, P230, DOI 10.1016/j.ceb.2004.04.002; Heard E, 2004, CURR OPIN CELL BIOL, V16, P247, DOI 10.1016/j.ceb.2004.03.005; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kawasaki H, 2005, CURR OPIN MOL THER, V7, P125; Krajewski WA, 2005, MOL CELL BIOL, V25, P1891, DOI 10.1128/MCB.25.5.1891-1899.2005; LAJEUNESSE D, 1995, MECH DEVELOP, V53, P123, DOI 10.1016/0925-4773(95)00430-0; LIPSHITZ HD, 1987, GENE DEV, V1, P307, DOI 10.1101/gad.1.3.307; Maile T, 2004, SCIENCE, V304, P1010, DOI 10.1126/science.1095001; MARTIN CH, 1995, P NATL ACAD SCI USA, V92, P8398, DOI 10.1073/pnas.92.18.8398; Matzke MA, 2005, NAT REV GENET, V6, P24, DOI 10.1038/nrg1500; Meller VH, 2002, EMBO J, V21, P1084, DOI 10.1093/emboj/21.5.1084; O'Neill MJ, 2005, HUM MOL GENET, V14, pR113, DOI 10.1093/hmg/ddi108; Orlando V, 2003, CELL, V112, P599, DOI 10.1016/S0092-8674(03)00157-0; Phelps CB, 1998, METHODS, V14, P367, DOI 10.1006/meth.1998.0592; Rank G, 2002, MOL CELL BIOL, V22, P8026, DOI 10.1128/MCB.22.22.8026-8034.2002; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Rozovskaia T, 1999, MOL CELL BIOL, V19, P6441; Schmitt S, 2005, GENE DEV, V19, P697, DOI 10.1101/gad.326205; Schramke V, 2004, CURR OPIN GENET DEV, V14, P174, DOI 10.1016/j.gde.2004.02.006; Sontheimer EJ, 2005, NAT REV MOL CELL BIO, V6, P127, DOI 10.1038/nrm1568; Tripoulas N, 1996, GENETICS, V143, P913; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Wutz A, 2003, BIOESSAYS, V25, P434, DOI 10.1002/bies.10274	37	186	214	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	2006	311	5764					1118	1123		10.1126/science.1117705	http://dx.doi.org/10.1126/science.1117705			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017IU	16497925				2022-12-28	WOS:000235688100039
J	Joensuu, H; Kellokumpu-Lehtinen, P; Bono, P; Alanko, T; Kataja, V; Asola, R; Utriainen, T; Kokko, R; Hemminki, A; Tarkkanen, M; Turpeenniemi-Hujanen, T; Jyrkkio, S; Flander, M; Helle, L; Ingalsuo, S; Johansson, K; Jaaskelainen, A; Pajunen, M; Rauhala, M; Kaleva-Kerola, J; Salminen, T; Leinonen, M; Elomaa, I; Isola, J				Joensuu, H; Kellokumpu-Lehtinen, P; Bono, P; Alanko, T; Kataja, V; Asola, R; Utriainen, T; Kokko, R; Hemminki, A; Tarkkanen, M; Turpeenniemi-Hujanen, T; Jyrkkio, S; Flander, M; Helle, L; Ingalsuo, S; Johansson, K; Jaaskelainen, A; Pajunen, M; Rauhala, M; Kaleva-Kerola, J; Salminen, T; Leinonen, M; Elomaa, I; Isola, J		FinHer Study Investigators	Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POOR-PROGNOSIS; CHEMOTHERAPY; PLUS; CYCLOPHOSPHAMIDE; AMPLIFICATION; COMBINATIONS; EPIRUBICIN; SURVIVAL; ONCOGENE; ANTIBODY	BACKGROUND: We compared docetaxel with vinorelbine for the adjuvant treatment of early breast cancer. Women with tumors that overexpressed HER2/neu were also assigned to receive concomitant treatment with trastuzumab or no such treatment. METHODS: We randomly assigned 1010 women with axillary-node-positive or high-risk node-negative cancer to receive three cycles of docetaxel or vinorelbine, followed by (in both groups) three cycles of fluorouracil, epirubicin, and cyclophosphamide. The 232 women whose tumors had an amplified HER2/neu gene were further assigned to receive or not to receive nine weekly trastuzumab infusions. The primary end point was recurrence-free survival. RESULTS: Recurrence-free survival at three years was better with docetaxel than with vinorelbine (91 percent vs. 86 percent; hazard ratio for recurrence or death, 0.58; 95 percent confidence interval, 0.40 to 0.85; P=0.005), but overall survival did not differ between the groups (P=0.15). Within the subgroup of patients who had HER2/neu-positive cancer, those who received trastuzumab had better three-year recurrence-free survival than those who did not receive the antibody (89 percent vs. 78 percent; hazard ratio for recurrence or death, 0.42; 95 percent confidence interval, 0.21 to 0.83; P=0.01). Docetaxel was associated with more adverse effects than was vinorelbine. Trastuzumab was not associated with decreased left ventricular ejection fraction or cardiac failure. CONCLUSIONS: Adjuvant treatment with docetaxel, as compared with vinorelbine, improves recurrence-free survival in women with early breast cancer. A short course of trastuzumab administered concomitantly with docetaxel or vinorelbine is effective in women with breast cancer who have an amplified HER2/neu gene.	Univ Helsinki, Cent Hosp, Dept Oncol, FIN-00029 Helsinki, Finland; Tampere Univ Hosp, Dept Oncol, Tampere, Finland; Univ Tampere, Inst Med Technol, Canc Biol Lab, FIN-33101 Tampere, Finland; Kuopio Univ Hosp, Dept Oncol, SF-70210 Kuopio, Finland; Satakunta Cent Hosp, Pori, Finland; Hameenlinna Cent Hosp, Hameenlinna, Finland; Oulu Univ Hosp, Dept Radiotherapy & Oncol, Oulu, Finland; Turku Univ, Cent Hosp, Dept Oncol, Turku, Finland; S Karelia Cent Hosp, Lappeenranta, Finland; Kotka Cent Hosp, Kotka, Finland; Vaasa Cent Hosp, Vaasa, Finland; Kokkola Cent Hosp, Kokkola, Finland; Jyvaskyla Cent Hosp, Jyvaskyla, Finland; Kajaani Cent Hosp, Kajaani, Finland; Kemi Cent Hosp, Kemi, Finland; 4Pharma, Turku, Finland; Univ Helsinki Hosp, Helsinki, Finland; Seinajoki Cent Hosp, Seinajoki, Finland; Joensuu Cent Hosp, Joensuu, Finland; Rovaniemi Cent Hosp, Rovaniemi, Finland	University of Helsinki; Helsinki University Central Hospital; Tampere University; Tampere University Hospital; Tampere University; Kuopio University Hospital; University of Eastern Finland; Satakunta Central Hospital; University of Oulu; University of Turku; Vaasa Central Hospital; Central Finland Central Hospital; University of Helsinki; Helsinki University Central Hospital; Seinajoki Central Hospital	Joensuu, H (corresponding author), Univ Helsinki, Cent Hosp, Dept Oncol, Haartmaninkatu 4,POB 180, FIN-00029 Helsinki, Finland.			Joensuu, Heikki/0000-0003-0281-2507; Kataja, Vesa/0000-0003-4846-4843				Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Bonneterre J, 2005, J CLIN ONCOL, V23, P2686, DOI 10.1200/JCO.2005.05.059; Isola J, 2004, CLIN CANCER RES, V10, P4793, DOI 10.1158/1078-0432.CCR-0428-03; Jahanzeb Mohammad, 2003, Clin Breast Cancer, V4, P28, DOI 10.3816/CBC.2003.n.009; JOENSUU H, 2003, P AN M AM SOC CLIN, V22, pA19; Lundin J, 2003, BRIT MED J, V326, P29, DOI 10.1136/bmj.326.7379.29; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; Owens Marilyn A, 2004, Clin Breast Cancer, V5, P63, DOI 10.3816/CBC.2004.n.011; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; Pegram MD, 2004, JNCI-J NATL CANCER I, V96, P739, DOI 10.1093/jnci/djh131; Perez EA, 2004, J CLIN ONCOL, V22, P3700, DOI 10.1200/JCO.2004.03.516; Perez EA, 2004, J CLIN ONCOL, V22, P322, DOI 10.1200/JCO.2004.01.120; Perez EA, 2005, J CLIN ONCOL, V23, p17S; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; POCOCK SJ, 1977, BIOMETRIKA, V64, P191, DOI 10.1093/biomet/64.2.191; Press MF, 1997, J CLIN ONCOL, V15, P2894, DOI 10.1200/JCO.1997.15.8.2894; RAVDIN PM, 1995, GENE, V159, P19, DOI 10.1016/0378-1119(94)00866-Q; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Untch M, 2004, EUR J CANCER, V40, P988, DOI 10.1016/j.ejca.2004.01.011	22	1119	1169	1	42	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 23	2006	354	8					809	820		10.1056/NEJMoa053028	http://dx.doi.org/10.1056/NEJMoa053028			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014CL	16495393				2022-12-28	WOS:000235456200005
J	Zuk, M				Zuk, M			Family values in black and white	NATURE			English	Editorial Material									Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside	Zuk, M (corresponding author), Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA.								0	11	12	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 23	2006	439	7079					917	917		10.1038/439917a	http://dx.doi.org/10.1038/439917a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014NE	16495977				2022-12-28	WOS:000235486100024
J	Bent, S; Padula, A; Avins, AL				Bent, S; Padula, A; Avins, AL			Brief communication: Better ways to question patients about adverse medical events - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							CONSORT STATEMENT; CLINICAL-TRIAL	Background: There is no standard method of identifying adverse events in clinical trials. Objective: To determine whether 3 different methods of questioning patients about adverse events in a clinical trial affect the frequency of reported events. Design: Randomized, single-blind, controlled trial. Setting: A Veterans Administration medical center, San Francisco, California. Participants: Men 50 years of age or older who had benign prostatic hyperplasia. Measurement: Frequency of self-reported medical problems. Intervention: The authors randomly assigned 214 men who were undergoing a 1-month, single-blind, placebo run-in period during an existing clinical trial to 3 groups to test different self-administered methods of assessing medical problems at the end of the run-in period. The first group was asked an open-ended question; the second group was asked an open-ended, defined question; and the third group was given a checklist of 53 common side effects. Results: All 214 patients completed the study. Patients assigned to the checklist group reported a total of 238 adverse events; in comparison, patients who were asked an open-ended question or an open-ended, defined question reported 11 and 14 adverse events, respectively (P < 0.001). The percentage of patients reporting any adverse event was also much higher in the group assigned to the checklist (77%) than in the first group (14%) or second group (13%) (P< 0.001). Limitations: The study included only relatively healthy, well-educated, middle-aged men and assessed only self-reported medical problems after the participants had taken placebo for 1 month. All personnel overseeing the study were aware of the group assignments. Conclusions: Different methods of collecting patient data regarding adverse events lead to large differences in the reported rates of adverse events in clinical trials, potentially reducing the validity of comparisons between the side effect profiles of drugs and other interventions.	San Francisco Vet Adm Med Ctr, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco	Bent, S (corresponding author), San Francisco Vet Adm Med Ctr, 111-A1,4150 Clermont St, San Francisco, CA 94121 USA.	bent@itsa.ucsf.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056199] Funding Source: NIH RePORTER; NIDDK NIH HHS [1 R01 DK56199-01] Funding Source: Medline; PHS HHS [1 K08 ATO1338-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; DOWNING RW, 1970, J CLIN PHARMACOL N D, V10, P289, DOI 10.1177/009127007001000501; Ethgen M, 2005, ANN INTERN MED, V143, P20, DOI 10.7326/0003-4819-143-1-200507050-00006; Gotzsche PC, 2000, BRIT MED J, V320, P1058, DOI 10.1136/bmj.320.7241.1058; GREENBLATT M, 1964, CLIN PHARMACOL THER, V5, P864; Ioannidis JPA, 2004, ANN INTERN MED, V141, P781, DOI 10.7326/0003-4819-141-10-200411160-00009; LAPIERRE YD, 1975, CAN PSYCHIAT ASSOC J, V20, P61, DOI 10.1177/070674377502000111; *NAT CTR COMPL ALT, 2005, CLIN TRIAL SAW PALM; REIDENBERG MM, 1968, NEW ENGL J MED, V279, P678, DOI 10.1056/NEJM196809262791304; Safer DJ, 2002, J NERV MENT DIS, V190, P583, DOI 10.1097/00005053-200209000-00002; *US FDA, 2005, CLIN SAF DAT MAN DEF; WALLANDER MA, 1991, EUR J CLIN PHARMACOL, V41, P187, DOI 10.1007/BF00315428; WALLIN J, 1981, CLIN THER, V3, P450	13	129	131	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 21	2006	144	4					257	261		10.7326/0003-4819-144-4-200602210-00007	http://dx.doi.org/10.7326/0003-4819-144-4-200602210-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	015HS	16490911				2022-12-28	WOS:000235543100004
J	Kyrgiou, M; Koliopoulos, G; Martin-Hirsch, P; Arbyn, M; Prendiville, W; Paraskevaidis, E				Kyrgiou, M; Koliopoulos, G; Martin-Hirsch, P; Arbyn, M; Prendiville, W; Paraskevaidis, E			Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis	LANCET			English	Article; Proceedings Paper	Annual Meeting of the British-Society-of-Colposcopy-and-Cervical-Pathology (BSCCP)	APR 28-30, 2005	Edinburgh, SCOTLAND	British Soc Colposcopy & Cerv Pathol			LOOP ELECTROSURGICAL EXCISION; DIOXIDE LASER CONIZATION; CONE BIOPSY; PREGNANCY; DELIVERY; MANAGEMENT; NEOPLASIA; WOMEN; FERTILITY; PATTERN	Background Conservative methods to treat cervical intraepithelial neoplasia and microinvasive cervical cancer are commonly used in young women because of the advent of effective screening programmes. In a meta-analysis, we investigated the effect of these procedures on subsequent fertility and pregnancy outcomes. Methods We searched for studies in MEDLINE and EMBASE and classified them by the conservative method used and the outcome measure studied regarding both fertility and pregnancy. Pooled relative risks and 95% CIs were calculated with a random-effects model and interstudy heterogeneity was assessed with Cochrane's Q test. Findings We identified 27 studies. Cold knife conisation was significantly associated with preterm delivery (<37 weeks; relative risk 2.59, 95% Cl 1.80-3.72, 100/704 [14%] vs 1494/27674 [5%]), low birthweight (<2500 g; 2.53, 1.19-5.36, 32/261 [12%] vs 905/13 229 [7%]), and Caesarean section (3.17, 1.07-9.40, 31/350 [9%] vs 22/670 [3%]). Large loop excision of the transformation zone (LLETZ) was also significantly associated with preterm delivery (1.70, 1.24-2.35, 156/1402 [11%] vs 120/1739 [7%]), low birthweight (1.82, 1.09-3.06, 77/996 [8%] vs 49/1192 [4%]), and premature rupture of the membranes (2.69, 1.62-4.46, 48/905 [5%] vs 22/1038 [2%]). Similar but marginally non-significant adverse effects were recorded for laser conisation (preterm delivery 1.71, 0.93-3.14). We did not detect significantly increased risks for obstetric outcomes after laser ablation. Although severe outcomes such as admission to a neonatal intensive care unit or perinatal mortality showed adverse trends, these changes were not significant. Interpretation All the excisional procedures to treat cervical intraepithelial neoplasia present similar pregnancy-related morbidity without apparent neonatal morbidity. Caution in the treatment of young women with mild cervical abnormalities should be recommended. Clinicians now have the evidence base to counsel women appropriately.	Cent Lancashire Teaching Hosp, Dept Obstet & Gynaecol, Preston, Lancs, England; John Radcliffe Hosp, Dept Obstet & Gynaecol, Oxford OX3 9DU, England; Sci Inst Publ Hlth, Brussels, Belgium; IARC, European Canc Network, Lyon, France; Coombe Womens Hosp, Dept Obstet & Gynaecol, Dublin, Ireland; Univ Hosp Ioannina, Dept Obstet & Gynaecol, Ioannina, Greece	University of Oxford; World Health Organization; International Agency for Research on Cancer (IARC); Trinity College Dublin; University Hospital Ioannina	Kyrgiou, M (corresponding author), Royal Preston Hosp, Dept Obstet & Gynaecol, Preston PR2 9HT, Lancs, England.	mkyrgiou@yahoo.com	Arbyn, Marc/B-6887-2009; Paraskevaidis, Evangelos/ABH-4990-2020					Althuisius SM, 2001, INT J GYNECOL OBSTET, V72, P31, DOI 10.1016/S0020-7292(00)00326-X; Bekassy Z, 1996, ARCH GYNECOL OBSTET, V258, P75, DOI 10.1007/BF00626027; BIGRIGG A, 1994, LANCET, V343, P32, DOI 10.1016/S0140-6736(94)90881-8; BLOMFIELD PI, 1993, AM J OBSTET GYNECOL, V169, P620, DOI 10.1016/0002-9378(93)90633-T; Braet P. G., 1994, Journal of Obstetrics and Gynaecology (Abingdon), V14, P79, DOI 10.3109/01443619409030016; BULLER RE, 1982, AM J OBSTET GYNECOL, V142, P506, DOI 10.1016/0002-9378(82)90752-9; Chew GK, 1999, INT J GYNECOL CANCER, V9, P487, DOI 10.1046/j.1525-1438.1999.99066.x; COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666; CRUICKSHANK ME, 1995, BRIT J OBSTET GYNAEC, V102, P467, DOI 10.1111/j.1471-0528.1995.tb11319.x; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529; El-Bastawissi AY, 1999, OBSTET GYNECOL, V93, P207, DOI 10.1016/S0029-7844(98)00386-X; FERENCZY A, 1995, AM J OBSTET GYNECOL, V172, P1246, DOI 10.1016/0002-9378(95)91487-0; Forsmo S, 1996, ACTA OBSTET GYN SCAN, V75, P139, DOI 10.3109/00016349609033306; Grio R, 2002, Minerva Ginecol, V54, P325; HAFFENDEN DK, 1993, BRIT J OBSTET GYNAEC, V100, P1059, DOI 10.1111/j.1471-0528.1993.tb15153.x; HAGEN B, 1993, BRIT J OBSTET GYNAEC, V100, P717, DOI 10.1111/j.1471-0528.1993.tb14261.x; HARTINHIRSCH P, 2000, COCHRANE DATABASES S, V2; Herbert A, 2000, CYTOPATHOLOGY, V11, P471, DOI 10.1046/j.1365-2303.2000.00272.x; Holowaty P, 1999, JNCI-J NATL CANCER I, V91, P252, DOI 10.1093/jnci/91.3.252; IARC, 2005, IARC HDB CANC PREV, V10, P1; Iwanari O, 1989, Nihon Gan Chiryo Gakkai Shi, V24, P2375; JONES JM, 1979, BRIT J OBSTET GYNAEC, V86, P913, DOI 10.1111/j.1471-0528.1979.tb11237.x; Kasum M, 1991, Jugosl Ginekol Perinatol, V31, P31; KEIJSER KGG, 1992, AM J OBSTET GYNECOL, V166, P1281, DOI 10.1016/S0002-9378(11)90622-X; KITCHENER HC, 1995, BRIT J OBSTET GYNAEC, V102, P549, DOI 10.1111/j.1471-0528.1995.tb11359.x; KRISTENSEN GB, 1985, ARCH GYNECOL, V236, P127, DOI 10.1007/BF02133954; KRISTENSEN J, 1993, OBSTET GYNECOL, V81, P1005; KUOPPALA T, 1986, ARCH GYNECOL OBSTET, V237, P149, DOI 10.1007/BF02133858; LARSSON G, 1982, ACTA OBSTET GYN SCAN, V61, P461, DOI 10.3109/00016348209156591; LUDVIKSSON K, 1982, EUR J OBSTET GYN R B, V14, P135, DOI 10.1016/0028-2243(82)90088-0; Mathevet P, 2003, EUR J OBSTET GYN R B, V106, P214, DOI 10.1016/S0301-2115(02)00245-2; Mitsuhashi A, 2000, INT J GYNECOL OBSTET, V71, P237, DOI 10.1016/S0020-7292(99)00173-3; *NHSCP, 2004, NHSCSPNAT HLTH SYST, V20, P4; Novikova EG, 1994, AKUSH GINEKOL MOSK, V2, P44; Nuovo J, 2000, INT J GYNECOL OBSTET, V68, P25, DOI 10.1016/S0020-7292(99)00162-9; OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186; Paraskevaidis E, 2002, GYNECOL ONCOL, V86, P10, DOI 10.1006/gyno.2002.6650; PARASKEVAIDIS E, 1991, OBSTET GYNECOL, V78, P80; PARASKEVAIDIS E, 1992, GYNECOL ONCOL, V45, P9, DOI 10.1016/0090-8258(92)90483-Y; PRAEST J, 1979, UGESKRIFT LAEGER, V51, P3509; PRENDIVILLE W, 1989, BRIT J OBSTET GYNAEC, V96, P1054, DOI 10.1111/j.1471-0528.1989.tb03380.x; Quinn M, 1999, BRIT MED J, V318, P904, DOI 10.1136/bmj.318.7188.904; Raio L, 1997, OBSTET GYNECOL, V90, P978, DOI 10.1016/S0029-7844(97)00489-4; Sadler L, 2004, JAMA-J AM MED ASSOC, V291, P2100, DOI 10.1001/jama.291.17.2100; SAGOT P, 1995, EUR J OBSTET GYN R B, V58, P53, DOI 10.1016/0028-2243(94)01986-H; Samson SLA, 2005, OBSTET GYNECOL, V105, P325, DOI 10.1097/01.AOG.0000151991.09124.bb; Soutter WP, 1997, LANCET, V349, P978, DOI 10.1016/S0140-6736(96)08295-5; SPITZER M, 1995, OBSTET GYNECOL, V86, P504, DOI 10.1016/0029-7844(95)00237-L; Spuhler S., 1995, Journal de Gynecologie Obstetrique et Biologie de la Reproduction, V24, P127; Tan Linda, 2004, J Obstet Gynaecol, V24, P25; Turlington WT, 1996, J REPROD MED, V41, P815; van Rooijen M, 1999, ACTA OBSTET GYN SCAN, V78, P346; Wakita K, 1990, J Clin Laser Med Surg, V8, P71; WEBER T, 1979, ACTA OBSTET GYN SCAN, V58, P347, DOI 10.3109/00016347909154594	55	803	852	4	60	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 11	2006	367	9509					489	498		10.1016/S0140-6736(06)68181-6	http://dx.doi.org/10.1016/S0140-6736(06)68181-6			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	013FF	16473126				2022-12-28	WOS:000235394500030
J	Barbera, AJ; Chodaparambil, JV; Kelley-Clarke, B; Joukov, V; Walter, JC; Luger, K; Kaye, KM				Barbera, AJ; Chodaparambil, JV; Kelley-Clarke, B; Joukov, V; Walter, JC; Luger, K; Kaye, KM			The nucleosomal surface as a docking station for Kaposi's sarcoma herpesvirus LANA	SCIENCE			English	Article							EPSTEIN-BARR-VIRUS; NUCLEAR ANTIGEN; DNA-SEQUENCES; CORE PARTICLE; EPISOME-MAINTENANCE; CRYSTAL-STRUCTURE; GENE-EXPRESSION; BINDING; PROTEIN; CHROMATIN	Kaposi's sarcoma-associated herpesvirus (KSHV) latency-associated nuclear antigen (LANA) mediates viral genome attachment to mitotic chromosomes. We find that N-terminal LANA docks onto chromosomes by binding nucleosomes through the folded region of histones H2A-H2B. The same LANA residues were required for both H2A-H2B binding and chromosome association. Further, LANA did not bind Xenopus sperm chromatin, which is deficient in H2A-H2B; chromatin binding was rescued after assembly of nucleosomes containing H2A-H2B. We also describe the 2.9-angstrom crystal structure of a nucleosome complexed with the first 23 LANA amino acids. The LANA peptide forms a hairpin that interacts exclusively with an acidic H2A-H2B region that is implicated in the formation of higher order chromatin structure. Our findings present a paradigm for how nucleosomes may serve as binding platforms for viral and cellular proteins and reveal a previously unknown mechanism for KSHV latency.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA; Colorado State Univ, Howard Hughes Med Inst, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Colorado State University; Howard Hughes Medical Institute; Colorado State University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Kaye, KM (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA.	kkaye@rics.bwh.harvard.edu	Joukov, Vladimir/K-3525-2019; Chodaparambil, Jayanth V/F-3229-2015	SCHNIZER-LUGER, KAROLINE/0000-0001-5136-5331; Walter, Johannes/0000-0002-4186-7570	NCI NIH HHS [CA82036] Funding Source: Medline; NIGMS NIH HHS [GM62267, GM067777, R01 GM067777] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067777, R01GM062267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; Barbera AJ, 2004, J VIROL, V78, P294, DOI 10.1128/JVI.78.1.294-301.2004; BARBERA AJ, UNPUB; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Cotter MA, 1999, VIROLOGY, V264, P254, DOI 10.1006/viro.1999.9999; Davey CA, 2002, J MOL BIOL, V319, P1097, DOI 10.1016/S0022-2836(02)00386-8; Decker LL, 1996, J EXP MED, V184, P283, DOI 10.1084/jem.184.1.283; Dorigo B, 2003, J MOL BIOL, V327, P85, DOI 10.1016/S0022-2836(03)00025-1; Fan JY, 2004, MOL CELL, V16, P655, DOI 10.1016/j.molcel.2004.10.023; Hung SC, 2001, P NATL ACAD SCI USA, V98, P1865, DOI 10.1073/pnas.031584698; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Kapoor P, 2001, EMBO J, V20, P222, DOI 10.1093/emboj/20.1.222; Krithivas A, 2000, J VIROL, V74, P9637, DOI 10.1128/JVI.74.20.9637-9645.2000; Krithivas A, 2002, J VIROL, V76, P11596, DOI 10.1128/JVI.76.22.11596-11604.2002; Luger K, 1998, CURR OPIN STRUC BIOL, V8, P33, DOI 10.1016/S0959-440X(98)80007-9; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Park JH, 2002, NAT GENET, V32, P273, DOI 10.1038/ng982; Park YJ, 2005, J BIOL CHEM, V280, P1817, DOI 10.1074/jbc.M411347200; PHILPOTT A, 1992, CELL, V69, P759, DOI 10.1016/0092-8674(92)90288-N; PHILPOTT A, 1991, CELL, V65, P569, DOI 10.1016/0092-8674(91)90089-H; Piolot T, 2001, J VIROL, V75, P3948, DOI 10.1128/JVI.75.8.3948-3959.2001; Renne R, 2001, J VIROL, V75, P458, DOI 10.1128/JVI.75.1.458-468.2001; Sears J, 2004, J VIROL, V78, P11487, DOI 10.1128/JVI.78.21.11487-11505.2004; Shinohara H, 2002, J VIROL, V76, P12917, DOI 10.1128/JVI.76.24.12917-12924.2002; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Suto RK, 2000, NAT STRUCT BIOL, V7, P1121; Tetsuka T, 2004, VIRUS GENES, V29, P175, DOI 10.1023/B:VIRU.0000036377.48454.d8; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Verma SC, 2003, FEMS MICROBIOL LETT, V222, P155, DOI 10.1016/S0378-1097(03)00261-1; Wong LY, 2004, J VIROL, V78, P10074, DOI 10.1128/JVI.78.18.10074-10085.2004; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; You J, 2004, CELL, V117, P349, DOI 10.1016/S0092-8674(04)00402-7	38	384	395	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	2006	311	5762					856	861		10.1126/science.1120541	http://dx.doi.org/10.1126/science.1120541			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XT	16469929				2022-12-28	WOS:000235374900051
J	Gwack, Y; Sharma, S; Nardone, J; Tanasa, B; Iuga, A; Srikanth, S; Okamura, H; Bolton, D; Feske, S; Hogan, PG; Rao, AJ				Gwack, Yousang; Sharma, Sonia; Nardone, Julie; Tanasa, Bogdan; Iuga, Alina; Srikanth, Sonal; Okamura, Heidi; Bolton, Diana; Feske, Stefan; Hogan, Patrick G.; Rao, Anjana			A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT	NATURE			English	Article							GLYCOGEN-SYNTHASE KINASE-3; TO-EMBRYO TRANSITION; PROTEIN-KINASES; DUAL-SPECIFICITY; ACTIVATION-LOOP; CA2+ SENSOR; CALCIUM; CELLS; STORE; GSK-3	Precise regulation of the NFAT ( nuclear factor of activated T cells) family of transcription factors (NFAT1 - 4) is essential for vertebrate development and function(1). In resting cells, NFAT proteins are heavily phosphorylated and reside in the cytoplasm; in cells exposed to stimuli that raise intracellular free Ca2+ levels, they are dephosphorylated by the calmodulin-dependent phosphatase calcineurin and translocate to the nucleus(1). NFAT dephosphorylation by calcineurin is countered by distinct NFAT kinases, among them casein kinase 1 (CK1) and glycogen synthase kinase 3 (GSK3)(1-5). Here we have used a genome-wide RNA interference ( RNAi) screen in Drosophila(6,7) to identify additional regulators of the signalling pathway leading from Ca2+- calcineurin to NFAT. This screen was successful because the pathways regulating NFAT subcellular localization (Ca2+ influx, Ca2+ - calmodulin calcineurin signalling and NFAT kinases) are conserved across species(8,9), even though Ca2+-regulated NFAT proteins are not themselves represented in invertebrates. Using the screen, we have identified DYRKs (dual-specificity tyrosine-phosphorylation regulated kinases) as novel regulators of NFAT. DYRK1A and DYRK2 counter calcineurin-mediated dephosphorylation of NFAT1 by directly phosphorylating the conserved serine-proline repeat 3 (SP-3) motif of the NFAT regulatory domain, thus priming further phosphorylation of the SP-2 and serine-rich region 1 (SRR1) motifs by GSK3 and CK1, respectively. Thus, genetic screening in Drosophila can be successfully applied to cross evolutionary boundaries and identify new regulators of a transcription factor that is expressed only in vertebrates.	Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Rao, AJ (corresponding author), Harvard Univ, Sch Med, CBR Inst Biomed Res, 200 Longwood Ave, Boston, MA 02115 USA.	arao@cbr.med.harvard.edu	Feske, stefan/ABB-3554-2021	Feske, stefan/0000-0001-5431-8178				Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Armknecht S, 2005, METHOD ENZYMOL, V392, P55, DOI 10.1016/S0076-6879(04)92004-6; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Becker W, 1999, PROG NUCLEIC ACID RE, V62, P1; Bhattacharyya A, 2003, GENES BRAIN BEHAV, V2, P179, DOI 10.1034/j.1601-183X.2003.00025.x; Boutros M, 2004, SCIENCE, V303, P832, DOI 10.1126/science.1091266; Campbell LE, 2002, FEBS LETT, V510, P31, DOI 10.1016/S0014-5793(01)03221-5; Carafoli E, 2003, NAT REV MOL CELL BIO, V4, P326, DOI 10.1038/nrm1073; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Harwood AJ, 2001, CELL, V105, P821, DOI 10.1016/S0092-8674(01)00412-3; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Kannan N, 2004, PROTEIN SCI, V13, P2059, DOI 10.1110/ps.04637904; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Lochhead PA, 2005, CELL, V121, P925, DOI 10.1016/j.cell.2005.03.034; Myers EW, 2000, SCIENCE, V287, P2196, DOI 10.1126/science.287.5461.2196; Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200; Nishi Y, 2005, DEV BIOL, V288, P139, DOI 10.1016/j.ydbio.2005.09.053; Okamura H, 2004, MOL CELL BIOL, V24, P4184, DOI 10.1128/MCB.24.10.4184-4195.2004; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Roderick HL, 2003, CURR BIOL, V13, pR976, DOI 10.1016/j.cub.2003.11.048; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Shirayama M, 2006, CURR BIOL, V16, P47, DOI 10.1016/j.cub.2005.11.070; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Wiechmann S, 2003, BIOCHEM BIOPH RES CO, V302, P403, DOI 10.1016/S0006-291X(03)00148-7; Woods YL, 2001, BIOCHEM J, V355, P609, DOI 10.1042/bj3550609; Yeromin AV, 2004, J GEN PHYSIOL, V123, P167, DOI 10.1085/jgp.200308982; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	30	287	309	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 1	2006	441	7093					646	650		10.1038/nature04631	http://dx.doi.org/10.1038/nature04631			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	048AU	16511445				2022-12-28	WOS:000237920800050
J	Boyman, O; Kovar, M; Rubinstein, MP; Surh, CD; Sprent, J				Boyman, O; Kovar, M; Rubinstein, MP; Surh, CD; Sprent, J			Selective stimulation of T cell subsets with antibody-cytokine immune complexes	SCIENCE			English	Article							RECOMBINANT INTERLEUKIN-2; IL-2 RECEPTOR; GAMMA-CHAIN; IN-VIVO; MEMORY; PROTEINS	Interleukin-2 (IL-2), which is a growth factor for T lymphocytes, can also sometimes be inhibitory. Thus, the proliferation of CD8(+) T cells in vivo is increased after the injection of a monoclonal antibody that is specific for IL-2 (IL-2 mAb), perhaps reflecting the removal of IL-2-dependent CD4(+) T regulatory cells (T regs). Instead, we show here that IL-2 mAb augments the proliferation of CD8(+) cells in mice simply by increasing the biological activity of preexisting IL-2 through the formation of immune complexes. When coupled with recombinant IL-2, some IL-2/IL-2 mAb complexes cause massive (>100-fold) expansion of CD8(+) cells in vivo, whereas others selectively stimulate CD4(+) T regs. Thus, different cytokine-antibody complexes can be used to selectively boost or inhibit the immune response.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; St Vincents Hosp, Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia	Scripps Research Institute; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Sprent, J (corresponding author), Scripps Res Inst, Dept Immunol, IMM4,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	j.sprent@garvan.org.au	Kovar, Marek/H-7793-2014	Boyman, Onur/0000-0001-8279-5545				BOYMAN O, UNPUB; COURTNEY LP, 1994, IMMUNOPHARMACOLOGY, V28, P223, DOI 10.1016/0162-3109(94)90058-2; FINKELMAN FD, 1993, J IMMUNOL, V151, P1235; Fontenot JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179; Kamimura D, 2004, J IMMUNOL, V173, P6041, DOI 10.4049/jimmunol.173.10.6041; KLEIN B, 1995, IMMUNOL TODAY, V16, P216, DOI 10.1016/0167-5699(95)80161-8; Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675; Malek TR, 2004, NAT REV IMMUNOL, V4, P665, DOI 10.1038/nri1435; Murakami M, 2002, P NATL ACAD SCI USA, V99, P8832, DOI 10.1073/pnas.132254399; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; SATO J, 1993, BIOTHERAPY, V6, P225, DOI 10.1007/BF01878084; Schluns KS, 2003, NAT REV IMMUNOL, V3, P269, DOI 10.1038/nri1052; Setoguchi R, 2005, J EXP MED, V201, P723, DOI 10.1084/jem.20041982; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; Sprent J, 2002, ANNU REV IMMUNOL, V20, P551, DOI 10.1146/annurev.immunol.20.100101.151926; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6; ZURAWSKI SM, 1986, J IMMUNOL, V137, P3354	19	643	672	1	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 31	2006	311	5769					1924	1927		10.1126/science.1122927	http://dx.doi.org/10.1126/science.1122927			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	027BD	16484453				2022-12-28	WOS:000236387800045
J	Karplus, R; Johnston, SP				Karplus, R; Johnston, SP			Plasmodium vivax microgametes	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Hadassah Hebrew Univ, Med Ctr, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center	Karplus, R (corresponding author), Hadassah Hebrew Univ, Med Ctr, IL-91120 Jerusalem, Israel.								0	7	7	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 9	2006	354	10					1064	1064		10.1056/NEJMicm040633	http://dx.doi.org/10.1056/NEJMicm040633			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	019FY	16525143				2022-12-28	WOS:000235822200010
J	Alle, H; Geiger, JRP				Alle, H; Geiger, JRP			Combined analog and action potential coding in hippocampal mossy fibers	SCIENCE			English	Article							DENTATE GRANULE CELLS; MECHANORECEPTOR NEURONS; IN-VIVO; SYNAPSES; BOUTONS; TRANSMISSION; MODULATION; ACTIVATION; PLASTICITY; CHANNELS	In the mammalian cortex, it is generally assumed that the output information of neurons is encoded in the number and the timing of action potentials. Here, we show, by using direct patch-clamp recordings from presynaptic hippocampal mossy fiber boutons, that axons transmit analog signals in addition to action potentials. Excitatory presynaptic potentials result from subthreshold dendritic synaptic inputs, which propagate several hundreds of micrometers along the axon and modulate action potential-evoked transmitter release at the mossy fiber-CA3 synapse. This combined analog and action potential coding represents an additional mechanism for information transmission in a major hippocampal pathway.	Max Planck Inst Brain Res, Independent Hertie Res Grp, D-60528 Frankfurt, Germany	Max Planck Society	Geiger, JRP (corresponding author), Max Planck Inst Brain Res, Independent Hertie Res Grp, D-60528 Frankfurt, Germany.	geiger@mpih-frankfurt.mpg.de						Acsady L, 1998, J NEUROSCI, V18, P3386; ALLE H, UNPUB; Awatramani GB, 2005, NEURON, V48, P109, DOI 10.1016/j.neuron.2005.08.038; Bischofberger J, 2002, J NEUROSCI, V22, P10593; DOUGLAS RJ, 1995, SCIENCE, V269, P981, DOI 10.1126/science.7638624; Engel D, 2005, NEURON, V45, P405, DOI 10.1016/j.neuron.2004.12.048; Gao TM, 1998, J NEUROPHYSIOL, V80, P2860, DOI 10.1152/jn.1998.80.6.2860; Geiger JRP, 2000, NEURON, V28, P927, DOI 10.1016/S0896-6273(00)00164-1; Hallermann S, 2003, P NATL ACAD SCI USA, V100, P8975, DOI 10.1073/pnas.1432836100; Ivanov AI, 2003, J NEUROSCI, V23, P1206, DOI 10.1523/JNEUROSCI.23-04-01206.2003; JACKSON MB, 1993, J NEUROPHYSIOL, V69, P692, DOI 10.1152/jn.1993.69.3.692; Juusola M, 1996, TRENDS NEUROSCI, V19, P292, DOI 10.1016/S0166-2236(96)10028-X; Katz PS, 2003, CURR BIOL, V13, pR554, DOI 10.1016/S0960-9822(03)00471-8; MUNOZ MD, 1990, BRAIN RES, V509, P91, DOI 10.1016/0006-8993(90)90313-Z; PASZTOR VM, 1982, SCIENCE, V215, P1635, DOI 10.1126/science.7071583; Penttonen M, 1997, HIPPOCAMPUS, V7, P437, DOI 10.1002/(SICI)1098-1063(1997)7:4<437::AID-HIPO9>3.0.CO;2-F; Petersen CCH, 2003, P NATL ACAD SCI USA, V100, P13638, DOI 10.1073/pnas.2235811100; Rieke F, 1998, SPIKES EXPLORING NEU; Ruiz A, 2003, NEURON, V39, P961, DOI 10.1016/S0896-6273(03)00559-2; Salin PA, 1996, P NATL ACAD SCI USA, V93, P13304, DOI 10.1073/pnas.93.23.13304; Schmidt-Hieber C, 2004, NATURE, V429, P184, DOI 10.1038/nature02553; Schmitz D, 2001, SCIENCE, V291, P1972, DOI 10.1126/science.1057105; Skaggs WE, 1996, HIPPOCAMPUS, V6, P149, DOI 10.1002/(SICI)1098-1063(1996)6:2<149::AID-HIPO6>3.0.CO;2-K; STALEY KJ, 1992, J NEUROPHYSIOL, V67, P1346, DOI 10.1152/jn.1992.67.5.1346; vanSteveninck RRD, 1996, NATURE, V379, P642, DOI 10.1038/379642a0	26	265	272	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	2006	311	5765					1290	1293		10.1126/science.1119055	http://dx.doi.org/10.1126/science.1119055			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019XB	16513983				2022-12-28	WOS:000235870400043
J	Qiao, YF; Molina, H; Pandey, A; Zhang, J; Cole, PA				Qiao, YF; Molina, H; Pandey, A; Zhang, J; Cole, PA			Chemical rescue of a mutant enzyme in living cells	SCIENCE			English	Article							SRC FAMILY KINASES; TYROSINE KINASE; V-SRC; TRANSFORMATION FINGERPRINT; ACTIVATION; PROTEIN; SPECIFICITY; ADHESIONS; INTEGRIN; ACTIN	The restoration of catalytic activity to mutant enzymes by small molecules is well established for in vitro systems. Here, we show that the protein tyrosine kinase Src arginine-388 -> alanine(R388A) mutant can be rescued in live cells with the use of the small molecule imidazole. Cellular rescue of a viral Src homolog was rapid and reversible and conferred predicted oncogenic properties. Using chemical rescue in combination with mass spectrometry, we confirmed six known Src kinase substrates and identified several new protein targets. Chemical rescue data suggest that cellular Src is active under basal conditions. Rescue of R388A cellular Src provided insights into the mitogen-activated protein kinase pathway. This chemical rescue approach will likely have many applications in cell signaling.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Cole, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.	pcole@jhmi.edu	Pandey, Akhilesh/B-4127-2009	Pandey, Akhilesh/0000-0001-9943-6127				AMANCHY R, 2005, SCI STKE, V267; BELL JG, 1975, J GEN VIROL, V27, P127, DOI 10.1099/0022-1317-27-2-127; BELSHAW PJ, 1995, ANGEW CHEM INT EDIT, V34, P2129, DOI 10.1002/anie.199521291; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARTER P, 1987, SCIENCE, V237, P394, DOI 10.1126/science.3299704; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HWANG YW, 1987, J BIOL CHEM, V262, P13081; Iguchi K, 2002, APOPTOSIS, V7, P519, DOI 10.1023/A:1020691026578; Kazansky AV, 2001, CELL GROWTH DIFFER, V12, P1; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Li LM, 2003, MOL CELL BIOL, V23, P2883, DOI 10.1128/MCB.23.8.2883-2892.2003; Lowry WE, 2002, DEV CELL, V2, P733, DOI 10.1016/S1534-5807(02)00175-2; Malek RL, 2002, ONCOGENE, V21, P7256, DOI 10.1038/sj.onc.1205900; Paz K, 2004, ONCOGENE, V23, P8455, DOI 10.1038/sj.onc.1207803; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Shah K, 2002, CHEM BIOL, V9, P35, DOI 10.1016/S1074-5521(02)00086-8; Shogren-Knaak MA, 2001, ANNU REV CELL DEV BI, V17, P405, DOI 10.1146/annurev.cellbio.17.1.405; Spritz RA, 1998, AM J MED GENET, V75, P101, DOI 10.1002/(SICI)1096-8628(19980106)75:1<101::AID-AJMG20>3.0.CO;2-P; Suprynowicz FA, 2002, ONCOGENE, V21, P1695, DOI 10.1038/sj.onc.1205223; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; Tran NH, 2003, J BIOL CHEM, V278, P11221, DOI 10.1074/jbc.M210318200; VIHINEN M, 1994, P NATL ACAD SCI USA, V91, P12803, DOI 10.1073/pnas.91.26.12803; Wang YX, 2005, NATURE, V434, P1040, DOI 10.1038/nature03469; Williams DM, 2000, J BIOL CHEM, V275, P38127, DOI 10.1074/jbc.C000606200; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366	30	91	92	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	2006	311	5765					1293	1297		10.1126/science.1122224	http://dx.doi.org/10.1126/science.1122224			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019XB	16513984				2022-12-28	WOS:000235870400044
J	Tonino, WAL; Winter, JB				Tonino, WAL; Winter, JB			Images in clinical medicine: The twiddler syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Tweesteden Hosp, Tilburg, Netherlands	Elisabeth-TweeSteden Ziekenhuis (ETZ)	Tonino, WAL (corresponding author), Tweesteden Hosp, Tilburg, Netherlands.								0	7	8	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 2	2006	354	9					956	956		10.1056/NEJMicm050761	http://dx.doi.org/10.1056/NEJMicm050761			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	017FN	16510749				2022-12-28	WOS:000235679600008
J	Horton, R				Horton, R			Roy Meadow: a welcome reversal of fortune, with lessons	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Horton, R (corresponding author), The Lancet, London NW1 7BY, England.							BLOMCOOPER L, 2006, PUBLIC LAW, V1, P3; DYER C, 2005, GUARDIAN        1017, P12; DYER C, 2006, GUARDIAN        0124; Hall DMB, 2006, J ROY SOC MED, V99, P6, DOI 10.1258/jrsm.99.1.6; Hammond CB, 2005, OBSTET GYNECOL, V106, P1055, DOI 10.1097/01.AOG.0000182587.83516.76; Horton R, 2005, LANCET, V366, P277, DOI 10.1016/S0140-6736(05)66965-6; Horton R, 2005, LANCET, V366, P3, DOI 10.1016/S0140-6736(05)66798-0; McCarthy M, 2005, LANCET, V366, P15, DOI 10.1016/S0140-6736(05)66803-1; Scott JR, 2005, OBSTET GYNECOL, V106, P902, DOI 10.1097/01.AOG.0000184919.74134.60	9	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 25	2006	367	9511					625	626		10.1016/S0140-6736(06)68237-8	http://dx.doi.org/10.1016/S0140-6736(06)68237-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	016HR	16503443				2022-12-28	WOS:000235611800004
J	Onyango, P; Lynch, MA				Onyango, P; Lynch, MA			Implementing the right to child protection: a challenge for developing countries	LANCET			English	Editorial Material									ANPPCAN Reg Off, Nairobi, Kenya; Inst Child Hlth, Ctr Int Child Hlth, London WC1 1EH, England	University of London; University College London	Onyango, P (corresponding author), ANPPCAN Reg Off, POB 1768-00200,City Sq, Nairobi, Kenya.	ponyango@anppcn.org						*SAV CHILDR, 2003, REP TOOL CHANG REP U, P9; ZUBERI F, 2005, ASSESSMENT VIOLENCE	2	13	13	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 25	2006	367	9511					693	694		10.1016/S0140-6736(06)68269-X	http://dx.doi.org/10.1016/S0140-6736(06)68269-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	016HR	16503469				2022-12-28	WOS:000235611800035
J	Penrose, A; Takaki, M				Penrose, A; Takaki, M			Children's rights in emergencies and disasters	LANCET			English	Editorial Material									Plan Asia Reg Off, Bangkok, Thailand		Penrose, A (corresponding author), Penquite House, Liskeard PL14 5AQ, Cornwall, England.	angela@penquite.com						*INT FED RED CROSS, WORLD DIAS REP 2001; JABRY A, 2005, CAMERAS HAVE GONE CH; MACLEOD H, 2000, COMPLEX HUMANITARIAN; Mandalakas A., 1999, HELPING CHILDREN PRA; Santos Pais M, 2000, POLITICAL PARTICIPAT, P3; The Sphere Project, 2004, HUM CHART MIN STAND; *UN HIGH COMM REF, 2002, M RIGHTS PROT NEEDS	7	34	34	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 25	2006	367	9511					698	699		10.1016/S0140-6736(06)68272-X	http://dx.doi.org/10.1016/S0140-6736(06)68272-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	016HR	16503472				2022-12-28	WOS:000235611800038
J	Banerjee, A; Santos, WL; Verdine, GL				Banerjee, A; Santos, WL; Verdine, GL			Structure of a DNA glycosylase searching for lesions	SCIENCE			English	Article							COLI FPG PROTEIN; ESCHERICHIA-COLI; DAMAGE RECOGNITION; CRYSTAL-STRUCTURE; REPAIR; BASE; 8-OXOGUANINE; SPECIFICITY; COMPLEXES; CLEAVAGE	DNA glycosylases must interrogate millions of base pairs of undamaged DNA in order to locate and then excise one damaged nucleobase. The nature of this search process remains poorly understood. Here we report the use of disulfide cross-linking (DXL) technology to obtain structures of a bacterial. DNA glycosylase, MutM, interrogating undamaged DNA. These structures, solved to 2.0 angstrom resolution, reveal the nature of the search process: The protein inserts a probe residue into the helical stack and severely buckles the target base pair, which remains intrahelical. MutM therefore actively interrogates the intact DNA helix white searching for damage.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University; Harvard University	Verdine, GL (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.	gregory_verdine@harvard.edu	Banerjee, Anirban/AAC-4286-2020	Banerjee, Anirban/0000-0002-9314-2862; banerjee, anirban/0000-0003-1494-6801; Santos, Webster/0000-0002-4731-8548	NATIONAL CANCER INSTITUTE [R01CA100742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044853, F32GM067380] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA100742] Funding Source: Medline; NIGMS NIH HHS [F32 GM067380, GM044853, R01 GM044853] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATHERTON FR, 1945, J CHEM SOC, P660, DOI 10.1039/jr9450000660; Banerjee A, 2005, NATURE, V434, P612, DOI 10.1038/nature03458; Banerjee A., UNPUB; Bhagwat M, 1996, BIOCHEMISTRY-US, V35, P659, DOI 10.1021/bi9522662; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; Cao CY, 2004, NAT STRUCT MOL BIOL, V11, P1230, DOI 10.1038/nsmb864; Coste F, 2004, J BIOL CHEM, V279, P44074, DOI 10.1074/jbc.M405928200; Fedorova OS, 2002, BIOCHEMISTRY-US, V41, P1520, DOI 10.1021/bi011524u; FROEHLER BC, 1986, TETRAHEDRON LETT, V27, P469, DOI 10.1016/S0040-4039(00)85507-0; Fromme JC, 2004, ADV PROTEIN CHEM, V69, P1; Fromme JC, 2003, J BIOL CHEM, V278, P51543, DOI 10.1074/jbc.M307768200; Fromme JC, 2002, NAT STRUCT BIOL, V9, P544, DOI 10.1038/nsb809; GEWIRTH DT, 1995, NAT STRUCT BIOL, V2, P386, DOI 10.1038/nsb0595-386; Gilboa R, 2002, J BIOL CHEM, V277, P19811, DOI 10.1074/jbc.M202058200; He C, 2005, MOL CELL, V20, P117, DOI 10.1016/j.molcel.2005.08.013; Huffman JL, 2005, MUTAT RES-FUND MOL M, V577, P55, DOI 10.1016/j.mrfmmm.2005.03.012; Ishchenko AA, 2002, BIOCHEMISTRY-US, V41, P7540, DOI 10.1021/bi0121297; Kalodimos CG, 2004, SCIENCE, V305, P386, DOI 10.1126/science.1097064; LETSINGER RL, 1981, J AM CHEM SOC, V103, P7394, DOI 10.1021/ja00414a086; LIPSCOMB LA, 1995, P NATL ACAD SCI USA, V92, P719, DOI 10.1073/pnas.92.3.719; ODA Y, 1991, NUCLEIC ACIDS RES, V19, P1407, DOI 10.1093/nar/19.7.1407; Parikh SS, 2000, MUTAT RES-DNA REPAIR, V460, P183, DOI 10.1016/S0921-8777(00)00026-4; Plum GE, 1995, BIOCHEMISTRY-US, V34, P16148, DOI 10.1021/bi00049a030; Serre L, 2002, EMBO J, V21, P2854, DOI 10.1093/emboj/cdf304; Stivers JT, 2004, PROG NUCLEIC ACID RE, V77, P37, DOI 10.1016/S0079-6603(04)77002-6; TCHOU J, 1994, J BIOL CHEM, V269, P15318; Verdine GL, 1997, CHEM BIOL, V4, P329, DOI 10.1016/S1074-5521(97)90123-X; Viadiu H, 2000, MOL CELL, V5, P889, DOI 10.1016/S1097-2765(00)80329-9; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; Zharkov DO, 2005, MUTAT RES-FUND MOL M, V577, P24, DOI 10.1016/j.mrfmmm.2005.03.011; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	32	168	186	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	2006	311	5764					1153	1157		10.1126/science.1120288	http://dx.doi.org/10.1126/science.1120288			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017IU	16497933				2022-12-28	WOS:000235688100049
J	Cowman, AF; Crabb, BS				Cowman, AF; Crabb, BS			Invasion of red blood cells by malaria parasites	CELL			English	Review							APICAL MEMBRANE ANTIGEN-1; MEROZOITE SURFACE PROTEIN-1; PLASMODIUM-FALCIPARUM MEROZOITES; TOXOPLASMA-GONDII; VACCINE CANDIDATE; ERYTHROCYTE INVASION; APICOMPLEXAN PARASITES; CRYSTAL-STRUCTURE; GLIDING MOTILITY; PARASITOPHOROUS VACUOLE	The malaria parasite is the most important member of the Apicomplexa, a large and highly successful phylum of intracellular parasites. Invasion of host cells allows apicomplexan parasites access to a rich source of nutrients in a niche that is largely protected from host defenses. All Apicomplexa adopt a common mode of host-cell entry, but individual species incorporate unique features and utilize a specific set of ligand-receptor interactions. These adhesins ultimately connect to a parasite actin-based motor, which provides the power for invasion. While some Apicomplexa can invade many different host cells, the disease-associated blood-stage form of the malaria parasite is restricted to erythrocytes.	Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia	Walter & Eliza Hall Institute	Cowman, AF (corresponding author), Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia.	cowman@wehi.edu.au; crabb@wehi.edu.au	Crabb, Brendan/F-5287-2013; Cowman, Alan F/C-7642-2013	Cowman, Alan F/0000-0001-5145-9004				AIKAWA M, 1983, CIBA F SYMP, V94, P45; Alexander DL, 2005, PLOS PATHOG, V1, P137, DOI 10.1371/journal.ppat.0010017; Aly ASI, 2005, J EXP MED, V202, P225, DOI 10.1084/jem.20050545; Bai T, 2005, P NATL ACAD SCI USA, V102, P12736, DOI 10.1073/pnas.0501808102; Balu B, 2005, P NATL ACAD SCI USA, V102, P16391, DOI 10.1073/pnas.0504679102; BANNISTER LH, 1990, BLOOD CELLS, V16, P257; Baum J, 2006, J BIOL CHEM, V281, P5197, DOI 10.1074/jbc.M509807200; Bergman LW, 2003, J CELL SCI, V116, P39, DOI 10.1242/jcs.00194; Brossier F, 2005, P NATL ACAD SCI USA, V102, P4146, DOI 10.1073/pnas.0407918102; Buscaglia CA, 2003, MOL BIOL CELL, V14, P4947, DOI 10.1091/mbc.E03-06-0355; CAMUS D, 1985, SCIENCE, V230, P553, DOI 10.1126/science.3901257; Chitarra V, 1999, MOL CELL, V3, P457, DOI 10.1016/S1097-2765(00)80473-6; Dobrowolski JM, 1997, MOL MICROBIOL, V26, P163, DOI 10.1046/j.1365-2958.1997.5671913.x; Dowse TJ, 2005, INT J PARASITOL, V35, P747, DOI 10.1016/j.ijpara.2005.04.001; Drew DR, 2004, J BIOL CHEM, V279, P20147, DOI 10.1074/jbc.M401114200; Duraisingh MT, 2003, P NATL ACAD SCI USA, V100, P4796, DOI 10.1073/pnas.0730883100; Duraisingh MT, 2003, EMBO J, V22, P1047, DOI 10.1093/emboj/cdg096; GALINSKI MR, 1992, CELL, V69, P1213, DOI 10.1016/0092-8674(92)90642-P; Gaskins E, 2004, J CELL BIOL, V165, P383, DOI 10.1083/jcb.200311137; Gerloff DL, 2005, P NATL ACAD SCI USA, V102, P13598, DOI 10.1073/pnas.0502378102; Gilberger TW, 2003, J CELL BIOL, V162, P317, DOI 10.1083/jcb.200301046; Glushakova S, 2005, CURR BIOL, V15, P1645, DOI 10.1016/j.cub.2005.07.067; Goel VK, 2003, P NATL ACAD SCI USA, V100, P5164, DOI 10.1073/pnas.0834959100; Hakansson S, 2001, EMBO J, V20, P3132, DOI 10.1093/emboj/20.12.3132; Harris PK, 2005, PLOS PATHOG, V1, P241, DOI 10.1371/journal.ppat.0010029; Harrison T, 2003, SCIENCE, V301, P1734, DOI 10.1126/science.1089324; He XL, 2002, NAT STRUCT BIOL, V9, P606, DOI 10.1038/nsb819; Healer J, 2002, INFECT IMMUN, V70, P5751, DOI 10.1128/IAI.70.10.5751-5758.2002; Herm-Gotz A, 2002, EMBO J, V21, P2149, DOI 10.1093/emboj/21.9.2149; Hodder AN, 2003, J BIOL CHEM, V278, P48169, DOI 10.1074/jbc.M306755200; Ishino T, 2005, MOL MICROBIOL, V58, P1264, DOI 10.1111/j.1365-2958.2005.04801.x; Jewett TJ, 2003, MOL CELL, V11, P885, DOI 10.1016/S1097-2765(03)00113-8; Kappe S, 1999, J CELL BIOL, V147, P937, DOI 10.1083/jcb.147.5.937; Keeley A, 2004, TRENDS CELL BIOL, V14, P528, DOI 10.1016/j.tcb.2004.08.002; Kieschnick H, 2001, J BIOL CHEM, V276, P12369, DOI 10.1074/jbc.M011045200; Lebrun M, 2005, CELL MICROBIOL, V7, P1823, DOI 10.1111/j.1462-5822.2005.00646.x; Lovett JL, 2003, J CELL SCI, V116, P3009, DOI 10.1242/jcs.00596; Maier AG, 2003, NAT MED, V9, P87, DOI 10.1038/nm807; Mayer DCG, 2001, P NATL ACAD SCI USA, V98, P5222, DOI 10.1073/pnas.081075398; Meissner M, 2005, P NATL ACAD SCI USA, V102, P2980, DOI 10.1073/pnas.0500112102; Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a; Miller SK, 2002, J BIOL CHEM, V277, P47524, DOI 10.1074/jbc.M206974200; Mital J, 2005, MOL BIOL CELL, V16, P4341, DOI 10.1091/mbc.E05-04-0281; Mitchell GH, 2004, INFECT IMMUN, V72, P154, DOI 10.1128/IAI.72.1.154-158.2004; Morgan WD, 1999, J MOL BIOL, V289, P113, DOI 10.1006/jmbi.1999.2753; Moskes C, 2004, MOL MICROBIOL, V54, P676, DOI 10.1111/j.1365-2958.2004.04313.x; Nair M, 2002, J MOL BIOL, V322, P741, DOI 10.1016/S0022-2836(02)00806-9; O'Donnell RA, 2001, J EXP MED, V193, P1403, DOI 10.1084/jem.193.12.1403; O'Donnell RA, 2000, NAT MED, V6, P91, DOI 10.1038/71595; Opitz C, 2002, MOL MICROBIOL, V45, P597, DOI 10.1046/j.1365-2958.2002.03056.x; ORLANDI PA, 1992, J CELL BIOL, V116, P901, DOI 10.1083/jcb.116.4.901; Pachebat JA, 2001, MOL BIOCHEM PARASIT, V117, P83, DOI 10.1016/S0166-6851(01)00336-X; Pizarro JC, 2003, J MOL BIOL, V328, P1091, DOI 10.1016/S0022-2836(03)00376-0; Pizarro JC, 2005, SCIENCE, V308, P408, DOI 10.1126/science.1107449; Preiser PR, 2002, SCIENCE, V295, P342, DOI 10.1126/science.1064938; Rayner JC, 2001, J EXP MED, V194, P1571, DOI 10.1084/jem.194.11.1571; Sahoo N, 2006, MOL BIOL CELL, V17, P895, DOI 10.1091/mbc.E05-06-0512; Sanders PR, 2005, J BIOL CHEM, V280, P40169, DOI 10.1074/jbc.M509631200; Schmitz S, 2005, J MOL BIOL, V349, P113, DOI 10.1016/j.jmb.2005.03.056; Schuler H, 2005, FEBS LETT, V579, P655, DOI 10.1016/j.febslet.2004.12.037; Silvie O, 2004, J BIOL CHEM, V279, P9490, DOI 10.1074/jbc.M311331200; SINGH SK, 2006, IN PRESS NATURE; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; Stubbs J, 2005, SCIENCE, V309, P1384, DOI 10.1126/science.1115257; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5; Thompson JK, 2001, MOL MICROBIOL, V41, P47, DOI 10.1046/j.1365-2958.2001.02484.x; Tolia NH, 2005, CELL, V122, P183, DOI 10.1016/j.cell.2005.05.033; Triglia T, 2005, MOL MICROBIOL, V55, P162, DOI 10.1111/j.1365-2958.2004.04388.x; Triglia T, 2000, MOL MICROBIOL, V38, P706, DOI 10.1046/j.1365-2958.2000.02175.x; Triglia T, 2001, INFECT IMMUN, V69, P1084, DOI 10.1128/IAI.69.2.1084-1092.2001; van Dijk MR, 2001, CELL, V104, P153, DOI 10.1016/S0092-8674(01)00199-4; Wickham ME, 2003, J BIOL CHEM, V278, P37658, DOI 10.1074/jbc.M305252200	72	632	650	0	123	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 24	2006	124	4					755	766		10.1016/j.cell.2006.02.006	http://dx.doi.org/10.1016/j.cell.2006.02.006			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	038RO	16497586	Bronze			2022-12-28	WOS:000237240900019
J	Greber, UF; Way, M				Greber, UF; Way, M			A superhighway to virus infection	CELL			English	Review							ACTIN-BASED MOTILITY; INTRACELLULAR ENVELOPED VIRIONS; GREEN FLUORESCENT PROTEIN; SWINE-FEVER VIRUS; LIGHT-CHAIN LC8; RABIES-VIRUS; PLASMA-MEMBRANE; TEGUMENT PROTEIN; MOLECULAR MOTORS; PHOSPHOPROTEIN-P	Microtubule-mediated transport of macromolecules and organelles (also known as "cargo") is essential for cells to function. Deficiencies in cytoplasmic transport are frequently associated with severe diseases and syndromes. Cytoplasmic transport also provides viruses with the means to reach their site of replication and is the route for newly assembled progeny to leave the infected cell. This parasitic relationship of viruses with the host cytoskeleton provides an excellent basis for cell biologists to unlock the secrets of cytoplasmic transport and unravel mechanisms of disease. Recent advances in live cell imaging and computational tracking of fluorescently labeled viruses are now revealing how complex the movements of single viruses are in infected cells. This review focuses on microtubule-based motility of viruses and highlights the mechanisms regulating cytoplasmic transport.	Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland; London Res Inst, London WC2A 3PX, England	University of Zurich	Greber, UF (corresponding author), Univ Zurich, Inst Zool, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	ufgreber@zool.unizh.ch; michael.way@cancer.org.uk	Greber, Urs F/G-9458-2015	Greber, Urs F/0000-0003-2278-120X; Way, Michael/0000-0001-7207-2722				Alonso C, 2001, J VIROL, V75, P9819, DOI 10.1128/JVI.75.20.9819-9827.2001; Andres G, 2001, J VIROL, V75, P6758, DOI 10.1128/JVI.75.15.6758-6768.2001; Basyuk E, 2003, DEV CELL, V5, P161, DOI 10.1016/S1534-5807(03)00188-6; Beigel H, 2005, NEW ENGL J MED, V353, P1374, DOI 10.1056/NEJMra052211; Bonnemann CG, 2004, CURR OPIN NEUROL, V17, P529; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Carter GC, 2003, J GEN VIROL, V84, P2443, DOI 10.1099/vir.0.19271-0; Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137; Coyne CB, 2006, CELL, V124, P119, DOI 10.1016/j.cell.2005.10.035; Cui ZQ, 2005, NUCLEIC ACIDS RES, V33, P3245, DOI 10.1093/nar/gki629; Deacon SW, 2003, J CELL BIOL, V160, P297, DOI 10.1083/jcb.200210066; Diefenbach RJ, 2002, J VIROL, V76, P3282, DOI 10.1128/JVI.76.7.3282-3291.2002; Dinh AT, 2005, BIOPHYS J, V89, P1574, DOI 10.1529/biophysj.105.059477; Dohner K, 2005, TRENDS MICROBIOL, V13, P320, DOI 10.1016/j.tim.2005.05.010; Dohner K, 2002, MOL BIOL CELL, V13, P2795, DOI 10.1091/mbc.01-07-0348; Douglas MW, 2004, J BIOL CHEM, V279, P28522, DOI 10.1074/jbc.M311671200; Favoreel HW, 2005, P NATL ACAD SCI USA, V102, P8990, DOI 10.1073/pnas.0409099102; Finke S, 2004, J VIROL, V78, P12333, DOI 10.1128/JVI.78.22.12333-12343.2004; Frischknecht F, 1999, CURR BIOL, V9, P89, DOI 10.1016/S0960-9822(99)80020-7; Geada MM, 2001, J GEN VIROL, V82, P2747, DOI 10.1099/0022-1317-82-11-2747; Giannakakou P, 2002, P NATL ACAD SCI USA, V99, P10855, DOI 10.1073/pnas.132275599; Greber UF, 2005, P NATL ACAD SCI USA, V102, P5639, DOI 10.1073/pnas.0501696102; Greber UF, 1997, EMBO J, V16, P5998, DOI 10.1093/emboj/16.19.5998; Gross SP, 2002, J CELL BIOL, V156, P715, DOI 10.1083/jcb.200109047; Gundersen GG, 2004, CURR OPIN CELL BIOL, V16, P106, DOI 10.1016/j.ceb.2003.11.010; Hall A, 2004, SCIENCE, V306, P65, DOI 10.1126/science.1104481; Herrero-Martinez E, 2005, J GEN VIROL, V86, P2961, DOI 10.1099/vir.0.81260-0; Hirokawa N, 2004, CURR OPIN NEUROBIOL, V14, P564, DOI 10.1016/j.conb.2004.08.011; Inomata H, 2003, J BIOL CHEM, V278, P22946, DOI 10.1074/jbc.M212160200; Jacob Y, 2000, J VIROL, V74, P10217, DOI 10.1128/JVI.74.21.10217-10222.2000; Jordens I, 2005, TRAFFIC, V6, P1070, DOI 10.1111/j.1600-0854.2005.00336.x; Jouvenet N, 2004, J VIROL, V78, P7990, DOI 10.1128/JVI.78.15.7990-8001.2004; Kamal A, 2002, CURR OPIN CELL BIOL, V14, P63, DOI 10.1016/S0955-0674(01)00295-2; Karcher RL, 2002, TRENDS CELL BIOL, V12, P21, DOI 10.1016/S0962-8924(01)02184-5; Kelkar SA, 2004, J VIROL, V78, P10122, DOI 10.1128/JVI.78.18.10122-10132.2004; Kim WK, 1998, J VIROL, V72, P6898, DOI 10.1128/JVI.72.8.6898-6901.1998; KING SM, 2003, MOL MOTORS, P45; Klumpp S, 2005, P NATL ACAD SCI USA, V102, P17284, DOI 10.1073/pnas.0507363102; Kural C, 2005, SCIENCE, V308, P1469, DOI 10.1126/science.1108408; Lakadamyali M, 2003, P NATL ACAD SCI USA, V100, P9280, DOI 10.1073/pnas.0832269100; Leopold PL, 2000, HUM GENE THER, V11, P151, DOI 10.1089/10430340050016238; Leopold PL, 1998, HUM GENE THER, V9, P367, DOI 10.1089/hum.1998.9.3-367; Luby-Phelps K, 2000, INT REV CYTOL, V192, P189; Lukashok SA, 2000, J VIROL, V74, P4705, DOI 10.1128/JVI.74.10.4705-4709.2000; Lux K, 2005, J VIROL, V79, P11776, DOI 10.1128/JVI.79.18.11776-11787.2005; Luxton GWG, 2006, J VIROL, V80, P201, DOI 10.1128/JVI.80.1.201-209.2006; Luxton GWG, 2005, P NATL ACAD SCI USA, V102, P5832, DOI 10.1073/pnas.0500803102; Mabit H, 2002, J VIROL, V76, P9962, DOI 10.1128/JVI.76.19.9962-9971.2002; Mallik R, 2004, CURR BIOL, V14, pR971, DOI 10.1016/j.cub.2004.10.046; Mandelkow E, 2002, TRENDS CELL BIOL, V12, P585, DOI 10.1016/S0962-8924(02)02400-5; Marsh M., 2006, CELL; Martinez-Moreno M, 2003, FEBS LETT, V544, P262, DOI 10.1016/S0014-5793(03)00516-7; McDonald D, 2002, J CELL BIOL, V159, P441, DOI 10.1083/jcb.200203150; Morfini G, 2004, EMBO J, V23, P2235, DOI 10.1038/sj.emboj.7600237; Mouland AJ, 2001, MOL CELL BIOL, V21, P2133, DOI 10.1128/MCB.21.6.2133-2143.2001; Muller U, 2001, TRENDS CELL BIOL, V11, P334, DOI 10.1016/S0962-8924(01)02046-3; Naranatt PP, 2005, J VIROL, V79, P1191, DOI 10.1128/JVI.79.2.1191-1206.2005; Newsome TP, 2006, CELL MICROBIOL, V8, P233, DOI 10.1111/j.1462-5822.2005.00613.x; Newsome TP, 2004, SCIENCE, V306, P124, DOI 10.1126/science.1101509; Petit C, 2003, J CELL SCI, V116, P3433, DOI 10.1242/jcs.00613; Pfister KK, 2005, J CELL BIOL, V171, P411, DOI 10.1083/jcb.200508078; Ploubidou A, 2000, EMBO J, V19, P3932, DOI 10.1093/emboj/19.15.3932; Poisson N, 2001, J GEN VIROL, V82, P2691, DOI 10.1099/0022-1317-82-11-2691; Rasalingam P, 2005, VIRUS RES, V111, P55, DOI 10.1016/j.virusres.2005.03.010; Raux H, 2000, J VIROL, V74, P10212, DOI 10.1128/JVI.74.21.10212-10216.2000; Reeves PM, 2005, NAT MED, V11, P731, DOI 10.1038/nm1265; Rietdorf J, 2001, NAT CELL BIOL, V3, P992, DOI 10.1038/ncb1101-992; Rodriguez-Crespo I, 2001, FEBS LETT, V503, P135, DOI 10.1016/S0014-5793(01)02718-1; Rondaij MG, 2006, ARTERIOSCL THROM VAS, V26, P49, DOI 10.1161/01.ATV.0000191639.08082.04; Rudner L, 2005, J VIROL, V79, P4055, DOI 10.1128/JVI.79.7.4055-4065.2005; Salman H, 2005, BIOPHYS J, V89, P2134, DOI 10.1529/biophysj.105.060160; Sampaio KL, 2005, J VIROL, V79, P2754, DOI 10.1128/JVI.79.5.2754-2767.2005; Sanderson CM, 1998, J VIROL, V72, P1235, DOI 10.1128/JVI.72.2.1235-1243.1998; Sanderson CM, 2000, J GEN VIROL, V81, P47, DOI 10.1099/0022-1317-81-1-47; Sanderson CM, 1998, J VIROL, V72, P9924, DOI 10.1128/JVI.72.12.9924-9933.1998; Sanjuan N, 2003, VIROLOGY, V313, P105, DOI 10.1016/S0042-6822(03)00309-X; Saxton MJ, 1997, ANNU REV BIOPH BIOM, V26, P373, DOI 10.1146/annurev.biophys.26.1.373; Sbalzarini IF, 2005, J STRUCT BIOL, V151, P182, DOI 10.1016/j.jsb.2005.06.002; Schliwa M, 2003, NATURE, V422, P759, DOI 10.1038/nature01601; Schnapp BJ, 2003, J CELL SCI, V116, P2125, DOI 10.1242/jcs.00488; Schroer TA, 2004, ANNU REV CELL DEV BI, V20, P759, DOI 10.1146/annurev.cellbio.20.012103.094623; Seisenberger G, 2001, SCIENCE, V294, P1929, DOI 10.1126/science.1064103; Sfakianos JN, 2003, TRAFFIC, V4, P660, DOI 10.1034/j.1600-0854.2003.00125.x; Smith AE, 2004, SCIENCE, V304, P237, DOI 10.1126/science.1094823; Smith GA, 2004, P NATL ACAD SCI USA, V101, P16034, DOI 10.1073/pnas.0404686101; Smith GA, 2001, P NATL ACAD SCI USA, V98, P3466, DOI 10.1073/pnas.061029798; Smith GL, 2003, ANNU REV MICROBIOL, V57, P323, DOI 10.1146/annurev.micro.57.030502.091037; Sodeik B, 2000, TRENDS MICROBIOL, V8, P465, DOI 10.1016/S0966-842X(00)01824-2; Sodeik B, 1997, J CELL BIOL, V136, P1007, DOI 10.1083/jcb.136.5.1007; Strunze S, 2005, MOL BIOL CELL, V16, P2999, DOI 10.1091/mbc.E05-02-0121; Suikkanen S, 2003, J VIROL, V77, P10270, DOI 10.1128/JVI.77.19.10270-10279.2003; Suomalainen M, 1999, J CELL BIOL, V144, P657, DOI 10.1083/jcb.144.4.657; Suomalainen M, 2001, EMBO J, V20, P1310, DOI 10.1093/emboj/20.6.1310; Tibbles LA, 2002, J VIROL, V76, P1559, DOI 10.1128/JVI.76.4.1559-1568.2002; Uetz P, 2006, SCIENCE, V311, P239, DOI 10.1126/science.1116804; Valderrama F, 2006, SCIENCE, V311, P377, DOI 10.1126/science.1122411; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Vallee RB, 2004, J NEUROBIOL, V58, P189, DOI 10.1002/neu.10314; Vallotton P, 2003, BIOPHYS J, V85, P1289, DOI 10.1016/S0006-3495(03)74564-0; van Eijl H, 2002, J GEN VIROL, V83, P195, DOI 10.1099/0022-1317-83-1-195; Verhey KJ, 2001, TRENDS BIOCHEM SCI, V26, P545, DOI 10.1016/S0968-0004(01)01931-4; Villarreal LP, 2004, SCI AM, V291, P100, DOI 10.1038/scientificamerican1204-100; Ward BM, 2005, J VIROL, V79, P4755, DOI 10.1128/JVI.79.8.4755-4763.2005; Ward BM, 2004, J VIROL, V78, P2486, DOI 10.1128/JVI.78.5.2486-2493.2004; Ward BM, 2003, J VIROL, V77, P4113, DOI 10.1128/JVI.77.7.4113-4126.2003; Ward BM, 2001, J VIROL, V75, P11651, DOI 10.1128/JVI.75.23.11651-11663.2001; Warrington KH, 2004, J VIROL, V78, P6595, DOI 10.1128/JVI.78.12.6595-6609.2004; Weiss RA, 2003, CURR TOP MICROBIOL, V278, P47; Welte MA, 2004, CURR BIOL, V14, pR525, DOI 10.1016/j.cub.2004.06.045; Wolfstein A, 2006, TRAFFIC, V7, P227, DOI 10.1111/j.1600-0854.2005.00379.x; Yanagisawa M, 2004, J BIOL CHEM, V279, P9512, DOI 10.1074/jbc.M310895200; Yonezawa A, 2005, J VIROL, V79, P918, DOI 10.1128/JVI.79.2.918-926.2005; Zhang WH, 2000, J VIROL, V74, P11654, DOI 10.1128/JVI.74.24.11654-11662.2000; Zhou ZH, 1999, J VIROL, V73, P3210, DOI 10.1128/JVI.73.4.3210-3218.1999	114	287	298	2	56	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 24	2006	124	4					741	754		10.1016/j.cell.2006.02.018	http://dx.doi.org/10.1016/j.cell.2006.02.018			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	038RO	16497585	Bronze, Green Accepted			2022-12-28	WOS:000237240900018
J	Kanani, RS; Drachman, DE				Kanani, RS; Drachman, DE			Malignant obstruction of the superior vena cava	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Kanani, RS (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 23	2006	354	8					E7	E7		10.1056/NEJMicm050661	http://dx.doi.org/10.1056/NEJMicm050661			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014CL	16495388				2022-12-28	WOS:000235456200010
J	McClung, MR; Lewiecki, EM; Cohen, SB; Bolognese, MA; Woodson, GC; Moffett, AH; Peacock, M; Miller, PD; Lederman, SN; Chesnut, CH; Lain, D; Kivitz, AJ; Holloway, DL; Zhang, C; Peterson, MC; Bekker, PJ				McClung, MR; Lewiecki, EM; Cohen, SB; Bolognese, MA; Woodson, GC; Moffett, AH; Peacock, M; Miller, PD; Lederman, SN; Chesnut, CH; Lain, D; Kivitz, AJ; Holloway, DL; Zhang, C; Peterson, MC; Bekker, PJ		AMG 162 Bone Loss Study Grp	Denosumab in postmenopausal women with low bone mineral density	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OSTEOCLAST DIFFERENTIATION; OSTEOPROTEGERIN LIGAND; TESTS	BACKGROUND: Receptor activator of nuclear factor-(kappa)B ligand (RANKL) is essential for osteoclast differentiation, activation, and survival. The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity and specificity and inhibits RANKL action. METHODS: The efficacy and safety of subcutaneously administered denosumab were evaluated over a period of 12 months in 412 postmenopausal women with low bone mineral density (T score of -1.8 to -4.0 at the lumbar spine or -1.8 to -3.5 at the proximal femur). Subjects were randomly assigned to receive denosumab either every three months (at a dose of 6, 14, or 30 mg) or every six months (at a dose of 14, 60, 100, or 210 mg), open-label oral alendronate once weekly (at a dose of 70 mg), or placebo. The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Changes in bone turnover were assessed by measurement of serum and urine telopeptides and bone-specific alkaline phosphatase. RESULTS: Denosumab treatment for 12 months resulted in an increase in bone mineral density at the lumbar spine of 3.0 to 6.7 percent (as compared with an increase of 4.6 percent with alendronate and a loss of 0.8 percent with placebo), at the total hip of 1.9 to 3.6 percent (as compared with an increase of 2.1 percent with alendronate and a loss of 0.6 percent with placebo), and at the distal third of the radius of 0.4 to 1.3 percent (as compared with decreases of 0.5 percent with alendronate and 2.0 percent with placebo). Near-maximal reductions in mean levels of serum C-telopeptide from baseline were evident three days after the administration of denosumab. The duration of the suppression of bone turnover appeared to be dose-dependent. CONCLUSIONS: In postmenopausal women with low bone mass, denosumab increased bone mineral density and decreased bone resorption. These preliminary data suggest that denosumab might be an effective treatment for osteoporosis.	Providence Portland Med Ctr, Portland, OR USA; New Mexico Clin Res & Osteoporosis Ctr, Albuquerque, NM USA; Radiant Res, Dallas, TX USA; Bethesda Hlth Res Ctr, Bethesda, MD USA; Atlanta Res Ctr, Decatur, GA USA; OB GYN Associates Mid Florida, Leesburg, FL USA; Indiana Univ, Sch Med, Indianapolis, IN USA; Colorado Ctr Bone Res, Lakewood, CO USA; Radiant Res, Lake Worth, FL USA; Univ Washington, Med Ctr, Seattle, WA 98195 USA; Arthrit Associates & Osteoporosis Ctr Colorado Sp, Colorado Springs, CO USA; Altoona Ctr Clin Res, Duncansville, PA USA; Amgen Corp, Thousand Oaks, CA 91320 USA	Providence Portland Medical Center; New Mexico Clinical Research & Osteoporosis Center; Indiana University System; Indiana University-Purdue University Indianapolis; Colorado Center For Bone Research; University of Washington; University of Washington Seattle; Altoona Center for Clinical Research; Amgen	McClung, MR (corresponding author), Oregon Osteoporosis Ctr, 5050 NE Hoyt St,Suite 651, Portland, OR 97213 USA.	mmcclung@orost.com	Lewiecki, E. Michael/B-3706-2018; McClung, Michael/ABA-4100-2021	Lewiecki, E. Michael/0000-0003-2026-9587; McClung, Michael/0000-0002-7827-0778				Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305; Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Klibanski A, 2001, JAMA-J AM MED ASSOC, V285, P785; Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002-9440(10)64556-7; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; McCombs JS, 2004, MATURITAS, V48, P271, DOI 10.1016/j.maturitas.2004.02.005; Schnitzer T, 2000, AGING CLIN EXP RES, V12, P1; Schroeder K, 2004, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD004804; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.1093/biomet/52.3-4.591; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	15	852	904	3	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 23	2006	354	8					821	831		10.1056/NEJMoa044459	http://dx.doi.org/10.1056/NEJMoa044459			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014CL	16495394				2022-12-28	WOS:000235456200006
J	Reddy, KS; Perry, CL; Stigler, MH; Arora, M				Reddy, KS; Perry, CL; Stigler, MH; Arora, M			Differences in tobacco use among young people in urban India by sex, socioeconomic status, age, and school grade: assessment of baseline survey data	LANCET			English	Article							YOUTH SMOKING; UNITED-STATES; ADOLESCENTS	Background The epidemic of tobacco use is shifting from developed to developing countries, including India, where increased use is expected to result in a large disease burden in the future. Changes in prevalence of tobacco use in adolescents are important to monitor, since increased use by young people might be a precursor to increased rates in the population. Methods 11642 students in the sixth and eighth grades in 32 schools in Delhi and Chennai, India, were surveyed about their tobacco use and psychosocial factors related to onset of tobacco use. Schools were representative of the range of types of school in these cities. Results Students who were in government schools, male, older, and in sixth grade were more likely to use tobacco than students who were in private schools, female, younger, and in eighth grade. Students in sixth grade were, overall, two to four times more likely to use tobacco than those in eighth grade. 24.8% (1529 of 6165) of sixth-grade students and 9.3% (509 of 5477) of eighth-grade students had ever used tobacco; 6.7% (413 of 6165) and 2.9% (159 of 5477), respectively, were current users. Psychosocial risk factors were greater in sixth-grade than in eighth-grade students. The increase in tobacco use by age within each grade was larger in sixth grade than in eighth grade in government schools, with older sixth-grade students at especially high risk. Discussion The finding that sixth-grade students use significantly more tobacco than eighth-grade students is unusual, and might indicate a new wave of increased tobacco use in urban India that warrants confirmation and early intervention.	Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Project MYTRI, Minneapolis, MN 55455 USA; All India Inst Med Sci, Dept Cardiol, New Delhi, India; MYTRO India, Hlth Related Informat & Disseminat Among Youth, New Delhi, India	University of Minnesota System; University of Minnesota Twin Cities; All India Institute of Medical Sciences (AIIMS) New Delhi	Perry, CL (corresponding author), Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Project MYTRI, Minneapolis, MN 55455 USA.	perry@epi.umn.edu			FOGARTY INTERNATIONAL CENTER [R01TW005952] Funding Source: NIH RePORTER; FIC NIH HHS [R01TW05952-01] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		BOTVIN GJ, 1992, PSYCHOL REP, V70, P171, DOI 10.2466/PR0.70.1.171-178; *CDCP, 80 CDCP GYTS; Centers for Disease Control and Prevention, GLOB YOUTH TOB SURV; ECKHARDT L, 1994, J SCHOOL HEALTH, V64, P67, DOI 10.1111/j.1746-1561.1994.tb06181.x; Ezzati M, 2003, LANCET, V362, P847, DOI 10.1016/S0140-6736(03)14338-3; Komro KA, 2004, J CHILD ADOLES SUBST, V13, P17, DOI 10.1300/J029v13n03_02; KOMRO KA, 1993, PREV MED, V22, P857, DOI 10.1006/pmed.1993.1077; Mishra A, 2005, HEALTH EDUC BEHAV, V32, P363, DOI 10.1177/1090198104272332; Perry CL, 1999, ARCH PEDIAT ADOL MED, V153, P935, DOI 10.1001/archpedi.153.9.935; PERRY CL, IN PRESS HLTH PROMOT; PIERCE JP, 1994, JAMA-J AM MED ASSOC, V271, P608, DOI 10.1001/jama.271.8.608; Pierce JP, 1996, HEALTH PSYCHOL, V15, P355, DOI 10.1037/0278-6133.15.5.355; PIERCE JP, 1995, HEALTH PSYCHOL, V14, P500, DOI 10.1037/0278-6133.14.6.500; Raudenbush SW, 2002, HIERARCHICAL LINEAR; Reddy K. S., 2004, TOBACCO CONTROL INDI; SHARMA S, 2005, HINDUSTAN TIMES 0302; Stewart B.W., 2003, WORLD CANC REPORT; *US DEP HHS, 1994, PREV TOB US YOUNG PE; Warren CW, 2000, B WORLD HEALTH ORGAN, V78, P868; World Health Organization, 2005, MILL DEV GOALS TOB C	20	64	65	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 18	2006	367	9510					589	594		10.1016/S0140-6736(06)68225-1	http://dx.doi.org/10.1016/S0140-6736(06)68225-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	013GM	16488802				2022-12-28	WOS:000235397800033
J	Servadei, F				Servadei, F			Coma scales	LANCET			English	Editorial Material							SCORE; TRAUMA; VALIDATION; INJURY; NEED		Osped Gen Provinciale M Bufalini, WHO, Neurotrauma Collaborating Ctr, I-47023 Cesena, Italy	World Health Organization	Servadei, F (corresponding author), Osped Gen Provinciale M Bufalini, WHO, Neurotrauma Collaborating Ctr, I-47023 Cesena, Italy.	francoservadei@libero.it	Servadei, Franco/ABX-4656-2022	Servadei, Franco/0000-0002-3595-3464				Bates D, 2001, J NEUROL NEUROSUR PS, V71, P20; BENZER A, 1991, LANCET, V338, P977, DOI 10.1016/0140-6736(91)91840-Q; BORN JD, 1988, ACTA NEUROCHIR, V91, P1, DOI 10.1007/BF01400520; Bouillon B, 1997, J TRAUMA, V42, P652, DOI 10.1097/00005373-199704000-00012; Chesnut RM, 2003, J TRAUMA, V54, P678; Gabbe Belinda J, 2003, Emerg Med (Fremantle), V15, P353, DOI 10.1046/j.1442-2026.2003.00474.x; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; MARRUBINI MB, 1984, INTENS CARE MED, V10, P217; MILLER JD, 1986, NEUROSURG REV, V9, P135, DOI 10.1007/BF01743065; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Norwood SH, 2002, J TRAUMA, V53, P503, DOI 10.1097/00005373-200209000-00018; Plum F, 1972, Contemp Neurol Ser, V10, P1; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; Stein SC, 2001, J TRAUMA, V50, P759, DOI 10.1097/00005373-200104000-00032; TEASDALE G, 1974, LANCET, V2, P81; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611	18	14	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 18	2006	367	9510					548	549		10.1016/S0140-6736(06)68197-X	http://dx.doi.org/10.1016/S0140-6736(06)68197-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013GM	16488781				2022-12-28	WOS:000235397800006
J	Van de Werf, F; Ross, A; Armstrong, P; Granger, C				Van de Werf, F; Ross, A; Armstrong, P; Granger, C		ASSENT-4 PCI Investigators	Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial	LANCET			English	Article							PRIMARY ANGIOPLASTY; REPERFUSION THERAPY; UNFRACTIONATED HEPARIN; IMMEDIATE THROMBOLYSIS; EMERGENCY-ROOM; PILOT TRIAL; ABCIXIMAB; TIROFIBAN; COMBINATION; STRATEGY	Background Primary percutaneous coronary intervention (PCI) is more effective than fibrinolytic therapy for ST-segment elevation acute myocardial infarction (STEMI), but time to intervention can be considerable. Our aim was to investigate whether the administration of full-dose tenecteplase before a delayed PCI could mitigate the negative effect of this delay. Methods We did a randomised study in which we assigned patients with STEMI of less than 6 It duration (scheduled to undergo primary PCI with an anticipated delay of 1-3 h) to standard PCI (n=838) or PCI preceded by administration of full-dose tenecteplase (n=829). All patients received aspirin and a bolus, without an infusion, of unfractionated heparin. Our primary endpoint was death or congestive heart failure or shock within 90 days. Analyses were by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00168792. Findings We planned to enrol 4000 patients, but early cessation of enrolment was recommended by the data and safety monitoring board because of a higher in-hospital mortality in the facilitated than in the standard PCI group (6% [43 of 664] vs 3% [22 of 656], p=0.0105). Of those enrolled, six were lost to follow-tip in the facilitated PCI group and seven in the other group. Median time from randomisation to first balloon inflation was similar in both groups. The median time from bolus tenecteplase to first balloon inflation was 104 min. We noted the primary endpoint in 19% (151 of 810) of patients assigned facilitated PCI versus 13% (110 of 819) of those randomised to primary PCI (relative risk 1.39, 95% CI 1.11-1.74; p=0.0045). During hospital stay, significantly more strokes (1.8% [15 of 8291 A vs 0, p<0.0001), but not major non-cerebral bleeding complications (6% [46 of 829] vs 4% [37 of 838], p=0.3118), were reported in patients assigned facilitated rather than standard PCI. We also noted more ischaemic cardiac complications, such as reinfarction (6% [49 of 805] vs 4% [30 of 820], p=0.0279) or repeat target vessel revascularisation (7% [53 of 805] vs 3% [28 of 818], p=0.0041) within 90 days in this study group. Interpretation A strategy of full-dose tenecteplase with antithrombotic co-therapy, as used in this study and preceding PCI by 1-3 h, was associated with more major adverse events than PCI alone in STEMI and cannot be recommended.	Univ Hosp Gasthuisberg, Dept Cardiol, B-3000 Louvain, Belgium	KU Leuven; University Hospital Leuven	Van de Werf, F (corresponding author), Univ Hosp Gasthuisberg, Dept Cardiol, Herestr 49, B-3000 Louvain, Belgium.	frans.vandewerf@uz.kuleuven.ac.be	Manolis, Antonis/F-5003-2014	Manolis, Antonis/0000-0002-0336-4745				Adams RJ, 2004, CIRCULATION, V110, P2512, DOI 10.1161/01.CIR.0000134791.68010.FA; Arntz HR, 2003, EUR HEART J, V24, P268, DOI 10.1016/S0195-668X(03)94640-9; Cutlip DE, 2003, AM J CARDIOL, V92, P977, DOI 10.1016/S0002-9149(03)00983-4; Danchin N, 2004, CIRCULATION, V110, P1909, DOI 10.1161/01.CIR.0000143144.82338.36; EISENBERG PR, 1992, J AM COLL CARDIOL, V19, P1065, DOI 10.1016/0735-1097(92)90296-Y; Ellis SG, 2004, AM HEART J, V147, DOI 10.1016/j.ahj.2003.07.025; Fernandez-Aviles F, 2004, EUR HEART J, V25, P33; Gabriel HM, 2003, EUR HEART J, V24, P543, DOI 10.1016/S0195-668X(03)95631-4; Gersh BJ, 2005, JAMA-J AM MED ASSOC, V293, P979, DOI 10.1001/jama.293.8.979; Giugliano RP, 2004, CIRCULATION, V110, P696; Huber K, 2005, EUR HEART J, V26, P2063, DOI 10.1093/eurheartj/ehi413; Kastrati A, 2004, JAMA-J AM MED ASSOC, V291, P947, DOI 10.1001/jama.291.8.947; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Le May MR, 2005, J AM COLL CARDIOL, V46, P417, DOI 10.1016/j.jacc.2005.04.042; Lee DP, 2003, CIRCULATION, V107, P1497, DOI 10.1161/01.CIR.0000056120.00513.7A; Martinez-Rios MA, 2004, AM J CARDIOL, V93, P280, DOI 10.1016/j.amjcard.2003.10.005; Nallamothu BK, 2005, CIRCULATION, V111, P761, DOI 10.1161/01.CIR.0000155258.44268.F8; ONEILL WW, 1992, CIRCULATION, V86, P1710, DOI 10.1161/01.CIR.86.6.1710; Ross AM, 1999, J AM COLL CARDIOL, V34, P1954, DOI 10.1016/S0735-1097(99)00444-1; Steg PG, 2003, CIRCULATION, V108, P2851, DOI 10.1161/01.CIR.0000103122.10021.F2; Stone GW, 2001, CIRCULATION, V104, P636, DOI 10.1161/hc3101.093701; Topol EJ, 2000, CIRCULATION, V101, P2788; Topol EJ, 2001, LANCET, V357, P1905; Van de Werf F, 1999, LANCET, V354, P716, DOI 10.1016/S0140-6736(99)07403-6; Van de Werf F, 2003, EUR HEART J, V24, P28, DOI 10.1016/S0195-668X(02)00618-8; Van de Werf F, 2001, LANCET, V358, P605; van't Hof AWJ, 2004, EUR HEART J, V25, P837, DOI 10.1016/j.ehj.2004.04.003; Vermeer F, 1999, HEART, V82, P426, DOI 10.1136/hrt.82.4.426; Wallentin L, 2003, CIRCULATION, V108, P135, DOI 10.1161/01.CIR.0000081659.72985.A8; Widimsky P, 2000, EUR HEART J, V21, P823, DOI 10.1053/euhj.1999.1993; Widimsky P, 2003, EUR HEART J, V24, P94, DOI 10.1016/S0195-668X(02)00468-2; Zeymer U, 2005, EUR HEART J, V26, P1971, DOI 10.1093/eurheartj/ehi293; Zorman S, 2002, AM J CARDIOL, V90, P533, DOI 10.1016/S0002-9149(02)02530-4	33	483	520	0	21	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 18	2006	367	9510					569	578		10.1016/S0140-6736(06)68147-6	http://dx.doi.org/10.1016/S0140-6736(06)68147-6			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013GM	16488800				2022-12-28	WOS:000235397800031
J	Nielsen, R				Nielsen, R			Evolution - Why sex?	SCIENCE			English	Editorial Material							REPRODUCTION; DROSOPHILA; DNA		Univ Copenhagen, Ctr Bioinformat, DK-2100 Copenhagen O, Denmark; Univ Copenhagen, Dept Biol, DK-2100 Copenhagen O, Denmark	University of Copenhagen; University of Copenhagen	Nielsen, R (corresponding author), Univ Copenhagen, Ctr Bioinformat, Univ Pk 15, DK-2100 Copenhagen O, Denmark.	rasmus@binf.ku.dk	Nielsen, Rasmus/D-4405-2009	Nielsen, Rasmus/0000-0003-0513-6591				Andolfatto P, 2005, NATURE, V437, P1149, DOI 10.1038/nature04107; BEGUN DJ, 1992, NATURE, V356, P519, DOI 10.1038/356519a0; HAMILTON WD, 1990, P NATL ACAD SCI USA, V87, P3566, DOI 10.1073/pnas.87.9.3566; JURINE L, 1820, HIST MONOCLES TROUVE; Kimura M., 1983, NEUTRAL THEORY MOL E; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; Maynard Smith J., 1978, EVOLUTION SEX, DOI DOI 10.1093/bioinformatics/btg412; Paland S, 2006, SCIENCE, V311, P990, DOI 10.1126/science.1118152; Williamson SH, 2005, P NATL ACAD SCI USA, V102, P7882, DOI 10.1073/pnas.0502300102	9	7	7	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 17	2006	311	5763					960	961		10.1126/science.1124663	http://dx.doi.org/10.1126/science.1124663			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014CS	16484481				2022-12-28	WOS:000235456900031
J	Phillips, BL; Brown, GP; Webb, JK; Shine, R				Phillips, BL; Brown, GP; Webb, JK; Shine, R			Invasion and the evolution of speed in toads	NATURE			English	Editorial Material							BUFO-MARINUS; DISPERSAL; POPULATIONS; AUSTRALIA		Univ Sydney, Sch Biol Sci A08, Sydney, NSW 2006, Australia	University of Sydney	Phillips, BL (corresponding author), Univ Sydney, Sch Biol Sci A08, Sydney, NSW 2006, Australia.	rics@bio.usyd.edu.au	Brown, Gregory P./F-9897-2011; Phillips, Ben/C-7957-2009; Shine, Richard/B-8711-2008	Brown, Gregory P./0000-0002-2924-9040; Phillips, Ben/0000-0003-2580-2336; Webb, Jonathan/0000-0003-4822-6829				Choi I, 2003, J EXP ZOOL PART A, V299A, P99, DOI 10.1002/jez.a.10293; Cox GW, 2004, ALIEN SPECIES EVOLUT; Crossland MR, 2000, ECOGRAPHY, V23, P283, DOI 10.1034/j.1600-0587.2000.d01-1636.x; FREELAND WJ, 1985, AUST WILDLIFE RES, V12, P555, DOI 10.1071/WR9850555; LEVER C., 2001, CANE TOAD HIST ECOLO; Simmons AD, 2004, AM NAT, V164, P378, DOI 10.1086/423430; Smith KG, 2005, BIOL CONSERV, V123, P433, DOI 10.1016/j.biocon.2005.01.005; Smith MA, 2005, ECOGRAPHY, V28, P110; Thomas CD, 2001, NATURE, V411, P577, DOI 10.1038/35079066; Travis JMJ, 2002, EVOL ECOL RES, V4, P1119	10	619	630	4	370	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 16	2006	439	7078					803	803		10.1038/439803a	http://dx.doi.org/10.1038/439803a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012JA	16482148	Bronze			2022-12-28	WOS:000235333600039
J	Taddio, A; Lee, C; Yip, A; Parvez, B; McNamara, PJ; Shah, V				Taddio, A; Lee, C; Yip, A; Parvez, B; McNamara, PJ; Shah, V			Intravenous morphine and topical tetracaine for treatment of pain in preterm neonates undergoing central line placement	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANALGESIA	Context There is limited evidence of the analgesic effectiveness of opioid analgesia or topical anesthesia during central line placement in neonates, and there are no previous studies of their relative effectiveness. Objective To determine the effectiveness and safety of topical tetracaine, intravenous morphine, or tetracaine plus morphine for alleviating pain in ventilated neonates during central line placement. Design, Setting, and Participants Randomized, double-blind, controlled trial enrolling 132 ventilated neonates (mean gestational age, 30.6 [SD, 4.6] weeks at study entry) and conducted between October 2000 and July 2005 in 2 neonatal intensive care units in Toronto, Ontario. Interventions Prior to central line insertion, neonates were randomly assigned to receive tetracaine (n=42), morphine (n=38), or both (n=31); a separate nonrandomized group of 21 neonates receiving neither tetracaine nor morphine was used as a control group. Main Outcome Measures The primary outcome measure was a pain score for the proportion of time neonates displayed facial grimacing (brow bulge) during different phases of the procedure (skin preparation, needle puncture, and recovery). In randomized neonates, safety assessments included blood pressure, ventilatory support, and local skin reactions. Results Compared with no treatment, pain scores were lower in the morphine and tetracaine-morphine groups during skin preparation (mean difference, -0.22; 95% confidence interval [CI], -0.4 to -0.04; P = .02 and -0.29; 95% CI, -0.49 to -0.09; P = .01, respectively), and needle puncture (mean difference, -0.35; 95% CI, -0.57 to -0.13; P=.003 and -0.47; 95% CI, -0.71 to -0.24; P<.001, respectively), but pain scores did not differ statistically for tetracaine alone vs no treatment. Pain scores were lower for morphine and tetracaine-morphine vs tetracaine during the skin preparation phase and for tetracaine-morphine vs tetracaine during needle puncture. Compared with neonates without morphine, morphine-treated neonates required larger increases in ventilation rate in the first 12 hours (mean difference, 3.9/min; 95% CI, 1.3-6.5/min; P=.003). Local skin reactions occurred in 30% of neonates given tetracaine vs 0% for morphine (risk difference, 0.30; 95% CI, 0.19-0.41; P<.001). Conclusion In this study of ventilated neonates undergoing central line placement, morphine and tetracaine plus morphine provided superior analgesia to tetracaine; however, morphine caused respiratory depression and tetracaine caused erythema.	Univ Toronto, Hosp Sick Children, Fac Pharmaceut Sci, Dept Pharm, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Fac Pharmaceut Sci, Dept Populat Hlth Sci, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Fac Pharmaceut Sci, Dept Paediat, Toronto, ON M5G 1X8, Canada; Mt Sinai Hosp, Dept Pharm, Toronto, ON M5G 1X5, Canada; Mt Sinai Hosp, Dept Paediat, Toronto, ON M5G 1X5, Canada; New York Med Coll, Dept Pediat, Maria Fareri Childrens Hosp, Valhalla, NY 10595 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; New York Medical College	Taddio, A (corresponding author), Univ Toronto, Hosp Sick Children, Fac Pharmaceut Sci, Dept Pharm, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	anna.taddio@sickkids.ca	Shah, Vibhuti/P-5853-2015; MCNAMARA, PATRICK J/M-6244-2018	McNamara, Patrick/0000-0001-7648-8872				Alderson P, 2004, BMJ-BRIT MED J, V328, P476, DOI 10.1136/bmj.328.7438.476; Anand KJS, 2005, CLIN THER, V27, P844, DOI 10.1016/j.clinthera.2005.06.018; Anand KJS, 2004, LANCET, V363, P1673, DOI 10.1016/S0140-6736(04)16251-X; Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; Ballantyne Marilyn, 2003, Adv Neonatal Care, V3, P297, DOI 10.1016/j.adnc.2003.09.006; Brown H., 1999, APPL MIXED MODELS ME; CRAIG KD, 1993, PAIN NEONATES, P67; Duhn Lenora J, 2004, Adv Neonatal Care, V4, P126, DOI 10.1016/j.adnc.2004.04.005; Garcia O C, 1997, J Perinatol, V17, P477; Giacoia GP, 2005, CLIN THER, V27, P796, DOI 10.1016/j.clinthera.2005.06.008; Gibbins Sharyn, 2003, Adv Neonatal Care, V3, P241, DOI 10.1016/j.adnc.2003.08.004; Health Canada, 2000, PER HLTH IND CAN RES; JOHNSTON CC, 1995, PAIN, V61, P471, DOI 10.1016/0304-3959(94)00213-X; LEMYRE B, 2005, J PAEDIAT CHILD H SB, V19, pB53; Moustogiannis AN, 1996, NEUROL RES, V18, P440; Norman G., 2014, BIOSTATISTICS BARE E, V4; O'Brien Lisa, 2005, Paediatr Drugs, V7, P41, DOI 10.2165/00148581-200507010-00004; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; Taddio A, 2005, CAN MED ASSOC J, V172, P1691, DOI 10.1503/cmaj.045316; TADDIO A, IN PRESS THER DRUG M; Taddio Anna, 2005, Paediatr Drugs, V7, P245, DOI 10.2165/00148581-200507040-00004	21	46	48	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	2006	295	7					793	800		10.1001/jama.295.7.793	http://dx.doi.org/10.1001/jama.295.7.793			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011YZ	16478902	Bronze			2022-12-28	WOS:000235306700024
J	Adachi, Y; Kawamura, K; Armi, L; Keeling, RF				Adachi, Y; Kawamura, K; Armi, L; Keeling, RF			Diffusive separation of the lower atmosphere	SCIENCE			English	Article							AR/N-2 RATIO		Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Keeling, RF (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, 9500 Gilman Dr, La Jolla, CA 92093 USA.	rkeeling@ucsd.edu	Kawamura, Kenji/C-7660-2011	Kawamura, Kenji/0000-0003-1163-700X; , Yosuke/0000-0001-6522-2753				Battle M, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017411; BIERI RH, 1970, J GEOPHYS RES, V75, P6731, DOI 10.1029/JC075i033p06731; Blaine T. W., 2005, THESIS U CALIF; DALTON J, 1926, PHILOS T R SOC LONDO, V116, P174; Keeling RF, 2004, TELLUS B, V56, P322, DOI 10.1111/j.1600-0889.2004.00117.x; Mirtov B.A., 1964, GASEOUS COMPOSITION; Severinghaus JP, 2001, GEOCHEM GEOPHY GEOSY, V2, DOI 10.1029/2000GC000146	7	6	6	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2006	311	5766					1429	1429		10.1126/science.1121312	http://dx.doi.org/10.1126/science.1121312			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527973				2022-12-28	WOS:000236029400039
J	Diehl, MR; Zhang, KC; Lee, HJ; Tirrell, DA				Diehl, MR; Zhang, KC; Lee, HJ; Tirrell, DA			Engineering cooperativity in biomotor-protein assemblies	SCIENCE			English	Article							KINESIN HEAD DOMAINS; MOLECULAR MOTORS; PROCESSIVITY; ELASTIN; OSCILLATIONS; CHEMISTRY; TRANSPORT; KIF1A		CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; CALTECH, Dept Appl Phys, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Diehl, MR (corresponding author), Rice Univ, Dept Bioengn, Houston, TX 77251 USA.	diehl@rice.edu						Badoual M, 2002, P NATL ACAD SCI USA, V99, P6696, DOI 10.1073/pnas.102692399; BURGESS SA, 1995, J MOL BIOL, V250, P52, DOI 10.1006/jmbi.1995.0357; Camalet S, 2000, P NATL ACAD SCI USA, V97, P3183, DOI 10.1073/pnas.97.7.3183; Camalet S, 1999, PHYS REV LETT, V82, P1590, DOI 10.1103/PhysRevLett.82.1590; Carter NJ, 2005, NATURE, V435, P308, DOI 10.1038/nature03528; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; Duke T, 2000, PHILOS T ROY SOC B, V355, P529, DOI 10.1098/rstb.2000.0594; Endow SA, 2000, NATURE, V406, P913, DOI 10.1038/35022617; Epshtein V, 2003, SCIENCE, V300, P801, DOI 10.1126/science.1083219; Gross SP, 2003, CURR BIOL, V13, P1660, DOI 10.1016/j.cub.2003.08.032; HACKNEY DD, 1995, BIOPHYS J, V68, pS267; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; Hyun J, 2004, J AM CHEM SOC, V126, P7330, DOI 10.1021/ja049721e; Inoue Y, 2001, BIOPHYS J, V81, P2838, DOI 10.1016/S0006-3495(01)75925-5; Julicher F, 1997, REV MOD PHYS, V69, P1269, DOI 10.1103/RevModPhys.69.1269; Julicher F, 1997, PHYS REV LETT, V78, P4510, DOI 10.1103/PhysRevLett.78.4510; Klopfenstein DR, 2002, CELL, V109, P347, DOI 10.1016/S0092-8674(02)00708-0; Kural C, 2005, SCIENCE, V308, P1469, DOI 10.1126/science.1108408; LEIBLER S, 1993, J CELL BIOL, V121, P1357, DOI 10.1083/jcb.121.6.1357; Meyer DE, 2004, BIOMACROMOLECULES, V5, P846, DOI 10.1021/bm034215n; Moll JR, 2001, PROTEIN SCI, V10, P649, DOI 10.1110/ps.39401; Okada Y, 2003, NATURE, V424, P574, DOI 10.1038/nature01804; Okada Y, 1999, SCIENCE, V283, P1152, DOI 10.1126/science.283.5405.1152; Urry DW, 2002, PHILOS T R SOC B, V357, P169, DOI 10.1098/rstb.2001.1023; Urry DW, 1997, J PHYS CHEM B, V101, P11007, DOI 10.1021/jp972167t; Vilfan A, 1998, EUR PHYS J B, V3, P535, DOI 10.1007/s100510050343	28	83	85	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 10	2006	311	5766					1468	1471		10.1126/science.1122125	http://dx.doi.org/10.1126/science.1122125			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527982	Green Submitted			2022-12-28	WOS:000236029400051
J	Stemmler, K; Ammann, M; Donders, C; Kleffmann, J; George, C				Stemmler, K; Ammann, M; Donders, C; Kleffmann, J; George, C			Photosensitized reduction of nitrogen dioxide on humic acid as a source of nitrous acid	NATURE			English	Article							DIFFERENTIAL OPTICAL-ABSORPTION; PHOTOCHEMICAL OXIDANT FORMATION; SIMULATED VERTICAL PROFILES; HETEROGENEOUS HYDROLYSIS; SOUTHERN SWITZERLAND; URBAN ATMOSPHERE; BOUNDARY-LAYER; HONO; CHEMISTRY; PHOTOLYSIS	Nitrous acid is a significant photochemical precursor of the hydroxyl radical(1-13), the key oxidant in the degradation of most air pollutants in the troposphere. The sources of nitrous acid in the troposphere, however, are still poorly understood. Recent atmospheric measurements(7,10-17) revealed a strongly enhanced formation of nitrous acid during daytime via unknown mechanisms. Here we expose humic acid films to nitrogen dioxide in an irradiated tubular gas flow reactor and find that reduction of nitrogen dioxide on light-activated humic acids is an important source of gaseous nitrous acid. Our findings indicate that soil and other surfaces containing humic acid exhibit an organic surface photochemistry that produces reductive surface species, which react selectively with nitrogen dioxide. The observed rate of nitrous acid formation could explain the recently observed high daytime concentrations of nitrous acid in the boundary layer, the photolysis of which accounts for up to 60 per cent of the integrated hydroxyl radical source strengths(3,6-13). We suggest that this photoinduced nitrous acid production on humic acid could have a potentially significant impact on the chemistry of the lowermost troposphere.	Paul Scherrer Inst, Lab Radio & Environm Chem, CH-5232 Villigen, Switzerland; Berg Univ Wuppertal, D-42097 Wuppertal, Germany; Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland; UCBL, CNRS, Lab Applicat Chim Environm, F-69622 Villeurbanne, France	Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; University of Wuppertal; University of Bern; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Stemmler, K (corresponding author), Paul Scherrer Inst, Lab Radio & Environm Chem, CH-5232 Villigen, Switzerland.	konrad.stemmler@psi.ch	Ammann, Markus/E-4576-2011; George, Christian/F-5220-2018	Ammann, Markus/0000-0001-5922-9000; George, Christian/0000-0003-1578-7056				Acker K, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL024643; Alicke B, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2000JD000075; Alicke B, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2001JD000579; Ammann M, 2005, PHYS CHEM CHEM PHYS, V7, P2513, DOI 10.1039/b501808k; Atkinson R, 2003, ATMOS ENVIRON, V37, pS197, DOI 10.1016/S1352-2310(03)00391-1; Aumont B, 2003, ATMOS ENVIRON, V37, P487, DOI 10.1016/S1352-2310(02)00920-2; Blough N. V., 1997, SEA SURFACE GLOBAL C, P383, DOI [10.1017/CBO9780511525025.014, DOI 10.1017/CBO9780511525025.014]; Finlayson-Pitts BJ, 2003, PHYS CHEM CHEM PHYS, V5, P223, DOI 10.1039/b208564j; George C, 2005, FARADAY DISCUSS, V130, P195, DOI 10.1039/b417888m; HARRIS GW, 1982, ENVIRON SCI TECHNOL, V16, P414, DOI 10.1021/es00101a009; Harrison RM, 1996, J GEOPHYS RES-ATMOS, V101, P14429, DOI 10.1029/96JD00341; Honrath RE, 2002, ATMOS ENVIRON, V36, P2629, DOI 10.1016/S1352-2310(02)00132-2; Janzen HH, 2004, AGR ECOSYST ENVIRON, V104, P399, DOI 10.1016/j.agee.2004.01.040; Kleffmann J, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL022524; Kleffmann J, 2003, ATMOS ENVIRON, V37, P2949, DOI 10.1016/S1352-2310(03)00242-5; Kleffmann J, 2002, ENVIRON SCI POLLUT R, P48; Krivacsy Z, 2000, ATMOS ENVIRON, V34, P4273, DOI 10.1016/S1352-2310(00)00211-9; Lammel G, 1996, CHEM SOC REV, V25, P361, DOI 10.1039/cs9962500361; PERNER D, 1979, GEOPHYS RES LETT, V6, P917, DOI 10.1029/GL006i012p00917; PLATT U, 1980, NATURE, V285, P312, DOI 10.1038/285312a0; Ramazan KA, 2004, PHYS CHEM CHEM PHYS, V6, P3836, DOI 10.1039/b402195a; Ren XR, 2003, ATMOS ENVIRON, V37, P3639, DOI 10.1016/S1352-2310(03)00459-X; Staffelbach T, 1997, J GEOPHYS RES-ATMOS, V102, P23345, DOI 10.1029/97JD00933; Staffelbach T, 1997, J GEOPHYS RES-ATMOS, V102, P23363, DOI 10.1029/97JD00932; STEVENSO.FJ, 1970, SOIL SCI SOC AM PRO, V34, P430, DOI 10.2136/sssaj1970.03615995003400030024x; Venterea RT, 2000, GLOBAL CHANGE BIOL, V6, P303, DOI 10.1046/j.1365-2486.2000.00309.x; Vogel B, 2003, ATMOS ENVIRON, V37, P2957, DOI 10.1016/S1352-2310(03)00243-7; ZEPP RG, 1992, ENVIRON SCI TECHNOL, V26, P313, DOI 10.1021/es00026a011; Zhou XL, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018620; Zhou XL, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001539	30	357	363	15	256	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	2006	440	7081					195	198		10.1038/nature04603	http://dx.doi.org/10.1038/nature04603			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019MC	16525469	Green Submitted, Bronze			2022-12-28	WOS:000235839500042
J	Shaw, GC; Cope, JJ; Li, LT; Corson, K; Hersey, C; Ackermann, GE; Gwynn, B; Lambert, AJ; Wingert, RA; Traver, D; Trede, NS; Barut, BA; Zhou, Y; Minet, E; Donovan, A; Brownlie, A; Balzan, R; Weiss, MJ; Peters, LL; Kaplan, J; Zon, LI; Paw, BH				Shaw, GC; Cope, JJ; Li, LT; Corson, K; Hersey, C; Ackermann, GE; Gwynn, B; Lambert, AJ; Wingert, RA; Traver, D; Trede, NS; Barut, BA; Zhou, Y; Minet, E; Donovan, A; Brownlie, A; Balzan, R; Weiss, MJ; Peters, LL; Kaplan, J; Zon, LI; Paw, BH			Mitoferrin is essential for erythroid iron assimilation	NATURE			English	Article							CARRIER PROTEIN; HELA-CELLS; ZEBRAFISH; YEAST; GENE; IDENTIFICATION; MITOCHONDRIA; BIOGENESIS; METABOLISM; EXPRESSION	Iron has a fundamental role in many metabolic processes, including electron transport, deoxyribonucleotide synthesis, oxygen transport and many essential redox reactions involving haemoproteins and Fe - S cluster proteins. Defective iron homeostasis results in either iron deficiency or iron overload(1). Precise regulation of iron transport in mitochondria is essential for haem biosynthesis(2), haemoglobin production and Fe - S cluster protein assembly(3,4) during red cell development. Here we describe a zebrafish mutant, frascati (frs)(5), that shows profound hypochromic anaemia and erythroid maturation arrest owing to defects in mitochondrial iron uptake. Through positional cloning, we show that the gene mutated in the frs mutant is a member of the vertebrate mitochondrial solute carrier family (SLC25)(6) that we call mitoferrin (mfrn). mfrn is highly expressed in fetal and adult haematopoietic tissues of zebrafish and mouse. Erythroblasts generated from murine embryonic stem cells null for Mfrn ( also known as Slc25a37) show maturation arrest with severely impaired incorporation of Fe-55 into haem. Disruption of the yeast mfrn orthologues, MRS3 and MRS4, causes defects in iron metabolism and mitochondrial Fe - S cluster biogenesis(7-10). Murine Mfrn rescues the defects in frs zebrafish, and zebrafish mfrn complements the yeast mutant, indicating that the function of the gene may be highly conserved. Our data show that mfrn functions as the principal mitochondrial iron importer essential for haem biosynthesis in vertebrate erythroblasts.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Hematol, Boston, MA 02115 USA; Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA; Harvard Univ, Sch Med, Childrens Hosp Boston, Howard Hughes Med Inst,Stem Cell Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp Boston, Div Hematol Oncol, Boston, MA 02115 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Univ Malta, Dept Physiol & Biochem, Msida MSD 06, Malta; Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Div Hematol, Philadelphia, PA 19104 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Utah System of Higher Education; University of Utah; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; Jackson Laboratory; University of Malta; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Paw, BH (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Hematol, Boston, MA 02115 USA.	bpaw@rics.bwh.harvard.edu	Weiss, Mitchell J/W-9814-2018; Shaw, George C/AAA-2678-2022; Wingert, Rebecca A/ABE-2786-2020; Weiss, Mitchell J/A-1245-2013; Balzan, Rena //B-3215-2008	Weiss, Mitchell J/0000-0003-2460-3036; Wingert, Rebecca A/0000-0003-3133-7549; Cutts, Alison/0000-0002-4986-573X; Paw, Barry/0000-0002-0492-1419; Peters, Luanne/0000-0002-0784-0534	NHLBI NIH HHS [P01 HL032262, R01 HL075714] Funding Source: Medline; NIDDK NIH HHS [R01 DK070838] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262, R01HL075714] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070838] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALZAN R, 1995, P NATL ACAD SCI USA, V92, P4219, DOI 10.1073/pnas.92.10.4219; Cantor AB, 2002, MOL CELL BIOL, V22, P4268, DOI 10.1128/MCB.22.12.4268-4279.2002; Cantor AB, 2001, CURR OPIN GENET DEV, V11, P513, DOI 10.1016/S0959-437X(00)00226-4; Foury F, 2002, J BIOL CHEM, V277, P24475, DOI 10.1074/jbc.M111789200; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Griffin KJP, 1998, DEVELOPMENT, V125, P3379; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; IUCHI I, 1983, J EXP ZOOL, V226, P409, DOI 10.1002/jez.1402260311; Kobayashi K, 1999, NAT GENET, V22, P159, DOI 10.1038/9667; Li FY, 2002, MAMM GENOME, V13, P20, DOI 10.1007/s00335-001-2094-y; Li FY, 2001, FEBS LETT, V494, P79, DOI 10.1016/S0014-5793(01)02319-5; Li LT, 2004, J BIOL CHEM, V279, P33653, DOI 10.1074/jbc.M403146200; Li QZ, 2001, MAMM GENOME, V12, P830, DOI 10.1007/s00335001-2075-1; Lill R, 2005, TRENDS BIOCHEM SCI, V30, P133, DOI 10.1016/j.tibs.2005.01.006; Lyons SE, 2002, P NATL ACAD SCI USA, V99, P5454, DOI 10.1073/pnas.082695299; McKee AE, 2005, BMC DEV BIOL, V5, DOI 10.1186/1471-213X-5-14; Muhlenhoff U, 2003, J BIOL CHEM, V278, P40612, DOI 10.1074/jbc.M307847200; Napier I, 2005, BLOOD, V105, P1867, DOI 10.1182/blood-2004-10-3856; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Paw BH, 2003, NAT GENET, V34, P59, DOI 10.1038/ng1137; Ransom DG, 1996, DEVELOPMENT, V123, P311; Rosenberg MJ, 2002, NAT GENET, V32, P175, DOI 10.1038/ng948; Rouault TA, 2005, NAT REV MOL CELL BIO, V6, P345, DOI 10.1038/nrm1620; Roy CN, 1999, J BIOL CHEM, V274, P9022, DOI 10.1074/jbc.274.13.9022; Shafizadeh E, 2004, CURR OPIN HEMATOL, V11, P255, DOI 10.1097/01.moh.0000138686.15806.71; STURROCK A, 1990, J BIOL CHEM, V265, P3139; Surinya KH, 1997, J BIOL CHEM, V272, P26585, DOI 10.1074/jbc.272.42.26585; Traver D, 2003, NAT IMMUNOL, V4, P1238, DOI 10.1038/ni1007; Wohlrab H, 2005, BBA-BIOENERGETICS, V1709, P157, DOI 10.1016/j.bbabio.2005.07.003; Zhang Y, 2005, J BIOL CHEM, V280, P19794, DOI 10.1074/jbc.M500397200	30	425	438	2	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	2006	440	7080					96	100		10.1038/nature04512	http://dx.doi.org/10.1038/nature04512			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017HW	16511496				2022-12-28	WOS:000235685700047
J	Rosenblatt, RA; Andrilla, CHA; Curtin, T; Hart, LG				Rosenblatt, RA; Andrilla, CHA; Curtin, T; Hart, LG			Shortages of medical personnel at community health centers - Implications for planned expansion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN WORKFORCE; FAMILY PHYSICIANS; SERVICE-CORPS; FOLLOW-UP; CARE; AREAS; RETENTION; URBAN; RECRUITMENT; EXPERIENCE	Context The US government is expanding the capacity of community health centers (CHCs) to provide care to underserved populations. Objective To examine the status of workforce shortages that may limit CHC expansion. Design and Setting Survey questionnaire of all 846 federally funded US CHCs that directly provide clinical services and are within the 50 states and the District of Columbia, conducted between May and September 2004. Questionnaires were completed by the chief executive officer of each grantee. Information was supplemented by data from the 2003 Bureau of Primary Health Care Uniform Data System and weighted to be nationally representative. Main Outcome Measures Staffing patterns and vacancies for major clinical disciplines by rural and urban location, use of federal and state recruitment programs, and perceived barriers to recruitment. Results Overall response rate was 79.3%. Primary care physicians made up 89.4% of physicians working in the CHCs, the majority of whom are family physicians. In rural CHCs, 46% of the direct clinical providers of care were nonphysician clinicians compared with 38.9% in urban CHCs. There were 428 vacant funded full-time equivalents (FTEs) for family physicians and 376 vacant FTEs for registered nurses. There were vacancies for 13.3% of family physician positions, 20.8% of obstetrician/ gynecologist positions, and 22.6% of psychiatrist positions. Rural CHCs had a higher proportion of vacancies and longer-term vacancies and reported greater difficulty filling positions compared with urban CHCs. Physician recruitment in CHCs was heavily dependent on National Health Service Corps scholarships, loan repayment programs, and international medical graduates with J-1 visa waivers. Major perceived barriers to recruitment included low salaries and, in rural CHCs, cultural isolation, poor-quality schools and housing, and lack of spousal job opportunities. Conclusions CHCs face substantial challenges in recruitment of clinical staff, particularly in rural areas. The largest numbers of unfilled positions were for family physicians at a time of declining interest in family medicine among graduating US medical students. The success of the current US national policy to expand CHCs may be challenged by these workforce issues.	Univ Washington, Dept Family Med, Rural Hlth Res Ctr, Seattle, WA 98195 USA; Natl Assoc Community Hlth Ctr, Bethesda, MD USA	University of Washington; University of Washington Seattle	Rosenblatt, RA (corresponding author), Univ Washington, Dept Family Med, Rural Hlth Res Ctr, Box 354696, Seattle, WA 98195 USA.	rosenb@u.washington.edu	Andrilla, Holly/AAC-6264-2019					Alpert JJ, 1998, AM J PUBLIC HEALTH, V88, P347, DOI 10.2105/AJPH.88.3.347; *AM AC FAM PHYS, 2005, NAT RES MATCH PROGR; [Anonymous], OR HLTH AM REP SURG; BOWMAN RC, BIRTH ORIGINS FP CHO; BURKE KJ, COMMUNICATION   1114; COOPER RA, 1995, JAMA-J AM MED ASSOC, V274, P1534, DOI 10.1001/jama.274.19.1534; DAVIS K, 1977, HLTH WAR POVERTY 10; Geiger HJ, 2005, J AMBUL CARE MANAG, V28, P313, DOI 10.1097/00004479-200510000-00006; Grumbach Kevin, 2003, Ann Fam Med, V1, P97, DOI 10.1370/afm.49; Gusmano MK, 2002, HEALTH AFFAIR, V21, P188, DOI 10.1377/hlthaff.21.6.188; Hart LG, 2005, AM J PUBLIC HEALTH, V95, P1149, DOI 10.2105/AJPH.2004.042432; Hawkins Daniel Jr, 2003, J Ambul Care Manage, V26, P285; Institute of Medicine, 2004, QUAL COLL FUT RUR HL; Institute of Medicine Committee on the Future of Rural Health Care Quality Board on Health Care Services., 2005, QUAL COLL FUT RUR HL; Institute of Medicine (US), 2002, CAR COV TOO LITTL TO; JONAS S, 1971, AM J PUBLIC HEALTH N, V61, P916, DOI 10.2105/AJPH.61.5.916; Knapp KK, 2000, J PUBLIC HEALTH DENT, V60, P43, DOI 10.1111/j.1752-7325.2000.tb03291.x; Krist AH, 2005, J RURAL HEALTH, V21, P3, DOI 10.1111/j.1748-0361.2005.tb00056.x; LANGWELL KM, 1987, PUBLIC HEALTH REP, V102, P317; Lefkowitz B, 2005, J AMBUL CARE MANAG, V28, P295, DOI 10.1097/00004479-200510000-00004; LEONG D, 1991, HLTH PROFESSIONALS H; McKinley Andrew, 2004, Issue Brief Health Policy Track Serv, P1; *MED PAYM ADV COMM, 2001, REP C MED RUR AM; Meyers D, 2002, Am Fam Physician, V66, P554; Morrill R, 1999, URBAN GEOGR, V20, P727, DOI 10.2747/0272-3638.20.8.727; *NAT ASS COMM HLTH, 2004, 0304 NAT ASS COMM HL; O'Malley AS, 2005, HEALTH AFFAIR, V24, P465, DOI 10.1377/hlthaff.24.2.465; Pathman DE, 2000, JAMA-J AM MED ASSOC, V284, P2084, DOI 10.1001/jama.284.16.2084; PATHMAN DE, 1992, JAMA-J AM MED ASSOC, V268, P1552; PAXTON GS, 1975, MED CARE, V13, P209, DOI 10.1097/00005650-197503000-00003; Plaska M, 1995, J Ambul Care Manage, V18, P3; Politzer RM, 1999, J RURAL HEALTH, V15, P11, DOI 10.1111/j.1748-0361.1999.tb00594.x; POLITZER RM, 1991, JAMA-J AM MED ASSOC, V266, P104, DOI 10.1001/jama.266.1.104; Probst JC, 2003, SOUTH MED J, V96, P775, DOI 10.1097/01.SMJ.0000051140.61690.86; Rabinowitz HK, 1999, JAMA-J AM MED ASSOC, V281, P255, DOI 10.1001/jama.281.3.255; RABINOWITZ HK, 1993, NEW ENGL J MED, V328, P934, DOI 10.1056/NEJM199304013281307; Redman Eric, 1973, DANCE LEGISLATION; Regan J, 2003, J RURAL HEALTH, V19, P117, DOI 10.1111/j.1748-0361.2003.tb00552.x; Reschovsky JD, 2005, HEALTH AFFAIR, V24, P1128, DOI 10.1377/hlthaff.24.4.1128; Ricketts TC, 1998, J RURAL HEALTH, V14, P287, DOI 10.1111/j.1748-0361.1998.tb00633.x; ROEMER MI, 1988, AM J PUBLIC HEALTH, V78, P1234, DOI 10.2105/AJPH.78.9.1234; Rosenblatt R A, 1996, J Am Board Fam Pract, V9, P23; Rosenblatt RA, 2004, NEW ENGL J MED, V351, P1049, DOI 10.1056/NEJMp048073; ROSENBLATT RA, 1992, JAMA-J AM MED ASSOC, V268, P1559, DOI 10.1001/jama.268.12.1559; ROSENBLATT RA, 1979, PUBLIC HEALTH REP, V94, P571; Rosenblatt RA, 1999, RURAL HEALTH IN THE UNITED STATES, P38; Salsberg ES, 2002, HEALTH AFFAIR, V21, P165, DOI 10.1377/hlthaff.21.5.165; SARDELL S, 1988, US EXPT SOCIAL MED C; Seacat M S, 1977, J Community Health, V3, P156, DOI 10.1007/BF01674237; Sempowski Ian P, 2004, Can J Rural Med, V9, P82; Shi L, 1993, J Rural Health, V9, P27, DOI 10.1111/j.1748-0361.1993.tb00492.x; Shi LY, 1998, J RURAL HEALTH, V14, P346, DOI 10.1111/j.1748-0361.1998.tb00640.x; SHI LY, 1994, PUBLIC HEALTH REP, V109, P809; Singer JD, 1998, MED CARE, V36, P1198, DOI 10.1097/00005650-199808000-00008; Straub L A, 1990, J Rural Health, V6, P467, DOI 10.1111/j.1748-0361.1990.tb00683.x; Taylor P, 2003, J RURAL HEALTH, V19, P125, DOI 10.1111/j.1748-0361.2003.tb00553.x; Tilson H H, 1973, Inquiry, V10, P27; *WHIT HOUS PRESS O, 2004, REM PRES BUSH CONV H; Whitcomb ME, 2005, ACAD MED, V80, P715, DOI 10.1097/00001888-200508000-00001; WOOLF MA, 1981, MED CARE, V19, P444, DOI 10.1097/00005650-198104000-00006; Zuvekas A, 1990, J Ambul Care Manage, V13, P1	61	214	214	0	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	2006	295	9					1042	1049		10.1001/jama.295.9.1042	http://dx.doi.org/10.1001/jama.295.9.1042			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	016XJ	16507805	Bronze			2022-12-28	WOS:000235656600024
J	Cooper, MD; Alder, MN				Cooper, MD; Alder, MN			The evolution of adaptive immune systems	CELL			English	Review							VARIABLE LYMPHOCYTE RECEPTORS; ANTIGEN-BINDING RECEPTORS; AGNATHAN SEA LAMPREY; V(D)J RECOMBINATION; SOMATIC DIVERSIFICATION; INNATE IMMUNITY; IMMUNOGLOBULIN GENES; JAWLESS VERTEBRATE; PACIFIC HAGFISH; PROTEINS	A clonally diverse anticipatory repertoire in which each lymphocyte bears a unique antigen receptor is the central feature of the adaptive immune system that evolved in our vertebrate ancestors. The survival advantage gained through adding this type of adaptive immune system to a pre-existing innate immune system led to the evolution of alternative ways for lymphocytes to generate diverse antigen receptors for use in recognizing and repelling pathogen invaders. All jawed vertebrates assemble their antigen-receptor genes through recombinatorial rearrangement of different immunoglobulin or T cell receptor gene segments. The surviving jawless vertebrates, lampreys and hagfish, instead solved the receptor diversification problem by the recombinatorial assembly of leucine-rich-repeat genetic modules to encode variable lymphocyte receptors. The convergent evolution of these remarkably different adaptive immune systems involved innovative genetic modification of innate-immune-system components.	Univ Alabama, Div Dev & Clin Immunol, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Div Dev & Clin Immunol, Dept Microbiol, Birmingham, AL 35294 USA; Univ Alabama, Div Dev & Clin Immunol, Dept Pediat, Birmingham, AL 35294 USA; Univ Alabama, Div Dev & Clin Immunol, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Howard Hughes Med Inst, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Howard Hughes Medical Institute; University of Alabama System; University of Alabama Birmingham	Cooper, MD (corresponding author), Univ Alabama, Div Dev & Clin Immunol, Dept Med, Birmingham, AL 35294 USA.	max.cooper@ccc.uab.edu		Alder, Matthew/0000-0003-2879-6576				Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alder MN, 2005, SCIENCE, V310, P1970, DOI 10.1126/science.1119420; Beutler B, 2004, MOL IMMUNOL, V40, P845, DOI 10.1016/j.molimm.2003.10.005; Borst P, 2002, CELL, V109, P5, DOI 10.1016/S0092-8674(02)00711-0; Buchanan SGS, 1996, PROG BIOPHYS MOL BIO, V65, P1, DOI 10.1016/S0079-6107(96)00003-X; BURNET M, 1959, CLONAL SELECTION THE; Cabanes D, 2002, TRENDS MICROBIOL, V10, P238, DOI 10.1016/S0966-842X(02)02342-9; Cannon JP, 2005, IMMUNOGENETICS, V56, P924, DOI 10.1007/s00251-004-0766-y; Cannon JP, 2004, IMMUNOL REV, V200, P12, DOI 10.1111/j.0105-2896.2004.00166.x; Cannon JP, 2002, NAT IMMUNOL, V3, P1200, DOI 10.1038/ni849; Conticello SG, 2005, MOL BIOL EVOL, V22, P367, DOI 10.1093/molbev/msi026; COOPER MD, 1965, NATURE, V205, P143, DOI 10.1038/205143a0; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; FINSTAD J, 1964, J EXP MED, V120, P1151, DOI 10.1084/jem.120.6.1151; Fischer A, 2004, NAT IMMUNOL, V5, P23, DOI 10.1038/ni1023; Flajnik MF, 2004, NATURE, V430, P157, DOI 10.1038/430157a; Flajnik MF, 2002, NAT REV IMMUNOL, V2, P688, DOI 10.1038/nri889; Flajnik MF, 2001, IMMUNITY, V15, P351, DOI 10.1016/S1074-7613(01)00198-4; FOREY P, 1993, NATURE, V361, P129, DOI 10.1038/361129a0; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HILDEMANN WH, 1969, TRANSPLANTATION, V7, P506, DOI 10.1097/00007890-196906000-00007; HIORM K, 1997, CELL, V88, P65; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Janvier P, 1999, NATURE, V402, P21, DOI 10.1038/46909; Jung D, 2004, CELL, V116, P299, DOI 10.1016/S0092-8674(04)00039-X; KAPITONOV VV, 2005, PLOS BIOL, DOI DOI 10.1371; Kasahara M, 2004, TRENDS IMMUNOL, V25, P105, DOI 10.1016/j.it.2003.11.005; Klein J, 2005, P NATL ACAD SCI USA, V102, P169, DOI 10.1073/pnas.0408480102; Lee SS, 2000, J EXP MED, V191, P1637, DOI 10.1084/jem.191.10.1637; Lewis SM, 2000, J EXP MED, V191, P1631, DOI 10.1084/jem.191.10.1631; Litman GF, 1999, ANNU REV IMMUNOL, V17, P109, DOI 10.1146/annurev.immunol.17.1.109; LITMAN GW, 1970, J IMMUNOL, V105, P1278; Mayer WE, 2002, P NATL ACAD SCI USA, V99, P14350, DOI 10.1073/pnas.212527499; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nagata T, 2002, IMMUNOGENETICS, V54, P286, DOI 10.1007/s00251-002-0469-1; Najakshin AM, 1999, EUR J IMMUNOL, V29, P375, DOI 10.1002/(SICI)1521-4141(199902)29:02<375::AID-IMMU375>3.3.CO;2-Y; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Ohno S, 1999, SEMIN CELL DEV BIOL, V10, P517, DOI 10.1006/scdb.1999.0332; Pancer Z, 2005, P NATL ACAD SCI USA, V102, P9224, DOI 10.1073/pnas.0503792102; Pancer Z, 2004, NATURE, V430, P174, DOI 10.1038/nature02740; Pancer Z, 2004, P NATL ACAD SCI USA, V101, P13273, DOI 10.1073/pnas.0405529101; Pancer Z, 2006, ANNU REV IMMUNOL, V24, P497, DOI 10.1146/annurev.immunol.24.021605.090542; Paul W. E., 2003, FUNDAMENTAL IMMUNOLO, V5th; Pulendran B, 2006, CELL, V124, P849, DOI 10.1016/j.cell.2006.02.019; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; Rothenberg EV, 2004, SEMIN IMMUNOL, V16, P227, DOI 10.1016/j.smim.2004.08.002; SUN SC, 1990, SCIENCE, V250, P1729, DOI 10.1126/science.2270488; Suzuki T, 2005, J IMMUNOL, V174, P2885, DOI 10.4049/jimmunol.174.5.2885; Takezaki N, 2003, MOL BIOL EVOL, V20, P287, DOI 10.1093/molbev/msg040; THOMPSON CB, 1987, CELL, V48, P369, DOI 10.1016/0092-8674(87)90188-7; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Uinuk-ool T, 2002, P NATL ACAD SCI USA, V99, P14356, DOI 10.1073/pnas.212527699; Watson FL, 2005, SCIENCE, V309, P1874, DOI 10.1126/science.1116887; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0; Zhang JR, 1997, CELL, V89, P275, DOI 10.1016/S0092-8674(00)80206-8; Zhang SM, 2004, SCIENCE, V305, P251, DOI 10.1126/science.1088069; Zhou LQ, 2004, NATURE, V432, P995, DOI 10.1038/nature03157	60	458	480	3	114	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 24	2006	124	4					815	822		10.1016/j.cell.2006.02.001	http://dx.doi.org/10.1016/j.cell.2006.02.001			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	038RO	16497590	Bronze			2022-12-28	WOS:000237240900023
J	Walther, TC; Brickner, JH; Aguilar, PS; Bernales, S; Walter, P				Walther, TC; Brickner, JH; Aguilar, PS; Bernales, S; Walter, P			Eisosomes mark static sites of endocytosis	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; PLASMA-MEMBRANE; GLOBAL ANALYSIS; PROTEIN; ACTIN; LOCALIZATION; INTERNALIZATION; MAINTENANCE; METABOLISM	Endocytosis functions to recycle plasma membrane components, to regulate cell-surface expression of signalling receptors and to internalize nutrients in all eukaryotic cells. Internalization of proteins, lipids and other cargo can occur by one of several pathways that have different, but often overlapping, molecular requirements(1-5). To mediate endocytosis, effectors assemble transiently underneath the plasma membrane, carry out the mechanics of membrane deformation, cargo selection and vesicle internalization, and then disassemble. The mechanism by which endocytosis initiates at particular locations on the plasma membrane has remained unknown. Sites of endocytosis might be formed randomly, induced by stochastic protein and/or lipid clustering. Alternatively, endocytosis might initiate at specific locations. Here we describe large immobile protein assemblies at the plasma membrane in the yeast Saccharomyces cerevisiae that mark endocytic sites. These structures, termed eisosomes (from the Greek 'eis', meaning into or portal, and 'soma', meaning body), are composed primarily of two cytoplasmic proteins, Pil1 and Lsp1. A plasma membrane protein, Sur7, localizes to eisosomes. These structures colocalize with sites of protein and lipid endocytosis, and their components genetically interact with known endocytic effectors. Loss of Pil1 leads to clustering of eisosome remnants and redirects endocytosis and endocytic effector proteins to these clusters.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Walther, TC (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, 600 16th St, San Francisco, CA 94143 USA.	twalther@itsa.ucsf.edu	Aguilar, Pablo/AAV-7336-2020; Aguilar, Pablo/E-4576-2010	Aguilar, Pablo/0000-0002-9312-2474; Walther, Tobias/0000-0003-1442-1327; Brickner, Jason/0000-0001-8019-3743				Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Brickner JH, 2004, PLOS BIOL, V2, P1843, DOI 10.1371/journal.pbio.0020342; deHart AKA, 2002, J CELL BIOL, V156, P241, DOI 10.1083/jcb.200107135; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; ENGQVISTGOLDSTEIN, 2003, ANNU REV CELL DEV BI, V19, P287; Friant S, 2001, EMBO J, V20, P6783, DOI 10.1093/emboj/20.23.6783; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Gundelfinger ED, 2003, NAT REV MOL CELL BIO, V4, P127, DOI 10.1038/nrm1016; Heiman MG, 2000, J CELL BIOL, V151, P719, DOI 10.1083/jcb.151.3.719; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Huckaba TM, 2004, J CELL BIOL, V167, P519, DOI 10.1083/jcb.200404173; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Kaksonen M, 2003, CELL, V115, P475, DOI 10.1016/S0092-8674(03)00883-3; Kaksonen M, 2005, CELL, V123, P305, DOI 10.1016/j.cell.2005.09.024; Kruckeberg AL, 1999, BIOCHEM J, V339, P299, DOI 10.1042/0264-6021:3390299; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Malinska K, 2004, J CELL SCI, V117, P6031, DOI 10.1242/jcs.01493; Marie B, 2004, NEURON, V43, P207, DOI 10.1016/j.neuron.2004.07.001; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Perret E, 2005, CURR OPIN CELL BIOL, V17, P423, DOI 10.1016/j.ceb.2005.06.008; Roelants FM, 2002, MOL BIOL CELL, V13, P3005, DOI 10.1091/mbc.E02-04-0201; Roos J, 1999, CURR BIOL, V9, P1411, DOI 10.1016/S0960-9822(00)80087-1; Sivadon P, 1997, YEAST, V13, P747, DOI 10.1002/(SICI)1097-0061(19970630)13:8<747::AID-YEA137>3.0.CO;2-L; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Wendland B, 1996, J CELL BIOL, V135, P1485, DOI 10.1083/jcb.135.6.1485; Young ME, 2002, MOL CELL BIOL, V22, P927, DOI 10.1128/MCB.22.3.927-934.2002; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824; Zhang XP, 2004, J BIOL CHEM, V279, P22030, DOI 10.1074/jbc.M400299200; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11721, DOI 10.1073/pnas.95.20.11721	30	247	253	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 23	2006	439	7079					998	1003		10.1038/nature04472	http://dx.doi.org/10.1038/nature04472			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014NE	16496001				2022-12-28	WOS:000235486100052
J	Freed, GL; Uren, RL; Hudson, EJ; Lakhani, I; Wheeler, JRC; Stockman, JA				Freed, GL; Uren, RL; Hudson, EJ; Lakhani, I; Wheeler, JRC; Stockman, JA		Res Advisory Comm Amer Board Pedia	Policies and practices related to the role of board certification and recertification of pediatricians in hospital privileging	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OUTCOMES; QUALITY; PATIENT	Context Privileging involves the granting of permission to perform specific professional activities under the jurisdiction of a governing body's (hospital) authority. In 1951, the Joint Commission on the Accreditation of Hospitals (later renamed the Joint Commission on Accreditation of Healthcare Organizations) was formed to codify the process of hospital assessment. In the early part of the 20th century, a parallel process was being undertaken by the medical specialties to evaluate and recognize competence among physicians through the creation of specialty boards. Objectives To describe the use of board certification in hospital privileging policies for general pediatricians and pediatric subspecialists and to identify any variation among types of hospitals. Design, Setting, and Participants A telephone survey between January 1 and June 30, 2005, of privileging personnel among a random, weighted sample of 200 nonspecialty hospitals stratified by teaching status, children's vs general hospitals, free-standing children's hospital vs part of hospital system, and urban vs rural location. Main Outcome Measures Proportion of hospitals that require board certification at initial privileging or at some point to maintain privileges and recertification to maintain privileges. Results Of 200 hospitals, 7 hospitals were ineligible because they did not have at least 1 pediatrician on staff. One hundred fifty-nine hospitals completed the telephone interview, resulting in an overall response rate of 82%. A total of 124 (78%) of 159 hospitals did not require general pediatricians to be board certified at initial privileging; however, 111 (70%) did require pediatricians to become board certified at some point during their tenure. Of these 124 hospitals, 52 (42%) did not report a time frame in which certification must be achieved. Forty-nine (43%) of 113 hospitals required pediatric subspecialists to achieve subspecialty certification within a specific time frame. Conclusions These results raise issues regarding the manner in which board certification is used or not used by hospitals in their efforts to ensure the practice of high-quality care within their institutions. The premise for recertification is the need to assure the public of continued competence of physicians over the course of their professional careers. Increased attention by the public and regulatory agencies regarding patient safety and quality of care will likely have an impact on hospital privileging processes.	Univ Michigan, Div Gen Pediat, Chil Hlth Evaluat & Res Unit, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Hlth Policy & Management, Ann Arbor, MI 48109 USA; Amer Board Pediat Inc, Chapel Hill, NC USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Freed, GL (corresponding author), Univ Michigan, Div Gen Pediat, Chil Hlth Evaluat & Res Unit, 300 N Ingalls Bldg 6E08, Ann Arbor, MI 48109 USA.	gfreed@med.umich.edu	Stockman, James/ABG-6085-2021					Batmangelich Sorush, 2004, J Contin Educ Health Prof, V24, P134, DOI 10.1002/chp.1340240303; Bornstein BH, 2000, J EVAL CLIN PRACT, V6, P255, DOI 10.1046/j.1365-2753.2000.00256.x; Brennan TA, 2004, JAMA-J AM MED ASSOC, V292, P1038, DOI 10.1001/jama.292.9.1038; Corrigan J, 2000, ERR IS HUMAN BUILDIN; GLASSOCK RJ, 1991, ANN INTERN MED, V114, P59, DOI 10.7326/0003-4819-114-1-59; Hillemeier AC, 2004, J PEDIATR GASTR NUTR, V38, P376, DOI 10.1097/00005176-200404000-00003; Horowitz SD, 2004, MED EDUC, V38, P10, DOI 10.1046/j.1365-2923.2004.01702.x; Institute of Medicine, 2001, CROSSING QUALITY CHA; *JOINT COMM ACCR H, 1996, COMPR MAN HOSP OFF H; *JOINT COMM ACCR H, 1953, STAND HOSP ACCR; Lipner RS, 2002, ACAD MED, V77, pS64, DOI 10.1097/00001888-200210001-00021; *NAT COUNC QUAL AS, 2005, CVO CERT PROGR STAND; NORCINI JJ, 1994, ACAD MED S, V69, P90; Peterson J L, 1998, Tex Med, V94, P91; ROBERTS JS, 1987, JAMA-J AM MED ASSOC, V258, P936, DOI 10.1001/jama.258.7.936; Sharp LK, 2002, ACAD MED, V77, P534, DOI 10.1097/00001888-200206000-00011; Silber JH, 2002, ANESTHESIOLOGY, V96, P1044, DOI 10.1097/00000542-200205000-00004	17	26	26	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	2006	295	8					905	912		10.1001/jama.295.8.905	http://dx.doi.org/10.1001/jama.295.8.905			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014DO	16493103	Bronze			2022-12-28	WOS:000235459200023
J	Lindenauer, PK; Behal, R; Murray, CK; Nsa, W; Bratzler, DW				Lindenauer, PK; Behal, R; Murray, CK; Nsa, W; Bratzler, DW			Volume, quality of care, and outcome in pneumonia	ANNALS OF INTERNAL MEDICINE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; ACUTE MYOCARDIAL-INFARCTION; IN-HOSPITAL MORTALITY; MEDICARE BENEFICIARIES; ELDERLY-PATIENTS; CONTROLLED-TRIAL; SURVIVAL; IMPLEMENTATION; ASSOCIATION; GUIDELINES	Background: The establishment of minimum volume thresholds has been proposed as a means of improving outcomes for patients with various medical and surgical conditions. Objective: To determine whether volume is associated with either quality of care or outcome in the treatment of pneumonia. Design: Retrospective cohort study. Setting: 3243 hospitals participating in the National Pneumonia Quality Improvement Project in 1998 and 1999. Patients: 13 480 patients with pneumonia cared for by 9741 physicians. Measurements: The association between the annual pneumonia caseload of physicians and hospitals and adherence to quality-of-care measures and severity-adjusted in-hospital and 30-day mortality rates. Results: Physician volume was unrelated to the timeliness of administration of antibiotics and the obtainment of blood cultures; however, physicians in the highest-volume quartile had lower rates of screening for and administration of influenza (21%, 19%, 20%, and 12% for quartiles 1 through 4, respectively; P < 0.01) and pneumococcal (16%, 13%, 13%, and 9% for quartiles 1 through 4, respectively; p < 0.01) vaccines. Among hospitals, the percentage of patients who received antibiotics within 4 hours of hospital arrival was inversely related to pneumonia volume (72%, 64%, 60%, and 56% for quartiles 1 through 4, respectively; P < 0.01), while selection of antibiotic, obtainment of blood cultures, and rates of immunization were similar. Physician volume was not associated with in-hospital or 30-day mortality rates. Odds ratios for in-hospital mortality rates rose with increasing hospital volume (1.14 [95% Cl, 0.87 to 1.491, 1.34 [Cl, 1.03 to 1.75], and 1.32 [Cl, 0.97 to 1.80] for quartiles 2 to 4, respectively); however, odds ratios for 30-day mortality rates were similar. Limitations: This study was limited to Medicare beneficiaries 65 years of age and older. Ascertainment of some measures of the quality of care and severity of illness depended on the documentation practices of the physician. Conclusion: Among both physicians and hospitals, higher pneumonia volume is associated with reduced adherence to selected guideline recommendations and no measurable improvement in patient outcomes.	Baystate Med Ctr, Div Healthcare Qual, Springfield, MA 01199 USA; Tufts Univ, Sch Med, Medford, MA 02155 USA; Univ Hlth Syst Consortium, Oak Brook, IL USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Univ Cent Oklahoma, Edmond, OK USA; Oklahoma Fdn Med Qual, Oklahoma City, OK USA; Univ Washington, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA	Baystate Medical Center; Tufts University; Northwestern University; Feinberg School of Medicine; University of Central Oklahoma; University of Washington; University of Washington Seattle	Lindenauer, PK (corresponding author), Baystate Med Ctr, Div Healthcare Qual, 759 Chestnut St P-5931, Springfield, MA 01199 USA.	Peter.Lindenauer@bhs.org	Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213; Behal, Raj/0000-0001-5418-2581				Auerbach AD, 2002, ANN INTERN MED, V137, P859, DOI 10.7326/0003-4819-137-11-200212030-00006; Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954; BENNETT CL, 1989, JAMA-J AM MED ASSOC, V261, P2975, DOI 10.1001/jama.261.20.2975; Birkmeyer JD., 2000, LEAPFROG SAFETY STAN; Bratzler DW, 2002, ARCH INTERN MED, V162, P2349, DOI 10.1001/archinte.162.20.2349; Casale PN, 1998, J AM COLL CARDIOL, V32, P885, DOI 10.1016/S0735-1097(98)00325-8; Chu LA, 2003, ARCH INTERN MED, V163, P326, DOI 10.1001/archinte.163.3.326; Fine MJ, 2003, AM J MED, V115, P343, DOI 10.1016/S0002-9343(03)00395-4; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Halm EA, 2002, ANN INTERN MED, V137, P511, DOI 10.7326/0003-4819-137-6-200209170-00012; HCUPnet, HEALTHC COST UT PROJ; Jencks SF, 2003, JAMA-J AM MED ASSOC, V289, P305, DOI 10.1001/jama.289.3.305; Jencks SF, 2000, JAMA-J AM MED ASSOC, V284, P1670, DOI 10.1001/jama.284.13.1670; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; Mandell LA, 2003, CLIN INFECT DIS, V37, P1405, DOI 10.1086/380488; Marrie TJ, 2000, JAMA-J AM MED ASSOC, V283, P749, DOI 10.1001/jama.283.6.749; Meehan TP, 1997, JAMA-J AM MED ASSOC, V278, P2080, DOI 10.1001/jama.278.23.2080; Meehan TP, 2001, AM J MED, V111, P203, DOI 10.1016/S0002-9343(01)00803-8; *NAT PNEUM PROJ, MED QUAL IMPR COMM; Niederman MS, 2001, AM J RESP CRIT CARE, V163, P1730, DOI 10.1164/ajrccm.163.7.at1010; Panageas KS, 2003, ANN INTERN MED, V139, P658, DOI 10.7326/0003-4819-139-8-200310210-00009; Rifkin WD, 2002, MAYO CLIN PROC, V77, P1053, DOI 10.4065/77.10.1053; SAINSBURY R, 1995, LANCET, V345, P1265, DOI 10.1016/S0140-6736(95)90924-9; Thiemann DR, 1999, NEW ENGL J MED, V340, P1640, DOI 10.1056/NEJM199905273402106; Wachter RM, 2002, JAMA-J AM MED ASSOC, V287, P487, DOI 10.1001/jama.287.4.487	25	50	51	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 21	2006	144	4					262	269		10.7326/0003-4819-144-4-200602210-00008	http://dx.doi.org/10.7326/0003-4819-144-4-200602210-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	015HS	16490912				2022-12-28	WOS:000235543100005
J	Dowdeswell, JA				Dowdeswell, JA			Atmospheric science - The Greenland Ice Sheet and global sea-level rise	SCIENCE			English	Editorial Material							ACCELERATION; GLACIER; SHELF		Univ Cambridge, Scott Polar Res Inst, Cambridge CB2 1ER, England	University of Cambridge	Dowdeswell, JA (corresponding author), Univ Cambridge, Scott Polar Res Inst, Cambridge CB2 1ER, England.	jd16@cam.ac.uk		Dowdeswell, Julian/0000-0003-1369-9482				Alley RB, 2005, SCIENCE, V310, P456, DOI 10.1126/science.1114613; Church JA, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P639; Gregory JM, 2004, NATURE, V428, P616, DOI 10.1038/428616a; Hanna E, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005641; Johannessen OM, 2005, SCIENCE, V310, P1013, DOI 10.1126/science.1115356; Joughin I, 2004, NATURE, V432, P608, DOI 10.1038/nature03130; Krabill W, 2000, SCIENCE, V289, P428, DOI 10.1126/science.289.5478.428; Rignot E, 2006, SCIENCE, V311, P986, DOI 10.1126/science.1121381; Scambos TA, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020670; Shepherd A, 2003, SCIENCE, V302, P856, DOI 10.1126/science.1089768; STEFFEN K, 2005, GREENLAND MELT EXTEN; Zwally HJ, 2005, J GLACIOL, V51, P509, DOI 10.3189/172756505781829007; Zwally HJ, 2002, SCIENCE, V297, P218, DOI 10.1126/science.1072708	13	53	61	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 17	2006	311	5763					963	964		10.1126/science.1124190	http://dx.doi.org/10.1126/science.1124190			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014CS	16484484				2022-12-28	WOS:000235456900034
J	Kato, T; Inagaki, H; Yamada, K; Kogo, H; Ohye, T; Kowa, H; Nagaoka, K; Taniguchi, M; Emanuel, BS; Kurahashi, H				Kato, T; Inagaki, H; Yamada, K; Kogo, H; Ohye, T; Kowa, H; Nagaoka, K; Taniguchi, M; Emanuel, BS; Kurahashi, H			Genetic variation affects de novo translocation frequency	SCIENCE			English	Article							AT-RICH PALINDROMES; CONSTITUTIONAL T(11/22); BREAKPOINT		Univ Penn, Sch Med, Inst Comprehens Med Sci, Div Mol Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Kurahashi, H (corresponding author), Univ Penn, Sch Med, Inst Comprehens Med Sci, Div Mol Genet, Philadelphia, PA 19104 USA.	kura@fujita-hu.ac.jp	Kogo, Hiroshi/AAB-8467-2019	Kogo, Hiroshi/0000-0003-0584-7158	NCI NIH HHS [CA39926, R01 CA039926, R01 CA039926-18] Funding Source: Medline; NIDCD NIH HHS [P01 DC002027, P01 DC002027-070006] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P01DC002027] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Edelmann L, 2001, AM J HUM GENET, V68, P1, DOI 10.1086/316952; Gotter AL, 2004, HUM MOL GENET, V13, P103, DOI 10.1093/hmg/ddh004; Kurahashi H, 2000, HUM MOL GENET, V9, P1665, DOI 10.1093/hmg/9.11.1665; Kurahashi H, 2003, AM J HUM GENET, V72, P733, DOI 10.1086/368062; Kurahashi H, 2001, HUM MOL GENET, V10, P2605, DOI 10.1093/hmg/10.23.2605; Kurahashi H, 2001, NAT GENET, V29, P139, DOI 10.1038/ng1001-139; Nimmakayalu MA, 2003, HUM MOL GENET, V12, P2817, DOI 10.1093/hmg/ddg301; Tapia-Paez I, 2001, HUM GENET, V109, P167; ZACKAI EH, 1980, AM J MED GENET, V7, P507, DOI 10.1002/ajmg.1320070412	9	61	62	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 17	2006	311	5763					971	971		10.1126/science.1121452	http://dx.doi.org/10.1126/science.1121452			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014CS	16484486	Green Accepted			2022-12-28	WOS:000235456900036
J	Navarro, VJ; Senior, JR				Navarro, VJ; Senior, JR			Current concepts - Drug-related hepatotoxicity	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INDUCED LIVER-INJURY; CAUSALITY ASSESSMENT; INDUCED HEPATITIS; ADVERSE REACTIONS; MEDICAL PROGRESS; UNITED-STATES; DISEASE; TROGLITAZONE; FAILURE; RISK		Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Gastroenterol & Hepatol, Philadelphia, PA 19107 USA; US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA	Jefferson University; US Food & Drug Administration (FDA)	Navarro, VJ (corresponding author), 132 S 10th St,Suite 480 Main, Philadelphia, PA 19107 USA.	victor.navarro@jefferson.edu						Ahmad SR, 1993, LANCET, V341, P1465; Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; Andrade Raul J, 2004, Expert Opin Drug Saf, V3, P329, DOI 10.1517/14740338.3.4.329; Andrade RJ, 2005, GASTROENTEROLOGY, V129, P1808; Andrade RJ, 2005, GASTROENTEROLOGY, V129, P512, DOI 10.1053/j.gastro.2005.05.006; Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1038/nrdp.2015.80; Arnaiz JA, 2001, EUR J CLIN PHARMACOL, V57, P89, DOI 10.1007/s002280100265; Assy N, 2000, DIGEST DIS SCI, V45, P1929, DOI 10.1023/A:1005661516165; BEAUNE P, 1987, P NATL ACAD SCI USA, V84, P551, DOI 10.1073/pnas.84.2.551; BENICHOU C, 1993, J CLIN EPIDEMIOL, V46, P1331, DOI 10.1016/0895-4356(93)90102-7; BENICHOU C, 1990, J HEPATOL, V11, P272; Bjornsson E, 2005, HEPATOLOGY, V42, P481, DOI 10.1002/hep.20800; Bohan TP, 2001, NEUROLOGY, V56, P1405, DOI 10.1212/WNL.56.10.1405; Chalasani N, 2004, GASTROENTEROLOGY, V126, P1287, DOI 10.1053/j.gastro.2004.02.015; Clark JM, 2003, GASTROENTEROLOGY, V124, P248, DOI 10.1053/gast.2003.50032; DANAN G, 1993, J CLIN EPIDEMIOL, V46, P1323, DOI 10.1016/0895-4356(93)90101-6; DEGOTT C, 1992, HEPATOLOGY, V15, P244, DOI 10.1002/hep.1840150212; Desmet V. J., 1997, Journal of Hepatology, V26, P31, DOI 10.1016/S0168-8278(97)82330-6; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; FDA Working Group, 2000, CDER PHRMA AASLD C 2; Graham DJ, 2003, AM J MED, V114, P299, DOI 10.1016/S0002-9343(02)01529-2; HONIG PK, 1992, CLIN PHARMACOL THER, V52, P231, DOI 10.1038/clpt.1992.135; Hoofnagle Jay H, 2004, Hepatology, V40, P773, DOI 10.1002/hep.1840400403; Huang YS, 2002, HEPATOLOGY, V35, P883, DOI 10.1053/jhep.2002.32102; Kaplowitz N, 2004, CLIN INFECT DIS, V38, pS44, DOI 10.1086/381446; Kaplowitz N, 2002, SEMIN LIVER DIS, V22, P137, DOI 10.1055/s-2002-30100; Kaplowitz N, 2001, HEPATOLOGY, V33, P308, DOI 10.1053/jhep.2001.21083; KESSLER DA, 1993, JAMA-J AM MED ASSOC, V269, P2765, DOI 10.1001/jama.269.21.2765; Knowles SR, 2000, LANCET, V356, P1587, DOI 10.1016/S0140-6736(00)03137-8; Lankisch TO, 2005, MOL PHARMACOL, V67, P1732, DOI 10.1124/mol.104.007146; Larrey D, 2002, SEMIN LIVER DIS, V22, P145, DOI 10.1055/s-2002-30101; Larrey D, 1997, J HEPATOL, V26, P12, DOI 10.1016/S0168-8278(97)80492-8; Larson AM, 2005, HEPATOLOGY, V42, P1364, DOI 10.1002/hep.20948; Lee WM, 2005, TOXICOL PATHOL, V33, P155, DOI 10.1080/01926230590522356; Lee WM, 2003, NEW ENGL J MED, V349, P474, DOI 10.1056/NEJMra021844; LEE WM, 2005, FDA PHRMA AASLD HEP; Lucena MA, 2001, HEPATOLOGY, V33, P123, DOI 10.1053/jhep.2001.20645; Maria VAJ, 1997, HEPATOLOGY, V26, P664, DOI 10.1002/hep.510260319; Mehra Ranee, 2005, Clin Colorectal Cancer, V5, P61, DOI 10.3816/CCC.2005.n.018; Nolan CM, 1999, JAMA-J AM MED ASSOC, V281, P1014, DOI 10.1001/jama.281.11.1014; Pessayre D, 2001, SEMIN LIVER DIS, V21, P57, DOI 10.1055/s-2001-12929; Polson J, 2005, HEPATOLOGY, V41, P1179, DOI 10.1002/hep.20703; PRESCOTT LF, 1983, ANNU REV PHARMACOL, V23, P87, DOI 10.1146/annurev.pa.23.040183.000511; Ray WA, 2003, NEW ENGL J MED, V349, P1592, DOI 10.1056/NEJMp038145; Reed JC, 2001, TRENDS MOL MED, V7, P314, DOI 10.1016/S1471-4914(01)02026-3; Robin Marie-Anne, 1997, Journal of Hepatology, V26, P23, DOI 10.1016/S0168-8278(97)82329-X; ROSALSKI SB, 1999, OXFORD HDB CLIN HEPA, P504; Rosner B, 1995, FUNDAMENTALS BIOSTAT, P82; Russo MW, 2004, GASTROENTEROLOGY, V126, P1477, DOI 10.1053/j.gastro.2004.03.030; Sgro C, 2002, HEPATOLOGY, V36, P451, DOI 10.1053/jhep.2002.34857; Temple R, 2006, HEPATOTOXICITY YEARS; Tolman KG, 2002, AM J CARDIOL, V89, P1374, DOI 10.1016/S0002-9149(02)02355-X; Trauner M, 1998, NEW ENGL J MED, V339, P1217, DOI 10.1056/NEJM199810223391707; Vandenbroucke JP, 2001, ANN INTERN MED, V134, P330, DOI 10.7326/0003-4819-134-4-200102200-00017; Watkins PB, 2005, HEPATOLOGY, V41, P229, DOI 10.1002/hep.20598; Watkins PB, 1998, NEW ENGL J MED, V338, P916, DOI 10.1056/NEJM199803263381314; WATKINS PB, 1994, JAMA-J AM MED ASSOC, V271, P992, DOI 10.1001/jama.271.13.992; Weinshilboum R, 2003, NEW ENGL J MED, V348, P529, DOI 10.1056/NEJMra020021; WHITCOMB DC, 1994, JAMA-J AM MED ASSOC, V272, P1845, DOI 10.1001/jama.272.23.1845; YUN CH, 1993, DRUG METAB DISPOS, V21, P403; Zimmerman H. J., 1978, HEPATOTOXICITY ADVER; Zimmerman HJ., 1999, HEPATOTOXICITY ADVER, V2nd ed	62	647	722	1	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 16	2006	354	7					731	739		10.1056/NEJMra052270	http://dx.doi.org/10.1056/NEJMra052270			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	012CP	16481640				2022-12-28	WOS:000235316100009
J	Watts, G				Watts, G			I'll scratch your back ... if you have one	LANCET			English	Editorial Material											Watts, G (corresponding author), 28 New End Sq, London NW3 1LS, England.	geoff@scileg.freeserve.co.uk						Glover AG, 2005, P ROY SOC B-BIOL SCI, V272, P2587, DOI 10.1098/rspb.2005.3275; Jackson RR, 2005, P NATL ACAD SCI USA, V102, P15155, DOI 10.1073/pnas.0507398102; Okamoto N, 2005, SCIENCE, V310, P287, DOI 10.1126/science.1116125; Sasakura Y, 2005, P NATL ACAD SCI USA, V102, P15134, DOI 10.1073/pnas.0503640102	4	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 11	2006	367	9509					459	460		10.1016/S0140-6736(06)68159-2	http://dx.doi.org/10.1016/S0140-6736(06)68159-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013FF	16473112				2022-12-28	WOS:000235394500010
J	Yoshikuni, Y; Ferrin, TE; Keasling, JD				Yoshikuni, Y; Ferrin, TE; Keasling, JD			Designed divergent evolution of enzyme function	NATURE			English	Article							GAMMA-HUMULENE SYNTHASE; DELTA-SELINENE SYNTHASE; CONFORMATIONAL DIVERSITY; SESQUITERPENE SYNTHASES; CATALYTIC PROMISCUITY; BACTERIAL EXPRESSION; TRICHODIENE SYNTHASE; CRYSTAL-STRUCTURE; IN-VITRO; PROTEIN	It is generally believed that proteins with promiscuous functions divergently evolved to acquire higher specificity and activity(1-5), and that this process was highly dependent on the ability of proteins to alter their functions with a small number of amino acid substitutions (plasticity)(6). The application of this theory of divergent molecular evolution to promiscuous enzymes may allow us to design enzymes with more specificity and higher activity. Many structural and biochemical analyses have identified the active or binding site residues important for functional plasticity (plasticity residues)(6-10). To understand how these residues contribute to molecular evolution, and thereby formulate a design methodology, plasticity residues were probed in the active site of the promiscuous sesquiterpene synthase gamma-humulene synthase(11,12). Identified plasticity residues were systematically recombined based on a mathematical model in order to construct novel terpene synthases, each catalysing the synthesis of one or a few very different sesquiterpenes. Here we present the construction of seven specific and active synthases that use different reaction pathways to produce the specific and very different products. Creation of these enzymes demonstrates the feasibility of exploiting the underlying evolvability of this scaffold, and provides evidence that rational approaches based on these ideas are useful for enzyme design.	Univ Calif Berkeley, UCSF UCB Joint Grad Grp Bioengn, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem Engn, Berkeley, CA 94720 USA; Univ Calif Berkeley, Calif Inst Quantitat Biomed Res QB3, Berkeley, CA 94720 USA; Lawrence Berkeley Lab, Phys Biosci Div, Synthet Biol Dept, Berkeley, CA 94710 USA; Univ Calif San Francisco, Dept Pharmaceut Chem & Biopharmaceut Sci, San Francisco, CA 94143 USA	University of California System; University of California Berkeley; University of California San Francisco; University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California San Francisco	Keasling, JD (corresponding author), Univ Calif Berkeley, UCSF UCB Joint Grad Grp Bioengn, Berkeley, CA 94720 USA.	keasling@berkeley.edu	Keasling, Jay D/J-9162-2012; Yoshikuni, Yasuo/A-8804-2019; Ferrin, Thomas E./W-8842-2019; Yoshikuni, Yasuo/K-7741-2019	Keasling, Jay D/0000-0003-4170-6088; Ferrin, Thomas E./0000-0001-6227-0637; Yoshikuni, Yasuo/0000-0002-8372-640X				Adams R.P., 1995, IDENTIFICATION ESSEN; Aharoni A, 2005, NAT GENET, V37, P73, DOI 10.1038/ng1482; Aharoni A, 2004, P NATL ACAD SCI USA, V101, P482, DOI 10.1073/pnas.2536901100; Aubourg S, 2002, MOL GENET GENOMICS, V267, P730, DOI 10.1007/s00438-002-0709-y; Baker D, 2001, SCIENCE, V294, P93, DOI 10.1126/science.1065659; Bohlmann J, 1998, P NATL ACAD SCI USA, V95, P4126, DOI 10.1073/pnas.95.8.4126; BONE R, 1989, NATURE, V339, P191, DOI 10.1038/339191a0; Caruthers JM, 2000, J BIOL CHEM, V275, P25533, DOI 10.1074/jbc.M000433200; Copley SD, 2003, CURR OPIN CHEM BIOL, V7, P265, DOI 10.1016/S1367-5931(03)00032-2; Gerlt JA, 2005, ARCH BIOCHEM BIOPHYS, V433, P59, DOI 10.1016/j.abb.2004.07.034; James LC, 2003, SCIENCE, V299, P1362, DOI 10.1126/science.1079731; James LC, 2003, TRENDS BIOCHEM SCI, V28, P361, DOI 10.1016/S0968-0004(03)00135-X; JENSEN RA, 1976, ANNU REV MICROBIOL, V30, P409, DOI 10.1146/annurev.mi.30.100176.002205; Joo H, 1999, NATURE, V399, P670, DOI 10.1038/21395; Lesburg CA, 1997, SCIENCE, V277, P1820, DOI 10.1126/science.277.5333.1820; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; Little DB, 2002, ARCH BIOCHEM BIOPHYS, V402, P120, DOI 10.1016/S0003-9861(02)00068-1; Martin DM, 2004, PLANT PHYSIOL, V135, P1908, DOI 10.1104/pp.104.042028; Martin VJJ, 2003, NAT BIOTECHNOL, V21, P796, DOI 10.1038/nbt833; Matsumura I, 2001, J MOL BIOL, V305, P331, DOI 10.1006/jmbi.2000.4259; Mildvan AS, 2004, BIOCHEMISTRY-US, V43, P14517, DOI 10.1021/bi048052e; O'Brien PJ, 1999, CHEM BIOL, V6, pR91, DOI 10.1016/S1074-5521(99)80033-7; Rynkiewicz MJ, 2002, BIOCHEMISTRY-US, V41, P1732, DOI 10.1021/bi011960g; Rynkiewicz MJ, 2001, P NATL ACAD SCI USA, V98, P13543, DOI 10.1073/pnas.231313098; SALI A, 1995, MOL MED TODAY, V1, P270, DOI 10.1016/s1357-4310(95)91170-7; Starks CM, 1997, SCIENCE, V277, P1815, DOI 10.1126/science.277.5333.1815; Steele CL, 1998, J BIOL CHEM, V273, P2078, DOI 10.1074/jbc.273.4.2078; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; van den Heuvel RHH, 2000, P NATL ACAD SCI USA, V97, P9455, DOI 10.1073/pnas.160175897	30	315	336	5	111	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 20	2006	440	7087					1078	1082		10.1038/nature04607	http://dx.doi.org/10.1038/nature04607			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	034DL	16495946				2022-12-28	WOS:000236906000042
J	Franssen, MTM; Korevaar, JC; van der Veen, F; Leschot, NJ; Bossuyt, PNM; Goddijn, M				Franssen, MTM; Korevaar, JC; van der Veen, F; Leschot, NJ; Bossuyt, PNM; Goddijn, M			Reproductive outcome after chromosome analysis in couples with two or more miscarriages: case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							REARRANGEMENTS; ABNORMALITIES; DIAGNOSIS; CARRIERS; RISK	Objective To compare reproductive outcomes in couples carrying a structural chromosome abnormality and non-carrier couples referred for chromosome analysis after two or more miscarriages. Design Case-control study. Setting Six centres for clinical genetics in the Netherlands. Participants 278 carrier Couples and 427 non-carrier Couples referred for chromosome analysis between 1992 and 2000 after two Or more miscarriages before 20 weeks of gestation. Couples were followed up for at. least 24 months after chromosome analysis. Main outcome measures The birth of at least. one healthy child, at least one more miscarriage, and viable offspring With Unbalanced chromosomal abnormalities after parental chromosome analysis Results Mean follow-up after chromosome analysis was 5.8 years. 120 of 2,17 (49%) carrier couples had one miscarriage or more after chromosome analysis compared with 122 of 409 (30%) non-carrier couples (difference 19%, 95% confidence interval 11% to 26%; P< 0.01). The percentage Of Couples with at least one healthy child was not significantly different in carrier couples (83%) and non-carrier couples (84%) (difference - 1%, - 7% to 5%). Among 550 pregnancies in carrier couples, two viable Unbalanced chromosome abnormalities were detected at prenatal diagnosis (0.4%) and the fetuses aborted and two children with all Unbalanced karyotype were born (0.4%). Conclusions Couples whose carrier status was ascertained after two or more miscarriages have a low risk Of Viable offspring with unbalanced chromosomal abnormalities. Their chances of having a healthy child are as high as non-carrier couples, despite a higher risk of miscarriage.	Univ Amsterdam, Acad Med Ctr, Dept Obstet & Gynaecol, Ctr Reprod Med, NL-1100 DD Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, NL-1012 WX Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1012 WX Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Franssen, MTM (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Obstet & Gynaecol, Ctr Reprod Med, NL-1100 DD Amsterdam, Netherlands.	maureen.franssen@planet.nl	Bossuyt, Patrick M/AAR-1183-2021; Goddijn, Mariette/L-7849-2013; Bossuyt, Patrick M./B-4557-2016	Bossuyt, Patrick M/0000-0003-4427-0128; Bossuyt, Patrick M./0000-0003-4427-0128; Goddijn, Mariette/0000-0001-9928-9673				[Anonymous], 2002, INT J GYNECOL OBSTET, V78, P179; Barisic I, 1996, CLIN GENET, V49, P145; BONE A, 1984, PRENAT DIAGN, V4, P45; CANS C, 1993, HUM GENET, V92, P598, DOI 10.1007/BF00420946; Carp H, 2004, FERTIL STERIL, V81, P1296, DOI 10.1016/j.fertnstert.2003.09.059; Carp HJA, 2004, HUM REPROD, V19, P1502, DOI 10.1093/humrep/deh293; DANIEL A, 1989, AM J MED GENET, V33, P14, DOI 10.1002/ajmg.1320330105; *DUTCH SOC OBST GY, 1999, 20 NVOG DUTCH SOC OB; FITZSIMMONS J, 1983, AM J MED GENET, V16, P583, DOI 10.1002/ajmg.1320160415; FORTUNY A, 1988, FERTIL STERIL, V49, P774; Franssen MTM, 2005, BMJ-BRIT MED J, V331, P137, DOI 10.1136/bmj.38498.669595.8F; Goddijn M, 2004, HUM REPROD, V19, P1013, DOI 10.1093/humrep/deh172; Munne S, 2000, FERTIL STERIL, V73, P1209, DOI 10.1016/S0015-0282(00)00495-7; *NVOG, 1999, 20 NVOG DUTCH SOC OB; PORTNOI MF, 1988, OBSTET GYNECOL, V72, P31; *RCOG, 2003, 17 RCOG; SACHS ES, 1985, OBSTET GYNECOL, V65, P375; STEVE J, 1988, CYTOGENETICS MAMMALI, P3; Sugiura-Ogasawara M, 2004, FERTIL STERIL, V81, P367, DOI 10.1016/j.fertnstert.2003.07.014; THARAPEL AT, 1985, BRIT J OBSTET GYNAEC, V92, P899, DOI 10.1111/j.1471-0528.1985.tb03069.x; 1995, ISCN 1995 RECOMMENDA	21	90	93	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	2006	332	7544					759	+		10.1136/bmj.38735.459144.2F	http://dx.doi.org/10.1136/bmj.38735.459144.2F			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	032JA	16495333	Green Published, Bronze			2022-12-28	WOS:000236769500021
J	Liu, PT; Stenger, S; Li, HY; Wenzel, L; Tan, BH; Krutzik, SR; Ochoa, MT; Schauber, J; Wu, K; Meinken, C; Kamen, DL; Wagner, M; Bals, R; Steinmeyer, A; Zugel, U; Gallo, RL; Eisenberg, D; Hewison, M; Hollis, BW; Adams, JS; Bloom, BR; Modlin, RL				Liu, PT; Stenger, S; Li, HY; Wenzel, L; Tan, BH; Krutzik, SR; Ochoa, MT; Schauber, J; Wu, K; Meinken, C; Kamen, DL; Wagner, M; Bals, R; Steinmeyer, A; Zugel, U; Gallo, RL; Eisenberg, D; Hewison, M; Hollis, BW; Adams, JS; Bloom, BR; Modlin, RL			Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response	SCIENCE			English	Article							NITRIC-OXIDE SYNTHASE; MYCOBACTERIUM-TUBERCULOSIS; SUSCEPTIBILITY; EXPRESSION; INFECTION	In innate immune responses, activation of Toll-like receptors (TLRs) triggers direct antimicrobial activity against intracellular bacteria, which in murine, but not human, monocytes and macrophages is mediated principally by nitric oxide. We report here that TLR activation of human macrophages up-regulated expression of the vitamin D receptor and the vitamin D-1-hydroxylase genes, leading to induction of the antimicrobial peptide cathelicidin and killing of intracellular Mycobacterium tuberculosis. We also observed that sera from African-American individuals, known to have increased susceptibility to tuberculosis, had low 25-hydroxyvitamin D and were inefficient in supporting cathelicidin messenger RNA induction. These data support a link between TLRs and vitamin D-mediated innate immunity and suggest that differences in ability of human populations to produce vitamin D may contribute to susceptibility to microbial infection.	Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Dermatol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Dept Chem & Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Genom & Proteom, Dept Energy, Los Angeles, CA 90095 USA; Univ Calif San Diego, Div Dermatol, La Jolla, CA 92161 USA; Univ Erlangen Nurnberg, Inst Klin Mikrobiol Immunol & Hyg, D-91054 Erlangen, Germany; Vet Affairs San Diego Healthcare Ctr, La Jolla, CA 92161 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Klinikum Nurnberg, Med Klin 3, D-90340 Nurnberg, Germany; Univ Marburg, D-35043 Marburg, Germany; Schering AG, CRBA Dermatol, D-13342 Berlin, Germany; Cedars Sinai Med Ctr, Dept Med, Div Endocrinol, Los Angeles, CA 90048 USA; Med Univ S Carolina, Dept Pediat Biochem & Mol Biol, Charleston, SC 29425 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California San Diego; University of Erlangen Nuremberg; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; Medical University of South Carolina; Klinikum Nurnberg Nord; Philipps University Marburg; Schering AG; Cedars Sinai Medical Center; Medical University of South Carolina; Harvard University; Harvard T.H. Chan School of Public Health	Modlin, RL (corresponding author), Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA.	rmodlin@mednet.ucla.edu	Liu, Philip/C-9638-2011; Liu, Philip/C-2524-2009; Gallo, Richard L/A-8931-2009; Adams, John S/I-3365-2013; Modlin, Robert L/M-7941-2014	Gallo, Richard L/0000-0002-1401-7861; Adams, John S/0000-0001-9607-5020; Modlin, Robert L/0000-0003-4720-031X; Liu, Philip/0000-0002-6144-0304; Ochoa, Maria T/0000-0001-6550-5008	NCRR NIH HHS [RR00425] Funding Source: Medline; NIAID NIH HHS [AI48176, K22 AI085025, AI052453, AI22553, AI47868] Funding Source: Medline; NIAMS NIH HHS [AR45676, AR50626] Funding Source: Medline; NICHD NIH HHS [HD043921] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD043921] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI047868, R21AI048176, R01AI022553, R01AI052453, R22AI022553, K22AI085025, R01AI047868, R37AI052453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045676, R01AR050626] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARNES PF, 1989, J CLIN INVEST, V83, P1527, DOI 10.1172/JCI114048; Bornman L, 2004, J INFECT DIS, V190, P1631, DOI 10.1086/424462; CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111; Giovannucci E, 2005, CANCER CAUSE CONTROL, V16, P83, DOI 10.1007/s10552-004-1661-4; Hertz CJ, 2003, J IMMUNOL, V171, P6820, DOI 10.4049/jimmunol.171.12.6820; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MATSUOKA LY, 1991, ARCH DERMATOL, V127, P536, DOI 10.1001/archderm.127.4.536; Modlin RL, 2004, NAT MED, V10, P1173, DOI 10.1038/nm1104-1173; Rich AR., 1944, PATHOGENESIS TUBERCU; Rockett KA, 1998, INFECT IMMUN, V66, P5314, DOI 10.1128/IAI.66.11.5314-5321.1998; Roth J, 2003, TRENDS IMMUNOL, V24, P155, DOI 10.1016/S1471-4906(03)00062-0; Sly LM, 2001, J BIOL CHEM, V276, P35482, DOI 10.1074/jbc.M102876200; STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Tauszig S, 2000, P NATL ACAD SCI USA, V97, P10520, DOI 10.1073/pnas.180130797; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909	17	2692	2846	7	264	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 24	2006	311	5768					1770	1773		10.1126/science.1123933	http://dx.doi.org/10.1126/science.1123933			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	024OA	16497887				2022-12-28	WOS:000236204300044
J	Chretien, JP; Blazes, DL				Chretien, JP; Blazes, DL			Global network could avert pandemics	NATURE			English	Editorial Material									DoD GEIS, Silver Spring, MD 20910 USA; US Naval Med Res Ctr Detachment, Lima, Peru		Chretien, JP (corresponding author), DoD GEIS, Silver Spring, MD 20910 USA.			Malone, Joseph/0000-0002-5515-6171				Canas LC, 2000, MIL MED, V165, P52, DOI 10.1093/milmed/165.suppl_2.52; Institute of Medicine, 1992, EM INF MICR THREATS	2	7	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2006	440	7080					25	26		10.1038/440025a	http://dx.doi.org/10.1038/440025a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017HW	16511470	Bronze			2022-12-28	WOS:000235685700020
J	Okie, S				Okie, S			Facial transplantation: Brave new face	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		*AM SOC PLAST SURG, 2006, FAC TRANSPL ASPS ASR; Morris PJ, 2004, TRANSPLANTATION, V77, P330, DOI 10.1097/01.TP.0000113810.54865.BE; Siemionow M, 2005, CLIN PLAST SURG, V32, P401, DOI 10.1016/j.cps.2005.02.003	3	34	35	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 2	2006	354	9					889	894		10.1056/NEJMp068005	http://dx.doi.org/10.1056/NEJMp068005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	017FN	16510742				2022-12-28	WOS:000235679600001
J	Vlemmings, WHT; Diamond, PJ; Imai, H				Vlemmings, WHT; Diamond, PJ; Imai, H			A magnetically collimated jet from an evolved star	NATURE			English	Article							ASYMPTOTIC-GIANT-BRANCH; PLANETARY-NEBULAE; CIRCUMSTELLAR ENVELOPES; MASER EMISSION; WATER MASERS; H2O MASERS; FIELDS; OUTFLOWS; BIPOLAR; POLARIZATION	Planetary nebulae often have asymmetric shapes, even though their progenitor stars were symmetric; this structure could be the result of collimated jets from the evolved stars before they enter the planetary nebula phase(1-3). Theoretical models have shown that magnetic fields could be the dominant source of jet-collimation in evolved stars(4,5), just as these fields are thought to collimate outflows in other astrophysical sources, such as active galactic nuclei(6-9) and proto-stars(10,11). But hitherto there have been no direct observations of both the magnetic field direction and strength in any collimated jet. Here we report measurements of the polarization of water vapour masers that trace the precessing jet emanating from the asymptotic giant branch star W43A ( at a distance of 2.6 kpc from the Sun), which is undergoing rapid evolution into a planetary nebula(2,12). The masers occur in two clusters at opposing tips of the jets, similar to 1,000 AU from the star. We conclude from the data that the magnetic field is indeed collimating the jet.	Univ Manchester, Jodrell Bank Observ, Macclesfield SK11 9DL, Cheshire, England; Kagoshima Univ, Fac Sci, Dept Phys, Kagoshima 8900065, Japan	University of Manchester; Jodrell Bank Centre for Astrophysics; Kagoshima University	Vlemmings, WHT (corresponding author), Univ Manchester, Jodrell Bank Observ, Macclesfield SK11 9DL, Cheshire, England.	wouter@jb.man.ac.uk		/0000-0002-2700-9916				Asada K, 2002, PUBL ASTRON SOC JPN, V54, pL39, DOI 10.1093/pasj/54.3.L39; Blackman EG, 2004, ASTR SOC P, V313, P401; Blackman EG, 2001, NATURE, V409, P485, DOI 10.1038/35054008; BLANDFORD RD, 1982, MON NOT R ASTRON SOC, V199, P883, DOI 10.1093/mnras/199.4.883; CHEVALIER RA, 1994, ASTROPHYS J, V421, P225, DOI 10.1086/173640; Crutcher RM, 1999, ASTROPHYS J, V520, P706, DOI 10.1086/307483; DIAMOND PJ, 1985, MON NOT R ASTRON SOC, V212, P1; ELITZUR M, 1992, ASTROPHYS J, V394, P221, DOI 10.1086/171574; Elitzur M., 1992, ASTRONOMICAL MASERS; Gabuzda DC, 2004, MON NOT R ASTRON SOC, V351, pL89, DOI 10.1111/j.1365-2966.2004.08037.x; Garcia-Segura G, 2005, ASTROPHYS J, V618, P919, DOI 10.1086/426110; Garcia-Segura G, 1999, ASTROPHYS J, V517, P767, DOI 10.1086/307205; GOLDREICH P, 1973, ASTROPHYS J, V179, P111, DOI 10.1086/151852; Imai H, 2002, NATURE, V417, P829, DOI 10.1038/nature00788; Imai H, 2005, ASTROPHYS J, V622, pL125, DOI 10.1086/429820; KEMBALL AJ, 1997, APJ, V481, P111; Lebedev SV, 2005, MON NOT R ASTRON SOC, V361, P97, DOI 10.1111/j.1365-2966.2005.09132.x; Lery T, 1999, ASTRON ASTROPHYS, V350, P254; Miranda LF, 2001, NATURE, V414, P284, DOI 10.1038/35104518; NEDOLUHA GE, 1992, ASTROPHYS J, V384, P185, DOI 10.1086/170862; Ouyed R, 1997, NATURE, V385, P409, DOI 10.1038/385409a0; PEARSON TJ, 1988, ASTROPHYS J, V328, P114, DOI 10.1086/166274; REID MJ, 1979, ASTROPHYS J, V227, pL89, DOI 10.1086/182873; Sahai R, 1998, ASTRON J, V116, P1357, DOI 10.1086/300504; Sahai R, 2002, REV MEX AST ASTR, V13, P133; Vlemmings WHT, 2005, ASTRON ASTROPHYS, V434, P1029, DOI 10.1051/0004-6361:20042488; Vlemmings WHT, 2002, ASTRON ASTROPHYS, V394, P589, DOI 10.1051/0004-6361:20021166; VLEMMINGS WHT, 2005, IN PRESS ASTRON ASTR; Xu C, 1999, ASTRON J, V118, P1169, DOI 10.1086/301007; Zinnecker H, 1998, NATURE, V394, P862, DOI 10.1038/29716	30	105	105	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	2006	440	7080					58	60		10.1038/nature04466	http://dx.doi.org/10.1038/nature04466			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017HW	16511488				2022-12-28	WOS:000235685700037
J	Cappola, AR; Fried, LP; Arnold, AM; Danese, MD; Kuller, LH; Burke, GL; Tracy, RP; Ladenson, PW				Cappola, AR; Fried, LP; Arnold, AM; Danese, MD; Kuller, LH; Burke, GL; Tracy, RP; Ladenson, PW			Thyroid status, cardiovascular risk, and mortality in older adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ISCHEMIC-HEART-DISEASE; 20-YEAR FOLLOW-UP; SUBCLINICAL HYPOTHYROIDISM; ATRIAL-FIBRILLATION; ALL-CAUSE; DYSFUNCTION; HYPERTHYROIDISM; ASSOCIATION; CHOLESTEROL; POPULATION	Context Previous studies have suggested that subclinical abnormalities in thyroid-stimulating hormone levels are associated with detrimental effects on the cardiovascular system. Objective To determine the relationship between baseline thyroid status and incident atrial fibrillation, incident cardiovascular disease, and mortality in older men and women not taking thyroid medication. Design, Setting, and Participants A total of 3233 US community-dwelling individuals aged 65 years or older with baseline serum thyroid-stimulating hormone levels were enrolled in 1989-1990 in the Cardiovascular Health Study, a large, prospective cohort study. Main Outcome Measures Incident atrial fibrillation, coronary heart disease, cerebrovascular disease, cardiovascular death, and all-cause death assessed through June 2002. Analyses are reported for 4 groups defined according to thyroid function test results: subclinical hyperthyroidism, euthyroidism, subclinical hypothyroidism, and overt hypothyroidism. Results Individuals with overt thyrotoxicosis ( n = 4) were excluded because of small numbers. Eighty-two percent of participants ( n = 2639) had normal thyroid function, 15% ( n = 496) had subclinical hypothyroidism, 1.6% ( n = 51) had overt hypothyroidism, and 1.5% ( n = 47) had subclinical hyperthyroidism. After exclusion of those with prevalent atrial fibrillation, individuals with subclinical hyperthyroidism had a greater incidence of atrial fibrillation compared with those with normal thyroid function ( 67 events vs 31 events per 1000 person-years; adjusted hazard ratio, 1.98; 95% confidence interval, 1.29-3.03). No differences were seen between the subclinical hyperthyroidism group and euthyroidism group for incident coronary heart disease, cerebrovascular disease, cardiovascular death, or all-cause death. Likewise, there were no differences between the subclinical hypothyroidism or overt hypothyroidism groups and the euthyroidism group for cardiovascular outcomes or mortality. Specifically, individuals with subclinical hypothyroidism had an adjusted hazard ratio of 1.07 ( 95% confidence interval, 0.90-1.28) for incident coronary heart disease. Conclusion Our data show an association between subclinical hyperthyroidism and development of atrial fibrillation but do not support the hypothesis that unrecognized subclinical hyperthyroidism or subclinical hypothyroidism is associated with other cardiovascular disorders or mortality.	Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Dept Med,Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Div Epidemiol,Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Johns Hopkins Med Inst, Div Geriatr Med & Gerontol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Ctr Aging & Hlth, Baltimore, MD 21205 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Outcomes Insights Inc, Newbury Pk, CA USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA; Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Winston Salem, NC USA; Univ Vermont, Dept Pathol, Burlington, VT 05405 USA; Univ Vermont, Dept Biochem, Burlington, VT 05405 USA; Johns Hopkins Univ, Sch Med, Div Endocrinol & Metab, Dept Med, Baltimore, MD USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Wake Forest University; University of Vermont; University of Vermont; Johns Hopkins University	Cappola, AR (corresponding author), Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Dept Med,Ctr Clin Epidemiol & Biostat, 718 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	acappola@cceb.med.upenn.edu			DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085085, N01HC085081, N01HC035129, N01HC085086, N01HC085080, N01HC085082, N01HC085084, N01HC015103, N01HC085083, N01HC085079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K23AG019161] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-85081, N01-HC-85086, N01-HC-85082, N01HC85086, N01HC85079, N01-HC-85083, N01-HC-85084, N01-HC-85080, N01-HC-85085, N01 HC035129, N01-HC-85079, N01 HC015103] Funding Source: Medline; NIA NIH HHS [K23-AG19161, K23 AG019161] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Auer J, 2001, AM HEART J, V142, P838, DOI 10.1067/mhj.2001.119370; BAGCHI N, 1990, ARCH INTERN MED, V150, P785, DOI 10.1001/archinte.150.4.785; BELL GM, 1983, CLIN ENDOCRINOL, V18, P511, DOI 10.1111/j.1365-2265.1983.tb02881.x; Berg AO, 2004, ANN INTERN MED, V140, P125, DOI 10.7326/0003-4819-140-2-200401200-00014; Biondi B, 1999, J CLIN ENDOCR METAB, V84, P2064, DOI 10.1210/jc.84.6.2064; Biondi B, 2000, J CLIN ENDOCR METAB, V85, P4701, DOI 10.1210/jc.85.12.4701; Canaris GJ, 2000, ARCH INTERN MED, V160, P526, DOI 10.1001/archinte.160.4.526; Cappola AR, 2003, J CLIN ENDOCR METAB, V88, P2438, DOI 10.1210/jc.2003-030398; Chu JW, 2001, J CLIN ENDOCR METAB, V86, P4591, DOI 10.1210/jc.86.10.4591; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Danese ND, 2000, J CLIN ENDOCR METAB, V85, P2993, DOI 10.1210/jcem.85.9.6841; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Gussekloo J, 2004, JAMA-J AM MED ASSOC, V292, P2591, DOI 10.1001/jama.292.21.2591; Hak AE, 2000, ANN INTERN MED, V132, P270, DOI 10.7326/0003-4819-132-4-200002150-00004; Helfand M, 1998, ANN INTERN MED, V129, P141, DOI 10.7326/0003-4819-129-2-199807150-00020; Helfand M, 2004, ANN INTERN MED, V140, P128, DOI 10.7326/0003-4819-140-2-200401200-00015; Hollowell JG, 2002, J CLIN ENDOCR METAB, V87, P489, DOI 10.1210/jc.87.2.489; Hoyert Donna L, 2005, Natl Vital Stat Rep, V53, P1; Imaizumi M, 2004, J CLIN ENDOCR METAB, V89, P3365, DOI 10.1210/jc.2003-031089; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; Kanaya AM, 2002, ARCH INTERN MED, V162, P773, DOI 10.1001/archinte.162.7.773; KULLER LH, 1995, CIRCULATION, V92, P720, DOI 10.1161/01.CIR.92.4.720; Kvetny J, 2004, CLIN ENDOCRINOL, V61, P232, DOI 10.1111/j.1365-2265.2004.02088.x; Ladenson PW, 2000, ARCH INTERN MED, V160, P1573, DOI 10.1001/archinte.160.11.1573; Lindeman RD, 1999, J AM GERIATR SOC, V47, P703, DOI 10.1111/j.1532-5415.1999.tb01593.x; Magnus P, 2001, ARCH INTERN MED, V161, P2657, DOI 10.1001/archinte.161.22.2657; Pahor M, 1999, ARCH INTERN MED, V159, P237, DOI 10.1001/archinte.159.3.237; Parle JV, 2001, LANCET, V358, P861, DOI 10.1016/S0140-6736(01)06067-6; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; Psaty BM, 1997, CIRCULATION, V96, P2455; Rodondi N, 2005, ARCH INTERN MED, V165, P2460, DOI 10.1001/archinte.165.21.2460; ROSENTHAL MJ, 1987, JAMA-J AM MED ASSOC, V258, P209, DOI 10.1001/jama.258.2.209; SAWIN CT, 1979, JAMA-J AM MED ASSOC, V242, P247, DOI 10.1001/jama.242.3.247; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; Surks MI, 2004, JAMA-J AM MED ASSOC, V291, P228, DOI 10.1001/jama.291.2.228; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x; Vanderpump MPJ, 1996, THYROID, V6, P155; Walsh JP, 2005, ARCH INTERN MED, V165, P2467, DOI 10.1001/archinte.165.21.2467	40	576	612	1	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	2006	295	9					1033	1041		10.1001/jama.295.9.1033	http://dx.doi.org/10.1001/jama.295.9.1033			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	016XJ	16507804	Green Accepted, Bronze			2022-12-28	WOS:000235656600023
J	Wharton, IP; Chaudhry, AH; French, ME				Wharton, IP; Chaudhry, AH; French, ME			A case of mumps epididymitis	LANCET			English	Editorial Material									City Gen Hosp, Univ Hosp N Staffordshire NHS Trust, Dept Urol, Stoke On Trent ST4 6QG, Staffs, England	University Hospital of North Staffordshire NHS Trust	Wharton, IP (corresponding author), City Gen Hosp, Univ Hosp N Staffordshire NHS Trust, Dept Urol, Stoke On Trent ST4 6QG, Staffs, England.	iain.wharton@keld.me.uk						Baum GB, 2000, PRINCIPLES PRACTICE, P1776; CORAN AG, 1965, NEW ENGL J MED, V272, P735, DOI 10.1056/NEJM196504082721409; HARTMAN HE, 1958, J UROLOGY, V79, P999, DOI 10.1016/S0022-5347(17)66381-X; Jequier AM, 2000, MALE INFERTILITY GUI, P254	4	14	15	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 25	2006	367	9511					702	702		10.1016/S0140-6736(06)68274-3	http://dx.doi.org/10.1016/S0140-6736(06)68274-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	016HR	16503474				2022-12-28	WOS:000235611800040
J	Falkow, S				Falkow, S			Is persistent bacterial infection good for your health?	CELL			English	Editorial Material							LYMPHOID-TISSUE LYMPHOMA; HELICOBACTER; DISEASE; PATHOGEN	Certain bacterial pathogens have evolved to survive in their human hosts for long periods without causing harm. Is it possible that these persistent bacterial infections provide a protective benefit to the host?.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Div Infect Dis & Geog Med, Dept Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Falkow, S (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA.	falkow@stanford.edu						Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Blaser MJ, 2004, J CLIN INVEST, V113, P321, DOI [10.1172/JCI200420925, 10.1172/JCI20925]; BLASER MJ, 2006, ENDING WAR METAPHOR; Falkow S, 1997, ASM NEWS, V63, P359; Monack DM, 2004, NAT REV MICROBIOL, V2, P747, DOI 10.1038/nrmicro955; Monack DM, 2004, J EXP MED, V199, P231, DOI 10.1084/jem.20031319; Mueller A, 2005, AM J PATHOL, V167, P797, DOI 10.1016/S0002-9440(10)62052-4; Mueller A, 2003, P NATL ACAD SCI USA, V100, P12289, DOI 10.1073/pnas.1635231100; Mueller A, 2003, P NATL ACAD SCI USA, V100, P1292, DOI 10.1073/pnas.242741699; Rosebury T, 1969, LIFE MAN; Segal S, 2005, BRIT MED BULL, V72, P65, DOI 10.1093/bmb/ldh041	11	44	50	0	9	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 24	2006	124	4					699	702		10.1016/j.cell.2006.02.004	http://dx.doi.org/10.1016/j.cell.2006.02.004			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	038RO	16497581	Bronze			2022-12-28	WOS:000237240900014
J	Kimmel, PL				Kimmel, PL			Update in nephrology and hypertension	ANNALS OF INTERNAL MEDICINE			English	Article							NUTRITION EXAMINATION SURVEY; CHRONIC KIDNEY-DISEASE; 3RD NATIONAL-HEALTH; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; HEART-FAILURE; RISK-FACTOR; MYOCARDIAL-INFARCTION; DIABETIC-NEPHROPATHY; US POPULATION		George Washington Univ, Med Ctr, Dept Med, Div Renal Dis & Hypertens, Washington, DC 20037 USA	George Washington University	Kimmel, PL (corresponding author), George Washington Univ, Med Ctr, Dept Med, Div Renal Dis & Hypertens, 2150 Penn Ave NW, Washington, DC 20037 USA.	pkimmel@mfa.gwu.edu						Anavekar NS, 2004, NEW ENGL J MED, V351, P1285, DOI 10.1056/NEJMoa041365; Bagshaw SM, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-38; Barnett AH, 2004, NEW ENGL J MED, V351, P1952, DOI 10.1056/NEJMoa042274; Best PJM, 2004, AM HEART J, V148, P230, DOI 10.1016/j.ahj.2004.04.011; Bozkurt B, 2003, J AM COLL CARDIOL, V41, P211, DOI 10.1016/S0735-1097(02)02694-3; Briguori C, 2003, PROG CARDIOVASC DIS, V45, P493, DOI 10.1053/pcad.2003.YPCAD16; Chaturvedi N, 2001, ANN INTERN MED, V134, P370, DOI 10.7326/0003-4819-134-5-200103060-00009; Cook DJ, 1999, ANN INTERN MED, V131, P707, DOI 10.7326/0003-4819-131-9-199911020-00013; Coresh J, 2003, AM J KIDNEY DIS, V41, P1, DOI 10.1053/ajkd.2003.50007; Ford ES, 2004, DIABETES CARE, V27, P2444, DOI 10.2337/diacare.27.10.2444; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Gerstein HC, 2001, JAMA-J AM MED ASSOC, V286, P421, DOI 10.1001/jama.286.4.421; Ghali WA, 2000, LANCET, V355, P579, DOI 10.1016/S0140-6736(05)73234-7; Golan L, 1999, ANN INTERN MED, V131, P660, DOI 10.7326/0003-4819-131-9-199911020-00005; Hostetter TH, 2004, NEW ENGL J MED, V351, P1344, DOI 10.1056/NEJMe048211; Jarman PR, 2003, BRIT MED J, V327, P812, DOI 10.1136/bmj.327.7418.812; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Mitch WE, 2004, NEW ENGL J MED, V351, P1934, DOI 10.1056/NEJMp048254; *NAT KIDN DIS ED P, HLTH PROF MDRD CALC; Park YW, 2003, ARCH INTERN MED, V163, P427, DOI 10.1001/archinte.163.4.427; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Weiner DE, 2004, AM J KIDNEY DIS, V44, P198, DOI 10.1053/j.ajkd.2004.04.024	23	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 21	2006	144	4					281	285		10.7326/0003-4819-144-4-200602210-00010	http://dx.doi.org/10.7326/0003-4819-144-4-200602210-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	015HS	16490914				2022-12-28	WOS:000235543100007
J	Gogas, H; Ioannovich, J; Dafni, U; Stavropoulou-Giokas, C; Frangia, K; Tsoutsos, D; Panagiotou, P; Polyzos, A; Papadopoulos, O; Stratigos, A; Markopoulos, C; Bafaloukos, D; Pectasides, D; Fountzilas, G; Kirkwood, JM				Gogas, H; Ioannovich, J; Dafni, U; Stavropoulou-Giokas, C; Frangia, K; Tsoutsos, D; Panagiotou, P; Polyzos, A; Papadopoulos, O; Stratigos, A; Markopoulos, C; Bafaloukos, D; Pectasides, D; Fountzilas, G; Kirkwood, JM			Prognostic significance of autoimmunity during treatment of melanoma with interferon	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COOPERATIVE-ONCOLOGY-GROUP; HIGH-DOSE INTERFERON; METASTATIC MELANOMA; THYROID-DYSFUNCTION; CUTANEOUS MELANOMA; ALPHA; INTERLEUKIN-2; THERAPY; TRIAL; HYPOTHYROIDISM	BACKGROUND: Immunotherapy for advanced melanoma induces serologic and clinical manifestations of autoimmunity. We assessed the prognostic significance of autoimmunity in patients with stage IIB, IIC, or III melanoma who were treated with high-dose adjuvant interferon alfa-2b. METHODS: We enrolled 200 patients in a substudy of a larger, ongoing randomized trial. Blood was obtained before the initiation of intravenous interferon therapy, after 1 month of therapy, and at 3, 6, 9, and 12 months. Serum was tested for antithyroid, antinuclear, anti-DNA, and anticardiolipin autoantibodies, and patients were examined for vitiligo. RESULTS: The median duration of follow-up was 45.6 months. Relapse occurred in 115 patients, and 82 patients died. The median relapse-free survival was 28.0 months, and the median overall survival was 58.7 months. Autoantibodies and clinical manifestations of autoimmunity were detected in 52 patients (26 percent). The median relapse-free survival was 16.0 months among patients without autoimmunity (108 of 148 had a relapse) and was not reached among patients with autoimmunity (7 of 52 had a relapse). The median survival was 37.6 months among patients without autoimmunity (80 of 148 died) and was not reached among patients with autoimmunity (2 of 52 died). In univariate and multivariate regression analyses, autoimmunity was an independent prognostic marker for improved relapse-free survival and overall survival (P<0.001). CONCLUSIONS: The appearance of autoantibodies or clinical manifestations of autoimmunity during treatment with interferon alfa-2b is associated with statistically significant improvements in relapse-free survival and overall survival in patients with melanoma.	Univ Athens, Laikon Hosp, Dept Med 1, Athens 11510, Greece; Andreas Sygros Hosp, Dept Dermatol, Athens, Greece; Natl & Kapodistrian Univ Athens, Athens, Greece; Gen Hosp Athens, Dept Plast Surg & Microsurg, Athens, Greece; Gen Hosp Athens, Dept Immunol, Athens, Greece; Gen Hosp Athens, Natl Tissue Typing Ctr, Athens, Greece; Univ Athens, Sch Nursing, Lab Biostat, Athens, Greece; Sotiria Gen Hosp, Dept Pathol, World Hlth Org Melanoma Program, Athens, Greece; Univ Pittsburgh, Pittsburgh Canc Inst, Pittsburgh, PA USA	Laiko General Hospital; National & Kapodistrian University of Athens; National & Kapodistrian University of Athens; General Hospital of N. Ionia Agia Olga; General Hospital of N. Ionia Agia Olga; General Hospital of N. Ionia Agia Olga; National & Kapodistrian University of Athens; World Health Organization; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Gogas, H (corresponding author), Univ Athens, Laikon Hosp, Dept Med 1, POB 14120, Athens 11510, Greece.	hgogas@hol.gr	Fountzilas, George/ABF-2139-2020; Dafni, Ourania/AAH-4453-2019; Markopoulos, Christos/AAD-8501-2019	Dafni, Ourania/0000-0003-4367-4497; Markopoulos, Christos/0000-0002-5072-6390				ATKINS MB, 1988, NEW ENGL J MED, V318, P1557, DOI 10.1056/NEJM198806163182401; Balch CM, 2001, J CLIN ONCOL, V19, P3622, DOI 10.1200/JCO.2001.19.16.3622; BECKER JC, 1994, CANCER, V73, P1621, DOI 10.1002/1097-0142(19940315)73:6<1621::AID-CNCR2820730613>3.0.CO;2-E; BYSTRYN JC, 1987, ARCH DERMATOL, V123, P1053, DOI 10.1001/archderm.123.8.1053; COX DR, 1972, J R STAT SOC B, V34, P187; Deutsch M, 1997, HEPATOLOGY, V26, P206, DOI 10.1002/hep.510260127; Dranoff G, 2005, J CLIN ONCOL, V23, P662, DOI 10.1200/JCO.2005.09.923; Franzke, 1999, J CLIN ONCOL, V17, P1330; Franzke A, 1999, J CLIN ONCOL, V17, P529, DOI 10.1200/JCO.1999.17.2.529; GOGAS H, 2000, P ASCO, V19, pA575; Kalkner KM, 1998, QJM-MON J ASSOC PHYS, V91, P393, DOI 10.1093/qjmed/91.6.393; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kirkwood JM, 2000, J CLIN ONCOL, V18, P2444, DOI 10.1200/JCO.2000.18.12.2444; Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7; Kirkwood JM, 2001, J CLIN ONCOL, V19, P2370, DOI 10.1200/JCO.2001.19.9.2370; Kirkwood JM, 2004, CLIN CANCER RES, V10, P1670, DOI 10.1158/1078-0432.CCR-1103-3; Kirkwood JM, 2002, J CLIN ONCOL, V20, P3703, DOI 10.1200/JCO.2002.03.052; Koh LKH, 1997, THYROID, V7, P891, DOI 10.1089/thy.1997.7.891; Krouse RS, 1995, J IMMUNOTHER, V18, P272, DOI 10.1097/00002371-199511000-00008; NORDLUND JJ, 1983, J AM ACAD DERMATOL, V9, P689, DOI 10.1016/S0190-9622(83)70182-9; Okanoue T, 1996, J HEPATOL, V25, P283, DOI 10.1016/S0168-8278(96)80113-9; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Phan GQ, 2001, J CLIN ONCOL, V19, P3477, DOI 10.1200/JCO.2001.19.15.3477; Ribas A, 2005, J CLIN ONCOL, V23, p716S; Rosenberg SA, 1996, J IMMUNOTHER, V19, P81, DOI 10.1097/00002371-199601000-00009; Sanderson K, 2005, J CLIN ONCOL, V23, P741, DOI 10.1200/JCO.2005.01.128; SCALZO S, 1990, EUR J CANCER, V26, P1152, DOI 10.1016/0277-5379(90)90275-X; SCHALLREUTER KU, 1991, DERMATOLOGICA, V183, P239, DOI 10.1159/000247693; VALLISA D, 1995, ACTA HAEMATOL-BASEL, V93, P31; WEIJL NI, 1993, J CLIN ONCOL, V11, P1376, DOI 10.1200/JCO.1993.11.7.1376; Wesche B, 2001, GUT, V48, P378, DOI 10.1136/gut.48.3.378; Zuffa E, 1996, HAEMATOLOGICA, V81, P533	32	517	537	1	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 16	2006	354	7					709	718		10.1056/NEJMoa053007	http://dx.doi.org/10.1056/NEJMoa053007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	012CP	16481638				2022-12-28	WOS:000235316100007
J	Vencovsky, J; Huizinga, TW				Vencovsky, J; Huizinga, TW			Rheumatoid arthritis: the goal rather than the health-care provider is key	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; TREATMENT STRATEGY; ONSET; PROGRESSION; DAMAGE		Inst Rheumatol, Prague 12850 2, Czech Republic; Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands	Institute of Rheumatology; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Vencovsky, J (corresponding author), Inst Rheumatol, Prague 12850 2, Czech Republic.	venc@revma.cz	Vencovsky, Jiri/G-6094-2017	Vencovsky, Jiri/0000-0002-0851-0713				Clarke AE, 2001, J RHEUMATOL, V28, P2416; Goekoop-Ruiterman YPM, 2005, ARTHRITIS RHEUM-US, V52, P3381, DOI [10.1002/art.21405, 10.1002/art.23364]; Grigor C, 2004, LANCET, V364, P263, DOI 10.1016/S0140-6736(04)16676-2; Hulsmans HMJ, 2000, ARTHRITIS RHEUM, V43, P1927, DOI 10.1002/1529-0131(200009)43:9<1927::AID-ANR3>3.0.CO;2-B; Klareskog L, 2004, LANCET, V363, P675, DOI 10.1016/S0140-6736(04)15640-7; McQueen FM, 1998, ANN RHEUM DIS, V57, P350, DOI 10.1136/ard.57.6.350; Smolen JS, 2005, BEST PRACT RES CL RH, V19, P163, DOI 10.1016/j.berh.2004.08.009; Symmons D, 2005, HEALTH TECHNOL ASSES, V9, pIII; van Aken J, 2004, ANN RHEUM DIS, V63, P274, DOI 10.1136/ard.2003.010298; Welsing PMJ, 2004, ARTHRITIS RHEUM-US, V50, P2082, DOI 10.1002/art.20350; Wolfe F, 1998, ARTHRITIS RHEUM, V41, P1571, DOI 10.1002/1529-0131(199809)41:9<1571::AID-ART7>3.0.CO;2-R	11	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 11	2006	367	9509					450	452		10.1016/S0140-6736(06)68154-3	http://dx.doi.org/10.1016/S0140-6736(06)68154-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013FF	16473107				2022-12-28	WOS:000235394500005
J	Check, E				Check, E			Biomedical funding remains flat	NATURE			English	News Item																		Gile J, 2006, NATURE, V439, P129, DOI 10.1038/439129b; 2003, NATURE, V428, P438	2	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 9	2006	439	7077					644	644						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	010KH	16496450				2022-12-28	WOS:000235193100012
J	Ourjoumtsev, A; Tualle-Brouri, R; Laurat, J; Grangier, P				Ourjoumtsev, A; Tualle-Brouri, R; Laurat, J; Grangier, P			Generating optical Schrodinger kittens for quantum information processing	SCIENCE			English	Article							RECONSTRUCTION; SUPERPOSITIONS; STATES	We present a detailed experimental analysis of a free-propagating light pulse prepared in a "Schrodinger kitten'' state, which is defined as a quantum superposition of "classical'' coherent states with small amplitudes. This kitten state is generated by subtracting one photon from a squeezed vacuum beam, and it clearly presents a negative Wigner function. The predicted influence of the experimental parameters is in excellent agreement with the experimental results. The amplitude of the coherent states can be amplified to transform our "Schrodinger kittens'' into bigger Schrodinger cats, providing an essential tool for quantum information processing.	CNRS, Unite Mixte Rech 8501, Lab Charles Fabry, F-91403 Orsay, France	Centre National de la Recherche Scientifique (CNRS)	Grangier, P (corresponding author), CNRS, Unite Mixte Rech 8501, Lab Charles Fabry, F-91403 Orsay, France.	philippe.grangier@iota.u-psud.fr	LAURAT, Julien/A-8542-2011; Laurat, Julien/Y-9272-2019	LAURAT, Julien/0000-0001-8318-6514; Ourjoumtsev, Alexei/0000-0003-4166-0518				Bartlett SD, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.042304; Bennett CH, 2000, NATURE, V404, P247, DOI 10.1038/35005001; Browne DE, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.062320; Brune M, 1996, PHYS REV LETT, V77, P4887, DOI 10.1103/PhysRevLett.77.4887; Dakna M, 1997, PHYS REV A, V55, P3184, DOI 10.1103/PhysRevA.55.3184; Eisert J, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.137903; Fiurasek J, 2005, PHYS REV A, V72, DOI 10.1103/PhysRevA.72.033822; Garcia-Patron R, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.130409; Giedke G, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.032316; GILCHRIST A, 2004, J OPT B-QUANTUM S O, V6, P5828; JEONG H, IN PRESS QUANTUM INF; Kim MS, 2005, PHYS REV A, V71, DOI 10.1103/PhysRevA.71.043805; Lvovsky AI, 2004, J OPT B-QUANTUM S O, V6, pS556, DOI 10.1088/1464-4266/6/6/014; Lvovsky AI, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.050402; Monroe C, 1996, SCIENCE, V272, P1131, DOI 10.1126/science.272.5265.1131; Nha H, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.020401; Nielsen M. A., 2000, QUANTUM COMPUTATION; Olivares S, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.032314; OLIVARES S, IN PRESS QUANT PHYS; Opatrny T, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.032302; SONG S, 1990, PHYS REV A, V41, P5261, DOI 10.1103/PhysRevA.41.5261; VOGEL K, 1989, PHYS REV A, V40, P2847, DOI 10.1103/PhysRevA.40.2847; Wenger J, 2005, EUR PHYS J D, V32, P391, DOI 10.1140/epjd/e2004-00190-3; Wenger J, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.153601; YURKE B, 1986, PHYS REV LETT, V57, P13, DOI 10.1103/PhysRevLett.57.13; Zavatta A, 2004, PHYS REV A, V70, DOI 10.1103/PhysRevA.70.053821	29	627	635	6	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 7	2006	312	5770					83	86		10.1126/science.1122858	http://dx.doi.org/10.1126/science.1122858			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	029SJ	16527930	Green Submitted			2022-12-28	WOS:000236584400034
J	Rees, J; Patel, B				Rees, J; Patel, B			10-minute consultation - Erectile dysfunction	BRITISH MEDICAL JOURNAL			English	Editorial Material									Backwell & Nailsea Med Grp, Nailsea BS48 1BZ, Avon, England; Cheltenham Gen Hosp, Cheltenham, England	Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General Hospital	Rees, J (corresponding author), Backwell & Nailsea Med Grp, Nailsea BS48 1BZ, Avon, England.	Jonrees@ukgateway.net							0	1	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 11	2006	332	7541					593	593		10.1136/bmj.332.7541.593	http://dx.doi.org/10.1136/bmj.332.7541.593			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	026CN	16528083	Green Published			2022-12-28	WOS:000236314400019
J	Brown, RH; Clark, RN; Buratti, BJ; Cruikshank, DP; Barnes, JW; Mastrapa, RME; Bauer, J; Newman, S; Momary, T; Baines, KH; Bellucci, G; Capaccioni, F; Cerroni, P; Combes, M; Coradini, A; Drossart, P; Formisano, V; Jaumann, R; Langevin, Y; Matson, DL; McCord, TB; Nelson, RM; Nicholson, PD; Sicardy, B; Sotin, C				Brown, RH; Clark, RN; Buratti, BJ; Cruikshank, DP; Barnes, JW; Mastrapa, RME; Bauer, J; Newman, S; Momary, T; Baines, KH; Bellucci, G; Capaccioni, F; Cerroni, P; Combes, M; Coradini, A; Drossart, P; Formisano, V; Jaumann, R; Langevin, Y; Matson, DL; McCord, TB; Nelson, RM; Nicholson, PD; Sicardy, B; Sotin, C			Composition and physical properties of Enceladus' surface	SCIENCE			English	Article							KINETIC INHIBITION; MAGNETIC-FIELD; OUTER PLANETS; N-2 REDUCTION; H2O ICE; SATELLITES; DISCOVERY; CHEMISTRY; ION; CO		Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; US Geol Survey, Denver, CO 80225 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; Inst Fis Spazio Interplanetario, I-0133 Rome, Italy; Ist Astrofis Spaziale, I-0133 Rome, Italy; Observ Paris, F-92195 Meudon, France; Deutsch Zentrum Luft & Raumfahrt, D-12489 Berlin, Germany; Univ Paris, Inst Astrophys Spatiale, F-91405 Orsay, France; Univ Washington, Dept Earth & Space Sci, Seattle, WA 98195 USA; Cornell Univ, Dept Astron, Ithaca, NY 14853 USA; Univ Nantes, F-44072 Nantes, France	University of Arizona; United States Department of the Interior; United States Geological Survey; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); National Aeronautics & Space Administration (NASA); NASA Ames Research Center; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Helmholtz Association; German Aerospace Centre (DLR); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Universite Paris Saclay; University of Washington; University of Washington Seattle; Cornell University; Nantes Universite	Brown, RH (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA.		Bellucci, Giancarlo/ABA-9201-2020; Barnes, Jason W/B-1284-2009; Drossart, Pierre/H-8670-2013; Jaumann, Ralf/N-1001-2018	Bellucci, Giancarlo/0000-0003-0867-8679; Barnes, Jason W/0000-0002-7755-3530; Jaumann, Ralf/0000-0002-9759-6597; Capaccioni, Fabrizio/0000-0003-1631-4314; Newman, Sarah/0000-0003-3126-5717; Cerroni, Priscilla/0000-0003-0239-2741				Brown RH, 2004, SPACE SCI REV, V115, P111, DOI 10.1007/s11214-004-1453-x; Cruikshank DP, 2005, ICARUS, V175, P268, DOI 10.1016/j.icarus.2004.09.003; Dougherty MK, 2006, SCIENCE, V311, P1406, DOI 10.1126/science.1120985; Emery JP, 2005, ASTRON ASTROPHYS, V435, P353, DOI 10.1051/0004-6361:20042482; Grundy WM, 1999, ICARUS, V142, P536, DOI 10.1006/icar.1999.6216; Hansen CJ, 2006, SCIENCE, V311, P1422, DOI 10.1126/science.1121254; Hansen GB, 2004, J GEOPHYS RES-PLANET, V109, DOI 10.1029/2003JE002149; Kargel JS, 1996, ICARUS, V119, P385, DOI 10.1006/icar.1996.0026; KARGEL JS, 1995, EARTH MOON PLANETS, V67, P101, DOI 10.1007/BF00613296; Kivelson MG, 1996, NATURE, V384, P537, DOI 10.1038/384537a0; LEWIS JS, 1974, SCI AM, V230, P51, DOI 10.1038/scientificamerican0374-50; LEWIS JS, 1974, SCIENCE, V186, P440, DOI 10.1126/science.186.4162.440; LEWIS JS, 1973, ANNU REV PHYS CHEM, V24, P339, DOI 10.1146/annurev.pc.24.100173.002011; LEWIS JS, 1971, SCIENCE, V172, P1127, DOI 10.1126/science.172.3988.1127; LEWIS JS, 1971, ICARUS, V15, P174, DOI 10.1016/0019-1035(71)90072-8; MCKINNON WB, 1987, REV GEOPHYS, V25, P260, DOI 10.1029/RG025i002p00260; Porco CC, 2006, SCIENCE, V311, P1393, DOI 10.1126/science.1123013; PRINN RG, 1981, ASTROPHYS J, V249, P308, DOI 10.1086/159289; Schubert G, 1996, NATURE, V384, P544, DOI 10.1038/384544a0; Spencer JR, 2006, SCIENCE, V311, P1401, DOI 10.1126/science.1121661; SQUYRES SW, 1983, ICARUS, V53, P319, DOI 10.1016/0019-1035(83)90152-5; STEVENSON DJ, 1982, NATURE, V298, P142, DOI 10.1038/298142a0; STEVENSON DJ, 1984, NASA C PUBL, V2330, P405; STRAZZULLA G, 1992, EUROPHYS LETT, V18, P517, DOI 10.1209/0295-5075/18/6/008; Waite JH, 2006, SCIENCE, V311, P1419, DOI 10.1126/science.1121290	26	159	160	2	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2006	311	5766					1425	1428		10.1126/science.1121031	http://dx.doi.org/10.1126/science.1121031			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527972				2022-12-28	WOS:000236029400038
J	Christianson, DW				Christianson, DW			Biochemistry - Five golden rings	SCIENCE			English	Editorial Material							PROTEIN FARNESYLTRANSFERASE; LIPID-II; BIOSYNTHESIS; CYCLASE; NISIN		Univ Penn, Dept Chem, Roy & Diana Vagelos Labs, Philadelphia, PA 19104 USA	University of Pennsylvania	Christianson, DW (corresponding author), Univ Penn, Dept Chem, Roy & Diana Vagelos Labs, Philadelphia, PA 19104 USA.	chris@sas.upenn.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056838] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56838] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Breukink E, 1999, SCIENCE, V286, P2361, DOI 10.1126/science.286.5448.2361; Chatterjee C, 2005, CHEM REV, V105, P633, DOI 10.1021/cr030105v; CHRISTIANSON DW, IN PRESS CHEM REV; DelvesBroughton J, 1996, ANTON LEEUW INT J G, V69, P193, DOI 10.1007/BF00399424; Hsu STD, 2004, NAT STRUCT MOL BIOL, V11, P963, DOI 10.1038/nsmb830; Huang CC, 1997, J BIOL CHEM, V272, P20; Li B, 2006, SCIENCE, V311, P1436, DOI 10.1126/science.1122190; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; Schlippe YVG, 2005, ARCH BIOCHEM BIOPHYS, V433, P266, DOI 10.1016/j.abb.2004.09.018; Thoma R, 2004, NATURE, V432, P118, DOI 10.1038/nature02993; Wendt KU, 1997, SCIENCE, V277, P1811, DOI 10.1126/science.277.5333.1811; Zhang XG, 2005, J ORG CHEM, V70, P6685, DOI 10.1021/jo051182o	12	13	13	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2006	311	5766					1382	1383		10.1126/science.1125298	http://dx.doi.org/10.1126/science.1125298			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527957				2022-12-28	WOS:000236029400023
J	King, MD; Humphrey, BJ; Wang, YF; Kourbatova, EV; Ray, SM; Blumberg, HM				King, MD; Humphrey, BJ; Wang, YF; Kourbatova, EV; Ray, SM; Blumberg, HM			Emergence of community-acquired methicillin-resistant Staphylococchus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections	ANNALS OF INTERNAL MEDICINE			English	Article							FIELD GEL-ELECTROPHORESIS; PANTON-VALENTINE LEUKOCIDIN; CHILDREN; STRAINS	Background: Studies have shown that community-acquired methicillin-resistant Staphylococcus aureus (MRSA) causes S. aureus skin and soft-tissue infection in selected populations. Objective: To determine the proportion of infections caused by community-acquired MRSA. the clinical characteristics associated with community-acquired MRSA, and the molecular epidemiology of community-acquired MRSA among persons with community-onset S. aureus skin and soft-tissue infection. Design: Active, prospective laboratory surveillance to identify S. aureus recovered from skin and soft-tissue sources. Setting: 1000-bed urban hospital and its affiliated outpatient clinics in Atlanta, Georgia. Patients: 384 persons with microbiologically confirmed community-onset S. aureus skin and soft-tissue infection. Measurements: Proportion of infections caused by and clinical factors associated with community-acquired MRSA among persons with community-onset S. aureus skin and soft-tissue infection. Pulsed-field gel electrophoresis and antimicrobial susceptibility patterns were used to epidemiologically classify community-onset S. aureus infections. Comm unity-acquired MRSA was defined by MRSA isolates that either demonstrated a USA 300 or USA 400 pulsed-field type or had a susceptibility pattern showing resistance only to beta-lactams and erythromycin (for isolates not available for pulsed-field gel electrophoresis). Results: Community-onset skin and soft-tissue infection due to S. aureus was identified in 389 episodes, with MRSA accounting for 72% (279 of 389 episodes). Among all S. aureus isolates, 63% (244 of 389 isolates) were community-acquired MRSA. Among MRSA isolates, 87% (244 of 279 isolates) were community-acquired MRSA. When analysis was restricted only to MRSA isolates that were available for pulsed-field gel electrophoresis, 91% (159 of 175 isolates) had a pulsed-field type consistent with community-acquired MRSA; of these, 99% (157 of 159 isolates) were the MRSA USA 300 clone. Factors independently associated with community-acquired MRSA infection were black race (prevalence ratio, 1.53 [95% Cl, 1.16 to 2.02]), female sex (prevalence ratio, 1.16 [CI, 1.02 to 1.32]), and hospitalization within the previous 12 months (prevalence ratio, 0.80 [CI, 0.66 to 0.97]). Inadequate initial antibiotic therapy was statistically significantly more common among those with community-acquired MRSA (65%) than among those with methicillin-susceptible S. aureus skin and soft-tissue infection (1%). Limitations: Some MRSA isolates were not available for molecular typing. Conclusions: The community-acquired MRSA USA 300 clone was the predominant cause of community-onset S. aureus skin and soft-tissue infection. Empirical use of agents active against community-acquired MRSA is warranted for patients presenting with serious skin and soft-tissue infections.	Emory Univ, Sch Med, Atlanta, GA 30322 USA; Grady Mem Hosp, Atlanta, GA USA	Emory University	Blumberg, HM (corresponding author), Emory Univ, Sch Med, Atlanta, GA 30322 USA.	henry.m.blumberg@emory.edu	Blumberg, Henry/W-2156-2019	Blumberg, Henry/0000-0002-3110-2443; Ray, Susan/0000-0002-6327-088X	NCRR NIH HHS [K12 RR 017643] Funding Source: Medline; NIAID NIH HHS [K23 AI054371] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [K12RR017643] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI054371] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baggett HC, 2004, J INFECT DIS, V189, P1565, DOI 10.1086/383247; BANNERMAN TL, 1995, J CLIN MICROBIOL, V33, P551, DOI 10.1128/JCM.33.3.551-555.1995; Begier EM, 2004, CLIN INFECT DIS, V39, P1446, DOI 10.1086/425313; *CDCP, 2006, CAMP PREV ANT RES PR; Charlebois ED, 2004, CLIN INFECT DIS, V39, P47, DOI 10.1086/421090; Diep BA, 2004, J CLIN MICROBIOL, V42, P2080, DOI 10.1128/JCM.42.5.2080-2084.2004; Dietrich DW, 2004, PEDIATRICS, V113, pE347, DOI 10.1542/peds.113.4.e347; Frank AL, 2002, PEDIATR INFECT DIS J, V21, P530, DOI 10.1097/00006454-200206000-00010; Gindler J. S., 1995, Morbidity and Mortality Weekly Report, V44, P1; Harrison LH, 2000, ARCH INTERN MED, V160, P89, DOI 10.1001/archinte.160.1.89; Healy CM, 2004, CLIN INFECT DIS, V39, P1460, DOI 10.1086/425321; Kourbatova EV, 2005, AM J INFECT CONTROL, V33, P385, DOI 10.1016/j.ajic.2005.06.006; Lee MC, 2004, PEDIATR INFECT DIS J, V23, P123, DOI 10.1097/01.inf.0000109288.06912.21; Lewis JS, 2005, CLIN INFECT DIS, V40, P280, DOI 10.1086/426894; Lina G, 1999, CLIN INFECT DIS, V29, P1128, DOI 10.1086/313461; Marcinak JF, 2003, CURR OPIN INFECT DIS, V16, P265, DOI 10.1097/00001432-200306000-00014; McDougal LK, 2003, J CLIN MICROBIOL, V41, P5113, DOI 10.1128/JCM.41.11.5113-5120.2003; Naimi TS, 2003, JAMA-J AM MED ASSOC, V290, P2976, DOI 10.1001/jama.290.22.2976; National Committee for Clinical Laboratory Standards, 2000, METH DIL ANT SUSC TE, V20; National Committee for Clinical Laboratory Standards, 2004, M100S14 NAT COMM CLI; Okuma K, 2002, J CLIN MICROBIOL, V40, P4289, DOI 10.1128/JCM.40.11.4289-4294.2002; Pastor P, 1998, CLIN INFECT DIS, V26, P590, DOI 10.1086/514589; ROSS JI, 1990, MOL MICROBIOL, V4, P1207, DOI 10.1111/j.1365-2958.1990.tb00696.x; Saiman L, 2003, CLIN INFECT DIS, V37, P1313, DOI 10.1086/379022; Seybold U, 2006, CLIN INFECT DIS, V42, P647, DOI 10.1086/499815; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; Young DM, 2004, ARCH SURG-CHICAGO, V139, P947, DOI 10.1001/archsurg.139.9.947; Young DM, 2004, ARCH SURG-CHICAGO, V139, P51; 2003, MMWR MORB MORTAL WKL, V52, P793; 2003, MMWR MORB MORTAL WKL, V52, P992; 2003, MMWR MORB MORTAL WKL, V52, P88	31	591	609	0	39	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 7	2006	144	5					309	317		10.7326/0003-4819-144-5-200603070-00005	http://dx.doi.org/10.7326/0003-4819-144-5-200603070-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	021EA	16520471	Green Published			2022-12-28	WOS:000235965300001
J	Azevedo, RBR; Lohaus, R; Srinivasan, S; Dang, KK; Burch, CL				Azevedo, RBR; Lohaus, R; Srinivasan, S; Dang, KK; Burch, CL			Sexual reproduction selects for robustness and negative epistasis in artificial gene networks	NATURE			English	Article							DELETERIOUS MUTATIONS; SYNERGISTIC EPISTASIS; EVOLUTION; CANALIZATION; DROSOPHILA; FITNESS; PERSPECTIVE; LOAD	The mutational deterministic hypothesis for the origin and maintenance of sexual reproduction posits that sex enhances the ability of natural selection to purge deleterious mutations after recombination brings them together into single genomes(1). This explanation requires negative epistasis, a type of genetic interaction where mutations are more harmful in combination than expected from their separate effects. The conceptual appeal of the mutational deterministic hypothesis has been offset by our inability to identify the mechanistic and evolutionary bases of negative epistasis. Here we show that negative epistasis can evolve as a consequence of sexual reproduction itself. Using an artificial gene network model(2,3), we find that recombination between gene networks imposes selection for genetic robustness, and that negative epistasis evolves as a by-product of this selection. Our results suggest that sexual reproduction selects for conditions that favour its own maintenance, a case of evolution forging its own path.	Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA; Univ N Carolina, Dept Biomed Engn, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of Houston System; University of Houston; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Azevedo, RBR (corresponding author), Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA.	razevedo@uh.edu	Azevedo, Ricardo/AAV-3963-2021	Azevedo, Ricardo/0000-0001-5402-7071; Burch, Christina/0000-0001-7830-0124; Dang, Kristen/0000-0002-7512-4476				Barton NH, 2002, NAT REV GENET, V3, P11, DOI 10.1038/nrg700; Bonhoeffer S, 2004, SCIENCE, V306, P1547, DOI 10.1126/science.1101786; Burch CL, 2004, GENETICS, V167, P559, DOI 10.1534/genetics.103.021196; Charlesworth B, 1996, GENET RES, V67, P27, DOI 10.1017/S0016672300033450; CRAWLEY MJ, 2002, STAT COMPUTING; de Visser JAGM, 2003, EVOLUTION, V57, P1959, DOI 10.1554/02-750R; deVisser JAGM, 1997, GENETICS, V145, P815; deVisser JAGM, 1997, EVOLUTION, V51, P1499, DOI 10.1111/j.1558-5646.1997.tb01473.x; Elena SF, 1997, NATURE, V390, P395, DOI 10.1038/37108; Jaeger J, 2004, GENETICS, V167, P1721, DOI 10.1534/genetics.104.027334; Kawecki TJ, 2000, EVOLUTION, V54, P1, DOI 10.1111/j.0014-3820.2000.tb00001.x; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; Lynch M, 1999, EVOLUTION, V53, P645, DOI 10.1111/j.1558-5646.1999.tb05361.x; MAYNARD SMITH J., 1978, EVOLUTION SEX; Michalakis Y, 2004, SCIENCE, V306, P1492, DOI 10.1126/science.1106677; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; MUKAI T, 1969, GENETICS, V61, P749; Nijhout HF, 2002, BIOESSAYS, V24, P553, DOI 10.1002/bies.10093; Rice SH, 1998, EVOLUTION, V52, P647, DOI 10.1111/j.1558-5646.1998.tb03690.x; Siegal ML, 2002, P NATL ACAD SCI USA, V99, P10528, DOI 10.1073/pnas.102303999; Stearns S. C., 1994, ACTA PALAEONTOL POL, V38, P215; Stelling J, 2004, CELL, V118, P675, DOI 10.1016/j.cell.2004.09.008; Wagner A, 1996, EVOLUTION, V50, P1008, DOI 10.1111/j.1558-5646.1996.tb02342.x; Wagner GP, 1997, EVOLUTION, V51, P329, DOI [10.2307/2411105, 10.1111/j.1558-5646.1997.tb02420.x]; Wagner GP, 1998, GENETICA, V102-3, P569, DOI 10.1023/A:1017088321094; WHITLOCK MC, 1995, ANNU REV ECOL SYST, V26, P601, DOI 10.1146/annurev.es.26.110195.003125; Whitlock MC, 2000, EVOLUTION, V54, P1654, DOI 10.1111/j.0014-3820.2000.tb00709.x; Wilke CO, 2001, P ROY SOC B-BIOL SCI, V268, P1469, DOI 10.1098/rspb.2001.1690; Wilke CO, 2001, NATURE, V412, P331, DOI 10.1038/35085569; You LC, 2002, GENETICS, V160, P1273	30	170	173	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	2006	440	7080					87	90		10.1038/nature04488	http://dx.doi.org/10.1038/nature04488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017HW	16511495				2022-12-28	WOS:000235685700045
J	Perry, L; Sandweiss, DH; Piperno, DR; Rademaker, K; Malpass, MA; Umire, A; de la Vera, P				Perry, L; Sandweiss, DH; Piperno, DR; Rademaker, K; Malpass, MA; Umire, A; de la Vera, P			Early maize agriculture and interzonal interaction in southern Peru	NATURE			English	Article							CAL KYR BP; AGE CALIBRATION; ORINOCO VALLEY; VENEZUELA; ECUADOR; REVEAL	Over the past decade, increasing attention to the recovery and identification of plant microfossil remains from archaeological sites located in lowland South America has significantly increased knowledge of pre-Columbian plant domestication and crop plant dispersals in tropical forests and other regions(1-4). Along the Andean mountain chain, however, the chronology and trajectory of plant domestication are still poorly understood for both important indigenous staple crops such as the potato ( Solanum sp.) and others exogenous to the region, for example, maize (Zea mays)(5,6). Here we report the analyses of plant microremains from a late preceramic house (3,431 +/- 45 to 3,745 +/- 65 C-14 BP or similar to 3,600 to 4,000 calibrated years BP) in the highland southern Peruvian site of Waynuna. Our results extend the record of maize by at least a millennium in the southern Andes, show on-site processing of maize into flour, provide direct evidence for the deliberate movement of plant foods by humans from the tropical forest to the highlands, and confirm the potential of plant microfossil analysis in understanding ancient plant use and migration in this region.	Smithsonian Inst, Natl Museum Nat Hist, Dept Anthropol, Archaeobiol Program, Washington, DC 20013 USA; Univ Maine, Dept Anthropol, Orono, ME 04469 USA; Univ Maine, Bryand Global Sci Ctr, Climate Change Inst, Orono, ME 04469 USA; Smithsonian Trop Res Inst, Balboa, Ancon, Panama; Ithaca Coll, Gannett Ctr G121, Dept Anthropol, Ithaca, NY 14850 USA; Museo Contisuyo, Moquegua, Peru; Inst Nacl Cultura, Arequipa, Peru	Smithsonian Institution; Smithsonian National Museum of Natural History; University of Maine System; University of Maine Orono; University of Maine System; University of Maine Orono; Smithsonian Institution; Smithsonian Tropical Research Institute	Perry, L (corresponding author), Smithsonian Inst, Natl Museum Nat Hist, Dept Anthropol, Archaeobiol Program, POB 37012,MRC 112, Washington, DC 20013 USA.	perryli@si.edu	Sandweiss, Daniel/K-5808-2019; Rademaker, Kurt/AAH-1075-2021	Rademaker, Kurt/0000-0001-5676-4884; Umire Alvarez, Adan/0000-0002-1707-4896				Babot M.P., 2003, TERRA AUSTRALIS, V19, P69; Brush Stephen B., 1977, MOUNTAIN FIELD FAMIL; BURGER RL, 1990, AM ANTHROPOL, V92, P85, DOI 10.1525/aa.1990.92.1.02a00060; Burger RL, 2000, J WORLD PREHIST, V14, P267, DOI 10.1023/A:1026509726643; FANNON JE, 1992, CEREAL CHEM, V69, P284; Fullagar R., 1998, CLOSER LOOK RECENT A, P49; HASTORF CA, 1998, PREHISTORY FOOD, P35; Iriarte J, 2004, NATURE, V432, P614, DOI 10.1038/nature02983; Jennings J., 2002, THESIS U CALIFORNIA; Lathrap D. W., 1973, VARIATION ANTHR ESSA, P91; LATHRAP DW, 1973, WORLD ARCHAEOL, V5, P170, DOI 10.1080/00438243.1973.9979564; LEACH HW, 1961, CEREAL CHEM, V38, P34; MALPASS M, 1992, ANDEAN PAST, V3, P137; McCormac FG, 2004, RADIOCARBON, V46, P1087, DOI 10.1017/S0033822200033014; Moseley M.E., 2001, INCAS THEIR ANCESTOR; Pearsall DM, 2004, J ARCHAEOL SCI, V31, P423, DOI 10.1016/j.jas.2003.09.010; Perry L, 2005, LAT AM ANTIQ, V16, P409, DOI 10.2307/30042507; Perry L, 2004, J ARCHAEOL SCI, V31, P1069, DOI 10.1016/j.jas.2004.01.002; Piperno D.R., 1998, ORIGINS AGR LOWLAND; Piperno DR, 2000, NATURE, V407, P894, DOI 10.1038/35038055; Piperno DR, 2003, SCIENCE, V299, P1054, DOI 10.1126/science.1080365; PIPERNO DR, IN PRESS PHYTOLITHS; Pozorski T., 1987, ORIGINS DEV ANDEAN S; Reimer PJ, 2004, RADIOCARBON, V46, P1029, DOI 10.1017/S0033822200032999; Sandweiss DH, 1998, SCIENCE, V281, P1830, DOI 10.1126/science.281.5384.1830; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; Trawick PB., 2002, STRUGGLE WATER PERU; UGENT D, 1982, ECON BOT, V36, P182, DOI 10.1007/BF02858715; VIDAL JP, 1987, GEOGRAFIA PERU; WILSON D, 1988, PREHISPANIC SETTLEME	30	94	100	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2006	440	7080					76	79		10.1038/nature04294	http://dx.doi.org/10.1038/nature04294			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017HW	16511492				2022-12-28	WOS:000235685700042
J	Bochenek, M; Delgado, F				Bochenek, M; Delgado, F			Children in custody in Brazil	LANCET			English	Editorial Material									Human Rights Watch, New York, NY 10118 USA; Harvard Law Sch, Human Rights Program, Cambridge, MA USA	Harvard University	Bochenek, M (corresponding author), Human Rights Watch, 350 5th Ave,34th Floor, New York, NY 10118 USA.	bochenm@hrw.org						Human Rights Watch, 2005, DARK HIDD AB DET YOU; Human Rights Watch, 2003, CRUEL CONF AB DET CH; Nelikhov A, 2010, PALEOMIR, V1, P60; *SECRE SP DIR HUM, 2004, LEV EST NUM AD CUMPR	4	8	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 25	2006	367	9511					696	697		10.1016/S0140-6736(06)68271-8	http://dx.doi.org/10.1016/S0140-6736(06)68271-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	016HR	16503471				2022-12-28	WOS:000235611800037
J	Li, WKW; Harrison, WG; Head, EJH				Li, WKW; Harrison, WG; Head, EJH			Coherent sign switching in multiyear trends of microbial plankton	SCIENCE			English	Article							CLIMATE-CHANGE; RECORDER DATA; PHYTOPLANKTON; CHLOROPHYLL; ABUNDANCE; BIOMASS; ECOLOGY; IMPACT	Since the 1990s, phytoplankton biomass on the continental shelf of Nova Scotia and in the Labrador Sea has undergone sustained changes in the spring and fait, which are accompanied by changes in bacterioplankton that are dampened in amplitude but coherent in the direction of change. A reversal of trend in biomass change, so-called sign switching, occurs both in time and in space. Thus, whenever (spring or fall) and wherever (Scotian Shelf or Labrador Sea) phytoplankton increase or decrease, so also does bacterioplankton. This tandem sign switch indicates coupling of the trophic levels at a multiyear time scale and contributes to an ecological fingerprint of systemwide forcing.	Bedford Inst Oceanog, Dartmouth, NS B2Y 4A2, Canada	Bedford Institute of Oceanography	Li, WKW (corresponding author), Bedford Inst Oceanog, POB 1006, Dartmouth, NS B2Y 4A2, Canada.	LiB@mar.dfo-mpo.gc.ca						Batten SD, 2003, J PLANKTON RES, V25, P697, DOI 10.1093/plankt/25.7.697; Chiba S, 2004, J OCEANOGR, V60, P149, DOI 10.1023/B:JOCE.0000038324.14054.cf; Cullen John J., 2002, P297; Ducklow HW, 2003, GLO CH IGBP, P3; Edwards M, 2004, NATURE, V430, P881, DOI 10.1038/nature02808; FOURNIER RO, 1977, J FISH RES BOARD CAN, V34, P1004, DOI 10.1139/f77-153; Frank KT, 2005, SCIENCE, V308, P1621, DOI 10.1126/science.1113075; Gasol JM, 2000, FEMS MICROBIOL ECOL, V31, P99, DOI 10.1111/j.1574-6941.2000.tb00675.x; Giovannoni SJ, 2005, NATURE, V437, P343, DOI 10.1038/nature04158; Greenan BJW, 2004, CONT SHELF RES, V24, P603, DOI 10.1016/j.csr.2003.11.006; Gregg WW, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021808; HAYS GC, 1994, J PLANKTON RES, V16, P23, DOI 10.1093/plankt/16.1.23; Lazier J, 2002, DEEP-SEA RES PT I, V49, P1819, DOI 10.1016/S0967-0637(02)00064-X; Li WKW, 2004, DEEP-SEA RES PT I, V51, P1529, DOI 10.1016/j.dsr.2004.06.012; Li WKW, 2002, NATURE, V419, P154, DOI 10.1038/nature00994; Malmstrom RR, 2005, APPL ENVIRON MICROB, V71, P2979, DOI 10.1128/AEM.71.6.2979-2986.2005; McClain CR, 2004, DEEP-SEA RES PT II, V51, P281, DOI 10.1016/j.dsr2.2003.08.002; Nagata T., 2000, MICROBIAL ECOLOGY OC, P121; Parmesan C, 2003, NATURE, V421, P37, DOI 10.1038/nature01286; Platt T, 2003, NATURE, V423, P398, DOI 10.1038/423398b; Richardson AJ, 2004, SCIENCE, V305, P1609, DOI 10.1126/science.1100958; Sameoto D, 2001, CAN J FISH AQUAT SCI, V58, P749, DOI 10.1139/cjfas-58-4-749; THERRIAULT JC, 1998, CAN TECH REP HYDROGR, V194, P1; Yokokawa T, 2004, LIMNOL OCEANOGR, V49, P1620, DOI 10.4319/lo.2004.49.5.1620	24	16	19	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	2006	311	5764					1157	1160		10.1126/science.1122748	http://dx.doi.org/10.1126/science.1122748			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017IU	16497934				2022-12-28	WOS:000235688100050
J	Nielsen, MA; Dowling, MR; Gu, M; Doherty, AC				Nielsen, MA; Dowling, MR; Gu, M; Doherty, AC			Quantum computation as geometry	SCIENCE			English	Article								Quantum computers hold great promise for solving interesting computational problems, but it remains a challenge to find efficient quantum circuits that can perform these complicated tasks. Here we show that finding optimal quantum circuits is essentially equivalent to finding the shortest path between two points in a certain curved geometry. By recasting the problem of finding quantum circuits as a geometric problem, we open up the possibility of using the mathematical techniques of Riemannian geometry to suggest new quantum algorithms or to prove limitations on the power of quantum computers.	Univ Queensland, Sch Phys Sci, St Lucia, Qld 4072, Australia	University of Queensland	Nielsen, MA (corresponding author), Univ Queensland, Sch Phys Sci, St Lucia, Qld 4072, Australia.	nielsen@physics.uq.edu.au	Gu, Mile/AAH-7813-2020; Doherty, Andrew/D-1816-2010; Gu, Mile/B-1994-2013	Gu, Mile/0000-0002-5459-4313; Doherty, Andrew/0000-0002-8069-7754; Gu, Mile/0000-0002-5459-4313; Dowling, Mark/0000-0002-8056-5348; Nielsen, Michael/0000-0002-6188-5389				Arnold V. I., 1998, TOPOLOGICAL METHODS, V125; Jurdjevic V., 1996, GEOMETRIC CONTROL TH; Khaneja N, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.032308; Khaneja N, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.032301; Montgomery R., 2002, TOUR SUBRIEMANNIAN G; NIELSEN MA, IN PRESS QUANT INF C; Nielsen Michael A., 2002, QUANTUM COMPUTATION; Shor P., 1994, P 35 ANN S FUND COMP; Wells R., 1969, MORSE THEORY	11	258	259	3	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	2006	311	5764					1133	1135		10.1126/science.1121541	http://dx.doi.org/10.1126/science.1121541			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017IU	16497928	Green Submitted			2022-12-28	WOS:000235688100043
J	Smith, EC; Lewicki, MS				Smith, EC; Lewicki, MS			Efficient auditory coding	NATURE			English	Article								The auditory neural code must serve a wide range of auditory tasks that require great sensitivity in time and frequency and be effective over the diverse array of sounds present in natural acoustic environments. It has been suggested(1-5) that sensory systems might have evolved highly efficient coding strategies to maximize the information conveyed to the brain while minimizing the required energy and neural resources. Here we show that, for natural sounds, the complete acoustic waveform can be represented efficiently with a nonlinear model based on a population spike code. In this model, idealized spikes encode the precise temporal positions and magnitudes of underlying acoustic features. We find that when the features are optimized for coding either natural sounds or speech, they show striking similarities to time-domain cochlear filter estimates, have a frequency-bandwidth dependence similar to that of auditory nerve fibres, and yield significantly greater coding efficiency than conventional signal representations. These results indicate that the auditory code might approach an information theoretic optimum and that the acoustic structure of speech might be adapted to the coding capacity of the mammalian auditory system.	Carnegie Mellon Univ, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Dept Comp Sci, Pittsburgh, PA 15213 USA	Carnegie Mellon University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University; Carnegie Mellon University	Lewicki, MS (corresponding author), Carnegie Mellon Univ, Ctr Neural Basis Cognit, 4400 5th Ave, Pittsburgh, PA 15213 USA.	lewicki@cnbc.cmu.edu						Aticky JJ, 2011, NETWORK-COMP NEURAL, V22, P4, DOI [10.1088/0954-898X/3/2/009, 10.3109/0954898X.2011.638888]; Barlow H. B., 1961, SENS COMMUN, P217, DOI DOI 10.7551/MITPRESS/9780262518420.003.0013; Carney LH, 1999, J ACOUST SOC AM, V105, P2384, DOI 10.1121/1.426843; CARNEY LH, 1990, J NEUROPHYSIOL, V64, P437, DOI 10.1152/jn.1990.64.2.437; Davis G, 1997, CONSTR APPROX, V13, P57, DOI 10.1007/s003659900033; DEBOER E, 1978, J ACOUST SOC AM, V63, P115, DOI 10.1121/1.381704; Emmons LH, 1997, SOUNDS NEOTROPICAL R; Irino T, 1997, J ACOUST SOC AM, V101, P412, DOI 10.1121/1.417975; Laughlin SB, 2003, SCIENCE, V301, P1870, DOI 10.1126/science.1089662; Lewicki MS, 1999, ADV NEUR IN, V11, P730; Lewicki MS, 2002, NEURAL INF PROCESS S, P243; Lewicki MS, 2002, NAT NEUROSCI, V5, P356, DOI 10.1038/nn831; MALLAT SG, 1993, IEEE T SIGNAL PROCES, V41, P3397, DOI 10.1109/78.258082; Olshausen BA, 2002, NEU INF PRO, P257; SHAMMA SA, 1985, J ACOUST SOC AM, V78, P1612, DOI 10.1121/1.392799; Simoncelli EP, 2001, ANNU REV NEUROSCI, V24, P1193, DOI 10.1146/annurev.neuro.24.1.1193; Smith E, 2005, NEURAL COMPUT, V17, P19, DOI 10.1162/0899766052530839; Temchin AN, 2005, J NEUROPHYSIOL, V93, P3635, DOI 10.1152/jn.00885.2004; VANSTEVENINCK RD, 1988, PROC R SOC SER B-BIO, V234, P379; YANG XW, 1992, IEEE T INFORM THEORY, V38, P824, DOI 10.1109/18.119739	20	361	380	5	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 23	2006	439	7079					978	982		10.1038/nature04485	http://dx.doi.org/10.1038/nature04485			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014NE	16495999				2022-12-28	WOS:000235486100048
J	Uebing, A; Steer, PJ; Yentis, SM; Gatzoulis, MA				Uebing, A; Steer, PJ; Yentis, SM; Gatzoulis, MA			Pregnancy and congenital heart disease	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GREAT-ARTERIES; EISENMENGERS-SYNDROME; MUSTARD OPERATION; CARDIAC DISEASE; AORTIC-STENOSIS; FOLLOW-UP; WOMEN; TRANSPOSITION; OUTCOMES; RISK		Royal Brompton & Harefield NHS Trust, Adult Congenital Heart Dis Unit, London SW3 6NP, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6NP, England; Univ London Imperial Coll Sci Technol & Med, Dept Obstet & Gynaecol, Chelsea & Westminster Hosp, Div Surg Oncol Reprod Med & Anaesthet,Fac Med, London SW3 6NP, England; Chelsea & Westminster Hosp, Magill Dept Anaesthesia Intens Care & Pain Manage, London, England	Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital; Imperial College London; Imperial College London; Imperial College London	Gatzoulis, MA (corresponding author), Royal Brompton & Harefield NHS Trust, Adult Congenital Heart Dis Unit, London SW3 6NP, England.	m.gatzoulis@rbh.nthames.nhs.uk	Uebing, Anselm Sebastian/AAY-2554-2020; Uebing, Anselm/A-8350-2010	Uebing, Anselm Sebastian/0000-0001-8504-0228; Uebing, Anselm/0000-0001-8504-0228				AVILA WS, 1995, EUR HEART J, V16, P460, DOI 10.1093/oxfordjournals.eurheartj.a060936; Bates S M, 1999, Pharm Pract Manag Q, V19, P51; Bates SA, 2004, CHEST, V126, p627S, DOI 10.1378/chest.126.3_suppl.627S; Beauchesne LM, 2001, J AM COLL CARDIOL, V38, P1728, DOI 10.1016/S0735-1097(01)01617-5; Burn J, 1998, LANCET, V351, P311, DOI 10.1016/S0140-6736(97)06486-6; Canobbio MM, 1996, J AM COLL CARDIOL, V28, P763, DOI 10.1016/0735-1097(96)00234-3; CAPPELLERI JC, 1995, AM HEART J, V130, P547, DOI 10.1016/0002-8703(95)90365-8; Chandler AM., 2001, EJSE ELECT J STRUCT, V1, P60; CLARKSON PM, 1994, J AM COLL CARDIOL, V24, P190, DOI 10.1016/0735-1097(94)90562-2; Connolly HM, 1999, J AM COLL CARDIOL, V33, P1692, DOI 10.1016/S0735-1097(99)00046-7; Drenthen W, 2005, EUR HEART J, V26, P2588, DOI 10.1093/eurheartj/ehi472; Easterling TR, 2001, OBSTET GYNECOL, V98, P427, DOI 10.1016/S0029-7844(01)01477-6; Elkayam U, 1999, J AM COLL CARDIOL, V33, P1642; Ellison J, 2001, BRIT J OBSTET GYNAEC, V108, P757; Gatzoulis MA, 2006, NAT CLIN PRACT CARD, V3, P2, DOI 10.1038/ncpcardio0382; Ginsberg JS, 1998, CHEST, V114, p524S, DOI 10.1378/chest.114.5_Supplement.524S; Guedes A, 2004, J AM COLL CARDIOL, V44, P433, DOI 10.1016/j.jacc.2004.04.037; Hyett J, 1999, BRIT MED J, V318, P81, DOI 10.1136/bmj.318.7176.81; LAO TT, 1993, AM J OBSTET GYNECOL, V169, P540, DOI 10.1016/0002-9378(93)90616-Q; Lewis G., 2004, WHY MOTHERS DIE 2000; Lupton M, 2002, CURR OPIN OBSTET GYN, V14, P137, DOI 10.1097/00001703-200204000-00006; Meijer JM, 2005, HEART, V91, P801, DOI 10.1136/hrt.2004.034108; Monnery L, 2001, BRIT J ANAESTH, V87, P295, DOI 10.1093/bja/87.2.295; Nieminen HP, 2001, CIRCULATION, V104, P570, DOI 10.1161/hc3101.093968; NORA JJ, 1994, J AM COLL CARDIOL, V23, P1468, DOI 10.1016/0735-1097(94)90393-X; Oakley C, 2003, EUR HEART J, V24, P761, DOI 10.1016/S0195-668X(03)00098-8; PRESBITERO P, 1994, CIRCULATION, V89, P2673, DOI 10.1161/01.CIR.89.6.2673; Qasqas Shadi A, 2004, Cardiol Rev, V12, P201, DOI 10.1097/01.crd.0000102420.62200.e1; Qasqas Shadi A, 2004, Cardiol Rev, V12, P240; Roberts N, 2001, BRIT J OBSTET GYNAEC, V108, P327; Romano-Zelekha O, 2001, CLIN GENET, V59, P325, DOI 10.1034/j.1399-0004.2001.590505.x; ROSSITER JP, 1995, AM J OBSTET GYNECOL, V173, P1599, DOI 10.1016/0002-9378(95)90655-X; sermer M, 2003, J Obstet Gynaecol, V23, P540; Shehata HA, 2001, BEST PRACT RES CL OB, V15, P971, DOI 10.1053/beog.2001.0241; Siu SC, 2001, CIRCULATION, V104, P515, DOI 10.1161/hc3001.093437; Siu SC, 2002, CIRCULATION, V105, P2179, DOI 10.1161/01.CIR.0000015699.48605.08; Siu SC, 1997, CIRCULATION, V96, P2789; Steer PJ, 2005, ADULT CONGENITAL HEA, P16; Suntharalingam G, 2001, INT J OBSTET ANESTH, V10, P129, DOI 10.1054/ijoa.2000.0720; Thorne S, 1996, ARCH DIS CHILD, V75, P6, DOI 10.1136/adc.75.1.6; Thorne SA, 2004, HEART, V90, P450, DOI 10.1136/hrt.2003.027888; Valencia L S, 2000, J Pediatr Adolesc Gynecol, V13, P53, DOI 10.1016/S1083-3188(00)00004-8; Veldtman GR, 2004, J AM COLL CARDIOL, V44, P174, DOI 10.1016/j.jacc.2003.11.067; Vitale N, 1999, J AM COLL CARDIOL, V33, P1637, DOI 10.1016/S0735-1097(99)00044-3; Weiss BM, 1998, AM J OBSTET GYNECOL, V179, P1643, DOI 10.1016/S0002-9378(98)70039-0; WHITTEMORE R, 1982, AM J CARDIOL, V50, P641, DOI 10.1016/0002-9149(82)90334-4; Wren C, 2001, HEART, V85, P438, DOI 10.1136/heart.85.4.438; Yentis SM, 1998, BRIT J OBSTET GYNAEC, V105, P921, DOI 10.1111/j.1471-0528.1998.tb10240.x; Zuber M, 1999, HEART, V81, P271, DOI 10.1136/hrt.81.3.271	49	107	121	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 18	2006	332	7538					401	406		10.1136/bmj.332.7538.401	http://dx.doi.org/10.1136/bmj.332.7538.401			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	017HZ	16484266	Green Published			2022-12-28	WOS:000235686000022
J	Aitman, TJ; Dong, R; Vyse, TJ; Norsworthy, PJ; Johnson, MD; Smith, J; Mangion, J; Roberton-Lowe, C; Marshall, AJ; Petretto, E; Hodges, MD; Bhangal, G; Patel, SG; Sheehan-Rooney, K; Duda, M; Cook, PR; Evans, DJ; Domin, J; Flint, J; Boyle, JJ; Pusey, CD; Cook, HT				Aitman, TJ; Dong, R; Vyse, TJ; Norsworthy, PJ; Johnson, MD; Smith, J; Mangion, J; Roberton-Lowe, C; Marshall, AJ; Petretto, E; Hodges, MD; Bhangal, G; Patel, SG; Sheehan-Rooney, K; Duda, M; Cook, PR; Evans, DJ; Domin, J; Flint, J; Boyle, JJ; Pusey, CD; Cook, HT			Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans	NATURE			English	Article							INSULIN-RESISTANCE; FC-RECEPTORS; GENE; EXPRESSION; MACROPHAGES; MECHANISM; NEPHRITIS; CELLS; ACID	Identification of the genes underlying complex phenotypes and the definition of the evolutionary forces that have shaped eukaryotic genomes are among the current challenges in molecular genetics(1-3). Variation in gene copy number is increasingly recognized as a source of inter-individual differences in genome sequence and has been proposed as a driving force for genome evolution and phenotypic variation(3-5). Here we show that copy number variation of the orthologous rat and human Fcgr3 genes is a determinant of susceptibility to immunologically mediated glomerulonephritis. Positional cloning identified loss of the newly described, rat-specific Fcgr3 paralogue, Fcgr3-related sequence (Fcgr3-rs), as a determinant of macrophage overactivity and glomerulonephritis in Wistar Kyoto rats. In humans, low copy number of FCGR3B, an orthologue of rat Fcgr3, was associated with glomerulonephritis in the autoimmune disease systemic lupus erythematosus. The finding that gene copy number polymorphism predisposes to immunologically mediated renal disease in two mammalian species provides direct evidence for the importance of genome plasticity in the evolution of genetically complex phenotypes, including susceptibility to common human disease.	Univ London Imperial Coll Sci Technol & Med, MRC, Ctr Clin Sci, Physiol Genom & Med Grp, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Rheumatol Sect, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Sect Renal Med, London W12 0NN, England; Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ London Imperial Coll Sci Technol & Med, Dept Histopathol, London W12 0NN, England	Imperial College London; Imperial College London; Imperial College London; University of Oxford; Wellcome Centre for Human Genetics; Imperial College London	Aitman, TJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, MRC, Ctr Clin Sci, Physiol Genom & Med Grp, London W12 0NN, England.	t.aitman@csc.mrc.ac.uk; t.h.cook@imperial.ac.uk	Hodges, Matthew/GZB-0433-2022	Aitman, Timothy/0000-0002-7875-4502; Norsworthy, Penny/0000-0002-5572-8491; Hodges, Matthew David John/0000-0002-6815-751X	Medical Research Council [G0400116, MC_U120097112, MC_U120061454] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0400116, MC_U120061454] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; BHAN AK, 1978, J EXP MED, V148, P246, DOI 10.1084/jem.148.1.246; Boyle JJ, 2004, CLIN EXP IMMUNOL, V137, P529, DOI 10.1111/j.1365-2249.2004.02565.x; CLARK MR, 1990, J CLIN INVEST, V86, P341, DOI 10.1172/JCI114706; Cook HT, 1999, KIDNEY INT, V55, P1319, DOI 10.1046/j.1523-1755.1999.00354.x; Coxon A, 2001, IMMUNITY, V14, P693, DOI 10.1016/S1074-7613(01)00150-9; Edberg JC, 2002, ARTHRITIS RHEUM, V46, P2132, DOI 10.1002/art.10438; Eichler EE, 2003, SCIENCE, V301, P793, DOI 10.1126/science.1086132; FARBER DL, 1993, J IMMUNOL, V150, P4364; Ferrario F, 1997, OX CLIN NEP SER, P59; Gittinger FS, 2002, TISSUE ANTIGENS, V60, P64, DOI 10.1034/j.1399-0039.2002.600108.x; Glazier AM, 2002, SCIENCE, V298, P2345, DOI 10.1126/science.1076641; Gonzalez E, 2005, SCIENCE, V307, P1434, DOI 10.1126/science.1101160; Isome M, 2004, NEPHROL DIAL TRANSPL, V19, P2997, DOI 10.1093/ndt/gfh558; Karassa FB, 2002, ARTHRITIS RHEUM-US, V46, P1563, DOI 10.1002/art.10306; KAWASAKI K, 1992, KIDNEY INT, V41, P1517, DOI 10.1038/ki.1992.221; Kim MK, 2003, BLOOD, V101, P4479, DOI 10.1182/blood.V101.11.4479; Koene HR, 1998, BLOOD, V91, P673, DOI 10.1182/blood.V91.2.673.673_673_679; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; OHNO S, 1968, HEREDITAS-GENETISK A, V59, P169; Pravenec M, 2001, NAT GENET, V27, P156, DOI 10.1038/84777; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; ROBERTON CA, 2003, THESIS U LONDON; Russell AI, 2004, HUM MOL GENET, V13, P137, DOI 10.1093/hmg/ddh021; SADO Y, 1986, J CLIN LAB IMMUNOL, V19, P193; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Stankiewicz P, 2002, TRENDS GENET, V18, P74, DOI 10.1016/S0168-9525(02)02592-1; Takai T, 2002, NAT REV IMMUNOL, V2, P580, DOI 10.1038/nri856; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; YAMORI Y, 1984, HDB HYPERTENSION, V4, P224	30	541	628	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 16	2006	439	7078					851	855		10.1038/nature04489	http://dx.doi.org/10.1038/nature04489			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012JA	16482158				2022-12-28	WOS:000235333600051
J	Keizer, RS; Goennenwein, STB; Klapwijk, TM; Miao, GX; Xiao, G; Gupta, A				Keizer, RS; Goennenwein, STB; Klapwijk, TM; Miao, GX; Xiao, G; Gupta, A			A spin triplet supercurrent through the half-metallic ferromagnet CrO2	NATURE			English	Article							THIN-FILMS; SUPERCONDUCTIVITY	In general, conventional superconductivity should not occur in a ferromagnet, though it has been seen in iron under pressure(1). Moreover, theory predicts that the current is always carried by pairs of electrons in a spin singlet state(2), so conventional superconductivity decays very rapidly when in contact with a ferromagnet, which normally prohibits the existence of singlet pairs. It has been predicted that this rapid spatial decay would not occur if spin triplet superconductivity could be induced in the ferromagnet(3,4). Here we report a Josephson supercurrent through the strong ferromagnet CrO2, from which we infer that it is a spin triplet supercurrent. Our experimental set-up is different from those envisaged in the earlier predictions, but we conclude that the underlying physical explanation for our result is a conversion from spin singlet pairs to spin triplets at the interface. The supercurrent can be switched with the direction of the magnetization, analogous to spin valve transistors, and therefore could enable magnetization-controlled Josephson junctions.	Delft Univ Technol, Fac Sci Appl, Kavli Inst Nanosci, NL-2628 CJ Delft, Netherlands; Univ Alabama, MINT Ctr, Tuscaloosa, AL 35487 USA; Brown Univ, Dept Phys, Providence, RI 02912 USA	Delft University of Technology; University of Alabama System; University of Alabama Tuscaloosa; Brown University	Keizer, RS (corresponding author), Delft Univ Technol, Fac Sci Appl, Kavli Inst Nanosci, NL-2628 CJ Delft, Netherlands.	r.s.keizer@tnw.tudelft.nl; t.m.klapwijk@tnw.tudelft.nl	Miao, Guo-Xing/S-9178-2019; Xiao, Gang/G-5691-2011; Miao, Guo-Xing/A-2411-2008; Klapwijk, Teunis M/C-8431-2016	Miao, Guo-Xing/0000-0002-8735-8077; Miao, Guo-Xing/0000-0002-4354-5540; Klapwijk, Teunis M/0000-0002-9369-9548; Goennenwein, Sebastian/0000-0002-5388-700X				Bergeret FS, 2005, REV MOD PHYS, V77, P1321, DOI 10.1103/RevModPhys.77.1321; Bergeret FS, 2001, PHYS REV LETT, V86, P4096, DOI 10.1103/PhysRevLett.86.4096; Coey JMD, 2002, J APPL PHYS, V91, P8345, DOI 10.1063/1.1447879; Eschrig M, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.137003; Giroud M, 1998, PHYS REV B, V58, P11872, DOI 10.1103/PhysRevB.58.R11872; Gupta A, 2000, J APPL PHYS, V87, P6073, DOI 10.1063/1.372616; Iosad NN, 2000, J APPL PHYS, V88, P5756, DOI 10.1063/1.1319653; Kadigrobov A, 2001, EUROPHYS LETT, V54, P394, DOI 10.1209/epl/i2001-00107-2; Kontos T, 2001, PHYS REV LETT, V86, P304, DOI 10.1103/PhysRevLett.86.304; Korotin MA, 1998, PHYS REV LETT, V80, P4305, DOI 10.1103/PhysRevLett.80.4305; LEGGETT AJ, 1975, REV MOD PHYS, V47, P331, DOI 10.1103/RevModPhys.47.331; Li XW, 1999, APPL PHYS LETT, V75, P713, DOI 10.1063/1.124491; Mackenzie AP, 2003, REV MOD PHYS, V75, P657, DOI 10.1103/RevModPhys.75.657; Parker JS, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.196601; Pena V, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.224502; Petrashov VT, 1999, PHYS REV LETT, V83, P3281, DOI 10.1103/PhysRevLett.83.3281; Ryazanov V. V., 1999, PHYS-USP, V42, P825; Saxena SS, 2000, NATURE, V406, P587, DOI 10.1038/35020500; Shimizu K, 2001, NATURE, V412, P316, DOI 10.1038/35085536; Soulen RJ, 1998, SCIENCE, V282, P85, DOI 10.1126/science.282.5386.85; Spinu L, 2000, PHYS REV B, V62, P8931, DOI 10.1103/PhysRevB.62.8931; Tinkham M., 1996, INTRO SUPERCONDUCTIV, V2nd ed.; Wilhelm FK, 1997, J LOW TEMP PHYS, V106, P305, DOI 10.1007/BF02399630	23	593	598	3	158	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 16	2006	439	7078					825	827		10.1038/nature04499	http://dx.doi.org/10.1038/nature04499			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012JA	16482152	Green Submitted			2022-12-28	WOS:000235333600044
J	Conway, BR; Fogarty, DG; Nelson, WE; Doherty, CC				Conway, BR; Fogarty, DG; Nelson, WE; Doherty, CC			Lesson of the week - Opiate toxicity in patients with renal failure	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Belfast City Hosp, Dept Nephrol, Belfast BT9 7AB, Antrim, North Ireland	Belfast City Hospital	Conway, BR (corresponding author), Belfast City Hosp, Dept Nephrol, Belfast BT9 7AB, Antrim, North Ireland.	BryanComvay@ntlworld.com	Fogarty, Damian/A-8925-2011					Barnung SK, 1997, PAIN, V71, P111, DOI 10.1016/S0304-3959(97)03350-2; BUNN R, 2004, RENAL DRUG HDB; Hanes SD, 1999, PHARMACOTHERAPY, V19, P897, DOI 10.1592/phco.19.10.897.31557; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; OSBORNE RJ, 1986, BRIT MED J, V292, P1548, DOI 10.1136/bmj.292.6535.1548; PARK GR, 1989, EUR J ANAESTH, V6, P303; Talbott GA, 1997, CLIN PEDIATR, V36, P171, DOI 10.1177/000992289703600308	7	19	20	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 11	2006	332	7537					345	346		10.1136/bmj.332.7537.345	http://dx.doi.org/10.1136/bmj.332.7537.345			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	012YI	16470057	Green Published, Green Submitted			2022-12-28	WOS:000235376400021
J	Harding, A				Harding, A			Profile - Ernest McCulloch: father of experimental haematology	LANCET			English	Biographical-Item												Anne_harding@yahoo.com							0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 11	2006	367	9509					467	467		10.1016/S0140-6736(06)68166-X	http://dx.doi.org/10.1016/S0140-6736(06)68166-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013FF	16473113	Bronze			2022-12-28	WOS:000235394500014
J	Shogren-Knaak, M; Ishii, H; Sun, JM; Pazin, MJ; Davie, JR; Peterson, CL				Shogren-Knaak, M; Ishii, H; Sun, JM; Pazin, MJ; Davie, JR; Peterson, CL			Histone H4-K16 acetylation controls chromatin structure and protein interactions	SCIENCE			English	Article							AMINO-TERMINAL TAIL; DOSAGE COMPENSATION; TRANSCRIPTION; YEAST; ARRAYS; MOF	Acetylation of histone H4 on lysine 16 (H4-K16Ac) is a prevalent and reversible posttranslational chromatin modification in eukaryotes. To characterize the structural and functional role of this mark, we used a native chemical ligation strategy to generate histone H4 that was homogeneously acetylated at K16. The incorporation of this modified histone into nucleosomal arrays inhibits the formation of compact 30-nanometer-like fibers and impedes the ability of chromatin to form cross-fiber interactions. H4-K16Ac also inhibits the ability of the adenosine triphosphate-utilizing chromatin assembly and remodeling enzyme ACF to mobilize a mononucleosome, indicating that this single histone modification modulates both higher order chromatin structure and functional interactions between a nonhistone protein and the chromatin fiber.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; NIA, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Manitoba; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Peterson, CL (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA.	craig.peterson@umassmed.edu		Pazin, Michael/0000-0002-7561-3640; Ishii, Haruhiko/0000-0002-1593-096X; Davie, James/0000-0002-0420-6888	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000524] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [GM54096, R01 GM054096] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; Clapier CR, 2001, MOL CELL BIOL, V21, P875, DOI 10.1128/MCB.21.3.875-883.2001; Corona DFV, 2002, EMBO REP, V3, P242, DOI 10.1093/embo-reports/kvf056; DAVIE JR, 1978, P NATL ACAD SCI USA, V75, P3574, DOI 10.1073/pnas.75.8.3574; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; Dorigo B, 2004, SCIENCE, V306, P1571, DOI 10.1126/science.1103124; Dorigo B, 2003, J MOL BIOL, V327, P85, DOI 10.1016/S0022-2836(03)00025-1; Eberharter A, 2004, METHOD ENZYMOL, V377, P344; Fry CJ, 2004, COLD SPRING HARB SYM, V69, P219, DOI 10.1101/sqb.2004.69.219; Hamiche A, 2001, P NATL ACAD SCI USA, V98, P14316, DOI 10.1073/pnas.251421398; Hansen J., COMMUNICATION; HANSEN JC, 1992, BIOCHEMISTRY-US, V31, P7977, DOI 10.1021/bi00149a032; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; LOHR D, 1977, BIOCHEMISTRY-US, V16, P463, DOI 10.1021/bi00622a020; Lowary PT, 1998, J MOL BIOL, V276, P19, DOI 10.1006/jmbi.1997.1494; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Offermann CA, 1936, J GENET, V32, P103, DOI 10.1007/BF02982505; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Schwarz PM, 1996, BIOCHEMISTRY-US, V35, P4009, DOI 10.1021/bi9525684; Shogren-Knaak MA, 2004, METHOD ENZYMOL, V375, P62; Smith CM, 2003, ANAL BIOCHEM, V316, P23, DOI 10.1016/S0003-2697(03)00032-0; Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602	25	1347	1391	7	154	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	2006	311	5762					844	847		10.1126/science.1124000	http://dx.doi.org/10.1126/science.1124000			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XT	16469925				2022-12-28	WOS:000235374900047
J	Rahi, JS; Cumberland, PM; Peckham, CS				Rahi, JS; Cumberland, PM; Peckham, CS			Does amblyopia affect educational, health, and social outcomes? Findings from 1958 British birth cohort	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIAL; VISUAL IMPAIRMENT; FOLLOW-UP; VISION; CHILDREN; POPULATION; RISK	Objective To determine the association of amblyopia with diverse educational, health, and social outcomes in order to inform current debate about population screening for this condition. Design, setting, and participants Comparison of 8432 people with normal vision in each eye with 429 (4.8%) people with amblyopia (childhood Unilateral reduced acuity when tested with correction and unaccounted for by eye disease) from the 1958 British birth cohort, with respect to subsequent health and social functioning. Results No functionally or clinically significant differences between people with and without amblyopia in education outcomes, behavioural difficulties or social maladjustment, participation in social activities, Unintended injuries (school, workplace, or road traffic accidents as driver), general or mental health and mortality, paid employment, or occupation based social class trajectories. Conclusions It may be difficult to distinguish, at population level, between the lives of people with amblyopia and those without, in terms of several important outcomes. A pressing need exists for further concerted research on what it means to have amblyopia and, specifically, how this varies with severity and how it changes with treatment, so that screening programmes can best serve those who have the most to gain from early identification.	Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 1EH, England	University of London; University College London	Rahi, JS (corresponding author), Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, 30 Guilford St, London WC1N 1EH, England.	j.rahi@ich.ucl.ac.uk	peckham, catherine s/I-6300-2013	Rahi, Jugnoo/0000-0002-5718-9209				Adams GGW, 1999, BRIT J OPHTHALMOL, V83, P380; [Anonymous], 2004, NATL CHILD DEV STUDY; Attebo K, 1998, OPHTHALMOLOGY, V105, P154, DOI 10.1016/S0161-6420(98)91862-0; Chua B, 2004, BRIT J OPHTHALMOL, V88, P1119, DOI 10.1136/bjo.2004.041863; Clarke MP, 2003, BMJ-BRIT MED J, V327, P1251, DOI 10.1136/bmj.327.7426.1251; CLARKE MP, 2003, BRIT MED J, V327, P1254; *DEP EMPL, 1972, CLASS OCC DIR OCC TI; Hall DMB, 2003, HLTH ALL CHILDREN; Holmes JM, 2004, J AAPOS, V8, P420, DOI 10.1016/j.jaapas.2004.07.007; Horwood J, 2005, INVEST OPHTH VIS SCI, V46, P1177, DOI 10.1167/iovs.04-0597; HOWMAN RJC, 1998, BR J OPHTHALMOL, V82, P543; Hrisos S, 2004, OPHTHALMOLOGY, V111, P1550, DOI 10.1016/j.ophtha.2003.12.059; JEFFERIS BJM, 2002, BRIT MED J, V335, P305; Leiba H, 2001, OPHTHALMOLOGY, V108, P1552, DOI 10.1016/S0161-6420(01)00697-2; Levi DM, 1993, EARLY VISUAL DEV NOR, P391; Packwood EA, 1999, J AAPOS, V3, P15, DOI 10.1016/S1091-8531(99)70089-3; Rahi JS, 2003, LANCET, V362, P1359, DOI 10.1016/S0140-6736(03)14631-4; Rahi JS, 1997, BMJ-BRIT MED J, V315, P1247, DOI 10.1136/bmj.315.7118.1247; Rahi JS, 2002, LANCET, V360, P597, DOI 10.1016/S0140-6736(02)09782-9; Rutter M., 1970, ED HLTH BEHAV; SNOWDON S, 1997, 9 NHS CRD U YORK; Stott D. H., 1987, SOCIAL ADJUSTMENT CH; WIESEL TN, 1982, NATURE, V299, P383; Williams C, 2002, BMJ-BRIT MED J, V324, P1549, DOI 10.1136/bmj.324.7353.1549; 2004, MILLENNIUM COHORT	25	66	70	0	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 8	2006	332	7545					820	824		10.1136/bmj.38751.597963.AE	http://dx.doi.org/10.1136/bmj.38751.597963.AE			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	032ZQ	16520328	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000236815900018
J	Dawson, MR; Marivaux, L; Li, CK; Beard, KC; Metais, G				Dawson, MR; Marivaux, L; Li, CK; Beard, KC; Metais, G			Laonastes and the "Lazarus effect'' in recent mammals	SCIENCE			English	Article							RODENTS		Carnegie Museum Nat Hist, Sect Vertebrate Paleontol, Pittsburgh, PA 15213 USA; Univ Montpellier 2, Inst Sci Evolut, Lab Paleontol, F-34095 Montpellier 05, France; Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, Beijing 100044, Peoples R China	Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS	Dawson, MR (corresponding author), Carnegie Museum Nat Hist, Sect Vertebrate Paleontol, 4400 Forbes Ave, Pittsburgh, PA 15213 USA.	dawsonm@carnegiemnh.org	Métais, Grégoire/F-6916-2010; Beard, K. Christopher/AAQ-4438-2021	Beard, K. Christopher/0000-0002-6279-9837				Fara E, 2001, GEOL J, V36, P291, DOI 10.1002/gj.879; Flynn L.J., 1986, AM MUS NOVIT, V2841, P1; Flynn Lawrence J., 2000, Himalayan Geology, V21, P39; FLYNN LJ, 2005, PALAONT ELECT, P1; Jablonski D., 1986, P183; Jenkins PD, 2004, SYST BIODIVERS, V2, P419, DOI DOI 10.1017/S1477200004001549; LI C-K, 1974, Vertebrata Palasiatica, V12, P43; Marivaux L, 2004, GEODIVERSITAS, V26, P493; Marivaux L, 2003, J VERTEBR PALEONTOL, V23, P420, DOI 10.1671/0272-4634(2003)023[0420:NDABRF]2.0.CO;2; Marivaux L, 2002, ZOOL SCR, V31, P225, DOI 10.1046/j.1463-6409.2002.00074.x; Marivaux L, 2004, ZOOL J LINN SOC-LOND, V142, P105, DOI 10.1111/j.1096-3642.2004.00131.x; Marshall L.G., 1982, Fieldiana Geology, V10, P1; Mein Pierre, 1997, Geodiversitas, V19, P783; NYERS N, 2000, NATURE, V403, P853; WETZEL RM, 1975, SCIENCE, V189, P379, DOI 10.1126/science.189.4200.379	15	65	76	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 10	2006	311	5766					1456	1458		10.1126/science.1124187	http://dx.doi.org/10.1126/science.1124187			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527978				2022-12-28	WOS:000236029400047
J	Bloche, MG				Bloche, MG			The supreme court and the purposes of medicine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Georgetown Univ, Washington, DC 20057 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA	Georgetown University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Bloche, MG (corresponding author), Georgetown Univ, Washington, DC 20057 USA.							BLOCHE MG, 2002, ETHICAL DIMENSIONS H, P133; HENDERSON JA, 1994, CORNELL LAW REV, V79, P1382	2	11	11	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 9	2006	354	10					993	995		10.1056/NEJMp068019	http://dx.doi.org/10.1056/NEJMp068019			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	019FY	16525134				2022-12-28	WOS:000235822200001
J	Joyce, T; Kaestner, R; Colman, S				Joyce, T; Kaestner, R; Colman, S			Changes in abortions and births and the Texas parental notification law	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INVOLVEMENT LAWS; MINORS ABORTIONS; UNITED-STATES; IMPACT; SERVICES; MINNESOTA; CONSENT	BACKGROUND: On January 1, 2000, Texas began enforcement of a law that requires physicians to notify a parent of a minor child seeking an abortion at least 48 hours before the procedure. METHODS: We assessed changes in the rates in Texas of abortions and births (events per 1000 age-specific population) before enforcement of the parental notification law (1998 to 1999) and after enforcement (2000 to 2002). We did this by comparing the rate changes among minors 15 to 17 years of age at the time of conception (i.e., those who were subject to the law) with those of teens 18 years of age at the time of conception (i.e., those who were not subject to the law). RESULTS: After enforcement of the law, abortion rates fell by 11 percent among 15-year-olds (rate ratio, 0.89; 95 percent confidence interval, 0.83 to 0.94), 20 percent among 16-year-olds (rate ratio, 0.80; 95 percent confidence interval, 0.76 to 0.85), and 16 percent among 17-year-olds (rate ratio 0.84; 95 percent confidence interval, 0.80 to 0.87), relative to the rates among 18-year-olds. Among the subgroup of minors 17.50 to 17.74 years of age at the time of conception (who would have been subject to the parental notification law in early pregnancy), birth rates rose by 4 percent relative to those of teens 18.00 to 18.24 years of age (rate ratio, 1.04; 95 percent confidence interval, 1.00 to 1.08). The adjusted odds ratio for having an abortion after 12 weeks' gestation among minors 17.50 to 17.74 years of age as compared with 18-year-olds was 1.34 (95 percent confidence interval, 1.10 to 1.62). CONCLUSIONS: The Texas parental notification law was associated with a decline in abortion rates among minors from 15 to 17 years of age. It was also associated with increased birth rates and rates of abortion during the second trimester among a subgroup of minors who were 17.50 to 17.74 years of age at the time of conception.	Natl Bur Econ Res, New York, NY 10016 USA; CUNY, Grad Ctr, New York, NY USA; CUNY, Baruch Coll, New York, NY 10021 USA; Univ Illinois, Chicago, IL USA	National Bureau of Economic Research; City University of New York (CUNY) System; City University of New York (CUNY) System; Baruch College (CUNY); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Joyce, T (corresponding author), Natl Bur Econ Res, 365 5th Ave,5th Fl, New York, NY 10016 USA.	ted_joyce@baruch.cuny.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD049359] Funding Source: NIH RePORTER; NICHD NIH HHS [1-R03-HD49359-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		*A GUTTM I, 2004, US TEEN PREGN STAT C; CARTOOF VG, 1986, AM J PUBLIC HEALTH, V76, P397, DOI 10.2105/AJPH.76.4.397; Elam-Evans Laurie D, 2003, MMWR Surveill Summ, V52, P1; ELAMEVANS LD, 2002, MMWR SURVEILL SUMM, V51, P11; Ellertson C, 1997, AM J PUBLIC HEALTH, V87, P1367, DOI 10.2105/AJPH.87.8.1367; Finer LB, 2003, PERSPECT SEX REPRO H, V35, P6, DOI 10.1111/j.1931-2393.2003.tb00079.x; GRIMES DA, 1984, FAM PLANN PERSPECT, V16, P260, DOI 10.2307/2134915; HaasWilson D, 1996, J HUM RESOUR, V31, P140, DOI 10.2307/146045; HENSHAW SK, 1992, FAM PLANN PERSPECT, V24, P196, DOI 10.2307/2135870; HENSHAW SK, 1995, FAM PLANN PERSPECT, V27, P120, DOI 10.2307/2136110; Jones RK, 2005, JAMA-J AM MED ASSOC, V293, P340, DOI 10.1001/jama.293.3.340; Joyce T, 1996, J HEALTH ECON, V15, P579, DOI 10.1016/S0167-6296(96)00496-1; Kane TJ, 1996, Q J ECON, V111, P467, DOI 10.2307/2946685; Kirkwood BR, 2003, ESSENTIAL MED STAT; Koonin Lisa M., 1995, Morbidity and Mortality Weekly Report, V44, P23; KOONIN LM, 1995, MMWR-MORBID MORTAL W, V44, P479; Levine PB, 2003, J HEALTH ECON, V22, P861, DOI 10.1016/S0167-6296(03)00063-8; *NAT AB REPR ACT R, 2005, STAT BY STAT REV AB; *NAT AB REPR ACT R, 1991, WHO DEC STAT BY STAT; OHSFELDT RL, 1994, CONTEMP ECON POLICY, V12, P65, DOI 10.1111/j.1465-7287.1994.tb00424.x; Reddy DM, 2002, JAMA-J AM MED ASSOC, V288, P710, DOI 10.1001/jama.288.6.710; ROGERS JL, 1991, AM J PUBLIC HEALTH, V81, P294, DOI 10.2105/AJPH.81.3.294; ROSENFIELD A, 1994, NEW ENGL J MED, V331, P324, DOI 10.1056/NEJM199408043310511; STOLBERG SG, 2005, NY TIMES        0308, pA17; *TEX LEG COUNC, NOT AB, pCH33; VENTURA SJ, 2002, TEENAGE BIRTHS US ST, V50	26	48	50	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 9	2006	354	10					1031	1038		10.1056/NEJMsa054047	http://dx.doi.org/10.1056/NEJMsa054047			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	019FY	16525140				2022-12-28	WOS:000235822200007
J	Takayesu, JK; Bazari, H; Linshaw, M				Takayesu, JK; Bazari, H; Linshaw, M			A 47-year-old man with altered mental status and acute renal failure - Ethylene glycol intoxication	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SERUM ANION GAP; DIABETIC-KETOACIDOSIS; SODIUM FLUORESCEIN; METABOLIC-ACIDOSIS; URINE FLUORESCENCE; INGESTION; ALCOHOL; METHANOL; BICARBONATE; ANTIFREEZE		Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Pediat, Div Nephrol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Med, Div Nephrol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Surg, Cambridge, MA 02138 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University; Harvard University; Brigham & Women's Hospital	Takayesu, JK (corresponding author), Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.							Adrogue HJ, 1999, NEW ENGL J MED, V340, P247; Adrogue HJ, 2004, J AM SOC NEPHROL, V15, P1667, DOI 10.1097/01.ASN.0000128354.88132.55; Adrogue HJ, 1998, NEW ENGL J MED, V338, P26, DOI 10.1056/NEJM199801013380106; Albertson TE, 1999, CRIT CARE MED, V27, P2834, DOI 10.1097/00003246-199912000-00043; BAUD FJ, 1988, NEW ENGL J MED, V319, P97, DOI 10.1056/NEJM198807143190206; BEASLEY VR, 1980, VET HUM TOXICOL, V22, P255; Brent J, 1999, NEW ENGL J MED, V340, P832, DOI 10.1056/NEJM199903183401102; Brent J, 2001, NEW ENGL J MED, V344, P424, DOI 10.1056/NEJM200102083440605; Broadley SA, 1997, J NEUROL NEUROSUR PS, V63, P261, DOI 10.1136/jnnp.63.2.261; Davis Daniel P., 1997, Journal of Emergency Medicine, V15, P653, DOI 10.1016/S0736-4679(97)00145-5; GABOW PA, 1985, KIDNEY INT, V27, P472, DOI 10.1038/ki.1985.34; GABOW PA, 1986, ANN INTERN MED, V105, P16, DOI 10.7326/0003-4819-105-1-16; GABOW PA, 1980, NEW ENGL J MED, V303, P854, DOI 10.1056/NEJM198010093031505; Gardner TB, 2004, J CLIN GASTROENTEROL, V38, P435, DOI 10.1097/00004836-200405000-00009; Glaser N, 2001, NEW ENGL J MED, V344, P264, DOI 10.1056/NEJM200101253440404; Ishihara K, 1998, SEMIN NEPHROL, V18, P83; JACOBSEN D, 1988, AM J MED, V84, P145, DOI 10.1016/0002-9343(88)90024-1; JACOBSEN D, 1986, MED TOXICOL ADV DRUG, V1, P309, DOI 10.1007/BF03259846; Jacobsen D, 1999, NEW ENGL J MED, V340, P879, DOI 10.1056/NEJM199903183401110; Kan G, 2003, NEPHROL DIAL TRANSPL, V18, P2665, DOI 10.1093/ndt/gfg432; Lewis LD, 1997, CLIN PHARMACOL THER, V61, P692, DOI 10.1016/S0009-9236(97)90105-3; Litovitz TL, 2002, AM J EMERG MED, V20, P391, DOI 10.1053/ajem.2002.34955; Mycyk MB, 2003, AM J EMERG MED, V21, P333, DOI 10.1016/S0735-6757(03)00079-2; PIERCE NF, 1970, ANN INTERN MED, V72, P633, DOI 10.7326/0003-4819-72-5-633; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Rose BD, 2001, CLIN PHYSL ACID BASE, P583; Trummel J, 1996, ANN EMERG MED, V27, P368, DOI 10.1016/S0196-0644(96)70274-3; Viallon A, 1999, CRIT CARE MED, V27, P2690, DOI 10.1097/00003246-199912000-00014; VUKMIR RB, 1995, CRIT CARE MED, V23, P515, DOI 10.1097/00003246-199503000-00017; WACKER WEC, 1965, J AMER MED ASSOC, V194, P1231, DOI 10.1001/jama.194.11.1231; WALKER JA, 1986, ARCH INTERN MED, V146, P1843, DOI 10.1001/archinte.146.9.1843; Wallace KL, 2001, ANN EMERG MED, V38, P49, DOI 10.1067/mem.2001.115531; WINTER ML, 1990, ANN EMERG MED, V19, P663, DOI 10.1016/S0196-0644(05)82472-2; WINTER S D, 1990, Archives of Internal Medicine, V150, P311, DOI 10.1001/archinte.150.2.311; 1987, MMWR MORB MORTAL WKL, V36, P611	35	16	17	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 9	2006	354	10					1065	1072		10.1056/NEJMcpc059043	http://dx.doi.org/10.1056/NEJMcpc059043			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	019FY	16525144				2022-12-28	WOS:000235822200012
J	Nolan, T; Berwick, DM				Nolan, T; Berwick, DM			All-or-none measurement raises the bar on performance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MYOCARDIAL-INFARCTION; HOSPITALS; THERAPY; TRIALS		Inst Healthcare Improvement, Cambridge, MA 02138 USA	Institute for Healthcare Improvement	Berwick, DM (corresponding author), Inst Healthcare Improvement, 20 Univ Ave,7th Floor, Cambridge, MA 02138 USA.	dberwick@ihi.org						*AHRQ, 2004, AHRQ PUBL; AMUNDSEN G, HEALTHPARTNERS 2004; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; *CTR MED MED SERV, MED HLTH OUTC SURV F; *CTR MED MED SERV, 8 SCOP WORK VERS 080; Dellinger EP, 2005, AM J SURG, V190, P9, DOI 10.1016/j.amjsurg.2004.12.001; Hennekens CH, 1996, NEW ENGL J MED, V335, P1660, DOI 10.1056/NEJM199611283352207; *JOINT COMM ACCR H, FACTS ORYX HOSP COR; *JOINT COMM ACCR H, ATTR COR PERF MEAS A; *NAT COMM QUAL ASS, HLTH EMPL DAT INF SE; Premier. Inc, SUMM COMP QUAL SCOR; Williams SC, 2005, NEW ENGL J MED, V353, P255, DOI 10.1056/NEJMsa043778	12	290	289	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	2006	295	10					1168	1170		10.1001/jama.295.10.1168	http://dx.doi.org/10.1001/jama.295.10.1168			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	019GB	16522838				2022-12-28	WOS:000235822500026
J	Englund, JA; Boeckh, M; Kuypers, J; Nichols, WG; Hackman, RC; Morrow, RA; Fredricks, DN; Corey, L				Englund, JA; Boeckh, M; Kuypers, J; Nichols, WG; Hackman, RC; Morrow, RA; Fredricks, DN; Corey, L			Brief communication: Fatal human metapneumovirus infection in stem-cell transplant recipients	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	46th Annual Meeting of the American-Society-of-Hematology	DEC 04-07, 2004	San Diego, CA	Amer Soc Hematol			RESPIRATORY-TRACT DISEASE; TIME RT-PCR; SYNCYTIAL VIRUS; CHILDREN; ADULTS; REPLICATION; SPECIMENS; YOUNG	Background: Human metapneumovirus (hMPV), a recently discovered respiratory virus, is associated with clinical disease in young and elderly persons. Objective: To determine the importance of hMPV in hematopoietic stem-cell transplant recipients. Design: Retrospective survey of patients with consecutive residual bronchoalveolar lavage (BAL) samples. Setting: Referral cancer center. Patients: Hematopoietic stem-cell transplant recipients who underwent BAL because of lower respiratory tract disease. Measurements: Bronchoalveolar lavage specimens were assayed by quantitative real-time polymerase chain reaction methods. Results: Human metapneumovirus was detected in BAL specimens from 5 of 163 patients (3.0%). Persistent viral infection was noted in 3 patients with several samples, and hMPV was detected in 1 of 2 lung specimens tested. Infected patients became symptomatic within the first 40 days after transplantation. Initial symptoms included fever, cough, nasal congestion, and sore throat. Clinical findings included respiratory failure, pulmonary hemorrhage, and culture-negative septic shock. Four of 5 patients died with acute respiratory failure. Limitations: This retrospective study did not evaluate asymptomatic patients or those with mild disease. Conclusion: Human metapneumovirus infection in the lower respiratory tract is associated with respiratory failure in immunocompromised adults who were previously considered to have "idiopathic pneumonia." The infection may result in fulminant respiratory decompensation and shock after transplantation.	Univ Washington, Childrens Hosp & Reg Med Ctr, Seattle, WA 98105 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA	Seattle Children's Hospital; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Englund, JA (corresponding author), Univ Washington, Childrens Hosp & Reg Med Ctr, 4800 Sand Point Way NE,Mail Stop W-8851, Seattle, WA 98105 USA.	janet.englund@seattlechildrens.org	Corey, Lawrence/AAE-1796-2020; Boeckh, Michael/AAA-1607-2022	Corey, Lawrence/0000-0002-2179-2436; Fredricks, David/0000-0003-2735-6800	NATIONAL CANCER INSTITUTE [P01CA018029, P30CA015704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030731] Funding Source: NIH RePORTER; NCI NIH HHS [CA 15704, P01 CA18029, P30 CA015704, CA 18029] Funding Source: Medline; NIAID NIH HHS [P01 AI 30731] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Boivin G, 2002, J INFECT DIS, V186, P1330, DOI 10.1086/344319; Cane PA, 2003, BONE MARROW TRANSPL, V31, P309, DOI 10.1038/sj.bmt.1703849; CORDONNIER C, 2003, TRANSPLANT INFECTION, P143; ENGLUND JA, 1988, ANN INTERN MED, V109, P203, DOI 10.7326/0003-4819-109-3-203; Falsey AR, 2003, J INFECT DIS, V187, P785, DOI 10.1086/367901; Fredricks DN, 1999, BIOTECHNIQUES, V26, P198, DOI 10.2144/99262bm04; Fredricks DN, 2000, EMERG INFECT DIS, V6, P273, DOI 10.3201/eid0603.000307; Fukuda T, 2003, BLOOD, V102, P2777, DOI 10.1182/blood-2003-05-1597; Kuiken T, 2004, AM J PATHOL, V164, P1893, DOI 10.1016/S0002-9440(10)63750-9; Kuypers J, 2005, J CLIN VIROL, V33, P299, DOI 10.1016/j.jcv.2004.11.023; Kuypers J, 2004, J CLIN VIROL, V31, P123, DOI 10.1016/j.jcv.2004.03.018; Maertzdorf J, 2004, J CLIN MICROBIOL, V42, P981, DOI 10.1128/JCM.42.3.981-986.2004; Musher B, 2004, J CLIN MICROBIOL, V42, P5517, DOI 10.1128/JCM.42.12.5517-5522.2004; Nichols WG, 2001, BLOOD, V98, P573, DOI 10.1182/blood.V98.3.573; Pelletier G, 2002, EMERG INFECT DIS, V8, P976, DOI 10.3201/eid0809.020238; Sumino KC, 2005, J INFECT DIS, V192, P1052, DOI 10.1086/432728; van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098; Williams JV, 2005, J INFECT DIS, V192, P1061, DOI 10.1086/432732; Williams JV, 2004, NEW ENGL J MED, V350, P443, DOI 10.1056/NEJMoa025472; Zerr DM, 2002, CLIN INFECT DIS, V34, P309, DOI 10.1086/338044	20	177	183	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 7	2006	144	5					344	349		10.7326/0003-4819-144-5-200603070-00010	http://dx.doi.org/10.7326/0003-4819-144-5-200603070-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	021EA	16520475				2022-12-28	WOS:000235965300005
J	Pignone, M; Earnshaw, S; Tice, JA; Pletcher, MJ				Pignone, M; Earnshaw, S; Tice, JA; Pletcher, MJ			Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: A cost-utility analysis	ANNALS OF INTERNAL MEDICINE			English	Article							LOW-DOSE ASPIRIN; CARDIOVASCULAR-DISEASE; SECONDARY PREVENTION; UNSTABLE ANGINA; ARTERY-DISEASE; RISK REDUCTION; STROKE; METAANALYSIS; PRAVASTATIN; MANAGEMENT	Background: Aspirin and statins are both effective for primary prevention of coronary heart disease (CHD), but their combined use has not been well studied. Objective: To perform a cost-utility analysis of the effects of aspirin therapy, statin therapy, combination therapy with both drugs, and no pharmacotherapy for the primary prevention of CHD events in men. Design: Markov model. Data Sources: Published literature. Target Population: Middle-aged men without a history of cardiovascular disease at 6 levels of 10-year risk for CHD (2.5%, 5%, 7.5%, 10%, 15%, and 25%). Time Horizon: Lifetime. Perspective: Third-party payer. Interventions: Low-dose aspirin, a statin, both drugs as combination therapy, or no therapy. Outcome Measure: Cost per quality-adjusted life-year gained. Results of Base-Case Analysis: For 45-year-old men who do not smoke, are not hypertensive, and have a 10-year risk for CHD of 7.5%, aspirin was more effective and less costly than no treatment. The addition of a statin to aspirin therapy produced an incremental cost-utility ratio of $56 200 per quality-adjusted life-year gained compared with aspirin alone. Results of Sensitivity Analysis: Excess risk for hemorrhagic stroke and gastrointestinal bleeding with aspirin, risk for CHD, the cost of statins, and the disutility of taking medication had important effects on the cost-utility ratios. Limitations: Several input parameters, particularly adverse event rates and utility values, are supported by limited empirical data. Results are applicable to middle-aged men only. Conclusions: Compared with no treatment, aspirin is less costly and more effective for preventing CHID events in middle-aged men whose 10-year risk for CHID is 7.5% or higher. The addition of a statin to aspirin therapy becomes more cost-effective when the patient's 10-year CHD risk before treatment is higher than 10%.	Univ N Carolina, RTI, Ctr Hlth Promot Econ, Chapel Hill, NC 27515 USA; RTI Hlth Solut, Res Triangle Pk, NC USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Research Triangle Institute; University of North Carolina; University of North Carolina Chapel Hill; Research Triangle Institute; University of California System; University of California San Francisco	Pignone, M (corresponding author), Univ N Carolina, UNC Hosp, Div Gen Internal Med, 5039 Old Clin Bldg, Chapel Hill, NC 27599 USA.	pignone@med.unc.edu		Pignone, Michael/0000-0002-6657-7342; Earnshaw, Stephanie/0000-0003-2975-6509; Tice, Jeffrey/0000-0002-9857-2028	OFFICE OF THE DIRECTOR, CENTERS FOR DISEASE CONTROL &PREVENTION [P30CD000138] Funding Source: NIH RePORTER; ODCDC CDC HHS [1P30CD000138-01] Funding Source: Medline	OFFICE OF THE DIRECTOR, CENTERS FOR DISEASE CONTROL &PREVENTION(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); ODCDC CDC HHS		*AM HEART ASS, 2003, HEART DIS STROK STAT, P1; ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; Ashraf T, 1996, AM J CARDIOL, V78, P409, DOI 10.1016/S0002-9149(96)00328-1; Augustovski FA, 1998, J GEN INTERN MED, V13, P824, DOI 10.1046/j.1525-1497.1998.00246.x; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Berg AO, 2002, ANN INTERN MED, V136, P157, DOI 10.7326/0003-4819-136-2-200201150-00015; Briel M, 2004, AM J MED, V117, P596, DOI 10.1016/j.amjmed.2004.04.022; Briggs AH, 2002, MED DECIS MAKING, V22, P290, DOI 10.1177/027298902400448867; Chen Q, 2000, INQUIRY-J HEALTH CAR, V37, P359; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Colwell John A, 2004, Diabetes Care, V27 Suppl 1, pS72; de Feyter PJ, 2002, CIRCULATION, V105, P2367, DOI 10.1161/01.CIR.0000016643.34907.17; DENNIS MS, 1993, STROKE, V24, P796, DOI 10.1161/01.STR.24.6.796; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Eisenstein EL, 2001, MED CARE, V39, P824, DOI 10.1097/00005650-200108000-00008; GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839; Graham DJ, 2004, JAMA-J AM MED ASSOC, V292, P2585, DOI 10.1001/jama.292.21.2585; Hart RG, 2000, ARCH NEUROL-CHICAGO, V57, P326, DOI 10.1001/archneur.57.3.326; Hayden M, 2002, ANN INTERN MED, V136, P161, DOI 10.7326/0003-4819-136-2-200201150-00016; He J, 1998, JAMA-J AM MED ASSOC, V280, P1930, DOI 10.1001/jama.280.22.1930; Hennekens CH, 2004, ARCH INTERN MED, V164, P40, DOI 10.1001/archinte.164.1.40; *ING, 2003, ESS RBRVS COMPR LIST; Jonsson B, 2003, J INTERN MED, V253, P472, DOI 10.1046/j.1365-2796.2003.01135.x; Kim C, 2004, AM J PREV MED, V27, P1, DOI 10.1016/j.amepre.2004.03.008; Ladabaum U, 2001, ANN INTERN MED, V135, P769, DOI 10.7326/0003-4819-135-9-200111060-00007; Lampe FC, 2000, EUR HEART J, V21, P1052, DOI 10.1053/euhj.1999.1866; LaRosa JC, 1999, JAMA-J AM MED ASSOC, V282, P2340, DOI 10.1001/jama.282.24.2340; Mahoney EM, 2002, JAMA-J AM MED ASSOC, V288, P1851, DOI 10.1001/jama.288.15.1851; Marshall T, 2003, BMJ-BRIT MED J, V327, P1264, DOI 10.1136/bmj.327.7426.1264; *MED EC CO, 2003, RED BOOK WIND VERS 5; Minino A M, 2001, Natl Vital Stat Rep, V49, P1; Murphy Michael, 2002, Clin Evid, P91; NAGLIE IG, 1992, MED DECIS MAKING, V12, P239, DOI 10.1177/0272989X9201200401; NEASE RF, 1995, JAMA-J AM MED ASSOC, V273, P1185, DOI 10.1001/jama.273.15.1185; Nelson MR, 2005, BMJ-BRIT MED J, V330, P1306, DOI 10.1136/bmj.38456.676806.8F; Pearson TA, 2002, CIRCULATION, V106, P388, DOI 10.1161/01.CIR.0000020190.45892.75; Pignone M, 2000, BRIT MED J, V321, P983, DOI 10.1136/bmj.321.7267.983; Pignone MP, 2001, AM J PREV MED, V20, P77, DOI 10.1016/S0749-3797(01)00255-0; Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613; Rosamond WD, 1999, STROKE, V30, P736, DOI 10.1161/01.STR.30.4.736; Rosenson RS, 2004, AM J MED, V116, P408, DOI 10.1016/j.amjmed.2003.10.033; Russell MW, 1998, AM J CARDIOL, V81, P1110, DOI 10.1016/S0002-9149(98)00136-2; Sanmuganathan PS, 2001, HEART, V85, P265, DOI 10.1136/heart.85.3.265; Sheridan S, 2003, J GEN INTERN MED, V18, P1039, DOI 10.1111/j.1525-1497.2003.30107.x; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; State Inpatient Database, 2015, HEALTHC COST UT PROJ; Sudlow C, 2001, Practitioner, V245, P859; Troche CJ, 1998, EUR HEART J, V19, pC59; TSEVAT J, 1993, MED DECIS MAKING, V13, P161, DOI 10.1177/0272989X9301300210; White HD, 2000, NEW ENGL J MED, V343, P317, DOI 10.1056/NEJM200008033430502	50	139	144	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 7	2006	144	5					326	336		10.7326/0003-4819-144-5-200603070-00007	http://dx.doi.org/10.7326/0003-4819-144-5-200603070-00007			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	021EA	16520473				2022-12-28	WOS:000235965300003
J	Maier, T; Jenni, S; Ban, N				Maier, T; Jenni, S; Ban, N			Architecture of mammalian fatty acid synthase at 4.5 angstrom resolution	SCIENCE			English	Article							BETA-KETOACYL SYNTHASE; POLYKETIDE BIOSYNTHESIS; CHICKEN LIVER; ACTIVE-SITE; THIOESTERASE; SYNTHETASE; SUBUNIT; ORGANIZATION; FLEXIBILITY; SPECIFICITY	The homodimeric mammalian fatty acid synthase is one of the most complex cellular multienzymes, in that each 270-kilodalton polypeptide chain carries all seven functional domains required for fatty acid synthesis. We have calculated a 4.5 angstrom-resolution x-ray crystallographic map of porcine fatty acid synthase, highly homologous to the human multienzyme, and placed homologous template structures of all individual catalytic domains responsible for the cyclic elongation of fatty acid chains into the electron density. The positioning of domains reveals the complex architecture of the multienzyme forming an intertwined dimer with two lateral semicircular reaction chambers, each containing a full set of catalytic domains required for fatty acid elongation. Large distances between active sites and conformational differences between the reaction chambers demonstrate that mobility of the acyl carrier protein and general flexibility of the multienzyme must accompany handover of the reaction intermediates during the reaction cycle.	ETH, Swiss Fed Inst Technol, Dept Biol, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Ban, N (corresponding author), ETH, Swiss Fed Inst Technol, Dept Biol, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland.	ban@mol.biol.ethz.ch	Maier, Timm/A-8835-2016	Maier, Timm/0000-0002-7459-1363				Asturias FJ, 2005, NAT STRUCT MOL BIOL, V12, P225, DOI 10.1038/nsmb899; Brink J, 2002, P NATL ACAD SCI USA, V99, P138, DOI 10.1073/pnas.012589499; Chakravarty B, 2004, P NATL ACAD SCI USA, V101, P15567, DOI 10.1073/pnas.0406901101; Chirala SS, 2001, P NATL ACAD SCI USA, V98, P3104, DOI 10.1073/pnas.051635998; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; Jenni S, 2006, SCIENCE, V311, P1263, DOI 10.1126/science.1123251; Joshi AK, 2005, BIOCHEMISTRY-US, V44, P4100, DOI 10.1021/bi047856r; Joshi AK, 1998, BIOCHEMISTRY-US, V37, P2515, DOI 10.1021/bi971886v; Joshi AK, 2003, CHEM BIOL, V10, P169, DOI 10.1016/S1074-5521(03)00023-1; JOSHI AK, 1993, J BIOL CHEM, V268, P22508; Keatinge-Clay AT, 2003, STRUCTURE, V11, P147, DOI 10.1016/S0969-2126(03)00004-2; Kimber MS, 2004, J BIOL CHEM, V279, P52593, DOI 10.1074/jbc.M408105200; KITAMOTO T, 1988, J MOL BIOL, V203, P183, DOI 10.1016/0022-2836(88)90101-5; Koski MK, 2005, J MOL BIOL, V345, P1157, DOI 10.1016/j.jmb.2004.11.009; Kuhajda FP, 2005, TRENDS PHARMACOL SCI, V26, P541, DOI 10.1016/j.tips.2005.09.002; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Kumar MV, 2002, P NATL ACAD SCI USA, V99, P1921, DOI 10.1073/pnas.042683699; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; LIBERTINI LJ, 1978, J BIOL CHEM, V253, P1393; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; LYNEN F, 1967, BIOCHEM J, V102, P381, DOI 10.1042/bj1020381; MATTICK JS, 1983, J BIOL CHEM, V258, P5300; Nordling E, 2002, EUR J BIOCHEM, V269, P4267, DOI 10.1046/j.1432-1033.2002.03114.x; Olsen JG, 2001, STRUCTURE, V9, P233, DOI 10.1016/S0969-2126(01)00583-4; Persson B, 2003, CHEM-BIOL INTERACT, V143, P271, DOI 10.1016/S0009-2797(02)00223-5; Price AC, 2001, BIOCHEMISTRY-US, V40, P12772, DOI 10.1021/bi010737g; Rangan VS, 1998, J BIOL CHEM, V273, P34949, DOI 10.1074/jbc.273.52.34949; Rangan VS, 2001, BIOCHEMISTRY-US, V40, P10792, DOI 10.1021/bi015535z; Reed MAC, 2003, ORG BIOMOL CHEM, V1, P463, DOI 10.1039/b208941f; Schweizer E, 2004, MICROBIOL MOL BIOL R, V68, P501, DOI 10.1128/MMBR.68.3.501-517.2004; Shen B, 2003, CURR OPIN CHEM BIOL, V7, P285, DOI 10.1016/S1367-5931(03)00020-6; Shimomura Y, 2003, J BACTERIOL, V185, P4211, DOI 10.1128/JB.185.14.4211-4218.2003; Smith S, 2003, PROG LIPID RES, V42, P289, DOI 10.1016/S0163-7827(02)00067-X; Staunton J, 2001, NAT PROD REP, V18, P380, DOI 10.1039/a909079g; Staunton J, 1996, NAT STRUCT BIOL, V3, P188, DOI 10.1038/nsb0296-188; TIAN WX, 1985, J BIOL CHEM, V260, P1375; White SW, 2005, ANNU REV BIOCHEM, V74, P791, DOI 10.1146/annurev.biochem.74.082803.133524; Witkowski A, 2004, CHEM BIOL, V11, P1667, DOI 10.1016/j.chembiol.2004.09.016; Witkowski A, 2002, BIOCHEMISTRY-US, V41, P10877, DOI 10.1021/bi0259047; YUAN Z, 1986, J BIOL CHEM, V261, P3643; Zhang YM, 2003, J LIPID RES, V44, P1, DOI 10.1194/jlr.R200016-JLR200	42	298	322	4	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	2006	311	5765					1258	1262		10.1126/science.1123248	http://dx.doi.org/10.1126/science.1123248			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019XB	16513975				2022-12-28	WOS:000235870400033
J	Kainosho, M; Torizawa, T; Iwashita, Y; Terauchi, T; Ono, AM; Guntert, P				Kainosho, M; Torizawa, T; Iwashita, Y; Terauchi, T; Ono, AM; Guntert, P			Optimal isotope labelling for NMR protein structure determinations	NATURE			English	Article							MALTODEXTRIN-BINDING-PROTEIN; MAGNETIC-RESONANCE SPECTRA; TORSION ANGLE DYNAMICS; CELL-FREE SYNTHESIS; CHEMICAL-SHIFT; MULTIDIMENSIONAL NMR; HETERONUCLEAR NMR; C-13; ASSIGNMENTS; RESOLUTION	Nuclear-magnetic-resonance spectroscopy can determine the three-dimensional structure of proteins in solution. However, its potential has been limited by the difficulty of interpreting NMR spectra in the presence of broadened and overlapping resonance lines and low signal-to-noise ratios. Here we present stereo-array isotope labelling ( SAIL), a technique that can overcome many of these problems by applying a complete stereospecific and regiospecific pattern of stable isotopes that is optimal with regard to the quality and information content of the resulting NMR spectra. SAIL uses exclusively chemically and enzymatically synthesized amino acids for cell-free protein expression. We demonstrate for the 17-kDa protein calmodulin and the 41-kDa maltodextrin-binding protein that SAIL offers sharpened lines, spectral simplification without loss of information, and the ability to rapidly collect the structural restraints required to solve a high-quality solution structure for proteins twice as large as commonly solved by NMR. It thus makes a large class of proteins newly accessible to detailed solution structure determination.	JST, CREST, Hachioji, Tokyo 1920397, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Hachioji, Tokyo 1920397, Japan; RIKEN Genom Sci Ctr, Tatsuo Miyazawa Mem Program, Yokohama, Kanagawa 2300045, Japan	Japan Science & Technology Agency (JST); Tokyo Metropolitan University; RIKEN	Kainosho, M (corresponding author), JST, CREST, 1-1 Minami Ohsawa, Hachioji, Tokyo 1920397, Japan.	kainosho@nmr.chem.metro-u.ac.jp	Güntert, Peter/L-5577-2013	Güntert, Peter/0000-0002-2911-7574				ARATA Y, 1994, METHOD ENZYMOL, V239, P440; Cavanagh J., 1996, PROTEIN NMR SPECTROS; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; Chou JJ, 2001, NAT STRUCT BIOL, V8, P990, DOI 10.1038/nsb1101-990; Clore GM, 1998, CURR OPIN CHEM BIOL, V2, P564, DOI 10.1016/S1367-5931(98)80084-7; CLORE GM, 1994, PROG BIOPHYS MOL BIO, V62, P153; CORNELL WD, 1995, J AM CHEM SOC, V117, P5197; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Farmer II B. T., 1999, MOD TECHNIQUES PROTE, V16, P75; Gardner KH, 1998, ANNU REV BIOPH BIOM, V27, P357, DOI 10.1146/annurev.biophys.27.1.357; Goto NK, 2000, CURR OPIN STRUC BIOL, V10, P585, DOI 10.1016/S0959-440X(00)00135-4; Guntert P, 2003, PROG NUCL MAG RES SP, V43, P105, DOI 10.1016/S0079-6565(03)00021-9; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1989, J AM CHEM SOC, V111, P3997; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; IKURA M, 1991, BIOCHEMISTRY-US, V30, P9216, DOI 10.1021/bi00102a013; KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7; Kennedy Michael A., 2002, Journal of Structural and Functional Genomics, V2, P155, DOI 10.1023/A:1021261026670; KIGAWA T, 1995, J BIOMOL NMR, V6, P129, DOI 10.1007/BF00211776; Koradi R, 2000, COMPUT PHYS COMMUN, V124, P139, DOI 10.1016/S0010-4655(99)00436-1; LEMASTER DM, 1987, FEBS LETT, V223, P191, DOI 10.1016/0014-5793(87)80534-3; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MARKLEY JL, 1968, SCIENCE, V161, P1249, DOI 10.1126/science.161.3847.1249; MCINTOSH LP, 1990, Q REV BIOPHYS, V23, P1, DOI 10.1017/S0033583500005400; Mueller GA, 2000, J MOL BIOL, V300, P197, DOI 10.1006/jmbi.2000.3842; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NILGES M, 1990, BIOPOLYMERS, V29, P813, DOI 10.1002/bip.360290415; Oba M, 2001, J ORG CHEM, V66, P5919, DOI 10.1021/jo010263r; Oba M, 1998, TETRAHEDRON LETT, V39, P1595, DOI 10.1016/S0040-4039(98)00037-9; Oba M, 1999, TETRAHEDRON-ASYMMETR, V10, P937, DOI 10.1016/S0957-4166(99)00083-X; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; SHARFF AJ, 1993, BIOCHEMISTRY-US, V32, P10553, DOI 10.1021/bi00091a004; Torizawa T, 2005, J AM CHEM SOC, V127, P12620, DOI 10.1021/ja051386m; Torizawa T, 2004, J BIOMOL NMR, V30, P311, DOI 10.1007/s10858-004-3534-2; VUISTER GW, 1992, J MAGN RESON, V98, P428, DOI 10.1016/0022-2364(92)90144-V; Yamazaki T, 1998, J AM CHEM SOC, V120, P5591, DOI 10.1021/ja980776o; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411	37	368	378	2	83	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2006	440	7080					52	57		10.1038/nature04525	http://dx.doi.org/10.1038/nature04525			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017HW	16511487				2022-12-28	WOS:000235685700036
J	Salamon, F; Hirsch, R; Tur-Kaspa, R; Kramer, MR				Salamon, F; Hirsch, R; Tur-Kaspa, R; Kramer, MR			Clinical problem-solving: Search for the complication	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PULMONARY VEIN STENOSIS; ATRIAL-FIBRILLATION; RADIOFREQUENCY ABLATION; CATHETER ABLATION		Rabin Med Ctr, Dept Med D, IL-49100 Petah Tiqwa, Israel; Rabin Med Ctr, Dept Cardiol, IL-49100 Petah Tiqwa, Israel; Rabin Med Ctr, Dept Pulm Med, IL-49100 Petah Tiqwa, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Rabin Medical Center; Rabin Medical Center; Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Salamon, F (corresponding author), Rabin Med Ctr, Dept Med D, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.	salamonf@post.tau.ac.il						Arentz T, 2003, EUR HEART J, V24, P963, DOI 10.1016/S0195-668X(03)00002-2; Cappato R, 2005, CIRCULATION, V111, P1100, DOI 10.1161/01.CIR.0000157153.30978.67; Haissaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003; Nanthakumar K, 2004, CHEST, V126, P645, DOI 10.1378/chest.126.2.645; Packer DL, 2005, CIRCULATION, V111, P546, DOI 10.1161/01.CIR.0000154541.58478.36; Qureshi AM, 2003, CIRCULATION, V108, P1336, DOI 10.1161/01.CIR.0000086322.21781.6A; Saad EB, 2003, ANN INTERN MED, V138, P634, DOI 10.7326/0003-4819-138-8-200304150-00010; Saad EB, 2003, CIRCULATION, V108, P3102, DOI 10.1161/01.CIR.0000104569.96907.7F; Yang M, 2001, J COMPUT ASSIST TOMO, V25, P34, DOI 10.1097/00004728-200101000-00006	9	3	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 2	2006	354	9					957	963		10.1056/NEJMcps050791	http://dx.doi.org/10.1056/NEJMcps050791			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	017FN	16510750				2022-12-28	WOS:000235679600010
J	Conroy, SP; Luxton, T; Dingwall, R; Harwood, RH; Gladman, JRF				Conroy, SP; Luxton, T; Dingwall, R; Harwood, RH; Gladman, JRF			Controversy - Cardiopulmonary resuscitation in continuing care settings: time for a rethink?	BRITISH MEDICAL JOURNAL			English	Article							HOSPITAL CARDIAC-ARREST; FUNCTIONAL STATUS; NURSING-HOMES; SURVIVORS; CPR; LIFE; GUIDELINES; OUTCOMES; EXPERIENCE; MORTALITY		Univ Nottingham, Sch Med, Queens Med Ctr, Div Rehabil & Ageing, Nottingham NG7 2UH, England; Cambridge Univ Hosp, Cambridge CB1 3DF, England; Univ Nottingham, Inst Study Genet Biorisks & Soc, Nottingham NG7 2RD, England; City Hosp Nottingham, Nottingham NG5 1PB, England	University of Nottingham; University of Cambridge; University of Nottingham; Nottingham University Hospital NHS Trust; Nottingham City Hospital	Conroy, SP (corresponding author), Univ Nottingham, Sch Med, Queens Med Ctr, Div Rehabil & Ageing, Nottingham NG7 2UH, England.	simon.conroy@nottingham.ac.uk	Dingwall, Robert WJ/A-9348-2008; Conroy, Simon/B-8832-2009; Gladman, John/M-7429-2015	Dingwall, Robert WJ/0000-0002-1588-3796; Harwood, Rowan/0000-0002-4920-6718; Gladman, John/0000-0002-8506-7786; Conroy, Simon/0000-0002-4306-6064				APPLEBAUM GE, 1990, J AM GERIATR SOC, V38, P197, DOI 10.1111/j.1532-5415.1990.tb03490.x; Ballew KA, 1995, RESUSCITATION, V30, P203, DOI 10.1016/0300-9572(95)00894-2; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BEER RJ, 1994, RESUSCITATION, V27, P189, DOI 10.1016/0300-9572(94)90032-9; Benkendorf R, 1997, Prehosp Emerg Care, V1, P68, DOI 10.1080/10903129708958790; BILSKY GS, 1992, AM J PHYS MED REHAB, V71, P232, DOI 10.1097/00002060-199208000-00006; Booth CM, 2004, JAMA-J AM MED ASSOC, V291, P870, DOI 10.1001/jama.291.7.870; Bowker L, 1999, RESUSCITATION, V40, P89, DOI 10.1016/S0300-9572(99)00008-8; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; De Maio VJ, 2001, ANN EMERG MED, V37, P602, DOI 10.1067/mem.2001.114302; de Vos R, 1999, ARCH INTERN MED, V159, P249, DOI 10.1001/archinte.159.3.249; *DEP HLTH, 2003, NAT DEF PROGR BACKGR; deVreedeSwagemakers JJM, 1997, J AM COLL CARDIOL, V30, P1500, DOI 10.1016/S0735-1097(97)00355-0; Diggory P, 2003, RESUSCITATION, V56, P159, DOI 10.1016/S0300-9572(02)00349-0; Ebell MH, 1998, J GEN INTERN MED, V13, P805, DOI 10.1046/j.1525-1497.1998.00244.x; Fitz Gerald JD, 1997, ARCH INTERN MED, V157, P72, DOI 10.1001/archinte.157.1.72; Gjerdingen DK, 1999, ARCH FAM MED, V8, P421, DOI 10.1001/archfami.8.5.421; Graves JR, 1997, RESUSCITATION, V35, P117; Herlitz J, 2005, CORONARY ARTERY DIS, V16, P51, DOI 10.1097/00019501-200502000-00010; Herlitz J, 2004, HEART, V90, P1114, DOI 10.1136/hrt.2003.029348; Kim C, 2000, ARCH INTERN MED, V160, P3439, DOI 10.1001/archinte.160.22.3439; Leung L P, 2001, Prehosp Emerg Care, V5, P308, DOI 10.1080/10903120190939887; Lim HC, 2001, RESUSCITATION, V51, P123, DOI 10.1016/S0300-9572(01)00399-9; LONGSTRETH WT, 1983, ANN INTERN MED, V98, P588, DOI 10.7326/0003-4819-98-5-588; Nichol G, 1999, ACAD EMERG MED, V6, P95, DOI 10.1111/j.1553-2712.1999.tb01044.x; O'Keeffe ST, 2001, AGE AGEING, V30, P19, DOI 10.1093/ageing/30.1.19; OBRIEN LA, 1995, JAMA-J AM MED ASSOC, V274, P1775, DOI 10.1001/jama.274.22.1775; OKEEFFE S, 1994, RESUSCITATION, V28, P21, DOI 10.1016/0300-9572(94)90050-7; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Pell JP, 2000, EUR HEART J, V21, P239, DOI 10.1053/euhj.1999.1629; *RES COUNC, 2001, DEC REL CARD RES JOI; Rothera IC, 2002, PUBLIC HEALTH, V116, P160, DOI 10.1038/sj.ph.190032; Stratton SJ, 1998, ANN EMERG MED, V32, P448, DOI 10.1016/S0196-0644(98)70174-X; TRESCH DD, 1993, AM J MED, V95, P123, DOI 10.1016/0002-9343(93)90252-K; Valentin A, 1995, RESUSCITATION, V30, P217, DOI 10.1016/0300-9572(95)00898-5	35	26	26	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	FEB 25	2006	332	7539					479	482		10.1136/bmj.332.7539.479	http://dx.doi.org/10.1136/bmj.332.7539.479			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	018VM	16497767	Green Published			2022-12-28	WOS:000235792900023
J	Peacock, S; Ruta, D; Mitton, C; Donaldson, C; Bate, A; Murtagh, M				Peacock, S; Ruta, D; Mitton, C; Donaldson, C; Bate, A; Murtagh, M			Health economics - Using economics to set pragmatic and ethical priorities	BRITISH MEDICAL JOURNAL			English	Editorial Material									British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada; Univ Newcastle Upon Tyne, Sch Populat & Hlth Sci, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Univ British Columbia, Fac Hlth & Social Dev, Kelowna, BC, Canada	British Columbia Cancer Agency; Newcastle University - UK; University of British Columbia	Peacock, S (corresponding author), British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada.	speacock@bccrc.ca	Ruta, Danny A/E-4472-2013; Peacock, Stuart J/P-2437-2018; Bate, Angela/AAR-1027-2020	Peacock, Stuart J/0000-0002-8243-8721; Bate, Angela/0000-0001-5277-4188; Ruta, Danny/0000-0002-2024-3267; Donaldson, Cam/0000-0003-4670-5340	Economic and Social Research Council [RES-451-25-4087] Funding Source: researchfish	Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))		Daniels N, 1998, HEALTH AFFAIR, V17, P50, DOI 10.1377/hlthaff.17.5.50; Ham C, 2001, J Health Serv Res Policy, V6, P163, DOI 10.1258/1355819011927422; HOPE T, 2002, MED SOCIAL JUSTICE; MacDonald R, 2002, USING HLTH EC HLTH S; MARTIN D, 2005, HLTH SERV J     0106, P12; Miller P, 1997, HEALTH POLICY, V40, P217, DOI 10.1016/S0168-8510(97)00902-0; Mitton C, 2002, HEALTH POLICY, V60, P39, DOI 10.1016/S0168-8510(01)00190-7; Mitton C, 2004, PRIORITY SETTING TOO; Mitton Craig, 2003, Appl Health Econ Health Policy, V2, P121; MOONEY G, 1999, LISTENING BUREAUCRAT; MOONEY G, 1992, 6 NAT ASS HLTH AUTH; MURTAGH MJ, 2003, AGEING INEQUALITIES; Peacock S., 1998, EVALUATION PROGRAMME; Ruta D, 2005, BRIT MED J, V330, P1501, DOI 10.1136/bmj.330.7506.1501; Smith J, 2004, REV EFFECTIVENESS PR; Wanless, 2002, SECURING OUR FUTURE	16	57	58	1	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 25	2006	332	7539					482	485		10.1136/bmj.332.7539.482	http://dx.doi.org/10.1136/bmj.332.7539.482			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	018VM	16497768	Green Published			2022-12-28	WOS:000235792900024
J	Woods, DR; Arun, CS; Corris, PA; Perros, P				Woods, DR; Arun, CS; Corris, PA; Perros, P			Lesson of the week - Cushing's syndrome without excess cortisol	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DOSE INHALED STEROIDS; FLUTICASONE PROPIONATE; ADRENAL INSUFFICIENCY; CYSTIC-FIBROSIS; ITRACONAZOLE; CORTICOSTEROIDS; ASPERGILLOSIS; SUPPRESSION; BUDESONIDE; PATIENT		Freeman Rd Hosp, Dept Endocrinol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; Freeman Rd Hosp, Dept Resp Med, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England	Newcastle Freeman Hospital; Newcastle University - UK; Newcastle Freeman Hospital; Newcastle University - UK	Arun, CS (corresponding author), Freeman Rd Hosp, Dept Endocrinol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.	csarun2003@yahoo.co.uk		Perros, Petros/0000-0001-7320-5574; arun, chankramath/0000-0002-6831-2524				Bolland MJ, 2004, ANN PHARMACOTHER, V38, P46, DOI 10.1345/aph.1D222; Clevenbergh P, 2002, J INFECTION, V44, P194, DOI 10.1053/jinf.2001.0928; De Wachter Elke, 2003, J Cyst Fibros, V2, P72, DOI 10.1016/S1569-1993(03)00022-5; GRANT SM, 1989, DRUGS, V37, P310, DOI 10.2165/00003495-198937030-00003; Lebrun-Vignes B, 2001, BRIT J CLIN PHARMACO, V51, P443, DOI 10.1046/j.1365-2125.2001.01372.x; Lipworth BJ, 1998, SEMIN RESP CRIT CARE, V19, P625, DOI 10.1055/s-2007-1009437; Main KM, 2002, ACTA PAEDIATR, V91, P1008, DOI 10.1080/080352502760272759; Parmar JS, 2002, THORAX, V57, P749, DOI 10.1136/thorax.57.8.749; Raaska K, 2002, CLIN PHARMACOL THER, V72, P362, DOI 10.1067/mcp.2002.127397; Sim D, 2003, EUR RESPIR J, V21, P633, DOI 10.1183/09031936.03.00306302; Skov M, 2002, EUR RESPIR J, V20, P127, DOI 10.1183/09031936.02.00248002; Soubani AO, 2002, CHEST, V121, P1988, DOI 10.1378/chest.121.6.1988; van Rossum EFC, 2004, RECENT PROG HORM RES, V59, P333, DOI 10.1210/rp.59.1.333; Venkatakrishnan K, 2000, CLIN PHARMACOKINET, V38, P111, DOI 10.2165/00003088-200038020-00002; Wilson AM, 1998, J ALLERGY CLIN IMMUN, V101, P470, DOI 10.1016/S0091-6749(98)70354-9; Wilson AM, 2000, CHEST, V117, P593, DOI 10.1378/chest.117.2.593; WONG J, 1992, BRIT MED J, V304, P1415, DOI 10.1136/bmj.304.6839.1415-a	17	10	10	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 25	2006	332	7539					469	470		10.1136/bmj.332.7539.469	http://dx.doi.org/10.1136/bmj.332.7539.469			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	018VM	16497762	Green Published			2022-12-28	WOS:000235792900020
J	Srivastava, R				Srivastava, R			Doctors need doctors too	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												docranjana@gmail.com							0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	2006	295	8					866	867		10.1001/jama.295.8.866	http://dx.doi.org/10.1001/jama.295.8.866			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014DO	16493091				2022-12-28	WOS:000235459200001
J	Fentiman, IS; Fourquet, A; Hartobagyi, GN				Fentiman, IS; Fourquet, A; Hartobagyi, GN			Male breast cancer	LANCET			English	Review							ANDROGEN RECEPTOR GENE; SENTINEL-NODE BIOPSY; RISK-FACTORS; KLINEFELTERS-SYNDROME; ELECTROMAGNETIC-FIELDS; ADJUVANT RADIOTHERAPY; PROGNOSTIC FACTORS; LOBULAR CARCINOMA; BRCA2 MUTATIONS; OCCUPATIONAL-EXPOSURE	Occurrence of male breast cancer, a rare disease, peaks at age 71 years. Familial cases usually have BRCA2 rather than BRCA1 mutations. Occupational risks include high temperature environments and exhaust fumes, but electromagnetic fields have not been implicated. Hyperoestrogenisation resulting from Klinefelter's, gonadal dysfunction, obesity, or excess alcohol, all increase risk as does exposure to radiation, whereas gynaecomastia does not. Presentation is usually a lump or nipple inversion, but is often late, with more than 40% of individuals having stage III or IV disease. Most tumours are ductal and 10% are ductal carcinoma in situ. Surgery is usually mastectomy with axillary clearance or sentinel node biopsy. Indications for radiotherapy, by stage, are similar to female breast cancer. Because 90% of tumours are oestrogen-receptor-positive, tamoxifen is standard adjuvant therapy, but some individuals could also benefit from chemotherapy. Hormonal therapy is the main treatment for metastatic disease, but chemotherapy can also provide palliation. National initiatives are increasingly needed to improve information and support for male breast cancer patients.	Guys Hosp, London SE1 9RT, England; Inst Curie, Dept Radiotherapie, Paris, France; Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA	Guy's & St Thomas' NHS Foundation Trust; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Texas System; UTMD Anderson Cancer Center	Fentiman, IS (corresponding author), Guys Hosp, Thomas Guy House, London SE1 9RT, England.	Ian.Fentiman@gstt.nhs.uk	Fentiman, Ian/AAB-9886-2020					ANDERSEN JA, 1982, ACTA PATH MICRO IM A, V90, P191; Anderson WF, 2004, BREAST CANCER RES TR, V83, P77, DOI 10.1023/B:BREA.0000010701.08825.2d; BAGLEY CS, 1987, AM J CLIN ONCOL-CANC, V10, P55, DOI 10.1097/00000421-198702000-00013; BALLERINI P, 1990, TUMORI, V76, P26, DOI 10.1177/030089169007600106; Basham VM, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr419; Behr TM, 2001, NEW ENGL J MED, V345, P995; Bhagwandin S, 1972, E AFR MED J, V49, P176; Bloom KJ, 2001, AM J SURG, V182, P389, DOI 10.1016/S0002-9610(01)00733-4; Brainard GC, 1999, J PINEAL RES, V26, P65, DOI 10.1111/j.1600-079X.1999.tb00568.x; CAREY AH, 1994, HUM MOL GENET, V3, P1873, DOI 10.1093/hmg/3.10.1873; CARLSSON G, 1981, CLIN ONCOL, V7, P149; CASAGRANDE JT, 1988, CANCER RES, V48, P1326; Chakravarthy A, 2002, RADIOTHER ONCOL, V65, P99, DOI 10.1016/S0167-8140(02)00210-4; CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3181, DOI 10.1093/nar/22.15.3181; CRICHLOW RW, 1972, SURG GYNECOL OBSTETR, V134, P1011; Cutuli B, 1995, EUR J CANCER, V31A, P1960, DOI 10.1016/0959-8049(95)00366-5; DAVANZO B, 1995, BRIT J CANCER, V71, P1359, DOI 10.1038/bjc.1995.264; De Cicco C, 2004, NUCL MED COMMUN, V25, P139, DOI 10.1097/00006231-200402000-00008; de Jong MM, 2002, J MED GENET, V39, P225, DOI 10.1136/jmg.39.4.225; de Toro MMM, 1998, J STEROID BIOCHEM, V67, P333, DOI 10.1016/S0960-0760(98)00124-1; DEAN C, 1987, J PSYCHOSOM RES, V31, P385, DOI 10.1016/0022-3999(87)90059-6; DEMERS PA, 1991, AM J EPIDEMIOL, V134, P340, DOI 10.1093/oxfordjournals.aje.a116095; Dicker AP, 2003, LANCET ONCOL, V4, P30, DOI 10.1016/S1470-2045(03)00958-6; Donegan WL, 1998, CANCER-AM CANCER SOC, V83, P498, DOI 10.1002/(SICI)1097-0142(19980801)83:3<498::AID-CNCR19>3.0.CO;2-R; DRELICHMAN A, 1980, UROLOGY, V16, P250, DOI 10.1016/0090-4295(80)90036-9; Early Breast Canc Trialists Collaborat, 2000, LANCET, V355, P1757, DOI 10.1016/S0140-6736(00)02263-7; ERLICHMAN C, 1984, J CLIN ONCOL, V2, P903, DOI 10.1200/JCO.1984.2.8.903; Ewertz M, 2001, ACTA ONCOL, V40, P467, DOI 10.1080/028418601750288181; Fackenthal JD, 2001, J MED GENET, V38, P159, DOI 10.1136/jmg.38.3.159; FARROW JOSEPH H., 1942, SCIENCE, V95, P654, DOI 10.1126/science.95.2478.654; FECZKO JD, 1995, ACTA CYTOL, V39, P803; FENTIMAN IS, 1988, LANCET, V1, P609; FENTIMAN IS, 1990, LANCET, V335, P1020, DOI 10.1016/0140-6736(90)91075-L; Forloni F, 2001, J ENDOCRINOL INVEST, V24, P454, DOI 10.1007/BF03351047; France L, 2000, BREAST, V9, P343, DOI 10.1054/brst.2000.0173; Frank TS, 2002, J CLIN ONCOL, V20, P1480, DOI 10.1200/JCO.20.6.1480; Friedman LS, 1997, AM J HUM GENET, V60, P313; GI S, 2001, J CLIN PATHOL, V54, P956; Giordano SH, 2004, CANCER, V101, P51, DOI 10.1002/cncr.20312; Giordano SH, 2002, AM J CLIN ONCOL-CANC, V25, P235, DOI 10.1097/00000421-200206000-00006; GIORDANO SH, 2005, CANCER, V104, P235; GIULIANO AE, 1994, ANN SURG, V220, P391, DOI 10.1097/00000658-199409000-00015; Goss PE, 1999, CANCER-AM CANCER SOC, V85, P629, DOI 10.1002/(SICI)1097-0142(19990201)85:3<629::AID-CNCR13>3.0.CO;2-V; Gudmundsdottir K, 2003, BRIT J CANCER, V88, P933, DOI 10.1038/sj.bjc.6600839; Guenel P, 2004, CANCER CAUSE CONTROL, V15, P571, DOI 10.1023/B:CACO.0000036154.18162.43; GUINEE VF, 1993, CANCER-AM CANCER SOC, V71, P154, DOI 10.1002/1097-0142(19930101)71:1<154::AID-CNCR2820710125>3.0.CO;2-#; Hansen J, 2000, AM J IND MED, V37, P349, DOI 10.1002/(SICI)1097-0274(200004)37:4<349::AID-AJIM4>3.0.CO;2-L; HARNDEN DG, 1971, J MED GENET, V8, P460, DOI 10.1136/jmg.8.4.460; HELLER KS, 1978, ANN SURG, V188, P60, DOI 10.1097/00000658-197807000-00010; Hittmair AP, 1998, CANCER-AM CANCER SOC, V83, P2139, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2139::AID-CNCR12>3.0.CO;2-F; Hsing AW, 1998, CANCER CAUSE CONTROL, V9, P269, DOI 10.1023/A:1008869003012; HULTBORN R, 1987, ACTA ONCOL, V26, P327, DOI 10.3109/02841868709104357; Hultborn R, 1997, ANTICANCER RES, V17, P4293; JAIYESIMI IA, 1992, ANN INTERN MED, V117, P771, DOI 10.7326/0003-4819-117-9-771; Johnson KC, 2002, EUR J CANCER PREV, V11, P253, DOI 10.1097/00008469-200206000-00009; Joshi MG, 1996, CANCER, V77, P490; KANTARJIAN H, 1983, ARCH INTERN MED, V143, P237, DOI 10.1001/archinte.143.2.237; Katz A, 2001, INT J RADIAT ONCOL, V50, P397, DOI 10.1016/S0360-3016(01)01465-1; Krag D, 1998, NEW ENGL J MED, V339, P941, DOI 10.1056/NEJM199810013391401; Kwiatkowska E, 2003, CLIN CANCER RES, V9, P4452; LAVECCHIA C, 1992, INT J CANCER, V51, P62, DOI 10.1002/ijc.2910510113; LENFANTPEJOVIC MH, 1990, INT J CANCER, V45, P661, DOI 10.1002/ijc.2910450415; LOBACCARO JM, 1993, NAT GENET, V5, P109, DOI 10.1038/ng1093-109; LOOMIS DP, 1992, LANCET, V339, P1482, DOI 10.1016/0140-6736(92)92078-T; LOPEZ M, 1985, ONCOLOGY, V42, P345, DOI 10.1159/000226061; LOWELL DM, 1968, CANCER, V22, P581, DOI 10.1002/1097-0142(196809)22:3<581::AID-CNCR2820220314>3.0.CO;2-N; Ma FC, 2005, AM J IND MED, V47, P509, DOI 10.1002/ajim.20160; MABUCHI K, 1985, J NATL CANCER I, V74, P371; Macdonald G, 2005, ANN ONCOL, V16, P1442, DOI 10.1093/annonc/mdi274; MAGUIRE GP, 1978, BMJ-BRIT MED J, V1, P963, DOI 10.1136/bmj.1.6118.963; Martin AM, 2000, JNCI-J NATL CANCER I, V92, P1126, DOI 10.1093/jnci/92.14.1126; Mauras N, 2000, J CLIN ENDOCR METAB, V85, P2370, DOI 10.1210/jc.85.7.2370; MCCLURE JA, 1951, JAMA-J AM MED ASSOC, V146, P7, DOI 10.1001/jama.1951.03670010011002; MCLAUGHLIN JK, 1988, BRIT J IND MED, V45, P275; Meijer-van Gelder ME, 2001, BREAST CANCER RES TR, V68, P249, DOI 10.1023/A:1012221921416; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; MEYSKENS FL, 1976, CANCER TREAT REV, V3, P83, DOI 10.1016/S0305-7372(76)80006-0; MICHAELS BM, 1994, SURGERY, V115, P402; MORRIS T, 1977, CANCER-AM CANCER SOC, V40, P2381, DOI 10.1002/1097-0142(197711)40:5<2381::AID-CNCR2820400555>3.0.CO;2-B; NAGASAWA H, 1993, LAB ANIM, V27, P358, DOI 10.1258/002367793780745570; NANCE KVA, 1989, HUM PATHOL, V20, P1220, DOI 10.1016/S0046-8177(89)80017-6; NIRMUL D, 1983, BRIT J CANCER, V48, P423, DOI 10.1038/bjc.1983.208; O'Malley CD, 2002, CANCER, V94, P2836, DOI 10.1002/cncr.10521; Ohayon T, 2004, INT J CANCER, V108, P479, DOI 10.1002/ijc.11603; OJARA EA, 1978, E AFR MED J, V55, P489; Okada Kenzo, 2003, Breast Cancer, V10, P163, DOI 10.1007/BF02967643; OLSSON H, 1988, JNCI-J NATL CANCER I, V80, P679, DOI 10.1093/jnci/80.9.679; Palli D, 2004, EUR J CANCER, V40, P2474, DOI 10.1016/j.ejca.2004.07.012; Paszat LF, 1998, J CLIN ONCOL, V16, P2625, DOI 10.1200/JCO.1998.16.8.2625; PATEL HZ, 1989, CANCER, V64, P1583, DOI 10.1002/1097-0142(19891015)64:8<1583::AID-CNCR2820640804>3.0.CO;2-Q; Pierce L J, 1996, Oncology (Williston Park), V10, P991; Pierce LJ, 2002, INT J RADIAT ONCOL, V52, P1220, DOI 10.1016/S0360-3016(01)02760-2; Pollan M, 2001, AM J IND MED, V39, P276, DOI 10.1002/1097-0274(200103)39:3<276::AID-AJIM1015>3.0.CO;2-B; PRICE WH, 1985, J EPIDEMIOL COMMUN H, V39, P330, DOI 10.1136/jech.39.4.330; Ramantanis G, 1980, World J Surg, V4, P621; Rayson D, 1998, CANCER, V83, P1947, DOI 10.1002/(SICI)1097-0142(19981101)83:9<1947::AID-CNCR10>3.0.CO;2-J; Remouchamps VM, 2003, INT J RADIAT ONCOL, V55, P392, DOI 10.1016/S0360-3016(02)04143-3; RIBEIRO G, 1992, BRIT J CANCER, V65, P252, DOI 10.1038/bjc.1992.50; Ribeiro GG, 1996, BREAST, V5, P141, DOI 10.1016/S0960-9776(96)90058-2; Ron E, 2005, J NATL CANCER I, V97, P603, DOI 10.1093/jnci/dji097; Rundle A, 2000, CARCINOGENESIS, V21, P1281, DOI 10.1093/carcin/21.7.1281; SACHS MD, 1941, RADIOLOGY, V37, P458; SANCHEZ AG, 1986, CANCER-AM CANCER SOC, V57, P1181, DOI 10.1002/1097-0142(19860315)57:6<1181::AID-CNCR2820570619>3.0.CO;2-T; SASCO AJ, 1993, INT J CANCER, V53, P538, DOI 10.1002/ijc.2910530403; Scheike O, 1975, Acta Pathol Microbiol Scand Suppl, VSuppl 251, P3; SCHOTTENFELD D, 1963, AM J PUBLIC HEALTH N, V53, P890, DOI 10.2105/AJPH.53.6.890; Schuchardt U, 1996, AM J CLIN ONCOL-CANC, V19, P330, DOI 10.1097/00000421-199608000-00002; Smith TR, 2003, CANCER EPIDEM BIOMAR, V12, P1200; Spear SL, 1998, PLAST RECONSTR SURG, V102, P1615, DOI 10.1097/00006534-199810000-00043; STALSBERG H, 1993, CANCER CAUSE CONTROL, V4, P143, DOI 10.1007/BF00053155; STEINITZ R, 1981, J MED SCI, V17, P816; Stewart RAL, 1997, CLIN RADIOL, V52, P739, DOI 10.1016/S0009-9260(97)80151-1; STIERER M, 1995, WORLD J SURG, V19, P687, DOI 10.1007/BF00295904; Stranzl H, 1999, RADIOTHER ONCOL, V53, P29, DOI 10.1016/S0167-8140(99)00122-X; SYMMERS WSC, 1968, BRIT MED J, V2, P83, DOI 10.1136/bmj.2.5597.83; Syrjakoski K, 2004, INT J CANCER, V108, P475, DOI 10.1002/ijc.11384; Syrjakoski K, 2003, BREAST CANCER RES TR, V77, P167, DOI 10.1023/A:1021369508561; THOMAS DB, 1992, AM J EPIDEMIOL, V135, P734, DOI 10.1093/oxfordjournals.aje.a116360; Thorlacius S, 1997, AM J HUM GENET, V60, P1079; TREVES N, 1955, CANCER, V8, P1239, DOI 10.1002/1097-0142(1955)8:6<1239::AID-CNCR2820080622>3.0.CO;2-E; TREVES N, 1944, SURG GYNECOL OBSTET, V79, P589; TYNES T, 1990, LANCET, V336, P1596, DOI 10.1016/0140-6736(90)93387-5; VANGEEL AN, 1985, BRIT J SURG, V72, P724, DOI 10.1002/bjs.1800720918; Veronesi U, 2003, NEW ENGL J MED, V349, P546, DOI 10.1056/NEJMoa012782; VISFELDT J, 1973, CANCER-AM CANCER SOC, V32, P985, DOI 10.1002/1097-0142(197310)32:4<985::AID-CNCR2820320433>3.0.CO;2-0; Volm MD, 1997, J SURG ONCOL, V64, P74, DOI 10.1002/(SICI)1096-9098(199701)64:1<74::AID-JSO14>3.0.CO;2-W; Waterhouse J, 1976, IARC SCI PUBL, V3, P15; Weiderpass E, 2001, CANCER CAUSE CONTROL, V12, P661, DOI 10.1023/A:1011216502678; Williams BG, 2003, BRIT J CANCER, V89, P1834, DOI 10.1038/sj.bjc.6601305; Willsher PC, 1997, AM J SURG, V173, P185, DOI 10.1016/S0002-9610(97)89592-X; WOOSTER R, 1992, NAT GENET, V2, P132, DOI 10.1038/ng1092-132; Yang WT, 2001, AM J ROENTGENOL, V176, P413, DOI 10.2214/ajr.176.2.1760413; YAP HY, 1979, CANCER, V44, P748, DOI 10.1002/1097-0142(197908)44:2<748::AID-CNCR2820440248>3.0.CO;2-9; Yildirim E, 1998, EUR J SURG ONCOL, V24, P548, DOI 10.1016/S0748-7983(98)93608-3; Young IE, 1999, BRIT J CANCER, V81, P141, DOI 10.1038/sj.bjc.6690663; Young IE, 2000, J MED GENET, V37, P139, DOI 10.1136/jmg.37.2.139; Zabel A, 2005, TUMORI, V91, P151, DOI 10.1177/030089160509100209; Zabolotny BP, 2005, J SURG ONCOL, V90, P26, DOI 10.1002/jso.20233	138	431	452	0	35	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 18	2006	367	9510					595	604		10.1016/S0140-6736(06)68226-3	http://dx.doi.org/10.1016/S0140-6736(06)68226-3			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013GM	16488803				2022-12-28	WOS:000235397800034
J	Beg, AA; Scheiffele, P				Beg, AA; Scheiffele, P			Neuroscience - SUMO wrestles the synapse	SCIENCE			English	Editorial Material							DENDRITIC GROWTH; TRANSCRIPTION; KINASE		Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University	Beg, AA (corresponding author), Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA.	ab2516@columbia.edu; ps2018@columbia.edu						Aizawa H, 2004, SCIENCE, V303, P197, DOI 10.1126/science.1089845; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; Flavell SW, 2006, SCIENCE, V311, P1008, DOI 10.1126/science.1122511; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Redmond L, 2002, NEURON, V34, P999, DOI 10.1016/S0896-6273(02)00737-7; Shalizi A, 2006, SCIENCE, V311, P1012, DOI 10.1126/science.1122513; Van Aelst L, 2004, CURR OPIN NEUROBIOL, V14, P297, DOI 10.1016/j.conb.2004.05.012; West AE, 2002, NAT REV NEUROSCI, V3, P921, DOI 10.1038/nrn987; Wong ROL, 2002, NAT REV NEUROSCI, V3, P803, DOI 10.1038/nrn941	9	6	6	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 17	2006	311	5763					962	963		10.1126/science.1124541	http://dx.doi.org/10.1126/science.1124541			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014CS	16484483				2022-12-28	WOS:000235456900033
J	Yin, L; Wang, J; Klein, PS; Lazar, MA				Yin, L; Wang, J; Klein, PS; Lazar, MA			Nuclear receptor Rev-erba is a critical lithium-sensitive component of the circadian clock	SCIENCE			English	Article							GENE-EXPRESSION; BIPOLAR DISORDER; VALPROIC ACID; TRANSCRIPTION; CELLS; DEACETYLASE; INHIBITORS; DROSOPHILA; MECHANISM; RHYTHMS	Lithium is commonly used to treat bipolar disorder, which is associated with altered circadian rhythm. Lithium is a potent inhibitor of glycogen synthase kinase 3 (GSK3), which regulates circadian rhythm in several organisms. In experiments with cultured cells, we show here that GSK3 beta phosphorylates and stabilizes the orphan nuclear receptor Rev-erb alpha, a negative component of the circadian clock. Lithium treatment of cells leads to rapid proteasomal degradation of Rev-erb alpha and activation of clock gene Bmal1. A form of Rev-erb alpha that is insensitive to lithium interferes with the expression of circadian genes. Control of Rev-erb alpha protein stability is thus a critical component of the peripheral clock and a biological target of lithium therapy.	Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Div Hematol & Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Inst Diabet Obes & Metab, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Lazar, MA (corresponding author), Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, 415 Curie Blvd, Philadelphia, PA 19104 USA.	lazar@mail.med.upenn.edu	Lazar, Mitchell A/AAF-3738-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045586, P30DK019525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH058324] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 19525, DK45586] Funding Source: Medline; NIMH NIH HHS [MH058324, R01 MH058324-07, R01 MH058324-08, R01 MH058324] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abe M, 2000, NEUROREPORT, V11, P3261, DOI 10.1097/00001756-200009280-00042; Adelmant G, 1996, P NATL ACAD SCI USA, V93, P3553, DOI 10.1073/pnas.93.8.3553; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Benedetti F, 2004, NEUROSCI LETT, V368, P123, DOI 10.1016/j.neulet.2004.06.050; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Dokucu ME, 2005, NEUROPSYCHOPHARMACOL, V30, P2216, DOI 10.1038/sj.npp.1300764; Eide EJ, 2005, METHOD ENZYMOL, V393, P408, DOI 10.1016/S0076-6879(05)93019-X; Gachon F, 2004, CHROMOSOMA, V113, P103, DOI 10.1007/s00412-004-0296-2; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GELENBERG AJ, 1989, NEW ENGL J MED, V321, P1489, DOI 10.1056/NEJM198911303212201; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Harms E, 2004, J BIOL RHYTHM, V19, P361, DOI 10.1177/0748730404268111; Iitaka C, 2005, J BIOL CHEM, V280, P29397, DOI 10.1074/jbc.M503526200; Iwahana E, 2004, EUR J NEUROSCI, V19, P2281, DOI 10.1111/j.0953-816X.2004.03322.x; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Lenox RH, 2002, AM J MED GENET, V114, P391, DOI 10.1002/ajmg.10360; Lowrey PL, 2004, ANNU REV GENOM HUM G, V5, P407, DOI 10.1146/annurev.genom.5.061903.175925; Mansour HA, 2005, ANN MED, V37, P196, DOI 10.1080/07853890510007377; Martinek S, 2001, CELL, V105, P769, DOI 10.1016/S0092-8674(01)00383-X; Nagoshi E, 2005, METHOD ENZYMOL, V393, P543, DOI 10.1016/S0076-6879(05)93028-0; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Ripperger JA, 2000, GENE DEV, V14, P679; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Ueda HR, 2002, NATURE, V418, P534, DOI 10.1038/nature00906; Yin L, 2005, MOL ENDOCRINOL, V19, P1452, DOI 10.1210/me.2005-0057; Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200	29	404	424	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 17	2006	311	5763					1002	1005		10.1126/science.1121613	http://dx.doi.org/10.1126/science.1121613			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014CS	16484495				2022-12-28	WOS:000235456900046
J	Brent, AJ; Ahmed, I; Ndiritu, M; Lewa, P; Ngetsa, C; Lowe, B; English, M; Berkeley, JA; Scott, JAG				Brent, AJ; Ahmed, I; Ndiritu, M; Lewa, P; Ngetsa, C; Lowe, B; English, M; Berkeley, JA; Scott, JAG			Incidence of clinically significant bacteraemia in children who present to hospital in Kenya: community-based observational study	LANCET			English	Article							PNEUMOCOCCAL CONJUGATE VACCINE; OCCULT BACTEREMIA; EMERGENCY-DEPARTMENT; FEBRILE CHILDREN; YOUNG-CHILDREN; DEATH; BLOOD	Background Estimates of the burden of invasive bacterial disease in sub-Saharan Africa have previously relied on selected groups of patients, such as inpatients; they are, therefore, probably underestimated, potentially hampering vaccine implementation. Our aim was to assess the incidence of bacteraemia in all children presenting to a hospital in Kenya, irrespective of clinical presentation or decision to admit. Methods We did a community-based observational study for which we cultured blood from 1093 children who visited a Kenyan hospital outpatient department. We estimated bacteraemia incidence with a Demographic Surveillance System, and investigated the clinical significance of bacteraemia and the capacity of clinical signs to identify cases. Results The yearly incidence of bacteraemia per 100 000 children aged younger than 2 years and younger than 5 years was 2440 (95% CI 1307-3573) and 1192 (692-1693), respectively. Incidence of pneumococcal bacteraemia was 597 (416-778) per 100 000 person-years of observation in children younger than age 5 years. Three-quarters of episodes had a clinical focus or required admission, or both; one in six was fatal. After exclusion of children with occult bacteraemia, the incidence of clinically significant bacteraemia per 100 000 children younger than age 2 years or 5 years fell to 1741 (790-2692) and 909 (475-1343), respectively, and the yearly incidence of clinically significant pneumococcal bacteraemia was 436 (132-739) per 100 000 children younger than 5 years old. Clinical signs identified bacteraemia poorly. Interpretation Clinically significant bacteraemia in children in Kilifil is twice as common, and pneumococcal bacteraemia four times as common, as previously estimated. Our data support the introduction of pneumococcal vaccine in sub-Saharan Africa.	Wellcome Trust KEMRI Ctr Geog Med Res, Kilifi, Kenya; Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England	University of Oxford; University of Oxford	Brent, AJ (corresponding author), John Radcliffe Hosp, Nuffield Dept Infect Dis & Microbiol, Oxford OX3 9DU, England.	andrew_brent@doctors.org.uk		Berkley, James/0000-0002-1236-849X	Wellcome Trust [061089, 050563, 083579, 081697, 081835] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alpern ER, 2000, PEDIATRICS, V106, P505, DOI 10.1542/peds.106.3.505; Bahwere P, 2001, Int J Infect Dis, V5, P180, DOI 10.1016/S1201-9712(01)90067-0; BASS JW, 1993, PEDIATR INFECT DIS J, V12, P466, DOI 10.1097/00006454-199306000-00003; Berkley JA, 2005, NEW ENGL J MED, V352, P1380; Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275; Berkley JA, 2003, BRIT MED J, V326, P361, DOI 10.1136/bmj.326.7385.361; Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8; Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6; FLEISHER GR, 1994, J PEDIATR-US, V124, P504, DOI 10.1016/S0022-3476(05)83126-9; GHIORGHIS B, 1992, E AFR MED J, V69, P74; JAFFE DM, 1987, NEW ENGL J MED, V317, P1175, DOI 10.1056/NEJM198711053171902; Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060; LEPAGE P, 1987, LANCET, V1, P1458; Luck S, 2003, LANCET, V361, P1953, DOI 10.1016/S0140-6736(03)13553-2; MCGOWAN JE, 1973, NEW ENGL J MED, V288, P1309, DOI 10.1056/NEJM197306212882501; MCINTYRE P, 1983, BRIT MED J, V286, P1055, DOI 10.1136/bmj.286.6370.1055-a; MCINTYRE P, 1983, BRIT MED J, V286, P203, DOI 10.1136/bmj.286.6360.203; Molyneux CS, 2002, J BIOSOC SCI, V34, P109, DOI 10.1017/S0021932002001098; Mulholland EK, 2005, NEW ENGL J MED, V352, P75, DOI 10.1056/NEJMe048306; Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7; Mulholland K, 1999, PEDIATR INFECT DIS J, V18, pS17; MUNGALA VO, 1994, E AFR MED J, V71, P747; Norton EB, 2004, PEDIATR INFECT DIS J, V23, P145, DOI 10.1097/01.inf.0000109258.82988.40; SAEZLLORENS X, 1995, PEDIATR INFECT DIS J, V14, P557, DOI 10.1097/00006454-199507000-00001; Stoll ML, 2004, ARCH PEDIAT ADOL MED, V158, P671, DOI 10.1001/archpedi.158.7.671; TEELE DW, 1975, J PEDIATR-US, V87, P227, DOI 10.1016/S0022-3476(75)80584-1; TEELE DW, 1979, PEDIATR CLIN N AM, V26, P773; UNAIDS AND WHO, 2003, AIDS EP UPD 2003, p[5, 20]; Walsh AL, 2000, PEDIATR INFECT DIS J, V19, P312, DOI 10.1097/00006454-200004000-00010; *WHO, 1997, IMCI JOINT WHO UNICE; *WHO, 1997, IMCI CHART BOOKL; World Health Organization, 2000, MAN CHILD SER INF SE; 2003, KENYA DEMOGRAPHIC HL, P38	33	115	117	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 11	2006	367	9509					482	488		10.1016/S0140-6736(06)68180-4	http://dx.doi.org/10.1016/S0140-6736(06)68180-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013FF	16473125				2022-12-28	WOS:000235394500029
J	Velicogna, I; Wahr, J				Velicogna, I; Wahr, J			Measurements of time-variable gravity show mass loss in Antarctica	SCIENCE			English	Article							CLIMATE EXPERIMENT; GRACE; RECOVERY	Using measurements of time-variable gravity from the Gravity Recovery and Climate Experiment satellites, we determined mass variations of the Antarctic ice sheet during 2002-2005. We found that the mass of the ice sheet decreased significantly, at a rate of 152 +/- 80 cubic kilometers of ice per year, which is equivalent to 0.4 +/- 0.2 millimeters of global sea-level rise per year. Most of this mass loss came from the West Antarctic Ice Sheet.	Univ Colorado, Cooperat Inst Res Environm Sci, Boulder, CO 80309 USA; Univ Colorado, Dept Phys, Boulder, CO 80309 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Wahr, J (corresponding author), Univ Colorado, Cooperat Inst Res Environm Sci, Campus Box 390, Boulder, CO 80309 USA.	isabella@colorado.edu; wahr@colorado.edu	Velicogna, Isabella/R-5561-2018	Velicogna, Isabella/0000-0002-9020-1898				Cheng MK, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2004JB003028; Church JA, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P639; DAVIS C, 2005, SCIENCE, V308, P5730; Ivins ER, 2005, ANTARCT SCI, V17, P541, DOI 10.1017/S0954102005002968; Lee T, 2002, J PHYS OCEANOGR, V32, P1404, DOI 10.1175/1520-0485(2002)032<1404:EOTITO>2.0.CO;2; Peltier WR, 2004, ANNU REV EARTH PL SC, V32, P111, DOI 10.1146/annurev.earth.32.082503.144359; Rignot E, 2002, SCIENCE, V297, P1502, DOI 10.1126/science.1073888; Rodell M, 2004, B AM METEOROL SOC, V85, P381, DOI 10.1175/BAMS-85-3-381; Swenson S, 2003, WATER RESOUR RES, V39, DOI 10.1029/2002WR001808; Tamisiea ME, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023961; Tapley BD, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019920; Thomas R, 2004, SCIENCE, V306, P255, DOI 10.1126/science.1099650; Velicogna I, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023955; Velicogna I, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB001735; WAHR I, IN PRESS GEOPHYS RES; Wahr J, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019779	16	408	440	6	86	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	2006	311	5768					1754	1756		10.1126/science.1123785	http://dx.doi.org/10.1126/science.1123785			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	024OA	16513944	Green Published			2022-12-28	WOS:000236204300038
J	Parkins, WE				Parkins, WE			Energy - Fusion power: Will it ever come?	SCIENCE			English	Editorial Material																		BADGER B, 1975, UWFDM150 U WISC FUS; LAKE JA, 2002, SCI AM           JAN, P73; METZ WD, 1976, SCIENCE, V192, P1320, DOI 10.1126/science.192.4246.1320; METZ WD, 1976, SCIENCE, V193, P38, DOI 10.1126/science.193.4247.38; METZ WD, 1976, SCIENCE, V193, P307, DOI 10.1126/science.193.4250.307; NAJMABADI F, 1991, UCLAPPG1323 U CAL LO; PARKINS WE, 1978, SCIENCE, V199, P1403, DOI 10.1126/science.199.4336.1403; PARKINS WE, 1997, PHYS TODAY       MAR, P15	8	10	11	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 10	2006	311	5766					1380	1380		10.1126/science.1125657	http://dx.doi.org/10.1126/science.1125657			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527955				2022-12-28	WOS:000236029400021
J	Eelkema, R; Pollard, MM; Vicario, J; Katsonis, N; Ramon, BS; Bastiaansen, CWM; Broer, DJ; Feringa, BL				Eelkema, R; Pollard, MM; Vicario, J; Katsonis, N; Ramon, BS; Bastiaansen, CWM; Broer, DJ; Feringa, BL			Nanomotor rotates microscale objects	NATURE			English	Editorial Material							MOLECULAR ROTOR; UNIDIRECTIONAL ROTATION		Univ Groningen, Stratingh Inst, Dept Organ & Mol Inorgan Chem, NL-9747 AG Groningen, Netherlands; Eindhoven Univ Technol, Fac Chem & Chem Engn, Dept Polymer Technol, NL-5600 MB Eindhoven, Netherlands; Philips Res Labs, Dept Biomol Engn, NL-5656 AE Eindhoven, Netherlands	University of Groningen; Eindhoven University of Technology; Philips; Philips Research	Eelkema, R (corresponding author), Univ Groningen, Stratingh Inst, Dept Organ & Mol Inorgan Chem, NL-9747 AG Groningen, Netherlands.	b.l.feringa@rug.nl	Feringa, Ben L./C-1665-2013; Broer, Dirk J/J-2614-2014; Eelkema, Rienk/D-7349-2011; Vicario, Javier/C-9893-2012	Broer, Dirk J/0000-0001-6136-3276; Eelkema, Rienk/0000-0002-2626-6371; Vicario, Javier/0000-0002-8976-0991				Balzani V., 2004, MOL DEVICES MACHINES; Dierking I., 2003, TEXTURES LIQUID CRYS; Kelly TR, 1999, NATURE, V401, P150, DOI 10.1038/43639; Koumura N, 1999, NATURE, V401, P152, DOI 10.1038/43646; Koumura N, 2000, J AM CHEM SOC, V122, P12005, DOI 10.1021/ja002755b; Leigh DA, 2003, NATURE, V424, P174, DOI 10.1038/nature01758; Liu Y, 2005, J AM CHEM SOC, V127, P9745, DOI 10.1021/ja051088p; SCHLIWA M, 2003, MOL MOTORS	8	651	656	8	402	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	2006	440	7081					163	163		10.1038/440163a	http://dx.doi.org/10.1038/440163a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019MC	16525460	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000235839500031
J	Wendler, D				Wendler, D			One-time general consent for research on biological samples	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							GENETIC RESEARCH; INFORMED-CONSENT; TISSUE SAMPLES; POPULATION; ATTITUDES; BLOOD; EXPERIENCE; PARTICIPATION; BIOBANKS; PROJECT		NIH, Dept Clin bioeth, Ctr Clin, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Wendler, D (corresponding author), NIH, Dept Clin bioeth, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA.	dwendler@nih.gov						Asai Atsushi, 2002, BMC Med Ethics, V3, pE1; Azarow KS, 2003, MIL MED, V168, P437, DOI 10.1093/milmed/168.6.437; Chen DT, 2005, ARCH INTERN MED, V165, P652, DOI 10.1001/archinte.165.6.652; DeCosta A, 2004, J MED ETHICS, V30, P318, DOI 10.1136/jme.2002.001065; Goodson ML, 2004, J CLIN PATHOL, V57, P135, DOI 10.1136/jcp.2003.9886; Hamajima N, 1998, JPN J CANCER RES, V89, P341, DOI 10.1111/j.1349-7006.1998.tb00568.x; Hoeyer K, 2005, ARCH INTERN MED, V165, P97, DOI 10.1001/archinte.165.1.97; Hoeyer K, 2004, SCAND J PUBLIC HEALT, V32, P224, DOI 10.1080/14034940310019506; Jack AL, 2003, BRIT MED J, V327, P262, DOI 10.1136/bmj.327.7409.262; Kozlowski LT, 2002, AM J EPIDEMIOL, V156, P68, DOI 10.1093/aje/kwf010; Malone T, 2002, J NATL CANCER I, V94, P769; Matsui K, 2005, J MED ETHICS, V31, P385, DOI 10.1136/jme.2004.009530; McQuillan GM, 2003, GENET MED, V5, P35, DOI 10.1097/00125817-200301000-00006; Merz J. F., 1998, STORED TISSUE SAMPLE, P198; Moutel G, 2001, Med Law, V20, P193; Nakayama T, 1999, AM J PUBLIC HEALTH, V89, P1433, DOI 10.2105/AJPH.89.9.1433; PHAN KLD, 1995, J CLIN ETHIC, V6, P237; Roberts LW, 2005, COMPR PSYCHIAT, V46, P27, DOI 10.1016/j.comppsych.2004.07.021; Schwartz MD, 2001, AM J MED GENET, V98, P336, DOI 10.1002/1096-8628(20010201)98:4<336::AID-AJMG1100>3.0.CO;2-7; Start RD, 1996, BRIT MED J, V313, P1366, DOI 10.1136/bmj.313.7069.1366; Stegmayr B, 2002, BMJ-BRIT MED J, V325, P634, DOI 10.1136/bmj.325.7365.634; Stolt UG, 2002, SOC SCI MED, V54, P1333; Wang S S, 2001, Community Genet, V4, P18, DOI 10.1159/000051152; *WELC TRUST, 2002, PUBL PERC COLL HUM B; WELLS JA, 2000, COMMISSIONED PAPERS, V2; Wendler D, 2002, ARCH INTERN MED, V162, P1457, DOI 10.1001/archinte.162.13.1457; Wendler David, 2005, IRB, V27, P1; White L, 2002, WAR HIST, V9, P1, DOI 10.1191/0968344502wh248oa; Wolf Leslie E, 2004, IRB, V26, P1, DOI 10.2307/3563696; Womack C, 2003, BRIT MED J, V327, P781, DOI 10.1136/bmj.327.7418.781; Wong ML, 2004, CLIN GENET, V65, P45, DOI 10.1111/j..2004.00192.x; PEOPLE SCI POLICY UK	32	159	159	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 4	2006	332	7540					544	547		10.1136/bmj.332.7540.544	http://dx.doi.org/10.1136/bmj.332.7540.544			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	023WB	16513715	Green Published			2022-12-28	WOS:000236155800022
J	Nicoll, RA; Tomita, S; Bredt, DS				Nicoll, RA; Tomita, S; Bredt, DS			Auxiliary subunits assist AMPA-type glutamate receptors	SCIENCE			English	Review							LONG-TERM POTENTIATION; CEREBELLAR GRANULE CELLS; SINGLE DENDRITIC SPINES; CHANNEL GAMMA-SUBUNIT; 2 DISTINCT MECHANISMS; SYNAPTIC PLASTICITY; EXCITATORY SYNAPSES; KAINATE RECEPTORS; STRUCTURAL BASIS; MOUSE STARGAZER	Glutamate, the major excitatory neurotransmitter in the brain, acts primarily on two types of ionotropic receptors: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors and N-methyl-D-aspartate (NMDA) receptors. Work over the past decade indicates that regulated changes in the number of synaptic AMPA receptors may serve as a mechanism for information storage. Recent studies demonstrate that a family of small transmembrane AMPA receptor regulatory proteins (TARPs) controls both AMPA receptor trafficking and channel gating. TARPs provide the first example of auxiliary subunits of ionotropic receptors. Here we review the pivotal role that TARPs play in the life cycle of AMPA receptors.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Nicoll, RA (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	nicoll@cmp.ucsf.edu						Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Bagal AA, 2005, P NATL ACAD SCI USA, V102, P14434, DOI 10.1073/pnas.0501956102; Barry MF, 2002, CURR OPIN NEUROBIOL, V12, P279, DOI 10.1016/S0959-4388(02)00329-X; Beique JC, 2003, J PHYSIOL-LONDON, V546, P859, DOI 10.1113/jphysiol.2002.031369; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; Bowie D, 2003, J PHYSIOL-LONDON, V547, P373, DOI 10.1113/jphysiol.2002.033076; Bredt DS, 2003, NEURON, V40, P361, DOI 10.1016/S0896-6273(03)00640-8; Burgess DL, 2001, GENOMICS, V71, P339, DOI 10.1006/geno.2000.6440; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Chen L, 1999, P NATL ACAD SCI USA, V96, P12132, DOI 10.1073/pnas.96.21.12132; Chen L, 2003, MOL PHARMACOL, V64, P703, DOI 10.1124/mol.64.3.703; Chung HJ, 2003, SCIENCE, V300, P1751, DOI 10.1126/science.1082915; Collingridge GL, 2004, NAT REV NEUROSCI, V5, P952, DOI 10.1038/nrn1556; Ehrlich I, 2004, J NEUROSCI, V24, P916, DOI 10.1523/JNEUROSCI.4733-03.2004; El-Hussein AE, 2000, SCIENCE, V290, P1364; Fukata Y, 2005, J CELL BIOL, V169, P399, DOI 10.1083/jcb.200501121; Hashimoto K, 1999, J NEUROSCI, V19, P6027, DOI 10.1523/JNEUROSCI.19-14-06027.1999; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; Jin RS, 2003, NAT NEUROSCI, V6, P803, DOI 10.1038/nn1091; Klugbauer N, 2000, FEBS LETT, V470, P189, DOI 10.1016/S0014-5793(00)01306-5; Lee SH, 2002, NEURON, V36, P661, DOI 10.1016/S0896-6273(02)01024-3; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; Lin Y, 2004, J NEUROSCI, V24, P10138, DOI 10.1523/JNEUROSCI.3159-04.2004; Liu SQJ, 2000, NATURE, V405, P454, DOI 10.1038/35013064; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Luthi A, 1999, NEURON, V24, P389, DOI 10.1016/S0896-6273(00)80852-1; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Matsuzaki M, 2004, NATURE, V429, P761, DOI 10.1038/nature02617; Nakagawa T, 2005, NATURE, V433, P545, DOI 10.1038/nature03328; Nicoll RA, 2005, NAT REV NEUROSCI, V6, P863, DOI 10.1038/nrn1786; Priel A, 2005, J NEUROSCI, V25, P2682, DOI 10.1523/JNEUROSCI.4834-04.2005; Rouach N, 2005, NAT NEUROSCI, V8, P1525, DOI 10.1038/nn1551; Schnell E, 2002, P NATL ACAD SCI USA, V99, P13902, DOI 10.1073/pnas.172511199; Sheng M, 2002, SCIENCE, V298, P776, DOI 10.1126/science.1075333; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Smith TC, 2000, J NEUROSCI, V20, P2073; Song I, 2002, TRENDS NEUROSCI, V25, P578, DOI 10.1016/S0166-2236(02)02270-1; Swanson GT, 1997, J NEUROSCI, V17, P58, DOI 10.1523/JNEUROSCI.17-01-00058.1997; Tomita S, 2005, NATURE, V435, P1052, DOI 10.1038/nature03624; Tomita S, 2003, J CELL BIOL, V161, P805, DOI 10.1083/jcb.200212116; Tomita S, 2005, NEURON, V45, P269, DOI 10.1016/j.neuron.2005.01.009; Tomita S, 2004, SCIENCE, V303, P1508, DOI 10.1126/science.1090262; Toth K, 1998, NAT NEUROSCI, V1, P572, DOI 10.1038/2807; Turetsky D, 2005, J NEUROSCI, V25, P7438, DOI 10.1523/JNEUROSCI.1108-05.2005; Vandenberghe W, 2005, J NEUROSCI, V25, P1095, DOI 10.1523/JNEUROSCI.3568-04.2005; Vandenberghe W, 2005, P NATL ACAD SCI USA, V102, P485, DOI 10.1073/pnas.0408269102; WYLLIE DJA, 1993, J PHYSIOL-LONDON, V463, P193, DOI 10.1113/jphysiol.1993.sp019591; Wyszynski M, 1999, J NEUROSCI, V19, P6528; Xia J, 2000, NEURON, V28, P499, DOI 10.1016/S0896-6273(00)00128-8; Yamazaki M, 2004, NEUROSCI RES, V50, P369, DOI 10.1016/j.neures.2004.10.002; Zamanillo D, 1999, SCIENCE, V284, P1805, DOI 10.1126/science.284.5421.1805; Zheng Y, 2004, NATURE, V427, P451, DOI 10.1038/nature02244	55	264	275	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	2006	311	5765					1253	1256		10.1126/science.1123339	http://dx.doi.org/10.1126/science.1123339			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019XB	16513974				2022-12-28	WOS:000235870400031
J	Oral, H; Pappone, C; Chugh, A; Good, E; Bogun, F; Pelosi, F; Bates, ER; Lehmann, MH; Vicedomini, G; Augello, G; Agricola, E; Sala, S; Santinelli, V; Morady, F				Oral, H; Pappone, C; Chugh, A; Good, E; Bogun, F; Pelosi, F; Bates, ER; Lehmann, MH; Vicedomini, G; Augello, G; Agricola, E; Sala, S; Santinelli, V; Morady, F			Circumferential pulmonary-vein ablation for chronic atrial fibrillation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CATHETER ABLATION; ESOPHAGEAL FISTULA; LONG-TERM; SUBSTRATE	Background: We conducted a randomized, controlled trial of circumferential pulmonary-vein ablation for the treatment of chronic atrial fibrillation. Methods: A total of 146 patients with a mean (+/-SD) age of 57+/-9 years who had chronic atrial fibrillation were randomly assigned to receive amiodarone and undergo two cardioversions during the first three months alone (the control group) or in combination with circumferential pulmonary-vein ablation. Cardiac rhythm was assessed with daily telephonic transmissions for one year. The left atrial diameter and the severity of symptoms were assessed at 12 months. Results: Among the 77 patients assigned to undergo circumferential pulmonary-vein ablation, ablation was repeated because of recurrent atrial fibrillation in 26 percent of patients and atypical atrial flutter in 6 percent. An intention-to-treat analysis showed that 74 percent of patients in the ablation group and 58 percent of those in the control group were free of recurrent atrial fibrillation or flutter without antiarrhythmic-drug therapy at one year (P=0.05). Among the 69 patients in the control group, 53 (77 percent) crossed over to undergo circumferential pulmonary-vein ablation for recurrent atrial fibrillation by one year and only 3 (4 percent) were in sinus rhythm without antiarrhythmic-drug therapy or ablation. There were significant decreases in the left atrial diameter (12+/-11 percent, P<0.001) and the symptom severity score (59+/-21 percent, P<0.001) among patients who remained in sinus rhythm after circumferential pulmonary-vein ablation. Except for atypical atrial flutter, there were no complications attributable to circumferential pulmonary-vein ablation. Conclusions: Sinus rhythm can be maintained long term in the majority of patients with chronic atrial fibrillation by means of circumferential pulmonary-vein ablation independently of the effects of antiarrhythmic-drug therapy, cardioversion, or both. The maintenance of sinus rhythm is associated with a significant decrease in both the severity of symptoms and the left atrial diameter.	Univ Michigan, Div Cardiovasc Med, Ann Arbor, MI 48109 USA; San Raffaele Univ Hosp, Electrophysiol & Cardiac Pacing Dept, Milan, Italy	University of Michigan System; University of Michigan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Oral, H (corresponding author), Univ Michigan, Div Cardiovasc Med, TCB1 140 D,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	oralh@umich.edu	Sala, Simone/AAP-2524-2020; Augello, Giuseppe/AAM-2338-2021; Agricola, Eustachio/AAC-2019-2019; Vicedomini, Gabriele/K-5182-2018; Santinelli, Vincenzo/J-9927-2016; Pappone, Carlo/J-9853-2016	Sala, Simone/0000-0003-3303-8892; Vicedomini, Gabriele/0000-0002-2300-3621; Agricola, Eustachio/0000-0002-4834-2187; Santinelli, Vincenzo/0000-0003-4169-3619; Pappone, Carlo/0000-0002-0901-6135				Han J, 2004, CIRCULATION, V110, pE528, DOI 10.1161/01.CIR.0000149750.18875.8C; Jalife J, 2003, J CARDIOVASC ELECTR, V14, P776, DOI 10.1046/j.1540-8167.2003.03136.x; Kottkamp H, 2004, J AM COLL CARDIOL, V44, P869, DOI 10.1016/j.jacc.2004.047.049; Lemola K, 2004, HEART RHYTHM, V1, P576, DOI 10.1016/j.hrthm.2004.07.020; Lin WS, 2003, CIRCULATION, V107, P3176, DOI 10.1161/01.CIR.0000074206.52056.2D; Moe G K, 1968, J Electrocardiol, V1, P145; Nademanee K, 2004, J AM COLL CARDIOL, V43, P2044, DOI 10.1016/j.jacc.2003.12.054; Oral H, 2003, CIRCULATION, V108, P2355, DOI 10.1161/01.CIR.0000095796.45180.88; Pappone C, 2004, CIRCULATION, V110, P3036, DOI 10.1161/01.CIR.0000147186.83715.95; Pappone C, 2004, CIRCULATION, V109, P2724, DOI 10.1161/01.CIR.0000131866.44650.46; Pappone C, 2003, J AM COLL CARDIOL, V42, P185, DOI 10.1016/S0735-1097(03)00577-1; Pappone C, 2004, CIRCULATION, V109, P327, DOI 10.1161/01.CIR.0000112641.16340.C7; Pappone C, 2001, CIRCULATION, V104, P2539, DOI 10.1161/hc4601.098517; Scanavacca MI, 2004, J CARDIOVASC ELECTR, V15, P960, DOI 10.1046/j.1540-8167.2004.04083.x; Stabile G, 2003, CIRCULATION, V108, P657, DOI 10.1161/01.CIR.0000086980.42626.34; Wyse DG, 2002, NEW ENGL J MED, V347, P1825, DOI 10.1056/nejmoa021328	16	702	742	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 2	2006	354	9					934	941		10.1056/NEJMoa050955	http://dx.doi.org/10.1056/NEJMoa050955			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	017FN	16510747				2022-12-28	WOS:000235679600006
J	Tildesley, MJ; Savill, NJ; Shaw, DJ; Deardon, R; Brooks, SP; Woolhouse, MEJ; Grenfell, BT; Keeling, MJ				Tildesley, MJ; Savill, NJ; Shaw, DJ; Deardon, R; Brooks, SP; Woolhouse, MEJ; Grenfell, BT; Keeling, MJ			Optimal reactive vaccination strategies for a foot-and-mouth outbreak in the UK	NATURE			English	Article							CONTROL POLICIES; GREAT-BRITAIN; EPIDEMIC; TRANSMISSION; SPREAD; DESIGN; IMPACT	Foot-and-mouth disease (FMD) in the UK provides an ideal opportunity to explore optimal control measures for an infectious disease. The presence of fine-scale spatio-temporal data for the 2001 epidemic has allowed the development of epidemiological models that are more accurate than those generally created for other epidemics(1-5) and provide the opportunity to explore a variety of alternative control measures. Vaccination was not used during the 2001 epidemic; however, the recent DEFRA ( Department for Environment Food and Rural Affairs) contingency plan(6) details how reactive vaccination would be considered in future. Here, using the data from the 2001 epidemic, we consider the optimal deployment of limited vaccination capacity in a complex heterogeneous environment. We use a model of FMD spread to investigate the optimal deployment of reactive ring vaccination of cattle constrained by logistical resources. The predicted optimal ring size is highly dependent upon logistical constraints but is more robust to epidemiological parameters. Other ways of targeting reactive vaccination can significantly reduce the epidemic size; in particular, ignoring the order in which infections are reported and vaccinating those farms closest to any previously reported case can substantially reduce the epidemic. This strategy has the advantage that it rapidly targets new foci of infection and that determining an optimal ring size is unnecessary.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Univ Warwick, Math Inst, Coventry CV4 7AL, W Midlands, England; Univ Cambridge, Ctr Math Sci, Stat Lab, Cambridge CB3 0WB, England; Univ Edinburgh, Ashworth Labs, Ctr Infect Dis, Epidemiol Grp, Edinburgh EH9 3JF, Midlothian, Scotland; Univ Edinburgh, Royal Dick Sch Vet Studies, Easter Bush Vet Ctr, Roslin EH25 9RG, Midlothian, Scotland; Univ Cambridge, Ctr Vet Sci, Cambridge Infect Dis Consortium, Cambridge CB3 0ES, England; Penn State Univ, Mueller Lab, Biol Dept 208, Ctr Infect Dis Dynam, University Pk, PA 16802 USA; NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA	University of Warwick; University of Warwick; University of Cambridge; University of Edinburgh; University of Edinburgh; University of Cambridge; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC)	Keeling, MJ (corresponding author), Univ Warwick, Dept Biol Sci, Gibbet Hill Rd, Coventry CV4 7AL, W Midlands, England.	m.j.keeling@warwick.ac.uk	Keeling, Matt J/J-9280-2012; Tildesley, Michael/B-6559-2008	Keeling, Matt J/0000-0003-4639-4765; Savill, Nicholas/0000-0002-9769-6168; Tildesley, Michael/0000-0002-6875-7232; Shaw, Darren/0000-0003-2016-1541	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Anderson I., 2002, FOOT MOUTH DIS 2001; Barnett PV, 2002, VACCINE, V20, P1505, DOI 10.1016/S0264-410X(01)00503-5; *DEFRA, 2004, DEFRA FOOT MOUTH DIS; Ferguson NM, 2001, NATURE, V413, P542, DOI 10.1038/35097116; Ferguson NM, 2001, SCIENCE, V292, P1155, DOI 10.1126/science.1061020; Ferguson NM, 2003, NATURE, V425, P681, DOI 10.1038/nature02007; Keeling MJ, 2001, SCIENCE, V294, P813, DOI 10.1126/science.1065973; Keeling MJ, 2003, NATURE, V421, P136, DOI 10.1038/nature01343; Matthews L, 2003, P ROY SOC B-BIOL SCI, V270, P1659, DOI 10.1098/rspb.2003.2429; McLean AR, 1995, TRENDS MICROBIOL, V3, P458, DOI 10.1016/S0966-842X(00)89010-1; Morris RS, 2001, VET REC, V149, P137, DOI 10.1136/vr.149.5.137; Muller J, 2000, J MATH BIOL, V41, P143, DOI 10.1007/s002850070003; Williams JR, 1996, J EPIDEMIOL COMMUN H, V50, P667, DOI 10.1136/jech.50.6.667; Woolhouse MEJ, 1997, P NATL ACAD SCI USA, V94, P338, DOI 10.1073/pnas.94.1.338; Woolhouse MEJ, 1997, VET J, V153, P41, DOI 10.1016/S1090-0233(97)80007-X; Woolhouse MEJ, 1996, EPIDEMIOL INFECT, V116, P363, DOI 10.1017/S0950268800052699	16	187	189	0	49	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 2	2006	440	7080					83	86		10.1038/nature04324	http://dx.doi.org/10.1038/nature04324			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017HW	16511494				2022-12-28	WOS:000235685700044
J	Pizarro-Cerda, J; Cossart, P				Pizarro-Cerda, J; Cossart, P			Bacterial adhesion and entry into host cells	CELL			English	Review							ENTEROPATHOGENIC ESCHERICHIA-COLI; IV PILUS; LISTERIA-MONOCYTOGENES; NEISSERIA-GONORRHOEAE; TYROSINE KINASES; III SECRETION; PROTEIN; INVASION; RECEPTOR; ACTIN	Successful establishment of infection by bacterial pathogens requires adhesion to host cells, colonization of tissues, and in certain cases, cellular invasion-followed by intracellular multiplication, dissemination to other tissues, or persistence. Bacteria use monomeric adhesins/invasins or highly sophisticated macromolecular machines such as type III secretion systems and retractile type IV pili to establish a complex host/pathogen molecular crosstalk that leads to subversion of cellular functions and establishment of disease.	Inst Pasteur, Unite Interact Bacteries Cellules, F-75015 Paris, France; INSERM, U604, F-75015 Paris, France; INRA, F-75015 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); INRAE	Pizarro-Cerda, J (corresponding author), Inst Pasteur, Unite Interact Bacteries Cellules, 25 Rue Dr Roux, F-75015 Paris, France.	pizarroj@pasteur.fr; pcossart@pasteur.fr						Agerer F, 2005, J CELL SCI, V118, P2189, DOI 10.1242/jcs.02328; Alrutz MA, 1998, P NATL ACAD SCI USA, V95, P13658, DOI 10.1073/pnas.95.23.13658; Anderson GG, 2003, SCIENCE, V301, P105, DOI 10.1126/science.1084550; Anderson KL, 2004, MOL CELL, V15, P647, DOI 10.1016/j.molcel.2004.08.003; Bann JG, 2004, P NATL ACAD SCI USA, V101, P17389, DOI 10.1073/pnas.0408072101; Berger CN, 2004, MOL MICROBIOL, V52, P963, DOI 10.1111/j.1365-2958.2004.04033.x; Bierne H, 2005, J CELL SCI, V118, P1537, DOI 10.1242/jcs.02285; Bierne H, 2001, J CELL BIOL, V155, P101, DOI 10.1083/jcb.200104037; Blocker A, 1999, J CELL BIOL, V147, P683, DOI 10.1083/jcb.147.3.683; Bougneres L, 2004, J CELL BIOL, V166, P225, DOI 10.1083/jcb.200402073; Bourdet-Sicard R, 1999, EMBO J, V18, P5853, DOI 10.1093/emboj/18.21.5853; Braun L, 2000, EMBO J, V19, P1458, DOI 10.1093/emboj/19.7.1458; Bruce-Staskal PJ, 2002, J CELL SCI, V115, P2689; Burton EA, 2003, EMBO J, V22, P5471, DOI 10.1093/emboj/cdg512; Campellone KG, 2005, MOL MICROBIOL, V56, P416, DOI 10.1111/j.1365-2958.2005.04558.x; Campellone KG, 2004, DEV CELL, V7, P217, DOI 10.1016/j.devcel.2004.07.004; Cossart P, 2004, SCIENCE, V304, P242, DOI 10.1126/science.1090124; Cotter SE, 2005, TRENDS MICROBIOL, V13, P199, DOI 10.1016/j.tim.2005.03.004; Craig L, 2004, NAT REV MICROBIOL, V2, P363, DOI 10.1038/nrmicro885; Deng WY, 2001, INFECT IMMUN, V69, P6323, DOI 10.1128/IAI.69.10.6323-6335.2001; Duncan MJ, 2004, J BIOL CHEM, V279, P18944, DOI 10.1074/jbc.M400769200; Dussurget O, 2004, ANNU REV MICROBIOL, V58, P587, DOI 10.1146/annurev.micro.57.030502.090934; Enninga J, 2005, NAT METHODS, V2, P959, DOI 10.1038/NMETH804; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; Fu YX, 1999, NATURE, V401, P293, DOI 10.1038/45829; Garmendia J, 2004, CELL MICROBIOL, V6, P1167, DOI 10.1111/j.1462-5822.2004.00459.x; Gill DB, 2005, CELL MICROBIOL, V7, P1672, DOI 10.1111/j.1462-5822.2005.00584.x; Hamburger ZA, 1999, SCIENCE, V286, P291, DOI 10.1126/science.286.5438.291; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hayward RD, 1999, EMBO J, V18, P4926, DOI 10.1093/emboj/18.18.4926; Henderson IR, 2004, MICROBIOL MOL BIOL R, V68, P692, DOI 10.1128/MMBR.68.4.692-744.2004; HULTGREN SJ, 1991, ANNU REV MICROBIOL, V45, P383, DOI 10.1146/annurev.micro.45.1.383; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; Joh D, 1999, MATRIX BIOL, V18, P211, DOI 10.1016/S0945-053X(99)00025-6; Jonquieres R, 2001, MOL MICROBIOL, V42, P955, DOI 10.1046/j.1365-2958.2001.02704.x; Kallstrom H, 1997, MOL MICROBIOL, V25, P639, DOI 10.1046/j.1365-2958.1997.4841857.x; Kenny B, 2002, MOL MICROBIOL, V44, P1095, DOI 10.1046/j.1365-2958.2002.02952.x; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; Khelef N, 2006, CELL MICROBIOL, V8, P457, DOI 10.1111/j.1462-5822.2005.00634.x; Kirchner M, 2005, MOL MICROBIOL, V56, P945, DOI 10.1111/j.1365-2958.2005.04600.x; Kreikemeyer B, 2004, INT J MED MICROBIOL, V294, P177, DOI 10.1016/j.ijmm.2004.06.017; Kubori T, 2003, CELL, V115, P333, DOI 10.1016/S0092-8674(03)00849-3; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; Kueltzo LA, 2003, J BIOL CHEM, V278, P2792, DOI 10.1074/jbc.M208383200; Lafont F, 2002, EMBO J, V21, P4449, DOI 10.1093/emboj/cdf457; Lauer P, 2005, SCIENCE, V309, P105, DOI 10.1126/science.1111563; Lecuit M, 2000, P NATL ACAD SCI USA, V97, P10008, DOI 10.1073/pnas.97.18.10008; Lecuit M, 2004, P NATL ACAD SCI USA, V101, P6152, DOI 10.1073/pnas.0401434101; Lecuit M, 2001, SCIENCE, V292, P1722, DOI 10.1126/science.1059852; Lecuit M, 1999, EMBO J, V18, P3956, DOI 10.1093/emboj/18.14.3956; Lee SW, 2005, CELL MICROBIOL, V7, P1271, DOI 10.1111/j.1462-5822.2005.00551.x; Li H, 1998, MICROB PATHOGENESIS, V24, P289, DOI 10.1006/mpat.1997.0197; Li N, 2005, TRAFFIC, V6, P459, DOI 10.1111/j.1600-0854.2005.00290.x; Mahdavi J, 2002, SCIENCE, V297, P573, DOI 10.1126/science.1069076; Maier B, 2004, P NATL ACAD SCI USA, V101, P10961, DOI 10.1073/pnas.0402305101; Marlovits TC, 2004, SCIENCE, V306, P1040, DOI 10.1126/science.1102610; Martinez JJ, 2005, CELL, V123, P1013, DOI 10.1016/j.cell.2005.08.046; Martinez JJ, 2004, J CELL SCI, V117, P5097, DOI 10.1242/jcs.01382; Martinez JJ, 2002, CELL MICROBIOL, V4, P19, DOI 10.1046/j.1462-5822.2002.00166.x; McGhie EJ, 2004, MOL CELL, V13, P497, DOI 10.1016/S1097-2765(04)00053-X; Monferran S, 2004, EMBO J, V23, P3758, DOI 10.1038/sj.emboj.7600403; Mora M, 2005, P NATL ACAD SCI USA, V102, P15641, DOI 10.1073/pnas.0507808102; Muenzner P, 2005, J CELL BIOL, V170, P825, DOI 10.1083/jcb.200412151; Niebuhr K, 2002, EMBO J, V21, P5069, DOI 10.1093/emboj/cdf522; Nummelin H, 2004, EMBO J, V23, P701, DOI 10.1038/sj.emboj.7600100; Oh JD, 2005, P NATL ACAD SCI USA, V102, P5186, DOI 10.1073/pnas.0407657102; Ozeri V, 2001, MOL MICROBIOL, V41, P561, DOI 10.1046/j.1365-2958.2001.02535.x; Parsot C, 2005, FEMS MICROBIOL LETT, V252, P11, DOI 10.1016/j.femsle.2005.08.046; Phillips N, 2004, NAT CELL BIOL, V6, P618, DOI 10.1038/ncb1148; Pizarro-Cerda J, 2004, NAT CELL BIOL, V6, P1026, DOI 10.1038/ncb1104-1026; Plancon L, 2003, CELL MICROBIOL, V5, P681, DOI 10.1046/j.1462-5822.2003.00308.x; Ramboarina S, 2005, J BIOL CHEM, V280, P40252, DOI 10.1074/jbc.M508099200; Sauer FG, 2000, CURR OPIN STRUC BIOL, V10, P548, DOI 10.1016/S0959-440X(00)00129-9; Schlumberger MC, 2005, P NATL ACAD SCI USA, V102, P12548, DOI 10.1073/pnas.0503407102; Schwarz-Linek U, 2003, NATURE, V423, P177, DOI 10.1038/nature01589; Servin AL, 2005, CLIN MICROBIOL REV, V18, P264, DOI 10.1128/CMR.18.2.264-292.2005; Seveau S, 2004, J CELL BIOL, V166, P743, DOI 10.1083/jcb.200406078; Shen Y, 2000, CELL, V103, P501, DOI 10.1016/S0092-8674(00)00141-0; Shin JS, 2000, SCIENCE, V289, P785, DOI 10.1126/science.289.5480.785; Sousa S, 2005, NAT CELL BIOL, V7, P954, DOI 10.1038/ncb1308; Sousa S, 2004, J CELL SCI, V117, P2121, DOI 10.1242/jcs.01066; Suh JY, 2001, BIOCHEMISTRY-US, V40, P3985, DOI 10.1021/bi002524h; Swimm A, 2004, MOL BIOL CELL, V15, P3520, DOI 10.1091/mbc.E04-02-0093; Thanassi DG, 1998, CURR OPIN MICROBIOL, V1, P223, DOI 10.1016/S1369-5274(98)80015-5; Tobe T, 2002, CELL MICROBIOL, V4, P29, DOI 10.1046/j.1462-5822.2002.00167.x; Ton-That H, 2004, TRENDS MICROBIOL, V12, P228, DOI 10.1016/j.tim.2004.03.004; Uchiyama T, 2003, ANN NY ACAD SCI, V990, P585, DOI 10.1111/j.1749-6632.2003.tb07431.x; van Putten JPM, 1998, MOL MICROBIOL, V29, P369, DOI 10.1046/j.1365-2958.1998.00951.x; Veiga E, 2005, NAT CELL BIOL, V7, P894, DOI 10.1038/ncb1292; Veiga E, 2002, EMBO J, V21, P2122, DOI 10.1093/emboj/21.9.2122; West NP, 2005, SCIENCE, V307, P1313, DOI 10.1126/science.1108472; Winther-Larsen HC, 2001, P NATL ACAD SCI USA, V98, P15276, DOI 10.1073/pnas.261574998; Wolfgang M, 2000, EMBO J, V19, P6408, DOI 10.1093/emboj/19.23.6408; Wolfgang M, 1998, P NATL ACAD SCI USA, V95, P14973, DOI 10.1073/pnas.95.25.14973; Wong KW, 2003, J EXP MED, V198, P603, DOI 10.1084/jem.20021363; Yoshida S, 2002, EMBO J, V21, P2923, DOI 10.1093/emboj/cdf319; Zhou DG, 2001, MOL MICROBIOL, V39, P248, DOI 10.1046/j.1365-2958.2001.02230.x; Zhou G, 2001, J CELL SCI, V114, P4095	101	628	647	2	90	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 24	2006	124	4					715	727		10.1016/j.cell.2006.02.012	http://dx.doi.org/10.1016/j.cell.2006.02.012			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	038RO	16497583	Bronze			2022-12-28	WOS:000237240900016
J	Umemoto, K; Wentzcovitch, RM; Allen, PB				Umemoto, K; Wentzcovitch, RM; Allen, PB			Dissociation of MgSiO3 in the cores of gas giants and terrestrial exoplanets	SCIENCE			English	Article							POST-PEROVSKITE PHASE; HIGH-PRESSURE; LOWER MANTLE; AB-INITIO; TRANSITION; STABILITY; SILICA; SIO2; MGO	CalrO(3)-type MgSiO3 is the planet-forming silicate stable at pressures and temperatures beyond those of Earth's core-mantle boundary. First-principles quasiharmonic free-energy computations show that this mineral should dissociate into CsCl-type MgO+cotunnite-type SiO2 at pressures and temperatures expected to occur in the cores of the gas giants and in terrestrial exoplanets. At similar to 10 megabars and similar to 10,000 kelvin, cotunnite-type SiO2 should have thermally activated electron carriers and thus electrical conductivity close to metallic values. Electrons wilt give a large contribution to thermal conductivity, and electronic damping will suppress radiative heat transport.	Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA; Univ Minnesota, Minnesota Supercomp Inst, Minneapolis, MN 55455 USA; SUNY Stony Brook, Dept Phys & Astron, Stony Brook, NY 11794 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Wentzcovitch, RM (corresponding author), Univ Minnesota, Dept Chem Engn & Mat Sci, 421 Washington Ave SE, Minneapolis, MN 55455 USA.	wentzcov@cems.umn.edu	Umemoto, Koichiro/A-2800-2014; Allen, Philip/O-2163-2019; Wentzcovitch, Renata M/J-8768-2015	Umemoto, Koichiro/0000-0003-2410-4042; 				ALLEN PB, 1976, J PHYS C SOLID STATE, V9, P2305, DOI 10.1088/0022-3719/9/12/013; [Anonymous], 1979, SOLID STATE PHYS, DOI 10.1016/S0081-1947(08)60359-8; CLARK SP, 1957, T AM GEOPHYS UNION, V38, P931; Dubrovinskaia NA, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.275501; Guillot T, 2004, PHYS TODAY, V57, P63, DOI 10.1063/1.1752424; HIXSON RS, 1990, PHYS REV B, V42, P6485, DOI 10.1103/PhysRevB.42.6485; Karki BB, 1999, SCIENCE, V286, P1705, DOI 10.1126/science.286.5445.1705; Karki BB, 1997, PHYS REV B, V55, P3465, DOI 10.1103/PhysRevB.55.3465; Kuwayama Y, 2005, SCIENCE, V309, P923, DOI 10.1126/science.1114879; LATT FJ, 1968, PHYS ELECT CONDUCTIO; Liu HZ, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL022068; MERMIN ND, 1965, PHYS REV, V137, P1441, DOI 10.1103/PhysRev.137.A1441; Murakami M, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016722; Murakami M, 2004, SCIENCE, V304, P855, DOI 10.1126/science.1095932; NAVROTSKY A, 1980, GEOPHYS RES LETT, V7, P709, DOI 10.1029/GL007i009p00709; Oganov AR, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.064104; Oganov AR, 2003, J CHEM PHYS, V118, P10174, DOI 10.1063/1.1570394; Oganov AR, 2004, NATURE, V430, P445, DOI 10.1038/nature02701; Ono S, 2002, EARTH PLANET SC LETT, V197, P187, DOI 10.1016/S0012-821X(02)00479-X; PARISE JB, 2004, EOS T AGU S, V85; Rivera EJ, 2005, ASTROPHYS J, V634, P625, DOI 10.1086/491669; Sato B, 2005, ASTROPHYS J, V633, P465, DOI 10.1086/449306; SONG KS, 1995, SELF TRAPPED EXCITON, pCH7; TACKLEY PJ, 1995, J GEOPHYS RES-SOL EA, V100, P15477, DOI 10.1029/95JB00318; Tsuchiya T, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019649; Tsuchiya T, 2004, EARTH PLANET SC LETT, V224, P241, DOI 10.1016/j.epsl.2004.05.017; VALENCIA D, IN PRESS ICARUS; VANDERBILT D, 1990, PHYS REV B, V41, P7892, DOI 10.1103/PhysRevB.41.7892; WEINBERG S, 1995, QUANTUM THEORY FIELD, V1, P100	30	121	125	3	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 17	2006	311	5763					983	986		10.1126/science.1120865	http://dx.doi.org/10.1126/science.1120865			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014CS	16484489				2022-12-28	WOS:000235456900040
J	Yu, B; Edstrom, WC; Benach, J; Hamuro, Y; Weber, PC; Gibney, BR; Hunt, JF				Yu, B; Edstrom, WC; Benach, J; Hamuro, Y; Weber, PC; Gibney, BR; Hunt, JF			Crystal structures of catalytic complexes of the oxidative DNA/RNA repair enzyme AlkB	NATURE			English	Article							ESCHERICHIA-COLI; ALKYLATION DAMAGE; DNA; DIOXYGENASE; BACTERIAL; 3-METHYLTHYMINE; DEMETHYLATION; MECHANISM; PROTEINS; IRON	Nucleic acid damage by environmental and endogenous alkylation reagents creates lesions that are both mutagenic and cytotoxic, with the latter effect accounting for their widespread use in clinical cancer chemotherapy(1,2). Escherichia coli AlkB(3-9) and the homologous human proteins ABH2 and ABH3 (refs 5, 7) promiscuously repair DNA and RNA bases damaged by S(N)2 alkylation reagents, which attach hydrocarbons to endocyclic ring nitrogen atoms (N1 of adenine and guanine and N3 of thymine and cytosine)(3,4,10-15). Although the role of AlkB in DNA repair has long been established based on phenotypic studies, its exact biochemical activity was only elucidated recently after sequence profile analysis revealed it to be a member of the Fe-oxoglutarate-dependent dioxygenase superfamily. These enzymes use an Fe(II) cofactor and 2-oxoglutarate co-substrate to oxidize organic substrates. AlkB hydroxylates an alkylated nucleotide base to produce an unstable product that releases an aldehyde to regenerate the unmodified base. Here we have determined crystal structures of substrate and product complexes of E. coli AlkB at resolutions from 1.8 to 2.3 angstrom. Whereas the Fe-2-oxoglutarate dioxygenase core matches that in other superfamily members, a unique subdomain holds a methylated trinucleotide substrate into the active site through contacts to the polynucleotide backbone. Amide hydrogen exchange studies and crystallographic analyses suggest that this substrate-binding 'lid' is conformationally flexible, which may enable docking of diverse alkylated nucleotide substrates in optimal catalytic geometry. Different crystal structures show open and closed states of a tunnel putatively gating O(2) diffusion into the active site. Exposing crystals of the anaerobic Michaelis complex to air yields slow but substantial oxidation of 2-oxoglutarate that is inefficiently coupled to nucleotide oxidation. These observations suggest that protein dynamics modulate redox chemistry and that a hypothesized migration of the reactive oxy-ferryl ligand on the catalytic Fe ion may be impeded when the protein is constrained in the crystal lattice.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Columbia Univ, Fairchild Ctr 702A, NE Struct Genom Consortium, New York, NY 10027 USA; ExSAR Corp, Monmouth Jct, NJ 08852 USA; Columbia Univ, Dept Chem, New York, NY 10027 USA	Columbia University; Columbia University; Columbia University	Hunt, JF (corresponding author), Columbia Univ, Dept Biol Sci, MC2434, New York, NY 10027 USA.	jfhunt@biology.columbia.edu		Gibney, Brian/0000-0002-8966-7463				Aas PA, 2003, NATURE, V421, P859, DOI 10.1038/nature01363; CHEN BRJ, 1994, J BACTERIOL, V176, P6255, DOI 10.1128/jb.176.20.6255-6261.1994; Delaney JC, 2005, NAT STRUCT MOL BIOL, V12, P855, DOI 10.1038/nsmb996; Delaney JC, 2004, P NATL ACAD SCI USA, V101, P14051, DOI 10.1073/pnas.0403489101; Drablos F, 2004, DNA REPAIR, V3, P1389, DOI 10.1016/j.dnarep.2004.05.004; Duncan T, 2002, P NATL ACAD SCI USA, V99, P16660, DOI 10.1073/pnas.262589799; Elkins JM, 2002, BIOCHEMISTRY-US, V41, P5185, DOI 10.1021/bi016014e; Falnes PO, 2002, NATURE, V419, P178, DOI 10.1038/nature01048; Falnes PO, 2004, NUCLEIC ACIDS RES, V32, P6260, DOI 10.1093/nar/gkh964; Falnes PO, 2004, NUCLEIC ACIDS RES, V32, P3456, DOI 10.1093/nar/gkh655; Hegg EL, 1999, BIOCHEMISTRY-US, V38, P16714, DOI 10.1021/bi991796l; KATAOKA H, 1983, J BACTERIOL, V153, P1301, DOI 10.1128/JB.153.3.1301-1307.1983; Koivisto P, 2004, J BIOL CHEM, V279, P40470, DOI 10.1074/jbc.M407960200; Koivisto P, 2003, J BIOL CHEM, V278, P44348, DOI 10.1074/jbc.M307361200; Krebs C, 2005, INORG CHEM, V44, P742, DOI 10.1021/ic048523l; Mishina Y, 2003, J AM CHEM SOC, V125, P8730, DOI 10.1021/ja034636c; Muller I, 2004, BIOCHEMISTRY-US, V43, P3075, DOI 10.1021/bi035752v; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Ougland R, 2004, MOL CELL, V16, P107, DOI 10.1016/j.molcel.2004.09.002; Price JC, 2005, BIOCHEMISTRY-US, V44, P8138, DOI 10.1021/bi050227c; Que L, 2004, J BIOL INORG CHEM, V9, P684, DOI 10.1007/s00775-004-0574-8; Rohde JU, 2003, SCIENCE, V299, P1037, DOI 10.1126/science.299.5609.1037; Schofield CJ, 1999, CURR OPIN STRUC BIOL, V9, P722, DOI 10.1016/S0959-440X(99)00036-6; Sedgwick B, 2004, NAT REV MOL CELL BIO, V5, P148, DOI 10.1038/nrm1312; Trewick SC, 2002, NATURE, V419, P174, DOI 10.1038/nature00908; Valegard K, 2004, NAT STRUCT MOL BIOL, V11, P95, DOI 10.1038/nsmb712; Wilmouth RC, 2002, STRUCTURE, V10, P93, DOI 10.1016/S0969-2126(01)00695-5; Zhang ZH, 2002, FEBS LETT, V517, P7, DOI 10.1016/S0014-5793(02)02520-6	28	184	191	2	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 16	2006	439	7078					879	884		10.1038/nature04561	http://dx.doi.org/10.1038/nature04561			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012JA	16482161				2022-12-28	WOS:000235333600057
J	Shishehbor, MH; Litaker, D; Pothier, CE; Lauer, MS				Shishehbor, MH; Litaker, D; Pothier, CE; Lauer, MS			Association of socioeconomic status with functional capacity, heart rate recovery, and all-cause mortality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR RISK; TREADMILL EXERCISE; INSULIN-RESISTANCE; SOCIAL-CLASS; HEALTH; DEATH; PREDICTOR; ACCESS; CARE	Context Lower socioeconomic status (SES) confers heightened cardiovascular risk and mortality, although the mediating pathways are unclear. Objective To evaluate the extent to which exercise physiologic characteristics account for the association between lower SES and mortality. Design, Setting, and Participants Prospective cohort study of 30 043 consecutive patients living in 7 counties in northeast Ohio referred between 1990 and 2002 for symptom-limited stress testing for evaluation of known or suspected coronary artery disease. Follow-up for mortality continued through February 2004. Main Outcome Measures Estimated functional capacity in metabolic equivalents and heart rate recovery, physiologic characteristics that are determined directly from exercise; testing and all-cause mortality during a median follow-up of 6.5 years. Results Multivariable models adjusting for demographics, insurance status, smoking status, and clinical confounders demonstrated a strong association between a composite SES score based on census block data and functional capacity (adjusted odds ratio comparing 25th with 75th percentile values, 1.72; 95% confidence interval [CI], 1.56-1.89; P<.001) as well as heart rate recovery (adjusted odds ratio comparing 25th with 75th percentile values, 1.18; 95% CI, 1.07-1.30; P<.001). There were 2174 deaths, with mortality risk increasing from 5% to 10% as SES decreased by quartile (P<.001). Cox proportional hazards models that included all confounding variables except exercise physiologic characteristics demonstrated increased mortality as SES decreased (adjusted hazard ratio comparing 25th with 75th percentile values, 1.32; 95% CI, 1.22-1.42; P<.001). After further adding functional capacity and heart rate recovery, the magnitude of this relationship was reduced (comparing 25th with 75th percentile values; adjusted hazard ratio, 1.17; 95% CI, 1.08-1.26; P<.001), with these variables explaining 47% of the association. Conclusions Impaired functional capacity and abnormal heart rate recovery were strongly associated with lower SES and accounted for a major proportion of the correlation between SES and mortality. Efforts to modify these clinical features among patients with low SES may narrow disparities in mortality.	Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Louis Stokes Cleveland VA Med Ctr, Dept Med, Cleveland, OH USA; Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University	Lauer, MS (corresponding author), Cleveland Clin, Dept Cardiovasc Med, Desk JJ-40, Cleveland, OH 44195 USA.	lauerm@ccf.org	Lauer, Michael S/L-9656-2013	Lauer, Michael S/0000-0002-9217-8177	NHLBI NIH HHS [R01 HL-072771-02, P50 HL-77107-1, R01 HL-66004-2] Funding Source: Medline; NICHD NIH HHS [K12 HD049091] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K12HD049091] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066004, R01HL072771, P50HL077107] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; Alter DA, 2004, JAMA-J AM MED ASSOC, V291, P1100, DOI 10.1001/jama.291.9.1100; Anderson RT, 1997, EPIDEMIOLOGY, V8, P42, DOI 10.1097/00001648-199701000-00007; Beachler M, 2003, J RURAL HEALTH, V19, P416; Berkman LF, 2005, CIRCULATION, V111, P3022, DOI 10.1161/CIRCULATIONAHA.104.509810; Birkmeyer JD, 2003, NEW ENGL J MED, V349, P2117, DOI 10.1056/NEJMsa035205; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; Braveman PA, 2005, JAMA-J AM MED ASSOC, V294, P2879, DOI 10.1001/jama.294.22.2879; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P143; CHEADLE A, 1991, PREV MED, V20, P250, DOI 10.1016/0091-7435(91)90024-X; Church TS, 2002, ARTERIOSCL THROM VAS, V22, P1869, DOI 10.1161/01.ATV.0000036611.77940.F8; Cole CR, 1999, NEW ENGL J MED, V341, P1351, DOI 10.1056/NEJM199910283411804; Eagle KA, 2002, CIRCULATION, V105, P1257, DOI 10.1161/hc1002.104956; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; Fagard RH, 1999, MED SCI SPORT EXER, V31, pS624, DOI 10.1097/00005768-199911001-00022; Fiscella K, 2000, JAMA-J AM MED ASSOC, V283, P2579, DOI 10.1001/jama.283.19.2579; GOLDSTEIN DS, 1987, BAILLIERE CLIN ENDOC, V1, P253, DOI 10.1016/S0950-351X(87)80063-0; Gulati M, 2003, CIRCULATION, V108, P1554, DOI 10.1161/01.CIR.0000091080.57509.E9; HAAN M, 1987, AM J EPIDEMIOL, V125, P989, DOI 10.1093/oxfordjournals.aje.a114637; HACKBARTH DP, 1995, J PUBLIC HEALTH POL, V16, P213, DOI 10.2307/3342593; Harrell F.E., 2015, REGRESSION MODELING, DOI [10.1007/978-3-319-19425-7, DOI 10.1007/978-3-319-19425-7, 10.1007/978-1-4757-3462-1]; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; Hemingway H, 2005, CIRCULATION, V111, P3071, DOI 10.1161/CIRCULATIONAHA.104.497347; *I MED COMM UND EL, 2003, UNEQ TREATM CONFR RA; IMAI K, 1994, J AM COLL CARDIOL, V24, P1529, DOI 10.1016/0735-1097(94)90150-3; Isganaitis E, 2005, ARTERIOSCL THROM VAS, V25, P2451, DOI 10.1161/01.ATV.0000186208.06964.91; Jackson L, 2005, HEART, V91, P10, DOI 10.1136/hrt.2004.045559; KRIEGER N, 1994, INT J HEALTH SERV, V24, P25, DOI 10.2190/2JG7-YMD5-WCP2-XXNT; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; Krieger N, 2002, AM J EPIDEMIOL, V156, P471, DOI 10.1093/aje/kwf068; Lantz PM, 1998, JAMA-J AM MED ASSOC, V279, P1703, DOI 10.1001/jama.279.21.1703; Lauer Michael S, 2003, J Cardiopulm Rehabil, V23, P88, DOI 10.1097/00008483-200303000-00003; Lauer MS, 1999, J AM COLL CARDIOL, V34, P618, DOI 10.1016/S0735-1097(99)00250-8; Lind L, 2002, AM HEART J, V144, P666, DOI 10.1067/mhj.2002.124836; MCEWEN BS, 1999, SOCIOECONOMIC STATUS; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; Myers J, 2002, NEW ENGL J MED, V346, P793, DOI 10.1056/NEJMoa011858; Newman TB, 1997, J AM MED INFORM ASSN, V4, P233, DOI 10.1136/jamia.1997.0040233; Nishime EO, 2000, JAMA-J AM MED ASSOC, V284, P1392, DOI 10.1001/jama.284.11.1392; Panzer C, 2002, DIABETES, V51, P803, DOI 10.2337/diabetes.51.3.803; Pitzalis MV, 2001, AM HEART J, V141, P765, DOI 10.1067/mhj.2001.114806; Robert SA, 1998, J HEALTH SOC BEHAV, V39, P18, DOI 10.2307/2676387; Roux AVD, 2005, CIRCULATION, V111, P3020, DOI 10.1016/CIRCULATIONAHA.105.542845; Roux AVD, 2001, NEW ENGL J MED, V345, P99, DOI 10.1056/NEJM200107123450205; Shishehbor MH, 2004, DIABETES CARE, V27, P936, DOI 10.2337/diacare.27.4.936; Shishehbor MH, 2002, AM J MED, V113, P643, DOI 10.1016/S0002-9343(02)01324-4; Smith GD, 1998, J EPIDEMIOL COMMUN H, V52, P399, DOI 10.1136/jech.52.6.399; Snader CE, 1997, J AM COLL CARDIOL, V30, P641, DOI 10.1016/S0735-1097(97)00217-9; Srivastava R, 2000, AM J MED, V109, P20, DOI 10.1016/S0002-9343(00)00441-1; Stewart MK, 2003, J RURAL HEALTH, V19, P391; Therneau TM, 2000, MODELING SURVIVAL DA; Tiukinhoy Susan, 2003, J Cardiopulm Rehabil, V23, P84, DOI 10.1097/00008483-200303000-00002; Tonne C, 2005, CIRCULATION, V111, P3063, DOI 10.1161/CIRCULATIONAHA.104.496174; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; U.S. Department of Health and Human Services, 2000, HLTH PEOPL 2010 UND; *US DEP HHS, 1996, PUBL US DEP HLTH HUM; Waitzman NJ, 1998, AM J PUBLIC HEALTH, V88, P973, DOI 10.2105/AJPH.88.6.973; Watanabe J, 2001, CIRCULATION, V104, P1911, DOI 10.1161/circ.104.16.1911; Wisloff U, 2005, SCIENCE, V307, P418, DOI 10.1126/science.1108177; Yen IH, 1999, AM J EPIDEMIOL, V149, P898	60	114	116	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	2006	295	7					784	792		10.1001/jama.295.7.784	http://dx.doi.org/10.1001/jama.295.7.784			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	011YZ	16478901	Bronze			2022-12-28	WOS:000235306700023
J	Pohlmann-Eden, B; Beghi, E; Camfield, C; Camfield, P				Pohlmann-Eden, B; Beghi, E; Camfield, C; Camfield, P			The first seizure and its management in adults and children	BMJ-BRITISH MEDICAL JOURNAL			English	Review							QUALITY STANDARDS SUBCOMMITTEE; UNPROVOKED SEIZURE; PRACTICE PARAMETER; 1ST-SEIZURE PRESENTATION; NEUROLOGY SOCIETY; AMERICAN ACADEMY; EPILEPSY; RECURRENCE; EPILEPTOLOGY; CHILDHOOD		Bethel Epilepsy Ctr, Bethel, Germany; Univ Milano Bicocca, Epilepsy Ctr, Monza, Italy; Univ Milano Bicocca, Dept Neurol, Monza, Italy; Mario Negri Inst Pharmacol Res, Lab Neurol Disorders, I-20157 Milan, Italy; Dalhousie Univ, Dept Pediat, Halifax, NS, Canada; IWK Hlth Ctr, Halifax, NS, Canada	University of Milano-Bicocca; University of Milano-Bicocca; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Dalhousie University; Dalhousie University	Pohlmann-Eden, B (corresponding author), Bethel Epilepsy Ctr, Bethel, Germany.	pohleden@gmx.net	Beghi, Ettore/AAA-7426-2020	Beghi, Ettore/0000-0003-2542-0469				ANNEGERS JF, 1995, EPILEPSIA, V36, P327, DOI 10.1111/j.1528-1157.1995.tb01005.x; BERG AT, 1991, NEUROLOGY, V41, P965, DOI 10.1212/WNL.41.7.965; BERG AT, 1994, NEUROLOGY, V44, P601, DOI 10.1212/WNL.44.4.601; Camfield C, 1996, NEUROLOGY, V46, P41, DOI 10.1212/WNL.46.1.41; Camfield P, 2000, EPILEPSIA, V41, P1230, DOI 10.1111/j.1528-1157.2000.tb00331.x; CAMFIELD PR, 1985, NEUROLOGY, V35, P1657, DOI 10.1212/WNL.35.11.1657; CHADWICK D, 1990, LANCET, V336, P291, DOI 10.1016/0140-6736(90)91815-R; Dulac O, 1997, EPILEPSIA, V38, P1054; HART YM, 1990, LANCET, V336, P1271, DOI 10.1016/0140-6736(90)92960-P; Hauser WA, 1998, NEW ENGL J MED, V338, P429, DOI 10.1056/NEJM199802123380704; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HAUSER WA, 1990, NEUROLOGY, V40, P1163, DOI 10.1212/WNL.40.8.1163; Hirtz D, 2003, NEUROLOGY, V60, P166, DOI 10.1212/01.WNL.0000033622.27961.B6; Hirtz D, 2000, NEUROLOGY, V55, P616, DOI 10.1212/WNL.55.5.616; Jacoby A, 2005, LANCET NEUROL, V4, P171, DOI 10.1016/S1474-4422(05)01014-8; King MA, 1998, LANCET, V352, P1007, DOI 10.1016/S0140-6736(98)03543-0; Marson A, 2005, LANCET, V365, P2007, DOI 10.1016/S0140-6736(05)66694-9; Musicco M, 1997, NEUROLOGY, V49, P991, DOI 10.1212/WNL.49.4.991; Pietrzak MP, 1996, ANN EMERG MED, V28, P114; Pohlmann-Eden B, 1998, LANCET, V352, P1855, DOI 10.1016/S0140-6736(05)79919-0; Schmedding E, 2004, ACTA NEUROL BELG, V104, P68; Schreiner A, 2003, CLIN ELECTROENCEPHAL, V34, P140, DOI 10.1177/155005940303400307; SCHREINER A, 1995, J NEUROL SCI, V130, P171, DOI 10.1016/0022-510X(95)00020-3; Sharma S, 2003, PEDIATRICS, V111, P1, DOI 10.1542/peds.111.1.1; Shinnar S, 2000, ANN NEUROL, V48, P140, DOI 10.1002/1531-8249(200008)48:2<140::AID-ANA2>3.0.CO;2-Y	25	65	69	2	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 11	2006	332	7537					339	342		10.1136/bmj.332.7537.339	http://dx.doi.org/10.1136/bmj.332.7537.339			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	012YI	16470055	Green Published			2022-12-28	WOS:000235376400019
J	Gresham, D; Ruderfer, DM; Pratt, SC; Schacherer, J; Dunham, MJ; Botstein, D; Kruglyak, L				Gresham, D; Ruderfer, DM; Pratt, SC; Schacherer, J; Dunham, MJ; Botstein, D; Kruglyak, L			Genome-wide detection of polymorphisms at nucleotide resolution with a single DNA microarray	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; OLIGONUCLEOTIDE ARRAYS; HIGH-THROUGHPUT; YEAST; EVOLUTION; EXPRESSION; MUTATIONS; RATES	A central challenge of genomics is to detect, simply and inexpensively, all differences in sequence among the genomes of individual members of a species. We devised a system to detect all single-nucleotide differences between genomes with the use of data from a single hybridization to a whole-genome DNA microarray. This allowed us to detect a variety of spontaneous single-base pair substitutions, insertions, and deletions, and most ( >90%) of the similar to 30,000 known single-nucleotide polymorphisms between two Saccharomyces cerevisiae strains. We applied this approach to elucidate the genetic basis of phenotypic variants and to identify the small number of single-base pair changes accumulated during experimental evolution of yeast.	Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA	Princeton University; Princeton University; Princeton University	Kruglyak, L (corresponding author), Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA.	dgresham@genomics.princeton.edu; leonid@genomics.princeton.edu	Ruderfer, Douglas M/M-5795-2016; Pratt, Stephen/C-5418-2011	Ruderfer, Douglas M/0000-0002-2365-386X; Dunham, Maitreya/0000-0001-9944-2666	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM071508, R01GM046406] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH059520] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM107466, P50 GM071508, R01 GM046406] Funding Source: Medline; NIMH NIH HHS [R37 MH059520] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Albert TJ, 2005, NAT METHODS, V2, P951, DOI 10.1038/NMETH805; Borevitz JO, 2003, GENOME RES, V13, P513, DOI 10.1101/gr.541303; Brem RB, 2002, SCIENCE, V296, P752, DOI 10.1126/science.1069516; Cheng J, 2005, SCIENCE, V308, P1149, DOI 10.1126/science.1108625; Colman-Lerner A, 2001, CELL, V107, P739, DOI 10.1016/S0092-8674(01)00596-7; Daran-Lapujade P, 2003, FEMS YEAST RES, V4, P259, DOI 10.1016/S1567-1356(03)00156-9; Deutschbauer AM, 2005, NAT GENET, V37, P1333, DOI 10.1038/ng1674; Dunham MJ, 2002, P NATL ACAD SCI USA, V99, P16144, DOI 10.1073/pnas.242624799; Ellis TP, 2004, J BIOL CHEM, V279, P15728, DOI 10.1074/jbc.M314162200; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; Gu ZL, 2005, P NATL ACAD SCI USA, V102, P1092, DOI 10.1073/pnas.0409159102; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; Hazen SP, 2005, PLANT PHYSIOL, V138, P990, DOI 10.1104/pp.105.061408; Maitra A, 2004, GENOME RES, V14, P812, DOI 10.1101/gr.2228504; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; MASKOS U, 1992, NUCLEIC ACIDS RES, V20, P1675, DOI 10.1093/nar/20.7.1675; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Racki WJ, 2000, EMBO J, V19, P4524, DOI 10.1093/emboj/19.17.4524; Ronald J, 2005, PLOS GENET, V1, P213, DOI 10.1371/journal.pgen.0010025; Ronald J, 2005, GENOME RES, V15, P284, DOI 10.1101/gr.2850605; Shendure J, 2005, SCIENCE, V309, P1728, DOI 10.1126/science.1117389; Sniegowski PD, 1997, NATURE, V387, P703, DOI 10.1038/42701; Steinmetz LM, 2002, NATURE, V416, P326, DOI 10.1038/416326a; Turner TL, 2005, PLOS BIOL, V3, P1572, DOI 10.1371/journal.pbio.0030285; Volkman SK, 2002, SCIENCE, V298, P216, DOI 10.1126/science.1075642; Winzeler EA, 2003, GENETICS, V163, P79; Winzeler EA, 1998, SCIENCE, V281, P1194, DOI 10.1126/science.281.5380.1194; Wong CW, 2004, GENOME RES, V14, P398, DOI 10.1101/gr.2141004; Yvert G, 2003, NAT GENET, V35, P57, DOI 10.1038/ng1222	29	217	224	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 31	2006	311	5769					1932	1936		10.1126/science.1123726	http://dx.doi.org/10.1126/science.1123726			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	027BD	16527929				2022-12-28	WOS:000236387800047
J	Bates, GP				Bates, GP			Biomedicine - One misfolded protein allows others to sneak by	SCIENCE			English	Editorial Material							AGGREGATION		Kings Coll London, Sch Med, London SE1 9RT, England	University of London; King's College London	Bates, GP (corresponding author), Kings Coll London, Sch Med, London SE1 9RT, England.	gillian.bates@genetics.kcl.ac.uk	Bates, Gillian/E-1146-2012	Bates, Gillian/0000-0002-4041-6305				BRIGNULL HR, COMMUNICATION; Gidalevitz T, 2006, SCIENCE, V311, P1471, DOI 10.1126/science.1124514; Morley JF, 2002, P NATL ACAD SCI USA, V99, P10417, DOI 10.1073/pnas.152161099; Nollen EAA, 2004, P NATL ACAD SCI USA, V101, P6403, DOI 10.1073/pnas.0307697101; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Wexler NS, 2004, P NATL ACAD SCI USA, V101, P3498, DOI 10.1073/pnas.0308479101	6	9	11	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 10	2006	311	5766					1385	1386		10.1126/science.1125246	http://dx.doi.org/10.1126/science.1125246			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527959				2022-12-28	WOS:000236029400025
J	Brumfiel, G				Brumfiel, G			Ringing the changes at Bell Labs	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2006	440	7081					146	147		10.1038/440146a	http://dx.doi.org/10.1038/440146a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019MC	16525439	Bronze			2022-12-28	WOS:000235839500014
J	Davidson, EA; Janssens, IA				Davidson, EA; Janssens, IA			Temperature sensitivity of soil carbon decomposition and feedbacks to climate change	NATURE			English	Review							ORGANIC-MATTER; ECOSYSTEM RESPIRATION; PLANT RESPIRATION; LIGNIN CONTROL; CO2 EMISSIONS; FOREST SOILS; TURNOVER; NITROGEN; STORAGE; MINERALIZATION	Significantly more carbon is stored in the world's soils-including peatlands, wetlands and permafrost-than is present in the atmosphere. Disagreement exists, however, regarding the effects of climate change on global soil carbon stocks. If carbon stored belowground is transferred to the atmosphere by a warming-induced acceleration of its decomposition, a positive feedback to climate change would occur. Conversely, if increases of plant-derived carbon inputs to soils exceed increases in decomposition, the feedback would be negative. Despite much research, a consensus has not yet emerged on the temperature sensitivity of soil carbon decomposition. Unravelling the feedback effect is particularly difficult, because the diverse soil organic compounds exhibit a wide range of kinetic properties, which determine the intrinsic temperature sensitivity of their decomposition. Moreover, several environmental constraints obscure the intrinsic temperature sensitivity of substrate decomposition, causing lower observed 'apparent' temperature sensitivity, and these constraints may, themselves, be sensitive to climate.	Woods Hole Res Ctr, Woods Hole, MA 02540 USA; Univ Antwerp, Dept Biol, B-2610 Antwerp, Belgium	Woods Hole Research Center; University of Antwerp	Davidson, EA (corresponding author), Woods Hole Res Ctr, Woods Hole, MA 02540 USA.	edavidson@whrc.org	Janssens, Ivan A/P-1331-2014; Davidson, Eric A/K-4984-2013	Janssens, Ivan A/0000-0002-5705-1787; Davidson, Eric A/0000-0002-8525-8697				ACIA: Arctic Climate Impact Assessment, 2004, IMP WARM ARCT ARCT C; Agren G.I, 1998, THEORETICAL ECOSYSTE; Agren GI, 2000, AMBIO, V29, P55, DOI 10.1639/0044-7447(2000)029[0055:TDOOSO]2.0.CO;2; Anisimov O. A., 1999, EARTH CRYOLOGY, V3, P15; Arrhenius S., 1889, Z PHYS CHEM, V4U, P226, DOI [10.1515/zpch-1889-0416, DOI 10.1515/ZPCH-1889-0416]; Atkin OK, 2005, FUNCT PLANT BIOL, V32, P87, DOI 10.1071/FP03176; Atkin OK, 2003, TRENDS PLANT SCI, V8, P343, DOI 10.1016/S1360-1385(03)00136-5; Batjes NH, 2014, EUR J SOIL SCI, V65, P10, DOI 10.1111/ejss.12114_2; Bellamy PH, 2005, NATURE, V437, P245, DOI 10.1038/nature04038; Berry J.A., 1981, PHYSIOLOGICAL PLANT, P277, DOI [10.1007/978-3-642-68090-8_11, DOI 10.1007/978-3-642-68090-8_11]; Bockheim JG, 1998, GEODERMA, V81, P281, DOI 10.1016/S0016-7061(97)00115-8; Bosatta E, 1999, SOIL BIOL BIOCHEM, V31, P1889, DOI 10.1016/S0038-0717(99)00105-4; CHADWICK OA, 1994, BIOGEOCHEMISTRY, V24, P115, DOI 10.1007/BF00003268; Chapin FS, 2005, SCIENCE, V310, P657, DOI 10.1126/science.1117368; Chapin FS, 2000, GLOBAL CHANGE BIOL, V6, P211, DOI 10.1046/j.1365-2486.2000.06022.x; Dalias P, 2001, SOIL BIOL BIOCHEM, V33, P1049, DOI 10.1016/S0038-0717(01)00009-8; Dalias P, 2001, GLOBAL CHANGE BIOL, V7, P181, DOI 10.1046/j.1365-2486.2001.00386.x; Davidson EA, 2000, BIOGEOCHEMISTRY, V48, P53, DOI 10.1023/A:1006204113917; Davidson EA, 2000, NATURE, V408, P789, DOI 10.1038/35048672; DAVIDSON EA, IN PRESS GLOB CHANGE; Elberling B, 2003, SOIL BIOL BIOCHEM, V35, P263, DOI 10.1016/S0038-0717(02)00258-4; Eliasson PE, 2005, GLOBAL CHANGE BIOL, V11, P167, DOI 10.1111/j.1365-2486.2004.00878.x; ESWARAN H, 1993, SOIL SCI SOC AM J, V57, P192, DOI 10.2136/sssaj1993.03615995005700010034x; Fang C., 2005, BIOGEOSCI DISCUSS, V2, P725, DOI 10.5194/BGD-2-725-2005; Fang CM, 2005, NATURE, V433, P57, DOI 10.1038/nature03138; FARQUHAR GD, 1980, PLANTA, V149, P78, DOI 10.1007/BF00386231; Fierer N, 2005, ECOLOGY, V86, P320, DOI 10.1890/04-1254; Freeman C, 2001, NATURE, V409, P149, DOI 10.1038/35051650; Giardina CP, 2000, NATURE, V404, P858, DOI 10.1038/35009076; Goulden ML, 1998, SCIENCE, V279, P214, DOI 10.1126/science.279.5348.214; Grogan P, 2005, GLOBAL CHANGE BIOL, V11, P465, DOI 10.1111/j.1365-2486.2005.00912.x; Gruber N., 2004, CO2 STABILIZATION IS, P45; Hanson PJ, 2003, ECOL STU AN, V166, P163; Holland EA, 2000, GLOBAL BIOGEOCHEM CY, V14, P1137, DOI 10.1029/2000GB001264; Hyvonen R, 2005, GLOBAL CHANGE BIOL, V11, P770, DOI 10.1111/j.1365-2486.2005.00947.x; Imriskova I, 2005, RES MICROBIOL, V156, P361, DOI 10.1016/j.resmic.2004.11.001; Janssens IA, 2001, GLOBAL CHANGE BIOL, V7, P269, DOI 10.1046/j.1365-2486.2001.00412.x; Janssens IA, 2003, CANOPY FLUXES ENERGY, P235; JENKINSON DS, 1990, PHILOS T R SOC B, V329, P361, DOI 10.1098/rstb.1990.0177; JENKINSON DS, 1977, SOIL SCI, V123, P298, DOI 10.1097/00010694-197705000-00005; JENKINSON DS, 1991, NATURE, V351, P304, DOI 10.1038/351304a0; Jenny H., 1980, The soil resource.; Jenny H., 1941, FACTORS SOIL FORMATI; Jobbagy EG, 2000, ECOL APPL, V10, P423, DOI 10.1890/1051-0761(2000)010[0423:TVDOSO]2.0.CO;2; Jones C, 2005, GLOBAL CHANGE BIOL, V11, P154, DOI 10.1111/j.1365-2486.2004.00885.x; Katterer T, 2005, BIOGEOSCIENCES DISCU, V2, P737; KELLEY KR, 1996, HUMIC SUBSTANCES TER, P407; Kirschbaum MUF, 2004, GLOBAL CHANGE BIOL, V10, P1870, DOI 10.1111/j.1365-2486.2004.00852.x; KIRSCHBAUM MUF, 1995, SOIL BIOL BIOCHEM, V27, P753, DOI 10.1016/0038-0717(94)00242-S; Kirschbaum MUF, 2000, BIOGEOCHEMISTRY, V48, P21, DOI 10.1023/A:1006238902976; Knorr W, 2005, NATURE, V433, P298, DOI 10.1038/nature03226; Knorr W., 2005, BIOGEOSCIENCES DISCU, V2, P749, DOI [10.5194/BGD-2-749-2005, DOI 10.5194/BGD-2-749-2005]; Koch KE, 1996, ANNU REV PLANT PHYS, V47, P509, DOI 10.1146/annurev.arplant.47.1.509; Lichter J, 2005, ECOLOGY, V86, P1835, DOI 10.1890/04-1205; LINKINS AE, 1984, CURRENT PERSPECTIVES, P572; Liski J, 1999, AMBIO, V28, P171; Luo YQ, 2001, NATURE, V413, P622, DOI 10.1038/35098065; MALTBY E, 1993, CHEMOSPHERE, V27, P999, DOI 10.1016/0045-6535(93)90065-D; McHale G, 2005, EUR J SOIL SCI, V56, P445, DOI 10.1111/j.1365-2389.2004.00683.x; MEENTEMEYER V, 1978, ECOLOGY, V59, P465, DOI 10.2307/1936576; MELILLO JM, 1982, ECOLOGY, V63, P621, DOI 10.2307/1936780; Melillo JM, 2002, SCIENCE, V298, P2173, DOI 10.1126/science.1074153; Michaelis L, 1913, BIOCHEM Z, V49, P333; Mikan CJ, 2002, SOIL BIOL BIOCHEM, V34, P1785, DOI 10.1016/S0038-0717(02)00168-2; OADES JM, 1988, BIOGEOCHEMISTRY, V5, P35, DOI 10.1007/BF02180317; Ogle SM, 2003, GLOBAL CHANGE BIOL, V9, P1521, DOI 10.1046/j.1365-2486.2003.00683.x; Osterkamp TE, 1999, PERMAFROST PERIGLAC, V10, P17, DOI 10.1002/(SICI)1099-1530(199901/03)10:1&lt;17::AID-PPP303&gt;3.0.CO;2-4; Page SE, 2002, NATURE, V420, P61, DOI 10.1038/nature01131; PARTON WJ, 1987, SOIL SCI SOC AM J, V51, P1173, DOI 10.2136/sssaj1987.03615995005100050015x; Post WM, 2004, BIOSCIENCE, V54, P895, DOI 10.1641/0006-3568(2004)054[0895:EOCSIU]2.0.CO;2; POST WM, 1982, NATURE, V298, P156, DOI 10.1038/298156a0; Powlson D, 2005, NATURE, V433, P204, DOI 10.1038/433204a; RAICH JW, 1995, GLOBAL BIOGEOCHEM CY, V9, P23, DOI 10.1029/94GB02723; Ramaswamy V, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P349; Reichstein M, 2003, GLOBAL BIOGEOCHEM CY, V17, DOI 10.1029/2003GB002035; Rustad LE, 2001, OECOLOGIA, V126, P543, DOI 10.1007/s004420000544; SCHIMEL DS, 1994, GLOBAL BIOGEOCHEM CY, V8, P279, DOI 10.1029/94GB00993; SCHLENTNER RE, 1985, CAN J FOREST RES, V15, P97, DOI 10.1139/x85-018; Schlesinger WH, 2000, BIOGEOCHEMISTRY, V48, P7, DOI 10.1023/A:1006247623877; Serreze MC, 2000, CLIMATIC CHANGE, V46, P159, DOI 10.1023/A:1005504031923; SHAVER GR, 1992, BIOSCIENCE, V42, P433, DOI 10.2307/1311862; SHEEN J, 1994, PHOTOSYNTH RES, V39, P427, DOI 10.1007/BF00014596; Six J, 2002, SOIL SCI SOC AM J, V66, P1981, DOI 10.2136/sssaj2002.1981; Smith LC, 2005, SCIENCE, V308, P1429, DOI 10.1126/science.1108142; Sollins P, 1996, GEODERMA, V74, P65, DOI 10.1016/S0016-7061(96)00036-5; Spaccini R, 2002, SOIL BIOL BIOCHEM, V34, P1839, DOI 10.1016/S0038-0717(02)00197-9; Telles EDC, 2003, GLOBAL BIOGEOCHEM CY, V17, DOI 10.1029/2002GB001953; Thornley JHM, 2001, ANN BOT-LONDON, V87, P591, DOI 10.1006/anbo.2001.1372; Tjoelker MG, 2001, GLOBAL CHANGE BIOL, V7, P223, DOI 10.1046/j.1365-2486.2001.00397.x; Trumbore S, 2000, ECOL APPL, V10, P399, DOI 10.1890/1051-0761(2000)010[0399:AOSOMA]2.0.CO;2; Trumbore SE, 1996, SCIENCE, V272, P393, DOI 10.1126/science.272.5260.393; Turetsky M, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014000; Turetsky MR, 2004, GLOBAL BIOGEOCHEM CY, V18, DOI 10.1029/2004GB002222; *USDA NAT RES CONS, 1997, SOIL ORG CARB MAP; van't Hoff J. H., 1898, LECT THEORETICAL P 1; Wetherald RT, 1999, CLIMATIC CHANGE, V43, P495, DOI 10.1023/A:1005499220385; WHALEN SC, 1990, NATURE, V346, P160, DOI 10.1038/346160a0; Woodwell GM, 1983, CHANGING CLIMATE, P216; Zak DR, 1999, SOIL SCI SOC AM J, V63, P575, DOI 10.2136/sssaj1999.03615995006300030021x; Zimov SA, 1997, SCIENCE, V277, P800, DOI 10.1126/science.277.5327.800	100	4077	4464	288	3825	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 9	2006	440	7081					165	173		10.1038/nature04514	http://dx.doi.org/10.1038/nature04514			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019MC	16525463	Bronze			2022-12-28	WOS:000235839500036
J	Ross, G				Ross, G			Richard Dalitz (1925-2006) - Particle physicist and creator of the Dalitz plot. Obituary	NATURE			English	Biographical-Item									Univ Oxford, Rudolf Peierls Ctr Theoret Phys, Oxford OX1 3NP, England	University of Oxford	Ross, G (corresponding author), Univ Oxford, Rudolf Peierls Ctr Theoret Phys, 1 Keble Rd, Oxford OX1 3NP, England.	g.ross@physics.ox.ac.uk						DALITZ RH, PUBLICATION LIST	1	0	0	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2006	440	7081					162	162		10.1038/440162a	http://dx.doi.org/10.1038/440162a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019MC	16525459	Bronze			2022-12-28	WOS:000235839500030
J	Coulton, S; Drummond, C; James, D; Godfrey, C; Bland, JM; Parrott, S; Peters, T				Coulton, S; Drummond, C; James, D; Godfrey, C; Bland, JM; Parrott, S; Peters, T		Stepwice Res Team	Opportunistic screening for alcohol use disorders in primary care: comparative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARBOHYDRATE-DEFICIENT TRANSFERRIN; GAMMA-GLUTAMYL-TRANSFERASE; GENERAL-PRACTICE; BRIEF INTERVENTIONS; DRINKERS; CONSUMPTION; EFFICACY; MARKERS; ADVICE	Objective To evaluate the efficacy and relative costs of different screening methods for the identification of alcohol use disorders in an opportunistic screening programme in primary care in the United Kingdom. Design Comparative study. Setting Six general practices in south Wales. Participants 194 male primary care attendees aged 18 or over who completed an alcohol use disorders identification test (AUDIT) questionnaire. Main outcome measures Scores on alcohol use disorders identification test and measures of gamma-glutamyltransferase, aspartate aminotransferase, per cent carbohydrate deficient transferrin, and erythrocyte mean cell volume. Hazardous alcohol consumption, weekly binge consumption, and monthly binge consumption were ascertained using the time line follow back method over the previous 180 days. Alcohol dependence was determined using the Diagnostic and Statistical Manual of Mental Disorders, fourth edition. Unit costs were established from published resource references and from actual costs of analysing the biochemical tests. Results A significant correlation was observed between alcohol consumption and score on the alcohol use disorders identification test (Pearson's correlation coefficient r = 0.74) and measures of gamma-glutamyltransferase (r = 0.20) and per cent carbohydrate deficient transferrin (r = 0.36) but not aspartate aminotransferase (r = 0.08) or erythrocyte mean cell volume (r = 0.02). The alcohol use disorders identification test exhibited significantly higher sensitivity, specificity, and positive predictive value than all of the biochemical markers for hazardous consumption (69%, 98%, and 95%), weekly binge consumption (75%, 90%, and 71%), monthly binge consumption (66%, 97%, and 91%), and alcohol dependence (84%, 83%, and 41%). The questionnaire was also more cost efficient with a lower cost per true positive for all consumption outcomes. Conclusion The alcohol use disorders identification test questionnaire is an efficient and cost efficient diagnostic tool for routine screening for alcohol use disorders in primary care.	Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England; St George Hosp, Sch Med, Sect Addict Behav, Div Mental Hlth, London SW17 0RE, England; Whitchurch Hosp, Dept Clin Psychol, Cardiff CF14 7XB, Wales; Kings Coll London, Dept Biochem, London WC2R 2LS, England	University of York - UK; St Georges University London; University of London; King's College London	Coulton, S (corresponding author), Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England.	sc21@york.ac.uk	Drummond, Colin/O-9141-2019	Drummond, Colin/0000-0001-9379-5452; Godfrey, Christine/0000-0001-6290-5532; Coulton, Simon/0000-0002-7704-3274; Parrott, Steven James/0000-0002-0165-1150				Aertgeerts B, 2001, BRIT J GEN PRACT, V51, P206; Allen JP, 2001, PREV MED, V33, P428, DOI 10.1006/pmed.2001.0910; ANDERSON P, 1992, BRIT J ADDICT, V87, P891; [Anonymous], [No title captured]; BABOR T, 1989, ALCOHOL HLTH RES WOR, V13; Ballesteros J, 2004, ALCOHOL CLIN EXP RES, V28, P608, DOI 10.1097/01.ALC.0000122106.84718.67; Beich A, 2003, BMJ-BRIT MED J, V327, P536, DOI 10.1136/bmj.327.7414.536; Bertholet N, 2005, ARCH INTERN MED, V165, P986, DOI 10.1001/archinte.165.9.986; Conigrave KM, 2003, ADDICTION, V98, P31, DOI 10.1046/j.1359-6357.2003.00581.x; Deehan A, 1998, DRUG ALCOHOL REV, V17, P259, DOI 10.1080/09595239800187091; DRUMMOND C, 2004, EFFECTIVENESS COST E; Fleming MF, 2002, ALCOHOL CLIN EXP RES, V26, P36, DOI 10.1111/j.1530-0277.2002.tb02429.x; Helander A, 1996, ALCOHOL ALCOHOLISM, V31, P101; Kaner EFS, 1999, ALCOHOL ALCOHOLISM, V34, P559, DOI 10.1093/alcalc/34.4.559; MAYNARD A, 1994, BRIT MED BULL, V50, P221, DOI 10.1093/oxfordjournals.bmb.a072880; Meerkerk GJ, 1999, ALCOHOL CLIN EXP RES, V23, P1052, DOI 10.1111/j.1530-0277.1999.tb04224.x; Moyer A, 2002, ADDICTION, V97, P279, DOI 10.1046/j.1360-0443.2002.00018.x; NETTEN A, 2002, UNIT COSTS SOCIAL HL; *PRIM MIN STRAT UN, 2004, ALC HARM RED STRAT E; *ROYAL COLL PHYS, 2003, ALC CAN NHS AFF IT; SAUNDERS JB, 1993, ADDICTION, V88, P25; SOBELL LC, 1992, MEASURING ALCOHOL CONSUMPTION, P41, DOI 10.1007/978-1-4612-0357-5_3; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663; Whitlock EP, 2004, ANN INTERN MED, V140, P557, DOI 10.7326/0003-4819-140-7-200404060-00017	24	49	49	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 4	2006	332	7540					511	514A		10.1136/bmj.38743.421574.7C	http://dx.doi.org/10.1136/bmj.38743.421574.7C			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	023WB	16488896	Green Published, Bronze			2022-12-28	WOS:000236155800013
J	Horwich, A; Shipley, J; Huddart, R				Horwich, A; Shipley, J; Huddart, R			Testicular germ-cell cancer	LANCET			English	Review							STAGE-I SEMINOMA; LYMPH-NODE DISSECTION; SINGLE-AGENT CARBOPLATIN; HIGH-DOSE CHEMOTHERAPY; LACTATE-DEHYDROGENASE ISOENZYME-1; POSITRON-EMISSION-TOMOGRAPHY; LONG-TERM SURVIVORS; C-KIT GENE; RANDOMIZED-TRIAL; PHASE-II	Testicular germ-cell tumours (TGCTs) represent the model of a curable malignancy; sensitive tumour markers, accurate prognostic classification, logical series of management trials, and high cure rates in both seminomas and non-seminomas have enabled a framework of effective cancer therapy. Understanding the molecular biology of TGCT could help improve treatment of other cancers. The typical presentation in young adults means that issues of long-term toxicity become especially important in judging appropriate management. A focus of recent developments has been to tailor aggressiveness of treatment to the severity of the prognosis. Recent changes affect the most common subtypes and include the reduction of chemotherapy for patients who have metastastic non-seminomas and a good prognosis, and alternatives to adjuvant radiotherapy in stage I seminomas. We summarise advances in the understanding and management of TGCT during the past decade.	Inst Canc Res, Sutton SM2 5PT, Surrey, England; Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England; Inst Canc Res, Surrey, England	University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Horwich, A (corresponding author), Inst Canc Res, Sutton SM2 5PT, Surrey, England.	alan.horwich@icr.ac.uk		huddart, robert/0000-0003-3604-1990; Shipley, Janet/0000-0001-6748-8678				AASS N, 1991, J CLIN ONCOL, V9, P818, DOI 10.1200/JCO.1991.9.5.818; Albanese JM, 2001, DIAGN MOL PATHOL, V10, P248, DOI 10.1097/00019606-200112000-00007; Almstrup K, 2004, CANCER RES, V64, P4736, DOI 10.1158/0008-5472.CAN-04-0679; ANDREYEV HJN, 1993, DIAGN ONCOL, V3, P67; [Anonymous], 1997, J Clin Oncol, V15, P594; Anzai Y, 2003, RADIOLOGY, V228, P777, DOI 10.1148/radiol.2283020872; Aparicio J, 2005, J CLIN ONCOL, V23, P8717, DOI 10.1200/JCO.2005.01.9810; ATKIN NB, 1982, LANCET, V2, P1349; BAJORIN DF, 1993, J CLIN ONCOL, V11, P598, DOI 10.1200/JCO.1993.11.4.598; Beyer J, 2002, ANN ONCOL, V13, P599, DOI 10.1093/annonc/mdf112; Beyer J, 1996, J CLIN ONCOL, V14, P2638, DOI 10.1200/JCO.1996.14.10.2638; Bhala N, 2004, CLIN ONCOL-UK, V16, P40, DOI 10.1016/S0936-6555(03)00166-3; Bhayani SB, 2003, UROLOGY, V62, P324, DOI 10.1016/S0090-4295(03)00324-8; Bokemeyer C, 1996, ANN ONCOL, V7, P31; Bokemeyer C, 1999, J CLIN ONCOL, V17, P3450, DOI 10.1200/JCO.1999.17.11.3450; Bokemeyer C, 2004, BRIT J CANCER, V91, P683, DOI 10.1038/sj.bjc.6602020; Bokemeyer C, 2002, J CLIN ONCOL, V20, P1864, DOI 10.1200/JCO.2002.07.062; Bokemeyer C, 1996, ANN ONCOL, V7, P1015; Boublikova L, 2002, GERM CELL TUMOURS V, P244; Bourdon V, 2002, CANCER RES, V62, P6218; Bower M, 1997, ANN ONCOL, V8, P477, DOI 10.1023/A:1008279222625; CHEVREAU C, 1993, EUR UROL, V23, P213; Christian JA, 2003, J CLIN ONCOL, V21, P871, DOI 10.1200/JCO.2003.05.155; Chung PWM, 2004, EUR UROL, V45, P754, DOI 10.1016/j.eururo.2004.01.020; Clark AT, 2004, STEM CELLS, V22, P169, DOI 10.1634/stemcells.22-2-169; Classen J, 2003, J CLIN ONCOL, V21, P1101, DOI 10.1200/JCO.2003.06.065; CLEMM C, 2000, ASCO 2000 36 ANN M A; Collette L, 1999, JNCI-J NATL CANCER I, V91, P839, DOI 10.1093/jnci/91.10.839; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Cremerius U, 1998, J NUCL MED, V39, P815; CULLEN MH, 1996, TESTICULAR CANC INVE, P181; De Miguel MP, 2002, P NATL ACAD SCI USA, V99, P10458, DOI 10.1073/pnas.122249399; De Santis M, 2004, J CLIN ONCOL, V22, P1034, DOI 10.1200/JCO.2004.07.188; de Wit R, 2001, J CLIN ONCOL, V19, P1629, DOI 10.1200/JCO.2001.19.6.1629; Dearnaley DP, 2005, BRIT J CANCER, V92, P2107, DOI 10.1038/sj.bjc.6602624; Dieckmann KP, 2001, EUR UROL, V40, P677, DOI 10.1159/000049857; Dieckmann KP, 2000, UROLOGY, V55, P102, DOI 10.1016/S0090-4295(99)00376-3; Dong C, 2001, EUR J CANCER, V37, P1878, DOI 10.1016/S0959-8049(01)00172-1; Donohue J P, 1998, Semin Urol Oncol, V16, P65; DROZ JP, 2001, 37 ANN M MAY 12 15 2, pA173; Duchesne GM, 1997, EUR J CANCER, V33, P829, DOI 10.1016/S0959-8049(97)00033-6; Einhorn LH, 1999, J CLIN ONCOL, V17, P509, DOI 10.1200/JCO.1999.17.2.509; Fizazi K, 2004, J CLIN ONCOL, V22, P3868, DOI 10.1200/JCO.2004.04.008; Fizazi K, 2002, BRIT J CANCER, V86, P1555, DOI 10.1038/sj.bjc.6600272; Fizazi K, 2001, J CLIN ONCOL, V19, P2647, DOI 10.1200/JCO.2001.19.10.2647; Fleer J, 2002, LANCET, V360, P1511, DOI 10.1016/S0140-6736(02)11448-6; Fleshner Neil, 2002, Semin Urol Oncol, V20, P227, DOI 10.1053/suro.2002.36979; FORMAN D, 1992, BRIT J CANCER, V65, P255, DOI 10.1038/bjc.1992.51; Fossa SD, 2000, BRIT J CANCER, V82, P737, DOI 10.1054/bjoc.1999.0989; Fossa SD, 2004, BRIT J CANCER, V90, P607, DOI 10.1038/sj.bjc.6601558; Fossa SD, 1999, J CLIN ONCOL, V17, P1146, DOI 10.1200/JCO.1999.17.4.1146; FOSSA SD, 1990, UROLOGICAL ONCOLOGY; FRY AM, 1991, CANCER RES, V51, P6592; GALLAGHER RP, 1995, CANCER CAUSE CONTROL, V6, P398, DOI 10.1007/BF00052179; GELDERMAN WAH, 1989, UROLOGY, V33, P10, DOI 10.1016/0090-4295(89)90057-5; Gerl A, 1997, ANN ONCOL, V8, P41, DOI 10.1023/A:1008253323854; GIWERCMAN A, 1991, J UROLOGY, V145, P77, DOI 10.1016/S0022-5347(17)38252-6; GIWERCMAN A, 1993, ENVIRON HEALTH PERSP, V101, P65, DOI 10.2307/3431378; Hain SF, 2000, BRIT J CANCER, V83, P863, DOI 10.1054/bjoc.2000.1389; Hain SF, 2000, EUR J NUCL MED, V27, P590, DOI 10.1007/s002590050547; HARDING MJ, 1993, LANCET, V341, P999, DOI 10.1016/0140-6736(93)91082-W; Harland SJ, 1998, J UROLOGY, V160, P1353, DOI 10.1016/S0022-5347(01)62535-7; HENDRY WF, 1995, EUR J CANCER, V31A, P649, DOI 10.1016/0959-8049(95)00009-8; Hendry WF, 2002, CANCER, V94, P1668, DOI 10.1002/cncr.10440; Henegariu O, 1998, J MOL MED-JMM, V76, P648, DOI 10.1007/s001090050262; Hinton S, 2002, J CLIN ONCOL, V20, P1859, DOI 10.1200/JCO.2002.07.158; Hoei-Hansen CE, 2004, CLIN CANCER RES, V10, P8521, DOI 10.1158/1078-0432.CCR-04-1285; Holzik M. F. L., 2004, Lancet Oncology, V5, P363, DOI 10.1016/S1470-2045(04)01493-7; Honorio S, 2003, ONCOGENE, V22, P461, DOI 10.1038/sj.onc.1206119; HORWICH A, 1994, RADIOTHER ONCOL, V30, P193, DOI 10.1016/0167-8140(94)90457-X; Horwich A, 1997, ANN ONCOL, V8, P37, DOI 10.1023/A:1008241904019; Horwich A, 2004, J CLIN ONCOL, V22, P585, DOI 10.1200/JCO.2004.12.966; Horwich A, 2000, BRIT J CANCER, V83, P1623, DOI 10.1054/bjoc.2000.1498; Horwich A, 1997, J CLIN ONCOL, V15, P1844, DOI 10.1200/JCO.1997.15.5.1844; Horwich A, 1998, BRIT J CANCER, V78, P5; HORWICH A, 1995, BRIT J CANCER, V71, P901, DOI 10.1038/bjc.1995.175; Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293; Huddart R, 2005, EJC SUPPL, V3, P227; HUDDART R, 2000, ASCO 36 ANN M 2000 M; Huddart RA, 2005, BRIT J CANCER, V93, P200, DOI 10.1038/sj.bjc.6602677; Huddart RA, 2003, J CLIN ONCOL, V21, P1513, DOI 10.1200/JCO.2003.04.173; Jacobsen R, 2000, BMJ-BRIT MED J, V321, P789, DOI 10.1136/bmj.321.7264.789; JENNINGS MT, 1985, J NEUROSURG, V63, P155, DOI 10.3171/jns.1985.63.2.0155; Jones WG, 2005, J CLIN ONCOL, V23, P1200, DOI 10.1200/JCO.2005.08.003; Jones WG, 1998, GERM CELL TUMOURS IV, P269; Kawakami T, 2004, LANCET, V363, P40, DOI 10.1016/S0140-6736(03)15170-7; Kemmer K, 2004, AM J PATHOL, V164, P305, DOI 10.1016/S0002-9440(10)63120-3; Kersemaekers AMF, 2002, J CLIN ONCOL, V20, P1551, DOI 10.1200/JCO.20.6.1551; Koberle B, 1999, CURR BIOL, V9, P273, DOI 10.1016/S0960-9822(99)80118-3; Kollmannsberger C, 2004, J CLIN ONCOL, V22, P108, DOI 10.1200/JCO.2004.06.068; Kollmannsberger C, 2002, J CLIN ONCOL, V20, P2031, DOI 10.1200/JCO.2002.08.050; Kondagunta GV, 2005, J CLIN ONCOL, V23, P6549, DOI 10.1200/JCO.2005.19.638; Koul Sanjay, 2002, Mol Cancer, V1, P8, DOI 10.1186/1476-4598-1-8; Lampe H, 1997, J CLIN ONCOL, V15, P239, DOI 10.1200/JCO.1997.15.1.239; Lassen U, 2003, EUR J NUCL MED MOL I, V30, P396, DOI 10.1007/s00259-002-1075-z; Levin HS, 2000, UROL CLIN N AM, V27, P543, DOI 10.1016/S0094-0143(05)70101-4; Li JH, 2003, DEV CELL, V5, P787, DOI 10.1016/S1534-5807(03)00328-9; Looijenga LHJ, 2003, CANCER RES, V63, P7674; Masters JRW, 2003, NAT REV CANCER, V3, P517, DOI 10.1038/nrc1120; Masters JRW, 1996, EUR J CANCER, V32A, P1248, DOI 10.1016/0959-8049(96)00033-0; McIntyre A, 2005, CANCER RES, V65, P8085, DOI 10.1158/0008-5472.CAN-05-0471; McIntyre A, 2004, ONCOGENE, V23, P9142, DOI 10.1038/sj.onc.1208115; Meijer C, 2000, INT J CANCER, V85, P777, DOI 10.1002/(SICI)1097-0215(20000315)85:6<777::AID-IJC6>3.0.CO;2-D; Meinardi MT, 2000, J CLIN ONCOL, V18, P1725, DOI 10.1200/JCO.2000.18.8.1725; MORATO P, IN PRESS ANN ONCOL; MOTZER RJ, 1994, J CLIN ONCOL, V12, P2277, DOI 10.1200/JCO.1994.12.11.2277; MOUL JW, 1992, GENE CHROMOSOME CANC, V5, P109, DOI 10.1002/gcc.2870050204; Nichols CR, 1998, J CLIN ONCOL, V16, P1287, DOI 10.1200/JCO.1998.16.4.1287; NICHOLS CR, 1987, J CLIN ONCOL, V5, P1290, DOI 10.1200/JCO.1987.5.8.1290; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; O'Sullivan JM, 2003, ANN ONCOL, V14, P91, DOI 10.1093/annonc/mdg020; Oldenburg J, 2003, J CLIN ONCOL, V21, P3310, DOI 10.1200/JCO.2003.03.184; OLIE RA, 1995, GENE CHROMOSOME CANC, V12, P110, DOI 10.1002/gcc.2870120205; Oliver RTD, 2005, LANCET, V366, P293, DOI 10.1016/S0140-6736(05)66984-X; OLIVER RTD, 1994, INT J RADIAT ONCOL, V29, P3, DOI 10.1016/0360-3016(94)90219-4; OOSTERHUIS JW, 1984, INT J CANCER, V34, P133, DOI 10.1002/ijc.2910340123; OOSTERHUIS JW, 1990, CANCER SURV, V9, P321; Ottesen AM, 2003, GENE CHROMOSOME CANC, V38, P117, DOI 10.1002/gcc.10244; PARRIS CN, 1990, CANCER RES, V50, P7513; Patterson H, 2001, RADIOTHER ONCOL, V59, P5, DOI 10.1016/S0167-8140(00)00240-1; PECKHAM MJ, 1983, BRIT J UROL, V55, P754, DOI 10.1111/j.1464-410X.1983.tb03420.x; Pectasides D, 2004, EUR UROL, V46, P216, DOI 10.1016/j.eururo.2004.03.001; PERA MF, 1987, CANCER RES, V47, P6810; Pico JL, 2005, ANN ONCOL, V16, P1152, DOI 10.1093/annonc/mdi228; Puc HS, 1996, J CLIN ONCOL, V14, P454, DOI 10.1200/JCO.1996.14.2.454; RAJPERTDEMEYTS E, 1994, INT J ANDROL, V17, P85; RajpertDeMeyts E, 1996, VIRCHOWS ARCH, V428, P133; Rapley EA, 2000, NAT GENET, V24, P197, DOI 10.1038/72877; Rapley EA, 2004, BRIT J CANCER, V90, P2397, DOI 10.1038/sj.bjc.6601880; Rapley EA, 2003, APMIS, V111, P128, DOI 10.1034/j.1600-0463.2003.11101171.x; Reiter WJ, 2001, J CLIN ONCOL, V19, P101, DOI 10.1200/JCO.2001.19.1.101; Rodriguez S, 2003, ONCOGENE, V22, P1880, DOI 10.1038/sj.onc.1206302; Roelofs H, 2000, AM J PATHOL, V157, P1155, DOI 10.1016/S0002-9440(10)64631-7; Rosenberg C, 2000, ONCOGENE, V19, P5858, DOI 10.1038/sj.onc.1203950; Sakuma Y, 2003, CANCER SCI, V94, P486, DOI 10.1111/j.1349-7006.2003.tb01470.x; SARK MWJ, 1995, BRIT J CANCER, V71, P684, DOI 10.1038/bjc.1995.135; Satge D, 1997, CANCER, V80, P929; Saxman SB, 1998, J CLIN ONCOL, V16, P702, DOI 10.1200/JCO.1998.16.2.702; Shahidi M, 2002, CANCER, V95, P520, DOI 10.1002/cncr.10691; Sharpe RM, 2003, INT J ANDROL, V26, P2, DOI 10.1046/j.1365-2605.2003.00367.x; Simpson AB, 1998, BRIT J CANCER, V78, P1061, DOI 10.1038/bjc.1998.628; Skotheim RI, 2003, NEOPLASIA, V5, P397, DOI 10.1016/S1476-5586(03)80042-8; Skotheim RI, 2002, CANCER RES, V62, P2359; Smiraglia DJ, 2002, ONCOGENE, V21, P3909, DOI 10.1038/sj.onc.1205488; Smith-Sorensen B, 2002, ONCOGENE, V21, P8878, DOI 10.1038/sj.onc.1205978; Sommerer F, 2004, ONCOGENE, V23, P554, DOI 10.1038/sj.onc.1207189; Sonneveld DJA, 2001, CANCER, V91, P1304, DOI 10.1002/1097-0142(20010401)91:7<1304::AID-CNCR1133>3.0.CO;2-A; Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100; Spermon JR, 2002, UROLOGY, V59, P923, DOI 10.1016/S0090-4295(02)01528-5; Steiner H, 2004, UROLOGY, V63, P550, DOI 10.1016/j.urology.2003.09.067; Steiner H, 2002, UROLOGY, V60, P324, DOI 10.1016/S0090-4295(02)01708-9; Steyerberg EW, 1997, J UROLOGY, V158, P474, DOI 10.1016/S0022-5347(01)64506-3; SUIJKERBUIJK RF, 1993, CANCER GENET CYTOGEN, V70, P85, DOI 10.1016/0165-4608(93)90173-J; Summersgill B, 1998, DIAGN MOL PATHOL, V7, P260, DOI 10.1097/00019606-199810000-00005; Summersgill BM, 2001, CANCER GENET CYTOGEN, V128, P120, DOI 10.1016/S0165-4608(01)00414-9; Surani MA, 2001, NATURE, V414, P122, DOI 10.1038/35102186; Sweeney P, 2003, J UROLOGY, V169, P2113, DOI 10.1097/01.ju.0000067601.29966.4a; Swerdlow AJ, 1997, LANCET, V350, P1723, DOI 10.1016/S0140-6736(97)05526-8; Tian QS, 1999, AM J PATHOL, V154, P1643, DOI 10.1016/S0002-9440(10)65419-3; TOLLERUD DJ, 1985, CANCER, V55, P1849, DOI 10.1002/1097-0142(19850415)55:8<1849::AID-CNCR2820550834>3.0.CO;2-1; Toner GC, 2004, J CLIN ONCOL, V22, P3842, DOI 10.1200/JCO.2004.06.923; Toner GC, 2001, LANCET, V357, P739, DOI 10.1016/S0140-6736(00)04165-9; Travis LB, 1997, JNCI-J NATL CANCER I, V89, P1429, DOI 10.1093/jnci/89.19.1429; VANLEEUWEN FE, 1993, J CLIN ONCOL, V11, P415, DOI 10.1200/JCO.1993.11.3.415; von Eyben FE, 2004, CANCER GENET CYTOGEN, V151, P93, DOI 10.1016/j.cancergencyto.2003.09.008; von Eyben FE, 2002, ACTA ONCOL, V41, P77, DOI 10.1080/028418602317314109; von Eyben FE, 2001, CLIN CHEM LAB MED, V39, P38; WALKER MC, 1987, J NATL CANCER I, V79, P213; Walsh J, 2003, APMIS, V111, P197, DOI 10.1034/j.1600-0463.2003.1110124.x; Warde P, 2002, J CLIN ONCOL, V20, P4448, DOI 10.1200/JCO.2002.01.038; WILLIAMS SD, 1987, NEW ENGL J MED, V316, P1435, DOI 10.1056/NEJM198706043162302; Zaehres H, 2005, STEM CELLS, V23, P299, DOI 10.1634/stemcells.2004-0252; Zagars GK, 2004, J CLIN ONCOL, V22, P640, DOI 10.1200/JCO.2004.05.205; Zagars GK, 1996, TESTICULAR CANC INVE, P99	174	290	299	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 4	2006	367	9512					754	765		10.1016/S0140-6736(06)68305-0	http://dx.doi.org/10.1016/S0140-6736(06)68305-0			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	020JX	16517276				2022-12-28	WOS:000235906000030
J	Leaper, DJ; Harding, KG				Leaper, DJ; Harding, KG			ABC of wound healing - Traumatic and surgical wounds	BRITISH MEDICAL JOURNAL			English	Editorial Material									Cardiff Univ, Wound Healing Res Unit, Cardiff, Wales; Cardiff & Vale NHS Trust, Cardiff, S Glam, Wales	Cardiff University; Cardiff University	Leaper, DJ (corresponding author), Cardiff Univ, Wound Healing Res Unit, Cardiff, Wales.							BALES S, 2000, INTRO WOUNDS; LEAPER DJ, 2002, RECENT ADV SURG; LEAPER DJ, 2004, CLIN SURG GEN; Leaper DJ, 2004, BAILEY LOVES SHORT P; TEOT L, 2004, SURG WOUNDS; Williams, 1998, WOUNDS BIOL MANAGEME	6	21	23	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 4	2006	332	7540					532	535		10.1136/bmj.332.7540.532	http://dx.doi.org/10.1136/bmj.332.7540.532			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	023WB	16513711	Green Published			2022-12-28	WOS:000236155800019
J	Warren, CW; Jones, NR; Eriksen, MP; Asma, S				Warren, CW; Jones, NR; Eriksen, MP; Asma, S		GTSS Collaborative Grp	Patterns of global tobacco use in young people and implications for future chronic disease burden in adults	LANCET			English	Article							YOUTH	Background Tobacco use is a leading preventable risk factor for many chronic disorders, which are expected to account for an increasing share of the global disease burden. As part of the Global Youth Tobacco Survey (GYTS), we aimed to assess the effect of tobacco use by young people on global mortality. Methods GYTS is a school-based survey of students aged 13-15 years. The survey was undertaken at 395 sites in 131 countries and the Gaza Strip and West Bank. We questioned students about current tobacco use, susceptibility to smoking among non-smokers, and exposure to secondhand smoke at home and in public places. Findings The difference in current cigarette smoking between boys and girls is narrower than expected in many regions of the world. Use of tobacco products other than cigarettes by students is as high as cigarette smoking in many regions. Almost one in five never-smokers reported they were susceptible to smoking in the next year. Student exposure to secondhand smoke was high both at home (more than four in ten) and in public places (more than five in ten). Never-smokers were significantly less likely than current smokers to be exposed to secondhand smoke at home (prevalence 39.1% [95% CI 36.6-41.6] vs 72.8% [64.0-81.6]) and in public places (49.5% [46.7-52.3] vs 81.2% [74.2-88.2]). Interpretation Our findings are troubling for the future of chronic disease and tobacco-related mortality. Reduction of tobacco consumption will require a redoubling of efforts to prevent initiation and promote cessation among the large proportion of young people who currently use tobacco. High exposure to secondhand smoke suggests a need for countries to pass strong and effective smoke-free policies.	Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA USA; Georgia State Univ, Inst Publ Hlth, Atlanta, GA 30303 USA	Centers for Disease Control & Prevention - USA; University System of Georgia; Georgia State University	Warren, CW (corresponding author), 4770 Buford Hwy,ME MS-K50, Atlanta, GA 30341 USA.	wcw1@cdc.gov	Carvalho Figueiredo, Valeska/D-4268-2018	Carvalho Figueiredo, Valeska/0000-0001-8617-5386; Figueiredo, Valeska/0000-0002-3379-0024				Asma S, 2004, PUBLIC HEALTH REP, V119, P253, DOI 10.1016/j.phr.2004.04.004; ASMA S, 2004, PROMOTING HLTH GLOBA; Asma Samira, 2003, Ethn Dis, V13, pS81; BRENER ND, 1995, AM J EPIDEMIOL, V141, P575, DOI 10.1093/oxfordjournals.aje.a117473; *CDCP, 2005, MMWR-MORBID MORTAL W, V54, P505; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Global Tobacco Surveillance Syst Collaborating Grp, 2005, J SCHOOL HEALTH, V75, P15; Global Youth Tobacco Survey Collabor, 2003, J SCHOOL HEALTH, V73, P207; Miguel-Baquilod M., 2005, Morbidity and Mortality Weekly Report, V54, P94; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; *PAHO, SMOK FREE AM; Peto R, 1994, MORTALITY SMOKING DE; Pierce JP, 1996, HEALTH PSYCHOL, V15, P355, DOI 10.1037/0278-6133.15.5.355; SHAH BV, 1997, SUDAAN SOFTWARE STAT; U.S. Department of Health and Human Services, 2001, WOM SMOK REP SURG GE; United Nations Children's Fund, 2002, STAT WORLDS CHILDR 2; Warren CW, 2000, B WORLD HEALTH ORGAN, V78, P868; *WHO, UPD STAT WHO FRAM CO; *WHO IARC, 2004, MON EV CARC RISKS HU, V83; *WHO IARC, 2004, MON EV CARC RISKS HU, V85; *WHO REG OFF S E A, 2005, REG STRAT UT GLOB YO; *WHO W PAC REG, 2005, TOB FREE IN REG ACT; World Health Organization, 1997, TOB HLTH GLOB STAT R; Yach D, 2002, TOB CONTROL, V11, P252, DOI 10.1136/tc.11.3.252	24	313	333	0	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 4	2006	367	9512					749	753		10.1016/S0140-6736(06)68192-0	http://dx.doi.org/10.1016/S0140-6736(06)68192-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	020JX	16517275				2022-12-28	WOS:000235906000029
J	Pulendran, B; Ahmed, R				Pulendran, B; Ahmed, R			Translating innate immunity into immunological memory: Implications for vaccine development	CELL			English	Review							CD8 T-CELLS; TOLL-LIKE RECEPTORS; ACTIVATED PROTEIN-KINASE; DENDRITIC CELLS; IN-VIVO; CUTTING EDGE; VIRAL-INFECTION; BONE-MARROW; B-CELLS; SMALLPOX VACCINATION	Vaccination is the most effective means of preventing infectious diseases. Despite the success of many vaccines, there is presently little knowledge of the immunological mechanisms that mediate their efficacy. Such information will be critical in the design of future vaccines against old and new infectious diseases. Recent advances in immunology are beginning to provide an intellectual framework with which to address fundamental questions about how the innate immune system shapes adaptive immunity. In this review, we summarize current knowledge about how the innate immune system modulates the quantity and quality of longterm T and B cell memory and protective immune responses to pathogens. In addition, we point out unanswered questions and identify critical challenges, the solution of which, we believe, will greatly facilitate the rational design of novel vaccines against a multitude of emerging infections.	Emory Vaccine Ctr, Dept Pathol, Atlanta, GA 30329 USA; Emory Vaccine Ctr, Dept Microbiol & Immunol, Atlanta, GA 30329 USA	Emory University; Emory University	Pulendran, B (corresponding author), Emory Vaccine Ctr, Dept Pathol, 954 Gatewood Rd, Atlanta, GA 30329 USA.	bpulend@rmy.emory.edu; ra@microbio.emory.edu	Pulendran, Bali/AAW-9550-2021	Pulendran, Bali/0000-0001-6517-4333				Aderem A, 2005, CELL, V121, P511, DOI 10.1016/j.cell.2005.04.020; Agrawal A, 2003, NATURE, V424, P329, DOI 10.1038/nature01794; Agrawal S, 2003, J IMMUNOL, V171, P4984, DOI 10.4049/jimmunol.171.10.4984; Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Baumgarth N, 2005, SPRINGER SEMIN IMMUN, V26, P347, DOI 10.1007/s00281-004-0182-2; Becker TC, 2005, J IMMUNOL, V174, P1269, DOI 10.4049/jimmunol.174.3.1269; Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Blattman JN, 2002, J EXP MED, V195, P657, DOI 10.1084/jem.20001021; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Butz EA, 1998, IMMUNITY, V8, P167, DOI 10.1016/S1074-7613(00)80469-0; Chang DH, 2005, J EXP MED, V201, P1503, DOI 10.1084/jem.20042592; Crotty S, 2003, J IMMUNOL, V171, P4969, DOI 10.4049/jimmunol.171.10.4969; Debes GF, 2005, NAT IMMUNOL, V6, P889, DOI 10.1038/ni1238; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; Di Rosa F, 2002, EUR J IMMUNOL, V32, P1873; Dillon S, 2004, J IMMUNOL, V172, P4733, DOI 10.4049/jimmunol.172.8.4733; DILLON S, 2006, IN PRESS J CLIN INVE; Fearon DT, 2000, ANNU REV IMMUNOL, V18, P393, DOI 10.1146/annurev.immunol.18.1.393; GEIJTENBEEK TB, 2000, ANNU REV IMMUNOL, V22, P33; Germain RN, 2004, NAT MED, V10, P1307, DOI 10.1038/nm1159; Gett AV, 2003, NAT IMMUNOL, V4, P355, DOI 10.1038/ni908; GRAY D, 1988, NATURE, V336, P70, DOI 10.1038/336070a0; Grayson JM, 2000, J IMMUNOL, V164, P3950, DOI 10.4049/jimmunol.164.8.3950; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; HAMANN A, 1994, J IMMUNOL, V152, P3282; Hammarlund E, 2003, NAT MED, V9, P1131, DOI 10.1038/nm917; Harte MT, 2003, J EXP MED, V197, P343, DOI 10.1084/jem.20021652; Hawiger D, 2001, J EXP MED, V194, P769, DOI 10.1084/jem.194.6.769; Haynes BF, 2005, SCIENCE, V308, P1906, DOI 10.1126/science.1111781; Homann D, 2001, NAT MED, V7, P913, DOI 10.1038/90950; Huang AYC, 2004, IMMUNITY, V21, P331, DOI 10.1016/S1074-7613(04)00235-3; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Itano AA, 2003, IMMUNITY, V19, P47, DOI 10.1016/S1074-7613(03)00175-4; Iwasaki A, 2001, J IMMUNOL, V166, P4884, DOI 10.4049/jimmunol.166.8.4884; Iwata M, 2004, IMMUNITY, V21, P527, DOI 10.1016/j.immuni.2004.08.011; Jego G, 2003, IMMUNITY, V19, P225, DOI 10.1016/S1074-7613(03)00208-5; Josien R, 2000, J EXP MED, V191, P495, DOI 10.1084/jem.191.3.495; Kaech SM, 2001, NAT IMMUNOL, V2, P415, DOI 10.1038/87720; Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778; Kaech SM, 2003, NAT IMMUNOL, V4, P1191, DOI 10.1038/ni1009; Kantele A, 1999, J IMMUNOL, V162, P5173; Kelsoe G, 2000, IMMUNOL RES, V22, P199, DOI 10.1385/IR:22:2-3:199; Kolumam GA, 2005, J EXP MED, V202, P637, DOI 10.1084/jem.20050821; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Lanzavecchia A, 2001, NAT IMMUNOL, V2, P487, DOI 10.1038/88678; Le Bon A, 2003, NAT IMMUNOL, V4, P1009, DOI 10.1038/ni978; Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633; Lopes-Carvalho T, 2004, IMMUNOL REV, V197, P192, DOI 10.1111/j.0105-2896.2004.0112.x; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; MacLennan ICM, 2003, IMMUNOL REV, V194, P8, DOI 10.1034/j.1600-065X.2003.00058.x; Maldonado-Lopez R, 1999, J EXP MED, V189, P587, DOI 10.1084/jem.189.3.587; Manjunath N, 2001, J CLIN INVEST, V108, P871, DOI 10.1172/JCI13296; Manz RA, 1997, NATURE, V388, P133, DOI 10.1038/40540; Marrack P, 2004, ANNU REV IMMUNOL, V22, P765, DOI 10.1146/annurev.immunol.22.012703.104554; Martin-Fontecha A, 2004, NAT IMMUNOL, V5, P1260, DOI 10.1038/ni1138; Maruyama M, 2000, NATURE, V407, P636, DOI 10.1038/35036600; Masopust D, 2004, J IMMUNOL, V172, P4875, DOI 10.4049/jimmunol.172.8.4875; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; McHeyzer-Williams LJ, 2005, ANNU REV IMMUNOL, V23, P487, DOI 10.1146/annurev.immunol.23.021704.115732; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Menges M, 2002, J EXP MED, V195, P15, DOI 10.1084/jem.20011341; Mercado R, 2000, J IMMUNOL, V165, P6833, DOI 10.4049/jimmunol.165.12.6833; Miller MJ, 2002, SCIENCE, V296, P1869, DOI 10.1126/science.1070051; MOSKOPHIDIS D, 1993, EUR J IMMUNOL, V23, P3306, DOI 10.1002/eji.1830231237; Mowen KA, 2004, IMMUNOL REV, V202, P203, DOI 10.1111/j.0105-2896.2004.00209.x; Murali-Krishna K, 1999, SCIENCE, V286, P1377, DOI 10.1126/science.286.5443.1377; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Nagai T, 2003, J IMMUNOL, V171, P5233, DOI 10.4049/jimmunol.171.10.5233; Napolitani G, 2005, NAT IMMUNOL, V6, P769, DOI 10.1038/ni1223; Nefedova Y, 2004, J IMMUNOL, V172, P464, DOI 10.4049/jimmunol.172.1.464; Norbury CC, 2002, NAT IMMUNOL, V3, P265, DOI 10.1038/ni762; O'Garra A, 2004, ADV IMMUNOL, V83, P133; O'Garra A, 2004, NAT MED, V10, P801, DOI 10.1038/nm0804-801; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Peng GY, 2005, SCIENCE, V309, P1380, DOI 10.1126/science.1113401; Plotkin SA, 2005, NAT MED, V11, pS5, DOI 10.1038/nm1209; Pugachev KV, 2005, CURR OPIN INFECT DIS, V18, P387, DOI 10.1097/01.qco.0000178823.28585.ad; Pulendran B, 2005, J IMMUNOL, V174, P2457, DOI 10.4049/jimmunol.174.5.2457; Pulendran B, 1999, P NATL ACAD SCI USA, V96, P1036, DOI 10.1073/pnas.96.3.1036; Pulendran B, 2004, IMMUNOL REV, V199, P227, DOI 10.1111/j.0105-2896.2004.00144.x; Querec T, 2006, J EXP MED, V203, P413, DOI 10.1084/jem.20051720; Rappuoli R, 2004, NAT MED, V10, P1177, DOI 10.1038/nm1129; Redecke V, 2004, J IMMUNOL, V172, P2739, DOI 10.4049/jimmunol.172.5.2739; Reid RR, 2002, J IMMUNOL, V169, P5433, DOI 10.4049/jimmunol.169.10.5433; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Shen L, 2004, NAT BIOTECHNOL, V22, P1546, DOI 10.1038/nbt1035; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; Skowera A, 2005, J IMMUNOL, V175, P7235, DOI 10.4049/jimmunol.175.11.7235; Slifka MK, 1998, IMMUNITY, V8, P363, DOI 10.1016/S1074-7613(00)80541-5; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Srivastava P, 2002, ANNU REV IMMUNOL, V20, P395, DOI 10.1146/annurev.immunol.20.100301.064801; Svensson M, 2002, J CLIN INVEST, V110, P1113, DOI 10.1172/JCI200215988; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tang HL, 1999, SCIENCE, V284, P819, DOI 10.1126/science.284.5415.819; van Stipdonk MJB, 2001, NAT IMMUNOL, V2, P423, DOI 10.1038/87730; Whitmire JK, 2000, CURR OPIN IMMUNOL, V12, P448, DOI 10.1016/S0952-7915(00)00119-9; Wille-Reece U, 2005, P NATL ACAD SCI USA, V102, P15190, DOI 10.1073/pnas.0507484102; Zabel BA, 1999, J EXP MED, V190, P1241, DOI 10.1084/jem.190.9.1241; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205	108	462	492	0	65	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 24	2006	124	4					849	863		10.1016/j.cell.2006.02.019	http://dx.doi.org/10.1016/j.cell.2006.02.019			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	038RO	16497593	Bronze			2022-12-28	WOS:000237240900026
J	Bouhifd, MA; Jephcoat, AP				Bouhifd, MA; Jephcoat, AP			Aluminium control of argon solubility in silicate melts under pressure	NATURE			English	Article							NOBLE-GAS SOLUBILITIES; MOLECULAR-DYNAMICS; BASALT MELT; MAGMA OCEAN; LIQUIDS; MANTLE; PARTITION; BEHAVIOR; GLASSES; XE	Understanding of the crystal chemistry of the Earth's deep mantle has evolved rapidly recently with the gradual acceptance of the importance of the effect of minor elements such as aluminium on the properties of major phases such as perovskite(1-3). In the early Earth, during its formation and segregation into rocky mantle and iron-rich core, it is likely that silicate liquids played a large part in the transport of volatiles to or from the deep interior. The importance of aluminium on solubility mechanisms at high pressure has so far received little attention, even though aluminium has long been recognized as exerting strong control on liquid structures at ambient conditions(4-6). Here we present constraints on the solubility of argon in aluminosilicate melt compositions up to 25 GPa and 3,000 K, using a laser-heated diamond-anvil cell. The argon contents reach a maximum that persists to pressures as high as 17 GPa (up to 500 km deep in an early magma ocean), well above that expected on the basis of Al-free melt experiments. A distinct drop in argon solubility observed over a narrow pressure range correlates well with the expected void loss in the melt structure predicted by recent molecular dynamics simulations(7-9). These results provide a process for noble gas sequestration in the mantle at various depths in a cooling magma ocean. The concept of shallow partial melting as a unique process for extracting noble gases from the early Earth, thereby defining the initial atmospheric abundance, may therefore be oversimplified.	Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England; Diamond Light Source Ltd, Didcot OX11 0QX, Oxon, England	University of Oxford; Diamond Light Source	Bouhifd, MA (corresponding author), Univ Oxford, Dept Earth Sci, Parks Rd, Oxford OX1 3PR, England.	alib@earth.ox.ac.uk; andrew@earth.ox.ac.uk		Bouhifd, Mohamed Ali/0000-0002-1722-1331	Natural Environment Research Council [NER/A/S/2003/00378] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Allegre CJ, 1996, GEOPHYS RES LETT, V23, P3555, DOI 10.1029/96GL03373; Allwardt J.R., 2005, ADV HIGH PRESSURE TE, P211; Bouhifd MA, 2003, EARTH PLANET SC LETT, V209, P245, DOI 10.1016/S0012-821X(03)00076-1; Brodholt JP, 2000, NATURE, V407, P620, DOI 10.1038/35036565; Brooker RA, 2003, NATURE, V423, P738, DOI 10.1038/nature01708; CARROLL MR, 1993, GEOCHIM COSMOCHIM AC, V57, P5039, DOI 10.1016/0016-7037(93)90606-W; Chamorro-Perez E, 1998, NATURE, V393, P352, DOI 10.1038/30706; ChamorroPerez E, 1996, EARTH PLANET SC LETT, V145, P97, DOI 10.1016/S0012-821X(96)00188-4; HIYAGON H, 1986, GEOCHIM COSMOCHIM AC, V50, P2045, DOI 10.1016/0016-7037(86)90258-9; JAMBON A, 1986, GEOCHIM COSMOCHIM AC, V50, P401, DOI 10.1016/0016-7037(86)90193-6; Jephcoat AP, 1998, GEOPH MONOG SERIES, V101, P287; JEPHCOAT AP, 1987, HYDROTHERMAL EXPT TE, P469; LUX G, 1987, GEOCHIM COSMOCHIM AC, V51, P1549, DOI 10.1016/0016-7037(87)90336-X; McCammon C, 2005, SCIENCE, V308, P807, DOI 10.1126/science.1110532; Mysen B. O., 2005, SILICATE GLASSES MEL, P231; Nevins D, 1998, AM MINERAL, V83, P1220, DOI 10.2138/am-1998-11-1210; Ozima M., 2022, NOBLE GAS GEOCHEMIST; PEPIN RO, 1991, ICARUS, V92, P2, DOI 10.1016/0019-1035(91)90036-S; Poe BT, 1997, SCIENCE, V276, P1245, DOI 10.1126/science.276.5316.1245; Poe BT, 2001, CHEM GEOL, V174, P21, DOI 10.1016/S0009-2541(00)00304-1; RUSTAD JR, 1990, PHYS REV A, V42, P2081, DOI 10.1103/PhysRevA.42.2081; Schmidt BC, 2002, EARTH PLANET SC LETT, V195, P277, DOI 10.1016/S0012-821X(01)00584-2; Shibata T, 1998, GEOCHIM COSMOCHIM AC, V62, P1241, DOI 10.1016/S0016-7037(98)00046-5; THIBAULT Y, 1995, GEOCHIM COSMOCHIM AC, V59, P991, DOI 10.1016/00167-0379(50)00178-; TONKS WB, 1993, J GEOPHYS RES-PLANET, V98, P5319, DOI 10.1029/92JE02726; Trave A, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.245504; WHITE BS, 1989, AM MINERAL, V74, P513; Wood BJ, 1996, SCIENCE, V273, P1522, DOI 10.1126/science.273.5281.1522; YARGER JL, 1995, SCIENCE, V270, P1964, DOI 10.1126/science.270.5244.1964	29	36	36	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 23	2006	439	7079					961	964		10.1038/nature04583	http://dx.doi.org/10.1038/nature04583			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014NE	16495996				2022-12-28	WOS:000235486100044
J	Hosten, O; Rakher, MT; Barreiro, JT; Peters, NA; Kwiat, PG				Hosten, O; Rakher, MT; Barreiro, JT; Peters, NA; Kwiat, PG			Counterfactual quantum computation through quantum interrogation	NATURE			English	Article								The logic underlying the coherent nature of quantum information processing often deviates from intuitive reasoning, leading to surprising effects. Counterfactual computation constitutes a striking example: the potential outcome of a quantum computation can be inferred, even if the computer is not run(1). Relying on similar arguments to interaction-free measurements(2) (or quantum interrogation(3)), counterfactual computation is accomplished by putting the computer in a superposition of 'running' and 'not running' states, and then interfering the two histories. Conditional on the as-yet-unknown outcome of the computation, it is sometimes possible to counterfactually infer information about the solution. Here we demonstrate counterfactual computation, implementing Grover's search algorithm with an all-optical approach(4). It was believed that the overall probability of such counterfactual inference is intrinsically limited(1,5), so that it could not perform better on average than random guesses. However, using a novel 'chained' version of the quantum Zeno effect(6), we show how to boost the counterfactual inference probability to unity, thereby beating the random guessing limit. Our methods are general and apply to any physical system, as illustrated by a discussion of trapped-ion systems. Finally, we briefly show that, in certain circumstances, counterfactual computation can eliminate errors induced by decoherence.	Univ Illinois, Dept Phys, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Hosten, O (corresponding author), Univ Illinois, Dept Phys, 1110 W Green St, Urbana, IL 61801 USA.	hosten@uiuc.edu	Barreiro, Julio T/P-2540-2018; Peters, Nicholas A/F-2530-2010; Rakher, Matthew/C-2287-2011	Barreiro, Julio T/0000-0002-1957-8211; Peters, Nicholas A/0000-0002-7215-9630; Rakher, Matthew/0000-0002-4490-4197				Brickman KA, 2005, PHYS REV A, V72, DOI 10.1103/PhysRevA.72.050306; DHAR D, 2005, PRESERVING QUANTUM S; ELITZUR AC, 1993, FOUND PHYS, V23, P987, DOI 10.1007/BF00736012; Franson JD, 2004, PHYS REV A, V70, DOI 10.1103/PhysRevA.70.062302; Grover LK, 1997, PHYS REV LETT, V79, P325, DOI 10.1103/PhysRevLett.79.325; HONG CK, 1986, PHYS REV LETT, V56, P58, DOI 10.1103/PhysRevLett.56.58; Jozsa R, 1999, LECT NOTES COMPUT SC, V1509, P103; KWIAT P, 1995, PHYS REV LETT, V74, P4763, DOI 10.1103/PhysRevLett.74.4763; Kwiat PG, 1999, PHYS REV LETT, V83, P4725, DOI 10.1103/PhysRevLett.83.4725; Kwiat PG, 2000, J MOD OPTIC, V47, P257, DOI 10.1080/095003400148187; MISRA B, 1977, J MATH PHYS, V18, P756, DOI 10.1063/1.523304; Mitchison G, 2001, P ROY SOC A-MATH PHY, V457, P1175, DOI 10.1098/rspa.2000.0714; Monroe C, 1996, SCIENCE, V272, P1131, DOI 10.1126/science.272.5265.1131; Nielsen M. A., 2000, QUANTUM COMPUTATION, P248; Rowe MA, 2001, NATURE, V409, P791, DOI 10.1038/35057215; RUDOLPH T, 2002, QUANTUM SEARCH CLASS; Viola L, 1998, PHYS REV A, V58, P2733, DOI 10.1103/PhysRevA.58.2733	17	137	138	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 23	2006	439	7079					949	952		10.1038/nature04523	http://dx.doi.org/10.1038/nature04523			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014NE	16495993				2022-12-28	WOS:000235486100041
J	Freed, GL; Singer, D; Lakhani, I; Wheeler, JRC; Stockman, JA				Freed, GL; Singer, D; Lakhani, I; Wheeler, JRC; Stockman, JA		Res Advisory Comm Amer Board Pedia	Use of board certification and recertification of pediatricians in health plan credentialing policies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPECIALISTS; CHOICE; ASTHMA	Context Health plans conduct credentialing processes to select and retain qualified physicians who will provide high-quality care to their subscribers. One of the tools available to health plans to help ensure physician competence is assessment of board certification status. Objective To determine the credentialing policies of health plans regarding the use of board certification and recertification for general pediatricians and pediatric subspecialists. Design, Setting, and Participants Telephone survey conducted February through July 2005 of credentialing personnel from a US national sample of 244 health plans stratified by enrollment size, Medicaid proportion, and for-profit or not-for-profit status. Main Outcome Measures Proportion of health plans that require general or subspecialty board certification at initial contract or at any time during association with the plan and recertification to maintain credentialing or to bill as a specialist or subspecialist; percentage of physicians credentialed in each health plan and credentialing goals for each plan regarding the proportion of physicians to be board certified. Results Response rate was 193 of 244 (79%). Overall, 174 (90%) of the plans do not require general pediatricians to be board certified at the time of initial credentialing, and only 41% ever require a general pediatrician to become board certified. Similarly, only 80 (40%) ever require subspecialists to become board certified in their subspecialty. Although 80 of 192 (41%) report requiring recertification of general pediatricians, almost half do not have a time frame in which recertification must occur. Seventy-seven percent of plans allow physicians to bill as subspecialists with expired certificates. Conclusions These findings, although specific to pediatrics, likely apply to other primary care disciplines and raise questions regarding the ability of plans to ensure initial or continued competence of their credentialed physicians. Growing public concern regarding patient safety, as well as demonstrated patient preferences for certified physicians, will likely result in greater emphasis on quality assessments in physician credentialing.	Univ Michigan, Div Gen Pediat, Child Hlth Evaluat & Res Unit, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Hlth Policy & Management, Ann Arbor, MI 48109 USA; Amer Board Pediat Inc, Chapel Hill, NC USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Freed, GL (corresponding author), Univ Michigan, Div Gen Pediat, Child Hlth Evaluat & Res Unit, 300 N Ingalls Bldg,6E08, Ann Arbor, MI 48109 USA.	gfreed@med.umich.edu	Stockman, James/ABG-6085-2021					[Anonymous], 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; Batmangelich Sorush, 2004, J Contin Educ Health Prof, V24, P134, DOI 10.1002/chp.1340240303; Bornstein BH, 2000, J EVAL CLIN PRACT, V6, P255, DOI 10.1046/j.1365-2753.2000.00256.x; Brennan TA, 2004, JAMA-J AM MED ASSOC, V292, P1038, DOI 10.1001/jama.292.9.1038; ENGEL W, 1989, MED CARE, V27, P306, DOI 10.1097/00005650-198903000-00009; Franks P, 1997, J FAM PRACTICE, V45, P47; Frieri M, 2002, J ASTHMA, V39, P405, DOI 10.1081/JAS-120004033; Hanson KL, 2001, J URBAN HEALTH, V78, P112, DOI 10.1093/jurban/78.1.112; Hillemeier AC, 2004, J PEDIATR GASTR NUTR, V38, P376, DOI 10.1097/00005176-200404000-00003; Horowitz SD, 2004, MED EDUC, V38, P10, DOI 10.1046/j.1365-2923.2004.01702.x; KAPLAN SR, 2004, MANAG HEALTHC EX JAN, P33; Kinchen KS, 2004, ANN FAM MED, V2, P245, DOI 10.1370/afm.68; Kohn KT, 2000, ERR IS HUMAN BUILDIN; *NAT COMM QUAL ASS, WHAT DOES NCQA REV I; Sharp LK, 2002, ACAD MED, V77, P534, DOI 10.1097/00001888-200206000-00011; SOBELMAN JS, 2001, PHYS NEWS DIGEST JUN; Solomon D, 2002, ARCH INTERN MED, V162, P2640, DOI 10.1001/archinte.162.17.2002; West J C, 2001, J Healthc Risk Manag, V21, P44	18	18	18	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	2006	295	8					913	918		10.1001/jama.295.8.913	http://dx.doi.org/10.1001/jama.295.8.913			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014DO	16493104				2022-12-28	WOS:000235459200024
J	Stone, GW; Gersh, BJ				Stone, GW; Gersh, BJ			Facilitated angioplasty: paradise lost	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; PERCUTANEOUS-CORONARY-INTERVENTION; MECHANICAL REPERFUSION THERAPY; TO-BALLOON TIME; PLASMINOGEN-ACTIVATOR; IMMEDIATE THROMBOLYSIS; MORTALITY; RISK; STRATEGY; SURVIVAL		Columbia Univ, Med Ctr, New York, NY 10032 USA; Cardiovasc Res Fdn, New York, NY 10032 USA; Mayo Clin, Rochester, MN USA	Columbia University; Cardiovascular Research Foundation (CRF); Mayo Clinic	Stone, GW (corresponding author), Columbia Univ, Med Ctr, New York, NY 10032 USA.	gs2184@columbia.edu						BARBASH GI, 1990, AM J CARDIOL, V66, P538, DOI 10.1016/0002-9149(90)90478-J; BOERSMA E, IN PRESS EUR HEART J; Brodie BR, 2006, J AM COLL CARDIOL, V47, P289, DOI 10.1016/j.jacc.2005.08.065; Cannon CP, 2000, JAMA-J AM MED ASSOC, V283, P2941, DOI 10.1001/jama.283.22.2941; Dalby M, 2003, CIRCULATION, V108, P1809, DOI 10.1161/01.CIR.0000091088.63921.8C; DAVIES MJ, 1985, BRIT HEART J, V53, P363; De Luca G, 2004, J AM COLL CARDIOL, V43, P1363, DOI 10.1016/j.jacc.2003.11.042; De Luca G, 2004, CIRCULATION, V109, P1223, DOI 10.1161/01.CIR.0000121424.76486.20; DEBONO DP, 1991, BMJ-BRIT MED J, V302, P555; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; Fernandez-Aviles F, 2004, LANCET, V364, P1045, DOI 10.1016/S0140-6736(04)17059-1; Gersh BJ, 2005, JAMA-J AM MED ASSOC, V293, P979, DOI 10.1001/jama.293.8.979; Gershlick AH, 2005, NEW ENGL J MED, V353, P2758, DOI 10.1056/NEJMoa050849; Halkin A, 2004, J AM COLL CARDIOL, V43, P1780, DOI 10.1016/j.jacc.2003.10.068; Kawano K, 1998, AM HEART J, V135, P268, DOI 10.1016/S0002-8703(98)70092-4; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Keeley EC, 2006, LANCET, V367, P579, DOI 10.1016/S0140-6736(06)68148-8; Le May MR, 2005, J AM COLL CARDIOL, V46, P417, DOI 10.1016/j.jacc.2005.04.042; McNamara RL, 2006, J AM COLL CARDIOL, V47, P45, DOI 10.1016/j.jacc.2005.04.071; Moreno R, 2002, J AM COLL CARDIOL, V39, P598, DOI 10.1016/S0735-1097(01)01796-X; Nallamothu BK, 2003, AM J CARDIOL, V92, P824, DOI 10.1016/S0002-9149(03)00891-9; OHNISHI Y, 1995, CIRCULATION, V92, P500, DOI 10.1161/01.CIR.92.3.500; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; REIMER KA, 1979, LAB INVEST, V40, P633; ROGERS WJ, 1990, CIRCULATION, V81, P1457, DOI 10.1161/01.CIR.81.5.1457; Rothman MT, 2005, NAT CLIN PRACT CARD, V2, P465, DOI 10.1038/ncpcardio0311; Scheller B, 2003, J AM COLL CARDIOL, V42, P634, DOI 10.1016/S0735-1097(03)00763-0; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; SIMOONS ML, 1988, LANCET, V1, P199; Stone GW, 2002, NEW ENGL J MED, V346, P957, DOI 10.1056/NEJMoa013404; Stone GW, 2001, CIRCULATION, V104, P636, DOI 10.1161/hc3101.093701; Van de Werf F, 2006, LANCET, V367, P569, DOI 10.1016/S0140-6736(06)68147-6; WALLER BF, 1987, J AM COLL CARDIOL, V9, P785, DOI 10.1016/S0735-1097(87)80234-6; Widimsky P, 2000, EUR HEART J, V21, P823, DOI 10.1053/euhj.1999.1993; Zahn R, 2005, HEART, V91, P1041, DOI 10.1136/hrt.2004.045336	35	30	31	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 18	2006	367	9510					543	546		10.1016/S0140-6736(06)68149-X	http://dx.doi.org/10.1016/S0140-6736(06)68149-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013GM	16488779				2022-12-28	WOS:000235397800004
J	Murray, CD				Murray, CD			Planetary science - Ringing the changes	SCIENCE			English	Editorial Material							SATELLITES		Univ London, Queen Mary, Astron Unit, London E1 4NS, England	University of London; Queen Mary University London	Murray, CD (corresponding author), Univ London, Queen Mary, Astron Unit, London E1 4NS, England.	c.d.murray@qmul.ac.uk						Duncan MJ, 1997, ICARUS, V125, P1, DOI 10.1006/icar.1996.5568; Karkoschka E, 2001, ICARUS, V151, P69, DOI 10.1006/icar.2001.6597; Porco CC, 2005, SCIENCE, V307, P1226, DOI 10.1126/science.1108056; Showalter MR, 2006, SCIENCE, V311, P973, DOI 10.1126/science.1122882	4	0	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 17	2006	311	5763					961	962		10.1126/science.1123986	http://dx.doi.org/10.1126/science.1123986			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014CS	16484482				2022-12-28	WOS:000235456900032
J	Esquivel, A; Meric-Bernstam, F; Bernstam, EV				Esquivel, A; Meric-Bernstam, F; Bernstam, EV			Accuracy and self correction of information received from an internet breast cancer list: content analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To determine the prevalence of false or misleading statements in messages posted by internet cancer support groups and whether these statements were identified as false or misleading and corrected by other participants in subsequent postings. Design Analysis of content of postings. Setting Internet cancer support group Breast Cancer, Mailing List. Main outcome measures Number of false or misleading statements posted from 1 January to 23 April 2005 and whether these were identified and corrected by participants in subsequent postings. Results 10 of 4600 postings (0.22%) were found to be false or misleading. Of these, seven were identified as false or misleading by other participants and corrected within an average of four hours and 33 minutes (maximum, nine hours and nine minutes). Conclusions Most posted information on breast cancer was accurate. Most false or misleading statements were rapidly corrected by participants in subsequent postings.	Univ Texas, Hlth Sci Ctr Houston, Sch Hlth Informat Sci, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center	Bernstam, EV (corresponding author), Univ Texas, Hlth Sci Ctr Houston, Sch Hlth Informat Sci, 7000 Fannin St, Houston, TX 77030 USA.	elmer.v.bernstam@uth.tmc.edu		Bernstam, Elmer/0000-0001-7643-791X	NATIONAL CANCER INSTITUTE [R15CA091895] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [K22LM008306] Funding Source: NIH RePORTER; NCI NIH HHS [1K08CA91895] Funding Source: Medline; NLM NIH HHS [5K22LM008306] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Biermann JS, 1999, CANCER, V86, P381, DOI 10.1002/(SICI)1097-0142(19990801)86:3<381::AID-CNCR4>3.3.CO;2-7; Culver JD, 1997, J GEN INTERN MED, V12, P466, DOI 10.1046/j.1525-1497.1997.00084.x; Eisenberg DM, 2001, ANN INTERN MED, V135, P344, DOI 10.7326/0003-4819-135-5-200109040-00011; Feenberg AL, 1996, J NEUROL SCI, V139, P129, DOI 10.1016/0022-510X(96)00093-7; Ferguson S., 2020, J ED ONLINE; FOX S, 2000, ONLINE HLTH CARE REV, P3; Hoch DB, 1999, SEIZURE-EUR J EPILEP, V8, P30, DOI 10.1053/seiz.1998.0217; Jadad AR, 1998, JAMA-J AM MED ASSOC, V279, P611, DOI 10.1001/jama.279.8.611; Mursch K, 2003, ZBL NEUROCHIR, V64, P71; Price SL, 1999, J AM MED INFORM ASSN, P911; Satterlund MJ, 2003, J MED INTERNET RES, V5, DOI 10.2196/jmir.5.3.e15; Till James E, 2003, Health Qual Life Outcomes, V1, P16, DOI 10.1186/1477-7525-1-16; Weinberg N, 1996, HEALTH SOC WORK, V21, P24, DOI 10.1093/hsw/21.1.24; 2000, AM SOC CLIN ONC 36 A	14	128	130	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 22	2006	332	7547					939	942		10.1136/bmj.38753.524201.7C	http://dx.doi.org/10.1136/bmj.38753.524201.7C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	037JV	16513686	Green Published, Bronze			2022-12-28	WOS:000237143900015
J	Koenig, SP; Kuritzkes, DR; Hirsch, MS; Leandre, F; Mukherjee, LS; Farmer, PE; del Rio, C				Koenig, SP; Kuritzkes, DR; Hirsch, MS; Leandre, F; Mukherjee, LS; Farmer, PE; del Rio, C			HIV and global health - Monitoring HIV treatment in developing countries	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							DIRECTLY OBSERVED THERAPY; RESOURCE-POOR SETTINGS; ANTIRETROVIRAL TREATMENT; DRUG-RESISTANCE; OUTCOMES; ADHERENCE; MUTATIONS; LESSONS; TIME; AIDS		Brigham & Womens Hosp, Div Social Med & Hlth Inequal, Boston, MA 02120 USA; Brigham & Womens Hosp, Sect Retroviral Therapeut, Boston, MA 02115 USA; Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; Partners Hlth, Boston, MA USA; Harvard Univ, Sch Med, Dept Social Med, Program Infect Dis & Social Change, Boston, MA 02115 USA; Zanmi Lasante, HIV Programme, Cange, Haiti; Zanmi Lasante, TB Programme, Cange, Haiti; Emory Univ, Ctr AIDS Res, Atlanta, GA 30322 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Partners Healthcare System; Harvard University; Harvard Medical School; Emory University	Koenig, SP (corresponding author), Brigham & Womens Hosp, Div Social Med & Hlth Inequal, 1620 Tremont St, Boston, MA 02120 USA.	skoenig@partners.org	del Rio, Carlos/B-3763-2012	del Rio, Carlos/0000-0002-0153-3517	FIC NIH HHS [D43 TW01042, 1K01TW007142-01] Funding Source: Medline; NCRR NIH HHS [K24 RR16482] Funding Source: Medline; NIAID NIH HHS [5T32AI007433-13, P30 AI60354, 2P30 AI50409-04A1] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [K01TW007142, D43TW001042] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K24RR016482] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007433, P30AI060354, P30AI050409] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Behforouz HL, 2004, CLIN INFECT DIS, V38, pS429, DOI 10.1086/421408; Calmy A, 2004, AIDS, V18, P2353; CASCADE Collaboration, 2000, LANCET, V355, P1158, DOI 10.1016/S0140-6736(00)02069-9; Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/00002030-200404090-00006; de la Rosa R, 2004, J ANTIMICROB CHEMOTH, V53, P95, DOI 10.1093/jac/dkh012; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; Gupta R, 2004, LANCET, V363, P320, DOI 10.1016/S0140-6736(03)15394-9; Harrigan PR, 2005, J INFECT DIS, V191, P339, DOI 10.1086/427192; ISEMAN MD, 1985, AM REV RESPIR DIS, V132, P735; *PARTN HLTH, 2005, ANN REP GFATM 2005; *PARTN HLTH HARV M, 2003, DOTS PLUS HDB GUID C; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Rabkin M, 2002, LANCET, V360, P1503, DOI 10.1016/S0140-6736(02)11478-4; Sethi AK, 2003, CLIN INFECT DIS, V37, P1112, DOI 10.1086/378301; Severe P, 2005, NEW ENGL J MED, V353, P2325, DOI 10.1056/NEJMoa051908; SUMARTOJO E, 1993, AM REV RESPIR DIS, V147, P1311, DOI 10.1164/ajrccm/147.5.1311; Walton DA, 2004, J PUBLIC HEALTH POL, V25, P137, DOI 10.1057/palgrave.jphp.3190013; Weinstock HS, 2004, J INFECT DIS, V189, P2174, DOI 10.1086/420789; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; *WHO, 2004, 3 TIMES 5 PROGR REPO; World Health Organization, 2004, SCAL ANT THER RES LT	22	28	29	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 11	2006	332	7541					602	604		10.1136/bmj.332.7541.602	http://dx.doi.org/10.1136/bmj.332.7541.602			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	026CN	16528087	Green Published			2022-12-28	WOS:000236314400022
J	Jafar, TH				Jafar, TH			The growing burden of chronic kidney disease in Pakistan	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Aga Khan Univ, Clin Epidemiol Unit, Karachi, Pakistan	Aga Khan University	Jafar, TH (corresponding author), Aga Khan Univ, Clin Epidemiol Unit, Karachi, Pakistan.							Ahmad K, 2005, J HYPERTENS, V23, P1979, DOI 10.1097/01.hjh.0000187258.86824.00; Bhargava SK, 2004, NEW ENGL J MED, V350, P865, DOI 10.1056/NEJMoa035698; Jafar TH, 2005, J AM SOC NEPHROL, V16, P1413, DOI 10.1681/ASN.2004121100; Jafar TH, 2005, CIRCULATION, V111, P1291, DOI 10.1161/01.CIR.0000157699.87728.F1	4	69	70	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 9	2006	354	10					995	997		10.1056/NEJMp058319	http://dx.doi.org/10.1056/NEJMp058319			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	019FY	16525135	Green Published			2022-12-28	WOS:000235822200002
J	Sidhu, R; Sanders, DS; McAlindon, ME				Sidhu, R; Sanders, DS; McAlindon, ME			Gastrointestinal capsule endoscopy: from tertiary centres to primary care	BRITISH MEDICAL JOURNAL			English	Article							SUSPECTED CROHNS-DISEASE; COMPUTED-TOMOGRAPHY ENTEROCLYSIS; PEUTZ-JEGHERS-SYNDROME; BARIUM FOLLOW-THROUGH; SMALL-BOWEL DISEASE; PUSH-ENTEROSCOPY; VIDEO CAPSULE; CELIAC-DISEASE; POLYPOSIS SYNDROMES; CONTROLLED-TRIAL		Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England	University of Sheffield	Sidhu, R (corresponding author), Royal Hallamshire Hosp, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.	reena_sidhu@yahoo.com						Adler DG, 2004, GASTROINTEST ENDOSC, V59, P492, DOI 10.1016/S0016-5107(03)02862-1; Appleyard M, 2001, NEW ENGL J MED, V344, P232, DOI 10.1056/NEJM200101183440316; Arguelles-Arias F, 2004, ENDOSCOPY, V36, P869, DOI 10.1055/s-2004-825854; Bar-Meir S, 2004, GASTROINTEST ENDOSC, V60, P711, DOI 10.1016/S0016-5107(04)02051-6; Bardan E, 2003, ENDOSCOPY, V35, P688; Boivin ML, 2005, ENDOSCOPY, V37, P808, DOI 10.1055/s-2005-870220; Caspari R, 2004, ENDOSCOPY, V36, P1054, DOI 10.1055/s-2004-826041; Cellier C, 2005, ENDOSCOPY, V37, P1055, DOI 10.1055/s-2005-870310; CHEN TS, 1995, HIST GASTROENTEROLOG; Chong AKH, 2005, GASTROINTEST ENDOSC, V61, P255, DOI 10.1016/S0016-5107(04)02571-4; Chong AKH, 2003, MED J AUSTRALIA, V178, P537, DOI 10.5694/j.1326-5377.2003.tb05354.x; Costamagna G, 2002, GASTROENTEROLOGY, V123, P999, DOI 10.1053/gast.2002.35988; Culliford A, 2005, GASTROINTEST ENDOSC, V62, P55, DOI 10.1016/S0016-5107(05)01566-X; Delvaux M, 2004, ENDOSCOPY, V36, P1067, DOI 10.1055/s-2004-826034; Eliakim R, 2004, DIGEST LIVER DIS, V36, P519, DOI 10.1016/j.dld.2004.03.011; Eliakim R, 2003, EUR J GASTROEN HEPAT, V15, P363, DOI 10.1097/00042737-200304000-00005; Eliakim R, 2004, ALIMENT PHARM THER, V20, P1083, DOI 10.1111/j.1365-2036.2004.02206.x; Ell C, 2002, ENDOSCOPY, V34, P685, DOI 10.1055/s-2002-33446; Fireman Z, 2003, GUT, V52, P390, DOI 10.1136/gut.52.3.390; Ge ZZ, 2004, WORLD J GASTROENTERO, V10, P1349; Ginsberg GG, 2002, GASTROINTEST ENDOSC, V56, P621, DOI 10.1016/S0016-5107(02)70106-5; Hara AK, 2004, RADIOLOGY, V230, P260, DOI 10.1148/radiol.2301021535; Hartmann D, 2003, Z GASTROENTEROL, V41, P377; Herrerias JM, 2003, ENDOSCOPY, V35, P564; Iddan G, 2000, NATURE, V405, P417, DOI 10.1038/35013140; Jones BH, 2005, AM J GASTROENTEROL, V100, P1058, DOI 10.1111/j.1572-0241.2005.40722.x; Joyce AM, 2005, ENDOSCOPY, V37, P594, DOI 10.1055/s-2005-861322; Kitiyakara T, 2005, GASTROINTEST ENDOSC, V62, P234, DOI 10.1016/S0016-5107(05)00292-0; Levinthal GN, 2003, AM J GASTROENTEROL, V98, P2669, DOI 10.1016/j.amjgastroenterol.2003.06.001; Lewis BS, 2002, GASTROINTEST ENDOSC, V56, P349, DOI 10.1067/mge.2002.126906; Lewis BS, 2005, ENDOSCOPY, V37, P960, DOI 10.1055/s-2005-870353; Liangpunsakul S, 2003, AM J GASTROENTEROL, V98, P1295, DOI 10.1016/S0002-9270(03)00245-4; Maieron A, 2004, ENDOSCOPY, V36, P864, DOI 10.1055/s-2004-825852; Mata A, 2004, ALIMENT PHARM THER, V20, P189, DOI 10.1111/j.1365-2036.2004.02067.x; Mata A, 2005, GASTROINTEST ENDOSC, V61, P721, DOI 10.1016/S0016-5107(05)00289-0; May A, 2005, GASTROINTEST ENDOSC, V62, P62, DOI 10.1016/S0016-5107(05)01586-5; Mow WS, 2004, CLIN GASTROENTEROL H, V2, P31, DOI 10.1016/S1542-3565(03)00289-1; Mylonaki M, 2003, GUT, V52, P1122, DOI 10.1136/gut.52.8.1122; Napierkowski JJ, 2005, J CLIN GASTROENTEROL, V39, P36; Nolan DJ, 1997, CLIN RADIOL, V52, P809, DOI 10.1016/S0009-9260(97)80075-X; Pennazio M, 2004, GASTROENTEROLOGY, V126, P643, DOI 10.1053/j.gastro.2003.11.057; Petroniene R, 2005, AM J GASTROENTEROL, V100, P685, DOI 10.1111/j.1572-0241.2005.41069.x; Pimentel M, 2000, AM J GASTROENTEROL, V95, P3458; Ramirez FC, 2005, AM J GASTROENTEROL, V100, P1065, DOI 10.1111/j.1572-0241.2005.41037.x; Sant'Anna AMGD, 2005, CLIN GASTROENTEROL H, V3, P264, DOI 10.1053/S1542-3565(04)00715-3; Saurin JC, 2003, ENDOSCOPY, V35, P576; Saurin JC, 2005, ENDOSCOPY, V37, P318, DOI 10.1055/s-2005-861114; Schulmann K, 2005, AM J GASTROENTEROL, V100, P27, DOI 10.1111/j.1572-0241.2005.40102.x; Soares J, 2004, ENDOSCOPY, V36, P1060, DOI 10.1055/s-2004-826038; Timmer A, 1999, INFLAMM BOWEL DIS, V5, P79, DOI 10.1097/00054725-199905000-00002; Van Gossum A, 2003, ACTA GASTRO-ENT BELG, V66, P199; Voderholzer WA, 2005, GUT, V54, P369, DOI 10.1136/gut.2004.040055; Voderholzer WA, 2003, ENDOSCOPY, V35, P1009, DOI 10.1055/s-2003-44583	53	27	30	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAR 4	2006	332	7540					528	531		10.1136/bmj.332.7540.528	http://dx.doi.org/10.1136/bmj.332.7540.528			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	023WB	16513710	Green Published			2022-12-28	WOS:000236155800018
J	Ghosh, A; Praefcke, GJK; Renault, L; Wittinghofer, A; Herrmann, C				Ghosh, A; Praefcke, GJK; Renault, L; Wittinghofer, A; Herrmann, C			How guanylate-binding proteins achieve assembly-stimulated processive cleavage of GTP to GMP	NATURE			English	Article							NUCLEOTIDE-BINDING; CRYSTAL-STRUCTURE; MEDIATED ENDOCYTOSIS; DOMAIN; DYNAMIN; IDENTIFICATION; INHIBITION; HYDROLYSIS; ACTIVATION; RECEPTOR	Interferons are immunomodulatory cytokines that mediate antipathogenic and anti-proliferative effects in cells(1). Interferon-gamma-inducible human guanylate binding protein 1 ( hGBP1) belongs to the family of dynamin-related large GTP-binding proteins(2), which share biochemical properties not found in other families of GTP-binding proteins such as nucleotide-dependent oligomerization and fast cooperative GTPase activity(3). hGBP1 has an additional property by which it hydrolyses GTP to GMP in two consecutive cleavage reactions(4,5). Here we show that the isolated aminoterminal G domain of hGBP1 retains the main enzymatic properties of the full-length protein and can cleave GDP directly. Crystal structures of the N-terminal G domain trapped at successive steps along the reaction pathway and biochemical data reveal the molecular basis for nucleotide-dependent homodimerization and cleavage of GTP. Similar to effector binding in other GTP-binding proteins, homodimerization is regulated by structural changes in the switch regions. Homodimerization generates a conformation in which an arginine finger and a serine are oriented for efficient catalysis. Positioning of the substrate for the second hydrolysis step is achieved by a change in nucleotide conformation at the ribose that keeps the guanine base interactions intact and positions the beta-phosphates in the gamma-phosphate-binding site.	Lab Enzymol & Biochim Struct, CNRS, UPR 9063, F-91198 Gif Sur Yvette, France; Max Planck Inst Mol Physiol, Abt Strukturelle Biol, D-44227 Dortmund, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Max Planck Society	Wittinghofer, A (corresponding author), Lab Enzymol & Biochim Struct, CNRS, UPR 9063, Ave Terrasse, F-91198 Gif Sur Yvette, France.	alfred.wittinghofer@mpi-dortmund.mpg.de		Praefcke, Gerrit/0000-0001-8818-1499; RENAULT, Louis/0000-0003-1722-074X; Ghosh, Agnidipta/0000-0002-7753-0240				Anderson SL, 1999, VIROLOGY, V256, P8, DOI 10.1006/viro.1999.9614; CHENG YSE, 1991, MOL CELL BIOL, V11, P4717, DOI 10.1128/MCB.11.9.4717; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Egea PF, 2004, NATURE, V427, P215, DOI 10.1038/nature02250; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Focia PJ, 2004, SCIENCE, V303, P373, DOI 10.1126/science.1090827; Ghosh A, 2004, MOL CELL, V15, P727, DOI 10.1016/j.molcel.2004.07.017; Guenzi E, 2003, EMBO J, V22, P3772, DOI 10.1093/emboj/cdg382; Guenzi E, 2001, EMBO J, V20, P5568, DOI 10.1093/emboj/20.20.5568; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; Lavie A, 1998, BIOCHEMISTRY-US, V37, P3677, DOI 10.1021/bi9720787; Leipe DD, 2003, J MOL BIOL, V333, P781, DOI 10.1016/j.jmb.2003.08.040; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Modiano N, 2005, P NATL ACAD SCI USA, V102, P8680, DOI 10.1073/pnas.0503227102; Neun R, 1996, FEBS LETT, V390, P69, DOI 10.1016/0014-5793(96)00628-X; Niemann HH, 2001, EMBO J, V20, P5813, DOI 10.1093/emboj/20.21.5813; Praefcke GJK, 2004, J MOL BIOL, V344, P257, DOI 10.1016/j.jmb.2004.09.026; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Praefcke GJK, 1999, J MOL BIOL, V292, P321, DOI 10.1006/jmbi.1999.3062; Prakash B, 2000, EMBO J, V19, P4555, DOI 10.1093/emboj/19.17.4555; Prakash B, 2000, NATURE, V403, P567, DOI 10.1038/35000617; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; SCHWEMMLE M, 1994, J BIOL CHEM, V269, P11299; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Song BD, 2004, J BIOL CHEM, V279, P40431, DOI 10.1074/jbc.M407007200; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sun YJ, 2002, NAT STRUCT BIOL, V9, P95, DOI 10.1038/nsb744; Uthaiah RC, 2003, J BIOL CHEM, V278, P29336, DOI 10.1074/jbc.M211973200; Zhu PP, 2003, J BIOL CHEM, V278, P49063, DOI 10.1074/jbc.M306702200	30	149	152	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	2006	440	7080					101	104		10.1038/nature04510	http://dx.doi.org/10.1038/nature04510			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017HW	16511497				2022-12-28	WOS:000235685700048
J	Foster, G				Foster, G			Children who live in communities affected by AIDS	LANCET			English	Editorial Material									Mutare Prov Hosp, Dept Paediat, Mutare, Zimbabwe		Foster, G (corresponding author), Mutare Prov Hosp, Dept Paediat, Box 30, Mutare, Zimbabwe.	gfoster@mweb.co.zw						Bauman L, 2005, GENERATION RISK GLOB; Birdthistle I., 2004, UNDERSTANDING NEEDS; Bonnel R., 2004, POVERTY REDUCTION ST; Forsyth BWC, 1996, ARCH PEDIAT ADOL MED, V150, P1015, DOI 10.1001/archpedi.1996.02170350017002; FOSTER G, RADAR COMMUNITY SAFE; Foster G., 2005, BOTTLENECKS DRIPFEED; Germann S., 2002, AIDS AFRICA, P664; Gilborn L.Z., 2001, MAKING DIFFERENCE CH; Heckman JJ, 1999, POLICIES FOSTER HUMA; Lindblade KA, 2003, TROP MED INT HEALTH, V8, P67, DOI 10.1046/j.1365-3156.2003.00987.x; Monasch R, 2004, AIDS, V18, pS55, DOI 10.1097/00002030-200406002-00007; Mutangadura G., 1999, REV HOUSEHOLD COMMUN; RICHTER L, IN PRESS STRENGTHENI; UNICEF, 2003, AFR ORPH GEN; *USAID UNICEF UNAI, CHILDR BRINK 2004 JO	15	31	32	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 25	2006	367	9511					700	701		10.1016/S0140-6736(06)68273-1	http://dx.doi.org/10.1016/S0140-6736(06)68273-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	016HR	16503473				2022-12-28	WOS:000235611800039
J	Kiro, C; Duncanson, M				Kiro, C; Duncanson, M			Statutory advocates and outcomes for children: viewpoint of the New Zealand Children's Commissioner	LANCET			English	Editorial Material									Off Childrens Commissioner, Wellington, New Zealand		Duncanson, M (corresponding author), Off Childrens Commissioner, POB 5610,Lambton Quay, Wellington, New Zealand.	m.duncanson@occ.org.nz	Duncanson, Mavis/M-3706-2016	Duncanson, Mavis/0000-0003-3845-2961; Kiro, Cynthia/0000-0002-9899-5311				*MIN SOC DEV, 2004, OPP NEW ZEAL; *MIN SOC DEV, 2002, NZ AG CHILDR FRAM NZ; *OFF COMM CHILDR, 2003, REP INV DEATHS SJ AL; Office of the Commissioner for Children, 2000, FIN REP INV DEATH J; Perry B., 2004, SOC POLICY J N Z, V22, P19; *UNICEF, 2005, CHILD POV RICH COUNT, P36; UNICEF, 2003, LEAG TABL CHILD MALT; WILLS R, ROYAL AUSTR COLL PHY	8	1	1	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 25	2006	367	9511					694	695		10.1016/S0140-6736(06)68270-6	http://dx.doi.org/10.1016/S0140-6736(06)68270-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	016HR	16503470				2022-12-28	WOS:000235611800036
J	Lansdown, G; Karkara, R				Lansdown, G; Karkara, R			Children's right to express views and have them taken seriously	LANCET			English	Editorial Material									Save Children Sweden, S & Cent Asia Reg Off, Kathmandu, Nepal	Save the Children	Lansdown, G (corresponding author), 30 Ellington Rd, London N10 3DG, England.	gerison@blueyonder.co.uk						ALDERSON P, 2001, HLTH CARE DECISIONS; FEINSTEIN C, 2004, INTR WORKSH REP CHIL; Lansdown G., 2005, EVOLVING CAPACITIES; *SAV CHILDR, 2003, STEPP TOG; *SAV CHILDR, 2005, UN STUD VIOL END PHY; *SAV CHILDR, 2005, RIGHT NOT LOS HOP AN; *SAV CHILDR, 2005, 10 ESS LEARN POINTS; *UNICEF, 2003, AD PROF EMP; *UNICEF, 2005, VOIC HOP AD TSUN	9	9	9	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 25	2006	367	9511					690	692		10.1016/S0140-6736(06)68268-8	http://dx.doi.org/10.1016/S0140-6736(06)68268-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	016HR	16503468				2022-12-28	WOS:000235611800034
J	Chisholm, ST; Coaker, G; Day, B; Staskawicz, BJ				Chisholm, ST; Coaker, G; Day, B; Staskawicz, BJ			Host-microbe interactions: Shaping the evolution of the plant immune response	CELL			English	Review							DISEASE RESISTANCE GENE; XANTHOMONAS-ORYZAE PV; III EFFECTORS; INNATE IMMUNITY; CLADOSPORIUM-FULVUM; PROTEASE INHIBITOR; SIGNALING PATHWAYS; MOLECULAR EVIDENCE; AVIRULENCE GENES; ARABIDOPSIS	The evolution of the plant immune response has culminated in a highly effective defense system that is able to resist potential attack by microbial pathogens. The primary immune response is referred to as PAMP-triggered immunity (PTI) and has evolved to recognize common features of microbial pathogens. In the coevolution of host-microbe interactions, pathogens acquired the ability to deliver effector proteins to the plant cell to suppress PTI, allowing pathogen growth and disease. In response to the delivery of pathogen effector proteins, plants acquired surveillance proteins (R proteins) to either directly or indirectly monitor the presence of the pathogen effector proteins. In this review, taking an evolutionary perspective, we highlight important discoveries over the last decade about the plant immune response.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Staskawicz, BJ (corresponding author), Colorado State Univ, C129 Plant Sci Bldg, Ft Collins, CO 80523 USA.	stask@nature.berkeley.edu		Day, Brad/0000-0002-9880-4319	NIGMS NIH HHS [R01-GM069680] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069680] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramovitch RB, 2003, EMBO J, V22, P60, DOI 10.1093/emboj/cdg006; Akeda Y, 2005, NATURE, V437, P911, DOI 10.1038/nature03992; Allen RL, 2004, SCIENCE, V306, P1957, DOI 10.1126/science.1104022; Armstrong MR, 2005, P NATL ACAD SCI USA, V102, P7766, DOI 10.1073/pnas.0500113102; Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; Ashfield T, 2004, PLANT CELL, V16, P309, DOI 10.1105/tpc.016725; Axtell MJ, 2003, MOL MICROBIOL, V49, P1537, DOI 10.1046/j.1365-2958.2003.03666.x; Axtell MJ, 2003, CELL, V112, P369, DOI 10.1016/S0092-8674(03)00036-9; BISGROVE SR, 1994, PLANT CELL, V6, P927, DOI 10.1105/tpc.6.7.927; Brunner F, 2002, EMBO J, V21, P6681, DOI 10.1093/emboj/cdf667; Catanzariti AM, 2006, PLANT CELL, V18, P243, DOI 10.1105/tpc.105.035980; Chang JH, 2005, P NATL ACAD SCI USA, V102, P2549, DOI 10.1073/pnas.0409660102; Chisholm ST, 2005, P NATL ACAD SCI USA, V102, P2087, DOI 10.1073/pnas.0409468102; Coaker G, 2005, SCIENCE, V308, P548, DOI 10.1126/science.1108633; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; Day B, 2005, PLANT CELL, V17, P1292, DOI 10.1105/tpc.104.030163; DebRoy S, 2004, P NATL ACAD SCI USA, V101, P9927, DOI 10.1073/pnas.0401601101; Deslandes L, 2003, P NATL ACAD SCI USA, V100, P8024, DOI 10.1073/pnas.1230660100; DEWIT PJGM, 1995, TRENDS MICROBIOL, V3, P251, DOI 10.1016/S0966-842X(00)88936-2; Dodds PN, 2004, PLANT CELL, V16, P755, DOI 10.1105/tpc.020040; Felix G, 1999, PLANT J, V18, P265, DOI 10.1046/j.1365-313X.1999.00265.x; Feys BJ, 2000, TRENDS GENET, V16, P449, DOI 10.1016/S0168-9525(00)02107-7; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; Fritz-Laylin LK, 2005, PLANT PHYSIOL, V138, P611, DOI 10.1104/pp.104.054452; Gehrig H, 1996, J MOL EVOL, V43, P71, DOI 10.1007/BF02352301; Gomez-Gomez L, 2002, TRENDS PLANT SCI, V7, P251, DOI 10.1016/S1360-1385(02)02261-6; Gomez-Gomez L, 2000, MOL CELL, V5, P1003, DOI 10.1016/S1097-2765(00)80265-8; Gu KY, 2005, NATURE, V435, P1122, DOI 10.1038/nature03630; Hauck P, 2003, P NATL ACAD SCI USA, V100, P8577, DOI 10.1073/pnas.1431173100; He P, 2004, PLANT J, V37, P589, DOI 10.1111/j.1365-313X.2003.01986.x; Heckman DS, 2001, SCIENCE, V293, P1129, DOI 10.1126/science.1061457; Hilgarth RS, 2004, J BIOL CHEM, V279, P53899, DOI 10.1074/jbc.R400021200; Hiller NL, 2004, SCIENCE, V306, P1934, DOI 10.1126/science.1102737; Jamir Y, 2004, PLANT J, V37, P554, DOI 10.1046/j.1365-313X.2003.01982.x; Janjusevic R, 2006, SCIENCE, V311, P222, DOI 10.1126/science.1120131; Jia Y, 2000, EMBO J, V19, P4004, DOI 10.1093/emboj/19.15.4004; Jones DA, 2004, CURR OPIN IMMUNOL, V16, P48, DOI 10.1016/j.coi.2003.11.016; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; JOOSTEN MHAJ, 1994, NATURE, V367, P384, DOI 10.1038/367384a0; Keshavarzi M, 2004, MOL PLANT MICROBE IN, V17, P805, DOI 10.1094/MPMI.2004.17.7.805; Kim HS, 2005, P NATL ACAD SCI USA, V102, P6496, DOI 10.1073/pnas.0500792102; Kim MG, 2005, CELL, V121, P749, DOI 10.1016/j.cell.2005.03.025; Kunkel BN, 2002, CURR OPIN PLANT BIOL, V5, P325, DOI 10.1016/S1369-5266(02)00275-3; Kunze G, 2004, PLANT CELL, V16, P3496, DOI 10.1105/tpc.104.026765; Lauge R, 1998, FUNGAL GENET BIOL, V24, P285, DOI 10.1006/fgbi.1998.1076; Mackey D, 2003, CELL, V112, P379, DOI 10.1016/S0092-8674(03)00040-0; Mackey D, 2002, CELL, V108, P743, DOI 10.1016/S0092-8674(02)00661-X; Mudgett MB, 2005, ANNU REV PLANT BIOL, V56, P509, DOI 10.1146/annurev.arplant.56.032604.144218; Nomura K, 2005, CURR OPIN PLANT BIOL, V8, P361, DOI 10.1016/j.pbi.2005.05.005; Nurnberger T, 2004, IMMUNOL REV, V198, P249, DOI 10.1111/j.0105-2896.2004.0119.x; Orbach MJ, 2000, PLANT CELL, V12, P2019, DOI 10.1105/tpc.12.11.2019; Rehmany AP, 2005, PLANT CELL, V17, P1839, DOI 10.1105/tpc.105.031807; Reymond P, 1998, CURR OPIN PLANT BIOL, V1, P404, DOI 10.1016/S1369-5266(98)80264-1; Ritter C, 1996, PLANT CELL, V8, P251, DOI 10.1105/tpc.8.2.251; Rivas S, 2005, ANNU REV PHYTOPATHOL, V43, P395, DOI 10.1146/annurev.phyto.43.040204.140224; Roden J, 2004, MOL PLANT MICROBE IN, V17, P633, DOI 10.1094/MPMI.2004.17.6.633; RONALD PC, 1992, MOL GEN GENET, V236, P113, DOI 10.1007/BF00279649; Rooney HCE, 2005, SCIENCE, V308, P1783, DOI 10.1126/science.1111404; Rose LE, 2004, GENETICS, V166, P1517, DOI 10.1534/genetics.166.3.1517; Shan WX, 2004, MOL PLANT MICROBE IN, V17, P394, DOI 10.1094/MPMI.2004.17.4.394; Shao F, 2003, SCIENCE, V301, P1230, DOI 10.1126/science.1085671; Shen YW, 2002, MICROBES INFECT, V4, P1361, DOI 10.1016/S1286-4579(02)00004-7; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; Soosaar JLM, 2005, NAT REV MICROBIOL, V3, P789, DOI 10.1038/nrmicro1239; Staskawicz BJ, 2001, SCIENCE, V292, P2285, DOI 10.1126/science.1062013; Tameling WIL, 2002, PLANT CELL, V14, P2929, DOI 10.1105/tpc.005793; Thomma BPHJ, 2001, CURR OPIN IMMUNOL, V13, P63, DOI 10.1016/S0952-7915(00)00183-7; Tian MY, 2004, J BIOL CHEM, V279, P26370, DOI 10.1074/jbc.M400941200; Tian MY, 2005, PLANT PHYSIOL, V138, P1785, DOI 10.1104/pp.105.061226; Tobias CM, 1999, PLANT J, V17, P41, DOI 10.1046/j.1365-313X.1999.00350.x; Underhill DM, 2002, CURR OPIN IMMUNOL, V14, P103, DOI 10.1016/S0952-7915(01)00304-1; van den Burg HA, 2003, J BIOL CHEM, V278, P27340, DOI 10.1074/jbc.M212196200; van der Biezen EA, 1998, TRENDS BIOCHEM SCI, V23, P454, DOI 10.1016/S0968-0004(98)01311-5; Wang GL, 1996, MOL PLANT MICROBE IN, V9, P850, DOI 10.1094/MPMI-9-0850; Yang B, 2000, P NATL ACAD SCI USA, V97, P9807, DOI 10.1073/pnas.170286897; Zhu WG, 1998, MOL PLANT MICROBE IN, V11, P824, DOI 10.1094/MPMI.1998.11.8.824; Zipfel C, 2005, CURR OPIN PLANT BIOL, V8, P353, DOI 10.1016/j.pbi.2005.05.004; Zipfel C, 2004, NATURE, V428, P764, DOI 10.1038/nature02485	78	1924	2074	27	804	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 24	2006	124	4					803	814		10.1016/j.cell.2006.02.008	http://dx.doi.org/10.1016/j.cell.2006.02.008			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	038RO	16497589	Bronze			2022-12-28	WOS:000237240900022
J	Abbott, A				Abbott, A			Rumblings from the fringe	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 23	2006	439	7079					910	911		10.1038/439910a	http://dx.doi.org/10.1038/439910a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014NE	16495966				2022-12-28	WOS:000235486100015
J	Longstreth, GF				Longstreth, GF			Functional dyspepsia - Managing the conundrum	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Kaiser Permanente Med Ctr, San Diego, CA USA; Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA	Kaiser Permanente; University of California System; University of California San Diego	Longstreth, GF (corresponding author), Kaiser Permanente Med Ctr, San Diego, CA USA.							Andrews CN, 2005, GASTROENTEROLOGY, V128, pA456, DOI 10.1053/j.gastro.2005.09.020; DROSSMAN DA, IN PRESS GASTROENTER; Talley NJ, 2005, AM J GASTROENTEROL, V100, P2324, DOI 10.1111/j.1572-0241.2005.00225.x	3	7	9	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 23	2006	354	8					791	793		10.1056/NEJMp058326	http://dx.doi.org/10.1056/NEJMp058326			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014CL	16495391				2022-12-28	WOS:000235456200003
J	Frigaard, NU; Martinez, A; Mincer, TJ; DeLong, EF				Frigaard, NU; Martinez, A; Mincer, TJ; DeLong, EF			Proteorhodopsin lateral gene transfer between marine planktonic Bacteria and Archaea	NATURE			English	Article							PHOTOTROPHY; LIBRARIES	Planktonic Bacteria, Archaea and Eukarya reside and compete in the ocean's photic zone under the pervasive influence of light. Bacteria in this environment were recently shown to contain photoproteins called proteorhodopsins, thought to contribute to cellular energy metabolism by catalysing light-driven proton translocation across the cell membrane(1-7). So far, proteorhodopsin genes have been well documented only in proteobacteria and a few other bacterial groups. Here we report the presence and distribution of proteorhodopsin genes in Archaea affiliated with the order Thermoplasmatales, in the ocean's upper water column. The genomic context and phylogenetic relationships of the archaeal and proteobacterial proteorhodopsins indicate its probable lateral transfer between planktonic Bacteria and Archaea. About 10% of the euryarchaeotes in the photic zone contained the proteorhodopsin gene adjacent to their small-subunit ribosomal RNA. The archaeal proteorhodopsins were also found in other genomic regions, in the same or in different microbial lineages. Although euryarchaeotes were distributed throughout the water column, their proteorhodopsins were found only in the photic zone. The cosmopolitan phylogenetic distribution of proteorhodopsins reflects their significant light-dependent fitness contributions, which drive the photoprotein's lateral acquisition and retention, but constrain its dispersal to the photic zone.	MIT, Dept Civil & Environm Engn, Cambridge, MA 02139 USA; MIT, Div Biol Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	DeLong, EF (corresponding author), MIT, Dept Civil & Environm Engn, Bldg 48,15 Vassar St, Cambridge, MA 02139 USA.	delong@mit.edu	Frigaard, Niels-Ulrik/H-1277-2011; chen, qi/C-8585-2011	Frigaard, Niels-Ulrik/0000-0002-9389-8109; Mincer, Tracy/0000-0002-4644-5609				Balashov SP, 2005, SCIENCE, V309, P2061, DOI 10.1126/science.1118046; Baliga NS, 2004, GENOME RES, V14, P2221, DOI 10.1101/gr.2700304; Beja O, 2000, SCIENCE, V289, P1902, DOI 10.1126/science.289.5486.1902; Beja O, 2001, NATURE, V411, P786, DOI 10.1038/35081051; Beja O, 2000, ENVIRON MICROBIOL, V2, P516, DOI 10.1046/j.1462-2920.2000.00133.x; de la Torre JR, 2003, P NATL ACAD SCI USA, V100, P12830, DOI 10.1073/pnas.2133554100; DELONG EF, 1992, P NATL ACAD SCI USA, V89, P5685, DOI 10.1073/pnas.89.12.5685; DeLong EF, 2003, ASM NEWS, V69, P503; DELONG EF, IN PRESS SCIENCE; FUHRMAN JA, 1992, NATURE, V356, P148, DOI 10.1038/356148a0; Giovannoni SJ, 2005, NATURE, V438, P82, DOI 10.1038/nature04032; Giovannoni SJ, 2005, SCIENCE, V309, P1242, DOI 10.1126/science.1114057; Giuliano G, 2003, TRENDS PLANT SCI, V8, P145, DOI 10.1016/S1360-1385(03)00053-0; Herndl GJ, 2005, APPL ENVIRON MICROB, V71, P2303, DOI 10.1128/AEM.71.5.2303-2309.2005; Karner MB, 2001, NATURE, V409, P507, DOI 10.1038/35054051; Konneke M, 2005, NATURE, V437, P543, DOI 10.1038/nature03911; Lerat E, 2005, PLOS BIOL, V3, P807, DOI 10.1371/journal.pbio.0030130; Massana R, 1997, APPL ENVIRON MICROB, V63, P50, DOI 10.1128/AEM.63.1.50-56.1997; Massana R, 2000, APPL ENVIRON MICROB, V66, P1777, DOI 10.1128/AEM.66.5.1777-1787.2000; Moreira D, 2004, ENVIRON MICROBIOL, V6, P959, DOI 10.1111/j.1462-2920.2004.00644.x; Ochman H, 2005, P NATL ACAD SCI USA, V102, P6595, DOI 10.1073/pnas.0502035102; Pearson A, 2001, GEOCHIM COSMOCHIM AC, V65, P3123, DOI 10.1016/S0016-7037(01)00657-3; Pernthaler A, 2002, APPL ENVIRON MICROB, V68, P661, DOI 10.1128/AEM.68.2.661-667.2002; Ruch S, 2005, MOL MICROBIOL, V55, P1015, DOI 10.1111/j.1365-2958.2004.04460.x; Sabehi G, 2005, PLOS BIOL, V3, P1409, DOI 10.1371/journal.pbio.0030273; Sabehi G, 2004, ENVIRON MICROBIOL, V6, P903, DOI 10.1111/j.1462-2920.2004.00676.x; Suzuki MT, 2004, MICROB ECOL, V48, P473, DOI 10.1007/s00248-004-0213-5; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Woese CR, 2004, MICROBIOL MOL BIOL R, V68, P173, DOI 10.1128/MMBR.68.2.173-186.2004; Wuchter C, 2003, FEMS MICROBIOL LETT, V219, P203, DOI 10.1016/S0378-1097(03)00060-0	30	226	243	3	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 16	2006	439	7078					847	850		10.1038/nature04435	http://dx.doi.org/10.1038/nature04435			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012JA	16482157				2022-12-28	WOS:000235333600050
J	Yellon, DM; Opie, LH				Yellon, DM; Opie, LH			Postconditioning for protection of the infarcting heart	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION; REPERFUSION; ISCHEMIA; INJURY		UCL Hosp, Hatter Cardiovasc Inst, London WC1E 6DB, England; Sch Med, London WC1E 6DB, England; Univ Cape Town, Fac Hlth Sci, Hatter Heart Res Inst, ZA-7925 Cape Town, South Africa	University College London Hospitals NHS Foundation Trust; University of London; University College London; University of Cape Town	Yellon, DM (corresponding author), UCL Hosp, Hatter Cardiovasc Inst, London WC1E 6DB, England.	hatter-institute@ucl.ac.uk	Yellon, Derek M/ABD-5110-2021	Hausenloy, Derek/0000-0003-0729-4956; Yellon, Derek/0000-0001-7791-9320				Bose AK, 2005, DIABETES, V54, P146, DOI 10.2337/diabetes.54.1.146; GRIFFITHS EJ, 1995, BIOCHEM J, V307, P93, DOI 10.1042/bj3070093; Hausenloy DJ, 2005, TRENDS CARDIOVAS MED, V15, P69, DOI 10.1016/j.tcm.2005.03.001; Hausenloy DJ, 2005, AM J PHYSIOL-HEART C, V288, pH971, DOI 10.1152/ajpheart.00374.2004; Hausenloy DJ, 2003, J MOL CELL CARDIOL, V35, P339, DOI 10.1016/S0022-2828(03)00043-9; Kin H, 2005, CARDIOVASC RES, V67, P124, DOI 10.1016/j.cardiores.2005.02.015; Kloner RA, 2004, J AM COLL CARDIOL, V44, P276, DOI 10.1016/j.jacc.2004.03.068; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Staat P, 2005, CIRCULATION, V112, P2143, DOI 10.1161/CIRCULATIONAHA.105.558122; van Domburg RT, 2005, J AM COLL CARDIOL, V46, P15, DOI 10.1016/j.jacc.2005.03.047; Yellon DM, 2003, PHYSIOL REV, V83, P1113, DOI 10.1152/physrev.00009.2003; Zhao ZQ, 2003, AM J PHYSIOL-HEART C, V285, pH579, DOI 10.1152/ajpheart.01064.2002	12	50	60	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 11	2006	367	9509					456	458		10.1016/S0140-6736(06)68157-9	http://dx.doi.org/10.1016/S0140-6736(06)68157-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013FF	16473110				2022-12-28	WOS:000235394500008
J	Sox, HC; Rennie, D				Sox, HC; Rennie, D			Research misconduct, retraction, and cleansing the medical literature: Lessons from the Poehlman case	ANNALS OF INTERNAL MEDICINE			English	Article							TARGET PLATELET ANTIGEN; IMMUNE THROMBOCYTOPENIA; SCIENTIFIC MISCONDUCT; HOMOSEXUAL MEN; EXPRESSION; ALLEGATIONS; WITHDRAWAL; FRAUD; AEGIS	The scientific literature is a record of the search for truth. Publication of faked data diverts this search. The scientific community has a duty to warn people to ignore an article containing faked data and must try to prevent inadvertent citation of it. The scientific community accomplishes these tasks by publishing a retraction and linking it to the fraudulent article's citation in electronic indexes of the medical literature, such as PubMed. This mechanism is far from perfect, as shown by a case history of scientific fraud perpetrated by Eric Poehlman, PhD. His institution notified 3 journals that they had published tainted articles. Two journals failed to retract. The third journal retracted immediately, but other authors continued to cite the retracted article. Another duty of the scientific community is to verify the integrity of other articles published by the author of a fraudulent article. This task falls to the author's institution and requires coauthors to vouch for their article's integrity by convincing institutional investigators that the suspect author could not have altered the raw scientific data from their study. Two universities are currently investigating PoehIman's published research. Maintaining the integrity of the scientific literature requires governmental institutions that have the authority to investigate and punish guilty scientists and requires that research institutions investigate alleged fraud. It requires journal editors to issue a retraction when they learn that their journal has published a tainted article. It requires research institutions to accept their responsibility to investigate every article published by a scientist who has published even 1 fraudulent article. Finally, it requires authors to take pains to avoid citing retracted articles and to issue a correction when they inadvertently cite a retracted article.	Amer Coll Physicians, Customer Serv, Philadelphia, PA 19106 USA; Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA	American College of Physicians; University of California System; University of California San Francisco	Sox, HC (corresponding author), Amer Coll Physicians, Customer Serv, 190 N Independence Mall W, Philadelphia, PA 19106 USA.							[Anonymous], 2000, MAN ALL SCI MISC GUI; Curfman GD, 2005, NEW ENGL J MED, V353, P2813, DOI 10.1056/NEJMe058314; CURTMAN GD, 2001, NEW ENGL J MED, V344, P1270; ENGLER RL, 1987, NEW ENGL J MED, V317, P1383, DOI 10.1056/NEJM198711263172205; Fuyuno I, 2006, NATURE, V439, P514, DOI 10.1038/439514a; GARFIELD E, 1990, JAMA-J AM MED ASSOC, V263, P1424, DOI 10.1001/jama.263.10.1424; HAMMERSCHMIDT DE, 1994, J LAB CLIN MED, V123, P795; HAMMERSCHMIDT DE, 1994, J LAB CLIN MED, V123, P792; Holden C, 2005, SCIENCE, V310, P34; Horton R, 2006, LANCET, V367, P196, DOI 10.1016/S0140-6736(06)68014-8; Horton R, 2005, LANCET, V366, P354, DOI 10.1016/S0140-6736(05)67006-7; International Committee of Medical Journal Editors, UN REQ MAN SUBM BIOM; Kennedy D, 2006, SCIENCE, V311, P36; KORN D, 1991, 1 INT C PEER REV BIO, P205; LUCENTINI J, 2005, SCIENTIST, V6, P2; MCCOOK A, 2005, SCIENTIST, V6, P1; PFEIFER MP, 1990, JAMA-J AM MED ASSOC, V263, P1420, DOI 10.1001/jama.263.10.1420; Poehlman ET, 2005, ANN INTERN MED, V142, P798, DOI 10.7326/0003-4819-142-9-200505030-00116; POEHLMAN ET, 1995, ANN INTERN MED, V123, P673, DOI 10.7326/0003-4819-123-9-199511010-00005; RENNIE D, 1993, JAMA-J AM MED ASSOC, V269, P915, DOI 10.1001/jama.269.7.915; Rennie D, 1997, JAMA-J AM MED ASSOC, V278, P579, DOI 10.1001/jama.278.7.579; SHUMAN MA, 1991, NEW ENGL J MED, V325, P1487, DOI 10.1056/NEJM199111213252106; Smith J, 2005, BMJ-BRIT MED J, V331, P245, DOI 10.1136/bmj.331.7511.245; Smith R, 2005, BMJ-BRIT MED J, V331, P288, DOI 10.1136/bmj.331.7511.288; Sox HC, 2005, ANN INTERN MED, V142, P798, DOI 10.7326/0003-4819-142-9-200505030-00115; Sox HC, 2003, ANN INTERN MED, V139, P227, DOI 10.7326/0003-4819-139-3-200308050-00012; STRICKER RB, 1985, NEW ENGL J MED, V313, P1375, DOI 10.1056/NEJM198511283132202; Sudbo J, 2004, NEW ENGL J MED, V350, P1405, DOI 10.1056/NEJMoa033374; SUDBO J, 2006, NEW ENGL J MED, V354, P638; *U VERM COLL MED, 2001, MATT ET POEHLM PH D; *US DEP HHS, 2005, PAP AFF DR POEHLM MI; *US DEP HHS, 2005, VOL EXCL SETTL AGR; White C, 2005, BMJ-BRIT MED J, V331, P281, DOI 10.1136/bmj.331.7511.281; WHITELY WP, 1994, JAMA-J AM MED ASSOC, V272, P170, DOI 10.1001/jama.272.2.170; 2005, FED REG, V70, P28369	35	135	141	3	60	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 18	2006	144	8					609	613		10.7326/0003-4819-144-8-200604180-00123	http://dx.doi.org/10.7326/0003-4819-144-8-200604180-00123			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	035QZ	16522625				2022-12-28	WOS:000237017900008
J	Sundstrom, J; Riserus, U; Byberg, L; Zethelius, B; Lithell, H; Lind, L				Sundstrom, J; Riserus, U; Byberg, L; Zethelius, B; Lithell, H; Lind, L			Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; INSULIN-RESISTANCE; ALL-CAUSE; PREVENTION; GLUCOSE; EVENTS; HEALTH; RISK	Objectives To find out if the presence of the metabolic syndrome increases the risk of subsequent total and cardiovascular mortality, taking into account established risk factors for cardiovascular disease. Design Prospective cohort study. Setting General population. Participants A community based sample of 2322 men followed since 1970 for a maximum of 32.7 years, investigated at ages 50 and 70. Main outcome measures The relations of die metabolic syndrome defined by the national cholesterol education programme (NCEP) of the US National Heart, Lung, and Blood Institute or criteria of the World Health Organization (WHO) to subsequent total and cardiovascular mortality. Results When adding the metabolic syndrome to models with established risk factors for cardiovascular disease (smoking, diabetes, hypertension, and serum cholesterol) at age 50, presence of the metabolic syndrome as defined in the NCEP significantly predicted total and cardiovascular mortality (Cox proportional hazard ratios 1.36, 95% confidence interval 1.17 to 1.58; and 1.59,1.29 to 1.95, respectively). The metabolic syndrome added prognostic information to that of the established risk factors for cardiovascular disease (likelihood ratio tests, P < 0.0001 for both outcomes). Similar results were obtained in a subsample without diabetes or manifest cardiovascular disease. Conclusions In a large, community based sample of middle aged men, the presence of the metabolic syndrome according to the definition of the NCEP gave long term prognostic information regarding total mid cardiovascular mortality if the status of established risk factors for cardiovascular disease was known. If confirmed this may indicate clinical value in diagnosing the metabolic syndrome.	Uppsala Univ, Dept Med Sci, SE-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Publ Hlth & Caring Sci, Uppsala, Sweden	Uppsala University; Uppsala University; Uppsala University Hospital	Sundstrom, J (corresponding author), Uppsala Univ, Dept Med Sci, SE-75185 Uppsala, Sweden.	johan.sundstrom@medsci.uu.se	Sundström, Johan/A-6286-2009; Sundstrom, Johan/R-2139-2019	Sundström, Johan/0000-0003-2247-8454; Sundstrom, Johan/0000-0003-2247-8454				[Anonymous], 1997, Diabetes Care, V20 Suppl 1, pS1; BATKAU B, 1999, DIABETIC MED, V16, P442; De Backer G, 2003, EUR HEART J, V24, P1601, DOI 10.1016/S0195-668X(03)00347-6; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; Ford ES, 2004, ATHEROSCLEROSIS, V173, P309, DOI 10.1016/j.atherosclerosis.2003.12.022; Girman CJ, 2004, AM J CARDIOL, V93, P136, DOI 10.1016/j.amjcard.2003.09.028; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Hedstrand H, 1975, Ups J Med Sci Suppl, V19, P1; Hunt KJ, 2004, CIRCULATION, V110, P1251, DOI 10.1161/01.CIR.0000140762.04598.F9; ILN G, 2004, ARCH INTERN MED, V164, P1066; Isomaa B, 2001, DIABETES CARE, V24, P683, DOI 10.2337/diacare.24.4.683; Kahn R, 2005, DIABETES CARE, V28, P2289, DOI 10.2337/diacare.28.9.2289; Katzmarzyk PT, 2004, ARCH INTERN MED, V164, P1092, DOI 10.1001/archinte.164.10.1092; Lakka HM, 2002, JAMA-J AM MED ASSOC, V288, P2709, DOI 10.1001/jama.288.21.2709; Malik S, 2004, CIRCULATION, V110, P1245, DOI 10.1161/01.CIR.0000140677.20606.0E; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Ridker PM, 2003, CIRCULATION, V107, P391, DOI 10.1161/01.CIR.0000055014.62083.05; Rutter MK, 2004, CIRCULATION, V110, P380, DOI 10.1161/01.CIR.0000136581.59584.0E; Sattar N, 2003, CIRCULATION, V108, P414, DOI 10.1161/01.CIR.0000080897.52664.94; Schillaci G, 2004, J AM COLL CARDIOL, V43, P1817, DOI 10.1016/j.jacc.2003.12.049; W.H. Organization, 1999, DEFINITION DIAGNOSIS; Zethelius B, 2005, DIABETOLOGIA, V48, P862, DOI 10.1007/s00125-005-1711-9	23	277	290	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 15	2006	332	7546					878	881		10.1136/bmj.38766.624097.1F	http://dx.doi.org/10.1136/bmj.38766.624097.1F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	037FK	16510492	Green Published, Bronze			2022-12-28	WOS:000237132100014
J	Hataye, J; Moon, JJ; Khoruts, A; Reilly, C; Jenkins, MK				Hataye, J; Moon, JJ; Khoruts, A; Reilly, C; Jenkins, MK			Naive and memory CD4(+) T cell survival controlled by clonal abundance	SCIENCE			English	Article							HOMEOSTATIC PROLIFERATION; TCR REPERTOIRE; IN-VIVO; MHC; ABSENCE; COMPETITION; INDUCTION; DIVERSITY; IMMUNITY; SIGNALS	Immunity to a plethora of microbes depends on a diverse repertoire of naive lymphocytes and the production of long-lived memory cells. We present evidence here that low clonal abundance in a polyclonal repertoire favors the survival and activation of naive CD4(+) T cells as well as the survival of their memory cell progeny. The inverse relation between clonal frequency and survival suggests that intraclonal competition could help maintain an optimally diverse repertoire of T cells and an optimal environment for the generation of long-lived memory cells.	Univ Minnesota, Sch Med, Ctr Immunol, Dept Microbiol, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Ctr Immunol, Dept Med, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Hataye, J (corresponding author), Univ Minnesota, Sch Med, Ctr Immunol, Dept Microbiol, Minneapolis, MN 55455 USA.	hata0006@umn.edu	Jenkins, Marc K/G-1063-2012; moon, james/F-1031-2014	Jenkins, Marc K/0000-0001-8009-7655; moon, james/0000-0001-8071-1491	NCI NIH HHS [T32 CA009138] Funding Source: Medline; NIAID NIH HHS [AI39614, T32-AI007313, F32 AI063793-01A1, AI27998, F32 AI063793] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007313, R01AI027998, R01AI039614, R37AI027998, F32AI063793] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Casrouge A, 2000, J IMMUNOL, V164, P5782, DOI 10.4049/jimmunol.164.11.5782; Clarke SRM, 2000, J IMMUNOL, V165, P2458, DOI 10.4049/jimmunol.165.5.2458; Dorfman JR, 2000, NAT IMMUNOL, V1, P329, DOI 10.1038/79783; Homann D, 2001, NAT MED, V7, P913, DOI 10.1038/90950; Jameson SC, 2002, NAT REV IMMUNOL, V2, P547, DOI 10.1038/nri853; Kassiotis G, 2002, NAT IMMUNOL, V3, P244, DOI 10.1038/ni766; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; Kieper WC, 2004, J IMMUNOL, V172, P40, DOI 10.4049/jimmunol.172.1.40; Labrecque N, 2001, IMMUNITY, V15, P71, DOI 10.1016/S1074-7613(01)00170-4; Marzo AL, 2005, NAT IMMUNOL, V6, P793, DOI 10.1038/ni1227; McSorley SJ, 2002, IMMUNITY, V16, P365, DOI 10.1016/S1074-7613(02)00289-3; Min B, 2004, P NATL ACAD SCI USA, V101, P3874, DOI 10.1073/pnas.0400606101; Moses CT, 2003, P NATL ACAD SCI USA, V100, P1185, DOI 10.1073/pnas.0334572100; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Nikolich-Zugich J, 2004, NAT REV IMMUNOL, V4, P123, DOI 10.1038/nri1292; Polic B, 2001, P NATL ACAD SCI USA, V98, P8744, DOI 10.1073/pnas.141218898; Reinhardt RL, 2001, NATURE, V410, P101, DOI 10.1038/35065111; Seddon B, 2003, NAT IMMUNOL, V4, P680, DOI 10.1038/ni946; Troy AE, 2003, J IMMUNOL, V170, P672, DOI 10.4049/jimmunol.170.2.672; Varga SM, 2001, J IMMUNOL, V166, P1554, DOI 10.4049/jimmunol.166.3.1554; Viret C, 1999, IMMUNITY, V10, P559, DOI 10.1016/S1074-7613(00)80055-2; Witherden D, 2000, J EXP MED, V191, P355, DOI 10.1084/jem.191.2.355	22	280	284	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 7	2006	312	5770					114	116		10.1126/science.1124228	http://dx.doi.org/10.1126/science.1124228			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	029SJ	16513943				2022-12-28	WOS:000236584400044
J	de Wit, M; Stankiewicz, J				de Wit, M; Stankiewicz, J			Changes in surface water supply across Africa with predicted climate change	SCIENCE			English	Article								Across Africa, perennial drainage density as a function of mean annual rainfall defines three regimes separated by threshold values of precipitation. This nonlinear response of drainage to rainfall will most seriously affect regions in the intermediate, unstable regime. A 10% decrease in precipitation in regions on the upper regime boundary (1000 millimeters per year) would reduce drainage by 17%, whereas in regions receiving 500 millimeters per year, such a drop would cut 50% of surface drainage. By using predicted precipitation changes, we calculate that a decrease in perennial drainage will significantly affect present surface water access across 25% of Africa by the end of this century.	Univ Cape Town, AEON, ZA-7701 Rondebosch, South Africa; Univ Cape Town, Dept Geol Sci, ZA-7701 Rondebosch, South Africa	University of Cape Town; University of Cape Town	de Wit, M (corresponding author), Univ Cape Town, AEON, ZA-7701 Rondebosch, South Africa.	maarten@cigces.uct.ac.za						BREMNER JM, 1990, T ROY SOC S AFR, V47, P247, DOI 10.1080/00359199009520243; *CCCMA, CGCM2 CCCMA; *CSAG, 2002, ASS IMP AD CLIM CHAN, V1; *CSIRO, MK2 CSIRO; *GRAPHPAD PRISM 4, GRAPHPAD SOFTW; Gregory K.J., 1976, GEOMORPHOLOGY CLIMAT, P289; *HADL CTR, HADCM3 HADL CTR; HEWITSON B, COMMUNICATION; HEWITSON BC, IN PRESS INT J CLIMA; Houghton J. T., 2001, CLIMATE CHANGE 2001; *IPCC, SPEC REP EM SCEN SRE; LEGATES DR, 1990, INT J CLIMATOL, V10, P111, DOI 10.1002/joc.3370100202; *M PLANCK I MET, ECHAM4 M PLANCK I ME; MATHIEU R, 2005, GEOPHYS RES LETT, V32, DOI DOI 10.1029/2005GL022436; Moglen GE, 1998, WATER RESOUR RES, V34, P855, DOI 10.1029/97WR02709; MONTGOMERY DR, 1988, NATURE, V336, P232, DOI 10.1038/336232a0; NAKICENOVIC N, 2000, 2000 SPECIAL REPORT, P570; *NCAR, PAR CLIM SYST MOD PC; *NCAR, CLIM SYST MOD CSM; Nyong A, 2005, IMPACTS CLIMATE CHAN; Stainforth DA, 2005, NATURE, V433, P403, DOI 10.1038/nature03301; Stankiewicz J, 2005, GEOCHEM GEOPHY GEOSY, V6, DOI 10.1029/2005GC000928; Strahler AN., 1957, EOS T AM GEOPHYS UN, V38, P913, DOI [10.1029/TR038i006p00913, DOI 10.1029/TR038I006P00913]; VANWARMELO W, 1922, S AFR IRRIGATION, V1, P244; von Storch H, 2004, SCIENCE, V306, P679, DOI 10.1126/science.1096109; World Bank, 2003, POV CLIM CHANG RED V	26	229	234	4	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 31	2006	311	5769					1917	1921		10.1126/science.1119929	http://dx.doi.org/10.1126/science.1119929			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	027BD	16513946				2022-12-28	WOS:000236387800043
J	Parker, MJ; Gillespie, WJ; Gillespie, LD				Parker, MJ; Gillespie, WJ; Gillespie, LD			Effectiveness of hip protectors for preventing hip fractures in elderly people: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CONTROLLED-TRIAL; ACCEPTANCE; RESIDENTS	Objectives To present the updated results of systematic review of the current evidence for the effectiveness of hip protectors from reports of completed randomised trials, and to explore the evolution of that evidence. Design Systematic review with meta-analysis. Data sources Cochrane Bone,joint, and Muscle Trauma Group trials register (January 2005), Cochrane central register of controlled trials (Cochrane Library Issue 1, 2005), Medline (1966 to January 2005), Embase (1988 to January 2005), and CINAHL (1982 to December 2004). Other databases and reference lists of relevant articles were searched and some trialists were contacted. Review methods Randomised or quasirandomised controlled trials reporting the incidence of hip fractures, pelvic fractures, and other fractures in elderly people offered hip protectors compared with a control group that was not. Results Outcomes for fracture were available from 14 randomised and quasirandomised trials. Pooling of data from 11 trials carried out in nursing or residential care settings, including six cluster randomised studies, showed evidence of a marginally statistically significant reduction in incidence of hip fracture (relative risk 0.77, 95% confidence interval 0.62 to 0.97). Pooling of data from three individually randomised trials of 5135 community dwelling participants showed no reduction in hip fracture incidence with provision of hip protectors (1.16, 0.85 to 1.59). No evidence was found of any significant effect of hip protectors on incidence of pelvic or other fractures. No important adverse effects of hip protectors were reported, but compliance, particularly in the long term, was poor. Conclusions On the basis of early reports of randomised trials, hip protectors were advocated. Accumulating evidence indicates that hip protectors are an ineffective intervention for those living at home and that their effectiveness in an institutional setting is uncertain.	Peterborough Dist Gen Hosp, Peterborough & Stamford Hosp NHS Fdn, Dept Orthopaed, Peterborough PE3 6DA, England; Univ Hull, Hull York Med Sch, Kingston Upon Hull HU6 7RX, N Humberside, England; Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England	University of Hull; University of York - UK; University of York - UK	Parker, MJ (corresponding author), Peterborough Dist Gen Hosp, Peterborough & Stamford Hosp NHS Fdn, Dept Orthopaed, Peterborough PE3 6DA, England.	martyn.parker@pbh-tr.nhs.uk						Birks YF, 2004, OSTEOPOROSIS INT, V15, P701, DOI 10.1007/s00198-004-1599-0; Birks YF, 2003, AGE AGEING, V32, P442, DOI 10.1093/ageing/32.4.442; Cameron ID, 2003, INJ PREV, V9, P138, DOI 10.1136/ip.9.2.138; Cameron ID, 2001, AGE AGEING, V30, P477, DOI 10.1093/ageing/30.6.477; Chan DK, 2000, ARCH GERONTOL GERIAT, V30, P25, DOI 10.1016/S0167-4943(99)00048-5; Ekman A, 1997, LANCET, V350, P563, DOI 10.1016/S0140-6736(05)63140-6; Harada A, 2001, OSTEOPOROSIS INT, V12, P215, DOI 10.1007/s001980170132; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hubacher M, 2001, OSTEOPOROSIS INT, V12, P794, DOI 10.1007/s001980170057; JANTTI P, 1996, SUOM LAAKARILEHTI, V51, P3387; Johnell O, 2004, OSTEOPOROSIS INT, V15, P38, DOI 10.1007/s00198-003-1490-4; Kannus P, 2000, NEW ENGL J MED, V343, P1506, DOI 10.1056/NEJM200011233432101; Kurrle SE, 2004, J GERONTOL A-BIOL, V59, P958; KURRLE SE, 2004, J GERONTOL A-BIOL, V39, pM958; LAURITZEN JB, 1993, LANCET, V341, P11, DOI 10.1016/0140-6736(93)92480-H; Macdonald GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub2; MEYER G, 2000, BMJ-BRIT MED J, V326, P6; MEYER G, 2003, BRIT MED J, V326, P6; O'Halloran PD, 2004, AGE AGEING, V33, P582, DOI 10.1093/ageing/afh200; Parker MJ, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001255.pub3; PARKER MJ, 1999, COCHRANE DB SYST REV; SAWKA AM, OSTEOPOROS INT  0308; SAWKA AM, 2005, OSTEOPOROS INT  0308; van Schoor NM, 2003, JAMA-J AM MED ASSOC, V289, P1957, DOI 10.1001/jama.289.15.1957; van Schoor NM, 2002, OSTEOPOROSIS INT, V13, P917, DOI 10.1007/s001980200128; VANSCHOOR NM, 2003, JAMA-J AM MED ASSOC, V239, P1957; Villar MTA, 1998, AGE AGEING, V27, P195, DOI 10.1093/ageing/27.2.195	27	141	147	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 11	2006	332	7541					571	573		10.1136/bmj.38753.375324.7C	http://dx.doi.org/10.1136/bmj.38753.375324.7C			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	026CN	16513687	Green Published, Bronze			2022-12-28	WOS:000236314400013
J	Dougherty, MK; Khurana, KK; Neubauer, FM; Russell, CT; Saur, J; Leisner, JS; Burton, ME				Dougherty, MK; Khurana, KK; Neubauer, FM; Russell, CT; Saur, J; Leisner, JS; Burton, ME			Identification of a dynamic atmosphere at Enceladus with the Cassini magnetometer	SCIENCE			English	Article							IO; SYSTEM; SATELLITES; ENGINE; SPACE		Univ London Imperial Coll Sci Technol & Med, Blackett Lab, London SW7 2AZ, England; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90025 USA; Univ Cologne, Inst Geophys & Meteorol, D-50923 Cologne, Germany; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	Imperial College London; University of California System; University of California Los Angeles; University of Cologne; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Dougherty, MK (corresponding author), Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Prince Consort Rd, London SW7 2AZ, England.	m.dougherty@imperial.ac.uk	Russell, Christopher T/E-7745-2012; Saur, Joachim/V-6780-2019	Russell, Christopher T/0000-0003-1639-8298; Saur, Joachim/0000-0003-1413-1231; Khurana, Krishan/0000-0002-2856-1171	Science and Technology Facilities Council [PP/D000912/1] Funding Source: researchfish; STFC [PP/D000912/1] Funding Source: UKRI	Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))		BELCHER JW, 1987, SCIENCE, V238, P170, DOI 10.1126/science.238.4824.170; Brown RH, 2006, SCIENCE, V311, P1425, DOI 10.1126/science.1121031; Dougherty MK, 2004, SPACE SCI REV, V114, P331, DOI 10.1007/s11214-004-1432-2; DRELL SD, 1965, J GEOPHYS RES, V70, P3131, DOI 10.1029/JZ070i013p03131; Esposito LW, 2005, SCIENCE, V307, P1251, DOI 10.1126/science.1105606; Hansen CJ, 2006, SCIENCE, V311, P1422, DOI 10.1126/science.1121254; Huddleston DE, 1998, J GEOPHYS RES-PLANET, V103, P19887, DOI 10.1029/97JE03557; Kivelson MG, 2001, J GEOPHYS RES-SPACE, V106, P26121, DOI 10.1029/2000JA002510; NEUBAUER FM, 1980, J GEOPHYS RES-SPACE, V85, P1171, DOI 10.1029/JA085iA03p01171; Porco CC, 2006, SCIENCE, V311, P1393, DOI 10.1126/science.1123013; Saur J, 2005, ASTROPHYS J, V620, pL115, DOI 10.1086/428665; Sittler EC, 2004, J GEOPHYS RES-SPACE, V109, DOI 10.1029/2002JA009647; SMITH BA, 1982, SCIENCE, V215, P504, DOI 10.1126/science.215.4532.504; Spencer JR, 2006, SCIENCE, V311, P1401, DOI 10.1126/science.1121661; Waite JH, 2006, SCIENCE, V311, P1419, DOI 10.1126/science.1121290	15	285	287	2	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 10	2006	311	5766					1406	1409		10.1126/science.1120985	http://dx.doi.org/10.1126/science.1120985			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527966				2022-12-28	WOS:000236029400032
J	Qiu, MH; Ren, ZF; Che, L; Dai, DX; Harich, SA; Wang, XY; Yang, XM; Xu, CX; Xie, DQ; Gustafsson, M; Skodje, RT; Sun, ZG; Zhang, DH				Qiu, MH; Ren, ZF; Che, L; Dai, DX; Harich, SA; Wang, XY; Yang, XM; Xu, CX; Xie, DQ; Gustafsson, M; Skodje, RT; Sun, ZG; Zhang, DH			Observation of Feshbach resonances in the F+H-2 -> HF+H reaction	SCIENCE			English	Article							POTENTIAL-ENERGY SURFACE; EXACT QUANTUM; SEMICLASSICAL REACTION; REACTION DYNAMICS; TRANSITION-STATE; CROSS-SECTIONS; MOLECULAR-BEAM; SCATTERING; F+H2; PROBABILITIES	Reaction resonances, or transiently stabilized transition-state structures, have proven highly challenging to capture experimentally. Here, we used the highly sensitive H atom Rydberg tagging time-of-flight method to conduct a crossed molecular beam scattering study of the F + H-2 --> HF + H reaction with full quantum-state resolution. Pronounced forward-scattered HF products in the v' = 2 vibrational state were clearly observed at a collision energy of 0.52 kcal/mol; this was attributed to both the ground and the first excited Feshbach resonances trapped in the peculiar HF(v' = 3)-H' vibrationally adiabatic potential, with substantial enhancement by constructive interference between the two resonances.	Chinese Acad Sci, State Key Lab Mol React Dynam, Dalian Inst Chem Phys, Dalian 116023, Peoples R China; Chinese Acad Sci, Dalian Inst Chem Phys, Ctr Theoret Computat Chem, Dalian 116023, Peoples R China; Dalian Jiaotong Univ, Dept Phys, Dalian, Peoples R China; Nanjing Univ, Dept Chem, Inst Theoret & Computat Chem, Nanjing 210093, Jiangsu, Peoples R China; Acad Sinica, Inst Atom & Mol Sci, Taipei, Taiwan; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Natl Univ Singapore, Dept Computat Sci, Singapore 119260, Singapore	Chinese Academy of Sciences; Dalian Institute of Chemical Physics, CAS; Chinese Academy of Sciences; Dalian Institute of Chemical Physics, CAS; Dalian Jiaotong University; Nanjing University; Academia Sinica - Taiwan; University of Colorado System; University of Colorado Boulder; National University of Singapore	Yang, XM (corresponding author), Chinese Acad Sci, State Key Lab Mol React Dynam, Dalian Inst Chem Phys, Dalian 116023, Peoples R China.	xmyang@dicp.ac.cn; dqxie@nju.edu.cn; zhangdh@dicp.ac.cn	Gustafsson, Magnus/A-1661-2010; Gustafsson, Magnus/GSD-2741-2022; Gustafsson, Magnus/GOV-3301-2022; Ren, Zefeng/B-1500-2009; Yang, Xueming/C-8764-2013; Ren, Zefeng/T-2259-2019; Sun, Zhigang/B-5757-2011	Gustafsson, Magnus/0000-0002-7629-0169; Gustafsson, Magnus/0000-0002-7629-0169; Gustafsson, Magnus/0000-0002-7629-0169; Ren, Zefeng/0000-0002-5263-9346; 				AOIZ FJ, 1994, CHEM PHYS LETT, V223, P215, DOI 10.1016/0009-2614(94)00435-8; Castillo JF, 1996, J CHEM PHYS, V104, P6531, DOI 10.1063/1.471373; Chao SD, 2000, J CHEM PHYS, V113, P3487, DOI 10.1063/1.1289526; Dai DX, 2003, SCIENCE, V300, P1730, DOI 10.1126/science.1084041; DUNNING TH, 1989, J CHEM PHYS, V90, P1007, DOI 10.1063/1.456153; Fernandez-Alonso F, 2002, ANNU REV PHYS CHEM, V53, P67, DOI 10.1146/annurev.physchem.53.091001.094554; Harich SA, 2002, NATURE, V419, P281, DOI 10.1038/nature01068; Hayes M, 2005, CHEM PHYS, V308, P259, DOI 10.1016/j.chemphys.2004.05.028; KNOWLES PJ, 1988, CHEM PHYS LETT, V145, P514, DOI 10.1016/0009-2614(88)87412-8; KUPPERMANN A, 1981, POTENTIAL ENERGY SUR, P375; LANGHOFF SR, 1974, INT J QUANTUM CHEM, V8, P61, DOI 10.1002/qua.560080106; LEE YT, 1987, SCIENCE, V236, P793, DOI 10.1126/science.236.4803.793; Liu KP, 2001, ANNU REV PHYS CHEM, V52, P139, DOI 10.1146/annurev.physchem.52.1.139; Liu XH, 2000, SCIENCE, V289, P1536, DOI 10.1126/science.289.5484.1536; MANOLOPOULOS DE, 1993, SCIENCE, V262, P1852, DOI 10.1126/science.262.5141.1852; NEUMARK DM, 1985, J CHEM PHYS, V82, P3045, DOI 10.1063/1.448254; NEUMARK DM, 1984, PHYS REV LETT, V53, P226, DOI 10.1103/PhysRevLett.53.226; Nizkorodov SA, 1999, J CHEM PHYS, V111, P8404, DOI 10.1063/1.480182; Rusin LY, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1873772; Russell CL, 1996, CHEM PHYS LETT, V256, P465, DOI 10.1016/0009-2614(96)00445-9; Schatz GC, 2000, SCIENCE, V288, P1599, DOI 10.1126/science.288.5471.1599; SCHATZ GC, 1973, J CHEM PHYS, V58, P4023, DOI 10.1063/1.1679760; SCHATZ GC, 1975, J CHEM PHYS, V63, P685, DOI 10.1063/1.431391; SCHATZ GC, 1975, J CHEM PHYS, V63, P674, DOI 10.1063/1.431390; Schnieder L, 1997, J CHEM PHYS, V107, P6175, DOI 10.1063/1.474283; Skodje RT, 2000, PHYS REV LETT, V85, P1206, DOI 10.1103/PhysRevLett.85.1206; Skouteris D, 2000, COMPUT PHYS COMMUN, V133, P128, DOI 10.1016/S0010-4655(00)00167-3; Stark K, 1996, J CHEM PHYS, V104, P6515, DOI 10.1063/1.471372; Strazisar BR, 2000, SCIENCE, V290, P958, DOI 10.1126/science.290.5493.958; WERNER HJ, 1988, J CHEM PHYS, V89, P5803, DOI 10.1063/1.455556; WU SF, 1973, MOL PHYS, V25, P839, DOI 10.1080/00268977300100731; Xie T, 2002, J CHEM PHYS, V116, P7461, DOI 10.1063/1.1467328	32	265	275	11	299	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2006	311	5766					1440	1443		10.1126/science.1123452	http://dx.doi.org/10.1126/science.1123452			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527975				2022-12-28	WOS:000236029400042
J	Cusumano, G; Mangano, V; Chincarini, G; Panaitescu, A; Burrows, DN; LaParola, V; Sakamoto, T; Campana, S; Mineo, T; Tagliaferri, G; Angelini, L; Barthelemy, SD; Beardmore, AP; Boyd, PT; Cominsky, LR; Gronwall, C; Fenimore, EE; Gehrels, N; Giommi, P; Goad, M; Hurley, K; Kennea, JA; Mason, KO; Marshall, F; Meszaros, P; Nousek, JA; Osborne, JP; Palmer, DM; Roming, PWA; Wells, A; White, NE; Zhang, B				Cusumano, G; Mangano, V; Chincarini, G; Panaitescu, A; Burrows, DN; LaParola, V; Sakamoto, T; Campana, S; Mineo, T; Tagliaferri, G; Angelini, L; Barthelemy, SD; Beardmore, AP; Boyd, PT; Cominsky, LR; Gronwall, C; Fenimore, EE; Gehrels, N; Giommi, P; Goad, M; Hurley, K; Kennea, JA; Mason, KO; Marshall, F; Meszaros, P; Nousek, JA; Osborne, JP; Palmer, DM; Roming, PWA; Wells, A; White, NE; Zhang, B			Huge explosion in the early Universe	NATURE			English	Editorial Material									INAF Ist Astrofis Spaziale & Fis Cosm Palermo, I-90146 Palermo, Italy; INAF Osservatorio Astron Brera, I-23807 Merate, Italy; Univ Milano Bicocca, Dipartimento Fis, I-20126 Milan, Italy; Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Penn State Univ, Dept Astron & Astrophys, University Pk, PA 16802 USA; Penn State Univ, Dept Phys, University Pk, PA 16802 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; CNR, Washington, DC 20418 USA; Univ Leicester, Dept Phys & Astron, Leicester LE1 7RH, Leics, England; Sonoma State Univ, Dept Phys & Astron, Rohnert Pk, CA 94928 USA; ASI Sci Data Ctr, I-00044 Frascati, Italy; Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA; UCL, Mullard Space Sci Lab, Dorking RH5 6NT, Surrey, England; Univ Nevada, Dept Phys, Las Vegas, NV 89154 USA	Istituto Nazionale Astrofisica (INAF); Istituto Nazionale Astrofisica (INAF); University of Milano-Bicocca; United States Department of Energy (DOE); Los Alamos National Laboratory; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of Leicester; California State University System; Sonoma State University; Agenzia Spaziale Italiana (ASI); University of California System; University of California Berkeley; University of London; University College London; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas	Cusumano, G (corresponding author), INAF Ist Astrofis Spaziale & Fis Cosm Palermo, I-90146 Palermo, Italy.	cusumano@ifc.inaf.it	Boyd, Patricia/D-3274-2012; Campana, Sergio/AAL-6012-2020; Kennea, Jamie/AAF-2090-2019; Tagliaferri, Gianpiero/ABD-7556-2021; White, Nicholas/B-6428-2012; Gehrels, Neil/D-2971-2012; giommi, paolo/L-1006-2018	Campana, Sergio/0000-0001-6278-1576; Kennea, Jamie/0000-0002-6745-4790; Tagliaferri, Gianpiero/0000-0003-0121-0723; White, Nicholas/0000-0003-3853-3462; Cusumano, Giancarlo/0000-0002-8151-1990; Goad, Michael/0000-0002-2908-7360; Mineo, Teresa/0000-0002-4931-8445; Mangano, Vanessa/0000-0003-4262-8616; La Parola, Valentina/0000-0002-8087-6488; giommi, paolo/0000-0002-2265-5003; Beardmore, Andrew/0000-0001-5186-5950				Becker RH, 2001, ASTRON J, V122, P2850, DOI 10.1086/324231; BROMM V, IN PRESS ASTROPHYS J; Burrows DN, 2005, SCIENCE, V309, P1833, DOI 10.1126/science.1116168; KAWAI N, 2005, 3937 GCN; MacFadyen AI, 2001, ASTROPHYS J, V550, P410, DOI 10.1086/319698; MINEO T, 2005, 3920 GCN; NOUSEK JA, IN PRESS ASTROPHYS J; SAKAMOTO T, 2005, 3938 GCN; Tagliaferri G, 2005, ASTRON ASTROPHYS, V443, pL1, DOI 10.1051/0004-6361:200500196; ZHANG B, IN PRESS ASTROPHYS J	11	65	67	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2006	440	7081					164	164		10.1038/440164a	http://dx.doi.org/10.1038/440164a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019MC	16525462	Bronze			2022-12-28	WOS:000235839500032
J	Lange, PF; Wartosch, L; Jentsch, TJ; Fuhrmann, JC				Lange, PF; Wartosch, L; Jentsch, TJ; Fuhrmann, JC			ClC-7 requires Ostm1 as a beta-subunit to support bone resorption and lysosomal function	NATURE			English	Article							GREY-LETHAL MUTATION; AUTOSOMAL RECESSIVE OSTEOPETROSIS; MALIGNANT OSTEOPETROSIS; CL-CHANNELS; MOUSE; GENE; PROTEINS; DISEASE; ATPASE; LEADS	Mutations in ClC-7, a late endosomal/lysosomal member of the CLC family of chloride channels and transporters(1,2), cause osteopetrosis(3) and lysosomal storage disease(4) in humans and mice. Severe osteopetrosis is also observed with mutations in the OSTM1 gene, which encodes a membrane protein of unknown function(5). Here we show that both ClC-7 and Ostm1 proteins co-localize in late endosomes and lysosomes of various tissues, as well as in the ruffled border of bone-resorbing osteoclasts. Co-immunoprecipitations show that ClC-7 and Ostm1 form a molecular complex and suggest that Ostm1 is a beta-subunit of ClC-7. ClC-7 is required for Ostm1 to reach lysosomes, where the highly glycosylated Ostm1 luminal domain is cleaved. Protein but not RNA levels of ClC-7 are greatly reduced in grey-lethal mice, which lack Ostm1, suggesting that the ClC-7-Ostm1 interaction is important for protein stability. As ClC-7 protein levels in Ostm1-deficient tissues and cells, including osteoclasts, are decreased below 10% of normal levels, Ostm1 mutations probably cause osteopetrosis by impairing the acidification of the osteoclast resorption lacuna, which depends on ClC-7 (ref. 3). The finding that grey-lethal mice, just like ClC-7-deficient mice(4), show lysosomal storage and neurodegeneration in addition to osteopetrosis implies a more general importance for ClC-7-Ostm1 complexes.	Univ Hamburg, ZMNH, Zentrum Mol Neurobiol Hamburg, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Jentsch, TJ (corresponding author), Univ Hamburg, ZMNH, Zentrum Mol Neurobiol Hamburg, Falkenried 94, D-20246 Hamburg, Germany.	Jentsch@zmnh.uni-hamburg.de	Lange, Philipp F/E-5752-2011; Lange, Philipp F/AAB-9073-2020	Lange, Philipp F/0000-0003-1171-5864; Lange, Philipp F/0000-0003-1171-5864; Fuhrmann, Jens/0000-0001-5730-381X; Jentsch, Thomas/0000-0002-3509-2553				Accardi A, 2004, NATURE, V427, P803, DOI 10.1038/nature02314; Boyce BF, 2003, NAT MED, V9, P395, DOI 10.1038/nm0403-395; Brandt S, 1995, FEBS LETT, V377, P15, DOI 10.1016/0014-5793(95)01298-2; Chalhoub N, 2003, NAT MED, V9, P399, DOI 10.1038/nm842; Cleiren E, 2001, HUM MOL GENET, V10, P2861, DOI 10.1093/hmg/10.25.2861; Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962-8924(03)00005-9; Fischer T, 2003, P NATL ACAD SCI USA, V100, P8270, DOI 10.1073/pnas.1432965100; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; Frattini A, 2003, J BONE MINER RES, V18, P1740, DOI 10.1359/jbmr.2003.18.10.1740; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; Jentsch TJ, 2005, CURR OPIN NEUROBIOL, V15, P319, DOI 10.1016/j.conb.2005.05.002; Jentsch TJ, 2005, ANNU REV PHYSIOL, V67, P779, DOI 10.1146/annurev.physiol.67.032003.153245; Kasper D, 2005, EMBO J, V24, P1079, DOI 10.1038/sj.emboj.7600576; Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Picollo A, 2005, NATURE, V436, P420, DOI 10.1038/nature03720; Quarello P, 2004, J BONE MINER RES, V19, P1194, DOI 10.1359/JBMR.040407; Rajapurohitam V, 2001, BONE, V28, P513, DOI 10.1016/S8756-3282(01)00416-1; Ramirez A, 2004, HUM MUTAT, V23, P471, DOI 10.1002/humu.20028; Scheel O, 2005, NATURE, V436, P424, DOI [10.1038/nature03860, 10.1038/nature0386O]; Scimeca JC, 2000, BONE, V26, P207, DOI 10.1016/S8756-3282(99)00278-1; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Vacher J, 1999, MAMM GENOME, V10, P239, DOI 10.1007/s003359900980	26	252	261	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	2006	440	7081					220	223		10.1038/nature04535	http://dx.doi.org/10.1038/nature04535			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019MC	16525474	Bronze			2022-12-28	WOS:000235839500048
J	Ciccarelli, FD; Doerks, T; von Mering, C; Creevey, CJ; Snel, B; Bork, P				Ciccarelli, FD; Doerks, T; von Mering, C; Creevey, CJ; Snel, B; Bork, P			Toward automatic reconstruction of a highly resolved tree of life	SCIENCE			English	Article							HORIZONTAL GENE-TRANSFER; ANIMAL PHYLOGENY; EVOLUTION; GENOMES; ECDYSOZOA; BACTERIA; HISTORY; VIEW	We have developed an automatable procedure for reconstructing the tree of life with branch lengths comparable across all three domains. The tree has its basis in a concatenation of 31 orthologs occurring in 191 species with sequenced genomes. It revealed interdomain discrepancies in taxonomic classification. Systematic detection and subsequent exclusion of products of horizontal gene transfer increased phylogenetic resolution, allowing us to confirm accepted relationships and resolve disputed and preliminary classifications. For example, we place the phylum Acidobacteria as a sister group of delta-Proteobacteria, support a Gram-positive origin of Bacteria, and suggest a thermophilic last universal common ancestor.	European Mol Biol Lab, D-69012 Heidelberg, Germany; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Fdn Italiana Ric Cancro, Inst Mol Oncol Fdn, I-20139 Milan, Italy; Radboud Univ Nijmegen Med Ctr, Nijmegen Ctr Mol Life Sci, Ctr Mol & Biomol Informat, NL-6525 ED Nijmegen, Netherlands; Max Delbruck Ctr, D-13092 Berlin, Germany	European Molecular Biology Laboratory (EMBL); IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology; Radboud University Nijmegen; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Bork, P (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69012 Heidelberg, Germany.	peer.bork@embl.de	Creevey, Christopher James/A-1836-2013; Snel, Berend/B-8886-2011; von Mering, Christian/B-3300-2008; Bork, Peer/F-1813-2013; Puigbò, Pere/A-2214-2008; Ciccarelli, Francesca/D-5380-2014	Creevey, Christopher James/0000-0001-7183-1555; Snel, Berend/0000-0002-5804-8547; von Mering, Christian/0000-0001-7734-9102; Bork, Peer/0000-0002-2627-833X; Ciccarelli, Francesca/0000-0002-9325-0900				Adoutte A, 2000, P NATL ACAD SCI USA, V97, P4453, DOI 10.1073/pnas.97.9.4453; Andersson SGE, 1998, TRENDS MICROBIOL, V6, P263, DOI 10.1016/S0966-842X(98)01312-2; Brochier C, 2000, TRENDS GENET, V16, P529, DOI 10.1016/S0168-9525(00)02142-9; Brochier C, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-5-r42; Brown JR, 2001, NAT GENET, V28, P281, DOI 10.1038/90129; Daubin V, 2003, SCIENCE, V301, P829, DOI 10.1126/science.1086568; Delsuc F, 2005, NAT REV GENET, V6, P361, DOI 10.1038/nrg1603; Doolittle WF, 1999, SCIENCE, V284, P2124, DOI 10.1126/science.284.5423.2124; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; Gogarten JP, 2002, MOL BIOL EVOL, V19, P2226, DOI 10.1093/oxfordjournals.molbev.a004046; Halanych KM, 2004, ANNU REV ECOL EVOL S, V35, P229, DOI 10.1146/annurev.ecolsys.35.112202.130124; Hillis DM, 2003, SYST BIOL, V52, P124, DOI 10.1080/10635150390132911; Honda D, 1999, J MOL EVOL, V48, P723, DOI 10.1007/PL00006517; Hugenholtz P, 1998, J BACTERIOL, V180, P4765, DOI 10.1128/JB.180.18.4765-4774.1998; Jain R, 1999, P NATL ACAD SCI USA, V96, P3801, DOI 10.1073/pnas.96.7.3801; Koch AL, 2003, TRENDS MICROBIOL, V11, P166, DOI 10.1016/S0966-842X(03)00063-5; Konstantinidis KT, 2005, J BACTERIOL, V187, P6258, DOI 10.1128/JB.187.18.6258-6264.2005; Koonin EV, 1996, TRENDS GENET, V12, P334, DOI 10.1016/0168-9525(96)20010-1; Kreil DP, 2001, NUCLEIC ACIDS RES, V29, P1608, DOI 10.1093/nar/29.7.1608; Kurland CG, 2000, MICROBIOL MOL BIOL R, V64, P786, DOI 10.1128/MMBR.64.4.786-820.2000; Moran NA, 1996, P NATL ACAD SCI USA, V93, P2873, DOI 10.1073/pnas.93.7.2873; NAGELI KW, 1849, ALLG SCHWEIZ GES GES, V10, P45; Philip GK, 2005, MOL BIOL EVOL, V22, P1175, DOI 10.1093/molbev/msi102; Philippe H, 2005, MOL BIOL EVOL, V22, P1246, DOI 10.1093/molbev/msi111; Philippe H, 2003, CURR OPIN MICROBIOL, V6, P498, DOI 10.1016/j.mib.2003.09.008; Raible F, 2005, SCIENCE, V310, P1325, DOI 10.1126/science.1119089; Wildman DE, 2003, P NATL ACAD SCI USA, V100, P7181, DOI 10.1073/pnas.1232172100; Wolf YI, 1999, GENOME RES, V9, P689	28	1123	1174	8	257	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	2006	311	5765					1283	1287		10.1126/science.1123061	http://dx.doi.org/10.1126/science.1123061			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019XB	16513982	Green Submitted			2022-12-28	WOS:000235870400041
J	Houston, SD				Houston, SD			An example of preclassic Mayan writing?	SCIENCE			English	Editorial Material									Brown Univ, Dept Anthropol, Providence, RI 02912 USA	Brown University	Houston, SD (corresponding author), Brown Univ, Dept Anthropol, Providence, RI 02912 USA.	stephen_houston@brown.edu						HOUSTON S.D., 2004, 1 WRITING SCRIPT INV; Saturno WA, 2006, SCIENCE, V311, P1281, DOI 10.1126/science.1121745	2	5	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	2006	311	5765					1249	1250		10.1126/science.1122724	http://dx.doi.org/10.1126/science.1122724			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019XB	16513971				2022-12-28	WOS:000235870400028
J	Kling, J				Kling, J			Working the systems	SCIENCE			English	Editorial Material																			0	5	7	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	2006	311	5765					1305	1306		10.1126/science.311.5765.1305	http://dx.doi.org/10.1126/science.311.5765.1305			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019XB	16513987				2022-12-28	WOS:000235870400047
J	Dornelas, M; Connolly, SR; Hughes, TP				Dornelas, M; Connolly, SR; Hughes, TP			Coral reef diversity refutes the neutral theory of biodiversity	NATURE			English	Article							SPECIES-ABUNDANCE DISTRIBUTION; FOREST BIODIVERSITY; LONG-TERM; COMMUNITIES; ECOLOGY; HYPOTHESIS; STABILITY; MODEL	The global decline of coral reefs(1,2) highlights the need to understand the mechanisms that regulate community structure and sustain biodiversity in these systems. The neutral theory, which assumes that individuals are demographically identical regardless of species, seeks to explain ubiquitous features of community structure and biodiversity patterns(3-5). Here we present a test of neutral-theory predictions with the use of an extensive species-level data set of Indo-Pacific coral communities. We show that coral assemblages differ markedly from neutral-model predictions for patterns of community similarity and the relative abundance of species. Within local communities, neutral models do not fit relative abundance distributions as well as the classical log-normal distribution. Relative abundances of species across local communities also differ markedly from neutral-theory predictions: coral communities exhibit community similarity values that are far more variable, and lower on average, than the neutral theory can produce. Empirical community similarities deviate from the neutral model in a direction opposite to that predicted in previous critiques of the neutral theory(6-9). Instead, our results support spatio-temporal environmental stochasticity as a major driver of diversity patterns on coral reefs(10,11).	James Cook Univ N Queensland, ARC Ctr Excellence Coral Reef Studies, Townsville, Qld 4811, Australia; James Cook Univ N Queensland, Sch Marine Biol & Aquaculture, Townsville, Qld 4811, Australia	James Cook University; James Cook University	Dornelas, M (corresponding author), James Cook Univ N Queensland, ARC Ctr Excellence Coral Reef Studies, Townsville, Qld 4811, Australia.	maria.dornelas@jcu.edu.au	Connolly, Sean R./E-7773-2011; Dornelas, Maria/E-3595-2010; Hughes, Terry P/L-4721-2013	Connolly, Sean R./0000-0003-1537-0859; Dornelas, Maria/0000-0003-2077-7055; Hughes, Terry P/0000-0002-5257-5063				Adler PB, 2004, ECOLOGY, V85, P1265, DOI 10.1890/03-0602; Bell G, 2000, AM NAT, V155, P606, DOI 10.1086/303345; Bellwood DR, 2005, ECOL LETT, V8, P643, DOI 10.1111/j.1461-0248.2005.00763.x; Bellwood DR, 2004, NATURE, V429, P827, DOI 10.1038/nature02691; Chave J, 2004, ECOL LETT, V7, P241, DOI 10.1111/j.1461-0248.2003.00566.x; Chave J, 2002, THEOR POPUL BIOL, V62, P153, DOI 10.1006/tpbi.2002.1597; CHESSON P, 1989, TRENDS ECOL EVOL, V4, P293, DOI 10.1016/0169-5347(89)90024-4; Clark JS, 2003, NATURE, V423, P635, DOI 10.1038/nature01632; Connell JH, 2004, ECOL MONOGR, V74, P179, DOI 10.1890/02-4043; Connolly SR, 2005, SCIENCE, V309, P1363, DOI 10.1126/science.1113281; Engen S, 1996, MATH BIOSCI, V132, P169, DOI 10.1016/0025-5564(95)00054-2; Gilbert B, 2004, P NATL ACAD SCI USA, V101, P7651, DOI 10.1073/pnas.0400814101; Hubbell SP, 1997, CORAL REEFS, V16, pS9, DOI 10.1007/s003380050237; Hubbell Stephen P., 2001, V32, pi; Hughes TP, 2003, SCIENCE, V301, P929, DOI 10.1126/science.1085046; Karlson RH, 2004, NATURE, V429, P867, DOI 10.1038/nature02685; Legendre P., 2012, NUMERICAL ECOLOGY; Maurer BA, 2004, BASIC APPL ECOL, V5, P413, DOI 10.1016/j.baae.2004.08.006; McGill B, 2003, OIKOS, V102, P679, DOI 10.1034/j.1600-0706.2003.12617.x; McGill BJ, 2003, NATURE, V422, P881, DOI 10.1038/nature01583; MCGILL BJ, IN PRESS ECOLOGY; Pandolfi JM, 1996, PALEOBIOLOGY, V22, P152, DOI 10.1017/S0094837300016158; Pitman NCA, 2001, ECOLOGY, V82, P2101, DOI 10.1890/0012-9658(2001)082[2101:DADOTS]2.0.CO;2; Rickfeld RE, 2003, OIKOS, V100, P185, DOI 10.1034/j.1600-0706.2003.12018.x; Terborgh J, 1996, ECOLOGY, V77, P561, DOI 10.2307/2265630; Volkov I, 2004, NATURE, V427, P696, DOI 10.1038/427696a; Volkov I, 2003, NATURE, V424, P1035, DOI 10.1038/nature01883; Whitfield J, 2002, NATURE, V417, P480, DOI 10.1038/417480a; Williamson M, 2005, J ANIM ECOL, V74, P409, DOI 10.1111/j.1365-2656.2005.00936.x; Wootton JT, 2005, NATURE, V433, P309, DOI 10.1038/nature03211	30	186	190	2	135	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	2006	440	7080					80	82		10.1038/nature04534	http://dx.doi.org/10.1038/nature04534			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017HW	16511493				2022-12-28	WOS:000235685700043
J	Wachter, RM				Wachter, RM			The "dis-location" of U.S. medicine - The implications of medical outsourcing	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARE		Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wachter, RM (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.							Angus DC, 2000, JAMA-J AM MED ASSOC, V284, P2762, DOI 10.1001/jama.284.21.2762; Breslow MJ, 2004, CRIT CARE MED, V32, P1632; Breslow MJ, 2004, CRIT CARE MED, V32, P31, DOI 10.1097/01.CCM.0000104204.61296.41; Christensen CM, 2000, HARVARD BUS REV, V78, P102; Frieman T., 2005, WORLD IS FLAT BRIEF; HERZLINGER R, 1997, MARKET DRIVEN HLTH C	6	46	46	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 16	2006	354	7					661	665		10.1056/NEJMp058258	http://dx.doi.org/10.1056/NEJMp058258			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	012CP	16481632				2022-12-28	WOS:000235316100001
J	Wachter, RM				Wachter, RM			International teleradiology	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Kalyanpur A, 2004, RADIOLOGY, V232, P415, DOI 10.1148/radiol.2322021555; Kalyanpur Arjun, 2003, Emerg Radiol, V10, P115, DOI 10.1007/s10140-003-0284-5	2	26	26	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 16	2006	354	7					662	663		10.1056/NEJMp058286	http://dx.doi.org/10.1056/NEJMp058286			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	012CP	16481633				2022-12-28	WOS:000235316100002
J	Michels, KM; Hofman, KJ; Keusch, GT; Hrynkow, SH				Michels, KM; Hofman, KJ; Keusch, GT; Hrynkow, SH			Stigma and global health: looking forward	LANCET			English	Editorial Material									NIH, Fogarty Int Ctr, Div Int Training & Res, Bethesda, MD 20892 USA; NIH, Fogarty Int Ctr, Div Adv Studies & Policy Anal, Bethesda, MD 20892 USA; NIH, Fogarty Int Ctr, Off Director, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC); National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC); National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC)	Michels, KM (corresponding author), NIH, Fogarty Int Ctr, Div Int Training & Res, Bldg 10, Bethesda, MD 20892 USA.	mischelsk@mail.nih.gov		HOFMAN, KAREN/0000-0001-9512-7220; /0000-0001-5724-2965					0	12	12	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 11	2006	367	9509					538	539		10.1016/S0140-6736(06)68190-7	http://dx.doi.org/10.1016/S0140-6736(06)68190-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013FF	16473135				2022-12-28	WOS:000235394500039
J	Wailoo, K				Wailoo, K			Stigma, race, and disease in 20th century America	LANCET			English	Editorial Material									Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, Dept Hist, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Wailoo, K (corresponding author), Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, Dept Hist, New Brunswick, NJ 08901 USA.	kwailoo@history.rutgers.edu						Goffman E., 1963, BEHAV PUBLIC PLACES, P3; MILLER CJ, 1932, SOUTH MED J, V25, P734; MYRDAL G, 1964, AM DILEMMA, V1, P100; PAULING L, 1968, UCLA LAW REV, V15, P269; Postell William Dosite, 1951, HLTH SLAVES SO PLANT; STILES CW, 1909, SOUTH MED J, V2, P1125; WAILOO K, 1997, DRAWING BLOOD TECHNO, P138; Wailoo Keith, 2001, DYING CITY BLUES SIC	8	34	35	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 11	2006	367	9509					531	533		10.1016/S0140-6736(06)68186-5	http://dx.doi.org/10.1016/S0140-6736(06)68186-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	013FF	16473131				2022-12-28	WOS:000235394500035
J	Lakhani, SA; Masud, A; Kuida, K; Porter, GA; Booth, CJ; Mehal, WZ; Inayat, I; Flavell, RA				Lakhani, SA; Masud, A; Kuida, K; Porter, GA; Booth, CJ; Mehal, WZ; Inayat, I; Flavell, RA			Caspases 3 and 7: Key mediators of mitochondrial events of apoptosis	SCIENCE			English	Article							CELL-DEATH; ACTIVATION; DISRUPTION; CLEAVAGE; COMPLEX; CPP32; MICE	The current model of apoptosis holds that upstream signals lead to activation of downstream effector caspases. We generated mice deficient in the two effectors, caspase 3 and caspase 7, which died immediately after birth with defects in cardiac development. Fibroblasts lacking both enzymes were highly resistant to both mitochondrial and death receptor-mediated apoptosis, displayed preservation of mitochondrial membrane potential, and had defective nuclear translocation of apoptosis-inducing factor (AIF). Furthermore, the early apoptotic events of Bax translocation and cytochrome c release were also delayed. We conclude that caspases 3 and 7 are critical mediators of mitochondrial events of apoptosis.	Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; Yale Univ, Sch Med, Comparat Med Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA; Vertex Pharmaceut, Cambridge, MA 02139 USA	Yale University; Yale University; Yale University; Yale University; Howard Hughes Medical Institute; Yale University; Vertex Pharmaceuticals	Flavell, RA (corresponding author), Yale Univ, Sch Med, Immunobiol Sect, 333 Cedar St, New Haven, CT 06520 USA.	richard.flavell@yale.edu	George A, Porter/E-7315-2013	George A, Porter/0000-0003-0726-9988; Lakhani, Saquib/0000-0003-3235-3460	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD000850, K12HD001401] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD044580] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002965, P30DK034989] Funding Source: NIH RePORTER; NICHD NIH HHS [K12 HD00850, K12 HD001401, K08 HD044580, K12 HD000850, 1 K08 HD044580, 5 K12 HD01401] Funding Source: Medline; NIDDK NIH HHS [NIDDK P30-34989, K08 DK002965, K08 DK002965-04] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cande C, 2004, CELL DEATH DIFFER, V11, P591, DOI 10.1038/sj.cdd.4401400; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Hausmann G, 2000, J CELL BIOL, V149, P623, DOI 10.1083/jcb.149.3.623; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Leonard JR, 2002, J NEUROPATH EXP NEUR, V61, P673, DOI 10.1093/jnen/61.8.673; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343	21	876	925	7	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	2006	311	5762					847	851		10.1126/science.1115035	http://dx.doi.org/10.1126/science.1115035			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XT	16469926	Green Accepted			2022-12-28	WOS:000235374900048
J	Jones, N; Blasutig, IM; Eremina, V; Ruston, JM; Bladt, F; Li, HP; Huang, HM; Larose, L; Li, SSC; Takano, T; Quaggin, SE; Pawson, T				Jones, N; Blasutig, IM; Eremina, V; Ruston, JM; Bladt, F; Li, HP; Huang, HM; Larose, L; Li, SSC; Takano, T; Quaggin, SE; Pawson, T			Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes	NATURE			English	Article							CONGENITAL NEPHROTIC SYNDROME; SLIT DIAPHRAGM; MICE LACKING; FAMILY; DEFICIENT; DISEASE; KINASE; GENE; FYN; ALPHA-ACTININ-4	The glomerular filtration barrier in the kidney is formed in part by a specialized intercellular junction known as the slit diaphragm, which connects adjacent actin-based foot processes of kidney epithelial cells (podocytes)(1). Mutations affecting a number of slit diaphragm proteins, including nephrin ( encoded by NPHS1)(2), lead to renal disease owing to disruption of the filtration barrier and rearrangement of the actin cytoskeleton(3), although the molecular basis for this is unclear. Here we show that nephrin selectively binds the Src homology 2 (SH2)/SH3 domain-containing Nck adaptor proteins(4), which in turn control the podocyte cytoskeleton in vivo. The cytoplasmic tail of nephrin has multiple YDxV sites that form preferred bindingmotifs for the Nck SH2 domain once phosphorylated by Src-family kinases. We show that this Nck - nephrin interaction is required for nephrin-dependent actin reorganization. Selective deletion of Nck from podocytes of transgenic mice results in defects in the formation of foot processes and in congenital nephrotic syndrome. Together, these findings identify a physiological signalling pathway in which nephrin is linked through phosphotyrosine-based interactions to Nck adaptors, and thus to the underlying actin cytoskeleton in podocytes. Simple and widely expressed SH2/SH3 adaptor proteins can therefore direct the formation of a specialized cellular morphology in vivo.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada; McGill Univ Hlth Ctr, Dept Med, Montreal, PQ H3A 2B4, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; St Michaels Hosp, Div Nephrol, Toronto, ON M5B 1W8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; McGill University; Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Pawson, T (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	pawson@mshri.on.ca	Pawson, Tony J/E-4578-2013	Blasutig, Ivan/0000-0001-7310-2647				Benzing T, 2004, J AM SOC NEPHROL, V15, P1382, DOI 10.1097/01.ASN.0000130167.30769.55; Bladt F, 2003, MOL CELL BIOL, V23, P4586, DOI 10.1128/MCB.23.13.4586-4597.2003; Buday L, 2002, CELL SIGNAL, V14, P723, DOI 10.1016/S0898-6568(02)00027-X; Chen M, 1998, J BIOL CHEM, V273, P25171, DOI 10.1074/jbc.273.39.25171; Ciani L, 2003, MOL CELL BIOL, V23, P3575, DOI 10.1128/MCB.23.10.3575-3582.2003; Donoviel DB, 2001, MOL CELL BIOL, V21, P4829, DOI 10.1128/MCB.21.14.4829-4836.2001; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Gruenheid S, 2001, NAT CELL BIOL, V3, P856, DOI 10.1038/ncb0901-856; Huber TB, 2003, MOL CELL BIOL, V23, P4917, DOI 10.1128/MCB.23.14.4917-4928.2003; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Kos CH, 2003, J CLIN INVEST, V111, P1683, DOI 10.1172/JCI200317988; Kreidberg JA, 1996, DEVELOPMENT, V122, P3537; Lahdenpera J, 2003, KIDNEY INT, V64, P404, DOI 10.1046/j.1523-1755.2003.00097.x; Lehtonen S, 2005, P NATL ACAD SCI USA, V102, P9814, DOI 10.1073/pnas.0504166102; Li H, 2004, J AM SOC NEPHROL, V15, P3006, DOI 10.1097/01.ASN.0000146689.88078.80; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Oh J, 2004, PEDIATR NEPHROL, V19, P130, DOI 10.1007/s00467-003-1367-y; Pavenstadt H, 2003, PHYSIOL REV, V83, P253, DOI 10.1152/physrev.00020.2002; Putaala H, 2000, J AM SOC NEPHROL, V11, P991, DOI 10.1681/ASN.V116991; Putaala H, 2001, HUM MOL GENET, V10, P1, DOI 10.1093/hmg/10.1.1; Rantanen M, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000016142.29721.22; Rivera GM, 2004, CURR BIOL, V14, P11, DOI 10.1016/j.cub.2003.12.033; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Roselli S, 2004, MOL CELL BIOL, V24, P550, DOI 10.1128/MCB.24.2.550-560.2004; Ruotsalainen V, 1999, P NATL ACAD SCI USA, V96, P7962, DOI 10.1073/pnas.96.14.7962; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Verma R, 2003, J BIOL CHEM, V278, P20716, DOI 10.1074/jbc.M301689200; Welsch T, 2001, AM J PHYSIOL-RENAL, V281, pF769, DOI 10.1152/ajprenal.2001.281.4.F769; Yu CCK, 2001, CURR BIOL, V11, P34, DOI 10.1016/S0960-9822(00)00024-5	30	358	375	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 6	2006	440	7085					818	823		10.1038/nature04662	http://dx.doi.org/10.1038/nature04662			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	029GH	16525419	Bronze			2022-12-28	WOS:000236548400046
J	Shiow, LR; Rosen, DB; Brdickova, N; Xu, Y; An, JP; Lanier, LL; Cyster, JG; Matloubian, M				Shiow, LR; Rosen, DB; Brdickova, N; Xu, Y; An, JP; Lanier, LL; Cyster, JG; Matloubian, M			CD69 acts downstream of interferon-alpha/beta to inhibit S1P(1) and lymphocyte egress from lymphoid organs	NATURE			English	Article							SPHINGOSINE 1-PHOSPHATE RECEPTOR-1; T-CELLS; EXPRESSION; MICE; ACTIVATION; LIGAND; SEQUESTRATION; EMIGRATION; THYMOCYTES; INDUCTION	Naive lymphocytes continually enter and exit lymphoid organs in a recirculation process that is essential for immune surveillance. During immune responses, the egress process can be shut down transiently(1). When this occurs locally it increases lymphocyte numbers in the responding lymphoid organ; when it occurs systemically it can lead to immunosuppression as a result of the depletion of recirculating lymphocytes. Several mediators of the innate immune system are known to cause shutdown, including interferon alpha/beta (IFN-alpha/beta) and tumour necrosis factor(2-5), but the mechanism has been unclear. Here we show that treatment with the IFN-alpha/beta inducer polyinosine polycytidylic acid (hereafter 'poly(I:C)') inhibited egress by a mechanism that was partly lymphocyte-intrinsic. The transmembrane C-type lectin CD69 was rapidly induced and CD69(-/-) cells were poorly retained in lymphoid tissues after treatment with poly(I:C) or infection with lymphocytic choriomeningitis virus. Lymphocyte egress requires sphingosine 1-phosphate receptor-1 (S1P(1)), and IFN-alpha/beta was found to inhibit lymphocyte responsiveness to S1P. By contrast, CD69(-/-) cells retained S1P(1) function after exposure to IFN-alpha/beta. In coexpression experiments, CD69 inhibited S1P(1) chemotactic function and led to downmodulation of S1P(1). In a reporter assay, S1P(1) crosslinking led to co-crosslinking and activation of a CD69-CD3 zeta chimaera. CD69 co-immunoprecipitated with S1P(1) but not the related receptor, S1P(3). These observations indicate that CD69 forms a complex with and negatively regulates S1P(1) and that it functions downstream of IFN-alpha/beta, and possibly other activating stimuli, to promote lymphocyte retention in lymphoid organs.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Biomed Sci Grad Program, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Cyster, JG (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.	jason.cyster@ucsf.edu; mehrdad.matloubian@ucsf.edu	Lanier, Lewis L/E-2139-2014	Lanier, Lewis L/0000-0003-1308-3952				Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Arase H, 2002, SCIENCE, V296, P1323, DOI 10.1126/science.1070884; Bikah G, 2000, NAT IMMUNOL, V1, P402, DOI 10.1038/80841; Brinkmann V, 2004, AM J TRANSPLANT, V4, P1019, DOI 10.1111/j.1600-6143.2004.00476.x; CHU P, 2003, J BIOL, V2; Cinamon G, 2004, NAT IMMUNOL, V5, P713, DOI 10.1038/ni1083; DEGRE M, 1973, P SOC EXP BIOL MED, V142, P1087; Esplugues E, 2003, J EXP MED, V197, P1093, DOI 10.1084/jem.20021337; Feng CG, 2002, INT IMMUNOL, V14, P535, DOI 10.1093/intimm/dxf020; Graeler M, 2002, FASEB J, V16, P1874, DOI 10.1096/fj.02-0548com; HALL JG, 1965, BRIT J EXP PATHOL, V46, P450; Kalaaji A N, 1988, Reg Immunol, V1, P56; KORNGOLD R, 1983, J IMMUNOL, V130, P2236; Lauzurica P, 2000, BLOOD, V95, P2312, DOI 10.1182/blood.V95.7.2312.007k16_2312_2320; Lo CG, 2005, J EXP MED, V201, P291, DOI 10.1084/jem.20041509; LOPEZCABRERA M, 1995, J BIOL CHEM, V270, P21545, DOI 10.1074/jbc.270.37.21545; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Murata K, 2003, INT IMMUNOL, V15, P987, DOI 10.1093/intimm/dxg102; Nakayama T, 2002, J IMMUNOL, V168, P87, DOI 10.4049/jimmunol.168.1.87; RAMIREZ R, 1994, J EXP MED, V180, P1147, DOI 10.1084/jem.180.3.1147; RISSO A, 1991, J IMMUNOL, V146, P4105; Rosen DB, 2005, J IMMUNOL, V175, P7796, DOI 10.4049/jimmunol.175.12.7796; Rosen H, 2003, P NATL ACAD SCI USA, V100, P10907, DOI 10.1073/pnas.1832725100; Rosen H, 2003, CURR OPIN CHEM BIOL, V7, P461, DOI 10.1016/S1367-5931(03)00085-1; Sancho D, 2005, TRENDS IMMUNOL, V26, P136, DOI 10.1016/j.it.2004.12.006; Sancho D, 2000, J IMMUNOL, V165, P3868, DOI 10.4049/jimmunol.165.7.3868; Schwab SR, 2005, SCIENCE, V309, P1735, DOI 10.1126/science.1113640; TESTI R, 1994, IMMUNOL TODAY, V15, P479, DOI 10.1016/0167-5699(94)90193-7; Young AJ, 2000, EUR J IMMUNOL, V30, P327, DOI 10.1002/1521-4141(200001)30:1<327::AID-IMMU327>3.3.CO;2-K	30	838	866	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 23	2006	440	7083					540	544		10.1038/nature04606	http://dx.doi.org/10.1038/nature04606			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	024DV	16525420				2022-12-28	WOS:000236176100058
J	Brown, S; Reynolds, NJ				Brown, S; Reynolds, NJ			Atopic and non-atopic eczema	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CONTROLLED-TRIAL; THYMIC STROMAL LYMPHOPOIETIN; INFLAMMATORY-BOWEL-DISEASE; SERINE-PROTEASE INHIBITOR; PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; DOUBLE-BLIND; MYCOPHENOLATE-MOFETIL; SUSCEPTIBILITY LOCI; DIAGNOSTIC-CRITERIA		Newcastle Univ, Sch Med, Sch Clin & Lab Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Royal Victoria Infirm, Dept Dermatol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Reynolds, NJ (corresponding author), Newcastle Univ, Sch Med, Sch Clin & Lab Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	N.J.Reynolds@ncl.ac.uk		Reynolds, Nick/0000-0002-6484-825X; Brown, Sara/0000-0002-3232-5251				Abramovits W, 2005, J AM ACAD DERMATOL, V53, pS86, DOI 10.1016/j.jaad.2005.04.034; Akdis M, 2005, J ALLERGY CLIN IMMUN, V116, P961, DOI 10.1016/j.jaci.2005.09.004; Annus T, 2005, PEDIAT ALLERG IMM-UK, V16, P315, DOI 10.1111/j.1399-3038.2005.00276.x; Anstey AV, 2004, BRIT J DERMATOL, V151, P1123, DOI 10.1111/j.1365-2133.2004.06323.x; Arima K, 2002, J ALLERGY CLIN IMMUN, V109, P980, DOI 10.1067/mai.2002.124656; Ashcroft DM, 2005, BMJ-BRIT MED J, V330, P516, DOI 10.1136/bmj.38376.439653.D3; Barnetson RS, 2002, BRIT MED J, V324, P1376, DOI 10.1136/bmj.324.7350.1376; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Beltrani VS, 2005, CURR OPIN ALLERGY CL, V5, P413, DOI 10.1097/01.all.0000182544.37724.b5; Ben-Gashir MA, 2004, J AM ACAD DERMATOL, V50, P349, DOI 10.1016/j.jaad.2003.09.004; Benjamin K, 2004, J AM ACAD DERMATOL, V50, P33, DOI 10.1016/S0190-9622(03)02480-0; Berth-Jones J, 2003, BRIT MED J, V326, P1367, DOI 10.1136/bmj.326.7403.1367; Berth-Jones J, 2002, BRIT J DERMATOL, V147, P324, DOI 10.1046/j.1365-2133.2002.04989.x; Bohme M, 2003, CLIN EXP ALLERGY, V33, P1226, DOI 10.1046/j.1365-2222.2003.01749.x; Bradley M, 2002, HUM MOL GENET, V11, P1539, DOI 10.1093/hmg/11.13.1539; Chamlin SL, 2005, J INVEST DERMATOL, V125, P1106, DOI 10.1111/j.0022-202X.2005.23911.x; Chamlin SL, 2004, PEDIATRICS, V114, P607, DOI 10.1542/peds.2004-0374; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; COLEMAN R, 1993, LANCET, V341, P1121, DOI 10.1016/0140-6736(93)93130-S; CONNELL WR, 1994, LANCET, V343, P1249, DOI 10.1016/S0140-6736(94)92150-4; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Cookson WOCM, 2001, NAT GENET, V27, P372, DOI 10.1038/86867; Cooper D, 2004, J INVEST DERMATOL, V123, P1086, DOI 10.1111/j.0022-202X.2004.23484.x; DIEPGEN TL, 2000, EPIDEMIOLOGY ATOPIC, P96; Dotterud LK, 1999, ACTA DERM-VENEREOL, V79, P448; EPINETTE WW, 1987, J AM ACAD DERMATOL, V17, P962, DOI 10.1016/S0190-9622(87)70285-0; Esche C, 2004, CURR ALLERGY ASTHM R, V4, P276, DOI 10.1007/s11882-004-0071-8; Evans WE, 2001, J CLIN ONCOL, V19, P2293, DOI 10.1200/JCO.2001.19.8.2293; Farrall M, 2005, HUM MOL GENET, V14, pR157, DOI 10.1093/hmg/ddi273; Farrall M, 2004, HUM MOL GENET, V13, pR1, DOI 10.1093/hmg/ddh084; Flohr C, 2004, J ALLERGY CLIN IMMUN, V114, P150, DOI 10.1016/j.jaci.2004.04.027; Fohr C, 2005, BRIT J DERMATOL, V152, P202, DOI [10.1111/J.1365-2133.2005.06436.X, 10.1111/j.1365-2133.2004.06436.x]; Foley P, 2001, ARCH DERMATOL, V137, P293; Folster-Holst R, 2005, BRIT J DERMATOL, V152, P1365, DOI 10.1111/j.1365-2133.2005.06602.x; Fonacier L, 2005, J ALLERGY CLIN IMMUN, V115, P1249, DOI 10.1016/j.jaci.2005.04.006; Friedmann PS, 2004, ROOKS TXB DERMATOLOG; Garside R, 2005, Health Technol Assess, V9, pxi; Garside R, 2005, HEALTH TECHNOL ASSES, V9, P1; Garside R, 2005, HEALTH TECHNOL ASSES, V9, pxi; Girolomoni G, 2003, ALLERGY, V58, P420, DOI 10.1034/j.1398-9995.2003.00112.x; Granlund H, 1998, ACTA DERM-VENEREOL, V78, P40; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Grundmann-Kollman M, 2001, ARCH DERMATOL, V137, P870; Gutgesell C, 2001, BRIT J DERMATOL, V145, P70, DOI 10.1046/j.1365-2133.2001.04283.x; Guzik TJ, 2005, CLIN EXP ALLERGY, V35, P448, DOI 10.1111/j.1365-2222.2005.02210.x; Haagerup A, 2004, ACTA DERM-VENEREOL, V84, P346, DOI 10.1080/00015550410034426; Hahn EL, 2005, IMMUNOL ALLERGY CLIN, V25, P231, DOI 10.1016/j.iac.2005.02.004; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; Hanifin JM, 2004, J AM ACAD DERMATOL, V50, P391, DOI 10.1016/j.jaad.2003.08.003; Hara J, 2000, J INVEST DERMATOL, V115, P406, DOI 10.1046/j.1523-1747.2000.00072.x; Harper JI, 2000, BRIT J DERMATOL, V142, P52, DOI 10.1046/j.1365-2133.2000.03241.x; Harris JM, 2001, BRIT J DERMATOL, V144, P795, DOI 10.1046/j.1365-2133.2001.04135.x; Hashizume H, 2005, BRIT J DERMATOL, V152, P1161, DOI 10.1111/j.1365-2133.2005.06449.x; Hirschhorn JN, 2005, NAT REV GENET, V6, P95, DOI 10.1038/nrg1521; Hoare C, 2000, Health Technol Assess, V4, P1; HOARE C, 2000, HLTH TECHNOL ASSESS, V4; Hoffjan S, 2005, J MOL MED, V83, P682, DOI 10.1007/s00109-005-0672-2; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; Iwanaga T, 2004, CLIN EXP ALLERGY, V34, P1037, DOI 10.1111/j.1365-2222.2004.02000.x; Johnke H, 2005, BRIT J DERMATOL, V153, P352, DOI 10.1111/j.1365-2133.2005.06491.x; JONES EL, 1975, J INVEST DERMATOL, V65, P537, DOI 10.1111/1523-1747.ep12610346; Kabesch M, 2004, CLIN EXP ALLERGY, V34, P340, DOI 10.1111/j.1365-2222.2004.01860.x; Kaiser HB, 2004, ALLERGY ASTHMA PROC, V25, P7; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kato A, 2003, BRIT J DERMATOL, V148, P665, DOI 10.1046/j.1365-2133.2003.05243.x; Kemp AS, 2003, PHARMACOECONOMICS, V21, P105, DOI 10.2165/00019053-200321020-00003; Kirby B, 2002, J AM ACAD DERMATOL, V47, pS165, DOI 10.1067/mjd.2002.106357; Komatsu N, 2002, J INVEST DERMATOL, V118, P436, DOI 10.1046/j.0022-202x.2001.01663.x; Kozma GT, 2002, ALLERGY, V57, P160, DOI 10.1034/j.1398-9995.2002.1s3361.x; Kramer MS, 2003, COCHRANE DB SYST REV; Krutmann J, 1998, J AM ACAD DERMATOL, V38, P589, DOI 10.1016/S0190-9622(98)70123-9; Kwon JH, 2005, CRIT REV ONCOL HEMAT, V56, P169, DOI 10.1016/j.critrevonc.2005.02.004; LARSEN FS, 1993, J AM ACAD DERMATOL, V28, P719, DOI 10.1016/0190-9622(93)70099-F; LARSEN FS, 1986, J AM ACAD DERMATOL, V15, P487; Laughter D, 2000, J AM ACAD DERMATOL, V43, P649, DOI 10.1067/mjd.2000.107773; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; Legat FJ, 2003, ARCH DERMATOL, V139, P223, DOI 10.1001/archderm.139.2.223; Lehmann HS, 2004, INT ARCH ALLERGY IMM, V135, P306, DOI 10.1159/000082324; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Leung DYM, 2003, CURR OPIN PEDIATR, V15, P399, DOI 10.1097/00008480-200308000-00008; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Leung DYM, 2001, J AM ACAD DERMATOL, V44, pS1, DOI 10.1067/mjd.2001.109815; Lewis-Jones S, 2001, HOSP MED, V62, P136, DOI 10.12968/hosp.2001.62.3.1531; Li M, 2005, P NATL ACAD SCI USA, V102, P14795, DOI 10.1073/pnas.0507385102; Lucky AW, 1997, PEDIATR DERMATOL, V14, P321, DOI 10.1111/j.1525-1470.1997.tb00968.x; Ludvigsson JF, 2005, PEDIAT ALLERG IMM-UK, V16, P201, DOI 10.1111/j.1399-3038.2005.00257.x; Majamaa H, 2001, PEDIAT ALLERG IMM-UK, V12, P283, DOI 10.1034/j.1399-3038.2001.00096.x; Meggitt SJ, 2006, LANCET, V367, P839, DOI 10.1016/S0140-6736(06)68340-2; Meggitt SJ, 2001, CLIN EXP DERMATOL, V26, P369, DOI 10.1046/j.1365-2230.2001.00837.x; MEGGITT SJ, 2006, IN PRESS LANCET; Moore MM, 2004, PEDIATRICS, V113, P468, DOI 10.1542/peds.113.3.468; MORAR N, 2006, J INVEST DERMATOL; Morar N, 2006, J INVEST DERMATOL, V126, P603, DOI 10.1038/sj.jid.5700108; MUDDE GC, 1990, IMMUNOLOGY, V69, P335; Murphy LA, 2002, BRIT J DERMATOL, V147, P308, DOI 10.1046/j.1365-2133.2002.04922.x; Neuber K, 2000, BRIT J DERMATOL, V143, P385, DOI 10.1046/j.1365-2133.2000.03667.x; Nickel RG, 2000, J IMMUNOL, V164, P1612, DOI 10.4049/jimmunol.164.3.1612; Nishio Y, 2003, GENES IMMUN, V4, P515, DOI 10.1038/sj.gene.6363889; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Novak N, 2005, J ALLERGY CLIN IMMUN, V115, P828, DOI 10.1016/j.jaci.2005.01.030; Olesen AB, 2005, ACTA DERM-VENEREOL, V85, P244, DOI 10.1080/00015550510026343; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Popescu CM, 1998, BRIT J DERMATOL, V138, P436, DOI 10.1046/j.1365-2133.1998.02121.x; Reitamo S, 2005, BRIT J DERMATOL, V152, P1282, DOI 10.1111/j.1365-2133.2005.06592.x; Reynolds NJ, 2001, LANCET, V357, P2012, DOI 10.1016/S0140-6736(00)05114-X; Riedi CA, 2005, J INVEST ALLERG CLIN, V15, P183; Robert C, 1999, NEW ENGL J MED, V341, P1817, DOI 10.1056/NEJM199912093412407; Roehr CC, 2001, J ALLERGY CLIN IMMUN, V107, P548, DOI 10.1067/mai.2001.112849; Rosenfeldt V, 2003, J ALLERGY CLIN IMMUN, V111, P389, DOI 10.1067/mai.2003.389; Saito H, 2005, INT ARCH ALLERGY IMM, V137, P319, DOI 10.1159/000086464; SALEK MS, 1993, BRIT J DERMATOL, V129, P422, DOI 10.1111/j.1365-2133.1993.tb03170.x; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; Shamssain MH, 1999, ARCH DIS CHILD, V81, P313, DOI 10.1136/adc.81.4.313; Shimizu M, 2005, HUM MOL GENET, V14, P2919, DOI 10.1093/hmg/ddi323; Sinha A, 2004, ACTA DERM-VENEREOL, V84, P327, DOI 10.1080/00015550410025967; Soderhall C, 2001, HUM GENET, V109, P129, DOI 10.1007/s004390100556; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; Sugiura H, 2005, BRIT J DERMATOL, V152, P146, DOI 10.1111/J.1365-2133.2005.06352.X; Takahashi N, 2005, HUM MOL GENET, V14, P3149, DOI 10.1093/hmg/ddi347; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Tazawa T, 2004, ARCH DERMATOL RES, V295, P459, DOI 10.1007/s00403-004-0455-6; Thomas KS, 2002, BRIT MED J, V324, P768, DOI 10.1136/bmj.324.7340.768; Trautmann A, 2000, APOPTOSIS, V5, P425, DOI 10.1023/A:1009620329213; Vasilopoulos Y, 2004, J INVEST DERMATOL, V123, P62, DOI 10.1111/j.0022-202X.2004.22708.x; Veal CD, 2005, J INVEST DERMATOL, V125, P399, DOI 10.1111/j.0022-202X.2005.23828.x; Verhagen J, 2006, J ALLERGY CLIN IMMUN, V117, P176, DOI 10.1016/j.jaci.2005.10.040; Wadonda-Kabondo N, 2003, BRIT J DERMATOL, V149, P1023, DOI 10.1111/j.1365-2133.2003.05605.x; Wadonda-Kabondo N, 2004, ARCH DIS CHILD, V89, P917, DOI 10.1136/adc.2003.034033; Walley AJ, 2001, NAT GENET, V29, P175, DOI 10.1038/ng728; Weidinger S, 2005, J ALLERGY CLIN IMMUN, V116, P177, DOI 10.1016/j.jaci.2005.02.034; Weidinger S, 2005, ALLERGY, V60, P1256, DOI 10.1111/j.1398-9995.2005.00879.x; Williams HC, 2005, NEW ENGL J MED, V352, P2314, DOI 10.1056/NEJMcp042803; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; WILLIAMS HC, 1995, J AM ACAD DERMATOL, V32, P212, DOI 10.1016/0190-9622(95)90128-0; Williams P. H., 1996, WORLD CONSERV, V1, P12; Wollenberg A, 2002, J INVEST DERMATOL, V119, P1096, DOI 10.1046/j.1523-1747.2002.19515.x; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Wright RJ, 2005, CURR OPIN ALLERGY CL, V5, P23, DOI 10.1097/00130832-200502000-00006; Wuthrich B, 2002, ALLERGY, V57, P267, DOI 10.1034/j.1398-9995.2002.1n3572.x; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zutavern A, 2005, CLIN EXP ALLERGY, V35, P1301, DOI 10.1111/j.1365-2222.2005.02350.x	145	52	63	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 11	2006	332	7541					584	588F		10.1136/bmj.332.7541.584	http://dx.doi.org/10.1136/bmj.332.7541.584			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	026CN	16528081	Green Published			2022-12-28	WOS:000236314400017
J	Daffonchio, D; Borin, S; Brusa, T; Brusetti, L; van der Wielen, PWJJ; Bolhuis, H; Yakimov, MM; D'Auria, G; Giuliano, L; Marty, D; Tamburini, C; McGenity, TJ; Hallsworth, JE; Sass, AM; Timmis, KN; Tselepides, A; de Lange, GJ; Hubner, A; Thomson, J; Varnavas, SP; Gasparoni, F; Gerber, HW; Malinverno, E; Corselli, C; Garcin, J; McKew, B; Golyshin, PN; Lampadariou, N; Polymenakou, P; Calore, D; Cenedese, S; Zanon, F; Hoog, S				Daffonchio, D; Borin, S; Brusa, T; Brusetti, L; van der Wielen, PWJJ; Bolhuis, H; Yakimov, MM; D'Auria, G; Giuliano, L; Marty, D; Tamburini, C; McGenity, TJ; Hallsworth, JE; Sass, AM; Timmis, KN; Tselepides, A; de Lange, GJ; Hubner, A; Thomson, J; Varnavas, SP; Gasparoni, F; Gerber, HW; Malinverno, E; Corselli, C; Garcin, J; McKew, B; Golyshin, PN; Lampadariou, N; Polymenakou, P; Calore, D; Cenedese, S; Zanon, F; Hoog, S		Biodeep Sci Party	Stratified prokaryote network in the oxic-anoxic transition of a deep-sea halocline	NATURE			English	Article							BRINE-SEAWATER INTERFACE; RNA GENE-SEQUENCES; KEBRIT DEEP; DIVERSITY; SEDIMENTS; COMMUNITY; BACTERIA; BASINS; SULFUR; TYRO	The chemical composition of the Bannock basin has been studied in some detail(1,2). We recently showed that unusual microbial populations, including a new division of Archaea (MSBL1)(3), inhabit the NaCl-rich hypersaline brine. High salinities tend to reduce biodiversity(4), but when brines come into contact with fresher water the natural haloclines formed frequently contain gradients of other chemicals, including permutations of electron donors and acceptors, that may enhance microbial diversity, activity and biogeochemical cycling(5,6). Here we report a 2.5-m-thick chemocline with a steep NaCl gradient at 3.3 km within the water column between Bannock anoxic hypersaline brine(7) and overlying sea water. The chemocline supports some of the most biomass-rich and active microbial communities in the deep sea, dominated by Bacteria rather than Archaea, and including four major new divisions of Bacteria. Significantly higher metabolic activities were measured in the chemocline than in the overlying sea water and underlying brine; functional analyses indicate that a range of biological processes is likely to occur in the chemocline. Many prokaryotic taxa, including the phylogenetically new groups, were confined to defined salinities, and collectively formed a diverse, sharply stratified, deep-sea ecosystem with sufficient biomass to potentially contribute to organic geological deposits.	Univ Milan, DiSTAM, CoNISMa, I-20133 Milan, Italy; Univ Groningen, CEES, Dept Microbial Ecol, NL-9751 NN Haren, Netherlands; CNR, Ist Ambiente Marino Costiero, I-98122 Messina, Italy; Univ Mediterranee, CNRS, UMR 6117, LMGEM, F-13288 Marseille, France; Univ Essex, Dept Biol Sci, Colchester CO4 3SQ, Essex, England; GBF, Div Microbiol, D-38122 Braunschweig, Germany; Inst Marine Biol Crete, Iraklion 71003, Greece; Univ Utrecht, Fac Geosci, NL-3584 CD Utrecht, Netherlands; Southampton Oceanog Ctr, Southampton SO14 3EE, Hants, England; Univ Patras, Dept Geol, Patras 26100, Greece; Tecnomare SpA, ENI Grp, I-30124 Venice, Italy; Univ Appl Sci, Tech Fachhsch Berlin, D-13353 Berlin, Germany; Univ Milano Bicocca, DGSG, CoNISMa, I-20126 Milan, Italy	CoNISMa; University of Milan; University of Groningen; Consiglio Nazionale delle Ricerche (CNR); L'Istituto per l'Ambiente Marino Costiero (IAMC-CNR); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Essex; Helmholtz Association; Helmholtz-Center for Infection Research; Utrecht University; NERC National Oceanography Centre; University of Southampton; University of Patras; Eni SpA; Technical University of Berlin; CoNISMa; University of Milano-Bicocca	Daffonchio, D (corresponding author), Univ Milan, DiSTAM, CoNISMa, I-20133 Milan, Italy.	daniele.daffonchio@unimi.it	Bolhuis, Henk/M-6677-2019; Lampadariou, Nikolaos/H-1201-2011; Tselepides, Anastasios/AAO-3965-2021; Bolhuis, Henk/S-2986-2019; Sass, Andrea Michaela/G-6537-2014; Tamburini, Christian/AAO-8577-2020; D'Auria, Giuseppe/E-6583-2010; Daffonchio, Daniele/AAF-4922-2019; McGenity, Terry/B-8661-2011; Giuliano, Laura/P-2204-2019; Corselli, Cesare/E-9970-2011; Bolhuis, Henk/H-8535-2014; Bolhuis, Henk/A-4308-2008; Tamburini, Christian/I-7821-2012; De Lange, Gert J/B-9639-2014; Polymenakou, Paraskevi/AAW-5313-2020; Hubner, Andreas/G-1751-2016; Yakimov, Michail/H-1829-2016; Hallsworth, John E./K-7876-2013	Bolhuis, Henk/0000-0002-4772-1898; Sass, Andrea Michaela/0000-0001-9396-7648; Tamburini, Christian/0000-0003-3752-7423; Daffonchio, Daniele/0000-0003-0947-925X; Bolhuis, Henk/0000-0002-4772-1898; Tamburini, Christian/0000-0003-3752-7423; De Lange, Gert J/0000-0002-9420-3022; Tselepides, Anastasios/0000-0002-7880-9091; Borin, Sara/0000-0001-7479-8199; van der Wielen, Paul/0000-0002-4851-5762; Hubner, Andreas/0000-0001-7342-9789; D'Auria, Giuseppe/0000-0003-0672-2541; Lampadariou, Nikolaos/0000-0003-2171-7150; Golyshin, Peter/0000-0002-5433-0350; Polymenakou, Paraskevi/0000-0002-9787-7372; McKew, Boyd/0000-0001-5607-6619; Yakimov, Michail/0000-0003-1418-363X; Malinverno, Elisa/0000-0002-9124-5155; McGenity, Terence/0000-0002-1497-8822; Hallsworth, John E./0000-0001-6797-9362; Brusetti, Lorenzo/0000-0002-1773-6618	NERC [soc010003] Funding Source: UKRI; Natural Environment Research Council [soc010003] Funding Source: researchfish	NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		[Anonymous], 1985, NATURE, V314, P152, DOI 10.1038/314152a0; Benlloch S, 2002, ENVIRON MICROBIOL, V4, P349, DOI 10.1046/j.1462-2920.2002.00306.x; CANFIELD DE, 1991, SCIENCE, V251, P1471, DOI 10.1126/science.11538266; Cardinale M, 2004, APPL ENVIRON MICROB, V70, P6147, DOI 10.1128/AEM.70.10.6147-6156.2004; Coolen MJL, 2002, SCIENCE, V296, P2407, DOI 10.1126/science.1071893; Coolen MJL, 2000, APPL ENVIRON MICROB, V66, P2589, DOI 10.1128/AEM.66.6.2589-2598.2000; D'Hondt S, 2004, SCIENCE, V306, P2216, DOI 10.1126/science.1101155; DELANGE GJ, 1990, MAR CHEM, V31, P205, DOI 10.1016/0304-4203(90)90039-F; DELANGE GJ, 1990, MAR CHEM, V31, P63, DOI 10.1016/S0304-4203(05)80005-2; Eder W, 1999, ARCH MICROBIOL, V172, P213, DOI 10.1007/s002030050762; Eder W, 2002, ENVIRON MICROBIOL, V4, P758, DOI 10.1046/j.1462-2920.2002.00351.x; Eder W, 2001, APPL ENVIRON MICROB, V67, P3077, DOI 10.1128/AEM.67.7.3077-3085.2001; Ferrer M, 2005, CHEM BIOL, V12, P895, DOI 10.1016/j.chembiol.2005.05.020; HENNEKE E, 1990, MAR CHEM, V31, P113, DOI 10.1016/0304-4203(90)90033-9; Henneke E, 1997, GEOCHIM COSMOCHIM AC, V61, P307, DOI 10.1016/S0016-7037(96)00355-9; Hinrichs KU, 1999, NATURE, V398, P802, DOI 10.1038/19751; Karner MB, 2001, NATURE, V409, P507, DOI 10.1038/35054051; LAROCK PA, 1979, APPL ENVIRON MICROB, V37, P466, DOI 10.1128/AEM.37.3.466-470.1979; Ludwig W, 2004, NUCLEIC ACIDS RES, V32, P1363, DOI 10.1093/nar/gkh293; LUTHER GW, 1990, MAR CHEM, V31, P137, DOI 10.1016/0304-4203(90)90035-B; Minz D, 1999, APPL ENVIRON MICROB, V65, P4659; Moune S, 2003, FEMS MICROBIOL ECOL, V44, P117, DOI 10.1016/S0168-6496(03)00017-5; Parkes RJ, 2005, NATURE, V436, P390, DOI 10.1038/nature03796; PEARSON TH, 1979, MAR BIOL, V53, P371, DOI 10.1007/BF00391620; Shannon C.E., 1963, MATH THEORY COMMUNIC; SIMON M, 1989, MAR ECOL PROG SER, V51, P201, DOI 10.3354/meps051201; Takai K, 2000, APPL ENVIRON MICROB, V66, P5066, DOI 10.1128/AEM.66.11.5066-5072.2000; Van Cappellen P, 1998, ENVIRON SCI TECHNOL, V32, P2931, DOI 10.1021/es980307m; van der Wielen PWJJ, 2005, SCIENCE, V307, P121, DOI 10.1126/science.1103569	29	137	145	0	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	2006	440	7081					203	207		10.1038/nature04418	http://dx.doi.org/10.1038/nature04418			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019MC	16525471	Bronze			2022-12-28	WOS:000235839500044
J	Sotelo, J; Briceno, E; Lopez-Gonzalez, MA				Sotelo, J; Briceno, E; Lopez-Gonzalez, MA			Adding chloroquine to conventional treatment for glioblastoma multiforme - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							HARDING-PASSEY MELANOMA; ANTIMALARIAL-DRUGS; MULTIDRUG-RESISTANCE; MONOLAYER-CULTURE; CELLS-INVITRO; GLIOMA-CELLS; RAT GLIOMA; CPG-DNA; QUINACRINE; RADIOTHERAPY	Background: Malignant cell clones resistant to chemotherapy and radiotherapy frequently lead to treatment failure in patients with glioblastoma multiforme. Preliminary studies suggest that adding chloroquine to conventional therapy may improve treatment outcomes. Objective: To examine the effect of adding chloroquine to conventional therapy for glioblastoma multiforme. Design: Randomized, double-blind, placebo-controlled trial. Setting: National Institute of Neurology and Neurosurgery of Mexico. Patients: 30 patients with surgically confirmed glioblastoma confined to 1 cerebral hemisphere, with a Karnofsky performance score greater than 70, no comorbid disease, and age younger than 60 years. Interventions: Oral chloroquine at 150 mg/d for 12 months beginning on postoperative clay 5 or placebo. All patients received conventional chemotherapy and radiotherapy. Measurements: Primary outcome was survival after surgery; surviving patients were followed up to October 2005. Periodic evaluation using the Karnofsky scale and imaging studies, as well as hematologic tests and ophthalmologic examinations, was done in all patients. Results: Median survival after surgery was 24 months for chloroquine-treated patients and 11 months for controls. At the end of the observation period, 6 patients treated with chloroquine had survived 59, 45, 30, 27, 27, and 20 months, respectively; 3 patients from the control group had survived 32, 25, and 22 months, respectively. Although not statistically significantly different, the rate of death with time was approximately half as large in patients receiving chloroquine as in patients receiving placebo (hazard ratio, 0.52 [95% Cl, 0.21 to 1.26]; P = 0.139). Limitations: The observed advantage of chloroquine may be due to chance; differences in pretreatment characteristics and conventional treatment regimens could not be adjusted for because of the small sample size. Conclusions: Chloroquine may improve mid-term survival when given in addition to conventional therapy for glioblastoma multiforme. These results suggest that larger, more definitive studies of chloroquine as adjuvant therapy for glioblastoma are warranted.	Natl Inst Neurol & Neurosurg Mexico, Mexico City 14269, DF, Mexico		Sotelo, J (corresponding author), Natl Inst Neurol & Neurosurg Mexico, Insurgentes Sur 3877, Mexico City 14269, DF, Mexico.	jsotelo@servidor.unam.mx	Gonzalez, Miguel A Lopez/M-2139-2015	Gonzalez, Miguel A Lopez/0000-0002-7172-6963				ALLISON JL, 1965, SCIENCE, V149, P1111, DOI 10.1126/science.149.3688.1111; BECK WT, 1988, BIOCHEM BIOPH RES CO, V153, P959, DOI 10.1016/S0006-291X(88)81321-4; BENNETT A, 1987, BRIT J CANCER, V55, P385, DOI 10.1038/bjc.1987.77; BILLER H, 1982, STRAHLENTHER ONKOL, V158, P450; Bondeson J, 1998, GEN PHARMACOL, V30, P357, DOI 10.1016/S0306-3623(97)00269-3; BRICENO E, THERAPY GLIOBLASTOMA; CAPALA J, 1991, INT J RADIAT BIOL, V60, P497, DOI 10.1080/09553009114552341; Cho J, 2000, NUCLEIC ACIDS RES, V28, P2158, DOI 10.1093/nar/28.10.2158; COHEN SN, 1965, P NATL ACAD SCI USA, V54, P521, DOI 10.1073/pnas.54.2.521; Dalpke AH, 2001, J IMMUNOL, V166, P7082, DOI 10.4049/jimmunol.166.12.7082; FERRANTE A, 1984, PARASITE IMMUNOL, V6, P571, DOI 10.1111/j.1365-3024.1984.tb00826.x; FILIPPOV A, 1989, GEN PHYSIOL BIOPHYS, V8, P113; GIAMPIETRI A, 1980, J NATL CANCER I, V64, P297, DOI 10.1093/jnci/64.2.297; Grossman SA, 2004, SEMIN ONCOL, V31, P635, DOI 10.1053/j.seminoncol.2004.07.005; Hawtrey A, 2002, DRUG DELIV, V9, P47, DOI 10.1080/107175402753413172; HOSTETLER KY, 1985, J BIOL CHEM, V260, P215; INABA M, 1988, CANCER RES, V48, P2064; Itaka K, 2003, BIOMATERIALS, V24, P4495, DOI 10.1016/S0142-9612(03)00347-8; JENSEN PB, 1994, CANCER RES, V54, P2959; Kaneko T, 1996, MOL GEN GENET, V250, P593; Kanzawa T, 2003, J BIOMED BIOTECHNOL, P25; KUNZE H, 1982, BIOCHIM BIOPHYS ACTA, V713, P112, DOI 10.1016/0005-2760(82)90173-4; LAW PY, 1984, J BIOL CHEM, V259, P4096; Lopez-Gonzalez MA, 2000, SURG NEUROL, V53, P157, DOI 10.1016/S0090-3019(99)00177-9; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1992, DOI 10.1001/jama.285.15.1992; National Cancer Institute, 1999, COMM TOX CRIT VERS 2; NIELSEN FC, 1990, PEPTIDES, V11, P1225, DOI 10.1016/0196-9781(90)90156-Y; Nosal R, 2002, THROMB RES, V105, P339, DOI 10.1016/S0049-3848(02)00036-1; PACUSZKA T, 1991, BIOCHIM BIOPHYS ACTA, V1083, P153, DOI 10.1016/0005-2760(91)90036-H; PFAB R, 1985, STRAHLENTHER ONKOL, V161, P711; POZZI D, 1990, MEMBRANE BIOCHEM, V9, P239, DOI 10.3109/09687689009025844; Reyes S, 2001, NEUROSURGERY, V49, P969, DOI 10.1097/00006123-200110000-00033; Riccio ES, 2001, ENVIRON MOL MUTAGEN, V38, P69, DOI 10.1002/em.1052; RUDLING MJ, 1983, CANCER RES, V43, P4600; SALMERON G, 1983, AM J MED, V75, P19, DOI 10.1016/0002-9343(83)91266-4; Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5; Snyder RD, 2000, ENVIRON MOL MUTAGEN, V35, P13, DOI 10.1002/(SICI)1098-2280(2000)35:1<13::AID-EM3>3.0.CO;2-1; Snyder RD, 2002, MUTAT RES-FUND MOL M, V503, P21, DOI 10.1016/S0027-5107(02)00028-3; Sohn TA, 2002, CARCINOGENESIS, V23, P949, DOI 10.1093/carcin/23.6.949; Souhami L, 2004, INT J RADIAT ONCOL, V60, P853, DOI 10.1016/j.ijrobp.2004.04.011; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tchernaenko V, 2003, J MOL BIOL, V326, P751, DOI 10.1016/S0022-2836(02)01360-8; Teulade-Fichou MP, 2003, NUCLEOS NUCLEOT NUCL, V22, P1483, DOI 10.1081/NCN-120023016; Wasserfallen JB, 2004, CANCER, V101, P2098, DOI 10.1002/cncr.20619; Weber SM, 2000, J IMMUNOL, V165, P1534, DOI 10.4049/jimmunol.165.3.1534; Yeo SJ, 2003, J BIOL CHEM, V278, P22563, DOI 10.1074/jbc.M302076200; Yin F, 2003, BIOSENS BIOELECTRON, V19, P297, DOI 10.1016/S0956-5663(03)00197-0; ZAMORA JM, 1988, MOL PHARMACOL, V33, P454; Zhu FG, 2003, IMMUNOLOGY, V109, P255, DOI 10.1046/j.1365-2567.2003.01653.x	49	352	370	0	19	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 7	2006	144	5					337	343		10.7326/0003-4819-144-5-200603070-00008	http://dx.doi.org/10.7326/0003-4819-144-5-200603070-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	021EA	16520474				2022-12-28	WOS:000235965300004
J	Kubo, T; Durham, WB; Stern, LA; Kirby, SH				Kubo, T; Durham, WB; Stern, LA; Kirby, SH			Grain size-sensitive creep in ice II	SCIENCE			English	Article							PRESSURE; RHEOLOGY; SATELLITES; DEFORMATION; VISCOSITY; EVOLUTION; VI	Rheological experiments on fine-grained water ice II at low strain rates reveal a creep mechanism that dominates at conditions of low stress. Using cryogenic scanning electron microscopy, we observed that a change in stress exponent from 5 to 2.5 correlates strongly with a decrease in grain size from about 40 to 6 micrometers. The grain size-sensitive creep of ice II demonstrated here plausibly dominates plastic strain at the low-stress conditions in the interior of medium- to large-sized icy moons of the outer solar system.	Kyushu Univ, Fac Sci, Dept Earth & Planetary Sci, Fukuoka 8128581, Japan; Lawrence Livermore Natl Lab, Livermore, CA 94550 USA; US Geol Survey, Menlo Pk, CA 94025 USA	Kyushu University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of the Interior; United States Geological Survey	Kubo, T (corresponding author), Kyushu Univ, Fac Sci, Dept Earth & Planetary Sci, Fukuoka 8128581, Japan.	kubotomo@geo.kyushu-u.ac.jp	Durham, William/P-7202-2019	Kirby, Stephen/0000-0001-8324-0971				BERTIE JE, 1963, J CHEM PHYS, V38, P840, DOI 10.1063/1.1733772; CONSOLMAGNO GJ, 1978, ICARUS, V34, P280, DOI 10.1016/0019-1035(78)90168-9; Durham WB, 1997, J GEOPHYS RES-PLANET, V102, P16293, DOI 10.1029/97JE00916; Durham WB, 1996, J GEOPHYS RES-SOL EA, V101, P2989, DOI 10.1029/95JB03542; DURHAM WB, 1988, J GEOPHYS RES-SOLID, V93, P10191, DOI 10.1029/JB093iB09p10191; Durham WB, 2001, J GEOPHYS RES-SOL EA, V106, P11031, DOI 10.1029/2000JB900446; ECHELMEYER K, 1986, GEOPHYS RES LETT, V13, P693, DOI 10.1029/GL013i007p00693; Edington J. W., 1976, PROG MATER SCI, V21, P61; ELLSWORTH K, 1983, ICARUS, V54, P490, DOI 10.1016/0019-1035(83)90242-7; FLETCHER NH, 1970, CHEM PHYSICS ICE, P57; Goldsby DL, 1997, SCRIPTA MATER, V37, P1399, DOI 10.1016/S1359-6462(97)00246-7; Goldsby DL, 2001, J GEOPHYS RES-SOL EA, V106, P11017, DOI 10.1029/2000JB900336; HEARD HC, 1990, GEOPHYS MONOGR SER, V56, P225; McKinnon WB, 1998, ASTROPHYS SPACE SC L, V227, P525, DOI 10.1007/978-94-011-5252-5_22; Poirier J., 1985, CREEP CRYSTALS; POIRIER JP, 1982, NATURE, V299, P683, DOI 10.1038/299683a0; POIRIER JP, 1981, NATURE, V292, P225, DOI 10.1038/292225a0; REYNOLDS RT, 1979, GEOPHYS RES LETT, V6, P121, DOI 10.1029/GL006i002p00121; ROTHERY DA, 1999, SATELLITES OUTER PLA; SCHUBERT G, 1981, ICARUS, V47, P46, DOI 10.1016/0019-1035(81)90090-7; SCHUBERT G, 1986, SATELLITES, P242; SOTIN C, 1987, J PHYS-PARIS, V48, P233, DOI 10.1051/jphyscol:1987132; Sotin C., 1985, ICES SOLAR SYSTEM, V156, P109; Stern LA, 1997, J GEOPHYS RES-SOL EA, V102, P5313, DOI 10.1029/96JB03894	24	15	15	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	2006	311	5765					1267	1269		10.1126/science.1121296	http://dx.doi.org/10.1126/science.1121296			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019XB	16513977				2022-12-28	WOS:000235870400035
J	Subarya, C; Chlieh, M; Prawirodirdjo, L; Avouac, JP; Bock, Y; Sieh, K; Meltzner, AJ; Natawidjaja, DH; McCaffrey, R				Subarya, C; Chlieh, M; Prawirodirdjo, L; Avouac, JP; Bock, Y; Sieh, K; Meltzner, AJ; Natawidjaja, DH; McCaffrey, R			Plate-boundary deformation associated with the great Sumatra-Andaman earthquake	NATURE			English	Article							GPS MEASUREMENTS; SUBDUCTION ZONE; CORAL MICROATOLLS; CRUSTAL MOTION; SEISMICITY; FAULT; ARC; CONSTRAINTS; INDONESIA; HISTORY	The Sumatra - Andaman earthquake of 26 December 2004 is the first giant earthquake ( moment magnitude M-w. 9.0) to have occurred since the advent of modern space-based geodesy and broadband seismology. It therefore provides an unprecedented opportunity to investigate the characteristics of one of these enormous and rare events. Here we report estimates of the ground displacement associated with this event, using near-field Global Positioning System ( GPS) surveys in northwestern Sumatra combined with in situ and remote observations of the vertical motion of coral reefs. These data show that the earthquake was generated by rupture of the Sunda subduction megathrust over a distance of >1,500 kilometres and a width of,150 kilometres. Megathrust slip exceeded 20 metres offshore northern Sumatra, mostly at depths shallower than 30 kilometres. Comparison of the geodetically and seismically inferred slip distribution indicates that,30 per cent additional fault slip accrued in the 1.5 months following the 500-second-long seismic rupture. Both seismic and aseismic slip before our re-occupation of GPS sites occurred on the shallow portion of the megathrust, where the large Aceh tsunami originated. Slip tapers off abruptly along strike beneath Simeulue Island at the southeastern edge of the rupture, where the earthquake nucleated and where an M-w = 7.2 earthquake occurred in late 2002. This edge also abuts the northern limit of slip in the 28 March 2005 M-w = 8.7 Nias - Simeulue earthquake.	CALTECH, Div Geol & Planetary Sci, Tecton Observ, Pasadena, CA 91125 USA; Natl Coordinating Agcy Surveys & Mapping, Cibinong 16911, Indonesia; Univ Calif San Diego, Scripps Inst Oceanog, Cecil H & Ida M Green Inst Geophys & Planetary Ph, La Jolla, CA 92093 USA; Indonesian Inst Sci, Res Ctr Geotechnol, Bandung 40135, Indonesia; Rensselaer Polytech Inst, Dept Earth & Environm Sci, Troy, NY 12180 USA	California Institute of Technology; University of California System; University of California San Diego; Scripps Institution of Oceanography; Indonesian Institute of Sciences; Rensselaer Polytechnic Institute	Avouac, JP (corresponding author), CALTECH, Div Geol & Planetary Sci, Tecton Observ, Pasadena, CA 91125 USA.	avouac@gps.caltech.edu	Meltzner, Aron J/A-5585-2009; Avouac, Jean-Philippe/B-5699-2015	Meltzner, Aron J/0000-0002-2955-0896; Avouac, Jean-Philippe/0000-0002-3060-8442; Chlieh, Mohamed/0000-0003-2252-2187				Agnew DC, 1997, J GEOPHYS RES-SOL EA, V102, P5109, DOI 10.1029/96JB03458; Altamimi Z, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000561; Ammon CJ, 2005, SCIENCE, V308, P1133, DOI 10.1126/science.1112260; Bilham R, 2005, SEISMOL RES LETT, V76, P299, DOI 10.1785/gssrl.76.3.299; Bock Y, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB000324; BOLLINGER L, 2004, J GEOPHYS RES, V109, DOI DOI 10.1029/2003GL019410; BRUNE JN, 1968, J GEOPHYS RES, V73, P777, DOI 10.1029/JB073i002p00777; CHLIEH M, 2004, EOS S, V85; Cohen SC, 1998, GEOPHYS RES LETT, V25, P1213, DOI 10.1029/98GL00860; Curray JR, 2005, J ASIAN EARTH SCI, V25, P187, DOI 10.1016/j.jseaes.2004.09.001; de Groot-Hedlin CD, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL022695; Engdahl ER, 1998, B SEISMOL SOC AM, V88, P722; Genrich JF, 2000, J GEOPHYS RES, V105, P722; Guilbert J, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL022966; Hsu YJ, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL014967; Hutton W, 2001, GEOPHYS J INT, V146, P637, DOI 10.1046/j.1365-246X.2001.00472.x; Hyndman RD, 1997, ISL ARC, V6, P244, DOI 10.1111/j.1440-1738.1997.tb00175.x; Jade S, 2005, CURR SCI INDIA, V88, P1980; KANAMORI H, 1983, EARTHQUAKES OBSERVAT, P597; Lay T, 2005, SCIENCE, V308, P1127, DOI 10.1126/science.1112250; McCaffrey R, 2000, J GEOPHYS RES-SOL EA, V105, P28363, DOI 10.1029/1999JB900362; McCaffrey R, 1997, J GEOPHYS RES-SOL EA, V102, P22839, DOI 10.1029/97JB01827; McCaffrey R., 2002, GEODYNAMICS, V30, P101, DOI 10.1029/030GD06; Meltzner AJ, 2006, J GEOPHYS RES-SOL EA, V111, DOI 10.1029/2005JB003891; Michel GW, 2001, EARTH PLANET SC LETT, V187, P239, DOI 10.1016/S0012-821X(01)00298-9; NATAWIDJAJA D, IN PRESS J GEOPHYS R; NATAWIDJAJA DH, 2004, J GEOPHYS RES, V109, DOI DOI 10.1029/2003JB0002398; NEWCOMB KR, 1987, J GEOPHYS RES-SOLID, V92, P421, DOI 10.1029/JB092iB01p00421; Ni S, 2005, NATURE, V434, P582, DOI 10.1038/434582a; Nikolaidis R., 2002, OBSERVATION GEODETIC; PACHECO JF, 1993, J GEOPHYS RES-SOL EA, V98, P14133, DOI 10.1029/93JB00349; Paul J, 2001, GEOPHYS RES LETT, V28, P647, DOI 10.1029/2000GL011832; Prawirodirdjo L, 1997, GEOPHYS RES LETT, V24, P2601, DOI 10.1029/97GL52691; RUFF L, 1980, PHYS EARTH PLANET IN, V23, P240, DOI 10.1016/0031-9201(80)90117-X; SCHOLZ CH, 1995, J GEOPHYS RES-SOL EA, V100, P22103, DOI 10.1029/95JB01869; SCHOLZ CH, 1990, MECH EARTHQUAKES FAU, pCH2; Sieh K, 2000, J GEOPHYS RES-SOL EA, V105, P28295, DOI 10.1029/2000JB900120; SIEH K, 2004, EOS S, V85; Simoes M, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002958; Tsai VC, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023813; UYEDA S, 1979, J GEOPHYS RES, V84, P1049, DOI 10.1029/JB084iB03p01049; Vigny C, 2005, NATURE, V436, P201, DOI 10.1038/nature03937; Zachariasen J, 2000, B SEISMOL SOC AM, V90, P897, DOI 10.1785/0119980016; Zachariasen J, 1999, J GEOPHYS RES-SOL EA, V104, P895, DOI 10.1029/1998JB900050	44	321	338	1	95	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	2006	440	7080					46	51		10.1038/nature04522	http://dx.doi.org/10.1038/nature04522			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017HW	16511486	Green Published			2022-12-28	WOS:000235685700035
J	Falagas, ME; Michalopoulos, A				Falagas, ME; Michalopoulos, A			Polymyxins: old antibiotics are back	LANCET			English	Editorial Material							RESISTANT PSEUDOMONAS-AERUGINOSA; INTRAVENOUS COLISTIN; INFECTIONS; ACINETOBACTER; EFFICACY; SAFETY		Alfa Inst Biomed Sci, Athens, Greece; Henry Dunant Hosp, Dept Med, Athens, Greece; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Henry Dunant Hosp, Intens Care Unit, Athens, Greece	Alfa Institute Of Biomedical Sciences; Henry Dunant Hospital; Tufts University; Henry Dunant Hospital	Falagas, ME (corresponding author), Alfa Inst Biomed Sci, Athens, Greece.	m.falagas@aibs.gr		Michalopoulos, Argyris/0000-0002-6904-164X				Conway SP, 2000, ANN PHARMACOTHER, V34, P1238; Falagas ME, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-24; Falagas ME, 2005, CLIN INFECT DIS, V40, P1333, DOI 10.1086/429323; Garnacho-Montero J, 2003, CLIN INFECT DIS, V36, P1111, DOI 10.1086/374337; Hsueh PR, 2005, CLIN MICROBIOL INFEC, V11, P670, DOI 10.1111/j.1469-0691.2005.01196.x; KOCHWESER J, 1970, ANN INTERN MED, V72, P331, DOI 10.7326/0003-4819-72-3-331; Levin AS, 1999, CLIN INFECT DIS, V28, P1008, DOI 10.1086/514732; Linden PK, 2003, CLIN INFECT DIS, V37, pE154, DOI 10.1086/379611; Ouderkirk JP, 2003, ANTIMICROB AGENTS CH, V47, P2659, DOI 10.1128/AAC.47.8.2659-2662.2003; Parchuri S, 2005, HEART LUNG, V34, P360, DOI 10.1016/j.hrtlng.2004.11.001; PERKINS RL, 1964, JAMA-J AM MED ASSOC, V190, P421; Reina R, 2005, INTENS CARE MED, V31, P1058, DOI 10.1007/s00134-005-2691-4	12	42	43	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 25	2006	367	9511					633	634		10.1016/S0140-6736(06)68241-X	http://dx.doi.org/10.1016/S0140-6736(06)68241-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	016HR	16503447				2022-12-28	WOS:000235611800008
J	Glodny, B; Glodny, DE				Glodny, B; Glodny, DE			John Loesch, discoverer of renovascular hypertension, and Harry Goldblatt: Two great pioneers in circulation research	ANNALS OF INTERNAL MEDICINE			English	Article							BLOOD-PRESSURE; RENIN	In 1934, Harry Goldblatt and colleagues published an article titled "The Production of Persistent Elevation of Systolic Blood Pressure by Means of Renal Ischemia" in the Journal of Experimental Medicine. One year earlier, John Loesch had published a similar study in a German-language journal, Zentralblatt fur Innere Medizin. His article appeared on 18 and 25 February 1933, in 3 parts, under the title "A Contribution to Experimental Nephritis and to Arterial Hypertension." The central proposition of both papers was the same: Renal ischemia causes persistent hypertension. Goldblatt's article is one of the best known in the history of medicine, and the words "Goldblatt kidney" are still commonly used. Although Loesch succeeded in producing persistent hypertension by inducing ischemia and in correctly interpreting this and its ramifications earlier than Goldblatt, his article has been cited only a few times. In this article, the authors share what is known about the studies of Loesch and of Goldblatt. They believe that both Loesch and Goldblatt should receive equal credit for these important first observations.	Univ Innsbruck, A-6020 Innsbruck, Austria	University of Innsbruck	Glodny, B (corresponding author), Innsbruck Med Univ, Dept Radiol, Anichstr 35, A-6020 Innsbruck, Austria.	bernhard.glodny@uibk.ac.at	Glodny, Bernhard/E-7984-2010					Allen FM, 1943, J UROLOGY, V49, P512, DOI 10.1016/S0022-5347(17)70581-2; ALLEN FM, 1923, J METAB RES, V4, P431; *AM MED ASS, 1933, Q CUMULATIVE INDEX M, V13, P747; Basso N, 2001, HYPERTENSION, V38, P1246, DOI 10.1161/hy1201.101214; Berman L B, 1977, JAMA, V238, P1846, DOI 10.1001/jama.238.17.1846; BUNN A, 2003, NY TIMES        0316; BUTTERFIELD D, EXCERPT SHOWDOWN DIA; *CAN DIAB ASS, DIAB HIST DIAB; *CAS W RES U DITTR, 1934, GOLDBL CLAMPS HYP EX; Cattell Jacques, 1933, AM MEN SCI BIOGRAPHI; CATTELL JM, 1938, AM MEN SCI BIOGRAPHI; GARFIELD E, 1986, ESSAYS INFORM SCI, V9, P55; Goldblatt H, 1941, J EXP MED, V73, P439, DOI 10.1084/jem.73.3.439; Goldblatt H, 1934, J EXP MED, V59, P347, DOI 10.1084/jem.59.3.347; Goldblatt Peter J., 1995, P23; GOLDBLATT PJ, 1997, MOL PATHOLOGY DIS; Laragh J, 1978, Trans Assoc Am Physicians, V91, P24; Loesch J, 1939, ARCH PATHOL, V28, P223; LOESCH J, 1948, AM REV TUBERC PULM, V58, P322; LOESCH J, 1932, Z PATHOLOGIE, V44, P351; LOESCH J, 1933, ZENTRALBLATT INNERE, V7, P144; LOESCH J, 1927, ARCH PATH, V4, P495; LOESCH J, 1933, ZENTRALBLATT INNERE, V8, P177; LOESCH J, 1944, AM REV TUBERC, V50, P500; Loesch J, 1947, AM J NURS, V47, P740, DOI 10.2307/3457723; LOESCH JOHN, 1939, AMER REV TUBERC, V40, P233; Page I.H., 1987, HYPERTENSION MECH; Stamey TA, 1963, RENOVASCULAR HYPERTE; Van Epps HL, 2005, J EXP MED, V201, P1351, DOI 10.1084/jem.2019fta; VANLEERSUM EC, 1911, ARCH GES PHYSL, V142, P377; 1934, INT BIBLIO ZEITSCH C, V56, P419	31	8	8	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 21	2006	144	4					286	295		10.7326/0003-4819-144-4-200602210-00011	http://dx.doi.org/10.7326/0003-4819-144-4-200602210-00011			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	015HS	16490915				2022-12-28	WOS:000235543100008
J	Keusch, GT; Wilentz, J; Kleinman, A				Keusch, GT; Wilentz, J; Kleinman, A			Stigma and global health: developing a research agenda	LANCET			English	Editorial Material									Harvard Univ, Cambridge, MA 02138 USA	Harvard University	Keusch, GT (corresponding author), Boston Univ Med Campus, Boston, MA 02118 USA.	keusch@bu.edu		/0000-0001-5724-2965				Goffman E., 1963, BEHAV PUBLIC PLACES, P3; Institute of Medicine,, 2001, NEUR PSYCH DEV DIS M; KLEINMAN A, 1995, SOC SCI MED, V40, P1319, DOI 10.1016/0277-9536(94)00254-Q; Office of the Surgeon General, 2019, SURG GEN ADV MAR US; *WHO, 2001, 166 WHO; WHO, 2001, WORLD HLTH REPORT 20	6	108	110	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 11	2006	367	9509					525	527		10.1016/S0140-6736(06)68183-X	http://dx.doi.org/10.1016/S0140-6736(06)68183-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	013FF	16473128				2022-12-28	WOS:000235394500032
J	Link, BG; Phelan, JC				Link, BG; Phelan, JC			Stigma and its public health implications	LANCET			English	Editorial Material							MENTAL-ILLNESS; REJECTION		Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA; Mailman Sch Publ Hlth, Dept Sociomed Sci, New York, NY 10032 USA		Link, BG (corresponding author), Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA.	bgl1@columbia.edu	Link, Bruce/AAO-9094-2021; Link, Bruce G/N-9087-2013	Link, Bruce/0000-0001-9980-7450				FARINA A, 1968, J PERS, V36, P169, DOI 10.1111/j.1467-6494.1968.tb01467.x; GIBBS JT, 1994, AM J COMMUN PSYCHOL, V22, P559, DOI 10.1007/BF02506893; JAMES SA, 1984, J BEHAV MED, V7, P259, DOI 10.1007/BF00845359; LINK B, 1982, AM SOCIOL REV, V47, P202, DOI 10.2307/2094963; Link B.G., 1989, AM SOCIOL REV, V54, P100; LINK BG, 1995, J HEALTH SOC BEHAV, V35, P80, DOI 10.2307/2626958; Link BG, 1997, J HEALTH SOC BEHAV, V38, P177, DOI 10.2307/2955424; LINK BG, 1987, AM SOCIOL REV, V52, P96, DOI 10.2307/2095395; Rosenfield S, 1997, AM SOCIOL REV, V62, P660, DOI 10.2307/2657432; Wright ER, 2000, J HEALTH SOC BEHAV, V41, P68, DOI 10.2307/2676361	10	764	782	3	116	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 11	2006	367	9509					528	529		10.1016/S0140-6736(06)68184-1	http://dx.doi.org/10.1016/S0140-6736(06)68184-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	013FF	16473129				2022-12-28	WOS:000235394500033
J	Baker, S; Robinson, JS; Haworth, CA; Teng, H; Smith, RA; Chirila, CC; Lein, M; Tisch, JWG; Marangos, JP				Baker, S; Robinson, JS; Haworth, CA; Teng, H; Smith, RA; Chirila, CC; Lein, M; Tisch, JWG; Marangos, JP			Probing proton dynamics in molecules on an attosecond time scale	SCIENCE			English	Article							PHOTOIONIZATION; METHANE; PULSES	We demonstrate a technique that uses high-order harmonic generation in molecules to probe nuclear dynamics and structural rearrangement on a subfemtosecond time scale. The chirped nature of the electron wavepacket produced by laser ionization in a strong field gives rise to a similar chirp in the photons emitted upon electron-ion recombination. Use of this chirp in the emitted light allows information about nuclear dynamics to be gained With 100-attosecond temporal resolution, from excitation by an 8-femtosecond pulse, in a single laser shot. Measurements on molecular hydrogen and deuterium agreed well With calculations of ultrafast nuclear dynamics in the H(2)(+) molecule, confirming the validity of the method. We then measured harmonic spectra from CH(4) and CD(4) to demonstrate a few femtosecond time scale for the onset of proton rearrangement in methane upon ionization.	Univ London Imperial Coll Sci Technol & Med, Blackett Lab, London SW7 2BZ, England; Max Planck Inst Nucl Phys, D-69117 Heidelberg, Germany	Imperial College London; Max Planck Society	Marangos, JP (corresponding author), Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Prince Consort Rd, London SW7 2BZ, England.	j.marangos@imperial.ac.uk	Lein, Manfred/F-4276-2011	Lein, Manfred/0000-0003-1489-8715; Chirila, Ciprian Constantin/0000-0002-6734-2043	Engineering and Physical Sciences Research Council [GR/S22400/01, EP/C530764/1] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Antoine P, 1996, PHYS REV LETT, V77, P1234, DOI 10.1103/PhysRevLett.77.1234; CORKUM PB, 1993, PHYS REV LETT, V71, P1994, DOI 10.1103/PhysRevLett.71.1994; FREY RF, 1988, J CHEM PHYS, V88, P1775, DOI 10.1063/1.454101; Itatani J, 2004, NATURE, V432, P867, DOI 10.1038/nature03183; Kienberger R, 2004, NATURE, V427, P817, DOI 10.1038/nature02277; KNIGHT LB, 1984, J AM CHEM SOC, V106, P3700, DOI 10.1021/ja00324a066; Latimer CJ, 1999, J PHYS B-AT MOL OPT, V32, P2667, DOI 10.1088/0953-4075/32/11/314; LATIMER CJ, 1995, J CHEM PHYS, V102, P722, DOI 10.1063/1.469185; Lein M, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.053004; Lein M, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.023805; Lein M, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.183903; LHuillier A., 1992, ATOMS INTENSE LASER, P139; LIANG Y, 1994, J PHYS B-AT MOL OPT, V27, P5119, DOI 10.1088/0953-4075/27/20/024; Mairesse Y, 2003, SCIENCE, V302, P1540, DOI 10.1126/science.1090277; Niikura H, 2003, NATURE, V421, P826, DOI 10.1038/nature01430; Niikura H, 2002, NATURE, V417, P917, DOI 10.1038/nature00787; Stapelfeldt H, 1997, PHYS REV LETT, V79, P2787, DOI 10.1103/PhysRevLett.79.2787; VAGER Z, 1986, PHYS REV LETT, V57, P2793, DOI 10.1103/PhysRevLett.57.2793	18	734	743	8	134	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 21	2006	312	5772					424	427		10.1126/science.1123904	http://dx.doi.org/10.1126/science.1123904			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	034OZ	16513942				2022-12-28	WOS:000236941800046
J	Delacretaz, E				Delacretaz, E			Supraventricular tachycardia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WOLFF-PARKINSON-WHITE; RADIOFREQUENCY CATHETER ABLATION; QUALITY-OF-LIFE; FLECAINIDE ACETATE; NATURAL-HISTORY; MEDICAL THERAPY; ARRHYTHMIAS; MANAGEMENT; ADENOSINE; EFFICACY		Univ Hosp Bern, Swiss Cardiovasc Ctr Bern, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern	Delacretaz, E (corresponding author), Univ Hosp Bern, Swiss Cardiovasc Ctr Bern, CH-3010 Bern, Switzerland.	delacretaz@insel.ch						Alboni P, 2001, J AM COLL CARDIOL, V37, P548, DOI 10.1016/S0735-1097(00)01128-1; ANDERSON JL, 1986, AM HEART J, V111, P466, DOI 10.1016/0002-8703(86)90050-5; ANDERSON JL, 1994, AM J CARDIOL, V74, P578, DOI 10.1016/0002-9149(94)90747-1; [Anonymous], 2001, CIRCULATION, V104, P2118; Bathina MN, 1998, AM J CARDIOL, V82, P589, DOI 10.1016/S0002-9149(98)00416-0; Blomstrom-Lundqvist C, 2003, CIRCULATION, V108, P1871, DOI 10.1161/01.CIR.0000091380.04100.84; BOAHENE KA, 1990, AM J CARDIOL, V65, P195, DOI 10.1016/0002-9149(90)90084-E; CALKINS H, 1991, NEW ENGL J MED, V324, P1612, DOI 10.1056/NEJM199106063242302; CHEN SA, 1994, CIRCULATION, V90, P1262, DOI 10.1161/01.CIR.90.3.1262; COSIO FG, 1993, AM J CARDIOL, V71, P705, DOI 10.1016/0002-9149(93)91014-9; Cosio FG, 2003, PACE, V26, P2157, DOI 10.1046/j.1460-9592.2003.00336.x; DIMARCO JP, 1990, ANN INTERN MED, V113, P996, DOI 10.7326/0003-4819-113-12-996_3; DIMARCO JP, 1990, ANN INTERN MED, V113, P104, DOI 10.7326/0003-4819-113-2-104; EPSTEIN LM, 1994, J AM COLL CARDIOL, V23, P1356, DOI 10.1016/0735-1097(94)90377-8; Fitzsimmons PJ, 2001, AM HEART J, V142, P530, DOI 10.1067/mhj.2001.117779; Friedman PL, 2004, HEART RHYTHM, V1, P129, DOI 10.1016/j.hrthm.2004.02.022; GANZ LI, 1995, NEW ENGL J MED, V332, P162, DOI 10.1056/NEJM199501193320307; Glatter K, 2001, CIRCULATION, V103, P253; Glatter KA, 2001, CIRCULATION, V104, P1933, DOI 10.1161/hc4101.097538; Glatter KA, 1999, CIRCULATION, V99, P1034, DOI 10.1161/01.CIR.99.8.1034; GURSOY S, 1992, NEW ENGL J MED, V327, P772, DOI 10.1056/NEJM199209103271105; Hellestrand KJ, 1996, AM J CARDIOL, V77, pA83, DOI 10.1016/S0002-9149(97)89122-9; HENTHORN RW, 1991, CIRCULATION, V83, P119, DOI 10.1161/01.CIR.83.1.119; JACKMAN WM, 1991, NEW ENGL J MED, V324, P1605, DOI 10.1056/NEJM199106063242301; JACKMAN WM, 1992, NEW ENGL J MED, V327, P313, DOI 10.1056/NEJM199207303270504; JOSEPHSON M E, 1990, Cardiology Clinics, V8, P411; KALL JG, 1995, PACE, V18, P300, DOI 10.1111/j.1540-8159.1995.tb02520.x; KAY GN, 1993, J CARDIOVASC ELECTR, V4, P371, DOI 10.1111/j.1540-8167.1993.tb01277.x; KIM SS, 1986, AM J CARDIOL, V58, P80, DOI 10.1016/0002-9149(86)90245-6; KLEIN GJ, 1979, NEW ENGL J MED, V301, P1080, DOI 10.1056/NEJM197911153012003; KLEIN GJ, 1989, CIRCULATION, V80, P1902, DOI 10.1161/01.CIR.80.6.1902; KUCK KH, 1991, LANCET, V337, P1557, DOI 10.1016/0140-6736(91)93258-B; LAU CP, 1995, PACE, V18, P424, DOI 10.1111/j.1540-8159.1995.tb02541.x; Lerman BB, 2003, NEW ENGL J MED, V349, P1787, DOI 10.1056/NEJMp038137; LESH MD, 1994, CIRCULATION, V89, P1074, DOI 10.1161/01.CIR.89.3.1074; Lessmeier TJ, 1997, ARCH INTERN MED, V157, P537, DOI 10.1001/archinte.157.5.537; LUDMER PL, 1987, J AM COLL CARDIOL, V9, P1357, DOI 10.1016/S0735-1097(87)80478-3; MUNGER TM, 1993, CIRCULATION, V87, P866, DOI 10.1161/01.CIR.87.3.866; Natale A, 2000, J AM COLL CARDIOL, V35, P1898, DOI 10.1016/S0735-1097(00)00635-5; Orejarena LA, 1998, J AM COLL CARDIOL, V31, P150, DOI 10.1016/S0735-1097(97)00422-1; Pappone C, 2003, J AM COLL CARDIOL, V41, P239, DOI 10.1016/S0735-1097(02)02706-7; PRITCHETT ELC, 1991, ANN INTERN MED, V114, P539, DOI 10.7326/0003-4819-114-7-539; RINKENBERGER RL, 1980, CIRCULATION, V62, P996, DOI 10.1161/01.CIR.62.5.996; Scheinman MM, 2000, PACE, V23, P1020, DOI 10.1111/j.1540-8159.2000.tb00891.x; Schilling RJ, 2002, HEART, V87, P299, DOI 10.1136/heart.87.3.299; SELLERS TD, 1977, CIRCULATION, V56, P260, DOI 10.1161/01.CIR.56.2.260; TIKKANEN I, 1985, LANCET, V2, P40; Todd DM, 2003, J AM COLL CARDIOL, V41, P245, DOI 10.1016/S0735-1097(02)02707-9; Wellens HJJ, 2003, PACE, V26, P1916, DOI 10.1046/j.1460-9592.2003.00295.x; WINNIFORD MD, 1984, AM J CARDIOL, V54, P1138, DOI 10.1016/S0002-9149(84)80162-9	50	113	120	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 9	2006	354	10					1039	1051		10.1056/NEJMcp051145	http://dx.doi.org/10.1056/NEJMcp051145			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	019FY	16525141				2022-12-28	WOS:000235822200008
J	Kawai, N; Kosugi, G; Aoki, K; Yamada, T; Totani, T; Ohta, K; Iye, M; Hattori, T; Aoki, W; Furusawa, H; Hurley, K; Kawabata, KS; Kobayashi, N; Komiyama, Y; Mizumoto, Y; Nomoto, K; Noumaru, J; Ogasawara, R; Sato, R; Sekiguchi, K; Shirasaki, Y; Suzuki, M; Takata, T; Tamagawa, T; Terada, H; Watanabe, J; Yatsu, Y; Yoshida, A				Kawai, N; Kosugi, G; Aoki, K; Yamada, T; Totani, T; Ohta, K; Iye, M; Hattori, T; Aoki, W; Furusawa, H; Hurley, K; Kawabata, KS; Kobayashi, N; Komiyama, Y; Mizumoto, Y; Nomoto, K; Noumaru, J; Ogasawara, R; Sato, R; Sekiguchi, K; Shirasaki, Y; Suzuki, M; Takata, T; Tamagawa, T; Terada, H; Watanabe, J; Yatsu, Y; Yoshida, A			An optical spectrum of the afterglow of a gamma-ray burst at a redshift of z=6.295	NATURE			English	Article							GUNN-PETERSON TROUGH; PROGENITOR; REIONIZATION; GRB-021004; UNIVERSE; DENSITY	The prompt gamma-ray emission from gamma-ray bursts (GRBs) should be detectable out to distances of z > 10 (ref. 1), and should therefore provide an excellent probe of the evolution of cosmic star formation, reionization of the intergalactic medium, and the metal enrichment history of the Universe(1-4). Hitherto, the highest measured redshift for a GRB has been z = 4.50 (ref. 5). Here we report the optical spectrum of the afterglow of GRB 050904 obtained 3.4 days after the burst; the spectrum shows a clear continuum at the long-wavelength end of the spectrum with a sharp cut-off at around 9,000 angstrom due to Lyman alpha absorption at z approximate to 6.3 (with a damping wing). A system of absorption lines of heavy elements at z = 6.295 +/- 0.002 was also detected, yielding the precise measurement of the redshift. The Si II fine-structure lines suggest a dense, metal-enriched environment around the progenitor of the GRB.	Tokyo Inst Technol, Dept Phys, Meguro Ku, Tokyo 1528551, Japan; Natl Astron Observ Japan, Tokyo 1818588, Japan; Natl Astron Observ Japan, Subaru Telescope, Hilo, HI 96720 USA; Kyoto Univ, Dept Astron, Sakyo Ku, Kyoto 6068502, Japan; Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA; Hiroshima Univ, Dept Phys Sci, Hiroshima 7398526, Japan; Univ Tokyo, Inst Astron, Tokyo 1810015, Japan; Univ Tokyo, Dept Astron, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; Aoyama Gakuin Univ, Dept Phys, Kanagawa 2298558, Japan	Tokyo Institute of Technology; National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ); National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ); Kyoto University; University of California System; University of California Berkeley; Hiroshima University; University of Tokyo; University of Tokyo; RIKEN; Aoyama Gakuin University	Kawai, N (corresponding author), Tokyo Inst Technol, Dept Phys, Meguro Ku, 2-12-1 Ookayama, Tokyo 1528551, Japan.	nkawai@phys.titech.ac.jp	Kawabata, Koji S/G-1957-2017; Takata, Tadafumi/ABD-9196-2021	Kawabata, Koji S/0000-0001-6099-9539; Takata, Tadafumi/0000-0002-6592-4250; Furusawa, Hisanori/0000-0002-6174-8165; Komiyama, Yutaka/0000-0002-3852-6329				Andersen MI, 2000, ASTRON ASTROPHYS, V364, pL54; ANTONELLI LA, 2005, 3924 GCN; Becker RH, 2001, ASTRON J, V122, P2850, DOI 10.1086/324231; BERGER E, UNPUB ASTROPHYS J; CHEN HW, IN PRESS ASTROPHYS J; Ciardi B, 2000, ASTROPHYS J, V540, P687, DOI 10.1086/309384; CUMMINGS J, 2005, 3910 GCN; FOX DB, 2005, 3912 GCN; Grevesse N, 1998, SPACE SCI REV, V85, P161, DOI 10.1023/A:1005161325181; GUNN JE, 1965, ASTROPHYS J, V142, P1633, DOI 10.1086/148444; Haislip J., 2005, 3913 GCN; HAISLIP J, 2005, 3914 GCN; Kashikawa N, 2002, PUBL ASTRON SOC JPN, V54, P819, DOI 10.1093/pasj/54.6.819; Klose S, 2004, ASTRON J, V128, P1942, DOI 10.1086/424539; Mirabal N, 2003, ASTROPHYS J, V595, P935, DOI 10.1086/377471; Miralda-Escude J, 1998, ASTROPHYS J, V501, P15, DOI 10.1086/305799; SAKAMOTO T, 2005, 3938 GCN; Schaefer BE, 2003, ASTROPHYS J, V588, P387, DOI 10.1086/373896; Silva AI, 2002, MON NOT R ASTRON SOC, V329, P135, DOI 10.1046/j.1365-8711.2002.04956.x; SPITZER L, 1978, PHYSICAL PROCESSES I, P51; VANMARLE AJ, IN PRESS ASTRON ASTR; Vreeswijk PM, 2004, ASTRON ASTROPHYS, V419, P927, DOI 10.1051/0004-6361:20040086; White RL, 2003, ASTRON J, V126, P1, DOI 10.1086/375547; [No title captured]	25	267	269	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2006	440	7081					184	186		10.1038/nature04498	http://dx.doi.org/10.1038/nature04498			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019MC	16525466	Bronze			2022-12-28	WOS:000235839500039
J	Lai, CL; Shouval, D; Lok, AS; Chang, TT; Cheinquer, H; Goodman, Z; DeHertogh, D; Wilber, R; Zink, RC; Cross, A; Colonno, R; Fernandes, L				Lai, CL; Shouval, D; Lok, AS; Chang, TT; Cheinquer, H; Goodman, Z; DeHertogh, D; Wilber, R; Zink, RC; Cross, A; Colonno, R; Fernandes, L		BEHoLD A1463027 Study Grp	Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	14th Biennial Meeting of the Asian-Pacific-Association-for-the-Study-of-the-Liver	DEC 14, 2004	New Delhi, INDIA	Asian Pacific Assoc Study Liver			LIVER-DISEASE; VIRUS; MANAGEMENT; PRECORE; HBV; EPIDEMIOLOGY; PREVENTION; EMERGENCE; RESISTANT; INFECTION	BACKGROUND: Entecavir is a potent and selective antiviral agent that has demonstrated efficacy in phase 2 studies in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. METHODS: In this phase 3, double-blind trial, we randomly assigned 648 patients with HBeAg-negative chronic hepatitis B who had not previously been treated with a nucleoside analogue to receive 0.5 mg of entecavir or 100 mg of lamivudine once daily for a minimum of 52 weeks. The primary efficacy end point was histologic improvement (a decrease by at least two points in the Knodell necroinflammatory score, without worsening of fibrosis). RESULTS: Histologic improvement after 48 weeks of treatment occurred in 208 of 296 patients in the entecavir group who had adequate baseline liver-biopsy specimens that could be evaluated (70 percent), as compared with 174 of 287 such patients in the lamivudine group (61 percent, P=0.01). More patients in the entecavir group than in the lamivudine group had undetectable serum hepatitis B virus (HBV) DNA levels according to a polymerase-chain-reaction assay (90 percent vs. 72 percent, P<0.001) and normalization of alanine aminotransferase levels (78 percent vs. 71 percent, P=0.045). The mean reduction in serum HBV DNA levels from baseline to week 48 was greater with entecavir than with lamivudine (5.0 vs. 4.5 log [on a base-10 scale] copies per milliliter, P<0.001). There was no evidence of resistance to entecavir. Safety and adverse-event profiles were similar in the two groups. CONCLUSIONS: Among patients with HBeAg-negative chronic hepatitis B who had not previously been treated with a nucleoside analogue, the rates of histologic improvement, virologic response, and normalization of alanine aminotransferase levels were significantly higher at 48 weeks with entecavir than with lamivudine. The safety profile of the two agents was similar, and there was no evidence of viral resistance to entecavir.	Queen Mary Hosp, Univ Dept Med, Hong Kong, Hong Kong, Peoples R China; Hadassah Hebrew Univ Hosp, Jerusalem, Israel; Univ Michigan, Ann Arbor, MI 48109 USA; Natl Cheng Kung Univ, Coll Med, Tainan 70101, Taiwan; Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil; Armed Forces Inst Pathol, Washington, DC 20306 USA; Univ Connecticut, Farmington, CT USA; Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA	University of Hong Kong; Hebrew University of Jerusalem; Hadassah University Medical Center; University of Michigan System; University of Michigan; National Cheng Kung University; Universidade Federal do Rio Grande do Sul; United States Department of Defense; University of Connecticut; Bristol-Myers Squibb	Lai, CL (corresponding author), Queen Mary Hosp, Univ Dept Med, Hong Kong, Hong Kong, Peoples R China.	hrmelcl@hkucc.hku.hk	Rafalskiy, Vladimir V/G-3172-2013; Shouval, Daniel/U-2779-2017; Lai, Ching Lung/C-4298-2009; Lok, Anna/B-8292-2009; Chang, Ting-Tsung/B-4306-2009; Cheinquer, Hugo/U-2117-2019	Rafalskiy, Vladimir V/0000-0002-2503-9580; Shouval, Daniel/0000-0002-0512-6513; Lai, Ching-Lung/0000-0002-5927-2436; Yang, Shuman/0000-0002-9638-0890				Brunetto MR, 2002, J HEPATOL, V36, P263, DOI 10.1016/S0168-8278(01)00266-5; Chan HLY, 2000, HEPATOLOGY, V31, P763, DOI 10.1002/hep.510310330; Chang TT, 2006, NEW ENGL J MED, V354, P1001, DOI 10.1056/NEJMoa051285; Chen DS, 2000, J GASTROEN HEPATOL, V15, P825, DOI 10.1046/j.1440-1746.2000.02322.x; Chu CJ, 2002, HEPATOLOGY, V36, P1408, DOI 10.1053/jhep.2002.36949; Conjeevaram HS, 2003, J HEPATOL, V38, P876, DOI 10.1016/S0168-8278(03)00195-8; Conjeevaram HS, 2003, J HEPATOL, V38, pS90, DOI 10.1016/S0168-8278(02)00431-2; de Franchis R, 2003, J HEPATOL, V39, pS3, DOI 10.1016/S0168-8278(03)00378-7; Di Marco V, 2004, HEPATOLOGY, V40, P883, DOI 10.1002/hep.20381; Fattovich Giovanna, 2003, Journal of Hepatology, V39, pS50; Funk ML, 2002, J VIRAL HEPATITIS, V9, P52, DOI 10.1046/j.1365-2893.2002.00304.x; Hadziyannis SJ, 2003, SEMIN LIVER DIS, V23, P81, DOI 10.1055/s-2003-37584; Hadziyannis SJ, 2003, NEW ENGL J MED, V348, P800, DOI 10.1056/NEJMoa021812; Hadziyannis SJ, 2001, HEPATOLOGY, V34, P617, DOI 10.1053/jhep.2001.27834; HADZIYANNIS SJ, 1995, VIRAL HEPATITIS REV, V1, P7; Innaimo SF, 1997, ANTIMICROB AGENTS CH, V41, P1444, DOI 10.1128/AAC.41.7.1444; Keeffe EB, 2004, CLIN GASTROENTEROL H, V2, P87, DOI 10.1016/S1542-3565(03)00312-4; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; Lavanchy D, 2004, J VIRAL HEPATITIS, V11, P97, DOI 10.1046/j.1365-2893.2003.00487.x; Liaw YF, 2004, NEW ENGL J MED, V351, P1521, DOI 10.1056/NEJMoa033364; Locarnini S, 2005, J HEPATOL, V42, P17; Lok AS, 2001, GASTROENTEROLOGY, V120, P1828, DOI 10.1053/gast.2001.24839; Lok ASF, 2004, HEPATOLOGY, V39, P857, DOI 10.1002/hep.20110; Manesis EK, 2001, GASTROENTEROLOGY, V121, P101, DOI 10.1053/gast.2001.25524; Manesis EK, 2003, AM J GASTROENTEROL, V98, P2261, DOI 10.1016/S0002-9270(03)00748-2; Marcellin P, 2004, NEW ENGL J MED, V351, P1206, DOI 10.1056/NEJMoa040431; Papatheodoridis GV, 2002, HEPATOLOGY, V36, P219, DOI 10.1053/jhep.2002.33894; Papatheodoridis GV, 2004, ALIMENT PHARM THER, V19, P25, DOI 10.1046/j.1365-2036.2003.01810.x; Rizzetto M, 2005, J HEPATOL, V42, P173, DOI 10.1016/j.jhep.2004.10.006; Rizzetto M, 2002, J MED VIROL, V66, P435, DOI 10.1002/jmv.2164; Tassopoulos NC, 1999, HEPATOLOGY, V29, P889, DOI 10.1002/hep.510290321; Tenney DJ, 2004, ANTIMICROB AGENTS CH, V48, P3498, DOI 10.1128/AAC.48.9.3498-3507.2004; *WHO, 2000, WHO204; Yuen MF, 2002, J INFECT DIS, V186, P1335, DOI 10.1086/344327	34	894	972	0	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 9	2006	354	10					1011	1020		10.1056/NEJMoa051287	http://dx.doi.org/10.1056/NEJMoa051287			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	019FY	16525138	Green Published			2022-12-28	WOS:000235822200005
J	Graham, PL; Lin, SX; Larson, EL				Graham, PL; Lin, SX; Larson, EL			A US population-based survey of Staphylococcus aureus colonization	ANNALS OF INTERNAL MEDICINE			English	Article							METHICILLIN-RESISTANT; NASAL CARRIAGE; RISK-FACTORS; COMMUNITY; PREVALENCE; EPIDEMIOLOGY; INFECTIONS; EMERGENCE; CHILDREN	Background: The epidemiology of staphylococcal colonization and community-associated methicillin-resistant Staphylococcus aureus (MRSA) is changing, and little is known from the national perspective. Objective: To describe the U.S. epidemiology of S. aureus nasal colonization, compare risk factors for colonization with methicillin-sensitive S. aureus (MSSA) versus MRSA, and compare antibiotic resistance patterns and genetic factors of colonizing strains of S. aureus. Design: Secondary analysis of data from the National Health and Nutrition Examination Survey (NHANES), a stratified, multistage probability sample. Setting: United States. Participants: 2001-2002 NHANES participants older than 1 year of age. Measurements: Colonization of MSSA and MRSA, risk factors for colonization, antimicrobial resistance, and percentage of isolates with selected genetic factors. Results: The prevalence of colonization with S. aureus and with MRSA was 31.6% and 0.84%, respectively, in the noninstitutionalized U.S. population. People younger than 65 years of age, men, persons with less education, and persons with asthma were more likely to acquire S. aureus. Persons of black race and those of Mexican birth had lower risk for S. aureus colonization. Persons 65 years of age or older, women, persons with diabetes, and those who were in long-term care in the past year were more likely to have MRSA colonization. Hispanic persons had statistically significantly less risk than white persons. Isolates of MRSA with staphylococcal chromosomal cassette mec type IV (which is often associated with community-associated MRSA) were statistically significantly more likely to be sensitive to erythromycin, clindamycin, and ciprofloxacin. Limitations: Colonizing isolates may be different from isolates associated with infection. Risk factors identified may differ from those associated with invasive disease. The 2001-2002 NHANES data are several years old and may not reflect the most recent changes in epidemiology, but they are the only national data available. Conclusions: Characteristics of persons with MSSA and MRSA seem to differ. These findings may be useful for differentiating those who may be at risk for MRSA.	Columbia Univ, Dept Pediat, New York, NY 10032 USA; New York Presbyterian Med Ctr, New York, NY USA	Columbia University	Graham, PL (corresponding author), Columbia Univ, Dept Pediat, 622 W 168th St,PH 4 W,Room 463, New York, NY 10032 USA.	pgl43@columbia.edu	Graham, Petra/V-8136-2019	Graham, Petra/0000-0003-2890-2447	NATIONAL CENTER FOR RESEARCH RESOURCES [K12RR017648, P20RR020616] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR020616, K12-RR017648, P20 RR020616-03] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bischoff WE, 2004, INFECT CONT HOSP EP, V25, P485, DOI 10.1086/502427; Charlebois ED, 2002, CLIN INFECT DIS, V34, P425, DOI 10.1086/338069; Dinges MM, 2000, CLIN MICROBIOL REV, V13, P16, DOI 10.1128/CMR.13.1.16-34.2000; Dufour P, 2002, CLIN INFECT DIS, V35, P819, DOI 10.1086/342576; Frank AL, 1999, PEDIATR INFECT DIS J, V18, P993, DOI 10.1097/00006454-199911000-00012; Fridkin SK, 2005, NEW ENGL J MED, V352, P1436, DOI 10.1056/NEJMoa043252; Gorak EJ, 1999, CLIN INFECT DIS, V29, P797, DOI 10.1086/520437; Herold BC, 1998, JAMA-J AM MED ASSOC, V279, P593, DOI 10.1001/jama.279.8.593; Jernigan JA, 2003, INFECT CONT HOSP EP, V24, P445, DOI 10.1086/502223; Kluytmans J, 1997, CLIN MICROBIOL REV, V10, P505, DOI 10.1128/CMR.10.3.505; Larson E, 2004, J URBAN HEALTH, V81, P498, DOI 10.1093/jurban/jth133; Larson E, 2003, EMERG INFECT DIS, V9, P1096; LAYTON MC, 1995, INFECT CONT HOSP EP, V16, P12; Lina G, 1999, CLIN INFECT DIS, V29, P1128, DOI 10.1086/313461; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Ma XX, 2002, ANTIMICROB AGENTS CH, V46, P1147, DOI 10.1128/AAC.46.4.1147-1152.2002; Maguire GP, 1996, MED J AUSTRALIA, V164, P721, DOI 10.5694/j.1326-5377.1996.tb122270.x; Mainous AG, 2005, EMERG INFECT DIS, V11, P883, DOI 10.3201/EID1106.040960; Naimi TS, 2003, JAMA-J AM MED ASSOC, V290, P2976, DOI 10.1001/jama.290.22.2976; Okuma K, 2002, J CLIN MICROBIOL, V40, P4289, DOI 10.1128/JCM.40.11.4289-4294.2002; Replogle ML, 2000, CLIN INFECT DIS, V30, P515, DOI 10.1086/313715; Sattler CA, 2002, PEDIATR INFECT DIS J, V21, P910, DOI 10.1097/00006454-200210000-00005; Solomon S, 2003, AM J INFECT CONTROL, V31, P481; Taylor JP, 2000, AM J PUBLIC HEALTH, V90, P271, DOI 10.2105/AJPH.90.2.271; *US DEP HHS NAT CT, 2005, NAT HLTH NUTR EX SUR; *US DEP HHS NAT CT, 2005, NHANES GEN AN GUID; *US DEP HHS NAT CT, 2005, NHANES 2001 2002 DAT; VandenBergh MFQ, 1999, J LAB CLIN MED, V133, P525, DOI 10.1016/S0022-2143(99)90181-6; Vandenesch F, 2003, EMERG INFECT DIS, V9, P978; von Eiff C, 2001, NEW ENGL J MED, V344, P11, DOI 10.1056/NEJM200101043440102; 1999, MMWR MORB MORTAL WKL, V48, P707	31	308	314	0	23	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 7	2006	144	5					318	325		10.7326/0003-4819-144-5-200603070-00006	http://dx.doi.org/10.7326/0003-4819-144-5-200603070-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	021EA	16520472				2022-12-28	WOS:000235965300002
J	Langer-Gould, A; Steinman, L				Langer-Gould, A; Steinman, L			What went wrong in the natalizumab trials?	LANCET			English	Editorial Material							PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMITTING MULTIPLE-SCLEROSIS; FOLLOW-UP; DIAGNOSTIC-CRITERIA; NATURAL-HISTORY; DISABILITY; GUIDELINES; PREDICTORS; THERAPY; DISEASE		Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	Stanford University; Stanford University	Steinman, L (corresponding author), Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA.	steinman@stanford.edu		Steinman, Lawrence/0000-0002-2437-2250	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS043207] Funding Source: NIH RePORTER; NINDS NIH HHS [NS43207-04] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Achiron A, 2003, MULT SCLER, V9, P486, DOI 10.1191/1352458503ms945oa; Amato MP, 1999, J NEUROL SCI, V168, P96, DOI 10.1016/S0022-510X(99)00143-4; Bergamaschi R, 2001, J NEUROL SCI, V189, P13, DOI 10.1016/S0022-510X(01)00572-X; Black WC, 1997, AM J ROENTGENOL, V168, P3, DOI 10.2214/ajr.168.1.8976910; BRYAN WW, 2005, 1251040 BLA FOOD DRU, P37; Confavreux C, 2003, BRAIN, V126, P770, DOI 10.1093/brain/awg081; Eriksson M, 2003, MULT SCLER J, V9, P260, DOI 10.1191/1352458503ms914oa; Kantarci O, 1998, NEUROLOGY, V51, P765, DOI 10.1212/WNL.51.3.765; Kleinschmidt-DeMasters BK, 2005, NEW ENGL J MED, V353, P369, DOI 10.1056/NEJMoa051782; Langer-Gould A, 2005, NEW ENGL J MED, V353, P375, DOI 10.1056/NEJMoa051847; Lynch SG, 2005, MULT SCLER J, V11, P469, DOI 10.1191/1352458505ms1182oa; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Myhr KM, 2001, MULT SCLER, V7, P59, DOI 10.1191/135245801667968135; Pittock SJ, 2004, NEUROLOGY, V62, P51, DOI 10.1212/01.WNL.0000101724.93433.00; Pompeii LA, 2005, J OCCUP REHABIL, V15, P69, DOI 10.1007/s10926-005-0875-y; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; RUNMARKER B, 1993, BRAIN, V116, P117, DOI 10.1093/brain/116.1.117; SCHUMACHER GA, 1965, ANN NY ACAD SCI, V122, P552; TROJANO M, 1995, J NEUROL NEUROSUR PS, V58, P300, DOI 10.1136/jnnp.58.3.300; *US FDA, 2006, QUEST ANSW TYS NAT R; Van Assche G, 2005, NEW ENGL J MED, V353, P362, DOI 10.1056/NEJMoa051586; WEINSHENKER BG, 1989, BRAIN, V112, P133, DOI 10.1093/brain/112.1.133	22	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 4	2006	367	9512					708	710		10.1016/S0140-6736(06)68279-2	http://dx.doi.org/10.1016/S0140-6736(06)68279-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	020JX	16517256				2022-12-28	WOS:000235906000006
J	Zohlnhofer, D; Ott, I; Mehilli, J; Schoming, K; Michalk, F; Ibrahim, T; Meisetschlager, G; von Wedel, J; Bollwein, H; Seyfarth, M; Dirschinger, J; Schmitt, C; Schwaiger, M; Kastrati, A; Schomig, A				Zohlnhofer, D; Ott, I; Mehilli, J; Schoming, K; Michalk, F; Ibrahim, T; Meisetschlager, G; von Wedel, J; Bollwein, H; Seyfarth, M; Dirschinger, J; Schmitt, C; Schwaiger, M; Kastrati, A; Schomig, A		REVIVAL-2 Investigators	Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENDOTHELIAL PROGENITOR CELLS; PERIPHERAL-BLOOD; CARDIAC MYOCYTES; REPAIR; REGENERATION; GROWTH; HEART; NEOVASCULARIZATION; TRANSPLANTATION; RECOVERY	Context Experimental studies and early phase clinical trials suggest that transplantation of blood-derived or bone marrow - derived stem cells may improve cardiac regeneration and neovascularization after acute myocardial infarction. Granulocyte colony-stimulating factor (G-CSF) induces mobilization of bone marrow stem cells. Objective To assess the value of stem cell mobilization by G-CSF therapy in patients with acute myocardial infarction. Design, Setting, and Patients Randomized, double-blind, placebo-controlled trial of patients diagnosed with ST-segment elevation acute myocardial infarction who had successful reperfusion by percutaneous coronary intervention within 12 hours after onset of symptoms in Germany between February 24, 2004, and February 2, 2005. Interventions Patients were randomly assigned to receive subcutaneously either a daily dose of 10 mu g/kg of G-CSF or placebo for 5 days. Main Outcome Measures The primary end point was reduction of left ventricular infarct size according to technetium Tc 99m sestamibi scintigraphy performed at baseline and at 4 to 6 months after randomization. Secondary end points included improvement of left ventricular ejection fraction measured by magnetic resonance imaging and the incidence of angiographic restenosis. Results Of the 114 patients, 56 were assigned to receive treatment with G-CSF and 58 were assigned to receive placebo. Treatment with G-CSF produced a significant mobilization of stem cells. Between baseline and follow-up, left ventricular infarct size according to scintigraphy was reduced by a mean (SD) of 6.2% (9.1%) in the G-CSF group and 4.9% (8.9%) in the placebo group (P=. 56) and left ventricular ejection fraction was improved by 0.5% (3.8%) in the G-CSF group and 2.0% ( 4.9%) in the placebo group ( P=. 14). Angiographic restenosis occurred in 19 (35.2%) of 54 patients in the G-CSF group and in 17 (30.9%) of 55 patients in the placebo group ( P=. 79). The most common adverse event among patients assigned to G-CSF was mild to moderate bone pain and muscle discomfort. Conclusion Stem cell mobilization by G-CSF therapy in patients with acute myocardial infarction and successful mechanical reperfusion has no influence on infarct size, left ventricular function, or coronary restenosis. Clinical Trial Registration ClinicalTrials. gov Identifier: NCT00126100.	Tech Univ Munich, Deutsch Herzzentrum, D-80636 Munich, Germany; Tech Univ Munich, Med Klin 1, Klinikum Rechts Isar, D-80636 Munich, Germany; Tech Univ Munich, Nukl Med Klin & Poliklin Rechts Isar, D-80636 Munich, Germany	German Heart Center Berlin; German Heart Centre Munich; Technical University of Munich; Technical University of Munich; Technical University of Munich	Schomig, A (corresponding author), Tech Univ Munich, Deutsch Herzzentrum, Lazarettstr 36, D-80636 Munich, Germany.	aschoemig@dhm.mhn.de	Mehilli, Julinda/F-2629-2016; , Kastrati/Y-2389-2019	schwaiger, markus/0000-0002-2305-7144				Abbott JD, 2004, CIRCULATION, V110, P3300, DOI 10.1161/01.CIR.0000147780.30124.CF; Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Barnett D, 2000, BRIT J HAEMATOL, V108, P784, DOI 10.1046/j.1365-2141.2000.01932.x; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Carion A, 2002, J HEMATOTH STEM CELL, V11, P491, DOI 10.1089/15258160260090951; Dimmeler S, 2005, J CLIN INVEST, V115, P572, DOI 10.1172/JCI200524283; Dlubek D, 2006, BONE MARROW TRANSPL, V37, P19, DOI 10.1038/sj.bmt.1705198; ELLIS SG, 1983, J AM COLL CARDIOL, V1, P1047, DOI 10.1016/S0735-1097(83)80107-7; Forrester JS, 2003, CIRCULATION, V108, P1139, DOI 10.1161/01.CIR.0000085305.82019.65; Harada M, 2005, NAT MED, V11, P305, DOI 10.1038/nm1199; Heil M, 2004, CIRC RES, V94, P573, DOI 10.1161/01.RES.0000124603.46777.EB; Hill JM, 2005, J AM COLL CARDIOL, V46, P1643, DOI 10.1016/j.jacc.2005.01.067; Hubel K, 2003, ANN HEMATOL, V82, P207, DOI 10.1007/s00277-003-0628-y; Ince H, 2005, CIRCULATION, V112, P3097, DOI 10.1161/CIRCULATIONAHA.105.541433; Janssens S, 2006, LANCET, V367, P113, DOI 10.1016/S0140-6736(05)67861-0; Kajstura J, 2005, CIRC RES, V96, P127, DOI 10.1161/01.RES.0000151843.79801.60; Kang HJ, 2004, LANCET, V363, P751, DOI 10.1016/S0140-6736(04)15689-4; Kastrati A, 2002, LANCET, V359, P920, DOI 10.1016/S0140-6736(02)08022-4; Kawamoto A, 2004, CIRCULATION, V110, P1398, DOI 10.1161/01.CIR.0000141563.71410.64; KLONER RA, 1989, AM J MED, V86, P14, DOI 10.1016/0002-9343(89)90005-3; KLONER RA, 1991, NEW ENGL J MED, V325, P1877, DOI 10.1056/NEJM199112263252610; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Krause DS, 1996, BLOOD, V87, P1; Laugwitz KL, 2005, NATURE, V433, P647, DOI 10.1038/nature03215; Leone AM, 2005, EUR HEART J, V26, P1196, DOI 10.1093/eurheartj/ehi164; Leri A, 2005, PHYSIOL REV, V85, P1373, DOI 10.1152/physrev.00013.2005; Massa M, 2005, BLOOD, V105, P199, DOI 10.1182/blood-2004-05-1831; Mathur A, 2004, LANCET, V364, P183, DOI 10.1016/S0140-6736(04)16632-4; Minatoguchi S, 2004, CIRCULATION, V109, P2572, DOI 10.1161/01.CIR.0000129770.93985.3E; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Ohki Y, 2005, FASEB J, V19, P2005, DOI 10.1096/fj.04-3496fje; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; PATEL B, 1988, ANN INTERN MED, V108, P626, DOI 10.7326/0003-4819-108-4-626; SCHACHINGER V, INTRACORONARY INFUSI; Schomig A, 2000, NEW ENGL J MED, V343, P385, DOI 10.1056/NEJM200008103430602; Schomig A, 2005, JAMA-J AM MED ASSOC, V293, P2865, DOI 10.1001/jama.293.23.2865; SCHOMIG K, IN PRESS EUR HEART J; Sesti C, 2005, J AM COLL CARDIOL, V46, P1662, DOI 10.1016/j.jacc.2005.08.012; SHEEHAN FH, 1985, CIRCULATION, V71, P1121, DOI 10.1161/01.CIR.71.6.1121; Shintani S, 2001, CIRCULATION, V103, P2776, DOI 10.1161/hc2301.092122; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Sugano Y, 2005, CARDIOVASC RES, V65, P446, DOI 10.1016/j.cardiores.2004.10.008; Valgimigli M, 2005, EUR HEART J, V26, P1838, DOI 10.1093/eurheartj/ehi289; Wojakowski W, 2006, EUR HEART J, V27, P283, DOI 10.1093/eurheartj/ehi628; Wojakowski W, 2004, CIRCULATION, V110, P3213, DOI 10.1161/01.CIR.0000147609.39780.02; Wollert KC, 2004, LANCET, V364, P141, DOI 10.1016/S0140-6736(04)16626-9	48	340	359	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	2006	295	9					1003	1010		10.1001/jama.295.9.1003	http://dx.doi.org/10.1001/jama.295.9.1003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	016XJ	16507801	Bronze			2022-12-28	WOS:000235656600020
J	Wilkinson, IB; McEniery, CM; Cockcroft, JR				Wilkinson, IB; McEniery, CM; Cockcroft, JR			Atenolol and cardiovascular risk: an issue close to the heart	LANCET			English	Editorial Material							BLOOD-PRESSURE; HYPERTENSION; TRIAL; METAANALYSIS; REDUCTION; MORTALITY; OUTCOMES; DISEASE		Wales Heart Res Inst, Dept Cardiol, Cardiff CF14 4XN, Wales; Univ Cambridge, Addenbrookes Hosp, Clin Pharmacol Unit, Cambridge CB2 2QQ, England	Cardiff University; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Cockcroft, JR (corresponding author), Wales Heart Res Inst, Dept Cardiol, Cardiff CF14 4XN, Wales.	cockcroftjr@cf.ac.uk		wilkinson, ian/0000-0001-6598-9399				*CAFE INV, 2006, CIRCULATION; Carlberg B, 2004, LANCET, V364, P1684, DOI 10.1016/S0140-6736(04)17355-8; Cockcroft JR, 2002, LANCET, V359, P2202, DOI 10.1016/S0140-6736(02)09075-X; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Dahlof B, 2005, LANCET, V366, P895, DOI 10.1016/S0140-6736(05)67185-1; Dhakam Z, 2006, AM J HYPERTENS, V19, P214, DOI 10.1016/j.amjhyper.2005.08.007; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981; KELLY R, 1989, HYPERTENSION, V14, P14, DOI 10.1161/01.HYP.14.1.14; Lindholm LH, 2005, LANCET, V366, P1545, DOI 10.1016/S0140-6736(05)67573-3; Morgan T, 2004, AM J HYPERTENS, V17, P118, DOI 10.1016/j.amjhyper.2003.09.012; REMINGTON JW, 1956, J APPL PHYSIOL, V9, P433, DOI 10.1152/jappl.1956.9.3.433; Safar ME, 2002, HYPERTENSION, V39, P735, DOI 10.1161/hy0202.098325; Staessen JA, 2001, LANCET, V358, P1305, DOI 10.1016/S0140-6736(01)06411-X; Wilkinson IB, 2000, J PHYSIOL-LONDON, V525, P263, DOI 10.1111/j.1469-7793.2000.t01-1-00263.x; Wilkinson IB, 1998, CURR OPIN LIPIDOL, V9, P237, DOI 10.1097/00041433-199806000-00009; Williams B, 2004, J HYPERTENS, V22, P447, DOI 10.1097/00004872-200403000-00002	16	27	27	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 25	2006	367	9511					627	629		10.1016/S0140-6736(06)68238-X	http://dx.doi.org/10.1016/S0140-6736(06)68238-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	016HR	16503444				2022-12-28	WOS:000235611800005
J	Hankey, GJ; Eikelboom, J				Hankey, GJ; Eikelboom, J			Aspirin resistance	LANCET			English	Review							LOW-DOSE ASPIRIN; PERCUTANEOUS CORONARY INTERVENTION; INCREASED PLATELET SENSITIVITY; TRANSIENT ISCHEMIC ATTACK; MULTIPLE RISK-FACTORS; MYOCARDIAL-INFARCTION; IN-VITRO; THROMBOXANE BIOSYNTHESIS; FUNCTION ANALYZER; ARACHIDONIC-ACID	Aspirin resistance is the inability of aspirin to reduce platelet production of thromboxane A, and thereby platelet activation and aggregation. Increasing degrees of aspirin resistance may correlate independently with increasing risk of cardiovascular events. Aspirin resistance can be detected by laboratory tests of platelet thromboxane A, production or platelet function that depend on platelet thromboxane production. Potential causes of aspirin resistance include inadequate dose, drug interactions, genetic polymorphisms of COX-1 and other genes involved in thromboxane biosynthesis, upregulation of non-platelet sources of thromboxane biosynthesis, and increased platelet turnover. Aspirin resistance can be overcome by treating the cause or causes, and reduced by minimising thromboxane production and activity, and blocking other pathways of platelet activation. Future research is aimed at defining aspirin resistance, developing reliable tests for it, and establishing the risk of associated cardiovascular events. Potential mechanisms of aspirin resistance can then be explored and treatments assessed.	McMaster Univ, HGH McMaster Clin, Dept Med, Hamilton, ON L9K 1H8, Canada; Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia; Royal Perth Hosp, Dept Neurol, Perth, WA, Australia	McMaster University; University of Western Australia; Royal Perth Hospital; University of Western Australia	Eikelboom, J (corresponding author), McMaster Univ, HGH McMaster Clin, Dept Med, 237 Barton St E, Hamilton, ON L9K 1H8, Canada.	eikelbj@mcmaster.ca	Eikelboom, John/AAG-6117-2019; Violi, Francesco/K-1509-2016; pignatelli, pasquale/K-2116-2016; Skoric, Bosko/O-3177-2013; Hankey, Graeme J/H-4968-2014	Eikelboom, John/0000-0003-4126-1285; Violi, Francesco/0000-0002-6610-7068; pignatelli, pasquale/0000-0002-2265-7455; Hankey, Graeme J/0000-0002-6044-7328				Alexander JH, 1999, AM J CARDIOL, V83, P1147, DOI 10.1016/S0002-9149(99)00049-1; *AM SOC HYP, MED EXP REDEFINE HYP; Anand BS, 1999, GASTROENTEROLOGY, V116, pA371; Andersen K, 2002, THROMB RES, V108, P37, DOI 10.1016/S0049-3848(02)00405-X; Andrioli G, 2000, BRIT J HAEMATOL, V110, P911, DOI 10.1046/j.1365-2141.2000.02300.x; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Bhatt DL, 2004, AM HEART J, V148, P263, DOI 10.1016/j.ahj.2004.03.028; Bhatt DL, 2004, J AM COLL CARDIOL, V43, P1127, DOI 10.1016/j.jacc.2004.01.022; Bhatt DL, 2003, NAT REV DRUG DISCOV, V2, P15, DOI 10.1038/nrd985; BUCHANAN MR, 1995, CAN J CARDIOL, V11, P221; BURCH JW, 1978, J CLIN INVEST, V61, P314, DOI 10.1172/JCI108941; Cambria-Kiely JA, 2002, J THROMB THROMBOLYS, V14, P51, DOI 10.1023/A:1022066305399; Cambria-Kiely JA, 2002, J THROMB THROMBOLYS, V13, P49, DOI 10.1023/A:1015324310374; Campbell CL, 2005, J THROMB HAEMOST, V3, P665, DOI 10.1111/j.1538-7836.2005.01119.x; Capone ML, 2005, J AM COLL CARDIOL, V45, P1295, DOI 10.1016/j.jacc.2005.01.045; Carney RM, 1998, BEHAV MED, V24, P35, DOI 10.1080/08964289809596379; Catella-Lawson F, 2001, NEW ENGL J MED, V345, P1809, DOI 10.1056/NEJMoa003199; Cattaneo M, 2004, ARTERIOSCL THROM VAS, V24, P1980, DOI 10.1161/01.ATV.0000145980.39477.a9; Cerletti C, 2003, CLIN PHARMACOKINET, V42, P1059, DOI 10.2165/00003088-200342120-00004; Chen WH, 2004, J AM COLL CARDIOL, V43, P1122, DOI 10.1016/j.jacc.2003.12.034; Cipollone F, 2004, JAMA-J AM MED ASSOC, V291, P2221, DOI 10.1001/jama.291.18.2221; Cipollone F, 2000, CIRCULATION, V102, P1007, DOI 10.1161/01.CIR.102.9.1007; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Curtis JP, 2004, J AM COLL CARDIOL, V43, P991, DOI 10.1016/j.jacc.2004.01.001; Davi G, 1999, CIRCULATION, V99, P224; DECATERINA R, 1985, THROMB HAEMOSTASIS, V54, P528; DECATERINA R, 1985, EUR HEART J, V6, P409, DOI 10.1093/oxfordjournals.eurheartj.a061879; Dippel DWJ, 2004, CEREBROVASC DIS, V17, P296, DOI 10.1159/000077340; Eikelboom John W, 2004, Am J Cardiovasc Drugs, V4, P57, DOI 10.2165/00129784-200404010-00006; Eikelboom JW, 2005, J THROMB HAEMOST, V3, P2649, DOI 10.1111/j.1538-7836.2005.01640.x; Eikelboom JW, 2002, CIRCULATION, V105, P1650, DOI 10.1161/01.CIR.0000013777.21160.07; *EUR SOC HYP, NEW DEF CLASS HYP AN; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; FITZGERALD GA, 1983, J CLIN INVEST, V71, P676, DOI 10.1172/JCI110814; Friend M, 2003, BRIT MED J, V326, P82, DOI 10.1136/bmj.326.7380.82; Golanski J, 2005, THER DRUG MONIT, V27, P484, DOI 10.1097/01.ftd.0000158084.84071.41; Gonzalez-Conejero R, 2005, STROKE, V36, P276, DOI 10.1161/01.STR.0000151362.65339.f9; GROTEMEYER KH, 1993, THROMB RES, V71, P397, DOI 10.1016/0049-3848(93)90164-J; Grundmann K, 2003, J NEUROL, V250, P63, DOI 10.1007/s00415-003-0954-y; Gum PA, 2003, J AM COLL CARDIOL, V41, P961, DOI 10.1016/S0735-1097(02)03014-0; Gum PA, 2001, AM J CARDIOL, V88, P230, DOI 10.1016/S0002-9149(01)01631-9; Gurbel PA, 2005, J AM COLL CARDIOL, V45, P1392, DOI 10.1016/j.jacc.2005.01.030; Gurbel PA, 2003, CIRCULATION, V107, P2908, DOI 10.1161/01.CIR.0000072771.11429.83; Halushka MK, 2003, CLIN PHARMACOL THER, V73, P122, DOI 10.1067/mcp.2003.1; Hankey GJ, 2004, BMJ-BRIT MED J, V328, P477, DOI 10.1136/bmj.328.7438.477; Harrison P, 2000, BRIT J HAEMATOL, V111, P733; Harrison P, 2005, STROKE, V36, P1001, DOI 10.1161/01.STR.0000162719.11058.bd; Hart RG, 2003, PHARMACOTHERAPY, V23, P579, DOI 10.1592/phco.23.5.579.32206; HELGASON CM, 1994, STROKE, V25, P2331, DOI 10.1161/01.STR.25.12.2331; HUNG J, 1995, CIRCULATION, V92, P2432, DOI 10.1161/01.CIR.92.9.2432; Inarrea P, 2000, SCAND J GASTROENTERO, V35, P242; Jefferson BK, 2005, AM J CARDIOL, V95, P805, DOI 10.1016/j.amjcard.2004.11.045; Karim S, 1996, J BIOL CHEM, V271, P12042, DOI 10.1074/jbc.271.20.12042; Kawasaki T, 2000, STROKE, V31, P591, DOI 10.1161/01.STR.31.3.591; Kong David F, 2004, Am J Cardiovasc Drugs, V4, P151, DOI 10.2165/00129784-200404030-00002; Kundu SK, 1996, CLIN APPL THROMB-HEM, V2, P241, DOI 10.1177/107602969600200404; Lee PY, 2005, AM J MED, V118, P723, DOI 10.1016/j.amjmed.2005.03.041; Macchi L, 2003, J AM COLL CARDIOL, V42, P1115, DOI 10.1016/S0735-1097(03)00921-5; Macchi L, 2002, THROMB RES, V107, P45, DOI 10.1016/S0049-3848(02)00210-4; MacDonald TM, 2003, LANCET, V361, P573, DOI 10.1016/S0140-6736(03)12509-3; Maclouf J, 1998, THROMB HAEMOSTASIS, V79, P691; MacMahon S, 2005, LANCET, V365, P1108; Malinin A, 2004, BLOOD COAGUL FIBRIN, V15, P295, DOI 10.1097/00001721-200406000-00002; Malinin AI, 2003, EUR J PHARMACOL, V462, P139, DOI 10.1016/S0014-2999(02)02956-4; Marshall PW, 1997, BRIT J CLIN PHARMACO, V44, P151, DOI 10.1046/j.1365-2125.1997.00639.x; Matetzky S, 2004, CIRCULATION, V109, P3171, DOI 10.1161/01.CIR.0000130846.46168.03; McNicol A, 2003, J PHARMACOL SCI, V93, P381, DOI 10.1254/jphs.93.381; MEHTA J, 1978, ATHEROSCLEROSIS, V31, P169, DOI 10.1016/0021-9150(78)90162-4; Michelson AD, 2000, CIRCULATION, V101, P1013, DOI 10.1161/01.CIR.101.9.1013; Michelson AD, 2004, CIRCULATION, V110, pE489, DOI 10.1161/01.CIR.0000147228.29325.F9; Michelson AD, 2005, J THROMB HAEMOST, V3, P1309, DOI 10.1111/j.1538-7836.2005.01351.x; MORROW JD, 1995, NEW ENGL J MED, V332, P1198, DOI 10.1056/NEJM199505043321804; Mueller MR, 1997, THROMB HAEMOSTASIS, V78, P1003; NEEDS CJ, 1985, CLIN PHARMACOKINET, V10, P164, DOI 10.2165/00003088-198510020-00004; O'Donnell CJ, 2001, CIRCULATION, V103, P3051, DOI 10.1161/01.CIR.103.25.3051; Patrignani P, 1999, J PHYSIOL PHARMACOL, V50, P661; PATRIGNANI P, 1982, J CLIN INVEST, V69, P1366, DOI 10.1172/JCI110576; Patrono C, 2005, CURR OPIN PHARMACOL, V5, P198, DOI 10.1016/j.coph.2004.11.003; Patrono C, 2003, J THROMB HAEMOST, V1, P1710, DOI 10.1046/j.1538-7836.2003.00284.x; Patrono C, 2004, CHEST, V126, p234S, DOI 10.1378/chest.126.3_suppl.234S; Patrono C, 2004, EUR HEART J, V25, P166, DOI 10.1016/j.ehj.2003.10.013; Payne DA, 2004, THROMB HAEMOSTASIS, V92, P89, DOI 10.1160/th03-12-0758; POLLACK A, 2004, NY TIMES        0720, pF1; Poulsen TS, 2004, ANN HEMATOL, V83, P728, DOI 10.1007/s00277-004-0940-1; Pulcinelli FM, 2004, J AM COLL CARDIOL, V43, P979, DOI 10.1016/j.jacc.2003.08.062; Rand ML, 2003, TRANSFUS APHER SCI, V28, P307, DOI 10.1016/S1473-0502(03)00050-8; Reilly M, 1996, CIRCULATION, V94, P19, DOI 10.1161/01.CIR.94.1.19; Rocca B, 2002, P NATL ACAD SCI USA, V99, P7634, DOI 10.1073/pnas.112202999; Roller RE, 2002, BLOOD COAGUL FIBRIN, V13, P277, DOI 10.1097/00001721-200206000-00001; ROTH GJ, 1994, BLOOD, V83, P885; ROTH GJ, 1975, J CLIN INVEST, V56, P624, DOI 10.1172/JCI108132; ROTH GJ, 1975, P NATL ACAD SCI USA, V72, P3073, DOI 10.1073/pnas.72.8.3073; Sabatine MS, 2005, NEW ENGL J MED, V352, P1179, DOI 10.1056/NEJMoa050522; Sanderson S, 2005, ANN INTERN MED, V142, P370, DOI 10.7326/0003-4819-142-5-200503010-00012; Santopinto J, 2001, AM HEART J, V141, P566, DOI 10.1067/mhj.2001.113994; Schonbeck U, 1999, AM J PATHOL, V155, P1281, DOI 10.1016/S0002-9440(10)65230-3; Schwartz KA, 2005, AM J CARDIOL, V95, P973, DOI 10.1016/j.amjcard.2004.12.038; Serebruany VL, 2005, AM J CARDIOL, V95, P1218, DOI 10.1016/j.amjcard.2005.01.049; Smith CJ, 1998, INHAL TOXICOL, V10, P765; Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411; Szczeklik A, 2000, BRIT J HAEMATOL, V110, P965, DOI 10.1046/j.1365-2141.2000.02267.x; Tarjan Jeno, 1999, Orvosi Hetilap, V140, P2339; TOHGI H, 1992, STROKE, V23, P1400, DOI 10.1161/01.STR.23.10.1400; van Gijn J, 2005, CEREBROVASC DIS, V19, P69, DOI 10.1159/000082782; Warlow C, 2003, LANCET, V362, P1211, DOI 10.1016/S0140-6736(03)14544-8; Weber AA, 1999, LANCET, V353, P900, DOI 10.1016/S0140-6736(99)00498-5; Weber AA, 2002, PLATELETS, V13, P37, DOI 10.1080/09537100120104890; Weber AA, 2000, PLATELETS, V11, P177; Weinshilboum R, 2003, NEW ENGL J MED, V348, P529, DOI 10.1056/NEJMra020021; WILLIAMS FM, 1985, CLIN PHARMACOKINET, V10, P392, DOI 10.2165/00003088-198510050-00002; Yusuf S, 2001, NEW ENGL J MED, V345, P494; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9; Zimmermann N, 2003, CIRCULATION, V108, P542, DOI 10.1161/01.CIR.0000081770.51929.5A	113	430	487	1	47	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 18	2006	367	9510					606	617		10.1016/S0140-6736(06)68040-9	http://dx.doi.org/10.1016/S0140-6736(06)68040-9			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013GM	16488805				2022-12-28	WOS:000235397800036
J	Roughgarden, J; Oishi, M; Akcay, E				Roughgarden, J; Oishi, M; Akcay, E			Reproductive social behavior: Cooperative games to replace sexual selection	SCIENCE			English	Review							EQUILIBRIUM SELECTION; EVOLUTION; SYSTEMS; MODEL	Theories about sexual selection can be traced back to Darwin in 1871. He proposed that mates fertilize as many females as possible with inexpensive sperm, whereas females, with a limited supply of large eggs, select the genetically highest quality mates to endow their offspring with superior capabilities. Since its proposal, problems with this narrative have continued to accumulate, and it is our view that sexual selection theory needs to be replaced. We suggest an approach that relies on the exchange of direct ecological benefits among cooperating animals without reference to genetic benefits. This approach can be expressed mathematically in a branch of game theory that pertains to bargaining and side payments.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Sandia Natl Labs, Albuquerque, NM 87185 USA	Stanford University; United States Department of Energy (DOE); Sandia National Laboratories	Roughgarden, J (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	joan.roughgarden@stanford.edu	Akcay, Erol/G-3167-2011	Akcay, Erol/0000-0001-8149-7124; Oishi, Meeko/0000-0003-3722-8837				Axelrod R., 1984, EVOLUTION COOPERATIO, DOI DOI 10.2307/3323905; Binmore K, 2003, GAME ECON BEHAV, V45, P296, DOI 10.1016/S0899-8256(03)00146-5; BINMORE K, 1986, RAND J ECON, V17, P176, DOI 10.2307/2555382; Buss D., 1994, EVOLUTION DESIRE, P20; Clutton-Brock Tim H., 2004, P24, DOI 10.1017/CBO9780511542459.004; COYNE J, 2004, TIMES LIT SUPPL 0730; Darwin C., 1871, P475; Ens Bruno J., 1996, V7, P186; FRIEDMAN JW, 1971, REV ECON STUD, V38, P1, DOI 10.2307/2296617; FUDENBERG D, 1986, ECONOMETRICA, V54, P533, DOI 10.2307/1911307; HAMEMERSTEIN P, 2003, GENETIC CULTURAL EVO; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; HARRIS MP, 1970, J ANIM ECOL, V39, P707, DOI 10.2307/2861; Heg D, 1998, NATURE, V391, P687, DOI 10.1038/35612; Huxley JS, 1938, AM NAT, V72, P416, DOI 10.1086/280795; Kambe S, 1999, GAME ECON BEHAV, V28, P217, DOI 10.1006/game.1998.0700; KANDORI M, 1993, ECONOMETRICA, V61, P29, DOI 10.2307/2951777; LUTBERG B, 1999, BEHAV ECOL, V10, P666; Maynard Smith J., 1982, pi; Nash J, 1953, ECONOMETRICA, V21, P128, DOI 10.2307/1906951; Nash JF, 1950, ECONOMETRICA, V18, P155, DOI 10.2307/1907266; NOE R, 1994, BEHAV ECOL SOCIOBIOL, V35, P1; NOE R, 1995, TRENDS ECOL EVOL, V10, P336, DOI 10.1016/S0169-5347(00)89123-5; Reeve HK, 1998, BEHAV ECOL, V9, P267, DOI 10.1093/beheco/9.3.267; Robson AJ, 1996, J ECON THEORY, V70, P65, DOI 10.1006/jeth.1996.0076; ROSE MR, 2006, EVOLUTION ECOLOGY OR, P570; Roughgarden Joan, 2004, EVOLUTIONS RAINBOW D; RUBINSTEIN A, 1982, ECONOMETRICA, V50, P97, DOI 10.2307/1912531; Shaikh MS, 2003, LECT NOTES COMPUT SC, V2623, P466; Straffin P., 1993, GAME THEORY STRATEGY; Tomlin CJ, 2003, P IEEE, V91, P986, DOI 10.1109/JPROC.2003.814621; VEHRENCAMP SL, 1983, ANIM BEHAV, V31, P667, DOI 10.1016/S0003-3472(83)80222-X; WARNER RR, 1995, BEHAV ECOL, V6, P73, DOI 10.1093/beheco/6.1.73; WASLANDER S, 2004, SERIES COMPUTERS OPE; Xu XP, 2004, IEEE T AUTOMAT CONTR, V49, P2, DOI 10.1109/TAC.2003.821417; YOUNG HP, 1993, J ECON THEORY, V59, P145, DOI 10.1006/jeth.1993.1009; 2005, ELLE             FEB	37	98	103	1	120	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 17	2006	311	5763					965	969		10.1126/science.1110105	http://dx.doi.org/10.1126/science.1110105			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	014CS	16484485				2022-12-28	WOS:000235456900035
J	Tierney, LM; Wang, KC				Tierney, LM; Wang, KC			Koplik's spots	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Vet Affairs Med Ctr, San Francisco, CA 94121 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Tierney, LM (corresponding author), Vet Affairs Med Ctr, San Francisco, CA 94121 USA.			Wang, Kevin/0000-0002-5305-6791					0	5	5	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 16	2006	354	7					740	740		10.1056/NEJMicm050576	http://dx.doi.org/10.1056/NEJMicm050576			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	012CP	16481641				2022-12-28	WOS:000235316100010
J	Blander, JM; Medzhitov, R				Blander, JM; Medzhitov, R			Toll-dependent selection of microbial antigens for presentation by dendritic cells	NATURE			English	Article							CLASS-II COMPLEXES; APOPTOTIC CELLS; MATURATION; RECEPTOR; ALPHA; TRANSPORT; LIPOPOLYSACCHARIDE; EXPRESSION; SIGNALS	Dendritic cells constitutively sample the tissue microenvironment and phagocytose both microbial and host apoptotic cells(1-4). This leads to the induction of immunity against invading pathogens or ;tolerance to peripheral self antigens, respectively(5-9). The outcome of antigen presentation by dendritic cells depends on their activation status, such that Toll-like receptor (TLR)-induced dendritic cell activation makes them immunogenic, whereas steady-state presentation of self antigens leads to tolerance(5,6,8,10). TLR-inducible expression of co-stimulatory signals is one of the mechanisms of self/ non-self discrimination(5,11). However, it is unclear whether or how the inducible expression of co-stimulatory signals would distinguish between self antigens and microbial antigens when both are encountered by dendritic cells during infection(6,8). Here we describe a new mechanism of antigen selection in dendritic cells for presentation by major histocompatibility complex class II molecules (MHCII) that is based on the origin of the antigen. We show that the efficiency of presenting antigens from phagocytosed cargo is dependent on the presence of TLR ligands within the cargo. Furthermore, we show that the generation of peptide - MHC class II complexes is controlled by TLRs in a strictly phagosome-autonomous manner.	Yale Univ, Sch Med, Immunobiol Sect, Howard Hughes Med Inst, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University	Medzhitov, R (corresponding author), Yale Univ, Sch Med, Immunobiol Sect, Howard Hughes Med Inst, 300 Cedar St, New Haven, CT 06520 USA.	ruslan.medzhitov@yale.edu		Blander, Julie Magarian/0000-0001-9207-1700				Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; Boes M, 2004, TRENDS CELL BIOL, V14, P175, DOI 10.1016/j.tcb.2004.02.004; Chow A, 2002, NATURE, V418, P988, DOI 10.1038/nature01006; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0; Henson PM, 2001, NAT REV MOL CELL BIO, V2, P627, DOI 10.1038/35085094; Henson PM, 2001, CURR BIOL, V11, pR795, DOI 10.1016/S0960-9822(01)00474-2; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Larsson M, 2001, TRENDS IMMUNOL, V22, P141, DOI 10.1016/S1471-4906(01)01860-9; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; Luhrmann A, 2000, Methods Cell Sci, V22, P329, DOI 10.1023/A:1017963401560; MATHIS DJ, 1983, P NATL ACAD SCI-BIOL, V80, P273, DOI 10.1073/pnas.80.1.273; Ravichandran KS, 2003, CELL, V113, P817, DOI 10.1016/S0092-8674(03)00471-9; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Thieblemont N, 1999, J EXP MED, V190, P523, DOI 10.1084/jem.190.4.523; Trombetta ES, 2005, ANNU REV IMMUNOL, V23, P975, DOI 10.1146/annurev.immunol.22.012703.104538; Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522; Viret C, 2000, J IMMUNOL, V164, P4627, DOI 10.4049/jimmunol.164.9.4627; Watts C, 2004, NAT IMMUNOL, V5, P685, DOI 10.1038/ni1088; West MA, 2004, SCIENCE, V305, P1153, DOI 10.1126/science.1099153; Zhong GM, 1997, P NATL ACAD SCI USA, V94, P13856, DOI 10.1073/pnas.94.25.13856	30	631	666	0	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 6	2006	440	7085					808	812		10.1038/nature04596	http://dx.doi.org/10.1038/nature04596			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	029GH	16489357				2022-12-28	WOS:000236548400044
J	Bell, CM; Urbach, DR; Ray, JG; Bayoumi, A; Rosen, AB; Greenberg, D; Neumann, PJ				Bell, CM; Urbach, DR; Ray, JG; Bayoumi, A; Rosen, AB; Greenberg, D; Neumann, PJ			Bias in published cost effectiveness studies: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PUBLICATION BIAS; UTILITY ANALYSES; DECISION-MAKING; CLINICAL-TRIALS; QUALITY; GUIDELINES; SPONSORSHIP; PERSPECTIVE; TECHNOLOGY; THRESHOLD	Objective To investigate if published studies tend to report favourable cost effectiveness ratios (below $20 000, $50 000, and $ 100 000 per quality adjusted life year (QALY) gained) and evaluate study characteristics associated with this phenomenon. Design Systematic review. Studies reviewed 494 English language studies measuring health effects in QALYs published up to December 2001 identified using Medline, HealthSTAR, CancerLit, Cur-rent Content and EconLit databases. Main outcome measures Incremental cost effectiveness ratios measured in dollars set to the year of publication. I Results Approximately half the reported incremental cost effectiveness ratios (712 of 1433) were below $20 000/QALY. Studies funded by industry were more likely to report cost effectiveness ratios below $20 000/QALY (adjusted odds ratio 2.1, 95% confidence interval 1.3 to 3.3),$50 000/QALY (3.2, 1.8 to 5.7), and $100 000/QALY (3.3,1.6 to 6.8). Studies of higher methodological quality (adjusted odds ratio 0.58, 0.37 to 0.91) and those conducted in Europe (0.59, 0.33 to 1.1) and the United States (0.44, 0.26 to 0.76) rather than elsewhere were less likely to report ratios below $20 000/QALY. Conclusion Most published analyses report favourable incremental cost effectiveness ratios. Studies funded by industry were more likely to report ratios below the three thresholds. Studies of higher methodological quality and those conducted in Europe and the US rather than elsewhere were less likely to report ratios below $20 000/QALY.	St Michaels Hosp, Toronto, ON M5B 1W8, Canada; Univ Hlth Network, Toronto, ON, Canada; Univ Michigan, Ann Arbor, MI 48109 USA; Ben Gurion Univ Negev, IL-84105 Beer Sheva, Israel; Tufts Univ, Sch Med, Ctr Evaluat Value & Risk Hlth, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Michigan System; University of Michigan; Ben Gurion University; Tufts University	Bell, CM (corresponding author), St Michaels Hosp, 30 Bond St, Toronto, ON M5B 1W8, Canada.	bellc@smh.toronto.on.ca	Bell, Chaim/C-4611-2015	Bell, Chaim/0000-0002-3778-9469; Greenberg, Dan/0000-0002-6759-3985	AHRQ HHS [R01 HS10919] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010919] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Baker CB, 2003, BRIT J PSYCHIAT, V183, P498, DOI 10.1192/bjp.183.6.498; *CAN COORD OFF HLT, 2005, COMM DRUG REV SUBM G; CHALMERS TC, 1990, JAMA-J AM MED ASSOC, V263, P1392, DOI 10.1001/jama.263.10.1392; Chapman GA, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-15-j0004.2000; Devlin N, 2004, HEALTH ECON, V13, P437, DOI 10.1002/hec.864; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; Eichler HG, 2004, VALUE HEALTH, V7, P518, DOI 10.1111/j.1524-4733.2004.75003.x; Evans Christopher, 2004, Health Care Manag Sci, V7, P43, DOI 10.1023/B:HCMS.0000005397.93173.bb; *FED RES BANK ST L, MONTHL EXCH RAT SER; Freemantle N, 1997, PHARMACOECONOMICS, V12, P10, DOI 10.2165/00019053-199712010-00002; Friedberg M, 1999, JAMA-J AM MED ASSOC, V282, P1453, DOI 10.1001/jama.282.15.1453; Garber AM, 1997, J HEALTH ECON, V16, P1, DOI 10.1016/S0167-6296(96)00506-1; Gold MR, 1996, COST EFFECTIVENESS H; Granata AV, 1998, ANN INTERN MED, V128, P56, DOI 10.7326/0003-4819-128-1-199801010-00009; Greenberg D, 2004, BMJ-BRIT MED J, V328, P1536, DOI 10.1136/bmj.38079.502326.AE; Haivas I, 2004, CAN MED ASSOC J, V171, P475, DOI 10.1503/cmaj.1031982; Hill SR, 2000, JAMA-J AM MED ASSOC, V283, P2116, DOI 10.1001/jama.283.16.2116; HILLMAN AL, 1991, NEW ENGL J MED, V324, P1362, DOI 10.1056/NEJM199105093241911; Hirth RA, 2000, MED DECIS MAKING, V20, P332, DOI 10.1177/0272989X0002000310; KASSIRER JP, 1994, NEW ENGL J MED, V331, P669, DOI 10.1056/NEJM199409083311009; Laupacis A, 2005, MED CARE, V43, P15; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167; Miners AH, 2005, BMJ-BRIT MED J, V330, P65, DOI 10.1136/bmj.38285.482350.82; MURRAY MD, 1993, ANN PHARMACOTHER, V27, P616; Neumann PJ, 2005, VALUE HEALTH, V8, P3, DOI 10.1111/j.1524-4733.2005.04010.x; Neumann PJ, 2000, HEALTH AFFAIR, V19, P92, DOI 10.1377/hlthaff.19.2.92; Neumann PJ, 2000, ANN INTERN MED, V132, P964, DOI 10.7326/0003-4819-132-12-200006200-00007; O'Brien BJ, 2002, HEALTH ECON, V11, P175, DOI 10.1002/hec.655; Oliver A, 2002, LANCET, V359, P1771, DOI 10.1016/S0140-6736(02)08664-6; Olson CM, 2002, JAMA-J AM MED ASSOC, V287, P2825, DOI 10.1001/jama.287.21.2825; Owens DK, 1998, J GEN INTERN MED, V13, P716, DOI 10.1046/j.1525-1497.1998.00211.x; Philips Z, 2004, HEALTH TECHNOL ASSES, V8, P1; Pignone M, 2005, ANN INTERN MED, V142, P1073, DOI 10.7326/0003-4819-142-12_Part_2-200506211-00007; Ray JG, 2002, QJM-INT J MED, V95, P769, DOI 10.1093/qjmed/95.12.769; Rennie D, 1998, JAMA-J AM MED ASSOC, V280, P214, DOI 10.1001/jama.280.3.214; Sculpher M, 2000, PHARMACOECONOMICS, V17, P461, DOI 10.2165/00019053-200017050-00005; SHARP DW, 1990, JAMA-J AM MED ASSOC, V263, P1390; TENGS TO, 1995, RISK ANAL, V15, P369, DOI 10.1111/j.1539-6924.1995.tb00330.x; Weinstein MC, 2003, VALUE HEALTH, V6, P9, DOI 10.1046/j.1524-4733.2003.00234.x; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	42	273	276	0	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 25	2006	332	7543					699	701		10.1136/bmj.38737.607558.80	http://dx.doi.org/10.1136/bmj.38737.607558.80			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	027VH	16495332	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000236443300019
J	Baker, J				Baker, J			Introduction - Tiger, tiger, burning bright	SCIENCE			English	Editorial Material																			0	2	2	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 10	2006	311	5766					1388	1388		10.1126/science.311.5766.1388	http://dx.doi.org/10.1126/science.311.5766.1388			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527961				2022-12-28	WOS:000236029400027
J	Barsoum, RS				Barsoum, RS			Chronic kidney disease in the developing world	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Cairo Univ, Cairo, Egypt	Egyptian Knowledge Bank (EKB); Cairo University	Barsoum, RS (corresponding author), Cairo Univ, Cairo, Egypt.			Barsoum, Rashad/0000-0003-1620-764X				Barsoum RS, 2002, ARTIF ORGANS, V26, P737, DOI 10.1046/j.1525-1594.2002.07061.x; BARSOUM RS, 2005, KIDNEY DIS DEV WORLD, P1; International Society of Nephrology, PROGR DET MAN CHRON; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047	4	312	336	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 9	2006	354	10					997	999		10.1056/NEJMp058318	http://dx.doi.org/10.1056/NEJMp058318			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	019FY	16525136				2022-12-28	WOS:000235822200003
J	Parker, HG; Kruglyak, L; Ostrander, EA				Parker, HG; Kruglyak, L; Ostrander, EA			DNA analysis of a putative dog clone	NATURE			English	Letter							RADIATION HYBRID MAP; JAN 20 2006; CANINE GENOME; RETRACTED SEE; PG 335; ARTICLE; CELLS		NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA; Princeton Univ, Dept Ecol & Evolutionary Biol, Carl Icahn Lab, Princeton, NJ 08544 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Princeton University; Princeton University	Parker, HG (corresponding author), NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA.	eostrand@mail.nih.gov	Parker, Heidi/C-6954-2008	Parker, Heidi G./0000-0002-9707-6380; Ostrander, Elaine/0000-0001-6075-9738	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG200325] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 HG999999] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		DeNise S, 2004, ANIM GENET, V35, P14, DOI 10.1046/j.1365-2052.2003.01074.x; Guyon R, 2003, P NATL ACAD SCI USA, V100, P5296, DOI 10.1073/pnas.0831002100; Halverson J, 2005, J FORENSIC SCI, V50, P352; Hwang WS, 2005, SCIENCE, V308, P1777, DOI 10.1126/science.1112286; Hwang WS, 2004, SCIENCE, V303, P1669, DOI 10.1126/science.1094515; Lee BC, 2005, NATURE, V436, P641, DOI 10.1038/436641a; Lindblad-Toh K, 2005, NATURE, V438, P803, DOI 10.1038/nature04338; Mellersh CS, 2000, MAMM GENOME, V11, P120, DOI 10.1007/s003350010024; *SEOUL NAT U INV C, 2006, NATURE, V440, DOI DOI 10.1038/NATURE04686; Weir B.S., 1996, GENETIC DATA ANAL	10	20	20	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	2006	440	7081					E1	E2		10.1038/nature04685	http://dx.doi.org/10.1038/nature04685			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019MC	16525421	Green Accepted, Bronze			2022-12-28	WOS:000235839500034
J	Sheiko, SS; Sun, FC; Randall, A; Shirvanyants, D; Rubinstein, M; Lee, H; Matyjaszewski, K				Sheiko, SS; Sun, FC; Randall, A; Shirvanyants, D; Rubinstein, M; Lee, H; Matyjaszewski, K			Adsorption-induced scission of carbon-carbon bonds	NATURE			English	Article							TENSILE-STRENGTH; SINGLE; POLYMERS; FORCE; DNA; MACROMOLECULES; POLYETHYLENE; DEGRADATION; MOLECULE; BRUSHES	Covalent carbon-carbon bonds are hard to break. Their strength is evident in the hardness of diamonds(1,2) and tensile strength of polymeric fibres(3-6); on the single-molecule level, it manifests itself in the need for forces of several nanonewtons to extend and mechanically rupture one bond. Such forces have been generated using extensional flow(7-9), ultrasonic irradiation(10), receding meniscus(11) and by directly stretching a single molecule with nanoprobes(12-16). Here we show that simple adsorption of brush-like macromolecules with long side chains on a substrate can induce not only conformational deformations(17), but also spontaneous rupture of covalent bonds in the macromolecular backbone. We attribute this behaviour to the fact that the attractive interaction between the side chains and the substrate is maximized by the spreading of the side chains, which in turn induces tension along the polymer backbone. Provided the side-chain densities and substrate interaction are sufficiently high, the tension generated will be strong enough to rupture covalent carbon-carbon bonds. We expect similar adsorption-induced backbone scission to occur for all macromolecules with highly branched architectures, such as brushes and dendrimers. This behaviour needs to be considered when designing surface-targeted macromolecules of this type either to avoid undesired degradation, or to ensure rupture at predetermined macromolecular sites.	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; Carnegie Mellon Univ, Dept Chem, Ctr Macromol Engn, Pittsburgh, PA 15213 USA	University of North Carolina; University of North Carolina Chapel Hill; Carnegie Mellon University	Sheiko, SS (corresponding author), Univ N Carolina, Dept Chem, CB 3290, Chapel Hill, NC 27599 USA.	sergei@email.unc.edu	Sheiko, Sergei S/H-5430-2017; ATRP, ATRP/A-3613-2009; Matyjaszewski, Krzysztof/A-2508-2008	Matyjaszewski, Krzysztof/0000-0003-1960-3402				[Anonymous], 1977, ADV POLYM SCI, DOI DOI 10.1007/3-540-07942-4_6; Austin RH, 1997, PHYS TODAY, V50, P32, DOI 10.1063/1.881674; BENSIMON A, 1994, SCIENCE, V265, P2096, DOI 10.1126/science.7522347; Boris D, 1996, MACROMOLECULES, V29, P7251, DOI 10.1021/ma960397k; Cluzel P, 1996, SCIENCE, V271, P792, DOI 10.1126/science.271.5250.792; DERRINGTON A, 1996, FINANCIAL TIMES 0713, pWFT2; Evans E, 2001, ANNU REV BIOPH BIOM, V30, P105, DOI 10.1146/annurev.biophys.30.1.105; FIELD JE, 1986, I PHYS C SER, V75, P181; HARRINGTON RE, 1965, J PHYS CHEM-US, V69, P161, DOI 10.1021/j100885a025; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; Matyjaszewski K, 2001, CHEM REV, V101, P2921, DOI 10.1021/cr940534g; Mehta AD, 1999, SCIENCE, V283, P1689, DOI 10.1126/science.283.5408.1689; Neugebauer D, 2004, POLYMER, V45, P8173, DOI 10.1016/j.polymer.2004.09.069; ODELL JA, 1988, J CHEM PHYS, V88, P4022, DOI 10.1063/1.453855; PORTER RS, 1994, POLYM ENG SCI, V34, P266, DOI 10.1002/pen.760340406; Salvetat JP, 1999, PHYS REV LETT, V82, P944, DOI 10.1103/PhysRevLett.82.944; Sheiko SS, 2003, J AM CHEM SOC, V125, P6725, DOI 10.1021/ja0346779; Sheiko SS, 2001, CHEM REV, V101, P4099, DOI 10.1021/cr990129v; SMITH P, 1981, J POLYM SCI POL PHYS, V19, P1007, DOI 10.1002/pol.1981.180190610; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; Sun F, 2004, J PHYS CHEM A, V108, P9682, DOI 10.1021/jp047929g; Xu H, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.206103; Yu MF, 2000, PHYS REV LETT, V84, P5552, DOI 10.1103/PhysRevLett.84.5552	24	306	310	8	157	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	2006	440	7081					191	194		10.1038/nature04576	http://dx.doi.org/10.1038/nature04576			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019MC	16525468	Bronze			2022-12-28	WOS:000235839500041
J	Stone, MB; Zaliznyak, IA; Hong, T; Broholm, CL; Reich, DH				Stone, MB; Zaliznyak, IA; Hong, T; Broholm, CL; Reich, DH			Quasiparticle breakdown in a quantum spin liquid	NATURE			English	Article							SUPERFLUID-HELIUM; EXCITATIONS; SPECTRUM; CHAIN	Much of modern condensed matter physics is understood in terms of elementary excitations, or quasiparticles-fundamental quanta of energy and momentum(1,2). Various strongly interacting atomic systems are successfully treated as a collection of quasiparticles with weak or no interactions. However, there are interesting limitations to this description: in some systems the very existence of quasiparticles cannot be taken for granted. Like unstable elementary particles, quasiparticles cannot survive beyond a threshold where certain decay channels become allowed by conservation laws; their spectrum terminates at this threshold. Such quasiparticle breakdown was first predicted for an exotic state of matter-super-fluid He-4 at temperatures close to absolute zero, a quantum Bose liquid where zero-point atomic motion precludes crystallization(1-4). Here we show, using neutron scattering, that quasiparticle breakdown can also occur in a quantum magnet and, by implication, in other systems with Bose quasiparticles. We have measured spin excitations in a two-dimensional quantum magnet, piperazinium hexachlorodicuprate (PHCC)(5), in which spin-1/2 copper ions form a non-magnetic quantum spin liquid, and find remarkable similarities with excitations in superfluid He-4. We observe a threshold momentum beyond which the quasiparticle peak merges with the two-quasiparticle continuum. It then acquires a finite energy width and becomes indistinguishable from a leading-edge singularity, so that excited states are no longer quasiparticles but occupy a wide band of energy. Our findings have important ramifications for understanding excitations with gapped spectra in many condensed matter systems, ranging from band insulators to high-transition-temperature superconductors(6).	Brookhaven Natl Lab, Dept Mat Sci, Upton, NY 11973 USA; Oak Ridge Natl Lab, Condensed Matter Sci Div, Oak Ridge, TN 37831 USA; Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA; Natl Inst Stand & Technol, Gaithersburg, MD 20899 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; United States Department of Energy (DOE); Oak Ridge National Laboratory; Johns Hopkins University; National Institute of Standards & Technology (NIST) - USA	Zaliznyak, IA (corresponding author), Brookhaven Natl Lab, Dept Mat Sci, Upton, NY 11973 USA.	zaliznyak@bnl.gov	Zaliznyak, Igor/AAW-2535-2020; Zaliznyak, Igor/E-8532-2014; Broholm, Collin Leslie/E-8228-2011; Hong, Tao/F-8166-2010; Stone, Matthew/G-3275-2011	Zaliznyak, Igor/0000-0002-8548-7924; Zaliznyak, Igor/0000-0002-8548-7924; Broholm, Collin Leslie/0000-0002-1569-9892; Hong, Tao/0000-0002-0161-8588; Stone, Matthew/0000-0001-7884-9715				ABRIKOSOV AA, 1975, METHODS QUANTUM FIEL, P235; ANDERSON PW, 1987, SCIENCE, V235, P1196, DOI 10.1126/science.235.4793.1196; COTTINGHAM WN, 1998, INTRO STANDARD MODEL; Fak B, 1998, J LOW TEMP PHYS, V112, P1, DOI 10.1023/A:1022299227239; FEYNMAN RP, 1956, PHYS REV, V102, P1189, DOI 10.1103/PhysRev.102.1189; Giamarchi T., 2005, QUANTUM PHYS ONE DIM; GIRVIN SM, 1986, PHYS REV B, V33, P2481, DOI 10.1103/PhysRevB.33.2481; GOPALAN S, 1994, PHYS REV B, V49, P8901, DOI 10.1103/PhysRevB.49.8901; HOHENBERG PC, 1974, PHYS REV B, V10, P128, DOI 10.1103/PhysRevB.10.128; Kapitza P, 1938, NATURE, V141, P74, DOI 10.1038/141074a0; LANDAU LD, 1981, COURSE THEORETICAL 2, V9, P125; MA SL, 1992, PHYS REV LETT, V69, P3571, DOI 10.1103/PhysRevLett.69.3571; MESHKOV SV, 1993, PHYS REV B, V48, P6167, DOI 10.1103/PhysRevB.48.6167; Montfrooij W, 2000, J LOW TEMP PHYS, V121, P293, DOI 10.1023/A:1017568722896; Pistolesi F, 1998, PHYS REV LETT, V81, P397, DOI 10.1103/PhysRevLett.81.397; PITAEVSKII LP, 1959, ZH EKSP TEOR FIZ, V9, P830; REGNAULT LP, 1993, J PHYS-CONDENS MAT, V5, pL677, DOI 10.1088/0953-8984/5/50/004; Ruegg C, 2003, NATURE, V423, P62, DOI 10.1038/nature01617; RUVALDS J, 1970, PHYS REV LETT, V25, P333, DOI 10.1103/PhysRevLett.25.333; SMITH AJ, 1977, J PHYS C SOLID STATE, V10, P543, DOI 10.1088/0022-3719/10/4/011; Stone MB, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.064423; Stone MB, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.144405; Tranquada JM, 2004, NATURE, V429, P534, DOI 10.1038/nature02574; WOODS ADB, 1973, REP PROG PHYS, V36, P1135, DOI 10.1088/0034-4885/36/9/002; Xu GY, 2000, SCIENCE, V289, P419, DOI 10.1126/science.289.5478.419; Xu GY, 2000, PHYS REV LETT, V84, P4465, DOI 10.1103/PhysRevLett.84.4465; Zaliznyak IA, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.017202	27	77	77	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	2006	440	7081					187	190		10.1038/nature04593	http://dx.doi.org/10.1038/nature04593			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019MC	16525467	Bronze, Green Submitted			2022-12-28	WOS:000235839500040
J	Chidambaram, JD; Alemayehu, W; Melese, M; Lakew, T; Yi, E; House, J; Cevallos, V; Zhou, ZX; Maxey, K; Lee, DC; Shapiro, BL; Srinivasan, M; Porco, T; Whitcher, JP; Gaynor, BD; Lietman, TM				Chidambaram, JD; Alemayehu, W; Melese, M; Lakew, T; Yi, E; House, J; Cevallos, V; Zhou, ZX; Maxey, K; Lee, DC; Shapiro, BL; Srinivasan, M; Porco, T; Whitcher, JP; Gaynor, BD; Lietman, TM			Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHLAMYDIA-TRACHOMATIS; DOSE AZITHROMYCIN; COMMUNITY; DISEASE; AREAS	Context The World Health Organization recommends mass antibiotic distributions in its strategy to eliminate blinding trachoma as a public health concern. Some hypothesize that a single distribution is sufficient to control the ocular strains of chlamydia that cause trachoma. Others believe infection will inevitably return and periodic treatments or other measures are essential. Objective To determine whether ocular chlamydial infection returns to the community up to 24 months after a single mass antibiotic distribution in a hyperendemic region of Ethiopia. Design, Setting, and Participants Longitudinal cohort study conducted March 2003 to March 2005 in the Gurage Zone of Ethiopia. Eight randomly selected villages were assessed for ocular chlamydial infection. Fifteen untreated villages were randomly chosen at 12 months to allow assessment of a secular trend. Intervention A single dose of oral azithromycin was offered to all residents of the 8 selected villages who were aged 1 year or older. Main Outcome Measure Prevalence of ocular chlamydial infection in all children aged 1 to 5 years from each intervention village prior to treatment and 2, 6, 12, 18, and 24 months after mass antibiotic treatment, and also in untreated villages enrolled at 12 months. Results Five hundred fifteen children were examined for ocular chlamydial infection at baseline. For the follow-up examinations, the mean participation rate was 83%. The mean prevalence of infection in children aged 1 to 5 years decreased from 43.5% (95% confidence interval [CI], 35.0%-52.0%) to 5.1% ( 95% CI, 1.1%-9.2%) after treatment. On average, infection returned gradually over 24 months to 11.3% ( 95% CI, 4.5%-18.1%; P = .001). In 7 of 8 villages, infection was higher at 24 months than at 2 months. In the remaining village, no infection could be identified at any point after treatment. Villages enrolled at 12 months had significantly fewer infections than those enrolled 12 months earlier, suggesting a secular trend ( P < .001). Conclusions Ocular chlamydial infection was not eliminated in children aged 1 to 5 years after a single mass azithromycin distribution; it slowly returned over 24 months, although not to baseline levels. Repeated treatments or other effective measures will be necessary for elimination.	Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Global Hlth, San Francisco, CA 94143 USA; Orbis Int, Addis Ababa, Ethiopia; Aravind Eye Hosp, Madural, India; Calif Dept Hlth Serv, Berkeley, CA 94704 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; California Department of Health Care Services	Lietman, TM (corresponding author), Univ Calif San Francisco, Francis I Proctor Fdn, Box 0412,513 Parnassus Ave,Med Sci S309, San Francisco, CA 94143 USA.	tom.lietman@ucsf.edu		Chidambaram, Jaya/0000-0001-5438-2858	NATIONAL EYE INSTITUTE [U10EY016214] Funding Source: NIH RePORTER; NEI NIH HHS [U10-EY016214] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bird M, 2003, J INFECT DIS, V187, P1669, DOI 10.1086/374743; Burton MJ, 2005, LANCET, V365, P1321, DOI 10.1016/S0140-6736(05)61029-X; Chidambaram JD, 2005, LANCET INFECT DIS, V5, P194, DOI 10.1016/S1473-3099(05)70032-3; Chidambaram JD, 2004, EMERG INFECT DIS, V10, P1895; Diamant J, 2001, Ophthalmic Epidemiol, V8, P109, DOI 10.1076/opep.8.2.109.4156; Dolin PJ, 1997, LANCET, V349, P1511, DOI 10.1016/S0140-6736(97)01355-X; Gaynor BD, 2003, EMERG INFECT DIS, V9, P596, DOI 10.3201/eid0905.020577; Gaynor Bruce D., 2002, International Ophthalmology Clinics, V42, P85; Hoechsmann A, 2001, Ophthalmic Epidemiol, V8, P145, DOI 10.1076/opep.8.2.145.4169; Jha H, 2002, CLIN INFECT DIS, V35, P765, DOI 10.1086/342298; Lietman T, 1999, NAT MED, V5, P572, DOI 10.1038/8451; Lietman TM, 2005, NEW ENGL J MED, V352, P414; Mariotti SP, 2004, NEW ENGL J MED, V351, P2004, DOI 10.1056/NEJMe048205; Melese M, 2004, JAMA-J AM MED ASSOC, V292, P721, DOI 10.1001/jama.292.6.721; Peeling RW, 1998, SEX TRANSM INFECT, V74, P66, DOI 10.1136/sti.74.1.66; Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844; Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5; Solomon AW, 2005, NEW ENGL J MED, V352, P414; Solomon AW, 2004, NEW ENGL J MED, V351, P1962, DOI 10.1056/NEJMoa040979; VERRENGIA JB, ANTIBIOTIC DOSE MAY; Wang SA, 2005, J INFECT DIS, V191, P917, DOI 10.1086/428290; West ES, 2005, INVEST OPHTH VIS SCI, V46, P83, DOI 10.1167/iovs.04-0327; WHO, 2004, WHOPBDGET042; Zhang JZ, 2004, PEDIATR INFECT DIS J, V23, P217, DOI 10.1097/01.inf.0000115501.60397.a6	24	101	101	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	2006	295	10					1142	1146		10.1001/jama.295.10.1142	http://dx.doi.org/10.1001/jama.295.10.1142			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	019GB	16522834	Bronze, Green Accepted			2022-12-28	WOS:000235822500022
J	Chapman, S				Chapman, S			Regulating the global vector for lung cancer	LANCET			English	Editorial Material							AUSTRALIAN TOBACCO INDUSTRY; PUBLIC-HEALTH; CONSULTANTS; ADDITIVES; SMOKING; MARKET		Univ Sydney, Sydney, NSW 2006, Australia	University of Sydney	Chapman, S (corresponding author), Univ Sydney, Sydney, NSW 2006, Australia.	simonchapman@health.usyd.edu.au	Chapman, Simon/D-4114-2009					Assunta M, 2004, TOB CONTROL, V13, P4, DOI 10.1136/tc.2003.005199; Bero L, 2003, ANNU REV PUBL HEALTH, V24, P267, DOI 10.1146/annurev.publhealth.24.100901.140813; Bialous SA, 2001, TOB CONTROL, V10, P96, DOI 10.1136/tc.10.2.96; Borland R, 2003, TOB CONTROL, V12, P374, DOI 10.1136/tc.12.4.374; *BRIT AM TOB, 2005, SMOK HLTH; Callard C, 2005, TOB CONTROL, V14, P278, DOI 10.1136/tc.2005.011353; *CAMPB JOHNS LTD, 1978, PUBL REL STRAT TOB A; Carter SM, 2003, TOB CONTROL, V12, P23; Chapman S, 2003, TOB CONTROL, V12, P45; Chapman S, 2003, TOB CONTROL, V12, P31; Cummings KM, 2002, TOB CONTROL, V11, pI110, DOI 10.1136/tc.11.suppl_1.i110; *DEP HLTH AG AUSTR, 2004, AUSTR CIG INGR INF; DiFranza JR, 2002, TOB CONTROL, V11, P228, DOI 10.1136/tc.11.3.228; Fields N, 2003, J EPIDEMIOL COMMUN H, V57, P571, DOI 10.1136/jech.57.8.571; Foulds J, 2003, TOB CONTROL, V12, P349, DOI 10.1136/tc.12.4.349; Hammond D, 2006, LANCET, V367, P781, DOI 10.1016/S0140-6736(06)68077-X; Henningfield JE, 2004, NICOTINE TOB RES, V6, P199; HIRSCHHORN N, 2005, GALEN DIGITAL L 0427; King W, 2003, TOB CONTROL, V12, P107, DOI 10.1136/tc.12.1.107; *P MORR INT, 2004, SMOK HLTH CLEAR CONS; SHIFFMAN S, 2001, TOBACCO CONTROL S1, V10, P17; Vagg R, 2005, ADDICTION, V100, P701, DOI 10.1111/j.1360-0443.2005.01014.x; Webb WH, 1984, STATUS MARLBORO DEV; WYNDER EL, 1965, J AMER MED ASSOC, V192, P88, DOI 10.1001/jama.1965.03080150018003; 1977, B W PROBLEM LAB BETT	25	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 4	2006	367	9512					706	708		10.1016/S0140-6736(06)68078-1	http://dx.doi.org/10.1016/S0140-6736(06)68078-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	020JX	16517255				2022-12-28	WOS:000235906000005
J	Watts, G				Watts, G			CO2 and trees: that sinking feeling	LANCET			English	Editorial Material											Watts, G (corresponding author), 28 New End Sq, London NW3 1LS, England.	geoff@scileg.freeserve.co.uk						Betts RA, 2000, NATURE, V408, P187, DOI 10.1038/35041545; *CLIM CAR, 2005, STAMP OUT GLOB WARM; Keppler F, 2006, NATURE, V439, P187, DOI 10.1038/nature04420; Korner C, 2005, SCIENCE, V309, P1360, DOI 10.1126/science.1113977	4	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 4	2006	367	9512					715	716		10.1016/S0140-6736(06)68282-2	http://dx.doi.org/10.1016/S0140-6736(06)68282-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	020JX	16517259				2022-12-28	WOS:000235906000009
J	Glickman, SW; Rasiel, EB; Hamilton, CD; Kubataev, A; Schulman, KA				Glickman, SW; Rasiel, EB; Hamilton, CD; Kubataev, A; Schulman, KA			A portfolio model of drug development for tuberculosis	SCIENCE			English	Editorial Material									Duke Univ, Fuqua Sch Business, Hlth Sector Management Program, Durham, NC 27708 USA; Duke Univ, Dept Econ, Durham, NC 27708 USA; Duke Univ, Sch Med, Dept Med, Div Gen Internal Med, Durham, NC 27710 USA; Amer Int Hlth Alliance, Moscow 125047, Russia; Duke Univ, Med Ctr, Duke Clin Res Inst, Ctr Clin & Genet Econ, Durham, NC 27715 USA	Duke University; Duke University; Duke University; Duke University	Schulman, KA (corresponding author), Duke Univ, Fuqua Sch Business, Hlth Sector Management Program, Durham, NC 27708 USA.	kevin.schulman@duke.edu						Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; Das P, 2002, LANCET INFECT DIS, V2, P54, DOI 10.1016/S1473-3099(01)00174-8; *MAN ASS INT FED P, 2004, RES DEV NEGL DIS LES; PhRMA (Pharmaceutical Research and Manufacturers of America), 2001, PHARM IND PROF 2001; Seaworth BJ, 2002, INFECT DIS CLIN N AM, V16, P73, DOI 10.1016/S0891-5520(03)00047-3; Sharpe P, 1998, HARVARD BUS REV, V76, P45; Slutsky AS, 2004, CAN MED ASSOC J, V171, P1203, DOI 10.1503/cmaj.1041634; Stonebraker JS, 2002, INTERFACES, V32, P77, DOI 10.1287/inte.32.6.77.6475; *STOP TB PARTN WOR, STRAT PLAN PREP GLOB; Tiggemann RF, 1998, DRUG INF J, V32, P813, DOI 10.1177/009286159803200321; *WHO, 2005, 104 WHO; WIDDUS R, 2004, COMB DIS ASS POV FIN; Zumla A, 2001, Lancet Infect Dis, V1, P199, DOI 10.1016/S1473-3099(01)00096-2	13	31	32	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	2006	311	5765					1246	1247		10.1126/science.1119299	http://dx.doi.org/10.1126/science.1119299			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019XB	16513969				2022-12-28	WOS:000235870400026
J	Wicks, CW; Thatcher, W; Dzurisin, D; Svarc, J				Wicks, CW; Thatcher, W; Dzurisin, D; Svarc, J			Uplift, thermal unrest and magma intrusion at Yellowstone caldera	NATURE			English	Article							VOLCANIC FIELD; EARTHQUAKE; BENEATH; PROPAGATION; FLUID	The Yellowstone caldera, in the western United States, formed similar to 640,000 years ago when an explosive eruption ejected,1,000km 3 of material(1). It is the youngest of a series of large calderas that formed during sequential cataclysmic eruptions that began similar to 16 million years ago in eastern Oregon and northern Nevada. The Yellowstone caldera was largely buried by rhyolite lava flows during eruptions that occurred from similar to 150,000 to,70,000 years ago(1). Since the last eruption, Yellowstone has remained restless, with high seismicity, continuing uplift/ subsidence episodes with movements of similar to 70 cm historically(2) to several metres since the Pleistocene epoch(3), and intense hydrothermal activity. Here we present observations of a new mode of surface deformation in Yellowstone, based on radar interferometry observations from the European Space Agency ERS-2 satellite. We infer that the observed pattern of uplift and subsidence results from variations in the movement of molten basalt into and out of the Yellowstone volcanic system.	US Geol Survey, Menlo Pk, CA 94555 USA; US Geol Survey, David A Johnston Cascades Volcano Observ, Vancouver, WA 98683 USA	United States Department of the Interior; United States Geological Survey; United States Department of the Interior; United States Geological Survey	Wicks, CW (corresponding author), US Geol Survey, MS 977, Menlo Pk, CA 94555 USA.	cwicks@usgs.gov						CHRISTIANSEN RL, 2001, US GEOL SURV PROF PA, V729, P1; Dahm T, 2000, GEOPHYS J INT, V141, P623, DOI 10.1046/j.1365-246x.2000.00102.x; DZURISIN D, 1990, B VOLCANOL, V52, P247, DOI 10.1007/BF00304098; EATON GP, 1975, SCIENCE, V188, P787, DOI 10.1126/science.188.4190.787; Fournier RO, 1999, ECON GEOL BULL SOC, V94, P1193, DOI 10.2113/gsecongeo.94.8.1193; Hanssen RF, 1999, SCIENCE, V283, P1297, DOI 10.1126/science.283.5406.1297; Humphreys E. D., 2000, GSA TODAY, V10, P1; Husen S, 2004, GEOLOGY, V32, P537, DOI 10.1130/G20381.1; Husen S, 2004, J VOLCANOL GEOTH RES, V131, P397, DOI 10.1016/S0377-0273(03)00416-5; INGEBRITSEN SE, 1993, SCIENCE, V262, P889, DOI 10.1126/science.262.5135.889; Ingebritsen SE, 2001, J VOLCANOL GEOTH RES, V111, P1, DOI 10.1016/S0377-0273(01)00207-4; Massonnet D, 1998, REV GEOPHYS, V36, P441, DOI 10.1029/97RG03139; MEERTENS CM, 2000, EOS, V81; Miller DS, 1999, J GEOPHYS RES-SOL EA, V104, P15105, DOI 10.1029/1998JB900095; PELTON JR, 1979, SCIENCE, V206, P1179, DOI 10.1126/science.206.4423.1179; Pierce K. L., 2002, 020142 US GEOL SURV, P1; RUBIN AM, 1995, ANNU REV EARTH PL SC, V23, P287, DOI 10.1146/annurev.ea.23.050195.001443; SAVAGE JC, 1993, J GEOPHYS RES-SOL EA, V98, P2145, DOI 10.1029/92JB02410; Toda S, 1998, J GEOPHYS RES-SOL EA, V103, P24543, DOI 10.1029/98JB00765; Waite GP, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002675; Waite GP, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000586; Watanabe T, 1999, J VOLCANOL GEOTH RES, V91, P65, DOI 10.1016/S0377-0273(99)00054-2; White D.E., 1988, US GEOL SURV PROF PA, P1, DOI 10.3133/pp1456; Wicks C, 1998, SCIENCE, V282, P458, DOI 10.1126/science.282.5388.458; Wolfe CJ, 2004, GEOCHEM GEOPHY GEOSY, V5, DOI 10.1029/2003GC000618	25	114	115	5	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	2006	440	7080					72	75		10.1038/nature04507	http://dx.doi.org/10.1038/nature04507			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017HW	16511491				2022-12-28	WOS:000235685700041
J	Camilli, A; Bassler, BL				Camilli, A; Bassler, BL			Bacterial small-molecule signaling pathways	SCIENCE			English	Review							TO-CELL COMMUNICATION; QUORUM-SENSING SIGNAL; C-DI-GMP; PSEUDOMONAS-AERUGINOSA; ACETOBACTER-XYLINUM; CYCLIC DIGUANYLATE; VIBRIO-CHOLERAE; CELLULOSE SYNTHESIS; GENE-EXPRESSION; PROTEIN	Bacteria use diverse small molecules for extra- and intracellular signaling. They scan small-molecule mixtures to access information about both their extracellular environment and their intracellular physiological status, and based on this information, they continuously interpret their circumstances and react rapidly to changes. Bacteria must integrate extra- and intracellular signaling information to mount appropriate responses to changes in their environment. We review recent research into two fundamental bacterial small-molecule signaling pathways: extracellular quorum-sensing signaling and intracellular cyclic dinucleotide signaling. We suggest how these two pathways may converge to control complex processes including multicellularity, biofilm formation, and virulence. We also outline new questions that have arisen from recent studies in these fields.	Tufts Univ, Howard Hughes Med Inst, Boston, MA 02111 USA; Tufts Univ, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Howard Hughes Medical Institute; Tufts University; Tufts University; Princeton University	Bassler, BL (corresponding author), Tufts Univ, Howard Hughes Med Inst, 136 Harrison Ave, Boston, MA 02111 USA.	bbassler@molbio.princeton.edu		Bassler, Bonnie/0000-0002-0043-746X	Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [R01 AI045746-04, R01 AI045746] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045746] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chan C, 2004, P NATL ACAD SCI USA, V101, P17084, DOI 10.1073/pnas.0406134101; Chen X, 2002, NATURE, V415, P545, DOI 10.1038/415545a; Chun CK, 2004, P NATL ACAD SCI USA, V101, P3587, DOI 10.1073/pnas.0308750101; Cui X, 2002, EUR J PHARMACOL, V451, P295, DOI 10.1016/S0014-2999(02)02294-X; Deziel E, 2004, P NATL ACAD SCI USA, V101, P1339, DOI 10.1073/pnas.0307694100; Dong YH, 2001, NATURE, V411, P813, DOI 10.1038/35081101; Fuqua C, 2001, ANNU REV GENET, V35, P439, DOI 10.1146/annurev.genet.35.102401.090913; Harman JG, 2001, BBA-PROTEIN STRUCT M, V1547, P1, DOI 10.1016/S0167-4838(01)00187-X; Hisert KB, 2005, MOL MICROBIOL, V56, P1234, DOI 10.1111/j.1365-2958.2005.04632.x; Jenal U, 2004, CURR OPIN MICROBIOL, V7, P185, DOI 10.1016/j.mib.2004.02.007; Ji GY, 1997, SCIENCE, V276, P2027, DOI 10.1126/science.276.5321.2027; Johnson MR, 2005, MOL MICROBIOL, V55, P664, DOI 10.1111/j.1365-2958.2004.04419.x; Kleerebezem M, 1997, MOL MICROBIOL, V24, P895, DOI 10.1046/j.1365-2958.1997.4251782.x; Kovacikova G, 2005, MOL MICROBIOL, V57, P420, DOI 10.1111/j.1365-2958.2005.04700.x; Lazdunski AM, 2004, NAT REV MICROBIOL, V2, P581, DOI 10.1038/nrmicro924; Manefield M, 2002, MICROBIOL-SGM, V148, P1119, DOI 10.1099/00221287-148-4-1119; Mashburn LM, 2005, NATURE, V437, P422, DOI 10.1038/nature03925; Miller ST, 2004, MOL CELL, V15, P677, DOI 10.1016/j.molcel.2004.07.020; More MI, 1996, SCIENCE, V272, P1655, DOI 10.1126/science.272.5268.1655; Novick RP, 2003, MOL MICROBIOL, V48, P1429, DOI 10.1046/j.1365-2958.2003.03526.x; Paul BJ, 2005, P NATL ACAD SCI USA, V102, P7823, DOI 10.1073/pnas.0501170102; Paul R, 2004, GENE DEV, V18, P715, DOI 10.1101/gad.289504; Perry SJ, 2002, SCIENCE, V298, P834, DOI 10.1126/science.1074683; Pesci EC, 1999, P NATL ACAD SCI USA, V96, P11229, DOI 10.1073/pnas.96.20.11229; REINESS G, 1975, P NATL ACAD SCI USA, V72, P2881, DOI 10.1073/pnas.72.8.2881; Romling U, 2005, MOL MICROBIOL, V57, P629, DOI 10.1111/j.1365-2958.2005.04697.x; ROSS P, 1987, NATURE, V325, P279, DOI 10.1038/325279a0; Ryjenkov DA, 2005, J BACTERIOL, V187, P1792, DOI 10.1128/JB.187.5.1792-1798.2005; Schuster M, 2003, J BACTERIOL, V185, P2066, DOI 10.1128/JB.185.7.2066-2079.2003; Singh PK, 2000, NATURE, V407, P762, DOI 10.1038/35037627; Taga ME, 2001, MOL MICROBIOL, V42, P777, DOI 10.1046/j.1365-2958.2001.02669.x; Tal R, 1998, J BACTERIOL, V180, P4416, DOI 10.1128/JB.180.17.4416-4425.1998; Tischler AD, 2004, MOL MICROBIOL, V53, P857, DOI 10.1111/j.1365-2958.2004.04155.x; Tischler AD, 2005, INFECT IMMUN, V73, P5873, DOI 10.1128/IAI.73.9.5873-5882.2005; Waters CM, 2005, ANNU REV CELL DEV BI, V21, P319, DOI 10.1146/annurev.cellbio.21.012704.131001; Weinhouse H, 1997, FEBS LETT, V416, P207, DOI 10.1016/S0014-5793(97)01202-7; Xavier KB, 2005, NATURE, V437, P750, DOI 10.1038/nature03960; Zhang RG, 2002, NATURE, V417, P971, DOI 10.1038/nature00833	38	723	799	10	363	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	2006	311	5764					1113	1116		10.1126/science.1121357	http://dx.doi.org/10.1126/science.1121357			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017IU	16497924	Green Accepted			2022-12-28	WOS:000235688100037
J	Carrel, L				Carrel, L			"X"-rated chromosomal rendezvous	SCIENCE			English	Editorial Material							INACTIVATION; MAMMALS; MICE	Female mammals inactivate one of their two X chromosomes to ensure a dosage of genes equal to that of mates who contain a single X. A brief union between the pair of X chromosomes may initiate this inactivation process.	Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Carrel, L (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA.	lcarrel@psu.edu						Alexander MK, 2005, CURR BIOL, V15, pR834, DOI 10.1016/j.cub.2005.10.002; BACHER CP, 2000, NAT CELL BIOL   0124; Clerc P, 2003, SEMIN CELL DEV BIOL, V14, P85, DOI 10.1016/S1084-9521(02)00140-4; LaSalle JM, 1996, SCIENCE, V272, P725, DOI 10.1126/science.272.5262.725; Lee JT, 2005, SCIENCE, V309, P768, DOI 10.1126/science.1113673; LYON MF, 1972, BIOL REV, V47, P1; Marahrens Y, 1999, GENE DEV, V13, P2624, DOI 10.1101/gad.13.20.2624; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; Rougeulle C, 2003, SEMIN CELL DEV BIOL, V14, P331, DOI 10.1016/j.semcdb.2003.09.014; Spilianakis CG, 2005, NATURE, V435, P637, DOI 10.1038/nature03574; Xu N, 2006, SCIENCE, V311, P1149, DOI 10.1126/science.1122984	13	12	12	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	2006	311	5764					1107	1109		10.1126/science.1124662	http://dx.doi.org/10.1126/science.1124662			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017IU	16497921				2022-12-28	WOS:000235688100034
J	Wu, ZH; Shi, YL; Tibbetts, RS; Miyamoto, S				Wu, ZH; Shi, YL; Tibbetts, RS; Miyamoto, S			Molecular linkage between the kinase ATM and NF-kappa B signaling in response to genotoxic stimuli (Publication with Expression of Concern. See vol. 371, pg. 1002, 2021)	SCIENCE			English	Article; Publication with Expression of Concern							ACTIVATION; UBIQUITIN; PROTEIN; PATHWAY	The transcription factor NF-kappa B modulates apoptotic responses induced by genotoxic stress. We show that NF-kappa B essential modulator (NEMO), the regulatory subunit of I kappa B kinase (IKK) (which phosphorylates the NF-kappa B inhibitor I kappa B), associates with activated ataxia telangiectasia mutated (ATM) after the induction of DNA double-strand breaks. ATM phosphorylates serine-85 of NEMO to promote its ubiquitin-dependent nuclear export. ATM is also exported in a NEMO-dependent manner to the cytoplasm, where it associates with and causes the activation of IKK in a manner dependent on another IKK regulator, a protein rich in glutamate, leucine, lysine, and serine (ELKS). Thus, regulated nuclear shuttling of NEMO links two signaling kinases, ATM and IKK, to activate NF-kappa B by genotoxic signals.	Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Miyamoto, S (corresponding author), Univ Wisconsin, Dept Pharmacol, 301 SMI,1300 Univ Ave, Madison, WI 53706 USA.	smiyamot@wisc.edu		Tibbetts, Randal/0000-0003-2245-2297	NATIONAL CANCER INSTITUTE [R01CA081065, R01CA077474] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067868] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA77474, R01-CA81065] Funding Source: Medline; NIGMS NIH HHS [R01-GM067868] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Hur GM, 2003, GENE DEV, V17, P873, DOI 10.1101/gad.1062403; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Piret B, 1999, ONCOGENE, V18, P2261, DOI 10.1038/sj.onc.1202541; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Sigala JLD, 2004, SCIENCE, V304, P1963, DOI 10.1126/science.1098387; Sun LJ, 2004, CURR OPIN CELL BIOL, V16, P119, DOI 10.1016/j.ceb.2004.02.005; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542	22	408	425	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	2006	311	5764					1141	1146		10.1126/science.1121513	http://dx.doi.org/10.1126/science.1121513			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017IU	16497931				2022-12-28	WOS:000235688100046
J	Morice, MC; Colombo, A; Meier, B; Serruys, P; Tamburino, C; Guagliumi, G; Sousa, E; Stoll, HP				Morice, MC; Colombo, A; Meier, B; Serruys, P; Tamburino, C; Guagliumi, G; Sousa, E; Stoll, HP		REALITY Trial Investigators	Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions - The REALITY trial: A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SLOW-RELEASE; DOUBLE-BLIND; TAXUS-STENT; DISEASE; REVASCULARIZATION; RESTENOSIS; CARDIOLOGY; ANGINA; SIRIUS	Context Compared with bare metal stents, sirolimus-eluting and paclitaxel-eluting stents have been shown to markedly improve angiographic and clinical outcomes after percutaneous coronary revascularization, but their performance in the treatment of de novo coronary lesions has not been compared in a prospective multicenter study. Objective To compare the safety and efficacy of sirolimus-eluting vs paclitax-eleluting coronary stents. Design Prospective, randomized comparative trial (the REALITY trial) conducted between August 2003 and February 2004, with angiographic follow-up at 8 months and clinical follow-up at 12 months. Setting Ninety hospitals in Europe, Latin America, and Asia. Patients A total of 1386 patients (mean age, 62.6 years; 73.1% men; 28.0% with diabetes) with angina pectoris and 1 or 2 de novo lesions (2.25-3.00 mm in diameter) in native coronary arteries. Intervention Patients were randomly assigned in a 1: 1 ratio to receive a sirolimus-eluting stent (n=701) or a paclitaxel-eluting stent (n=685). Main Outcome Measures The primary end point was in-lesion binary restenosis (presence of a more than 50% luminal-diameter stenosis) at 8 months. Secondary end points included 1-year rates of target lesion and vessel revascularization and a composite end point of cardiac death, Q-wave or non-Q-wave myocardial infarction, coronary artery bypass graft surgery, or repeat target lesion revascularization. Results In-lesion binary restenosis at 8 months occurred in 86 patients (9.6%) with a sirolimus-eluting stent vs 95 (11.1%) with a paclitaxel-eluting stent (relative risk [RR], 0.84; 95% confidence interval [CI], 0.61-1.17; P=.31). For sirolimus- vs paclitax-eleluting stents, respectively, the mean (SD) in-stent late loss was 0.09 (0.43) mm vs 0.31 (0.44) mm (difference, -0.22 mm; 95% CI, -0.26 to -0.18 mm; P<.001), mean (SD) in-stent diameter stenosis was 23.1% (16.6%) vs 26.7% (15.8%) (difference, -3.60%; 95% CI, -5.12% to -2.08%; P<.001), and the number of major adverse cardiac events at 1 year was 73 (10.7%) vs 76 (11.4%) (RR, 0.94; 95% CI, 0.69-1.27; P=.73). Conclusion In this trial comparing sirolimus- and paclitaxel-eluting coronary stents, there were no differences in the rates of binary restenosis or major adverse cardiac events. Clinical Trial Registration ClinicalTrials.gov Identifier: NCT00235092.	Inst Cardiovasc Paris Sud, Massy, France; Ctr Cuore Columbus, Milan, Italy; Hosp San Raffaele, I-20132 Milan, Italy; Univ Hosp, Bern, Switzerland; Erasmus Med Ctr, Rotterdam, Netherlands; Ferrarotto Hosp, Catania, Italy; Azienda Osped Riuniti Bergamo, Bergamo, Italy; Inst Dante Pazzanese, Sao Paulo, Brazil; Cordis Clin Res Europe, Waterloo, Belgium	UDICE-French Research Universities; Universite Paris Saclay; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Bern; University Hospital of Bern; Erasmus University Rotterdam; Erasmus MC; Ospedali Riuniti di Bergamo; Instituto Dante Pazzanese de Cardiologia; Johnson & Johnson	Morice, MC (corresponding author), Inst Hosp Jacques Cartier, Inst Cardiovasc Paris Sud, Ave Noyer Lambert, F-91300 Massy, France.	mc.morice@icps.com.fr	Guagliumi, Giulio/K-8006-2016	TAMBURINO, Corrado/0000-0002-4940-9742				BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; Colombo A, 2003, CIRCULATION, V108, P788, DOI 10.1161/01.CIR.0000086926.62288.A6; Edelman ER, 1999, CIRCULATION, V100, P896, DOI 10.1161/01.CIR.100.9.896; Fajadet J, 2005, CIRCULATION, V111, P1040, DOI 10.1161/01.CIR.0000156334.24955.B2; Goy JJ, 2005, J AM COLL CARDIOL, V45, P308, DOI 10.1016/j.jacc.2004.10.062; Grube E, 2003, CIRCULATION, V107, P38, DOI 10.1161/01.CIR.0000047700.58683.A1; Hausleiter J, 2003, AM HEART J, V146, P882, DOI 10.1016/S0002-8703(03)00435-6; Iakovou I, 2005, JAMA-J AM MED ASSOC, V293, P2126, DOI 10.1001/jama.293.17.2126; Kastrati A, 2005, JAMA-J AM MED ASSOC, V294, P819, DOI 10.1001/jama.294.7.819; Kastrati A, 2005, JAMA-J AM MED ASSOC, V293, P165, DOI 10.1001/jama.293.2.165; KASTRATI A, 2005, 2005 SCI SESS AM COL; Mauri L, 2005, CIRCULATION, V111, P321, DOI 10.1161/01.CIR.0000153356.72810.97; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; Moses JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMoa035071; Ong ATL, 2005, J AM COLL CARDIOL, V45, P1135, DOI 10.1016/j.jacc.2005.01.008; Perin Emerson C, 2005, Rev Cardiovasc Med, V6 Suppl 1, pS13; Schampaert E, 2004, J AM COLL CARDIOL, V43, P1110, DOI 10.1016/j.jacc.2004.01.024; Schofer J, 2003, LANCET, V362, P1093, DOI 10.1016/S0140-6736(03)14462-5; Serruys P.W., 1994, QUANTITATIVE CORONAR; Stone GW, 2004, CIRCULATION, V109, P1942, DOI 10.1161/01.CIR.0000127110.49192.72; Stone GW, 2004, NEW ENGL J MED, V350, P221, DOI 10.1056/NEJMoa032441; Windecker S, 2005, J AM COLL CARDIOL, V45, p7A	23	369	406	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	2006	295	8					895	904		10.1001/jama.295.8.895	http://dx.doi.org/10.1001/jama.295.8.895			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014DO	16493102	Green Published			2022-12-28	WOS:000235459200022
J	Oakley, A; Strange, V; Bonell, C; Allen, E; Stephenson, J				Oakley, A; Strange, V; Bonell, C; Allen, E; Stephenson, J		RIPPLE Study Team	Health services research - Process evaluation in randomised controlled trials of complex interventions	BRITISH MEDICAL JOURNAL			English	Editorial Material							LED SEX-EDUCATION; PREVENTION; ENGLAND; CARE	Most randomised controlled trials focus on outcomes, not on the processes involved in implementing an intervention. Using an example from school based health promotion, this paper argues that including a process evaluation would improve the science of many randomised controlled trials.	Univ London, Inst Educ, Social Sci Res Unit, London WC1H ONR, England; Univ London London Sch Hyg & Trop Med, Publ Environm Hlth Res Unit, London WC1E 7HT, England; Ctr Sexual Hlth & HIV Res, London WC1E 6AU, England	University of London; University of London; London School of Hygiene & Tropical Medicine	Oakley, A (corresponding author), Univ London, Inst Educ, Social Sci Res Unit, London WC1H ONR, England.	a.oakley@ioe.ac.uk			MRC [G9626797] Funding Source: UKRI; Medical Research Council [G9626797] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bradley F, 1999, BMJ-BRIT MED J, V318, P711; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; Elford J, 2002, AIDS CARE, V14, P351, DOI 10.1080/09540120220123739; Gueron JudithM., 2002, EVIDENCE MATTERS RAN, P15; HARDEN A, 2001, HLTH ED J, V60, P363; Hawe P, 2004, J EPIDEMIOL COMMUN H, V58, P788, DOI 10.1136/jech.2003.014415; Hawe P, 2004, BMJ-BRIT MED J, V328, P1561, DOI 10.1136/bmj.328.7455.1561; Helitzer DL, 1999, AM J CLIN NUTR, V69, p816S, DOI 10.1093/ajcn/69.4.816S; Hotopf M, 2002, ADV PSYCHIAT TREAT, V8, P326, DOI DOI 10.1192/APT.8.5.326; OAKLEY A, IN PRESS HDB HLTH RE; Oakley A., 2004, EVALUATION, V10, P440, DOI DOI 10.1177/1356389004050220; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; Power R, 2004, HEALTH EDUC RES, V19, P570, DOI 10.1093/her/cyg073; ROSS DA, 2002, EFFECTIVE SEXUAL HLT, P35; Rychetnik L, 2002, J EPIDEMIOL COMMUN H, V56, P119, DOI 10.1136/jech.56.2.119; STAME N, 2002, EVALUATION, V10, P58; Stephenson JM, 2004, LANCET, V364, P338, DOI 10.1016/S0140-6736(04)16722-6; Stephenson JM, 2003, CONTROL CLIN TRIALS, V24, P643, DOI 10.1016/S0197-2456(03)00070-9; Stephenson JM, 1998, SEX TRANSM INFECT, V74, P405, DOI 10.1136/sti.74.6.405; STRANGE V, IN PRESS EVALUATION; Toroyan T, 2004, CHILD CARE HLTH DEV, V30, P691, DOI 10.1111/j.1365-2214.2004.00481.x; Victora CG, 1997, INT J EPIDEMIOL, V26, P224, DOI 10.1093/ije/26.1.224; WIGGINS M, HLTH TECHNOLOGY ASSE, V8, P32; Wight D, 2002, EFFECTIVE SEXUAL HLT, P151; Wolff N, 2001, J Health Serv Res Policy, V6, P123, DOI 10.1258/1355819011927224	25	790	791	0	59	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	FEB 18	2006	332	7538					413	416		10.1136/bmj.332.7538.413	http://dx.doi.org/10.1136/bmj.332.7538.413			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	017HZ	16484270	Green Submitted, Green Published, Green Accepted			2022-12-28	WOS:000235686000025
J	Samuelson, MH				Samuelson, MH			Breast cancer: not for women only	LANCET			English	Editorial Material											Samuelson, MH (corresponding author), 18 Overlook Dr, N Kingstown, RI 02852 USA.	michael@michael-samuelson.com							0	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 18	2006	367	9510					605	605		10.1016/S0140-6736(06)68227-5	http://dx.doi.org/10.1016/S0140-6736(06)68227-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013GM	16488804				2022-12-28	WOS:000235397800035
J	Blaisdell, AP; Sawa, K; Leising, KJ; Waldmann, MR				Blaisdell, AP; Sawa, K; Leising, KJ; Waldmann, MR			Causal reasoning in rats	SCIENCE			English	Article							TOOL; KNOWLEDGE; RELEVANT; FEATURES; CHILDREN	Empirical research with nonhuman primates appears to support the view that causal reasoning is a key cognitive faculty that divides humans from animals. The claim is that animals approximate causal learning using associative processes. The present results cast doubt on that conclusion. Rats made causal inferences in a basic task that taps into core features of causal reasoning without requiring complex physical knowledge. They derived predictions of the outcomes of interventions after passive observational learning of different kinds of causal models. These competencies cannot be explained by current associative theories but are consistent with causal Bayes net theories.	Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA; Nagoya Univ, Japan Soc Promot Sci, Nagoya, Aichi 4648601, Japan; Univ Gottingen, Dept Psychol, D-37073 Gottingen, Germany	University of California System; University of California Los Angeles; Japan Society for the Promotion of Science; Nagoya University; University of Gottingen	Blaisdell, AP (corresponding author), Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA.	blaisdell@psych.ucla.edu	Blaisdell, Aaron/B-8409-2016	Blaisdell, Aaron/0000-0002-6063-1010; Sawa, Kosuke/0000-0002-1807-9277	NIMH NIH HHS [MH12531] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		[Anonymous], 2000, CAUSALITY; Dickinson A, 1995, SYMP SYSSEN FDN, P5; Dickinson A, 2002, STEVENS HDB EXPT PSY, P497, DOI DOI 10.1002/0471214426.PAS0312; Gopnik A, 2004, PSYCHOL REV, V111, P3, DOI 10.1037/0033-295X.111.1.3; Gopnik A, 2004, TRENDS COGN SCI, V8, P371, DOI 10.1016/j.tics.2004.06.005; Hume D., 1739, TREATISE HUMAN NATUR; Mulcahy NJ, 2005, J COMP PSYCHOL, V119, P23, DOI 10.1037/0735-7036.119.1.23; Perales JC, 2004, LEARN MOTIV, V35, P115, DOI 10.1016/S0023-9690(03)00042-0; Povinelli DJ, 2000, FOLK PHYS APES; Santos LR, 2003, ANIM COGN, V6, P269, DOI 10.1007/s10071-003-0171-1; Savastano HI, 1998, BEHAV PROCESS, V44, P147, DOI 10.1016/S0376-6357(98)00046-1; Sloman SA, 2005, COGNITIVE SCI, V29, P5, DOI 10.1207/s15516709cog2901_2; Spirtes P., 2000, CAUSATION PREDICTION, Vsecond; Tomasello M, 1997, PRIMATE COGNITION; VISALBERGHI E, 1994, J COMP PSYCHOL, V108, P15, DOI 10.1037/0735-7036.108.1.15; Waldmann MR, 2000, J EXP PSYCHOL LEARN, V26, P53, DOI 10.1037/0278-7393.26.1.53; Woodward James, 2005, MAKING THINGS HAPPEN; YIN H, 1994, J EXP PSYCHOL ANIM B, V20, P419, DOI 10.1037/0097-7403.20.4.419	19	170	173	14	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 17	2006	311	5763					1020	1022		10.1126/science.1121872	http://dx.doi.org/10.1126/science.1121872			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	014CS	16484500				2022-12-28	WOS:000235456900051
J	Vandermeer, J; Perfecto, I				Vandermeer, J; Perfecto, I			A keystone mutualism drives pattern in a power function	SCIENCE			English	Article							DISTURBANCE; SIGNATURES; DYNAMICS	Data that can be described by a power function are ubiquitous in nature. Although there is consensus that such data frequently emerge generally from nonlinear complex systems, a variety of specific mechanisms may be responsible for creating the pattern in particular cases. Here, we report on the distribution of a scale insect (Coccus viridis) that is a common agricultural pest. Its distribution in an organic coffee farm in southern Mexico generally follows a power function, but there are subtle deviations from that function. We offer a biological explanation for both adherence to the power functions and associated deviations, along with supporting evidence.	Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Nat Resources & Environm, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Vandermeer, J (corresponding author), Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA.	jvander@umich.edu						[Anonymous], 1991, FRACTALS CHAOS POWER; Bak P., 1996, NATURE WORKS SCI SEL; BESS HENRY A., 1958, PROC HAWAIIAN ENT SOC, V16, P349; Guichard F, 2003, AM NAT, V161, P889, DOI 10.1086/375300; Holldobler B., 1990, pi; Levin S. A., 1997, SPATIAL ECOLOGY ROLE, P271; Pascual M, 2005, TRENDS ECOL EVOL, V20, P88, DOI 10.1016/j.tree.2004.11.012; Pascual M, 2002, PHILOS T ROY SOC B, V357, P657, DOI 10.1098/rstb.2001.0983; Pascual M, 2001, ECOLOGY, V82, P2357, DOI 10.1890/0012-9658(2001)082[2357:ODASST]2.0.CO;2; Philpott SM, 2004, OIKOS, V105, P141, DOI 10.1111/j.0030-1299.2004.12889.x; Rietkerk M, 2004, SCIENCE, V305, P1926, DOI 10.1126/science.1101867; Smith M. R., 1942, JOUR AGRIC UNIV PUERTO RICO, V26, P21; STERN VM, 1973, ANNU REV ENTOMOL, V18, P259, DOI 10.1146/annurev.en.18.010173.001355; VANDERMEER JR, UNPUB; YOUNG GR, 1982, TROP PEST MANAGE, V28, P107, DOI 10.1080/09670878209370686	15	44	45	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 17	2006	311	5763					1000	1002		10.1126/science.1121432	http://dx.doi.org/10.1126/science.1121432			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014CS	16484494				2022-12-28	WOS:000235456900045
J	Burris, S				Burris, S			Stigma and the law	LANCET			English	Editorial Material									Temple Univ, Beasley Sch Law, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Burris, S (corresponding author), Temple Univ, Beasley Sch Law, Philadelphia, PA 19122 USA.	scott.burris@temple.edu		Burris, Scott/0000-0002-6013-5842				Burris S, 2002, J LAW MED ETHICS, V30, P179, DOI 10.1111/j.1748-720X.2002.tb00385.x; BURRIS S, 1993, AIDS LAW TODAY NEW G, P82; Engel David M., 2003, RIGHTINCLUSION LAW; Link BG, 2001, ANNU REV SOCIOL, V27, P363, DOI 10.1146/annurev.soc.27.1.363; MOSS K, 2001, KANS LAW REV, V50, P1; Scambler G., 1989, EPILEPSY	6	31	31	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 11	2006	367	9509					529	531		10.1016/S0140-6736(06)68185-3	http://dx.doi.org/10.1016/S0140-6736(06)68185-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	013FF	16473130				2022-12-28	WOS:000235394500034
J	Samet, J; Wipfli, H; Perez-Padilla, R; Yach, D				Samet, J; Wipfli, H; Perez-Padilla, R; Yach, D			Mexico and the tobacco industry: doing the wrong thing for the right reason?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; Inst Nacl Enfermedades Resp, Mexico City 14080, DF, Mexico; Rockefeller Fdn, New York, NY 10018 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Wipfli, H (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.	hwipfli@jhsph.edu						*PRES REP, 2004, AP IND TAB 4 MILL PE; Schroeder SA, 2004, NEW ENGL J MED, V350, P293, DOI 10.1056/NEJMsr031421; *SECR HAC CRED PUB, 2004, DECRETO QUE EX PAG I; SOLIS RC, 2005, PRIMER INFORME COMBA, P133; VALDESSALGADO R, 2005, PRIMER INFORME COMBA; VALDESSALGADO R, 2004, ENCUESTA TABAQUISMO; 2005, REFORMA         0531, pA3	8	24	24	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 11	2006	332	7537					353	354		10.1136/bmj.332.7537.353	http://dx.doi.org/10.1136/bmj.332.7537.353			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	012YI	16470060	Green Published			2022-12-28	WOS:000235376400023
J	Chamberlain, SR; Muller, U; Blackwell, AD; Clark, L; Robbins, TW; Sahakian, BJ				Chamberlain, SR; Muller, U; Blackwell, AD; Clark, L; Robbins, TW; Sahakian, BJ			Neurochemical modulation of response inhibition and probabilistic learning in humans	SCIENCE			English	Article							ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; PREFRONTAL SEROTONIN DEPLETION; OBSESSIVE-COMPULSIVE DISORDER; ORBITOFRONTAL CORTEX; TRYPTOPHAN DEPLETION; EXTRACELLULAR LEVELS; REUPTAKE INHIBITION; RAT-BRAIN; NOREPINEPHRINE	Cognitive functions dependent on the prefrontal cortex, such as the ability to suppress behavior (response inhibition) and to learn from complex feedback (probabilistic learning), play critical roles in activities of daily life. To what extent do different neurochemical systems modulate these two cognitive functions? Here, using stop-signal and probabilistic learning tasks, we show a double dissociation for the involvement of noradrenaline and serotonin in human cognition. In healthy volunteers, inhibition of central noradrenaline reuptake improved response inhibition but had no effect on probabilistic learning, whereas inhibition of central serotonin reuptake impaired probabilistic learning with no effect on response inhibition.	Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Psychiat, Cambridge CB2 2QQ, England; Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England; Univ Cambridge, Behav & Clin Neurosci Inst, Cambridge CB2 3EB, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge; University of Cambridge	Chamberlain, SR (corresponding author), Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Psychiat, Box 189, Cambridge CB2 2QQ, England.	src33@cam.ac.uk	Sahakian, Barbara/AAW-1198-2020; Robbins, Trevor W/A-7551-2008; Chamberlain, Samuel R/A-7839-2008	Sahakian, Barbara/0000-0001-7352-1745; Chamberlain, Samuel R/0000-0001-7014-8121; Robbins, Trevor/0000-0003-0642-5977; Clark, Luke/0000-0003-1103-2422	Medical Research Council [G0001354, G0401099] Funding Source: Medline; Wellcome Trust [076274] Funding Source: Medline; Medical Research Council [G0001354B] Funding Source: researchfish; MRC [G0401099] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Arnsten AFT, 2005, BIOL PSYCHIAT, V57, P1377, DOI 10.1016/j.biopsych.2004.08.019; Aron AR, 2005, BIOL PSYCHIAT, V57, P1285, DOI 10.1016/j.biopsych.2004.10.026; Aron AR, 2003, NAT NEUROSCI, V6, P115, DOI 10.1038/nn1003; Biederman J, 2004, INT J NEUROPSYCHOPH, V7, P77, DOI 10.1017/S1461145703003973; Bymaster FP, 2002, NEUROPSYCHOPHARMACOL, V27, P699, DOI 10.1016/S0893-133X(02)00346-9; Bymaster FP, 2002, PSYCHOPHARMACOLOGY, V160, P353, DOI 10.1007/s00213-001-0986-x; Chamberlain Samuel R, 2004, Curr Psychiatry Rep, V6, P451; Chamberlain SR, 2006, PSYCHOL MED, V36, P91, DOI 10.1017/S0033291705006124; Chamberlain SR, 2005, NEUROSCI BIOBEHAV R, V29, P399, DOI 10.1016/j.neubiorev.2004.11.006; CHAMBERLAIN SR, IN PRESS AM J PSYCHI; CHAPUT Y, 1986, N-S ARCH PHARMACOL, V333, P342, DOI 10.1007/BF00500007; Clark L, 2004, BRAIN COGNITION, V55, P41, DOI 10.1016/s0278-2626(03)00284-7; Clark L, 2005, PSYCHOPHARMACOLOGY, V182, P570, DOI 10.1007/s00213-005-0104-6; Clarke HF, 2004, SCIENCE, V304, P878, DOI 10.1126/science.1094987; Clarke HF, 2005, J NEUROSCI, V25, P532, DOI 10.1523/JNEUROSCI.3690-04.2005; Cools R, 2004, PHILOS T R SOC A, V362, P2871, DOI 10.1098/rsta.2004.1468; Cox SML, 2005, J NEUROSCI, V25, P2733, DOI 10.1523/JNEUROSCI.3360-04.2005; El Mansari M, 2005, J PSYCHIATR NEUROSCI, V30, P268; Elliott R, 2000, CEREB CORTEX, V10, P308, DOI 10.1093/cercor/10.3.308; Evers EAT, 2005, NEUROPSYCHOPHARMACOL, V30, P1138, DOI 10.1038/sj.npp.1300663; Fellows LK, 2003, BRAIN, V126, P1830, DOI 10.1093/brain/awg180; Hollander E, 2000, J PSYCHOPHARMACOL, V14, pS39, DOI 10.1177/02698811000142S106; Liprando LA, 2004, SYNAPSE, V52, P233, DOI 10.1002/syn.20023; LOGAN GD, 1984, J EXP PSYCHOL HUMAN, V10, P276, DOI 10.1037/0096-1523.10.2.276; Ma CL, 2003, NEUROREPORT, V14, P1013, DOI 10.1097/01.wnr.0000070831.57864.7b; Monterosso JR, 2005, DRUG ALCOHOL DEPEN, V79, P273, DOI 10.1016/j.drugalcdep.2005.02.002; Murphy FC, 1999, PSYCHOL MED, V29, P1307, DOI 10.1017/S0033291799001233; Murphy FC, 2003, PSYCHOL MED, V33, P455, DOI 10.1017/S0033291702007018; Overtoom CCE, 2003, BEHAV BRAIN RES, V145, P7, DOI 10.1016/S0166-4328(03)00097-4; PARK SB, 1994, NEUROPHARMACOLOGY, V33, P575, DOI 10.1016/0028-3908(94)90089-2; Remijnse PL, 2005, NEUROIMAGE, V26, P609, DOI 10.1016/j.neuroimage.2005.02.009; Robbins TW, 2000, PROG BRAIN RES, V126, P469; Rogers RD, 1999, PSYCHOPHARMACOLOGY, V146, P482, DOI 10.1007/PL00005494; Rubia K, 2005, AM J PSYCHIAT, V162, P1067, DOI 10.1176/appi.ajp.162.6.1067; Schoenbaum G, 2005, NEURON, V47, P633, DOI 10.1016/j.neuron.2005.07.018; SOUBRIE P, 1986, BEHAV BRAIN SCI, V9, P319, DOI 10.1017/S0140525X00022871; Spinks D, 2002, CURR MED CHEM, V9, P799, DOI 10.2174/0929867024606795; Swann AC, 2005, BIOL PSYCHIAT, V57, P1209, DOI 10.1016/j.biopsych.2005.02.007; WONG DT, 1982, J PHARMACOL EXP THER, V222, P61; Zahrt J, 1997, J NEUROSCI, V17, P8528	40	380	383	2	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	2006	311	5762					861	863		10.1126/science.1121218	http://dx.doi.org/10.1126/science.1121218			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	012XT	16469930	Green Accepted			2022-12-28	WOS:000235374900052
J	Osborn, TJ; Briffa, KR				Osborn, TJ; Briffa, KR			The spatial extent of 20th-century warmth in the context of the past 1200 years	SCIENCE			English	Article							NORTHERN-HEMISPHERE TEMPERATURES; LAST MILLENNIUM; CLIMATE; RECONSTRUCTIONS; RESOLUTION; SIGNALS	Periods of widespread warmth or cold are identified by positive or negative deviations that are synchronous across a number of temperature-sensitive proxy records drawn from the Northern Hemisphere. The most significant and longest duration feature during the last 1200 years is the geographical extent of warmth in the middle to late 20th century. Positive anomalies during 890 to 1170 and negative anomalies during 1580 to 1850 are consistent with the concepts of a Medieval Warm Period and a Little Ice Age, but comparison with instrumental temperatures shows the spatial extent of recent warmth to be of greater significance than that during the medieval period.	Univ E Anglia, Sch Environm Sci, Climat Res Unit, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Osborn, TJ (corresponding author), Univ E Anglia, Sch Environm Sci, Climat Res Unit, Norwich NR4 7TJ, Norfolk, England.	t.osborn@uea.ac.uk	Osborn, Timothy/E-9740-2011; Briffa, Keith/C-8834-2009; Osborn, Timothy/AAK-9279-2020	Osborn, Timothy/0000-0001-8425-6799; Osborn, Timothy/0000-0001-8425-6799; Briffa, Keith/0000-0003-3323-3639				Bigg GR, 2003, INT J CLIMATOL, V23, P1127, DOI 10.1002/joc.926; Briffa KR, 2001, J GEOPHYS RES-ATMOS, V106, P2929, DOI 10.1029/2000JD900617; Briffa KR, 2000, QUATERNARY SCI REV, V19, P87, DOI 10.1016/S0277-3791(99)00056-6; Crowley TJ, 2000, SCIENCE, V289, P270, DOI 10.1126/science.289.5477.270; Crowley TJ, 2000, AMBIO, V29, P51, DOI 10.1579/0044-7447-29.1.51; Crowley TJ, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017801; Esper J, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021236; Esper J, 2002, SCIENCE, V295, P2250, DOI 10.1126/science.1066208; Hegerl GC, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016635; IPCC, 2001, 3 IPCC; Jones PD, 2001, SCIENCE, V292, P662, DOI 10.1126/science.1059126; Jones PD, 1998, HOLOCENE, V8, P455, DOI 10.1191/095968398667194956; Jones PD, 2004, REV GEOPHYS, V42, DOI 10.1029/2003RG000143; Jones PD, 2003, J CLIMATE, V16, P206, DOI 10.1175/1520-0442(2003)016<0206:HALSSA>2.0.CO;2; Jones PD, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003695; Lamb H.H., 1977, CLIMATE PRESENT FUTU, P835; Mann M. E., 2003, EOS, V84, P256, DOI DOI 10.1029/2003EO270003; Mann ME, 2005, J CLIMATE, V18, P4097, DOI 10.1175/JCLI3564.1; Mann ME, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017814; Mann ME, 1998, NATURE, V392, P779, DOI 10.1038/33859; Mann ME, 1999, GEOPHYS RES LETT, V26, P759, DOI 10.1029/1999GL900070; Moberg A, 2005, NATURE, V433, P613, DOI 10.1038/nature03265; Ogilvie AEJ, 2001, CLIMATIC CHANGE, V48, P9, DOI 10.1023/A:1005625729889; OSBORN TJ, IN PRESS CLIM DYN; Pollack HN, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD004163; Rutherford S, 2005, J CLIMATE, V18, P2308, DOI 10.1175/JCLI3351.1; Soon W, 2003, CLIM RES, V23, P89, DOI 10.3354/cr023089; von Storch H, 2004, SCIENCE, V306, P679, DOI 10.1126/science.1096109	28	200	225	0	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	2006	311	5762					841	844		10.1126/science.1120514	http://dx.doi.org/10.1126/science.1120514			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XT	16469924				2022-12-28	WOS:000235374900046
J	Park-Wyllie, LY; Juurlink, DN; Kopp, A; Shah, BR; Stukel, TA; Stumpo, C; Dresser, L; Low, DE; Mamdani, MM				Park-Wyllie, LY; Juurlink, DN; Kopp, A; Shah, BR; Stukel, TA; Stumpo, C; Dresser, L; Low, DE; Mamdani, MM			Outpatient gatifloxacin therapy and dysglycemia in older adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DRUG-INDUCED DISORDERS; SOCIOECONOMIC-STATUS; COMORBIDITY ADJUSTMENT; GLUCOSE-HOMEOSTASIS; ELDERLY-PATIENTS; HYPOGLYCEMIA; PERFORMANCE; SCORES; CIPROFLOXACIN; HYPERGLYCEMIA	BACKGROUND: Gatifloxacin has been associated with both hypoglycemia and hyperglycemia. We examined dysglycemia-related health outcomes associated with various antibiotics in a population of approximately 1.4 million Ontario, Canada, residents 66 years of age or older. METHODS: We conducted two population-based, nested case-control studies. In the first, case patients were persons treated in the hospital for hypoglycemia after outpatient treatment with a macrolide, a second-generation cephalosporin, or a respiratory fluoroquinolone (gatifloxacin, levofloxacin, moxifloxacin, or ciprofloxacin). In the second, case patients were persons who received hospital care for hyperglycemia. For each case patient, we identified up to five controls matched according to age, sex, the presence or absence of diabetes, and the timing of antibiotic therapy. RESULTS: Between April 2002 and March 2004, we identified 788 patients treated for hypoglycemia within 30 days after antibiotic therapy. As compared with macrolide antibiotics, gatifloxacin was associated with an increased risk of hypoglycemia (adjusted odds ratio, 4.3; 95 percent confidence interval, 2.9 to 6.3). Levofloxacin was also associated with a slightly increased risk (adjusted odds ratio, 1.5; 95 percent confidence interval, 1.2 to 2.0), but no such risk was seen with moxifloxacin, ciprofloxacin, or cephalosporins. We then identified 470 patients treated for hyperglycemia within 30 days after antibiotic therapy. As compared with macrolides, gatifloxacin was associated with a considerably increased risk of hyperglycemia (adjusted odds ratio, 16.7; 95 percent confidence interval, 10.4 to 26.8), but no risk was noted with the other antibiotics. Risks were similar in the two studies regardless of the presence or absence of diabetes. CONCLUSIONS: As compared with the use of other broad-spectrum oral antibiotics, including other fluoroquinolones, the use of gatifloxacin among outpatients is associated with an increased risk of in-hospital treatment for both hypoglycemia and hyperglycemia.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Med, Toronto, ON M4N 3M5, Canada; Univ Toronto, Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada; Univ Toronto, St Michaels Hosp, Dept Family & Community Med, Ctr Res Inner City Hlth, Toronto, ON M4N 3M5, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Clin Epidemiol Unit, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Pediat, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Pharm, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Microbiol, Toronto, ON M4N 3M5, Canada; Toronto E Gen & Orthoped Hosp, Dept Pharm, Toronto, ON, Canada; Mt Sinai Hosp, Dept Pharm, Toronto, ON M5G 1X5, Canada; Mt Sinai Hosp, Univ Hlth Network, Dept Microbiol, Toronto, ON M5G 1X5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University Health Network Toronto	Juurlink, DN (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Med, 2075 Bayview Ave,G Wng 106, Toronto, ON M4N 3M5, Canada.	dnj@ices.on.ca	Low, Donald/B-1726-2012	Stukel, Therese/0000-0002-2951-1360				Alter DA, 2004, JAMA-J AM MED ASSOC, V291, P1100, DOI 10.1001/jama.291.9.1100; Alter DA, 1999, NEW ENGL J MED, V341, P1359, DOI 10.1056/NEJM199910283411806; Alter DA, 2002, MED CARE, V40, P60, DOI 10.1097/00005650-200201000-00008; Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; Ambrose PG, 2003, J ANTIMICROB CHEMOTH, V52, P435, DOI 10.1093/jac/dkg370; Arce Francis Clifford A, 2004, Endocr Pract, V10, P40; ASSAN R, 1993, DIABETES METAB, V19, P262; Baker SE, 2002, ANN PHARMACOTHER, V36, P1722; Ball P, 2000, INT J ANTIMICROB AG, V16, P263, DOI 10.1016/S0924-8579(00)00254-5; Basaria S, 2005, AM J MED, V118, P706, DOI 10.1016/j.amjmed.2004.11.028; Bhatia Vishal, 2004, Endocr Pract, V10, P86; Biggs WS, 2003, J AM BOARD FAM PRACT, V16, P455, DOI 10.3122/jabfm.16.5.455; Brogan SE, 2005, ANESTH ANALG, V101, P635, DOI 10.1213/01.ANE.0000175305.08998.1B; Canadian Institute for Health Information, 2003, INT STAT CLASS DIS R; Cannon CP, 2005, NEW ENGL J MED, V352, P1646, DOI 10.1056/NEJMoa043528; Chan JCN, 1996, DRUG SAFETY, V15, P135, DOI 10.2165/00002018-199615020-00005; *CTR DRUG EV REV, MED PROD SAF INF; *CTR DRUG EV REV, 2005, 21061 NDA CTR DRUG E; *CTR DRUG EV REV, 2003, QUEST ANSW TROV PUBL; Donaldson AR, 2004, ANN PHARMACOTHER, V38, P602, DOI 10.1345/aph.1D360; *FOOD DRUG ADM, 1998, P9216 FOOD DRUG ADM; *FOOD DRUG ADM, 1999, GLAX WELLC VOL RAX; Frothingham R, 2005, CLIN INFECT DIS, V41, P1269, DOI 10.1086/496929; Frothingham R, 2004, EMERG INFECT DIS, V10, P156, DOI 10.3201/eid1001.030307; FROTHINGHAM R, 2004, 44 INT C ANT AG CHEM, P19; Gajjar DA, 2000, PHARMACOTHERAPY, V20, p76S, DOI 10.1592/phco.20.8.76S.35182; Glazier RH, 2003, CAN J PUBLIC HEALTH, V94, P140, DOI 10.1007/BF03404588; GRASELA D, 1999, 39 INT C ANT AG CHEM, P11; Graumlich JF, 2005, PHARMACOTHERAPY, V25, P1296, DOI 10.1592/phco.2005.25.10.1296; Greenberg AL, 2005, CLIN INFECT DIS, V40, P1210, DOI 10.1086/428847; Happe MR, 2004, ANN INTERN MED, V141, P968, DOI 10.7326/0003-4819-141-12-200412210-00021; Juurlink DN, 2004, NEW ENGL J MED, V351, P543, DOI 10.1056/NEJMoa040135; Juurlink DN, 2003, JAMA-J AM MED ASSOC, V289, P1652, DOI 10.1001/jama.289.13.1652; Kahn, 2001, CHEMOTHERAPY, V47, P44; Khovidhunkit W, 2004, ANN INTERN MED, V141, P969, DOI 10.7326/0003-4819-141-12-200412210-00022; LeBlanc M, 2004, PHARMACOTHERAPY, V24, P926, DOI 10.1592/phco.24.9.926.36093; LETOURNEAU G, 2003, CAN ADVERSE REACT NE, V13, P1; Levy Adrian R, 2003, Can J Clin Pharmacol, V10, P67; Linder JA, 2005, AM J MED, V118, P259, DOI 10.1016/j.amjmed.2004.09.015; Maeda N, 1996, BRIT J PHARMACOL, V117, P372, DOI 10.1111/j.1476-5381.1996.tb15201.x; Mamdani M, 2004, LANCET, V363, P1751, DOI 10.1016/S0140-6736(04)16299-5; Mamdani MM, 2000, CAN MED ASSOC J, V162, P1421; Menzies DJ, 2002, AM J MED, V113, P232, DOI 10.1016/S0002-9343(02)01158-0; Mohr JF, 2005, PHARMACOTHERAPY, V25, P1303, DOI 10.1592/phco.2005.25.10.1303; PANDIT MK, 1993, ANN INTERN MED, V118, P529, DOI 10.7326/0003-4819-118-7-199304010-00008; Ray JG, 2001, ARCH INTERN MED, V161, P1405, DOI 10.1001/archinte.161.11.1405; Rubinstein E, 2001, CHEMOTHERAPY, V47, P3, DOI 10.1159/000057838; Saraya A, 2004, EUR J PHARMACOL, V497, P111, DOI 10.1016/j.ejphar.2004.06.032; Schneeweiss S, 2000, INT J EPIDEMIOL, V29, P891, DOI 10.1093/ije/29.5.891; Schneeweiss S, 2004, J GEN INTERN MED, V19, P444, DOI 10.1111/j.1525-1497.2004.30109.x; Schneeweiss S, 2003, HEALTH SERV RES, V38, P1103, DOI 10.1111/1475-6773.00165; Schneeweiss S, 2001, AM J EPIDEMIOL, V154, P854, DOI 10.1093/aje/154.9.854; SCHWARZBARD L, 2005, 45 INT C ANT AG CHEM, P463; *STAT CAN, 2005, POP SEX AG GROUP PRO; Tailor S.A.N., 2004, CAN J HOSP PHARM, V57, P12	55	263	272	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 30	2006	354	13					1352	1361		10.1056/NEJMoa055191	http://dx.doi.org/10.1056/NEJMoa055191			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	026KO	16510739	Green Published			2022-12-28	WOS:000236338000004
J	Clay, KD; Hanson, JS; Pope, SD; Rissmiller, RW; Purclum, PP; Banks, PM				Clay, KD; Hanson, JS; Pope, SD; Rissmiller, RW; Purclum, PP; Banks, PM			Brief communication: Severe hepatotoxicity of telithromycin: Three case reports and literature review	ANNALS OF INTERNAL MEDICINE			English	Review							COMMUNITY-ACQUIRED PNEUMONIA; DRUG-INDUCED HEPATOTOXICITY; ACUTE EXACERBATIONS; CHRONIC-BRONCHITIS; CEFUROXIME AXETIL; EFFICACY; TOLERABILITY; CLARITHROMYCIN; THERAPY; SAFETY	Background: Telithromycin is a ketolide antibiotic approved by the U.S. Food and Drug Administration for acute bacterial infections causing sinusitis, bronchitis, and community-acquired pneumonia. Objective: To describe 3 cases of severe hepatotoxicity in patients receiving telithromycin. Design: Case reports. Setting: A tertiary care medical center. Patients: 3 previously healthy patients who had recently taken telithromycin and took no other prescription medications. Measurements: Serologic, histologic, and liver function tests. Results: Within a few days of receiving telithromycin, the patients presented with acute hepatitis. All had jaundice and markedly abnormal results on liver function tests. Results of viral serologic tests were negative. One patient spontaneously recovered, 1 required orthotopic liver transplantation, and 1 died. Histologic examination in the latter 2 patients showed massive hepatic necrosis. Limitations: Two patients had some history of alcohol use. The frequency of severe telithromycin-related hepatotoxicity cannot be established with case reports. Conclusions: Telithromycin can cause severe hepatotoxicity. Caution is advised in prescribing this drug pending additional postmarketing surveillance data.	Carolinas Med Ctr, Charlotte Gastroenterol & Hepatol, Carolinas HealthCare Syst, Charlotte, NC 28203 USA; Carolinas Pathol Grp, Charlotte, NC USA	Carolinas HealthCare System; Carolinas Medical Center	Clay, KD (corresponding author), Carolinas Med Ctr, Charlotte Gastroenterol & Hepatol, Carolinas HealthCare Syst, 1000 Blythe Blvd, Charlotte, NC 28203 USA.	kimberly.clay@carolinashealthcare.org						Andrade Raul J, 2004, Expert Opin Drug Saf, V3, P329, DOI 10.1517/14740338.3.4.329; Aubier M, 2002, RESP MED, V96, P862, DOI 10.1053/rmed.2002.1382; *AV PHARM INC, 2004, PROD INF KET TEL; Buchanan PP, 2003, AM J RHINOL, V17, P369, DOI 10.1177/194589240301700610; Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140-6736(00)02799-9; Ferguson BJ, 2004, OTOLARYNG HEAD NECK, V131, P207, DOI 10.1016/j.otohns.2004.05.010; Hagberg L, 2002, INFECTION, V30, P378, DOI 10.1007/s15010-002-2096-z; Kanathur N, 2001, Tenn Med, V94, P339; Larrey D, 2005, EUR J GASTROEN HEPAT, V17, P141, DOI 10.1097/00042737-200502000-00002; Lee WM, 2003, NEW ENGL J MED, V349, P474, DOI 10.1056/NEJMra021844; Luterman M, 2003, ENT-EAR NOSE THROAT, V82, P86; Luterman Maynard, 2003, Ear Nose Throat J, V82, P576; Maddrey WC, 2005, J CLIN GASTROENTEROL, V39, pS83, DOI 10.1097/01.mcg.0000155548.91524.6e; MATHERS DL, 2004, CLIN THER, V26, P48; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Norrby SR, 2001, SCAND J INFECT DIS, V33, P883, DOI 10.1080/00365540110077443; *PFIZ INC, 2003, PROD INF ZITHR AZ; Pullman J, 2003, INT J CLIN PRACT, V57, P377; Quinn J, 2003, CLIN THER, V25, P422, DOI 10.1016/S0149-2918(03)80087-5; Tellier G, 2004, J ANTIMICROB CHEMOTH, V54, P515, DOI 10.1093/jac/dkh356; *US FDA, 2005, ADV EV REP SYST AERS; Zervos MJ, 2003, J INT MED RES, V31, P157, DOI 10.1177/147323000303100301	22	105	108	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 21	2006	144	6					415	420		10.7326/0003-4819-144-6-200503210-00121	http://dx.doi.org/10.7326/0003-4819-144-6-200503210-00121			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	025FX	16481451				2022-12-28	WOS:000236251800005
J	Patel, GK; Grey, JE; Harding, KG				Patel, GK; Grey, JE; Harding, KG			ABC of wound healing - Uncommon causes of ulceration	BRITISH MEDICAL JOURNAL			English	Editorial Material									Cardiff Univ, Wound Healing Res Unit, Cardiff, S Glam, Wales; Cardiff & Vale NHS Trust, Cardiff, S Glam, Wales; Univ Wales Hosp, Cardiff CF4 4XW, S Glam, Wales	Cardiff University; Cardiff University; Cardiff University	Patel, GK (corresponding author), Cardiff Univ, Wound Healing Res Unit, Cardiff, S Glam, Wales.	joseph.grey@cardiffandvale.wales.nhs.uk	Patel, Girish/N-7075-2013; Harding, Keith/J-5605-2013	Harding, Keith/0000-0003-0048-3279				Enoch Stuart, 2005, Int Wound J, V2, P142, DOI 10.1111/j.1742-4801.2005.00096.x; Enoch Stuart, 2004, Int Wound J, V1, P165, DOI 10.1111/j.1742-4801.2004.00056.x; Falanga V., 2001, CUTANEOUS WOUND HEAL; LEAPER DJ, 1998, WOUND BIOL MANAGEMEN; ROVEE DT, 2003, EPIDERMIS WOUND HEAL	5	9	9	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 11	2006	332	7541					594	596		10.1136/bmj.332.7541.594	http://dx.doi.org/10.1136/bmj.332.7541.594			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	026CN	16528084	Green Published			2022-12-28	WOS:000236314400020
J	Rinterknecht, VR; Clark, PU; Raisbeck, GM; Yiou, F; Bitinas, A; Brook, EJ; Marks, L; Zelcs, V; Lunkka, JP; Pavlovskaya, IE; Piotrowski, JA; Raukas, A				Rinterknecht, VR; Clark, PU; Raisbeck, GM; Yiou, F; Bitinas, A; Brook, EJ; Marks, L; Zelcs, V; Lunkka, JP; Pavlovskaya, IE; Piotrowski, JA; Raukas, A			The last deglaciation of the southeastern sector of the Scandinavian Ice Sheet	SCIENCE			English	Article							SEA-LEVEL; GLACIAL MAXIMUM; NORTH-ATLANTIC; CALIBRATION; EXTENT; GISP2; AGE	The Scandinavian Ice Sheet (SIS) was an important component of the global ice sheet system during the last glaciation, but the timing of its growth to or retreat from its maximum extent remains poorly known. We used 115 cosmogenic beryllium-10 ages and 70 radiocarbon ages to constrain the timing of three substantial ice-margin fluctuations of the SIS between 25,000 and 12,000 years before the present. The age of initial deglaciation indicates that the SIS may have contributed to an abrupt rise in global sea level. Subsequent ice-margin fluctuations identify opposite mass-balance responses to North Atlantic climate change, indicating differing ice-sheet sensitivities to mean climate state.	Oregon State Univ, Dept Geosci, Corvallis, OR 97331 USA; Ctr Spectrometrie Nucl & Spectrometrie Masse, F-91405 Orsay, France; Geol Survey Lithuania, LT-03123 Vilnius, Lithuania; Polish Geol Inst, PL-00975 Warsaw, Poland; Univ Latvia, Dept Geog & Earth Sci, LV-1586 Riga, Latvia; Univ Oulu, Inst Geosci, Linnanmaa 90014, Finland; Natl Acad Sci Belarus, Inst Geol Sci, Minsk 220141, BELARUS; Univ Aarhus, Dept Earth Sci, DK-8000 Aarhus, Denmark; Tallinn Univ Technol, Inst Geol, EE-10143 Tallinn, Estonia	Oregon State University; UDICE-French Research Universities; Universite Paris Saclay; Polish Geological Institute - National Research Institute; University of Latvia; University of Oulu; National Academy of Sciences of Belarus (NASB); Aarhus University; Tallinn University of Technology	Rinterknecht, VR (corresponding author), Oregon State Univ, Dept Geosci, Corvallis, OR 97331 USA.	vincent@ldeo.columbia.edu	rinterknecht, vincent/A-9229-2010; Marks, Leszek/ABF-3641-2020; Brook, Edward/AAB-7807-2021; Marks, Leszek/F-2981-2013; Piotrowski, Jan A/A-5289-2012	Marks, Leszek/0000-0002-4507-1828; Rinterknecht, Vincent/0000-0002-5410-2075				BARD E, 1990, NATURE, V345, P405, DOI 10.1038/345405a0; Bard E, 2000, SCIENCE, V289, P1321, DOI 10.1126/science.289.5483.1321; BAUMANN KH, 1995, QUATERNARY RES, V43, P185, DOI 10.1006/qres.1995.1019; BOND GC, 1995, SCIENCE, V267, P1005, DOI 10.1126/science.267.5200.1005; Boulton GS, 2004, DEV QUA SCI, V2, P441; Clark PU, 2004, SCIENCE, V304, P1141, DOI 10.1126/science.1094449; Clark PU, 2002, QUATERNARY SCI REV, V21, P1, DOI 10.1016/S0277-3791(01)00118-4; Denton G. H., 1981, LAST GREAT ICE SHEET; DREIMANIS P, 1995, GLAC DEP NE EUR, P105; Ehlers J, 2004, DEV QUA SCI, V2, P135; Gibbard P. L, 2004, QUATERNARY GLACIAT 1; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; Hanebuth T, 2000, SCIENCE, V288, P1033, DOI 10.1126/science.288.5468.1033; Hostetler SW, 1999, J GEOPHYS RES-ATMOS, V104, P3947, DOI 10.1029/1998JD200067; Hughen K, 2004, SCIENCE, V303, P202, DOI 10.1126/science.1090300; Huybrechts P, 2004, GLOBAL PLANET CHANGE, V42, P83, DOI 10.1016/j.gloplacha.2003.11.011; Kramarska R, 1998, GEOL Q, V42, P277; Lambeck K, 1998, GEOPHYS J INT, V134, P102, DOI 10.1046/j.1365-246x.1998.00541.x; Landvik JY, 1998, QUATERNARY SCI REV, V17, P43, DOI 10.1016/S0277-3791(97)00066-8; Larsen E, 1999, BOREAS, V28, P115, DOI 10.1111/j.1502-3885.1999.tb00209.x; LETREUT H, 1983, J GEOPHYS RES-OCEANS, V88, P5167, DOI 10.1029/JC088iC09p05167; LIIVA A, 1966, RADIOCARBON, V8, P430, DOI 10.1017/S0033822200000278; Lundqvist J, 2001, QUATERNARY SCI REV, V20, P1127; Mangerud J, 2004, DEV QUA SCI, V2, P271; McManus JF, 2004, NATURE, V428, P834, DOI 10.1038/nature02494; Milne GA, 2001, SCIENCE, V291, P2381, DOI 10.1126/science.1057022; Nebout NC, 2002, GEOLOGY, V30, P863, DOI 10.1130/0091-7613(2002)030<0863:EAAAHP>2.0.CO;2; Piotrowski JA, 1997, J GLACIOL, V43, P495, DOI 10.3189/S0022143000035103; Rainio H., 1995, GLACIAL DEPOSITS NE, P57; Reimer PJ, 2004, RADIOCARBON, V46, P1029, DOI 10.1017/S0033822200032999; Rinterknecht VR, 2004, QUATERNARY SCI REV, V23, P2283, DOI 10.1016/j.quascirev.2004.06.012; Rotnicki K., 1995, PRACE PANSTWOWEGO I, V149, P84; Saarnisto M, 2001, GLOBAL PLANET CHANGE, V31, P387, DOI 10.1016/S0921-8181(01)00131-X; Stuiver M, 2000, QUATERNARY RES, V53, P277, DOI 10.1006/qres.2000.2127; Svendsen JI, 2004, QUATERNARY SCI REV, V23, P1229, DOI 10.1016/j.quascirev.2003.12.008; Taylor J. R., 1997, INTRO ERROR ANAL; Tschudi S, 2000, BOREAS, V29, P287, DOI 10.1080/030094800448046; VELICHKO AA, 1986, QUATERNARY SCI REV, V5, P447, DOI 10.1016/0277-3791(86)90211-8; Yokoyama Y, 2000, NATURE, V406, P713, DOI 10.1038/35021035; Zwally HJ, 2002, SCIENCE, V297, P218, DOI 10.1126/science.1072708	40	193	197	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2006	311	5766					1449	1452		10.1126/science.1120702	http://dx.doi.org/10.1126/science.1120702			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527977				2022-12-28	WOS:000236029400045
J	Yin, HM; Kable, SH; Zhang, X; Bowman, JM				Yin, HM; Kable, SH; Zhang, X; Bowman, JM			Signatures of H2CO photodissociation from two electronic states	SCIENCE			English	Article							UNIMOLECULAR DECOMPOSITION; FORMALDEHYDE; THRESHOLD; DYNAMICS; ENERGY	Even in small molecules, the influence of electronic state on rotational and vibrational product energies is not well understood. Here, we use experiments and theory to address this issue in photodissociation of formaldehyde, H2CO, to the radical products H + HCO. These products result from dissociation from the singlet ground electronic state or the first excited triplet state (T-1) of H2CO. Fluorescence spectra reveal a sudden decrease in the HCO rotational energy with increasing photolysis energy accompanied by substantial HCO vibrational excitation. Calculations of the rotational distribution using an ab initio potential energy surface for the T-1 state are in very good agreement with experiment and strongly support dominance of the T-1 state in the dynamics at the higher photolysis energies.	Univ Sydney, Sch Chem, Sydney, NSW 2006, Australia; Emory Univ, Dept Chem, Atlanta, GA 30322 USA; Emory Univ, Cherry L Emerson Ctr Sci Computat, Atlanta, GA 30322 USA	University of Sydney; Emory University; Emory University	Kable, SH (corresponding author), Univ Sydney, Sch Chem, Sydney, NSW 2006, Australia.	s.kable@chem.usyd.edu.au; jmbowma@emory.edu		Kable, Scott/0000-0002-0331-6137				Bowman JM, 2006, PHYS CHEM CHEM PHYS, V8, P321, DOI 10.1039/b512847c; CHANG YT, 1992, J CHEM PHYS, V96, P4341, DOI 10.1063/1.462826; CHUANG MC, 1987, J CHEM PHYS, V87, P3855, DOI 10.1063/1.452940; Dulligan MJ, 1997, CHEM PHYS LETT, V276, P84, DOI 10.1016/S0009-2614(97)00815-4; KEMPER MJH, 1981, J CHEM PHYS, V74, P5744, DOI 10.1063/1.440940; LEE SH, 1995, J CHEM PHYS, V103, P104, DOI 10.1063/1.469648; MOORE CB, 1983, ANNU REV PHYS CHEM, V34, P525, DOI 10.1146/annurev.pc.34.100183.002521; Terentis AC, 1996, CHEM PHYS LETT, V258, P626, DOI 10.1016/0009-2614(96)00705-1; Terentis AC, 1998, J CHEM PHYS, V108, P3187, DOI 10.1063/1.475736; Townsend D, 2004, SCIENCE, V306, P1158, DOI 10.1126/science.1104386; Tyndall G.S., 1999, ATMOSPHERIC CHEM GLO; Valachovic LR, 2000, J CHEM PHYS, V112, P2752, DOI 10.1063/1.480849; Yamaguchi Y, 1998, J CHEM PHYS, V108, P5281, DOI 10.1063/1.476315; Yin HM, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1902863; Zhang XB, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1872838; Zhang XB, 2004, J PHYS CHEM A, V108, P8980, DOI [10.1021/jp048339l, 10.1021/jp0483391]	16	67	69	0	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2006	311	5766					1443	1446		10.1126/science.1123397	http://dx.doi.org/10.1126/science.1123397			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527976				2022-12-28	WOS:000236029400043
J	Gilad, Y; Oshlack, A; Smyth, GK; Speed, TP; White, KP				Gilad, Y; Oshlack, A; Smyth, GK; Speed, TP; White, KP			Expression profiling in primates reveals a rapid evolution of human transcription factors	NATURE			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; GENE-EXPRESSION; NATURAL-SELECTION; HUMAN GENOME; PATTERNS; DIVERGENCE; DROSOPHILA; SEQUENCE; CHIMPANZEES; MUTATION	Although it has been hypothesized for thirty years that many human adaptations are likely to be due to changes in gene regulation(1), almost nothing is known about the modes of natural selection acting on regulation in primates. Here we identify a set of genes for which expression is evolving under natural selection. We use a new multi-species complementary DNA array to compare steady-state messenger RNA levels in liver tissues within and between humans, chimpanzees, orangutans and rhesus macaques. Using estimates from a linear mixed model, we identify a set of genes for which expression levels have remained constant across the entire phylogeny (similar to 70 million years), and are therefore likely to be under stabilizing selection. Among the top candidates are five genes with expression levels that have previously been shown to be altered in liver carcinoma. We also find a number of genes with similar expression levels among non-human primates but significantly elevated or reduced expression in the human lineage, features that point to the action of directional selection. Among the gene set with a human-specific increase in expression, there is an excess of transcription factors; the same is not true for genes with increased expression in chimpanzee.	Yale Univ, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06510 USA; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia; Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA; Univ Calif Berkeley, Program Biostat, Berkeley, CA 94720 USA	Yale University; Yale University; Walter & Eliza Hall Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Gilad, Y (corresponding author), Yale Univ, Dept Genet, New Haven, CT 06510 USA.	gilad@uchicago.edu; kevin.white@yale.edu	Smyth, Gordon/B-5276-2008; Speed, Terence P/B-8085-2009; Oshlack, Alicia/P-6139-2014	Smyth, Gordon/0000-0001-9221-2892; Speed, Terence P/0000-0002-5403-7998; Oshlack, Alicia/0000-0001-9788-5690				BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boffelli D, 2003, SCIENCE, V299, P1391, DOI 10.1126/science.1081331; Bustamante CD, 2005, NATURE, V437, P1153, DOI 10.1038/nature04240; Caceres M, 2003, P NATL ACAD SCI USA, V100, P13030, DOI 10.1073/pnas.2135499100; Chiba T, 2005, EUR J CANCER, V41, P1185, DOI 10.1016/j.ejca.2005.02.014; Denver DR, 2005, NAT GENET, V37, P544, DOI 10.1038/ng1554; Enard W, 2002, SCIENCE, V296, P340, DOI 10.1126/science.1068996; Gilad Y, 2005, GENOME RES, V15, P674, DOI 10.1101/gr.3335705; Glazko GV, 2003, MOL BIOL EVOL, V20, P424, DOI 10.1093/molbev/msg050; Hsieh WP, 2003, GENETICS, V165, P747; Karaman MW, 2003, GENOME RES, V13, P1619, DOI 10.1101/gr.1289803; Khaitovich P, 2005, SCIENCE, V309, P1850, DOI 10.1126/science.1108296; Khaitovich P, 2005, GENETICS, V170, P929, DOI 10.1534/genetics.104.037135; Khaitovich P, 2004, PLOS BIOL, V2, P682, DOI 10.1371/journal.pbio.0020132; Khaitovich P, 2004, GENOME RES, V14, P1462, DOI 10.1101/gr.2538704; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; Lemos B, 2005, EVOLUTION, V59, P126; Ludwig MZ, 2005, PLOS BIOL, V3, P588, DOI 10.1371/journal.pbio.0030093; Nuzhdin SV, 2004, MOL BIOL EVOL, V21, P1308, DOI 10.1093/molbev/msh128; Park SW, 2004, BRIT J CANCER, V91, P753, DOI 10.1038/sj.bjc.6602023; PATTERSON HD, 1971, BIOMETRIKA, V58, P545, DOI 10.1093/biomet/58.3.545; Pinheiro J, 2001, MIXED EFFECTS MODELS; Ranz JM, 2003, SCIENCE, V300, P1742, DOI 10.1126/science.1085881; Rifkin SA, 2005, NATURE, V438, P220, DOI 10.1038/nature04114; Rifkin SA, 2003, NAT GENET, V33, P138, DOI 10.1038/ng1086; Rise ML, 2004, GENOME RES, V14, P478, DOI 10.1101/gr.1687304; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Sugeno H, 2004, ANTICANCER RES, V24, P1045; Yang E, 2003, GENOME RES, V13, P1863, DOI 10.1101/gr.1272403; Zhu Z, 2005, WORLD J GASTROENTERO, V11, P1903	30	230	233	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2006	440	7081					242	245		10.1038/nature04559	http://dx.doi.org/10.1038/nature04559			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019MC	16525476	Bronze			2022-12-28	WOS:000235839500053
J	Dominici, F; Peng, RD; Bell, ML; Pham, L; McDermott, A; Zeger, SL; Samet, JM				Dominici, F; Peng, RD; Bell, ML; Pham, L; McDermott, A; Zeger, SL; Samet, JM			Fine particulate air pollution and hospital admission for cardiovascular and respiratory diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TIME-SERIES; DISTRIBUTED LAG; DAILY MORTALITY; US CITIES; RESPONSE RELATIONSHIPS; NATIONAL MORBIDITY; UNITED-STATES; CLAIMS DATA; EXPOSURE; MODELS	Context Evidence on the health risks associated with short-term exposure to fine particles (particulate matter <= 2.5 mu m in aerodynamic diameter [PM2.5]) is limited. Results from the new national monitoring network for PM2.5 make possible systematic research on health risks at national and regional scales. Objectives To estimate risks of cardiovascular and respiratory hospital admissions associated with short-term exposure to PM2.5 for Medicare enrollees and to explore heterogeneity of the variation of risks across regions. Design, Setting, and Participants A national database comprising daily time-series data daily for 1999 through 2002 on hospital admission rates (constructed from the Medicare National Claims History Files) for cardiovascular and respiratory outcomes and injuries, ambient PM2.5 levels, and temperature and dew-point temperature for 204 US urban counties (population >200 000) with 11.5 million Medicare enrollees (aged >65 years) living an average of 5.9 miles from a PM2.5 monitor. Main Outcome Measures Daily counts of county-wide hospital admissions for primary diagnosis of cerebrovascular, peripheral, and ischemic heart diseases, heart rhythm, heart failure, chronic obstructive pulmonary disease, and respiratory infection, and injuries as a control outcome. Results There was a short-term increase in hospital admission rates associated with PM2.5 for all of the health outcomes except injuries. The largest association was for heart failure, which had a 1.28% (95% confidence interval, 0.78%-1.78%) increase in risk per 10-mu g/m(3) increase in same-day PM2.5. Cardiovascular risks tended to be higher in counties located in the Eastern region of the United States, which included the Northeast, the Southeast, the Midwest, and the South. Conclusion Short-term exposure to PM2.5 increases the risk for hospital admission for cardiovascular and respiratory diseases.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Yale Univ, Sch Forestry & Environm Studies, New Haven, CT 06511 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Yale University	Dominici, F (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biostat, 615 N Wolfe St, Baltimore, MD 21205 USA.	fdominic@jhsph.edu	Bell, Michelle/Y-4608-2018	Bell, Michelle/0000-0002-3965-1359; Zeger, Scott/0000-0001-8907-1603	NIEHS NIH HHS [P30 ES003819, R01 ES012054, P30 ES 03819, ES012054-03] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819, R01ES012054] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALMON S, 1965, ECONOMETRICA, V33, P178, DOI 10.2307/1911894; [Anonymous], 2005, R LANG ENV STAT COMP; BAICKER K, 2004, HLTH AFF MILLWOOD, V23; Bell ML, 2005, EPIDEMIOLOGY, V16, P436, DOI 10.1097/01.ede.0000165817.40152.85; Bell ML, 2004, JAMA-J AM MED ASSOC, V292, P2372, DOI 10.1001/jama.292.19.2372; Brook RD, 2004, CIRCULATION, V109, P2655, DOI 10.1161/01.CIR.0000128587.30041.C8; Burnett RT, 1997, ENVIRON HEALTH PERSP, V105, P614, DOI 10.1289/ehp.97105614; *CLEAN AIR SCI ADV, 2005, REV NAT AMB AIR QUAL; Curriero FC, 2002, AM J EPIDEMIOL, V155, P80, DOI 10.1093/aje/155.1.80; Dominici F, 2000, J ROY STAT SOC A STA, V163, P263, DOI 10.1111/1467-985X.00170; Dominici F, 2004, J AM STAT ASSOC, V99, P938, DOI 10.1198/016214504000000656; Dominici F, 2002, J AM STAT ASSOC, V97, P100, DOI 10.1198/016214502753479266; DOMINID F, 2003, REVISED ANAL TIME SE; DUMOUCHEL WH, 1983, J AM STAT ASSOC, V78, P293, DOI 10.2307/2288631; Everson PJ, 2000, J ROY STAT SOC B, V62, P399, DOI 10.1111/1467-9868.00239; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; Gelman A., 2003, BAYESIAN DATA ANAL; Hartigan J., 1975, CLUSTERING ALGORITHM; Havranek EP, 2004, ARCH INTERN MED, V164, P1186, DOI 10.1001/archinte.164.11.1186; Ito K, 2005, EPIDEMIOLOGY, V16, P446, DOI 10.1097/01.ede.0000165821.90114.7f; Kelsall JE, 1997, AM J EPIDEMIOL, V146, P750; Kiyota Y, 2004, AM HEART J, V148, P99, DOI 10.1016/j.ahj.2004.02.013; Kunzli N, 2005, ENVIRON HEALTH PERSP, V113, P201, DOI 10.1289/ehp.7523; Le Tertre A, 2002, J EPIDEMIOL COMMUN H, V56, P773, DOI 10.1136/jech.56.10.773; LINDLEY DV, 1972, J ROY STAT SOC B, V34, P1; Lippmann M, 2000, Res Rep Health Eff Inst, P5; Losina E, 2003, J CLIN EPIDEMIOL, V56, P515, DOI 10.1016/S0895-4356(03)00056-8; MacQueen J., 1967, P BERK S MATH STAT P; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; Moolgavkar SH, 2000, ENVIRON HEALTH PERSP, V108, P777, DOI 10.2307/3434732; Moolgavkar SH, 2000, INHAL TOXICOL, V12, P75, DOI 10.1080/089583700750019512; *NAT RES COUNC COM, 2004, RES PRIOR AIRB PART, V4; National Center for Environmental Assessment, 2004, AIR QUAL CRIT PART M; *OFF AIR QUAL PLAN, 2000, QUAL ASS PROJ PLAN P; Peng RD, 2006, J R STAT SOC A STAT, V169, P179, DOI 10.1111/j.1467-985X.2006.00410.x; Peng RD, 2005, AM J EPIDEMIOL, V161, P585, DOI 10.1093/aje/kwi075; Pope CA, 2004, CIRCULATION, V109, P71, DOI 10.1161/01.CIR.0000108927.80044.7F; Pope CA, 2004, ENVIRON HEALTH PERSP, V112, P339, DOI 10.1289/ehp.6588; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Samoli E, 2005, ENVIRON HEALTH PERSP, V113, P88, DOI 10.1289/ehp.7387; Schwartz J, 2000, EPIDEMIOLOGY, V11, P320, DOI 10.1097/00001648-200005000-00016; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; SHEPPARD L, 2003, REVISED ANAL TIME SE, P227; Stieb DM, 2003, J AIR WASTE MANAGE, V53, P258, DOI 10.1080/10473289.2003.10466149; Sun QH, 2005, JAMA-J AM MED ASSOC, V294, P3003, DOI 10.1001/jama.294.23.3003; Touloumi G, 1997, AM J EPIDEMIOL, V146, P177, DOI 10.1093/oxfordjournals.aje.a009249; Touloumi G, 2005, EPIDEMIOLOGY, V16, P49, DOI 10.1097/01.ede.0000142152.62400.13; *US EPA, 1997, FED REGISTER, V62, P138; *US EPA OFF RES DE, 1996, AIR QUAL CRIT PART M; Welty LJ, 2005, AM J EPIDEMIOL, V162, P80, DOI 10.1093/aje/kwi157; *WHO, 1977, INT CLASSIFICATION D, V9; Zanobetti A, 2000, Biostatistics, V1, P279, DOI 10.1093/biostatistics/1.3.279	52	1812	1911	11	630	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	2006	295	10					1127	1134		10.1001/jama.295.10.1127	http://dx.doi.org/10.1001/jama.295.10.1127			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	019GB	16522832	Bronze, Green Accepted			2022-12-28	WOS:000235822500020
J	Diep, BA; Gill, SR; Chang, RF; Phan, TH; Chen, JH; Davidson, MG; Lin, F; Lin, J; Carleton, HA; Mongodin, EF; Sensabaugh, GF; Perdreau-Remington, F				Diep, BA; Gill, SR; Chang, RF; Phan, TH; Chen, JH; Davidson, MG; Lin, F; Lin, J; Carleton, HA; Mongodin, EF; Sensabaugh, GF; Perdreau-Remington, F			Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus	LANCET			English	Article							PANTON-VALENTINE LEUKOCIDIN; CASSETTE CHROMOSOME MEC; METHICILLIN-RESISTANT; GENE-EXPRESSION; EVOLUTION; VIRULENCE; INFECTION; STRAINS; PNEUMONIA; INSIGHTS	Background USA300, a clone of meticillin-resistant Staphylococcus aureus, is a major source of community-acquired infections in the USA, Canada, and Europe. Our aim was to sequence its genome and compare it with those of other strains of S aureus to try to identify genes responsible for its distinctive epidemiological and virulence properties. Methods We ascertained the genome sequence of FPR3757, a multidrug resistant USA300 strain, by random shotgun sequencing, then compared it with the sequences of ten other staphylococcal strains. Findings Compared with closely related S aureus, we noted that almost all of the unique genes in USA300 clustered in novel allotypes of mobile genetic elements. Some of the unique genes are involved in pathogenesis, including Panton-Valentine leucocidin and molecular variants of enterotoxin Q and K. The most striking feature of the USA300 genome is the horizontal acquisition of a novel mobile genetic element that encodes an arginine deiminase pathway and an oligopeptide permease system that could contribute to growth and survival of USA300. We did not detect this element, termed arginine catabolic mobile element (ACME), in other S aureus strains. We noted a high prevalence of ACME in S epidermidis, suggesting not only that ACME transfers into USA300 from S epidermidis, but also that this element confers a selective advantage to this ubiquitous commensal of the human skin. Interpretation USA300 has acquired mobile genetic elements that encode resistance and virulence determinants that could enhance fitness and pathogenicity.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis, Berkeley, CA 94720 USA; SUNY Buffalo, Dept Oral Biol, Buffalo, NY 14260 USA; Inst Genom Res, Rockville, MD USA	University of California System; University of California San Francisco; University of California System; University of California Berkeley; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; J. Craig Venter Institute	Diep, BA (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, 1001 Potrero Ave,Box 0811, San Francisco, CA 94143 USA.	bdiep@epi-center.ucsf.edu	Mongodin, Emmanuel/AAF-1850-2020	Mongodin, Emmanuel/0000-0003-3833-7437	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI060537] Funding Source: NIH RePORTER; NIAID NIH HHS [5T32AI060537-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baba T, 2002, LANCET, V359, P1819, DOI 10.1016/S0140-6736(02)08713-5; Chambers HF, 2005, NEW ENGL J MED, V352, P1485, DOI 10.1056/NEJMe058023; Coulter SN, 1998, MOL MICROBIOL, V30, P393, DOI 10.1046/j.1365-2958.1998.01075.x; de Haas CJC, 2004, J EXP MED, V199, P687, DOI 10.1084/jem.20031636; Degnan BA, 1998, INFECT IMMUN, V66, P3050, DOI 10.1128/IAI.66.7.3050-3058.1998; Degnan BA, 2000, INFECT IMMUN, V68, P2441, DOI 10.1128/IAI.68.5.2441-2448.2000; DIEP BA, IN PRESS J INFECT DI; Ehlers C, 2001, SKIN RES TECHNOL, V7, P90, DOI 10.1034/j.1600-0846.2001.70206.x; Enright MC, 2000, J CLIN MICROBIOL, V38, P1008, DOI 10.1128/JCM.38.3.1008-1015.2000; Francis JS, 2005, CLIN INFECT DIS, V40, P100, DOI 10.1086/427148; Genestier AL, 2005, J CLIN INVEST, V115, P3117, DOI 10.1172/JCI22684; Gill SR, 2005, J BACTERIOL, V187, P2426, DOI 10.1128/JB.187.7.2426-2438.2005; Gillet Y, 2002, LANCET, V359, P753, DOI 10.1016/S0140-6736(02)07877-7; Gonzalez BE, 2005, PEDIATRICS, V115, P642, DOI 10.1542/peds.2004-2300; Holden MTG, 2004, P NATL ACAD SCI USA, V101, P9786, DOI 10.1073/pnas.0402521101; Ito T, 2001, ANTIMICROB AGENTS CH, V45, P1323, DOI 10.1128/AAC.45.5.1323-1336.2001; Katayama Y, 2000, ANTIMICROB AGENTS CH, V44, P1549, DOI 10.1128/AAC.44.6.1549-1555.2000; Kazakova SV, 2005, NEW ENGL J MED, V352, P468, DOI 10.1056/NEJMoa042859; Laupland KB, 2003, CLIN INFECT DIS, V37, P933, DOI 10.1086/377735; Lu CD, 1999, J BACTERIOL, V181, P2459, DOI 10.1128/JB.181.8.2459-2464.1999; Ma XX, 2002, ANTIMICROB AGENTS CH, V46, P1147, DOI 10.1128/AAC.46.4.1147-1152.2002; McDougal LK, 2003, J CLIN MICROBIOL, V41, P5113, DOI 10.1128/JCM.41.11.5113-5120.2003; Miller LG, 2005, NEW ENGL J MED, V352, P1445, DOI 10.1056/NEJMoa042683; Miragaia M, 2005, MICROB DRUG RESIST, V11, P83, DOI 10.1089/mdr.2005.11.83; Mongkolrattanothai K, 2004, ANTIMICROB AGENTS CH, V48, P1823, DOI 10.1128/AAC.48.5.1823-1836.2004; Pan ES, 2005, J INFECT DIS, V192, P811, DOI 10.1086/432072; Pan ES, 2003, CLIN INFECT DIS, V37, P1384, DOI 10.1086/379019; Podbielski A, 1996, MOL MICROBIOL, V21, P1087, DOI 10.1046/j.1365-2958.1996.661421.x; Resch A, 2005, APPL ENVIRON MICROB, V71, P2663, DOI 10.1128/AEM.71.5.2663-2676.2005; Schmitz FJ, 1998, ANTIMICROB AGENTS CH, V42, P1249, DOI 10.1128/AAC.42.5.1249; Takahashi T, 1997, J VET MED SCI, V59, P775, DOI 10.1292/jvms.59.775; Takeuchi F, 2005, J BACTERIOL, V187, P7292, DOI 10.1128/JB.187.21.7292-7308.2005; Tenover FC, 2006, J CLIN MICROBIOL, V44, P108, DOI 10.1128/JCM.44.1.108-118.2006; Voyich JA, 2005, J IMMUNOL, V175, P3907, DOI 10.4049/jimmunol.175.6.3907; Weigel LM, 2003, SCIENCE, V302, P1569, DOI 10.1126/science.1090956; Weinrick B, 2004, J BACTERIOL, V186, P8407, DOI 10.1128/JB.186.24.8407-8423.2004; Wisplinghoff H, 2003, ANTIMICROB AGENTS CH, V47, P3574, DOI 10.1128/AAC.47.11.3574-3579.2003; Yarwood JM, 2002, J BIOL CHEM, V277, P13138, DOI 10.1074/jbc.M111661200	38	1162	1929	2	148	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 4	2006	367	9512					731	739		10.1016/S0140-6736(06)68231-7	http://dx.doi.org/10.1016/S0140-6736(06)68231-7			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	020JX	16517273				2022-12-28	WOS:000235906000027
J	Melis, AP; Hare, B; Tomasello, M				Melis, AP; Hare, B; Tomasello, M			Chimpanzees recruit the best collaborators	SCIENCE			English	Article							RECIPROCAL ALTRUISM; EVOLUTION; MONKEYS; COOPERATION; LABOR; RANK	Humans collaborate with non-kin in special ways, but the evolutionary foundations of these collaborative skills remain unclear. We presented chimpanzees with collaboration problems in which they had to decide when to recruit a partner and which potential partner to recruit. In an initial study, individuals recruited a collaborator only when solving the problem required collaboration. In a second study, individuals recruited the more effective of two partners on the basis of their experience with each of them on a previous day. Therefore, recognizing when collaboration is necessary and determining who is the best collaborative partner are skills shared by both chimpanzees and humans, so such skills may have been present in their common ancestor before humans evolved their own complex forms of collaboration.	Max Planck Inst Evolutionary Anthropol, D-04103 Leipzig, Germany	Max Planck Society	Melis, AP (corresponding author), Max Planck Inst Evolutionary Anthropol, D-04103 Leipzig, Germany.	melis@eva.mpg.de; hare@eva.mpg.de	Galantucci, Bruno/E-5770-2010					Boesch C, 2000, CHIMPANZEES TAI FORE; CHALMEAU R, 1994, PRIMATES, V35, P385, DOI 10.1007/BF02382735; Crawford M.P., 1937, COMP PSYCHOL MONOGR, V14, P1; de Waal FBM, 2000, NATURE, V404, P563, DOI 10.1038/35007138; DEWAAL FBM, 1988, ETHOL SOCIOBIOL, V9, P101, DOI 10.1016/0162-3095(88)90016-7; Engh AL, 2005, ANIM BEHAV, V69, P209, DOI 10.1016/j.anbehav.2004.04.013; Fehr E, 2004, TRENDS COGN SCI, V8, P185, DOI 10.1016/j.tics.2004.02.007; HARCOURT A, 1992, COALLITIONS ALLIANCE; Hattori Y, 2005, J COMP PSYCHOL, V119, P335, DOI 10.1037/0735-7036.119.3.335; Hauser MD, 2003, P ROY SOC B-BIOL SCI, V270, P2363, DOI 10.1098/rspb.2003.2509; HEMELRIJK CK, 1991, ANIM BEHAV, V41, P923, DOI 10.1016/S0003-3472(05)80630-X; Henrich J., 2005, FDN HUMAN SOCIALITY; Hirata S., 2003, HATTATSU, V95, P103; KOYAMA NF, IN PRESS INT J PRIMA; MELIS A, IN PRESS ANIM BEHAV; Povinelli DJ, 2000, UNDERSTANDING OTHER, P459; Silk JB, 1999, ANIM BEHAV, V58, P45, DOI 10.1006/anbe.1999.1129; STAMMBACH E, 1988, BEHAVIOUR, V107, P241, DOI 10.1163/156853988X00368; Stevens JR, 2004, TRENDS COGN SCI, V8, P60, DOI 10.1016/j.tics.2003.12.003; Tomasello M, 1997, PRIMATE COGNITION; TOMASELLO M, IN PRESS BEHAV BRAIN; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; WARNEKEN F, IN PRESS CHILD DEV; WATTS D, 2002, DIVERSITY CHIMPANZEE, P244; Wilson E.O., 1975, P1; Wilson ML, 2001, ANIM BEHAV, V61, P1203, DOI 10.1006/anbe.2000.1706; Wrangham RW, 1999, YEARB PHYS ANTHROPOL, V42, P1	27	331	337	2	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	2006	311	5765					1297	1300		10.1126/science.1123007	http://dx.doi.org/10.1126/science.1123007			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019XB	16513985				2022-12-28	WOS:000235870400045
J	Haug, GH; Peterson, LC				Haug, GH; Peterson, LC			Nicholas Shackleton (1937-2006) - A founding father of palaeoclimatology, and an avid clarinettist.	NATURE			English	Biographical-Item									Geoforschungszentrum Potsdam, D-14473 Potsdam, Germany; Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Miami, FL 33149 USA	Helmholtz Association; Helmholtz-Center Potsdam GFZ German Research Center for Geosciences; University of Miami	Haug, GH (corresponding author), Geoforschungszentrum Potsdam, D-14473 Potsdam, Germany.	haug@gfz-potsdam.de; lpeterson@rsmas.miami.edu							0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 23	2006	439	7079					928	928		10.1038/439928a	http://dx.doi.org/10.1038/439928a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014NE	16495987	Green Submitted			2022-12-28	WOS:000235486100035
J	Ruiz-Palomo, F				Ruiz-Palomo, F			Osteopetrosis type II	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Hosp Univ Ramon & Cajal, Madrid 28034, Spain	Hospital Universitario Ramon y Cajal	Ruiz-Palomo, F (corresponding author), Hosp Univ Ramon & Cajal, Madrid 28034, Spain.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 23	2006	354	8					849	849		10.1056/NEJMicm050464	http://dx.doi.org/10.1056/NEJMicm050464			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014CL	16495397				2022-12-28	WOS:000235456200009
J	Sulheim, S; Holme, I; Ekeland, A; Bahr, R				Sulheim, S; Holme, I; Ekeland, A; Bahr, R			Helmet use and risk of head injuries in alpine skiers and snowboarders	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SKIING INJURIES; CHILDREN; SPINE	Context Although using a helmet is assumed to reduce the risk of head injuries in alpine sports, this effect is questioned. In contrast to bicycling or inline skating, there is no policy of mandatory helmet use for recreational alpine skiers and snowboarders. Objective To determine the effect of wearing a helmet on the risk of head injury among skiers and snowboarders while correcting for other potential risk factors. Design, Setting, and Participants Case-control study at 8 major Norwegian alpine resorts during the 2002 winter season, involving 3277 injured skiers and snowboarders reported by the ski patrol and 2992 noninjured controls who were interviewed on Wednesdays and Saturdays. The controls comprised every 10th person entering the bottom main ski lift at each resort during peak hours. The number of participants interviewed corresponded with each resort's anticipated injury count based on earlier years. Main Outcome Measure Injury type, helmet use, and other risk factors (age, sex, nationality, skill level, equipment used, ski school attendance, rented or own equipment) were recorded. A multivariate logistic regression analysis was used to assess the relationship between individual risk factors (including helmet wear) and risk of head injury by comparing skiers with head injuries with uninjured controls, as well as to skiers with injuries other than head injuries. Results Head injuries accounted for 578 injuries (17.6%). Using a helmet was associated with a 60% reduction in the risk for head injury (odds ratio [OR], 0.40; 95% confidence interval [CI], 0.30-0.55; adjusted for other risk factors) when comparing skiers with head injuries with uninjured controls. The effect was slightly reduced (OR, 0.45; 95% CI, 0.34-0.59) when skiers with other injuries were used as controls. For the 147 potentially severe head injuries, those who were referred to an emergency physician or for hospital treatment, the adjusted OR was 0.43 (95% CI, 0.25-0.77). The risk for head injury was higher among snowboarders than for alpine skiers (adjusted OR, 1.53; 95% CI, 1.22-1.91). Conclusion Wearing a helmet is associated with reduced risk of head injury among snowboarders and alpine skiers.	Norwegian Sch Sport Sci, Dept Sports Med, Oslo Sports Trauma Res Ctr, N-0806 Oslo, Norway; Martina Hansens Hosp, Baerum, Norway	Norwegian School of Sport Sciences	Bahr, R (corresponding author), Norwegian Sch Sport Sci, Dept Sports Med, Oslo Sports Trauma Res Ctr, N-0806 Oslo, Norway.	roald.bahr@nih.no	Bahr, Roald/B-6964-2014	Bahr, Roald/0000-0001-5725-4237; Ekeland, Arne/0000-0001-6998-8676				*AM MED ASS, 1999, 19 AM MED ASS COUNC; Buller DB, 2003, J TRAUMA, V55, P939, DOI 10.1097/01.TA.0000078694.53320.CA; Chow TK, 1996, J TRAUMA, V41, P321, DOI 10.1097/00005373-199608000-00021; Deibert MC, 1998, J BONE JOINT SURG AM, V80A, P25, DOI 10.2106/00004623-199801000-00006; Dohjima T, 2001, ACTA ORTHOP SCAND, V72, P657, DOI 10.1080/000164701317269111; Ekeland A, 2003, AM SOC TEST MATER, V1440, P97, DOI 10.1520/STP10963S; EKELAND A, 1993, AM J SPORT MED, V21, P201, DOI 10.1177/036354659302100207; FURRER M, 1995, J TRAUMA, V39, P737, DOI 10.1097/00005373-199510000-00024; Gindler J. S., 1995, Morbidity and Mortality Weekly Report, V44, P1; Hackam DJ, 1999, J PEDIATR SURG, V34, P65, DOI 10.1016/S0022-3468(99)90230-0; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; Hentschel S, 2001, CAN J NEUROL SCI, V28, P42; Hunter RE, 1999, AM J SPORT MED, V27, P381, DOI 10.1177/03635465990270032101; Jorgensen U, 1998, KNEE SURG SPORT TR A, V6, P194, DOI DOI 10.1007/S001670050098; Levy AS, 2000, SEMIN NEUROL, V20, P233, DOI 10.1055/s-2000-9833; Macnab AJ, 2002, INJURY PREV, V8, P324, DOI 10.1136/ip.8.4.324; MYLES ST, 1992, CAN J SURG, V35, P643; Nakaguchi H, 1999, J TRAUMA, V46, P1066, DOI 10.1097/00005373-199906000-00017; OLIVER BC, 1991, ASTM STP, V1104, P164; PRALL JA, 1995, INJURY, V26, P539, DOI 10.1016/0020-1383(95)00085-N; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; Thompson DC, 1999, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001855, DOI 10.1002/14651858.CD001855]; TORJUSSEN J, IN PRESS BR J SPORTS	23	173	175	0	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	2006	295	8					919	924		10.1001/jama.295.8.919	http://dx.doi.org/10.1001/jama.295.8.919			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014DO	16493105	Bronze			2022-12-28	WOS:000235459200025
J	Go, AS; Iribarren, C; Chandra, M; Lathon, PV; Fortmann, SP; Quertermous, T; Hlatky, MA				Go, AS; Iribarren, C; Chandra, M; Lathon, PV; Fortmann, SP; Quertermous, T; Hlatky, MA		ADVANCE Study	Statin and beta-blocker therapy and the initial presentation of coronary heart disease	ANNALS OF INTERNAL MEDICINE			English	Article							INTIMA-MEDIA THICKNESS; NITRIC-OXIDE SYNTHASE; CARDIOVASCULAR-DISEASE; PRIMARY PREVENTION; MYOCARDIAL-INFARCTION; HOSPITAL OUTCOMES; RANDOMIZED TRIAL; GLOBAL REGISTRY; ANGINA-PECTORIS; BLOOD-PRESSURE	Background: Coronary atherosclerosis develops slowly over decades but is frequently characterized clinically by sudden unstable episodes. Patients who present with unstable coronary disease, such as acute myocardial infarction, may systematically differ from patients who present with relatively stable coronary disease, such as exertional angina. Objective: To examine whether medication use or patient characteristics influence the mode of initial clinical presentation of coronary disease. Design: Case-control study Setting: Large integrated health care delivery system in northern California. Patients: Adults whose first clinical presentation of coronary disease was either acute myocardial infarction (n = 916) or stable exertional angina (n = 468). Measurements: Use of cardiac medications before the event from pharmacy databases and demographic, lifestyle, and clinical characteristics from self-report and clinical and administrative databases. Results: Compared with patients with incident stable exertional angina, patients with incident acute myocardial infarction were more likely to be men, smokers, physically inactive, and hypertensive but were less likely to have a parental history of coronary disease. Patients presenting with myocardial infarction were much less likely to have received statins (19.3% vs. 40.4%; P < 0.001) and beta-blockers (19.0% vs. 47.7%; P < 0.001) than patients presenting with exertional angina. After adjustment for potential confounders, recent use of statins (adjusted odds ratio, 0.45 [95% Cl, 0.32 to 0.62]) and beta-blockers (adjusted odds ratio, 0.26 [Cl, 0.19 to 0.35]) was associated with lower likelihoods of presenting with an acute myocardial infarction than with stable angina. Limitations: This observational study did not have information on all possible confounding factors, including use of aspirin therapy. Conclusion: Statin and beta-blocker use was associated with lower odds of presenting with an acute myocardial infarction than with stable angina. Additional studies are needed to confirm that these therapies protect against unstable, higher-risk clinical presentations of coronary disease.	Kaiser Permanente No Calif, Div Res, Oakland, CA 94612 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA	Kaiser Permanente; University of California System; University of California San Francisco; Stanford University	Go, AS (corresponding author), Kaiser Permanente No Calif, Div Res, 2000 Broadway St,3rd Floor, Oakland, CA 94612 USA.	Alan.S.Go@kp.org	Go, Alan S./AAE-7745-2019	Quertermous, Thomas/0000-0002-7645-9067; Hlatky, Mark/0000-0003-4686-9441				Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64; Alexander M, 1999, ARCH INTERN MED, V159, P2673, DOI 10.1001/archinte.159.22.2673; Ambrose JA, 2004, J AM COLL CARDIOL, V43, P1731, DOI 10.1016/j.jacc.2003.12.047; ANDREWS TC, 1993, CIRCULATION, V88, P92, DOI 10.1161/01.CIR.88.1.92; ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; Balk EM, 2003, ANN INTERN MED, V139, P670, DOI 10.7326/0003-4819-139-8-200310210-00011; Barua RS, 2002, CIRCULATION, V106, P905, DOI 10.1161/01.CIR.0000029091.61707.6B; Bazzano LA, 2003, ANN INTERN MED, V138, P891, DOI 10.7326/0003-4819-138-11-200306030-00010; Billinger A, 2001, J AM COLL CARDIOL, V38, P1866, DOI 10.1016/S0735-1097(01)01664-3; Black HR, 2003, JAMA-J AM MED ASSOC, V289, P2073, DOI 10.1001/jama.289.16.2073; Braunwald E, 2004, NEW ENGL J MED, V351, P2058; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; CURB JD, 1983, JAMA-J AM MED ASSOC, V250, P2814; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Dunder K, 2004, AM HEART J, V147, P502, DOI 10.1016/j.ahj.2003.09.010; Fireman BH, 2000, J NATL CANCER I, V92, P136, DOI 10.1093/jnci/92.2.136; Fox CS, 2004, JAMA-J AM MED ASSOC, V292, P2495, DOI 10.1001/jama.292.20.2495; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981; GERSH BJ, 2001, HEART DIS TXB CARDIO, V2, P1273; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Hedblad B, 2001, CIRCULATION, V103, P1721, DOI 10.1161/01.CIR.103.13.1721; Hernandez-Perera O, 1998, J CLIN INVEST, V101, P2711, DOI 10.1172/JCI1500; Hosmer DW, 1997, STAT MED, V16, P965; Hsia J, 2004, AM J CARDIOL, V93, P673, DOI 10.1016/j.amjcard.2003.12.002; Julius S, 2004, LANCET, V363, P2022, DOI 10.1016/S0140-6736(04)16451-9; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; Lee WY, 2004, AM J CARDIOL, V94, P1147, DOI 10.1016/j.amjcard.2004.07.081; Nissen SE, 2004, JAMA-J AM MED ASSOC, V292, P2217, DOI 10.1001/jama.292.18.2217; Patel H, 2004, AM HEART J, V148, P27, DOI 10.1016/j.ahj.2004.03.005; Pepine CJ, 2003, JAMA-J AM MED ASSOC, V290, P2805, DOI 10.1001/jama.290.21.2805; PETTERSSON K, 1990, CIRC RES, V67, P1027, DOI 10.1161/01.RES.67.4.1027; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; PSATY BM, 1989, JAMA-J AM MED ASSOC, V261, P2087, DOI 10.1001/jama.261.14.2087; Psaty BN, 2003, JAMA-J AM MED ASSOC, V289, P2534, DOI 10.1001/jama.289.19.2534; Rautaharju PM, 1998, J ELECTROCARDIOL, V31, P157, DOI 10.1016/S0022-0736(98)90132-7; Schartl M, 2001, CIRCULATION, V104, P387, DOI 10.1161/hc2901.093188; Selby JV, 1997, DIABETES CARE, V20, P1396, DOI 10.2337/diacare.20.9.1396; Shah Prediman K., 2003, Cardiology Clinics, V21, P303, DOI 10.1016/S0733-8651(03)00058-4; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Spencer FA, 2002, AM J CARDIOL, V90, P1056, DOI 10.1016/S0002-9149(02)02769-8; Steg PG, 2002, AM J CARDIOL, V90, P358, DOI 10.1016/S0002-9149(02)02489-X; Weber MA, 2004, LANCET, V363, P2049, DOI 10.1016/S0140-6736(04)16456-8; Wiklund O, 2002, STROKE, V33, P572, DOI 10.1161/hs0202.102332; WIKSTRAND J, 1988, JAMA-J AM MED ASSOC, V259, P1976, DOI 10.1001/jama.259.13.1976; Wilt TJ, 2004, ARCH INTERN MED, V164, P1427, DOI 10.1001/archinte.164.13.1427; Yusuf S, 2000, NEW ENGL J MED, V342, P145	51	66	67	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 21	2006	144	4					229	238		10.7326/0003-4819-144-4-200602210-00004	http://dx.doi.org/10.7326/0003-4819-144-4-200602210-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	015HS	16490908				2022-12-28	WOS:000235543100001
J	Rein, DB; Fiore, AE; Bell, BP				Rein, DB; Fiore, AE; Bell, BP			What's next for the hepatitis A vaccine?	LANCET			English	Editorial Material							IMMUNIZATION; AREA		RTI Int, Publ Hlth Econ, Atlanta, GA 30306 USA; US Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr Infect Dis, Atlanta, GA USA	Research Triangle Institute; Centers for Disease Control & Prevention - USA	Rein, DB (corresponding author), RTI Int, Publ Hlth Econ, Atlanta, GA 30306 USA.	drein@rti.org	Fiore, Anthony/AAO-8956-2020	Rein, David/0000-0002-1271-5789				Dagan R, 2005, JAMA-J AM MED ASSOC, V294, P202, DOI 10.1001/jama.294.2.202; Fitzsimons D, 2005, SCAND J INFECT DIS, V37, P549, DOI 10.1080/00365540510043284; Ginsberg GM, 2001, J HEPATOL, V34, P92, DOI 10.1016/S0168-8278(00)00007-6; Jacobsen KH, 2004, EPIDEMIOL INFECT, V132, P1005, DOI 10.1017/S0950268804002857; Lopalco PL, 2000, VACCINE, V19, P470, DOI 10.1016/S0264-410X(00)00193-6; MacIntyre CR, 2003, J PAEDIATR CHILD H, V39, P83, DOI 10.1046/j.1440-1754.2003.00098.x; Postma MJ, 2004, VACCINE, V22, P1862, DOI 10.1016/j.vaccine.2003.11.012; *US CDCP, 2005, M ADV COMM IMM PRACT; *US CDCP, 2006, MMWR-MORBID MORTAL W, V54, pQ1; Van Damme P, 2003, LANCET, V362, P1065, DOI 10.1016/S0140-6736(03)14418-2; Victor JC, 2006, AM J EPIDEMIOL, V163, P204, DOI 10.1093/aje/kwj029; Wasley A, 2005, JAMA-J AM MED ASSOC, V294, P194, DOI 10.1001/jama.294.2.194; *WHO, 2000, MMWR WKLY EPIDEMIOL, V75, P38	13	9	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 18	2006	367	9510					546	548		10.1016/S0140-6736(06)68196-8	http://dx.doi.org/10.1016/S0140-6736(06)68196-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013GM	16488780				2022-12-28	WOS:000235397800005
J	Christakis, NA; Allison, PD				Christakis, NA; Allison, PD			Mortality after the hospitalization of a spouse	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICARE DATA; HEALTH-CARE; DEATH; INFORMATION; DEMENTIA; DISEASES; DECLINE; BURDEN	BACKGROUND: The illness of a spouse can affect the health of a caregiving partner. We examined the association between the hospitalization of a spouse and a partner's risk of death among elderly people. METHODS: We studied 518,240 couples who were enrolled in Medicare in 1993. We used Cox regression analysis and fixed-effects (case-time-control) methods to assess hospitalizations and deaths during nine years of follow-up. RESULTS: Overall, 383,480 husbands (74 percent) and 347,269 wives (67 percent) were hospitalized at least once, and 252,557 husbands (49 percent) and 156,004 wives (30 percent) died. Mortality after the hospitalization of a spouse varied according to the spouse's diagnosis. Among men, 6.4 percent died within a year after a spouse's hospitalization for colon cancer, 6.9 percent after a spouse's hospitalization for stroke, 7.5 percent after a spouse's hospitalization for psychiatric disease, and 8.6 percent after a spouse's hospitalization for dementia. Among women, 3.0 percent died within a year after a spouse's hospitalization for colon cancer, 3.7 percent after a spouse's hospitalization for stroke, 5.7 percent after a spouse's hospitalization for psychiatric disease, and 5.0 percent after a spouse's hospitalization for dementia. After adjustment for measured covariates, the risk of death for men was not significantly higher after a spouse's hospitalization for colon cancer (hazard ratio, 1.02; 95 percent confidence interval, 0.95 to 1.09) but was higher after hospitalization for stroke (hazard ratio, 1.06; 95 percent confidence interval, 1.03 to 1.09), congestive heart failure (hazard ratio, 1.12; 95 percent confidence interval, 1.07 to 1.16), hip fracture (hazard ratio, 1.15; 95 percent confidence interval, 1.11 to 1.18), psychiatric disease (hazard ratio, 1.19; 95 percent confidence interval, 1.12 to 1.26), or dementia (hazard ratio, 1.22; 95 percent confidence interval, 1.12 to 1.32). For women, the various risks of death after a spouse's hospitalization were similar. Overall, for men, the risk of death associated with a spouse's hospitalization was 22 percent of that associated with a spouse's death (95 percent confidence interval, 17 to 27 percent); for women, the risk was 16 percent of that associated with death (95 percent confidence interval, 8 to 24 percent). CONCLUSIONS: Among elderly people hospitalization of a spouse is associated with an increased risk of death, and the effect of the illness of a spouse varies among diagnoses. Such interpersonal health effects have clinical and policy implications for the care of patients and their families.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Med, Palliat Care Serv, Boston, MA 02114 USA; Harvard Univ, Dept Sociol, Cambridge, MA 02138 USA; Univ Penn, Dept Sociol, Philadelphia, PA 19104 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; University of Pennsylvania	Christakis, NA (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	christakis@hcp.med.harvard.edu	Christakis, Nicholas A/C-3205-2009; Allison, Paul/A-1345-2007; Christakis, Nicholas A/B-6690-2008	Allison, Paul/0000-0002-0646-5242; 	NIA NIH HHS [R-01 AG17548-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG017548] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLISON PD, IN PRESS SOCIOL METH; Benesch, 1998, NEUROLOGY, V50, P306; Benesch C, 1997, NEUROLOGY, V49, P660, DOI 10.1212/WNL.49.3.660; Christakis NA, 2004, BRIT MED J, V329, P184, DOI 10.1136/bmj.329.7459.184; Christakis NA, 2003, SOC SCI MED, V57, P465, DOI 10.1016/S0277-9536(02)00370-2; CLIPP EC, 1993, GERONTOLOGIST, V33, P534, DOI 10.1093/geront/33.4.534; Cohen S, 1997, JAMA-J AM MED ASSOC, V277, P1940; Cooper GS, 1999, MED CARE, V37, P436, DOI 10.1097/00005650-199905000-00003; Dunkin JJ, 1998, NEUROLOGY, V51, pS53, DOI 10.1212/WNL.51.1_Suppl_1.S53; ELWERT F, IN PRESS AM SOCIOL R; Ferrucci L, 1997, JAMA-J AM MED ASSOC, V277, P728; Gill TM, 2004, JAMA-J AM MED ASSOC, V292, P2115, DOI 10.1001/jama.292.17.2115; Greenland S, 1996, EPIDEMIOLOGY, V7, P231, DOI 10.1097/00001648-199605000-00003; HALL MJ, 2003, ADV DATA VITAL HLTH, V332; Hatten J, 1980, Health Care Financ Rev, V2, P53; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; Iwashyna TJ, 1998, DEMOGRAPHY, V35, P413, DOI 10.2307/3004010; IWASHYNA TJ, 2002, HLTH SERVICES OUTCOM, V3, P75; Kalra L, 2004, BMJ-BRIT MED J, V328, P1099, DOI 10.1136/bmj.328.7448.1099; Lauderdale DS, 1996, AM J PUBLIC HEALTH, V86, P712, DOI 10.2105/AJPH.86.5.712; Li J, 2005, NEW ENGL J MED, V352, P1190, DOI 10.1056/NEJMoa033160; LILLARD LA, 1995, AM J SOCIOL, V100, P1131, DOI 10.1086/230634; Magliano L, 2005, SOC SCI MED, V61, P313, DOI 10.1016/j.socscimed.2004.11.064; Martikainen P, 1996, AM J PUBLIC HEALTH, V86, P1087, DOI 10.2105/AJPH.86.8_Pt_1.1087; Martikainen P, 1996, J EPIDEMIOL COMMUN H, V50, P264, DOI 10.1136/jech.50.3.264; Pope GC, 1998, HEALTH CARE FINANC R, V20, P109; PRUCHNO RA, 1989, J GERONTOL, V44, pS177, DOI 10.1093/geronj/44.5.S177; Reimer WJMSO, 1998, STROKE, V29, P1605, DOI 10.1161/01.STR.29.8.1605; Rosen A, 2000, MED CARE, V38, P647, DOI 10.1097/00005650-200006000-00006; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Shaw WS, 1997, ANN BEHAV MED, V19, P101, DOI 10.1007/BF02883326; Sprangers MAG, 2000, J CLIN EPIDEMIOL, V53, P895, DOI 10.1016/S0895-4356(00)00204-3; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Suissa S, 1998, EPIDEMIOLOGY, V9, P441, DOI 10.1097/00001648-199807000-00016; THOITS PA, 1995, J HLTH SOCIAL BEHAV; UMBERSON D, 1992, SOC SCI MED, V34, P907, DOI 10.1016/0277-9536(92)90259-S; Zhang JX, 1999, MED CARE, V37, P1128, DOI 10.1097/00005650-199911000-00005	37	297	305	1	35	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 16	2006	354	7					719	730		10.1056/NEJMsa050196	http://dx.doi.org/10.1056/NEJMsa050196			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	012CP	16481639	Green Published			2022-12-28	WOS:000235316100008
J	Jones, PM; Appelbaum, PS; Siegel, DM				Jones, PM; Appelbaum, PS; Siegel, DM		Massachusetts Work Grp Law Enforce	Law enforcement interviews of hospital patients - A conundrum for clinicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							EYEWITNESS TESTIMONY; POLICE		Univ Massachusetts, Sch Med, Dept Psychiat, Worcester, MA 01655 USA; New England Sch Law, Ctr Law & Social Responsibil, Boston, MA USA	University of Massachusetts System; University of Massachusetts Worcester	Jones, PM (corresponding author), NYU, Sch Med, Dept Psychiat,Child Study Ctr, Div Child & Adolescent Psychiat, 550 1st Ave,NBV 21 S6, New York, NY 10016 USA.	jonesp03@med.nyu.edu						Bloche MG, 2005, NEW ENGL J MED, V353, P6, DOI 10.1056/NEJMp058145; EDWARDS MJ, 1997, SOCIAL MED READER, P393; GRIFFITH EEH, 1988, HOSP COMMUNITY PSYCH, V39, P1166; HeatonArmstrong A, 1995, MED SCI LAW, V35, P136, DOI 10.1177/002580249503500207; Kassin SM, 2001, AM PSYCHOL, V56, P405, DOI 10.1037//0003-066X.56.5.405; Norfolk GA, 1997, MED SCI LAW, V37, P228, DOI 10.1177/002580249703700307; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; Pasquale M, 1998, J TRAUMA, V44, P941, DOI 10.1097/00005373-199806000-00001; PINALS DA, 2004, FORENSIC PSYCHIAT CL, P393; Shepherd JP, 2001, ANN EMERG MED, V38, P430, DOI 10.1067/mem.2001.114317; SPUNGEN D, 2002, WORK CHILDR TRAUM HO; *US DEP JUST, 2004, NAT PROT SEX ASS MED; Wilks M, 2005, LANCET, V366, P429, DOI 10.1016/S0140-6736(05)67035-3; WILLIAMS KD, 1992, HDB PSYCHOL LAW, P147; Williamson T, 1996, MED SCI LAW, V36, P135, DOI 10.1177/002580249603600208; Zonana H, 2005, PSYCHIAT SERV, V56, P1021, DOI 10.1176/appi.ps.56.8.1021; 1993, HOSP SECUR SAF MANAG, V13, P5	17	8	9	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	2006	295	7					822	825		10.1001/jama.295.7.822	http://dx.doi.org/10.1001/jama.295.7.822			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011YZ	16478905				2022-12-28	WOS:000235306700028
J	Chalmers, I; Matthews, R				Chalmers, I; Matthews, R			What are the implications of optimism bias in clinical research?	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED-TRIALS; SUPERIOR; ONCOLOGY		James Lind Lib, Oxford OX2 7LG, England; Aston Univ, Birmingham B4 7ET, W Midlands, England	Aston University	Chalmers, I (corresponding author), James Lind Lib, Summertown Pavil, Oxford OX2 7LG, England.	ichalmers@jameslindlibrary.org		Matthews, Robert/0000-0002-1253-6107				Chalmers I, 2005, CLIN TRIALS, V2, P229; Chalmers I, 1997, BRIT MED J, V314, P74, DOI 10.1136/bmj.314.7073.74a; Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457; Di Blasi Z, 2001, LANCET, V357, P757, DOI 10.1016/S0140-6736(00)04169-6; Djulbegovic B, 2000, LANCET, V356, P635, DOI 10.1016/S0140-6736(00)02605-2; GOTZSCHE PC, 1987, BRIT MED J, V295, P654, DOI 10.1136/bmj.295.6599.654; GOTZSCHE PC, 1990, DAN MED BULL, V37, P329; Ioannidis JPA, 2005, JAMA-J AM MED ASSOC, V294, P218, DOI 10.1001/jama.294.2.218; Kumar A, 2005, BMJ-BRIT MED J, V331, P1295, DOI 10.1136/bmj.38628.561123.7C; KUMAR A, 2005, 13 COCHR C MELB 22 2; Mann Howard, 2003, BMC Med Res Methodol, V3, P7, DOI 10.1186/1471-2288-3-7; Matthews RAJ, 2001, DRUG INF J, V35, P1469, DOI 10.1177/009286150103500442; Montori VM, 2005, JAMA-J AM MED ASSOC, V294, P2203, DOI 10.1001/jama.294.17.2203; Soares HP, 2005, JAMA-J AM MED ASSOC, V293, P970, DOI 10.1001/jama.293.8.970; Spiegelhalter DJ, 2004, STAT SCI, V19, P156, DOI 10.1214/088342304000000080; SPIEGELHALTER DJ, 1994, J R STAT SOC A STAT, V157, P357, DOI 10.2307/2983527	16	78	79	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 11	2006	367	9509					449	450		10.1016/S0140-6736(06)68153-1	http://dx.doi.org/10.1016/S0140-6736(06)68153-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013FF	16473106				2022-12-28	WOS:000235394500004
J	Neira, MI; Sanchez, J; Moreno, I; Chiaraviglio, A; Rayo, A; Gutierrez, J; Erice, A				Neira, MI; Sanchez, J; Moreno, I; Chiaraviglio, A; Rayo, A; Gutierrez, J; Erice, A			Occam can be wrong: a young man with lumbar pain and acute weakness of the legs	LANCET			English	Editorial Material									Hosp Asepeyo, Dept Internal Med, Madrid 28820, Spain; Hosp Asepeyo, Dept Orthopaed Surg, Madrid 28820, Spain; Hosp Asepeyo, Dept Phys Med & Rehabil, Madrid 28820, Spain; Hosp Asepeyo, Clin Lab, Madrid 28820, Spain		Erice, A (corresponding author), Hosp Asepeyo, Dept Internal Med, Madrid 28820, Spain.	aericecalvo-sotelo@asepeyo.es						Hauser SL, 2005, HARRISONS PRINCIPLES, P2513; Hilliard AA, 2004, NEW ENGL J MED, V350, P599, DOI 10.1056/NEJMcps031794; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; VISSER LH, 1995, BRAIN, V118, P841, DOI 10.1093/brain/118.4.841	4	4	4	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 11	2006	367	9509					540	540		10.1016/S0140-6736(06)68191-9	http://dx.doi.org/10.1016/S0140-6736(06)68191-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013FF	16473136				2022-12-28	WOS:000235394500040
J	Terszowski, G; Muller, SM; Bleul, CC; Blum, C; Schirmbeck, R; Reimann, J; Du Pasquier, L; Amagai, T; Boehm, T; Rodewald, HR				Terszowski, G; Muller, SM; Bleul, CC; Blum, C; Schirmbeck, R; Reimann, J; Du Pasquier, L; Amagai, T; Boehm, T; Rodewald, HR			Evidence for a functional second thymus in mice	SCIENCE			English	Article							T-CELL REPERTOIRE; DIFFERENTIATION; PHENOTYPE; SELECTION; STEPS; GENE	The thymus organ supports the development of T cells and is located in the thorax. Here, we report the existence of a second thymus in the mouse neck, which develops after birth and grows to the size of a small lymph node. The cervical thymus had a typical medulla-cortex structure, was found to support T cell development, and could correct T cell deficiency in athymic nude mice upon transplantation. The identification of a regular second thymus in the mouse may provide evolutionary links to thymus organogenesis in other vertebrates and suggests a need to reconsider the effect of thoracic thymectomy on de novo T cell production.	Univ Ulm, Dept Immunol, D-89081 Ulm, Germany; Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Max Planck Inst Immunobiol, D-79108 Freiburg, Germany; Univ Basel, Inst Zool & Evolutionary Biol, CH-4051 Basel, Switzerland; Meiji Univ Oriental Med, Dept Immunol & Microbiol, Hiyoshi, Kyoto 6290392, Japan	Ulm University; Ulm University; Max Planck Society; University of Basel	Rodewald, HR (corresponding author), Univ Ulm, Dept Immunol, D-89081 Ulm, Germany.	hans-reimer.rodewald@uni-ulm.de						Anderson G, 2006, IMMUNOL REV, V209, P10, DOI 10.1111/j.0105-2896.2006.00347.x; Benoist C, 1999, FUNDAM IMMUNOL, V4th, P367; Boehm T, 2003, IMMUNOL REV, V195, P15, DOI 10.1034/j.1600-065X.2003.00070.x; BOEHM T, UNPUB; Cornu A S, 2001, Acta Otorhinolaryngol Belg, V55, P295; Eberl G, 2005, SCIENCE, V308, DOI 10.1126/science.1107558; Gill J, 2002, NAT IMMUNOL, V3, P635, DOI 10.1038/ni812; Itoi M, 2001, INT IMMUNOL, V13, P1203, DOI 10.1093/intimm/13.9.1203; Jerome LA, 2001, NAT GENET, V27, P286, DOI 10.1038/85845; Klug DB, 1998, P NATL ACAD SCI USA, V95, P11822, DOI 10.1073/pnas.95.20.11822; LAW L. W., 1964, WISTAR INST SYMP MONOGR, V2, P105; Lindsay EA, 2001, NATURE, V410, P97, DOI 10.1038/35065105; Loney DA, 1998, INT J PEDIATR OTORHI, V43, P77, DOI 10.1016/S0165-5876(97)00155-9; Manley NR, 2000, SEMIN IMMUNOL, V12, P421, DOI 10.1006/smim.2000.0263; MILLER JF, 1961, LANCET, V2, P748; Muller SM, 2005, P NATL ACAD SCI USA, V102, P10587, DOI 10.1073/pnas.0502752102; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Nehls M, 1996, SCIENCE, V272, P886, DOI 10.1126/science.272.5263.886; NORRIS EH, 1938, CONTRIB EMBRYOL, V166, P191; Pai L, 2005, INT J PEDIATR OTORHI, V69, P573, DOI 10.1016/j.ijporl.2004.11.022; PAPAIOANNOU V, UNPUB; PICKER LJ, 1999, FUNDAMENTAL IMMUNOLO, P486; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; Rocha B, 2005, SCIENCE, V308, DOI 10.1126/science.1107363; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; von Boehmer H, 2003, IMMUNOL REV, V191, P62, DOI 10.1034/j.1600-065X.2003.00010.x; Von Boehmer H, 2004, ADV IMMUNOL, V84, P201, DOI 10.1016/S0065-2776(04)84006-9; VONGAUDECKER B, 1990, HUMANEMBRYOLOGIE, V183, P340; Wu SL, 2001, ARCH PATHOL LAB MED, V125, P842	29	111	114	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 14	2006	312	5771					284	287		10.1126/science.1123497	http://dx.doi.org/10.1126/science.1123497			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	032HK	16513945				2022-12-28	WOS:000236765300054
J	Greenhalgh, T; Russell, J; Dunkley, L; Boynton, P; Lefford, F; Chopra, N				Greenhalgh, T; Russell, J; Dunkley, L; Boynton, P; Lefford, F; Chopra, N			"We were treated like adults" - development of a pre-medicine summer school for 16 year olds from deprived socioeconomic backgrounds: action research study	BRITISH MEDICAL JOURNAL			English	Article								Objective To develop a one week widening access summer school for 16 year old pupils from, non-traditional backgrounds who are considering applying to medical school, and to identify its short term impact and key success factors. Design Action research with partnership schools tit deprived inner-city areas in five overlapping phases: schools liaison, recruitment of pupils and assessment of needs, programme design, programme delivery, and evaluation. The design phase incorporated findings from one-to-one interviews with every pupil, and workshops and focus groups for pupils, Parents, teachers, medical student assistants, NHS staff, and other stakeholders. An in-depth process evaluation of the summer School was undertaken from the perspective of multiple stakeholders using questionnaires, interviews, focus groups, and observation. Participants 40 pupils aged 16 years from socioeconomically deprived and under-represented ethnic Minority groups. Results The summer school was popular with pupils, parents, teachers, and staff. It substantially raised pupils' confidence and motivation to apply to medical school. Critical success factors were identified as an atmosphere of "respect"; a focus on hands-on work in small groups; the input. of medical students as role models; and vision and leadership from senior staff. A particularly popular and effective aspect Of the course was a grand round held Oil the last clay, in which pupils gave group presentations of real cases. Conclusion An action research format allowed us to draw the different stakeholders into a collaborative endeavour characterised by enthusiasm, interpersonal support, and mutual respect. The input from pupils to the programme design ensured high engagement and low drop-out rates. Hands-on activities in small groups and social drama of preparing and giving a grand round presentation were particularly important.	UCL, Dept Primary Care & Populat Sci, London N19 5LW, England; Acad Ctr Med Educ, London N19 5LW, England	University of London; University College London; University of London; University College London	Greenhalgh, T (corresponding author), UCL, Dept Primary Care & Populat Sci, London N19 5LW, England.	p.greenhalgh@pcps.ucl.ac.uk	Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088; Boynton, Petra/0000-0001-6699-2266				[Anonymous], 1998, RAISING THEIR VOICES; Archer L, 2000, BETTERING YOURSELF D; BANDURA A, 1986, SOCIAL FDN THOUGHT A; Bloom BS, 1984, BLOOM TAXONOMY ED OB; Bordieu P., 1990, REPROD ED SOC CULTUR; BRUENR J, 1997, CULTURE ED; Bruner J., 1997, CULTURE ED; *COUNC HEADS MED S, MED ED RES CHMS STAT; *DEP HLTH, 2004, DRIV MOR DOCT NURS D; ELWYN G, 2000, GROUPS HANDS ON GUID; ELWYN G, 2000, GROUPS A HANDS ON GU; ERAUT M, 1999, INFORMAL LEARNING; Goffman E., 1969, PRESENTATION SELF EV, DOI DOI 10.1073/PNAS.75.2.580; GOOFMAN E, 1969, PRESENTATION SELF EV; Green J., 2004, QUALITATIVE METHODS; Greenhalgh T, 2004, BRIT MED J, V328, P1541, DOI 10.1136/bmj.328.7455.1541; PARLETT M, 1972, NUMBER GAME READER E; Polanyi M., 1962, TACIT DIMENSION; Ryan G. W., 2005, HDB QUALITATIVE RES; Schuller T., 2004, BENEFITS LEARNING IM; Secretary of State for Education, 2004, MED SCH DEL DOCT FUT; TERRELL C, 2003, J DENT EDUC, V67, P148; Terrell Charles, 2003, J Dent Educ, V67, P1048; TURNER V, 1980, CRIT INQUIRY, V7, P141, DOI 10.1086/448092; *U UK, 2003, FAIR EN WID ACC U ID; Waterman H, 2001, Health Technol Assess, V5, piii; Weick K.E., 1995, SENSEMAKING ORG; Weick KE., 1995, SENSMAKING ORG; Wenger Etienne, 1996, COMMUNITIES PRACTICE; Willis P., 1977, LEARNING LABOUR	30	25	25	0	15	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 1	2006	332	7544					762	766B		10.1136/bmj.38755.582500.55	http://dx.doi.org/10.1136/bmj.38755.582500.55			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	032JA	16495331	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000236769500022
J	Zare, RN				Zare, RN			Chemistry - Resonances in reaction dynamics	SCIENCE			English	Editorial Material							ELECTRONS; ENERGY; PATH		Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University	Zare, RN (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.	zare@stanford.edu	Zare, Richard N./A-8410-2009	Zare, Richard/0000-0001-5266-4253				BIONDI MA, 1979, PHYS TODAY, V32, P44, DOI 10.1063/1.2995241; Boudaiffa B, 2000, SCIENCE, V287, P1658, DOI 10.1126/science.287.5458.1658; Liu K, 2002, PHYSCHEMCOMM, V5, P27, DOI 10.1039/b110570a; NEUMARK DM, 1985, J CHEM PHYS, V82, P3045, DOI 10.1063/1.448254; Pomerantz AE, 2005, J AM CHEM SOC, V127, P16368, DOI 10.1021/ja055440a; Qiu MH, 2006, SCIENCE, V311, P1440, DOI 10.1126/science.1123452; SCHULZ GJ, 1963, PHYS REV LETT, V10, P104, DOI 10.1103/PhysRevLett.10.104; Townsend D, 2004, SCIENCE, V306, P1158, DOI 10.1126/science.1104386; Yin HM, 2006, SCIENCE, V311, P1443, DOI 10.1126/science.1123397	9	32	35	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 10	2006	311	5766					1383	1385		10.1126/science.1124421	http://dx.doi.org/10.1126/science.1124421			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527958				2022-12-28	WOS:000236029400024
J	Gosgnach, S; Lanuza, GM; Butt, SJB; Saueressig, H; Zhang, Y; Velasquez, T; Riethmacher, D; Callaway, EM; Kiehn, O; Goulding, M				Gosgnach, S; Lanuza, GM; Butt, SJB; Saueressig, H; Zhang, Y; Velasquez, T; Riethmacher, D; Callaway, EM; Kiehn, O; Goulding, M			V1 spinal neurons regulate the speed of vertebrate locomotor outputs	NATURE			English	Article							IN-VITRO; INTERNEURONS; CORD; ENGRAILED-1; NETWORKS; CIRCUITS; PAX6; IDENTIFICATION; SPECIFICATION; MOTONEURONS	The neuronal networks that generate vertebrate movements such as walking and swimming are embedded in the spinal cord(1-3). These networks, which are referred to as central pattern generators (CPGs), are ideal systems for determining how ensembles of neurons generate simple behavioural outputs. In spite of efforts to address the organization of the locomotor CPG in walking animals(2,4-6), little is known about the identity and function of the spinal interneuron cell types that contribute to these locomotor networks. Here we use four complementary genetic approaches to directly address the function of mouse V1 neurons, a class of local circuit inhibitory interneurons that selectively express the transcription factor Engrailed1. Our results show that V1 neurons shape motor outputs during locomotion and are required for generating 'fast' motor bursting. These findings outline an important role for inhibition in regulating the frequency of the locomotor CPG rhythm, and also suggest that V1 neurons may have an evolutionarily conserved role in controlling the speed of vertebrate locomotor movements.	Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Syst Neurobiol Lab, La Jolla, CA 92037 USA; Karolinska Inst, Dept Neurosci, Mammalian Locomotor Lab, S-17177 Stockholm, Sweden; Univ Hamburg, Ctr Mol Neurobiol, D-20251 Hamburg, Germany	Salk Institute; Salk Institute; Karolinska Institutet; University of Hamburg	Goulding, M (corresponding author), Salk Inst Biol Studies, Mol Neurobiol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	goulding@salk.edu	Butt, Simon/I-2689-2019; Kiehn, Ole/C-4679-2008; Riethmacher, Dieter/AAB-8690-2022; kiehn, ole/AAT-7881-2021; Callaway, Edward/D-4336-2011; Lanuza, Guillermo/AAT-6286-2020; Riethmacher, Dieter/A-6242-2010; kiehn, ole/AAB-1262-2019; Riethmacher, Dieter/AAP-2227-2021	Butt, Simon/0000-0002-2399-0102; Callaway, Edward/0000-0002-6366-5267; Lanuza, Guillermo/0000-0003-3311-2263; Riethmacher, Dieter/0000-0002-4206-5529; Zhang, Ying/0000-0003-4363-5666; Kiehn, Ole/0000-0002-5954-469X	NIMH NIH HHS [R01 MH063912, R01 MH063912-05, R01 MH063912-06] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063912] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alvarez FJ, 2005, J COMP NEUROL, V493, P177, DOI 10.1002/cne.20711; Angel MJ, 2005, J PHYSIOL-LONDON, V563, P597, DOI 10.1113/jphysiol.2004.076034; Borodinsky LN, 2004, NATURE, V429, P523, DOI 10.1038/nature02518; Brandon EP, 2004, J NEUROSCI, V24, P5459, DOI 10.1523/JNEUROSCI.1106-04.2004; Brockschnieder D, 2004, MOL CELL BIOL, V24, P7636, DOI 10.1128/MCB.24.17.7636-7642.2004; BURKE RE, 1998, SYNAPTIC ORG BRAIN, P77; Butt SJB, 2003, NEURON, V38, P953, DOI 10.1016/S0896-6273(03)00353-2; Butt SJB, 2002, J NEUROSCI, V22, P9961; Danielian PS, 1996, NATURE, V383, P332, DOI 10.1038/383332a0; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; FU TC, 1975, BRAIN RES, V85, P99, DOI 10.1016/0006-8993(75)91012-4; Grillner S, 2003, NAT REV NEUROSCI, V4, P573, DOI 10.1038/nrn1137; Higashijima S, 2004, J NEUROSCI, V24, P5827, DOI 10.1523/JNEUROSCI.5342-03.2004; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; Jiang ZY, 1999, BRAIN RES, V816, P493, DOI 10.1016/S0006-8993(98)01199-8; Kiehn O, 1998, ANN NY ACAD SCI, V860, P110, DOI 10.1111/j.1749-6632.1998.tb09043.x; KIEHN O, 1997, NEURONS NETWORKS MOT, P47; Kjaerulff O, 1996, J NEUROSCI, V16, P5777; Kjaerulff O, 1997, J NEUROSCI, V17, P9433; Kullander K, 2003, SCIENCE, V299, P1889, DOI 10.1126/science.1079641; Lanuza GM, 2004, NEURON, V42, P375, DOI 10.1016/S0896-6273(04)00249-1; Lechner HAE, 2002, J NEUROSCI, V22, P5287; Li WC, 2004, J NEUROSCI, V24, P5840, DOI 10.1523/JNEUROSCI.1633-04.2004; Myers CP, 2005, NEURON, V46, P37, DOI 10.1016/j.neuron.2005.02.022; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Roberts A, 1998, ANN NY ACAD SCI, V860, P19, DOI 10.1111/j.1749-6632.1998.tb09036.x; Sapir T, 2004, J NEUROSCI, V24, P1255, DOI 10.1523/JNEUROSCI.3187-03.2004; Saueressig H, 1999, DEVELOPMENT, V126, P4201; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Wenner P, 2000, J NEUROPHYSIOL, V84, P2651, DOI 10.1152/jn.2000.84.5.2651	30	266	268	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	2006	440	7081					215	219		10.1038/nature04545	http://dx.doi.org/10.1038/nature04545			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019MC	16525473	Bronze			2022-12-28	WOS:000235839500047
J	Suma, K; Sumiyoshi, Y; Endo, Y				Suma, K; Sumiyoshi, Y; Endo, Y			The rotational spectrum of the water-hydroperoxy radical (H2O-HO2) complex	SCIENCE			English	Article							DOUBLE-RESONANCE SPECTROSCOPY; SELF-REACTION; MICROWAVE-SPECTRUM; AB-INITIO; DEPENDENCE; KINETICS; HO2; EXISTENCE; H2O	Peroxy radicals and their derivatives are elusive but important intermediates in a wide range of oxidation processes. We observed pure rotational transitions of the water-hydroperoxy radical complex, H2O-HO2, in a supersonic jet by means of a Fourier transform microwave spectrometer combined with a double-resonance technique. The observed rotational transitions were found to split into two components because of the internal rotation of the water moiety. The molecular constants for the two components were determined precisely, supporting a molecular structure in which HO2 acts as a proton donor to form a nearly planar five-membered ring, and one hydrogen atom of water sticks out from the ring plane. The structure and the spectral splittings due to internal rotation provide information on the nature of the bonding interaction between open- and closed-shell species, and they also provide accurate transition frequencies that are applicable to remote sensing of this complex, which may elucidate its potential roles in atmospheric and combustion chemistry.	Univ Tokyo, Grad Sch Arts & Sci, Dept Basic Sci, Meguro Ku, Tokyo 1538902, Japan	University of Tokyo	Endo, Y (corresponding author), Univ Tokyo, Grad Sch Arts & Sci, Dept Basic Sci, Meguro Ku, Komaba 3-8-1, Tokyo 1538902, Japan.	endo@bunshi.c.u-tokyo.ac.jp	Endo, Yasuki/AAA-8611-2022					Aloisio S, 2000, J PHYS CHEM A, V104, P6597, DOI 10.1021/jp0006330; Aloisio S, 1998, J PHYS CHEM A, V102, P1899, DOI 10.1021/jp972173p; Belair SD, 2004, J AM CHEM SOC, V126, P3024, DOI 10.1021/ja030604d; Brauer CS, 2005, CHEM PHYS LETT, V401, P420, DOI 10.1016/j.cplett.2004.11.090; Chance KV, 1997, J MOL SPECTROSC, V183, P418, DOI 10.1006/jmsp.1997.7282; Dennis CR, 2001, J CHEM PHYS, V115, P1367, DOI 10.1063/1.1377027; ENDO Y, 1994, FARADAY DISCUSS, V97, P341; Frisch M.J., 2016, GAUSSIAN16 REV B01; HAMILTON EJ, 1977, INT J CHEM KINET, V9, P875, DOI 10.1002/kin.550090604; HAMILTON EJ, 1975, J CHEM PHYS, V63, P3682, DOI 10.1063/1.431772; HUTSON JM, 1990, ANNU REV PHYS CHEM, V41, P123, DOI 10.1146/annurev.pc.41.100190.001011; IIDA M, 1991, J CHEM PHYS, V94, P6989, DOI 10.1063/1.460232; Kanno N, 2005, J PHYS CHEM A, V109, P3153, DOI 10.1021/jp044592+; KASAI Y, 2000, 55 INT S MOL SPECTR; KENDALL RA, 1992, J CHEM PHYS, V96, P6796, DOI 10.1063/1.462569; Klopper W, 2000, PHYS CHEM CHEM PHYS, V2, P2227, DOI 10.1039/a910312k; Lester MI, 2000, J CHEM PHYS, V113, P9889, DOI 10.1063/1.1330235; LONGUETHIGGINS HC, 1963, MOL PHYS, V6, P445, DOI 10.1080/00268976300100501; NANAYAKKARA AA, 1992, J PHYS CHEM-US, V96, P3662, DOI 10.1021/j100188a021; Nelander B, 1997, J PHYS CHEM A, V101, P9092, DOI 10.1021/jp972502d; ODUTOLA JA, 1980, J CHEM PHYS, V72, P5062, DOI 10.1063/1.439795; Ohshima Y, 2005, J AM CHEM SOC, V127, P1108, DOI 10.1021/ja0442973; Suma K, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1889429; Suma K, 2004, J CHEM PHYS, V121, P8351, DOI 10.1063/1.1792591; Sumiyoshi Y, 2005, J CHEM PHYS, V123, DOI 10.1063/1.1943967; Zhu RS, 2002, CHEM PHYS LETT, V354, P217, DOI 10.1016/S0009-2614(02)00063-5	26	67	68	3	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	2006	311	5765					1278	1281		10.1126/science.1124022	http://dx.doi.org/10.1126/science.1124022			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019XB	16513981				2022-12-28	WOS:000235870400039
J	Grey, JE; Enoch, S; Harding, KG				Grey, JE; Enoch, S; Harding, KG			ABC of wound healing - Pressure ulcers	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Wales Hosp, Cardiff & Vale NHS Trust, Cardiff, Wales; Cardiff Univ, Wound Healing Res Unit, Cardiff, Wales	Cardiff University; Cardiff University	Grey, JE (corresponding author), Univ Wales Hosp, Cardiff & Vale NHS Trust, Cardiff, Wales.		Harding, Keith/J-5605-2013	Harding, Keith/0000-0003-0048-3279				Brem Harold, 2004, Am J Surg, V188, P9, DOI 10.1016/S0002-9610(03)00285-X; Brem Harold, 2003, Surg Technol Int, V11, P85; CHERRY GW, 2001, OXFORD TXB SURG; Clark RAF, 1998, MOL CELLULAR BIOL WO; Cullum N., 2004, COCHRANE DB SYST REV, V3, P1735, DOI DOI 10.1002/14651858.CD001735.PUB2; *EUR PRESS ULC ADV, PRESS ULC PREV GUID; Excellence NIfHaC, 2005, PRESSURE ULCER MANAG; Glat P, 1997, GRABB SMITHS PLASTIC; Langer G, 2014, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD003216; 2003, PRESSURE RELIEVING D	10	111	114	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 25	2006	332	7539					472	475		10.1136/bmj.332.7539.472	http://dx.doi.org/10.1136/bmj.332.7539.472			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	018VM	16497764	Green Published			2022-12-28	WOS:000235792900022
J	Finlay, BB; McFadden, G				Finlay, BB; McFadden, G			Anti-immunology: Evasion of the host immune system by bacterial and viral pathogens	CELL			English	Review							TOLL-LIKE RECEPTORS; NF-KAPPA-B; COMPLEMENT CONTROL PROTEIN; T-CELL-ACTIVATION; ANTIVIRAL SIGNALING PROTEIN; CHEMOKINE BINDING-PROTEINS; HERPESVIRUS ENTRY MEDIATOR; NITRIC-OXIDE SYNTHASE; DENDRITIC CELLS; INNATE IMMUNITY	Multicellular organisms possess very sophisticated defense mechanisms that are designed to effectively counter the continual microbial insult of the environment within the vertebrate host. However, successful microbial pathogens have in turn evolved complex and efficient,methods to overcome innate and adaptive immune mechanisms, which can result in disease or chronic infections. Although the various virulence strategies used by viral and bacterial pathogens are numerous, there are several general mechanisms that are used to subvert and exploit immune systems that are shared between these diverse microbial pathogens. The success of each pathogen is directly dependant on its ability to mount an effective anti-immune response within the infected host, which can ultimately result in acute disease, chronic infection, or pathogen clearance. In this review, we highlight and compare some of the many molecular mechanisms that bacterial and viral pathogens use to evade host immune defenses.	Univ British Columbia, Michael Smith Labs, Vancouver, BC V6T 1Z4, Canada; Univ Western Ontario, Robarts Res Inst, London, ON N6G 2V4, Canada	University of British Columbia; Western University (University of Western Ontario)	Finlay, BB (corresponding author), Univ British Columbia, Michael Smith Labs, Vancouver, BC V6T 1Z4, Canada.	bfinlay@interchange.ubc.ca; mcfadden@robarts.ca		McFadden, Grant/0000-0002-2556-3526				Ackerman AL, 2004, NAT IMMUNOL, V5, P678, DOI 10.1038/ni1082; Ahr B, 2004, RETROVIROLOGY, V1, P1, DOI DOI 10.1186/1742-4690-1-12; Alcami A, 2003, NAT REV IMMUNOL, V3, P36, DOI 10.1038/nri980; Ambagala APN, 2005, VET IMMUNOL IMMUNOP, V107, P1, DOI 10.1016/j.vetimm.2005.04.006; Andrews DM, 2005, MOL IMMUNOL, V42, P547, DOI 10.1016/j.molimm.2004.07.040; Bader MW, 2005, CELL, V122, P461, DOI 10.1016/j.cell.2005.05.030; Badr G, 2005, J IMMUNOL, V175, P302, DOI 10.4049/jimmunol.175.1.302; Bautista EA, 2005, J VIROL, V79, P4838, DOI 10.1128/JVI.79.8.4838-4847.2005; Bergman MP, 2004, J EXP MED, V200, P979, DOI 10.1084/jem.20041061; Bieniasz PD, 2004, NAT IMMUNOL, V5, P1109, DOI 10.1038/ni1125; Blom AM, 2004, SCAND J CLIN LAB INV, V64, P479, DOI 10.1080/00365510410002904; Boehme KW, 2004, J VIROL, V78, P7867, DOI 10.1128/JVI.78.15.7867-7873.2004; Boneca IG, 2005, CURR OPIN MICROBIOL, V8, P46, DOI 10.1016/j.mib.2004.12.008; Bonjardim CA, 2005, MICROBES INFECT, V7, P569, DOI 10.1016/j.micinf.2005.02.001; Boomker JM, 2005, CYTOKINE GROWTH F R, V16, P91, DOI 10.1016/j.cytogfr.2004.12.002; Boulton IC, 2002, NAT IMMUNOL, V3, P229, DOI 10.1038/ni769; Bowen DG, 2005, NATURE, V436, P946, DOI 10.1038/nature04079; Bowie AG, 2005, MOL IMMUNOL, V42, P859, DOI 10.1016/j.molimm.2004.11.007; Bowie AG, 2004, J CELL BIOCHEM, V91, P1099, DOI 10.1002/jcb.20026; Boya P, 2004, BBA-BIOENERGETICS, V1659, P178, DOI 10.1016/j.bbabio.2004.08.007; Breiman A, 2005, J VIROL, V79, P3969, DOI 10.1128/JVI.79.7.3969-3978.2005; Cabanes D, 2004, MOL MICROBIOL, V51, P1601, DOI 10.1111/j.1365-2958.2003.03945.x; Cameron CM, 2005, J VIROL, V79, P6052, DOI 10.1128/JVI.79.10.6052-6067.2005; Cantin R, 2005, J VIROL, V79, P6577, DOI 10.1128/JVI.79.11.6577-6587.2005; Celli J, 2002, TRENDS MICROBIOL, V10, P232, DOI 10.1016/S0966-842X(02)02343-0; Chakravortty D, 2003, MICROBES INFECT, V5, P621, DOI 10.1016/S1286-4579(03)00096-0; Chang YJ, 2005, VACCINE, V23, P4658, DOI 10.1016/j.vaccine.2005.04.034; Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327; Cheung TC, 2005, P NATL ACAD SCI USA, V102, P13218, DOI 10.1073/pnas.0506172102; Christie PJ, 2005, ANNU REV MICROBIOL, V59, P451, DOI 10.1146/annurev.micro.58.030603.123630; Coombes BK, 2004, CURR BIOL, V14, pR856, DOI 10.1016/j.cub.2004.09.043; Couty JP, 2005, TRENDS PHARMACOL SCI, V26, P405, DOI 10.1016/j.tips.2005.06.004; D'Agostino DM, 2005, ADV CANCER RES, V94, P87, DOI 10.1016/S0065-230X(05)94003-7; Darveau RP, 2004, INFECT IMMUN, V72, P5041, DOI 10.1128/IAI.72.9.5041-5051.2004; Derdeyn CA, 2005, CURR OPIN IMMUNOL, V17, P366, DOI 10.1016/j.coi.2005.06.001; Deretic V, 2005, TRENDS IMMUNOL, V26, P523, DOI 10.1016/j.it.2005.08.003; DiPerna G, 2004, J BIOL CHEM, V279, P36570, DOI 10.1074/jbc.M400567200; Dorner BG, 2004, J IMMUNOL, V172, P3119, DOI 10.4049/jimmunol.172.5.3119; Edelmann KH, 2004, VIROLOGY, V322, P231, DOI 10.1016/j.virol.2004.01.033; Elena SF, 2005, J VIROL, V79, P11555, DOI 10.1128/JVI.79.18.11555-11558.2005; Ernst RK, 2001, MICROBES INFECT, V3, P1327, DOI 10.1016/S1286-4579(01)01494-0; Fan T, 1998, J EXP MED, V187, P487, DOI 10.1084/jem.187.4.487; Fauci AS, 2005, NAT IMMUNOL, V6, P743, DOI 10.1038/ni0805-743; Fensterl V, 2005, J VIROL, V79, P10968, DOI 10.1128/JVI.79.17.10968-10977.2005; Finberg RW, 2004, MICROBES INFECT, V6, P1356, DOI 10.1016/j.micinf.2004.08.013; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; Finlay BB, 2004, NAT REV MICROBIOL, V2, P497, DOI 10.1038/nrmicro908; Flano E, 2005, J IMMUNOL, V175, P3225, DOI 10.4049/jimmunol.175.5.3225; Foster-Cuevas M, 2004, J VIROL, V78, P7667, DOI 10.1128/JVI.78.14.7667-7676.2004; Foy E, 2005, P NATL ACAD SCI USA, V102, P2986, DOI 10.1073/pnas.0408707102; Freigang S, 2005, TRENDS IMMUNOL, V26, P13, DOI 10.1016/j.it.2004.11.013; French AR, 2004, IMMUNITY, V20, P747, DOI 10.1016/j.immuni.2004.05.006; Freundt EC, 2005, P NATL ACAD SCI USA, V102, P17539, DOI 10.1073/pnas.0509221102; Gebert B, 2003, SCIENCE, V301, P1099, DOI 10.1126/science.1086871; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Gomez MI, 2004, NAT MED, V10, P842, DOI 10.1038/nm1079; Gougeon ML, 2005, CELL DEATH DIFFER, V12, P845, DOI 10.1038/sj.cdd.4401616; Guiney DG, 2005, CURR TOP MICROBIOL, V289, P131; Hamerman JA, 2005, CURR OPIN IMMUNOL, V17, P29, DOI 10.1016/j.coi.2004.11.001; Hancock R E, 2001, Lancet Infect Dis, V1, P156, DOI 10.1016/S1473-3099(01)00092-5; Handel TM, 2005, ANNU REV BIOCHEM, V74, P385, DOI 10.1146/annurev.biochem.72.121801.161747; Harte MT, 2003, J EXP MED, V197, P343, DOI 10.1084/jem.20021652; Hegde NR, 2005, J CLIN INVEST, V115, P1146, DOI 10.1172/JCI200525000; Hengel H, 2005, TRENDS IMMUNOL, V26, P396, DOI 10.1016/j.it.2005.05.004; Hilleman MR, 2004, P NATL ACAD SCI USA, V101, P14560, DOI 10.1073/pnas.0404758101; Holm GH, 2005, J VIROL, V79, P6299, DOI 10.1128/JVI.79.10.6299-6311.2005; Hornef MW, 2002, NAT IMMUNOL, V3, P1033, DOI 10.1038/ni1102-1033; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Jha P, 2003, J BIOSCIENCES, V28, P265, DOI 10.1007/BF02970146; Johnson Z, 2005, TRENDS IMMUNOL, V26, P268, DOI 10.1016/j.it.2005.03.001; Jutras I, 2005, ANNU REV CELL DEV BI, V21, P511, DOI 10.1146/annurev.cellbio.20.010403.102755; Kahler CM, 1998, CRIT REV MICROBIOL, V24, P281, DOI 10.1080/10408419891294216; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kawai T, 2005, CURR OPIN IMMUNOL, V17, P338, DOI 10.1016/j.coi.2005.02.007; Kawasaki K, 2004, J BIOL CHEM, V279, P20044, DOI 10.1074/jbc.M401275200; Kim DW, 2005, P NATL ACAD SCI USA, V102, P14046, DOI 10.1073/pnas.0504466102; Klenerman P, 2005, NAT IMMUNOL, V6, P873, DOI 10.1038/ni1241; Knodler LA, 2005, J BIOL CHEM, V280, P9058, DOI 10.1074/jbc.M412588200; Kotb M, 2002, NAT MED, V8, P1398, DOI 10.1038/nm800; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; Lau EK, 2004, ADV PROTEIN CHEM, V68, P351; Lenz LL, 2003, P NATL ACAD SCI USA, V100, P12432, DOI 10.1073/pnas.2133653100; Letvin NL, 2005, ANNU REV MED, V56, P213, DOI 10.1146/annurev.med.54.101601.152349; Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Li XD, 2005, P NATL ACAD SCI USA, V102, P17717, DOI 10.1073/pnas.0508531102; Likos AM, 2005, J GEN VIROL, V86, P2661, DOI 10.1099/vir.0.81215-0; Lilley BN, 2005, IMMUNOL REV, V207, P126, DOI 10.1111/j.0105-2896.2005.00318.x; Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633; Lodoen MB, 2005, NAT REV MICROBIOL, V3, P59, DOI 10.1038/nrmicro1066; Lucas A, 2004, J IMMUNOL, V173, P4765, DOI 10.4049/jimmunol.173.8.4765; Lybarger L, 2005, CURR OPIN IMMUNOL, V17, P71, DOI 10.1016/j.coi.2004.11.009; Madden JC, 2001, CELL, V104, P143, DOI 10.1016/S0092-8674(01)00198-2; Majumder B, 2005, J VIROL, V79, P7990, DOI 10.1128/JVI.79.13.7990-8003.2005; Mark L, 2004, J BIOL CHEM, V279, P45093, DOI 10.1074/jbc.M407558200; Monack DM, 2000, J EXP MED, V192, P249, DOI 10.1084/jem.192.2.249; Morens DM, 2004, NATURE, V430, P242, DOI 10.1038/nature02759; Morgan BP, 2005, IMMUNOL LETT, V97, P171, DOI 10.1016/j.imlet.2004.11.010; Mota LJ, 2005, ANN MED, V37, P234, DOI 10.1080/07853890510037329; Moynagh PN, 2005, TRENDS IMMUNOL, V26, P469, DOI 10.1016/j.it.2005.06.009; Mullick J, 2005, J VIROL, V79, P12382, DOI 10.1128/JVI.79.19.12382-12393.2005; Mullick J, 2005, J VIROL, V79, P5850, DOI 10.1128/JVI.79.9.5850-5856.2005; Nagai H, 2002, SCIENCE, V295, P679, DOI 10.1126/science.1067025; Navarre WW, 2000, CELL MICROBIOL, V2, P265, DOI 10.1046/j.1462-5822.2000.00056.x; Navarro L, 2005, CURR OPIN MICROBIOL, V8, P21, DOI 10.1016/j.mib.2004.12.014; Netea MG, 2004, TRENDS MICROBIOL, V12, P484, DOI 10.1016/j.tim.2004.09.004; Nicholas J, 2005, J INTERF CYTOK RES, V25, P373, DOI 10.1089/jir.2005.25.373; Paludan C, 2005, SCIENCE, V307, P593, DOI 10.1126/science.1104904; Park JM, 2002, SCIENCE, V297, P2048, DOI 10.1126/science.1073163; PARRALOPEZ C, 1993, EMBO J, V12, P4053, DOI 10.1002/j.1460-2075.1993.tb06089.x; Perfettini JL, 2005, CELL DEATH DIFFER, V12, P916, DOI 10.1038/sj.cdd.4401584; Petrovas C, 2005, CELL DEATH DIFFER, V12, P859, DOI 10.1038/sj.cdd.4401595; Philpott DJ, 2004, MOL IMMUNOL, V41, P1099, DOI 10.1016/j.molimm.2004.06.012; Pollara G, 2005, INT J EXP PATHOL, V86, P187, DOI 10.1111/j.0959-9673.2005.00440.x; Portnoy DA, 2005, CURR OPIN IMMUNOL, V17, P25, DOI 10.1016/j.coi.2004.11.002; Rajagopalan S, 2005, TRENDS IMMUNOL, V26, P403, DOI 10.1016/j.it.2005.06.008; Renukaradhya GJ, 2005, J IMMUNOL, V175, P4301, DOI 10.4049/jimmunol.175.7.4301; Rinaldo CR, 2004, TRENDS MICROBIOL, V12, P337, DOI 10.1016/j.tim.2004.05.003; Rooijakkers SHM, 2005, NAT IMMUNOL, V6, P920, DOI 10.1038/ni1235; Rosenberger CM, 2004, P NATL ACAD SCI USA, V101, P2422, DOI 10.1073/pnas.0304455101; Rosenberger CM, 2003, NAT REV MOL CELL BIO, V4, P385, DOI 10.1038/nrm1104; Rosenkilde MM, 2005, NEUROPHARMACOLOGY, V48, P1, DOI 10.1016/j.neuropharm.2004.09.017; Rossi M, 2005, J IMMUNOL, V175, P1373, DOI 10.4049/jimmunol.175.3.1373; Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543; Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034; Sanchez DJ, 2005, J CLIN INVEST, V115, P1369, DOI 10.1172/JCI200524041; Sansonetti PJ, 2004, NAT REV IMMUNOL, V4, P953, DOI 10.1038/nri1499; Schauber-Plewa C, 2005, GENE THER, V12, P238, DOI 10.1038/sj.gt.3302399; Schroder M, 2005, TRENDS IMMUNOL, V26, P462, DOI 10.1016/j.it.2005.07.002; Seet BT, 2003, ANNU REV IMMUNOL, V21, P377, DOI 10.1146/annurev.immunol.21.120601.141049; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Shackelton LA, 2005, P NATL ACAD SCI USA, V102, P379, DOI 10.1073/pnas.0406765102; Sing A, 2005, P NATL ACAD SCI USA, V102, P16049, DOI 10.1073/pnas.0504728102; Sing A, 2002, J EXP MED, V196, P1017, DOI 10.1084/jem.20020908; Sodhi A, 2004, NAT REV MOL CELL BIO, V5, P998, DOI 10.1038/nrm1529; Spear PG, 2004, CELL MICROBIOL, V6, P401, DOI 10.1111/j.1462-5822.2004.00389.x; Stack J, 2005, J EXP MED, V201, P1007, DOI 10.1084/jem.20041442; Stanley SA, 2003, P NATL ACAD SCI USA, V100, P13001, DOI 10.1073/pnas.2235593100; Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Tato CM, 2002, INFECT IMMUN, V70, P3311, DOI 10.1128/IAI.70.7.3311-3317.2002; Tewari MK, 2005, NAT IMMUNOL, V6, P287, DOI 10.1038/ni1171; Underhill DM, 2004, CURR OPIN IMMUNOL, V16, P483, DOI 10.1016/j.coi.2004.05.012; Vallance BA, 2002, INFECT IMMUN, V70, P6424, DOI 10.1128/IAI.70.11.6424-6435.2002; Vazquez-Torres A, 2000, SCIENCE, V287, P1655, DOI 10.1126/science.287.5458.1655; Viboud GI, 2005, ANNU REV MICROBIOL, V59, P69, DOI 10.1146/annurev.micro.59.030804.121320; Walzer T, 2005, EUR J IMMUNOL, V35, P391, DOI 10.1002/eji.200425669; Wang T, 2004, NAT MED, V10, P1366, DOI 10.1038/nm1140; Watts TH, 2005, P NATL ACAD SCI USA, V102, P13365, DOI 10.1073/pnas.0506707102; Webb LMC, 2005, MINI-REV MED CHEM, V5, P833, DOI 10.2174/1389557054867110; Weber F, 2004, VIRAL IMMUNOL, V17, P498, DOI 10.1089/vim.2004.17.498; Wieland SF, 2005, J VIROL, V79, P9369, DOI 10.1128/JVI.79.15.9369-9380.2005; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yewdell JW, 2005, ANNU REV IMMUNOL, V23, P651, DOI 10.1146/annurev.immunol.23.021704.115702; Yokoyama WM, 2005, IMMUNOL RES, V32, P317, DOI 10.1385/IR:32:1-3:317; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	157	562	603	5	113	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 24	2006	124	4					767	782		10.1016/j.cell.2006.01.034	http://dx.doi.org/10.1016/j.cell.2006.01.034			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	038RO	16497587	Bronze			2022-12-28	WOS:000237240900020
J	Ramaswamy, V; Schwarzkopf, MD; Randel, WJ; Santer, BD; Soden, BJ; Stenchikov, GL				Ramaswamy, V; Schwarzkopf, MD; Randel, WJ; Santer, BD; Soden, BJ; Stenchikov, GL			Anthropogenic and natural influences in the evolution of lower stratospheric cooling	SCIENCE			English	Article							TEMPERATURE TRENDS; WATER-VAPOR; VARIABILITY	Observations reveal that the substantial cooling of the global lower stratosphere over 1979-2003 occurred in two pronounced steplike transitions. These arose in the aftermath of two major volcanic eruptions, with each cooling transition being followed by a period of relatively steady temperatures. Climate model simulations indicate that the space-time structure of the observed cooling is largely attributable to the combined effect of changes in both anthropogenic factors (ozone depletion and increases in welt-mixed greenhouse gases) and natural factors (solar irradiance variation and volcanic aerosols). The anthropogenic factors drove the overall cooling during the period, and the natural ones modulated the evolution of the cooling.	Natl Ocean & Atmospher Adm, Geophys Fluid Dynam Lab, Princeton, NJ 08542 USA; Natl Ctr Atmospher Res, Boulder, CO 80303 USA; Lawrence Livermore Natl Lab, Program Climate Model Diag & Intercomparison, Livermore, CA 94550 USA; Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Miami, FL 33149 USA; Rutgers State Univ, Dept Environm Sci, New Brunswick, NJ 08901 USA	National Oceanic Atmospheric Admin (NOAA) - USA; National Center Atmospheric Research (NCAR) - USA; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of Miami; Rutgers State University New Brunswick	Ramaswamy, V (corresponding author), Natl Ocean & Atmospher Adm, Geophys Fluid Dynam Lab, Princeton, NJ 08542 USA.		Santer, Ben/ABA-1099-2021; Stenchikov, Georgiy/AAA-4371-2022; Santer, Benjamin D/F-9781-2011; Georgiy, Stenchikov/J-8569-2013; Soden, Brian/ABC-3659-2021; Randel, William J/K-3267-2016; Ramaswamy, Venkatachalam/AAJ-6265-2021	Randel, William J/0000-0002-5999-7162; Ramaswamy, Venkatachalam/0000-0002-1984-6423; Soden, Brian/0000-0001-9693-8236; Stenchikov, Georgiy Lvovich/0000-0001-9033-4925				AUSTIN J, UNPUB; Broccoli AJ, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003812; CHIPPERFIELD MP, 2003, 47 GLOB OZ RES MON P, pCH4; Dameris M, 2005, ATMOS CHEM PHYS, V5, P2121, DOI 10.5194/acp-5-2121-2005; DELWORTH T, IN PRESS J CLIM; Forster PMD, 1999, GEOPHYS RES LETT, V26, P3309, DOI 10.1029/1999GL010487; GINOUX P, UNPUB; Hansen J, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001143; Haywood JM, 1999, SCIENCE, V283, P1299, DOI 10.1126/science.283.5406.1299; Horowitz LW, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002853; KNUTSON TR, IN PRESS J CLIM; LABITZKE K, 1995, J METEOROL SOC JPN, V73, P883, DOI 10.2151/jmsj1965.73.5_883; Langematz U, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002069; Lean J, 2005, SOL PHYS, V230, P27, DOI 10.1007/s11207-005-1527-2; Mears CA, 2003, J CLIMATE, V16, P3650, DOI 10.1175/1520-0442(2003)016<3650:AROTMC>2.0.CO;2; Ramaswamy V, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015141; RAMASWAMY V, 1994, J GEOPHYS RES-ATMOS, V99, P18909, DOI 10.1029/94JD01310; Ramaswamy V, 2001, REV GEOPHYS, V39, P71, DOI 10.1029/1999RG000065; Ramaswamy V., 2001, CLIMATE CHANGE 2001, P349; Randel WJ, 1999, GEOPHYS RES LETT, V26, P3089, DOI 10.1029/1999GL900615; Randel WJ, 2004, J ATMOS SCI, V61, P2133, DOI 10.1175/1520-0469(2004)061<2133:ICOSWV>2.0.CO;2; Randel WJ, 1999, J ATMOS SCI, V56, P457, DOI 10.1175/1520-0469(1999)056<0457:GQCDFU>2.0.CO;2; RANDEL WJ, UNPUB; Santer BD, 2005, SCIENCE, V309, P1551, DOI 10.1126/science.1114867; Santer BD, 2003, SCIENCE, V301, P479, DOI 10.1126/science.1084123; Seidel DJ, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD004414; Shine KP, 2003, Q J ROY METEOR SOC, V129, P1565, DOI 10.1256/QJ.02.186; Solomon S, 1996, J GEOPHYS RES-ATMOS, V101, P6713, DOI 10.1029/95JD03353; Stenchikov G, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2002JD002090; STENCHIKOV G, IN PRESS J GEOPHYS R; Thompson DWJ, 2005, J CLIMATE, V18, P4785, DOI 10.1175/JCLI3585.1; Tie XX, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005359	32	109	116	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	2006	311	5764					1138	1141		10.1126/science.1122587	http://dx.doi.org/10.1126/science.1122587			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017IU	16497930				2022-12-28	WOS:000235688100045
J	Ryan, PD; Harisinghani, M; Lerwill, MF; Kaufman, DS; McDougal, WS				Ryan, PD; Harisinghani, M; Lerwill, MF; Kaufman, DS; McDougal, WS			A 71-year-old woman with urinary incontinence and a mass in the bladder - Infiltrating lobular carcinoma of the breast, metastatic to the urinary bladder and ovaries.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							URETERAL OBSTRUCTION; CANCER; IMMUNOHISTOCHEMISTRY; SECONDARY; THERAPY; BRCA2		Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Ryan, PD (corresponding author), Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA 02114 USA.		Harisinghani, Mukesh/G-1347-2010					American Cancer Society, 2004, CANC FACTS FIG 2004; Baldwin L, 2005, HISTOPATHOLOGY, V46, P50, DOI 10.1111/j.1365-2559.2005.02051.x; Bates AW, 2000, HISTOPATHOLOGY, V36, P32; Bates AW, 1998, CURR DIAGNOST PATHOL, V5, P188; Feldman Paul A, 2002, Urology, V59, P138, DOI 10.1016/S0090-4295(01)01489-3; FEUN LG, 1979, CANCER, V44, P1164, DOI 10.1002/1097-0142(197909)44:3<1164::AID-CNCR2820440355>3.0.CO;2-B; Goldgar DE, 2004, AM J HUM GENET, V75, P535, DOI 10.1086/424388; HARRIS M, 1984, BRIT J CANCER, V50, P23, DOI 10.1038/bjc.1984.135; Herr HW., 2001, CANC PRINCIPLES PRAC, V6, P1396; Kaufmann O, 1998, J PATHOL, V186, P165; Lerwill MF, 2004, AM J SURG PATHOL, V28, P1076, DOI 10.1097/01.pas.0000126780.10029.f0; Messing EM, 2002, CAMPBELLS UROLOGY, P2732; RECLOUX P, 1988, CANCER, V61, P1904, DOI 10.1002/1097-0142(19880501)61:9<1904::AID-CNCR2820610930>3.0.CO;2-1; Saphner T, 1996, J CLIN ONCOL, V14, P2738, DOI 10.1200/JCO.1996.14.10.2738; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Tavassoli F A, 2003, WHO CLASSIFICATION T, V5; TRAVIS LB, 1995, J NATL CANCER I, V87, P524, DOI 10.1093/jnci/87.7.524; WANG NP, 1995, APPL IMMUNOHISTOCHEM, V3, P99; ZADRA JA, 1987, CANCER, V60, P1353, DOI 10.1002/1097-0142(19870915)60:6<1353::AID-CNCR2820600632>3.0.CO;2-5	19	12	12	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 23	2006	354	8					850	856		10.1056/NEJMcpc059042	http://dx.doi.org/10.1056/NEJMcpc059042			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014CL	16495398				2022-12-28	WOS:000235456200011
J	Rogers, WA				Rogers, WA			Pressures on confidentiality	LANCET			English	Editorial Material									Flinders Univ S Australia, Dept Med Educ, Adelaide, SA 5001, Australia	Flinders University South Australia	Rogers, WA (corresponding author), Flinders Univ S Australia, Dept Med Educ, Adelaide, SA 5001, Australia.	wendy.rogers@flinders.edu.au		Rogers, Wendy/0000-0001-9186-870X				*BRIT MED ASS, 1999, CONFDISCL HLTH INF; DRAPER H, 2005, ADV PSYCHIAT TREAT, V11, P115; Jones C, 2003, J MED ETHICS, V29, P348, DOI 10.1136/jme.29.6.348; Kelman CW, 2002, AUST NZ J PUBL HEAL, V26, P251, DOI 10.1111/j.1467-842X.2002.tb00682.x; Lang F, 2002, AM FAM PHYSICIAN, V65, P1351; McWhinney I, 1997, TXB FAMILY MED; Mendelson Danuta, 2003, J Law Med, V11, P136; PATTERSON M, 2003, J LAW MED, V10, P460; Perez-Carceles MD, 2005, J MED ETHICS, V31, P531, DOI 10.1136/jme.2004.010157; Rogers WA, 2003, J MED ETHICS, V29, P220, DOI 10.1136/jme.29.4.220; Shrier L, 1998, ACAD MED, V73, P710, DOI 10.1097/00001888-199806000-00021; SIEGLER M, 1982, NEW ENGL J MED, V307, P1518, DOI 10.1056/NEJM198212093072411; Wardman L, 2000, BRIT J GEN PRACT, V50, P901; Weijer C, 2000, BRIT MED J, V321, P1466	14	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 18	2006	367	9510					553	554		10.1016/S0140-6736(06)68200-7	http://dx.doi.org/10.1016/S0140-6736(06)68200-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013GM	16488784				2022-12-28	WOS:000235397800009
J	Snow, DR; Gahegan, M; Giles, CL; Hirth, KG; Milner, GR; Mitra, P; Wang, JZ				Snow, DR; Gahegan, M; Giles, CL; Hirth, KG; Milner, GR; Mitra, P; Wang, JZ			Information science - Cybertools and archaeology	SCIENCE			English	Editorial Material							CYBERINFRASTRUCTURE		Penn State Univ, Dept Anthropol, University Pk, PA 16802 USA; Penn State Univ, Dept Geog, University Pk, PA 16802 USA; Penn State Univ, Sch Informat Sci & Technol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Snow, DR (corresponding author), Penn State Univ, Dept Anthropol, University Pk, PA 16802 USA.	drs17@psu.edu	Gahegan, Mark/C-9297-2009					Buetow KH, 2005, SCIENCE, V308, P821, DOI 10.1126/science.1112120; CARROLL MS, 2002, DELIVERING ARCHAEOLO; CHAU M, 2002, 2 ASS COMP MACH IEEE; CHILDS ST, 2003, 1 NAT PARK SERV; CHILDS ST, 2004, 5 NAT PARK SERV; DRENNAN RD, 2001, ARCHAEOLOGICAL RES H; ELMAGARMID A, 1999, MANAGEMENT HETEROGEN; Foster I, 2005, SCIENCE, V308, P814, DOI 10.1126/science.1110411; Giles C.L., 1998, CITESEER AUTOMATIC C; Hey T, 2005, SCIENCE, V308, P817, DOI 10.1126/science.1110410; LAGOZE C, IN PRESS INT J DIGIT; Lawrence S, 1999, COMPUTER, V32, P67, DOI 10.1109/2.769447; Maurer SM, 2000, NATURE, V405, P117, DOI 10.1038/35012169; MITRA P, 2002, P ECAI 2002 15 EUR C; PIKE W, 2003, 2 INT SEM WEB C SAN; Rodriguez MA, 2003, IEEE T KNOWL DATA EN, V15, P442, DOI 10.1109/TKDE.2003.1185844; TOOBY P, 2005, SPEEDING SCI WORKFLO; Wang JZ, 2001, IEEE T PATTERN ANAL, V23, P947, DOI 10.1109/34.955109	18	49	49	3	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 17	2006	311	5763					958	959		10.1126/science.1121556	http://dx.doi.org/10.1126/science.1121556			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	014CS	16484480				2022-12-28	WOS:000235456900030
J	Urich, T; Gomes, CM; Kletzin, A; Frazao, C				Urich, T; Gomes, CM; Kletzin, A; Frazao, C			X-ray structure of a self-compartmentalizing sulfur cycle metalloenzyme	SCIENCE			English	Article							OXYGENASE-REDUCTASE; CRYSTAL-STRUCTURE; INORGANIC SULFUR; DESULFUROLOBUS-AMBIVALENS; ACIDIANUS-AMBIVALENS; DIOXYGEN ACTIVATION; ELEMENTAL SULFUR; OXIDATION; BACTERIA; ENZYMES	Numerous microorganisms oxidize sulfur for energy conservation and contribute to the global biogeochemical sulfur cycle. We have determined the 1.7 angstrom-resolution structure of the sulfur oxygenase reductase from the thermoacidophilic archaeon Acidianus ambivalens, which catalyzes an oxygen-dependent disproportionation of elemental sulfur. Twenty-four monomers form a large hollow sphere enclosing a positively charged nanocompartment. Apolar channels provide access for linear sulfur species. A cysteine persulfide and a low-potential mononuclear non-heme iron site ligated by a 2-His-1-carboxylate facial triad in a pocket of each subunit constitute the active sites, accessible from the inside of the sphere. The iron is likely the site of both sulfur oxidation and sulfur reduction.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2781901 Oeiras, Portugal; TH Darmstadt, Inst Microbiol & Genet, D-64287 Darmstadt, Germany	Universidade Nova de Lisboa; Technical University of Darmstadt	Kletzin, A (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Ave Republ EAN, P-2781901 Oeiras, Portugal.	kletzin@bio.tu-darmstadt.de; frazao@itqb.unl.pt	Gomes, Cláudio M./A-8152-2008; Urich, Tim/C-2887-2013; Kletzin, Arnulf/AAO-7366-2020; Urich, Tim/J-8241-2016; Frazao, Carlos/C-1965-2008	Gomes, Cláudio M./0000-0003-4662-6933; Urich, Tim/0000-0002-5718-1354; Frazao, Carlos/0000-0002-7725-1671; Kletzin, Arnulf/0000-0002-4500-2232				Andersen OA, 2002, J MOL BIOL, V320, P1095, DOI 10.1016/S0022-2836(02)00560-0; Bamford VA, 2002, EMBO J, V21, P5599, DOI 10.1093/emboj/cdf566; Beinert H, 2000, EUR J BIOCHEM, V267, P5657, DOI 10.1046/j.1432-1327.2000.01637.x; Bordo D, 2000, J MOL BIOL, V298, P691, DOI 10.1006/jmbi.2000.3651; BOULEGUE J, 1978, PHOSPHORUS SULFUR, V5, P127, DOI 10.1080/03086647808069875; Chen ZW, 2005, APPL ENVIRON MICROB, V71, P621, DOI 10.1128/AEM.71.2.621-628.2005; Costas M, 2004, CHEM REV, V104, P939, DOI 10.1021/cr020628n; Ebihara Akio, 2005, Journal of Structural and Functional Genomics, V6, P21, DOI 10.1007/s10969-005-1103-x; EMMEL T, 1986, J GEN MICROBIOL, V132, P3415; Friedrich CG, 2005, CURR OPIN MICROBIOL, V8, P253, DOI 10.1016/j.mib.2005.04.005; Friedrich CG, 2001, APPL ENVIRON MICROB, V67, P2873, DOI 10.1128/AEM.67.7.2873-2882.2001; He ZG, 2000, FEMS MICROBIOL LETT, V193, P217, DOI 10.1111/j.1574-6968.2000.tb09427.x; Kappler U, 2005, FEBS LETT, V579, P2491, DOI 10.1016/j.febslet.2005.03.060; Karlsson A, 2003, SCIENCE, V299, P1039, DOI 10.1126/science.1078020; KELLY DP, 1982, PHILOS T R SOC B, V298, P499, DOI 10.1098/rstb.1982.0094; Kelly DP, 1997, ANTON LEEUW INT J G, V71, P95, DOI 10.1023/A:1000135707181; KLETZIN A, 1992, J BACTERIOL, V174, P5854, DOI 10.1128/jb.174.18.5854-5859.1992; Kletzin A, 2004, J BIOENERG BIOMEMBR, V36, P77, DOI 10.1023/B:JOBB.0000019600.36757.8c; KLETZIN A, 1989, J BACTERIOL, V171, P1638, DOI 10.1128/jb.171.3.1638-1643.1989; Koehntop KD, 2005, J BIOL INORG CHEM, V10, P87, DOI 10.1007/s00775-005-0624-x; Lang D, 2000, SCIENCE, V289, P1546, DOI 10.1126/science.289.5484.1546; Lin YJ, 2004, BIOCHEMISTRY-US, V43, P1418, DOI 10.1021/bi0356597; Macedo S, 2003, NAT STRUCT BIOL, V10, P285, DOI 10.1038/nsb909; Olson GJ, 2003, APPL MICROBIOL BIOT, V63, P249, DOI 10.1007/s00253-003-1404-6; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SCHONHEIT P, 1995, WORLD J MICROB BIOT, V11, P26, DOI 10.1007/BF00339135; Sciara G, 2003, EMBO J, V22, P205, DOI 10.1093/emboj/cdg031; THAUER RK, 1977, BACTERIOL REV, V41, P100, DOI 10.1128/MMBR.41.1.100-180.1977; Urich T, 2005, FEMS MICROBIOL LETT, V248, P171, DOI 10.1016/j.femsle.2005.05.031; Urich T, 2004, BIOCHEM J, V381, P137, DOI 10.1042/BJ20040003; Wu RY, 2005, J BIOL CHEM, V280, P2840, DOI 10.1074/jbc.M409526200; Zhang C, 2000, J MOL BIOL, V299, P1075, DOI 10.1006/jmbi.2000.3678	33	67	80	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 17	2006	311	5763					996	1000		10.1126/science.1120306	http://dx.doi.org/10.1126/science.1120306			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014CS	16484493				2022-12-28	WOS:000235456900044
J	Bruzzi, JF				Bruzzi, JF			The words count - Radiology and medical linguistics	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Texas, MD Anderson Canc Ctr, Dept Diagnost Imaging, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Bruzzi, JF (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Diagnost Imaging, 1515 Holcombe Blvd, Houston, TX 77030 USA.								0	9	9	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 16	2006	354	7					665	667		10.1056/NEJMp058262	http://dx.doi.org/10.1056/NEJMp058262			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	012CP	16481634				2022-12-28	WOS:000235316100003
J	Walton, DS; Mukai, S; Grabowski, EF; Munzenrider, JE; Dryja, TP; Wiegand, T; Mukai, S; Harris, NL				Walton, DS; Mukai, S; Grabowski, EF; Munzenrider, JE; Dryja, TP; Wiegand, T; Mukai, S; Harris, NL			An 11-year-old girl with loss of vision in the right eye - Retinoblastoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DIFFUSE INFILTRATING RETINOBLASTOMA; PROTON-RADIATION-THERAPY; CANCER; SKULL; BASE; RISK; DIAGNOSIS; CHILDREN; TUMORS		Massachusetts Gen Hosp, Serv Pediat, Boston, MA 02114 USA; Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Eye & Ear Infirmary; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Walton, DS (corresponding author), Massachusetts Gen Hosp, Serv Pediat, Boston, MA 02114 USA.							Abramson DH, 1998, J PEDIATR-US, V132, P505, DOI 10.1016/S0022-3476(98)70028-9; Balasubramanya R, 2004, J PEDIAT OPHTH STRAB, V41, P18, DOI 10.3928/0191-3913-20040101-06; BENK V, 1995, INT J RADIAT ONCOL, V31, P577, DOI 10.1016/0360-3016(94)00395-2; BHATNAGAR R, 1991, OPHTHALMOLOGY, V98, P1657; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cohen JG, 2001, MED PEDIATR ONCOL, V37, P372, DOI 10.1002/mpo.1213; DRYJA TP, 1984, NEW ENGL J MED, V310, P550, DOI 10.1056/NEJM198403013100902; Endo EG, 1996, ARCH OPHTHALMOL-CHIC, V114, P757, DOI 10.1001/archopht.1996.01100130749023; GOBLE RR, 1990, BRIT J OPHTHALMOL, V74, P97, DOI 10.1136/bjo.74.2.97; Grabowski E F, 1987, Hematol Oncol Clin North Am, V1, P721; Grossniklaus HE, 1998, RETINA-J RET VIT DIS, V18, P238, DOI 10.1097/00006982-199803000-00008; Hagstrom SA, 1999, P NATL ACAD SCI USA, V96, P2952, DOI 10.1073/pnas.96.6.2952; Hug EB, 2000, INT J RADIAT ONCOL, V47, P979, DOI 10.1016/S0360-3016(00)00545-9; Hug EB, 2002, INT J RADIAT ONCOL, V52, P1017, DOI 10.1016/S0360-3016(01)02725-0; Hug EB, 2002, STRAHLENTHER ONKOL, V178, P239, DOI 10.1007/s00066-002-0931-x; Jagsi R, 2004, J CLIN ONCOL, V22, P2246, DOI 10.1200/JCO.2004.10.083; Khelfaoui F, 1996, CANCER-AM CANCER SOC, V77, P1206, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1206::AID-CNCR30>3.3.CO;2-Q; Krengli M, 2005, INT J RADIAT ONCOL, V61, P583, DOI 10.1016/j.ijrobp.2004.06.003; Noorani HZ, 1996, AM J HUM GENET, V59, P301; Palazzi M, 1990, J Pediatr Ophthalmol Strabismus, V27, P255; Paysse EA, 2003, ARCH OPHTHALMOL-CHIC, V121, P119; RUBENFELD M, 1986, OPHTHALMOLOGY, V93, P1016; SCHOFIELD P B, 1960, Br J Ophthalmol, V44, P35, DOI 10.1136/bjo.44.1.35; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shields CL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1653; SHIELDS CL, 1991, OPHTHALMOLOGY, V98, P395; Shields JA, 2000, J PEDIAT OPHTH STRAB, V37, P311; SHIELDS JA, 1991, RETINA-J RET VIT DIS, V11, P232, DOI 10.1097/00006982-199111020-00009; SHIELDS JA, 1991, J PEDIATR OPHTHALMOL, V28, P338, DOI 10.3928/0191-3913-19911101-12; Wong FL, 1997, JAMA-J AM MED ASSOC, V278, P1262, DOI 10.1001/jama.278.15.1262	30	5	5	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 16	2006	354	7					741	748		10.1056/NEJMcpc059041	http://dx.doi.org/10.1056/NEJMcpc059041			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	012CP	16481642				2022-12-28	WOS:000235316100012
J	Tugwell, P; de Savigny, D; Hawker, G; Robinson, V				Tugwell, P; de Savigny, D; Hawker, G; Robinson, V			Applying clinical epidemiological methods to health equity: the equity effectiveness loop	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Ottawa, Inst Populat Hlth, Ottawa Hlth Res Inst, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Inst Populat Hlth, Ctr Global Hlth, Ottawa, ON K1N 6N5, Canada; Int Dev Res Ctr, Canada Tanzania Essential Hlth Intervent Project, CH-4002 Basel, Switzerland; Swiss Trop Inst, CH-4002 Basel, Switzerland; Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M5S 1B2, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Basel; Swiss Tropical & Public Health Institute; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Tugwell, P (corresponding author), Univ Ottawa, Inst Populat Hlth, Ottawa Hlth Res Inst, 1 Stewart St, Ottawa, ON K1N 6N5, Canada.	elacasse@uottawa.ca	Tugwell, Peter/AFD-8076-2022	Tugwell, Peter/0000-0001-5062-0556; Welch, Vivian/0000-0002-5238-7097					0	129	131	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 11	2006	332	7537					358	361		10.1136/bmj.332.7537.358	http://dx.doi.org/10.1136/bmj.332.7537.358			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	012YI	16470062	Green Published, Green Accepted			2022-12-28	WOS:000235376400025
J	Giraldez, AJ; Mishima, Y; Rihel, J; Grocock, RJ; Van Dongen, S; Inoue, K; Enright, AJ; Schier, AF				Giraldez, AJ; Mishima, Y; Rihel, J; Grocock, RJ; Van Dongen, S; Inoue, K; Enright, AJ; Schier, AF			Zebrafish MiR-430 promotes deadenylation and clearance of maternal mRNAs	SCIENCE			English	Article							MICRORNA TARGETS; C-ELEGANS; POSTTRANSCRIPTIONAL REGULATION; CAENORHABDITIS-ELEGANS; P-BODIES; LET-7; POLYADENYLATION; MORPHOGENESIS; TRANSCRIPTION; MECHANISMS	MicroRNAs (miRNAs) comprise 1 to 3% of all vertebrate genes, but their in vivo functions and mechanisms of action remain largely unknown. Zebrafish miR-430 is expressed at the onset of zygotic transcription and regulates morphogenesis during early development. By using a microarray approach and in vivo target validation, we find that miR-430 directly regulates several hundred target messenger RNA molecules (mRNAs). Most targets are maternally expressed mRNAs that accumulate in the absence of miR-430. We also show that miR-430 accelerates the deadenylation of target mRNAs. These results suggest that miR-430 facilitates the deadenylation and clearance of maternal mRNAs during early embryogenesis.	NYU, Sch Med, Skirball Inst Biomol Med, Dev Genet Program, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Kobe Univ, Grad Sch Sci & Technol, Dept Biol, Nada Ku, Kobe, Hyogo 6578501, Japan; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England	New York University; New York University; Harvard University; Kobe University; Wellcome Trust Sanger Institute	Giraldez, AJ (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, Dev Genet Program, New York, NY 10016 USA.	giraldez@mcb.harvard.edu; schier@fas.harvard.edu	Enright, Anton/F-3094-2011; Rihel, Jason/G-7106-2011; Mishima, Yuichiro/I-3881-2019	Enright, Anton/0000-0002-6090-3100; Mishima, Yuichiro/0000-0002-1075-9454; Giraldez, Antonio/0000-0002-6823-137X; Schier, Alexander Franz/0000-0001-7645-5325; Rihel, Jason/0000-0003-4067-2066				Alvarez-Garcia I, 2005, DEVELOPMENT, V132, P4653, DOI 10.1242/dev.02073; Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Chen PY, 2005, GENE DEV, V19, P1288, DOI 10.1101/gad.1310605; de Moor CH, 2005, SEMIN CELL DEV BIOL, V16, P49, DOI 10.1016/j.semcdb.2004.11.007; Ding L, 2005, MOL CELL, V19, P437, DOI 10.1016/j.molcel.2005.07.013; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Enright AJ, 2004, GENOME BIOL, V5; Farh KKH, 2005, SCIENCE, V310, P1817, DOI 10.1126/science.1121158; Giraldez AJ, 2005, SCIENCE, V308, P833, DOI 10.1126/science.1109020; Grosshans H, 2005, DEV CELL, V8, P321, DOI 10.1016/j.devcel.2004.12.019; Harfe BD, 2005, P NATL ACAD SCI USA, V102, P10898, DOI 10.1073/pnas.0504834102; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnston RJ, 2003, NATURE, V426, P845, DOI 10.1038/nature02255; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lai EC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-115; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Liu JD, 2005, NAT CELL BIOL, V7, P1261, DOI 10.1038/ncb1333; Liu JD, 2005, NAT CELL BIOL, V7, P719, DOI 10.1038/ncb1274; Mathavan S, 2005, PLOS GENET, V1, P260, DOI 10.1371/journal.pgen.0010029; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Pillai RS, 2005, SCIENCE, V309, P1573, DOI 10.1126/science.1115079; Pillai RS, 2005, RNA, V11, P1753, DOI 10.1261/rna.2248605; Rehwinkel J, 2005, RNA, V11, P1640, DOI 10.1261/rna.2191905; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Rhoades MW, 2002, CELL, V110, P513, DOI 10.1016/S0092-8674(02)00863-2; Richter JD, 1999, MICROBIOL MOL BIOL R, V63, P446, DOI 10.1128/MMBR.63.2.446-456.1999; Salles FJ, 1999, METHODS, V17, P38, DOI 10.1006/meth.1998.0705; Stark A, 2005, CELL, V123, P1133, DOI 10.1016/j.cell.2005.11.023; Stark A, 2003, PLOS BIOL, V1, P397, DOI 10.1371/journal.pbio.0000060; Vasudevan S, 2006, GENE DEV, V20, P138, DOI 10.1101/gad.1398906; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4	39	1190	1248	8	108	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 7	2006	312	5770					75	79		10.1126/science.1122689	http://dx.doi.org/10.1126/science.1122689			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	029SJ	16484454				2022-12-28	WOS:000236584400032
J	Derry, LA				Derry, LA			Atmospheric science - Fungi, weathering, and the emergence of animals	SCIENCE			English	Editorial Material									Cornell Univ, Dept Earth & Atmospher Sci, Ithaca, NY 14853 USA	Cornell University	Derry, LA (corresponding author), Cornell Univ, Dept Earth & Atmospher Sci, Ithaca, NY 14853 USA.	lad9@cornell.edu	Derry, Louis A/H-5637-2016	Derry, Louis A/0000-0001-7062-7333				Canfield DE, 1996, NATURE, V382, P127, DOI 10.1038/382127a0; Condon D, 2005, SCIENCE, V308, P95, DOI 10.1126/science.1107765; DERRY LA, 1992, GEOCHIM COSMOCHIM AC, V56, P1317, DOI 10.1016/0016-7037(92)90064-P; EDMOND JM, 1992, SCIENCE, V258, P1594, DOI 10.1126/science.258.5088.1594; Heckman DS, 2001, SCIENCE, V293, P1129, DOI 10.1126/science.1061457; Hurtgen MT, 2005, GEOLOGY, V33, P41, DOI 10.1130/G20923.1; Kennedy M, 2006, SCIENCE, V311, P1446, DOI 10.1126/science.1118929; Peterson KJ, 2005, P NATL ACAD SCI USA, V102, P9547, DOI 10.1073/pnas.0503660102; RUNNEGAR B, 1982, ALCHERINGA, V6, P223, DOI 10.1080/03115518208565415; Xiao SH, 1998, NATURE, V391, P553, DOI 10.1038/35318; Yuan XL, 2005, SCIENCE, V308, P1017, DOI 10.1126/science.1111347	11	9	10	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2006	311	5766					1386	1387		10.1126/science.1124183	http://dx.doi.org/10.1126/science.1124183			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527960				2022-12-28	WOS:000236029400026
J	Li, B; Yu, JPJ; Brunzelle, JS; Moll, GN; van der Donk, WA; Nair, SK				Li, B; Yu, JPJ; Brunzelle, JS; Moll, GN; van der Donk, WA; Nair, SK			Structure and mechanism of the lantibiotic cyclase involved in nisin biosynthesis	SCIENCE			English	Article							CRYSTAL-STRUCTURE; PROTEIN FARNESYLTRANSFERASE; METHIONINE SYNTHASE; ANGSTROM RESOLUTION; LIPID-II; PEPTIDE; ZINC; COMPLEX; LACTICIN-481; SUBSTRATE		Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA; Argonne Natl Labs, Life Sci Collaborat Access Team, Argonne, IL 60439 USA; BiOMaDe Technol Fdn, Groningen, Netherlands	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; United States Department of Energy (DOE); Argonne National Laboratory	van der Donk, WA (corresponding author), Univ Illinois, Dept Biochem, 600 S Mathews Ave, Urbana, IL 61801 USA.	vddonk@uiuc.edu; s-nair@life.uiuc.edu	Li, Bo/H-8516-2013; van der Donk, Wilfred/K-2961-2015; Nair, Satish/AAY-2510-2021	van der Donk, Wilfred/0000-0002-5467-7071; Yu, John-Paul/0000-0003-1878-052X; Li, Bo/0000-0002-8019-8891	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM058822, R01GM079038, R01GM058822] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58822, R01 GM079038] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESHIN A, 1992, J BIOL CHEM, V267, P19291; Alzari PM, 1996, STRUCTURE, V4, P265, DOI 10.1016/S0969-2126(96)00031-7; Bauer H, 2000, BIOCHEM BIOPH RES CO, V275, P69, DOI 10.1006/bbrc.2000.3260; Blisnick T, 2005, MOL BIOCHEM PARASIT, V141, P39, DOI 10.1016/j.molbiopara.2005.01.013; Breukink E, 1999, SCIENCE, V286, P2361, DOI 10.1126/science.286.5448.2361; CARSON M, 1997, METHOD ENZYMOL, V277, P646; Chan WC, 1996, APPL ENVIRON MICROB, V62, P2966, DOI 10.1128/AEM.62.8.2966-2969.1996; Chatterjee C, 2005, CHEM REV, V105, P633, DOI 10.1021/cr030105v; Chatterjee C, 2005, J AM CHEM SOC, V127, P15332, DOI 10.1021/ja0543043; DelvesBroughton J, 1996, ANTON LEEUW INT J G, V69, P193, DOI 10.1007/BF00399424; Evans JC, 2004, P NATL ACAD SCI USA, V101, P3729, DOI 10.1073/pnas.0308082100; Ferrer JL, 2004, J BIOL CHEM, V279, P44235, DOI 10.1074/jbc.C400325200; Hightower KE, 1999, CURR OPIN CHEM BIOL, V3, P176, DOI 10.1016/S1367-5931(99)80030-1; Hsu STD, 2004, NAT STRUCT MOL BIOL, V11, P963, DOI 10.1038/nsmb830; KALETTA C, 1989, J BACTERIOL, V171, P1597, DOI 10.1128/jb.171.3.1597-1601.1989; Kuipers A, 2004, J BIOL CHEM, V279, P22176, DOI 10.1074/jbc.M312789200; Lesburg CA, 1997, SCIENCE, V277, P1820, DOI 10.1126/science.277.5333.1820; Long SB, 2000, STRUCTURE, V8, P209, DOI 10.1016/S0969-2126(00)00096-4; Long SB, 1998, BIOCHEMISTRY-US, V37, P9612, DOI 10.1021/bi980708e; MYERS LC, 1993, SCIENCE, V261, P1164, DOI 10.1126/science.8395079; Okeley NM, 2003, BIOCHEMISTRY-US, V42, P13613, DOI 10.1021/bi0354942; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; Pejchal R, 2005, PLOS BIOL, V3, P254, DOI 10.1371/journal.pbio.0030031; Pitts KE, 2002, BIOCHEMISTRY-US, V41, P10287, DOI 10.1021/bi0259148; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Sakon J, 1997, NAT STRUCT BIOL, V4, P810, DOI 10.1038/nsb1097-810; Siegers K, 1996, J BIOL CHEM, V271, P12294, DOI 10.1074/jbc.271.21.12294; Starks CM, 1997, SCIENCE, V277, P1815, DOI 10.1126/science.277.5333.1815; vandenHooven HW, 1996, EUR J BIOCHEM, V235, P382, DOI 10.1111/j.1432-1033.1996.00382.x; Wendt KU, 1997, SCIENCE, V277, P1811, DOI 10.1126/science.277.5333.1811; WILKER JJ, 1995, J AM CHEM SOC, V117, P8682, DOI 10.1021/ja00138a031; Xie LL, 2004, SCIENCE, V303, P679, DOI 10.1126/science.1092600; Zhu YT, 2003, ORG BIOMOL CHEM, V1, P3304, DOI 10.1039/b304945k	33	240	247	3	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2006	311	5766					1464	1467		10.1126/science.1121422	http://dx.doi.org/10.1126/science.1121422			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527981				2022-12-28	WOS:000236029400050
J	Wernet, MF; Mazzoni, EO; Celik, A; Duncan, DM; Duncan, I; Desplan, C				Wernet, MF; Mazzoni, EO; Celik, A; Duncan, DM; Duncan, I; Desplan, C			Stochastic spineless expression creates the retinal mosaic for colour vision	NATURE			English	Article							PHOTORECEPTOR CELLS; TARSAL DEVELOPMENT; ANTENNAL IDENTITY; OPSIN GENE; DROSOPHILA; RHODOPSIN; R7; RECEPTOR; ARISTAPEDIA; RH3	Drosophila colour vision is achieved by R7 and R8 photoreceptor cells present in every ommatidium. The fly retina contains two types of ommatidia, called 'pale' and 'yellow', defined by different rhodopsin pairs expressed in R7 and R8 cells. Similar to the human cone photoreceptors, these ommatidial subtypes are distributed stochastically in the retina. The choice between pale versus yellow ommatidia is made in R7 cells, which then impose their fate onto R8. Here we report that the Drosophila dioxin receptor Spineless is both necessary and sufficient for the formation of the ommatidial mosaic. A short burst of spineless expression at mid-pupation in a large subset of R7 cells precedes rhodopsin expression. In spineless mutants, all R7 and most R8 cells adopt the pale fate, whereas overexpression of spineless is sufficient to induce the yellow R7 fate. Therefore, this study suggests that the entire retinal mosaic required for colour vision is defined by the stochastic expression of a single transcription factor, Spineless.	NYU, Dept Biol, Ctr Dev Genet, New York, NY 10003 USA; Washington Univ, Dept Biol, St Louis, MO 63130 USA	New York University; Washington University (WUSTL)	Desplan, C (corresponding author), NYU, Dept Biol, Ctr Dev Genet, 100 Washington Pl, New York, NY 10003 USA.	claude.desplan@nyu.edu	Fuss, ARZU Celik/AAD-2870-2020	Fuss, ARZU Celik/0000-0001-9889-6957; mazzoni, esteban/0000-0001-8994-681X; Desplan, Claude/0000-0002-6914-1413	NEI NIH HHS [R01 EY013010-10, R01 EY013010] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013010] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Briscoe AD, 2001, ANNU REV ENTOMOL, V46, P471, DOI 10.1146/annurev.ento.46.1.471; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; BURGESS EA, 1990, MOL GEN GENET, V221, P347, DOI 10.1007/BF00259398; Casares F, 1998, NATURE, V392, P723, DOI 10.1038/33706; Chou WH, 1996, NEURON, V17, P1101, DOI 10.1016/S0896-6273(00)80243-3; Chou WH, 1999, DEVELOPMENT, V126, P607; Duncan DM, 1998, GENE DEV, V12, P1290, DOI 10.1101/gad.12.9.1290; Emmons RB, 1999, DEVELOPMENT, V126, P3937; FEILER R, 1992, J NEUROSCI, V12, P3862; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; FRANCESCHINI N, 1981, SCIENCE, V213, P1264, DOI 10.1126/science.7268434; FRYXELL KJ, 1987, EMBO J, V6, P443, DOI 10.1002/j.1460-2075.1987.tb04774.x; Gegenfurtner KR, 2003, ANNU REV NEUROSCI, V26, P181, DOI 10.1146/annurev.neuro.26.041002.131116; Haider NB, 2000, NAT GENET, V24, P127, DOI 10.1038/72777; HEISENBERG M, 1977, J COMP PHYSIOL, V117, P127, DOI 10.1007/BF00612784; Huber A, 1997, FEBS LETT, V406, P6, DOI 10.1016/S0014-5793(97)00210-X; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Mazzoni EO, 2004, DEV NEUROSCI-BASEL, V26, P388, DOI 10.1159/000082281; Mikeladze-Dvali T, 2005, CELL, V122, P775, DOI 10.1016/j.cell.2005.07.026; MILLER GV, 1981, J INSECT PHYSIOL, V27, P813, DOI 10.1016/0022-1910(81)90073-1; MONTELL C, 1987, J NEUROSCI, V7, P1558; MOSES K, 1991, GENE DEV, V5, P583, DOI 10.1101/gad.5.4.583; Ng L, 2001, NAT GENET, V27, P94, DOI 10.1038/83829; Papatsenko D, 1997, DEVELOPMENT, V124, P1665; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; Roorda A, 1999, NATURE, V397, P520, DOI 10.1038/17383; Schmitt A, 2005, J EXP BIOL, V208, P1247, DOI 10.1242/jeb.01527; Sherry DM, 1998, VISUAL NEUROSCI, V15, P1175, DOI 10.1017/S0952523898156201; Stowers RS, 1999, GENETICS, V152, P1631; Tahayato A, 2003, DEV CELL, V5, P391, DOI 10.1016/S1534-5807(03)00239-9; Tomlinson A, 2003, DEV CELL, V5, P799, DOI 10.1016/S1534-5807(03)00326-5; VONPHILIPSBORN A, 1990, J COMP PHYSIOL A, V167, P737, DOI 10.1007/BF00189764; Vosshall LB, 1999, CELL, V96, P725, DOI 10.1016/S0092-8674(00)80582-6; WADA S, 1974, Z MORPHOL TIERE, V77, P87, DOI 10.1007/BF00374212; Wakakuwa M, 2005, NATURWISSENSCHAFTEN, V92, P464, DOI 10.1007/s00114-005-0018-5; Wernet MF, 2004, TRENDS CELL BIOL, V14, P576, DOI 10.1016/j.tcb.2004.09.007; Wernet MF, 2003, CELL, V115, P267, DOI 10.1016/S0092-8674(03)00848-1; White RH, 2003, J EXP BIOL, V206, P3337, DOI 10.1242/jeb.00571; WOLF R, 1980, J COMP PHYSIOL, V139, P177, DOI 10.1007/BF00657080; Wolff Tanya, 1993, P1277; XU T, 1993, DEVELOPMENT, V117, P1223; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	42	264	266	2	21	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 9	2006	440	7081					174	180		10.1038/nature04615	http://dx.doi.org/10.1038/nature04615			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019MC	16525464	Green Accepted, Bronze			2022-12-28	WOS:000235839500037
J	Krauss, B; Green, SM				Krauss, B; Green, SM			Procedural sedation and analgesia in children	LANCET			English	Review							PEDIATRIC EMERGENCY-DEPARTMENT; ADVERSE EVENTS; CONSCIOUS SEDATION; ORAL MIDAZOLAM; KETAMINE SEDATION; CONTROLLED TRIAL; SAFETY PROFILE; NITROUS-OXIDE; INTRAMUSCULAR KETAMINE; DISSOCIATIVE SEDATION	Procedural sedation and analgesia for children-the use of sedative, analgesic, or dissociative drugs to relieve anxiety and pain associated with diagnostic and therapeutic procedures-is now widely practised by a diverse group of specialists outside the operating theatre. We review the principles underlying safe and effective procedural sedation and analgesia and the spectrum of procedures for which it is currently done. We discuss the decision-making process used to determine appropriate drug selection, dosing, and sedation endpoint. We detail the pharmacopoeia for procedural sedation and analgesia, reviewing the pharmacology and adverse effects of these drugs. International differences in practice are described along with current areas of controversy and future directions.	Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Loma Linda Univ, Med Ctr, Dept Emergency Med, Loma Linda, CA USA; Childrens Hosp, Loma Linda, CA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Loma Linda University; Children's Hospital Los Angeles	Krauss, B (corresponding author), Childrens Hosp, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	baruch.krauss@childrens.harvard.edu	Soleimanpour, Hassan/AAZ-4667-2020; Krauss, Baruch/U-6182-2019; Golzari, Samad EJ/L-5785-2017	Soleimanpour, Hassan/0000-0002-1311-4096; Golzari, Samad EJ/0000-0003-3815-8770				Abbott/American Association of Critical-Care Nurses, 2004, Crit Care Nurse, V24, P33; Acworth JP, 2001, EMERG MED J, V18, P39, DOI 10.1136/emj.18.1.39; Agrawal D, 2004, ANN EMERG MED, V43, P247, DOI 10.1016/S0196-0644(03)00721-2; Agrawal D, 2003, ANN EMERG MED, V42, P636, DOI 10.1016/S0196-0644(03)00516-X; *AM AC PER, 2001, J PERIODONTOL, V72, P968; *AM NURS ASS, 1992, SCI NURS, V9, P55; American Academy of Pediatric Dentistry, 2004, Pediatr Dent, V26, P104; Annequin D, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.4.e47; [Anonymous], 1985, PEDIATRICS, V76, P317; [Anonymous], 1990, PEDIATRICS, V86, P484; [Anonymous], COMPR ACCR MAN HOSP; Antmen B, 2005, PEDIATR ANESTH, V15, P214, DOI 10.1111/j.1460-9592.2004.01411.x; *ASS OP ROOM NURS, 1993, AORN J, V57, P978; *AUSTR COLL EM MED, 2003, EMERG MED FREMANTLE, V15, P205; Barbi E, 2003, ARCH PEDIAT ADOL MED, V157, P1097, DOI 10.1001/archpedi.157.11.1097; BARSAN WG, 1989, AM J EMERG MED, V7, P155, DOI 10.1016/0735-6757(89)90128-9; Bassett KE, 2003, ANN EMERG MED, V42, P773, DOI 10.1016/S0196-0644(03)00619-X; BATES BA, 1994, ANN EMERG MED, V24, P646, DOI 10.1016/S0196-0644(94)70274-8; Beekman RP, 1996, EUR J PEDIATR, V155, P820; BELL GD, 1991, GUT, V32, P823, DOI 10.1136/gut.32.7.823; BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V254, P1073; BILLMIRE DA, 1985, J TRAUMA, V25, P1079; Burton JH, 2002, ANN EMERG MED, V40, P496, DOI 10.1067/mem.2002.126607; Burton JH, 1998, ACAD EMERG MED, V5, P112, DOI 10.1111/j.1553-2712.1998.tb02594.x; *CAN ASS EM PHYS, 1999, J EMERGENCY MED, V17, P145; Chen BK, 2001, CURR OPIN PEDIATR, V13, P324, DOI 10.1097/00008480-200108000-00007; Chen E, 1999, J CONSULT CLIN PSYCH, V67, P481, DOI 10.1037/0022-006X.67.4.481; Chumpa A, 2001, AM J EMERG MED, V19, P545, DOI 10.1053/ajem.2001.27141; Cohen LL, 2001, J PEDIATR PSYCHOL, V26, P367, DOI 10.1093/jpepsy/26.6.367; CONNORS K, 1994, ANN EMERG MED, V24, P1074, DOI 10.1016/S0196-0644(94)70236-5; COTE CJ, 1986, CAN J ANAESTH, V33, P315, DOI 10.1007/BF03010743; Cote CJ, 2000, PEDIATRICS, V105, P805, DOI 10.1542/peds.105.4.805; Cote CJ, 2000, PEDIATRICS, V106, P633, DOI 10.1542/peds.106.4.633; Cravero JP, 2004, ANESTH ANALG, V99, P1355, DOI 10.1213/01.ANE.0000134810.60270.E8; Davies FC, 1998, J ACCID EMERG MED, V15, P244; Dickinson R, 2001, ACAD EMERG MED, V8, P74, DOI 10.1111/j.1553-2712.2001.tb00558.x; Duff AJA, 2003, ARCH DIS CHILD, V88, P931, DOI 10.1136/adc.88.10.931; Egelhoff JC, 1997, AM J ROENTGENOL, V168, P1259, DOI 10.2214/ajr.168.5.9129423; *EM NURS ASS, 2000, CONSC SED POS STAT; Everitt Ian, 2002, Emerg Med (Fremantle), V14, P62, DOI 10.1046/j.1442-2026.2002.00285.x; Faigel DO, 2002, GASTROINTEST ENDOSC, V56, P613; FATOVICH DM, 1995, ANN EMERG MED, V25, P209, DOI 10.1016/S0196-0644(95)70326-8; FRANK NC, 1995, J PEDIATR PSYCHOL, V20, P277, DOI 10.1093/jpepsy/20.3.277; *GEN DENT COUNC, 1999, SAAD DIG, V16, P16; *GEN DENT COUNC, 1999, SAAD DIG, V16, P17; Ghaffar S, 2002, J AM SOC ECHOCARDIOG, V15, P980, DOI 10.1067/mje.2002.121274; Gill M, 2003, ANN EMERG MED, V41, P234, DOI 10.1067/mem.2003.53; GLASIER CM, 1995, AM J NEURORADIOL, V16, P111; Godwin SA, 2005, ANN EMERG MED, V45, P177, DOI 10.1016/j.annemergmed.2004.11.002; Golparvar M, 2004, PEDIATR ANESTH, V14, P924, DOI 10.1111/j.1460-9592.2004.01349.x; Gorman R, 2002, PEDIATRICS, V110, P836; Green SM, 1996, ACAD EMERG MED, V3, P598; Green SM, 2004, ANN EMERG MED, V44, P460, DOI 10.1016/j.annemergmed.2004.06.006; Green SM, 2003, ANN EMERG MED, V42, P792, DOI 10.1016/S0196-0644(03)00746-7; Green SM, 2003, ANN EMERG MED, V42, P647, DOI 10.1016/S0196-0644(03)00636-X; Green SM, 2002, ANN EMERG MED, V39, P433, DOI 10.1067/mem.2002.122770; Green SM, 2002, ACAD EMERG MED, V9, P35, DOI 10.1197/aemj.9.1.35; Green SM, 1998, ACAD EMERG MED, V5, P971, DOI 10.1111/j.1553-2712.1998.tb02773.x; Green SM, 1998, ANN EMERG MED, V31, P688, DOI 10.1016/S0196-0644(98)70226-4; Green SM, 2000, ANN EMERG MED, V35, P35, DOI 10.1016/S0196-0644(00)70102-8; Green SM, 2001, J PEDIATR GASTR NUTR, V32, P26, DOI 10.1097/00005176-200101000-00010; Green SM, 2000, ANN EMERG MED, V36, P480, DOI 10.1067/mem.2000.111426; GREENBERG SB, 1993, AM J ROENTGENOL, V161, P639, DOI 10.2214/ajr.161.3.8352124; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Guenther E, 2003, ANN EMERG MED, V42, P783, DOI 10.1016/S0196-0644(03)00634-6; HENNRIKUS WL, 1995, J BONE JOINT SURG AM, V77A, P335, DOI 10.2106/00004623-199503000-00001; Iverson RE, 1999, PLAST RECONSTR SURG, V104, P1559, DOI 10.1097/00006534-199910000-00054; KAUFFMAN RE, 1993, PEDIATRICS, V92, P471; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; Kendall JM, 2001, BMJ-BRIT MED J, V322, P261, DOI 10.1136/bmj.322.7281.261; Kennedy RM, 1998, PEDIATRICS, V102, P956, DOI 10.1542/peds.102.4.956; Kim G, 2003, ACAD EMERG MED, V10, P140, DOI 10.1111/j.1553-2712.2003.tb00031.x; Klein EJ, 2002, PEDIATRICS, V109, P894, DOI 10.1542/peds.109.5.894; Knape J T, 1999, Ned Tijdschr Geneeskd, V143, P1098; Krauss B, 2000, NEW ENGL J MED, V342, P938, DOI 10.1056/NEJM200003303421306; KRAUSS B, 1999, PEDIAT PROCEDURAL SE; Levati A, 2004, Minerva Anestesiol, V70, P675; Litman RS, 1999, ARCH PEDIAT ADOL MED, V153, P1085, DOI 10.1001/archpedi.153.10.1085; Lowrie L, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.3.e30; Luhmann JD, 2001, ANN EMERG MED, V37, P20, DOI 10.1067/mem.2001.112003; Malviya S, 1997, ANESTH ANALG, V85, P1207, DOI 10.1097/00000539-199712000-00005; Mandell GA, 1997, J NUCL MED, V38, P1640; MANULI MA, 1994, AM J ROENTGENOL, V162, P466; Mason KP, 2004, RADIOLOGY, V230, P537, DOI 10.1148/radiol.2302030107; Massanari M, 1997, CLIN PEDIATR, V36, P681, DOI 10.1177/000992289703601202; *MED ASS S AFR, 1997, S AFR MED J, V87, P484; Miner JR, 2005, ACAD EMERG MED, V12, P124, DOI 10.1197/j.aem.2004.08.054; Moro-Sutherland DM, 2000, ACAD EMERG MED, V7, P1370, DOI 10.1111/j.1553-2712.2000.tb00494.x; Nasraway SA, 2002, CRIT CARE MED, V30, P117, DOI 10.1097/00003246-200201000-00019; Nichols DP, 2005, PEDIATR ANESTH, V15, P199, DOI 10.1111/j.1460-9592.2005.01416.x; *NZ COLL AN, 1992, SAAD DIG, V9, P70; OJALA R, 1999, EMERG MED AUSTRALAS, V11, P258; Olson DM, 2001, PEDIATRICS, V108, P163, DOI 10.1542/peds.108.1.163; OLSSON GL, 1984, ACTA ANAESTH SCAND, V28, P567, DOI 10.1111/j.1399-6576.1984.tb02121.x; Pena BMG, 1999, ANN EMERG MED, V34, P483, DOI 10.1016/S0196-0644(99)80050-X; PEREIRA JK, 1993, PEDIATR RADIOL, V23, P341, DOI 10.1007/BF02011952; Picard P, 2000, ANESTH ANALG, V90, P963; Pitetti RD, 2003, ARCH PEDIAT ADOL MED, V157, P1090, DOI 10.1001/archpedi.157.11.1090; Poirier MP, 1998, AM J EMERG MED, V16, P350, DOI 10.1016/S0735-6757(98)90125-5; Pomeranz ES, 2000, PEDIATRICS, V105, P1110, DOI 10.1542/peds.105.5.1110; Powers SW, 1999, J PEDIATR PSYCHOL, V24, P131, DOI 10.1093/jpepsy/24.2.131; QURESHI FA, 1995, PEDIATR EMERG CARE, V11, P93, DOI 10.1097/00006565-199504000-00009; Roback MG, 2004, ANN EMERG MED, V44, P454, DOI 10.1016/j.annemergmed.2004.03.015; ROWLAND AS, 1995, AM J EPIDEMIOL, V141, P531, DOI 10.1093/oxfordjournals.aje.a117468; Schenarts CL, 2001, ACAD EMERG MED, V8, P1, DOI 10.1111/j.1553-2712.2001.tb00537.x; SCHWANDA AE, 1993, AM J PEDIAT HEMATOL, V15, P370; *SCOTT INT GUID, 2002, SAAD DIG, V19, P3; Sedik H, 2001, ARCH PEDIAT ADOL MED, V155, P665, DOI 10.1001/archpedi.155.6.665; Shannon M, 1997, J PEDIATR-US, V131, P582, DOI 10.1016/S0022-3476(97)70066-0; Sherwin TS, 2000, ANN EMERG MED, V35, P229, DOI 10.1016/S0196-0644(00)70073-4; *SOC GASTR NURS AS, 2004, GASTROENTEROL NURS, V27, P142; Soto RG, 2004, ANESTH ANALG, V99, P379; Standing Dental Advisory Committee, 2004, SAAD Dig, V21, P20; STEVENS B, 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD001069.P1B2; Tait AR, 2005, ANESTH ANALG, V100, P59, DOI 10.1213/01.ANE.0000139653.53618.91; Tanaka M, 2000, ANESTHESIOLOGY, V93, P1217, DOI 10.1097/00000542-200011000-00014; THEROUX MC, 1993, PEDIATRICS, V91, P624; Treston Greg, 2004, Emerg Med Australas, V16, P145, DOI 10.1111/j.1742-6723.2004.00583.x; *UK NAT CLIN GUID, 2002, INT J PAEDIATR DENT, V12, P359; Vargo JJ, 2002, GASTROENTEROLOGY, V123, P8, DOI 10.1053/gast.2002.34232; Vargo JJ, 2002, GASTROINTEST ENDOSC, V55, P826, DOI 10.1067/mge.2002.124208; Waring JP, 2003, GASTROINTEST ENDOSC, V58, P317, DOI 10.1067/S0016-5107(03)00001-4; Warner MA, 1999, ANESTHESIOLOGY, V90, P896; Wathen JE, 2000, ANN EMERG MED, V36, P579, DOI 10.1067/mem.2000.111131; Weber F, 2005, ACTA ANAESTH SCAND, V49, P277, DOI 10.1111/j.1399-6576.2005.00626.x; Wilson JA, 1997, J ACCID EMERG MED, V14, P70	127	326	348	1	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 4	2006	367	9512					766	780		10.1016/S0140-6736(06)68230-5	http://dx.doi.org/10.1016/S0140-6736(06)68230-5			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	020JX	16517277				2022-12-28	WOS:000235906000031
J	Smith, S				Smith, S			Architectural options for a fatty acid synthase	SCIENCE			English	Editorial Material									Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute	Smith, S (corresponding author), Childrens Hosp, Oakland Res Inst, 747 52nd St, Oakland, CA 94609 USA.	ssmith@chori.org						Asturias FJ, 2005, NAT STRUCT MOL BIOL, V12, P225, DOI 10.1038/nsmb899; Chakravarty B, 2004, P NATL ACAD SCI USA, V101, P15567, DOI 10.1073/pnas.0406901101; Chirala SS, 2001, P NATL ACAD SCI USA, V98, P3104, DOI 10.1073/pnas.051635998; Jenni S, 2006, SCIENCE, V311, P1263, DOI 10.1126/science.1123251; Kolodziej SJ, 1996, J BIOL CHEM, V271, P28422, DOI 10.1074/jbc.271.45.28422; KRESGE N, 2006, J BIOL CHEM, V281, pE5; Maier T, 2006, SCIENCE, V311, P1258, DOI 10.1126/science.1123248; Rangan VS, 2001, BIOCHEMISTRY-US, V40, P10792, DOI 10.1021/bi015535z; WERKMEISTER K, 1981, EUR J BIOCHEM, V116, P303, DOI 10.1111/j.1432-1033.1981.tb05334.x; Witkowski A, 2004, CHEM BIOL, V11, P1667, DOI 10.1016/j.chembiol.2004.09.016; Witkowski A, 1999, J BIOL CHEM, V274, P11557, DOI 10.1074/jbc.274.17.11557	11	15	19	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	2006	311	5765					1251	1252		10.1126/science.1125411	http://dx.doi.org/10.1126/science.1125411			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019XB	16513973				2022-12-28	WOS:000235870400030
J	Iosson, N				Iosson, N			Images in clinical medicine: Nebulizer-associated anisocoria	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Southampton Univ Hosp, Natl Hlth Serv Trust, Southampton SO16 6YD, Hants, England	University of Southampton	Iosson, N (corresponding author), Southampton Univ Hosp, Natl Hlth Serv Trust, Southampton SO16 6YD, Hants, England.								0	28	28	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 2	2006	354	9					E8	E8		10.1056/NEJMicm050851	http://dx.doi.org/10.1056/NEJMicm050851			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	017FN	16510741				2022-12-28	WOS:000235679600009
J	Imaizumi, M; Usa, T; Tominaga, T; Neriishi, K; Akahoshi, M; Nakashima, E; Ashizawa, K; Hida, A; Soda, M; Fujiwara, S; Yamada, M; Ejima, E; Yokoyama, N; Okubo, M; Sugino, K; Suzuki, G; Maeda, R; Nagataki, S; Eguchi, K				Imaizumi, M; Usa, T; Tominaga, T; Neriishi, K; Akahoshi, M; Nakashima, E; Ashizawa, K; Hida, A; Soda, M; Fujiwara, S; Yamada, M; Ejima, E; Yokoyama, N; Okubo, M; Sugino, K; Suzuki, G; Maeda, R; Nagataki, S; Eguchi, K			Radiation dose-response relationships for thyroid nodules and autoimmune thyroid diseases in Hiroshima and Nagasaki Atomic Bomb survivors 55-58 years after radiation exposure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							X-RAY TREATMENT; GRAVES-DISEASE; FOLLOW-UP; RECEPTOR ANTIBODIES; RADIOACTIVE FALLOUT; MARSHALL-ISLANDS; HIGH PREVALENCE; I-131 THERAPY; SERUM TSH; CANCER	Context Effects of irradiation on thyroid diseases such as thyroid nodules and autoimmune thyroid diseases have not been evaluated among people exposed to radiation more than 50 years in the past. Objective To evaluate the prevalence of thyroid diseases and their radiation-dose responses in atomic bomb survivors. Design, Setting, and Participants Survey study comprising 4091 cohort members ( mean age, 70 [SD, 9] years; 1352 men and 2739 women) who participated in the thyroid study at the Radiation Effects Research Foundation. Thyroid examinations were conducted between March 2000 and February 2003. Main Outcome Measures Prevalence of thyroid diseases, including thyroid nodules ( malignant and benign) and autoimmune thyroid diseases, and the dose-response relationship of atomic bomb radiation in each thyroid disease. Results Thyroid diseases were identified in 1833 ( 44.8%) of the total participants ( 436 men [32.2% of men] and 1397 women [51.0% of women]) ( P <. 001). In 3185 participants, excluding persons exposed in utero, not in the city at the time of the atomic bombings, or with unknown radiation dose, the prevalence of all solid nodules, malignant tumors, benign nodules, and cysts was 14.6%, 2.2%, 4.9%, and 7.7%, respectively. The prevalence of positive thyroid antibodies, antithyroid antibody - positive hypothyroidism, and Graves disease was 28.2%, 3.2%, and 1.2%, respectively. A significant linear dose-response relationship was observed for the prevalence of all solid nodules, malignant tumors, benign nodules, and cysts ( P <. 001). We estimate that about 28% of all solid nodules, 37% of malignant tumors, 31% of benign nodules, and 25% of cysts are associated with radiation exposure at a mean and median thyroid radiation dose of 0.449 Sv and 0.087 Sv, respectively. No significant dose- response relationship was observed for positive antithyroid antibodies (P=. 20), antithyroid antibody - positive hypothyroidism ( P=. 92), or Graves disease ( P=. 10). Conclusions A significant linear radiation dose response for thyroid nodules, including malignant tumors and benign nodules, exists in atomic bomb survivors. However, there is no significant dose response for autoimmune thyroid diseases.	Radiat Effects Res Fdn, Dept Clin Studies, Nagasaki 8500013, Japan; Radiat Effects Res Fdn, Dept Stat, Nagasaki 8500013, Japan; Radiat Effects Res Fdn, Dept Stat, Hiroshima, Japan; Radiat Effects Res Fdn, Dept Clin Studies, Hiroshima, Japan; Nagasaki Univ, Dept Internal Med 1, Grad Sch Biochem Sci, Nagasaki 852, Japan; Sasebo Chuo Hosp, Nagasaki, Japan; Nagasaki Saiseikai Hosp, Hiroshima, Japan; Hisayasu Clin, Hiroshima, Japan; Tsuchiya Gen Hosp, Hiroshima, Japan; Japan Radioisotope Assoc, Tokyo, Japan	Radiation Effects Research Foundation - Japan; Radiation Effects Research Foundation - Japan; Radiation Effects Research Foundation - Japan; Radiation Effects Research Foundation - Japan; Nagasaki University	Imaizumi, M (corresponding author), Radiat Effects Res Fdn, Dept Clin Studies, 1-8-6 Nakagawa, Nagasaki 8500013, Japan.	misaima@rerf.or.jp		nagataki, shigenobu/0000-0002-9974-3554				AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Akaike H, 1973, P 2 INT S INF THEOR, P267, DOI DOI 10.1007/978-1-4612-1694-0_15; AKIBA S, 1992, 591 RAD EFF RES FDN; *AT BOMB CAS COMM, 1962, 1162 ABCC; CHIOVATO L, 1994, CLIN ENDOCRINOL, V40, P803, DOI 10.1111/j.1365-2265.1994.tb02516.x; Cologne JB, 2000, LANCET, V356, P303, DOI 10.1016/S0140-6736(00)02506-X; Cox DR, 1974, THEORETICAL STAT; Davis S, 2004, JAMA-J AM MED ASSOC, V292, P2600, DOI 10.1001/jama.292.21.2600; Davis S., 2002, HANFORD THYROID DIS; DEGROOT LJ, 1983, AM J MED, V74, P852, DOI 10.1016/0002-9343(83)91077-X; DEMIDCHIK E, 1998, RAD THYR CANC C JUL; DOBYNS BM, 1974, J CLIN ENDOCR METAB, V38, P976, DOI 10.1210/jcem-38-6-976; Eheman CR, 2003, THYROID, V13, P453, DOI 10.1089/105072503322021115; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; FUJIWARA S, 1994, RADIAT RES, V137, P89, DOI 10.2307/3578795; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; Hedinger CE., 1988, HISTOLOGICAL TYPING; *HLTH EXP GROUP, 2005, HLTH EFF CHERN ACC S; Hollowell JG, 2002, J CLIN ENDOCR METAB, V87, P489, DOI 10.1210/jc.87.2.489; ITO M, 1995, THYROID, V5, P365, DOI 10.1089/thy.1995.5.365; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; KERBER RA, 1993, JAMA-J AM MED ASSOC, V270, P2076; Klugbauer S, 1995, ONCOGENE, V11, P2459; MORIMOTO I, 1987, J NUCL MED, V28, P1115; NAGATAKI S, 1989, LANCET, V2, P385; NAGATAKI S, 1994, JAMA-J AM MED ASSOC, V272, P364, DOI 10.1001/jama.272.5.364; Nikiforov YE, 1997, CANCER RES, V57, P1690; Nygaard B, 1997, J CLIN ENDOCR METAB, V82, P2926, DOI 10.1210/jc.82.9.2926; Nygaard B, 1999, THYROID, V9, P477, DOI 10.1089/thy.1999.9.477; OKAMURA K, 1989, J AM GERIATR SOC, V37, P317, DOI 10.1111/j.1532-5415.1989.tb05497.x; Pacini F, 1998, LANCET, V352, P763, DOI 10.1016/S0140-6736(97)11397-6; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; PIERCE DA, 1990, RADIAT RES, V123, P275, DOI 10.2307/3577733; Pierce DA, 1996, RADIAT RES, V146, P1, DOI 10.2307/3579391; POTTERN LM, 1990, J CLIN EPIDEMIOL, V43, P449, DOI 10.1016/0895-4356(90)90133-A; PRESTON D. L., 1993, EPICURE USERS GUIDE; Preston DL, 2003, RADIAT RES, V160, P381, DOI 10.1667/RR3049; Preston DL, 2004, RADIAT RES, V162, P377, DOI 10.1667/RR3232; Roesch WC, 1987, US JAPAN JOINT REASS; RON E, 1989, RADIAT RES, V120, P516, DOI 10.2307/3577801; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; SCHNEIDER AB, 1993, J CLIN ENDOCR METAB, V77, P362, DOI 10.1210/jc.77.2.362; Shibata Y, 2001, LANCET, V358, P1965, DOI 10.1016/S0140-6736(01)06971-9; Shimizu Y, 1999, RADIAT RES, V152, P374, DOI 10.2307/3580222; SHORE RE, 1993, AM J EPIDEMIOL, V137, P1068, DOI 10.1093/oxfordjournals.aje.a116610; Shore RE, 2003, HEALTH PHYS, V85, P404, DOI 10.1097/00004032-200310000-00003; SHORE RE, 1985, J NATL CANCER I, V74, P1177; SHORE RE, 1993, RADIAT RES, V134, P217, DOI 10.2307/3578462; SODA M, 2003, CANC INCIDENCE 5 CON, V8, P390; Soule J, 2001, THYROID, V11, P91, DOI 10.1089/10507250150500720; Takahashi T, 2003, J EPIDEMIOL, V13, P99, DOI 10.2188/jea.13.99; Takahashi T, 1999, INT J EPIDEMIOL, V28, P742, DOI 10.1093/ije/28.4.742; Tan GH, 1997, ANN INTERN MED, V126, P226, DOI 10.7326/0003-4819-126-3-199702010-00009; THOMPSON DE, 1994, RAD RES S, V137, P17; VANDERPUMP MPJ, 2000, WERNER INGBARS THYRO, P467; Wallaschofski H, 2001, HORM METAB RES, V33, P504, DOI 10.1055/s-2001-16945; Williams ED, 2004, BRIT J CANCER, V90, P2219, DOI 10.1038/sj.bjc.6601860; Yamada M, 2004, RADIAT RES, V161, P622, DOI 10.1667/RR3183; YOSHIMOTO Y, 1995, RADIAT RES, V141, P278, DOI 10.2307/3579004; Young RW, 2005, REASSESSMENT ATOMIC	60	130	136	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	2006	295	9					1011	1022		10.1001/jama.295.9.1011	http://dx.doi.org/10.1001/jama.295.9.1011			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	016XJ	16507802	Bronze			2022-12-28	WOS:000235656600021
J	Fidler, H; Thompson, C; Freeman, A; Hogan, D; Walker, G; Weinman, J				Fidler, H; Thompson, C; Freeman, A; Hogan, D; Walker, G; Weinman, J			Barriers to implementing a policy not to attempt resuscitation in acute medical admissions: prospective, cross sectional study of a successive cohort	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To establish whether acutely unwell patients admitted to hospital wish to participate in discussions about resuscitation. Design Prospective, cross sectional study of a successive cohort of patients. Setting Admission through the emergency department. Participants 374 adult patients. Main outcome measure Whether acutely unwell patients wished to participate in discussions about resuscitation. Results Of the total sample, 74 patients consented to take part in the Study and provide full data. Of the remaining patients, 189 could not be approached for practical reasons and 111 did not wish to participate. Of the 74 patients who read the leallet, 65 (88%) reported having little or no prior knowledge, 70 (95%) understood it, 56 (76%) preferred for resuscitation decisions to be discussed with them, and 55 (74%) did not mind discussing resuscitation within 24 hours of admission and overall showed a decline in their anxiety score. Conclusion Many patients admitted through the emergency department for medical reasons cannot participate in their decision not to attempt resuscitation within 24 hours of admission. Patients who were willing to participate rated the information leaflet that was provided positively.	Inst Psychiat, Dept Psychol, Hlth Psychol Sect, London SE5 8AH, England; Univ Hosp Lewisham, Dept Gastroenterol, London SE13 6LH, England; Univ Hosp Lewisham, Emergency Dept, London SE13 6LH, England	University of London; King's College London; University of London; King's College London; University of London; King's College London	Weinman, J (corresponding author), Inst Psychiat, Dept Psychol, Hlth Psychol Sect, London SE5 8AH, England.	john.weinman@kcl.ac.uk		Weinman, John Alfred/0000-0002-6786-0166				*BMA RES COUNC UK, 2002, DEC REL CARD RES JOI; Cauchi L, 2004, RESUSCITATION, V63, P157, DOI 10.1016/j.resuscitation.2004.05.017; KIRK P, 2004, BRIT MED J, V328, P1344; MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x; Vedula KC, 2004, ANN EMERG MED, V44, pS68, DOI 10.1016/j.annemergmed.2004.07.226	5	12	12	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 25	2006	332	7539					461	462		10.1136/bmj.38740.855914.BE	http://dx.doi.org/10.1136/bmj.38740.855914.BE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	018VM	16473857	Green Published, Bronze			2022-12-28	WOS:000235792900018
J	Chen, M; Wang, YH; Wang, YH; Huang, L; Sandoval, H; Liu, YJ; Wang, J				Chen, M; Wang, YH; Wang, YH; Huang, L; Sandoval, H; Liu, YJ; Wang, J			Dendritic cell apoptosis in the maintenance of immune tolerance	SCIENCE			English	Article							TRANSGENIC MICE; AUTOIMMUNE-DISEASE; T-LYMPHOCYTES; FAS LIGAND; IN-VIVO; ACTIVATION; EXPRESSION; PROLIFERATION; THYMOCYTES; MUTATIONS	Apoptosis in the immune system is critical for maintaining self-tolerance and preventing autoimmunity. Nevertheless, inhibiting apoptosis in lymphocytes is not alone sufficient to break self-tolerance, suggesting the involvement of other cell types. We investigated whether apoptosis in dendritic cells (DCs) helps regulate self-tolerance by generating transgenic mice expressing the baculoviral caspase inhibitor, p35, in DCs (DC-p35). DC-p35 mice displayed defective DC apoptosis, resulting in their accumulation and, in turn, chronic lymphocyte activation and systemic autoimmune manifestations. The observation that a defect in DC apoptosis can independently lead to autoimmunity is consistent with a central rote for these cells in maintaining immune self-tolerance.	Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Chen, M (corresponding author), Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA.	minc@bcm.edu; jinwang@bcm.edu		Sandoval, Hector/0000-0002-9186-7384; Chen, Min/0000-0002-0093-9056; Wang, Jin/0000-0002-3116-0838				Banchereau J, 2004, IMMUNITY, V20, P539, DOI 10.1016/S1074-7613(04)00108-6; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Brocker T, 1997, J EXP MED, V185, P541, DOI 10.1084/jem.185.3.541; Chen M., UNPUB; Doerfler P, 2000, J IMMUNOL, V164, P4071, DOI 10.4049/jimmunol.164.8.4071; Fields ML, 2001, J IMMUNOL, V167, P2370, DOI 10.4049/jimmunol.167.4.2370; Hao ZY, 2004, J EXP MED, V199, P1355, DOI 10.1084/jem.20032196; Izquierdo M, 1999, EMBO J, V18, P156, DOI 10.1093/emboj/18.1.156; Lanzavecchia A, 2001, CELL, V106, P263, DOI 10.1016/S0092-8674(01)00455-X; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; Liu YJ, 2001, CELL, V106, P259, DOI 10.1016/S0092-8674(01)00456-1; Ludewig B, 1998, J EXP MED, V188, P1493, DOI 10.1084/jem.188.8.1493; Maas A, 1999, J IMMUNOL, V162, P6526; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Nakano H, 2001, J EXP MED, V194, P1171, DOI 10.1084/jem.194.8.1171; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Nopora A, 2002, J IMMUNOL, V169, P3006, DOI 10.4049/jimmunol.169.6.3006; RATHMELL JC, 2002, CELL S, V109, P97; Roskrow MA, 1999, LEUKEMIA RES, V23, P549, DOI 10.1016/S0145-2126(99)00045-4; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wu ZQ, 2004, J IMMUNOL, V172, P6313, DOI 10.4049/jimmunol.172.10.6313; Xu GZ, 2001, NATURE, V410, P494, DOI 10.1038/35068604; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S; Zornig M, 1998, CURR BIOL, V8, P467, DOI 10.1016/S0960-9822(98)70182-4	29	248	260	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	2006	311	5764					1160	1164		10.1126/science.1122545	http://dx.doi.org/10.1126/science.1122545			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017IU	16497935				2022-12-28	WOS:000235688100051
J	Dai, ZG; Wang, XY; Wu, XF; Zhang, B				Dai, ZG; Wang, XY; Wu, XF; Zhang, B			X-ray flares from postmerger millisecond pulsars	SCIENCE			English	Article							NEUTRON-STARS; BURST AFTERGLOWS; HOST GALAXY; GRB-050709; MERGERS; DECAY	Recent observations support the suggestion that short-duration gamma-ray bursts are produced by compact star mergers. The x-ray flares discovered in two short gamma-ray bursts last much longer than the previously proposed postmerger energy-release time scales. Here, we show that they can be produced by differentially rotating, millisecond pulsars after the mergers of binary neutron stars. The differential rotation leads to windup of interior poloidal magnetic fields and the resulting toroidal fields are strong enough to float up and break through the stellar surface. Magnetic reconnection-driven explosive events then occur, leading to multiple x-ray flares minutes after the original gamma-ray burst.	Nanjing Univ, Dept Astron, Nanjing 210093, Peoples R China; Nanjing Univ, Purple Mt Observ, Joint Ctr Particle Nucl Phys & Cosmol, Nanjing 210008, Peoples R China; Univ Nevada, Dept Phys, Las Vegas, NV 89154 USA	Nanjing University; Chinese Academy of Sciences; Nanjing Institute of Astronomical Optics & Technology, NAOC, CAS; Nanjing University; Purple Mountain Observatory, CAS; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas	Dai, ZG (corresponding author), Nanjing Univ, Dept Astron, Nanjing 210093, Peoples R China.	dzg@nju.edu.cn	Wu, Xuefeng/G-5316-2015	Wu, Xuefeng/0000-0002-6299-1263; Zhang, Bing/0000-0002-9725-2524				Aloy MA, 2005, ASTRON ASTROPHYS, V436, P273, DOI 10.1051/0004-6361:20041865; Barthelmy SD, 2005, NATURE, V438, P994, DOI 10.1038/nature04392; Berger E, 2005, NATURE, V438, P988, DOI 10.1038/nature04238; Bloom JS, 2006, ASTROPHYS J, V638, P354, DOI 10.1086/498107; Burrows DN, 2005, SCIENCE, V309, P1833, DOI 10.1126/science.1116168; Dai ZG, 1998, ASTRON ASTROPHYS, V333, pL87; Dai ZG, 1998, PHYS REV LETT, V81, P4301, DOI 10.1103/PhysRevLett.81.4301; Davies MB, 2005, MON NOT R ASTRON SOC, V356, P54, DOI 10.1111/j.1365-2966.2004.08423.x; EICHLER D, 1989, NATURE, V340, P126, DOI 10.1038/340126a0; Fan YZ, 2005, MON NOT R ASTRON SOC, V364, pL42, DOI 10.1111/j.1745-3933.2005.00102.x; Fox DB, 2005, NATURE, V437, P845, DOI 10.1038/nature04189; Gehrels N, 2005, NATURE, V437, P851, DOI 10.1038/nature04142; GOLDREICH P, 1992, ASTROPHYS J, V395, P250, DOI 10.1086/171646; Hjorth J, 2005, NATURE, V437, P859, DOI 10.1038/nature04174; Kluzniak W, 1998, ASTROPHYS J, V505, pL113, DOI 10.1086/311622; Kouveliotou C., 1993, APJ, V413, P101; MacFadyen AI, 1999, ASTROPHYS J, V524, P262, DOI 10.1086/307790; MOCHKOVITCH R, 1993, NATURE, V361, P236, DOI 10.1038/361236a0; Morrison IA, 2004, ASTROPHYS J, V610, P941, DOI 10.1086/421897; NARAYAN R, 1992, APJ, V395, P83; Nice DJ, 2005, ASTROPHYS J, V634, P1242, DOI 10.1086/497109; OBRIEN PT, UNPUB; PANAITESCU A, UNPUB; Popham R, 1999, ASTROPHYS J, V518, P356, DOI 10.1086/307259; Rosswog S, 2003, MON NOT R ASTRON SOC, V345, P1077, DOI 10.1046/j.1365-2966.2003.07032.x; Shibata M, 2005, PHYS REV D, V71, DOI 10.1103/PhysRevD.71.084021; Spruit HC, 1999, ASTRON ASTROPHYS, V341, pL1; Villasenor JS, 2005, NATURE, V437, P855, DOI 10.1038/nature04213; Zhang B, 2004, INT J MOD PHYS A, V19, P2385, DOI 10.1142/S0217751X0401746X; ZHANG B, IN PRESS ASTROPHYS J	30	265	281	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	2006	311	5764					1127	1129		10.1126/science.1123606	http://dx.doi.org/10.1126/science.1123606			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017IU	16497927	Green Submitted			2022-12-28	WOS:000235688100041
J	Scanlon, JD				Scanlon, JD			Skull of the large non-macrostomatan snake Yurlunggur from the Australian Oligo-Miocene	NATURE			English	Article							FOSSIL SNAKE; ANATOMY; MORPHOLOGY; EVOLUTION; SQUAMATA; WONAMBI	Understanding the origin and early evolution of snakes from lizards depends on accurate morphological knowledge of the skull in basal lineages, but fossil specimens of archaic snakes have been rare, and either fragmentary or difficult to study as a result of compression by enclosing sediments(1-6). A number of Cenozoic fossil snakes from Australia have vertebral morphology diagnostic of an extinct group, Madtsoiidae, that was widespread in Gondwana from mid-Cretaceous (Cenomanian) to Eocene times, and also reached Europe in the late Cretaceous period(3,7-11). Despite this long history, only about half the skull is known from the best-known species Wonambi naracoortensis(7,11-13), and the few known cranial elements of other species have added little further evidence for phylogenetic relationships(10,14-19). Conflicting hypotheses have been proposed for their relationships and evolutionary significance, either as basal ophidians with many ancestral (varanoid- or mosasaur-like) features, or advanced (macrostomatan) alethinophidians of little relevance to snake origins(3,4,7,11-15,20). Here I report two partial skeletons referred to Yurlunggur(8), from the late Oligocene and early Miocene of northern Australia, which together represent almost the complete skull and mandible. The exceptionally preserved skulls provide new evidence linking Yurlunggur with Wonambi and other madtsoiids, falsifying predictions of the macrostomatan hypothesis, and supporting the exclusion of Madtsoiidae from the clade including all extant snakes.	Outback Isa, Riversleigh Fossil Ctr, Mt Isa, Qld 4825, Australia; S Australian Museum, Adelaide, SA 5000, Australia		Scanlon, JD (corresponding author), Outback Isa, Riversleigh Fossil Ctr, POB 1094, Mt Isa, Qld 4825, Australia.	riversleigh@outbackatisa.com.au						Archer Michael, 1997, Memoires et Travaux de l'Institut de Montpellier de l'Ecole Pratique des Hautes Etudes, V21, P131; BARRIE DJ, 1990, MEMOIRS QUEENSLAND M, V28, P139; Caldwell MW, 2002, J VERTEBR PALEONTOL, V22, P861, DOI 10.1671/0272-4634(2002)022[0861:EPSOTC]2.0.CO;2; Coates M, 2000, TRENDS ECOL EVOL, V15, P503, DOI 10.1016/S0169-5347(00)01999-6; CUNDALL D, 1993, ZOOL J LINN SOC-LOND, V109, P235, DOI 10.1006/zjls.1993.1038; CUNDALL D, 1995, J ZOOL, V237, P353, DOI 10.1111/j.1469-7998.1995.tb02767.x; ESTES R, 1970, Bulletin of the Museum of Comparative Zoology, V140, P25; Estes R., 1988, P119; Lee MSY, 2002, BIOL REV, V77, P333, DOI 10.1017/S1464793102005924; Lee MSY, 1998, PHILOS T ROY SOC B, V353, P1521, DOI 10.1098/rstb.1998.0308; McDowell SB, 1987, SNAKES ECOLOGY EVOLU, P1; Rage J.C., 1999, Palaeontologia Africana, V35, P85; Rage Jean-Claude, 1998, Palaeovertebrata (Montpellier), V27, P109; Rieppel O, 2002, J VERTEBR PALEONTOL, V22, P812, DOI 10.1671/0272-4634(2002)022[0812:TTPROT]2.0.CO;2; Rieppel O, 2003, J PALEONTOL, V77, P536, DOI 10.1666/0022-3360(2003)077<0536:TAAROH>2.0.CO;2; Rieppel O, 2000, ZOOL J LINN SOC-LOND, V129, P489, DOI 10.1006/zjls.1999.0215; Scanlon J.D., 1996, THESIS U NEW S WALES; Scanlon JD, 2005, ACTA PALAEONTOL POL, V50, P139; Scanlon JD, 2003, J VERTEBR PALEONTOL, V23, P971, DOI 10.1671/24; Scanlon JD, 2003, GEOBIOS-LYON, V36, P573, DOI 10.1016/S0016-6995(03)00056-1; Scanlon JD, 2002, J HERPETOL, V36, P100; Scanlon JD, 2000, NATURE, V403, P416, DOI 10.1038/35000188; Scanlon John D., 1993, Kaupia Darmstaedter Beitraege zur Naturgeschichte, V3, P3; Scanlon John D., 2004, Beagle, V20, P207; Scanlon John D., 2005, Memoirs of the Queensland Museum, V51, P215; Scanlon John D., 1992, Beagle, V9, P49; Scanlon John D., 2001, Memoir of the Association of Australasian Palaeontologists, V25, P1; Scanlon John D., 1997, Memoirs of the Queensland Museum, V41, P393; Simpson GG, 1933, B AM MUS NAT HIST, V67, P1; SWOFFORD DL, 1999, PAUP VERSION 4 PHYLO	30	56	58	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 16	2006	439	7078					839	842		10.1038/nature04137	http://dx.doi.org/10.1038/nature04137			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012JA	16482156				2022-12-28	WOS:000235333600048
J	Goldberger, Z; Lampert, R				Goldberger, Z; Lampert, R			Implantable cardioverter-defibrillators - Expanding indications and technologies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							SUDDEN CARDIAC DEATH; ANTIARRHYTHMIC-DRUG-THERAPY; CORONARY-ARTERY-DISEASE; CHRONIC HEART-FAILURE; NONSUSTAINED VENTRICULAR-TACHYCARDIA; NONISCHEMIC DILATED CARDIOMYOPATHY; INTRAVENTRICULAR-CONDUCTION DELAY; ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CLINICAL-TRIAL; SINUS NODE DYSFUNCTION	Context Sudden cardiac death (SCD) is a major challenge facing contemporary cardiology. For an increasing number of patients, the current standard of care for the treatment and prevention of SCD is the implantable cardioverter-defibrillator (ICD). Since its introduction, there have been numerous advances in ICD technology, and indications for its use have expanded greatly in the past year. Objective To highlight the evolving indications for and the numerous advances in ICD technology, with emphasis on primary and secondary prophylaxis of SCD. Evidence Acquisition Electronic literature search of the Pubmed and MEDLINE databases from January 1996 to July 2005, using the Medical Subject Heading implantable defibrillator. Abstracts and titles were reviewed to identify English-language randomized controlled trials that included an ICD group and a non-ICD group and that had end points of all-cause mortality, cardiac death, and/or arrhythmic mortality as the main outcome. A further MEDLINE search was conducted to identify randomized controlled trials of cardiac resynchronization therapy (CRT) with a CRT and a non-CRT group ( including both mortality and other end points). Other studies were included that clarify aspects of device function and other relevant issues. A total of 22 trials were identified. Evidence Synthesis ICD implantation improves survival in patients with a history of life-threatening ventricular arrhythmia. More recent evidence shows that ICD implantation also improves survival as primary prophylaxis against SCD in patients at high risk for ventricular arrhythmias, including those with left ventricular ejection fraction (LVEF) of 35% or less and New York Heart Association class II or III heart failure and those with a history of myocardial infarction and LVEF of 30% or less. Cardiac resynchronization improves symptoms, quality of life, and survival for patients with advanced heart failure and intraventricular conduction delays and ventricular dyssynchrony. Conclusions ICDs have been shown to improve survival as both primary and secondary prophylaxis in an expanding population of patients. Ongoing ICD research may continue to delineate groups with survival benefit from ICDs, and the use and indications of these devices in clinical practice will continue to expand.	Yale Univ, Sch Med, Cardiol Sect, Dept Med, New Haven, CT 06520 USA; Univ Washington, Med Ctr, Dept Med, Seattle, WA 98195 USA	Yale University; University of Washington; University of Washington Seattle	Lampert, R (corresponding author), Yale Univ, Sch Med, Cardiol Sect, Dept Med, 333 Cedar St,FMP 3, New Haven, CT 06520 USA.	rachel.lampert@yale.edu						Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; *AM COLL CARD, CLIN STAT GUID; Anderson JL, 1999, CIRCULATION, V99, P1692, DOI 10.1161/01.CIR.99.13.1692; Ansalone G, 2001, AM HEART J, V142, P881, DOI 10.1067/mhj.2001.117324; Auricchio A, 2002, J AM COLL CARDIOL, V39, P2026, DOI 10.1016/S0735-1097(02)01895-8; Auricchio A, 2003, J AM COLL CARDIOL, V42, P2109, DOI 10.1016/j.jacc.2003.04.003; Bailey JJ, 2001, J AM COLL CARDIOL, V38, P1902, DOI 10.1016/S0735-1097(01)01667-9; Bansch D, 2002, CIRCULATION, V105, P1453, DOI 10.1161/01.CIR.0000012350.99718.AD; Bardy GH, 2005, NEW ENGL J MED, V352, P225, DOI 10.1056/NEJMoa043399; Barold HS, 1998, PACE, V21, P1347, DOI 10.1111/j.1540-8159.1998.tb00204.x; Begley DA, 2003, PACE, V26, P1887, DOI 10.1046/j.1460-9592.2003.00285.x; BHANDARI AK, 1992, AM HEART J, V124, P87, DOI 10.1016/0002-8703(92)90924-K; Bigger JT, 1997, NEW ENGL J MED, V337, P1569, DOI 10.1056/NEJM199711273372201; Bigger JT, 2002, NEW ENGL J MED, V346, P931, DOI 10.1056/NEJMe020011; Blanc JJ, 1997, CIRCULATION, V96, P3273; BLANCK Z, 1994, AM J CARDIOL, V74, P1249, DOI 10.1016/0002-9149(94)90557-6; Bloomfield DM, 2004, CIRCULATION, V110, P1885, DOI 10.1161/01.CIR.0000143160.14610.53; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Buxton AE, 1999, NEW ENGL J MED, V341, P1882, DOI 10.1056/NEJM199912163412503; Buxton AE, 2000, NEW ENGL J MED, V342, P1937, DOI 10.1056/NEJM200006293422602; Buxton AE, 2005, NEW ENGL J MED, V352, P2638, DOI 10.1056/NEJMe058085; Buxton AE, 2005, CIRCULATION, V111, P2537, DOI 10.1161/01.CIR.0000165057.88551.2C; Buxton AE, 2003, ANN INTERN MED, V138, P512, DOI 10.7326/0003-4819-138-6-200303180-00018; Buxton AE, 2002, CIRCULATION, V106, P2466, DOI 10.1161/01.CIR.0000037224.15873.83; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; Cazeau S, 1996, PACE, V19, P1748, DOI 10.1111/j.1540-8159.1996.tb03218.x; Cleland JGF, 2005, NEW ENGL J MED, V352, P1539, DOI 10.1056/NEJMoa050496; *CLIN TRIALS GOV, MADIT CRT AUT DEF IM; Coats AJS, 2002, INT J CARDIOL, V82, P1; Connolly SJ, 2000, CIRCULATION, V101, P1297, DOI 10.1161/01.CIR.101.11.1297; Connolly SJ, 2000, EUR HEART J, V21, P2071, DOI 10.1053/euhj.2000.2476; Cooper JM, 2002, NEW ENGL J MED, V346, P2062, DOI 10.1056/NEJMra012144; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; Corrado D, 2003, CIRCULATION, V108, P3084, DOI 10.1161/01.CIR.0000103130.33451.D2; Daoud EG, 2000, CIRCULATION, V102, P1407, DOI 10.1161/01.CIR.102.12.1407; DELUNA AB, 1989, AM HEART J, V117, P151, DOI 10.1016/0002-8703(89)90670-4; deVreedeSwagemakers JJM, 1997, J AM COLL CARDIOL, V30, P1500, DOI 10.1016/S0735-1097(97)00355-0; DiMarco JP, 2003, NEW ENGL J MED, V349, P1836, DOI 10.1056/NEJMra035432; ESTES NAM, 1994, AM HEART J, V127, P1038, DOI 10.1016/0002-8703(94)90084-1; FEUER JM, 1989, AM J CARDIOL, V64, P1376, DOI 10.1016/0002-9149(89)90586-9; FLAKER GC, 1992, J AM COLL CARDIOL, V20, P527, DOI 10.1016/0735-1097(92)90003-6; Friedman PA, 2001, CIRCULATION, V104, P1023, DOI 10.1161/hc3401.095039; Ganz LI, 1997, J CARDIOVASC ELECTR, V8, P1175, DOI 10.1111/j.1540-8167.1997.tb01005.x; Gold MR, 2000, J AM COLL CARDIOL, V36, P2247, DOI 10.1016/S0735-1097(00)01017-2; Goldberger Z, 2005, J AM COLL CARDIOL, V46, P850, DOI 10.1016/j.jacc.2005.05.061; Goldman L, 2005, NEW ENGL J MED, V353, P1513, DOI 10.1056/NEJM2e058214; Gollob MH, 2001, CHEST, V119, P1210, DOI 10.1378/chest.119.4.1210; Gregoratos G, 2002, J CARDIOVASC ELECTR, V13, P1183; Guerra JM, 2003, J CARDIOVASC ELECTR, V14, P1245, DOI 10.1046/j.1540-8167.2003.03303.x; Hauser RG, 2005, CIRCULATION, V112, P2040, DOI 10.1161/CIRCULATIONAHA.105.580381; Hauser RG, 2004, HEART RHYTHM, V1, P399, DOI 10.1016/j.hrthm.2004.05.006; HESSELSON AB, 1992, J AM COLL CARDIOL, V19, P1542, DOI 10.1016/0735-1097(92)90616-U; Higgins SL, 2003, J AM COLL CARDIOL, V42, P1454, DOI 10.1016/S0735-1097(03)01042-8; Hohnloser SH, 2004, NEW ENGL J MED, V351, P2481, DOI 10.1056/NEJMoa041489; Huikuri HV, 2001, NEW ENGL J MED, V345, P1473, DOI 10.1056/NEJMra000650; Hurst TM, 1999, J AM COLL CARDIOL, V34, P402, DOI 10.1016/S0735-1097(99)00194-1; Israel CW, 2001, PACE, V24, P183, DOI 10.1046/j.1460-9592.2001.00183.x; Josephson M, 2004, CIRCULATION, V109, P2685, DOI 10.1161/01.CIR.0000129322.97266.F3; Kadish A, 2004, NEW ENGL J MED, V350, P2151, DOI 10.1056/NEJMoa033088; Kadish A, 2005, NEW ENGL J MED, V352, P285, DOI 10.1056/NEJMe048351; KANNEL WB, 1985, J AM COLL CARDIOL, V5, pB141, DOI 10.1016/S0735-1097(85)80545-3; Kuck KH, 2000, CIRCULATION, V102, P748, DOI 10.1161/01.CIR.102.7.748; Kusumoto FM, 2002, JAMA-J AM MED ASSOC, V287, P1848, DOI 10.1001/jama.287.14.1848; La Rovere MT, 2001, CIRCULATION, V103, P2072; Lampert R, 1998, PACE, V21, P1225, DOI 10.1111/j.1540-8159.1998.tb00181.x; Lau EW, 2004, EUROPACE, V6, P257, DOI 10.1016/j.eupc.2004.03.009; Leclercq C, 2002, J AM COLL CARDIOL, V39, P194, DOI 10.1016/S0735-1097(01)01747-8; LIKOFF MJ, 1987, AM J CARDIOL, V59, P634; LUU M, 1989, CIRCULATION, V80, P1675, DOI 10.1161/01.CIR.80.6.1675; Maisel WH, 2001, JAMA-J AM MED ASSOC, V286, P793, DOI 10.1001/jama.286.7.793; MARKEWITZ A, 1986, PACE, V9, P1115, DOI 10.1111/j.1540-8159.1986.tb06679.x; Maron BJ, 2003, CIRCULATION, V107, P2872, DOI 10.1161/01.CIR.0000072343.81530.75; Mattke S, 1997, PACE, V20, P2775, DOI 10.1111/j.1540-8159.1997.tb05435.x; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; McSwain RL, 2005, J CARDIOVASC ELECTR, V16, P1168, DOI 10.1111/j.1540-8167.2005.40719.x; MIDDLEKAUFF HR, 1995, ARCH INTERN MED, V155, P913; MIROWSKI M, 1980, NEW ENGL J MED, V303, P322, DOI 10.1056/NEJM198008073030607; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; MYERBURG RJ, 1993, ANN INTERN MED, V119, P1187, DOI 10.7326/0003-4819-119-12-199312150-00006; Mykytsey A, 2005, J CARDIOVASC ELECTR, V16, P655, DOI 10.1111/j.1540-8167.2005.40764.x; Nademanee K, 2003, CIRCULATION, V107, P2221, DOI 10.1161/01.CIR.0000066319.56234.C8; NATTEL S, 1994, DRUGS, V48, P345, DOI 10.2165/00003495-199448030-00003; Nielsen JC, 2003, J AM COLL CARDIOL, V42, P614, DOI 10.1016/S0735-1097(03)00757-5; PFEIFFER D, 1994, AM HEART J, V127, P1073, DOI 10.1016/0002-8703(94)90090-6; Prystowsky E N, 1996, Am J Cardiol, V78, P35, DOI 10.1016/S0002-9149(96)00564-4; Reynolds MR, 2003, CIRCULATION, V108, P1779, DOI 10.1161/01.CIR.0000086777.82110.F5; Rivero-Ayerza M, 2004, CIRCULATION, V109, P2924, DOI 10.1161/01.CIR.0000130731.98722.F8; ROSENQVIST M, 1991, AM J CARDIOL, V67, P148, DOI 10.1016/0002-9149(91)90437-P; SAKSENA S, 1994, AM HEART J, V127, P1010, DOI 10.1016/0002-8703(94)90080-9; Sanders GD, 2005, NEW ENGL J MED, V353, P1471, DOI 10.1056/NEJMsa051989; Santini M, 1996, AM J CARDIOL, V78, P116, DOI 10.1016/S0002-9149(96)00513-9; Schoels W, 2001, J CARDIOVASC ELECTR, V12, P521, DOI 10.1046/j.1540-8167.2001.00521.x; Sharif MN, 1998, CAN J CARDIOL, V14, P1241; Solomon SD, 2005, NEW ENGL J MED, V352, P2581, DOI 10.1056/NEJMoa043938; Stadler RW, 2003, PACE, V26, P1189, DOI 10.1046/j.1460-9592.2003.t01-1-00168.x; Steinbrook R, 2005, NEW ENGL J MED, V353, P221, DOI 10.1056/NEJMp058158; Strickberger SA, 2003, J AM COLL CARDIOL, V41, P1707, DOI 10.1016/S0735-1097(03)00297-3; Sweeney MO, 2004, CIRCULATION, V110, P444; Sweeney MO, 2004, HEART RHYTHM, V1, P160, DOI 10.1016/j.hrthm.2004.03.059; Sweeney MO, 2003, CIRCULATION, V107, P2932, DOI 10.1161/01.CIR.0000072769.17295.B1; *US FDA, 2005, POL C PAC ICD PERF S; Watanabe H, 2005, J CARDIOVASC ELECTR, V16, P262, DOI 10.1046/j.1540-8167.2005.40579.x; Wathen MS, 2004, CIRCULATION, V110, P2591, DOI 10.1161/01.CIR.0000145610.64014.E4; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WILBER DJ, 1990, CIRCULATION, V82, P350, DOI 10.1161/01.CIR.82.2.350; Wilkoff BL, 2002, JAMA-J AM MED ASSOC, V288, P3115; Wonisch M, 2005, CHEST, V127, P787, DOI 10.1378/chest.127.3.787; YEE R, 1992, CIRCULATION, V85, P196, DOI 10.1161/01.CIR.85.1.196; Young JB, 2003, JAMA-J AM MED ASSOC, V289, P2685, DOI 10.1001/jama.289.20.2685; ZANINI R, 1990, PACE, V13, P2076, DOI 10.1111/j.1540-8159.1990.tb06945.x; Zareba W, 2003, J CARDIOVASC ELECTR, V14, P337, DOI 10.1046/j.1540-8167.2003.02545.x	112	189	195	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	2006	295	7					809	818		10.1001/jama.295.7.809	http://dx.doi.org/10.1001/jama.295.7.809			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011YZ	16478904	Bronze			2022-12-28	WOS:000235306700026
J	Kohli, P; Greenland, P				Kohli, P; Greenland, P			Role of the metabolic syndrome in risk assessment for coronary heart disease - Commentary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEALTH-CARE PROFESSIONALS; CARDIOVASCULAR-DISEASE; PRIMARY PREVENTION; PREDICTION; FRAMINGHAM; MORTALITY; STATEMENT; ASSOCIATION; POPULATION; PREVALENCE		Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; NW Mem Hosp, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern Memorial Hospital	Greenland, P (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, 680 N Lake Shore Dr,Suite 1102, Chicago, IL 60611 USA.	p-greenland@northwestern.edu	Greenland, Philip/ABD-5528-2021					AHRENS EH, 1976, ANN INTERN MED, V85, P87, DOI 10.7326/0003-4819-85-1-87; Alexander CM, 2003, DIABETES, V52, P1210, DOI 10.2337/diabetes.52.5.1210; Grundy Scott M, 2005, Crit Pathw Cardiol, V4, P198; Assmann G, 2002, CIRCULATION, V105, P310, DOI 10.1161/hc0302.102575; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Cooper JA, 2005, ATHEROSCLEROSIS, V181, P93, DOI 10.1016/j.atherosclerosis.2004.12.026; Ferrario M, 2005, INT J EPIDEMIOL, V34, P413, DOI 10.1093/ije/dyh405; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Ginsburg GS, 2005, J AM COLL CARDIOL, V46, P1615, DOI 10.1016/j.jacc.2005.06.075; Grundy SM, 1998, CIRCULATION, V97, P1876, DOI 10.1161/01.CIR.97.18.1876; Grundy SM, 1999, CIRCULATION, V100, P1481, DOI 10.1161/01.CIR.100.13.1481; Hu FB, 2000, NEW ENGL J MED, V343, P530, DOI 10.1056/NEJM200008243430802; Hunink MGM, 1997, JAMA-J AM MED ASSOC, V277, P535, DOI 10.1001/jama.277.7.535; Kahn R, 2005, DIABETES CARE, V28, P2289, DOI 10.2337/diacare.28.9.2289; Lakka HM, 2002, JAMA-J AM MED ASSOC, V288, P2709, DOI 10.1001/jama.288.21.2709; Malik S, 2004, CIRCULATION, V110, P1245, DOI 10.1161/01.CIR.0000140677.20606.0E; McNeill AM, 2005, DIABETES CARE, V28, P385, DOI 10.2337/diacare.28.2.385; Pearson TA, 2002, CIRCULATION, V106, P388, DOI 10.1161/01.CIR.0000020190.45892.75; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Robson J, 2000, BRIT MED J, V320, P702, DOI 10.1136/bmj.320.7236.702; Sattar N, 2003, CIRCULATION, V108, P414, DOI 10.1161/01.CIR.0000080897.52664.94; Stephens JW, 2004, EUR J CARDIOV PREV R, V11, P521, DOI 10.1097/00149831-200412000-00013; Stern MP, 2004, DIABETES CARE, V27, P2676, DOI 10.2337/diacare.27.11.2676; Unal B, 2005, BMJ-BRIT MED J, V331, P614, DOI 10.1136/bmj.38561.633345.8F; Wannamethee SG, 2005, ARCH INTERN MED, V165, P2644, DOI 10.1001/archinte.165.22.2644; Yarnell JWG, 1998, HEART, V79, P248, DOI 10.1136/hrt.79.3.248	27	32	34	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	2006	295	7					819	821		10.1001/jama.295.7.819	http://dx.doi.org/10.1001/jama.295.7.819			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011YZ	16482657				2022-12-28	WOS:000235306700027
J	Li, CB; Zhou, AL; Sang, T				Li, CB; Zhou, AL; Sang, T			Rice domestication by reducing shattering	SCIENCE			English	Article							ORYZA-SATIVA; EVOLUTION; TRAITS	Crop domestication frequently began with the selection of plants that did not naturally shed ripe fruits or seeds. The reduction in grain shattering that led to cereal domestication involved genetic loci of large effect. The molecular basis of this key domestication transition, however, remains unknown. Here we show that human selection of an amino acid substitution in the predicted DNA binding domain encoded by a gene of previously unknown function was primarily responsible for the reduction of grain shattering in rice domestication. The substitution undermined the gene function necessary for the normal development of an abscission layer that controls the separation of a grain from the pedicel.	Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA	Michigan State University	Sang, T (corresponding author), Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA.	sang@msu.edu						Cai HW, 2000, THEOR APPL GENET, V100, P840, DOI 10.1007/s001220051360; Chang TT, 2002, W CROP SCI, P3; Choi DS, 2003, PLANT CELL, V15, P1386, DOI 10.1105/tpc.011965; Doebley J, 1997, NATURE, V386, P485, DOI 10.1038/386485a0; Feng Q, 2002, NATURE, V420, P316, DOI 10.1038/nature01183; Frary A, 2000, SCIENCE, V289, P85, DOI 10.1126/science.289.5476.85; Garris AJ, 2005, GENETICS, V169, P1631, DOI 10.1534/genetics.104.035642; Hancock J.F., 2004, PLANT EVOLUTION ORIG; Harlan J.R., 1975, CROPS MAN; Li CB, 2006, NEW PHYTOL, V170, P185, DOI 10.1111/j.1469-8137.2005.01647.x; Liu JP, 2002, P NATL ACAD SCI USA, V99, P13302, DOI 10.1073/pnas.162485999; Nagai YS, 2002, RICE GENET NEWSL, V19, P74; Oka H. I., 1988, Origin of cultivated rice.; Paterson AH, 2002, NEW PHYTOL, V154, P591, DOI 10.1046/j.1469-8137.2002.00420.x; Patterson SE, 2001, PLANT PHYSIOL, V126, P494, DOI 10.1104/pp.126.2.494; Poncet V, 2000, THEOR APPL GENET, V100, P147, DOI 10.1007/s001220050020; Riechmann JL, 2000, SCIENCE, V290, P2105, DOI 10.1126/science.290.5499.2105; Sharma SD, 2000, RICE BREEDING AND GENETICS, P349; SOBRIZAL K, 1999, RICE GENET NEWSLETT, V16, P74; Vaughan D.A., 1994, GENETIC HDB; Wang H, 2005, NATURE, V436, P714, DOI 10.1038/nature03863; Xiong LX, 1999, THEOR APPL GENET, V98, P243, DOI 10.1007/s001220051064; Yamasaki K, 2005, PLANT CELL, V17, P944, DOI 10.1105/tpc.104.026435	23	554	630	7	240	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 31	2006	311	5769					1936	1939		10.1126/science.1123604	http://dx.doi.org/10.1126/science.1123604			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	027BD	16527928				2022-12-28	WOS:000236387800048
J	Penengo, L; Mapelli, M; Murachelli, AG; Confalonieri, S; Magri, L; Musacchio, A; Di Fiore, PP; Polo, S; Schneider, TR				Penengo, L; Mapelli, M; Murachelli, AG; Confalonieri, S; Magri, L; Musacchio, A; Di Fiore, PP; Polo, S; Schneider, TR			Crystal structure of the ubiquitin binding domains of rabex-5 reveals two modes of interaction with ubiquitin	CELL			English	Article							GROWTH-FACTOR RECEPTOR; NUCLEOTIDE EXCHANGE; CUE DOMAIN; PROTEIN-TRANSPORT; ZINC FINGERS; RECOGNITION; ENDOCYTOSIS; MECHANISM; COMPLEX; VPS9P	The interaction between ubiquitinated proteins and intracellular proteins harboring ubiquitin binding domains (UBDs) is critical to a multitude of cellular processes. Here, we report that Rabex-5, a guanine nucleotide exchange factor for Rab5, binds to Ub through two independent UBDs. These UBDs determine a number of properties of Rabex-5, including its coupled monoubiquitination and interaction in vivo with ubiquitinated EGFRs. Structural and biochemical characterization of the UBDs of Rabex-5 revealed that one of them (MIU, motif interacting with ubiquitin) binds to Ub with modes superimposable to those of the UIM (ubiquitin-interacting motif):Ub interaction, although in the opposite orientation, The other UBD, RUZ (Rabex-5 ubiquitin binding zinc finger) binds to a surface of Ub centered on Asp58(Ub) and distinct from the "canonical" Ile44(Ub)-based surface. The two binding surfaces allow Ub to interact simultaneously with different UBDs, thus opening new perspectives in Ub-mediated signaling.	IFOM, I-20139 Milan, Italy; Euopean Inst Oncol, I-20141 Milan, Italy; Univ Milan, I-20122 Milan, Italy	IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO); University of Milan	Di Fiore, PP (corresponding author), IFOM, Via Adamello 16, I-20139 Milan, Italy.	pierpaolo.difiore@ifom-ieo-campus.it; simona.polo@ifom-ieo-campus.it; thomas.schneider@ifom-ieo-campus.it	Schneider, Thomas/B-7442-2011; Confalonieri, Stefano/AAQ-6786-2020; Polo, Simona/P-3509-2014; Di Fiore, Pier Paolo/K-2130-2012; Mapelli, Marina/AAC-7346-2022	Schneider, Thomas/0000-0001-6955-7374; Confalonieri, Stefano/0000-0001-6886-9851; Di Fiore, Pier Paolo/0000-0002-2252-0950; Mapelli, Marina/0000-0001-8502-0649; Murachelli, Andrea Giovanni/0000-0003-2968-8972; Musacchio, Andrea/0000-0003-2362-8784; Polo, Simona/0000-0001-5536-9399				Alam SL, 2004, EMBO J, V23, P1411, DOI 10.1038/sj.emboj.7600114; Barbieri MA, 2003, J BIOL CHEM, V278, P32027, DOI 10.1074/jbc.M304324200; Bienko M, 2005, SCIENCE, V310, P1821, DOI 10.1126/science.1120615; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Davies BA, 2003, J BIOL CHEM, V278, P19826, DOI 10.1074/jbc.M301059200; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; FAZIOLI F, 1992, J BIOL CHEM, V267, P5155; Fisher RD, 2003, J BIOL CHEM, V278, P28976, DOI 10.1074/jbc.M302596200; Frank DJ, 2004, CURR OPIN CELL BIOL, V16, P189, DOI 10.1016/j.ceb.2004.02.001; Hama H, 1999, J BIOL CHEM, V274, P15284, DOI 10.1074/jbc.274.21.15284; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; Karplus K, 1998, BIOINFORMATICS, V14, P846, DOI 10.1093/bioinformatics/14.10.846; Kawasaki M, 2005, GENES CELLS, V10, P639, DOI 10.1111/j.1365-2443.2005.00865.x; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE S, 2006, IN PRESS NAT STRUCT; MATTERA R, 2006, IN PRESS J BIOL CHEM; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Miller SLH, 2004, J BIOL CHEM, V279, P33528, DOI 10.1074/jbc.M313097200; Morris RJ, 2002, ACTA CRYSTALLOGR D, V58, P968, DOI 10.1107/S0907444902005462; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Ohno A, 2005, STRUCTURE, V13, P521, DOI 10.1016/j.str.2005.01.011; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; POLO S, 2003, SCI STKE, pRE17, DOI DOI 10.1126/STKE.2132003RE17; POMILLOS O, 2002, EMBO J, V21, P2397; Prag G, 2003, CELL, V113, P609, DOI 10.1016/S0092-8674(03)00364-7; Prag G, 2005, P NATL ACAD SCI USA, V102, P2334, DOI 10.1073/pnas.0500118102; Raasi S, 2004, J MOL BIOL, V341, P1367, DOI 10.1016/j.jmb.2004.06.057; Reverter D, 2005, NATURE, V435, P687, DOI 10.1038/nature03588; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P195, DOI 10.1107/S0907444901019291; Sessa F, 2005, MOL CELL, V18, P379, DOI 10.1016/j.molcel.2005.03.031; Sheldrick GM, 2002, Z KRISTALLOGR, V217, P644, DOI 10.1524/zkri.217.12.644.20662; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Song J, 2005, J BIOL CHEM, V280, P40122, DOI 10.1074/jbc.M507059200; Sun LJ, 2004, CURR OPIN CELL BIOL, V16, P119, DOI 10.1016/j.ceb.2004.02.005; Sundquist WI, 2004, MOL CELL, V13, P783, DOI 10.1016/S1097-2765(04)00129-7; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; Varadan R, 2004, J BIOL CHEM, V279, P7055, DOI 10.1074/jbc.M309184200; Wang B, 2003, J BIOL CHEM, V278, P20225, DOI 10.1074/jbc.M300459200; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707	52	225	232	2	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 24	2006	124	6					1183	1195		10.1016/j.cell.2006.02.020	http://dx.doi.org/10.1016/j.cell.2006.02.020			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	038RS	16499958	Bronze, Green Accepted			2022-12-28	WOS:000237241400019
J	Fong, LG; Frost, D; Meta, M; Qiao, X; Yang, SH; Coffinier, C; Young, SG				Fong, LG; Frost, D; Meta, M; Qiao, X; Yang, SH; Coffinier, C; Young, SG			A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria	SCIENCE			English	Article							PHASE-I TRIAL; LAMIN-A; TRANSFERASE INHIBITOR; PRELAMIN-A; ZMPSTE24; FARNESYLATION; FIBROBLASTS; COMBINATION; DEFICIENCY; TIPIFARNIB	Progerias are rare genetic diseases characterized by premature aging. Several progeroid disorders are caused by mutations that lead to the accumulation of a lipid-modified (farnesylated) form of prelamin A, a protein that contributes to the structural scaffolding for the cell nucleus. In progeria, the accumulation of farnesyl-prelamin A disrupts this scaffolding, leading to misshapen nuclei. Previous studies have shown that farnesyltransferase inhibitors (FTIs) reverse this cellular abnormality. We tested the efficacy of an FTI (ABT-100) in Zmpste24-deficient mice, a mouse model of progeria. The FTI-treated mice exhibited improved body weight, grip strength, bone integrity, and percent survival at 20 weeks of age. These results suggest that FTIs may have beneficial effects in humans with progeria.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA; Abbott Labs, Abbott Pk, IL 60064 USA; Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94107 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Abbott Laboratories; University of California System; University of California San Francisco	Fong, LG (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA.	lfong@mednet.ucla.edu; sgyoung@mednet.ucla.edu		Young, Stephen/0000-0001-7270-3176	NHLBI NIH HHS [HL76839] Funding Source: Medline; NIAMS NIH HHS [AR050200] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050200] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adjei AA, 2000, CLIN CANCER RES, V6, P2318; Adjei AA, 2003, CLIN CANCER RES, V9, P2520; Agarwal AK, 2003, HUM MOL GENET, V12, P1995, DOI 10.1093/hmg/ddg213; Alsina M, 2004, BLOOD, V103, P3271, DOI 10.1182/blood-2003-08-2764; Bergo MO, 2002, P NATL ACAD SCI USA, V99, P13049, DOI 10.1073/pnas.192460799; Capell BC, 2005, P NATL ACAD SCI USA, V102, P12879, DOI 10.1073/pnas.0506001102; DEBUSK FL, 1972, J PEDIATR-US, V80, P697, DOI 10.1016/S0022-3476(72)80229-4; Dy GK, 2005, CLIN CANCER RES, V11, P1877, DOI 10.1158/1078-0432.CCR-04-1769; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Ferguson D, 2005, CLIN CANCER RES, V11, P3045, DOI 10.1158/1078-0432.CCR-04-2041; Fong LG, 2004, P NATL ACAD SCI USA, V101, P18111, DOI 10.1073/pnas.0408558102; Glynn MW, 2005, HUM MOL GENET, V14, P2959, DOI 10.1093/hmg/ddi326; HENNEKES H, 1994, J CELL SCI, V107, P1019; Izbicka E, 2005, ANTICANCER RES, V25, P3215; Kim ES, 2005, CANCER, V104, P561, DOI 10.1002/cncr.21188; LIN F, 1993, J BIOL CHEM, V268, P16321; Mallampalli MP, 2005, P NATL ACAD SCI USA, V102, P14416, DOI 10.1073/pnas.0503712102; Moulson CL, 2005, J INVEST DERMATOL, V125, P913, DOI 10.1111/j.0022-202X.2005.23846.x; Navarro CL, 2005, HUM MOL GENET, V14, P1503, DOI 10.1093/hmg/ddi159; Shackleton S, 2005, J MED GENET, V42, DOI 10.1136/jmg.2004.029751; Sun JZ, 2003, CANCER RES, V63, P8922; Toth JI, 2005, P NATL ACAD SCI USA, V102, P12873, DOI 10.1073/pnas.0505767102; Yang SH, 2005, P NATL ACAD SCI USA, V102, P10291, DOI 10.1073/pnas.0504641102; Young SG, 2005, J LIPID RES, V46, P2531, DOI 10.1194/jlr.R500011-JLR200	24	243	264	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 17	2006	311	5767					1621	1623		10.1126/science.1124875	http://dx.doi.org/10.1126/science.1124875			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BK	16484451				2022-12-28	WOS:000236029500050
J	Kivelson, MG				Kivelson, MG			Perspective - Does Enceladus govern magnetospheric dynamics at Saturn?	SCIENCE			English	Editorial Material							MAGNETIC-FIELD; PLASMA; IO; INTERCHANGE; INSERTION; ORBIT		Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Kivelson, MG (corresponding author), Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA.	mkivelson@igpp.ucla.edu	Kivelson, Margaret G/I-9019-2012	Kivelson, Margaret G/0000-0003-3859-8581				ACUNA MH, 1983, J GEOPHYS RES-SPACE, V88, P8771, DOI 10.1029/JA088iA11p08771; Brown RH, 2006, SCIENCE, V311, P1425, DOI 10.1126/science.1121031; CONNERNEY JEP, 1983, J GEOPHYS RES-SPACE, V88, P8779, DOI 10.1029/JA088iA11p08779; de Pater I., 2015, PLANETARY SCI; Dougherty MK, 2006, SCIENCE, V311, P1406, DOI 10.1126/science.1120985; Dougherty MK, 2005, SCIENCE, V307, P1266, DOI 10.1126/science.1106098; Espinosa SA, 2003, J GEOPHYS RES-SPACE, V108, DOI 10.1029/2001JA005084; EVIATAR A, 1992, ANN GEOPHYS, V10, P511; Gurnett DA, 2005, SCIENCE, V307, P1255, DOI 10.1126/science.1105356; Hansen CJ, 2006, SCIENCE, V311, P1422, DOI 10.1126/science.1121254; Hill T. W., 1983, PHYSICS JOVIAN MAGNE, P353, DOI DOI 10.1017/CBO9780511564574.012; HILL TW, 1976, PLANET SPACE SCI, V24, P1151, DOI 10.1016/0032-0633(76)90152-5; Jones GH, 2006, SCIENCE, V311, P1412, DOI 10.1126/science.1121011; Jurac S, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015855; Kaiser M. L., 1984, SATURN, P378; Kargel JS, 2006, SCIENCE, V311, P1389, DOI 10.1126/science.1124495; Kivelson MG, 1997, GEOPHYS RES LETT, V24, P2127, DOI 10.1029/97GL02202; Krimigis SM, 2005, SCIENCE, V307, P1270, DOI 10.1126/science.1105978; LECACHEUX A, 1997, PLANETARY RADIO EMIS, V4, P313; LEISNER, 2005, GEOPHYS RES LETT, V32, DOI DOI 10.1029/2005GL022652; NEUBAUER FM, 1980, J GEOPHYS RES-SPACE, V85, P1171, DOI 10.1029/JA085iA03p01171; Paranicas C, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023656; Porco CC, 2006, SCIENCE, V311, P1393, DOI 10.1126/science.1123013; SHEMANSKY DE, 1993, NATURE, V363, P329, DOI 10.1038/363329a0; SOUTHWOOD DJ, 1980, J GEOPHYS RES-SPACE, V85, P5959, DOI 10.1029/JA085iA11p05959; Southwood DJ, 2001, J GEOPHYS RES-SPACE, V106, P30109, DOI 10.1029/2001JA900110; SOUTHWOOD DJ, 2005, AM GEOPH UN FALL M S; Spahn F, 2006, SCIENCE, V311, P1416, DOI 10.1126/science.1121375; Spencer JR, 2006, SCIENCE, V311, P1401, DOI 10.1126/science.1121661; Tokar RL, 2006, SCIENCE, V311, P1409, DOI 10.1126/science.1121061; Waite JH, 2006, SCIENCE, V311, P1419, DOI 10.1126/science.1121290; Young DT, 2005, SCIENCE, V307, P1262, DOI 10.1126/science.1106151	32	26	26	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2006	311	5766					1391	1392		10.1126/science.1124494	http://dx.doi.org/10.1126/science.1124494			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527963				2022-12-28	WOS:000236029400029
J	Bird, SM				Bird, SM			UK statistical indifference to its military casualties in Iraq	LANCET			English	Editorial Material									MRC, Biostat Unit, Cambridge CB2 2SR, England	MRC Biostatistics Unit	Bird, SM (corresponding author), MRC, Biostat Unit, Cambridge CB2 2SR, England.	Sheila.bird@mrc-bsu.cam.ac.uk						Bird SM, 2004, LANCET, V364, P1831, DOI 10.1016/S0140-6736(04)17452-7; BIRD SM, 2006, SCOTSMAN        0204, P24; CHAMBERLAIN G, 2006, SCOTSMAN        0131, P1; *DASA, 1990, GULF CONFL UK GULF V; Horton R, 2004, LANCET, V364, P1831, DOI 10.1016/S0140-6736(04)17451-5; *MIN DEF, OP TEL BRIT FORC; NORTONTAYLOR N, 2006, GUARDIAN        0213, P3; Roberts L, 2004, LANCET, V364, P1857, DOI 10.1016/S0140-6736(04)17441-2; *ROYAL STAT SOC WO, 2005, J ROYAL STAT SOC A, V168, P1; 2006, HANSARD         0213; 2005, BBC NEWS        1208	11	10	10	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 4	2006	367	9512					713	715		10.1016/S0140-6736(06)68281-0	http://dx.doi.org/10.1016/S0140-6736(06)68281-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	020JX	16517258				2022-12-28	WOS:000235906000008
J	Butcher, J; Summerskill, W				Butcher, J; Summerskill, W			The research legacy of 2005	LANCET			English	Editorial Material							RETRACTED SEE; PG 335; ARTICLE; VIRUS		The Lancet, London NW1 7BY, England		Butcher, J (corresponding author), The Lancet, London NW1 7BY, England.			Butcher, James/0000-0001-8546-6093				Hwang WS, 2005, SCIENCE, V308, P1777, DOI 10.1126/science.1112286; Hwang WS, 2004, SCIENCE, V303, P1669, DOI 10.1126/science.1094515; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613; Taubenberger JK, 2005, NATURE, V437, P889, DOI 10.1038/nature04230; Tumpey TM, 2005, SCIENCE, V310, P77, DOI 10.1126/science.1119392	6	2	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 25	2006	367	9511					636	636		10.1016/S0140-6736(06)68243-3	http://dx.doi.org/10.1016/S0140-6736(06)68243-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	016HR	16503449				2022-12-28	WOS:000235611800010
J	Chitty, LS; Kagan, KO; Molina, FS; Waters, JJ; Nicolaides, KH				Chitty, LS; Kagan, KO; Molina, FS; Waters, JJ; Nicolaides, KH			Fetal nuchal translucency scan and early prenatal diagnosis of chromosomal abnormalities by rapid aneuploidy screening: observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DOWNS-SYNDROME; AMNIO-PCR	Objective To investigate an approach for the analysis of samples obtained in screening for trisomy 21 that retains the advantages of quantitative fluorescent polymerase chain reaction (qf-PCR) over full karyotyping and maximises the detection of clinically significant abnormalities. Design Observational study. Setting Tertiary referral centre. Subjects 17 446 pregnancies, from which chorionic villous samples had been taken after assessment of risk for trisomy 21 by measurement of fetal nuchal translucency (NT) thickness at 11 to 13(+6) weeks of gestation. Interventions Analysis of chorionic villous samples by full karyotyping and by qf-PCR for chromosomes 13, 18, 2 1, X, and Y. Main outcome measure Detection of clinically significant chromosomal abnormalities. Results The fetal karyotype was normal in 15 548 (89.1%) cases and abnormal in 1898 (10.9%) cases, including 1722 with a likely clinically significant adverse outcome. Karyotyping all cases would lead to the diagnosis of all clinically significant abnormalities, and a policy of relying entirely on qf-PCR would lead to the diagnosis of 97.9% of abnormalities. An alternative strategy whereby qf-PCR is the main method of analysis and full karyotyping is reserved for those cases with a minimum fetal NT thickness of 4 mm would require full karyotyping in 10.1% of the cases, would identify 99.0% of the significant abnormalities, and would cost 60% less than full karyotyping for all. Conclusions In the diagnosis of chromosomal abnormalities after first trimester screening for trisomy 2 1, a policy of qf-PCR for all samples and karyotyping only if the fetal NT thickness is increased would reduce the economic costs, provide rapid delivery of results, and identify 99% of the clinically significant chromosomal abnormalities.	Kings Coll Hosp London, Sch Med, Harris Birthright Res Ctr Fetal Med, London SE5 9RS, England; Inst Child Hlth, London WC1N 1EH, England; UCLH, London WC1N 1EH, England; Great Ormond St Hosp Sick Children, N E Thames Genet Serv, Cytogenet Lab, London WC1N 3BG, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Nicolaides, KH (corresponding author), Kings Coll Hosp London, Sch Med, Harris Birthright Res Ctr Fetal Med, Denmark Hill, London SE5 9RS, England.	kypros@fetalmedicine.com		Nicolaides, Kypros/0000-0003-1266-0711; Molina, Francisca/0000-0001-9190-5654; chitty, lyn/0000-0002-4857-7138				Adinolfi M, 2001, LANCET, V358, P1030, DOI 10.1016/S0140-6736(01)06229-8; DANIEL A, 1988, CYTOGENETICS MAMMALI, P73; Department of Health, 2003, OUR INH OUR FUT REAL; Evans MI, 1999, HUM REPROD, V14, P1213, DOI 10.1093/humrep/14.5.1213; Grimshaw G M, 2003, Health Technol Assess, V7, P1; Leung WC, 2002, PRENATAL DIAG, V22, P256, DOI 10.1002/pd.314; Levett LJ, 2001, ULTRASOUND OBST GYN, V17, P115, DOI 10.1046/j.1469-0705.2001.00340.x; Mann K, 2001, LANCET, V358, P1057, DOI 10.1016/S0140-6736(01)06183-9; PERTL B, 1994, LANCET, V343, P1197, DOI 10.1016/S0140-6736(94)92404-X; Snijders RJM, 1998, LANCET, V352, P343, DOI 10.1016/S0140-6736(97)11280-6; Souka AP, 2005, AM J OBSTET GYNECOL, V192, P1005, DOI 10.1016/j.ajog.2004.12.093; Verma L, 1998, LANCET, V352, P9, DOI 10.1016/S0140-6736(97)11090-X	12	49	55	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 25	2006	332	7539					452	454		10.1136/bmj.38730.655197.AE	http://dx.doi.org/10.1136/bmj.38730.655197.AE			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	018VM	16476673	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000235792900015
J	Armakolas, A; Klar, AJS				Armakolas, A; Klar, AJS			Cell type regulates selective segregation of mouse chromosome 7 DNA strands in mitosis	SCIENCE			English	Article							STEM-CELLS; MITOTIC RECOMBINATION; COSEGREGATION; CHROMATIDS; DROSOPHILA	After chromosome replication, sister chromatid copies are generally thought to segregate randomly to daughter cells. However, sister chromatids differ in their DNA strands, with each chromatid inheriting one older strand that is paired to a newly synthesized strand. Genetic analysis with a homologous chromosome pair indicated nonrandom chromatid distribution in embryonic stem cells. Biased segregation pattern was also found in all 100 endoderm cells examined, but not in any of the 165 neuroectoderm cells. In contrast, the mesoderm, cardiomyocyte, and pancreatic cells exhibited a random mode of segregation. Strand distribution mechanisms regulated by cell, type may have consequences for cellular differentiation and for evolving strategies for developmental mechanisms.	NCI, Ctr Canc Res, Gene Regulat & Chromosome Biol Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Klar, AJS (corresponding author), NCI, Ctr Canc Res, Gene Regulat & Chromosome Biol Lab, Frederick, MD 21702 USA.	klar@ncifcrf.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC010386, Z01BC010386] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMAKOLAS A, UNPUB; Beumer KJ, 1998, GENETICS, V150, P173; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; ITO K, 1987, CELL, V49, P329, DOI 10.1016/0092-8674(87)90285-6; ITO K, 1988, GENE DEV, V2, P929, DOI 10.1101/gad.2.8.929; Karpowicz P, 2005, J CELL BIOL, V170, P721, DOI 10.1083/jcb.200502073; Klar AJS, 2004, GENETICS, V167, P1833, DOI 10.1534/genetics.104.028217; KLAR AJS, 1994, TRENDS GENET, V10, P392, DOI 10.1016/0168-9525(94)90055-8; LARK KG, 1966, SCIENCE, V154, P1202, DOI 10.1126/science.154.3753.1202; Liu PT, 2002, NAT GENET, V30, P66, DOI 10.1038/ng788; Merok JR, 2002, CANCER RES, V62, P6791; Nelson K, 2003, CELL BIOL INT, V27, P567, DOI 10.1016/S1065-6995(03)00097-0; PIMPINELLI S, 1986, P NATL ACAD SCI USA, V83, P3900, DOI 10.1073/pnas.83.11.3900; Potten CS, 2004, J INVEST DERM SYMP P, V9, P183, DOI 10.1111/j.1087-0024.2004.09305.x; POTTEN CS, 1978, CELL, V15, P899, DOI 10.1016/0092-8674(78)90274-X; Rambhatla L, 2005, CANCER RES, V65, P3155, DOI 10.1158/0008-5472.CAN-04-3161; ROSENBERGER RF, 1968, J BACTERIOL, V96, P1208, DOI 10.1128/JB.96.4.1208-1213.1968; Smith GH, 2005, DEVELOPMENT, V132, P681, DOI 10.1242/dev.01609; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0	19	79	81	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	2006	311	5764					1146	1149		10.1126/science.1120519	http://dx.doi.org/10.1126/science.1120519			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017IU	16497932				2022-12-28	WOS:000235688100047
J	Raskin, DM; Seshadri, R; Pukatzki, SU; Mekalanosl, JJ				Raskin, DM; Seshadri, R; Pukatzki, SU; Mekalanosl, JJ			Bacterial genomics and pathogen evolution	CELL			English	Review							GLOBAL TRANSPOSON MUTAGENESIS; CHOLERAE RTX TOXIN; VIBRIO-CHOLERAE; HELICOBACTER-PYLORI; ESCHERICHIA-COLI; ESSENTIAL GENES; MYCOBACTERIUM-TUBERCULOSIS; STAPHYLOCOCCUS-EPIDERMIDIS; PSEUDOMONAS-AERUGINOSA; VIRULENCE GENES	The availability of hundreds of bacterial genome sequences has altered the study of bacterial pathogenesis, affecting both design of experiments and analysis of results. Comparative genomics and genomic tools have been used to identify virulence factors and genes involved in environmental persistence of pathogens. However, a major stumbling block in the genomics revolution has been the large number of genes with unknown function that have been identified in every organism sequenced to date.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Inst Gen Res, Rockville, MD 20850 USA	Harvard University; Harvard Medical School	Mekalanosl, JJ (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA.	jmekalanos@hms.harvard.edu		Raskin, David/0000-0001-7421-7809				Akada JK, 2003, MICROBIOL-SGM, V149, P1901, DOI 10.1099/mic.0.26129-0; Akerley BJ, 1998, P NATL ACAD SCI USA, V95, P8927, DOI 10.1073/pnas.95.15.8927; Beres SB, 2002, P NATL ACAD SCI USA, V99, P10078, DOI 10.1073/pnas.152298499; Bina J, 2003, P NATL ACAD SCI USA, V100, P2801, DOI 10.1073/pnas.2628026100; Boshoff HIM, 2003, CELL, V113, P183, DOI 10.1016/S0092-8674(03)00270-8; Boyce JD, 2004, EMERG INFECT DIS, V10, P1357, DOI 10.3201/eid1008.031036; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; Chain Patrick, 2003, Briefings in Bioinformatics, V4, P105, DOI 10.1093/bib/4.2.105; Chan K, 2005, INFECT IMMUN, V73, P5438, DOI 10.1128/IAI.73.9.5438-5449.2005; Dobrindt U, 2003, J BACTERIOL, V185, P1831, DOI 10.1128/JB.185.6.1831-1840.2003; Doulatov S, 2004, NATURE, V431, P476, DOI 10.1038/nature02833; Dziejman M, 2005, P NATL ACAD SCI USA, V102, P3465, DOI 10.1073/pnas.0409918102; Dziejman M, 2002, P NATL ACAD SCI USA, V99, P1556, DOI 10.1073/pnas.042667999; Faruque SM, 2003, TRENDS MICROBIOL, V11, P505, DOI 10.1016/j.tim.2003.09.003; Field D, 2005, MICROBIOL-SGM, V151, P2125, DOI 10.1099/mic.0.28006-0; Fitzgerald JR, 2001, P NATL ACAD SCI USA, V98, P8821, DOI 10.1073/pnas.161098098; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Fleischmann RD, 2002, J BACTERIOL, V184, P5479, DOI 10.1128/JB.184.19.5479-5490.2002; Forsyth RA, 2002, MOL MICROBIOL, V43, P1387, DOI 10.1046/j.1365-2958.2002.02832.x; Fortune SM, 2005, P NATL ACAD SCI USA, V102, P10676, DOI 10.1073/pnas.0504922102; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; Fukiya S, 2004, J BACTERIOL, V186, P3911, DOI 10.1128/JB.186.12.3911-3921.2004; Gerdes SY, 2003, J BACTERIOL, V185, P5673, DOI 10.1128/JB.185.19.5673-5684.2003; Gil R, 2004, MICROBIOL MOL BIOL R, V68, P518, DOI 10.1128/MMBR.68.3.518-537.2004; Gill SR, 2005, J BACTERIOL, V187, P2426, DOI 10.1128/JB.187.7.2426-2438.2005; Glass JI, 2006, P NATL ACAD SCI USA, V103, P425, DOI 10.1073/pnas.0510013103; Goodman AL, 2004, DEV CELL, V7, P745, DOI 10.1016/j.devcel.2004.08.020; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; Hiramatsu K, 2001, TRENDS MICROBIOL, V9, P486, DOI 10.1016/S0966-842X(01)02175-8; HOROWITZ NH, 1951, COLD SPRING HARB SYM, V16, P65, DOI 10.1101/SQB.1951.016.01.006; Hutchison CA, 1999, SCIENCE, V286, P2165, DOI 10.1126/science.286.5447.2165; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; Israel DA, 2001, P NATL ACAD SCI USA, V98, P14625, DOI 10.1073/pnas.251551698; Jacobs MA, 2003, P NATL ACAD SCI USA, V100, P14339, DOI 10.1073/pnas.2036282100; Ji YD, 2001, SCIENCE, V293, P2266, DOI 10.1126/science.1063566; Judson N, 2000, NAT BIOTECHNOL, V18, P740, DOI 10.1038/77305; Kalman S, 1999, NAT GENET, V21, P385, DOI 10.1038/7716; Kobayashi K, 2003, P NATL ACAD SCI USA, V100, P4678, DOI 10.1073/pnas.0730515100; LaRocque RC, 2005, INFECT IMMUN, V73, P4488, DOI 10.1128/IAI.73.8.4488-4493.2005; LEUNG KY, 1991, P NATL ACAD SCI USA, V88, P11470, DOI 10.1073/pnas.88.24.11470; Lin W, 1999, P NATL ACAD SCI USA, V96, P1071, DOI 10.1073/pnas.96.3.1071; MAHAN MJ, 1993, SCIENCE, V259, P686, DOI 10.1126/science.8430319; MEJEAN V, 1981, GENE, V15, P289, DOI 10.1016/0378-1119(81)90139-6; Merrell DS, 2002, NATURE, V417, P642, DOI 10.1038/nature00778; Merrell DS, 2003, INFECT IMMUN, V71, P3529, DOI 10.1128/IAI.71.6.3529-3539.2003; Mushegian AR, 1996, P NATL ACAD SCI USA, V93, P10268, DOI 10.1073/pnas.93.19.10268; Nilsson C, 2003, INFECT IMMUN, V71, P6573, DOI 10.1128/IAI.71.11.6573-6581.2003; Paulsen IT, 2003, SCIENCE, V299, P2071, DOI 10.1126/science.1080613; Perna NT, 2001, NATURE, V409, P529, DOI 10.1038/35054089; Posfai G, 1999, NUCLEIC ACIDS RES, V27, P4409, DOI 10.1093/nar/27.22.4409; Pukatzki S, 2006, P NATL ACAD SCI USA, V103, P1528, DOI 10.1073/pnas.0510322103; Rediers H, 2005, MICROBIOL MOL BIOL R, V69, P217, DOI 10.1128/MMBR.69.2.217-261.2005; Rengarajan J, 2004, MOL MICROBIOL, V53, P275, DOI 10.1111/j.1365-2958.2004.04120.x; Rieder G, 2005, CURR OPIN MICROBIOL, V8, P67, DOI 10.1016/j.mib.2004.12.004; Salama NR, 2004, J BACTERIOL, V186, P7926, DOI 10.1128/JB.186.23.7926-7935.2004; Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100; Sassetti CM, 2001, P NATL ACAD SCI USA, V98, P12712, DOI 10.1073/pnas.231275498; Schnappinger D, 2003, J EXP MED, V198, P693, DOI 10.1084/jem.20030846; Seshadri G, 2004, P NATL ACAD SCI USA, V101, P5646, DOI 10.1073/pnas.0307639101; Sheahan KL, 2004, P NATL ACAD SCI USA, V101, P9798, DOI 10.1073/pnas.0401104101; Soberon-Chavez G, 2005, CRIT REV MICROBIOL, V31, P171, DOI 10.1080/10408410591005138; TAYLOR RK, 1987, P NATL ACAD SCI USA, V84, P2833, DOI 10.1073/pnas.84.9.2833; Tettelin H, 2005, P NATL ACAD SCI USA, V102, P13950, DOI 10.1073/pnas.0506758102; van Belkum A, 1999, RES MICROBIOL, V150, P617, DOI 10.1016/S0923-2508(99)00129-1; Vance RE, 2004, P NATL ACAD SCI USA, V101, P2135, DOI 10.1073/pnas.0307308101; Vuong C, 2004, CELL MICROBIOL, V6, P753, DOI 10.1111/j.1462-5822.2004.00401.x; Welch RA, 2002, P NATL ACAD SCI USA, V99, P17020, DOI 10.1073/pnas.252529799; Wolfgang MC, 2003, P NATL ACAD SCI USA, V100, P8484, DOI 10.1073/pnas.0832438100; Xu Q, 2003, P NATL ACAD SCI USA, V100, P1286, DOI 10.1073/pnas.0337479100; Zhu J, 2003, DEV CELL, V5, P647, DOI 10.1016/S1534-5807(03)00295-8	72	100	109	0	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 24	2006	124	4					703	714		10.1016/j.cell.2006.02.002	http://dx.doi.org/10.1016/j.cell.2006.02.002			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	038RO	16497582	Bronze			2022-12-28	WOS:000237240900015
J	Neher, JO				Neher, JO			First response	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Valley Family Med, Renton, WA 98055 USA; Univ Washington, Renton, WA 98055 USA	University of Washington	Neher, JO (corresponding author), Valley Family Med, 3915 Talbot Rd S,Suite 401, Renton, WA 98055 USA.								0	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 21	2006	144	4					301	302		10.7326/0003-4819-144-4-200602210-00014	http://dx.doi.org/10.7326/0003-4819-144-4-200602210-00014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	015HS	16490918				2022-12-28	WOS:000235543100011
J	Edmonds, ME; Foster, AVM				Edmonds, ME; Foster, AVM			ABC of wound healing - Diabetic foot ulcers	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Kings Coll Hosp London, Diabet Foot Clin, London, England	King's College Hospital NHS Foundation Trust; King's College Hospital	Edmonds, ME (corresponding author), Kings Coll Hosp London, Diabet Foot Clin, London, England.							[Anonymous], TYP 2 DIAB PREV MAN; BOULTON A, 2000, FOOT DIABETES; Bowker JH., 2001, LEVIN ONEALS DIABETI, V6th; EDMONDS ME, 2004, PRACTICAL MANUAL DIA; International Working Group on the Diabetic Foot, 2003, INT CONS DIAB FOOT; Veves A, 2002, DIABETIC FOOT MED SU	6	63	64	1	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 18	2006	332	7538					407	410		10.1136/bmj.332.7538.407	http://dx.doi.org/10.1136/bmj.332.7538.407			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	017HZ	16484268	Green Published			2022-12-28	WOS:000235686000024
J	Weiss, MG; Ramakrishna, J				Weiss, MG; Ramakrishna, J			Stigma interventions and research for international health	LANCET			English	Editorial Material							DEPRESSION		Swiss Trop Inst, Dept Publ Hlth & Epidemiol, CH-4002 Basel, Switzerland; Natl Inst Mental Hlth & Neurosci, Dept Hlth Educ, Bangalore 560029, Karnataka, India	University of Basel; Swiss Tropical & Public Health Institute; National Institute of Mental Health & Neurosciences - India	Weiss, MG (corresponding author), Swiss Trop Inst, Dept Publ Hlth & Epidemiol, CH-4002 Basel, Switzerland.	mitchell-g.weiss@unibas.ch						KLEINMAN A, 1995, WRITING MARGINS DISC, pCH7; LANG NG, 1991, HUM ORGAN, V50, P66, DOI 10.17730/humo.50.1.aj57686546256901; Lerner BH, 1996, AM J PUBLIC HEALTH, V86, P257, DOI 10.2105/AJPH.86.2.257; MILLER CT, 2000, SOCIAL PSYCHOL STIGM, pCH9; *NAT I MENT HLTH, 1996, AIDS STIGM CONC FRAM; Radzeviius A., 2021, P POLISH HYDROPOWER; Raguram R, 1996, AM J PSYCHIAT, V153, P1043; Wahl OF, 1999, SCHIZOPHRENIA BULL, V25, P467, DOI 10.1093/oxfordjournals.schbul.a033394; Weiss M.G., 2001, ANTHROPOL MED, V8, P5, DOI [10.1080/13648470120070980, DOI 10.1080/13648470120070980]; Weiss M.G., 2001, ANTHROPOL MED, V8, P71, DOI DOI 10.1080/13648470120063906	10	125	132	0	20	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 11	2006	367	9509					536	538		10.1016/S0140-6736(06)68189-0	http://dx.doi.org/10.1016/S0140-6736(06)68189-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013FF	16473134				2022-12-28	WOS:000235394500038
J	Foster, DJ; Wilson, MA				Foster, DJ; Wilson, MA			Reverse replay of behavioural sequences in hippocampal place cells during the awake state	NATURE			English	Article							SLOW-WAVE SLEEP; MEMORY; MODEL; IMPAIRMENT; EXPERIENCE; NAVIGATION; LESIONS; TASK; RATS	The hippocampus has long been known to be involved in spatial navigational learning in rodents(1,2), and in memory for events in rodents(3,4), primates(5) and humans(6). A unifying property of both navigation and event memory is a requirement for dealing with temporally sequenced information. Reactivation of temporally sequenced memories for previous behavioural experiences has been reported in sleep in rats(7,8). Here we report that sequential replay occurs in the rat hippocampus during awake periods immediately after spatial experience. This replay has a unique form, in which recent episodes of spatial experience are replayed in a temporally reversed order. This replay is suggestive of a role in the evaluation of event sequences in the manner of reinforcement learning models. We propose that such replay might constitute a general mechanism of learning and memory.	MIT, Dept Brain & Cognit Sci, Picower Inst Learning & Memory, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Northwell Health	Foster, DJ (corresponding author), MIT, Dept Brain & Cognit Sci, Picower Inst Learning & Memory, 77 Massachusetts Ave,46-5223, Cambridge, MA 02139 USA.	djfoster@mit.edu						BUZSAKI G, 1986, BRAIN RES, V398, P242, DOI 10.1016/0006-8993(86)91483-6; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; Cichosz P, 1999, CYBERNET SYST, V30, P341, DOI 10.1080/019697299125127; Foster DJ, 2000, HIPPOCAMPUS, V10, P1, DOI 10.1002/(SICI)1098-1063(2000)10:1<1::AID-HIPO1>3.0.CO;2-1; GAFFAN D, 1994, J COGNITIVE NEUROSCI, V6, P305, DOI 10.1162/jocn.1994.6.4.305; Kaelbling LP, 1996, J ARTIF INTELL RES, V4, P237, DOI 10.1613/jair.301; Lee AK, 2002, NEURON, V36, P1183, DOI 10.1016/S0896-6273(02)01096-6; LIN LJ, 1992, MACH LEARN, V8, P293, DOI 10.1007/BF00992699; Louie K, 2001, NEURON, V29, P145, DOI 10.1016/S0896-6273(01)00186-6; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OLTON DS, 1976, J EXP PSYCHOL-ANIM B, V2, P97, DOI 10.1037/0097-7403.2.2.97; PRESS WH, 1992, NUMERICAL RECIPES; RANCK FB, 1973, EXP NEUROL, V42, P461; REYNOLDS S, 2002, CSRP021 BIRM U; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Siapas AG, 1998, NEURON, V21, P1123, DOI 10.1016/S0896-6273(00)80629-7; Steele RJ, 1999, HIPPOCAMPUS, V9, P118, DOI 10.1002/(SICI)1098-1063(1999)9:2<118::AID-HIPO4>3.0.CO;2-8; Stickgold R, 2000, J COGNITIVE NEUROSCI, V12, P246, DOI 10.1162/089892900562075; Sutton R. S., 1988, Machine Learning, V3, P9, DOI 10.1023/A:1022633531479; SUTTON RS, 1994, P 8 YAL WORKSH AD LE, P31; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520	24	974	1001	0	87	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2006	440	7084					680	683		10.1038/nature04587	http://dx.doi.org/10.1038/nature04587			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	026OY	16474382				2022-12-28	WOS:000236350400046
J	Cassell, MM; Halperin, DT; Shelton, JD; Stanton, D				Cassell, MM; Halperin, DT; Shelton, JD; Stanton, D			HIV and risk behaviour - Risk compensation: the Achilles' heel of innovations in HIV prevention?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ACTIVE ANTIRETROVIRAL THERAPY; CONDOM USE; PARTNER REDUCTION; MALE CIRCUMCISION; TRANSMISSION; POPULATION; AVAILABILITY; INFECTION; HIV/AIDS; RAKAI		US Agcy Int Dev, Off HIV AIDS, Washington, DC 20523 USA; US Agcy Int Dev, Off Populat & Reprod Hlth, Washington, DC 20523 USA; US Agcy Int Dev, So African Reg HIV AIDS Program, Mbabane, Eswatini	United States Agency for International Development (USAID); United States Agency for International Development (USAID)	Cassell, MM (corresponding author), US Agcy Int Dev, Off HIV AIDS, Washington, DC 20523 USA.	mcassell@usaid.gov						Ahmed S, 2001, AIDS, V15, P2171, DOI 10.1097/00002030-200111090-00013; AHMED S, 2003, POP ASS AM ANN M MAY; Allen T., 2004, Journal of International Development, V16, P1141, DOI 10.1002/jid.1168; Autier P, 1998, JNCI-J NATL CANCER I, V90, P1873, DOI 10.1093/jnci/90.24.1873; Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298; Blower Sally, 2003, Current Drug Targets - Infectious Disorders, V3, P345, DOI 10.2174/1568005033480999; Chin-Hong PV, 2005, JAIDS-J ACQ IMM DEF, V40, P463, DOI 10.1097/01.qai.0000162238.93988.0c; COATES TJ, 2005, JOHANNESBURG ST 1031; COSTELLO D, 2005, LOS ANGELES TIM 1219; Crepaz N, 2004, JAMA-J AM MED ASSOC, V292, P224, DOI 10.1001/jama.292.2.224; da Silva CGM, 2005, AIDS, V19, pS31, DOI 10.1097/01.aids.0000191488.77038.bb; Dilley JW, 2003, AIDS CARE, V15, P27, DOI 10.1080/0954012021000039734; Dukers NHTM, 2001, AIDS, V15, P369, DOI 10.1097/00002030-200102160-00010; Foss AM, 2003, AIDS, V17, P1227, DOI 10.1097/00002030-200305230-00015; Glanz K., 2002, HLTH BEHAV THEORY RE; Global HIV Prevention Working Group, 2004, HIV PREV ER EXP TREA; Gray RH, 2003, AIDS, V17, P1941, DOI 10.1097/00002030-200309050-00013; GREEN EC, IN PRESS AIDS BEHAV; Green Edward, 2003, RETHINKING AIDS PREV; Gregson S, 2006, SCIENCE, V311, P664, DOI 10.1126/science.1121054; Gremy I, 2004, AIDS, V18, P805, DOI [10.1097/01.aids.0000111390.02002.f4, 10.1097/00002030-200403260-00013]; Halperin DT, 2004, LANCET, V364, P1913, DOI 10.1016/S0140-6736(04)17487-4; Hearst N, 2004, STUD FAMILY PLANN, V35, P39, DOI 10.1111/j.1728-4465.2004.00004.x; Jones R, 2005, BMJ-BRIT MED J, V331, P1285, DOI 10.1136/bmj.331.7528.1285; Kajubi P, 2005, JAIDS-J ACQ IMM DEF, V40, P77, DOI 10.1097/01.qai.0000157391.63127.b2; *MEAS DHS ORC MACR, 2004, HIV AIDS IND COUNTR; Porter K, 2001, BRIT MED J, V322, P1087, DOI 10.1136/bmj.322.7294.1087; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Reynolds SJ, 2004, LANCET, V363, P1039, DOI 10.1016/S0140-6736(04)15840-6; Richens J, 2000, LANCET, V355, P400, DOI 10.1016/S0140-6736(99)09109-6; RUSSELL S, 2004, SAN FRANCISCO C 1201; Shelton JD, 2006, PLOS MED, V3, P137, DOI 10.1371/journal.pmed.0030065; Shelton JD, 2004, BMJ-BRIT MED J, V328, P891, DOI 10.1136/bmj.328.7444.891; Stolte IG, 2004, AIDS, V18, P303, DOI 10.1097/00002030-200401230-00021; Stoneburner RL, 2004, SCIENCE, V304, P714, DOI 10.1126/science.1093166; Tun W, 2003, AIDS, V17, P1953, DOI 10.1097/00002030-200309050-00014; *UNAIDS, AIDS EP UPD DEC 2005; USAID/AIDSMark, 2003, MAL CIRC CURR EP FIE; van der Straten A, 2000, AIDS, V14, pF47, DOI 10.1097/00002030-200003100-00003; Weiss HA, 2000, AIDS, V14, P2361, DOI 10.1097/00002030-200010200-00018; Wilson D, 2004, BRIT MED J, V328, P848, DOI 10.1136/bmj.328.7444.848	41	280	284	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 11	2006	332	7541					605	607		10.1136/bmj.332.7541.605	http://dx.doi.org/10.1136/bmj.332.7541.605			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	026CN	16528088	Green Published			2022-12-28	WOS:000236314400023
J	Broadhead, R; Dawe, HR; Farr, H; Griffiths, S; Hart, SR; Portman, N; Shaw, MK; Ginger, ML; Gaskell, SJ; McKean, PG; Gull, K				Broadhead, R; Dawe, HR; Farr, H; Griffiths, S; Hart, SR; Portman, N; Shaw, MK; Ginger, ML; Gaskell, SJ; McKean, PG; Gull, K			Flagellar motility is required for the viability of the bloodstream trypanosome	NATURE			English	Article							PROTEOMIC ANALYSIS; PARAFLAGELLAR ROD; BRUCEI; GENE; PROTEIN; CILIA; IDENTIFICATION; EXPRESSION; GENOMICS; PROTOZOA	The 9+2 microtubule axoneme of flagella and cilia represents one of the most iconic structures built by eukaryotic cells and organisms. Both unity and diversity are present among cilia and flagella on the evolutionary as well as the developmental scale. Some cilia are motile, whereas others function as sensory organelles and can variously possess 9+2 and 9+0 axonemes and other associated structures(1). How such unity and diversity are reflected in molecular repertoires is unclear. The flagellated protozoan parasite Trypanosoma brucei is endemic in sub-Saharan Africa, causing devastating disease in humans and other animals(2). There is little hope of a vaccine for African sleeping sickness and a desperate need for modern drug therapies(3). Here we present a detailed proteomic analysis of the trypanosome flagellum. RNA interference (RNAi)-based interrogation of this proteome provides functional insights into human ciliary diseases and establishes that flagellar function is essential to the bloodstream-form trypanosome. We show that RNAi-mediated ablation of various proteins identified in the trypanosome flagellar proteome leads to a rapid and marked failure of cytokinesis in bloodstream-form ( but not procyclic insect-form) trypanosomes, suggesting that impairment of flagellar function may provide a method of disease control. A postgenomic meta-analysis, comparing the evolutionarily ancient trypanosome with other eukaryotes including humans, identifies numerous trypanosome-specific flagellar proteins, suggesting new avenues for selective intervention.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Lancaster, Dept Biol Sci, Lancaster LA1 4YQ, England; Univ Manchester, Sch Chem, Michael Barber Ctr Mass Spectrometry, Manchester M60 1QD, Lancs, England	University of Oxford; Lancaster University; University of Manchester	Gull, K (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	keith.gull@path.ox.ac.uk		Ginger, Michael/0000-0002-9643-8482; McKean, Paul Gerard/0000-0002-0445-0741; Portman, Neil/0000-0003-0248-0258; Hart, Sarah/0000-0003-0521-6284	Biotechnology and Biological Sciences Research Council [EGH17741] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Afzelius BA, 2004, J PATHOL, V204, P470, DOI 10.1002/path.1652; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Avidor-Reiss T, 2004, CELL, V117, P527, DOI 10.1016/S0092-8674(04)00412-X; Bastin P, 1998, NATURE, V391, P548, DOI 10.1038/35300; Bastin P, 2000, J CELL SCI, V113, P3321; Briggs LJ, 2004, CURR BIOL, V14, pR611, DOI 10.1016/j.cub.2004.07.041; Chodhari R, 2004, Paediatr Respir Rev, V5, P69, DOI 10.1016/j.prrv.2003.09.005; Davy BE, 2003, HUM MOL GENET, V12, P1163, DOI 10.1093/hmg/ddg122; Field MC, 2004, TRAFFIC, V5, P905, DOI 10.1111/j.1600-0854.2004.00234.x; Gadelha C, 2005, EUKARYOT CELL, V4, P516, DOI 10.1128/EC.4.3.516-525.2005; Hill KL, 2003, EUKARYOT CELL, V2, P200, DOI 10.1128/EC.2.2.200-208.2003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li JB, 2004, CELL, V117, P541, DOI 10.1016/S0092-8674(04)00450-7; Liska F, 2003, FOLIA BIOL-PRAGUE, V49, P129; Lorenzetti D, 2004, P NATL ACAD SCI USA, V101, P8402, DOI 10.1073/pnas.0401832101; Moreira-Leite FF, 2001, SCIENCE, V294, P610, DOI 10.1126/science.1063775; Ostrowski LE, 2002, MOL CELL PROTEOMICS, V1, P451, DOI 10.1074/mcp.M200037-MCP200; Padma P, 2003, MOL BIOL CELL, V14, P774, DOI 10.1091/mbc.02-06-0089; Pazour GJ, 2005, J CELL BIOL, V170, P103, DOI 10.1083/jcb.200504008; ROBINSON D, 1991, METHOD ENZYMOL, V196, P285; SHERWIN T, 1989, PHILOS T R SOC B, V323, P573, DOI 10.1098/rstb.1989.0037; Smith JC, 2005, J PROTEOME RES, V4, P909, DOI 10.1021/pr050013h; Sternberg JM, 2004, PARASITE IMMUNOL, V26, P469, DOI 10.1111/j.0141-9838.2004.00731.x; Steverding D, 2005, EXPERT OPIN INV DRUG, V14, P939, DOI 10.1517/13543784.14.8.939; Sun ZX, 2004, DEVELOPMENT, V131, P4085, DOI 10.1242/dev.01240; Tam LW, 2002, CELL MOTIL CYTOSKEL, V51, P197, DOI 10.1002/cm.10023; Wickstead B, 2002, MOL BIOCHEM PARASIT, V125, P211, DOI 10.1016/S0166-6851(02)00238-4; WIRTZ E, 1995, SCIENCE, V268, P1179, DOI 10.1126/science.7761835; WOODWARD R, 1990, J CELL SCI, V95, P49	29	368	371	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	2006	440	7081					224	227		10.1038/nature04541	http://dx.doi.org/10.1038/nature04541			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019MC	16525475	Bronze			2022-12-28	WOS:000235839500049
J	Chang, TT; Gish, RG; de Man, R; Gadano, A; Sollano, J; Chao, YC; Lok, AS; Han, KH; Goodman, Z; Zhu, J; Cross, A; DeHertogh, D; Wilber, R; Colonno, R; Apelian, D				Chang, TT; Gish, RG; de Man, R; Gadano, A; Sollano, J; Chao, YC; Lok, AS; Han, KH; Goodman, Z; Zhu, J; Cross, A; DeHertogh, D; Wilber, R; Colonno, R; Apelian, D		BEHoLD A1463022 Study Grp	A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	14th Biennial Meeting of the Asian-Pacific-Association-for-the-Study-of-the-Liver	DEC 14, 2004	New Delhi, INDIA	Asian Pacific Assoc Study Liver			HEPATOCELLULAR-CARCINOMA; ADEFOVIR DIPIVOXIL; VIRUS-INFECTION; DNA LEVEL; THERAPY; EMERGENCE; RESISTANT; SUPERIOR; EFFICACY; TRIALS	BACKGROUND: Entecavir is a potent and selective guanosine analogue with significant activity against hepatitis B virus (HBV). METHODS: In this phase 3, double-blind trial, we randomly assigned 715 patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B who had not previously received a nucleoside analogue to receive either 0.5 mg of entecavir or 100 mg of lamivudine once daily for a minimum of 52 weeks. The primary efficacy end point was histologic improvement (a decrease by at least two points in the Knodell necroinflammatory score, without worsening of fibrosis) at week 48. Secondary end points included a reduction in the serum HBV DNA level, HBeAg loss and seroconversion, and normalization of the alanine aminotransferase level. RESULTS: Histologic improvement after 48 weeks occurred in 226 of 314 patients in the entecavir group (72 percent) and 195 of 314 patients in the lamivudine group (62 percent, P=0.009). More patients in the entecavir group than in the lamivudine group had undetectable serum HBV DNA levels according to a polymerase-chain-reaction assay (67 percent vs. 36 percent, P<0.001) and normalization of alanine aminotransferase levels (68 percent vs. 60 percent, P=0.02). The mean reduction in serum HBV DNA from baseline to week 48 was greater with entecavir than with lamivudine (6.9 vs. 5.4 log [on a base-10 scale] copies per milliliter, P<0.001). HBeAg seroconversion occurred in 21 percent of entecavir-treated patients and 18 percent of those treated with lamivudine (P=0.33). No viral resistance to entecavir was detected. Safety was similar in the two groups. CONCLUSIONS: Among patients with HBeAg-positive chronic hepatitis B, the rates of histologic, virologic, and biochemical improvement are significantly higher with entecavir than with lamivudine. The safety profile of the two agents is similar, and there is no evidence of viral resistance to entecavir.	Natl Cheng Kung Univ, Coll Med, Tainan 70101, Taiwan; Calif Pacific Med Ctr, San Francisco, CA USA; Univ Rotterdam Hosp, Rotterdam, Netherlands; Univ Santo Tomas, Manila, Philippines; Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina; Tri Serv Gen Hosp, Taipei, Taiwan; Univ Michigan, Ann Arbor, MI 48109 USA; Yonsei Univ, Coll Med, Severance Hosp, Seoul, South Korea; Armed Forces Inst Pathol, Washington, DC 20306 USA; Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA; Univ Connecticut, Farmington, CT USA; GlobeImmune, Louisville, CO USA	National Cheng Kung University; California Pacific Medical Center; Erasmus University Rotterdam; Erasmus MC; University of Santo Tomas; Hospital Italiano de Buenos Aires; University of Buenos Aires; Tri-Service General Hospital; University of Michigan System; University of Michigan; Yonsei University; Yonsei University Health System; United States Department of Defense; Bristol-Myers Squibb; University of Connecticut	Chang, TT (corresponding author), Natl Cheng Kung Univ Hosp, Dept Internal Med, 138 Sheng Li Rd, Tainan 704, Taiwan.	ttchang@mail.ncku.edu.tw	Rafalskiy, Vladimir V/G-3172-2013; Chang, Ting-Tsung/B-4306-2009; Lok, Anna/B-8292-2009; Gish, Robert/B-3605-2018	Rafalskiy, Vladimir V/0000-0002-2503-9580; Gish, Robert/0000-0001-6306-3189; Chao, You-Chen/0000-0002-8831-2265; Yang, Shuman/0000-0002-9638-0890				Ayres A, 2003, J CLIN VIROL, V27, P111, DOI 10.1016/S1386-6532(02)00167-1; Chang TT, 2005, GASTROENTEROLOGY, V129, P1198, DOI 10.1053/j.gastro.2005.06.055; Chang TT, 2004, J GASTROEN HEPATOL, V19, P1276, DOI 10.1111/j.1440-1746.2004.03428.x; Chen CJ, 2006, JAMA-J AM MED ASSOC, V295, P65, DOI 10.1001/jama.295.1.65; Colonno RJ, 2001, J INFECT DIS, V184, P1236, DOI 10.1086/324003; Dienstag JL, 1999, NEW ENGL J MED, V341, P1256, DOI 10.1056/NEJM199910213411702; Dienstag JL, 2003, GASTROENTEROLOGY, V124, P105, DOI 10.1053/gast.2003.50013; Dunnett CW, 1996, STAT MED, V15, P1729; Ghany MG, 2000, HEPATOLOGY, V32, p376A, DOI 10.1053/jhep.2000.17912; Goodman Z., 1999, Journal of Hepatology, V30, P59; Hadziyannis SJ, 2005, NEW ENGL J MED, V352, P2673, DOI 10.1056/NEJMoa042957; Innaimo SF, 1997, ANTIMICROB AGENTS CH, V41, P1444, DOI 10.1128/AAC.41.7.1444; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KROGSGAARD K, 1994, J HEPATOL, V21, P646, DOI 10.1016/S0168-8278(94)80114-2; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Lai CL, 2002, GASTROENTEROLOGY, V123, P1831, DOI 10.1053/gast.2002.37058; Lau GKK, 2005, NEW ENGL J MED, V352, P2682, DOI 10.1056/NEJMoa043470; Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406; Leung NWY, 2001, HEPATOLOGY, V33, P1527, DOI 10.1053/jhep.2001.25084; Liaw YF, 1999, HEPATOLOGY, V30, P567, DOI 10.1002/hep.510300221; Liaw YF, 2003, J GASTROEN HEPATOL, V18, P239, DOI 10.1046/j.1440-1746.2003.03037.x; Liaw YF, 2000, GASTROENTEROLOGY, V119, P172, DOI 10.1053/gast.2000.8559; Liaw YF, 2004, NEW ENGL J MED, V351, P1521, DOI 10.1056/NEJMoa033364; Liaw Yun-Fan, 2001, Antiviral Chemistry and Chemotherapy, V12, P67; Marcellin P, 2003, NEW ENGL J MED, V348, P808, DOI 10.1056/NEJMoa020681; MARCELLIN P, 2004, HEPATOLOGY SU, V40, pA665, DOI DOI 10.1002/HEP.20257; Mutimer D, 2001, J CLIN VIROL, V21, P239, DOI 10.1016/S1386-6532(00)00166-9; Sherman M, 2004, HEPATOLOGY, V40, p664A; Tenney DJ, 2004, ANTIMICROB AGENTS CH, V48, P3498, DOI 10.1128/AAC.48.9.3498-3507.2004; *WHO, 2000, WHO204; Yu MW, 2005, JNCI-J NATL CANCER I, V97, P265, DOI 10.1093/jnci/dji043	31	1068	1168	0	62	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 9	2006	354	10					1001	1010		10.1056/NEJMoa051285	http://dx.doi.org/10.1056/NEJMoa051285			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	019FY	16525137				2022-12-28	WOS:000235822200004
J	Lilford, R; Girling, A; Stevens, A; Almasri, A; Mohammed, MA; Braunholtz, D				Lilford, R; Girling, A; Stevens, A; Almasri, A; Mohammed, MA; Braunholtz, D			Adjusting for treatment refusal in rationing decisions	BRITISH MEDICAL JOURNAL			English	Editorial Material							PROSTATE		Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England; Univ Aberdeen, Gates Fdn, Aberdeen, Scotland	University of Birmingham; University of Birmingham; University of Aberdeen	Lilford, R (corresponding author), Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England.	R.J.Lilford@bham.ac.uk	Girling, Alan J/A-7843-2012	Stevens, Andrew/0000-0003-2079-3397; Girling, Alan/0000-0003-2022-045X	Engineering and Physical Sciences Research Council [GR/S29874/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		BEKKER H, 1999, HLTH TECHNOL ASSESS, V3; CHADWICK DJ, 1991, LANCET, V338, P613; DAVIES SC, 2000, HEALTH TECHNOL ASSES, V4, P34; Hundrup YA, 2002, SCAND J PUBLIC HEALT, V30, P47, DOI 10.1080/140349401753481583; KIRBY RS, 1994, BRIT J UROL, V74, P64, DOI 10.1111/j.1464-410X.1994.tb16549.x; Lilford RJ, 1995, J ROY SOC MED, V88, P552; Metcalfe KA, 2005, FAM CANCER, V4, P97, DOI 10.1007/s10689-005-4215-3; Ryan M, 2001, HLTH TECHNOL ASSESS, V5; THORNTON JG, 1995, BMJ-BRIT MED J, V311, P1127, DOI 10.1136/bmj.311.7013.1127; *US C, 1995, COSTS EFF PROST CANC; Zeelenberg M, 1999, J BEHAV DECIS MAKING, V12, P93, DOI 10.1002/(SICI)1099-0771(199906)12:2<93::AID-BDM311>3.0.CO;2-S	11	2	2	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 4	2006	332	7540					542	544		10.1136/bmj.332.7540.542	http://dx.doi.org/10.1136/bmj.332.7540.542			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	023WB	16513714	Green Published			2022-12-28	WOS:000236155800021
J	Schwenk, TL				Schwenk, TL			You can't unring a bell	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												tschwenk@umich.edu							0	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	2006	295	9					977	978		10.1001/jama.295.9.977	http://dx.doi.org/10.1001/jama.295.9.977			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	016XJ	16507788				2022-12-28	WOS:000235656600001
J	Pais, MS; Bissell, S				Pais, MS; Bissell, S			Overview and implementation of the UN Convention on the Rights of the Child	LANCET			English	Editorial Material									UNICEF, Innocenti Res Ctr, I-50122 Florence, Italy		Bissell, S (corresponding author), UNICEF, Innocenti Res Ctr, Piazza SS Annunziata 12, I-50122 Florence, Italy.	sbissell@unicef.org							0	24	24	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 25	2006	367	9511					689	690						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	016HR	16503467				2022-12-28	WOS:000235611800033
J	Sharp, D				Sharp, D			Bovine tuberculosis and badger blame	LANCET			English	Editorial Material							MYCOBACTERIUM-BOVIS; MELES-MELES; CATTLE; INFECTION; DISEASE; IMPACT		The Lancet, London NW1 7BY, England		Sharp, D (corresponding author), The Lancet, London NW1 7BY, England.							Ayele WY, 2004, INT J TUBERC LUNG D, V8, P924; CLIFTONHADLEY RS, 1995, EPIDEMIOL INFECT, V114, P179, DOI 10.1017/S0950268800052031; Corner LAL, 2006, VET MICROBIOL, V112, P303, DOI 10.1016/j.vetmic.2005.11.015; Delahay RJ, 2002, VET J, V164, P90, DOI 10.1053/tvjl.2001.0667; DELARUADOMENECH R, 2005, TUBERCULOSIS EDINB, DOI DOI 10.1016/J.TUBE.2005.05; Donnelly CA, 2006, NATURE, V439, P843, DOI 10.1038/nature04454; Donnelly CA, 2003, NATURE, V426, P834, DOI 10.1038/nature02192; Esteban J, 2005, CLIN MICROBIOL INFEC, V11, P840, DOI 10.1111/j.1469-0691.2005.01225.x; Garnett BT, 2005, APPL ANIM BEHAV SCI, V94, P331, DOI 10.1016/j.applanim.2005.02.013; Griffin JM, 2005, PREV VET MED, V67, P237, DOI 10.1016/j.prevetmed.2004.10.009; HANCOX M, 2002, MICROBIOL TODAY, V29, P166; Hope JC, 2005, EXPERT REV VACCINES, V4, P891, DOI 10.1586/14760584.4.6.891; Krebs J., 1997, PB3423 HMSO; LEFEVRE AM, IMPACT LOCALISED REA; O Mairtin D, 1998, PREV VET MED, V34, P47, DOI 10.1016/S0167-5877(97)00067-6; Prasad HK, 2005, TUBERCULOSIS, V85, P421, DOI 10.1016/j.tube.2005.08.005; Reynolds D, 2006, VET MICROBIOL, V112, P119, DOI 10.1016/j.vetmic.2005.11.042; Roper TJ, 2003, NATURE, V426, P782, DOI 10.1038/nature02219; Smith GC, 2007, VET J, V173, P302, DOI 10.1016/j.tvjl.2005.11.017; White PCL, 2004, PREV VET MED, V63, P1, DOI 10.1016/j.prevetmed.2004.02.003; WILSMORE T, 2005, REV INT EVIDENCE INT; Winters A., 2005, Morbidity and Mortality Weekly Report, V54, P605	22	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 25	2006	367	9511					631	633		10.1016/S0140-6736(06)68240-8	http://dx.doi.org/10.1016/S0140-6736(06)68240-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	016HR	16503446				2022-12-28	WOS:000235611800007
J	Waterston, T; Davies, R				Waterston, T; Davies, R			The convention on the rights of the child	LANCET			English	Editorial Material									Newcastle Gen Hosp, Community Paediat Dept, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; The Lancet, London NW1 7BY, England	Newcastle General Hospital	Waterston, T (corresponding author), Newcastle Gen Hosp, Community Paediat Dept, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	rachael.davies@lancet.com						Horton R, 2006, LANCET, V367, P3, DOI 10.1016/S0140-6736(06)67899-9; *INT I CHILD RIGHT, 2006, STAT REP PRES UN COM; Lansdown G, 1996, BRIT MED J, V313, P1565, DOI 10.1136/bmj.313.7072.1565; Waterston T, 2005, ARCH DIS CHILD, V90, P171, DOI 10.1136/adc.2004.064899	4	1	1	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 25	2006	367	9511					635	635		10.1016/S0140-6736(06)68242-1	http://dx.doi.org/10.1016/S0140-6736(06)68242-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	016HR	16503448				2022-12-28	WOS:000235611800009
J	Freeman, KC				Freeman, KC			Sorting out the colors of globular clusters	SCIENCE			English	Editorial Material								The colors of the stars in globular clusters fall into two groups. Originally thought to result from stars with different ages, the colors can now be explained by the stars' composition.	Australian Natl Univ, Res Sch Astron & Astrophys, Canberra, ACT 2611, Australia	Australian National University	Freeman, KC (corresponding author), Australian Natl Univ, Res Sch Astron & Astrophys, Canberra, ACT 2611, Australia.	kcf@mso.anu.edu.au		Freeman, Kenneth/0000-0001-6280-1207				ASHMAN KM, 1992, ASTROPHYS J, V384, P50, DOI 10.1086/170850; Yoon SJ, 2006, SCIENCE, V311, P1129, DOI 10.1126/science.1122294; ZEPF SE, 1995, ASTROPHYS J, V443, P570, DOI 10.1086/175549	3	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	2006	311	5764					1105	1106		10.1126/science.1123992	http://dx.doi.org/10.1126/science.1123992			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017IU	16497919				2022-12-28	WOS:000235688100032
J	Birkmeyer, NJO; Birkmeyer, JD				Birkmeyer, NJO; Birkmeyer, JD			Strategies for improving surgical quality - Should payers reward excellence or effort?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PERFORMANCE REPORTS; HOSPITAL QUALITY; CARE; MORTALITY; VOLUME; IMPROVEMENT; SURGERY; BENEFITS; IMPACT		Univ Michigan, Dept Surg, Michigan Surg Collaborat Outcomes Res & Evaluat, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Birkmeyer, NJO (corresponding author), Univ Michigan, Dept Surg, Michigan Surg Collaborat Outcomes Res & Evaluat, Ann Arbor, MI 48109 USA.							ADLER AG, 2004, MANAGED CARE     DEC; AVERY S, 2004, NEWS OBSERVER    SEP; BIRKMEYER J, IN PRESS ANN SURG; Birkmeyer JD, 2003, NEW ENGL J MED, V349, P2117, DOI 10.1056/NEJMsa035205; Birkmeyer JD, 2004, SURGERY, V135, P569, DOI 10.1016/j.surg.2004.03.004; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; Birkmeyer NJO, 2005, SURGERY, V138, P815, DOI 10.1016/j.surg.2005.06.037; Chassin MR, 1996, NEW ENGL J MED, V334, P394, DOI 10.1056/NEJM199602083340611; Daley J, 2002, SURGERY, V131, P16, DOI 10.1067/msy.2002.120237; Darr Kurt, 2003, Hosp Top, V81, P30; de Brantes Francois, 2004, Am Heart Hosp J, V2, P170, DOI 10.1111/j.1541-9215.2004.03322.x; DEVERS K, 2004, 77 CTR STUD HLTH SYS; Dimick JB, 2004, J AM COLL SURGEONS, V199, P531, DOI 10.1016/j.jamcollsurg.2004.05.276; Dimick JB, 2004, JAMA-J AM MED ASSOC, V292, P847, DOI 10.1001/jama.292.7.847; DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969; DOYLE E, 2005, TODAYS HOSP      APR; Dudley RA, 2000, JAMA-J AM MED ASSOC, V283, P1159, DOI 10.1001/jama.283.9.1159; DUNN P, 2005, HOSP PERFORMANCE MEA; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; GALVIN R, 2005, DEFICIENCY WILL AMBI; Galvin RS, 2005, HEALTH AFFAIR, V24, P228, DOI 10.1377/hlthaff.24.1.228; GARNESKI S, 2005, AM COLL SURGEONS BLU; GAWANDE A, 2004, NEW YORKER      1206, P81; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; Hannan EL, 2005, MED CARE, V43, P726, DOI 10.1097/01.mlr.0000167802.27044.44; *HARV MED SCH DEP, 2004, TECHN REP AD COR ART; Hibbard JH, 2003, HEALTH AFFAIR, V22, P84, DOI 10.1377/hlthaff.22.2.84; Hibbard JH, 2005, HEALTH AFFAIR, V24, P1150, DOI 10.1377/hlthaff.24.4.1150; Jencks SF, 2003, JAMA-J AM MED ASSOC, V289, P305, DOI 10.1001/jama.289.3.305; Jencks SF, 2002, JAMA-J AM MED ASSOC, V289, P2649; Jha AK, 2005, NEW ENGL J MED, V353, P265, DOI 10.1056/NEJMsa051249; Jones RS, 2004, ANN SURG, V240, P395, DOI 10.1097/01.sla.0000136939.87012.05; Khuri SF, 2002, ARCH SURG-CHICAGO, V137, P20, DOI 10.1001/archsurg.137.1.20; Lee TH, 2004, NEW ENGL J MED, V350, P2409, DOI 10.1056/NEJMsb041193; Mannion R, 2002, J EVAL CLIN PRACT, V8, P215, DOI 10.1046/j.1365-2753.2002.00331.x; Marshall MN, 2000, JAMA-J AM MED ASSOC, V283, P1866, DOI 10.1001/jama.283.14.1866; Mehrotra A, 2003, HEALTH AFFAIR, V22, P60, DOI 10.1377/hlthaff.22.2.60; MOSCUCCI M, IN PRESS CIRCULATION; MOSCUCCI M, 2003, AM HEART ASS SCI SES; Moscucci Mauro, 2002, J Interv Cardiol, V15, P381, DOI 10.1111/j.1540-8183.2002.tb01071.x; Narins CR, 2005, ARCH INTERN MED, V165, P83, DOI 10.1001/archinte.165.1.83; Nelson EC, 2005, JT COMM J QUAL PATIE, V31, P573, DOI 10.1016/S1553-7250(05)31075-0; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; Omoigui NA, 1996, CIRCULATION, V93, P27, DOI 10.1161/01.CIR.93.1.27; Romano PS, 2004, MED CARE, V42, P367, DOI 10.1097/01.mlr.0000118872.33251.11; Rosenthal MB, 2004, HEALTH AFFAIR, V23, P127, DOI 10.1377/hlthaff.23.2.127; Schneider EC, 1998, JAMA-J AM MED ASSOC, V279, P1638, DOI 10.1001/jama.279.20.1638; Sheikh K, 2003, MED CARE, V41, P1111, DOI 10.1097/01.MLR.0000088085.61714.AE; Werner RM, 2005, JAMA-J AM MED ASSOC, V293, P1239, DOI 10.1001/jama.293.10.1239; Wibe A, 2003, Colorectal Dis, V5, P471, DOI 10.1046/j.1463-1318.2003.00506.x; Wibe A, 2002, DIS COLON RECTUM, V45, P857, DOI 10.1007/s10350-004-6317-7; Zhan CL, 2003, JAMA-J AM MED ASSOC, V290, P1868, DOI 10.1001/jama.290.14.1868; 2004, LEAPFROG GROUP FACT	53	124	124	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 23	2006	354	8					864	870		10.1056/NEJMsb053364	http://dx.doi.org/10.1056/NEJMsb053364			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014CL	16495401				2022-12-28	WOS:000235456200014
J	Sharpee, TO; Sugihara, H; Kurgansky, AV; Rebrik, SP; Stryker, MP; Miller, KD				Sharpee, TO; Sugihara, H; Kurgansky, AV; Rebrik, SP; Stryker, MP; Miller, KD			Adaptive filtering enhances information transmission in visual cortex	NATURE			English	Article							LATERAL GENICULATE-NUCLEUS; CONTRAST GAIN-CONTROL; RECEPTIVE-FIELDS; NATURAL SCENES; SPATIAL SCALE; V1 NEURONS; ADAPTATION; STATISTICS; RETINA; CELLS	Sensory neuroscience seeks to understand how the brain encodes natural environments. However, neural coding has largely been studied using simplified stimuli. In order to assess whether the brain's coding strategy depends on the stimulus ensemble, we apply a new information-theoretic method that allows unbiased calculation of neural filters (receptive fields) from responses to natural scenes or other complex signals with strong multipoint correlations. In the cat primary visual cortex we compare responses to natural inputs with those to noise inputs matched for luminance and contrast. We find that neural filters adaptively change with the input ensemble so as to increase the information carried by the neural response about the filtered stimulus. Adaptation affects the spatial frequency composition of the filter, enhancing sensitivity to under-represented frequencies in agreement with optimal encoding arguments. Adaptation occurs over 40 s to many minutes, longer than most previously reported forms of adaptation.	Univ Calif San Francisco, Sloan Swartz Ctr Theoret Neurobiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Columbia Univ, Sch Med, Ctr Theoret Neurosci, Ctr Neurobiol & Behav, New York, NY 10032 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Columbia University	Sharpee, TO (corresponding author), Univ Calif San Francisco, Sloan Swartz Ctr Theoret Neurobiol, 513 Parnassus Ave, San Francisco, CA 94143 USA.	sharpee@phy.ucsf.edu	Kurgansky, Andrei V/X-6695-2018; Sharpee, Tatyana/E-8663-2010	Sugihara, Hiroki/0000-0002-0637-3700; Sharpee, Tatyana/0000-0002-7483-5081; Stryker, Michael/0000-0003-1546-5831	NATIONAL EYE INSTITUTE [R01EY013595] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY013595, R01 EY013595-04] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALBRECHT DG, 1984, J PHYSIOL-LONDON, V347, P713, DOI 10.1113/jphysiol.1984.sp015092; ATICK JJ, 1992, NEURAL COMPUT, V4, P196, DOI 10.1162/neco.1992.4.2.196; Baddeley R, 1997, P ROY SOC B-BIOL SCI, V264, P1775, DOI 10.1098/rspb.1997.0246; BLAKEMORE C, 1969, J PHYSIOL-LONDON, V200, pP11; Brenner N, 2000, NEURON, V26, P695, DOI 10.1016/S0896-6273(00)81205-2; Brenner N, 2000, NEURAL COMPUT, V12, P1531, DOI 10.1162/089976600300015259; Brown SP, 2001, NAT NEUROSCI, V4, P44, DOI 10.1038/82888; Dan Y, 1996, J NEUROSCI, V16, P3351; David SV, 2004, J NEUROSCI, V24, P6991, DOI 10.1523/JNEUROSCI.1422-04.2004; DEBOER E, 1968, IEEE T BIO-MED ENG, VBM15, P169, DOI 10.1109/TBME.1968.4502561; DONG DW, 1995, NETWORK-COMP NEURAL, V6, P345, DOI 10.1088/0954-898X/6/3/003; Dragoi V, 2000, NEURON, V28, P287, DOI 10.1016/S0896-6273(00)00103-3; Emondi AA, 2004, J NEUROSCI METH, V135, P95, DOI 10.1016/j.jneumeth.2003.12.022; Fairhall AL, 2001, NATURE, V412, P787, DOI 10.1038/35090500; Felsen G, 2005, PLOS BIOL, V3, P1819, DOI 10.1371/journal.pbio.0030342; FIELD DJ, 1994, NEURAL COMPUT, V6, P559, DOI 10.1162/neco.1994.6.4.559; FIELD DJ, 1987, J OPT SOC AM A, V4, P2379, DOI 10.1364/JOSAA.4.002379; Hosoya T, 2005, NATURE, V436, P71, DOI 10.1038/nature03689; Kohn A, 2004, NAT NEUROSCI, V7, P764, DOI 10.1038/nn1267; Kvale MN, 2004, J NEUROPHYSIOL, V91, P604, DOI 10.1152/jn.00484.2003; MAFFEI L, 1973, SCIENCE, V182, P1036, DOI 10.1126/science.182.4116.1036; MOVSHON JA, 1979, NATURE, V278, P850, DOI 10.1038/278850a0; Nolt MJ, 2004, J NEUROPHYSIOL, V92, P1708, DOI 10.1152/jn.00176.2004; OHZAWA I, 1985, J NEUROPHYSIOL, V54, P651, DOI 10.1152/jn.1985.54.3.651; Rieke F., 1997, SPIKES EXPLORING NEU; Ringach DL, 2002, J VISION, V2, P12, DOI 10.1167/2.1.2; Rust NC, 2005, NEURON, V46, P945, DOI 10.1016/j.neuron.2005.05.021; SAUL AB, 1989, VISUAL NEUROSCI, V2, P593, DOI 10.1017/S0952523800003527; Sceniak MP, 2002, J NEUROPHYSIOL, V88, P1363, DOI 10.1152/jn.2002.88.3.1363; SHAPLEY R, 1979, VISION RES, V19, P431, DOI 10.1016/0042-6989(79)90109-3; SHAPLEY R, 1984, PROGR RETINAL RES, P263; Sharpee T, 2004, NEURAL COMPUT, V16, P223, DOI 10.1162/089976604322742010; Simoncelli EP, 2001, ANNU REV NEUROSCI, V24, P1193, DOI 10.1146/annurev.neuro.24.1.1193; SKOTTUN BC, 1991, VISION RES, V31, P1079, DOI 10.1016/0042-6989(91)90033-2; Smyth D, 2003, J NEUROSCI, V23, P4746; Solomon SG, 2004, NEURON, V42, P155, DOI 10.1016/S0896-6273(04)00178-3; Theunissen FE, 2000, J NEUROSCI, V20, P2315; Theunissen FE, 2001, NETWORK-COMP NEURAL, V12, P289, DOI 10.1088/0954-898X/12/3/304; VICTOR JD, 1987, J PHYSIOL-LONDON, V386, P219, DOI 10.1113/jphysiol.1987.sp016531; Wainwright MJ, 1999, VISION RES, V39, P3960, DOI 10.1016/S0042-6989(99)00101-7	44	227	232	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 23	2006	439	7079					936	942		10.1038/nature04519	http://dx.doi.org/10.1038/nature04519			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014NE	16495990	Green Accepted			2022-12-28	WOS:000235486100038
J	Roman, MJ; Moeller, E; Davis, A; Paget, SA; Crow, MK; Lockshin, MD; Sammaritano, L; Devereux, RB; Schwartz, JE; Levine, DM; Salmon, JE				Roman, MJ; Moeller, E; Davis, A; Paget, SA; Crow, MK; Lockshin, MD; Sammaritano, L; Devereux, RB; Schwartz, JE; Levine, DM; Salmon, JE			Preclinical carotid atherosclerosis in patients with rheumatoid arthritis	ANNALS OF INTERNAL MEDICINE			English	Article							ARTERIAL-WALL THICKNESS; CARDIOVASCULAR MORBIDITY; RISK-FACTORS; MORTALITY; ASSOCIATION; PREVALENCE; DISEASE; PLAQUE; WOMEN; REPRODUCIBILITY	Background: Rheumatoid arthritis is associated with increased morbidity and mortality because of cardiovascular disease, independent of traditional risk factors. Objective: To determine the prevalence of preclinical atherosclerosis in patients with rheumatoid arthritis and to identify clinical and biological markers for atherosclerotic disease in this patient population. Design: Matched, cross-sectional study. Setting: Hospital for Special Surgery in New York City Patients: 98 consecutive outpatients with rheumatoid arthritis who were followed by rheumatologists and 98 controls matched on age, sex, and ethnicity. Measurements: Cardiovascular risk factor ascertainment and carotid ultrasonography in all participants; disease severity, disease treatment, and inflammatory markers in patients with rheumatoid arthritis. Results: Despite a more favorable risk factor profile, patients with rheumatoid arthritis had a 3-fold increase in carotid atherosclerotic plaque (44% vs. 15%; p < 0.001). The relationship between rheumatoid arthritis and carotid atherosclerotic plaque remained after accounting for age, serum cholesterol levels, smoking history, and hypertensive status; adjusted predicted prevalence was 7.4% (95% Cl, 3.4% to 15.2%) for the control group and 38.5% (Cl, 25.4% to 53.5%) for patients with rheumatoid arthritis. Age (P < 0.001) and current cigarette use (P < 0.014) were also significantly associated with carotid atherosclerotic plaque. Among patients with rheumatoid arthritis, atherosclerosis was related to age, hypertension status, and use of tumor necrosis factor-a inhibitors (a possible marker of disease severity). Limitations: The study had a cross-sectional design, and inflammatory markers were determined only once. Conclusions: Patients with rheumatoid arthritis have a high prevalence of preclinical atherosclerosis independent of traditional risk factors, suggesting that chronic inflammation and, possibly, disease severity are atherogenic in this population.	Cornell Univ, Hosp Special Surg, Weill Med Coll, New York, NY 10021 USA; SUNY Stony Brook, Stony Brook, NY 11794 USA	Cornell University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Roman, MJ (corresponding author), Cornell Univ, Weill Med Coll, Div Cardiol, 525 E 68th St, New York, NY 10021 USA.	mroman@med.cornell.edu	Crow, Mary/R-8480-2019	Schwartz, Joseph/0000-0002-8944-3566	NCRR NIH HHS [M10RR0047] Funding Source: Medline; NHLBI NIH HHS [P01 HL047540] Funding Source: Medline; NIAMS NIH HHS [AR 45591] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000047] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045591] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Belcaro G, 1996, ARTERIOSCL THROM VAS, V16, P851, DOI 10.1161/01.ATV.16.7.851; Chambless LE, 1997, AM J EPIDEMIOL, V146, P483, DOI 10.1093/oxfordjournals.aje.a009302; Choi HK, 2002, LANCET, V359, P1173, DOI 10.1016/S0140-6736(02)08213-2; del Rincon I, 2003, ARTHRITIS RHEUM, V48, P1833, DOI 10.1002/art.11078; del Rincon I, 2001, ARTHRITIS RHEUM-US, V44, P2737, DOI 10.1002/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#; del Sol AI, 2001, STROKE, V32, P1532, DOI 10.1161/01.STR.32.7.1532; Fischer LM, 2004, AM J CARDIOL, V93, P198, DOI 10.1016/j.amjcard.2003.09.037; Gerli R, 2004, CIRCULATION, V109, P2744, DOI 10.1161/01.CIR.0000131450.66017.B3; Joakimsen O, 1997, STROKE, V28, P2201, DOI 10.1161/01.STR.28.11.2201; Jonsson SW, 2001, J RHEUMATOL, V28, P2597; Krishnan E, 2004, CIRCULATION, V110, P1774, DOI 10.1161/01.CIR.0000142864.83780.81; Kumeda Y, 2002, ARTHRITIS RHEUM-US, V46, P1489, DOI 10.1002/art.10269; Manzi S, 1999, ARTHRITIS RHEUM-US, V42, P51, DOI 10.1002/1529-0131(199901)42:1<51::AID-ANR7>3.0.CO;2-D; McCarey DW, 2004, LANCET, V363, P2015, DOI 10.1016/S0140-6736(04)16449-0; MYLLYKANGASLUOSUJARVI R, 1995, J RHEUMATOL, V22, P1065; Orces CH, 2002, ARTHRIT RHEUM-ARTHR, V47, P67, DOI 10.1002/art1.10160; Park YB, 2002, ARTHRITIS RHEUM, V46, P1714, DOI 10.1002/art.10359; PERSSON J, 1992, ARTERIOSCLER THROMB, V12, P261, DOI 10.1161/01.ATV.12.2.261; Pincus T, 1999, ARTHRITIS RHEUM-US, V42, P2220, DOI 10.1002/1529-0131(199910)42:10<2220::AID-ANR26>3.0.CO;2-5; Roman MJ, 1996, J AM COLL CARDIOL, V28, P751, DOI 10.1016/0735-1097(96)00225-2; ROMAN MJ, 1995, HYPERTENSION, V26, P369, DOI 10.1161/01.HYP.26.2.369; ROMAN MJ, 1992, CIRCULATION, V86, P1909, DOI 10.1161/01.CIR.86.6.1909; Roman MJ, 2003, NEW ENGL J MED, V349, P2399, DOI 10.1056/NEJMoa035471; Salonen JT, 1997, INTIMA-MEDIA THICKNESS AN ATHEROSCLEROSIS, P97; SALONEN JT, 1993, CIRCULATION, V87, P56; Solomon DH, 2003, CIRCULATION, V107, P1303, DOI 10.1161/01.CIR.0000054612.26458.B2; Turesson C, 2004, ANN RHEUM DIS, V63, P952, DOI 10.1136/ard.2003.018101; WallbergJonsson S, 1997, J RHEUMATOL, V24, P445; WOLFE F, 1994, ARTHRITIS RHEUM-US, V37, P481, DOI 10.1002/art.1780370408	30	222	229	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 21	2006	144	4					249	256		10.7326/0003-4819-144-4-200602210-00006	http://dx.doi.org/10.7326/0003-4819-144-4-200602210-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	015HS	16490910				2022-12-28	WOS:000235543100003
J	Ashrafian, H				Ashrafian, H			Cancer's sweet tooth: the Janus effect of glucose metabolism in tumorigenesis	LANCET			English	Article							ACTIVATED PROTEIN-KINASE; COLORECTAL-CANCER; AMP; DISEASE; MUTATIONS; PATHWAY; TUMORS; CELLS; RISK	Despite Otto Warburg's 1931 Nobel Prize for his work affirming the role of metabolism in carcinogenesis, there has been little further interest in this association between metabolism and cancer. Disinterest has, in part, been attributable to the notion that Warburg's description of a relation between a shift to glycolysis in carcinogenesis may be an epiphenomenon rather than a mechanistic determinant. By studying the critical cellular energy sensor AMP-activated protein kinase (AMPK), I postulate that the association between intermediary metabolism and tumours varies over time. Through accumulation of carbohydrates and pan-inhibition of AMPK, premalignant tumours may gain a replicative advantage through the repression of senescence. Conversely, malignant tumours, with a defective tumour suppressor contingent, undergo a "glycolytic switch", in part by tolerating a degree of AMPK activation, to mitigate substrate limitation. I contend that this Janus-faced relation with intermediary metabolism contributes to carcinogenesis; if proven, this finding would have important implications for public health, in that it would lend support to the idea that prevention of obesity, and caloric restriction and exercise could reduce the predisposition to cancer.	Harefield Hosp, Dept Cardiol, Harefield UB9 6JH, Middx, England	Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital	Ashrafian, H (corresponding author), Harefield Hosp, Dept Cardiol, Harefield UB9 6JH, Middx, England.	ashrafian@hotmail.com		Ashrafian, Houman/0000-0003-3988-378X				Bannasch P, 1997, J BIOENERG BIOMEMBR, V29, P303, DOI 10.1023/A:1022438528634; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; BIANCHI L, 1993, EUR J PEDIATR, V152, pS63; Birnbaum MJ, 2005, MOL CELL, V19, P289, DOI 10.1016/j.molcel.2005.07.012; Blair E, 2001, HUM MOL GENET, V10, P1215, DOI 10.1093/hmg/10.11.1215; Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622; Cooney KA, 2005, JAMA-J AM MED ASSOC, V293, P235, DOI 10.1001/jama.293.2.235; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Forcet C, 2005, HUM MOL GENET, V14, P1283, DOI 10.1093/hmg/ddi139; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kim J.W., 2005, DRUG DISCOV TODAY, V2, P233, DOI DOI 10.1016/J.DDMEC.2005.04.001; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Nemunaitis J, 2000, J CLIN ONCOL, V18, P609, DOI 10.1200/JCO.2000.18.3.609; Patel AC, 2004, J NUTR, V134, p3394S, DOI 10.1093/jn/134.12.3394S; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Sakoda H, 2005, AM J PHYSIOL-ENDOC M, V289, pE474, DOI 10.1152/ajpendo.00003.2005; Sharpless NE, 2005, NATURE, V436, P636, DOI 10.1038/436636a; Svensson E, 2005, CANCER CAUSE CONTROL, V16, P215, DOI 10.1007/s10552-004-3073-x; Swinnen JV, 2005, CANCER RES, V65, P2441, DOI 10.1158/0008-5472.CAN-04-3025; Takahashi S, 1999, J GASTROENTEROL, V34, P474, DOI 10.1007/s005350050299; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wynne K, 2005, DIABETES, V54, P2390, DOI 10.2337/diabetes.54.8.2390; Yasuda S, 2001, J NUCL MED, V42, P989; Younes M, 1996, CLIN CANCER RES, V2, P1151	28	64	68	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 18	2006	367	9510					618	621		10.1016/S0140-6736(06)68228-7	http://dx.doi.org/10.1016/S0140-6736(06)68228-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013GM	16488806				2022-12-28	WOS:000235397800037
J	Tofaris, GK; Wistow, T				Tofaris, GK; Wistow, T			An unusual cause of rigors and microscopic haematuria	LANCET			English	Editorial Material							ENDOCARDITIS		Royal Brompton Hosp, Dept Cardiol, London SW3 6NP, England; Norfolk & Norwich Univ Hosp, Dept Cardiol, Norwich NR4 7UU, Norfolk, England	Royal Brompton Hospital; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital	Tofaris, GK (corresponding author), Royal Brompton Hosp, Dept Cardiol, London SW3 6NP, England.	gt223@doctors.net.uk		Tofaris, George/0000-0002-9252-5933				Akram M, 2001, ANGIOLOGY, V52, P211, DOI 10.1177/000331970105200309; GALLAGHER PG, 1986, REV INFECT DIS, V8, P175; Jassal DS, 2005, CAN J CARDIOL, V21, P365; Ramadan FB, 2000, CAN J CARDIOL, V16, P1282	4	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 18	2006	367	9510					622	622		10.1016/S0140-6736(06)68229-9	http://dx.doi.org/10.1016/S0140-6736(06)68229-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013GM	16488807				2022-12-28	WOS:000235397800038
J	McLaughlin, MA; Lyne, AG; Lorimer, DR; Kramer, M; Faulkner, AJ; Manchester, RN; Cordes, JM; Camilo, F; Possenti, A; Stairs, IH; Hobbs, G; D'Amico, N; Burgay, M; O'Brien, JT				McLaughlin, MA; Lyne, AG; Lorimer, DR; Kramer, M; Faulkner, AJ; Manchester, RN; Cordes, JM; Camilo, F; Possenti, A; Stairs, IH; Hobbs, G; D'Amico, N; Burgay, M; O'Brien, JT			Transient radio bursts from rotating neutron stars	NATURE			English	Article							MULTIBEAM PULSAR SURVEY; GIANT PULSES; DISCOVERY	The radio sky is relatively unexplored for transient signals(1), although the potential of radio-transient searches is high. This was demonstrated recently by the discovery of a previously unknown type of source(2,3), varying on timescales of minutes to hours. Here we report a search for radio sources that vary on much shorter timescales. We found eleven objects characterized by single, dispersed bursts having durations between 2 and 30 ms. The average time intervals between bursts range from 4 min to 3 h with radio emission typically detectable for < 1 s per day. From an analysis of the burst arrival times, we have identified periodicities in the range 0.4 - 7 s for ten of the eleven sources, suggesting origins in rotating neutron stars. Despite the small number of sources detected at present, their ephemeral nature implies a total Galactic population significantly exceeding that of the regularly pulsing radio pulsars. Five of the ten sources have periods > 4 s, and the rate of change of the pulse period has been measured for three of them; for one source, we have inferred a high magnetic field strength of 5 x 10(13) G. This suggests that the new population is related to other classes of isolated neutron stars observed at X-ray and gamma-ray wavelengths(4).	Univ Manchester, Jodrell Bank Observ, Macclesfield SK11 9DL, Cheshire, England; CSIRO, Australia Telescope Natl Facil, Epping, NSW 1710, Australia; Cornell Univ, Dept Astron, Ithaca, NY 14853 USA; Cornell Univ, Natl Astron & Ionosphere Ctr, Ithaca, NY 14853 USA; Columbia Univ, Columbia Astrophys Lab, New York, NY 10027 USA; INAF, Osservatorio Astron Cagliari, I-09012 Capoterra, Italy; Univ British Columbia, Dept Phys & Astron, Vancouver, BC V6T 1Z1, Canada; Univ Cagliari, Dipartimento Fis, I-09042 Monserrato, Italy	University of Manchester; Jodrell Bank Centre for Astrophysics; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Cornell University; Cornell University; Columbia University; Istituto Nazionale Astrofisica (INAF); University of British Columbia; University of Cagliari	McLaughlin, MA (corresponding author), Univ Manchester, Jodrell Bank Observ, Macclesfield SK11 9DL, Cheshire, England.	Maura.McLaughlin@manchester.ac.uk	D'Amico, Nichi/A-5715-2009; Hobbs, George/AAS-5025-2020; Lorimer, Duncan/ABH-7909-2020	McLaughlin, Maura/0000-0001-7697-7422; Kramer, Michael/0000-0002-4175-2271; Burgay, Marta/0000-0002-8265-4344				Cordes JM, 2004, NEW ASTRON REV, V48, P1459, DOI 10.1016/j.newar.2004.09.038; Cordes JM, 2004, ASTROPHYS J, V612, P375, DOI 10.1086/422495; Cordes JM, 2003, ASTROPHYS J, V596, P1142, DOI 10.1086/378231; CORDES JM, 2002, NE2001, V1; Haberl F, 2004, ADV SPACE RES-SERIES, V33, P638, DOI 10.1016/j.asr.2003.07.022; Hankins TH, 2003, NATURE, V422, P141, DOI 10.1038/nature01477; Hobbs G, 2004, MON NOT R ASTRON SOC, V352, P1439, DOI 10.1111/j.1365-2966.2004.08042.x; Hyman SD, 2005, NATURE, V434, P50, DOI 10.1038/nature03400; Johnston S, 2003, ASTROPHYS J, V590, pL95, DOI 10.1086/376826; Kaplan DL, 2005, ASTROPHYS J, V628, pL45, DOI 10.1086/432536; Kulkarni SR, 2005, NATURE, V434, P28, DOI 10.1038/434028a; Lorimer D. R., 2012, HDB PULSAR ASTRONOMY; Lorimer DR, 2004, IAU SYMP, P105; Lyne AG, 1998, MON NOT R ASTRON SOC, V295, P743, DOI 10.1046/j.1365-8711.1998.01144.x; Manchester RN, 2001, MON NOT R ASTRON SOC, V328, P17, DOI 10.1046/j.1365-8711.2001.04751.x; McLaughlin MA, 2003, ASTROPHYS J, V591, pL135, DOI 10.1086/377212; Soglasnov VA, 2004, ASTROPHYS J, V616, P439, DOI 10.1086/424908; Tauris TM, 1998, MON NOT R ASTRON SOC, V298, P625, DOI 10.1046/j.1365-8711.1998.01369.x; Vranesevic N, 2004, ASTROPHYS J, V617, pL139, DOI 10.1086/427208; WOODS PM, IN PRESS COMPACT STE	20	448	459	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 16	2006	439	7078					817	820		10.1038/nature04440	http://dx.doi.org/10.1038/nature04440			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012JA	16482150				2022-12-28	WOS:000235333600042
J	Hunt, TL; Lipo, CP				Hunt, TL; Lipo, CP			Late colonization of Easter Island	SCIENCE			English	Article							NEW-ZEALAND; PALEOENVIRONMENTAL EVIDENCE; POLYNESIAN COLONIZATION; RADIOCARBON-DATES	Easter Island (Rapa Nui) provides a model of human-induced environmental degradation. A reliable chronology is central to understanding the cultural, ecological, and demographic processes involved. Radiocarbon dates for the earliest stratigraphic layers at Anakena, Easter Island, and analysis of previous radiocarbon dates imply that the island was colonized late, about 1200 A. D. Substantial ecological impacts and major cultural investments in monumental architecture and statuary thus began soon after initial settlement.	Univ Hawaii Manoa, Dept Anthropol, Honolulu, HI 96822 USA; Calif State Univ Long Beach, Dept Anthropol, Long Beach, CA 90840 USA; Calif State Univ Long Beach, Inst Integrated Res Mat Environm & Soc, Long Beach, CA 90840 USA	University of Hawaii System; University of Hawaii Manoa; California State University System; California State University Long Beach; California State University System; California State University Long Beach	Hunt, TL (corresponding author), Univ Hawaii Manoa, Dept Anthropol, 2424 Maile Way, Honolulu, HI 96822 USA.	thunt@hawaii.edu	Lipo, Carl/C-9154-2013	Lipo, Carl/0000-0003-4391-3590				ANDERSON A, 1995, J POLYNESIAN SOC, V104, P110; ANDERSON A, 1991, ANTIQUITY, V65, P767, DOI 10.1017/S0003598X00080510; ANDERSON A, 1994, ANTIQUITY, V68, P845, DOI 10.1017/S0003598X00047566; ANDERSON A, 2002, ASIAN PERSPECT, V41, P242, DOI DOI 10.1353/ASI.2003.0002; Athens J. Stephen, 2002, Archaeology in Oceania, V37, P57; AYRES WS, 1971, J POLYNESIAN SOC, V80, P497; Beck JW, 2003, EASTER ISLAND: SCIENTIFIC EXPLORATION INTO THE WORLD'S ENVIRONMENTAL PROBLEMS IN MICROCOSM, P93; BIRDSELL JB, 1957, COLD SPRING HARB SYM, V22, P47, DOI 10.1101/SQB.1957.022.01.008; Butler K, 2004, RADIOCARBON, V46, P395, DOI 10.1017/S0033822200039709; DIAMOND JM, 1984, NATURE, V311, P704, DOI 10.1038/311704a0; FLENLEY JR, 1993, EASTER ISLAND STUDIE, P27; GREEN R, 1966, J POLYNESIAN SOC, V75, P6; Higham TFG, 1997, RADIOCARBON, V39, P149, DOI 10.1017/S0033822200051997; Hunt TL, 2001, PACIFIC 2000: PROCEEDINGS OF THE FIFTH INTERNATIONAL CONFERENCE ON EASTER ISLAND AND THE PACIFIC, P103; KIRCH P, 2004, ARCHAEOLOGICAL INVES, P149; KIRCH PV, 1994, ANTIQUITY, V68, P310, DOI 10.1017/S0003598X00046615; KIRCH PV, 2000, ROAD WINDS ARCHAEOLO; Mann D, 2003, EASTER ISLAND: SCIENTIFIC EXPLORATION INTO THE WORLD'S ENVIRONMENTAL PROBLEMS IN MICROCOSM, P133; Martinsson-Wallin H., 2002, ASIAN PERSPECT, V4, P244, DOI DOI 10.1353/ASI.2001.0016; McCormac FG, 2004, RADIOCARBON, V46, P1087, DOI 10.1017/S0033822200033014; McGlone MS, 1999, QUATERN INT, V59, P5, DOI 10.1016/S1040-6182(98)00067-6; Mieth A., 2004, EASTER ISLAND RAPA N; Peiser Benny, 2005, ENERGY ENV, V16, P513, DOI DOI 10.1260/0958305054672385; Rainbird P, 2002, WORLD ARCHAEOL, V33, P436, DOI 10.1080/00438240120107468; SMITH C, 1961, ARCHAEOLOGY EASTER I, V1, P393; SPRIGGS M, 1993, ANTIQUITY, V67, P200, DOI 10.1017/S0003598X00045324; Steadman David W., 1994, Asian Perspectives, V33, P79; Stuiver M., CALIB 5 0; Wilmshurst JM, 2004, HOLOCENE, V14, P801, DOI 10.1191/0959683604hl760ft	29	198	205	0	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2006	311	5767					1603	1606		10.1126/science.1121879	http://dx.doi.org/10.1126/science.1121879			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BK	16527931				2022-12-28	WOS:000236029500044
J	Eddy, SR				Eddy, SR			Genetics - Total information awareness for worm genetics	SCIENCE			English	Editorial Material									Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63108 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63108 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)	Eddy, SR (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63108 USA.	eddy@genetics.wustl.edu		Eddy, Sean/0000-0001-6676-4706				SIMON MA, 1994, DEV BIOL, V166, P431, DOI 10.1006/dbio.1994.1327; Zhong WW, 2006, SCIENCE, V311, P1481, DOI 10.1126/science.1123287	2	5	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 10	2006	311	5766					1381	1382		10.1126/science.1125655	http://dx.doi.org/10.1126/science.1125655			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527956				2022-12-28	WOS:000236029400022
J	Porco, CC; Helfenstein, P; Thomas, PC; Ingersoll, AP; Wisdom, J; West, R; Neukum, G; Denk, T; Wagner, R; Roatsch, T; Kieffer, S; Turtle, E; McEwen, A; Johnson, TV; Rathbun, J; Veverka, J; Wilson, D; Perry, J; Spitale, J; Brahic, A; Burns, JA; DelGenio, AD; Dones, L; Murray, CD; Squyres, S				Porco, CC; Helfenstein, P; Thomas, PC; Ingersoll, AP; Wisdom, J; West, R; Neukum, G; Denk, T; Wagner, R; Roatsch, T; Kieffer, S; Turtle, E; McEwen, A; Johnson, TV; Rathbun, J; Veverka, J; Wilson, D; Perry, J; Spitale, J; Brahic, A; Burns, JA; DelGenio, AD; Dones, L; Murray, CD; Squyres, S			Cassini observes the active South Pole of Enceladus	SCIENCE			English	Article							IMAGING SCIENCE; SOLAR-SYSTEM; E-RING; SATELLITES; SATURN; TECTONICS; EVOLUTION; EUROPA; WATER		Space Sci Inst, Cassini Imaging Cent Lab Operat, Boulder, CO 80301 USA; Univ London, Queen Mary, Astron Unit, London E1 4NS, England; SW Res Inst, Dept Space Studies, Boulder, CO 80302 USA; NASA, Goddard Inst Space Studies, New York, NY 10025 USA; Univ Paris 07, Ctr Etud Saclay, F-91191 Gif Sur Yvette, France; Univ Redlands, Dept Phys, Redlands, CA 92373 USA; Univ Arizona, Dept Planetary Sci, Tucson, AZ 85721 USA; Univ Illinois, Dept Geol, Urbana, IL 61801 USA; German Aerosp Res Estab, Inst Planetary Res, D-12489 Berlin, Germany; Free Univ Berlin, Inst Geol Wissensch, D-12249 Berlin, Germany; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; Cornell Univ, Dept Astron, Ithaca, NY 14853 USA	University of London; Queen Mary University London; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; UDICE-French Research Universities; Universite Paris Cite; University of Arizona; University of Illinois System; University of Illinois Urbana-Champaign; Helmholtz Association; German Aerospace Centre (DLR); Free University of Berlin; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Massachusetts Institute of Technology (MIT); California Institute of Technology; Cornell University	Porco, CC (corresponding author), Space Sci Inst, Cassini Imaging Cent Lab Operat, 4750 Walnut St,Suite 205, Boulder, CO 80301 USA.	carolyn@ciclops.org	Del Genio, Anthony/D-4663-2012; Turtle, Elizabeth/K-8673-2012	Del Genio, Anthony/0000-0001-7450-1359; Turtle, Elizabeth/0000-0003-1423-5751				Brown RH, 2006, SCIENCE, V311, P1425, DOI 10.1126/science.1121031; CRUIKSHANK DP, 1980, ICARUS, V41, P246, DOI 10.1016/0019-1035(80)90008-1; DERMOTT SF, 1994, ICARUS, V109, P241, DOI 10.1006/icar.1994.1090; DERMOTT SF, 1979, ICARUS, V37, P575, DOI 10.1016/0019-1035(79)90015-0; Dougherty MK, 2006, SCIENCE, V311, P1406, DOI 10.1126/science.1120985; Eluszkiewicz J, 2003, ICARUS, V166, P375, DOI 10.1016/j.icarus.2003.08.013; Gaidos EJ, 2000, NATURE, V405, P637, DOI 10.1038/35015170; Goldsby DL, 2001, J GEOPHYS RES-SOL EA, V106, P11017, DOI 10.1029/2000JB900336; Hansen CJ, 2006, SCIENCE, V311, P1422, DOI 10.1126/science.1121254; HANSEN GJ, COMMUNICATION; HANSEN JE, 1971, J ATMOS SCI, V28, P1400, DOI 10.1175/1520-0469(1971)028<1400:MSOPLI>2.0.CO;2; HEDMAN M, COMMUNICATION; HELFENSTEIN P, 1983, ICARUS, V53, P415, DOI 10.1016/0019-1035(83)90206-3; HOREDT GP, 1984, J GEOPHYS RES, V89, P405, DOI 10.1029/JB089iB12p10405; IONASESCU R, 2005, 343J05017 IOM JET PR; JACOBSON RA, COMMUNICATION; Jones GH, 2006, SCIENCE, V311, P1412, DOI 10.1126/science.1121011; Juhasz A, 2002, J GEOPHYS RES-SPACE, V107, DOI 10.1029/2001JA000182; Kargel JS, 1996, ICARUS, V119, P385, DOI 10.1006/icar.1996.0026; KIEFFER SW, 1982, SATELLITES JUPITER, P647; LEWIS JS, 1971, ICARUS, V15, P174, DOI 10.1016/0019-1035(71)90072-8; MELOSH HJ, 1977, ICARUS, V31, P221, DOI 10.1016/0019-1035(77)90035-5; Neukum G., 1985, Advances in Space Research, V5, P107, DOI 10.1016/0273-1177(85)90247-9; Neukum G, 2001, SPACE SCI REV, V96, P55, DOI 10.1023/A:1011989004263; Neukum G., 2005, LUN PLAN SCI C; NEUKUM G, 1983, THESIS L MAXIMILIANS; PANG KD, 1984, J GEOPHYS RES, V89, P9459, DOI 10.1029/JB089iB11p09459; Peale SJ, 1999, ANNU REV ASTRON ASTR, V37, P533, DOI 10.1146/annurev.astro.37.1.533; Porco CC, 2004, SPACE SCI REV, V115, P363, DOI 10.1007/s11214-004-1456-7; Porco CC, 2005, SCIENCE, V307, P1237, DOI 10.1126/science.1107981; ROSS MN, 1989, ICARUS, V78, P90, DOI 10.1016/0019-1035(89)90071-7; Schubert G., 1986, SATELLITES, P224; SMITH BA, 1981, SCIENCE, V212, P163, DOI 10.1126/science.212.4491.163; Spahn F, 2006, SCIENCE, V311, P1416, DOI 10.1126/science.1121375; Spencer JR, 2006, SCIENCE, V311, P1401, DOI 10.1126/science.1121661; SQUYRES SW, 1983, ICARUS, V53, P319, DOI 10.1016/0019-1035(83)90152-5; Verbiscer AJ, 2005, ICARUS, V173, P66, DOI 10.1016/j.icarus.2004.05.001; WAGNER R, 2005, B AM ASTRON SOC, V37, P701; Waite JH, 2006, SCIENCE, V311, P1419, DOI 10.1126/science.1121290; Wisdom J, 2004, ASTRON J, V128, P484, DOI 10.1086/421360; YODER CF, 1979, NATURE, V279, P767, DOI 10.1038/279767a0; Zahnle K, 2003, ICARUS, V163, P263, DOI 10.1016/S0019-1035(03)00048-4	42	778	787	3	178	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2006	311	5766					1393	1401		10.1126/science.1123013	http://dx.doi.org/10.1126/science.1123013			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527964				2022-12-28	WOS:000236029400030
J	Spencer, JR; Pearl, JC; Segura, M; Flasar, FM; Mamoutkine, A; Romani, P; Buratti, BJ; Hendrix, AR; Spilker, LJ; Lopes, RMC				Spencer, JR; Pearl, JC; Segura, M; Flasar, FM; Mamoutkine, A; Romani, P; Buratti, BJ; Hendrix, AR; Spilker, LJ; Lopes, RMC			Cassini encounters Enceladus: Background and the discovery of a south polar hot spot	SCIENCE			English	Article							SATURNS E-RING; MASS; ATMOSPHERE; EVOLUTION; DYNAMICS; TETHYS; ORIGIN; SYSTEM		SW Res Inst, Dept Space Studies, Boulder, CO 80302 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Spencer, JR (corresponding author), SW Res Inst, Dept Space Studies, 1050 Walnut St,Suite 400, Boulder, CO 80302 USA.	spencer@boulder.swri.edu	Flasar, F Michael/C-8509-2012; Lopes, Rosaly M.C./D-1608-2016; Romani, Paul N/D-2729-2012	Lopes, Rosaly M.C./0000-0002-7928-3167; 				Brown RH, 2006, SCIENCE, V311, P1425, DOI 10.1126/science.1121031; BROWN RH, 1990, SCIENCE, V250, P431, DOI 10.1126/science.250.4979.431; BRYSON CE, 1974, J CHEM ENG DATA, V19, P107, DOI 10.1021/je60061a021; BURATTI B, 1984, ICARUS, V58, P254, DOI 10.1016/0019-1035(84)90042-3; BURATTI BJ, 1988, ICARUS, V75, P113, DOI 10.1016/0019-1035(88)90130-3; CRUIKSHANK DP, 1980, ICARUS, V41, P246, DOI 10.1016/0019-1035(80)90008-1; Czechowski L, 2005, PLANET SPACE SCI, V53, P749, DOI 10.1016/j.pss.2005.01.004; CZECHOWSKI L, 2004, 35 COMM SPAC RES COS; DERMOTT SF, 1994, ICARUS, V109, P241, DOI 10.1006/icar.1994.1090; Dougherty MK, 2006, SCIENCE, V311, P1406, DOI 10.1126/science.1120985; Emery JP, 2005, ASTRON ASTROPHYS, V435, P353, DOI 10.1051/0004-6361:20042482; Flasar FM, 2004, SPACE SCI REV, V115, P169, DOI 10.1007/s11214-004-1454-9; HAFF PK, 1983, ICARUS, V56, P426, DOI 10.1016/0019-1035(83)90164-1; HAMILTON DP, 1994, SCIENCE, V264, P550, DOI 10.1126/science.264.5158.550; HANEL R, 1982, SCIENCE, V215, P544, DOI 10.1126/science.215.4532.544; Hansen CJ, 2006, SCIENCE, V311, P1422, DOI 10.1126/science.1121254; HORANYI M, 1992, ICARUS, V97, P248, DOI 10.1016/0019-1035(92)90131-P; Hussmann H, 2004, ICARUS, V171, P391, DOI 10.1016/j.icarus.2004.05.020; Jurac S, 2001, ICARUS, V149, P384, DOI 10.1006/icar.2000.6528; Kargel JS, 1996, ICARUS, V119, P385, DOI 10.1006/icar.1996.0026; KLINGER J, 1980, SCIENCE, V209, P271, DOI 10.1126/science.209.4453.271; MATSON DL, 1989, ICARUS, V77, P67, DOI 10.1016/0019-1035(89)90007-9; McEwen AS, 2004, CAMB PLANET, P307; MCKINNON WB, 1983, LUNAR PLANET SCI, V14, P487; PANG KD, 1984, J GEOPHYS RES, V89, P9459, DOI 10.1029/JB089iB11p09459; Porco CC, 2006, SCIENCE, V311, P1393, DOI 10.1126/science.1123013; ROSS MN, 1989, ICARUS, V78, P90, DOI 10.1016/0019-1035(89)90071-7; Schubert G., 1986, SATELLITES, P224; SMITH BA, 1982, SCIENCE, V215, P504, DOI 10.1126/science.215.4532.504; Spahn F, 2006, SCIENCE, V311, P1416, DOI 10.1126/science.1121375; Spencer J.R., 1997, PLUTO CHARON, P435; SQUYRES SW, 1983, ICARUS, V53, P319, DOI 10.1016/0019-1035(83)90152-5; Tokar RL, 2006, SCIENCE, V311, P1409, DOI 10.1126/science.1121061; Verbiscer AJ, 2005, ICARUS, V173, P66, DOI 10.1016/j.icarus.2004.05.001; Waite JH, 2006, SCIENCE, V311, P1419, DOI 10.1126/science.1121290; Wisdom J, 2004, ASTRON J, V128, P484, DOI 10.1086/421360	36	374	377	1	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2006	311	5766					1401	1405		10.1126/science.1121661	http://dx.doi.org/10.1126/science.1121661			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527965				2022-12-28	WOS:000236029400031
J	Le Henanff, A; Giraudeau, B; Baron, G; Ravaud, P				Le Henanff, A; Giraudeau, B; Baron, G; Ravaud, P			Quality of reporting of noninferiority and equivalence randomized trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NON-INFERIORITY TRIALS; CLINICAL-TRIALS; THERAPEUTIC EQUIVALENCE; NULL HYPOTHESIS; PROTOCOLS; ISSUES	Context Noninferiority and equivalence trials aim to show that the experimental treatment is not clinically worse than (noninferior) or clinically similar to (equivalent) a control active treatment. These study objectives imply particular planning and analysis. Objective To assess the methodologic quality of reports of randomized controlled trials of noninferiority and equivalence. Design We searched MEDLINE and the Cochrane Central Register of Controlled Trials for reports of randomized controlled trials of noninferiority and equivalence hypotheses published between January 1, 2003, and December 31, 2004. Main Outcome Measures Data extracted by use of a standardized form involved assessment of choice of noninferiority or equivalence margins, sample size calculation, sets of patients analyzed, method of statistical testing and reporting results, and conclusions. Results A total of 162 reports were included in the analysis ( 116 reports of noninferiority and 46 of equivalence). The margin defining noninferiority or equivalence was described in most reports (156 [96.3%]), with justification of the margin in only 33 (20.4%). Almost one quarter of the reports (35 [21.6%]) did not describe a sample size calculation, and an additional 11 (6.8%) did not take into account a prespecified noninferiority or equivalence margin. Less than half of the reports (69 [42.6%]) described both an intent-to-treat (ITT; all randomized patients are included in the analysis) or modified ITT (patients who never received treatment are excluded) and per-protocol (patients who did not complete the treatment are excluded) analysis, and only about half of those (39 [56.5%]) described both types of results. Results were displayed with confidence intervals in 136 reports (84.0%). Only 33 articles (20.3%) fulfilled reporting requirements specific to noninferiority and equivalence trials, 4 of them (12.1%) with misleading conclusions. Conclusions Reporting of noninferiority and equivalence trials has important deficiencies: absence of noninferiority or equivalence margin, only an ITT (or a per-protocol) analysis performed, and results not adequately reported. Moreover, even for articles fulfilling these requirements, conclusions are sometimes misleading.	INSERM, CIC 202, F-37032 Tours, France; INSERM, U738, Paris, France; Univ Paris 07, Dept Epidemiol Biostat & Rech Clin, Grp Hosp Bichat Claude Bernard Hop Paris, Fac Xavier Bichat, Paris, France; INSERM, U 717, Paris, France; Univ Tours, Tours, France; Ctr Hosp Reg Univ Tours, Tours, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; CHU Tours	Giraudeau, B (corresponding author), INSERM, CIC 202, 10 Bd Tonnelle, F-37032 Tours, France.	giraudeau@med.univ-tours.fr	ravaud, philippe/C-1694-2009; Giraudeau, Bruno/L-9003-2015	Giraudeau, Bruno/0000-0003-3031-8258; Ravaud, Philippe/0000-0001-8264-9206				BLACKWELDER WC, 1984, CONTROL CLIN TRIALS, V5, P97, DOI 10.1016/0197-2456(84)90116-8; BLACKWELDER WC, 1982, CONTROL CLIN TRIALS, V3, P345, DOI 10.1016/0197-2456(82)90024-1; Brittain E, 2005, STAT MED, V24, P1, DOI 10.1002/sim.1934; Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457; D'Agostino RB, 2003, STAT MED, V22, P169, DOI 10.1002/sim.1425; DURRLEMAN S, 1990, BIOMETRICS, V46, P329, DOI 10.2307/2531438; Ebbutt AF, 1998, STAT MED, V17, P1691, DOI 10.1002/(SICI)1097-0258(19980815/30)17:15/16<1691::AID-SIM971>3.3.CO;2-A; European Medicines Agency Committee for Medicinal Products for Human Use, GUID CHOIC NON MARG; Garrett AD, 2003, STAT MED, V22, P741, DOI 10.1002/sim.1360; Greene WL, 2000, ANN INTERN MED, V132, P715, DOI 10.7326/0003-4819-132-9-200005020-00006; Hill CL, 2002, J CLIN EPIDEMIOL, V55, P783, DOI 10.1016/S0895-4356(02)00440-7; Hill CL, 2002, ARTHRITIS RHEUM, V46, P779, DOI 10.1002/art.512; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; Piaggio G, 2001, STAT MED, V20, P3571, DOI 10.1002/sim.1078; Pildal J, 2005, BMJ-BRIT MED J, V330, P1049, DOI 10.1136/bmj.38414.422650.8F; Rohmel J, 1998, STAT MED, V17, P1703; *US FDA, ICH TOP E9 STAT PRIN; *US FDA, 2000, INT C HARM GUID CHOI; Wiens BL, 2002, CONTROL CLIN TRIALS, V23, P2, DOI 10.1016/S0197-2456(01)00196-9	19	183	183	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	2006	295	10					1147	1151		10.1001/jama.295.10.1147	http://dx.doi.org/10.1001/jama.295.10.1147			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	019GB	16522835	Bronze			2022-12-28	WOS:000235822500023
J	Umpierrez, GE; Smiley, D; Kitabchi, AE				Umpierrez, GE; Smiley, D; Kitabchi, AE			Narrative review: Ketosis-prone type 2 diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Review							BETA-CELL DYSFUNCTION; TRANSCRIPTION FACTOR HNF-1-ALPHA; AFRICAN-AMERICANS; PAX4 GENE; CLINICAL PATHOPHYSIOLOGY; NORMOGLYCEMIC REMISSION; MISSENSE MUTATION; ATYPICAL TYPE-1; IN-VIVO; INSULIN	Several investigators have reported that more than half of African-American persons with new diagnoses of diabetic ketoacidosis have clinical, metabolic, and immunologic features of type 2 diabetes during follow-up. These patients are usually obese, have a strong family history of diabetes, have a low prevalence of autoimmune markers, and lack a genetic association with HLA. Their initial presentation is acute, with a few days to weeks of polyuria, polydipsia, and weight loss and lack of a precipitating cause of metabolic decompensation. At presentation, they have markedly impaired insulin secretion and insulin action, but intensified diabetic management results in significant improvement in beta-cell function and insulin sensitivity sufficient to allow discontinuation of insulin therapy within a few months of follow-up. On discontinuation of insulin therapy, the period of near-normoglycemic remission may last for a few months to several years. The absence of autoimmune markers and the presence of measurable insulin secretion have proven useful in predicting near-normoglycemic remission and long-term insulin dependence in adult patients with a history of diabetic ketoacidosis. This clinical presentation is commonly reported in African and African-American persons but is also observed in Hispanic persons and those from other minority ethnic groups. The underlying mechanisms for beta-cell dysfunction in ketosis-prone type 2 diabetes are not known; however, preliminary evidence suggests an increased susceptibility to glucose desensitization.	Emory Univ, Sch Med, Atlanta, GA 30303 USA; Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA	Emory University; University of Tennessee System; University of Tennessee Health Science Center	Umpierrez, GE (corresponding author), Emory Univ, Sch Med, 49 Jesse Hill Jr Dr, Atlanta, GA 30303 USA.	geumpie@emory.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000211, M01RR000039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK073190] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00211, M01-RR00039] Funding Source: Medline; NIDDK NIH HHS [R03 DK073190-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADADEVOH BK, 1968, T ROY SOC TROP MED H, V62, P528; Aguilera E, 2004, DIABETES CARE, V27, P1108, DOI 10.2337/diacare.27.5.1108; Ahren B, 1985, Diabet Med, V2, P262; AIZAWA T, 1995, AM J MED SCI, V310, P198, DOI 10.1097/00000441-199511000-00004; Balasubramanyam A, 1999, ARCH INTERN MED, V159, P2317, DOI 10.1001/archinte.159.19.2317; Banerji MA, 1996, DIABETES, V45, P337, DOI 10.2337/diabetes.45.3.337; BANERJI MA, 1994, DIABETES, V43, P741, DOI 10.2337/diabetes.43.6.741; BANERJI MA, 1990, MEDICINE, V69, P176, DOI 10.1097/00005792-199005000-00005; Barman KK, 2003, POSTGRAD MED J, V79, P606, DOI 10.1136/pmj.79.937.606; Borg H, 2002, DIABETES, V51, P1754, DOI 10.2337/diabetes.51.6.1754; Boutin P, 1999, DIABETOLOGIA, V42, P380; Cefalu WT, 2001, EXP BIOL MED, V226, P13, DOI 10.1177/153537020122600103; DODU SRA, 1967, BMJ-BRIT MED J, V2, P747, DOI 10.1136/bmj.2.5554.747; Ducorps M, 1996, Med Trop (Mars), V56, P264; ELLEMANN K, 1984, DIABETES CARE, V7, P528, DOI 10.2337/diacare.7.6.528; FAICH GA, 1983, AM J EPIDEMIOL, V117, P551, DOI 10.1093/oxfordjournals.aje.a113577; FAJANS SS, 1990, DIABETES CARE, V13, P49, DOI 10.2337/diacare.13.1.49; Fajans SS, 2001, NEW ENGL J MED, V345, P971, DOI 10.1056/NEJMra002168; Frayling TM, 2001, DIABETES, V50, pS94, DOI 10.2337/diabetes.50.2007.S94; Froguel P, 1999, TRENDS ENDOCRIN MET, V10, P142, DOI 10.1016/S1043-2760(98)00134-9; Gosmanov A, 2003, DIABETES, V52, pA287; Gosmanov AR, 2004, AM J PHYSIOL-ENDOC M, V287, pE8, DOI 10.1152/ajpendo.00485.2003; GROOP LC, 1986, DIABETES, V35, P237, DOI 10.2337/diabetes.35.2.237; HAGOPIAN WA, 1993, J CLIN INVEST, V91, P368, DOI 10.1172/JCI116195; Harmon JS, 1999, DIABETES, V48, P1995, DOI 10.2337/diabetes.48.10.1995; HSIN YE, 2001, DIABETIC MED, V18, P895; Kahn SE, 2001, J CLIN ENDOCR METAB, V86, P4047, DOI 10.1210/jc.86.9.4047; Kitabchi AE, 2003, J CLIN ENDOCR METAB, V88, P5087, DOI 10.1210/jc.2003-031656; Kitabchi AE, 2003, DIABETES CARE, V26, P2484, DOI 10.2337/diacare.26.8.2484-a; Kobayashi T, 1996, DIABETES, V45, P622, DOI 10.2337/diabetes.45.5.622; KOBAYASHI T, 1987, DIABETES, V36, P510, DOI 10.2337/diabetes.36.4.510; KOBAYASHI T, 1994, DIABETES RES CLIN PR, V24, pS95, DOI 10.1016/0168-8227(94)90234-8; LEAHY JL, 1992, DIABETES CARE, V15, P442, DOI 10.2337/diacare.15.3.442; Maldonado M, 2003, J CLIN ENDOCR METAB, V88, P5090, DOI 10.1210/jc.2003-030180; Maldonado MR, 2004, ETHNIC DIS, V14, P243; Maldonado MR, 2003, DIABETES CARE, V26, P2469, DOI 10.2337/diacare.26.8.2469; Mauvais-Jarvis F, 2003, DIABETOLOGIA, V46, P728, DOI 10.1007/s00125-003-1093-9; Mauvais-Jarvis F, 2004, HUM MOL GENET, V13, P3151, DOI 10.1093/hmg/ddh341; Mauvais-Jarvis F, 2004, DIABETES, V53, P645, DOI 10.2337/diabetes.53.3.645; McFarlane SI, 2001, DIABETIC MED, V18, P10, DOI 10.1046/j.1464-5491.2001.00395.x; McKinnon CM, 2001, DIABETOLOGIA, V44, P1203, DOI 10.1007/s001250100628; Melloul D, 2002, DIABETES, V51, pS320, DOI 10.2337/diabetes.51.2007.S320; Mohan V, 2003, J CLIN GASTROENTEROL, V36, P337, DOI 10.1097/00004836-200304000-00012; Nagasaka S, 1998, DIABETES CARE, V21, P1376, DOI 10.2337/diacare.21.8.1376; OLI JM, 1978, TROP GEOGR MED, V30, P57; Osman AA, 2000, AM J PHYSIOL-ENDOC M, V278, pE992, DOI 10.1152/ajpendo.2000.278.6.E992; Pinero-Pilona A, 2001, DIABETES CARE, V24, P1014, DOI 10.2337/diacare.24.6.1014; Pinero-Pilona A, 2001, J DIABETES COMPLICAT, V15, P328, DOI 10.1016/S1056-8727(01)00172-6; Pitteloud N, 2000, SCHWEIZ MED WSCHR, V130, P576; Porte D, 2001, DIABETES, V50, pS160, DOI 10.2337/diabetes.50.2007.S160; Pozzilli P, 2001, DIABETES CARE, V24, P1460, DOI 10.2337/diacare.24.8.1460; Rasouli N, 2004, J CLIN ENDOCR METAB, V89, P6331, DOI 10.1210/jc.2004-1016; ROBERTSON RP, 1994, DIABETES, V43, P1085, DOI 10.2337/diabetes.43.9.1085; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; Schiel R, 2000, DIABETES RES CLIN PR, V49, P33, DOI 10.1016/S0168-8227(00)00139-X; Shimajiri Y, 2001, DIABETES, V50, P2864, DOI 10.2337/diabetes.50.12.2864; Sobngwi E, 2002, DIABETIC MED, V19, P832, DOI 10.1046/j.1464-5491.2002.00802.x; Sobngwi E, 2002, DIABETES METAB, V28, P5; Sobngwi E, 2002, DIABETOLOGIA, V45, P283, DOI 10.1007/s00125-001-0739-8; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; Stride A, 2002, ANN MED, V34, P207, DOI 10.1080/713782136; Tan KCB, 2000, DIABETES CARE, V23, P335, DOI 10.2337/diacare.23.3.335; Tuomi T, 1999, DIABETES, V48, P150, DOI 10.2337/diabetes.48.1.150; TUOMI T, 1993, DIABETES, V42, P359, DOI 10.2337/diabetes.42.2.359; Umpierrez GE, 1997, ARCH INTERN MED, V157, P669, DOI 10.1001/archinte.157.6.669; UMPIERREZ GE, 1995, DIABETES, V44, P790, DOI 10.2337/diabetes.44.7.790; Umpierrez GE, 1999, DIABETES CARE, V22, P1517, DOI 10.2337/diacare.22.9.1517; Umpierrez GE, 1997, DIABETES CARE, V20, P479, DOI 10.2337/diacare.20.4.479; Volinic JL, 2006, MOL ENDOCRINOL, V20, P167, DOI 10.1210/me.2005-0127; Wilson C, 1997, ARCH INTERN MED, V157, P2098, DOI 10.1001/archinte.157.18.2098; Winter WE, 2000, CURR OPIN PEDIATR, V12, P388, DOI 10.1097/00008480-200008000-00019; WINTER WE, 1987, NEW ENGL J MED, V316, P285, DOI 10.1056/NEJM198702053160601; Yamada K, 1996, DIABETES CARE, V19, P671, DOI 10.2337/diacare.19.6.671a; Yan SH, 2000, INTERNAL MED, V39, P10, DOI 10.2169/internalmedicine.39.10; YKIJARVINEN H, 1992, ENDOCR REV, V13, P415, DOI 10.1210/er.13.3.415; Zimmet P, 1999, DIABETES CARE, V22, pB59	76	154	165	1	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 7	2006	144	5					350	357		10.7326/0003-4819-144-5-200603070-00011	http://dx.doi.org/10.7326/0003-4819-144-5-200603070-00011			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	021EA	16520476				2022-12-28	WOS:000235965300006
J	Enright, MC				Enright, MC			Genome of an epidemic community-acquired MRSA	LANCET			English	Editorial Material							RESISTANT STAPHYLOCOCCUS-AUREUS		Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, London W2 1PG, England	Imperial College London	Enright, MC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, London W2 1PG, England.	m.c.enright@imperial.ac.uk		Enright, Mark/0000-0001-5273-8750				Biedenbach DJ, 2004, DIAGN MICR INFEC DIS, V50, P59, DOI 10.1016/j.diagmicrobio.2004.05.003; Daum RS, 2002, J INFECT DIS, V186, P1344, DOI 10.1086/344326; Diekema DJ, 2000, INT J ANTIMICROB AG, V13, P257, DOI 10.1016/S0924-8579(99)00131-4; Diep BA, 2006, LANCET, V367, P731, DOI 10.1016/S0140-6736(06)68231-7; Gillet Y, 2002, LANCET, V359, P753, DOI 10.1016/S0140-6736(02)07877-7; Hunt C, 1999, JAMA-J AM MED ASSOC, V282, P1123; JEVONS MP, 1961, BRIT MED J, V1, P124, DOI 10.1136/bmj.1.5219.124-a; Johnson AP, 2001, J ANTIMICROB CHEMOTH, V48, P143, DOI 10.1093/jac/48.1.143; Miller LG, 2005, NEW ENGL J MED, V352, P1445, DOI 10.1056/NEJMoa042683; Robinson DA, 2003, ANTIMICROB AGENTS CH, V47, P3926, DOI 10.1128/AAC.47.12.3926-3934.2003; [No title captured]	11	13	14	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 4	2006	367	9512					705	706		10.1016/S0140-6736(06)68233-0	http://dx.doi.org/10.1016/S0140-6736(06)68233-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	020JX	16517254				2022-12-28	WOS:000235906000004
J	Hammond, D; Collishaw, NE; Callard, C				Hammond, D; Collishaw, NE; Callard, C			Secret science: tobacco industry research on smoking behaviour and cigarette toxicity	LANCET			English	Article							LUNG-CANCER; NICOTINE; SMOKERS	A lack of scientific data remains the principal obstacle to regulating cigarette toxicity. In particular, there is an immediate need to improve our understanding of the interaction between smoking behaviour and product design, and its influence on cigarette deliveries. This article reviews internal tobacco industry documents on smoking behaviour research under-taken by Imperial Tobacco Limited (ITL) and British-American Tobacco (BAT). BAT documents indicate that smokers vary their puffing behaviour to regulate nicotine levels and compensate for low-yield cigarettes by smoking them more intensely. BAT research also shows that the tar and nicotine delivered to smokers is substantially greater than the machine-smoked yields reported to consumers and regulators. Internal documents describe a strategy to maximise this discrepancy through product design. In particular, BAT developed elastic cigarettes that produced low yields under standard testing protocols, whereas in consumers' hands they elicited more intensive smoking and provided higher concentrations of tar and nicotine to smokers. Documents also show that BAT pursued this product strategy despite the health risks to consumers and ethical concerns raised by senior scientists, and paired it with an equally successful marketing campaign that promoted these cigarettes as low-tar alternatives for health-concerned smokers. Overall, the documents seem to reveal a product strategy intended to exploit the limitations of the testing protocols and to intentionally conceal from consumers and regulators the potential toxicity of BAT products revealed by BAT's own research. Tobacco industry research underscores the serious limitations of the current cigarette testing protocols and the documents describe deceptive business practices that remain in place.	Univ Waterloo, Dept Hlth Studies, Waterloo, ON N2L 3G1, Canada; Phys Smoke Free Canada, Ottawa, ON, Canada	University of Waterloo	Hammond, D (corresponding author), Univ Waterloo, Dept Hlth Studies, Waterloo, ON N2L 3G1, Canada.	dhammond@uwaterloo.ca			NCI NIH HHS [P50 CA111236, R01 CA100362] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100362, P50CA111236] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AYRES CI, 1984, P SMOK BEH MARK C 84; BENOWITZ NL, 1996, SMOKING TOBACCO CONT, V7; Bialous SA, 2001, TOB CONTROL, V10, P96, DOI 10.1136/tc.10.2.96; BLACKMAN LCF, 1983, RES C RIO DE JAN BRA; BROOKS G, 1984, P SMOK BEH MARK C JU; BURNS DR, 2001, NCI SMOKING TOBACCO, V13, P65; CREIGHTON D, 1979, COMPARISON HUMAN SMO; CREIGHTON DE, 1977, RD1406; CREIGHTON DE, 1977, EFFECT SMOKING PATTE; Creighton DE., 1984, STRUCTURED CREATIVIT; CREIGHTON DE, 1976, 1300 RD; Djordjevic MV, 2000, JNCI-J NATL CANCER I, V92, P106, DOI 10.1093/jnci/92.2.106; DUNN P, BAT SMOKE ASSESSMENT; DUNN PJ, VARIATIONS TAR NICOT; DUNN PJ, 1983, BAT RES C RIO DE JAN; DUNN PJ, 1975, USE FREIRI SLAVE S 1; *GRIEG CC BAT SOUT, STRUCT CREAT GROUP M; Harris JE, 2004, BMJ-BRIT MED J, V328, P72, DOI 10.1136/bmj.37936.585382.44; HASLAM F, 1977, COMMUNICATION   0913; HAUSER B, 1984, NIC C SOUTH 6 8 JUN; HENNINGFIELD JE, 1993, J CONSULT CLIN PSYCH, V61, P743, DOI 10.1037/0022-006X.61.5.743; HIRJI T, 1982, RES C CAN SIM EFF HU; HIRJI T, 1984, PRODUCT OPPORTUNITIE; Hoffmann D, 1995, J SMOKING RELATED DI, V6, P9; Hurt RD, 1998, JAMA-J AM MED ASSOC, V280, P1173, DOI 10.1001/jama.280.13.1173; itc, 1972, COMMUNICATION   0324; Jarvis MJ, 2001, JNCI-J NATL CANCER I, V93, P134, DOI 10.1093/jnci/93.2.134; KENNEDY JE, 1972, C HUM SMOK HAB IMP T; Kozlowski LT, 2005, TOB CONTROL, V14, P64, DOI 10.1136/tc.2004.009167; Mai SK, 2007, HLTH CONS SMOK REP S, V2, P30; MASSEY SR, 1985, COMMUNICATION   0605; MASSEY SR, 1986, STUDY INVESTIGATION; MCBRIDE C, 1985, INVESTIGATION INTERA; MCBRIDE C, 1986, FURTHER INVESTIGATIO; OLDMAN M, 1982, RES C CAN AUG 1982 U; Polley R, 2001, RISKS ASS SMOKING CI, P199; PROCTOR CJ, POSITION PAPER REGAR; *RJ REYN, 1982, DES CIG COURS OUTL; ROE FJ, 1978, INTEGRATED LEAGUE TA; SANDHU PK, 1987, COMPARISON DELIVERY; Scherer G, 1999, PSYCHOPHARMACOLOGY, V145, P1, DOI 10.1007/s002130051027; SHORT PL, 1977, CIGARETTE DESIGN COM; SLADE J, 1995, JAMA-J AM MED ASSOC, V274, P225, DOI 10.1001/jama.274.3.225; SMITH TA, 1972, COMPENSATION SMOKERS; THORNTON RE, 1978, MEASUREMENT DEGREE V; Thun MJ, 1997, JNCI-J NATL CANCER I, V89, P1580, DOI 10.1093/jnci/89.21.1580; *TOB FREE IN, 2000, FIN REP ADV KNOWL RE; US Department of Health and Human Services, 2001, RISKS ASS SMOK CIG L; YOUSSEF M, 1993, IMPERIAL TOBACCO LTD; YOUSSEF M, 1994, IMPERIAL PROGRESS RE; FED REG, V62, P48158	51	53	55	1	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 4	2006	367	9512					781	787		10.1016/S0140-6736(06)68077-X	http://dx.doi.org/10.1016/S0140-6736(06)68077-X			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	020JX	16517278				2022-12-28	WOS:000235906000032
J	Holtmann, G; Talley, NJ; Liebregts, T; Adam, B; Parow, C				Holtmann, G; Talley, NJ; Liebregts, T; Adam, B; Parow, C			A placebo-controlled trial of itopride in functional dyspepsia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONULCER DYSPEPSIA; HELICOBACTER-PYLORI; DRUG-TREATMENT; RECOMMENDATIONS; METAANALYSIS; DISORDERS; EFFICACY	BACKGROUND: The treatment of patients with functional dyspepsia remains unsatisfactory. We assessed the efficacy of itopride, a dopamine D2 antagonist with acetylcholinesterase effects, in patients with functional dyspepsia. METHODS: Patients with functional dyspepsia were randomly assigned to receive either itopride (50, 100, or 200 mg three times daily) or placebo. After eight weeks of treatment, three primary efficacy end points were analyzed: the change from baseline in the severity of symptoms of functional dyspepsia (as assessed by the Leeds Dyspepsia Questionnaire), patients' global assessment of efficacy (the proportion of patients without symptoms or with marked improvement), and the severity of pain or fullness as rated on a five-grade scale. RESULTS: We randomly assigned 554 patients; 523 had outcome data and could be included in the analyses. After eight weeks, 41 percent of the patients receiving placebo were symptom-free or had marked improvement, as compared with 57 percent, 59 percent, and 64 percent receiving itopride at a dose of 50, 100, or 200 mg three times daily, respectively (P<0.05 for all comparisons between placebo and itopride). Although the symptom score improved significantly in all four groups, an overall analysis revealed that itopride was significantly superior to placebo, with the greatest symptom-score improvement in the 100- and 200-mg groups (-6.24 and -6.27, vs. -4.50 in the placebo group; P=0.05). Analysis of the combined end point of pain and fullness showed that itopride yielded a greater rate of response than placebo (73 percent vs. 63 percent, P=0.04). CONCLUSIONS: Itopride significantly improves symptoms in patients with functional dyspepsia.	Royal Adelaide Hosp, Dept Gastroenterol Hepatol & Gen Med, Adelaide, SA 5000, Australia; Univ Adelaide, Adelaide, SA, Australia; Univ Sydney, Nepean Hosp, Dept Med, Penrith, Australia; Mayo Clin Coll Med, Rochester, MN USA; Abbott, Global Sci Support, Ludwigshafen, Germany	Royal Adelaide Hospital; University of Adelaide; Nepean Hospital; University of Sydney; Mayo Clinic	Holtmann, G (corresponding author), Royal Adelaide Hosp, Dept Gastroenterol Hepatol & Gen Med, N Terrace, Adelaide, SA 5000, Australia.	gholtman@mail.rah.sa.gov.au	Talley, Nicholas J/D-5399-2013; Holtmann, Gerald/S-4065-2019; Holtmann, Gerald/I-5341-2014	Talley, Nicholas J/0000-0003-2537-3092; Holtmann, Gerald/0000-0002-0206-2358				AGREUS L, 1995, GASTROENTEROLOGY, V109, P671, DOI 10.1016/0016-5085(95)90373-9; Andrews CN, 2005, GASTROENTEROLOGY, V128, pA456, DOI 10.1053/j.gastro.2005.09.020; DINAN TG, 1993, J PSYCHOPHARMACOL, V7, P126, DOI 10.1177/026988119300700104; DOBRILLA G, 1989, J CLIN GASTROENTEROL, V11, P169, DOI 10.1097/00004836-198904000-00011; HOLM S, 1979, SCAND J STAT, V6, P65; HOLTMANN G, 1993, DRUGS, V45, P918, DOI 10.2165/00003495-199345060-00005; Holtmann G, 2000, GUT, V47, P332, DOI 10.1136/gut.47.3.332; Holtmann G, 1998, AM J GASTROENTEROL, V93, P1222, DOI 10.1111/j.1572-0241.1998.00399.x; Iwanaga Y, 1996, JPN J PHARMACOL, V71, P129, DOI 10.1254/jjp.71.129; Laine L, 2001, ANN INTERN MED, V134, P361, DOI 10.7326/0003-4819-134-5-200103060-00008; Moayyedi P, 1998, ALIMENT PHARM THER, V12, P1257; Moayyedi P, 2004, GASTROENTEROLOGY, V127, P1329, DOI 10.1053/j.gastro.2004.08.026; RICHTER JE, 1991, SCAND J GASTROENTERO, V26, P11, DOI 10.3109/00365529109109531; SAS Institute, 1990, SAS STAT US GUID, V1; SAS Institute, 1997, SAS STAT SOFTW CHANG; SAS Institute, 1990, SAS STAT US GUID, V2; Talley N, 1991, GASTROENTEROL INT, V4, P145; Talley NI, 1999, ALIMENT PHARM THERAP, V13, P225; Talley NJ, 1999, GUT, V45, P37; TALLEY NJ, 1995, ALIMENT PHARM THER, V9, P107; TALLEY NJ, 1986, GASTROENTEROLOGY, V91, P149, DOI 10.1016/0016-5085(86)90451-8; van Zanten SJOV, 2001, AM J GASTROENTEROL, V96, P689; vanZanten SJOV, 1996, AM J GASTROENTEROL, V91, P660; ZIGHELBOIM, 1993, GASTROENTEROLOGY, V105, P649; ZIGHELBOIM J, 1993, GASTROENTEROLOGY, V104, P1196, DOI 10.1016/0016-5085(93)90293-L	25	177	219	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 23	2006	354	8					832	840		10.1056/NEJMoa052639	http://dx.doi.org/10.1056/NEJMoa052639			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014CL	16495395				2022-12-28	WOS:000235456200007
J	Jarillo-Herrero, P; van Dam, JA; Kouwenhoven, LP				Jarillo-Herrero, P; van Dam, JA; Kouwenhoven, LP			Quantum supercurrent transistors in carbon nanotubes	NATURE			English	Article							SUPERCONDUCTORS	Electronic transport through nanostructures is greatly affected by the presence of superconducting leads(1-3). If the interface between the nanostructure and the superconductors is sufficiently transparent, a dissipationless current (supercurrent) can flow through the device owing to the Josephson effect(4,5). A Josephson coupling, as measured by the zero-resistance supercurrent, has been obtained using tunnel barriers, superconducting constrictions, normal metals and semiconductors. The coupling mechanisms vary from tunnelling to Andreev reflection(5-8). The latter process has hitherto been observed only in normal-type systems with a continuous density of electronic states. Here we investigate a supercurrent flowing through a discrete density of states-that is, the quantized single particle energy states of a quantum dot(9), or 'artificial atom', placed between superconducting electrodes. For this purpose, we exploit the quantum properties of finite-sized carbon nanotubes(10). By means of a gate electrode, successive discrete energy states are tuned on- and off-resonance with the Fermi energy in the superconducting leads, resulting in a periodic modulation of the critical current and a non-trivial correlation between the conductance in the normal state and the supercurrent. We find, in good agreement with existing theory(11), that the product of the critical current and the normal state resistance becomes an oscillating function, in contrast to being constant as in previously explored regimes.	Delft Univ Technol, Kavli Inst Neurosci, NL-2600 GA Delft, Netherlands	Delft University of Technology	Jarillo-Herrero, P (corresponding author), Delft Univ Technol, Kavli Inst Neurosci, POB 5046, NL-2600 GA Delft, Netherlands.	Pablo@qt.tn.tudelft.nl	Jarillo-Herrero, Pablo/E-3755-2013	Jarillo-Herrero, Pablo/0000-0001-8217-8213				ANDREEV AF, 1964, SOV PHYS JETP-USSR, V19, P1228; Babic B, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.195408; BEENAKKER CWJ, 1992, SPRIN S ELE, V31, P175; BLONDER GE, 1982, PHYS REV B, V25, P4515, DOI 10.1103/PhysRevB.25.4515; Buitelaar MR, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.057005; Buitelaar MR, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.256801; Buitelaar MR, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.156801; Choi MS, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.020502; DEGENNES PG, 1964, REV MOD PHYS, V36, P225, DOI 10.1103/RevModPhys.36.225; Doh YJ, 2005, SCIENCE, V309, P272, DOI 10.1126/science.1113523; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; Galaktionov AV, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.184507; Haruyama J, 2004, APPL PHYS LETT, V84, P4714, DOI 10.1063/1.1755416; Jarillo-Herrero P, 2005, NATURE, V434, P484, DOI 10.1038/nature03422; JOSEPHSON BD, 1962, PHYS LETT, V1, P251, DOI 10.1016/0031-9163(62)91369-0; JOYEZ P, 1994, PHYS REV LETT, V72, P2458, DOI 10.1103/PhysRevLett.72.2458; Kasumov AY, 1999, SCIENCE, V284, P1508, DOI 10.1126/science.284.5419.1508; Kouwenhoven L, 2001, PHYS WORLD, V14, P33; Liang WJ, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.126801; Liang WJ, 2001, NATURE, V411, P665, DOI 10.1038/35079517; LIKHAREV KK, 1979, REV MOD PHYS, V51, P101, DOI 10.1103/RevModPhys.51.101; McEuen PL, 2000, PHYS WORLD, V13, P31; Morpurgo AF, 1999, SCIENCE, V286, P263, DOI 10.1126/science.286.5438.263; RALPH DC, 1995, PHYS REV LETT, V74, P3241, DOI 10.1103/PhysRevLett.74.3241; Sapmaz S, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.153402; Sohn L.L., 1997, MESOSCOPIC ELECT TRA; TAKAYANAGI H, 1985, PHYS REV LETT, V54, P2449, DOI 10.1103/PhysRevLett.54.2449; Tinkham M., 1996, INTRO SUPERCONDUCTIV, V2nd ed.	30	302	304	0	114	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 23	2006	439	7079					953	956		10.1038/nature04550	http://dx.doi.org/10.1038/nature04550			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014NE	16495994	Green Submitted			2022-12-28	WOS:000235486100042
J	Saviane, C; Silver, RA				Saviane, C; Silver, RA			Fast vesicle reloading and a large pool sustain high bandwidth transmission at a central synapse	NATURE			English	Article							NEOCORTICAL PYRAMIDAL NEURONS; CEREBELLAR MOSSY FIBER; GRANULE CELL SYNAPSES; SHORT-TERM PLASTICITY; NEUROTRANSMITTER RELEASE; EXCITATORY SYNAPSES; TRANSMITTER RELEASE; RAT; CALYX; PROBABILITY	What limits the rate at which sensory information can be transmitted across synaptic connections in the brain? High-frequency signalling is restricted to brief bursts at many central excitatory synapses(1,2), whereas graded ribbon-type synapses can sustain release(3) and transmit information(4) at high rates. Here we investigate transmission at the cerebellar mossy fibre terminal, which can fire at over 200 Hz for sustained periods in vivo(5), yet makes few synaptic contacts onto individual granule cells(6). We show that connections between mossy fibres and granule cells can sustain high-frequency signalling at physiological temperature. We use fluctuation analysis(7) and pharmacological block of desensitization to identify the quantal determinants of short-term plasticity and combine these with a short-term plasticity model and cumulative excitatory postsynaptic current analysis to quantify the determinants of sustained high-frequency transmission. We show that release is maintained at each release site by rapid reloading of release-ready vesicles from an unusually large releasable pool of vesicles(8) (similar to 300 per site). Our results establish that sustained vesicular release at high rates is not restricted to graded ribbon-type synapses and that mossy fibres are well suited for transmitting broad-bandwidth rate-coded information to the input layer of the cerebellar cortex.	UCL, Dept Physiol, London WC1E 6BT, England	University of London; University College London	Silver, RA (corresponding author), UCL, Dept Physiol, Gower St, London WC1E 6BT, England.	a.silver@ucl.ac.uk		Silver, Robin/0000-0002-5480-6638	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BETZ WJ, 1970, J PHYSIOL-LONDON, V206, P629, DOI 10.1113/jphysiol.1970.sp009034; Chadderton P, 2004, NATURE, V428, P856, DOI 10.1038/nature02442; DiGregorio DA, 2002, NEURON, V35, P521, DOI 10.1016/S0896-6273(02)00787-0; Griesinger CB, 2005, NATURE, V435, P212, DOI 10.1038/nature03567; Hallermann S, 2003, P NATL ACAD SCI USA, V100, P8975, DOI 10.1073/pnas.1432836100; HAMORI J, 1983, J COMP NEUROL, V220, P365, DOI 10.1002/cne.902200402; Hempel CM, 2000, J NEUROPHYSIOL, V83, P3031, DOI 10.1152/jn.2000.83.5.3031; Iwasaki S, 2001, J PHYSIOL-LONDON, V534, P861, DOI 10.1111/j.1469-7793.2001.00861.x; JAKAB RL, 1988, ANAT EMBRYOL, V179, P81, DOI 10.1007/BF00305102; Markram H, 1998, P NATL ACAD SCI USA, V95, P5323, DOI 10.1073/pnas.95.9.5323; Mercer A, 2005, CEREB CORTEX, V15, P1485, DOI 10.1093/cercor/bhi027; Palay SL, 1974, CEREBELLAR CORTEX CO; Rizzoli SO, 2005, NAT REV NEUROSCI, V6, P57, DOI 10.1038/nrn1583; Royle SJ, 2003, J PHYSIOL-LONDON, V553, P345, DOI 10.1113/jphysiol.2003.049221; Sakaba T, 2001, NEURON, V32, P1119, DOI 10.1016/S0896-6273(01)00543-8; Sargent PB, 2005, J NEUROSCI, V25, P8173, DOI 10.1523/JNEUROSCI.2051-05.2005; Scheuss V, 2002, J NEUROSCI, V22, P728, DOI 10.1523/JNEUROSCI.22-03-00728.2002; Schneggenburger R, 1999, NEURON, V23, P399, DOI 10.1016/S0896-6273(00)80789-8; Silver RA, 2003, J NEUROSCI METH, V130, P127, DOI 10.1016/j.jneumeth.2003.09.030; Silver RA, 2003, SCIENCE, V302, P1981, DOI 10.1126/science.1087160; Silver RA, 1996, J PHYSIOL-LONDON, V494, P231, DOI 10.1113/jphysiol.1996.sp021487; Sola E, 2004, J PHYSIOL-LONDON, V557, P843, DOI 10.1113/jphysiol.2003.060285; Taschenberger H, 2002, NEURON, V36, P1127, DOI 10.1016/S0896-6273(02)01137-6; Tsodyks MV, 1997, P NATL ACAD SCI USA, V94, P719, DOI 10.1073/pnas.94.2.719; VANKAN PLE, 1993, J NEUROPHYSIOL, V69, P74, DOI 10.1152/jn.1993.69.1.74; vanSteveninck RRD, 1996, NATURE, V379, P642, DOI 10.1038/379642a0; von Gersdorff H, 2002, NAT REV NEUROSCI, V3, P53, DOI 10.1038/nrn705; Xu-Friedman MA, 2004, PHYSIOL REV, V84, P69, DOI 10.1152/physrev.00016.2003; Xu-Friedman MA, 2003, J NEUROSCI, V23, P2182; Zenisek D, 2000, NATURE, V406, P849, DOI 10.1038/35022500	30	172	174	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 23	2006	439	7079					983	987		10.1038/nature04509	http://dx.doi.org/10.1038/nature04509			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014NE	16496000				2022-12-28	WOS:000235486100049
J	Crawford, BAL; Kam, C; Pavlovic, J; Byth, K; Handelsman, DJ; Angus, PW; McCaughan, GW				Crawford, BAL; Kam, C; Pavlovic, J; Byth, K; Handelsman, DJ; Angus, PW; McCaughan, GW			Zoledronic acid prevents bone loss after liver transplantation - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							PRIMARY BILIARY-CIRRHOSIS; MINERAL DENSITY; INTRAVENOUS BISPHOSPHONATE; CARDIAC TRANSPLANTATION; CYCLICAL ETIDRONATE; OSTEOPOROSIS; DISEASE; CALCITONIN; FRACTURES; THERAPY	Background: Clinically important rapid bone loss occurs within 3 to 6 months after liver transplantation and may be associated with osteoporotic fractures. Objective: To determine whether bisphosphonate treatment with zoledronic acid reduces transplant-related bone loss more than placebo in adults having liver transplantation for chronic liver disease. Design: 12-month randomized, double-blind, placebo-controlled trial. Setting: 2 large liver transplantation centers in Australia. Patients: 62 adults having liver transplantation for chronic liver disease. Interventions: Infusions of zoledronic acid, 4 mg (n = 32), or saline (n = 30) were given within 7 days of transplantation and again at months 1, 3, 6, and 9 after transplantation. All patients received supplementation with calcium carbonate, 600 mg/d, and ergocalciferol, 1000 U/d. Measurements: The primary outcome was bone mineral density (BMD) measured by dual x-ray absorptiometry before transplantation and 3, 6, and 12 months later. Secondary outcomes included bone turnover markers that were measured before transplantation and 1, 3, 6, 9, and 12 months later. Results: There were statistically significant interactions between treatment effects and time for BMD measurements at the lumbar spine (P = 0.002), femoral neck (P = 0.001), and total hip (P < 0.001). Differences in acute bone loss 3 months after transplantation favored zoledronic acid over placebo. Differences between groups in percentage change from baseline adjusted for baseline weight and serum parathyroid hormone (PTH) level were 4.0% (95% Cl, 1.1 % to 7.0%) for the lumbar spine, 4.7% (Cl, 1.9% to 7.6%) for the femoral neck, and 3.8% (Cl, 1.7% to 6.0%) for the total hip. At 12 months after transplantation, the difference in percentage change from baseline between the 2 groups adjusted for baseline weight and serum PTH level was 1.1 % (Cl, -2.1% to 4.4%) for the lumbar spine, 2.7% (Cl, 0.0% to 5.4%) for the femoral neck, and 2.4% (Cl, 0.1% to 4.7%) for the total hip. Treatment with zoledronic acid induced temporary secondary hyperparathyroidism and postinfusion hypocalcemia statistically significantly more often than did placebo. Limitations: The trial was not powered to assess fractures, and 10 of 62 (16%) patients were not included in adjusted analyses because of missing weight or serum PTH measurements. Conclusion: Treatment with zoledronic acid can prevent bone loss within the first year after liver transplantation.	Univ New S Wales, Royal Prince Alfred Hosp, NHMRC Clin Trials Ctr, Liver Unit E9, Camperdown, NSW 2050, Australia; Univ Sydney, Sydney, NSW 2006, Australia; Austin Hlth, Melbourne, Vic, Australia	University of New South Wales Sydney; University of Sydney; University of Sydney; Austin Research Institute; Florey Institute of Neuroscience & Mental Health	McCaughan, GW (corresponding author), Univ New S Wales, Royal Prince Alfred Hosp, NHMRC Clin Trials Ctr, Liver Unit E9, Missenden Rd, Camperdown, NSW 2050, Australia.		Handelsman, David/AAR-9580-2021	MCCAUGHAN, GEOFFREY/0000-0002-1483-1636; Handelsman, David/0000-0002-4200-7476; Byth Wilson, Karen/0000-0002-1253-6393				Chang JT, 2003, NEW ENGL J MED, V349, P1676; Cheer SM, 2001, DRUGS, V61, P799, DOI 10.2165/00003495-200161060-00010; Compston JE, 2003, LIVER TRANSPLANT, V9, P321, DOI 10.1053/jlts.2003.50044; Crawford BAL, 2003, OSTEOPOROSIS INT, V14, P987, DOI 10.1007/s00198-003-1495-z; DIAMOND T, 1989, AM J MED, V86, P282, DOI 10.1016/0002-9343(89)90297-0; DIAMOND TH, 1989, GASTROENTEROLOGY, V96, P213, DOI 10.1016/0016-5085(89)90783-X; Dodidou P, 2003, OSTEOPOROSIS INT, V14, P82, DOI 10.1007/s00198-002-1315-x; Feller RB, 1999, LIVER TRANSPLANT SUR, V5, P407, DOI 10.1002/lt.500050507; Floreani A, 1998, LIVER TRANSPLANT SUR, V4, P311, DOI 10.1002/lt.500040413; Gallego-Rojo FJ, 1998, HEPATOLOGY, V28, P695, DOI 10.1002/hep.510280315; GarciaDelgado I, 1997, CALCIFIED TISSUE INT, V60, P155, DOI 10.1007/s002239900206; Giannini S, 2000, OSTEOPOROSIS INT, V11, P417, DOI 10.1007/s001980070109; GUANABENS N, 1990, AM J GASTROENTEROL, V85, P1356; HANDELSMAN DJ, 1995, CLIN ENDOCRINOL, V43, P331, DOI 10.1111/j.1365-2265.1995.tb02040.x; Hay JE, 2001, J HEPATOL, V34, P292, DOI 10.1016/S0168-8278(00)00093-3; Henderson K, 2001, J BONE MINER RES, V16, P565, DOI 10.1359/jbmr.2001.16.3.565; Hussaini SH, 1999, EUR J GASTROEN HEPAT, V11, P157, DOI 10.1097/00042737-199902000-00016; Keogh JB, 1999, NUTRITION, V15, P661, DOI 10.1016/S0899-9007(99)00121-5; Leslie WD, 2003, GASTROENTEROLOGY, V125, P941, DOI 10.1016/S0016-5085(03)01062-X; Maclsaac RJ, 2002, J ROY SOC MED, V95, P615, DOI 10.1258/jrsm.95.12.615; MCCAUGHAN GW, 1994, DIGEST DIS, V12, P223, DOI 10.1159/000171456; MCDONALD JA, 1991, HEPATOLOGY, V14, P613, DOI 10.1002/hep.1840140407; Monegal A, 1997, CALCIFIED TISSUE INT, V60, P148, DOI 10.1007/s002239900205; Monegal A, 2001, OSTEOPOROSIS INT, V12, P484, DOI 10.1007/s001980170094; NEUHAUS R, 1995, TRANSPLANT P, V27, P1226; Ninkovic M, 2000, EUR J GASTROEN HEPAT, V12, P931, DOI 10.1097/00042737-200012080-00013; Ninkovic M, 2002, J HEPATOL, V37, P93, DOI 10.1016/S0168-8278(02)00100-9; Peter R, 2004, BMJ-BRIT MED J, V328, P335, DOI 10.1136/bmj.328.7435.335; Pocock SJ., 2013, CLIN TRIALS PRACTICA; Reeves HL, 1998, LIVER TRANSPLANT SUR, V4, P404, DOI 10.1002/lt.500040508; Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807; Riemens SC, 1996, OSTEOPOROSIS INT, V6, P213, DOI 10.1007/BF01622737; Shane E, 2004, NEW ENGL J MED, V350, P767, DOI 10.1056/NEJMoa035617; Shane E, 1998, J HEART LUNG TRANSPL, V17, P1089; Smith MR, 2003, J UROLOGY, V169, P2008, DOI 10.1097/01.ju.0000063820.94994.95; STELLON AJ, 1987, HEPATOLOGY, V7, P137, DOI 10.1002/hep.1840070127; VALERO MA, 1995, CALCIFIED TISSUE INT, V57, P15, DOI 10.1007/BF00298990; VanCleemput J, 1996, TRANSPLANTATION, V61, P1495, DOI 10.1097/00007890-199605270-00015	38	105	108	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 21	2006	144	4					239	248		10.7326/0003-4819-144-4-200602210-00005	http://dx.doi.org/10.7326/0003-4819-144-4-200602210-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	015HS	16490909				2022-12-28	WOS:000235543100002
J	Kang, KS; Meng, YS; Breger, J; Grey, CP; Ceder, G				Kang, KS; Meng, YS; Breger, J; Grey, CP; Ceder, G			Electrodes with high power and high capacity for rechargeable lithium batteries	SCIENCE			English	Article							ION BATTERIES; INSERTION MATERIAL; CATHODE MATERIALS; CHEMISTRY; LINI1/2MN1/2O2; DIFFUSION; STABILITY; BEHAVIOR; OXIDES; CHARGE	New applications such as hybrid electric vehicles and power backup require rechargeable batteries that combine high energy density with high charge and discharge rate capability. Using ab initio computational modeling, we identified useful strategies to design higher rate battery electrodes and tested them on lithium nickel manganese oxide [Li(Ni0.5Mn0.5)O-2], a safe, inexpensive material that has been thought to have poor intrinsic rate capability. By modifying its crystal structure, we obtained unexpectedly high rate-capability, considerably better than lithium cobalt oxide (LiCoO2), the current battery electrode material of choice.	MIT, Ctr Mat Sci & Engn, Cambridge, MA 02139 USA; MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA; SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Ceder, G (corresponding author), MIT, Ctr Mat Sci & Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	gceder@mit.edu	Kang, Kisuk/B-5776-2011; Wang, Kevin/E-7153-2011; Grey, Clare P/Q-8860-2017; Ceder, Gerbrand/Y-2544-2019; Meng, Shirley/I-1276-2013	Grey, Clare P/0000-0001-5572-192X; Kang, Kisuk/0000-0002-8696-1886				Armstrong AR, 1996, NATURE, V381, P499, DOI 10.1038/381499a0; Delmas C, 1999, INT J INORG MATER, V1, P11, DOI 10.1016/S1463-0176(99)00003-4; DELMAS C, 1982, REV CHIM MINER, V19, P343; Delmas C, 1997, J POWER SOURCES, V68, P120, DOI 10.1016/S0378-7753(97)02664-5; Grey CP, 2004, ELECTROCHEM SOLID ST, V7, pA290, DOI 10.1149/1.1783113; JIANG J, 2005, J ELECTROCHEM SOC, V152; Kang K, 2003, CHEM MATER, V15, P4503, DOI 10.1021/cm034455+; Kobayashi H, 2003, J MATER CHEM, V13, P590, DOI 10.1039/b211558a; Lu ZH, 2001, ELECTROCHEM SOLID ST, V4, pA191, DOI 10.1149/1.1407994; Lu ZH, 2002, J ELECTROCHEM SOC, V149, pA778, DOI 10.1149/1.1471541; Lu ZH, 2001, ELECTROCHEM SOLID ST, V4, pA200, DOI 10.1149/1.1413182; Makimura Y, 2003, J POWER SOURCES, V119, P156, DOI 10.1016/S0378-7753(03)00170-8; Meng YS, 2005, CHEM MATER, V17, P2386, DOI 10.1021/cm047779m; Ohzuku T, 2001, CHEM LETT, P744; Ohzuku T, 2001, CHEM LETT, P642; Paulsen JM, 2000, J ELECTROCHEM SOC, V147, P2478, DOI 10.1149/1.1393556; Reed J, 2002, ELECTROCHEM SOLID ST, V5, pA145, DOI 10.1149/1.1480135; Thackeray MM, 1997, PROG SOLID STATE CH, V25, P1, DOI 10.1016/S0079-6786(97)81003-5; Van der Ven A, 2000, ELECTROCHEM SOLID ST, V3, P301, DOI 10.1149/1.1391130; Van der Ven A, 2001, J POWER SOURCES, V97-8, P529, DOI 10.1016/S0378-7753(01)00638-3; WHITTINGHAM MS, 1976, SCIENCE, V192, P1126, DOI 10.1126/science.192.4244.1126; Whittingham MS, 1975, US Patent, Patent No. 4007055; Wu EJ, 1998, PHILOS MAG B, V77, P1039, DOI 10.1080/13642819808206403; Yoon WS, 2002, ELECTROCHEM SOLID ST, V5, pA263, DOI 10.1149/1.1513001	24	2179	2256	78	2780	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 17	2006	311	5763					977	980		10.1126/science.1122152	http://dx.doi.org/10.1126/science.1122152			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014CS	16484487				2022-12-28	WOS:000235456900038
J	Shalizi, A; Gaudilliere, B; Yuan, ZQ; Stegmuller, J; Shirogane, T; Ge, QY; Tan, Y; Schulman, B; Harper, JW; Bonni, A				Shalizi, A; Gaudilliere, B; Yuan, ZQ; Stegmuller, J; Shirogane, T; Ge, QY; Tan, Y; Schulman, B; Harper, JW; Bonni, A			A calcium-regulated MEF2 surnoylation switch controls postsynaptic differentiation	SCIENCE			English	Article							TRANSCRIPTION FACTOR MEF2; HISTONE DEACETYLASES; DENDRITE DEVELOPMENT; NERVOUS-SYSTEM; SUMO; ACTIVATION; APOPTOSIS; SYNAPSES; SURVIVAL	Postsynaptic differentiation of dendrites is an essential step in synapse formation. We report here a requirement for the transcription factor myocyte enhancer factor 2A (MEF2A) in the morphogenesis of postsynaptic granule neuron dendritic claws in the cerebellar cortex. A transcriptional repressor form of MEF2A that is sumoylated at lysine-403 promoted dendritic claw differentiation. Activity-dependent calcium signaling induced a calcineurin-mediated dephosphorytation of MEF2A at serine-408 and, thereby, promoted a switch from sumoylation to acetylation at lysine-403, which led to inhibition of dendritic claw differentiation. Our findings define a mechanism underlying postsynaptic differentiation that may modulate activity-dependent synapse development and plasticity in the brain.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Biol & Biomed Sci, Boston, MA 02115 USA; Cell Signaling Technol Inc, Beverly, MA 01915 USA; St Jude Childrens Hosp, Howard Hughes Med Inst, Dept Biol Struct, Memphis, TN 38105 USA; St Jude Childrens Hosp, Howard Hughes Med Inst, Dept Genet, Memphis, TN 38105 USA; St Jude Childrens Hosp, Howard Hughes Med Inst, Dept Tumor Cell Biol, Memphis, TN 38105 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; St Jude Children's Research Hospital; Howard Hughes Medical Institute; St Jude Children's Research Hospital; Howard Hughes Medical Institute; St Jude Children's Research Hospital	Bonni, A (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 77 Louis Pasteur Ave, Boston, MA 02115 USA.	azad_bonni@hms.harvard.edu	Yuan, Zengqiang/G-5245-2017	Shalizi, Aryaman/0000-0001-9226-0800; Yuan, Zengqiang/0000-0001-5739-2867; Harper, Jeffrey/0000-0002-6944-7236	NIA NIH HHS [AG11085] Funding Source: Medline; NINDS NIH HHS [NS41021] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Altman J, 1997, DEV CEREBELLAR SYSTE; Cajal SRY., 1995, HISTOLOGY NERVOUS SY, V1; Gaudilliere B, 2004, NEURON, V41, P229, DOI 10.1016/S0896-6273(03)00841-9; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Gong XM, 2003, NEURON, V38, P33, DOI 10.1016/S0896-6273(03)00191-0; Gregoire S, 2005, MOL CELL BIOL, V25, P2273, DOI 10.1128/MCB.25.6.2273-2287.2005; HAMORI J, 1983, J COMP NEUROL, V220, P365, DOI 10.1002/cne.902200402; Heidenreich KA, 2004, MOL NEUROBIOL, V29, P155, DOI 10.1385/MN:29:2:155; Jan YN, 2003, NEURON, V40, P229, DOI 10.1016/S0896-6273(03)00631-7; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Konishi Y, 2004, SCIENCE, V303, P1026, DOI 10.1126/science.1093712; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Palay S. L., 1974, CEREBELLAR CORTEX CY; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Shalizi AK, 2005, CURR TOP DEV BIOL, V69, P239, DOI 10.1016/S0070-2153(05)69009-6; Whitford KL, 2002, ANNU REV NEUROSCI, V25, P127, DOI 10.1146/annurev.neuro.25.112701.142932; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Zhou Q, 2004, NEURON, V44, P749, DOI 10.1016/j.neuron.2004.11.011; Zhu BM, 2004, MOL CELL BIOL, V24, P8264, DOI 10.1128/MCB.24.18.8264-8275.2004	23	354	367	2	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 17	2006	311	5763					1012	1017		10.1126/science.1122513	http://dx.doi.org/10.1126/science.1122513			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014CS	16484498				2022-12-28	WOS:000235456900049
J	Bangser, M				Bangser, M			Obstetric fistula and stigma	LANCET			English	Editorial Material									Womens Dign Project, Dar Es Salaam, Tanzania		Bangser, M (corresponding author), Womens Dign Project, POB 79402, Dar Es Salaam, Tanzania.	mbangser@womensdignity.org						ABOUZAHR C, 1998, HLTH DIMENSIONS SEX, P243	1	61	62	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 11	2006	367	9509					535	536		10.1016/S0140-6736(06)68188-9	http://dx.doi.org/10.1016/S0140-6736(06)68188-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013FF	16473133				2022-12-28	WOS:000235394500037
J	Reichhardt, T				Reichhardt, T			Science at NASA takes a hit	NATURE			English	News Item																		2006, NATURE, V439, P515	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 9	2006	439	7077					645	645						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	010KH	16496449				2022-12-28	WOS:000235193100013
J	Moller, H; Davies, E				Moller, H; Davies, E			Rate of over-diagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: follow-up study - Commentary: Over-diagnosis in breast cancer screening	BRITISH MEDICAL JOURNAL			English	Editorial Material									Kings Coll London, Thames Canc Registry, London SE1 3QD, England	University of London; King's College London	Moller, H (corresponding author), Kings Coll London, Thames Canc Registry, London SE1 3QD, England.	henrik.moller@kcl.ac.uk		Moller, Henrik/0000-0001-8200-5929; Davies, Elizabeth/0000-0003-2325-0849				Duffy SW, 2005, J MED SCREEN, V12, P128, DOI 10.1258/0969141054855319; International Agency for Research on Cancer, 2002, IARC HDB CANC PREV; Moller B, 2005, EUR J CANCER PREV, V14, P117, DOI 10.1097/00008469-200504000-00007; Zackrisson S, 2006, BRIT MED J, V332, P689, DOI 10.1136/bmj.38764.572569.7C	4	9	9	1	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAR 25	2006	332	7543					691	692		10.1136/bmj.38768.401030.7C	http://dx.doi.org/10.1136/bmj.38768.401030.7C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	027VH	16517549	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000236443300016
J	Pan, XW; Ye, P; Yuan, DS; Wang, XL; Bader, JS; Boeke, JD				Pan, XW; Ye, P; Yuan, DS; Wang, XL; Bader, JS; Boeke, JD			A DNA integrity network in the yeast Saccharomyces cerevisiae	CELL			English	Article							SISTER-CHROMATID COHESION; S-PHASE; DAMAGE CHECKPOINT; CELL-CYCLE; REPLICATION STRESS; PROTEIN COMPLEXES; GENES; IDENTIFICATION; REPAIR; MRC1	A network governing DNA integrity was identified in yeast by a global genetic analysis of synthetic fitness or lethality defect (SFL) interactions. Within this network, 16 functional modules or minipathways were defined based on patterns of global SFL interactions. Modules or genes involved in DNA replication, DNA-replication checkpoint (DRC) signaling, and oxidative stress response were identified as the major guardians against lethal spontaneous DNA damage, efficient repair of which requires the functions of the DNA-damage checkpoint signaling and multiple DNA-repair pathways. This genome-wide genetic interaction network also identified novel components (DIA2, NPT1, HST3, HST4, and the CSM1 module) that potentially contribute to mitotic DNA replication and genomic stability and revealed novel functions of well-studied genes (the CTF18 module) in DRC signaling. This network will guide more detailed characterization of mechanisms governing DNA integrity in yeast and other organisms.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, High Throughput Biol Ctr, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Boeke, JD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 733 N Broadway, Baltimore, MD 21205 USA.	jboeke@jhmi.edu	Bader, Joel/A-1818-2009	Bader, Joel/0000-0002-6020-4625; Boeke, Jef/0000-0001-5322-4946	NCRR NIH HHS [RR020839] Funding Source: Medline; NHGRI NIH HHS [HG02432] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020839] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002432] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Amon A, 1998, P NATL ACAD SCI USA, V95, P85, DOI 10.1073/pnas.95.1.85; Bao MZ, 2004, CELL, V119, P991, DOI 10.1016/j.cell.2004.11.052; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bassett DE, 1997, NAT GENET, V15, P339, DOI 10.1038/ng0497-339; Bennett CB, 2001, NAT GENET, V29, P426, DOI 10.1038/ng778; Birrell GW, 2001, P NATL ACAD SCI USA, V98, P12608, DOI 10.1073/pnas.231366398; Brachmann CB, 1998, YEAST, V14, P115; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; Costanzo M, 2004, CELL, V117, P899, DOI 10.1016/j.cell.2004.05.024; de Bruin RAM, 2004, CELL, V117, P887, DOI 10.1016/j.cell.2004.05.025; Dimmer KS, 2002, MOL BIOL CELL, V13, P847, DOI 10.1091/mbc.01-12-0588; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Enyenihi AH, 2003, GENETICS, V163, P47; Foss EJ, 2001, GENETICS, V157, P567; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Giannattasio M, 2005, J BIOL CHEM, V280, P9879, DOI 10.1074/jbc.M414453200; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Grunweller A, 2002, GENETICS, V162, P59; Hartman JL, 2001, SCIENCE, V291, P1001, DOI 10.1126/science.291.5506.1001; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Huang ME, 2005, MOL CELL, V17, P709, DOI 10.1016/j.molcel.2005.02.008; Huang ME, 2003, P NATL ACAD SCI USA, V100, P11529, DOI 10.1073/pnas.2035018100; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Kelley R, 2005, NAT BIOTECHNOL, V23, P561, DOI 10.1038/nbt1096; Kolodner RD, 2002, SCIENCE, V297, P552, DOI 10.1126/science.1075277; Krogan NJ, 2004, P NATL ACAD SCI USA, V101, P13513, DOI 10.1073/pnas.0405753101; Kus BM, 2004, PROTEINS, V54, P455, DOI 10.1002/prot.10620; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lemoine FJ, 2005, CELL, V120, P587, DOI 10.1016/j.cell.2004.12.039; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Mayer ML, 2001, MOL CELL, V7, P959, DOI 10.1016/S1097-2765(01)00254-4; Mayer ML, 2004, MOL BIOL CELL, V15, P1736, DOI 10.1091/mbc.E03-08-0619; Merrill BJ, 1998, GENETICS, V148, P611; Morrison AJ, 2005, CELL CYCLE, V4, P568; Myung KJ, 2001, CELL, V104, P397, DOI 10.1016/S0092-8674(01)00227-6; Naiki T, 2001, MOL CELL BIOL, V21, P5838, DOI 10.1128/MCB.21.17.5838-5845.2001; Osborn AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/gad.1098303; Pan XW, 2004, MOL CELL, V16, P487, DOI 10.1016/j.molcel.2004.09.035; Parsons AB, 2004, NAT BIOTECHNOL, V22, P62, DOI 10.1038/nbt919; Rabitsch KP, 2003, DEV CELL, V4, P535, DOI 10.1016/S1534-5807(03)00086-8; Rajavel M, 1998, BIOCHEMISTRY-US, V37, P4181, DOI 10.1021/bi9720134; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Schuldiner M, 2005, CELL, V123, P507, DOI 10.1016/j.cell.2005.08.031; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sharp JA, 2001, CURR BIOL, V11, P463, DOI 10.1016/S0960-9822(01)00140-3; Shen XT, 2003, MOL CELL, V12, P147, DOI 10.1016/S1097-2765(03)00264-8; Sutton A, 2001, MOL CELL BIOL, V21, P3514, DOI 10.1128/MCB.21.10.3514-3522.2001; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Warren CD, 2004, MOL BIOL CELL, V15, P1724, DOI 10.1091/mbc.E03-09-0637; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X; Wysocka M, 2004, EXP CELL RES, V294, P592, DOI 10.1016/j.yexcr.2003.12.008; Xu H, 2004, MOL CELL BIOL, V24, P7082, DOI 10.1128/MCB.24.16.7082-7090.2004; Ye P, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100034; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	60	433	450	2	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 10	2006	124	5					1069	1081		10.1016/j.cell.2005.12.036	http://dx.doi.org/10.1016/j.cell.2005.12.036			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	038RQ	16487579	Bronze			2022-12-28	WOS:000237241200026
J	Zhong, WW; Sternberg, PW				Zhong, WW; Sternberg, PW			Genome-wide prediction of C-elegans genetic interactions	SCIENCE			English	Article							PROTEIN; NETWORKS; KINASE; TOOL; MAP		CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Sternberg, PW (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.	pws@caltech.edu						Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Baudot A, 2006, BIOINFORMATICS, V22, P248, DOI 10.1093/bioinformatics/bti757; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; Boulton SJ, 2002, SCIENCE, V295, P127, DOI 10.1126/science.1065986; Clandinin TR, 1998, CELL, V92, P523, DOI 10.1016/S0092-8674(00)80945-9; Gunsalus KC, 2005, NATURE, V436, P861, DOI 10.1038/nature03876; IWASAKI K, 1995, P NATL ACAD SCI USA, V92, P10317, DOI 10.1073/pnas.92.22.10317; Jansen R, 2003, SCIENCE, V302, P449, DOI 10.1126/science.1087361; Lee I, 2004, SCIENCE, V306, P1555, DOI 10.1126/science.1099511; Lee J, 2004, J MOL BIOL, V344, P585, DOI 10.1016/j.jmb.2004.09.050; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; Moghal N, 2003, DEVELOPMENT, V130, P4553, DOI 10.1242/dev.00670; O'Brien KP, 2005, NUCLEIC ACIDS RES, V33, pD476, DOI 10.1093/nar/gki107; Rhodes DR, 2005, NAT BIOTECHNOL, V23, P951, DOI 10.1038/nbt1103; Schwarz EM, 2006, NUCLEIC ACIDS RES, V34, pD475, DOI 10.1093/nar/gkj061; Troyanskaya OG, 2003, P NATL ACAD SCI USA, V100, P8348, DOI 10.1073/pnas.0832373100; Walker DS, 2002, MOL BIOL CELL, V13, P1329, DOI 10.1091/mbc.01-08-0422; Wong SL, 2004, P NATL ACAD SCI USA, V101, P15682, DOI 10.1073/pnas.0406614101; WU Y, 1994, GENE DEV, V8, P147, DOI 10.1101/gad.8.2.147	20	205	229	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2006	311	5766					1481	1484		10.1126/science.1123287	http://dx.doi.org/10.1126/science.1123287			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527984				2022-12-28	WOS:000236029400055
J	Deeks, SG				Deeks, SG			Challenges of developing R5 inhibitors in antiretroviral naive HIV-infected patients	LANCET			English	Editorial Material							SHORT-TERM MONOTHERAPY; CCR5 ANTAGONIST; EFFICACY; THERAPY; SAFETY		Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA 94110 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Deeks, SG (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA 94110 USA.	sdeeks@php.ucsf.edu						AJEUBOR MN, 2005, J IMMUNOL, V174, P8207; Deeks SG, 2003, LANCET, V362, P2002, DOI 10.1016/S0140-6736(03)15022-2; Fatkenheuer G, 2005, NAT MED, V11, P1170, DOI 10.1038/nm1319; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; GREAVES W, 2006, 13 C RETR OPP INF; Gulick RM, 2004, NEW ENGL J MED, V350, P1850, DOI 10.1056/NEJMoa031772; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; Lalezari J, 2005, AIDS, V19, P1443, DOI 10.1097/01.aids.0000183633.06580.8a; Mocroft A, 2004, J INFECT DIS, V190, P1947, DOI 10.1086/425424; Moore JP, 2004, AIDS RES HUM RETROV, V20, P111, DOI 10.1089/088922204322749567; Moreno C, 2005, HEPATOLOGY, V42, P854, DOI 10.1002/hep.20865; Spudich SS, 2005, J INFECT DIS, V191, P890, DOI 10.1086/428095; Wolinsky SM, 2004, VIROLOGY, V328, P19, DOI 10.1016/j.virol.2004.07.021	13	17	17	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 4	2006	367	9512					711	713		10.1016/S0140-6736(06)68280-9	http://dx.doi.org/10.1016/S0140-6736(06)68280-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	020JX	16517257				2022-12-28	WOS:000235906000007
J	Jorgensen, KJ; Gotzsche, PC				Jorgensen, KJ; Gotzsche, PC			Content of invitations for publicly funded screening mammography	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SWEDISH RANDOMIZED TRIALS; CARCINOMA IN-SITU; BREAST-CANCER; UNITED-STATES; BENEFITS; INFORMATION; SWEDEN; HARMS; WOMEN		Rigshosp, Nordic Cochrane Ctr, Dept 7112, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen	Jorgensen, KJ (corresponding author), Rigshosp, Nordic Cochrane Ctr, Dept 7112, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	kj@cochrane.dk		Jorgensen, Karsten/0000-0001-8554-0388				Aro AR, 2000, EUR J CANCER, V36, P1089, DOI 10.1016/S0959-8049(00)00065-4; Barratt A, 1999, J EPIDEMIOL COMMUN H, V53, P716, DOI 10.1136/jech.53.11.716; Barratt A, 2005, BMJ-BRIT MED J, V330, P936, DOI 10.1136/bmj.38398.469479.8F; Barratt AL, 1997, MED J AUSTRALIA, V167, P521, DOI 10.5694/j.1326-5377.1997.tb138871.x; Bonfill X., 2001, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002943, DOI 10.1002/14651858.CD002943]; Chamot E, 2004, MED DECIS MAKING, V24, P379, DOI 10.1177/0272989X04267011; Consedine NS, 2004, CANCER EPIDEM BIOMAR, V13, P501; Croft E, 2002, J FAM PRACTICE, V51, P858; Domenighetti G, 2003, INT J EPIDEMIOL, V32, P816, DOI 10.1093/ije/dyg257; Domenighetti Gianfranco, 2000, Health Expect, V3, P145; Douek M, 2003, BRIT J SURG, V90, P44; Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601; FAHEY T, 1995, BRIT MED J, V311, P1056, DOI 10.1136/bmj.311.7012.1056; *GMC, SEEK PAT CONS ETH CO; Gotzsche PC, 2004, INT J EPIDEMIOL, V33, P56, DOI 10.1093/ije/dyh014; Humphrey LL, 2002, ANN INTERN MED, V137, P347, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00012; Jonsson H, 2005, INT J CANCER, V117, P842, DOI 10.1002/ijc.21228; Jorgensen KJ, 2004, BMJ-BRIT MED J, V328, P148, DOI 10.1136/bmj.328.7432.148; Kosters J P, 2003, Cochrane Database Syst Rev, pCD003373, DOI 10.1002/14651858.CD003373; MILLER D, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002942.PUB2; Nystrom L, 2002, LANCET, V359, P909, DOI 10.1016/S0140-6736(02)08020-0; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; Olsen O, 2001, LANCET, V358, P1340, DOI 10.1016/S0140-6736(01)06449-2; Perry N, 2001, EUROPEAN GUIDELINES; Rasky E, 2004, SOZ PRAVENTIV MED, V49, P391, DOI 10.1007/s00038-004-3092-0; Schwartz LM, 2000, BMJ-BRIT MED J, V320, P1635, DOI 10.1136/bmj.320.7250.1635; Schwartz LM, 2004, JAMA-J AM MED ASSOC, V291, P71, DOI 10.1001/jama.291.1.71; Slaytor EK, 1998, BRIT MED J, V317, P263, DOI 10.1136/bmj.317.7153.263; Smith-Bindman R, 2003, JAMA-J AM MED ASSOC, V290, P2129, DOI 10.1001/jama.290.16.2129; Spix C, 2003, STAT MED, V22, P2877, DOI 10.1002/sim.1533; Vainio H, 2002, IARC HDB CANC PREVEN, V7; Welch HG, 1997, ANN INTERN MED, V127, P1023, DOI 10.7326/0003-4819-127-11-199712010-00014; Welch HG, 2004, SHOULD I BE TESTED C; Zahl PH, 2004, JAMA-J AM MED ASSOC, V292, P2579, DOI 10.1001/jama.292.21.2579; Zahl PH, 2004, BMJ-BRIT MED J, V328, P921, DOI 10.1136/bmj.38044.666157.63	35	104	104	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 4	2006	332	7540					538	541		10.1136/bmj.332.7540.538	http://dx.doi.org/10.1136/bmj.332.7540.538			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	023WB	16513713	Green Published			2022-12-28	WOS:000236155800020
J	Yasui-Furukori, N; Kaneko, S				Yasui-Furukori, N; Kaneko, S			Digitalis intoxication induced by paroxetine co-administration	LANCET			English	Editorial Material							P-GLYCOPROTEIN; DEPRESSION; DISEASE		Hirosaki Univ, Sch Med, Dept Neuropsychiat, Hirosaki, Aomori 0368562, Japan	Hirosaki University	Yasui-Furukori, N (corresponding author), Hirosaki Univ, Sch Med, Dept Neuropsychiat, Hirosaki, Aomori 0368562, Japan.	yasufuru@cc.hirosaki-u.ac.jp						Koren G, 1998, VET HUM TOXICOL, V40, P45; Mitka M, 2005, JAMA-J AM MED ASSOC, V293, P283, DOI 10.1001/jama.293.3.283; Musselman DL, 1998, ARCH GEN PSYCHIAT, V55, P580, DOI 10.1001/archpsyc.55.7.580; Solai LK, 2002, J CLIN PSYCHOPHARM, V22, P481, DOI 10.1097/00004714-200210000-00007; Weiss J, 2003, J PHARMACOL EXP THER, V305, P197, DOI 10.1124/jpet.102.046532	5	14	15	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 4	2006	367	9512					788	788		10.1016/S0140-6736(06)68306-2	http://dx.doi.org/10.1016/S0140-6736(06)68306-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	020JX	16517279				2022-12-28	WOS:000235906000033
J	Jenni, S; Leibundgut, M; Maier, T; Ban, N				Jenni, S; Leibundgut, M; Maier, T; Ban, N			Architecture of a fungal fatty acid synthase at 5 angstrom resolution	SCIENCE			English	Article							ACYL CARRIER PROTEIN; COENZYME-A CARBOXYLASE; CRYSTAL-STRUCTURE; MYCOBACTERIUM-TUBERCULOSIS; SACCHAROMYCES-CEREVISIAE; MULTIENZYME COMPLEX; SUBSTRATE-BINDING; YEAST; SYNTHETASE; BIOSYNTHESIS	All steps of fatty acid synthesis in fungi are catalyzed by the fatty acid synthase, which forms a 2.6-megadalton alpha(6)beta(6) complex. We have determined the molecular architecture of this multienzyme by fitting the structures of homologous enzymes that catalyze the individual steps of the reaction pathway into a 5 angstrom x-ray crystallographic electron density map. The huge assembly contains two separated reaction chambers, each equipped with three sets of active sites separated by distances up to similar to 130 angstroms, across which acyl carrier protein shuttles substrates during the reaction cycle. Regions of the electron density arising from well-defined structural features outside the catalytic domains separate the two reaction chambers and serve as a matrix in which domains carrying the various active sites are embedded. The structure rationalizes the compartmentalization of fatty acid synthesis, and the spatial arrangement of the active sites has specific implications for our understanding of the reaction cycle mechanism and of the architecture of multienzymes in general.	Swiss Fed Inst Technol, Dept Biol, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Jenni, S (corresponding author), Swiss Fed Inst Technol, Dept Biol, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland.	ban@mol.biol.ethz.ch	Maier, Timm/A-8835-2016	Maier, Timm/0000-0002-7459-1363				Brown DW, 1996, P NATL ACAD SCI USA, V93, P14873, DOI 10.1073/pnas.93.25.14873; Davis MS, 2001, J BACTERIOL, V183, P1499, DOI 10.1128/JB.183.4.1499-1503.2001; Dover LG, 2004, FEMS MICROBIOL REV, V28, P225, DOI 10.1016/j.femsre.2003.10.001; Fichtlscherer F, 2000, EUR J BIOCHEM, V267, P2666, DOI 10.1046/j.1432-1327.2000.01282.x; Fisher M, 2000, STRUCTURE, V8, P339, DOI 10.1016/S0969-2126(00)00115-5; FOX JL, 1980, EUR J BIOCHEM, V109, P417, DOI 10.1111/j.1432-1033.1980.tb04810.x; HACKENJOS WA, 1987, BIOL CHEM H-S, V368, P19, DOI 10.1515/bchm3.1987.368.1.19; HORI T, 1987, J BIOCHEM-TOKYO, V101, P949, DOI 10.1093/oxfordjournals.jbchem.a121964; Huang XY, 2001, ANNU REV BIOCHEM, V70, P149, DOI 10.1146/annurev.biochem.70.1.149; Keatinge-Clay AT, 2003, STRUCTURE, V11, P147, DOI 10.1016/S0969-2126(03)00004-2; Kimber MS, 2004, J BIOL CHEM, V279, P52593, DOI 10.1074/jbc.M408105200; Kolodziej SJ, 1996, J BIOL CHEM, V271, P28422, DOI 10.1074/jbc.271.45.28422; Kolodziej SJ, 1997, J STRUCT BIOL, V120, P158, DOI 10.1006/jsbi.1997.3911; Koski MK, 2005, J MOL BIOL, V345, P1157, DOI 10.1016/j.jmb.2004.11.009; Kostrewa D, 2005, PROTEIN SCI, V14, P1570, DOI 10.1110/ps.051373005; LINDQVIST Y, 1991, J BIOL CHEM, V266, P3198; LYNEN F, 1980, EUR J BIOCHEM, V112, P431; Maier T, 2006, SCIENCE, V311, P1258, DOI 10.1126/science.1123248; Nagano N, 2002, J MOL BIOL, V321, P741, DOI 10.1016/S0022-2836(02)00649-6; Olsen JG, 1999, FEBS LETT, V460, P46, DOI 10.1016/S0014-5793(99)01303-4; Parris KD, 2000, STRUCT FOLD DES, V8, P883, DOI 10.1016/S0969-2126(00)00178-7; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; Schweizer E, 2004, MICROBIOL MOL BIOL R, V68, P501, DOI 10.1128/MMBR.68.3.501-517.2004; Smith S, 2003, PROG LIPID RES, V42, P289, DOI 10.1016/S0163-7827(02)00067-X; STOOPS JK, 1980, P NATL ACAD SCI-BIOL, V77, P4544, DOI 10.1073/pnas.77.8.4544; STOOPS JK, 1992, P NATL ACAD SCI USA, V89, P6585, DOI 10.1073/pnas.89.14.6585; STOOPS JK, 1978, J BIOL CHEM, V253, P4464; SUMPER M, 1969, EUR J BIOCHEM, V10, P377, DOI 10.1111/j.1432-1033.1969.tb00701.x; Takayama K, 2005, CLIN MICROBIOL REV, V18, P81, DOI 10.1128/CMR.18.1.81-101.2005; Tang LJ, 1997, J BACTERIOL, V179, P3697, DOI 10.1128/jb.179.11.3697-3705.1997; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; Watanabe CMH, 2002, CHEM BIOL, V9, P981, DOI 10.1016/S1074-5521(02)00213-2; WERKMEISTER K, 1981, EUR J BIOCHEM, V116, P303, DOI 10.1111/j.1432-1033.1981.tb05334.x; White SW, 2005, ANNU REV BIOCHEM, V74, P791, DOI 10.1146/annurev.biochem.74.082803.133524; WIELAND F, 1978, P NATL ACAD SCI USA, V75, P5792, DOI 10.1073/pnas.75.12.5792; Woloshuk CP, 1998, FEMS MICROBIOL LETT, V160, P169, DOI [10.1111/j.1574-6968.1998.tb12907.x, 10.1016/S0378-1097(97)00588-0]	37	120	125	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	2006	311	5765					1263	1267		10.1126/science.1123251	http://dx.doi.org/10.1126/science.1123251			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019XB	16513976				2022-12-28	WOS:000235870400034
J	Mischenko, AS; Zhang, Q; Scott, JF; Whatmore, RW; Mathur, ND				Mischenko, AS; Zhang, Q; Scott, JF; Whatmore, RW; Mathur, ND			Giant electrocaloric effect in thin-film PbZr0.95Ti0.05O3	SCIENCE			English	Article							CERAMICS; POLARIZATION; CAPACITORS	An applied electric field can reversibly change the temperature of an electrocaloric material under adiabatic conditions, and the effect is strongest near phase transitions. We demonstrate a giant electrocaloric effect (0.48 kelvin per volt) in 350-nanometer PbZr0.95Ti0.05O3 films near the ferroelectric Curie temperature of 222-degrees. A large electrocaloric effect may find application in electrical refrigeration.	Univ Cambridge, Dept Mat Sci, Cambridge CB2 3QZ, England; Cranfield Univ, Sch Ind & Mfg Sci, Dept Adv Mat, Cranfield MK43 0AL, Beds, England; Univ Cambridge, Dept Earth Sci, Ctr Ferro, Cambridge CB2 3EQ, England	University of Cambridge; Cranfield University; University of Cambridge	Mischenko, AS (corresponding author), Univ Cambridge, Dept Mat Sci, Pembroke St, Cambridge CB2 3QZ, England.	am507@cam.ac.uk	Whatmore, Roger/AFU-5459-2022	Whatmore, Roger/0000-0001-9455-5848; Zhang, Qi/0000-0002-1368-4259	EPSRC [EP/D506638/1] Funding Source: UKRI; Engineering and Physical Sciences Research Council [EP/D506638/1] Funding Source: researchfish	EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		DAVITADZE ST, 2003, THESIS LOMONOSOV MOS; Ellerkmann U, 2003, INTEGR FERROELECTR, V52, P63, DOI 10.1080/10584580390254123; Fatuzzo E., 1967, FERROELECTRICITY; Fu DS, 2002, JPN J APPL PHYS 2, V41, pL1103, DOI 10.1143/JJAP.41.L1103; Jona F., 1962, FERROELECTRIC CRYSTA; KINGSMITH RD, 1993, PHYS REV B, V47, P1651, DOI 10.1103/PhysRevB.47.1651; LAWLESS WN, 1977, PHYS REV B, V16, P433, DOI 10.1103/PhysRevB.16.433; Lines M.E., 2001, PRINCIPLES APPL FERR; Maki K, 2003, INTEGR FERROELECTR, V52, P19, DOI 10.1080/10584580390254088; Mitsui T., 1976, INTRO PHYS FERROELEC; NYE JF, 2003, PHYS PROPERTIES CRYS, pCH10; OSBOND PC, 1991, FERROELECTRICS, V118, P93, DOI 10.1080/00150199108014749; PAN WY, 1989, J APPL PHYS, V66, P6014, DOI 10.1063/1.343578; RESTA R, 1994, REV MOD PHYS, V66, P899, DOI 10.1103/RevModPhys.66.899; Saad MM, 2004, J PHYS-CONDENS MAT, V16, pL451, DOI 10.1088/0953-8984/16/41/L04; SAWAGUCHI E, 1953, J PHYS SOC JPN, V8, P615, DOI 10.1143/JPSJ.8.615; Scott J.F., 2000, FERROELECTRIC MEMORI; STRUKOV BA, 1967, SOV PHYS CRYSTALLOGR, V11, P757; SUCHANEK G, 2002, MAT RES SOC P, V718; THACHER PD, 1968, J APPL PHYS, V39, P1996, DOI 10.1063/1.1656478; TUTTLE BA, 1981, FERROELECTRICS, V37, P603, DOI 10.1080/00150198108223496; TUTTLE BA, 1981, THESIS U ILLINOIS UR; Whatmore R. W., 1977, THESIS CAMBRIDGE U; WHATMORE RW, 1978, J PHYS C SOLID STATE, V11, P3089, DOI 10.1088/0022-3719/11/14/029; Zhang Q, 2004, J PHYS D APPL PHYS, V37, P98, DOI 10.1088/0022-3727/37/1/016; Zhang Q, 2003, J APPL PHYS, V94, P5228, DOI 10.1063/1.1613370	26	1224	1260	32	620	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	2006	311	5765					1270	1271		10.1126/science.1123811	http://dx.doi.org/10.1126/science.1123811			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019XB	16513978	Green Submitted			2022-12-28	WOS:000235870400036
J	Martin, W; Koonin, EV				Martin, W; Koonin, EV			Introns and the origin of nucleus-cytosol compartmentalization	NATURE			English	Article							EXON THEORY; RNA DECAY; EVOLUTION; TRANSLATION; GENES; EUKARYOTES; CLASSIFICATION; PHYLOGENY; CONTAIN; NETWORK	The origin of the eukaryotic nucleus marked a seminal evolutionary transition. We propose that the nuclear envelope's incipient function was to allow mRNA splicing, which is slow, to go to completion so that translation, which is fast, would occur only on mRNA with intact reading frames. The rapid, fortuitous spread of introns following the origin of mitochondria is adduced as the selective pressure that forged nucleus - cytosol compartmentalization.	Univ Dusseldorf, Inst Bot 3, D-40225 Dusseldorf, Germany; Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA	Heinrich Heine University Dusseldorf; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Martin, W (corresponding author), Univ Dusseldorf, Inst Bot 3, D-40225 Dusseldorf, Germany.	w.martin@uni-duesseldorf.de	Martin, William F./O-5446-2015; Martin, William/C-5680-2008	Martin, William F./0000-0003-1478-6449; 	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Adl SM, 2005, J EUKARYOT MICROBIOL, V52, P399, DOI 10.1111/j.1550-7408.2005.00053.x; Anantharaman V, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-12-r81; Audibert A, 2002, MOL CELL BIOL, V22, P6706, DOI 10.1128/MCB.22.19.6706-6718.2002; Cavalier-Smith T, 2002, INT J SYST EVOL MICR, V52, P297, DOI 10.1099/00207713-52-2-297; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; Collins L, 2005, MOL BIOL EVOL, V22, P1053, DOI 10.1093/molbev/msi091; Cosson B, 2003, BIOL CELL, V95, P321, DOI 10.1016/S0248-4900(03)00059-5; Cousineau B, 2001, NATURE, V414, P84, DOI 10.1038/35102087; Dahlberg JE, 2004, CURR OPIN CELL BIOL, V16, P335, DOI 10.1016/j.ceb.2004.03.006; DARNELL JE, 1978, SCIENCE, V202, P1257, DOI 10.1126/science.364651; DARNELL JE, 1986, P NATL ACAD SCI USA, V83, P1271, DOI 10.1073/pnas.83.5.1271; DOOLITTLE W F, 1991, Current Biology, V1, P145, DOI 10.1016/0960-9822(91)90214-H; Doolittle WE, 1998, TRENDS GENET, V14, P307; DOOLITTLE WF, 1980, TRENDS BIOCHEM SCI, V5, P146; DOOLITTLE WF, 1978, NATURE, V272, P581, DOI 10.1038/272581a0; Fasken MB, 2005, NAT STRUCT MOL BIOL, V12, P482, DOI 10.1038/nsmb945; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; FINLAY BJ, 1992, EUR J PROTISTOL, V28, P127, DOI 10.1016/S0932-4739(11)80041-6; Forterre P, 1999, BIOESSAYS, V21, P871, DOI 10.1002/(SICI)1521-1878(199910)21:10<871::AID-BIES10>3.0.CO;2-Q; Gabaldon T, 2003, SCIENCE, V301, P609, DOI 10.1126/science.1085463; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GILBERT W, 1987, COLD SPRING HARB SYM, V52, P901, DOI 10.1101/SQB.1987.052.01.098; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; HEATH IB, 1980, INT REV CYTOL, V64, P1, DOI 10.1016/S0074-7696(08)60235-1; Hrdy I, 2004, NATURE, V432, P618, DOI 10.1038/nature03149; Iborra FJ, 2001, SCIENCE, V293, P1139, DOI 10.1126/science.1061216; Jeffares DC, 1998, J MOL EVOL, V46, P18, DOI 10.1007/PL00006280; Khusial P, 2005, TRENDS BIOCHEM SCI, V30, P522, DOI 10.1016/j.tibs.2005.07.006; Lambowitz AM, 2004, ANNU REV GENET, V38, P1, DOI 10.1146/annurev.genet.38.072902.091600; Levine T, 2005, CURR OPIN CELL BIOL, V17, P362, DOI 10.1016/j.ceb.2005.06.005; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; Lynch M, 2003, SCIENCE, V302, P1401, DOI 10.1126/science.1089370; Lynch M, 2002, CURR OPIN GENET DEV, V12, P701, DOI 10.1016/S0959-437X(02)00360-X; Makarova KS, 2005, NUCLEIC ACIDS RES, V33, P4626, DOI 10.1093/nar/gki775; Mans BJ, 2004, CELL CYCLE, V3, P1612; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; Nixon JEJ, 2002, P NATL ACAD SCI USA, V99, P3701, DOI 10.1073/pnas.042700299; PALMITER RD, 1975, CELL, V4, P189, DOI 10.1016/0092-8674(75)90167-1; Poole A, 1999, BIOESSAYS, V21, P880, DOI 10.1002/(SICI)1521-1878(199910)21:10<880::AID-BIES11>3.0.CO;2-P; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Rivera MC, 2004, NATURE, V431, P152, DOI 10.1038/nature02848; ROGER AJ, 1993, NATURE, V364, P289, DOI 10.1038/364289a0; Rogozin IB, 2003, CURR BIOL, V13, P1512, DOI 10.1016/S0960-9822(03)00558-X; Roy SW, 2005, P NATL ACAD SCI USA, V102, P5773, DOI 10.1073/pnas.0500383102; Simpson AGB, 2002, NATURE, V419, P270, DOI 10.1038/419270a; SORENSEN MA, 1989, J MOL BIOL, V207, P365, DOI 10.1016/0022-2836(89)90260-X; Staub E, 2004, BIOESSAYS, V26, P567, DOI 10.1002/bies.20032; STOLTZFUS A, 1994, SCIENCE, V265, P202, DOI 10.1126/science.8023140; Tovar J, 2003, NATURE, V426, P172, DOI 10.1038/nature01945; van der Giezen M, 2005, EMBO REP, V6, P525, DOI 10.1038/sj.embor.7400440; Vanacova S, 2005, P NATL ACAD SCI USA, V102, P4430, DOI 10.1073/pnas.0407500102; Vellai T, 1998, J MOL EVOL, V46, P499, DOI 10.1007/PL00006331; von Dohlen CD, 2001, NATURE, V412, P433, DOI 10.1038/35086563; Yang S, 2005, P NATL ACAD SCI USA, V102, P373, DOI 10.1073/pnas.0408810102	57	357	368	0	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	2006	440	7080					41	45		10.1038/nature04531	http://dx.doi.org/10.1038/nature04531			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017HW	16511485				2022-12-28	WOS:000235685700034
J	Rudick, RA; Stuart, WH; Calabresi, PA; Confavreux, C; Galetta, SL; Radue, EW; Lublin, FD; Weinstock-Guttman, B; Wynn, DR; Lynn, F; Panzara, MA; Sandrock, AW; Fazekas, F; Enzinger, C; Seifert, T; Storch, M; Strasser-Fuchs, S; Berger, T; Dilitz, E; Egg, R; Deisenhammer, F; Decoo, D; Lampaert, J; Bartholome, E; Bier, J; Stenager, E; Rasmussen, M; Binzer, M; Shorsh, K; Christensen, M; Ravnborg, M; Sorensen, PS; Blinkenberg, M; Petersen, B; Hansen, HJ; Bech, E; Petersen, T; Kirkegaard, M; Eralinna, J; Ruutiainen, J; Soilu-Hanninen, M; Sako, E; Laaksonen, M; Reunanen, M; Remes, A; Keskinarkaus, I; Moreau, T; Noblet, M; Rouaud, O; Couvreur, G; Edan, G; LePage, E; Drapier, S; De Burghgraeve, V; Yaouanq, J; Merienne, M; Cahagne, V; Gout, O; Deschamps, R; Le Canuet, P; Moulignier, A; Vermersch, P; De Seze, J; Stojkovic, T; Griffie, G; Engles, A; Ferriby, D; Debouverie, M; Pittion-Vouyouvitch, S; Lacour, JC; Pelletier, J; Feuillet, L; Suchet, L; Dalecky, A; Tammam, D; Lubetzki, C; Youssov, K; Mrejen, S; Charles, P; Yaici, S; Clavelou, P; Aufauvre, D; Renouil-Guy, N; Cesaro, P; Degos, F; Benisty, S; Rumbach, L; Decavel, P; Confavreux, C; Blanc, S; Aubertin, P; Riche, G; Brochet, B; Ouallet, JC; Anne, O; Menck, S; Grupe, A; Guttman, E; Lensch, E; Fucik, E; Heitmann, S; Hartung, HP; Schroter, M; Kurz, FMW; Heidenreich, F; Trebst, C; Pul, R; Hohlfeld, R; Krumbholz, M; Pellkofer, H; Haas, J; Segert, A; Anagnostou, P; Meyer, R; Kabus, C; Poehlau, D; Schneider, K; Hoffmann, V; Zettl, U; Steinhagen, V; Adler, S; Steinbrecher, A; Rothenfusser-Korber, E; Zellner, R; Baum, K; Gunther, A; Blasing, H; Stoll, G; Gold, R; Bayas, A; Kleinschnitz, C; Limmroth, V; Katsarava, Z; Kastrup, O; Haller, P; Stoeve, S; Hobel, D; Oschmann, P; Voigt, K; Burger, CV; Abramsky, O; Karusiss, D; Achiron, A; Kishner, I; Stern, Y; Sarove-Pinhas, I; Dolev, M; Magalashvili, D; Pozzili, C; Lenzi, D; Scontrini, A; Millefiorini, E; Buttinelli, C; Gallo, P; Ranzato, F; Tiberio, M; Perini, P; Laroni, A; Marrosu, M; Marchi, ECP; Spinicci, G; Massole, S; Mascia, M; Floris, G; Trojano, M; Bellacosa, A; Paolicelli, D; Zimatore, GB; Simone, IL; Giorelli, M; Di Monte, E; Mancardi, G; Pizzorno, M; Murialdo, A; Narciso, E; Capello, A; Comi, G; Martinelli, V; Rodegher, M; Esposito, F; Colombo, B; Rossi, P; Polman, CH; Jasperse, MMS; Zwemmer, JNP; Nielsen, J; Kragt, JJ; Jongen, PJH; De Smet, E; Tacken, H; Frequin, STFM; Siegers, HP; Mauser, HW; Fernandez-Fernandez, O; Leon, A; Romero, F; Alonso, A; Tamayo, J; Montalban, X; Nos, C; Pelayo, R; Tellez, N; Rio, J; Tintore, M; Arbizu, T; Romero, L; Moral, E; Martinez, S; Kappos, L; Achtnichts, L; Wilmes, S; Karabudak, R; Kurne, A; Erdem, S; Siva, A; Saip, S; Altintas, A; Atamer, A; Eraksoy, M; Bilgili, F; Topcular, B; Giovannoni, G; Lim, ET; Lava, N; Murnane, M; Dentinger, M; Zimmerman, E; Reiss, M; Gupta, V; Scott, T; Brillman, J; Kunschner, L; Wright, D; Perel, A; Babu, A				Rudick, RA; Stuart, WH; Calabresi, PA; Confavreux, C; Galetta, SL; Radue, EW; Lublin, FD; Weinstock-Guttman, B; Wynn, DR; Lynn, F; Panzara, MA; Sandrock, AW; Fazekas, F; Enzinger, C; Seifert, T; Storch, M; Strasser-Fuchs, S; Berger, T; Dilitz, E; Egg, R; Deisenhammer, F; Decoo, D; Lampaert, J; Bartholome, E; Bier, J; Stenager, E; Rasmussen, M; Binzer, M; Shorsh, K; Christensen, M; Ravnborg, M; Sorensen, PS; Blinkenberg, M; Petersen, B; Hansen, HJ; Bech, E; Petersen, T; Kirkegaard, M; Eralinna, J; Ruutiainen, J; Soilu-Hanninen, M; Sako, E; Laaksonen, M; Reunanen, M; Remes, A; Keskinarkaus, I; Moreau, T; Noblet, M; Rouaud, O; Couvreur, G; Edan, G; LePage, E; Drapier, S; De Burghgraeve, V; Yaouanq, J; Merienne, M; Cahagne, V; Gout, O; Deschamps, R; Le Canuet, P; Moulignier, A; Vermersch, P; De Seze, J; Stojkovic, T; Griffie, G; Engles, A; Ferriby, D; Debouverie, M; Pittion-Vouyouvitch, S; Lacour, JC; Pelletier, J; Feuillet, L; Suchet, L; Dalecky, A; Tammam, D; Lubetzki, C; Youssov, K; Mrejen, S; Charles, P; Yaici, S; Clavelou, P; Aufauvre, D; Renouil-Guy, N; Cesaro, P; Degos, F; Benisty, S; Rumbach, L; Decavel, P; Confavreux, C; Blanc, S; Aubertin, P; Riche, G; Brochet, B; Ouallet, JC; Anne, O; Menck, S; Grupe, A; Guttman, E; Lensch, E; Fucik, E; Heitmann, S; Hartung, HP; Schroter, M; Kurz, FMW; Heidenreich, F; Trebst, C; Pul, R; Hohlfeld, R; Krumbholz, M; Pellkofer, H; Haas, J; Segert, A; Anagnostou, P; Meyer, R; Kabus, C; Poehlau, D; Schneider, K; Hoffmann, V; Zettl, U; Steinhagen, V; Adler, S; Steinbrecher, A; Rothenfusser-Korber, E; Zellner, R; Baum, K; Gunther, A; Blasing, H; Stoll, G; Gold, R; Bayas, A; Kleinschnitz, C; Limmroth, V; Katsarava, Z; Kastrup, O; Haller, P; Stoeve, S; Hobel, D; Oschmann, P; Voigt, K; Burger, CV; Abramsky, O; Karusiss, D; Achiron, A; Kishner, I; Stern, Y; Sarove-Pinhas, I; Dolev, M; Magalashvili, D; Pozzili, C; Lenzi, D; Scontrini, A; Millefiorini, E; Buttinelli, C; Gallo, P; Ranzato, F; Tiberio, M; Perini, P; Laroni, A; Marrosu, M; Marchi, ECP; Spinicci, G; Massole, S; Mascia, M; Floris, G; Trojano, M; Bellacosa, A; Paolicelli, D; Zimatore, GB; Simone, IL; Giorelli, M; Di Monte, E; Mancardi, G; Pizzorno, M; Murialdo, A; Narciso, E; Capello, A; Comi, G; Martinelli, V; Rodegher, M; Esposito, F; Colombo, B; Rossi, P; Polman, CH; Jasperse, MMS; Zwemmer, JNP; Nielsen, J; Kragt, JJ; Jongen, PJH; De Smet, E; Tacken, H; Frequin, STFM; Siegers, HP; Mauser, HW; Fernandez-Fernandez, O; Leon, A; Romero, F; Alonso, A; Tamayo, J; Montalban, X; Nos, C; Pelayo, R; Tellez, N; Rio, J; Tintore, M; Arbizu, T; Romero, L; Moral, E; Martinez, S; Kappos, L; Achtnichts, L; Wilmes, S; Karabudak, R; Kurne, A; Erdem, S; Siva, A; Saip, S; Altintas, A; Atamer, A; Eraksoy, M; Bilgili, F; Topcular, B; Giovannoni, G; Lim, ET; Lava, N; Murnane, M; Dentinger, M; Zimmerman, E; Reiss, M; Gupta, V; Scott, T; Brillman, J; Kunschner, L; Wright, D; Perel, A; Babu, A		SENTINEL Investigators	Natalizumab plus interferon beta-1a for relapsing multiple sclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; CONTROLLED TRIAL; DISABILITY; METHOTREXATE; COMBINATION; EXPRESSION; THERAPY; MULTICENTER	Background: Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon beta therapy, many patients have relapses. Natalizumab, an (alpha)(sub 4) integrin antagonist, appeared to be safe and effective alone and when added to interferon beta-1a in preliminary studies. Methods: We randomly assigned 1171 patients who, despite interferon beta-1a therapy, had had at least one relapse during the 12-month period before randomization to receive continued interferon beta-1a in combination with 300 mg of natalizumab (589 patients) or placebo (582 patients) intravenously every 4 weeks for up to 116 weeks. The primary end points were the rate of clinical relapse at 1 year and the cumulative probability of disability progression sustained for 12 weeks, as measured by the Expanded Disability Status Scale, at 2 years. Results: Combination therapy resulted in a 24 percent reduction in the relative risk of sustained disability progression (hazard ratio, 0.76; 95 percent confidence interval, 0.61 to 0.96; P=0.02). Kaplan-Meier estimates of the cumulative probability of progression at two years were 23 percent with combination therapy and 29 percent with interferon beta-1a alone. Combination therapy was associated with a lower annualized rate of relapse over a two-year period than was interferon beta-1a alone (0.34 vs. 0.75, P<0.001) and with fewer new or enlarging lesions on T(sub 2)-weighted magnetic resonance imaging (0.9 vs. 5.4, P<0.001). Adverse events associated with combination therapy were anxiety, pharyngitis, sinus congestion, and peripheral edema. Two cases of progressive multifocal leukoencephalopathy, one of which was fatal, were diagnosed in natalizumab-treated patients. Conclusions: Natalizumab added to interferon beta-1a was significantly more effective than interferon beta-1a alone in patients with relapsing multiple sclerosis. Additional research is needed to elucidate the benefits and risks of this combination treatment.	Cleveland Clin Fdn, Mellen Ctr Multiple Sclerosis Treatment & Res, 9500 Euclid Ave, Cleveland, OH 44195 USA; MS Ctr Atlanta, Atlanta, GA USA; Johns Hopkins Multiple Sclerosis Ctr, Baltimore, MD USA; Hop Neurol, Lyon, France; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Univ Basel Hosp, CH-4031 Basel, Switzerland; Mt Sinai Sch Med, New York, NY USA; SUNY Buffalo, Buffalo, NY USA; Multiple Sclerosis Ctr, Northbrook, IL USA; Biogen Idec Inc, Cambridge, MA USA; Univ Klin Neurol, Graz, Austria; Univ Klin Neurol, Innsbruck, Austria; Elizabeth Ziekenhuis, Sijsele, Belgium; Erasme Univ Hosp, Brussels, Belgium; Scleroseklinik, Sydvestjysk Sygehus, Esbjerg, Denmark; Scleroseklinik, Rigshosp, Copenhagen, Denmark; Aarhus Hosp, Scleroseklinik, Neurologisk Afdeling F, Aarhus, Denmark; Finnish Special Neurol Ctr, Turku, Finland; Oulu Univ Hosp, Oulu, Finland; Ctr Hosp Univ, Dijon, France; Ctr Hosp Univ, Rennes, France; Hop Rothschild, Paris, France; Hop B Roger Salengro, Lille, France; Ctr Hosp, Nancy, France; Hop Adultes Timone, Marseille, France; Hop La Pitie Salpetriere, Paris, France; Hop Gabriel Montpied, Clermont Ferrand, France; Hop Henri Mondor, Creteil, France; Hop Jean Minjoz, Besancon, France; Hop Neurol, Lyon, France; Hop Pellegrin, Bordeaux, France; Asklepios Klin Schildautal, Seesen, Germany; Asklepios Klin Schildautal, Harz, Germany; Deutsch Klin Diagnost, Wiesbaden, Germany; Univ Dusseldorf, Dusseldorf, Germany; Henrietten Stiftung Hannover, Hannover, Germany; Inst Klin Neuroimmunol, Munich, Germany; Judisches Krakenhaus, Berlin, Germany; Kamillus Klin, Asbach, Germany; Neurol Klin & Poliklin, Rostock, Germany; Univ Regensburg, Neurol Klin & Poliklin, Regensburg, Germany; Krankenhaus Hennigsdorf, Hennigsdorf, Germany; Neurol Klin & Poliklin, Wurzburg, Germany; Univ Klinikum Essen, Essen, Germany; Stadtische Klin Osnabruck, Osnabruck, Germany; Univ Giessen Klinikum, Giessen, Germany; Hadassah Univ Hosp Ein Kerem, Jerusalem, Israel; MS Ctr, Tel Hashomer, Israel; Univ Roma La Sapienza, Policlin Umberto I, Rome, Italy; Azienda Osped Padova, Clin Neurol 1, Padua, Italy; Osped Binaghi, Ctr Reg Sclerosi Multipla, Cagliari, Italy; Univ Bari, Policlin Bari, Dipartimento Sci Neurol & Psichiat, Bari, Italy; Univ Genoa, Clin Neurol, Dipartimento Neurosci Oftalmol & Genet, Genoa, Italy; Univ Vita Salute Dimer, Milan, Italy; Acad Ziekenhuis, Amsterdam, Netherlands; Multiple Sclerose Ctr, Nijmegen, Netherlands; St Antonius Hosp, Nieuwegein, Netherlands; Complejo Hosp Carlos Haya, Malaga, Spain; Hosp Gen Valle Hebron, Barcelona, Spain; Serv Neurol, Unitat Esclerosis Multiple, Barcelona, Spain; Univ Hosp Basel, Basel, Switzerland; Hacettepe Univ, Ankara, Turkey; Istanbul Univ, Istanbul, Turkey; Istanbul Univ, Istanbul, Turkey; Natl Hosp Neurol & Neurosurg, London, England; Albany Med Ctr, Albany, NY USA; Alexian Bros Ctrv Clin Res, Elk Grove Village, IL USA; Allegheny Singer Res Inst, Pittsburgh, PA USA; Alpha Neurol, Staten Isl, NY USA	Cleveland Clinic Foundation; Johns Hopkins University; Johns Hopkins Medicine; CHU Lyon; University of Pennsylvania; University of Basel; Icahn School of Medicine at Mount Sinai; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Biogen; Universite Libre de Bruxelles; Rigshospitalet; University of Copenhagen; Aarhus University; University of Oulu; CHU Dijon Bourgogne; CHU Rennes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Rothschild - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite de Lille - ISITE; CHU Lille; CHU de Nancy; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Clermont Ferrand; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Universite de Franche-Comte; CHU Besancon; CHU Lyon; CHU Bordeaux; Heinrich Heine University Dusseldorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Regensburg; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Duisburg Essen; University Hospital of Giessen & Marburg; Hebrew University of Jerusalem; Sapienza University Rome; University Hospital Sapienza Rome; University of Padua; Azienda Ospedaliera - Universita di Padova; Universita degli Studi di Bari Aldo Moro; University of Genoa; St. Antonius Hospital Utrecht; Hospital Carlos Haya; Hospital Universitari Vall d'Hebron; University of Basel; Hacettepe University; Istanbul University; Istanbul University; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Albany Medical College	Rudick, RA (corresponding author), Cleveland Clin Fdn, Mellen Ctr Multiple Sclerosis Treatment & Res, 9500 Euclid Ave, Cleveland, OH 44195 USA.	rudickr@ccf.org	Edan, Gilles/AAI-5944-2020; Ranzato, Francesco/X-7250-2019; Alessandra, Murialdo/AAA-9033-2022; Macedo, Ana/L-9912-2018; Stenager, Egon/O-2275-2017; Mancardi, Giovanni Luigi/K-8656-2016; Martinelli, Vittorio/AAN-7240-2020; , Bier/H-3536-2019; Altintas, Ayse/AAO-6416-2020; katsarava, zaza/AAH-6404-2019; STOJKOVIC, Tanya/AAA-3967-2021; Laroni, Alice/K-4714-2016; Esposito, Felice/AAC-4646-2019; Suchet, Laurent/AAK-1698-2020; Stenager, Egon/AAU-4463-2020; Lublin, Fred/L-8405-2017; Ranzato, Francesco/G-5170-2012; Drapier, Sylvain/O-9439-2019; Siva, Aksel/A-5132-2016; Eraksoy, Mefkure/AAE-4872-2020; Calabresi, Peter A./AAF-2288-2019; Simone, sabella laura/K-9755-2018	Ranzato, Francesco/0000-0003-0159-0068; Alessandra, Murialdo/0000-0003-2124-3768; Macedo, Ana/0000-0002-6978-8989; Mancardi, Giovanni Luigi/0000-0001-8427-118X; Altintas, Ayse/0000-0002-8524-5087; katsarava, zaza/0000-0002-9932-1159; Laroni, Alice/0000-0001-5599-9788; Esposito, Felice/0000-0003-1051-5924; Drapier, Sylvain/0000-0003-1795-9034; Siva, Aksel/0000-0002-8340-6641; Panzara, Michael/0000-0003-2810-4832				BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; Beck A.T., 1996, BDI 2 BECK DEPRESSIO, DOI [10.1037/t00742-000, DOI 10.1037/T00742-000]; Beck RW, 2002, ANN NEUROL, V51, P481, DOI 10.1002/ana.10148; Berger JR, 2005, NEW ENGL J MED, V353, P414, DOI 10.1056/NEJMe058122; Calabresi PA, 1997, NEUROLOGY, V49, P1111, DOI 10.1212/WNL.49.4.1111; Calabresi PA, 1997, ANN NEUROL, V41, P669, DOI 10.1002/ana.410410517; Carman CV, 2004, J CELL BIOL, V167, P377, DOI 10.1083/jcb.200404129; Clair EWS, 2004, ARTHRITIS RHEUM-US, V50, P3432, DOI 10.1002/art.20568; Clanet M, 2002, NEUROLOGY, V59, P1507, DOI 10.1212/01.WNL.0000032256.35561.D6; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0; Ebers GC, 1999, LANCET, V353, P678; Gerards AH, 2003, ANN RHEUM DIS, V62, P1126; Gerards AH, 2003, ANN RHEUM DIS, V62, P291, DOI 10.1136/ard.62.4.291; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; Jacobs LD, 2000, NEW ENGL J MED, V343, P898, DOI 10.1056/NEJM200009283431301; Jacobs LD, 1996, ANN NEUROL, V40, P480; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; Kleinschmidt-DeMasters BK, 2005, NEW ENGL J MED, V353, P369, DOI 10.1056/NEJMoa051782; Kozovska ME, 1999, NEUROLOGY, V53, P1692, DOI 10.1212/WNL.53.8.1692; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Langer-Gould A, 2005, NEW ENGL J MED, V353, P375, DOI 10.1056/NEJMoa051847; Lehman AJ, 2005, ARTHRITIS RHEUM-US, V52, P1360, DOI 10.1002/art.21018; LOBB RR, 1994, J CLIN INVEST, V94, P1722, DOI 10.1172/JCI117519; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Muraro PA, 2004, J NEUROIMMUNOL, V150, P123, DOI 10.1016/j.jneuroim.2004.01.002; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; Rep MHG, 1996, J NEUROIMMUNOL, V67, P111; Rudick R, 1998, NEUROLOGY, V50, pA342; Rudick R, 1997, ANN NEUROL, V42, P379, DOI 10.1002/ana.410420318; Rudick RA, 2004, ANN NEUROL, V56, P548, DOI 10.1002/ana.20224; Schreiber K, 2001, ACTA NEUROL SCAND, V104, P24, DOI 10.1034/j.1600-0404.2001.00041.x; Traboulsee A, 2003, MULT SCLER J, V9, P566, DOI 10.1191/1352458503ms958oa; Van Assche G, 2005, NEW ENGL J MED, V353, P362, DOI 10.1056/NEJMoa051586; Vollmer TL, 2004, MULT SCLER J, V10, P511, DOI 10.1191/1352458504ms1084oa; Weinblatt ME, 2003, ARTHRITIS RHEUM-US, V48, P35, DOI 10.1002/art.10697; WEINBLATT ME, 2004, ARTHRITIS RHEUM, V50, P144; WEINSHENKER BG, 1989, BRAIN, V112, P133, DOI 10.1093/brain/112.1.133; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; Yousry TA, 2006, NEW ENGL J MED, V354, P924, DOI 10.1056/NEJMoa054693; Zang YCQ, 2001, J NEUROIMMUNOL, V112, P174, DOI 10.1016/S0165-5728(00)00397-0	43	962	999	0	49	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 2	2006	354	9					911	923		10.1056/NEJMoa044396	http://dx.doi.org/10.1056/NEJMoa044396			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	017FN	16510745				2022-12-28	WOS:000235679600004
J	Cisse, B; Sokhna, C; Boulanger, D; Milet, J; Ba, EH; Richardson, K; Hallett, R; Sutherland, C; Simondon, K; Simondon, F; Alexander, N; Gaye, O; Targett, G; Lines, J; Greenwood, B; Trape, JF				Cisse, B; Sokhna, C; Boulanger, D; Milet, J; Ba, EH; Richardson, K; Hallett, R; Sutherland, C; Simondon, K; Simondon, F; Alexander, N; Gaye, O; Targett, G; Lines, J; Greenwood, B; Trape, JF			Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial	LANCET			English	Article							PLASMODIUM-FALCIPARUM; DIHYDROFOLATE-REDUCTASE; IRON SUPPLEMENTATION; CHILDHOOD MORTALITY; TANZANIAN INFANTS; SEVERE ANEMIA; CHEMOPROPHYLAXIS; RESISTANCE; CHLOROQUINE; GAMBIA	Background In the Sahel and sub-Sahelian regions of Africa, malaria transmission is highly seasonal. During a short period of high malaria transmission, mortality and morbidity are high in children under age 5 years. We assessed the efficacy of seasonal intermittent preventive treatment-a lull dose of antimalarial treatment given at defined times without previous testing for malaria infection. Methods We did a randomised, placebo-controlled, double-blind trial of the effect of intermittent preventive treatment on morbidity from malaria in three health-care centres in Niakhar, a rural area of Senegal. 1136 children aged 2-59 months received either one dose of artesunate plus one dose of sulfadoxine-pyrimethamine or two placebos on three occasions during the malaria transmission season. The primary outcome was a first or single episode of clinical malaria detected through active or passive case detection. Primary analysis was by intention-to-treat. This study is registered with ClinicalTrials.gov, number NCT00132561. Findings During 13 weeks of follow-up, the intervention led to an 86% (95% CI 80-90) reduction in the occurrence of clinical episodes of malaria. With passive case detection, protective efficacy against malaria was 86% (77-92), and when detected actively was 86% (78-91). The incidence of malaria in children on active drugs was 308 episodes per 1000 person-years at risk, whereas in those on placebo it was 2250 episodes per 1000 person-years at risk. 13 children were not included in the intention-to-treat analysis, which was restricted to children who received a first dose of antimalarial or placebo. There was an increase in vomiting in children who received the active drugs, but generally the intervention was well tolerated. Interpretation Intermittent preventive treatment could be highly effective for prevention of malaria in children under 5 years of age living in areas of seasonal malaria infection.	London Sch Hyg & Trop Med, London WC1B 3DP, England; Inst Rech Dev, Dakar, Senegal; Univ Cheikh Anta Diop Dakar, Dakar, Senegal	University of London; London School of Hygiene & Tropical Medicine; Institut de Recherche pour le Developpement (IRD); University Cheikh Anta Diop Dakar	Cisse, B (corresponding author), London Sch Hyg & Trop Med, London WC1B 3DP, England.	badara.cisse@lshtm.ac.uk	Sutherland, Colin/AAN-3939-2020; BOULANGER, Denis/G-9644-2016	Sutherland, Colin/0000-0003-1592-6407; BOULANGER, Denis/0000-0002-8757-0350; Lines, Jo/0000-0001-5380-4916; Bork, Kirsten/0000-0002-5909-7332; MILET, Jacqueline/0000-0003-2710-1517; Simondon, Francois/0000-0003-0395-1314	Medical Research Council [G0700837] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALLEN SJ, 1990, J TROP MED HYG, V93, P313; BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133, DOI 10.1080/02724936.1993.11747637; Delaunay V, 2001, INT J EPIDEMIOL, V30, P1286, DOI 10.1093/ije/30.6.1286; Desai MR, 2003, J INFECT DIS, V187, P658, DOI 10.1086/367986; DICKO A, 2004, AM J TROP MED HYG  S, V71, P6; Doherty JF, 1999, T ROY SOC TROP MED H, V93, P543, DOI 10.1016/S0035-9203(99)90376-0; Etard JF, 2004, INT J EPIDEMIOL, V33, P1286, DOI 10.1093/ije/dyh259; Geerligs PDP, 2003, B WORLD HEALTH ORGAN, V81, P205; Greenwood B, 2004, AM J TROP MED HYG, V70, P1; GREENWOOD BM, 1988, LANCET, V1, P1121; *INT PREV TREATM I, INT PREV TREATM INF; Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x; Marsh K, 1998, LANCET, V352, P924, DOI 10.1016/S0140-6736(05)61510-3; Massaga JJ, 2003, LANCET, V361, P1853, DOI 10.1016/S0140-6736(03)13504-0; MCGREGOR IA, 1956, BRIT MED J, V2, P686, DOI 10.1136/bmj.2.4994.686; Menendez C, 1997, LANCET, V350, P844, DOI 10.1016/S0140-6736(97)04229-3; NDIAYE F, 1998, ENDEMIE PALUSTRE SIT, P118; OMEARA WP, 2005, MALARIA J, V4, pE33; Pearce RJ, 2003, ANTIMICROB AGENTS CH, V47, P1347, DOI 10.1128/AAC.47.4.1347-1354.2003; PLOWE CV, 1995, AM J TROP MED HYG, V52, P565, DOI 10.4269/ajtmh.1995.52.565; Rapuoda B, 2003, TROP MED INT HEALTH, V8, P860, DOI 10.1046/j.1360-2276.2003.01114.x; Robert V, 1998, TROP MED INT HEALTH, V3, P667, DOI 10.1046/j.1365-3156.1998.00288.x; Schellenberg D, 2005, LANCET, V365, P1481, DOI 10.1016/S0140-6736(05)66418-5; Schellenberg D, 2001, LANCET, V357, P1471, DOI 10.1016/S0140-6736(00)04643-2; SCHULTZ LJ, 1994, AM J TROP MED HYG, V51, P515, DOI 10.4269/ajtmh.1994.51.515; Shulman CE, 1999, LANCET, V353, P632, DOI 10.1016/S0140-6736(98)07318-8; Trape JF, 1998, CR ACAD SCI III-VIE, V321, P689, DOI 10.1016/S0764-4469(98)80009-7; TRAPE JF, 1994, 4 C INT SOC OUEST AF, P40; Trigg JK, 1997, ACTA TROP, V63, P185, DOI 10.1016/S0001-706X(96)00617-1; Verhoef H, 2002, LANCET, V360, P908, DOI 10.1016/S0140-6736(02)11027-0; Verhoeff FH, 1998, ANN TROP MED PARASIT, V92, P141, DOI 10.1080/00034989859979; von Seidlein L, 2003, T ROY SOC TROP MED H, V97, P217, DOI 10.1016/S0035-9203(03)90125-8; von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X; White NJ, 2005, PLOS MED, V2, P28, DOI 10.1371/journal.pmed.0020003; *WHO DEP CHILD AD, 2002, PROP MORT FIV REG ES; *WHO EXP COMM, 2001, PREL M MIT PROT DEV; *WHO UNICEF, 2003, AFR MAL REP	37	154	157	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 25	2006	367	9511					659	667		10.1016/S0140-6736(06)68264-0	http://dx.doi.org/10.1016/S0140-6736(06)68264-0			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	016HR	16503464				2022-12-28	WOS:000235611800030
J	Karin, M; Lawrence, T; Nizet, V				Karin, M; Lawrence, T; Nizet, V			Innate immunity gone awry: Linking microbial infections to chronic inflammation and cancer	CELL			English	Review							NF-KAPPA-B; RECEPTOR TYROSINE KINASE; TUMOR-NECROSIS-FACTOR; IKK-BETA; CROHNS-DISEASE; APOPTOTIC CELLS; DENDRITIC CELLS; MICE LACKING; RIG-I; TNF	Clinical and epidemiologic studies have suggested an association between infectious agents and chronic inflammatory disorders and cancer. Better understanding of microbial pattern-recognition receptors and innate immune signaling pathways of the host is helping to elucidate the connection between microbial infection and chronic disease. We propose that a key aspect of pathogenesis is an aberrant epithelial barrier that can be instigated by microbial toxins, environmental insults, or the genetic predisposition of the host. Loss of epithelial integrity results in activation of resident inflammatory cells by microbial invaders or endogenous ligands. When coupled with a failure of normal control mechanisms that limit leukocyte activation, a cascade is established that induces chronic inflammation and its consequences. Here, we outline this mechanistic framework and briefly review how alteration of innate immune response genes in murine models can provide insights into the potential microbial origins of diverse conditions including Crohn's disease, psoriasis, atherosclerosis, diabetes, and liver cancer.	Univ Calif San Diego, Sch Med, Lab Gene Express & Signal Transduct, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Div Infect Dis, Dept Pediat, La Jolla, CA 92093 USA; Univ London Imperial Coll Sci Technol & Med, Fac Med, Kennedy Inst Rheumatol Div, London W6 8LH, England	University of California System; University of California San Diego; University of California System; University of California San Diego; Imperial College London; University of Oxford	Karin, M (corresponding author), Univ Calif San Diego, Sch Med, Lab Gene Express & Signal Transduct, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	karinoffice@ucsd.edu; vnizet@ucsd.edu	Lawrence, Toby/GLU-3895-2022; Nizet, Victor/AAF-3190-2019	Lawrence, Toby/0000-0003-0967-6122; Nizet, Victor/0000-0003-3847-0422				Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; Barrat FJ, 2005, J EXP MED, V202, P1131, DOI 10.1084/jem.20050914; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Benoist C, 2001, NAT IMMUNOL, V2, P797, DOI 10.1038/ni0901-797; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Chen J, 1997, ONCOGENE, V14, P2033, DOI 10.1038/sj.onc.1201039; Chieppa M, 2003, J IMMUNOL, V171, P4552, DOI 10.4049/jimmunol.171.9.4552; CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.iy.13.040195.000333; Christensen SR, 2005, J EXP MED, V202, P321, DOI 10.1084/jem.20050338; Cohen PL, 2002, J EXP MED, V196, P135, DOI 10.1084/jem.20012094; Cotena A, 2004, J IMMUNOL, V173, P6427, DOI 10.4049/jimmunol.173.10.6427; Covert MW, 2005, SCIENCE, V309, P1854, DOI 10.1126/science.1112304; Eckmann L, 2005, IMMUNITY, V22, P661, DOI 10.1016/j.immuni.2005.06.004; Economou M, 2004, AM J GASTROENTEROL, V99, P2393, DOI 10.1111/j.1572-0241.2004.40304.x; Erdman SE, 2003, CANCER RES, V63, P6042; Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939; Feldmann M, 2005, NATURE, V435, P612, DOI 10.1038/nature03727; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Hacker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369; Hawkins PN, 2003, NEW ENGL J MED, V348, P2583, DOI 10.1056/NEJM200306193482523; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; HISCOTT J, 2006, IN PRESS TRENDS MOL; Hoek RM, 2000, SCIENCE, V290, P1768, DOI 10.1126/science.290.5497.1768; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Houghton J, 2004, SCIENCE, V306, P1568, DOI 10.1126/science.1099513; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Isaacs KL, 2004, GASTROENTEROL CLIN N, V33, P335, DOI 10.1016/j.gtc.2004.02.006; Ishii KJ, 2006, NAT IMMUNOL, V7, P40, DOI 10.1038/ni1282; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 2005, IUBMB LIFE, V57, P283, DOI 10.1080/15216540500097111; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kawane K, 2003, NAT IMMUNOL, V4, P138, DOI 10.1038/ni881; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Kim SJ, 2004, IMMUNITY, V21, P643, DOI 10.1016/j.immuni.2004.09.009; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; Kotzin BL, 1996, CELL, V85, P303, DOI 10.1016/S0092-8674(00)81108-3; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Kuper H, 2000, J INTERN MED, V248, P171, DOI 10.1046/j.1365-2796.2000.00742.x; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lu QX, 2001, SCIENCE, V293, P306, DOI 10.1126/science.1061663; Maeda S, 2005, SCIENCE, V307, P734, DOI 10.1126/science.1103685; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Maeda S, 2003, IMMUNITY, V19, P725, DOI 10.1016/S1074-7613(03)00301-7; Martin M, 2003, J IMMUNOL, V171, P717, DOI 10.4049/jimmunol.171.2.717; Martinon F, 2004, CELL, V117, P561, DOI 10.1016/j.cell.2004.05.004; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Michelsen KS, 2004, P NATL ACAD SCI USA, V101, P10679, DOI 10.1073/pnas.0403249101; Morrison AC, 2004, J IMMUNOL, V172, P1825, DOI 10.4049/jimmunol.172.3.1825; Muppidi JR, 2004, IMMUNITY, V21, P461, DOI 10.1016/j.immuni.2004.10.001; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Nickoloff BJ, 2004, J CLIN INVEST, V113, P1664, DOI 10.1172/JCI200422147; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Park JM, 2005, IMMUNITY, V23, P319, DOI 10.1016/j.immuni.2005.08.010; Park KJ, 2003, J BIOL CHEM, V278, P30711, DOI 10.1074/jbc.M209623200; Patole PS, 2005, J AM SOC NEPHROL, V16, P1326, DOI 10.1681/ASN.2004100820; Pauleau AL, 2003, MOL CELL BIOL, V23, P7531, DOI 10.1128/MCB.23.21.7531-7539.2003; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; Prakken BJ, 2001, CURR DIRECT AUTOIMMU, V3, P51; Pucher Jeffery, 2004, Curr Diab Rep, V4, P46, DOI 10.1007/s11892-004-0011-y; Pulendran B, 2006, CELL, V124, P849, DOI 10.1016/j.cell.2006.02.019; Rahman P, 2003, AM J HUM GENET, V73, P677, DOI 10.1086/378076; Rioux JD, 2005, NATURE, V435, P584, DOI 10.1038/nature03723; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Savill J, 2003, SCIENCE, V302, P1516, DOI 10.1126/science.1092533; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Sospedra M, 2005, ANNU REV IMMUNOL, V23, P683, DOI 10.1146/annurev.immunol.23.021704.115707; Steere AC, 2004, NAT REV IMMUNOL, V4, P143, DOI 10.1038/nri1267; Stuart LM, 2002, J IMMUNOL, V168, P1627, DOI 10.4049/jimmunol.168.4.1627; Sun JL, 2005, JNCI-J NATL CANCER I, V97, P525, DOI 10.1093/jnci/dji070; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; Werner SL, 2005, SCIENCE, V309, P1857, DOI 10.1126/science.1113319; Wright GJ, 2000, IMMUNITY, V13, P233, DOI 10.1016/S1074-7613(00)00023-6; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zenz R, 2005, NATURE, V437, P369, DOI 10.1038/nature03963; Zenz R, 2003, DEV CELL, V4, P879, DOI 10.1016/S1534-5807(03)00161-8	101	707	743	2	106	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 24	2006	124	4					823	835		10.1016/j.cell.2006.02.016	http://dx.doi.org/10.1016/j.cell.2006.02.016			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	038RO	16497591	Bronze			2022-12-28	WOS:000237240900024
J	Fuyuno, I				Fuyuno, I			Across China's frontier	NATURE			English	News Item																		2005, NATURE, V438, P420	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 16	2006	439	7078					781	781		10.1038/439781a	http://dx.doi.org/10.1038/439781a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012JA	16482125	Bronze			2022-12-28	WOS:000235333600015
J	Goldraij, A; Kondo, K; Lee, CB; Hancock, CN; Sivaguru, M; Vazquez-Santana, S; Kim, S; Phillips, TE; Cruz-Garcia, F; McClure, B				Goldraij, A; Kondo, K; Lee, CB; Hancock, CN; Sivaguru, M; Vazquez-Santana, S; Kim, S; Phillips, TE; Cruz-Garcia, F; McClure, B			Compartmentalization of S-RNase and HT-B degradation in self-incompatible Nicotiana	NATURE			English	Article							F-BOX PROTEIN; POLLEN-REJECTION; 120-KDA GLYCOPROTEIN; NATURAL-POPULATION; PRUNUS-AVIUM; GENE; ALATA; IDENTIFICATION; LYCOPERSICON; ALLELES	Pollen - pistil interactions are crucial for controlling plant mating. For example, S-RNase-based self-incompatibility prevents inbreeding in diverse angiosperm species. S-RNases are thought to function as specific cytotoxins that inhibit pollen that has an S-haplotype that matches one of those in the pistil. Thus, pollen and pistil factors interact to prevent mating between closely related individuals. Other pistil factors, such as HT-B, 4936-factor and the 120 kDa glycoprotein, are also required for pollen rejection but do not contribute to S-haplotype-specificity per se. Here we show that S-RNase is taken up and sorted to a vacuolar compartment in the pollen tubes. Antibodies to the 120 kDa glycoprotein label the compartment membrane. When the pistil does not express HT-B or 4936-factor, S-RNase remains sequestered, unable to cause rejection. Similarly, in wild-type pistils, compatible pollen tubes degrade HT-B and sequester S-RNase. We suggest that S-RNase trafficking and the stability of HT-B are central to S-specific pollen rejection.	Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CIQUIBIC, RA-5000 Cordoba, Argentina; 105 Life Sci Ctr, Div Biochem, Columbia, MO 65211 USA; Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA; Dept Plant Biol, Athens, GA 30602 USA; Univ Nacl Autonoma Mexico, Fac Quim, Dept Bioquim, Mexico City 04510, DF, Mexico; Univ Nacl Autonoma Mexico, Fac Ciencias, Dept Biol, Mexico City 04510, DF, Mexico	National University of Cordoba; University of Missouri System; University of Missouri Columbia; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	McClure, B (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CIQUIBIC, Ciudad Univ, RA-5000 Cordoba, Argentina.	mcclureb@missouri.edu	Sivaguru, Mayandi/L-7845-2019; Sivaguru, Mayandi/M-3393-2019; Cruz-Garcia, Felipe/A-5817-2008; Hancock, Charles/AAA-5249-2020	Sivaguru, Mayandi/0000-0001-5532-4393; Hancock, Charles Nathan/0000-0002-0875-8495; Phillips, Thomas/0000-0002-9709-0684				AI YJ, 1991, MOL GEN GENET, V230, P353, DOI 10.1007/BF00280291; ANDERSON MA, 1989, PLANT CELL, V1, P483, DOI 10.1105/tpc.1.5.483; Beecher B, 2001, SEX PLANT REPROD, V14, P69, DOI 10.1007/s004970100078; BERNATZKY R, 1995, BIOCHEM GENET, V33, P215, DOI 10.1007/BF02401852; CORNISH EC, 1987, NATURE, V326, P99, DOI 10.1038/326099a0; Cruz-Garcia F, 2005, PLANT J, V42, P295, DOI 10.1111/j.1365-313X.2005.02375.x; Entani T, 2003, GENES CELLS, V8, P203, DOI 10.1046/j.1365-2443.2003.00626.x; Geitmann A., 1999, FERTILIZATION HIGHER, V41, P283; Hancock CN, 2005, PLANT J, V43, P716, DOI 10.1111/j.1365-313X.2005.02490.x; Hicks GR, 2004, PLANT PHYSIOL, V134, P1227, DOI 10.1104/pp.103.037382; Ikeda K, 2004, SEX PLANT REPROD, V16, P235, DOI 10.1007/s00497-003-0200-x; Jauh GY, 1999, PLANT CELL, V11, P1867, DOI 10.1105/tpc.11.10.1867; Kao TH, 2004, PLANT CELL, V16, pS72, DOI 10.1105/tpc.016154; KHO YO, 1968, EUPHYTICA, V17, P299; Kondo K, 2002, PLANT J, V30, P143, DOI 10.1046/j.1365-313X.2002.01275.x; Kondo K, 2002, PLANT J, V29, P627, DOI 10.1046/j.0960-7412.2001.01245.x; LEE HS, 1994, NATURE, V367, P560, DOI 10.1038/367560a0; Lind JL, 1996, SEX PLANT REPROD, V9, P75, DOI 10.1007/BF02153054; LIND JL, 1994, PLANT J, V6, P491, DOI 10.1046/j.1365-313X.1994.6040491.x; Luu DT, 2000, NATURE, V407, P649, DOI 10.1038/35036623; MacIntosh GC, 2001, P NATL ACAD SCI USA, V98, P1018, DOI 10.1073/pnas.98.3.1018; MARTIN FW, 1968, GENETICS, V60, P101; McClure B, 2004, PLANT CELL, V16, P2840, DOI 10.1105/tpc.104.161130; McClure B, 1999, P NATL ACAD SCI USA, V96, P13548, DOI 10.1073/pnas.96.23.13548; MCCLURE BA, 1990, NATURE, V347, P757, DOI 10.1038/347757a0; McClure BA, 2000, ANN BOT-LONDON, V85, P113, DOI 10.1006/anbo.1999.1061; Murfett J, 1996, PLANT CELL, V8, P943, DOI 10.1105/tpc.8.6.943; MURFETT J, 1994, NATURE, V367, P563, DOI 10.1038/367563a0; Nettancourt, 2001, INCOMPATIBILITY INCO; O'Brien K, 2002, HASTINGS CENT REP, V32, P12; Paris N, 1996, PLANT PHYSIOL BIOCH, V34, P223; Qiao H, 2004, PLANT CELL, V16, P2307, DOI 10.1105/tpc.104.024919; Qiao H, 2004, PLANT CELL, V16, P582, DOI 10.1105/tpc.017673; Rogers SW, 1997, PLANT J, V11, P1359, DOI 10.1046/j.1365-313X.1997.11061359.x; Sijacic P, 2004, NATURE, V429, P302, DOI 10.1038/nature02523; Sonneveld T, 2005, PLANT CELL, V17, P37, DOI 10.1105/tpc.104.026963; Tanner VA, 1996, J HISTOCHEM CYTOCHEM, V44, P1481, DOI 10.1177/44.12.8985140; Tsukamoto T, 1999, SEX PLANT REPROD, V12, P6, DOI 10.1007/s004970050166; Tsukamoto T, 2003, SEX PLANT REPROD, V15, P255, DOI 10.1007/s00497-002-0161-5; Ushijima K, 2004, PLANT J, V39, P573, DOI 10.1111/j.1365-313X.2004.02154.x; Ushijima K, 2003, PLANT CELL, V15, P771, DOI 10.1105/tpc.009290; VANDEURS B, 1988, J CELL BIOL, V106, P253, DOI 10.1083/jcb.106.2.253; Wesche J, 1999, J BIOL CHEM, V274, P34443, DOI 10.1074/jbc.274.48.34443	43	187	207	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 16	2006	439	7078					805	810		10.1038/nature04491	http://dx.doi.org/10.1038/nature04491			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012JA	16482149				2022-12-28	WOS:000235333600040
J	Langhoff-Roos, J; Kesmodel, U; Jacobsson, B; Rasmussen, S; Vogel, I				Langhoff-Roos, J; Kesmodel, U; Jacobsson, B; Rasmussen, S; Vogel, I			Spontaneous preterm delivery in primiparous women at low risk in Denmark: population based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GESTATIONAL-AGE; BIRTH; RATES	Objectives To analyse trends in preterm delivery and the factors contributing to preterm delivery in Denmark. To construct a standard population at low risk (white European, 20-40 years of age, with a Singleton spontaneous pregnancy) and describe the changes in this population so that time trends can be compared internationally Design population based study Participants 99.8% of all deliveries in Denmark, 1995-2004. Main outcome measures Proportion of babies born at less than 37 weeks completed gestation for each year in the overall population and in a standard population at low risk. Results Overall, the proportion of preterm deliveries increased by 22% from 1995 to 2004. During the same period, known risk factors for preterm delivery such as in vitro fertilisation, multiple pregnancies, and elective deliveries also increased, and logistic regression analyses showed that these factors were associated with all increased risk of preterm delivery Spontaneous preterm deliveries in primiparous women at low risk rose 51% (from 3.8% to 5.7%) during this time compared with 20% (2.7% to 3.2%) in multiparous women at low risk. Conclusions The overall proportion of preterm deliveries increased significantly from 1995 to 2004 and primiparity and multiple birth were the most important contributing factors. The rise in spontaneous preterm deliveries in the standard population of primiparous women at low risk was greater than in the total population.	Rigshosp, Juliane Marie Ctr, Dept Obstet, DK-2100 Copenhagen, Denmark; Aarhus Univ, Inst Publ Hlth, Dept Epidemiol, NANEA, DK-8000 Aarhus, Denmark; Sahlgrenska Univ Hosp Ostra, Perinatal Ctr, Dept Obstet & Gynecol, SE-41345 Gothenburg, Sweden; Natl Board Hlth, Hlth Stat, DK-2300 Copenhagen, Denmark; Aarhus Univ, Dept Clin Genet, DK-8000 Aarhus C, Denmark	Rigshospitalet; University of Copenhagen; Aarhus University; Sahlgrenska University Hospital; Aarhus University	Langhoff-Roos, J (corresponding author), Rigshosp, Juliane Marie Ctr, Dept Obstet, DK-2100 Copenhagen, Denmark.	jlr@dadlnet.dk	Jacobsson, Bo/O-8007-2014; Vogel, Ida/AAD-1087-2019	Jacobsson, Bo/0000-0001-5079-2374; Vogel, Ida/0000-0002-1125-0393; Langhoff-Roos, Jens/0000-0003-2838-2533				Balchin I, 2004, BJOG-INT J OBSTET GY, V111, P160, DOI 10.1046/j.1471-0528.2003.00026.x; Hedegaard M, 1996, ACTA OBSTET GYN SCAN, V75, P32, DOI 10.3109/00016349609033280; Mancuso RA, 2004, PSYCHOSOM MED, V66, P762, DOI 10.1097/01.psy.0000138284.70670.d5; *MED BIRTH REG NOR, PRET BIRTHS NORW 199; *NAT CTR HLTH STAT, PRET BIRTH US 1992 2; Yang H, 2002, AM J OBSTET GYNECOL, V186, P433, DOI 10.1067/mob.2002.120487	6	154	160	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 22	2006	332	7547					937	939		10.1136/bmj.38751.524132.2F	http://dx.doi.org/10.1136/bmj.38751.524132.2F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	037JV	16497733	Green Published, Bronze			2022-12-28	WOS:000237143900014
J	Kalsin, AM; Fialkowski, M; Paszewski, M; Smoukov, SK; Bishop, KJM; Grzybowski, BA				Kalsin, AM; Fialkowski, M; Paszewski, M; Smoukov, SK; Bishop, KJM; Grzybowski, BA			Electrostatic self-assembly of binary nanoparticle crystals with a diamond-like lattice	SCIENCE			English	Article							COLLOIDS; PHASE; SUPERLATTICES; ORGANIZATION; AU	Self-assembly of charged, equally sized metal nanoparticles of two types (gold and silver) leads to the formation of large, sphalerite (diamond-like) crystals, in which each nanoparticle has four oppositely charged neighbors. Formation of these non-close-packed structures is a consequence of electrostatic effects specific to the nanoscale, where the thickness of the screening layer is commensurate with the dimensions of the assembling objects. Because of electrostatic stabilization of larger crystallizing particles by smaller ones, better-quality crystals can be obtained from more polydisperse nanoparticle solutions.	Northwestern Univ, Dept Biol & Chem Engn, Evanston, IL 60208 USA; Northwestern Univ, NW Inst Complex Syst, Evanston, IL 60208 USA	Northwestern University; Northwestern University	Grzybowski, BA (corresponding author), Northwestern Univ, Dept Biol & Chem Engn, 2145 Sheridan Rd, Evanston, IL 60208 USA.	grzybor@northwestern.edu	Bishop, Kyle J M/F-1742-2010; Smoukov, Stoyan/F-8545-2011; Grzybowski, Bartosz A/H-5741-2017; Han, Kyuhee/B-6201-2009; Kalsin, Alexander/I-3645-2014	Kalsin, Alexander/0000-0002-7027-6550; Grzybowski, Bartosz/0000-0001-6613-4261; Fialkowski, Marcin/0000-0003-1529-2539; Smoukov, Stoyan/0000-0003-1738-818X				[Anonymous], 1992, INTERMOLECULAR SURFA; BAIN CD, 1989, J AM CHEM SOC, V111, P321, DOI 10.1021/ja00183a049; BALL RC, 1987, PHYS REV LETT, V58, P274, DOI 10.1103/PhysRevLett.58.274; Chaikin P. M., 2000, PRINCIPLES CONDENSED; Grunes J, 2002, J PHYS CHEM B, V106, P11463, DOI 10.1021/jp021641e; Grzybowski BA, 2003, NAT MATER, V2, P241, DOI 10.1038/nmat860; Hoinville J, 2003, J APPL PHYS, V93, P7187, DOI 10.1063/1.1555896; Hynninen AP, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.018303; Jana NR, 2003, J AM CHEM SOC, V125, P14280, DOI 10.1021/ja038219b; Kittel C, 2021, INTRO SOLID STATE PH; Kolny J, 2002, NANO LETT, V2, P361, DOI 10.1021/nl0156843; Leunissen ME, 2005, NATURE, V437, P235, DOI 10.1038/nature03946; Link S, 1999, J PHYS CHEM B, V103, P3529, DOI 10.1021/jp990387w; Liu Y, 2005, LANGMUIR, V21, P8883, DOI 10.1021/la050019l; Lyklema J., 1995, FUNDAMENTALS INTERFA; Maier SA, 2003, NAT MATER, V2, P229, DOI 10.1038/nmat852; OHARA PC, 1995, PHYS REV LETT, V75, P3466, DOI 10.1103/PhysRevLett.75.3466; Rasa M, 2004, J COLLOID INTERF SCI, V278, P115, DOI 10.1016/j.jcis.2004.05.020; Redl FX, 2003, NATURE, V423, P968, DOI 10.1038/nature01702; Rogach AL, 2004, ANGEW CHEM INT EDIT, V43, P148, DOI 10.1002/anie.200301704; SALEM L, 1962, J CHEM PHYS, V37, P2100, DOI 10.1063/1.1733431; SANYAL S, 1992, EUROPHYS LETT, V18, P107, DOI 10.1209/0295-5075/18/2/003; Saunders AE, 2005, CHEMPHYSCHEM, V6, P61, DOI 10.1002/cphc.200400382; Sharma CVK, 2000, CHEM COMMUN, P1023, DOI 10.1039/b002084m; Shevchenko EV, 2006, NATURE, V439, P55, DOI 10.1038/nature04414; Stoeva S, 2002, J AM CHEM SOC, V124, P2305, DOI 10.1021/ja012076g; Tohver V, 2001, P NATL ACAD SCI USA, V98, P8950, DOI 10.1073/pnas.151063098; Verwey E J W, 1999, THEORY STABILITY LYO; Witt D, 2004, CURR ORG CHEM, V8, P1763, DOI 10.2174/1385272043369421; Wu JZ, 1999, J CHEM PHYS, V111, P7084, DOI 10.1063/1.480000; Zayats M, 2003, J AM CHEM SOC, V125, P16006, DOI 10.1021/ja0379215; Ziherl P, 2000, PHYS REV LETT, V85, P3528, DOI 10.1103/PhysRevLett.85.3528; Ziherl P, 2001, J PHYS CHEM B, V105, P10147, DOI 10.1021/jp010944q	33	728	738	19	499	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 21	2006	312	5772					420	424		10.1126/science.1125124	http://dx.doi.org/10.1126/science.1125124			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	034OZ	16497885				2022-12-28	WOS:000236941800045
J	Li, B; Zhao, J; Onda, K; Jordan, KD; Yang, JL; Petek, H				Li, B; Zhao, J; Onda, K; Jordan, KD; Yang, JL; Petek, H			Ultrafast interfacial proton-coupled electron transfer	SCIENCE			English	Article							METHANOL; DYNAMICS; SURFACES; TIO2(110); SOLVATION; ALCOHOLS; WATER	The coupling of electron and nuclear motions in ultrafast charge transfer at molecule-semiconductor interfaces is central to many phenomena, including catalysis, photocatalysis, and molecular electronics. By using femtosecond laser excitation, we transferred electrons from a rutile titanium dioxide (110) surface into a CH3OH overlayer state that is 2.3 +/- 0.2 electron volts above the Fermi level. The redistributed charge was stabilized within 30 femtoseconds by the inertial motion of substrate ions ( polaron formation) and, more slowly, by adsorbate molecules ( solvation). According to a pronounced deuterium isotope effect (CH3OD), this motion of heavy atoms transforms the reverse charge transfer from a purely electronic process (nonadiabatic) to a correlated response of electrons and protons.	Univ Pittsburgh, Dept Phys & Astron, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA; Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Anhua 230026, Peoples R China	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Petek, H (corresponding author), Univ Pittsburgh, Dept Phys & Astron, Pittsburgh, PA 15260 USA.	petek@pitt.edu	Zhao, Jin/E-2735-2016; Yang, Jinlong/D-3465-2009; Onda, Ken/H-3389-2014; Petek, Hrvoje/A-3912-2009	Zhao, Jin/0000-0003-1346-5280; Onda, Ken/0000-0003-1724-2009; Petek, Hrvoje/0000-0001-9605-2590				Bates SP, 1998, J PHYS CHEM B, V102, P2017, DOI 10.1021/jp9804998; Cukier RI, 1998, ANNU REV PHYS CHEM, V49, P337, DOI 10.1146/annurev.physchem.49.1.337; Decornez H, 2000, J PHYS CHEM A, V104, P9370, DOI 10.1021/jp001967s; DELLEY B, 1990, J CHEM PHYS, V92, P508, DOI 10.1063/1.458452; FOX MA, 1993, CHEM REV, V93, P341, DOI 10.1021/cr00017a016; FUJISHIMA A, 1972, NATURE, V238, P37, DOI 10.1038/238037a0; Gratzel M, 2001, NATURE, V414, P338, DOI 10.1038/35104607; Hammes-Schiffer S, 2001, ACCOUNTS CHEM RES, V34, P273, DOI 10.1021/ar9901117; Henderson MA, 1999, FARADAY DISCUSS, V114, P313, DOI 10.1039/a902070e; Hendry E, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.081101; JONES RO, 1989, REV MOD PHYS, V61, P689, DOI 10.1103/RevModPhys.61.689; KAMAT PV, 1993, CHEM REV, V93, P267, DOI 10.1021/cr00017a013; KAWAI T, 1980, J CHEM SOC CHEM COMM, P694, DOI 10.1039/c39800000694; Lin JP, 2005, SCIENCE, V310, P1311, DOI 10.1126/science.1118316; Liu SH, 2002, J PHYS CHEM B, V106, P12908, DOI 10.1021/jp025772r; Lu QB, 1999, PHYS REV LETT, V82, P4122, DOI 10.1103/PhysRevLett.82.4122; Minary P, 1999, J CHEM PHYS, V110, P10953, DOI 10.1063/1.479032; MONNIER R, 1978, PHYS REV B, V18, P656, DOI 10.1103/PhysRevB.18.656; Onda K, 2005, SURF SCI, V593, P32, DOI 10.1016/j.susc.2005.06.044; Onda K, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.045415; Onda K, 2005, SCIENCE, V308, P1154, DOI 10.1126/science.1109366; Perdew JP, 1997, PHYS REV LETT, V78, P1396, DOI 10.1103/PhysRevLett.78.1396; Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865; Petek H, 1997, PROG SURF SCI, V56, P239, DOI 10.1016/S0079-6816(98)00002-1; Pshenichnikov MS, 2004, CHEM PHYS LETT, V389, P171, DOI 10.1016/j.cplett.2004.03.107; Rego LGC, 2003, J AM CHEM SOC, V125, P7989, DOI 10.1021/ja0346330; SHI XL, 1995, J PHYS CHEM-US, V99, P6917, DOI 10.1021/j100018a024; Shirota H, 1997, CHEM PHYS LETT, V281, P27, DOI 10.1016/S0009-2614(97)01230-X; Stier W, 2002, J PHYS CHEM B, V106, P8047, DOI 10.1021/jp014267b; Tanner C, 2003, SCIENCE, V302, P1736, DOI 10.1126/science.1091708; Tauber MJ, 2004, J AM CHEM SOC, V126, P3414, DOI 10.1021/ja031816d; Tributsch H, 1998, SCIENCE, V279, P1891, DOI 10.1126/science.279.5358.1891; Turi L, 1999, J CHEM PHYS, V110, P10364, DOI 10.1063/1.478969; Wang R, 1997, NATURE, V388, P431, DOI 10.1038/41233; Weida MJ, 2000, J OPT SOC AM B, V17, P1443, DOI 10.1364/JOSAB.17.001443; Zhao J.Z., UNPUB	36	188	191	5	266	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2006	311	5766					1436	1440		10.1126/science.1122190	http://dx.doi.org/10.1126/science.1122190			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527974				2022-12-28	WOS:000236029400041
J	Parker, JD; Burkepile, DE; Hay, ME				Parker, JD; Burkepile, DE; Hay, ME			Opposing effects of native and exotic herbivores on plant invasions	SCIENCE			English	Article							BIOLOGICAL-CONTROL; BIOTIC RESISTANCE; RELEASE; ALIEN; SUCCESS		Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology	Parker, JD (corresponding author), Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA.	jdp52@cornell.edu; mark.hay@biology.gatech.edu	Parker, John D/F-9761-2010; Burkepile, Deron/F-2368-2013; Hay, Mark E/D-9752-2011	Parker, John D/0000-0002-3632-7625; Hay, Mark E/0000-0002-6130-9349				Chase JM, 2000, ECOLOGY, V81, P2485, DOI 10.1890/0012-9658(2000)081[2485:TEOPHA]2.0.CO;2; Colautti RI, 2004, ECOL LETT, V7, P721, DOI 10.1111/j.1461-0248.2004.00616.x; Crawley M.J., 1989, P45; Crawley MJ, 1996, PHILOS T R SOC B, V351, P1251, DOI 10.1098/rstb.1996.0108; CROSBY AW, 1986, ECOLOGICAL IMPERIALI, P368; Darwin C., 1877, ORIGIN SPECIES; DeWalt SJ, 2004, ECOLOGY, V85, P471, DOI 10.1890/02-0728; Elton C., 1958; Hay Mark E., 1992, P371; HOKKANEN HMT, 1989, CAN ENTOMOL, V121, P829, DOI 10.4039/Ent121829-10; Holmgren Milena, 2002, Biological Invasions, V4, P25, DOI 10.1023/A:1020535628776; Keane RM, 2002, TRENDS ECOL EVOL, V17, P164, DOI 10.1016/S0169-5347(02)02499-0; Lodge DM, 1998, ECOL STU AN, V131, P149; Louda SM, 1997, SCIENCE, V277, P1088, DOI 10.1126/science.277.5329.1088; MACK RN, 1982, AM NAT, V119, P757, DOI 10.1086/283953; Mack RN, 2000, ECOL APPL, V10, P689, DOI 10.1890/1051-0761(2000)010[0689:BICEGC]2.0.CO;2; Maron JL, 2001, OIKOS, V95, P361, DOI 10.1034/j.1600-0706.2001.950301.x; Mitchell CE, 2003, NATURE, V421, P625, DOI 10.1038/nature01317; Parker JD, 2005, ECOL LETT, V8, P959, DOI 10.1111/j.1461-0248.2005.00799.x; Pimentel D, 2005, ECOL ECON, V52, P273, DOI 10.1016/j.ecolecon.2004.10.002; Siemann E, 2003, ECOLOGY, V84, P1489, DOI 10.1890/0012-9658(2003)084[1489:HDRLAS]2.0.CO;2; Simberloff Daniel, 1999, Biological Invasions, V1, P21, DOI 10.1023/A:1010086329619; Stohlgren TJ, 1999, ECOL APPL, V9, P45, DOI 10.1890/1051-0761(1999)009[0045:HGASQA]2.0.CO;2; Torchin ME, 2003, NATURE, V421, P628, DOI 10.1038/nature01346; Wilcove DS, 1998, BIOSCIENCE, V48, P607, DOI 10.2307/1313420; Williamson M, 1996, ECOLOGY, V77, P1661, DOI 10.2307/2265769; Wolfe LM, 2002, AM NAT, V160, P705, DOI 10.1086/343872	27	457	473	8	292	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2006	311	5766					1459	1461		10.1126/science.1121407	http://dx.doi.org/10.1126/science.1121407			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527979				2022-12-28	WOS:000236029400048
J	Wang, HP; Su, WC				Wang, HP; Su, WC			Veiled right kidney sign in a patient with Valentino's syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Natl Taiwan Univ Hosp, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital	Wang, HP (corresponding author), Natl Taiwan Univ Hosp, Taipei, Taiwan.								0	6	6	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 9	2006	354	10					E9	E9		10.1056/NEJMicm050410	http://dx.doi.org/10.1056/NEJMicm050410			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	019FY	16525133				2022-12-28	WOS:000235822200011
J	Cornelis, MC; El-Sohemy, A; Kabagambe, EK; Campos, H				Cornelis, MC; El-Sohemy, A; Kabagambe, EK; Campos, H			Coffee, CYP1A2 genotype, and risk of myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; GENETIC-POLYMORPHISM; CAFFEINE INTAKE; HUMAN HEALTH; FOLLOW-UP; CONSUMPTION; DEATH; METAANALYSIS; ASSOCIATION; CHOLESTEROL	Context The association between coffee intake and risk of myocardial infarction (MI) remains controversial. Coffee is a major source of caffeine, which is metabolized by the polymorphic cytochrome P450 1A2 (CYP1A2) enzyme. Individuals who are homozygous for the CYP1A2*1A allele are "rapid" caffeine metabolizers, whereas carriers of the variant CYP1A2*1F are "slow" caffeine metabolizers. Objective To determine whether CYP1A2 genotype modifies the association between coffee consumption and risk of acute nonfatal MI. Design, Setting, and Participants Cases (n = 2014) with a first acute nonfatal MI and population-based controls (n = 2014) living in Costa Rica between 1994 and 2004, matched for age, sex, and area of residence, were genotyped by restriction fragment length polymorphism polymerase chain reaction. A food frequency questionnaire was used to assess the intake of caffeinated coffee. Main Outcome Measure Relative risk of nonfatal MI associated with coffee intake, calculated using unconditional logistic regression. Results Fifty-five percent of cases (n = 1114) and 54% of controls (n = 1082) were carriers of the slow *1F allele. For carriers of the slow *1F allele, the multivariate-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) of nonfatal MI associated with consuming less than 1, 1, 2 to 3, and 4 or more cups of coffee per day were 1.00 ( reference), 0.99 (0.69-1.44), 1.36 (1.01-1.83), and 1.64 (1.14-2.34), respectively. Corresponding ORs ( 95% CIs) for individuals with the rapid *1A/*1A genotype were 1.00, 0.75 (0.51-1.12), 0.78 (0.56-1.09), and 0.99 (0.66-1.48) (P = .04 for gene X coffee interaction). For individuals younger than the median age of 59 years, the ORs ( 95% CIs) associated with consuming less than 1, 1, 2 to 3, or 4 or more cups of coffee per day were 1.00, 1.24 (0.71-2.18), 1.67 (1.08-2.60), and 2.33 (1.39-3.89), respectively, among carriers of the *1F allele. The corresponding ORs ( 95% CIs) for those with the *1A/*1A genotype were 1.00, 0.48 (0.26-0.87), 0.57 (0.35-0.95), and 0.83 (0.46-1.51). Conclusion Intake of coffee was associated with an increased risk of nonfatal MI only among individuals with slow caffeine metabolism, suggesting that caffeine plays a role in this association.	Univ Toronto, Dept Nutr Sci, Toronto, ON M5S 3E2, Canada; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Univ Costa Rica, Ctr Centroamer Poblac, San Pedro Montes de Oca, Costa Rica	University of Toronto; Harvard University; Harvard T.H. Chan School of Public Health; Universidad Costa Rica	El-Sohemy, A (corresponding author), Univ Toronto, Dept Nutr Sci, 150 Coll St, Toronto, ON M5S 3E2, Canada.	a.el.sohemy@utoronto.ca	Kabagambe, Edmond/A-3147-2008	El-Sohemy, Ahmed/0000-0002-8877-6414; Kabagambe, Edmond/0000-0002-8993-3186	NHLBI NIH HHS [HL 071888, HL 60692] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060692, R01HL071888] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAK AAA, 1989, NEW ENGL J MED, V321, P1432, DOI 10.1056/NEJM198911233212103; BUTLER MA, 1989, P NATL ACAD SCI USA, V86, P7696, DOI 10.1073/pnas.86.20.7696; Castorena-Torres F, 2005, TOXICOL LETT, V156, P331, DOI 10.1016/j.toxlet.2004.12.005; Cornelis MC, 2004, J MED GENET, V41, P758, DOI 10.1136/jmg.2004.022012; Fisone G, 2004, CELL MOL LIFE SCI, V61, P857, DOI 10.1007/s00018-003-3269-3; Goodman MT, 2003, NUTR CANCER, V46, P23, DOI 10.1207/S15327914NC4601_03; GREENLAND S, 1993, EPIDEMIOLOGY, V4, P366, DOI 10.1097/00001648-199307000-00013; GU L, 1992, PHARMACOGENETICS, V2, P73, DOI 10.1097/00008571-199204000-00004; HALL C, 1985, DELLPLAIN LATIN AM S, V17; Hamdy SI, 2003, BRIT J CLIN PHARMACO, V55, P321, DOI 10.1046/j.1365-2125.2003.01787.x; Hammar N, 2003, J INTERN MED, V253, P653, DOI 10.1046/j.1365-2796.2003.01142.x; Han XM, 2001, PHARMACOGENETICS, V11, P429, DOI 10.1097/00008571-200107000-00006; Happonen P, 2004, J NUTR, V134, P2381, DOI 10.1093/jn/134.9.2381; HORI M, 1991, HYPERTENSION, V18, P565, DOI 10.1161/01.HYP.18.5.565; Jee SH, 2001, AM J EPIDEMIOL, V153, P353, DOI 10.1093/aje/153.4.353; Kabagambe EK, 2001, AM J EPIDEMIOL, V154, P1126, DOI 10.1093/aje/154.12.1126; KALOW W, 1993, CLIN PHARMACOL THER, V53, P503, DOI 10.1038/clpt.1993.63; KALOW W, 1991, CLIN PHARMACOL THER, V49, P44, DOI 10.1038/clpt.1991.8; KAWACHI I, 1994, BRIT HEART J, V72, P269; Kleemola P, 2000, ARCH INTERN MED, V160, P3393, DOI 10.1001/archinte.160.22.3393; LACROIX AZ, 1986, NEW ENGL J MED, V315, P977, DOI 10.1056/NEJM198610163151601; Le Hir H, 2003, TRENDS BIOCHEM SCI, V28, P215, DOI 10.1016/S0968-0004(03)00052-5; LUNDSBERG LS, 1998, CAFFEINE, P199; MYERS MG, 1992, ARCH INTERN MED, V152, P1767, DOI 10.1001/archinte.152.9.1767; Nakajima M, 1999, J BIOCHEM-TOKYO, V125, P803, DOI 10.1093/oxfordjournals.jbchem.a022352; Nawrot P, 2003, FOOD ADDIT CONTAM A, V20, P1, DOI 10.1080/0265203021000007840; PALMER JR, 1995, AM J EPIDEMIOL, V141, P724, DOI 10.1093/oxfordjournals.aje.a117494; Panagiotakos DB, 2003, J NUTR, V133, P3228, DOI 10.1093/jn/133.10.3228; Ranheim T, 2005, MOL NUTR FOOD RES, V49, P274, DOI 10.1002/mnfr.200400109; Rasmussen BB, 2002, PHARMACOGENETICS, V12, P473, DOI 10.1097/00008571-200208000-00008; ROSENBERG L, 1988, AM J EPIDEMIOL, V128, P570, DOI 10.1093/oxfordjournals.aje.a115004; Sachse C, 1999, BRIT J CLIN PHARMACO, V47, P445, DOI 10.1046/j.1365-2125.1999.00898.x; SCHREIBER GB, 1988, PREV MED, V17, P280, DOI 10.1016/0091-7435(88)90004-7; SCHREIBER GB, 1988, PREV MED, V17, P295, DOI 10.1016/0091-7435(88)90005-9; SHYROCK JC, 1997, AM J CARDIOL, V79, P2; SMITS P, 1987, J CARDIOVASC PHARM, V10, P136, DOI 10.1097/00005344-198708000-00002; Spiller M. A., 1998, CAFFEINE, P97; Stensvold I, 1996, BRIT MED J, V312, P544, DOI 10.1136/bmj.312.7030.544; Tavani A, 2001, EUR J EPIDEMIOL, V17, P1131, DOI 10.1023/A:1021276932160; THELLE DS, 1987, ATHEROSCLEROSIS, V67, P97, DOI 10.1016/0021-9150(87)90270-X; Tiwari AK, 2005, PHARMACOGENOMICS J, V5, P60, DOI 10.1038/sj.tpj.6500282; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; TVERDAL A, 1990, BRIT MED J, V300, P566, DOI 10.1136/bmj.300.6724.566; VANDUSSELDORP M, 1991, ARTERIOSCLER THROMB, V11, P586, DOI 10.1161/01.ATV.11.3.586; Willet W, 1998, NUTR EPIDEMIOLOGY; Willett WC, 1996, JAMA-J AM MED ASSOC, V275, P458, DOI 10.1001/jama.275.6.458; Woodward M, 1999, J EPIDEMIOL COMMUN H, V53, P481, DOI 10.1136/jech.53.8.481	47	313	324	0	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	2006	295	10					1135	1141		10.1001/jama.295.10.1135	http://dx.doi.org/10.1001/jama.295.10.1135			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	019GB	16522833	Bronze			2022-12-28	WOS:000235822500021
J	Chen, IF				Chen, IF			Thinking big about global health	CELL			English	Editorial Material								The Gates Foundation is funding high-risk research into new ways to improve health in developing countries, but ensuring that the fruits of these studies reach the people who need them most may be the biggest challenge of all.											0	8	8	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 24	2006	124	4					661	663		10.1016/j.cell.2006.02.014	http://dx.doi.org/10.1016/j.cell.2006.02.014			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	038RO	16497574	Bronze			2022-12-28	WOS:000237240900007
J	Deb, K; Sivaguru, M; Yong, HY; Roberts, RM				Deb, K; Sivaguru, M; Yong, HY; Roberts, RM			RETRACTED: Cdx2 gene expression and trophectoderm lineage specification in mouse embryos (Retracted article. See vol 317, pg 450, 2007)	SCIENCE			English	Article; Retracted Publication							1ST CLEAVAGE; POSTIMPLANTATION DEVELOPMENT; EMERGING ASYMMETRY; BLASTOCYST AXIS; 4-CELL EMBRYO; CELL LINEAGE; BLASTOMERES; PLANE; EGGS; DIFFERENTIATION	Controversy exists as to whether individual. blastomeres from two-cell-stage mouse embryos have identical developmental properties and fate. We show that the transcription factor Cdx2 is expressed in the nuclei of cells derived from the late-dividing but not the first-dividing blastomere of two-cell embryos and, by lineage tracing and RNA interference knock-down experiments, that this tagging cell is the precursor of trophectoderm. Cdx2 mRNA is localized toward the vegetal pole of oocytes, reorients after fertilization, and becomes concentrated in the late-dividing, two-cell-stage blastomere. The asymmetrical distribution of Cdx2 gene products in the oocyte and embryo defines the lineage to trophectoderm.	Univ Missouri, Dept Anim Sci, Columbia, MO 65211 USA; Univ Missouri, Dept Biol Sci, Columbia, MO 65211 USA; Univ Missouri, Dept Biochem, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Roberts, RM (corresponding author), Univ Missouri, Dept Anim Sci, Columbia, MO 65211 USA.	robertrm@missouri.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021896, R01HD042201] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR013438] Funding Source: NIH RePORTER; NCRR NIH HHS [R01 RR13438] Funding Source: Medline; NICHD NIH HHS [R01 HD42201, R01 HD21896] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alarcon VB, 2003, BIOL REPROD, V69, P1208, DOI 10.1095/biolreprod.103.018283; BRULET P, 1980, P NATL ACAD SCI-BIOL, V77, P4113, DOI 10.1073/pnas.77.7.4113; DEB K, UNPUB; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; Fujimori T, 2003, DEVELOPMENT, V130, P5113, DOI 10.1242/dev.00725; Gardner Richard L, 2005, Birth Defects Res C Embryo Today, V75, P142, DOI 10.1002/bdrc.20038; Gardner RL, 2001, DEVELOPMENT, V128, P839; Gardner RL, 2003, PHILOS T ROY SOC B, V358, P1331, DOI 10.1098/rstb.2003.1322; Gray D, 2004, CURR BIOL, V14, P397, DOI 10.1016/j.cub.2004.02.031; Hiiragi T, 2004, NATURE, V430, P360, DOI 10.1038/nature02595; JOHNSON WH, 1995, VET REC, V137, P15, DOI 10.1136/vr.137.1.15; King ML, 2005, BIOL CELL, V97, P19; McConnell J, 2005, MOL REPROD DEV, V71, P399, DOI 10.1002/mrd.20318; Motosugi N, 2005, GENE DEV, V19, P1081, DOI 10.1101/gad.1304805; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; Piotrowska K, 2001, DEVELOPMENT, V128, P3739; Piotrowska-Nitsche K, 2005, DEVELOPMENT, V132, P479, DOI 10.1242/dev.01602; Plusa B, 2005, NATURE, V434, P391, DOI 10.1038/nature03388; Rossant J, 2004, DEV CELL, V7, P155, DOI 10.1016/j.devcel.2004.07.012; ROSSANT J, 1976, J EMBRYOL EXP MORPH, V36, P283; Schatten G, 2004, NATURE, V430, P301, DOI 10.1038/430301a; Strumpf D, 2005, DEVELOPMENT, V132, P2093, DOI 10.1242/dev.01801; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; TARKOWSKI AK, 1961, NATURE, V190, P857, DOI 10.1038/190857a0; Tarkowski AK, 2001, INT J DEV BIOL, V45, P811; TARKOWSKI AK, 1959, NATURE, V184, P1286, DOI 10.1038/1841286a0; Tolkunova E, 2006, STEM CELLS, V24, P139, DOI 10.1634/stemcells.2005-0240; Vogel G, 2005, SCIENCE, V308, P782, DOI 10.1126/science.308.5723.782; WILLADSEN SM, 1981, J EMBRYOL EXP MORPH, V65, P165; Zernicka-Goetz MZ, 2005, NAT REV MOL CELL BIO, V6, P919, DOI 10.1038/nrm1782; ZIOMEK CA, 1982, J EXP ZOOL, V221, P345, DOI 10.1002/jez.1402210310	31	70	72	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 17	2006	311	5763					992	996		10.1126/science.1120925	http://dx.doi.org/10.1126/science.1120925			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014CS	16484492				2022-12-28	WOS:000235456900043
J	Lee, SJ; Lindquist, K; Segal, MR; Covinsky, KE				Lee, SJ; Lindquist, K; Segal, MR; Covinsky, KE			Development and validation of a prognostic index for 4-year mortality in older adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; PREDICTIVE MODEL; COMORBIDITY; RISK; PREVENTION; MORBIDITY; VALIDITY; DELIRIUM; SAMPLE	Context Both comorbid conditions and functional measures predict mortality in older adults, but few prognostic indexes combine both classes of predictors. Combining easily obtained measures into an accurate predictive model could be useful to clinicians advising patients, as well as policy makers and epidemiologists interested in risk adjustment. Objective To develop and validate a prognostic index for 4-year mortality using information that can be obtained from patient report. Design, Setting, and Participants Using the 1998 wave of the Health and Retirement Study (HRS), a population-based study of community-dwelling US adults older than 50 years, we developed the prognostic index from 11 701 individuals and validated the index with 8009. Individuals were asked about their demographic characteristics, whether they had specific diseases, and whether they had difficulty with a series of functional measures. We identified variables independently associated with mortality and weighted the variables to create a risk index. Main Outcome Measure Death by December 31, 2002. Results The overall response rate was 81%. During the 4-year follow-up, there were 1361 deaths (12%) in the development cohort and 1072 deaths (13%) in the validation cohort. Twelve independent predictors of mortality were identified: 2 demographic variables (age: 60-64 years, 1 point; 65-69 years, 2 points; 70-74 years, 3 points; 75-79 years, 4 points; 80-84 years, 5 points, >85 years, 7 points and male sex, 2 points), 6 comorbid conditions (diabetes, 1 point; cancer, 2 points; lung disease, 2 points; heart failure, 2 points; current tobacco use, 2 points; and body mass index <25, 1 point), and difficulty with 4 functional variables (bathing, 2 points; walking several blocks, 2 points; managing money, 2 points, and pushing large objects, 1 point. Scores on the risk index were strongly associated with 4-year mortality in the validation cohort, with 0 to 5 points predicting a less than 4% risk, 6 to 9 points predicting a 15% risk, 10 to 13 points predicting a 42% risk, and 14 or more points predicting a 64% risk. The risk index showed excellent discrimination with a c statistic of 0.84 in the development cohort and 0.82 in the validation cohort. Conclusion This prognostic index, incorporating age, sex, self-reported comorbid conditions, and functional measures, accurately stratifies community-dwelling older adults into groups at varying risk of mortality.	San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94121 USA; Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lee, SJ (corresponding author), San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94121 USA.	sei.lee@va.gov		Lindquist, Karla/0000-0002-1971-2273	AHRQ HHS [K02-HS00006] Funding Source: Medline; NIA NIH HHS [U01AG09740, R01AG023626] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K02HS000006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023626, U01AG009740] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AG HEALTHC RES QU, 2002, GUID INP QUAL IND QU; *AG HEALTHC RES QU, 2001, GUID PREV QUAL IND A; Agency for Healthcare Research and Quality, 2003, AHRQ QUAL IND GUID P; Amer Geriatrics Soc Clinical Pract, 2000, J AM GERIATR SOC, V48, P842; [Anonymous], 1999, DEATH FORETOLD PROPH; Berg AO, 2002, ANN INTERN MED, V137, P129, DOI 10.7326/0003-4819-137-2-200207160-00014; Berg AO, 2002, ANN INTERN MED, V137, P344, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00011; *CA REP CABG SURG, 2005, 2000 2002 HOSP DAT; Carey EC, 2004, J GEN INTERN MED, V19, P1027, DOI 10.1111/j.1525-1497.2004.40016.x; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Cleves MA, 1997, J CLIN EPIDEMIOL, V50, P903, DOI 10.1016/S0895-4356(97)00091-7; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; Covinsky KE, 2000, J AM GERIATR SOC, V48, P164, DOI 10.1111/j.1532-5415.2000.tb03907.x; Fan VS, 2002, J CLIN EPIDEMIOL, V55, P371, DOI 10.1016/S0895-4356(01)00493-0; Fillenbaum GG, 2000, J GERONTOL A-BIOL, V55, pM84; FONDA SH, 2004, DOCUMENTATION PHYSIC, P14; Fried LP, 1998, JAMA-J AM MED ASSOC, V279, P585, DOI 10.1001/jama.279.8.585; Hook EB, 1997, AM J EPIDEMIOL, V145, P1138; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Iezzoni LI, 2003, RISK ADJUSTMENT MEAS; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; Inouye SK, 1998, JAMA-J AM MED ASSOC, V279, P1187, DOI 10.1001/jama.279.15.1187; Justice AC, 1999, ANN INTERN MED, V130, P515, DOI 10.7326/0003-4819-130-6-199903160-00016; Katz JN, 1996, MED CARE, V34, P73, DOI 10.1097/00005650-199601000-00006; Krumholz HM, 2002, JAMA-J AM MED ASSOC, V287, P1277, DOI 10.1001/jama.287.10.1277; NAGI SZ, 1976, MILBANK FUND Q, V54, P439, DOI 10.2307/3349677; *NY STAT DEP HLTH, 2004, AD CARD SURG NEW YOR; Petitti DB, 1998, JAMA-J AM MED ASSOC, V280, P650, DOI 10.1001/jama.280.7.650; Redelmeier DA, 2001, JAMA-J AM MED ASSOC, V285, P3024, DOI 10.1001/jama.285.23.3024; REILLY BM, 1994, ARCH INTERN MED, V154, P2299, DOI 10.1001/archinte.154.20.2299; ROSOW I, 1966, J GERONTOL, V21, P556, DOI 10.1093/geronj/21.4.556; Saliba D, 2001, J AM GERIATR SOC, V49, P1691, DOI 10.1046/j.1532-5415.2001.49281.x; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; Southern DA, 2004, MED CARE, V42, P355, DOI 10.1097/01.mlr.0000118861.56848.ee; *U MICH, 2002, HLTH RET STUD; *U MICH, 1999, HLTH RET SURV; *U MICH, 1996, HLTH RET SURV; *U MICH, 2005, HRS RESTR DAT WHATS; VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1; Vittinghoff E, 2005, STAT BIOL HEALTH, P1, DOI 10.1007/b138825; Walter LC, 2001, JAMA-J AM MED ASSOC, V285, P2750, DOI 10.1001/jama.285.21.2750; Walter LC, 2001, JAMA-J AM MED ASSOC, V285, P2987, DOI 10.1001/jama.285.23.2987; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837	46	517	523	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	2006	295	7					801	808		10.1001/jama.295.7.801	http://dx.doi.org/10.1001/jama.295.7.801			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011YZ	16478903	Bronze			2022-12-28	WOS:000235306700025
J	Cleaton-Jones, P				Cleaton-Jones, P		Network Chairs Human Hlth Res Ethi	Research injury in clinical trials in South Africa	LANCET			English	Editorial Material									Dent Res Inst, ZA-2050 Johannesburg, South Africa		Cleaton-Jones, P (corresponding author), Dent Res Inst, ZA-2050 Johannesburg, South Africa.	cleatonjonesp@dentistry.wits.ac.za	Cleaton-Jones, Peter E/L-4090-2016; Wassenaar, Douglas/N-5301-2013	Wassenaar, Douglas/0000-0003-0839-9231				BENATAR SR, 2002, GUIDELINES ETHICS ME; *DEP HLTH, 2000, CLIN TRIALS GUID 200; *DEP HLTH, 2004, ETH HLTH RES PRINC S; hhs, 1979, BELM REP ETH PRINC G; *I MED, 2004, WOM HLTH RES ETH LEG, V1; International Conference on Harmonisation of technical requirements for pharmaceuticals for human use (ICH), 1996, GUID GOOD CLIN PRACT; *WORLD MED ASS DEC, 2000, ETH PRINC MED RES IN	7	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 11	2006	367	9509					458	459		10.1016/S0140-6736(06)68158-0	http://dx.doi.org/10.1016/S0140-6736(06)68158-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	013FF	16473111				2022-12-28	WOS:000235394500009
J	Ciosk, R; DePalma, M; Priess, JR				Ciosk, R; DePalma, M; Priess, JR			Translational regulators maintain totipotency in the Caenorhabditis elegans germline	SCIENCE			English	Article							KH DOMAIN PROTEIN; C-ELEGANS; OVARIAN TERATOMAS; GLD-1; RNA; EMBRYOS; PAL-1; PROLIFERATION; ACTIVATION; FERTILITY	The molecular mechanisms that maintain totipotency of the germline are not well understood. Here, we show that two conserved translational regulators, MEX-3 and GLD-1, are essential for maintaining totipotency in the Cenorhabditis elegans germline. In mex-3 gld-1 mutants, germ cells transdifferentiate into various somatic cell types such as muscles or neurons. Our findings implicate RNA regulation in the maintenance of totipotency, suggest that multiple mechanisms maintain totipotency at different stages of germline development, and establish a genetically tractable model for studying the development of teratomas.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Howard Hughes Med Inst, Seattle, WA 98109 USA; Univ Washington, Dept Biol, Seattle, WA 98195 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Ciosk, R (corresponding author), Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland.	rafal.ciosk@fmi.ch	Ciosk, Rafal/L-7327-2013	Ciosk, Rafal/0000-0003-2234-6216				Baugh LR, 2005, DEVELOPMENT, V132, P1843, DOI 10.1242/dev.01782; Berry LW, 1997, DEVELOPMENT, V124, P925; Ciosk R, 2004, DEVELOPMENT, V131, P4831, DOI 10.1242/dev.01352; Cougot N, 2004, J CELL BIOL, V165, P31, DOI 10.1083/jcb.200309008; Detwiler MR, 2001, DEV CELL, V1, P187, DOI 10.1016/S1534-5807(01)00026-0; Donnini M, 2004, J BIOL CHEM, V279, P20154, DOI 10.1074/jbc.M314071200; Donovan PJ, 2003, CURR OPIN GENET DEV, V13, P463, DOI 10.1016/j.gde.2003.08.010; Draper BW, 1996, CELL, V87, P205, DOI 10.1016/S0092-8674(00)81339-2; EPPIG JJ, 1977, NATURE, V269, P517, DOI 10.1038/269517a0; Fong YY, 2002, SCIENCE, V296, P2235, DOI 10.1126/science.1070790; FRANCIS R, 1995, GENETICS, V139, P579; FRANCIS R, 1995, GENETICS, V139, P607; Fukushige T, 2005, DEVELOPMENT, V132, P1795, DOI 10.1242/dev.01774; Hansen D, 2004, DEVELOPMENT, V131, P93, DOI 10.1242/dev.00916; Hunter CP, 1996, CELL, V87, P217, DOI 10.1016/S0092-8674(00)81340-9; Jan E, 1999, EMBO J, V18, P258, DOI 10.1093/emboj/18.1.258; Jones AR, 1996, DEV BIOL, V180, P165, DOI 10.1006/dbio.1996.0293; Kadyk LC, 1998, DEVELOPMENT, V125, P1803; Kawasaki I, 1998, CELL, V94, P635, DOI 10.1016/S0092-8674(00)81605-0; Kuznicki KA, 2000, DEVELOPMENT, V127, P2907; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; LINDER D, 1975, NEW ENGL J MED, V292, P63, DOI 10.1056/NEJM197501092920202; Mootz D, 2004, DEVELOPMENT, V131, P3263, DOI 10.1242/dev.01196; Saffman EE, 1999, CELL MOL LIFE SCI, V55, P1141, DOI 10.1007/s000180050363; Seydoux G, 2001, INT REV CYTOL, V203, P139; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Ulbright TM, 2005, MODERN PATHOL, V18, pS61, DOI 10.1038/modpathol.3800310; Unhavaithaya Y, 2002, CELL, V111, P991, DOI 10.1016/S0092-8674(02)01202-3; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; Xu L, 2001, GENETICS, V159, P1007	30	130	136	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 10	2006	311	5762					851	853		10.1126/science.1122491	http://dx.doi.org/10.1126/science.1122491			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XT	16469927				2022-12-28	WOS:000235374900049
J	Toncian, T; Borghesi, M; Fuchs, J; d'Humieres, E; Antici, P; Audebert, P; Brambrink, E; Cecchetti, CA; Pipahl, A; Romagnani, L; Willi, O				Toncian, T; Borghesi, M; Fuchs, J; d'Humieres, E; Antici, P; Audebert, P; Brambrink, E; Cecchetti, CA; Pipahl, A; Romagnani, L; Willi, O			Ultrafast laser-driven microlens to focus and energy-select mega-electron volt protons	SCIENCE			English	Article							PLASMA INTERACTION; INTENSE LASERS; HOT-ELECTRONS; BEAMS; ACCELERATION; GENERATION; IGNITION; SOLIDS	We present a technique for simultaneous focusing and energy selection of high-current, mega-electron volt proton beams With the use of radial, transient electric fields (107 to 1010 volts per meter) triggered on the inner walls of a hollow microcylinder by an intense subpicosecond laser pulse. Because of the transient nature of the focusing fields, the proposed method allows selection of a desired range out of the spectrum of the polyenergetic proton beam. This technique addresses current drawbacks of laser-accelerated proton beams, such as their broad spectrum and divergence at the source.	Univ Dusseldorf, D-40225 Dusseldorf, Germany; Queens Univ Belfast, Sch Math & Phys, Belfast BT7 1NN, Antrim, North Ireland; Univ Paris 06, Ecole Polytech, CEA, Lab Utilisat Lasers Intenses,CNRS,UMR 7605, F-91128 Palaiseau, France; Ecole Polytech, Ctr Phys Theor, CNRS, UMR 7644, F-91128 Palaiseau, France	Heinrich Heine University Dusseldorf; Queens University Belfast; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; CEA; Institut Polytechnique de Paris; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Institut Polytechnique de Paris	Willi, O (corresponding author), Univ Dusseldorf, D-40225 Dusseldorf, Germany.	oswald.willi@laserphy.uni-duesseldorf.de	Willi, Oswald/AAA-6942-2022; Romagnani, Lorenzo/ABE-3974-2020; Fuchs, Julien/D-3450-2016; audebert, patrick/ABG-1351-2020; Borghesi, Marco/K-2974-2012; Willi, Oswald/H-6611-2016	Fuchs, Julien/0000-0001-9765-0787; audebert, patrick/0000-0002-1330-3946; Borghesi, Marco/0000-0001-9165-0073; Willi, Oswald/0000-0001-7804-6373; d'Humieres, Emmanuel/0000-0003-3463-3343; Romagnani, Lorenzo/0000-0002-7053-3967				Allen M, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.265004; Borghesi M, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.055003; Borghesi M, 2002, PHYS PLASMAS, V9, P2214, DOI 10.1063/1.1459457; Bulanov SV, 2002, PHYS LETT A, V299, P240, DOI 10.1016/S0375-9601(02)00521-2; Clark EL, 2000, PHYS REV LETT, V84, P670, DOI 10.1103/PhysRevLett.84.670; Cowan TE, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.204801; Fuchs J, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.045004; GITOMER SJ, 1986, PHYS FLUIDS, V29, P2679, DOI 10.1063/1.865510; GORDIENKO S, COMMUNICATION; Hegelich BM, 2006, NATURE, V439, P441, DOI 10.1038/nature04400; Key MH, 1998, PHYS PLASMAS, V5, P1966, DOI 10.1063/1.872867; Ledingham KWD, 2003, SCIENCE, V300, P1107, DOI 10.1126/science.1080552; Lefebvre E, 2003, NUCL FUSION, V43, P629, DOI 10.1088/0029-5515/43/7/317; Luo W, 2005, MED PHYS, V32, P794, DOI 10.1118/1.1861772; Maksimchuk A, 2000, PHYS REV LETT, V84, P4108, DOI 10.1103/PhysRevLett.84.4108; Malka V, 2005, PLASMA PHYS CONTR F, V47, pB481, DOI 10.1088/0741-3335/47/12B/S34; Patel PK, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.125004; PERRY MD, 1994, SCIENCE, V264, P917, DOI 10.1126/science.264.5161.917; Remington BA, 1999, SCIENCE, V284, P1488, DOI 10.1126/science.284.5419.1488; Romagnani L, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.195001; Roth M, 2001, PHYS REV LETT, V86, P436, DOI 10.1103/PhysRevLett.86.436; Rousse A, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.135005; Schwoerer H, 2006, NATURE, V439, P445, DOI 10.1038/nature04492; Snavely RA, 2000, PHYS REV LETT, V85, P2945, DOI 10.1103/PhysRevLett.85.2945; Spencer I, 2001, NUCL INSTRUM METH B, V183, P449, DOI 10.1016/S0168-583X(01)00771-6; TABAK M, 1994, PHYS PLASMAS, V1, P1626, DOI 10.1063/1.870664; Wattellier B, 2004, OPT LETT, V29, P2494, DOI 10.1364/OL.29.002494; Wilks SC, 2001, PHYS PLASMAS, V8, P542, DOI 10.1063/1.1333697	29	277	289	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 21	2006	312	5772					410	413		10.1126/science.1124412	http://dx.doi.org/10.1126/science.1124412			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	034OZ	16484452	Green Submitted			2022-12-28	WOS:000236941800042
J	Tokar, RL; Johnson, RE; Hill, TW; Pontius, DH; Kurth, WS; Crary, FJ; Young, DT; Thomsen, MF; Reisenfeld, DB; Coates, AJ; Lewis, GR; Sittler, EC; Gurnett, DA				Tokar, RL; Johnson, RE; Hill, TW; Pontius, DH; Kurth, WS; Crary, FJ; Young, DT; Thomsen, MF; Reisenfeld, DB; Coates, AJ; Lewis, GR; Sittler, EC; Gurnett, DA			The interaction of the atmosphere of Enceladus with Saturn's plasma	SCIENCE			English	Article							CASSINI; SPECTROMETER; ION		Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Univ Virginia, Charlottesville, VA 22904 USA; Rice Univ, Houston, TX 77251 USA; Birmingham So Coll, Birmingham, AL 35254 USA; Univ Iowa, Iowa City, IA 52242 USA; SW Res Inst, San Antonio, TX 78228 USA; Univ Montana, Missoula, MT 59812 USA; UCL, Mullard Space Sci Lab, Dorking RH5 6NT, Surrey, England; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; University of Virginia; Rice University; University of Iowa; Southwest Research Institute; University of Montana System; University of Montana; University of London; University College London; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Tokar, RL (corresponding author), Los Alamos Natl Lab, POB 1663, Los Alamos, NM 87545 USA.	rlt@lanl.gov	Kurth, William/AAA-7334-2019; Reisenfeld, Daniel/F-7614-2015; Coates, Andrew/C-2396-2008	Kurth, William/0000-0002-5471-6202; Coates, Andrew/0000-0002-6185-3125	UK Space Agency [PP/D00084X/1] Funding Source: researchfish	UK Space Agency		Dougherty MK, 2006, SCIENCE, V311, P1406, DOI 10.1126/science.1120985; Gurnett DA, 2004, SPACE SCI REV, V114, P395, DOI 10.1007/s11214-004-1434-0; Hill TW, 1998, J GEOPHYS RES-PLANET, V103, P19879, DOI 10.1029/98JE00945; JOHNSON RE, IN PRESS GEOPHYS RES; Jurac S, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015855; Moore LE, 2004, ICARUS, V172, P503, DOI 10.1016/j.icarus.2004.07.007; Richardson JD, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020959; SHEMANSKY DE, 1993, NATURE, V363, P329, DOI 10.1038/363329a0; Sittler EC, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL022653; Strobel D. F., 1983, PHYSICS JOVIAN MAGNE, P51, DOI [10.1017/CBO9780511564574.004, DOI 10.1017/CB09780511564574.004]; Waite JH, 2006, SCIENCE, V311, P1419, DOI 10.1126/science.1121290; Young DT, 2004, SPACE SCI REV, V114, P1, DOI 10.1007/s11214-004-1406-4	12	163	163	3	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2006	311	5766					1409	1412		10.1126/science.1121061	http://dx.doi.org/10.1126/science.1121061			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527967				2022-12-28	WOS:000236029400033
J	Crowhurst, JC; Goncharov, AF; Sadigh, B; Evans, CL; Morrall, PG; Ferreira, JL; Nelson, AJ				Crowhurst, JC; Goncharov, AF; Sadigh, B; Evans, CL; Morrall, PG; Ferreira, JL; Nelson, AJ			Synthesis and characterization of the nitrides of platinum and iridium	SCIENCE			English	Article							HAFNIUM NITRIDE; NITROGEN; SPECTROSCOPY; ENERGY; PYRITE; FILMS; FES2	Transition metal nitrides are of great technological and fundamental importance because of their strength and durability and because of their useful optical, electronic, and magnetic properties. We have evaluated a recently synthesized platinum nitride (PtN) that was shown to have a large bulk modulus, and we propose a structure that is isostructural with pyrite and has the stoichiometry PtN2. We have also synthesized a recoverable nitride of iridium under nearly the same conditions of pressure and temperature as PtN2. Although it has the same stoichiometry, it exhibits much lower structural symmetry. Preliminary results suggest that the bulk modulus of this material is also very large.	Lawrence Livermore Natl Lab, Livermore, CA 94551 USA; Carnegie Inst Washington, Geophys Lab, Washington, DC 20015 USA; AWE, Reading RG7 4PR, Berks, England	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Carnegie Institution for Science	Crowhurst, JC (corresponding author), Lawrence Livermore Natl Lab, 7000 East Ave, Livermore, CA 94551 USA.	crowhurst1@llnl.gov	Goncharov, Alexander F./AAX-9943-2020	Goncharov, Alexander F./0000-0002-6422-8819; Nelson, Art/0000-0003-4050-0141; Sadigh, Babak/0000-0002-8487-7859				Arranz A, 2004, SURF SCI, V563, P1, DOI 10.1016/j.susc.2004.06.162; Barreca D., 2000, Surface Science Spectra, V7, P303, DOI 10.1116/1.1375573; Blaha P., 2001, COMPUTER CODE WIEN2K; Blanchard M, 2005, J PHYS CHEM B, V109, P22067, DOI 10.1021/jp053540x; BOZACK MJ, 1994, SURF SCI SPECTRA, V2, P123; Eremets MI, 2004, NAT MATER, V3, P558, DOI 10.1038/nmat1146; Fan CZ, 2005, CHINESE PHYS LETT, V22, P2637, DOI 10.1088/0256-307X/22/10/050; Goncharov AF, 2005, J LOW TEMP PHYS, V139, P727, DOI 10.1007/s10909-005-5484-9; Gregoryanz E, 2004, NAT MATER, V3, P294, DOI 10.1038/nmat1115; Jhi SH, 1999, NATURE, V399, P132, DOI 10.1038/20148; Kleppe AK, 2004, MINERAL MAG, V68, P433, DOI 10.1180/0026461046830196; Kresse G, 1996, PHYS REV B, V54, P11169, DOI 10.1103/PhysRevB.54.11169; Kresse G, 1999, PHYS REV B, V59, P1758, DOI 10.1103/PhysRevB.59.1758; Kroll P, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.125501; MAILHIOT C, 1992, PHYS REV B, V46, P14419, DOI 10.1063/1.46314; MERNAGH TP, 1993, CHEM GEOL, V103, P113, DOI 10.1016/0009-2541(93)90295-T; OLIJNYK H, 1990, J CHEM PHYS, V93, P8968, DOI 10.1063/1.459236; Oyama S.T., 1996, CHEM TRANSITION META, DOI 10.1007/978-94-009-1565-7; PATIL SKR, IN PRESS PHYS REV B; PERDEW JP, 1992, PHYS REV B, V45, P13244, DOI 10.1103/PhysRevB.45.13244; PIERSON HO, 1996, HDB REFRACTORY CARBI, pCH9; Rignanese GM, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.205416; Sahu BR, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.119901; Sahu BR, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.041101; Soto G, 2004, MATER LETT, V58, P2178, DOI 10.1016/j.matlet.2004.01.019; Uddin J, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.119902; Uddin J, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.035101; VOGT H, 1983, J PHYS CHEM SOLIDS, V44, P869, DOI 10.1016/0022-3697(83)90124-5; Yu R, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1890466; Yu R, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.054103; Zerr A, 2003, NAT MATER, V2, P185, DOI 10.1038/nmat836; Zerr A, 1999, NATURE, V400, P340, DOI 10.1038/22493	32	437	449	7	231	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	2006	311	5765					1275	1278		10.1126/science.1121813	http://dx.doi.org/10.1126/science.1121813			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019XB	16513980				2022-12-28	WOS:000235870400038
J	Davey, G; Fekade, D; Parry, E				Davey, G; Fekade, D; Parry, E			Must aid hinder attempts to reach the Millennium Development Goals?	LANCET			English	Editorial Material							HEALTH-PROGRAMS; RESOURCES; AFRICA		Fac Med, Addis Ababa, Ethiopia; Trop Hlth & Educ Trust, London NW1 2BE, England		Davey, G (corresponding author), Fac Med, Addis Ababa, Ethiopia.	nerurkar@ethionet.et		Davey, Gail/0000-0003-2796-7468				Cairncross S, 1997, LANCET, V349, P20; Chen L, 2004, LANCET, V364, P1984, DOI 10.1016/S0140-6736(04)17482-5; COLEMAN AME, 2005, AMJ, V331, P1203; Eastwood JB, 2005, LANCET, V365, P1893, DOI 10.1016/S0140-6736(05)66623-8; MENSAH K, 2005, MEDACT           FEB; MILLS A, 1983, SOC SCI MED, V17, P1971, DOI 10.1016/0277-9536(83)90137-5; *MIN HLTH REP GHAN, MISS STAT; PAVIGNANI E, 2005, ANAL DISRUPTED HLTH; Segall M, 2003, INT J HEALTH PLAN M, V18, pS5, DOI 10.1002/hpm.719	9	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 25	2006	367	9511					629	631		10.1016/S0140-6736(06)68239-1	http://dx.doi.org/10.1016/S0140-6736(06)68239-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	016HR	16503445				2022-12-28	WOS:000235611800006
J	Marks, DJB; Harbord, MWN; MacAllister, R; Rahman, FZ; Young, J; Al-Lazikani, B; Lees, W; Novelli, M; Bloom, S; Segal, AW				Marks, DJB; Harbord, MWN; MacAllister, R; Rahman, FZ; Young, J; Al-Lazikani, B; Lees, W; Novelli, M; Bloom, S; Segal, AW			Defective acute inflammation in Crohn's disease: a clinical investigation	LANCET			English	Article							CHRONIC GRANULOMATOUS-DISEASE; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; BOWEL-DISEASE; MURAMYL DIPEPTIDE; ASP299GLY POLYMORPHISM; VASCULAR-RESPONSES; CIGARETTE-SMOKING; NOD2 GENE; MUTATION	Background The cause of Crohn's disease has not been mechanistically proven. We tested the hypothesis that the disease is a form of immunodeficiency caused by impaired innate immunity. Methods We investigated inflammatory responses in patients and controls by quantifying neutrophil recruitment and cytokine production after acute trauma, interleukin 8 secretion by cultured monocyte-derived macrophages after exposure to inflammatory mediators, and local inflammatory and vascular changes in response to subcutaneous injection of heat-killed Escherichia coli. Findings In patients with Crohn's disease, trauma to rectum, ileum, or skin led to abnormally low neutrophil accumulation (differences from healthy individuals of 79%, n=8, p=0.0003; 57%, n=3, p=0.05; 50%, n=13, P<0.0001, respectively) and lower production of proinflammatory interleukin 8 (63%, n=7, p=0.003; 63%, n=3, p=0.05; 45%, n=8, p<0.0001) and interleukin 10 (50%, n=8, p=0.0005). Interleukin 8 secretion by cultured macrophages was reduced after exposure to acute wound fluid (38%, n=50, p<0.0001), C5a (48%, n=41, p=0.0005), or tumour necrosis factor alpha (52%, n=27, p<0.0001). Local inflammatory reaction to inoculation with E coli was attenuated, as quantified by changes in bloodflow (ileal disease 50%, n=6, p=0.01; colonic disease 77%, n=6, p=0.0003). This response was mediated by nitric oxide in controls, was increased by sildenafil in patients, and was not related to CARD15 genotype. Interpretation in Crohn's disease, a constitutionally weak immune response predisposes to accumulation of intestinal contents that breach the mucosal barrier of the bowel wall, resulting in granuloma formation and chronic inflammation. Polymorphisms in CARD15 do not underlie this phenotype, but incapacitate the NOD2 pathway that can compensate for impairment of innate inflammation. Current treatment of secondary chronic inflammation might exaggerate the underlying lesion and promote chronic disease.	UCL, Dept Med, London WC1E 6JJ, England; Inpharmatica, London, England; UCL Hosp NHS Fdn Trust, Dept Imaging, London, England; UCL Hosp NHS Fdn Trust, Dept Histopathol, London, England; UCL Hosp NHS Fdn Trust, Dept Gastroenterol, London, England	University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London	Segal, AW (corresponding author), UCL, Dept Med, London WC1E 6JJ, England.	t.segal@ucl.ac.uk	Al-Lazikani, Bissan/AAG-4723-2022; Eckhardt, Erik/G-1567-2010; Al-Lazikani, Bissan/AFK-6457-2022	Al-Lazikani, Bissan/0000-0003-3367-2519; Segal, Anthony/0000-0001-7602-9043	Wellcome Trust [067287] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Anton P A, 1999, Semin Gastrointest Dis, V10, P14; Bonen DK, 2003, GASTROENTEROLOGY, V124, P140, DOI 10.1053/gast.2003.50019; Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132; Brant SR, 2004, INFLAMM BOWEL DIS, V10, P300, DOI 10.1097/00054725-200405000-00019; BURMAN JH, 1969, GUT, V10, P1054; Clapp BR, 2005, CIRCULATION, V111, P1530, DOI 10.1161/01.CIR.0000159336.31613.31; Cobrin GM, 2005, IMMUNOL REV, V206, P277, DOI 10.1111/j.0105-2896.2005.00293.x; Connelly L, 2005, J BIOL CHEM, V280, P10040, DOI 10.1074/jbc.M411991200; Cuthbert AP, 2002, GASTROENTEROLOGY, V122, P867, DOI 10.1053/gast.2002.32415; Don BR, 2000, J NEPHROL, V13, P249; Farrar MD, 2005, J APPL MICROBIOL, V98, P1191, DOI 10.1111/j.1365-2672.2005.02565.x; Farthing MJG, 2004, BEST PRACT RES CL GA, V18, P233, DOI 10.1016/j.bpg.2003.11.001; Franchimont D, 2004, GUT, V53, P987, DOI 10.1136/gut.2003.030205; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Glossmann H, 1999, EXP GERONTOL, V34, P305, DOI 10.1016/S0531-5565(99)00003-0; Greenstein RJ, 2003, LANCET INFECT DIS, V3, P507, DOI 10.1016/S1473-3099(03)00724-2; Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835; Hampe J, 2001, LANCET, V357, P1925, DOI 10.1016/S0140-6736(00)05063-7; HARVEY RF, 1980, LANCET, V1, P514; Hehlgans T, 2005, IMMUNOLOGY, V115, P1, DOI 10.1111/j.1365-2567.2005.02143.x; Hugot JP, 2003, LANCET, V362, P2012, DOI 10.1016/S0140-6736(03)15024-6; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Hunter MM, 2004, ALIMENT PHARM THER, V19, P167, DOI 10.1111/j.0269-2813.2004.01803.x; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Ishiyama M, 1996, BIOL PHARM BULL, V19, P1518; ISSEKUTZ AC, 1981, LAB INVEST, V45, P435; James DG, 2000, POSTGRAD MED J, V76, P457, DOI 10.1136/pmj.76.898.457; Kishimoto T, 2005, ANNU REV IMMUNOL, V23, P1, DOI 10.1146/annurev.immunol.23.021704.115806; Klein W, 2002, SCAND J GASTROENTERO, V37, P189, DOI 10.1080/003655202753416867; Kleinert H, 2003, BIOL CHEM, V384, P1343, DOI 10.1515/BC.2003.152; Korzenik JR, 2005, J CLIN GASTROENTEROL, V39, pS59, DOI 10.1097/01.mcg.0000155553.28348.fc; Li J, 2004, HUM MOL GENET, V13, P1715, DOI 10.1093/hmg/ddh182; Li YM, 2004, J EXP MED, V200, P613, DOI 10.1084/jem.20040725; Lucey DR, 1996, CLIN MICROBIOL REV, V9, P532, DOI 10.1128/CMR.9.4.532; Maeda S, 2005, SCIENCE, V307, P734, DOI 10.1126/science.1103685; Marciano BE, 2004, PEDIATRICS, V114, P462, DOI 10.1542/peds.114.2.462; MARIN J, 1990, GEN PHARMACOL-VASC S, V21, P575, DOI 10.1016/0306-3623(90)91002-9; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ouburg S, 2005, GUT, V54, P439; Pauleau AL, 2003, MOL CELL BIOL, V23, P7531, DOI 10.1128/MCB.23.21.7531-7539.2003; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Ryan P, 2004, AM J GASTROENTEROL, V99, P1539, DOI 10.1111/j.1572-0241.2004.40103.x; Seftel AD, 2004, CLIN CARDIOL, V27, pI14; SEGAL AW, 1976, LANCET, V2, P219; Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653; Shanahan F, 2002, LANCET, V359, P62, DOI 10.1016/S0140-6736(02)07284-7; Sher ME, 1999, INFLAMM BOWEL DIS, V5, P73, DOI 10.1097/00054725-199905000-00001; SHIMIZU S, 1979, BIOCHEM BIOPH RES CO, V91, P108, DOI 10.1016/0006-291X(79)90589-8; Sopori M, 2002, NAT REV IMMUNOL, V2, P372, DOI 10.1038/nri803; Stallmach Andreas, 2004, Int J Colorectal Dis, V19, P308, DOI 10.1007/s00384-003-0554-4; SUTHERLAND LR, 1990, GASTROENTEROLOGY, V98, P1123, DOI 10.1016/0016-5085(90)90324-T; van Heel DA, 2005, LANCET, V365, P1794, DOI 10.1016/S0140-6736(05)66582-8; Vavricka SR, 2004, GASTROENTEROLOGY, V127, P1401, DOI 10.1053/j.gastro.2004.07.024; Watanabe T, 2005, GUT, V54, P1515, DOI 10.1136/gut.2005.071795; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; Zimmerman DDE, 2005, DIS COLON RECTUM, V48, P1228, DOI 10.1007/s10350-004-0943-y; ZWAHLEN R, 1993, INT REV EXP PATHOL, V34, P27	58	309	322	1	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 25	2006	367	9511					668	678		10.1016/S0140-6736(06)68265-2	http://dx.doi.org/10.1016/S0140-6736(06)68265-2			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	016HR	16503465				2022-12-28	WOS:000235611800031
J	Tully, J; Viner, RM; Coen, PG; Stuart, JM; Zambon, M; Peckham, C; Booth, C; Klein, N; Kaczmarski, E; Booy, R				Tully, J; Viner, RM; Coen, PG; Stuart, JM; Zambon, M; Peckham, C; Booth, C; Klein, N; Kaczmarski, E; Booy, R			Risk and protective factors for meningococcal disease in adolescents: matched cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MANNOSE-BINDING LECTIN; NEISSERIA-MENINGITIDIS; INFLUENZA-A; INFECTION; SMOKING; SURVEILLANCE; MYCOPLASMA; CARRIAGE; OUTBREAK; VIRUSES	Objective To examine biological and social risk factors for meningococcal disease in adolescents. Design Prospective, population based, matched cohort study with controls matched for age and sex in 1:1 matching. Controls were sought front the general practitioner. Setting Six contiguous regions of England, which represent some 65% of the Country's population. Participants 15-19 year olds with meningococcal disease recruited at hospital admission in six regions (representing 65% of the population of England) from January 1999 to June 2000, and their matched controls. Methods Blood samples and pernasal and throat. swabs were taken from case patients at admission to hospital and front cases and matched controls at interview. Data on potential risk factors were gathered by confidential interview. Data were analysed by using univariate and multivariate conditional logistic regression. Results 144 case control pairs were recruited (74 male (51%); median age 17.6). 114 cases (79%) were confirmed microbiologically. Significant independent risk factors for meningococcal disease were history of preceding illness (matched odds ratio 2.9, 95% confidence interval 1.4 to 5.9), intimate kissing with multiple partners (3.7, 1.7 to 8.1), being a university student (3.4, 1.2 to 10) and preterm birth (3.7, 1.0 to 13.5). Religious observance (0.09, 0.02 to 0.6) and meningococcal vaccination (0.12, 0.04 to 0.4) were associated with protection. Conclusions Activities and events increasing risk for meningococcal disease in adolescence are different from risks in childhood. Students are at higher risk. Altering personal behaviours could moderate the risk. However, the development of further effective meningococcal vaccines remains a key public health priority.	Univ London, Barts & London, Queen Marys Sch Med & Dent, Acad Ctr Child Hlth, London E1 1BB, England; UCL, Royal Free & Univ Coll Med Sch, Dept Paediat, London WC1E 6BT, England; Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 3JH, England; Hlth Protect Agcy S W, Stonehouse GL10 3RF, Scotland; Hlth Protect Agcy, Resp Virus Unit, London NW9 5HT, England; Inst Child Hlth, Infect Dis & Microbiol Unit, London, England; Manchester Royal Infirm, Hlth Protect Agcy, Meningococcal Reference Unit, Manchester M13 9WZ, Lancs, England	University of London; Queen Mary University London; University of London; University College London; University of London; University College London; Health Protection Agency; University of London; University College London; Health Protection Agency; University of Manchester	Booy, R (corresponding author), Univ London, Barts & London, Queen Marys Sch Med & Dent, Acad Ctr Child Hlth, London E1 1BB, England.	robertb2@chw.edu.au	peckham, catherine s/I-6300-2013; Booy, Robert/D-4188-2011	Klein, Nigel/0000-0003-3925-9258; Tully, Joanna/0000-0002-3918-6063				Bose A, 2003, LANCET, V361, P675, DOI 10.1016/S0140-6736(03)12563-9; Bruce MG, 2001, JAMA-J AM MED ASSOC, V286, P688, DOI 10.1001/jama.286.6.688; CARTWRIGHT KAV, 1991, LANCET, V338, P554, DOI 10.1016/0140-6736(91)91112-8; CARTWRIGHT KAV, 1987, EPIDEMIOL INFECT, V99, P591, DOI 10.1017/S0950268800066449; Coen PG, 2000, INT J EPIDEMIOL, V29, P180, DOI 10.1093/ije/29.1.180; Connolly M, 1999, EPIDEMIOL INFECT, V122, P41, DOI 10.1017/S0950268898001848; Davison K L, 2002, Commun Dis Public Health, V5, P205; Ellis JS, 1997, J CLIN MICROBIOL, V35, P2076, DOI 10.1128/JCM.35.8.2076-2082.1997; EVANS AS, 1998, VIRAL INFECT HUMANS, P253; Fanger NA, 1997, J IMMUNOL, V158, P3090; Fischer M, 1997, PEDIATR INFECT DIS J, V16, P979, DOI 10.1097/00006454-199710000-00015; Gray SJ, 2001, METH MOLEC MED, V67, P61, DOI 10.1385/1-59259-149-3:61; HANEBERG B, 1983, NIPH (National Institute of Public Health) Annals (Oslo), V6, P169; Harrison LH, 1999, JAMA-J AM MED ASSOC, V281, P1906, DOI 10.1001/jama.281.20.1906; Harrison LH, 2001, JAMA-J AM MED ASSOC, V286, P694, DOI 10.1001/jama.286.6.694; HARRISON LH, 1991, ARCH INTERN MED, V151, P1005, DOI 10.1001/archinte.151.5.1005; Hibberd ML, 1999, LANCET, V353, P1049, DOI 10.1016/S0140-6736(98)08350-0; Hibberd ML, 1999, LANCET, V354, P337, DOI 10.1016/S0140-6736(05)75242-9; Hosmer D, 1989, WILEY SERIES PROBABI; Hotchin NA, 1991, CURRENT TOPICS CLIN, P115; Imrey PB, 1996, AM J EPIDEMIOL, V143, P624, DOI 10.1093/oxfordjournals.aje.a008792; Jack D, 1997, HUM MUTAT, V9, P41, DOI 10.1002/(SICI)1098-1004(1997)9:1<41::AID-HUMU7>3.0.CO;2-S; JONES DM, 1993, J INFECTION, V27, P83, DOI 10.1016/0163-4453(93)93978-D; JUNKER AK, 1986, CLIN IMMUNOL IMMUNOP, V40, P436, DOI 10.1016/0090-1229(86)90188-1; Koenig HG, 1997, INT J PSYCHIAT MED, V27, P233, DOI 10.2190/40NF-Q9Y2-0GG7-4WH6; Kriz P, 2000, ARCH DIS CHILD, V83, P117, DOI 10.1136/adc.83.2.117; Kutscher S, 2002, NEUROPSYCHOBIOLOGY, V45, P144, DOI 10.1159/000054955; McCullough ME, 2000, HEALTH PSYCHOL, V19, P211, DOI 10.1037//0278-6133.19.3.211; McDade TW, 2001, AM J CLIN NUTR, V74, P543; Moodley JR, 1999, S AFR MED J, V89, P56; MOORE PS, 1990, JAMA-J AM MED ASSOC, V264, P1271, DOI 10.1001/jama.264.10.1271; Neal KR, 2000, BRIT MED J, V320, P846, DOI 10.1136/bmj.320.7238.846; Nelson SJ, 2001, EPIDEMIOL INFECT, V126, P211, DOI 10.1017/S0950268801005301; Nuorti JP, 2000, NEW ENGL J MED, V342, P681, DOI 10.1056/NEJM200003093421002; Ramsay M, 1997, Commun Dis Rep CDR Rev, V7, pR49; Robinson P, 2001, EPIDEMIOL INFECT, V127, P261, DOI 10.1017/S0950268801005696; Schulz KF, 2002, LANCET, V359, P431, DOI 10.1016/S0140-6736(02)07605-5; SMART JM, 1989, LANCET, V2, P723; Stallard N, 2004, STAT MED, V23, P3193, DOI 10.1002/sim.1884; STANWELLSMITH RE, 1994, EPIDEMIOL INFECT, V112, P315, DOI 10.1017/S0950268800057733; Stuart JM, 1996, EPIDEMIOL INFECT, V117, P107, DOI 10.1017/S0950268800001199; Tashkin DP, 2002, J CLIN PHARMACOL, V42, p71S, DOI 10.1002/j.1552-4604.2002.tb06006.x; Tong CYW, 1999, J CLIN PATHOL, V52, P257, DOI 10.1136/jcp.52.4.257; Tully J, 2000, BRIT MED J, V320, P1179, DOI 10.1136/bmj.320.7243.1179; Turner MW, 2000, HUM MOL GENET, V9, P1481, DOI 10.1093/hmg/9.10.1481; Walker Z, 2002, BRIT MED J, V325, P524, DOI 10.1136/bmj.325.7363.524; Watson JM, 1996, INT CONGR SER, V1123, P82; YOUNG LS, 1972, NEW ENGL J MED, V287, P5, DOI 10.1056/NEJM197207062870102; Zaleski EH, 2000, J ADOLESCENCE, V23, P223, DOI 10.1006/jado.2000.0309	49	64	67	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 25	2006	332	7539					445	448A		10.1136/bmj.38725.728472.BE	http://dx.doi.org/10.1136/bmj.38725.728472.BE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	018VM	16473859	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000235792900013
J	Bartek, J; Lukas, J				Bartek, J; Lukas, J			The stress of finding NEMO	SCIENCE			English	Editorial Material							NF-KAPPA-B; DNA-DAMAGE RESPONSE; ACTIVATION; CHECKPOINT; KINASES; CANCER; ATM	A cell's response to damaged DNA is triggered when two proteins leave the nucleus and converge upon a signaling complex in the cytoplasm. This activates a key transcription factor that then moves into the nucleus to promote cell survival.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Danish Canc Soc, Ctr Genotox Stress Res, DK-2100 Copenhagen, Denmark	Danish Cancer Society; Danish Cancer Society	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.	jb@cancer.dk	Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X				Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Sigala JLD, 2004, SCIENCE, V304, P1963, DOI 10.1126/science.1098387; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022	15	20	21	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	2006	311	5764					1110	1111		10.1126/science.1124540	http://dx.doi.org/10.1126/science.1124540			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017IU	16497923				2022-12-28	WOS:000235688100036
J	Kellam, P; Weiss, RA				Kellam, P; Weiss, RA			Infectogenomics: Insights from the host genome into infectious diseases	CELL			English	Editorial Material							HIV-1 INFECTION; PATHOGENS; RESPONSES; RISK; AIDS; SUSCEPTIBILITY; PROGRESSION	Five years into the human postgenomic era, we are gaining considerable knowledge about host-pathogen interactions through host genomes. This "infectogenomics" approach should yield further insights into both diagnostic and therapeutic advances, as well as normal cellular function.	UCL, Div Infect & Immun, MRC, UCL,Ctr Med Mol Virol, London W1T 4JF, England	University of London; University College London	Weiss, RA (corresponding author), UCL, Div Infect & Immun, MRC, UCL,Ctr Med Mol Virol, London W1T 4JF, England.	r.weiss@ucl.ac.uk		Kellam, Paul/0000-0003-3166-4734				An P, 2004, J VIROL, V78, P11070, DOI 10.1128/JVI.78.20.11070-11076.2004; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Carrington M, 2003, ANNU REV MED, V54, P535, DOI 10.1146/annurev.med.54.101601.152346; del Real G, 2004, J EXP MED, V200, P541, DOI 10.1084/jem.20040061; Gonzalez E, 2005, SCIENCE, V307, P1434, DOI 10.1126/science.1101160; Griffiths MJ, 2005, J INFECT DIS, V191, P1599, DOI 10.1086/429297; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Jenner RG, 2003, P NATL ACAD SCI USA, V100, P10399, DOI 10.1073/pnas.1630810100; Jenner RG, 2005, NAT REV MICROBIOL, V3, P281, DOI 10.1038/nrmicro1126; Kellam P, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-1-201; Sawyer SL, 2006, CURR BIOL, V16, P95, DOI 10.1016/j.cub.2005.11.045; Scherer A, 2004, P NATL ACAD SCI USA, V101, P12266, DOI 10.1073/pnas.0404091101; Shrestha S, 2006, J INFECT DIS, V193, P16, DOI 10.1086/498532; van Opijnen T, 2005, REV MED VIROL, V15, P219, DOI 10.1002/rmv.472; Vignuzzi M, 2006, NATURE, V439, P344, DOI 10.1038/nature04388; Weiss RA, 2004, NAT MED, V10, pS70, DOI 10.1038/nm1150; Whitney AR, 2003, P NATL ACAD SCI USA, V100, P1896, DOI 10.1073/pnas.252784499	17	34	37	0	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	FEB 24	2006	124	4					695	697		10.1016/j.cell.2006.02.003	http://dx.doi.org/10.1016/j.cell.2006.02.003			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	038RO	16497580	Green Published, Bronze			2022-12-28	WOS:000237240900013
J	Martin, T				Martin, T			Early mammalian evolutionary experiments	SCIENCE			English	Editorial Material								Before the extinction of the dinosaurs, most early mammals were thought to be small, nocturnal, and terrestrial. A new large Middle Jurassic fossil with fur and a beaverlike tail suggests that some were aquatic.	Forschungsinst Senckenberg, Mammal Sect, D-60325 Frankfurt, Germany	Senckenberg Gesellschaft fur Naturforschung (SGN)	Martin, T (corresponding author), Forschungsinst Senckenberg, Mammal Sect, D-60325 Frankfurt, Germany.	tmartin@senckenberg.de						Carroll RL, 1988, VERTEBRATE PALEONTOL; Flynn JJ, 1999, NATURE, V401, P57, DOI 10.1038/43420; JENKINS FA, 1976, PHILOS T ROY SOC B, V273, P387, DOI 10.1098/rstb.1976.0022; Ji Q, 2006, SCIENCE, V311, P1123, DOI 10.1126/science.1123026; KERMACK DM, 1971, ZOOL J LINN SOC S1, V50; KIELANJAWOROWSK.Z, 2004, MAMMALS AGE DINOSAUR; KREBS B, 1991, BERL GEOWISS ABH, V133, P19; Krusat G., 1991, CONTRIBUTIONS PALEON, V364, P37; Lillegraven JA, 1979, MESOZOIC MAMMALS 1 2; Luo ZX, 2005, SCIENCE, V308, P103, DOI 10.1126/science.1108875; Martin T, 2005, ZOOL J LINN SOC-LOND, V145, P219, DOI 10.1111/j.1096-3642.2005.00187.x; Martin Thomas, 2000, P91; Rauhut OWM, 2002, NATURE, V416, P165, DOI 10.1038/416165a; Rich Thomas H., 1999, Records of the Queen Victoria Museum, V106, P1; Sigogneau-Russell Denise, 1995, Acta Palaeontologica Polonica, V40, P149; Simpson G. G., 1929, AM MESOZOIC MAMMALIA; SIMPSON G. G., 1928, CATALOGUE MESOZOIC M	17	7	11	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	2006	311	5764					1109	1110		10.1126/science.1124294	http://dx.doi.org/10.1126/science.1124294			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017IU	16497922	Green Submitted			2022-12-28	WOS:000235688100035
J	Bardgett, RD; Smith, RS; Shiel, RS; Peacock, S; Simkin, JM; Quirk, H; Hobbs, PJ				Bardgett, RD; Smith, RS; Shiel, RS; Peacock, S; Simkin, JM; Quirk, H; Hobbs, PJ			Parasitic plants indirectly regulate below-ground properties in grassland ecosystems	NATURE			English	Article							FUNCTIONAL-ROLE; BARTSIA-ALPINA; COMMUNITY; IMPACT; DECOMPOSITION; RESTORATION; MANAGEMENT; DYNAMICS	Parasitic plants are one of the most ubiquitous groups of generalist parasites in both natural and managed ecosystems, with over 3,000 known species worldwide(1-3). Although much is known about how parasitic plants influence host peformance(1-4), their role as drivers of community- and ecosystem-level properties remains largely unexplored(5). Parasitic plants have the potential to influence directly the productivity and structure of plant communities because they cause harm to particular host plants, indirectly increasing the competitive status of non-host species(6-10). Such parasite-driven above-ground effects might also have important indirect consequences through altering the quantity and quality of resources that enter soil, thereby affecting the activity of decomposer organisms(3,11-13). Here we show in model grassland communities that the parasitic plant Rhinanthus minor, which occurs widely throughout Europe and North America(14), has strong direct effects on above-ground community properties, increasing plant diversity and reducing productivity. We also show that these direct effects of R. minor on the plant community have marked indirect effects on below-ground properties, ultimately increasing rates of nitrogen cycling. Our study provides evidence that parasitic plants act as a major driver of both above-ground and below-ground properties of grassland ecosystems.	Univ Lancaster, Inst Environm & Nat Sci, Soil & Ecosyst Ecol Lab, Lancaster LA1 4YQ, England; Newcastle Univ, Sch Biol & Psychol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Newcastle Univ, Sch Agr Food & Rural Dev, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Inst Grassland & Environm Res, N Wyke Res Stn, Okehampton EX20 2SB, Devon, England	Lancaster University; Newcastle University - UK; Newcastle University - UK	Bardgett, RD (corresponding author), Univ Lancaster, Inst Environm & Nat Sci, Soil & Ecosyst Ecol Lab, Lancaster LA1 4YQ, England.	r.bardgett@lancaster.ac.uk						[Anonymous], 1969, BIOL PARASITIC FLOWE; Bardgett RD, 2003, ECOLOGY, V84, P2258, DOI 10.1890/02-0274; Bardgett RD, 2003, ECOLOGY, V84, P1277, DOI 10.1890/0012-9658(2003)084[1277:SMCEWP]2.0.CO;2; Bardgett RD, 1996, BIOL FERT SOILS, V22, P261, DOI 10.1007/BF00382522; Bardgett RD., 2005, THE BIOL OF SOIL, DOI [10.1093/acprof:oso/9780198525035.001.0001, DOI 10.1093/ACPROF:OSO/9780198525035.001.0001]; Davies DM, 1997, BIOL CONSERV, V82, P87, DOI 10.1016/S0006-3207(97)00010-4; GIBSON CC, 1992, OECOLOGIA, V89, P62, DOI 10.1007/BF00319016; GIBSON CC, 1991, OECOLOGIA, V86, P81, DOI 10.1007/BF00317393; GRIME JP, 1990, ABRIDGE COMP PLANT E; Marvier MA, 1998, ECOLOGY, V79, P2616, DOI 10.1890/0012-9658(1998)079[2616:PIOHCP]2.0.CO;2; MCGONIGLE TP, 1990, NEW PHYTOL, V115, P495, DOI 10.1111/j.1469-8137.1990.tb00476.x; McNaughton SJ, 1997, SCIENCE, V278, P1798, DOI 10.1126/science.278.5344.1798; Parker C., 1993, PARASITIC WEEDS WORL; Pennings SC, 1996, ECOLOGY, V77, P1410, DOI 10.2307/2265538; Press M.C., 1995, PARASITIC PLANTS; Press MC, 1998, OIKOS, V82, P609, DOI 10.2307/3546383; Pywell RF, 2004, J APPL ECOL, V41, P880, DOI 10.1111/j.0021-8901.2004.00940.x; Quested HM, 2003, ECOLOGY, V84, P3209, DOI 10.1890/02-0426; Quested HM, 2003, OECOLOGIA, V135, P606, DOI 10.1007/s00442-003-1225-4; Quested HM, 2002, OECOLOGIA, V130, P88, DOI 10.1007/s004420100780; RODWELL JS, 1992, GRASSLANDS MONTANE C; Smith D, 2000, AM NAT, V155, P13, DOI 10.1086/303294; Smith RS, 2003, J APPL ECOL, V40, P51, DOI 10.1046/j.1365-2664.2003.00780.x; Smith S., 1997, MYCORRHIZAL SYMBIOSI, V2nd Edn; Stevens CJ, 2004, SCIENCE, V303, P1876, DOI 10.1126/science.1094678; TERBRAAK CJF, 2002, CANOCO REFERENCE MAN, P265; THOMAS F, 2005, PARASITES GRAND SCHE; Wardle DA, 2004, SCIENCE, V304, P1629, DOI 10.1126/science.1094875; WESTBURY DB, 2004, J ECOL, V63, P335	29	136	149	4	136	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 23	2006	439	7079					969	972		10.1038/nature04197	http://dx.doi.org/10.1038/nature04197			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014NE	16495998				2022-12-28	WOS:000235486100046
J	Paland, S; Lynch, M				Paland, S; Lynch, M			Transitions to asexuality result in excess amino acid substitutions	SCIENCE			English	Article							DELETERIOUS MUTATIONS; MOLECULAR EVOLUTION; MULLERS RATCHET; BACKGROUND SELECTION; DAPHNIA-PULEX; RECOMBINATION; DROSOPHILA; LINKAGE; RATES; SEX	Theory predicts that linkage between genetic loci reduces the efficiency of purifying selection. Because of the permanent linkage of all heritable genetic material, asexual lineages may be exceptionally prone to deleterious-mutation accumulation in both nuclear and organelle genes. Here, we show that the ratio of the rate of amino acid to silent substitution (K-a/K-s) in mitochondrial protein-coding genes is higher in obligately asexual lineages than in sexual lineages of the microcrustacean Daphnia pulex. Using a phylogeny-based approach to quantify the frequency of mutational-effect classes, we estimate that mitochondrial protein-coding genes in asexual lineages accumulate deleterious amino acid substitutions at four times the rate in sexual lineages. These results support the hypothesis that sexual reproduction plays a prominent role in reducing the mutational burden in populations.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Paland, S (corresponding author), Indiana Univ, Dept Biol, 1001 E 3rd St, Bloomington, IN 47405 USA.	spaland@indiana.edu; milynch@indiana.edu			NIGMS NIH HHS [R01 GM036827, GM36827] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036827] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachtrog D, 2004, NAT GENET, V36, P518, DOI 10.1038/ng1347; Barton NH, 1998, SCIENCE, V281, P1986, DOI 10.1126/science.281.5385.1986; Bell G., 1982, MASTERPIECE NATURE; Betancourt AJ, 2002, P NATL ACAD SCI USA, V99, P13616, DOI 10.1073/pnas.212277199; BIRKY CW, 1988, P NATL ACAD SCI USA, V85, P6414, DOI 10.1073/pnas.85.17.6414; BUTCHER D, 1995, GENETICS, V141, P431; Charlesworth B, 1997, GENET RES, V70, P63, DOI 10.1017/S0016672397002899; CHARLESWORTH B, 1994, GENET RES, V63, P213, DOI 10.1017/S0016672300032365; Eyre-Walker A, 1999, NATURE, V397, P344, DOI 10.1038/16915; Fay JC, 2002, NATURE, V415, P1024, DOI 10.1038/4151024a; FELSENSTEIN J, 1974, GENETICS, V78, P737; Gillespie JH, 2000, GENETICS, V155, P909; Gordo I, 2001, GENET RES, V78, P149, DOI 10.1017/S0016672301005213; HILL WG, 1966, GENET RES, V8, P269, DOI 10.1017/S0016672300010156; INNES DJ, 1988, EVOLUTION, V42, P1024, DOI 10.1111/j.1558-5646.1988.tb02521.x; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KONDRASHOV AS, 1993, J HERED, V84, P372, DOI 10.1093/oxfordjournals.jhered.a111358; LYNCH M, 1993, J HERED, V84, P339, DOI 10.1093/oxfordjournals.jhered.a111354; MAYNARD JS, 1978, EVOLUTION SEX; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; McVean GAT, 2000, GENETICS, V155, P929; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8; Otto SP, 2002, NAT REV GENET, V3, P252, DOI 10.1038/nrg761; Paland S, 2005, EVOLUTION, V59, P800; PECK JR, 1994, GENETICS, V137, P597; Weinreich DM, 2000, GENETICS, V156, P385; Welch DBM, 2001, P NATL ACAD SCI USA, V98, P6720, DOI 10.1073/pnas.111144598	27	162	163	0	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 17	2006	311	5763					990	992		10.1126/science.1118152	http://dx.doi.org/10.1126/science.1118152			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014CS	16484491				2022-12-28	WOS:000235456900042
J	Gilmore, AB; Collin, J; McKee, M				Gilmore, AB; Collin, J; McKee, M			British American tobacco's erosion of health legislation in Uzbekistan	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									London Sch Hyg & Trop Med, European Ctr Hlth Soc Transit, London, England; Univ Edinburgh, Ctr Int Hlth Policy, Edinburgh EH8 9YL, Midlothian, Scotland	University of London; London School of Hygiene & Tropical Medicine; University of Edinburgh	Gilmore, AB (corresponding author), London Sch Hyg & Trop Med, European Ctr Hlth Soc Transit, London, England.	anna.gilmore@lshtm.ac.uk	gilmore, anna B/I-7130-2012; McKee, Marc D/E-2187-2011; McKee, Martin/E-6673-2018	gilmore, anna B/0000-0003-0281-1248; McKee, Marc D/0000-0001-8349-965X; McKee, Martin/0000-0002-0121-9683	NCI NIH HHS [R01 CA91021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA091021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOYSE S, 1994, UZBEKISTAN DECREE; Collin J, 2004, LANCET, V363, P1746, DOI 10.1016/S0140-6736(04)16334-4; Gilmore AB, 2004, TOB CONTROL, V13, P136, DOI 10.1136/tc.2002.002667; HAVRYLYSHYN O, 1999, WP996 INT MON FUND; HERTER U, 1994, NOTE CHIEF EXECUTIVE; MARR M, 1993, PRELIMINARY MARKETIN; MARR M, IN PRESS UZBEKISTAN; MONBIOT G, 2003, GUARDIAN        1028; SCHRODERS, 1994, M BE HELD WINDS HOUS; SIMS D, MARKETING REPORT UZB; TUINSTRA T, 1998, TOBACCO REPORTER OCT, P143; VANWAAY A, 1994, UZBEKISTAN MARKET SI; WAGSTYL S, 2005, FINANCIAL TIMES 0518; WELLS W, 1994, PROJECT UMPIRE BAIN; WELLS W, 1994, PROJECT UMPIRE UZBEK; WELLS W, 1993, IN PRESS PROJECT UMP; *WORLD BANK, 2002, TRANS 1 10 YEARS AN; 1995, BATE B           AUG; 1996, TOB J INT, V4, P63	19	36	37	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 11	2006	332	7537					355	358		10.1136/bmj.332.7537.355	http://dx.doi.org/10.1136/bmj.332.7537.355			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	012YI	16470061	Green Published, Green Accepted			2022-12-28	WOS:000235376400024
J	Salganik, MJ; Dodds, PS; Watts, DJ				Salganik, MJ; Dodds, PS; Watts, DJ			Experimental study of inequality and unpredictability in an artificial cultural market	SCIENCE			English	Article							CASCADES; CONFORMITY; INDUSTRY; MODEL; FADS	Hit songs, books, and movies are many times more successful than average, suggesting that "the best" alternatives are qualitatively different from "the rest"; yet experts routinely fail to predict which products wilt succeed. We investigated this paradox experimentally, by creating an artificial "music market" in which 14,341 participants downloaded previously unknown songs either with or without knowledge of previous participants' choices. Increasing the strength of social influence increased both inequality and unpredictabitity of success. Success was also only partly determined by quality: The best songs rarely did poorly, and the worst rarely did well, but any other result was possible.	Columbia Univ, Dept Sociol, New York, NY 10027 USA; Columbia Univ, Inst Social & Econ Res & Policy, New York, NY 10027 USA; Santa Fe Inst, Santa Fe, NM 87501 USA	Columbia University; Columbia University; The Santa Fe Institute	Salganik, MJ (corresponding author), Columbia Univ, Dept Sociol, 413 Fayerweather Hall, New York, NY 10027 USA.	mjs2105@columbia.edu; pd315@columbia.edu; djw24@columbia.edu	Dodds, Peter S/C-9119-2014; Watts, Duncan J/J-6483-2012	Dodds, Peter S/0000-0003-1973-8614; 				ADLER M, 1985, AM ECON REV, V75, P208; ALLISON PD, 1978, AM SOCIOL REV, V43, P865, DOI 10.2307/2094626; Anderson LR, 1997, AM ECON REV, V87, P847; BIELBY WT, 1994, AM J SOCIOL, V99, P1287, DOI 10.1086/230412; BIKHCHANDANI S, 1992, J POLIT ECON, V100, P992, DOI 10.1086/261849; Bond R, 1996, PSYCHOL BULL, V119, P111, DOI 10.1037/0033-2909.119.1.111; Caves R.E., 2000, CREATIVE IND; CHUNG KH, 1994, REV ECON STAT, V76, P771, DOI 10.2307/2109778; Cialdini RB, 2004, ANNU REV PSYCHOL, V55, P591, DOI 10.1146/annurev.psych.55.090902.142015; Coleman JS., 1990, FDN SOCIAL THEORY; de Vany A., 2004, HOLLYWOOD EC; Frank R.H., 1995, WINNER TAKE ALL SOC; Hedstrom Peter., 1998, SOCIAL MECH ANAL APP, P306; HIRSCH PM, 1972, AM J SOCIOL, V77, P639, DOI 10.1086/225192; Kubler D, 2004, REV ECON STUD, V71, P425, DOI 10.1111/0034-6527.00290; PETERSON RA, 1971, ADMIN SCI QUART, V16, P97, DOI 10.2307/2391293; ROSEN S, 1981, AM ECON REV, V71, P845; Vogel H.L., 2004, ENTERTAINMENT IND EC; Watts DJ, 2002, P NATL ACAD SCI USA, V99, P5766, DOI 10.1073/pnas.082090499	19	1049	1066	17	228	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	2006	311	5762					854	856		10.1126/science.1121066	http://dx.doi.org/10.1126/science.1121066			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	012XT	16469928				2022-12-28	WOS:000235374900050
J	Hsieh, LLC; Kuo, CH; Lee, LH; Yen, AMF; Chien, KL; Chen, THH				Hsieh, LLC; Kuo, CH; Lee, LH; Yen, AMF; Chien, KL; Chen, THH			Treatment of low back pain by acupressure and physical therapy: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ALTERNATIVE MEDICINE; QUESTIONNAIRE	Objective To evaluate the effectiveness of acupressure for treating low back pain in terms of disability, pain scores, and functional status. Design Randomised controlled trial. Setting Orthopaedic clinic in Kaohsiung, Taiwan. Participants 129 patients with chronic low back pain. Intervention Acupressure or physical therapy for one month. Main outcome measures Self administered Chinese versions of standard outcome measures for low back pain (primary outcome: Roland and Morris disability questionnaire) at baseline, after treatment, and at six month follow-up. Results The mean total Roland and Morris disability questionnaire score after treatment was significantly lower in die acupressure group than in the physical therapy group regardless of the difference in absolute score (- 3.8, 95% confidence interval - 5.7 to - 1.9) or mean change from the baseline (- 4.64, - 6.39 to - 2.89). Acupressure conferred an 89% (95% confidence interval 61% to 97%) reduction in significant disability compared with physical therapy. The improvement in disability score in the acupressure group compared with the physical group remained at six month follow-up. Statistically significant differences also occurred between the two groups for all six domains of the core outcome, pain visual scale, and modified Oswestry disability questionnaire after treatment and at six month follow-up. Conclusions Acupressure was effective in reducing low back pain in terms of disability, pain scores, and functional status. The benefit was sustained for six months.	Natl Taiwan Univ, Inst Prevent Med, Coll Publ Hlth, Taipei 10764, Taiwan; Orthoped Special Clin, Kaohsiung, Taiwan; Chang Gung Mem Hosp, Kaohsiung, Taiwan	National Taiwan University; Chang Gung Memorial Hospital	Chen, THH (corresponding author), Natl Taiwan Univ, Inst Prevent Med, Coll Publ Hlth, Taipei 10764, Taiwan.	stony@episerv.cph.ntu.edu.tw		Chen, Hsiu-Hsi/0000-0002-5799-6705; CHIEN, KUO-LIONG/0000-0003-4979-8351				Altman D.G., 1991, PRACTICAL STAT MED R; COSTE J, 1993, REV RHUM, V60, P335; Deyo RA, 1998, SPINE, V23, P2003, DOI 10.1097/00007632-199809150-00018; Efron B., 1994, MONOGRAPHS STAT APPL; Ehrlich GE, 1999, LOW BACK PAIN INITIA; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 1998, ARCH INTERN MED, V158, P2235, DOI 10.1001/archinte.158.20.2235; FLESKETH T, 1997, BRIT MED J, V315, P115; Flynn TW, 2003, ARCH PHYS MED REHAB, V84, P1057, DOI 10.1016/S0003-9993(03)00048-0; Hesketh T, 1997, BRIT MED J, V315, P115, DOI 10.1136/bmj.315.7100.115; Hsieh LLC, 2004, PREV MED, V39, P168, DOI 10.1016/j.ypmed.2004.01.036; MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109; MELZACK R, 1971, ANESTHESIOLOGY, V34, P50; Mills SY, 2001, BRIT MED J, V322, P158, DOI 10.1136/bmj.322.7279.158; Roland M, 2000, SPINE, V25, P3115, DOI 10.1097/00007632-200012150-00006; Suzukamo Yoshimi, 2003, J Orthop Sci, V8, P543, DOI 10.1007/s00776-003-0679-x	16	85	89	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 25	2006	332	7543					696	698A		10.1136/bmj.38744.672616.AE	http://dx.doi.org/10.1136/bmj.38744.672616.AE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	027VH	16488895	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000236443300018
J	Cross, M				Cross, M			Information technology - Will connecting for health deliver its promises?	BRITISH MEDICAL JOURNAL			English	Editorial Material											Cross, M (corresponding author), POB 40073, London N6 5ZJ, England.	michaelcross@fastmail.fm						BRENNAN S, 2005, NHS IT PROJECT; Carnell D, 2001, BRIT MED J, V323, P1386; *DEP HLTH, 2002, DEL 21ST CENT IT SUP; *DEP HLTH, 2005, NHS CONN HLTH 1 ANN; *DEP HLTH, 1998, INF HLTH; *HM TREAS, 2002, GOV SPEND REV 2002; HUTTON J, 2004, HOUSE COMMONS OFFICI; WALSH C, 2003, OBSERVER        0831; Wanless, 2002, SECURING OUR FUTURE	9	25	25	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAR 11	2006	332	7541					599	601		10.1136/bmj.332.7541.599	http://dx.doi.org/10.1136/bmj.332.7541.599			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	026CN	16528086	Green Published			2022-12-28	WOS:000236314400021
J	Hansen, CJ; Esposito, L; Stewart, AIF; Colwell, J; Hendrix, A; Pryor, W; Shemansky, D; West, R				Hansen, CJ; Esposito, L; Stewart, AIF; Colwell, J; Hendrix, A; Pryor, W; Shemansky, D; West, R			Enceladus' water vapor plume	SCIENCE			English	Article							SATURNS E-RING; OSCILLATOR-STRENGTHS; SYSTEM; ATMOSPHERES; PLASMA		CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Colorado, Lab Air & Space Phys, Boulder, CO 80303 USA; Space Environm Technol, Pasadena, CA 91107 USA; Cent Arizona Coll, Coolidge, AZ 85228 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Colorado System; University of Colorado Boulder	Hansen, CJ (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.	Candice.j.Hansen@jpl.nasa.gov	ESPOSITO, LARRY W/AAB-3673-2021; Colwell, Joshua/AAP-2692-2020	ESPOSITO, LARRY W/0000-0003-3381-2016; Colwell, Joshua/0000-0001-8269-6408				BURATTI BJ, 1988, ICARUS, V75, P113, DOI 10.1016/0019-1035(88)90130-3; CHAN WF, 1993, CHEM PHYS, V178, P387, DOI 10.1016/0301-0104(93)85078-M; Dougherty MK, 2006, SCIENCE, V311, P1406, DOI 10.1126/science.1120985; EIDELSBERG M, 1992, J CHEM PHYS, V96, P5585, DOI 10.1063/1.462700; Esposito LW, 2004, SPACE SCI REV, V115, P299, DOI 10.1007/s11214-004-1455-8; Esposito LW, 2005, SCIENCE, V307, P1251, DOI 10.1126/science.1105606; HARREVELT RV, 2001, J CHEM PHYS, V114, P9453; HORANYI M, 1992, ICARUS, V97, P248, DOI 10.1016/0019-1035(92)90131-P; Juhasz A, 2002, J GEOPHYS RES-SPACE, V107, DOI 10.1029/2001JA000182; Jurac S, 2005, J GEOPHYS RES-SPACE, V110, DOI 10.1029/2004JA010635; Jurac S, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015855; Jurac S, 2001, ICARUS, V149, P384, DOI 10.1006/icar.2000.6528; Nicholson PD, 1996, SCIENCE, V272, P509, DOI 10.1126/science.272.5261.509; Saur J, 2005, ASTROPHYS J, V620, pL115, DOI 10.1086/428665; SHEMANSKY D, 2004, M COMM SPAC RES PAR; SHEMANSKY DE, 1993, NATURE, V363, P329, DOI 10.1038/363329a0; SHOWALTER MR, 1991, ICARUS, V94, P451, DOI 10.1016/0019-1035(91)90241-K; SMITH BA, 1982, SCIENCE, V215, P504, DOI 10.1126/science.215.4532.504; SMITH GR, 1990, REV GEOPHYS, V28, P117, DOI 10.1029/RG028i002p00117; Spencer JR, 2006, SCIENCE, V311, P1401, DOI 10.1126/science.1121661; Terrile R.J., 1981, LUNAR PLANET SCI SA, V428, P10; Waite JH, 2006, SCIENCE, V311, P1419, DOI 10.1126/science.1121290	22	389	392	5	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 10	2006	311	5766					1422	1425		10.1126/science.1121254	http://dx.doi.org/10.1126/science.1121254			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527971				2022-12-28	WOS:000236029400037
J	Jones, GH; Roussos, E; Krupp, N; Paranicas, C; Woch, J; Lagg, A; Mitchell, DG; Krimigis, SM; Dougherty, MK				Jones, GH; Roussos, E; Krupp, N; Paranicas, C; Woch, J; Lagg, A; Mitchell, DG; Krimigis, SM; Dougherty, MK			Enceladus' varying imprint on the magnetosphere of Saturn	SCIENCE			English	Article							E-RING; MICROSIGNATURES; ORBIT; ABSORPTION; PARTICLES; PROTONS; TETHYS; MODEL; MIMI		Max Planck Inst Sonnensyst Forsch, D-37191 Katlenburg Lindau, Germany; Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20723 USA; Univ London Imperial Coll Sci Technol & Med, Blackett Lab, London SW7 2BW, England	Max Planck Society; Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; Imperial College London	Jones, GH (corresponding author), Max Planck Inst Sonnensyst Forsch, Max Planck Str 2, D-37191 Katlenburg Lindau, Germany.	jones@mps.mpg.de	Roussos, Elias/H-2249-2011; Paranicas, Christopher/B-1470-2016; Jones, Geraint H./C-1682-2008; Krimigis, Stamatios/G-4591-2019; Mitchell, Donald G/H-4601-2016; Korpi-Lagg, Andreas/W-8166-2019	Paranicas, Christopher/0000-0002-4391-8255; Jones, Geraint H./0000-0002-5859-1136; Krimigis, Stamatios/0000-0003-2781-2386; Mitchell, Donald G/0000-0003-1960-2119; Korpi-Lagg, Andreas/0000-0003-1459-7074; Roussos, Elias/0000-0002-5699-0678	STFC [PP/D000912/1] Funding Source: UKRI; Science and Technology Facilities Council [PP/D000912/1] Funding Source: researchfish	STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))		BRIDGE HS, 1981, SCIENCE, V212, P217, DOI 10.1126/science.212.4491.217; Brown RH, 2006, SCIENCE, V311, P1425, DOI 10.1126/science.1121031; CARBARY JF, 1983, J GEOPHYS RES-SPACE, V88, P8947, DOI 10.1029/JA088iA11p08947; Dougherty MK, 2006, SCIENCE, V311, P1406, DOI 10.1126/science.1120985; Esposito LW, 2005, SCIENCE, V307, P1251, DOI 10.1126/science.1105606; Gurnett DA, 2005, SCIENCE, V307, P1255, DOI 10.1126/science.1105356; Jurac S, 2001, ICARUS, V149, P384, DOI 10.1006/icar.2000.6528; Krimigis SM, 2004, SPACE SCI REV, V114, P233, DOI 10.1007/s11214-004-1410-8; Krimigis SM, 2005, SCIENCE, V307, P1270, DOI 10.1126/science.1105978; Mauk BH, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL022485; Paranicas C, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL024072; Paranicas C, 2000, J GEOPHYS RES-SPACE, V105, P16005, DOI 10.1029/1999JA000350; Paranicas C, 1997, ICARUS, V125, P380, DOI 10.1006/icar.1996.5635; Roddier C, 1998, ICARUS, V136, P50, DOI 10.1006/icar.1998.6014; Roussos E, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL024084; Saur J, 2004, J GEOPHYS RES-SPACE, V109, DOI 10.1029/2003JA010207; Spahn F, 2006, SCIENCE, V311, P1416, DOI 10.1126/science.1121375; Spencer JR, 2006, SCIENCE, V311, P1401, DOI 10.1126/science.1121661; THOMSEN MF, 1979, GEOPHYS RES LETT, V6, P893, DOI 10.1029/GL006i011p00893; THOMSEN MF, 1980, J GEOPHYS RES-SPACE, V85, P5831, DOI 10.1029/JA085iA11p05831; Tokar RL, 2006, SCIENCE, V311, P1409, DOI 10.1126/science.1121061; VANALLEN JA, 1980, J GEOPHYS RES-SPACE, V85, P5709, DOI 10.1029/JA085iA11p05709; VANALLEN JA, 1983, J GEOPHYS RES-SPACE, V88, P6911, DOI 10.1029/JA088iA09p06911	23	53	53	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 10	2006	311	5766					1412	1415		10.1126/science.1121011	http://dx.doi.org/10.1126/science.1121011			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527968				2022-12-28	WOS:000236029400034
J	Zou, ZH; Buck, LB				Zou, ZH; Buck, LB			RETRACTED: Combinatorial effects of odorant mixes in olfactory cortex (Retracted article. See vol. 329, pg. 1598, 2010)	SCIENCE			English	Article; Retracted Publication							RECEPTOR GENE-EXPRESSION; IMMEDIATE-EARLY GENE; PIRIFORM CORTEX; SENSORY MAP; BULB; MIXTURES; MOUSE; NEURONS; DISCRIMINATION; ORGANIZATION		Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; Fred Hutchinson Cancer Center	Buck, LB (corresponding author), Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, 1100 Fairview Ave N, Seattle, WA 98109 USA.	lbuck@fhcrc.org			NIDCD NIH HHS [R03 DC008700-01, R21 DC008628-01] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R21DC008628, R03DC008700] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Duchamp-Viret P, 2003, EUR J NEUROSCI, V18, P2690, DOI 10.1111/j.1460-9568.2003.03001.x; Giraudet P, 2002, J NEUROPHYSIOL, V88, P829, DOI 10.1152/jn.2002.88.2.829; Godfrey PA, 2004, P NATL ACAD SCI USA, V101, P2156, DOI 10.1073/pnas.0308051100; Guzowski JF, 1999, NAT NEUROSCI, V2, P1120, DOI 10.1038/16046; Haberly LB, 2001, CHEM SENSES, V26, P551, DOI 10.1093/chemse/26.5.551; Illig KR, 2003, J COMP NEUROL, V457, P361, DOI 10.1002/cne.10557; Kajiya K, 2001, J NEUROSCI, V21, P6018, DOI 10.1523/JNEUROSCI.21-16-06018.2001; Kandel E., 2000, PRINCIPLES NEURAL SC; KANG JS, 1995, J NEUROPHYSIOL, V74, P1435, DOI 10.1152/jn.1995.74.4.1435; LAING DG, 1989, PHYSIOL BEHAV, V46, P809, DOI 10.1016/0031-9384(89)90041-3; Lin DY, 2005, NATURE, V434, P470, DOI 10.1038/nature03414; LINK W, 1995, P NATL ACAD SCI USA, V92, P5734, DOI 10.1073/pnas.92.12.5734; LYFORD GL, 1995, NEURON, V14, P433, DOI 10.1016/0896-6273(95)90299-6; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; MARGOT C, COMMUNICATION; Mombaerts P, 2004, NAT REV NEUROSCI, V5, P263, DOI 10.1038/nrn1365; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Neville K.R., 2004, SYNAPTIC ORG BRAIN, P415, DOI DOI 10.1093/ACPR0F:0S0/9780195159561.003.0010; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Shepherd G.M., 2004, SYNAPTIC ORG BRAIN, DOI [DOI 10.1093/ACPROF:OSO/9780195159561.001.1, 10.1093/acprof:oso/9780195159561.001.1]; Tabor R, 2004, J NEUROSCI, V24, P6611, DOI 10.1523/JNEUROSCI.1834-04.2004; Tagawa Y, 2005, NAT NEUROSCI, V8, P380, DOI 10.1038/nn1410; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Wilson DA, 2003, J NEUROPHYSIOL, V90, P65, DOI 10.1152/jn.00133.2003; Wilson DA, 2001, CHEM SENSES, V26, P577, DOI 10.1093/chemse/26.5.577; Young JM, 2002, HUM MOL GENET, V11, P1153, DOI 10.1093/hmg/11.10.1153; Zhang XM, 2002, NAT NEUROSCI, V5, P124, DOI 10.1038/nn800; Zou ZH, 2005, P NATL ACAD SCI USA, V102, P7724, DOI 10.1073/pnas.0503027102; Zou ZH, 2001, NATURE, V414, P173, DOI 10.1038/35102506	33	120	123	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2006	311	5766					1477	1481		10.1126/science.1124755	http://dx.doi.org/10.1126/science.1124755			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527983				2022-12-28	WOS:000236029400054
J	Taylor, WC				Taylor, WC			A 71-year-old woman contemplating a screening colonoscopy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FECAL-OCCULT-BLOOD; COMPUTED TOMOGRAPHIC COLONOGRAPHY; CONTRAST BARIUM ENEMA; COLORECTAL-CANCER; AVERAGE-RISK; COST-EFFECTIVENESS; LYNCH-SYNDROME; COLON-CANCER; PRIMARY-CARE; LUNG-CANCER		Harvard Univ, Sch Med, Tosteson Med Educ Ctr, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Taylor, WC (corresponding author), Harvard Univ, Sch Med, Tosteson Med Educ Ctr, 260 Longwood Ave, Boston, MA 02115 USA.	wtaylor@bidmc.harvard.edu						Amer Geriatrics Soc Ethics Comm, 2003, J AM GERIATR SOC, V51, P270; Angell M, 2000, NEW ENGL J MED, V342, P1516, DOI 10.1056/NEJM200005183422009; Balluz Lina, 2004, Morbidity and Mortality Weekly Report, V53, P1; BARISH MA, 2001, EC VIRTUAL COLONOSCO; Blakeborough A, 1997, CLIN RADIOL, V52, P142, DOI 10.1016/S0009-9260(97)80108-0; Boyle P, 2002, BRIT MED BULL, V64, P1, DOI 10.1093/bmb/64.1.1; Brennan TA, 2003, ANN INTERN MED, V139, P267, DOI 10.7326/0003-4819-139-4-200308190-00009; Chatrenet P, 1993, Eur J Med, V2, P411; Collins JF, 2005, ANN INTERN MED, V142, P81, DOI 10.7326/0003-4819-142-2-200501180-00006; Ederer F, 1997, J NATL CANCER I, V89, P1423, DOI 10.1093/jnci/89.19.1423; Farmer P, 1999, AM J PUBLIC HEALTH, V89, P1486, DOI 10.2105/AJPH.89.10.1486; Fearnhead NS, 2002, BRIT MED BULL, V64, P27, DOI 10.1093/bmb/64.1.27; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Feld AD, 2004, AM J GASTROENTEROL, V99, P1641, DOI 10.1111/j.1572-0241.2004.40943.x; FORROW L, 1988, JAMA-J AM MED ASSOC, V259, P3161, DOI 10.1001/jama.259.21.3161; Frazier AL, 2000, JAMA-J AM MED ASSOC, V284, P1954, DOI 10.1001/jama.284.15.1954; FUCHS CS, 1994, NEW ENGL J MED, V331, P1669, DOI 10.1056/NEJM199412223312501; Gay G, 2004, ENDOSCOPY, V36, P913, DOI 10.1055/s-2004-825868; Grady C, 1999, Adv Intern Med, V44, P389; Haug U, 2005, CANCER EPIDEM BIOMAR, V14, P422, DOI 10.1158/1055-9965.EPI-04-0411; Heiskanen I, 2000, SCAND J GASTROENTERO, V35, P1284; HERRINTON LJ, 1995, AM J EPIDEMIOL, V142, P961, DOI 10.1093/oxfordjournals.aje.a117744; Houlston RS, 2001, GASTROENTEROLOGY, V121, P282, DOI 10.1053/gast.2001.26265; Iannaccone R, 2004, GASTROENTEROLOGY, V127, P1300, DOI 10.1053/j.gastro.2004.08.025; Imperiale TF, 2000, NEW ENGL J MED, V343, P169, DOI 10.1056/NEJM200007203430302; Imperiale TF, 2004, NEW ENGL J MED, V351, P2704, DOI 10.1056/NEJMoa033403; Jarvinen HJ, 2000, GASTROENTEROLOGY, V118, P829, DOI 10.1016/S0016-5085(00)70168-5; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jo WS, 2005, SEMIN ONCOL, V32, P11, DOI 10.1053/j.seminoncol.2004.09.034; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; LANG CA, 1994, JAMA-J AM MED ASSOC, V271, P1011, DOI 10.1001/jama.271.13.1011; Leslie A, 2002, BRIT J SURG, V89, P845, DOI 10.1046/j.1365-2168.2002.02120.x; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Lieberman D, 2004, ANN INTERN MED, V141, P401, DOI 10.7326/0003-4819-141-5-200409070-00018; Lynch HT, 2005, NEW ENGL J MED, V352, P1920, DOI 10.1056/NEJMe058058; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MANDEL JS, 1993, NEW ENGL J MED, V329, P672; Merenstein D, 2004, JAMA-J AM MED ASSOC, V291, P15, DOI 10.1001/jama.291.1.15; MEYER KB, 1987, NEW ENGL J MED, V317, P238, DOI 10.1056/NEJM198707233170410; Miller Walter J, 2004, J Transl Med, V2, P4, DOI 10.1186/1479-5876-2-4; Mulhall BP, 2005, ANN INTERN MED, V142, P635, DOI 10.7326/0003-4819-142-8-200504190-00013; MULLER AD, 1995, ARCH INTERN MED, V155, P1741, DOI 10.1001/archinte.155.16.1741; Nadel MR, 2005, ANN INTERN MED, V142, P86, DOI 10.7326/0003-4819-142-2-200501180-00007; *NAT CANC I DCCPS, 2004, SEER STAT DAT INC SE; PAUKER SG, 1992, J GERONTOL, V47, P142; Pickhardt PJ, 2004, ANN INTERN MED, V141, P352, DOI 10.7326/0003-4819-141-5-200409070-00009; Pickhardt PJ, 2003, NEW ENGL J MED, V349, P2191, DOI 10.1056/NEJMoa031618; Pignone M, 2002, ANN INTERN MED, V137, P132, DOI 10.7326/0003-4819-137-2-200207160-00015; Pignone M, 2002, ANN INTERN MED, V137, P96, DOI 10.7326/0003-4819-137-2-200207160-00007; Pignone M, 2005, EC MODELS COLORECTAL; Podolsky DK, 2000, NEW ENGL J MED, V343, P207, DOI 10.1056/NEJM200007203430309; Ransohoff DF, 2002, NEW ENGL J MED, V346, P40, DOI 10.1056/NEJMcp010886; Rex DK, 1997, GASTROENTEROLOGY, V112, P24, DOI 10.1016/S0016-5085(97)70214-2; Rockey DC, 2005, LANCET, V365, P305; SACKETT DL, 1987, J FAM PRACTICE, V24, P233; Samowitz WS, 2001, GASTROENTEROLOGY, V121, P830, DOI 10.1053/gast.2001.27996; Schoenfeld P, 2005, NEW ENGL J MED, V352, P2061, DOI 10.1056/NEJMoa042990; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; Smith RA, 2001, CA-CANCER J CLIN, V51, P38, DOI 10.3322/canjclin.51.1.38; Sondhi M, 2005, MED DECIS MAKING, V25, P82, DOI 10.1177/0272989X05274523; Sox HC, 2002, ANN INTERN MED, V136, P243, DOI 10.7326/0003-4819-136-3-200202050-00012; TAYLOR WC, 1991, JAMA-J AM MED ASSOC, V265, P3011, DOI 10.1001/jama.265.22.3011; TAYLOR WC, 1980, ANN INTERN MED, V93, P773, DOI 10.7326/0003-4819-93-5-773; TAYLOR WC, 1987, TXB GEN MED PRIMARY, P41; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Vasen HFA, 2005, JAMA-J AM MED ASSOC, V293, P2028, DOI 10.1001/jama.293.16.2028; Walter LC, 2001, JAMA-J AM MED ASSOC, V285, P2750, DOI 10.1001/jama.285.21.2750; Welch HG, 1996, ANN INTERN MED, V124, P577, DOI 10.7326/0003-4819-124-6-199603150-00007; Welch HG, 2004, SHOULD I BE TESTED C; Wiesner R, 2003, GASTROENTEROLOGY, V124, P91, DOI 10.1053/gast.2003.50016; Willett WC, 2005, JAMA-J AM MED ASSOC, V293, P233, DOI 10.1001/jama.293.2.233; Winawer S, 2003, GASTROENTEROLOGY, V124, P544, DOI 10.1053/gast.2003.50044; Winawer SJ, 2003, ANN INTERN MED, V139, P1034, DOI 10.7326/0003-4819-139-12-200312160-00013; Winawer SJ, 2000, NEW ENGL J MED, V342, P1766, DOI 10.1056/NEJM200006153422401; Woolf SH, 2004, NEW ENGL J MED, V351, P2755, DOI 10.1056/NEJMe048259; Yarnall KSH, 2003, AM J PUBLIC HEALTH, V93, P635, DOI 10.2105/AJPH.93.4.635	77	3	4	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	2006	295	10					1161	1167		10.1001/jama.295.10.1161	http://dx.doi.org/10.1001/jama.295.10.1161			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	019GB	16522837				2022-12-28	WOS:000235822500025
J	Johnson, DC				Johnson, DC			Clinical implications of basic research: Silencing herpes simplex virus with a vaginal microbicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA	Oregon Health & Science University	Johnson, DC (corresponding author), Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.							Leung RKM, 2005, PHARMACOL THERAPEUT, V107, P222, DOI 10.1016/j.pharmthera.2005.03.004; Lu PY, 2005, ADV GENET, V54, P117, DOI 10.1016/S0065-2660(05)54006-9; Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263	3	3	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 2	2006	354	9					970	971		10.1056/NEJMcibr055613	http://dx.doi.org/10.1056/NEJMcibr055613			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	017FN	16510753				2022-12-28	WOS:000235679600013
J	Waters, A				Waters, A			Malaria: New vaccines for old?	CELL			English	Editorial Material							PLASMODIUM-FALCIPARUM; LIFE-CYCLE; PROTEINS; SURFACE; SPOROZOITES; ANTIGEN	Detailed analyses of the 5500 genes revealed by the complete Plasmodium genome sequence are yielding new candidate parasite antigens and strategies that may contribute to a successful vaccine against malaria in the coming decade.	Leiden Univ, Ctr Med, Dept Parasitol, NL-2333 ZA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Waters, A (corresponding author), Leiden Univ, Ctr Med, Dept Parasitol, NL-2333 ZA Leiden, Netherlands.	waters@lumc.nl	Waters, Andy P/C-9377-2009	Waters, Andy P/0000-0001-8900-2982				Alonso PL, 2005, LANCET, V366, P2012, DOI 10.1016/S0140-6736(05)67669-6; CHOEN S, 1970, NATURE, V225, P732, DOI 10.1038/225732a0; CLYDE DF, 1973, AM J MED SCI, V266, P169, DOI 10.1097/00000441-197309000-00002; Crewther PE, 1996, INFECT IMMUN, V64, P3310, DOI 10.1128/IAI.64.8.3310-3317.1996; DEANS JA, 1988, PARASITE IMMUNOL, V10, P535, DOI 10.1111/j.1365-3024.1988.tb00241.x; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Graves P, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000129.pub2; Hall N, 2005, SCIENCE, V307, P82, DOI 10.1126/science.1103717; Kariu T, 2002, J EXP MED, V195, P1317, DOI 10.1084/jem.20011876; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Mueller AK, 2005, P NATL ACAD SCI USA, V102, P3022, DOI 10.1073/pnas.0408442102; Sam-Yellowe TY, 2004, GENOME RES, V14, P1052, DOI 10.1101/gr.2126104; Sanders PR, 2005, J BIOL CHEM, V280, P40169, DOI 10.1074/jbc.M509631200; Silvie O, 2004, J BIOL CHEM, V279, P9490, DOI 10.1074/jbc.M311331200; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; Targett GA, 2005, TRENDS PARASITOL, V21, P499, DOI 10.1016/j.pt.2005.08.018; Tomas AM, 2001, EMBO J, V20, P3975, DOI 10.1093/emboj/20.15.3975; van Dijk MR, 2005, P NATL ACAD SCI USA, V102, P12194, DOI 10.1073/pnas.0500925102; Viebig NK, 2005, EMBO REP, V6, P775, DOI 10.1038/sj.embor.7400466; Vincensini L, 2005, MOL CELL PROTEOMICS, V4, P582, DOI 10.1074/mcp.M400176-MCP200	21	15	21	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 24	2006	124	4					689	693		10.1016/j.cell.2006.02.011	http://dx.doi.org/10.1016/j.cell.2006.02.011			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	038RO	16497579	Bronze			2022-12-28	WOS:000237240900012
J	Delsuc, F; Brinkmann, H; Chourrout, D; Philippe, H				Delsuc, F; Brinkmann, H; Chourrout, D; Philippe, H			Tunicates and not cephalochordates are the closest living relatives of vertebrates	NATURE			English	Article							PHYLOGENETIC ANALYSIS; MITOCHONDRIAL GENOME; MAXIMUM-LIKELIHOOD; OIKOPLEURA-DIOICA; NEURAL CREST; DEUTEROSTOME; TREE; AMPHIOXUS; EVOLUTION; ANIMALS	Tunicates or urochordates (appendicularians, salps and sea squirts), cephalochordates (lancelets) and vertebrates (including lamprey and hagfish) constitute the three extant groups of chordate animals. Traditionally, cephalochordates are considered as the closest living relatives of vertebrates, with tunicates representing the earliest chordate lineage(1,2). This view is mainly justified by overall morphological similarities and an apparently increased complexity in cephalochordates and vertebrates relative to tunicates(2). Despite their critical importance for understanding the origins of vertebrates(3), phylogenetic studies of chordate relationships have provided equivocal results(4-7). Taking advantage of the genome sequencing of the appendicularian Oikopleura dioica, we assembled a phylogenomic data set of 146 nuclear genes (33,800 unambiguously aligned amino acids) from 14 deuterostomes and 24 other slowly evolving species as an outgroup. Here we show that phylogenetic analyses of this data set provide compelling evidence that tunicates, and not cephalochordates, represent the closest living relatives of vertebrates. Chordate monophyly remains uncertain because cephalochordates, albeit with a non-significant statistical support, surprisingly grouped with echinoderms, a hypothesis that needs to be tested with additional data. This new phylogenetic scheme prompts a reappraisal of both morphological and palaeontological data and has important implications for the interpretation of developmental and genomic studies in which tunicates and cephalochordates are used as model animals.	Univ Montreal, Ctr Robert Cedergren, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Univ Bergen, Bergen High Technol Ctr, Sars Ctr Marine Mol Biol, N-5008 Bergen, Norway	Universite de Montreal; University of Bergen	Philippe, H (corresponding author), Univ Montreal, Ctr Robert Cedergren, Dept Biochim, Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	herve.philippe@umontreal.ca	Delsuc, Frederic/B-4381-2009	Delsuc, Frederic/0000-0002-6501-6287				Blair JE, 2005, MOL BIOL EVOL, V22, P2275, DOI 10.1093/molbev/msi225; Bourlat SJ, 2003, NATURE, V424, P925, DOI 10.1038/nature01851; Delsuc F, 2005, NAT REV GENET, V6, P361, DOI 10.1038/nrg1603; Edvardsen RB, 2005, CURR BIOL, V15, pR12, DOI 10.1016/j.cub.2004.12.010; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; Felsenstein J., 2004, INFERRING PHYLOGENIE; Gee H, 2001, SYST ASSOC SPEC VOL, V61, P1; Gee H., 1996, BACKBONE VIEWS ORIGI; Holland LZ, 2004, CELL MOL LIFE SCI, V61, P2290, DOI 10.1007/s00018-004-4075-2; Jefferies R.P.S., 1986, ANCESTRY VERTEBRATES; JEFFERIES RPS, 1991, CIBA F SYMP, V162, P94; Jefferies RPS, 1997, LETHAIA, V30, P1; Jeffery WR, 2004, NATURE, V431, P696, DOI 10.1038/nature02975; Morris SC, 2000, P NATL ACAD SCI USA, V97, P4426, DOI 10.1073/pnas.97.9.4426; Oda H, 2004, J CELL SCI, V117, P2757, DOI 10.1242/jcs.01045; PETERSON KJ, 1995, LETHAIA, V28, P25, DOI 10.1111/j.1502-3931.1995.tb01591.x; Philippe H, 2005, MOL BIOL EVOL, V22, P1246, DOI 10.1093/molbev/msi111; Rowe T, 2004, ASSEMBLING THE TREE OF LIFE, P384; Ruiz-Trillo I, 2004, MOL PHYLOGENET EVOL, V33, P321, DOI 10.1016/j.ympev.2004.06.002; Ruppert EE, 2005, CAN J ZOOL, V83, P8, DOI 10.1139/Z04-158; SCHAEFFER B, 1987, EVOL BIOL, V21, P179; Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502; Seo HC, 2004, NATURE, V431, P67, DOI 10.1038/nature02709; Shimodaira H, 2001, BIOINFORMATICS, V17, P1246, DOI 10.1093/bioinformatics/17.12.1246; Stone JR, 2004, EVOL DEV, V6, P123, DOI 10.1111/j.1525-142X.2004.04014.x; Swofford D. L., 2011, PAUP PHYLOGENETIC AN; Winchell CJ, 2002, MOL BIOL EVOL, V19, P762, DOI 10.1093/oxfordjournals.molbev.a004134; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Yokobori S, 2005, MOL PHYLOGENET EVOL, V34, P273, DOI 10.1016/j.ympev.2004.10.002; Zrzavy J, 1998, CLADISTICS, V14, P249, DOI 10.1111/j.1096-0031.1998.tb00338.x	30	1168	1207	1	132	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 23	2006	439	7079					965	968		10.1038/nature04336	http://dx.doi.org/10.1038/nature04336			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014NE	16495997	Green Submitted			2022-12-28	WOS:000235486100045
J	Hayden, FG				Hayden, FG			Antiviral resistance in influenza viruses - Implications for management and pandemic response	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Virginia, Sch Med, Dept Internal Med, Div Infect Dis & Int Hlth, Charlottesville, VA 22908 USA	University of Virginia	Hayden, FG (corresponding author), Univ Virginia, Sch Med, Dept Internal Med, Div Infect Dis & Int Hlth, Charlottesville, VA 22908 USA.							Bright RA, 2005, LANCET, V366, P1175, DOI 10.1016/S0140-6736(05)67338-2; BRIGHT RA, IN PRESS JAMA; de Jong MD, 2005, NEW ENGL J MED, V353, P2667, DOI 10.1056/NEJMoa054512; Hayden F, 2005, ANTIVIR THER, V10, P873; Ziegler T, 1999, J INFECT DIS, V180, P935, DOI 10.1086/314994	5	139	159	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 23	2006	354	8					785	788		10.1056/NEJMp068030	http://dx.doi.org/10.1056/NEJMp068030			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014CL	16495389				2022-12-28	WOS:000235456200001
J	Mellars, P				Mellars, P			A new radiocarbon revolution and the dispersal of modern humans in Eurasia	NATURE			English	Review							MODERN HUMAN ORIGINS; CALIBRATION; SCALE; NEANDERTHAL; CHRONOLOGY; PROGRESS; NORTH; DATES; AGES; BP	Radiocarbon dating has been fundamental to the study of human cultural and biological development over the past 50,000 yr. Two recent developments in the methodology of radiocarbon dating show that the speed of colonization of Europe by modern human populations was more rapid than previously believed, and that their period of coexistence with the preceding Neanderthal was shorter.	Univ Cambridge, Dept Archaeol, Cambridge CB2 3DZ, England	University of Cambridge	Mellars, P (corresponding author), Univ Cambridge, Dept Archaeol, Cambridge CB2 3DZ, England.	pam59@cam.ac.uk						Aitken M. J., 1990, SCI BASED DATING ARC; Aldhouse-Green S., 2000, PAVILAND CAVE RED LA; Bard E, 2004, RADIOCARBON, V46, P1189, DOI 10.1017/S0033822200033087; Bard E, 2004, SCIENCE, V303, P178, DOI 10.1126/science.1091964; BARRON E, 2003, NEANDERTHALS MODERN, P57; BARTOLOMEI G, 1992, PREISTORIA ALPINA, V28, P131; BARYOSEF O, 2000, BULLETIN, V8, P107; Beck JW, 2001, SCIENCE, V292, P2453, DOI 10.1126/science.1056649; Bickerton Derek, 1995, LANGUAGE HUMAN BEHAV; CARBONELL E, 2000, B HARVARD U, V8, P5; Clottes J, 2001, GROTTE CHAUVET ART O; Conard NJ, 2003, J HUM EVOL, V44, P331, DOI 10.1016/S0047-2484(02)00202-6; d'Errico F, 2003, QUATERNARY SCI REV, V22, P769, DOI 10.1016/S0277-3791(03)00009-X; Fairbanks RG, 2005, QUATERNARY SCI REV, V24, P1781, DOI 10.1016/j.quascirev.2005.04.007; Forster P, 2005, SCIENCE, V308, P965, DOI 10.1126/science.1113261; Forster P, 2004, PHILOS T R SOC B, V359, P255, DOI 10.1098/rstb.2003.1394; Gamble C., 1999, PALAEOLITHIC SOC EUR; Gravina B, 2005, NATURE, V438, P51, DOI 10.1038/nature04006; Haesaerts P., 2003, CHRONOLOGY AURIGNACI, P133; HUBLIN JJ, 2000, B HARVARD U, V8, P157; Hughen K, 2004, SCIENCE, V303, P202, DOI 10.1126/science.1090300; JACOBI RM, IN PRESS J QUAT SCI; Joris O., 2003, TRABAJOS PREHIST, V60, P15, DOI DOI 10.3989/TP.2003.V60.I2.79; Kitagawa H, 1998, SCIENCE, V279, P1187, DOI 10.1126/science.279.5354.1187; Kozlowski JK, 2000, J ANTHROPOL RES, V56, P513, DOI 10.1086/jar.56.4.3630929; Kuhn S., 2000, PEABODY MUSEUM B, V8, P49; Laj C, 2002, EARTH PLANET SC LETT, V200, P177, DOI 10.1016/S0012-821X(02)00618-0; LEBON F, 2002, MEMOIRE SOC PREHISTO, V29; Lewis-Williams D., 2002, MIND CAVE; Maillo Fernandez J.M., 2001, PREHISTORIA ARQUEOLO, V14, P145; Mellars P, 2004, NATURE, V432, P461, DOI 10.1038/nature03103; Mellars P, 1998, NEANDERTALS AND MODERN HUMANS IN WESTERN ASIA, P493; MELLARS P, 1989, ANTIQUITY, V63, P761, DOI 10.1017/S0003598X00076894; Mellars P. A., 2001, PEOPLING BRITAIN SHA, P39; MELLARS PA, 1992, PHILOS T ROY SOC B, V337, P225, DOI 10.1098/rstb.1992.0100; MELLARS PA, 1996, LOWER MIDDLE PALAEOL, P225; MELLARS PA, 2000, GEOGRAPHY NEANDERTAL, P493; MELLARS PA, IN PRESS EVOL ANTHR; Mithen S., 1996, PREHISTORY MIND; Ramsey CB, 2004, RADIOCARBON, V46, P17, DOI 10.1017/S0033822200039308; Ramsey CB, 2004, RADIOCARBON, V46, P155, DOI 10.1017/S0033822200039473; Richter J., M M O GERMANIA, V80, P1, DOI DOI 10.11588/GER.2002.60508; Shackleton NJ, 2004, QUATERNARY SCI REV, V23, P1513, DOI 10.1016/j.quascirev.2004.03.006; Shackleton NJ, 2000, PALEOCEANOGRAPHY, V15, P565, DOI 10.1029/2000PA000513; Smith FH, 1999, P NATL ACAD SCI USA, V96, P12281, DOI 10.1073/pnas.96.22.12281; Stringer C, 2002, PHILOS T R SOC B, V357, P563, DOI 10.1098/rstb.2001.1057; STRINGER C, 2003, NEANDERTHALS MODERN, P233; Stringer C., 1989, PALEORIENT, V15, P99, DOI DOI 10.3406/paleo.1989.4512; Uthmeier T., 1996, ARCHAOL KORRES-BLATT, V26, P233; Van Andel TH., 2003, NEANDERTHALS MODERN, P31; van der Plicht J, 2004, RADIOCARBON, V46, P1225, DOI 10.1017/S0033822200033117; Voelker AHL, 1998, RADIOCARBON, V40, P517; Wheeler P, 2003, NEANDERTHALS MODERN, P147; White R., 1993, LASCAUX COMPLEX RECO, P277; WHITTLE A, 1998, PREHISTORIC EUROPE I, P136; Zilhao J, 2003, TRABALHOS ARQUEOLOGI, P313, DOI DOI 10.1007/S10814-006-9008-1	56	245	256	2	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 23	2006	439	7079					931	935		10.1038/nature04521	http://dx.doi.org/10.1038/nature04521			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	014NE	16495989				2022-12-28	WOS:000235486100037
J	Holty, JEC; Bravata, DM; Liu, H; Olshen, RA; McDonald, KM; Owens, DK				Holty, JEC; Bravata, DM; Liu, H; Olshen, RA; McDonald, KM; Owens, DK			Systematic review: A century of inhalational anthrax cases from 1900 to 2005	ANNALS OF INTERNAL MEDICINE			English	Review							BIOTERRORISM-RELATED ANTHRAX; 2 SURVIVING PATIENTS; NEW-YORK-CITY; BACILLUS-ANTHRACIS; UNITED-STATES; PULMONARY ANTHRAX; CLINICAL-FEATURES; NONLETHAL COURSE; TEXTILE WORKER; 1ST	Background: Mortality from inhalational anthrax during the 2001 U.S. attack was substantially lower than that reported historically. Purpose: To systematically review all published inhalational anthrax case reports to evaluate the predictors of disease progression and mortality. Data Sources: MEDLINE (1966-2005), 14 selected journal indexes (1900-1966), and bibliographies of all retrieved articles. Study Selection: Case reports (in any language) between 1900 and 2005 that met predefined criteria. Data Extraction: Two authors (1 author for non-English-language reports) independently abstracted patient data. Data Synthesis: The authors found 106 reports of 82 cases of inhalational anthrax. Mortality was statistically significantly lower for patients receiving antibiotics or anthrax antiserum during the prodromal phase of disease, multidrug antibiotic regimens, or pleural fluid drainage. Patients in the 2001 U.S. attack were less likely to die than historical anthrax case-patients (45% vs. 92%; P < 0.001) and were more likely to receive antibiotics during the prodromal phase (64% vs. 13 %; P < 0.001), multidrug regimens (91 % vs. 50%; P = 0.027), or pleural fluid drainage (73 % vs. 11 %; P < 0.001). Patients who progressed to the fulminant phase had a mortality rate of 97% (regardless of the treatment they received), and all patients with anthrax meningoencephalitis died. Limitations: This was a retrospective case review of previously published heterogeneous reports. Conclusions: Despite advances in supportive care, fulminant-phase inhalational anthrax is usually fatal. Initiation of antibiotic or anthrax antiserum therapy during the prodromal phase is associated with markedly improved survival, although other aspects of care, differences in clinical circumstances, or unreported factors may contribute to this observed reduction in mortality. Efforts to improve early diagnosis and timely initiation of appropriate antibiotics are critical to reducing mortality.	Stanford Univ, Sch Med, Div Pulm & Crit Care Med, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA; Stanford Univ Univ Calif San Francisco, Evidence Based Practice Ctr, Stanford, CA USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Holty, JEC (corresponding author), Stanford Univ, Sch Med, Div Pulm & Crit Care Med, Ctr Primary Care & Outcomes Res, 300 Pasteur Dr,H3143, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002784] Funding Source: NIH RePORTER; NIBIB NIH HHS [2-R01-EB-002784-30] Funding Source: Medline; PHS HHS [290-02-0017] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABRAMOVA FA, 1993, P NATL ACAD SCI USA, V90, P2291, DOI 10.1073/pnas.90.6.2291; ALBRINK WS, 1961, BACTERIOL REV, V25, P268, DOI 10.1128/MMBR.25.3.268-273.1961; ALBRINK WS, 1960, AM J PATHOL, V36, P457; AMIDI S, 1974, Tropenmedizin und Parasitologie, V25, P96; AMIDI S, 1973, Z TROPENMED PARASIT, V24, P250; ANGSUGRAN J, 1964, VITTAYASARN SENARAK, V17, P219; *ARM FORC I PATH D, 2001, INH ANTHR; Bales ME, 2002, EMERG INFECT DIS, V8, P1163, DOI 10.3201/eid0810.020223; Barakat LA, 2002, JAMA-J AM MED ASSOC, V287, P863, DOI 10.1001/jama.287.7.863; BASHENIN VA, 1955, KURS CHASTNOI EMPIDE; BEER K, 1978, SCHWEIZ RUNDSCH MED, V67, P1552; BEER K, 1973, PATHOL MICROBIOL, V39, P12, DOI 10.1159/000162609; Bell H., 1924, J MISSOURI STATE MED, V21, P407; BERKA F, 2004, WIEN KLIN WOCHENSCHR, V17, P365; BEYER, 1910, MUNCHEN MED WOCHEN, P385; BEZZI C, 1952, G Batteriol Immunol, V44, P353; Bloas J Y, 1978, Med Trop (Mars), V38, P270; Borio L, 2001, JAMA-J AM MED ASSOC, V286, P2554, DOI 10.1001/jama.286.20.2554; BOUDIN G, 1964, Bull Mem Soc Med Hop Paris, V115, P183; Boutin J P, 1985, Med Trop (Mars), V45, P79; Brachman P S, 1980, Ann N Y Acad Sci, V353, P83, DOI 10.1111/j.1749-6632.1980.tb18910.x; Brachman P.S., 1998, BACTERIAL INFECT HUM, P95; BRACHMAN PS, 1962, AM J PUBLIC HEALTH N, V52, P632, DOI 10.2105/AJPH.52.4.632; BRACHMAN PS, 1970, ANN NY ACAD SCI, V174, P577, DOI 10.1111/j.1749-6632.1970.tb45583.x; BRACHMAN PS, 1960, AM J HYG, V72, P6, DOI 10.1093/oxfordjournals.aje.a120135; BRACHMAN PS, 1961, NEW ENGL J MED, V265, P203, DOI 10.1056/NEJM196108032650501; BRACHMAN PS, 1959, EPIDEMIC INHALATION; Bravata DM, 2004, AHRQ PUBLICATION; Brooksher WR, 1920, J AMER MED ASSOC, V74, P323, DOI 10.1001/jama.1920.26210050002012a; BURMEISTER E, 1907, THESIS U ROSTOCK ROS; Bush LM, 2001, NEW ENGL J MED, V345, P1607, DOI 10.1056/NEJMoa012948; Cavallo JD, 2002, ANTIMICROB AGENTS CH, V46, P2307, DOI 10.1128/AAC.46.7.2307-2309.2002; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P909; CLARKE PS, 1952, BRIT MED J, V1, P86, DOI 10.1136/bmj.1.4749.86; Coker PR, 2002, ANTIMICROB AGENTS CH, V46, P3843, DOI 10.1128/AAC.46.12.3843-3845.2002; COUES WP, 1928, NEW ENGL J MED, V198, P148; COWDERY JS, 1947, ARCH PATHOL, V43, P396; CROIX IC, 1975, MED MALADIES INFECT, V5, P583; Cymet Tyler C., 2002, Journal of the American Osteopathic Association, V102, P41; DAGOSTINO S, 1962, AGGIORN PEDIATR, V13, P663; Dewan PK, 2002, EMERG INFECT DIS, V8, P1066, DOI 10.3201/eid0810.020330; DOUST JY, 1968, DIS CHEST, V53, P773; DUPUISDEMONGEOT MF, 1974, THESIS U REIMS REIMS; DURST UN, 1986, SCHWEIZ MED WSCHR, V116, P1222; Dutz W, 1971, Pathol Annu, V6, P209; Earls JP, 2002, RADIOLOGY, V222, P305, DOI 10.1148/radiol.2222011830; ENTICKNAP J, 1967, MED SCI LAW, V7, P136, DOI 10.1177/002580246700700311; ENTICKNAP JB, 1968, BRIT J IND MED, V25, P72; Eurich FW, 1933, BRIT MED J, V1933, P50, DOI 10.1136/bmj.2.3783.50; EURICH FW, 1930, SYSTEM BACTERIOLOGY, V5, P439; FAHR, 2006, MUNCHEN MED WOCHEN, V53, P480; FRAENKEL E, 1900, MUNCHEN MED WOCHEN, V47, P911; FRAENKEL E, 1925, VIRCHOWS ARCH, V254, P363; FRAENKEL E, 1900, DEUT MED WOCHENSCHR, V26, P239; FRIEDLANDER AM, 1997, TXB MILITARY MED MED, V5, P467; GARROD LP, 1952, ANTIBIOT CHEMOTHER, V2, P689; Gill JR, 2002, ARCH PATHOL LAB MED, V126, P993; GLAS E, 1906, MUNCHEN MED WOCHEN, V53, P496; GLAS E, 1928, HDB HALS NASEN OHREN, V4, P398; GOLD H, 1967, FED PROC, V26, P1563; GOLD H, 1955, ARCH INTERN MED, V96, P387, DOI 10.1001/archinte.1955.00250140109012; Greene CM, 2002, EMERG INFECT DIS, V8, P1048, DOI 10.3201/eid0810.020329; Griffith KS, 2003, EMERG INFECT DIS, V9, P681; Grinberg L. M., 1993, Arkhiv Patologii, V55, P23; Grinberg LM, 2001, MODERN PATHOL, V14, P482, DOI 10.1038/modpathol.3880337; Guarner J, 2003, AM J PATHOL, V163, P701, DOI 10.1016/S0002-9440(10)63697-8; Guillemin J., 1999, ANTHRAX INVESTIGATIO; HAIGHT TH, 1952, AM J MED SCI, V224, P57, DOI 10.1097/00000441-195207000-00009; HAMMER, 1902, WIEN KLIN WOCHENSCHR, V15, P1237; HAMMER H, 1901, Z HEILKUNDE, V22, P383; Harrington TF, 1917, BOSTON MED SURG J, V177, P867, DOI 10.1056/NEJM191712201772503; Heilman F. R., 1944, PROC STAFF MEET MAYO CLINIC, V19, P492; HENDERSON D. W., 1956, JOUR HYG, V54, P28; Holtz TH, 2003, EMERG INFECT DIS, V9, P689; Hupert N, 2003, ANN INTERN MED, V139, P337, DOI 10.7326/0003-4819-139-5_Part_1-200309020-00009; INDA F F, 1947, Sem Med, V54, P38; INDA FF, 1947, SEMANA MED, V2, P890; INDA FF, 1943, SEM MED, V50, P754; Inglesby TV, 2002, JAMA-J AM MED ASSOC, V287, P2236, DOI 10.1001/jama.287.17.2236; Jackson PJ, 1998, P NATL ACAD SCI USA, V95, P1224, DOI 10.1073/pnas.95.3.1224; Jernigan DB, 2002, EMERG INFECT DIS, V8, P1019, DOI 10.3201/eid0810.020353; Jernigan JA, 2001, EMERG INFECT DIS, V7, P933, DOI 10.3201/eid0706.010604; JOHNSON K, 2001, NY TIMES        1203, pA1; Karginov VA, 2004, FEMS IMMUNOL MED MIC, V40, P71, DOI 10.1016/S0928-8244(03)00302-X; KER WG, 1944, E AFR MED J, V21, P93; Koch R., 1877, BEIRT BIOL PFLANZ, V2, P277; KOHOUT E, 1964, AM J MED SCI, V247, P565, DOI 10.1097/00000441-196405000-00006; Koshi G, 1981, J Assoc Physicians India, V29, P59; KRAUSS F, 1943, ARCH OTOLARYNGOL, V37, P238; KREISSL B, 1901, WIEN KLIN WCHNSCHR, V14, P1027; Krol CM, 2002, AM J ROENTGENOL, V178, P1063, DOI 10.2214/ajr.178.5.1781063; KRONBERGER H, 1917, BEITR KLIN TUBERK SP, V38, P135; KRZYSZKOWSKI J, 1901, PRZEGL LEK, V40, P543; KRZYSZKOWSKI J, 1901, PRZEGL LEK, V40, P556; Kyriacou DN, 2004, LANCET, V364, P449, DOI 10.1016/S0140-6736(04)16769-X; LAFORCE FM, 1969, ARCH ENVIRON HEALTH, V18, P798, DOI 10.1080/00039896.1969.10665490; LEIMAN V N, 1959, Zh Mikrobiol Epidemiol Immunobiol, V30, P130; LENGFELLNER K, 1907, MUNCHEN MED WOCHEN, V54, P526; LOUBEJAC A M, 1946, Arch Urug Med Cir Espec, V29, P184; Lucchesi PF, 1932, AM J MED SCI, V183, P795, DOI 10.1097/00000441-193206000-00008; Maillard JM, 2002, EMERG INFECT DIS, V8, P1035, DOI 10.3201/eid0810.020389; Materna A, 1929, BEITR PATHOL ANAT AL, V82, P424; Mathias, 1914, DEUT MED WOCHENSCHR, V40, P1860; Mayer TA, 2001, JAMA-J AM MED ASSOC, V286, P2549, DOI 10.1001/jama.286.20.2549; McFadyean John, 1903, J COMP PATHOL, V16, P346; McKitterick JC, 1929, AM J DIS CHILD, V38, P1252; MESELSON M, 1994, SCIENCE, V266, P1202, DOI 10.1126/science.7973702; Meyer FGA, 1908, DEUT MED WOCHENSCHR, V34, P108, DOI 10.1055/s-0028-1143480; Mina B, 2002, JAMA-J AM MED ASSOC, V287, P858, DOI 10.1001/jama.287.7.858; Mitchell W, 1911, BRIT MED J, V1911, P751, DOI 10.1136/bmj.1.2622.751; Mohammed MJ, 2002, J CLIN MICROBIOL, V40, P1902, DOI 10.1128/JCM.40.6.1902-1907.2002; MOLTRECHT, 1902, MUNCHEN MED WOCHEN, V49, P817; MULLER M, 1954, Ann Med Leg Criminol Police Sci Toxicol, V34, P84; MULLER M, 1954, PRESSE MED, V62, P694; PANDEY R, 1977, INDIAN J OTOLARYNGOL, V29, P140; PARSONS JG, 1908, JAMA-J AM MED ASSOC, V51, P1697; Pascha ZN, 1908, DEUT MED WOCHENSCHR, V34, P1430, DOI 10.1055/s-0028-1135665; PASHA ZN, 1921, BMJ-BRIT MED J, V2, P446; PAULET R, 1994, PRESSE MED, V23, P477; PFISTERER RM, 1991, SCHWEIZ MED WSCHR, V121, P813; Pile JC, 1998, ARCH INTERN MED, V158, P429, DOI 10.1001/archinte.158.5.429; Plotkin SA, 2002, AM J MED, V112, P4, DOI 10.1016/S0002-9343(01)01050-6; PLOTKIN SA, 1960, AM J MED, V29, P992, DOI 10.1016/0002-9343(60)90079-6; PLOTKIN SA, 2002, AM J MED, V112, P2, DOI DOI 10.1016/S0002-9343(01)01050-6; PLUOT M, 1976, ACTA NEUROPATHOL, V36, P339, DOI 10.1007/BF00699639; POLLAK L, 1912, WIEN KLIN WCHNSCHR, V25, P1702; POPOV NV, 1914, RUSSK VRACH, V13, P885; POPOV NV, 1914, RUSS VRACH, V13, P848; Quintiliani Richard Jr, 2002, Conn Med, V66, P261; QUINTILLIANI R, 2001, J IBARAKI HLTH SCI C, V47, P3; Reece RJ, 1917, LANCET, V1, P406; Regan JC, 1921, AM J MED SCI, V162, P406; REYE E, 1914, MUNCHEN MED WOCHEN, P844; REYE E, 1914, BERLINER KLIN WOSCHE, P670; RISEL, 1902, DEUT MED WOCHENSCHR, V28, P283; RISEL W, 1903, Z HYG, V42, P381; SAMSON E, 1970, Central African Journal of Medicine, V16, P6; SCHAETZ, 1924, MUNCHEN MED WOCHEN, V71, P1149; SCHEREFFETIN O, 1931, WIEN KLIN WOCHENSCHR, V44, P1083; SCLAVO A, 1903, RIV IGIENE SANITA PU, V14, P519; Serraino D, 2003, INFECTION, V31, P128, DOI 10.1007/s15010-003-3140-3; SEVERN M, 1976, BRIT MED J, V1, P748, DOI 10.1136/bmj.1.6012.748; Shennan T, 1910, J PATHOL BACTERIOL, V14, P556, DOI 10.1002/path.1700140416; SIMMONDS, 2004, MUNCHEN MED WOCHEN, V51, P139; SIROL J, 1971, PRESSE MED, V79, P1635; Skolubovich G V, 1995, Klin Med (Mosk), V73, P54; Skolubovich G V, 1995, Zh Mikrobiol Epidemiol Immunobiol, P102; SOLOVEV ZP, 1909, VRACH SAN KHRONIKA S, P5; SPEARMAN B, 1917, BMJ-BRIT MED J, V1, P809; STEIN J, 1909, ZENTRABL BAKTERIOL, V51, P625; Sturdy J C, 1901, Br Med J, V2, P135; SUFFIN SC, 1978, HUM PATHOL, V9, P594, DOI 10.1016/S0046-8177(78)80140-3; Suic M, 1966, Lijec Vjesn, V88, P1449; Swartz MN, 2001, NEW ENGL J MED, V345, P1621, DOI 10.1056/NEJMra012892; Teacher JH, 1906, LANCET, V1, P1306; Teacher JH, 1906, LANCET, V2, P830; TEACHER JH, 1905, GLASGOW MED J, V64, P127; THEODOROV A, 1907, WIEN KLIN WOCHENSCHR, V20, P764; Traeger MS, 2002, EMERG INFECT DIS, V8, P1029, DOI 10.3201/eid0810.020354; TURNBULL BW, 1976, J R STAT SOC B, V38, P290; U. S. Commission on National Security in the 21st Century, 1999, NEW WORLD COM AM SEC; VACCAREZZA RF, 1939, PRESSE MEED, V94, P1642; VELIMIROVIC B, 1992, SCHWEIZ MED WSCHR, V122, P442; VESSAL K, 1975, CLIN RADIOL, V26, P471, DOI 10.1016/S0009-9260(75)80100-0; WINTER H, 1991, SCHWEIZ MED WSCHR, V121, P832; Wood BJ, 2003, AM J ROENTGENOL, V181, P1071, DOI 10.2214/ajr.181.4.1811071; WRIGHT F J, 1954, East Afr Med J, V31, P516; Yang Q K, 1979, Zhonghua Fang She Xue Za Zhi, V13, P242; Yorgancigil B, 2001, Int J Infect Dis, V5, P220, DOI 10.1016/S1201-9712(01)90075-X; YORGANCIGIL B, 1998, TURKISH J MED SCI, V28, P457; 1908, BR MED J, V1, P837; 1957, MMWR MORB MORTAL WKL, V6, P2; 1954, P S ANTHR MAN HOSP U; 2007, BR MED J, V1, P955; 1904, LANCET, V2, P423; 1918, BOSTON MED SURG J, V178, P132; 2001, MMWR MORB MORTAL WKL, V50, P1049; 1961, MMWR MORB MORTAL WKL, V10, P2; 1906, LANCET, V2, P192; 1909, LANCET, V2, P1392; 1906, LANCET, V1, P189	181	175	187	0	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 21	2006	144	4					270	280		10.7326/0003-4819-144-4-200602210-00009	http://dx.doi.org/10.7326/0003-4819-144-4-200602210-00009			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	015HS	16490913				2022-12-28	WOS:000235543100006
J	Townley, WA; Baker, R; Sheppard, N; Grobbelaar, AO				Townley, WA; Baker, R; Sheppard, N; Grobbelaar, AO			Dupuytren's contracture unfolded	BRITISH MEDICAL JOURNAL			English	Review							DISEASE; COMPLICATIONS; EPIDEMIOLOGY; FASCIOTOMY; MANAGEMENT; EXPRESSION; COLLAGEN; ALCOHOL		Mt Vernon Hosp, RAFT Inst Plast & Reconstruct Surg, Northwood HA6 2RN, Middx, England; Mt Vernon Hosp, Dept Plast & Reconstruct Surg, Northwood HA6 2RN, Middx, England; Wexham Pk Hosp, Dept Plast & Reconstruct Surg, Slough SL2 4HL, Berks, England		Townley, WA (corresponding author), 110 Sinclair Rd, London W14 0NJ, England.	willtownley@hotmail.com		Grobbelaar, Adriaan/0000-0003-2001-5173				ATTALI P, 1987, ARCH INTERN MED, V147, P1065, DOI 10.1001/archinte.147.6.1065; Badalamente MA, 2002, J HAND SURG-AM, V27A, P788, DOI 10.1053/jhsu.2002.35299; BAIRD KS, 1993, J CLIN PATHOL, V46, P425, DOI 10.1136/jcp.46.5.425; Bisson MA, 2003, J HAND SURG-BRIT EUR, V28B, P351, DOI 10.1016/S0266-7681(03)00135-9; BRICKLEYPARSONS D, 1981, J BONE JOINT SURG AM, V63, P787, DOI 10.2106/00004623-198163050-00014; BRYAN AS, 1988, J HAND SURG-BRIT EUR, V13B, P254, DOI 10.1016/0266-7681(88)90079-4; Bulstrode NW, 2005, J HAND SURG-AM, V30A, P1021, DOI 10.1016/j.jhsa.2005.05.008; Elliot D, 1999, HAND CLIN, V15, P1; Fitzgerald AMP, 1999, J HAND SURG-BRIT EUR, V24B, P395, DOI 10.1054/jhsb.1999.0207; Foucher G, 2003, J HAND SURG-BRIT EUR, V28B, P427, DOI 10.1016/S0266-7681(03)00013-5; Geoghegan JM, 2004, J HAND SURG-BRIT EUR, V29B, P423, DOI 10.1016/j.jhsb.2004.06.006; Godtfredsen NS, 2004, J CLIN EPIDEMIOL, V57, P858, DOI 10.1016/j.jclinepi.2003.11.015; Gudmundsson KG, 2000, J CLIN EPIDEMIOL, V53, P291, DOI 10.1016/S0895-4356(99)00145-6; Hall PN, 1997, J HAND SURG-BRIT EUR, V22B, P193, DOI 10.1016/S0266-7681(97)80061-7; Jemec B, 1999, J HAND SURG-BRIT EUR, V24B, P511, DOI 10.1054/jhsb.1999.0251; Keilholz L, 1996, INT J RADIAT ONCOL, V36, P891, DOI 10.1016/S0360-3016(96)00421-X; LUCK JV, 1959, J BONE JOINT SURG AM, V41, P635, DOI 10.2106/00004623-195941040-00008; MCCASH C R, 1964, Br J Plast Surg, V17, P271, DOI 10.1016/S0007-1226(64)80043-6; MCFARLANE RM, 1991, J HAND SURG-AM, V16A, P775, DOI 10.1016/S0363-5023(10)80134-0; MCFARLANE RM, 1983, J HAND SURG-AM, V8, P703, DOI 10.1016/S0363-5023(83)80251-2; MCGROUTHER DA, 1982, HAND, V14, P215, DOI 10.1016/S0072-968X(82)80055-7; Mikkelsen O A, 1976, Hand, V8, P265, DOI 10.1016/0072-968X(76)90013-9; Moermans JP, 1996, J HAND SURG-BRIT EUR, V21B, P797, DOI 10.1016/S0266-7681(96)80195-1; MURRELL GAC, 1987, BMJ-BRIT MED J, V295, P1373, DOI 10.1136/bmj.295.6610.1373; PITTET B, 1994, PLAST RECONSTR SURG, V93, P1224, DOI 10.1097/00006534-199405000-00018; Rayan GM, 1999, HAND CLIN, V15, P87; RODRIGO JJ, 1976, J BONE JOINT SURG AM, V58, P380, DOI 10.2106/00004623-197658030-00016; Ross DC, 1999, HAND CLIN, V15, P53; SANDERSON PL, 1992, J BONE JOINT SURG BR, V74, P923, DOI 10.1302/0301-620X.74B6.1447259; SHELLEY WB, 1993, LANCET, V342, P366, DOI 10.1016/0140-6736(93)91507-I; Smith HS, 2002, EUR J PAIN-LONDON, V6, P13, DOI 10.1016/S1090-3801(02)90003-0	31	84	86	0	17	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	FEB 18	2006	332	7538					397	400A		10.1136/bmj.332.7538.397	http://dx.doi.org/10.1136/bmj.332.7538.397			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	017HZ	16484265	Green Published			2022-12-28	WOS:000235686000021
J	van Weel, C; Schellevis, FG				van Weel, C; Schellevis, FG			Comorbidity and guidelines: conflicting interests	LANCET			English	Editorial Material							GENERAL-PRACTICE; CARE; DEPRESSION; MORBIDITY; DISEASES; QUALITY		Radboud Univ Nijmegen Med Ctr, Dept Gen Practice, NL-6500 HB Nijmegen, Netherlands; Netherlands Inst Hlth Serv Res, Utrecht, Netherlands	Radboud University Nijmegen; Netherlands Institute for Health Services Research	van Weel, C (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Gen Practice, NL-6500 HB Nijmegen, Netherlands.	c.vanweel@hag.umcn.nl	van Weel, Chris/D-4375-2009	van Weel, Chris/0000-0003-3653-4701				Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; Campbell SM, 2005, BMJ-BRIT MED J, V331, P1121, DOI 10.1136/bmj.38632.611123.AE; FEINSTEIN AR, 1970, J CHRON DIS, V23, P455, DOI 10.1016/0021-9681(70)90054-8; Fried LP, 2004, J GERONTOL A-BIOL, V59, P255; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; Nuyen J, 2005, PSYCHOL MED, V35, P1185, DOI 10.1017/S0033291705004812; OLSHANSKY SJ, 1986, MILBANK Q, V64, P355, DOI 10.2307/3350025; SCHELLEVIS FG, 1993, J CLIN EPIDEMIOL, V46, P469, DOI 10.1016/0895-4356(93)90024-U; SCHELLEVIS FG, 1994, BRIT J GEN PRACT, V44, P259; Starfield Barbara, 2003, Ann Fam Med, V1, P8, DOI 10.1370/afm.1; van den Akker M, 1998, J CLIN EPIDEMIOL, V51, P367, DOI 10.1016/S0895-4356(97)00306-5; van Os TWDP, 2005, J AFFECT DISORDERS, V84, P43, DOI 10.1016/j.jad.2004.09.005; VANWEEL C, 1996, EUR J GEN PRACT, V2, P17; WESTERT GP, IN PRESS MORBIDITY P	14	136	150	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 18	2006	367	9510					550	551		10.1016/S0140-6736(06)68198-1	http://dx.doi.org/10.1016/S0140-6736(06)68198-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	013GM	16488782	Green Submitted			2022-12-28	WOS:000235397800007
J	Flavell, SW; Cowan, CW; Kim, TK; Greer, PL; Lin, YX; Paradis, S; Griffith, EC; Hu, LS; Chen, CF; Greenberg, ME				Flavell, SW; Cowan, CW; Kim, TK; Greer, PL; Lin, YX; Paradis, S; Griffith, EC; Hu, LS; Chen, CF; Greenberg, ME			Activity-dependent regulation of MEF2 transcription factors suppresses excitatory synapse number	SCIENCE			English	Article							NEURONAL-ACTIVITY; PLASTICITY; SURVIVAL	In the mammalian nervous system, neuronal activity regulates the strength and number of synapses formed. The genetic program that coordinates this process is poorly understood. We show that myocyte enhancer factor 2 (MEF2) transcription factors suppressed excitatory synapse number in a neuronal activity- and calcineurin-dependent manner as hippocampal neurons formed synapses. In response to increased neuronal activity, calcium influx into neurons induced the activation of the calcium/calmodulin-regulated phosphatase calcineurin, which dephosphorylated and activated MEF2. When activated, MEF2 promoted the transcription of a set of genes, including arc and synGAP, that restrict synapse number. These findings define an activity-dependent transcriptional program that may control synapse number during development.	Harvard Univ, Sch Med, Childrens Hosp, Neurobiol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Greenberg, ME (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Neurobiol Program, 300 Longwood Ave, Boston, MA 02115 USA.	michael.greenberg@childrens.harvard.edu	Cowan, Christopher W/I-2497-2014; Kim, Tae-Kyung/AAX-4230-2020	Kim, Tae-Kyung/0000-0001-5161-9864; /0000-0002-7002-1275; Griffith, Eric/0000-0003-0428-3215; Flavell, Steven/0000-0001-9464-1877	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY013613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS028829, R01NS028829] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F32AG005870] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY013613] Funding Source: Medline; NIA NIH HHS [AG05870] Funding Source: Medline; NICHD NIH HHS [HD18655] Funding Source: Medline; NINDS NIH HHS [NS28829] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bonhoeffer T, 2002, NEURON, V35, P1019, DOI 10.1016/S0896-6273(02)00906-6; Burrone J, 2002, NATURE, V420, P414, DOI 10.1038/nature01242; Chen CF, 2000, NEURON, V28, P955, DOI 10.1016/S0896-6273(00)00166-5; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Gong XM, 2003, NEURON, V38, P33, DOI 10.1016/S0896-6273(03)00191-0; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Mao ZX, 1999, J BIOL CHEM, V274, P31102, DOI 10.1074/jbc.274.43.31102; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Nagerl UV, 2004, NEURON, V44, P759, DOI 10.1016/j.neuron.2004.11.016; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Shalizi A, 2003, J NEUROSCI, V23, P7326; SHEPHERD JD, 2004, 2004 ABSTRACT VIEWER; Vazquez LE, 2004, J NEUROSCI, V24, P8862, DOI 10.1523/JNEUROSCI.3213-04.2004; West AE, 2002, NAT REV NEUROSCI, V3, P921, DOI 10.1038/nrn987; Zeng HK, 2001, CELL, V107, P617, DOI 10.1016/S0092-8674(01)00585-2	17	423	439	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 17	2006	311	5763					1008	1012		10.1126/science.1122511	http://dx.doi.org/10.1126/science.1122511			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014CS	16484497				2022-12-28	WOS:000235456900048
J	Jackson, RD; LaCroix, AZ; Gass, M; Wallace, RB; Robbins, J; Lewis, CE; Bassford, T; Beresford, SAA; Black, HR; Blanchette, P; Bonds, DE; Brunner, RL; Brzyski, RG; Caan, B; Cauley, JA; Chlebowski, RT; Cummings, SR; Granek, I; Hays, J; Heiss, G; Hendrix, SL; Howard, BV; Hsia, J; Hubbell, FA; Johnson, KC; Judd, H; Kotchen, JM; Kuller, LH; Langer, RD; Lasser, NL; Limacher, MC; Ludlam, S; Manson, JE; Margolis, KL; McGowan, J; Ockene, JK; O'Sullivan, MJ; Phillips, L; Prentice, RL; Sarto, GE; Stefanick, ML; Van Horn, L; Wactawski-Wende, J; Whitlock, E; Anderson, GL; Assaf, AR; Barad, D				Jackson, RD; LaCroix, AZ; Gass, M; Wallace, RB; Robbins, J; Lewis, CE; Bassford, T; Beresford, SAA; Black, HR; Blanchette, P; Bonds, DE; Brunner, RL; Brzyski, RG; Caan, B; Cauley, JA; Chlebowski, RT; Cummings, SR; Granek, I; Hays, J; Heiss, G; Hendrix, SL; Howard, BV; Hsia, J; Hubbell, FA; Johnson, KC; Judd, H; Kotchen, JM; Kuller, LH; Langer, RD; Lasser, NL; Limacher, MC; Ludlam, S; Manson, JE; Margolis, KL; McGowan, J; Ockene, JK; O'Sullivan, MJ; Phillips, L; Prentice, RL; Sarto, GE; Stefanick, ML; Van Horn, L; Wactawski-Wende, J; Whitlock, E; Anderson, GL; Assaf, AR; Barad, D		Womens Hlth Initiative Investigat	Calcium plus vitamin D supplementation and the risk of fractures	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; POSTMENOPAUSAL BONE LOSS; ELDERLY-WOMEN; OSTEOPOROTIC FRACTURES; MINERAL DENSITY; CLINICAL-TRIAL; HIP-FRACTURES; PREVENTION; METAANALYSIS; ESTROGEN	BACKGROUND: The efficacy of calcium with vitamin D supplementation for preventing hip and other fractures in healthy postmenopausal women remains equivocal. METHODS: We recruited 36,282 postmenopausal women, 50 to 79 years of age, who were already enrolled in a Women's Health Initiative (WHI) clinical trial. We randomly assigned participants to receive 1000 mg of calcium carbonate with 400 IU of vitamin D(sub 3) daily or placebo. Fractures were ascertained for an average follow-up period of 7.0 years. Bone density was measured at three WHI centers. RESULTS: Hip bone density was 1.06 percent higher in the calcium plus vitamin D group than in the placebo group (P<0.01). Intention-to-treat analysis indicated that participants receiving calcium plus vitamin D supplementation had a hazard ratio of 0.88 for hip fracture (95 percent confidence interval, 0.72 to 1.08), 0.90 for clinical spine fracture (0.74 to 1.10), and 0.96 for total fractures (0.91 to 1.02). The risk of renal calculi increased with calcium plus vitamin D (hazard ratio, 1.17; 95 percent confidence interval, 1.02 to 1.34). Censoring data from women when they ceased to adhere to the study medication reduced the hazard ratio for hip fracture to 0.71 (95 percent confidence interval, 0.52 to 0.97). Effects did not vary significantly according to prerandomization serum vitamin D levels. CONCLUSIONS: Among healthy postmenopausal women, calcium with vitamin D supplementation resulted in a small but significant improvement in hip bone density, did not significantly reduce hip fracture, and increased the risk of kidney stones.	Ohio State Univ, Div Endocrinol, Columbus, OH 43210 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Univ Cincinnati, Cincinnati, OH USA; Univ Iowa, Iowa City, IA USA; Univ Iowa, Davenport, IA USA; Univ Calif Davis, Sacramento, CA 95817 USA; Univ Alabama, Birmingham, AL USA; Univ Arizona, Tucson, AZ USA; Univ Arizona, Phoenix, AZ USA; Univ Washington, Seattle, WA 98195 USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL USA; Univ Hawaii, Honolulu, HI 96822 USA; Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA; Univ Nevada, Reno, NV 89557 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; Kaiser Permanente, Div Res, Oakland, CA USA; Univ Pittsburgh, Pittsburgh, PA USA; Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA; San Francisco Coordinating Ctr, San Francisco, CA USA; SUNY Stony Brook, Stony Brook, NY 11794 USA; Baylor Coll Med, Houston, TX 77030 USA; Univ N Carolina, Chapel Hill, NC USA; Wayne State Univ, Sch Med, Detroit, MI USA; Hutzel Hosp, Detroit, MI 48201 USA; Howard Univ, MedStar Res Inst, Washington, DC 20059 USA; George Washington Univ, Med Ctr, Washington, DC 20037 USA; Univ Calif Irvine, Irvine, CA USA; Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; Univ Calif Los Angeles, Los Angeles, CA USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; Univ Calif San Diego, La Jolla, CA 92093 USA; Univ Calif San Diego, Chula Vista, CA USA; Univ Med & Dent New Jersey, Newark, NJ 07103 USA; Univ Florida, Gainesville, FL USA; Univ Florida, Jacksonville, FL USA; NHLBI, Bethesda, MD 20892 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Minnesota, Minneapolis, MN USA; NIAMSD, Bethesda, MD 20892 USA; Univ Massachusetts, Fallon Clin, Worcester, MA 01605 USA; Univ Miami, Miami, FL 33152 USA; Emory Univ, Atlanta, GA 30322 USA; Univ Wisconsin, Madison, WI USA; Stanford Prevent Res Ctr, Stanford, CA USA; Northwestern Univ, Chicago, IL 60611 USA; Northwestern Univ, Evanston, IL USA; SUNY Buffalo, Buffalo, NY USA; Kaiser Permanente Ctr Hlth Res, Portland, OR USA; Brown Univ, Providence, RI 02912 USA; Albert Einstein Coll Med, Bronx, NY 10467 USA	University System of Ohio; Ohio State University; Fred Hutchinson Cancer Center; University System of Ohio; University of Cincinnati; University of Iowa; University of Iowa; University of California System; University of California Davis; University of Alabama System; University of Alabama Birmingham; University of Arizona; University of Arizona; University of Washington; University of Washington Seattle; Rush University; University of Hawaii System; Wake Forest University; Nevada System of Higher Education (NSHE); University of Nevada Reno; University of Texas System; University of Texas Health San Antonio; Kaiser Permanente; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute; California Pacific Medical Center; California Pacific Medical Center Research Institute; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Baylor College of Medicine; University of North Carolina; University of North Carolina Chapel Hill; Wayne State University; Howard University; George Washington University; University of California System; University of California Irvine; University of Tennessee System; University of Tennessee Health Science Center; University of California System; University of California Los Angeles; Medical College of Wisconsin; University of California System; University of California San Diego; University of California System; University of California San Diego; Rutgers State University New Brunswick; Rutgers State University Medical Center; State University System of Florida; University of Florida; State University System of Florida; University of Florida; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Massachusetts System; University of Massachusetts Worcester; University of Miami; Emory University; University of Wisconsin System; University of Wisconsin Madison; Stanford University; Northwestern University; Northwestern University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Kaiser Permanente; Brown University; Yeshiva University; Albert Einstein College of Medicine	Jackson, RD (corresponding author), Ohio State Univ, Div Endocrinol, 485 McCampbell,1581 Dodd Dr, Columbus, OH 43210 USA.	jackson.20@osu.edu	Cauley, Jane A/N-4836-2015; Wactawski-Wende, Jean/AGH-5457-2022	Cauley, Jane A/0000-0003-0752-4408; Wactawski-Wende, Jean/0000-0003-3096-9595; Hays-Grudo, Jennifer/0000-0002-8107-1243; Caan, Bette/0000-0002-5803-310X; Margolis, Karen/0000-0003-1862-7402				Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Bischoff-Ferrari HA, 2004, JAMA-J AM MED ASSOC, V291, P1999, DOI 10.1001/jama.291.16.1999; Bischoff-Ferrari HA, 2005, JAMA-J AM MED ASSOC, V293, P2257, DOI 10.1001/jama.293.18.2257; Cauley JA, 2003, JAMA-J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729; CHAPUY MC, 1994, BRIT MED J, V308, P1081, DOI 10.1136/bmj.308.6936.1081; Chapuy MC, 2002, OSTEOPOROSIS INT, V13, P257, DOI 10.1007/s001980200023; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; CHEVALLEY T, 1994, OSTEOPOROSIS INT, V4, P245, DOI 10.1007/BF01623348; Cumming RG, 1997, J BONE MINER RES, V12, P1321, DOI 10.1359/jbmr.1997.12.9.1321; CUMMING RG, 1990, CALCIFIED TISSUE INT, V47, P194; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; Department of Health and Human Services, 2004, BON HLTH OST REP SUR; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; *FOOD NUTR BOARD I, 1997, DIET REF INT CALC PH, V38, P144; GARLAND CF, 1980, INT J EPIDEMIOL, V9, P227, DOI 10.1093/ije/9.3.227; GILLESPIE WJ, 2001, COCHRANE DB SYST REV, V1; Grant AM, 2005, LANCET, V365, P1621, DOI 10.1016/S0140-6736(05)63013-9; Jackson RD, 2003, ANN EPIDEMIOL, V13, pS98, DOI 10.1016/S1047-2797(03)00046-2; Kanis JA, 1999, BONE, V24, P279, DOI 10.1016/S8756-3282(99)00010-1; Larsen ER, 2004, J BONE MINER RES, V19, P370, DOI 10.1359/JBMR.0301240; LeBoff MS, 1999, JAMA-J AM MED ASSOC, V281, P1505, DOI 10.1001/jama.281.16.1505; Lips P, 1996, ANN INTERN MED, V124, P400, DOI 10.7326/0003-4819-124-4-199602150-00003; Looker AC, 1997, J BONE MINER RES, V12, P1761, DOI 10.1359/jbmr.1997.12.11.1761; MELTON LJ, 1995, J BONE MINER RES, V10, P175; Meyer HE, 2002, J BONE MINER RES, V17, P709, DOI 10.1359/jbmr.2002.17.4.709; Papadimitropoulos E, 2002, ENDOCR REV, V23, P560, DOI 10.1210/er.2001-8002; Patterson RE, 1999, ANN EPIDEMIOL, V9, P178, DOI 10.1016/S1047-2797(98)00055-6; Porthouse J, 2005, BMJ-BRIT MED J, V330, P1003, DOI 10.1136/bmj.330.7498.1003; Recker RR, 1996, J BONE MINER RES, V11, P1961; Robins JM, 2000, BIOMETRICS, V56, P779, DOI 10.1111/j.0006-341X.2000.00779.x; Shea B, 2002, ENDOCR REV, V23, P552, DOI 10.1210/er.2001-7002; Sirola J, 2003, CALCIFIED TISSUE INT, V72, P659, DOI 10.1007/s00223-002-2069-3; Trivedi DP, 2003, BMJ-BRIT MED J, V326, P469, DOI 10.1136/bmj.326.7387.469; Vieth R, 2004, J STEROID BIOCHEM, V89-90, P575, DOI 10.1016/j.jsbmb.2004.03.038; Wactawski-Wende J, 2006, NEW ENGL J MED, V354, P684, DOI 10.1056/NEJMoa055222; Yates AA, 1998, J AM DIET ASSOC, V98, P699, DOI 10.1016/S0002-8223(98)00160-6; 2003, HEALTHCARE COST UTIL	37	1219	1273	1	129	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 16	2006	354	7					669	683		10.1056/NEJMoa055218	http://dx.doi.org/10.1056/NEJMoa055218			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	012CP	16481635				2022-12-28	WOS:000235316100004
J	Kargel, JS				Kargel, JS			Perspective - Enceladus: Cosmic gymnast, volatile miniworld	SCIENCE			English	Editorial Material							ICY SATELLITES; ORIGIN; SATURN; SPECTROMETER; MAGNETOMETER; ATMOSPHERE; VOLCANISM; SURFACE; OCEAN; PLUME		Univ Arizona, Dept Hydrol & Water Resources, Tucson, AZ 85721 USA	University of Arizona	Kargel, JS (corresponding author), Univ Arizona, Dept Hydrol & Water Resources, Tucson, AZ 85721 USA.	kargel@hwr.arizona.edu						Brown RH, 2006, SCIENCE, V311, P1425, DOI 10.1126/science.1121031; CROFT SK, 1996, NEPTUNE TRITON, P879; Dougherty MK, 2006, SCIENCE, V311, P1406, DOI 10.1126/science.1120985; GREENBERG R, 1991, URANUS, P410; Hansen CJ, 2006, SCIENCE, V311, P1422, DOI 10.1126/science.1121254; Irion R, 2006, SCIENCE, V311, P589, DOI 10.1126/science.311.5761.589; Jones GH, 2006, SCIENCE, V311, P1412, DOI 10.1126/science.1121011; Kargel JS, 1996, ICARUS, V119, P385, DOI 10.1006/icar.1996.0026; KARGEL JS, 1992, ICARUS, V100, P556, DOI 10.1016/0019-1035(92)90118-Q; Kargel JS, 2000, ICARUS, V148, P226, DOI 10.1006/icar.2000.6471; Kivelson MG, 2000, SCIENCE, V289, P1340, DOI 10.1126/science.289.5483.1340; Kivelson MG, 2006, SCIENCE, V311, P1391, DOI 10.1126/science.1124494; Lebreton JP, 2005, NATURE, V438, P758, DOI 10.1038/nature04347; LUNINE JI, 1987, ICARUS, V70, P61, DOI 10.1016/0019-1035(87)90075-3; McCord TB, 1998, SCIENCE, V280, P1242, DOI 10.1126/science.280.5367.1242; Pappalardo R. T., 1999, J GEOPHYS RES, V104, P24105; PLESCIA JB, 1983, NATURE, V301, P666, DOI 10.1038/301666a0; Porco CC, 2006, SCIENCE, V311, P1393, DOI 10.1126/science.1123013; PRIETO O, 2002, LUNAR PLANET SCI, V33; PRIETOBALLESTER.O, 2006, LUN PLAN SCI C, V37; Ross RG, 1998, ASTROPHYS SPACE SC L, V227, P33, DOI 10.1007/978-94-011-5252-5_2; SMITH BA, 1982, SCIENCE, V215, P504, DOI 10.1126/science.215.4532.504; Spahn F, 2006, SCIENCE, V311, P1416, DOI 10.1126/science.1121375; Spencer JR, 2006, SCIENCE, V311, P1401, DOI 10.1126/science.1121661; SQUYRES SW, 1983, ICARUS, V53, P319, DOI 10.1016/0019-1035(83)90152-5; STEVENSON DJ, 1982, NATURE, V298, P142, DOI 10.1038/298142a0; Tokar RL, 2006, SCIENCE, V311, P1409, DOI 10.1126/science.1121061; Waite JH, 2006, SCIENCE, V311, P1419, DOI 10.1126/science.1121290	29	44	44	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 10	2006	311	5766					1389	1391		10.1126/science.1124495	http://dx.doi.org/10.1126/science.1124495			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527962				2022-12-28	WOS:000236029400028
J	Spahn, F; Schmidt, J; Albers, N; Horning, M; Makuch, M; Seiss, M; Kempf, S; Srama, R; Dikarev, V; Helfert, S; Moragas-Klostermeyer, G; Krivov, AV; Sremcevic, M; Tuzzolino, AJ; Economou, T; Grun, E				Spahn, F; Schmidt, J; Albers, N; Horning, M; Makuch, M; Seiss, M; Kempf, S; Srama, R; Dikarev, V; Helfert, S; Moragas-Klostermeyer, G; Krivov, AV; Sremcevic, M; Tuzzolino, AJ; Economou, T; Grun, E			Cassini dust measurements at Enceladus and implications for the origin of the E ring	SCIENCE			English	Article							SATURNS E-RING; PLANETARY SATELLITES; DYNAMICS; CLOUDS; PARTICLES; PLASMA		Univ Potsdam, Inst Phys, D-14469 Potsdam, Germany; Max Planck Inst Kernphys, D-69117 Heidelberg, Germany; Univ Jena, Inst Astrophys, D-07745 Jena, Germany; Univ Hawaii, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA; Univ Colorado, Atmospher & Space Phys Lab, Boulder, CO 80303 USA; Univ Chicago, Lab Astrophys & Space Res, Chicago, IL 60637 USA	University of Potsdam; Max Planck Society; Friedrich Schiller University of Jena; University of Hawaii System; University of Colorado System; University of Colorado Boulder; University of Chicago	Schmidt, J (corresponding author), Univ Potsdam, Inst Phys, Neuen Palais 10,Haus 19, D-14469 Potsdam, Germany.	jschmidt@agnld.uni-potsdam.de	Hörning, Marcel/F-4375-2010; Spahn, Frank/AAP-6234-2020	Hörning, Marcel/0000-0001-8934-048X; KEMPF, SASCHA/0000-0001-5236-3004				COLWELL JE, 1993, ICARUS, V106, P536, DOI 10.1006/icar.1993.1191; Dikarev VV, 1999, ASTRON ASTROPHYS, V346, P1011; Dougherty MK, 2006, SCIENCE, V311, P1406, DOI 10.1126/science.1120985; HAFF PK, 1983, ICARUS, V56, P426, DOI 10.1016/0019-1035(83)90164-1; HAMILTON DP, 1994, SCIENCE, V264, P550, DOI 10.1126/science.264.5158.550; Hansen CJ, 2006, SCIENCE, V311, P1422, DOI 10.1126/science.1121254; HORANYI M, 1992, ICARUS, V97, P248, DOI 10.1016/0019-1035(92)90131-P; Juhasz A, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020999; Kargel JS, 1996, ICARUS, V119, P385, DOI 10.1006/icar.1996.0026; Krivov AV, 2003, PLANET SPACE SCI, V51, P251, DOI 10.1016/S0032-0633(02)00147-2; Kruger H, 1999, NATURE, V399, P558, DOI 10.1038/21136; Nicholson PD, 1996, SCIENCE, V272, P509, DOI 10.1126/science.272.5261.509; Porco CC, 2006, SCIENCE, V311, P1393, DOI 10.1126/science.1123013; SHOWALTER MR, 1991, ICARUS, V94, P451, DOI 10.1016/0019-1035(91)90241-K; Spahn F, 1999, J GEOPHYS RES-PLANET, V104, P24111, DOI 10.1029/1999JE001031; Spencer JR, 2006, SCIENCE, V311, P1401, DOI 10.1126/science.1121661; Srama R, 2004, SPACE SCI REV, V114, P465, DOI 10.1007/s11214-004-1435-z; Sremcevic M, 2005, PLANET SPACE SCI, V53, P625, DOI 10.1016/j.pss.2004.10.001; Sremcevic M, 2003, PLANET SPACE SCI, V51, P455, DOI 10.1016/S0032-0633(03)00050-3; Waite JH, 2006, SCIENCE, V311, P1419, DOI 10.1126/science.1121290	20	213	214	3	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2006	311	5766					1416	1418		10.1126/science.1121375	http://dx.doi.org/10.1126/science.1121375			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16527969	Green Submitted			2022-12-28	WOS:000236029400035
J	Barlogie, B; Tricot, G; Anaissie, E; Shaughnessy, J; Rasmussen, E; van Rhee, F; Fassas, A; Zangari, M; Hollmig, K; Pineda-Roman, M; Lee, C; Talamo, G; Thertulien, R; Kiwan, E; Krishna, S; Fox, M; Crowley, J				Barlogie, B; Tricot, G; Anaissie, E; Shaughnessy, J; Rasmussen, E; van Rhee, F; Fassas, A; Zangari, M; Hollmig, K; Pineda-Roman, M; Lee, C; Talamo, G; Thertulien, R; Kiwan, E; Krishna, S; Fox, M; Crowley, J			Thalidomide and hematopoietic-cell transplantation for multiple myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AUTOLOGOUS TRANSPLANTATION; PLUS DEXAMETHASONE; RANDOMIZED-TRIAL; ORAL MELPHALAN; THERAPY; BORTEZOMIB; CHEMOTHERAPY; COMBINATION; DOXORUBICIN; PREDNISONE	BACKGROUND: High-dose therapy with melphalan can prolong survival among patients with multiple myeloma. We assessed whether the addition of thalidomide, which has activity against advanced and refractory myeloma, would further improve survival. METHODS: Between October 1998 and February 2004, 668 patients with newly diagnosed multiple myeloma received two cycles of intensive melphalan-based chemotherapy, each supported by autologous hematopoietic stem-cell transplantation. A total of 323 were randomly assigned to receive thalidomide from the outset until disease progression or undue adverse effects, and 345 did not receive thalidomide. The primary end point was the five-year event-free survival rate. Secondary end points were complete response and overall survival. RESULTS: After a median follow-up of 42 months among survivors, the thalidomide and control groups had rates of complete response of 62 percent and 43 percent, respectively (P<0.001), and five-year event-free survival rates of 56 percent and 44 percent (P=0.01). The five-year rate of overall survival was approximately 65 percent in both groups (P=0.90). Median survival after relapse was 1.1 years in the thalidomide group and 2.7 years in the control group (P=0.001). Severe peripheral neuropathy and deep-vein thrombosis occurred more frequently in the thalidomide group than in the control group. CONCLUSIONS: When incorporated into high-dose therapy for myeloma, thalidomide increased the frequency of complete responses and extended event-free survival at the expense of added adverse effects without improving overall survival.	Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA; Univ Washington, Canc Res & Biostat, Seattle, WA 98195 USA	University of Arkansas System; University of Arkansas Medical Sciences; Cancer Research & Biostatistics; University of Washington; University of Washington Seattle	Barlogie, B (corresponding author), Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, 4301 W Markham St,Mail Slot 816, Little Rock, AR 72205 USA.	barlogiebart@uams.edu	Krishna, Somashekar G/V-2593-2019; Krishna, Somashekar/F-1331-2014; Krishna, Somashekar/AAH-7145-2019	Krishna, Somashekar G/0000-0001-5748-7890; Krishna, Somashekar/0000-0001-5748-7890	NCI NIH HHS [CA55819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055819] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANIAN R, 2004, BLOOD, V104, pA98; Attal M, 2004, BLOOD, V104, p155A; Attal M, 2004, NEW ENGL J MED, V350, P1467; Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204; Barlogie B, 2004, BLOOD, V103, P20, DOI 10.1182/blood-2003-04-1045; BARLOGIE B, 1989, ANN INTERN MED, V110, P521, DOI 10.7326/0003-4819-110-7-521; Barlogie B, 1997, BLOOD, V89, P789, DOI 10.1182/blood.V89.3.789; BARLOGIE B, 1985, J CLIN INVEST, V76, P765, DOI 10.1172/JCI112033; Barlogie B, 2001, BLOOD, V98, P492, DOI 10.1182/blood.V98.2.492; BARLOGIE B, 1984, NEW ENGL J MED, V310, P1353, DOI 10.1056/NEJM198405243102104; Barlogie B, 2005, WILLIAMS HEMATOLOGY, P1501; Cavo M, 2005, HAEMATOLOGICA, V90, P39; Child JA, 2003, NEW ENGL J MED, V348, P1875, DOI 10.1056/NEJMoa022340; COX DR, 1972, J R STAT SOC B, V34, P187; CROWLEY J, 1994, STAT MED, V13, P1391, DOI 10.1002/sim.4780131314; FASSAS A, 2004, BLOOOD, V104, P924; Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O; Greipp PR, 2005, J CLIN ONCOL, V23, P6281, DOI 10.1200/JCO.2005.07.904; Greipp PR, 2005, J CLIN ONCOL, V23, P3412, DOI 10.1200/JCO.2005.04.242; Harousseau JL, 2004, BLOOD, V104, p416A, DOI 10.1182/blood.V104.11.1490.1490; Jagannath S, 2005, BRIT J HAEMATOL, V129, P776, DOI 10.1111/j.1365-2141.2005.05540.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lee CK, 2003, J CLIN ONCOL, V21, P2732, DOI 10.1200/JCO.2003.01.055; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Orlowski RZ, 2005, BLOOD, V105, P3058, DOI 10.1182/blood-2004-07-2911; Palumbo A, 2005, CANCER-AM CANCER SOC, V104, P1428, DOI 10.1002/cncr.21342; Palumbo A, 2004, BLOOD, V104, p63A, DOI 10.1182/blood.V104.11.207.207; Rajkumar SV, 2002, J CLIN ONCOL, V20, P4319, DOI 10.1200/JCO.2002.02.116; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Richardson PG, 2002, BLOOD, V100, P3063, DOI 10.1182/blood-2002-03-0996; Sawyers CL, 2005, NAT MED, V11, P824, DOI 10.1038/nm0805-824; Shaughnessy J, 2003, BRIT J HAEMATOL, V120, P44, DOI 10.1046/j.1365-2141.2003.03948.x; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102; Singhal S, 2000, NEW ENGL J MED, V342, P364; Weber D, 2003, J CLIN ONCOL, V21, P16, DOI 10.1200/JCO.2003.03.139; Zangari M, 2002, BLOOD, V100, P1168, DOI 10.1182/blood-2002-01-0335	36	574	594	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 9	2006	354	10					1021	1030		10.1056/NEJMoa053583	http://dx.doi.org/10.1056/NEJMoa053583			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	019FY	16525139				2022-12-28	WOS:000235822200006
J	Darst, CR; Cummings, ME				Darst, CR; Cummings, ME			Predator learning favours mimicry of a less-toxic model in poison frogs	NATURE			English	Article							EVOLUTION; DISTASTEFULNESS; SPECIALIZATION; COLOR	Batesian mimicry-resemblance of a toxic model by an edible mimic-depends on deceiving predators(1). Mimetic advantage is considered to be dependent on frequency because an increase in mimic abundance leads to breakdown of the warning signal(2,3). Where multiple toxic species are available, batesian polymorphism(4) is predicted-that is, mimics diversify to match sympatric models. Despite the prevalence of batesian mimicry in nature(5), batesian polymorphism is relatively rare(6). Here we explore a poison-frog mimicry complex comprising two parapatric models and a geographically dimorphic mimic that shows monomorphism where models co-occur. Contrary to classical predictions, our toxicity assays, field observations and spectral reflectances show that mimics resemble the less-toxic and less-abundant model. We examine "stimulus generalization"(7) as a mechanism for this non-intuitive result with learning experiments using naive avian predators and live poison frogs. We find that predators differ in avoidance generalization depending on toxicity of the model, conferring greater protection to mimics resembling the less-toxic model owing to overlap of generalized avoidance curves. Our work supports a mechanism of toxicity-dependent stimulus generalization(8), revealing an additional solution for batesian mimicry where multiple models coexist.	Univ Texas, Sect Integrat Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Darst, CR (corresponding author), Univ Texas, Sect Integrat Biol, 1 Univ Stn, Austin, TX 78712 USA.	catdarst@mail.utexas.edu						Bates H.W., 1862, T LINN SOC LOND, V23, P495; BRODIE ED, 1980, SCIENCE, V208, P181, DOI 10.1126/science.208.4440.181; BROWER JV, 1960, AM NAT, V94, P271, DOI 10.1086/282128; BROWER LP, 1962, ECOLOGY, V43, P154; Daly M, 1999, ONCOLOGY-NY, V13, P161; Darst CR, 2005, AM NAT, V165, P56, DOI 10.1086/426599; DUNCAN C. J., 1965, BEHAVIOUR, V24, P269, DOI 10.1163/156853965X00066; Edmunds M, 2000, BIOL J LINN SOC, V70, P459; EDMUNDS M, 1974, DEFENCE ANIMALS; ENDLER JA, 1990, BIOL J LINN SOC, V41, P315, DOI 10.1111/j.1095-8312.1990.tb00839.x; Fisher R.A., 1930, GENETICAL THEORY NAT; Ford EB, 1971, ECOLOGICAL GENETICS; FROST DR, 2004, AMPHIBIAN SPECIES WO; GOODALE MA, 1977, ANIM BEHAV, V25, P660, DOI 10.1016/0003-3472(77)90117-8; GREENE HW, 1981, SCIENCE, V213, P1207, DOI 10.1126/science.213.4513.1207; Johnstone RA, 2002, NATURE, V418, P524, DOI 10.1038/nature00845; Joron M, 1998, TRENDS ECOL EVOL, V13, P461, DOI 10.1016/S0169-5347(98)01483-9; Lindstrom L, 1997, P ROY SOC B-BIOL SCI, V264, P149, DOI 10.1098/rspb.1997.0022; Master Terry L., 1998, Herpetological Review, V29, P164; Osorio D, 1999, J EXP BIOL, V202, P2951; Pavlov I.P., 1927, CONDITIONED REFLEXES; Santos JC, 2003, P NATL ACAD SCI USA, V100, P12792, DOI 10.1073/pnas.2133521100; *SAS I, 2000, JMP STAT GRPH GUID V; Sherratt TN, 2002, BEHAV ECOL, V13, P821, DOI 10.1093/beheco/13.6.821; Sokal R. R., 1981, BIOMETRY; TURNER JRG, 1987, ECOL ENTOMOL, V12, P81, DOI 10.1111/j.1365-2311.1987.tb00987.x; Wallace A.R., 1865, T LINN SOC LOND, V1, P1, DOI [10.1111/j.1096-3642.1865.tb00178.x, DOI 10.1111/J.1096-3642.1865.TB00178.X]	27	125	130	1	127	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2006	440	7081					208	211		10.1038/nature04297	http://dx.doi.org/10.1038/nature04297			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019MC	16525472	Bronze			2022-12-28	WOS:000235839500045
J	Piaggio, G; Elbourne, DR; Altman, DG; Pocock, SJ; Evans, SJW				Piaggio, G; Elbourne, DR; Altman, DG; Pocock, SJ; Evans, SJW		CONSORT Grp	Reporting of noninferiority and equivalence randomized trials - An extension of the CONSORT Statement	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NON-INFERIORITY; CLINICAL-TRIALS; DESIGN; REGIMENS; QUALITY; ISSUES; ADULTS; INTERVENTION; PREVENTION; ZIDOVUDINE	The CONSORT (Consolidated Standards of Reporting Trials) Statement, including a checklist and a flow diagram, was developed to help authors improve their reporting of randomized controlled trials. Its primary focus was on individually randomized trials with 2 parallel groups that assess the possible superiority of one treatment compared with another but is now being extended to other trial designs. Noninferiority and equivalence trials have methodological features that differ from superiority trials and present particular difficulties in design, conduct, analysis, and interpretation. Although the rationale for such trials occurs frequently, those designed and described specifically as noninferiority or equivalence trials appear less commonly in the medical literature. The quality of reporting of those that are published is often inadequate. In this article, we present an adapted CONSORT checklist for reporting noninferiority and equivalence trials and provide illustrative examples and explanations for those items amended from the original CONSORT checklist. The intent is to improve reporting of noninferiority and equivalence trials, enabling readers to assess the validity of their results and conclusions.	WHO, Dept Reprod Hlth & Res, Stat & Informat Serv Grp, CH-1211 Geneva 27, Switzerland; London Sch Hyg & Trop Med, Med Stat Unit, London WC1, England; Ctr Stat Med, Oxford, England	World Health Organization; University of London; London School of Hygiene & Tropical Medicine; University of Oxford	Piaggio, G (corresponding author), WHO, Dept Reprod Hlth & Res, Stat & Informat Serv Grp, CH-1211 Geneva 27, Switzerland.	piaggiog@who.int		Evans, Stephen/0000-0002-1474-2596				Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Bernard P, 2002, BMJ-BRIT MED J, V325, P864, DOI 10.1136/bmj.325.7369.864; Brittain E, 2005, STAT MED, V24, P1, DOI 10.1002/sim.1934; Campbell MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702; CARLIER C, 1993, BRIT MED J, V307, P1106, DOI 10.1136/bmj.307.6912.1106; Chadwick D, 1999, LANCET, V354, P13, DOI 10.1016/S0140-6736(98)10531-7; Chan FKL, 2001, NEW ENGL J MED, V344, P967, DOI 10.1056/NEJM200103293441304; Committee for Proprietary Medicnal Products, 2004, NOT GUID EV MED PROD; Costa LJM, 2004, CONTROL CLIN TRIALS, V25, P525, DOI 10.1016/j.cct.2004.08.001; D'Agostino RB, 2003, STAT MED, V22, P169, DOI 10.1002/sim.1425; DETSKY AS, 1985, ARCH INTERN MED, V145, P709, DOI 10.1001/archinte.145.4.709; Devereaux PJ, 2002, CONTROL CLIN TRIALS, V23, P380, DOI 10.1016/S0197-2456(02)00214-3; Dimick JB, 2001, ARCH SURG-CHICAGO, V136, P796, DOI 10.1001/archsurg.136.7.796; Djulbegovic B, 2001, JAMA-J AM MED ASSOC, V285, P1206, DOI 10.1001/jama.285.9.1206; DUNNETT CW, 1977, BIOMETRICS, V33, P593, DOI 10.2307/2529457; Dunnett CW, 1996, STAT MED, V15, P1729; Durkalski VL, 2002, CONTROL CLIN TRIALS, V23, P570, DOI 10.1016/S0197-2456(02)00232-5; DURRLEMAN S, 1990, BIOMETRICS, V46, P329, DOI 10.2307/2531438; Egger M, 2003, Health Technol Assess, V7, P1; Egger M, 2001, JAMA-J AM MED ASSOC, V285, P1996, DOI 10.1001/jama.285.15.1996; Elbourne D, 2002, LANCET, V360, P2009, DOI 10.1016/S0140-6736(02)12024-1; *EMEA, 2004, POINTS CONS CHOIC NO; EMEA (European Agency for the Evaluation of Medicinal Products-Committee for Proprietary Medicinal Products), 2000, POINTS CONS SWITCH S; Ferguson JJ, 2004, JAMA-J AM MED ASSOC, V292, P45; FLEISS JL, 1992, J PERIODONTAL RES, V27, P306, DOI 10.1111/j.1600-0765.1992.tb01684.x; Greene WL, 2000, ANN INTERN MED, V132, P715, DOI 10.7326/0003-4819-132-9-200005020-00006; Gulmezoglu AM, 2001, LANCET, V358, P689, DOI 10.1016/S0140-6736(01)05835-4; Gunnell D, 2005, BMJ-BRIT MED J, V330, P385, DOI 10.1136/bmj.330.7488.385; Halperin JL, 2003, AM HEART J, V146, P431, DOI 10.1016/S0002-8703(03)00325-9; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; *ICH STEER COMM, 2000, HARM TRIP GUID CHOIC; ICH Steering Committee, 1998, STAT PRINC CLIN TRIA; Ioannidis JPA, 2004, ANN INTERN MED, V141, P781, DOI 10.7326/0003-4819-141-10-200411160-00009; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Kapur A, 2005, AM HEART J, V149, P13, DOI 10.1016/j.ahj.2004.07.001; Kim MY, 2001, STAT MED, V20, P2065, DOI 10.1002/sim.847; Krysan DJ, 2002, PEDIATR INFECT DIS J, V21, P753, DOI 10.1097/00006454-200208000-00011; Lallemant M, 2000, NEW ENGL J MED, V343, P982, DOI 10.1056/NEJM200010053431401; Lewis JA, 2002, STAT MED, V21, P2931, DOI 10.1002/sim.1297; Lincoff AM, 2003, JAMA-J AM MED ASSOC, V289, P853, DOI 10.1001/jama.289.7.853; McAlister FA, 2001, AM J MED, V111, P553, DOI 10.1016/S0002-9343(01)00900-7; MOHER D, 1994, JAMA-J AM MED ASSOC, V272, P122, DOI 10.1001/jama.272.2.122; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1992, DOI 10.1001/jama.285.15.1992; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Nelson H, 2004, NEW ENGL J MED, V350, P2050; Piaggio G, 2001, STAT MED, V20, P3571, DOI 10.1002/sim.1078; POCOCK SJ, 2000, SCI PLACEBO INTERDIS, P236; Prandoni P, 2002, ARCH INTERN MED, V162, P1966, DOI 10.1001/archinte.162.17.1966; Rothman KJ, 1996, BMJ-BRIT MED J, V313, P3, DOI 10.1136/bmj.313.7048.3a; ROTHMAN KJ, 1986, ANN INTERN MED, V105, P445, DOI 10.7326/0003-4819-105-3-445; Rothmann M, 2003, STAT MED, V22, P239, DOI 10.1002/sim.1400; Sackett David L, 2004, ACP J Club, V140, pA11; Schulz KF, 1996, LANCET, V348, P596, DOI 10.1016/S0140-6736(96)01201-9; SENN S, 2002, STAT ISSUES DRUG DEV, P207; Smyth A, 2005, LANCET, V365, P573, DOI 10.1016/S0140-6736(05)17906-9; Staszewski S, 2001, JAMA-J AM MED ASSOC, V285, P1155, DOI 10.1001/jama.285.9.1155; Tamayo-Sarver JH, 2005, ACAD EMERG MED, V12, P536, DOI 10.1197/j.aem.2005.01.010; Topol EJ, 2001, NEW ENGL J MED, V344, P1888, DOI 10.1056/NEJM200106213442502; Van de Werf F, 1999, LANCET, V354, P716, DOI 10.1016/S0140-6736(99)07403-6; Villar J, 2001, LANCET, V357, P1551, DOI 10.1016/S0140-6736(00)04722-X; von Hertzen H, 2002, LANCET, V360, P1803, DOI 10.1016/S0140-6736(02)11767-3; WELLEK S, 2003, TEST STAT HYP EQ; Wiens BL, 2002, CONTROL CLIN TRIALS, V23, P2, DOI 10.1016/S0197-2456(01)00196-9; 2004, COCHRANE LIB	66	952	977	0	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	2006	295	10					1152	1160		10.1001/jama.295.10.1152	http://dx.doi.org/10.1001/jama.295.10.1152			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	019GB	16522836	Green Accepted			2022-12-28	WOS:000235822500024
J	Weinberger, SE				Weinberger, SE			Update in pulmonary medicine	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							FIBROSIS; THERAPY		Amer Coll Physicians, Med Knowledge & Educ Div, Philadelphia, PA 19106 USA	American College of Physicians	Weinberger, SE (corresponding author), Amer Coll Physicians, Med Knowledge & Educ Div, 190 N Independence Mall W, Philadelphia, PA 19106 USA.	sweinberger@acponline.org						Cookson W, 2004, NEW ENGL J MED, V351, P1794, DOI 10.1056/NEJMe048232; Flaherty KR, 2001, AM J MED, V110, P278, DOI 10.1016/S0002-9343(00)00711-7; Selman M, 2001, ANN INTERN MED, V134, P136, DOI 10.7326/0003-4819-134-2-200101160-00015; van Beek EJR, 2001, CLIN RADIOL, V56, P838, DOI 10.1053/crad.2001.0778; Ziesche R, 1999, NEW ENGL J MED, V341, P1264, DOI 10.1056/NEJM199910213411703	5	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 7	2006	144	5					358	363		10.7326/0003-4819-144-5-200603070-00012	http://dx.doi.org/10.7326/0003-4819-144-5-200603070-00012			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	021EA	16520477				2022-12-28	WOS:000235965300007
J	Park, T; Ronning, F; Yuan, HQ; Salamon, MB; Movshovich, R; Sarrao, JL; Thompson, JD				Park, T; Ronning, F; Yuan, HQ; Salamon, MB; Movshovich, R; Sarrao, JL; Thompson, JD			Hidden magnetism and quantum criticality in the heavy fermion superconductor CeRhIn5	NATURE			English	Article							HIGH-TEMPERATURE SUPERCONDUCTOR; UNCONVENTIONAL SUPERCONDUCTIVITY; ANTIFERROMAGNETIC ORDER; PRESSURE; FIELD; SPIN	With only a few exceptions that are well understood, conventional superconductivity does not coexist with long-range magnetic order ( for example, ref. 1). Unconventional superconductivity, on the other hand, develops near a phase boundary separating magnetically ordered and magnetically disordered phases(2,3). A maximum in the superconducting transition temperature T-c develops where this boundary extrapolates to zero Kelvin, suggesting that fluctuations associated with this magnetic quantum-critical point are essential for unconventional superconductivity(4,5). Invariably, though, unconventional superconductivity masks the magnetic phase boundary when T < T-c, preventing proof of a magnetic quantum-critical point(5). Here we report specific-heat measurements of the pressure-tuned unconventional superconductor CeRhIn5 in which we find a line of quantum-phase transitions induced inside the superconducting state by an applied magnetic field. This quantum-critical line separates a phase of coexisting antiferromagnetism and superconductivity from a purely unconventional superconducting phase, and terminates at a quantum tetracritical point where the magnetic field completely suppresses superconductivity. The T --> 0 K magnetic field - pressure phase diagram of CeRhIn5 is well described with a theoretical model(6,7) developed to explain field-induced magnetism in the high-T-c copper oxides, but in which a clear delineation of quantum - phase boundaries has not been possible. These experiments establish a common relationship among hidden magnetism, quantum criticality and unconventional superconductivity in copper oxides and heavy-electron systems such as CeRhIn5.	Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Univ Illinois, Dept Phys, Urbana, IL 61801 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; University of Illinois System; University of Illinois Urbana-Champaign	Park, T (corresponding author), Los Alamos Natl Lab, POB 1663, Los Alamos, NM 87545 USA.	tuson@lanl.gov	Park, Tuson/A-1520-2012	Movshovich, Roman/0000-0002-3667-634X; Ronning, Filip/0000-0002-2679-7957; Park, Tuson/0000-0003-2974-8410				Bao W, 2000, PHYS REV B, V62, P14621, DOI 10.1103/PhysRevB.62.R14621; Coleman P, 2005, NATURE, V433, P226, DOI 10.1038/nature03279; Cornelius AL, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.144411; Curro NJ, 2005, NATURE, V434, P622, DOI 10.1038/nature03428; Demler E, 2004, REV MOD PHYS, V76, P909, DOI 10.1103/RevModPhys.76.909; Demler E, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.067202; Fisher RA, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.224509; Fujita M, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.014514; Hegger H, 2000, PHYS REV LETT, V84, P4986, DOI 10.1103/PhysRevLett.84.4986; Kang HJ, 2003, NATURE, V423, P522, DOI 10.1038/nature01641; Khaykovich B, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.220508; Knebel G, 2004, J PHYS-CONDENS MAT, V16, P8905, DOI 10.1088/0953-8984/16/49/008; Lake B, 2001, SCIENCE, V291, P1759, DOI 10.1126/science.1056986; Lake B, 2002, NATURE, V415, P299, DOI 10.1038/415299a; Lefebvre S, 2000, PHYS REV LETT, V85, P5420, DOI 10.1103/PhysRevLett.85.5420; Llobet A, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.024403; Mathur ND, 1998, NATURE, V394, P39, DOI 10.1038/27838; Mito T, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.077004; Moriya T, 2003, REP PROG PHYS, V66, P1299, DOI 10.1088/0034-4885/66/8/202; Muller KH, 2001, REP PROG PHYS, V64, P943, DOI 10.1088/0034-4885/64/8/202; Nicklas M, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.020505; Panagopoulos C, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.064501; Shishido H, 2005, J PHYS SOC JPN, V74, P1103, DOI 10.1143/JPSJ.74.1103; Si QM, 2001, NATURE, V413, P804, DOI 10.1038/35101507; Zhang Y, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.094501	25	363	365	3	126	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	2006	440	7080					65	68		10.1038/nature04571	http://dx.doi.org/10.1038/nature04571			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017HW	16511490	Green Submitted			2022-12-28	WOS:000235685700039
J	Heymann, DL				Heymann, DL			Resistance to anti-infective drugs and the threat to public health	CELL			English	Editorial Material								Increasing resistance of pathogens to anti-infective drugs is an urgent public health problem that must be addressed through more prudent use of these drugs in human medicine and in animal husbandry, agriculture, and aquaculture.	WHO, CH-1211 Geneva 27, Switzerland	World Health Organization	Heymann, DL (corresponding author), WHO, CH-1211 Geneva 27, Switzerland.	heymannd@who.int						[Anonymous], 2001, WHO GLOB STRAT CONT; Armstrong GL, 1999, JAMA-J AM MED ASSOC, V281, P61, DOI 10.1001/jama.281.1.61; *CDC, 2005, HIGH LEV AD RES AM I; Cosgrove SE, 2006, CLIN INFECT DIS, V42, pS82, DOI 10.1086/499406; Curtis V, 2003, LANCET INFECT DIS, V3, P275, DOI 10.1016/S1473-3099(03)00606-6; de Jong MD, 2005, NEW ENGL J MED, V353, P2667, DOI 10.1056/NEJMoa054512; Dye C, 2002, J INFECT DIS, V185, P1197, DOI 10.1086/339818; Escoto-Delgadillo M, 2005, HIV MED, V6, P403, DOI 10.1111/j.1468-1293.2005.00326.x; HEYMANNDL, 2004, NEW ENGL J MED, V351, P1275; Jezek Z, 1988, HUMAN MONKEYPOX; Jung M, 2004, CURR MED CHEM, V11, P1265, DOI 10.2174/0929867043365233; Kondro W, 1997, LANCET, V349, P1156, DOI 10.1016/S0140-6736(05)63043-7; Levy Stuart B., 1992, ANTIBIOTIC PARADOX M; *NAS, 1998, US EPA ANT RES ISS O, P53; Suttajit Siritree, 2005, Southeast Asian Journal of Tropical Medicine and Public Health, V36, P489; World Health Organization, 1999, REM OBST HLTH DEV	16	58	60	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 24	2006	124	4					671	675		10.1016/j.cell.2006.02.009	http://dx.doi.org/10.1016/j.cell.2006.02.009			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	038RO	16497576	Bronze			2022-12-28	WOS:000237240900009
J	Mendillo, M; Withers, P; Hinson, D; Rishbeth, H; Reinisch, B				Mendillo, M; Withers, P; Hinson, D; Rishbeth, H; Reinisch, B			Effects of solar flares on the ionosphere of Mars	SCIENCE			English	Article								All planetary atmospheres respond to the enhanced x-rays and ultraviolet (UV) light emitted from the Sun during a flare. Yet only on Earth are observations so continuous that the consequences of these essentially unpredictable events can be measured reliably. Here, we report observations of solar flares, causing up to 200% enhancements to the ionosphere of Mars, as recorded by the Mars Global Surveyor in April 2001. Modeling the attitude dependence of these effects requires that relative enhancements in the soft x-ray fluxes far exceed those in the UV.	Boston Univ, Ctr Space Phys, Boston, MA 02215 USA; Stanford Univ, Dept Elect Engn, Stanford, CA 94305 USA; Univ Southampton, Sch Phys & Astron, Southampton SO17 1BJ, Hants, England; Univ Massachusetts, Ctr Atmospher Res, Lowell, MA 01854 USA	Boston University; Stanford University; University of Southampton; University of Massachusetts System; University of Massachusetts Lowell	Withers, P (corresponding author), Boston Univ, Ctr Space Phys, Boston, MA 02215 USA.	withers@bu.edu	Mendillo, Michael/H-4397-2014; Withers, Paul/H-2241-2014	Hinson, David/0000-0002-1620-4011				Bhardwaj A, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021497; Bhardwaj A, 2005, ASTROPHYS J, V624, pL121, DOI 10.1086/430521; Bornmann PL, 1996, P SOC PHOTO-OPT INS, V2812, P309, DOI 10.1117/12.254078; CHAMBERLIN PC, 2005, 2005 AM GEOPH UN AGU; DONNELLY RF, 1971, SOL PHYS, V20, P188, DOI 10.1007/BF00146110; Fox JL, 2004, J GEOPHYS RES-SPACE, V109, DOI 10.1029/2004JA010380; Hinson DP, 1999, J GEOPHYS RES-PLANET, V104, P26997, DOI 10.1029/1999JE001069; Judge DL, 2002, ADV SPACE RES, V29, P1963, DOI 10.1016/S0273-1177(02)00251-X; Kohl H., 1996, MODERN IONOSPHERIC S, P440; Martinis CR, 2003, J GEOPHYS RES-SPACE, V108, DOI 10.1029/2003JA009973; Mendillo M, 2003, J GEOPHYS RES-SPACE, V108, DOI 10.1029/2003JA009961; Prange R, 2004, NATURE, V432, P78, DOI 10.1038/nature02986; Rishbeth H., 1969, INTRO IONOSPHERIC PH, VVolume 14; SCHUNK RW, 2000, IONOSPHERES; Thomson NR, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL019345	15	100	101	2	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	2006	311	5764					1135	1138		10.1126/science.1122099	http://dx.doi.org/10.1126/science.1122099			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017IU	16497929				2022-12-28	WOS:000235688100044
J	Weaver, HA; Stern, SA; Mutchler, MJ; Steffl, AJ; Buie, MW; Merline, WJ; Spencer, JR; Young, EF; Young, LA				Weaver, HA; Stern, SA; Mutchler, MJ; Steffl, AJ; Buie, MW; Merline, WJ; Spencer, JR; Young, EF; Young, LA			Discovery of two new satellites of Pluto	NATURE			English	Article							ADVANCED CAMERA; CHARON; CONSTRAINTS; PERFORMANCE; SIZE	Pluto's first known satellite, Charon, was discovered(1) in 1978. It has a diameter (similar to 1,200 km) about half that of Pluto(2-4,17), which makes it larger, relative to its primary, than any other moon in the Solar System. Previous searches for other satellites around Pluto have been unsuccessful(5-7), but they were not sensitive to objects less than or similar to 150 km in diameter and there are no fundamental reasons why Pluto should not have more satellites(6). Here we report the discovery of two additional moons around Pluto, provisionally designated S/2005 P1 (hereafter P1) and S/2005 P2 (hereafter P2), which makes Pluto the first Kuiper belt object known to have multiple satellites. These new satellites are much smaller than Charon, with estimates of P1's diameter ranging from 60 km to 165 km, depending on the surface reflectivity; P2 is about 20 per cent smaller than P1. Although definitive orbits cannot be derived, both new satellites appear to be moving in circular orbits in the same orbital plane as Charon, with orbital periods of similar to 38 days (P1) and similar to 25 days (P2).	Johns Hopkins Univ, Appl Phys Lab, Dept Space, Laurel, MD 20723 USA; SW Res Inst, Dept Space Studies, Boulder, CO 80302 USA; Lowell Observ, Flagstaff, AZ 86001 USA; Space Telescope Sci Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; Space Telescope Science Institute	Weaver, HA (corresponding author), Johns Hopkins Univ, Appl Phys Lab, Dept Space, 11100 Johns Hopkins Rd, Laurel, MD 20723 USA.	hal.weaver@jhuapl.edu	Weaver, Harold A/D-9188-2016	Weaver, Harold A/0000-0003-0951-7762; Mutchler, Maximilian/0000-0002-0088-3021				Allen C. W., 1976, ASTROPHYSICAL QUANTI; Bernstein GM, 2004, ASTRON J, V128, P1364, DOI 10.1086/422919; BUIE MW, 1992, ICARUS, V97, P211, DOI 10.1016/0019-1035(92)90129-U; CHRISTY JW, 1978, ASTRON J, V83, P1005, DOI 10.1086/112284; Gulbis AAS, 2006, NATURE, V439, P48, DOI 10.1038/nature04276; Hartig GF, 2003, P SOC PHOTO-OPT INS, V4854, P532, DOI 10.1117/12.459787; Lamy PL, 2004, SPACE SCI S, P223; MARCIALIS RL, 1992, ASTRON J, V103, P1389, DOI 10.1086/116153; Russell HN, 1916, ASTROPHYS J, V43, P103, DOI 10.1086/142237; Sicardy B, 2006, NATURE, V439, P52, DOI 10.1038/nature04351; Sirianni M, 2005, PUBL ASTRON SOC PAC, V117, P1049, DOI 10.1086/444553; STEFFL AJ, UNPUB ASTRON J; STERN SA, 1991, ICARUS, V94, P246, DOI 10.1016/0019-1035(91)90154-L; STERN SA, 1994, ICARUS, V108, P234, DOI 10.1006/icar.1994.1058; STERN SA, 2003, LUNAR PLANET I C, V34; Young L.A, 1994, THESIS MIT	16	103	104	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 23	2006	439	7079					943	945		10.1038/nature04547	http://dx.doi.org/10.1038/nature04547			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014NE	16495991				2022-12-28	WOS:000235486100039
J	Buscemi, N; Vandermeer, B; Hooton, N; Pandya, R; Tjosvold, L; Hartling, L; Vohra, S; Klassen, TP; Baker, G				Buscemi, N; Vandermeer, B; Hooton, N; Pandya, R; Tjosvold, L; Hartling, L; Vohra, S; Klassen, TP; Baker, G			Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PLACEBO-CONTROLLED TRIAL; JET-LAG; METHODOLOGICAL QUALITY; NIGHT-SHIFT; BIAS; ALLEVIATION; CHILDREN; MOOD	Objective To conduct a systematic review of the efficacy and safety of exogenous melatonin in managing secondary sleep disorders and sleep disorders accompanying sleep restriction, such as jet lag and shiftwork disorder. Data sources 13 electronic databases and reference lists of relevant reviews and included Studies; Associated Professional Steel) Society abstracts (1999 to 2003). Study selection The efficacy review included randomised controlled trials; die safety review included randomised and non-randomised controlled trials. Quality assessment Randomised controlled trials were assessed by using the Jadad Scale and criteria by Schulz et al, and non-randomised controlled trials by the Downs and Black checklist. Data extraction and synthesis One reviewer extracted data and another reviewer verified the data extracted. The inverse variance method was Used to weight studies and the random effects model was used to analyse data. Main results Six randomised controlled trials with 97 participants showed no evidence that melatonin had an effect on sleep onset latency in people with secondary sleep disorders (weighted mean difference - 13.2 (95% confidence interval - 27.3 to 0.9) min). Nine randomised controlled trials with 427 participants showed no evidence that melatonin had an effect on sleep onset latency in people who had sleep disorders accompanying sleep restriction (- 1.0 2.3 to 0.3) min). 17 randomised controlled trials with 651 participants showed no evidence of adverse effects of melatonin with short term use (three months or less). Conclusions There is no evidence that melatonin is effective in treating secondary steel) disorders or sleep disorders accompanying sleep restriction, such as jet lag and shiftwork disorder. There is evidence that melatonin is safe with short term use.	Univ Alberta, Capital Hlth Evidence Based Practice Ctr, Dept Pediat, Edmonton, AB T6G 2J3, Canada; Univ Alberta, Complementary & Alternat Res & Educ Program, Dept Pediat, Edmonton, AB T6G 2J3, Canada; Univ Alberta, Dept Psychiat, Edmonton, AB T6G 2J3, Canada	University of Alberta; University of Alberta; University of Alberta	Buscemi, N (corresponding author), Univ Alberta, Capital Hlth Evidence Based Practice Ctr, Dept Pediat, Edmonton, AB T6G 2J3, Canada.	nina.buscemi@ualberta.ca	Vohra, Sunita/F-5755-2016	Vohra, Sunita/0000-0002-6210-7933; Klassen, Terry/0000-0002-5309-7091; Tjosvold, Lisa/0000-0002-5667-6312	PHS HHS [290-02-0023] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Beaumont M, 2004, J APPL PHYSIOL, V96, P50, DOI 10.1152/japplphysiol.00940.2002; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Camfield P, 1996, J CHILD NEUROL, V11, P341, DOI 10.1177/088307389601100414; CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204; Chase JE, 1997, ANN PHARMACOTHER, V31, P1218, DOI 10.1177/106002809703101015; CLAUSTRAT B, 1992, BIOL PSYCHIAT, V32, P705, DOI 10.1016/0006-3223(92)90300-O; Deeks JJ, 2001, SYSTEMATIC REV HLTH, P285, DOI DOI 10.1002/9780470693926.CH15; Dodge NN, 2001, J CHILD NEUROL, V16, P581, DOI 10.2310/7010.2001.16810; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529; Edwards BJ, 2000, ERGONOMICS, V43, P1501, DOI 10.1080/001401300750003934; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Elbourne DR, 2002, INT J EPIDEMIOL, V31, P140, DOI 10.1093/ije/31.1.140; FOLKARD S, 1993, CHRONOBIOL INT, V10, P315, DOI 10.3109/07420529309064485; Herxheimer A, 2002, COCHRANE DB SYST REV, V2, DOI [10.1002/14651858.CD001520, DOI 10.1002/14651858.CD001520]; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; James M, 1998, AM J EMERG MED, V16, P367, DOI 10.1016/S0735-6757(98)90129-2; James W., 1907, PHILOS REV, V16, P1, DOI DOI 10.2307/2177575; JAN JE, 1994, DEV MED CHILD NEUROL, V36, P97; Jean-Louis G, 1998, J PINEAL RES, V25, P177, DOI 10.1111/j.1600-079X.1998.tb00557.x; Jockovich M, 2000, ACAD EMERG MED, V7, P955, DOI 10.1111/j.1553-2712.2000.tb02082.x; Jorgensen KM, 1998, ANN EMERG MED, V31, P699, DOI 10.1016/S0196-0644(98)70227-6; McArthur AJ, 1998, DEV MED CHILD NEUROL, V40, P186; *NIH, 2003, NAT CTR SLEEP DIS RE; O'Callaghan FJK, 1999, DEV MED CHILD NEUROL, V41, P123, DOI 10.1017/S0012162299000237; PETRIE K, 1989, BRIT MED J, V298, P705, DOI 10.1136/bmj.298.6675.705; PETRIE K, 1993, BIOL PSYCHIAT, V33, P526, DOI 10.1016/0006-3223(93)90007-Z; Reiter RJ, 2003, BEST PRACT RES CL EN, V17, P273, DOI 10.1016/S1521-690X(03)00016-2; ROLLER L, 2002, AUST J PHARM, V83, P443; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Serfaty M, 2002, INT J GERIATR PSYCH, V17, P1120, DOI 10.1002/gps.760; SERFATY MA, 2003, BIOL MED RHYTHM RES, P1191; Shamir E, 2000, J CLIN PSYCHIAT, V61, P373, DOI 10.4088/JCP.v61n0509; Shamir E, 2000, J CLIN PSYCHOPHARM, V20, P691, DOI 10.1097/00004714-200012000-00017; Singer C, 2003, SLEEP, V26, P893, DOI 10.1093/sleep/26.7.893; Suhner A, 2001, AVIAT SPACE ENVIR MD, V72, P638; Suhner A, 1998, CHRONOBIOL INT, V15, P655, DOI 10.3109/07420529808993201; Sutton AJ, 2000, METHODS METAANALYSIS, P58; Vallieres A, 2003, SLEEP, V26, P902, DOI 10.1093/sleep/26.7.902; van Wieringen S, 2001, CLIN DRUG INVEST, V21, P813, DOI 10.2165/00044011-200121120-00003; WALDHAUSER F, 1990, PSYCHOPHARMACOLOGY, V100, P222, DOI 10.1007/BF02244410; Wright SW, 1998, ANN EMERG MED, V32, P334, DOI 10.1016/S0196-0644(98)70010-1	43	278	292	0	32	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 18	2006	332	7538					385	388C		10.1136/bmj.38731.532766.F6	http://dx.doi.org/10.1136/bmj.38731.532766.F6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	017HZ	16473858	Bronze, Green Published			2022-12-28	WOS:000235686000014
J	Berry, MA; Hargadon, B; Shelley, M; Parker, D; Shaw, DE; Green, RH; Bradding, P; Brightling, CE; Wardlaw, AJ; Pavord, ID				Berry, MA; Hargadon, B; Shelley, M; Parker, D; Shaw, DE; Green, RH; Bradding, P; Brightling, CE; Wardlaw, AJ; Pavord, ID			Evidence of a role of tumor necrosis factor alpha in refractory asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NITRIC-OXIDE; MAST-CELL; TNF-ALPHA; INFLAMMATION; INCREASES; CYTOKINES; AIRWAYS; FORM	BACKGROUND: The development of tumor necrosis factor alpha (TNF-alpha) antagonists has made it feasible to investigate the role of this cytokine in refractory asthma. METHODS: We measured markers of TNF-alpha activity on peripheral-blood monocytes in 10 patients with refractory asthma, 10 patients with mild-to-moderate asthma, and 10 control subjects. We also investigated the effects of treatment with the soluble TNF-alpha receptor etanercept (25 mg twice weekly) in the patients with refractory asthma in a placebo-controlled, double-blind, crossover pilot study. RESULTS: As compared with patients with mild-to-moderate asthma and controls, patients with refractory asthma had increased expression of membrane-bound TNF-alpha, TNF-alpha receptor 1, and TNF-alpha-converting enzyme by peripheral-blood monocytes. In the clinical trial, as compared with placebo, 10 weeks of treatment with etanercept was associated with a significant increase in the concentration of methacholine required to provoke a 20 percent decrease in the forced expiratory volume in one second (FEV1 (mean difference in doubling concentration changes between etanercept and placebo, 3.5; 95 percent confidence interval, 0.07 to 7.0; P=0.05), an improvement in the asthma-related quality-of-life score (by 0.85 point; 95 percent confidence interval, 0.16 to 1.54 on a 7-point scale; P=0.02), and a 0.32-liter increase in post-bronchodilator FEV1 (95 percent confidence interval, 0.08 to 0.55; P=0.01). CONCLUSIONS: Patients with refractory asthma have evidence of up-regulation of the TNF-alpha axis.	Glenfield Gen Hosp, Inst Lung Hlth, Univ Hosp Leicester Natl Hlth Serv Trust, Leicester LE3 9QP, Leics, England	University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital	Pavord, ID (corresponding author), Glenfield Gen Hosp, Inst Lung Hlth, Univ Hosp Leicester Natl Hlth Serv Trust, Groby Rd, Leicester LE3 9QP, Leics, England.	ian.pavord@uhl-tr.nhs.uk	shaw, dominick/N-1293-2014	shaw, dominick/0000-0003-4106-8469; Bradding, Peter/0000-0001-8403-0319; Pavord, Ian/0000-0002-4288-5973; brightling, chris/0000-0002-9345-4903; Wardlaw, Andrew/0000-0001-6583-0791				Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Amrani Y, 2000, Respir Res, V1, P49, DOI 10.1186/rr12; Armstrong L, 2000, AM J RESP CELL MOL, V22, P68, DOI 10.1165/ajrcmb.22.1.3728; Berry M, 2005, EUR RESPIR J, V25, P986, DOI 10.1183/09031936.05.00132404; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; Busse W, 1999, AM J RESP CRIT CARE, V160, P1035, DOI 10.1164/ajrccm.160.3.9902064; DAVIS JM, 1987, BIOCHEMISTRY-US, V26, P1322, DOI 10.1021/bi00379a018; Franchimont D, 1999, J CLIN ENDOCR METAB, V84, P2834, DOI 10.1210/jc.84.8.2834; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Juniper E, 1994, HISTAMINE METHACHOLI; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; KIPS JC, 1992, AM REV RESPIR DIS, V145, P332, DOI 10.1164/ajrccm/145.2_Pt_1.332; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; Marshall BG, 2000, EUR RESPIR J, V15, P764, DOI 10.1034/j.1399-3003.2000.15d22.x; National Heart Lung and Blood Institute Division of blood diseases and resources, 2002, NIH PUBL; Pellegrini JD, 1996, SHOCK, V6, P389, DOI 10.1097/00024382-199612000-00001; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Rouhani FN, 2005, RESP MED, V99, P1175, DOI 10.1016/j.rmed.2005.02.031; Serra-Batlles J, 1998, EUR RESPIR J, V12, P1322, DOI 10.1183/09031936.98.12061322; SMITH RA, 1987, J BIOL CHEM, V262, P6951; THOMAS PS, 1995, AM J RESP CRIT CARE, V152, P76, DOI 10.1164/ajrccm.152.1.7599866; Waserman S, 2000, Can Respir J, V7, P229; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Zheng YF, 2004, J BIOL CHEM, V279, P42898, DOI 10.1074/jbc.M403193200	29	627	660	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 16	2006	354	7					697	708		10.1056/NEJMoa050580	http://dx.doi.org/10.1056/NEJMoa050580			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	012CP	16481637				2022-12-28	WOS:000235316100006
J	Grey, JE; Enoch, S; Harding, KG				Grey, JE; Enoch, S; Harding, KG			ABC of wound healing - Venous and arterial leg ulcers	BRITISH MEDICAL JOURNAL			English	Editorial Material							ULCERATION ESCHAR; COMPRESSION; SURGERY; TRIAL		Cardiff & Vale NHS Trust, Univ Wales Hosp, Cardiff, Wales; Cardiff Univ, Wound Healing Res Unit, Cardiff, Wales; Royal Coll Surgeons England, London WC2A 3PN, England	Cardiff University; Cardiff University; Royal College of Surgeons of England	Grey, JE (corresponding author), Cardiff & Vale NHS Trust, Univ Wales Hosp, Cardiff, Wales.	joseph.grey@cardiffandvale.wales.nhs.uk	Harding, Keith/J-5605-2013	Harding, Keith/0000-0003-0048-3279				Barwell JR, 2004, LANCET, V363, P1854, DOI 10.1016/S0140-6736(04)16353-8; Burnand KG, 2005, NEW AIRDS COMPANION; Cullum N, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000265; Gohel MS, 2005, BRIT J SURG, V92, P291, DOI 10.1002/bjs.4837; Morris P, 2001, OXFORD TXB SURG; Nelson EA, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002303; Simon DA, 2004, BMJ-BRIT MED J, V328, P1358, DOI 10.1136/bmj.328.7452.1358; Williams D, 2005, WOUND REPAIR REGEN, V13, P131, DOI 10.1111/j.1067-1927.2005.130203.x	8	103	109	0	16	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 11	2006	332	7537					347	350		10.1136/bmj.332.7537.347	http://dx.doi.org/10.1136/bmj.332.7537.347			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	012YI	16470058	Green Published			2022-12-28	WOS:000235376400022
J	Latthe, P; Mignini, L; Gray, R; Hills, R; Khan, K				Latthe, P; Mignini, L; Gray, R; Hills, R; Khan, K			Factors predisposing women to chronic pelvic pain: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EXPLORING HETEROGENEITY; CIGARETTE-SMOKING; GENERAL-PRACTICE; METAANALYSIS; PREVALENCE; ASSOCIATION; LAPAROSCOPY; VARIABLES; QUALITY; DISEASE	Objective To evaluate factors predisposing women to chronic and recurrent pelvic pain. Design, data sources, and methods Systematic review Of relevant studies without language restrictions identified through Medline, Embase, PsycINFO, Cochrane Library, SCISEARCH, conference papers, and bibliographies of retrieved primary and review articles. Two reviewers independently extracted clam Oil study characteristics, quality and results.. Exposure to risk factors was compared between women with and without pelvic pain. Results were pooled within subgroups defined by type of pain and risk factors. Results There were 122 studies (in 111 articles) of which 63 (in 64 286 women) evaluated 54 risk factors for dysmenorrhoea, 19 (in 18 601 women) evaluated 14 risk factors for dyspareunia, and 40 (in 12 040 women) evaluated 48 factors for non-cyclical pelvic pain. Age < 30 years, low body mass index, smoking, earlier menarche (< 12 years), longer cycles, heavy menstrual flow, nullliparity, premenstrual syndrome, sterilisation, clinically suspected pelvic inflammatory disease, sexual abuse, and psychological symptoms were associated with dysmenorrhoea. Younger age at first childbirth, exercise, and oral contraceptives were negatively associated with dysmenorrhoea. Menopause, pelvic inflammatory disease, sexual abuse, anxiety, and depression were associated with dyspareunia. Drug Or alcohol abuse, miscarriage, heavy menstrual flow, pelvic inflammatory disease, previous caesarean section, pelvic pathology, abuse, and psychological comorbidity were associated with all increased risk of non-cyclical pelvic pain. Conclusion Several gynaecological and psychosocial factors are strongly associated with chronic pelvic pain. Randomised controlled trials of interventions targeting these potentially modifiable factors are needed to assess their clinical relevance in chronic pelvic pain.	Univ Birmingham, Acad Dept Obstet & Gynaecol, Birmingham B15 2TG, W Midlands, England; Univ Birmingham, Clin Trials Unit, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham	Latthe, P (corresponding author), Univ Birmingham, Acad Dept Obstet & Gynaecol, Birmingham B15 2TG, W Midlands, England.	pallavi@doctors.org.uk	Khan, Khalid S/AAT-8824-2020	Khan, Khalid S/0000-0001-5084-7312; Latthe, Pallavi/0000-0003-0529-0409; Hills, Robert/0000-0003-0166-0062; Gray, Richard/0000-0003-4440-574X				BAK AP, 1990, J PSYCHOSOM OBST GYN, V11, P29, DOI 10.3109/01674829009078486; BOOTH A, 1997, BECOMING ADEPT APPL; BRIERE J, 1990, CHILD ABUSE NEGLECT, V14, P357, DOI 10.1016/0145-2134(90)90007-G; BROWN S, 1988, BRIT J OBSTET GYNAEC, V95, P905, DOI 10.1111/j.1471-0528.1988.tb06578.x; BUKMAN A, 1990, J PSYCHOSOM OBST GYN, V11, P147, DOI 10.3109/01674829009084411; CAMPBELL F, 1994, BRIT J ANAESTH, V73, P571, DOI 10.1093/bja/73.5.571; Chinn S, 2000, STAT MED, V19, P3127, DOI 10.1002/1097-0258(20001130)19:22<3127::AID-SIM784>3.0.CO;2-M; Davies L, 1992, J OBSTET GYNECOL, V12, P46; DEEK SJ, 2001, SYSTEMATIC REV HLTH; Elcombe S, 1997, PSYCHOL MED, V27, P1041, DOI 10.1017/S0033291797004868; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; FONTANA D, 1982, BRIT J EDUC PSYCHOL, V52, P199, DOI 10.1111/j.2044-8279.1982.tb00826.x; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; Hegarty K, 2004, BRIT MED J, V328, P621, DOI 10.1136/bmj.328.7440.621; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Hornsby PP, 1998, EPIDEMIOLOGY, V9, P193, DOI 10.1097/00001648-199803000-00016; Howard F M, 1993, Obstet Gynecol Surv, V48, P357, DOI 10.1097/00006254-199306000-00001; International Association for the Study of Pain: Subcommittee on Taxonomy, 1986, PAIN S, V3, pS1, DOI DOI 10.1016/0304-3959(86)90106-5; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; KENNEDY SH, 2005, 41 RCOG; KHAN KS, 2001, 4 CRD U YORK NHS CTR; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; MACLEAN AB, 2001, PAIN OBSTET GYNAECOL; MANTEL N, 1959, J NATL CANCER I, V22, P719; Mathias SD, 1996, OBSTET GYNECOL, V87, P321, DOI 10.1016/0029-7844(95)00458-0; McGowan LPA, 1998, PSYCHOL HEALTH, V13, P937, DOI 10.1080/08870449808407441; Phillips Carl V, 2004, Epidemiol Perspect Innov, V1, P3, DOI 10.1186/1742-5573-1-3; Proctor ML, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002248.pub3; Proctor ML, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001896.pub2; Proctor ML., 2002, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD002123; REITER RC, 1990, OBSTET GYNECOL, V75, P428; ROBINSON JC, 1993, CURR OPIN OBSTET GYN, V5, P740; Song, 2000, HEALTH TECHNOL ASSES, V4, P1, DOI DOI 10.3310/HTA4100; Song FJ, 2001, EVAL HEALTH PROF, V24, P126, DOI 10.1177/01632780122034849; Song FJ, 1999, J CLIN EPIDEMIOL, V52, P725, DOI 10.1016/S0895-4356(99)00066-9; Steege J F, 1993, Obstet Gynecol Surv, V48, P95, DOI 10.1097/00006254-199302000-00014; Sterne JAC, 2002, STAT MED, V21, P1513, DOI 10.1002/sim.1184; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Swank DJ, 2003, LANCET, V361, P1247, DOI 10.1016/S0140-6736(03)12979-0; THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351; Thornton JG, 1997, EUR J OBSTET GYN R B, V74, P57, DOI 10.1016/S0301-2115(97)00082-1; VERCELLINI P, 1989, J REPROD MED, V34, P827; WALKER EA, 1993, OBSTET GYN CLIN N AM, V20, P795; WALLER KG, 1995, FERTIL STERIL, V63, P796, DOI 10.1016/S0015-0282(16)57484-6; WILSON ML, 2001, COCHRANE DB SYST REV; Winkel CA, 2001, INT J GYNECOL OBSTET, V74, pS15, DOI 10.1016/S0020-7292(01)00460-X; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; Zondervan K, 2000, BEST PRACT RES CL OB, V14, P403, DOI 10.1053/beog.1999.0083; Zondervan KT, 1998, BRIT J OBSTET GYNAEC, V105, P93, DOI 10.1111/j.1471-0528.1998.tb09357.x; Zondervan KT, 1999, BRIT J OBSTET GYNAEC, V106, P1149, DOI 10.1111/j.1471-0528.1999.tb08140.x	50	324	337	0	33	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	2006	332	7544					749	751		10.1136/bmj.38748.697465.55	http://dx.doi.org/10.1136/bmj.38748.697465.55			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	032JA	16484239	Green Published, Bronze			2022-12-28	WOS:000236769500015
J	Frohman, EM; Racke, MK; Raine, CS				Frohman, EM; Racke, MK; Raine, CS			Medical progress: Multiple sclerosis - The plaque and its pathogenesis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; T-CELL RESPONSES; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; TECHNOLOGY-ASSESSMENT SUBCOMMITTEE; ALTERED PEPTIDE LIGAND; CENTRAL-NERVOUS-SYSTEM; ACADEMY-OF-NEUROLOGY; MULTIFOCAL LEUKOENCEPHALOPATHY; CEREBROSPINAL-FLUID		Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Ophthalmol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Immunol, Dallas, TX 75390 USA; Albert Einstein Coll Med, Div Neuropathol, Dept Pathol & Neurol, Bronx, NY 10467 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Yeshiva University; Albert Einstein College of Medicine	Frohman, EM (corresponding author), Univ Texas, SW Med Ctr, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	frohman@utsouthwestern.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K24NS044250, P50NS011920, P01NS011920, R01NS037513] Funding Source: NIH RePORTER; NINDS NIH HHS [NS11920, NS08952, NS37513, NS44250] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDO DG, 1989, CELL IMMUNOL, V124, P132, DOI 10.1016/0008-8749(89)90117-2; Arnett HA, 2004, SCIENCE, V306, P2111, DOI 10.1126/science.1103709; BALASHOV KE, 1995, J CLIN INVEST, V95, P2711, DOI 10.1172/JCI117973; Barnett MH, 2004, ANN NEUROL, V55, P458, DOI 10.1002/ana.20016; Bechtold DA, 2004, ANN NEUROL, V55, P607, DOI 10.1002/ana.20045; Bettelli E, 2004, J EXP MED, V200, P79, DOI 10.1084/jem.20031819; Bielekova B, 2000, NAT MED, V6, P1412; Bielekova B, 2000, NAT MED, V6, P1167, DOI 10.1038/80516; Bitsch A, 2000, BRAIN, V123, P1174, DOI 10.1093/brain/123.6.1174; Bjartmar C, 2000, ANN NEUROL, V48, P893, DOI 10.1002/1531-8249(200012)48:6<893::AID-ANA10>3.0.CO;2-B; Bjartmar C, 2003, J NEUROL SCI, V206, P165, DOI 10.1016/S0022-510X(02)00069-2; Capello E, 1997, ANN NEUROL, V41, P797, DOI 10.1002/ana.410410616; Cercignani M, 2001, J NEUROL NEUROSUR PS, V70, P311, DOI 10.1136/jnnp.70.3.311; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; Chitnis T, 2001, J CLIN INVEST, V108, P739, DOI 10.1172/JCI200112563; Crawford MP, 2004, BLOOD, V103, P4222, DOI 10.1182/blood-2003-11-4025; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Deng C, 2003, J IMMUNOL, V170, P2833, DOI 10.4049/jimmunol.170.6.2833; Dhib-Jalbut S, 2002, NEUROLOGY, V58, pS3, DOI 10.1212/WNL.58.8_suppl_4.S3; Diestel A, 2003, J EXP MED, V198, P1729, DOI 10.1084/jem.20030975; Dowling P, 1996, J EXP MED, V184, P1513, DOI 10.1084/jem.184.4.1513; Farrar JD, 2000, IMMUNOL TODAY, V21, P484, DOI 10.1016/S0167-5699(00)01710-2; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; Frohman EM, 2003, NEUROLOGY, V61, P602, DOI 10.1212/01.WNL.0000082654.99838.EF; Frohman EM, 2002, NEUROLOGY, V59, P480; Frohman EM, 2001, NEUROLOGY, V57, P762, DOI 10.1212/WNL.57.5.762; Genain CP, 1999, NAT MED, V5, P170, DOI 10.1038/5532; Geurts JJG, 2005, AM J NEURORADIOL, V26, P572; Goodin DS, 2002, NEUROLOGY, V58, P169, DOI 10.1212/WNL.58.2.169; Huseby ES, 2001, J EXP MED, V194, P669, DOI 10.1084/jem.194.5.669; John GR, 2002, NAT MED, V8, P1115, DOI 10.1038/nm781; Kalkers NF, 2002, MULT SCLER, V8, P532, DOI 10.1191/1352458502ms849xx; Kappos L, 2000, NAT MED, V6, P1176, DOI 10.1038/80525; Kappos L, 2001, NAT MED, V7, P129; Kerfoot SM, 2004, J IMMUNOL, V173, P7070, DOI 10.4049/jimmunol.173.11.7070; Kivisakk P, 2004, ANN NEUROL, V55, P627, DOI 10.1002/ana.20049; Kleinschmidt-DeMasters BK, 2005, NEW ENGL J MED, V353, P369, DOI 10.1056/NEJMoa051782; Kornek B, 2000, AM J PATHOL, V157, P267, DOI 10.1016/S0002-9440(10)64537-3; Langer-Gould A, 2005, NEW ENGL J MED, V353, P375, DOI 10.1056/NEJMoa051847; Lo AC, 2003, J NEUROPHYSIOL, V90, P3566, DOI 10.1152/jn.00434.2003; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; Lovett-Racke AE, 1998, J CLIN INVEST, V101, P725, DOI 10.1172/JCI1528; Lovett-Racke AE, 2004, IMMUNITY, V21, P719, DOI 10.1016/j.immuni.2004.09.010; Lovett-Racke AE, 1998, J CLIN INVEST, V101, P1543; Lucchinetti C, 1999, BRAIN, V122, P2279, DOI 10.1093/brain/122.12.2279; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; Lucchinetti CF, 1996, BRAIN PATHOL, V6, P259, DOI 10.1111/j.1750-3639.1996.tb00854.x; Mi S, 2005, NAT NEUROSCI, V8, P745, DOI 10.1038/nn1460; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Monson NL, 2005, J NEUROIMMUNOL, V158, P170, DOI 10.1016/j.jneuroim.2004.04.022; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; Omari KM, 2005, BRAIN, V128, P1003, DOI 10.1093/brain/awh479; Owens GP, 2003, J IMMUNOL, V171, P2725, DOI 10.4049/jimmunol.171.5.2725; PETTINELLI CB, 1981, J IMMUNOL, V127, P1420; PRINEAS JW, 1981, ANN NEUROL, V10, P149, DOI 10.1002/ana.410100205; PRINEAS JW, 1993, ANN NEUROL, V33, P137, DOI 10.1002/ana.410330203; Qin YF, 1998, J CLIN INVEST, V102, P1045, DOI 10.1172/JCI3568; RAINE CS, 1994, ANN NEUROL, V36, pS61, DOI 10.1002/ana.410360716; RAINE CS, 1981, LAB INVEST, V45, P534; RAINE CS, 1991, TXB NEUROPATHOLOGY, P535; Scholz C, 1998, J IMMUNOL, V160, P1532; Scolding N, 1998, BRAIN, V121, P2221, DOI 10.1093/brain/121.12.2221; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Trinchieri G, 2003, IMMUNITY, V19, P641, DOI 10.1016/S1074-7613(03)00296-6; Van Assche G, 2005, NEW ENGL J MED, V353, P362, DOI 10.1056/NEJMoa051586; van Waesberghe JHTM, 1999, ANN NEUROL, V46, P747; Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579; Waldner H, 2004, J CLIN INVEST, V113, P990, DOI 10.1172/JCI200419388; Wandinger KP, 2001, ANN NEUROL, V50, P349, DOI 10.1002/ana.1096; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Waxman SG, 2004, TRENDS PHARMACOL SCI, V25, P584, DOI 10.1016/j.tips.2004.09.001; Werner P, 2001, ANN NEUROL, V50, P169, DOI 10.1002/ana.1077; Wilkins A, 2003, J NEUROSCI, V23, P4967, DOI 10.1523/jneurosci.23-12-04967.2003; Wolswijk G, 2000, BRAIN, V123, P105, DOI 10.1093/brain/123.1.105; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; Zang YCQ, 2004, J IMMUNOL, V172, P5120, DOI 10.4049/jimmunol.172.8.5120; Zhang GX, 2003, J IMMUNOL, V170, P2153, DOI 10.4049/jimmunol.170.4.2153	78	1226	1268	1	99	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 2	2006	354	9					942	955		10.1056/NEJMra052130	http://dx.doi.org/10.1056/NEJMra052130			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	017FN	16510748				2022-12-28	WOS:000235679600007
J	Browne, K; Hamilton-Giachritsis, C; Johnson, R; Ostergren, M				Browne, K; Hamilton-Giachritsis, C; Johnson, R; Ostergren, M			Child health - Overuse of institutional care for children in Europe	BRITISH MEDICAL JOURNAL			English	Editorial Material							MENTAL-HEALTH; ADOLESCENTS; PRIVATION; BRAIN		Univ Birmingham, Ctr Forens & Family Psychol, Birmingham B15 2TT, W Midlands, England; WHO, Reg Off Europe, DK-2100 Copenhagen, Denmark	University of Birmingham; World Health Organization	Browne, K (corresponding author), Univ Birmingham, Ctr Forens & Family Psychol, Birmingham B15 2TT, W Midlands, England.	K.D.Browne@bham.ac.uk	Hamilton-Giachritsis, Catherine/B-7844-2013	Hamilton-Giachritsis, Catherine/0000-0001-9796-2107				Arie Sophie, 2005, BMJ, V331, P129, DOI 10.1136/bmj.331.7509.129; Bainham A, 2003, CHILD FAM LAW Q, V15, P233; Balbernie R, 2001, J CHILD PSYCHOTHERAP, V27, P237, DOI DOI 10.1080/00754170110087531; Bowlby John, 1952, MATERNAL CARE MENTAL; BROWNE KD, 2005, 2003046C WHO U BIRM; Browne K, 2005, ADOPT FOSTER, V29, P23, DOI 10.1177/030857590502900405; Fisher L, 1997, INT J BEHAV DEV, V20, P67, DOI 10.1080/016502597385441; Giese S, 1999, S AFR J PSYCHOL, V29, P17, DOI 10.1177/008124639902900103; Glaser D, 2000, J CHILD PSYCHOL PSYC, V41, P97, DOI 10.1111/1469-7610.00551; HODGES J, 1989, J CHILD PSYCHOL PSYC, V30, P77, DOI 10.1111/j.1469-7610.1989.tb00770.x; HODGES J, 1989, J CHILD PSYCHOL PSYC, V30, P53, DOI 10.1111/j.1469-7610.1989.tb00769.x; *INT SOC PREV CHIL, 1998, WORLD PERSP CHILD AB; Jenkins R, 2005, BMJ-BRIT MED J, V331, P173, DOI 10.1136/bmj.331.7510.173; Marcovitch S, 1997, INT J BEHAV DEV, V20, P17, DOI 10.1080/016502597385414; O'Connor TG, 2000, CHILD DEV, V71, P376, DOI 10.1111/1467-8624.00151; Rushton A., 2002, CHILD ADOLESCENT PSY, P359; Rutter M, 1998, J CHILD PSYCHOL PSYC, V39, P465, DOI 10.1017/S0021963098002236; Schore AN, 2001, INFANT MENT HEALTH J, V22, P7, DOI 10.1002/1097-0355(200101/04)22:1<7::AID-IMHJ2>3.0.CO;2-N; Trevarthen C, 2001, J CHILD PSYCHOL PSYC, V42, P3, DOI 10.1111/1469-7610.00701; *UNICEF, 2004, STAT WORLDS CHILDR; UNICEF, 2004, INN SOC MON EC GROWT	21	51	51	2	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 25	2006	332	7539					485	487		10.1136/bmj.332.7539.485	http://dx.doi.org/10.1136/bmj.332.7539.485			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	018VM	16497769	Green Published, Green Submitted			2022-12-28	WOS:000235792900025
J	Douek, DC; Kwong, PD; Nabell-, GJ				Douek, DC; Kwong, PD; Nabell-, GJ			The rational design of an AIDS vaccine	CELL			English	Editorial Material							EVOLUTIONARY	The extraordinary genetic diversity and immune evasion of human immunodeficiency virus (HIV) pose significant challenges for vaccine development. AIDS vaccine design requires a scientifically driven, rational approach that encompasses the latest advances in viral molecular genetics, structural biology, and immunology.	NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Nabell-, GJ (corresponding author), NIAID, Vaccine Res Ctr, NIH, Room 4502,Bldg 40,MSC-3005,40 Convent Dr, Bethesda, MD 20892 USA.	gnabel@nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI005024, Z01AI005024, Z01AI005078, ZIAAI005078] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Burton DR, 2005, P NATL ACAD SCI USA, V102, P14943, DOI 10.1073/pnas.0505126102; Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327; Korber B, 2000, SCIENCE, V288, P1789, DOI 10.1126/science.288.5472.1789; Korber B, 2001, BRIT MED BULL, V58, P19, DOI 10.1093/bmb/58.1.19; Pantaleo G, 2004, NAT MED, V10, P806, DOI 10.1038/nm0804-806	5	110	122	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 24	2006	124	4					677	681		10.1016/j.cell.2006.02.005	http://dx.doi.org/10.1016/j.cell.2006.02.005			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	038RO	16497577	Bronze			2022-12-28	WOS:000237240900010
J	Rignot, E; Kanagaratnam, P				Rignot, E; Kanagaratnam, P			Changes in the velocity structure of the Greenland ice sheet	SCIENCE			English	Article							JAKOBSHAVN ISBRAE; RADAR; ACCELERATION; DISCHARGE	Using satellite radar interferometry observations of Greenland, we detected widespread glacier acceleration below 66 degrees north between 1996 and 2000, which rapidly expanded to 70 degrees north in 2005. Accelerated ice discharge in the west and particularly in the east doubled the ice sheet mass deficit in the last decade from 90 to 220 cubic kilometers per year. As more glaciers accelerate farther north, the contribution of Greenland to sea-level rise will continue to increase.	Univ Kansas, Ctr Remote Sensing Ice Sheets, Lawrence, KS 66045 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	University of Kansas; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Rignot, E (corresponding author), Univ Kansas, Ctr Remote Sensing Ice Sheets, Lawrence, KS 66045 USA.	eric.rignot@jpl.nasa.gov; pannir@ku.edu	Rignot, Eric/A-4560-2014	Rignot, Eric/0000-0002-3366-0481				ABDALATI W, 2001, J GEOPHYS RES, V106, P33279; CARBONNELL M, 1968, 173 MEDD GRONL; Clarke TS, 1996, J GLACIOL, V42, P219, DOI 10.3189/S0022143000004081; Gogineni S, 1998, J GLACIOL, V44, P659, DOI 10.3189/S0022143000002161; Hanna E, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005641; Howat IM, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL024737; Jezek KC, 2003, RADIO SCI, V38, DOI 10.1029/2002RS002643; Joughin I, 2004, NATURE, V432, P608, DOI 10.1038/nature03130; Krabill W, 2000, SCIENCE, V289, P428, DOI 10.1126/science.289.5478.428; Krabill W, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL021533; KRIMMEL RM, 1987, J GEOPHYS RES-SOLID, V92, P8961, DOI 10.1029/JB092iB09p08961; Luckman A, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL022519; Michel R, 1999, J GLACIOL, V45, P93, DOI 10.3189/S0022143000003075; OLESEN OB, 1969, GRONLANDS GEOLOGISKE, V21, P41; Rignot E, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019474; Rignot E, 2001, J GEOPHYS RES-ATMOS, V106, P34007, DOI 10.1029/2001JD900071; Rignot EJ, 1997, SCIENCE, V276, P934, DOI 10.1126/science.276.5314.934; Thomas RH, 2004, J GLACIOL, V50, P57, DOI 10.3189/172756504781830321; Thomas RH, 2003, J GLACIOL, V49, P231, DOI 10.3189/172756503781830764; Thomas RH, 2000, GEOPHYS RES LETT, V27, P1291, DOI 10.1029/1999GL008473; Weide-Zaage K, 2003, MAT SCI SEMICON PROC, V6, P85, DOI 10.1016/S1369-8001(03)00075-1; Weidick A., 1995, SATELLITE IMAGE ATLA; Zwally HJ, 2002, SCIENCE, V297, P218, DOI 10.1126/science.1072708	23	882	916	2	196	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 17	2006	311	5763					986	990		10.1126/science.1121381	http://dx.doi.org/10.1126/science.1121381			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014CS	16484490	Green Submitted			2022-12-28	WOS:000235456900041
J	Bottke, WF; Nesvorny, D; Grimm, RE; Morbidelli, A; O'Brien, DP				Bottke, WF; Nesvorny, D; Grimm, RE; Morbidelli, A; O'Brien, DP			Iron meteorites as remnants of planetesimals formed in the terrestrial planet region	NATURE			English	Article							ASTEROID BELT; SOLAR NEBULA; MAIN-BELT; AL-26; EXCITATION; OBJECTS	Iron meteorites are core fragments from differentiated and subsequently disrupted planetesimals(1). The parent bodies are usually assumed to have formed in the main asteroid belt, which is the source of most meteorites. Observational evidence, however, does not indicate that differentiated bodies or their fragments were ever common there. This view is also difficult to reconcile with the fact that the parent bodies of iron meteorites were as small as 20 km in diameter(2,3) and that they formed 1-2 Myr earlier than the parent bodies of the ordinary chondrites(4-6). Here we show that the iron-meteorite parent bodies most probably formed in the terrestrial planet region. Fast accretion times there allowed small planetesimals to melt early in Solar System history by the decay of short-lived radionuclides ( such as Al-26, Fe-60)(7-9). The protoplanets emerging from this population not only induced collisional evolution among the remaining planetesimals but also scattered some of the survivors into the main belt, where they stayed for billions of years before escaping via a combination of collisions, Yarkovsky thermal forces, and resonances(10). We predict that some asteroids are main-belt interlopers ( such as ( 4) Vesta). A select few may even be remnants of the long-lost precursor material that formed the Earth.	SW Res Inst, Boulder, CO 80302 USA; Observ Cote Azur, F-06034 Nice 4, France	UDICE-French Research Universities; Universite Cote d'Azur; Observatoire de la Cote d'Azur	Bottke, WF (corresponding author), SW Res Inst, 1050 Walnut St,Suite 400, Boulder, CO 80302 USA.	bottke@boulder.swri.edu		Grimm, Robert/0000-0002-7588-1194				Baker J, 2005, NATURE, V436, P1127, DOI 10.1038/nature03882; Bizzarro M, 2005, ASTROPHYS J, V632, pL41, DOI 10.1086/497638; Bottke W. F., 2002, ASTEROIDS, P395; Bottke WF, 2002, ICARUS, V156, P399, DOI 10.1006/icar.2001.6788; Bottke WF, 2005, ICARUS, V179, P63, DOI 10.1016/j.icarus.2005.05.017; BOTTKE WF, 1994, ICARUS, V107, P255, DOI 10.1006/icar.1994.1021; BOTTKE WF, 1908, ICARUS, V175, P111; Bottke WF, 2005, IAU COLLOQ, V197, P357, DOI 10.1017/S1743921304008865; Burbine T. H., 2002, ASTEROIDS, VIII, P653, DOI DOI 10.2307/J.CTV1V7ZDN4.50; Bus SJ, 2002, ICARUS, V158, P106, DOI 10.1006/icar.2002.6857; CELLINO A, 2003, ASTEROIDS, V3, P632; CHABOT NL, IN PRESS METEORITES, V2; Eugster O, 2003, CHEM ERDE-GEOCHEM, V63, P3, DOI 10.1078/0009-2819-00021; Gladman BJ, 1997, SCIENCE, V277, P197, DOI 10.1126/science.277.5323.197; Gomes R, 2005, NATURE, V435, P466, DOI 10.1038/nature03676; GRADIE J, 1982, SCIENCE, V216, P1405, DOI 10.1126/science.216.4553.1405; KLEINE T, 2005, LUNAR PLANET SCI C, V36, P1431; Lazzaro D, 2000, SCIENCE, V288, P2033, DOI 10.1126/science.288.5473.2033; MITTLEFEHLDT DW, 1998, REV MINERAL, V36; Russell SS, 1996, SCIENCE, V273, P757, DOI 10.1126/science.273.5276.757; SANDERS IS, 2005, ASP C SER, V0341, P00915; SCOTT ERD, 2002, ASTEROIDS, V3, P697; Srinivasan G, 1999, SCIENCE, V284, P1348, DOI 10.1126/science.284.5418.1348; STEVENSON DJ, 1988, ICARUS, V75, P146, DOI 10.1016/0019-1035(88)90133-9; Sunshine JM, 2004, METEORIT PLANET SCI, V39, P1343, DOI 10.1111/j.1945-5100.2004.tb00950.x; WEIDENSCHILLING SJ, 1977, ASTROPHYS SPACE SCI, V51, P153, DOI 10.1007/BF00642464	30	213	213	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 16	2006	439	7078					821	824		10.1038/nature04536	http://dx.doi.org/10.1038/nature04536			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012JA	16482151				2022-12-28	WOS:000235333600043
J	Hazelwood, S; Burton, D				Hazelwood, S; Burton, D			Colonic ileus	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Mt Sinai Sch Med, Jersey City, NJ 07302 USA; Dept Vet Affairs, Washington, DC 20420 USA	Icahn School of Medicine at Mount Sinai	Hazelwood, S (corresponding author), Mt Sinai Sch Med, Jersey City, NJ 07302 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 16	2006	354	7					E6	E6		10.1056/NEJMicm050019	http://dx.doi.org/10.1056/NEJMicm050019			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	012CP	16481631				2022-12-28	WOS:000235316100011
